{"patient_id":"ANODE_SYNTH_2025_001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":86,"sex":"female","bmi":36.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-32},"pfs_months":24.08},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.9,"censored":false},"longitudinal_labs":[{"date":"2020-04-06","hemoglobin_g_dL":14.0,"wbc_k_uL":8.5,"platelets_k_uL":197,"creatinine_mg_dL":0.94,"alt_U_L":15},{"date":"2020-11-23","hemoglobin_g_dL":13.9,"wbc_k_uL":6.6,"platelets_k_uL":176,"creatinine_mg_dL":1.32,"alt_U_L":45},{"date":"2022-06-12","hemoglobin_g_dL":13.0,"wbc_k_uL":5.9,"platelets_k_uL":339,"creatinine_mg_dL":1.1,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":83,"sex":"female","bmi":33.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-58},"pfs_months":27.14},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":true},"longitudinal_labs":[{"date":"2023-05-05","hemoglobin_g_dL":14.4,"wbc_k_uL":8.8,"platelets_k_uL":426,"creatinine_mg_dL":1.09,"alt_U_L":58},{"date":"2023-12-21","hemoglobin_g_dL":12.1,"wbc_k_uL":5.3,"platelets_k_uL":164,"creatinine_mg_dL":1.59,"alt_U_L":100},{"date":"2025-11-21","hemoglobin_g_dL":9.8,"wbc_k_uL":4.3,"platelets_k_uL":130,"creatinine_mg_dL":0.86,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_003","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":72,"sex":"female","bmi":30.1,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-10-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-48},"pfs_months":30.26},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":52.4,"censored":false},"longitudinal_labs":[{"date":"2024-08-28","hemoglobin_g_dL":14.7,"wbc_k_uL":7.1,"platelets_k_uL":191,"creatinine_mg_dL":0.65,"alt_U_L":28},{"date":"2025-04-24","hemoglobin_g_dL":11.1,"wbc_k_uL":8.4,"platelets_k_uL":351,"creatinine_mg_dL":1.31,"alt_U_L":75},{"date":"2027-07-02","hemoglobin_g_dL":11.5,"wbc_k_uL":6.6,"platelets_k_uL":198,"creatinine_mg_dL":1.88,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":68,"sex":"female","bmi":27.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-75},"pfs_months":32.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.3,"censored":false},"longitudinal_labs":[{"date":"2022-05-13","hemoglobin_g_dL":11.8,"wbc_k_uL":9.9,"platelets_k_uL":344,"creatinine_mg_dL":0.76,"alt_U_L":25},{"date":"2023-01-07","hemoglobin_g_dL":14.0,"wbc_k_uL":7.5,"platelets_k_uL":351,"creatinine_mg_dL":1.07,"alt_U_L":55},{"date":"2025-04-18","hemoglobin_g_dL":10.3,"wbc_k_uL":7.9,"platelets_k_uL":321,"creatinine_mg_dL":1.7,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":87,"sex":"female","bmi":20.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-83},"pfs_months":14.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.4,"censored":true},"longitudinal_labs":[{"date":"2021-04-14","hemoglobin_g_dL":13.9,"wbc_k_uL":5.2,"platelets_k_uL":328,"creatinine_mg_dL":0.94,"alt_U_L":34},{"date":"2021-12-12","hemoglobin_g_dL":10.1,"wbc_k_uL":7.5,"platelets_k_uL":279,"creatinine_mg_dL":1.2,"alt_U_L":17},{"date":"2022-10-26","hemoglobin_g_dL":10.5,"wbc_k_uL":3.7,"platelets_k_uL":100,"creatinine_mg_dL":1.97,"alt_U_L":90}]}
{"patient_id":"ANODE_SYNTH_2025_006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":65,"sex":"male","bmi":28.2,"smoking_pack_years":73,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-07-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-32},"pfs_months":15.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.6,"censored":true},"longitudinal_labs":[{"date":"2022-07-02","hemoglobin_g_dL":13.8,"wbc_k_uL":5.7,"platelets_k_uL":318,"creatinine_mg_dL":1.09,"alt_U_L":16},{"date":"2023-01-16","hemoglobin_g_dL":11.3,"wbc_k_uL":4.4,"platelets_k_uL":272,"creatinine_mg_dL":0.91,"alt_U_L":76},{"date":"2023-12-29","hemoglobin_g_dL":9.9,"wbc_k_uL":4.2,"platelets_k_uL":321,"creatinine_mg_dL":1.87,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":62,"sex":"female","bmi":28.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-59},"pfs_months":38.6},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.5,"censored":false},"longitudinal_labs":[{"date":"2022-09-04","hemoglobin_g_dL":14.3,"wbc_k_uL":6.5,"platelets_k_uL":215,"creatinine_mg_dL":0.74,"alt_U_L":34},{"date":"2023-05-12","hemoglobin_g_dL":10.6,"wbc_k_uL":8.1,"platelets_k_uL":320,"creatinine_mg_dL":1.43,"alt_U_L":98},{"date":"2026-02-20","hemoglobin_g_dL":11.8,"wbc_k_uL":6.8,"platelets_k_uL":341,"creatinine_mg_dL":0.96,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":68,"sex":"female","bmi":37.6,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-06-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-49},"pfs_months":28.58},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.7,"censored":false},"longitudinal_labs":[{"date":"2022-04-06","hemoglobin_g_dL":12.2,"wbc_k_uL":10.0,"platelets_k_uL":169,"creatinine_mg_dL":0.76,"alt_U_L":12},{"date":"2022-12-09","hemoglobin_g_dL":11.5,"wbc_k_uL":8.0,"platelets_k_uL":354,"creatinine_mg_dL":1.13,"alt_U_L":68},{"date":"2024-12-12","hemoglobin_g_dL":12.8,"wbc_k_uL":6.1,"platelets_k_uL":241,"creatinine_mg_dL":1.86,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":82,"sex":"male","bmi":25.3,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-10-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-84},"pfs_months":42.09},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":65.1,"censored":true},"longitudinal_labs":[{"date":"2024-08-06","hemoglobin_g_dL":12.1,"wbc_k_uL":8.3,"platelets_k_uL":408,"creatinine_mg_dL":0.65,"alt_U_L":65},{"date":"2025-04-12","hemoglobin_g_dL":11.1,"wbc_k_uL":5.8,"platelets_k_uL":379,"creatinine_mg_dL":1.41,"alt_U_L":24},{"date":"2028-05-09","hemoglobin_g_dL":10.8,"wbc_k_uL":5.9,"platelets_k_uL":184,"creatinine_mg_dL":1.53,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":66,"sex":"female","bmi":27.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-52},"pfs_months":20.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":false},"longitudinal_labs":[{"date":"2024-12-14","hemoglobin_g_dL":14.5,"wbc_k_uL":6.1,"platelets_k_uL":220,"creatinine_mg_dL":1.19,"alt_U_L":62},{"date":"2025-07-19","hemoglobin_g_dL":12.2,"wbc_k_uL":8.5,"platelets_k_uL":310,"creatinine_mg_dL":1.3,"alt_U_L":19},{"date":"2026-11-09","hemoglobin_g_dL":10.1,"wbc_k_uL":4.8,"platelets_k_uL":203,"creatinine_mg_dL":1.7,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_011","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":56,"sex":"female","bmi":34.1,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-11-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-32},"pfs_months":25.76},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":47.2,"censored":true},"longitudinal_labs":[{"date":"2021-10-27","hemoglobin_g_dL":13.8,"wbc_k_uL":9.1,"platelets_k_uL":190,"creatinine_mg_dL":0.68,"alt_U_L":21},{"date":"2022-05-15","hemoglobin_g_dL":12.8,"wbc_k_uL":8.3,"platelets_k_uL":321,"creatinine_mg_dL":1.56,"alt_U_L":80},{"date":"2024-03-03","hemoglobin_g_dL":11.8,"wbc_k_uL":6.1,"platelets_k_uL":171,"creatinine_mg_dL":1.04,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":69,"sex":"male","bmi":18.7,"smoking_pack_years":76,"ecog_performance_status":2,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-39},"pfs_months":21.59},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.6,"censored":true},"longitudinal_labs":[{"date":"2025-05-20","hemoglobin_g_dL":12.4,"wbc_k_uL":6.6,"platelets_k_uL":202,"creatinine_mg_dL":0.64,"alt_U_L":38},{"date":"2025-11-30","hemoglobin_g_dL":13.5,"wbc_k_uL":8.4,"platelets_k_uL":184,"creatinine_mg_dL":1.06,"alt_U_L":97},{"date":"2027-04-13","hemoglobin_g_dL":10.3,"wbc_k_uL":4.4,"platelets_k_uL":252,"creatinine_mg_dL":1.35,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":48,"sex":"male","bmi":31.9,"smoking_pack_years":21,"ecog_performance_status":2,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-09-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-70},"pfs_months":30.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":44.8,"censored":false},"longitudinal_labs":[{"date":"2020-07-19","hemoglobin_g_dL":15.1,"wbc_k_uL":5.9,"platelets_k_uL":322,"creatinine_mg_dL":0.78,"alt_U_L":76},{"date":"2021-03-25","hemoglobin_g_dL":10.3,"wbc_k_uL":8.9,"platelets_k_uL":155,"creatinine_mg_dL":1.01,"alt_U_L":49},{"date":"2023-06-23","hemoglobin_g_dL":12.1,"wbc_k_uL":3.2,"platelets_k_uL":307,"creatinine_mg_dL":1.12,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":48,"sex":"female","bmi":28.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-47},"pfs_months":28.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.2,"censored":true},"longitudinal_labs":[{"date":"2023-07-23","hemoglobin_g_dL":15.2,"wbc_k_uL":8.8,"platelets_k_uL":322,"creatinine_mg_dL":0.84,"alt_U_L":62},{"date":"2024-02-14","hemoglobin_g_dL":10.2,"wbc_k_uL":4.0,"platelets_k_uL":256,"creatinine_mg_dL":1.46,"alt_U_L":99},{"date":"2026-02-16","hemoglobin_g_dL":9.6,"wbc_k_uL":7.1,"platelets_k_uL":344,"creatinine_mg_dL":1.24,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":69,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-82},"pfs_months":22.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":false},"longitudinal_labs":[{"date":"2024-11-16","hemoglobin_g_dL":14.1,"wbc_k_uL":7.7,"platelets_k_uL":424,"creatinine_mg_dL":0.92,"alt_U_L":13},{"date":"2025-07-23","hemoglobin_g_dL":12.0,"wbc_k_uL":5.1,"platelets_k_uL":149,"creatinine_mg_dL":1.16,"alt_U_L":15},{"date":"2026-12-29","hemoglobin_g_dL":12.8,"wbc_k_uL":3.2,"platelets_k_uL":242,"creatinine_mg_dL":1.18,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":51,"sex":"female","bmi":24.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-62},"pfs_months":11.07},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":false},"longitudinal_labs":[{"date":"2020-09-05","hemoglobin_g_dL":14.4,"wbc_k_uL":10.2,"platelets_k_uL":209,"creatinine_mg_dL":0.62,"alt_U_L":60},{"date":"2021-03-22","hemoglobin_g_dL":11.7,"wbc_k_uL":7.4,"platelets_k_uL":376,"creatinine_mg_dL":1.38,"alt_U_L":33},{"date":"2021-10-25","hemoglobin_g_dL":11.2,"wbc_k_uL":5.8,"platelets_k_uL":213,"creatinine_mg_dL":1.12,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":88,"sex":"female","bmi":37.6,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-05-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-41},"pfs_months":11.27},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":15.4,"censored":false},"longitudinal_labs":[{"date":"2025-04-23","hemoglobin_g_dL":14.5,"wbc_k_uL":8.8,"platelets_k_uL":281,"creatinine_mg_dL":0.89,"alt_U_L":13},{"date":"2025-11-11","hemoglobin_g_dL":13.7,"wbc_k_uL":5.0,"platelets_k_uL":331,"creatinine_mg_dL":1.13,"alt_U_L":120},{"date":"2026-05-28","hemoglobin_g_dL":10.7,"wbc_k_uL":5.7,"platelets_k_uL":281,"creatinine_mg_dL":1.18,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":51,"sex":"female","bmi":18.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-79},"pfs_months":19.61},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.6,"censored":true},"longitudinal_labs":[{"date":"2024-01-16","hemoglobin_g_dL":13.3,"wbc_k_uL":4.6,"platelets_k_uL":150,"creatinine_mg_dL":1.22,"alt_U_L":29},{"date":"2024-09-13","hemoglobin_g_dL":10.4,"wbc_k_uL":6.7,"platelets_k_uL":140,"creatinine_mg_dL":1.0,"alt_U_L":72},{"date":"2025-11-21","hemoglobin_g_dL":11.8,"wbc_k_uL":3.5,"platelets_k_uL":237,"creatinine_mg_dL":0.92,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":68,"sex":"male","bmi":20.8,"smoking_pack_years":72,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-12-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-32},"pfs_months":11.33},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":15.3,"censored":false},"longitudinal_labs":[{"date":"2022-11-12","hemoglobin_g_dL":11.9,"wbc_k_uL":9.4,"platelets_k_uL":439,"creatinine_mg_dL":0.88,"alt_U_L":21},{"date":"2023-06-12","hemoglobin_g_dL":12.4,"wbc_k_uL":7.4,"platelets_k_uL":260,"creatinine_mg_dL":1.12,"alt_U_L":72},{"date":"2024-01-13","hemoglobin_g_dL":12.6,"wbc_k_uL":3.9,"platelets_k_uL":243,"creatinine_mg_dL":1.44,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":67,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-45},"pfs_months":16.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.4,"censored":false},"longitudinal_labs":[{"date":"2021-05-22","hemoglobin_g_dL":12.6,"wbc_k_uL":7.6,"platelets_k_uL":317,"creatinine_mg_dL":1.17,"alt_U_L":55},{"date":"2021-12-25","hemoglobin_g_dL":10.8,"wbc_k_uL":6.0,"platelets_k_uL":183,"creatinine_mg_dL":1.28,"alt_U_L":31},{"date":"2022-12-03","hemoglobin_g_dL":10.5,"wbc_k_uL":5.1,"platelets_k_uL":159,"creatinine_mg_dL":1.22,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":66,"sex":"male","bmi":37.2,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-10-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-48},"pfs_months":48.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":76.6,"censored":false},"longitudinal_labs":[{"date":"2023-09-04","hemoglobin_g_dL":13.7,"wbc_k_uL":9.0,"platelets_k_uL":319,"creatinine_mg_dL":0.77,"alt_U_L":46},{"date":"2024-03-30","hemoglobin_g_dL":11.2,"wbc_k_uL":7.8,"platelets_k_uL":330,"creatinine_mg_dL":1.05,"alt_U_L":80},{"date":"2027-12-10","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":166,"creatinine_mg_dL":1.56,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_022","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":67,"sex":"male","bmi":29.0,"smoking_pack_years":75,"ecog_performance_status":2,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-04-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-46},"pfs_months":20.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":true},"longitudinal_labs":[{"date":"2021-02-26","hemoglobin_g_dL":11.9,"wbc_k_uL":6.8,"platelets_k_uL":191,"creatinine_mg_dL":0.96,"alt_U_L":26},{"date":"2021-10-20","hemoglobin_g_dL":11.3,"wbc_k_uL":6.0,"platelets_k_uL":168,"creatinine_mg_dL":0.78,"alt_U_L":26},{"date":"2023-02-14","hemoglobin_g_dL":10.3,"wbc_k_uL":7.8,"platelets_k_uL":181,"creatinine_mg_dL":1.64,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":60,"sex":"female","bmi":22.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-54},"pfs_months":25.99},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.2,"censored":true},"longitudinal_labs":[{"date":"2022-11-13","hemoglobin_g_dL":13.0,"wbc_k_uL":6.2,"platelets_k_uL":380,"creatinine_mg_dL":1.09,"alt_U_L":35},{"date":"2023-06-08","hemoglobin_g_dL":12.1,"wbc_k_uL":7.1,"platelets_k_uL":212,"creatinine_mg_dL":1.16,"alt_U_L":78},{"date":"2025-03-22","hemoglobin_g_dL":12.0,"wbc_k_uL":4.5,"platelets_k_uL":199,"creatinine_mg_dL":1.22,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":63,"sex":"female","bmi":24.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-40},"pfs_months":22.93},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.0,"censored":false},"longitudinal_labs":[{"date":"2025-08-09","hemoglobin_g_dL":14.3,"wbc_k_uL":10.5,"platelets_k_uL":418,"creatinine_mg_dL":0.73,"alt_U_L":62},{"date":"2026-02-25","hemoglobin_g_dL":10.5,"wbc_k_uL":5.6,"platelets_k_uL":285,"creatinine_mg_dL":1.58,"alt_U_L":102},{"date":"2027-09-25","hemoglobin_g_dL":9.7,"wbc_k_uL":3.2,"platelets_k_uL":272,"creatinine_mg_dL":1.09,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":62,"sex":"female","bmi":21.1,"smoking_pack_years":57,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-03-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-76},"pfs_months":39.13},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":62.6,"censored":true},"longitudinal_labs":[{"date":"2022-02-26","hemoglobin_g_dL":12.2,"wbc_k_uL":7.5,"platelets_k_uL":319,"creatinine_mg_dL":0.64,"alt_U_L":41},{"date":"2022-09-16","hemoglobin_g_dL":10.7,"wbc_k_uL":5.8,"platelets_k_uL":172,"creatinine_mg_dL":0.87,"alt_U_L":60},{"date":"2025-08-22","hemoglobin_g_dL":10.4,"wbc_k_uL":7.3,"platelets_k_uL":115,"creatinine_mg_dL":1.82,"alt_U_L":149}]}
{"patient_id":"ANODE_SYNTH_2025_026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":83,"sex":"female","bmi":36.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-34},"pfs_months":15.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.8,"censored":false},"longitudinal_labs":[{"date":"2020-12-28","hemoglobin_g_dL":13.0,"wbc_k_uL":6.0,"platelets_k_uL":299,"creatinine_mg_dL":0.71,"alt_U_L":28},{"date":"2021-08-26","hemoglobin_g_dL":10.0,"wbc_k_uL":7.8,"platelets_k_uL":194,"creatinine_mg_dL":1.25,"alt_U_L":109},{"date":"2022-07-08","hemoglobin_g_dL":12.9,"wbc_k_uL":4.2,"platelets_k_uL":314,"creatinine_mg_dL":0.83,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":53,"sex":"female","bmi":23.7,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-12-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-54},"pfs_months":8.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":false},"longitudinal_labs":[{"date":"2024-11-23","hemoglobin_g_dL":13.5,"wbc_k_uL":4.9,"platelets_k_uL":416,"creatinine_mg_dL":0.88,"alt_U_L":78},{"date":"2025-06-14","hemoglobin_g_dL":10.8,"wbc_k_uL":8.8,"platelets_k_uL":297,"creatinine_mg_dL":1.59,"alt_U_L":56},{"date":"2025-10-18","hemoglobin_g_dL":11.1,"wbc_k_uL":4.1,"platelets_k_uL":347,"creatinine_mg_dL":0.83,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_028","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":54,"sex":"male","bmi":23.9,"smoking_pack_years":60,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-12-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-73},"pfs_months":34.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.0,"censored":false},"longitudinal_labs":[{"date":"2024-10-12","hemoglobin_g_dL":13.8,"wbc_k_uL":4.8,"platelets_k_uL":182,"creatinine_mg_dL":0.6,"alt_U_L":25},{"date":"2025-06-03","hemoglobin_g_dL":10.6,"wbc_k_uL":4.6,"platelets_k_uL":361,"creatinine_mg_dL":1.13,"alt_U_L":74},{"date":"2027-10-31","hemoglobin_g_dL":11.9,"wbc_k_uL":3.5,"platelets_k_uL":183,"creatinine_mg_dL":0.81,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_029","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":65,"sex":"female","bmi":20.8,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-50},"pfs_months":23.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.2,"censored":true},"longitudinal_labs":[{"date":"2023-05-21","hemoglobin_g_dL":15.1,"wbc_k_uL":7.1,"platelets_k_uL":222,"creatinine_mg_dL":0.66,"alt_U_L":76},{"date":"2024-01-12","hemoglobin_g_dL":11.8,"wbc_k_uL":8.1,"platelets_k_uL":335,"creatinine_mg_dL":0.96,"alt_U_L":53},{"date":"2025-09-12","hemoglobin_g_dL":10.2,"wbc_k_uL":3.1,"platelets_k_uL":188,"creatinine_mg_dL":1.66,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":84,"sex":"female","bmi":35.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-40},"pfs_months":18.73},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":true},"longitudinal_labs":[{"date":"2023-08-18","hemoglobin_g_dL":12.8,"wbc_k_uL":6.6,"platelets_k_uL":421,"creatinine_mg_dL":1.07,"alt_U_L":45},{"date":"2024-03-30","hemoglobin_g_dL":11.5,"wbc_k_uL":5.2,"platelets_k_uL":238,"creatinine_mg_dL":0.89,"alt_U_L":108},{"date":"2025-06-17","hemoglobin_g_dL":11.8,"wbc_k_uL":5.3,"platelets_k_uL":294,"creatinine_mg_dL":1.39,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_031","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":48,"sex":"female","bmi":29.2,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-82},"pfs_months":14.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.5,"censored":false},"longitudinal_labs":[{"date":"2023-12-11","hemoglobin_g_dL":12.3,"wbc_k_uL":5.6,"platelets_k_uL":248,"creatinine_mg_dL":0.91,"alt_U_L":42},{"date":"2024-06-24","hemoglobin_g_dL":13.7,"wbc_k_uL":8.6,"platelets_k_uL":314,"creatinine_mg_dL":0.86,"alt_U_L":60},{"date":"2025-04-28","hemoglobin_g_dL":11.3,"wbc_k_uL":3.6,"platelets_k_uL":312,"creatinine_mg_dL":1.49,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":71,"sex":"female","bmi":32.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-33},"pfs_months":13.17},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.4,"censored":false},"longitudinal_labs":[{"date":"2024-12-01","hemoglobin_g_dL":13.2,"wbc_k_uL":9.8,"platelets_k_uL":262,"creatinine_mg_dL":0.69,"alt_U_L":64},{"date":"2025-08-04","hemoglobin_g_dL":11.1,"wbc_k_uL":7.4,"platelets_k_uL":279,"creatinine_mg_dL":1.25,"alt_U_L":102},{"date":"2026-04-27","hemoglobin_g_dL":11.3,"wbc_k_uL":5.5,"platelets_k_uL":254,"creatinine_mg_dL":1.73,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.8,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":50,"sex":"male","bmi":37.0,"smoking_pack_years":42,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-03-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-44},"pfs_months":17.81},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.4,"censored":false},"longitudinal_labs":[{"date":"2022-01-12","hemoglobin_g_dL":13.7,"wbc_k_uL":7.0,"platelets_k_uL":335,"creatinine_mg_dL":0.61,"alt_U_L":54},{"date":"2022-09-16","hemoglobin_g_dL":10.4,"wbc_k_uL":4.0,"platelets_k_uL":184,"creatinine_mg_dL":1.42,"alt_U_L":112},{"date":"2023-10-18","hemoglobin_g_dL":12.3,"wbc_k_uL":4.7,"platelets_k_uL":148,"creatinine_mg_dL":1.44,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_034","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":54,"sex":"male","bmi":20.7,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-02-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-35},"pfs_months":5.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":18.3,"censored":false},"longitudinal_labs":[{"date":"2024-12-16","hemoglobin_g_dL":13.3,"wbc_k_uL":7.9,"platelets_k_uL":238,"creatinine_mg_dL":0.74,"alt_U_L":36},{"date":"2025-08-12","hemoglobin_g_dL":10.1,"wbc_k_uL":8.5,"platelets_k_uL":235,"creatinine_mg_dL":1.09,"alt_U_L":87},{"date":"2025-08-12","hemoglobin_g_dL":10.3,"wbc_k_uL":4.5,"platelets_k_uL":117,"creatinine_mg_dL":0.87,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":79,"sex":"female","bmi":20.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-33},"pfs_months":24.74},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.6,"censored":false},"longitudinal_labs":[{"date":"2025-01-23","hemoglobin_g_dL":13.2,"wbc_k_uL":9.3,"platelets_k_uL":383,"creatinine_mg_dL":0.94,"alt_U_L":54},{"date":"2025-09-28","hemoglobin_g_dL":12.9,"wbc_k_uL":6.4,"platelets_k_uL":127,"creatinine_mg_dL":0.89,"alt_U_L":77},{"date":"2027-06-22","hemoglobin_g_dL":12.7,"wbc_k_uL":5.0,"platelets_k_uL":298,"creatinine_mg_dL":0.82,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":51,"sex":"female","bmi":22.4,"smoking_pack_years":21,"ecog_performance_status":2,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-12-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-61},"pfs_months":42.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-08-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":70.4,"censored":false},"longitudinal_labs":[{"date":"2024-12-08","hemoglobin_g_dL":12.9,"wbc_k_uL":6.7,"platelets_k_uL":216,"creatinine_mg_dL":1.2,"alt_U_L":35},{"date":"2025-06-28","hemoglobin_g_dL":13.3,"wbc_k_uL":7.2,"platelets_k_uL":204,"creatinine_mg_dL":1.0,"alt_U_L":90},{"date":"2028-08-13","hemoglobin_g_dL":10.2,"wbc_k_uL":4.7,"platelets_k_uL":255,"creatinine_mg_dL":1.12,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_037","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":72,"sex":"female","bmi":21.6,"smoking_pack_years":68,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-30},"pfs_months":25.92},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.0,"censored":false},"longitudinal_labs":[{"date":"2023-06-25","hemoglobin_g_dL":13.4,"wbc_k_uL":10.5,"platelets_k_uL":418,"creatinine_mg_dL":1.11,"alt_U_L":75},{"date":"2024-01-09","hemoglobin_g_dL":13.8,"wbc_k_uL":7.4,"platelets_k_uL":241,"creatinine_mg_dL":1.32,"alt_U_L":119},{"date":"2025-10-15","hemoglobin_g_dL":11.2,"wbc_k_uL":6.9,"platelets_k_uL":101,"creatinine_mg_dL":1.4,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":65,"sex":"female","bmi":22.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-80},"pfs_months":19.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-24","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.8,"censored":false},"longitudinal_labs":[{"date":"2020-10-05","hemoglobin_g_dL":14.7,"wbc_k_uL":5.3,"platelets_k_uL":396,"creatinine_mg_dL":0.97,"alt_U_L":30},{"date":"2021-05-04","hemoglobin_g_dL":12.0,"wbc_k_uL":7.8,"platelets_k_uL":222,"creatinine_mg_dL":1.04,"alt_U_L":66},{"date":"2022-08-24","hemoglobin_g_dL":11.4,"wbc_k_uL":4.4,"platelets_k_uL":310,"creatinine_mg_dL":1.57,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_039","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":84,"sex":"male","bmi":27.7,"smoking_pack_years":37,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-63},"pfs_months":15.31},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.1,"censored":false},"longitudinal_labs":[{"date":"2022-04-02","hemoglobin_g_dL":13.3,"wbc_k_uL":6.6,"platelets_k_uL":228,"creatinine_mg_dL":1.04,"alt_U_L":12},{"date":"2022-11-29","hemoglobin_g_dL":13.9,"wbc_k_uL":7.3,"platelets_k_uL":130,"creatinine_mg_dL":1.33,"alt_U_L":47},{"date":"2023-10-05","hemoglobin_g_dL":12.5,"wbc_k_uL":4.4,"platelets_k_uL":263,"creatinine_mg_dL":1.08,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":75,"sex":"female","bmi":32.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-01-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-75},"pfs_months":17.45},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.1,"censored":false},"longitudinal_labs":[{"date":"2021-12-27","hemoglobin_g_dL":13.7,"wbc_k_uL":5.6,"platelets_k_uL":216,"creatinine_mg_dL":1.01,"alt_U_L":75},{"date":"2022-07-16","hemoglobin_g_dL":10.5,"wbc_k_uL":4.7,"platelets_k_uL":139,"creatinine_mg_dL":1.13,"alt_U_L":54},{"date":"2023-08-26","hemoglobin_g_dL":10.4,"wbc_k_uL":6.4,"platelets_k_uL":304,"creatinine_mg_dL":1.83,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":71,"sex":"female","bmi":18.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-60},"pfs_months":28.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":47.5,"censored":false},"longitudinal_labs":[{"date":"2024-12-25","hemoglobin_g_dL":11.8,"wbc_k_uL":6.8,"platelets_k_uL":402,"creatinine_mg_dL":1.06,"alt_U_L":70},{"date":"2025-07-16","hemoglobin_g_dL":11.2,"wbc_k_uL":6.8,"platelets_k_uL":365,"creatinine_mg_dL":0.78,"alt_U_L":46},{"date":"2027-08-03","hemoglobin_g_dL":11.3,"wbc_k_uL":4.2,"platelets_k_uL":146,"creatinine_mg_dL":1.94,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_042","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":58,"sex":"male","bmi":24.9,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-11-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-57},"pfs_months":31.77},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.2,"censored":false},"longitudinal_labs":[{"date":"2023-11-02","hemoglobin_g_dL":14.9,"wbc_k_uL":10.3,"platelets_k_uL":162,"creatinine_mg_dL":1.01,"alt_U_L":49},{"date":"2024-05-25","hemoglobin_g_dL":13.3,"wbc_k_uL":4.9,"platelets_k_uL":178,"creatinine_mg_dL":0.91,"alt_U_L":120},{"date":"2026-08-17","hemoglobin_g_dL":12.9,"wbc_k_uL":4.6,"platelets_k_uL":173,"creatinine_mg_dL":0.81,"alt_U_L":149}]}
{"patient_id":"ANODE_SYNTH_2025_043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":88,"sex":"female","bmi":31.8,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-33},"pfs_months":30.19},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-08-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.1,"censored":false},"longitudinal_labs":[{"date":"2025-11-06","hemoglobin_g_dL":14.5,"wbc_k_uL":7.3,"platelets_k_uL":416,"creatinine_mg_dL":0.81,"alt_U_L":39},{"date":"2026-06-04","hemoglobin_g_dL":13.1,"wbc_k_uL":8.5,"platelets_k_uL":251,"creatinine_mg_dL":1.54,"alt_U_L":93},{"date":"2028-08-01","hemoglobin_g_dL":13.0,"wbc_k_uL":3.9,"platelets_k_uL":264,"creatinine_mg_dL":0.94,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":56,"sex":"female","bmi":24.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-47},"pfs_months":23.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":false},"longitudinal_labs":[{"date":"2022-04-11","hemoglobin_g_dL":11.8,"wbc_k_uL":9.8,"platelets_k_uL":274,"creatinine_mg_dL":0.9,"alt_U_L":35},{"date":"2022-12-09","hemoglobin_g_dL":12.5,"wbc_k_uL":8.3,"platelets_k_uL":307,"creatinine_mg_dL":0.85,"alt_U_L":56},{"date":"2024-07-23","hemoglobin_g_dL":12.0,"wbc_k_uL":6.8,"platelets_k_uL":140,"creatinine_mg_dL":0.84,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_045","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":59,"sex":"female","bmi":21.7,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-03-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-82},"pfs_months":25.82},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.3,"censored":false},"longitudinal_labs":[{"date":"2024-02-28","hemoglobin_g_dL":15.0,"wbc_k_uL":6.3,"platelets_k_uL":210,"creatinine_mg_dL":0.67,"alt_U_L":59},{"date":"2024-09-13","hemoglobin_g_dL":10.8,"wbc_k_uL":3.9,"platelets_k_uL":262,"creatinine_mg_dL":1.51,"alt_U_L":90},{"date":"2026-05-30","hemoglobin_g_dL":11.1,"wbc_k_uL":4.7,"platelets_k_uL":132,"creatinine_mg_dL":1.75,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_046","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":60,"sex":"male","bmi":36.8,"smoking_pack_years":35,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-03-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-61},"pfs_months":14.65},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.3,"censored":false},"longitudinal_labs":[{"date":"2020-01-28","hemoglobin_g_dL":11.7,"wbc_k_uL":7.7,"platelets_k_uL":246,"creatinine_mg_dL":0.79,"alt_U_L":22},{"date":"2020-08-30","hemoglobin_g_dL":12.5,"wbc_k_uL":8.2,"platelets_k_uL":137,"creatinine_mg_dL":1.27,"alt_U_L":110},{"date":"2021-05-27","hemoglobin_g_dL":12.1,"wbc_k_uL":7.9,"platelets_k_uL":242,"creatinine_mg_dL":1.15,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":58,"sex":"female","bmi":20.7,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2021-09-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-75},"pfs_months":24.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":false},"longitudinal_labs":[{"date":"2021-08-17","hemoglobin_g_dL":14.0,"wbc_k_uL":7.3,"platelets_k_uL":445,"creatinine_mg_dL":1.24,"alt_U_L":66},{"date":"2022-03-18","hemoglobin_g_dL":10.8,"wbc_k_uL":7.5,"platelets_k_uL":216,"creatinine_mg_dL":1.59,"alt_U_L":30},{"date":"2023-11-26","hemoglobin_g_dL":10.7,"wbc_k_uL":6.1,"platelets_k_uL":253,"creatinine_mg_dL":1.91,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":78,"sex":"female","bmi":24.9,"smoking_pack_years":21,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-03-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-61},"pfs_months":13.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.8,"censored":false},"longitudinal_labs":[{"date":"2024-03-09","hemoglobin_g_dL":13.2,"wbc_k_uL":10.2,"platelets_k_uL":298,"creatinine_mg_dL":0.92,"alt_U_L":26},{"date":"2024-09-27","hemoglobin_g_dL":10.4,"wbc_k_uL":8.7,"platelets_k_uL":249,"creatinine_mg_dL":1.33,"alt_U_L":69},{"date":"2025-07-04","hemoglobin_g_dL":10.0,"wbc_k_uL":7.7,"platelets_k_uL":286,"creatinine_mg_dL":1.26,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":66,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-80},"pfs_months":25.72},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":49.1,"censored":false},"longitudinal_labs":[{"date":"2022-07-11","hemoglobin_g_dL":13.7,"wbc_k_uL":6.4,"platelets_k_uL":295,"creatinine_mg_dL":1.03,"alt_U_L":76},{"date":"2023-02-08","hemoglobin_g_dL":12.5,"wbc_k_uL":5.4,"platelets_k_uL":250,"creatinine_mg_dL":1.02,"alt_U_L":99},{"date":"2024-10-27","hemoglobin_g_dL":11.0,"wbc_k_uL":7.3,"platelets_k_uL":233,"creatinine_mg_dL":1.99,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":60,"sex":"female","bmi":20.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-37},"pfs_months":24.84},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.4,"censored":true},"longitudinal_labs":[{"date":"2022-04-20","hemoglobin_g_dL":13.7,"wbc_k_uL":7.1,"platelets_k_uL":373,"creatinine_mg_dL":0.9,"alt_U_L":46},{"date":"2022-11-05","hemoglobin_g_dL":13.2,"wbc_k_uL":5.7,"platelets_k_uL":189,"creatinine_mg_dL":1.06,"alt_U_L":49},{"date":"2024-06-13","hemoglobin_g_dL":10.4,"wbc_k_uL":7.3,"platelets_k_uL":216,"creatinine_mg_dL":0.94,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":66,"sex":"female","bmi":23.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-76},"pfs_months":24.41},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.9,"censored":false},"longitudinal_labs":[{"date":"2022-03-28","hemoglobin_g_dL":13.3,"wbc_k_uL":4.8,"platelets_k_uL":182,"creatinine_mg_dL":1.17,"alt_U_L":62},{"date":"2022-10-30","hemoglobin_g_dL":11.3,"wbc_k_uL":6.4,"platelets_k_uL":251,"creatinine_mg_dL":1.22,"alt_U_L":88},{"date":"2024-06-06","hemoglobin_g_dL":11.7,"wbc_k_uL":3.3,"platelets_k_uL":229,"creatinine_mg_dL":1.92,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":51,"sex":"male","bmi":26.7,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-05-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-56},"pfs_months":41.1},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":60.1,"censored":true},"longitudinal_labs":[{"date":"2023-04-27","hemoglobin_g_dL":14.6,"wbc_k_uL":10.5,"platelets_k_uL":330,"creatinine_mg_dL":0.8,"alt_U_L":31},{"date":"2023-11-10","hemoglobin_g_dL":12.0,"wbc_k_uL":6.6,"platelets_k_uL":292,"creatinine_mg_dL":1.15,"alt_U_L":32},{"date":"2026-11-20","hemoglobin_g_dL":9.8,"wbc_k_uL":4.7,"platelets_k_uL":149,"creatinine_mg_dL":1.38,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":72,"sex":"female","bmi":24.1,"smoking_pack_years":37,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-76},"pfs_months":30.92},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.9,"censored":false},"longitudinal_labs":[{"date":"2025-01-02","hemoglobin_g_dL":12.6,"wbc_k_uL":5.5,"platelets_k_uL":176,"creatinine_mg_dL":1.18,"alt_U_L":29},{"date":"2025-07-15","hemoglobin_g_dL":10.4,"wbc_k_uL":6.5,"platelets_k_uL":171,"creatinine_mg_dL":1.2,"alt_U_L":120},{"date":"2027-10-04","hemoglobin_g_dL":11.1,"wbc_k_uL":4.9,"platelets_k_uL":191,"creatinine_mg_dL":1.79,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_054","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":87,"sex":"female","bmi":22.2,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-07-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-64},"pfs_months":20.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":28.3,"censored":true},"longitudinal_labs":[{"date":"2020-05-27","hemoglobin_g_dL":15.0,"wbc_k_uL":6.3,"platelets_k_uL":258,"creatinine_mg_dL":0.96,"alt_U_L":73},{"date":"2021-01-06","hemoglobin_g_dL":11.9,"wbc_k_uL":7.8,"platelets_k_uL":272,"creatinine_mg_dL":0.96,"alt_U_L":116},{"date":"2022-05-17","hemoglobin_g_dL":9.8,"wbc_k_uL":4.0,"platelets_k_uL":333,"creatinine_mg_dL":0.83,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":83,"sex":"female","bmi":36.8,"smoking_pack_years":53,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-04-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-30},"pfs_months":27.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":false},"longitudinal_labs":[{"date":"2022-04-09","hemoglobin_g_dL":13.2,"wbc_k_uL":7.2,"platelets_k_uL":396,"creatinine_mg_dL":0.89,"alt_U_L":50},{"date":"2022-10-20","hemoglobin_g_dL":11.1,"wbc_k_uL":7.5,"platelets_k_uL":251,"creatinine_mg_dL":1.06,"alt_U_L":41},{"date":"2024-09-04","hemoglobin_g_dL":12.6,"wbc_k_uL":5.2,"platelets_k_uL":317,"creatinine_mg_dL":1.39,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":71,"sex":"female","bmi":34.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-03-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-80},"pfs_months":23.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.9,"censored":false},"longitudinal_labs":[{"date":"2025-12-22","hemoglobin_g_dL":15.4,"wbc_k_uL":8.2,"platelets_k_uL":161,"creatinine_mg_dL":1.07,"alt_U_L":58},{"date":"2026-08-29","hemoglobin_g_dL":12.5,"wbc_k_uL":7.6,"platelets_k_uL":316,"creatinine_mg_dL":1.4,"alt_U_L":54},{"date":"2028-04-05","hemoglobin_g_dL":11.1,"wbc_k_uL":4.5,"platelets_k_uL":280,"creatinine_mg_dL":1.79,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":66,"sex":"male","bmi":36.1,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-02-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-66},"pfs_months":35.88},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":64.5,"censored":false},"longitudinal_labs":[{"date":"2023-02-04","hemoglobin_g_dL":11.9,"wbc_k_uL":8.9,"platelets_k_uL":347,"creatinine_mg_dL":1.15,"alt_U_L":18},{"date":"2023-08-19","hemoglobin_g_dL":11.8,"wbc_k_uL":7.5,"platelets_k_uL":192,"creatinine_mg_dL":0.8,"alt_U_L":45},{"date":"2026-04-10","hemoglobin_g_dL":12.6,"wbc_k_uL":3.3,"platelets_k_uL":195,"creatinine_mg_dL":0.91,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":73,"sex":"male","bmi":25.3,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-01-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-77},"pfs_months":4.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":11.9,"censored":false},"longitudinal_labs":[{"date":"2025-11-27","hemoglobin_g_dL":15.5,"wbc_k_uL":9.8,"platelets_k_uL":189,"creatinine_mg_dL":1.23,"alt_U_L":53},{"date":"2026-07-08","hemoglobin_g_dL":12.6,"wbc_k_uL":8.2,"platelets_k_uL":365,"creatinine_mg_dL":0.75,"alt_U_L":83},{"date":"2026-06-18","hemoglobin_g_dL":12.4,"wbc_k_uL":4.6,"platelets_k_uL":301,"creatinine_mg_dL":1.22,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":57,"sex":"male","bmi":30.1,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-63},"pfs_months":7.69},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.0,"censored":false},"longitudinal_labs":[{"date":"2021-06-17","hemoglobin_g_dL":13.9,"wbc_k_uL":8.5,"platelets_k_uL":276,"creatinine_mg_dL":1.05,"alt_U_L":64},{"date":"2022-01-02","hemoglobin_g_dL":12.4,"wbc_k_uL":6.9,"platelets_k_uL":192,"creatinine_mg_dL":0.76,"alt_U_L":43},{"date":"2022-04-12","hemoglobin_g_dL":10.1,"wbc_k_uL":7.9,"platelets_k_uL":141,"creatinine_mg_dL":1.25,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":63,"sex":"female","bmi":20.7,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-01-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-84},"pfs_months":7.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.9,"censored":false},"longitudinal_labs":[{"date":"2025-11-11","hemoglobin_g_dL":11.6,"wbc_k_uL":8.0,"platelets_k_uL":302,"creatinine_mg_dL":1.1,"alt_U_L":43},{"date":"2026-07-01","hemoglobin_g_dL":11.2,"wbc_k_uL":8.4,"platelets_k_uL":324,"creatinine_mg_dL":1.1,"alt_U_L":76},{"date":"2026-10-13","hemoglobin_g_dL":11.1,"wbc_k_uL":3.3,"platelets_k_uL":152,"creatinine_mg_dL":1.08,"alt_U_L":108}]}
{"patient_id":"ANODE_SYNTH_2025_061","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":53,"sex":"female","bmi":23.5,"smoking_pack_years":75,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-02-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-56},"pfs_months":13.6},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2021-01-25","hemoglobin_g_dL":14.5,"wbc_k_uL":10.8,"platelets_k_uL":318,"creatinine_mg_dL":0.98,"alt_U_L":76},{"date":"2021-08-13","hemoglobin_g_dL":10.4,"wbc_k_uL":5.3,"platelets_k_uL":139,"creatinine_mg_dL":1.54,"alt_U_L":85},{"date":"2022-05-16","hemoglobin_g_dL":10.1,"wbc_k_uL":3.2,"platelets_k_uL":157,"creatinine_mg_dL":1.11,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":67,"sex":"female","bmi":23.9,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-04-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-33},"pfs_months":37.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":61.3,"censored":false},"longitudinal_labs":[{"date":"2025-03-18","hemoglobin_g_dL":14.1,"wbc_k_uL":5.9,"platelets_k_uL":235,"creatinine_mg_dL":0.71,"alt_U_L":31},{"date":"2025-10-01","hemoglobin_g_dL":11.4,"wbc_k_uL":4.2,"platelets_k_uL":356,"creatinine_mg_dL":0.89,"alt_U_L":16},{"date":"2028-06-05","hemoglobin_g_dL":12.4,"wbc_k_uL":7.9,"platelets_k_uL":346,"creatinine_mg_dL":1.67,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":69,"sex":"male","bmi":32.8,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-06-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-67},"pfs_months":26.12},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":59.0,"censored":false},"longitudinal_labs":[{"date":"2023-04-14","hemoglobin_g_dL":14.6,"wbc_k_uL":6.2,"platelets_k_uL":387,"creatinine_mg_dL":1.1,"alt_U_L":80},{"date":"2023-12-08","hemoglobin_g_dL":11.5,"wbc_k_uL":5.7,"platelets_k_uL":264,"creatinine_mg_dL":1.31,"alt_U_L":26},{"date":"2025-09-22","hemoglobin_g_dL":12.5,"wbc_k_uL":7.8,"platelets_k_uL":350,"creatinine_mg_dL":1.51,"alt_U_L":125}]}
{"patient_id":"ANODE_SYNTH_2025_064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":49,"sex":"female","bmi":22.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-53},"pfs_months":15.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":23.8,"censored":true},"longitudinal_labs":[{"date":"2024-04-18","hemoglobin_g_dL":14.1,"wbc_k_uL":9.7,"platelets_k_uL":381,"creatinine_mg_dL":1.22,"alt_U_L":47},{"date":"2024-11-12","hemoglobin_g_dL":12.8,"wbc_k_uL":5.4,"platelets_k_uL":135,"creatinine_mg_dL":1.59,"alt_U_L":101},{"date":"2025-10-26","hemoglobin_g_dL":9.6,"wbc_k_uL":7.7,"platelets_k_uL":279,"creatinine_mg_dL":1.41,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":55,"sex":"female","bmi":25.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-85},"pfs_months":28.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":true},"longitudinal_labs":[{"date":"2020-05-09","hemoglobin_g_dL":12.4,"wbc_k_uL":8.5,"platelets_k_uL":361,"creatinine_mg_dL":1.06,"alt_U_L":50},{"date":"2021-01-09","hemoglobin_g_dL":10.2,"wbc_k_uL":7.2,"platelets_k_uL":231,"creatinine_mg_dL":1.24,"alt_U_L":37},{"date":"2023-01-18","hemoglobin_g_dL":12.2,"wbc_k_uL":7.2,"platelets_k_uL":261,"creatinine_mg_dL":1.03,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":84,"sex":"female","bmi":24.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-68},"pfs_months":31.51},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":false},"longitudinal_labs":[{"date":"2024-08-11","hemoglobin_g_dL":14.3,"wbc_k_uL":6.6,"platelets_k_uL":389,"creatinine_mg_dL":0.96,"alt_U_L":42},{"date":"2025-03-03","hemoglobin_g_dL":11.9,"wbc_k_uL":3.8,"platelets_k_uL":233,"creatinine_mg_dL":0.91,"alt_U_L":81},{"date":"2027-05-13","hemoglobin_g_dL":11.7,"wbc_k_uL":6.9,"platelets_k_uL":261,"creatinine_mg_dL":1.34,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":51,"sex":"female","bmi":20.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-07-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-53},"pfs_months":22.83},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.3,"censored":false},"longitudinal_labs":[{"date":"2021-06-04","hemoglobin_g_dL":13.9,"wbc_k_uL":7.5,"platelets_k_uL":373,"creatinine_mg_dL":0.86,"alt_U_L":36},{"date":"2022-01-05","hemoglobin_g_dL":11.5,"wbc_k_uL":7.7,"platelets_k_uL":224,"creatinine_mg_dL":1.2,"alt_U_L":78},{"date":"2023-07-14","hemoglobin_g_dL":12.2,"wbc_k_uL":7.9,"platelets_k_uL":237,"creatinine_mg_dL":1.63,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":55,"sex":"female","bmi":35.4,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-05-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-38},"pfs_months":37.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.7,"censored":false},"longitudinal_labs":[{"date":"2025-04-18","hemoglobin_g_dL":11.9,"wbc_k_uL":7.6,"platelets_k_uL":387,"creatinine_mg_dL":1.15,"alt_U_L":21},{"date":"2025-11-07","hemoglobin_g_dL":12.4,"wbc_k_uL":7.3,"platelets_k_uL":315,"creatinine_mg_dL":0.96,"alt_U_L":27},{"date":"2028-07-18","hemoglobin_g_dL":12.3,"wbc_k_uL":4.4,"platelets_k_uL":297,"creatinine_mg_dL":1.67,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":80,"sex":"female","bmi":18.9,"smoking_pack_years":54,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-74},"pfs_months":39.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.1,"censored":false},"longitudinal_labs":[{"date":"2023-03-04","hemoglobin_g_dL":12.5,"wbc_k_uL":6.1,"platelets_k_uL":362,"creatinine_mg_dL":1.05,"alt_U_L":72},{"date":"2023-10-23","hemoglobin_g_dL":10.5,"wbc_k_uL":6.0,"platelets_k_uL":380,"creatinine_mg_dL":1.59,"alt_U_L":56},{"date":"2026-10-02","hemoglobin_g_dL":9.8,"wbc_k_uL":5.5,"platelets_k_uL":147,"creatinine_mg_dL":1.21,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":67,"sex":"female","bmi":30.8,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-08-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-33},"pfs_months":37.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.1,"censored":false},"longitudinal_labs":[{"date":"2024-07-20","hemoglobin_g_dL":13.4,"wbc_k_uL":5.5,"platelets_k_uL":383,"creatinine_mg_dL":1.0,"alt_U_L":27},{"date":"2025-02-11","hemoglobin_g_dL":10.6,"wbc_k_uL":4.1,"platelets_k_uL":324,"creatinine_mg_dL":1.41,"alt_U_L":76},{"date":"2027-10-15","hemoglobin_g_dL":11.3,"wbc_k_uL":6.3,"platelets_k_uL":127,"creatinine_mg_dL":2.0,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":80,"sex":"female","bmi":22.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-44},"pfs_months":19.09},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.1,"censored":true},"longitudinal_labs":[{"date":"2021-11-17","hemoglobin_g_dL":13.3,"wbc_k_uL":8.7,"platelets_k_uL":377,"creatinine_mg_dL":0.99,"alt_U_L":75},{"date":"2022-06-23","hemoglobin_g_dL":13.6,"wbc_k_uL":8.1,"platelets_k_uL":263,"creatinine_mg_dL":0.8,"alt_U_L":34},{"date":"2023-09-23","hemoglobin_g_dL":11.0,"wbc_k_uL":7.5,"platelets_k_uL":181,"creatinine_mg_dL":0.91,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_072","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":76,"sex":"female","bmi":19.7,"smoking_pack_years":55,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-47},"pfs_months":21.16},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.4,"censored":true},"longitudinal_labs":[{"date":"2023-03-19","hemoglobin_g_dL":13.9,"wbc_k_uL":10.9,"platelets_k_uL":162,"creatinine_mg_dL":1.22,"alt_U_L":42},{"date":"2023-10-29","hemoglobin_g_dL":10.1,"wbc_k_uL":6.4,"platelets_k_uL":356,"creatinine_mg_dL":0.88,"alt_U_L":53},{"date":"2025-03-31","hemoglobin_g_dL":12.3,"wbc_k_uL":3.5,"platelets_k_uL":125,"creatinine_mg_dL":1.48,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":60,"sex":"female","bmi":31.6,"smoking_pack_years":45,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-05-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-81},"pfs_months":35.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":62.8,"censored":false},"longitudinal_labs":[{"date":"2022-03-27","hemoglobin_g_dL":12.3,"wbc_k_uL":8.8,"platelets_k_uL":256,"creatinine_mg_dL":1.18,"alt_U_L":55},{"date":"2022-11-22","hemoglobin_g_dL":10.6,"wbc_k_uL":6.5,"platelets_k_uL":293,"creatinine_mg_dL":1.02,"alt_U_L":62},{"date":"2025-06-01","hemoglobin_g_dL":10.3,"wbc_k_uL":5.4,"platelets_k_uL":310,"creatinine_mg_dL":1.86,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":79,"sex":"male","bmi":28.5,"smoking_pack_years":32,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-03-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-76},"pfs_months":11.33},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.5,"censored":false},"longitudinal_labs":[{"date":"2024-01-14","hemoglobin_g_dL":11.6,"wbc_k_uL":6.3,"platelets_k_uL":189,"creatinine_mg_dL":1.08,"alt_U_L":37},{"date":"2024-09-15","hemoglobin_g_dL":11.9,"wbc_k_uL":9.0,"platelets_k_uL":233,"creatinine_mg_dL":0.85,"alt_U_L":79},{"date":"2025-04-11","hemoglobin_g_dL":11.4,"wbc_k_uL":3.7,"platelets_k_uL":264,"creatinine_mg_dL":1.27,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_075","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":78,"sex":"female","bmi":35.6,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-06-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-38},"pfs_months":19.38},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.5,"censored":false},"longitudinal_labs":[{"date":"2021-05-15","hemoglobin_g_dL":12.7,"wbc_k_uL":10.8,"platelets_k_uL":332,"creatinine_mg_dL":1.18,"alt_U_L":11},{"date":"2021-12-01","hemoglobin_g_dL":11.4,"wbc_k_uL":6.0,"platelets_k_uL":225,"creatinine_mg_dL":1.24,"alt_U_L":106},{"date":"2023-03-11","hemoglobin_g_dL":11.6,"wbc_k_uL":5.3,"platelets_k_uL":247,"creatinine_mg_dL":1.3,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":78,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-44},"pfs_months":20.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":false},"longitudinal_labs":[{"date":"2024-09-21","hemoglobin_g_dL":14.4,"wbc_k_uL":4.6,"platelets_k_uL":321,"creatinine_mg_dL":0.63,"alt_U_L":61},{"date":"2025-04-23","hemoglobin_g_dL":12.2,"wbc_k_uL":8.8,"platelets_k_uL":343,"creatinine_mg_dL":0.92,"alt_U_L":67},{"date":"2026-07-12","hemoglobin_g_dL":10.5,"wbc_k_uL":3.4,"platelets_k_uL":314,"creatinine_mg_dL":1.43,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":55,"sex":"female","bmi":23.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-54},"pfs_months":29.44},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.7,"censored":true},"longitudinal_labs":[{"date":"2023-08-26","hemoglobin_g_dL":13.0,"wbc_k_uL":7.6,"platelets_k_uL":409,"creatinine_mg_dL":0.69,"alt_U_L":44},{"date":"2024-04-15","hemoglobin_g_dL":12.5,"wbc_k_uL":5.4,"platelets_k_uL":283,"creatinine_mg_dL":1.38,"alt_U_L":16},{"date":"2026-05-04","hemoglobin_g_dL":10.5,"wbc_k_uL":6.9,"platelets_k_uL":265,"creatinine_mg_dL":1.84,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":60,"sex":"female","bmi":25.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-56},"pfs_months":19.84},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.7,"censored":false},"longitudinal_labs":[{"date":"2023-11-05","hemoglobin_g_dL":12.9,"wbc_k_uL":8.6,"platelets_k_uL":393,"creatinine_mg_dL":0.71,"alt_U_L":45},{"date":"2024-05-27","hemoglobin_g_dL":13.0,"wbc_k_uL":4.6,"platelets_k_uL":313,"creatinine_mg_dL":1.26,"alt_U_L":60},{"date":"2025-08-25","hemoglobin_g_dL":10.0,"wbc_k_uL":4.5,"platelets_k_uL":216,"creatinine_mg_dL":1.83,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":66,"sex":"male","bmi":29.7,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-02-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-46},"pfs_months":36.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":67.0,"censored":false},"longitudinal_labs":[{"date":"2022-12-22","hemoglobin_g_dL":12.0,"wbc_k_uL":7.2,"platelets_k_uL":335,"creatinine_mg_dL":0.79,"alt_U_L":14},{"date":"2023-08-11","hemoglobin_g_dL":11.0,"wbc_k_uL":4.3,"platelets_k_uL":166,"creatinine_mg_dL":1.06,"alt_U_L":29},{"date":"2026-03-07","hemoglobin_g_dL":10.0,"wbc_k_uL":7.7,"platelets_k_uL":334,"creatinine_mg_dL":1.92,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":87,"sex":"male","bmi":27.6,"smoking_pack_years":12,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-03-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-41},"pfs_months":30.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":50.0,"censored":true},"longitudinal_labs":[{"date":"2025-02-10","hemoglobin_g_dL":13.2,"wbc_k_uL":10.8,"platelets_k_uL":278,"creatinine_mg_dL":0.66,"alt_U_L":18},{"date":"2025-09-20","hemoglobin_g_dL":13.6,"wbc_k_uL":4.3,"platelets_k_uL":189,"creatinine_mg_dL":1.23,"alt_U_L":83},{"date":"2027-11-23","hemoglobin_g_dL":12.1,"wbc_k_uL":3.2,"platelets_k_uL":178,"creatinine_mg_dL":1.3,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":65,"sex":"female","bmi":20.3,"smoking_pack_years":68,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-07-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-80},"pfs_months":36.44},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.3,"censored":false},"longitudinal_labs":[{"date":"2022-05-08","hemoglobin_g_dL":11.9,"wbc_k_uL":8.4,"platelets_k_uL":216,"creatinine_mg_dL":1.13,"alt_U_L":51},{"date":"2023-01-08","hemoglobin_g_dL":13.3,"wbc_k_uL":4.2,"platelets_k_uL":209,"creatinine_mg_dL":1.47,"alt_U_L":46},{"date":"2025-08-07","hemoglobin_g_dL":11.1,"wbc_k_uL":6.8,"platelets_k_uL":233,"creatinine_mg_dL":1.28,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_082","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":57,"sex":"male","bmi":34.7,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-41},"pfs_months":18.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":false},"longitudinal_labs":[{"date":"2021-07-02","hemoglobin_g_dL":12.4,"wbc_k_uL":5.2,"platelets_k_uL":340,"creatinine_mg_dL":1.01,"alt_U_L":37},{"date":"2022-02-14","hemoglobin_g_dL":10.9,"wbc_k_uL":8.0,"platelets_k_uL":170,"creatinine_mg_dL":1.11,"alt_U_L":56},{"date":"2023-05-06","hemoglobin_g_dL":10.5,"wbc_k_uL":7.7,"platelets_k_uL":107,"creatinine_mg_dL":1.36,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":83,"sex":"female","bmi":24.3,"smoking_pack_years":65,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-10-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-83},"pfs_months":43.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-06-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.4,"censored":false},"longitudinal_labs":[{"date":"2025-09-20","hemoglobin_g_dL":12.2,"wbc_k_uL":5.7,"platelets_k_uL":388,"creatinine_mg_dL":1.16,"alt_U_L":71},{"date":"2026-04-11","hemoglobin_g_dL":11.0,"wbc_k_uL":6.2,"platelets_k_uL":244,"creatinine_mg_dL":1.55,"alt_U_L":50},{"date":"2029-06-13","hemoglobin_g_dL":9.5,"wbc_k_uL":3.8,"platelets_k_uL":162,"creatinine_mg_dL":1.19,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":68,"sex":"male","bmi":19.3,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-51},"pfs_months":35.22},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":61.2,"censored":false},"longitudinal_labs":[{"date":"2020-12-28","hemoglobin_g_dL":14.7,"wbc_k_uL":10.3,"platelets_k_uL":245,"creatinine_mg_dL":1.05,"alt_U_L":40},{"date":"2021-09-04","hemoglobin_g_dL":12.2,"wbc_k_uL":7.9,"platelets_k_uL":278,"creatinine_mg_dL":0.9,"alt_U_L":69},{"date":"2024-03-02","hemoglobin_g_dL":9.8,"wbc_k_uL":3.8,"platelets_k_uL":261,"creatinine_mg_dL":0.81,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":62,"sex":"female","bmi":28.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-47},"pfs_months":26.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.8,"censored":false},"longitudinal_labs":[{"date":"2023-02-08","hemoglobin_g_dL":13.0,"wbc_k_uL":8.9,"platelets_k_uL":162,"creatinine_mg_dL":0.65,"alt_U_L":25},{"date":"2023-09-12","hemoglobin_g_dL":11.2,"wbc_k_uL":5.4,"platelets_k_uL":277,"creatinine_mg_dL":0.83,"alt_U_L":89},{"date":"2025-07-01","hemoglobin_g_dL":10.7,"wbc_k_uL":3.1,"platelets_k_uL":138,"creatinine_mg_dL":1.82,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_086","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":84,"sex":"male","bmi":21.8,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-52},"pfs_months":21.55},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":27.7,"censored":false},"longitudinal_labs":[{"date":"2023-05-08","hemoglobin_g_dL":12.3,"wbc_k_uL":8.6,"platelets_k_uL":402,"creatinine_mg_dL":0.66,"alt_U_L":65},{"date":"2023-11-29","hemoglobin_g_dL":12.7,"wbc_k_uL":4.9,"platelets_k_uL":334,"creatinine_mg_dL":0.85,"alt_U_L":105},{"date":"2025-03-31","hemoglobin_g_dL":12.3,"wbc_k_uL":7.6,"platelets_k_uL":123,"creatinine_mg_dL":1.81,"alt_U_L":28}]}
{"patient_id":"ANODE_SYNTH_2025_087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":66,"sex":"female","bmi":25.3,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-46},"pfs_months":31.38},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.9,"censored":false},"longitudinal_labs":[{"date":"2022-10-26","hemoglobin_g_dL":11.5,"wbc_k_uL":6.5,"platelets_k_uL":361,"creatinine_mg_dL":1.09,"alt_U_L":35},{"date":"2023-05-31","hemoglobin_g_dL":13.2,"wbc_k_uL":7.8,"platelets_k_uL":332,"creatinine_mg_dL":0.96,"alt_U_L":65},{"date":"2025-08-01","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":192,"creatinine_mg_dL":1.97,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":67,"sex":"female","bmi":18.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-33},"pfs_months":28.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.1,"censored":true},"longitudinal_labs":[{"date":"2023-12-01","hemoglobin_g_dL":12.5,"wbc_k_uL":6.7,"platelets_k_uL":328,"creatinine_mg_dL":0.79,"alt_U_L":53},{"date":"2024-07-01","hemoglobin_g_dL":12.3,"wbc_k_uL":6.7,"platelets_k_uL":300,"creatinine_mg_dL":0.87,"alt_U_L":43},{"date":"2026-06-18","hemoglobin_g_dL":11.7,"wbc_k_uL":6.9,"platelets_k_uL":305,"creatinine_mg_dL":1.19,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":62,"sex":"male","bmi":30.8,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-82},"pfs_months":17.38},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":25.6,"censored":false},"longitudinal_labs":[{"date":"2023-07-07","hemoglobin_g_dL":13.3,"wbc_k_uL":7.1,"platelets_k_uL":403,"creatinine_mg_dL":0.78,"alt_U_L":16},{"date":"2024-03-13","hemoglobin_g_dL":12.1,"wbc_k_uL":4.5,"platelets_k_uL":232,"creatinine_mg_dL":1.23,"alt_U_L":25},{"date":"2025-04-24","hemoglobin_g_dL":12.4,"wbc_k_uL":4.1,"platelets_k_uL":159,"creatinine_mg_dL":1.04,"alt_U_L":31}]}
{"patient_id":"ANODE_SYNTH_2025_090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":62,"sex":"female","bmi":29.8,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-10-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-64},"pfs_months":36.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":60.8,"censored":false},"longitudinal_labs":[{"date":"2020-09-12","hemoglobin_g_dL":12.8,"wbc_k_uL":9.1,"platelets_k_uL":241,"creatinine_mg_dL":1.04,"alt_U_L":66},{"date":"2021-04-15","hemoglobin_g_dL":10.1,"wbc_k_uL":4.9,"platelets_k_uL":345,"creatinine_mg_dL":1.46,"alt_U_L":92},{"date":"2024-01-06","hemoglobin_g_dL":10.8,"wbc_k_uL":6.9,"platelets_k_uL":261,"creatinine_mg_dL":1.32,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":58,"sex":"male","bmi":30.9,"smoking_pack_years":31,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-35},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":12.1,"censored":false},"longitudinal_labs":[{"date":"2025-05-11","hemoglobin_g_dL":12.0,"wbc_k_uL":4.5,"platelets_k_uL":196,"creatinine_mg_dL":1.21,"alt_U_L":22},{"date":"2025-12-15","hemoglobin_g_dL":10.1,"wbc_k_uL":5.2,"platelets_k_uL":292,"creatinine_mg_dL":1.09,"alt_U_L":69},{"date":"2025-10-20","hemoglobin_g_dL":10.7,"wbc_k_uL":5.4,"platelets_k_uL":261,"creatinine_mg_dL":1.03,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":48,"sex":"female","bmi":29.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-02-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-81},"pfs_months":12.19},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.3,"censored":false},"longitudinal_labs":[{"date":"2023-12-02","hemoglobin_g_dL":12.7,"wbc_k_uL":6.1,"platelets_k_uL":335,"creatinine_mg_dL":1.25,"alt_U_L":56},{"date":"2024-08-08","hemoglobin_g_dL":12.7,"wbc_k_uL":5.1,"platelets_k_uL":299,"creatinine_mg_dL":1.13,"alt_U_L":64},{"date":"2025-04-10","hemoglobin_g_dL":11.6,"wbc_k_uL":7.4,"platelets_k_uL":162,"creatinine_mg_dL":1.57,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":59,"sex":"female","bmi":37.3,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-72},"pfs_months":5.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":11.8,"censored":false},"longitudinal_labs":[{"date":"2025-06-19","hemoglobin_g_dL":11.5,"wbc_k_uL":8.8,"platelets_k_uL":448,"creatinine_mg_dL":0.77,"alt_U_L":44},{"date":"2026-01-06","hemoglobin_g_dL":10.3,"wbc_k_uL":4.0,"platelets_k_uL":358,"creatinine_mg_dL":1.28,"alt_U_L":89},{"date":"2026-01-25","hemoglobin_g_dL":11.7,"wbc_k_uL":7.6,"platelets_k_uL":274,"creatinine_mg_dL":1.63,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":52,"sex":"male","bmi":35.8,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-56},"pfs_months":26.68},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.7,"censored":false},"longitudinal_labs":[{"date":"2025-04-17","hemoglobin_g_dL":12.6,"wbc_k_uL":8.8,"platelets_k_uL":198,"creatinine_mg_dL":0.86,"alt_U_L":44},{"date":"2025-12-17","hemoglobin_g_dL":12.4,"wbc_k_uL":4.7,"platelets_k_uL":187,"creatinine_mg_dL":1.21,"alt_U_L":64},{"date":"2027-10-26","hemoglobin_g_dL":12.7,"wbc_k_uL":3.2,"platelets_k_uL":177,"creatinine_mg_dL":1.84,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":61,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-63},"pfs_months":29.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.2,"censored":false},"longitudinal_labs":[{"date":"2023-01-25","hemoglobin_g_dL":14.4,"wbc_k_uL":6.8,"platelets_k_uL":172,"creatinine_mg_dL":0.97,"alt_U_L":70},{"date":"2023-09-11","hemoglobin_g_dL":13.2,"wbc_k_uL":4.8,"platelets_k_uL":158,"creatinine_mg_dL":0.98,"alt_U_L":32},{"date":"2025-10-14","hemoglobin_g_dL":12.3,"wbc_k_uL":4.6,"platelets_k_uL":256,"creatinine_mg_dL":1.91,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":64,"sex":"female","bmi":26.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-51},"pfs_months":25.69},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.4,"censored":true},"longitudinal_labs":[{"date":"2023-09-06","hemoglobin_g_dL":14.5,"wbc_k_uL":5.1,"platelets_k_uL":188,"creatinine_mg_dL":0.62,"alt_U_L":65},{"date":"2024-04-10","hemoglobin_g_dL":10.8,"wbc_k_uL":3.9,"platelets_k_uL":248,"creatinine_mg_dL":1.03,"alt_U_L":112},{"date":"2026-01-21","hemoglobin_g_dL":10.7,"wbc_k_uL":5.9,"platelets_k_uL":298,"creatinine_mg_dL":1.5,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_097","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":77,"sex":"female","bmi":27.1,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-52},"pfs_months":21.03},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.0,"censored":false},"longitudinal_labs":[{"date":"2024-07-18","hemoglobin_g_dL":14.0,"wbc_k_uL":10.5,"platelets_k_uL":356,"creatinine_mg_dL":0.87,"alt_U_L":78},{"date":"2025-03-04","hemoglobin_g_dL":12.7,"wbc_k_uL":5.7,"platelets_k_uL":293,"creatinine_mg_dL":1.1,"alt_U_L":69},{"date":"2026-06-14","hemoglobin_g_dL":10.3,"wbc_k_uL":5.7,"platelets_k_uL":174,"creatinine_mg_dL":1.07,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":56,"sex":"female","bmi":31.6,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-43},"pfs_months":43.89},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":75.6,"censored":false},"longitudinal_labs":[{"date":"2022-07-06","hemoglobin_g_dL":15.3,"wbc_k_uL":5.2,"platelets_k_uL":307,"creatinine_mg_dL":1.26,"alt_U_L":68},{"date":"2023-02-14","hemoglobin_g_dL":12.3,"wbc_k_uL":8.6,"platelets_k_uL":296,"creatinine_mg_dL":0.74,"alt_U_L":81},{"date":"2026-04-25","hemoglobin_g_dL":10.5,"wbc_k_uL":7.0,"platelets_k_uL":237,"creatinine_mg_dL":1.97,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":57,"sex":"female","bmi":30.3,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-36},"pfs_months":40.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":60.3,"censored":false},"longitudinal_labs":[{"date":"2022-11-07","hemoglobin_g_dL":15.2,"wbc_k_uL":7.2,"platelets_k_uL":243,"creatinine_mg_dL":1.0,"alt_U_L":70},{"date":"2023-06-02","hemoglobin_g_dL":11.8,"wbc_k_uL":6.7,"platelets_k_uL":320,"creatinine_mg_dL":1.25,"alt_U_L":28},{"date":"2026-05-04","hemoglobin_g_dL":12.5,"wbc_k_uL":5.7,"platelets_k_uL":208,"creatinine_mg_dL":0.82,"alt_U_L":99}]}
{"patient_id":"ANODE_SYNTH_2025_100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":52,"sex":"male","bmi":34.1,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-51},"pfs_months":26.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":53.4,"censored":false},"longitudinal_labs":[{"date":"2020-12-08","hemoglobin_g_dL":14.5,"wbc_k_uL":10.2,"platelets_k_uL":428,"creatinine_mg_dL":0.66,"alt_U_L":43},{"date":"2021-06-26","hemoglobin_g_dL":13.3,"wbc_k_uL":9.0,"platelets_k_uL":180,"creatinine_mg_dL":1.14,"alt_U_L":32},{"date":"2023-04-06","hemoglobin_g_dL":12.6,"wbc_k_uL":3.1,"platelets_k_uL":343,"creatinine_mg_dL":1.61,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":88,"sex":"female","bmi":34.3,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-04-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-60},"pfs_months":16.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.0,"censored":false},"longitudinal_labs":[{"date":"2021-02-10","hemoglobin_g_dL":14.3,"wbc_k_uL":7.4,"platelets_k_uL":235,"creatinine_mg_dL":1.14,"alt_U_L":44},{"date":"2021-10-03","hemoglobin_g_dL":12.0,"wbc_k_uL":5.9,"platelets_k_uL":175,"creatinine_mg_dL":1.07,"alt_U_L":46},{"date":"2022-08-21","hemoglobin_g_dL":10.6,"wbc_k_uL":4.9,"platelets_k_uL":202,"creatinine_mg_dL":1.77,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":59,"sex":"female","bmi":22.3,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-70},"pfs_months":7.43},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":18.4,"censored":false},"longitudinal_labs":[{"date":"2021-08-08","hemoglobin_g_dL":14.4,"wbc_k_uL":4.7,"platelets_k_uL":314,"creatinine_mg_dL":1.23,"alt_U_L":45},{"date":"2022-03-18","hemoglobin_g_dL":12.3,"wbc_k_uL":3.9,"platelets_k_uL":268,"creatinine_mg_dL":0.71,"alt_U_L":48},{"date":"2022-06-14","hemoglobin_g_dL":11.8,"wbc_k_uL":4.9,"platelets_k_uL":182,"creatinine_mg_dL":1.9,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":64,"sex":"female","bmi":37.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-69},"pfs_months":23.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.6,"censored":false},"longitudinal_labs":[{"date":"2025-12-01","hemoglobin_g_dL":12.3,"wbc_k_uL":10.5,"platelets_k_uL":250,"creatinine_mg_dL":0.99,"alt_U_L":68},{"date":"2026-06-25","hemoglobin_g_dL":13.2,"wbc_k_uL":8.2,"platelets_k_uL":323,"creatinine_mg_dL":1.26,"alt_U_L":113},{"date":"2028-01-12","hemoglobin_g_dL":12.8,"wbc_k_uL":7.3,"platelets_k_uL":333,"creatinine_mg_dL":0.94,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_104","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":57,"sex":"male","bmi":26.5,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-75},"pfs_months":23.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.8,"censored":false},"longitudinal_labs":[{"date":"2023-04-27","hemoglobin_g_dL":13.7,"wbc_k_uL":9.7,"platelets_k_uL":176,"creatinine_mg_dL":1.21,"alt_U_L":80},{"date":"2023-12-30","hemoglobin_g_dL":11.3,"wbc_k_uL":6.2,"platelets_k_uL":293,"creatinine_mg_dL":0.79,"alt_U_L":111},{"date":"2025-07-21","hemoglobin_g_dL":11.3,"wbc_k_uL":3.8,"platelets_k_uL":156,"creatinine_mg_dL":1.87,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":83,"sex":"female","bmi":19.1,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-10-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-37},"pfs_months":44.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-09-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":61.0,"censored":true},"longitudinal_labs":[{"date":"2025-09-23","hemoglobin_g_dL":14.2,"wbc_k_uL":7.3,"platelets_k_uL":436,"creatinine_mg_dL":1.04,"alt_U_L":15},{"date":"2026-04-28","hemoglobin_g_dL":11.8,"wbc_k_uL":4.1,"platelets_k_uL":266,"creatinine_mg_dL":1.55,"alt_U_L":57},{"date":"2029-09-13","hemoglobin_g_dL":10.3,"wbc_k_uL":6.0,"platelets_k_uL":186,"creatinine_mg_dL":1.46,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":86,"sex":"female","bmi":30.9,"smoking_pack_years":76,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-02-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-37},"pfs_months":49.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":72.0,"censored":true},"longitudinal_labs":[{"date":"2024-01-22","hemoglobin_g_dL":14.1,"wbc_k_uL":7.0,"platelets_k_uL":226,"creatinine_mg_dL":0.69,"alt_U_L":79},{"date":"2024-08-21","hemoglobin_g_dL":12.5,"wbc_k_uL":8.0,"platelets_k_uL":226,"creatinine_mg_dL":1.17,"alt_U_L":108},{"date":"2028-04-23","hemoglobin_g_dL":9.5,"wbc_k_uL":3.4,"platelets_k_uL":202,"creatinine_mg_dL":1.34,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":56,"sex":"male","bmi":32.6,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-10-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-55},"pfs_months":11.66},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":22.5,"censored":false},"longitudinal_labs":[{"date":"2023-08-09","hemoglobin_g_dL":13.3,"wbc_k_uL":6.1,"platelets_k_uL":185,"creatinine_mg_dL":1.2,"alt_U_L":23},{"date":"2024-04-13","hemoglobin_g_dL":11.0,"wbc_k_uL":6.3,"platelets_k_uL":230,"creatinine_mg_dL":1.52,"alt_U_L":105},{"date":"2024-12-03","hemoglobin_g_dL":10.4,"wbc_k_uL":7.4,"platelets_k_uL":115,"creatinine_mg_dL":1.91,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":69,"sex":"female","bmi":26.0,"smoking_pack_years":65,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-12-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-53},"pfs_months":8.18},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.4,"censored":false},"longitudinal_labs":[{"date":"2020-10-24","hemoglobin_g_dL":15.4,"wbc_k_uL":5.3,"platelets_k_uL":263,"creatinine_mg_dL":1.19,"alt_U_L":64},{"date":"2021-06-01","hemoglobin_g_dL":13.5,"wbc_k_uL":6.2,"platelets_k_uL":316,"creatinine_mg_dL":1.43,"alt_U_L":71},{"date":"2021-10-03","hemoglobin_g_dL":11.0,"wbc_k_uL":4.6,"platelets_k_uL":242,"creatinine_mg_dL":1.48,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_109","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":66,"sex":"male","bmi":33.1,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-12-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-48},"pfs_months":17.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.9,"censored":false},"longitudinal_labs":[{"date":"2022-10-25","hemoglobin_g_dL":13.1,"wbc_k_uL":9.6,"platelets_k_uL":326,"creatinine_mg_dL":1.15,"alt_U_L":64},{"date":"2023-06-19","hemoglobin_g_dL":12.1,"wbc_k_uL":6.1,"platelets_k_uL":307,"creatinine_mg_dL":1.38,"alt_U_L":80},{"date":"2024-06-23","hemoglobin_g_dL":12.1,"wbc_k_uL":7.8,"platelets_k_uL":344,"creatinine_mg_dL":1.43,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":62,"sex":"female","bmi":37.3,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-65},"pfs_months":32.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-10","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":49.1,"censored":false},"longitudinal_labs":[{"date":"2025-03-24","hemoglobin_g_dL":14.6,"wbc_k_uL":10.0,"platelets_k_uL":309,"creatinine_mg_dL":1.0,"alt_U_L":34},{"date":"2025-11-01","hemoglobin_g_dL":12.4,"wbc_k_uL":8.2,"platelets_k_uL":311,"creatinine_mg_dL":1.6,"alt_U_L":64},{"date":"2028-02-10","hemoglobin_g_dL":9.9,"wbc_k_uL":7.4,"platelets_k_uL":288,"creatinine_mg_dL":1.89,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":63,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-53},"pfs_months":25.92},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":51.0,"censored":false},"longitudinal_labs":[{"date":"2023-09-15","hemoglobin_g_dL":15.1,"wbc_k_uL":10.1,"platelets_k_uL":177,"creatinine_mg_dL":0.64,"alt_U_L":45},{"date":"2024-04-02","hemoglobin_g_dL":12.5,"wbc_k_uL":6.3,"platelets_k_uL":208,"creatinine_mg_dL":1.11,"alt_U_L":64},{"date":"2026-01-19","hemoglobin_g_dL":11.6,"wbc_k_uL":7.1,"platelets_k_uL":104,"creatinine_mg_dL":1.35,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":72,"sex":"female","bmi":30.5,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-02-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-85},"pfs_months":43.47},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.3,"censored":true},"longitudinal_labs":[{"date":"2022-01-13","hemoglobin_g_dL":12.5,"wbc_k_uL":9.8,"platelets_k_uL":288,"creatinine_mg_dL":1.2,"alt_U_L":31},{"date":"2022-08-05","hemoglobin_g_dL":10.8,"wbc_k_uL":8.3,"platelets_k_uL":203,"creatinine_mg_dL":1.01,"alt_U_L":50},{"date":"2025-10-20","hemoglobin_g_dL":11.1,"wbc_k_uL":7.3,"platelets_k_uL":287,"creatinine_mg_dL":1.83,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":55,"sex":"female","bmi":36.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-67},"pfs_months":15.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.6,"censored":true},"longitudinal_labs":[{"date":"2021-03-01","hemoglobin_g_dL":13.5,"wbc_k_uL":6.1,"platelets_k_uL":295,"creatinine_mg_dL":0.71,"alt_U_L":60},{"date":"2021-10-29","hemoglobin_g_dL":12.6,"wbc_k_uL":7.6,"platelets_k_uL":315,"creatinine_mg_dL":1.4,"alt_U_L":17},{"date":"2022-09-18","hemoglobin_g_dL":11.1,"wbc_k_uL":7.7,"platelets_k_uL":222,"creatinine_mg_dL":1.37,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":79,"sex":"male","bmi":28.2,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-09-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-83},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":6.9,"censored":false},"longitudinal_labs":[{"date":"2024-09-01","hemoglobin_g_dL":14.9,"wbc_k_uL":6.5,"platelets_k_uL":411,"creatinine_mg_dL":1.15,"alt_U_L":70},{"date":"2025-03-20","hemoglobin_g_dL":10.1,"wbc_k_uL":6.3,"platelets_k_uL":353,"creatinine_mg_dL":0.72,"alt_U_L":57},{"date":"2025-02-06","hemoglobin_g_dL":10.3,"wbc_k_uL":6.8,"platelets_k_uL":226,"creatinine_mg_dL":1.21,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_115","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":88,"sex":"male","bmi":18.5,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2025-09-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-68},"pfs_months":9.76},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.3,"censored":false},"longitudinal_labs":[{"date":"2025-07-14","hemoglobin_g_dL":13.3,"wbc_k_uL":6.7,"platelets_k_uL":223,"creatinine_mg_dL":0.84,"alt_U_L":23},{"date":"2026-02-28","hemoglobin_g_dL":10.1,"wbc_k_uL":7.3,"platelets_k_uL":138,"creatinine_mg_dL":1.08,"alt_U_L":115},{"date":"2026-08-11","hemoglobin_g_dL":11.9,"wbc_k_uL":3.7,"platelets_k_uL":214,"creatinine_mg_dL":1.53,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":68,"sex":"female","bmi":33.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-59},"pfs_months":16.85},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":false},"longitudinal_labs":[{"date":"2025-05-17","hemoglobin_g_dL":15.2,"wbc_k_uL":6.3,"platelets_k_uL":323,"creatinine_mg_dL":0.99,"alt_U_L":27},{"date":"2026-01-02","hemoglobin_g_dL":12.6,"wbc_k_uL":4.9,"platelets_k_uL":269,"creatinine_mg_dL":1.07,"alt_U_L":110},{"date":"2027-01-12","hemoglobin_g_dL":10.9,"wbc_k_uL":7.3,"platelets_k_uL":324,"creatinine_mg_dL":1.53,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":80,"sex":"female","bmi":35.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-02-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-46},"pfs_months":25.72},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.3,"censored":false},"longitudinal_labs":[{"date":"2022-01-04","hemoglobin_g_dL":13.6,"wbc_k_uL":7.0,"platelets_k_uL":167,"creatinine_mg_dL":1.25,"alt_U_L":24},{"date":"2022-08-02","hemoglobin_g_dL":11.9,"wbc_k_uL":4.3,"platelets_k_uL":226,"creatinine_mg_dL":1.21,"alt_U_L":76},{"date":"2024-04-08","hemoglobin_g_dL":11.2,"wbc_k_uL":7.9,"platelets_k_uL":127,"creatinine_mg_dL":1.7,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":62,"sex":"female","bmi":21.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-72},"pfs_months":26.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.5,"censored":true},"longitudinal_labs":[{"date":"2020-05-05","hemoglobin_g_dL":13.9,"wbc_k_uL":6.3,"platelets_k_uL":373,"creatinine_mg_dL":1.17,"alt_U_L":50},{"date":"2020-12-11","hemoglobin_g_dL":12.4,"wbc_k_uL":8.3,"platelets_k_uL":167,"creatinine_mg_dL":1.17,"alt_U_L":71},{"date":"2022-09-12","hemoglobin_g_dL":12.3,"wbc_k_uL":3.3,"platelets_k_uL":319,"creatinine_mg_dL":1.83,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":88,"sex":"female","bmi":32.9,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-47},"pfs_months":37.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":73.7,"censored":false},"longitudinal_labs":[{"date":"2023-10-11","hemoglobin_g_dL":14.9,"wbc_k_uL":10.2,"platelets_k_uL":163,"creatinine_mg_dL":1.04,"alt_U_L":68},{"date":"2024-05-02","hemoglobin_g_dL":13.5,"wbc_k_uL":5.5,"platelets_k_uL":163,"creatinine_mg_dL":1.26,"alt_U_L":46},{"date":"2026-12-30","hemoglobin_g_dL":12.1,"wbc_k_uL":7.6,"platelets_k_uL":290,"creatinine_mg_dL":1.34,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_120","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":49,"sex":"female","bmi":19.2,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-12-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-40},"pfs_months":25.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":false},"longitudinal_labs":[{"date":"2024-11-17","hemoglobin_g_dL":12.4,"wbc_k_uL":5.4,"platelets_k_uL":268,"creatinine_mg_dL":1.22,"alt_U_L":18},{"date":"2025-06-09","hemoglobin_g_dL":12.9,"wbc_k_uL":4.5,"platelets_k_uL":283,"creatinine_mg_dL":0.91,"alt_U_L":26},{"date":"2027-02-20","hemoglobin_g_dL":10.6,"wbc_k_uL":6.3,"platelets_k_uL":303,"creatinine_mg_dL":1.9,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":73,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-79},"pfs_months":20.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.2,"censored":false},"longitudinal_labs":[{"date":"2023-10-08","hemoglobin_g_dL":14.7,"wbc_k_uL":5.1,"platelets_k_uL":222,"creatinine_mg_dL":1.23,"alt_U_L":73},{"date":"2024-05-13","hemoglobin_g_dL":13.3,"wbc_k_uL":5.8,"platelets_k_uL":308,"creatinine_mg_dL":0.82,"alt_U_L":33},{"date":"2025-08-22","hemoglobin_g_dL":12.0,"wbc_k_uL":4.8,"platelets_k_uL":190,"creatinine_mg_dL":1.69,"alt_U_L":166}]}
{"patient_id":"ANODE_SYNTH_2025_122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":86,"sex":"male","bmi":31.6,"smoking_pack_years":13,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-10-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-71},"pfs_months":28.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":49.7,"censored":false},"longitudinal_labs":[{"date":"2021-08-05","hemoglobin_g_dL":14.0,"wbc_k_uL":5.5,"platelets_k_uL":183,"creatinine_mg_dL":0.73,"alt_U_L":65},{"date":"2022-03-30","hemoglobin_g_dL":13.8,"wbc_k_uL":6.6,"platelets_k_uL":155,"creatinine_mg_dL":1.32,"alt_U_L":54},{"date":"2024-03-05","hemoglobin_g_dL":11.3,"wbc_k_uL":4.3,"platelets_k_uL":338,"creatinine_mg_dL":1.47,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":75,"sex":"female","bmi":29.8,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-07-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-46},"pfs_months":50.04},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":77.3,"censored":false},"longitudinal_labs":[{"date":"2021-05-18","hemoglobin_g_dL":14.3,"wbc_k_uL":10.4,"platelets_k_uL":439,"creatinine_mg_dL":0.6,"alt_U_L":39},{"date":"2022-01-10","hemoglobin_g_dL":10.6,"wbc_k_uL":5.8,"platelets_k_uL":171,"creatinine_mg_dL":1.1,"alt_U_L":45},{"date":"2025-10-30","hemoglobin_g_dL":9.7,"wbc_k_uL":7.9,"platelets_k_uL":128,"creatinine_mg_dL":1.16,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":83,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-70},"pfs_months":23.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.5,"censored":false},"longitudinal_labs":[{"date":"2022-03-19","hemoglobin_g_dL":14.3,"wbc_k_uL":5.7,"platelets_k_uL":415,"creatinine_mg_dL":0.94,"alt_U_L":46},{"date":"2022-11-01","hemoglobin_g_dL":12.2,"wbc_k_uL":4.7,"platelets_k_uL":301,"creatinine_mg_dL":0.89,"alt_U_L":105},{"date":"2024-05-16","hemoglobin_g_dL":10.8,"wbc_k_uL":5.5,"platelets_k_uL":153,"creatinine_mg_dL":1.52,"alt_U_L":197}]}
{"patient_id":"ANODE_SYNTH_2025_125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":65,"sex":"female","bmi":31.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-80},"pfs_months":17.48},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.1,"censored":true},"longitudinal_labs":[{"date":"2025-11-14","hemoglobin_g_dL":15.2,"wbc_k_uL":10.9,"platelets_k_uL":304,"creatinine_mg_dL":1.11,"alt_U_L":72},{"date":"2026-05-31","hemoglobin_g_dL":14.0,"wbc_k_uL":6.2,"platelets_k_uL":221,"creatinine_mg_dL":0.84,"alt_U_L":17},{"date":"2027-06-10","hemoglobin_g_dL":11.8,"wbc_k_uL":7.5,"platelets_k_uL":125,"creatinine_mg_dL":1.02,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":84,"sex":"male","bmi":37.0,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-33},"pfs_months":37.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.7,"censored":false},"longitudinal_labs":[{"date":"2020-01-22","hemoglobin_g_dL":13.8,"wbc_k_uL":9.5,"platelets_k_uL":439,"creatinine_mg_dL":1.04,"alt_U_L":62},{"date":"2020-09-11","hemoglobin_g_dL":12.6,"wbc_k_uL":6.6,"platelets_k_uL":369,"creatinine_mg_dL":1.59,"alt_U_L":85},{"date":"2023-04-28","hemoglobin_g_dL":12.3,"wbc_k_uL":3.2,"platelets_k_uL":213,"creatinine_mg_dL":1.29,"alt_U_L":125}]}
{"patient_id":"ANODE_SYNTH_2025_127","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":80,"sex":"female","bmi":23.7,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-10-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-77},"pfs_months":23.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":false},"longitudinal_labs":[{"date":"2023-09-13","hemoglobin_g_dL":13.0,"wbc_k_uL":7.2,"platelets_k_uL":273,"creatinine_mg_dL":0.64,"alt_U_L":36},{"date":"2024-04-27","hemoglobin_g_dL":12.1,"wbc_k_uL":6.8,"platelets_k_uL":121,"creatinine_mg_dL":0.75,"alt_U_L":104},{"date":"2025-11-25","hemoglobin_g_dL":12.9,"wbc_k_uL":3.5,"platelets_k_uL":279,"creatinine_mg_dL":1.25,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_128","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":70,"sex":"female","bmi":31.4,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-11-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-70},"pfs_months":15.41},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.0,"censored":true},"longitudinal_labs":[{"date":"2022-10-16","hemoglobin_g_dL":12.5,"wbc_k_uL":9.1,"platelets_k_uL":359,"creatinine_mg_dL":0.71,"alt_U_L":75},{"date":"2023-04-30","hemoglobin_g_dL":13.9,"wbc_k_uL":9.0,"platelets_k_uL":376,"creatinine_mg_dL":1.42,"alt_U_L":55},{"date":"2024-03-29","hemoglobin_g_dL":12.4,"wbc_k_uL":3.5,"platelets_k_uL":155,"creatinine_mg_dL":0.97,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":88,"sex":"male","bmi":37.2,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-35},"pfs_months":36.8},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.8,"censored":false},"longitudinal_labs":[{"date":"2021-05-25","hemoglobin_g_dL":11.6,"wbc_k_uL":4.6,"platelets_k_uL":436,"creatinine_mg_dL":1.11,"alt_U_L":14},{"date":"2021-12-07","hemoglobin_g_dL":13.5,"wbc_k_uL":8.2,"platelets_k_uL":197,"creatinine_mg_dL":1.6,"alt_U_L":21},{"date":"2024-08-28","hemoglobin_g_dL":12.1,"wbc_k_uL":7.9,"platelets_k_uL":254,"creatinine_mg_dL":1.91,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":60,"sex":"male","bmi":34.2,"smoking_pack_years":22,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-12-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-67},"pfs_months":26.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.0,"censored":true},"longitudinal_labs":[{"date":"2020-11-05","hemoglobin_g_dL":13.3,"wbc_k_uL":10.2,"platelets_k_uL":266,"creatinine_mg_dL":1.23,"alt_U_L":59},{"date":"2021-05-31","hemoglobin_g_dL":13.3,"wbc_k_uL":8.2,"platelets_k_uL":358,"creatinine_mg_dL":1.59,"alt_U_L":25},{"date":"2023-03-28","hemoglobin_g_dL":12.6,"wbc_k_uL":3.2,"platelets_k_uL":274,"creatinine_mg_dL":1.39,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":79,"sex":"female","bmi":28.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-43},"pfs_months":24.57},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.9,"censored":false},"longitudinal_labs":[{"date":"2022-08-08","hemoglobin_g_dL":14.5,"wbc_k_uL":8.5,"platelets_k_uL":385,"creatinine_mg_dL":0.81,"alt_U_L":66},{"date":"2023-02-23","hemoglobin_g_dL":10.7,"wbc_k_uL":5.1,"platelets_k_uL":353,"creatinine_mg_dL":1.09,"alt_U_L":29},{"date":"2024-10-06","hemoglobin_g_dL":10.5,"wbc_k_uL":5.5,"platelets_k_uL":195,"creatinine_mg_dL":1.98,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":55,"sex":"male","bmi":23.6,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-05-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-42},"pfs_months":13.77},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-08-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.1,"censored":false},"longitudinal_labs":[{"date":"2020-04-13","hemoglobin_g_dL":14.4,"wbc_k_uL":4.8,"platelets_k_uL":297,"creatinine_mg_dL":1.22,"alt_U_L":74},{"date":"2020-11-20","hemoglobin_g_dL":10.1,"wbc_k_uL":4.6,"platelets_k_uL":276,"creatinine_mg_dL":1.3,"alt_U_L":100},{"date":"2021-08-12","hemoglobin_g_dL":12.6,"wbc_k_uL":6.5,"platelets_k_uL":258,"creatinine_mg_dL":1.46,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":60,"sex":"female","bmi":22.0,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-05-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-54},"pfs_months":10.15},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.7,"censored":false},"longitudinal_labs":[{"date":"2020-05-03","hemoglobin_g_dL":12.4,"wbc_k_uL":4.7,"platelets_k_uL":242,"creatinine_mg_dL":0.71,"alt_U_L":60},{"date":"2020-11-19","hemoglobin_g_dL":12.6,"wbc_k_uL":8.4,"platelets_k_uL":233,"creatinine_mg_dL":1.14,"alt_U_L":89},{"date":"2021-05-23","hemoglobin_g_dL":10.1,"wbc_k_uL":7.6,"platelets_k_uL":256,"creatinine_mg_dL":1.26,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":72,"sex":"female","bmi":36.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-65},"pfs_months":19.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":true},"longitudinal_labs":[{"date":"2024-06-16","hemoglobin_g_dL":14.5,"wbc_k_uL":9.1,"platelets_k_uL":313,"creatinine_mg_dL":1.18,"alt_U_L":55},{"date":"2025-01-13","hemoglobin_g_dL":11.0,"wbc_k_uL":6.5,"platelets_k_uL":379,"creatinine_mg_dL":1.56,"alt_U_L":89},{"date":"2026-03-03","hemoglobin_g_dL":12.2,"wbc_k_uL":4.1,"platelets_k_uL":130,"creatinine_mg_dL":1.58,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":54,"sex":"female","bmi":27.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-32},"pfs_months":24.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.5,"censored":false},"longitudinal_labs":[{"date":"2024-08-14","hemoglobin_g_dL":11.8,"wbc_k_uL":8.3,"platelets_k_uL":420,"creatinine_mg_dL":0.85,"alt_U_L":44},{"date":"2025-03-02","hemoglobin_g_dL":13.5,"wbc_k_uL":4.7,"platelets_k_uL":362,"creatinine_mg_dL":1.56,"alt_U_L":34},{"date":"2026-10-26","hemoglobin_g_dL":11.2,"wbc_k_uL":5.5,"platelets_k_uL":253,"creatinine_mg_dL":1.14,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":83,"sex":"female","bmi":36.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-62},"pfs_months":27.7},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.5,"censored":false},"longitudinal_labs":[{"date":"2021-11-28","hemoglobin_g_dL":13.9,"wbc_k_uL":8.8,"platelets_k_uL":327,"creatinine_mg_dL":0.88,"alt_U_L":34},{"date":"2022-06-23","hemoglobin_g_dL":13.2,"wbc_k_uL":5.5,"platelets_k_uL":316,"creatinine_mg_dL":0.91,"alt_U_L":67},{"date":"2024-04-26","hemoglobin_g_dL":12.9,"wbc_k_uL":4.0,"platelets_k_uL":114,"creatinine_mg_dL":1.41,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":53,"sex":"female","bmi":26.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-52},"pfs_months":20.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.5,"censored":false},"longitudinal_labs":[{"date":"2022-04-16","hemoglobin_g_dL":14.0,"wbc_k_uL":8.1,"platelets_k_uL":284,"creatinine_mg_dL":0.85,"alt_U_L":43},{"date":"2022-11-06","hemoglobin_g_dL":10.4,"wbc_k_uL":5.6,"platelets_k_uL":306,"creatinine_mg_dL":1.41,"alt_U_L":94},{"date":"2024-03-18","hemoglobin_g_dL":12.1,"wbc_k_uL":4.0,"platelets_k_uL":125,"creatinine_mg_dL":0.93,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":81,"sex":"male","bmi":37.7,"smoking_pack_years":52,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-03-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-72},"pfs_months":35.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":56.6,"censored":true},"longitudinal_labs":[{"date":"2022-01-14","hemoglobin_g_dL":15.3,"wbc_k_uL":5.4,"platelets_k_uL":193,"creatinine_mg_dL":0.9,"alt_U_L":58},{"date":"2022-09-05","hemoglobin_g_dL":11.8,"wbc_k_uL":5.6,"platelets_k_uL":165,"creatinine_mg_dL":1.31,"alt_U_L":17},{"date":"2025-03-12","hemoglobin_g_dL":11.3,"wbc_k_uL":4.7,"platelets_k_uL":159,"creatinine_mg_dL":1.87,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_139","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":63,"sex":"male","bmi":28.4,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-02-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-69},"pfs_months":30.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.4,"censored":false},"longitudinal_labs":[{"date":"2023-12-21","hemoglobin_g_dL":12.2,"wbc_k_uL":6.8,"platelets_k_uL":289,"creatinine_mg_dL":1.17,"alt_U_L":46},{"date":"2024-08-21","hemoglobin_g_dL":13.2,"wbc_k_uL":8.4,"platelets_k_uL":154,"creatinine_mg_dL":1.29,"alt_U_L":51},{"date":"2026-10-19","hemoglobin_g_dL":11.6,"wbc_k_uL":4.2,"platelets_k_uL":143,"creatinine_mg_dL":1.66,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":84,"sex":"female","bmi":32.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-30},"pfs_months":17.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.4,"censored":false},"longitudinal_labs":[{"date":"2023-01-22","hemoglobin_g_dL":12.7,"wbc_k_uL":5.4,"platelets_k_uL":239,"creatinine_mg_dL":0.86,"alt_U_L":65},{"date":"2023-09-20","hemoglobin_g_dL":11.8,"wbc_k_uL":4.7,"platelets_k_uL":310,"creatinine_mg_dL":1.4,"alt_U_L":48},{"date":"2024-10-19","hemoglobin_g_dL":12.7,"wbc_k_uL":3.2,"platelets_k_uL":343,"creatinine_mg_dL":1.41,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":64,"sex":"female","bmi":22.9,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-09-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-40},"pfs_months":36.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":50.9,"censored":false},"longitudinal_labs":[{"date":"2020-08-05","hemoglobin_g_dL":15.4,"wbc_k_uL":10.4,"platelets_k_uL":314,"creatinine_mg_dL":1.16,"alt_U_L":15},{"date":"2021-03-23","hemoglobin_g_dL":13.2,"wbc_k_uL":3.9,"platelets_k_uL":224,"creatinine_mg_dL":1.31,"alt_U_L":103},{"date":"2023-11-01","hemoglobin_g_dL":11.7,"wbc_k_uL":4.7,"platelets_k_uL":137,"creatinine_mg_dL":1.22,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":75,"sex":"female","bmi":29.7,"smoking_pack_years":47,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-68},"pfs_months":11.37},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":16.1,"censored":true},"longitudinal_labs":[{"date":"2025-07-24","hemoglobin_g_dL":15.3,"wbc_k_uL":6.3,"platelets_k_uL":337,"creatinine_mg_dL":0.79,"alt_U_L":72},{"date":"2026-02-15","hemoglobin_g_dL":13.3,"wbc_k_uL":6.5,"platelets_k_uL":198,"creatinine_mg_dL":1.31,"alt_U_L":28},{"date":"2026-09-25","hemoglobin_g_dL":10.9,"wbc_k_uL":6.1,"platelets_k_uL":176,"creatinine_mg_dL":1.97,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":84,"sex":"female","bmi":32.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-39},"pfs_months":24.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.5,"censored":false},"longitudinal_labs":[{"date":"2020-03-23","hemoglobin_g_dL":14.7,"wbc_k_uL":6.4,"platelets_k_uL":324,"creatinine_mg_dL":0.86,"alt_U_L":44},{"date":"2020-10-05","hemoglobin_g_dL":13.0,"wbc_k_uL":8.4,"platelets_k_uL":283,"creatinine_mg_dL":1.21,"alt_U_L":103},{"date":"2022-05-04","hemoglobin_g_dL":10.3,"wbc_k_uL":7.1,"platelets_k_uL":157,"creatinine_mg_dL":0.82,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_144","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":57,"sex":"male","bmi":37.7,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-04-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-42},"pfs_months":23.85},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.2,"censored":true},"longitudinal_labs":[{"date":"2025-02-23","hemoglobin_g_dL":14.0,"wbc_k_uL":8.4,"platelets_k_uL":405,"creatinine_mg_dL":1.09,"alt_U_L":61},{"date":"2025-10-14","hemoglobin_g_dL":10.4,"wbc_k_uL":7.5,"platelets_k_uL":220,"creatinine_mg_dL":1.59,"alt_U_L":49},{"date":"2027-05-09","hemoglobin_g_dL":9.8,"wbc_k_uL":5.0,"platelets_k_uL":305,"creatinine_mg_dL":1.79,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":73,"sex":"female","bmi":36.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-67},"pfs_months":18.69},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.6,"censored":false},"longitudinal_labs":[{"date":"2022-02-01","hemoglobin_g_dL":13.0,"wbc_k_uL":6.0,"platelets_k_uL":162,"creatinine_mg_dL":0.64,"alt_U_L":23},{"date":"2022-09-30","hemoglobin_g_dL":12.2,"wbc_k_uL":6.1,"platelets_k_uL":255,"creatinine_mg_dL":1.02,"alt_U_L":96},{"date":"2023-12-21","hemoglobin_g_dL":10.2,"wbc_k_uL":6.0,"platelets_k_uL":292,"creatinine_mg_dL":1.51,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":67,"sex":"female","bmi":32.2,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-05-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-71},"pfs_months":42.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":69.6,"censored":true},"longitudinal_labs":[{"date":"2022-03-26","hemoglobin_g_dL":12.7,"wbc_k_uL":10.4,"platelets_k_uL":429,"creatinine_mg_dL":0.82,"alt_U_L":62},{"date":"2022-11-15","hemoglobin_g_dL":10.2,"wbc_k_uL":6.4,"platelets_k_uL":276,"creatinine_mg_dL":1.42,"alt_U_L":49},{"date":"2026-01-23","hemoglobin_g_dL":9.8,"wbc_k_uL":5.1,"platelets_k_uL":167,"creatinine_mg_dL":1.23,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":75,"sex":"male","bmi":36.1,"smoking_pack_years":37,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-10-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-75},"pfs_months":38.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":57.8,"censored":true},"longitudinal_labs":[{"date":"2021-10-01","hemoglobin_g_dL":14.0,"wbc_k_uL":6.7,"platelets_k_uL":412,"creatinine_mg_dL":1.04,"alt_U_L":53},{"date":"2022-04-21","hemoglobin_g_dL":13.5,"wbc_k_uL":5.2,"platelets_k_uL":197,"creatinine_mg_dL":0.97,"alt_U_L":18},{"date":"2025-01-20","hemoglobin_g_dL":12.5,"wbc_k_uL":3.7,"platelets_k_uL":174,"creatinine_mg_dL":1.77,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":78,"sex":"female","bmi":35.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-40},"pfs_months":26.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.5,"censored":true},"longitudinal_labs":[{"date":"2023-12-06","hemoglobin_g_dL":14.3,"wbc_k_uL":7.2,"platelets_k_uL":380,"creatinine_mg_dL":0.83,"alt_U_L":45},{"date":"2024-07-14","hemoglobin_g_dL":12.3,"wbc_k_uL":4.5,"platelets_k_uL":270,"creatinine_mg_dL":1.18,"alt_U_L":72},{"date":"2026-04-20","hemoglobin_g_dL":10.2,"wbc_k_uL":4.2,"platelets_k_uL":159,"creatinine_mg_dL":1.91,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":50,"sex":"male","bmi":22.4,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-03-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-44},"pfs_months":43.33},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":69.7,"censored":false},"longitudinal_labs":[{"date":"2023-01-25","hemoglobin_g_dL":14.4,"wbc_k_uL":5.1,"platelets_k_uL":222,"creatinine_mg_dL":0.83,"alt_U_L":39},{"date":"2023-09-02","hemoglobin_g_dL":12.0,"wbc_k_uL":4.3,"platelets_k_uL":144,"creatinine_mg_dL":0.8,"alt_U_L":80},{"date":"2026-10-27","hemoglobin_g_dL":9.5,"wbc_k_uL":3.4,"platelets_k_uL":177,"creatinine_mg_dL":2.0,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":62,"sex":"female","bmi":35.0,"smoking_pack_years":53,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-01-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-30},"pfs_months":49.18},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":64.2,"censored":false},"longitudinal_labs":[{"date":"2022-12-18","hemoglobin_g_dL":15.0,"wbc_k_uL":7.0,"platelets_k_uL":177,"creatinine_mg_dL":0.75,"alt_U_L":78},{"date":"2023-07-09","hemoglobin_g_dL":10.6,"wbc_k_uL":6.7,"platelets_k_uL":318,"creatinine_mg_dL":1.55,"alt_U_L":108},{"date":"2027-04-16","hemoglobin_g_dL":9.6,"wbc_k_uL":6.3,"platelets_k_uL":248,"creatinine_mg_dL":1.65,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":49,"sex":"male","bmi":32.6,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-08-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-67},"pfs_months":5.88},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":9.8,"censored":false},"longitudinal_labs":[{"date":"2024-07-14","hemoglobin_g_dL":14.1,"wbc_k_uL":6.1,"platelets_k_uL":343,"creatinine_mg_dL":0.68,"alt_U_L":42},{"date":"2025-02-07","hemoglobin_g_dL":11.3,"wbc_k_uL":8.1,"platelets_k_uL":196,"creatinine_mg_dL":1.47,"alt_U_L":114},{"date":"2025-03-18","hemoglobin_g_dL":12.2,"wbc_k_uL":8.0,"platelets_k_uL":158,"creatinine_mg_dL":1.07,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":71,"sex":"female","bmi":21.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-12-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-69},"pfs_months":24.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.1,"censored":false},"longitudinal_labs":[{"date":"2021-10-02","hemoglobin_g_dL":13.5,"wbc_k_uL":7.4,"platelets_k_uL":183,"creatinine_mg_dL":0.77,"alt_U_L":33},{"date":"2022-06-05","hemoglobin_g_dL":11.1,"wbc_k_uL":7.5,"platelets_k_uL":126,"creatinine_mg_dL":1.54,"alt_U_L":88},{"date":"2024-01-01","hemoglobin_g_dL":10.4,"wbc_k_uL":7.0,"platelets_k_uL":188,"creatinine_mg_dL":1.48,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":59,"sex":"female","bmi":24.0,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-08-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-76},"pfs_months":40.05},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":57.0,"censored":true},"longitudinal_labs":[{"date":"2024-08-12","hemoglobin_g_dL":13.7,"wbc_k_uL":6.8,"platelets_k_uL":316,"creatinine_mg_dL":0.99,"alt_U_L":24},{"date":"2025-02-23","hemoglobin_g_dL":13.7,"wbc_k_uL":3.9,"platelets_k_uL":165,"creatinine_mg_dL":0.98,"alt_U_L":24},{"date":"2028-01-20","hemoglobin_g_dL":9.5,"wbc_k_uL":6.2,"platelets_k_uL":206,"creatinine_mg_dL":1.89,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":87,"sex":"female","bmi":27.6,"smoking_pack_years":21,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-39},"pfs_months":10.02},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.7,"censored":false},"longitudinal_labs":[{"date":"2022-01-27","hemoglobin_g_dL":14.1,"wbc_k_uL":6.4,"platelets_k_uL":436,"creatinine_mg_dL":0.68,"alt_U_L":18},{"date":"2022-09-18","hemoglobin_g_dL":10.5,"wbc_k_uL":7.8,"platelets_k_uL":122,"creatinine_mg_dL":1.52,"alt_U_L":58},{"date":"2023-02-21","hemoglobin_g_dL":12.3,"wbc_k_uL":7.1,"platelets_k_uL":234,"creatinine_mg_dL":1.78,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":62,"sex":"female","bmi":25.3,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-50},"pfs_months":17.58},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.9,"censored":false},"longitudinal_labs":[{"date":"2022-09-16","hemoglobin_g_dL":12.8,"wbc_k_uL":5.8,"platelets_k_uL":251,"creatinine_mg_dL":0.72,"alt_U_L":63},{"date":"2023-04-02","hemoglobin_g_dL":12.8,"wbc_k_uL":7.6,"platelets_k_uL":223,"creatinine_mg_dL":0.85,"alt_U_L":56},{"date":"2024-04-28","hemoglobin_g_dL":12.1,"wbc_k_uL":4.6,"platelets_k_uL":162,"creatinine_mg_dL":0.88,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":56,"sex":"male","bmi":31.9,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-10-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-56},"pfs_months":10.02},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.8,"censored":false},"longitudinal_labs":[{"date":"2020-09-23","hemoglobin_g_dL":13.4,"wbc_k_uL":6.2,"platelets_k_uL":183,"creatinine_mg_dL":1.04,"alt_U_L":74},{"date":"2021-04-12","hemoglobin_g_dL":11.4,"wbc_k_uL":5.1,"platelets_k_uL":227,"creatinine_mg_dL":1.1,"alt_U_L":72},{"date":"2021-09-03","hemoglobin_g_dL":12.9,"wbc_k_uL":4.6,"platelets_k_uL":288,"creatinine_mg_dL":1.51,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":18.0,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":59,"sex":"male","bmi":35.4,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2024-03-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-61},"pfs_months":25.86},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.3,"censored":false},"longitudinal_labs":[{"date":"2024-02-18","hemoglobin_g_dL":14.7,"wbc_k_uL":6.8,"platelets_k_uL":396,"creatinine_mg_dL":0.75,"alt_U_L":76},{"date":"2024-09-16","hemoglobin_g_dL":12.9,"wbc_k_uL":5.9,"platelets_k_uL":339,"creatinine_mg_dL":1.32,"alt_U_L":115},{"date":"2026-06-05","hemoglobin_g_dL":12.9,"wbc_k_uL":5.5,"platelets_k_uL":252,"creatinine_mg_dL":1.8,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_158","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":62,"sex":"female","bmi":35.9,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-12-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-72},"pfs_months":13.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":19.4,"censored":false},"longitudinal_labs":[{"date":"2024-11-11","hemoglobin_g_dL":14.5,"wbc_k_uL":10.9,"platelets_k_uL":179,"creatinine_mg_dL":1.02,"alt_U_L":21},{"date":"2025-06-19","hemoglobin_g_dL":10.2,"wbc_k_uL":8.9,"platelets_k_uL":368,"creatinine_mg_dL":1.47,"alt_U_L":68},{"date":"2026-03-13","hemoglobin_g_dL":9.9,"wbc_k_uL":7.3,"platelets_k_uL":313,"creatinine_mg_dL":1.5,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_159","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":66,"sex":"female","bmi":24.2,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-02-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-40},"pfs_months":26.28},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.5,"censored":false},"longitudinal_labs":[{"date":"2020-01-16","hemoglobin_g_dL":14.5,"wbc_k_uL":6.8,"platelets_k_uL":287,"creatinine_mg_dL":0.71,"alt_U_L":75},{"date":"2020-08-17","hemoglobin_g_dL":13.0,"wbc_k_uL":8.6,"platelets_k_uL":358,"creatinine_mg_dL":0.7,"alt_U_L":61},{"date":"2022-06-22","hemoglobin_g_dL":9.7,"wbc_k_uL":7.2,"platelets_k_uL":309,"creatinine_mg_dL":1.35,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":80,"sex":"female","bmi":26.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-37},"pfs_months":24.51},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.3,"censored":false},"longitudinal_labs":[{"date":"2020-11-14","hemoglobin_g_dL":12.8,"wbc_k_uL":7.8,"platelets_k_uL":443,"creatinine_mg_dL":0.63,"alt_U_L":37},{"date":"2021-07-14","hemoglobin_g_dL":13.4,"wbc_k_uL":6.6,"platelets_k_uL":258,"creatinine_mg_dL":1.55,"alt_U_L":36},{"date":"2023-03-29","hemoglobin_g_dL":9.6,"wbc_k_uL":7.5,"platelets_k_uL":279,"creatinine_mg_dL":1.99,"alt_U_L":99}]}
{"patient_id":"ANODE_SYNTH_2025_161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":55,"sex":"female","bmi":21.6,"smoking_pack_years":32,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-04-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-76},"pfs_months":21.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":31.9,"censored":false},"longitudinal_labs":[{"date":"2020-03-21","hemoglobin_g_dL":12.3,"wbc_k_uL":10.6,"platelets_k_uL":383,"creatinine_mg_dL":0.78,"alt_U_L":53},{"date":"2020-10-08","hemoglobin_g_dL":11.0,"wbc_k_uL":5.5,"platelets_k_uL":224,"creatinine_mg_dL":1.12,"alt_U_L":21},{"date":"2022-02-18","hemoglobin_g_dL":13.0,"wbc_k_uL":5.4,"platelets_k_uL":169,"creatinine_mg_dL":1.57,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":70,"sex":"female","bmi":18.5,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-42},"pfs_months":8.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":17.0,"censored":false},"longitudinal_labs":[{"date":"2025-06-15","hemoglobin_g_dL":12.3,"wbc_k_uL":9.2,"platelets_k_uL":303,"creatinine_mg_dL":0.8,"alt_U_L":75},{"date":"2026-02-07","hemoglobin_g_dL":12.3,"wbc_k_uL":6.2,"platelets_k_uL":177,"creatinine_mg_dL":1.28,"alt_U_L":39},{"date":"2026-05-19","hemoglobin_g_dL":11.7,"wbc_k_uL":7.9,"platelets_k_uL":335,"creatinine_mg_dL":1.71,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_163","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":61,"sex":"male","bmi":18.9,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-32},"pfs_months":31.97},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-09-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":62.8,"censored":false},"longitudinal_labs":[{"date":"2025-10-25","hemoglobin_g_dL":14.9,"wbc_k_uL":7.7,"platelets_k_uL":201,"creatinine_mg_dL":0.98,"alt_U_L":21},{"date":"2026-06-07","hemoglobin_g_dL":11.9,"wbc_k_uL":4.2,"platelets_k_uL":149,"creatinine_mg_dL":1.43,"alt_U_L":110},{"date":"2028-09-09","hemoglobin_g_dL":11.2,"wbc_k_uL":7.5,"platelets_k_uL":304,"creatinine_mg_dL":0.97,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_164","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":54,"sex":"male","bmi":38.0,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-57},"pfs_months":16.92},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.2,"censored":true},"longitudinal_labs":[{"date":"2020-12-10","hemoglobin_g_dL":12.8,"wbc_k_uL":9.3,"platelets_k_uL":352,"creatinine_mg_dL":1.23,"alt_U_L":37},{"date":"2021-07-14","hemoglobin_g_dL":13.9,"wbc_k_uL":8.9,"platelets_k_uL":339,"creatinine_mg_dL":0.93,"alt_U_L":91},{"date":"2022-08-02","hemoglobin_g_dL":12.2,"wbc_k_uL":3.1,"platelets_k_uL":245,"creatinine_mg_dL":1.6,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":86,"sex":"male","bmi":25.7,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-05-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-45},"pfs_months":40.15},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-25","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":57.3,"censored":false},"longitudinal_labs":[{"date":"2023-04-15","hemoglobin_g_dL":14.6,"wbc_k_uL":10.7,"platelets_k_uL":421,"creatinine_mg_dL":1.08,"alt_U_L":40},{"date":"2023-11-07","hemoglobin_g_dL":10.2,"wbc_k_uL":7.3,"platelets_k_uL":137,"creatinine_mg_dL":1.39,"alt_U_L":45},{"date":"2026-09-25","hemoglobin_g_dL":9.8,"wbc_k_uL":3.3,"platelets_k_uL":126,"creatinine_mg_dL":1.51,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":72,"sex":"female","bmi":24.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-38},"pfs_months":11.89},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.1,"censored":false},"longitudinal_labs":[{"date":"2025-01-02","hemoglobin_g_dL":13.8,"wbc_k_uL":10.3,"platelets_k_uL":289,"creatinine_mg_dL":1.3,"alt_U_L":61},{"date":"2025-07-19","hemoglobin_g_dL":13.3,"wbc_k_uL":8.8,"platelets_k_uL":273,"creatinine_mg_dL":0.89,"alt_U_L":120},{"date":"2026-01-22","hemoglobin_g_dL":11.9,"wbc_k_uL":5.4,"platelets_k_uL":158,"creatinine_mg_dL":1.2,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":68,"sex":"female","bmi":18.6,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-11-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-42},"pfs_months":16.99},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.9,"censored":false},"longitudinal_labs":[{"date":"2025-09-27","hemoglobin_g_dL":15.2,"wbc_k_uL":8.9,"platelets_k_uL":160,"creatinine_mg_dL":1.21,"alt_U_L":40},{"date":"2026-05-11","hemoglobin_g_dL":12.9,"wbc_k_uL":6.4,"platelets_k_uL":140,"creatinine_mg_dL":1.51,"alt_U_L":65},{"date":"2027-05-12","hemoglobin_g_dL":9.7,"wbc_k_uL":6.2,"platelets_k_uL":216,"creatinine_mg_dL":1.03,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_168","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":51,"sex":"female","bmi":34.7,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-04-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-59},"pfs_months":28.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.4,"censored":false},"longitudinal_labs":[{"date":"2025-03-16","hemoglobin_g_dL":15.0,"wbc_k_uL":6.7,"platelets_k_uL":277,"creatinine_mg_dL":1.27,"alt_U_L":15},{"date":"2025-10-12","hemoglobin_g_dL":10.5,"wbc_k_uL":3.9,"platelets_k_uL":205,"creatinine_mg_dL":1.19,"alt_U_L":62},{"date":"2027-10-30","hemoglobin_g_dL":12.6,"wbc_k_uL":6.1,"platelets_k_uL":150,"creatinine_mg_dL":1.14,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_169","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":69,"sex":"male","bmi":34.7,"smoking_pack_years":15,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-01-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-39},"pfs_months":22.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.9,"censored":false},"longitudinal_labs":[{"date":"2025-12-26","hemoglobin_g_dL":12.9,"wbc_k_uL":4.7,"platelets_k_uL":333,"creatinine_mg_dL":0.78,"alt_U_L":31},{"date":"2026-07-28","hemoglobin_g_dL":10.3,"wbc_k_uL":6.1,"platelets_k_uL":320,"creatinine_mg_dL":1.41,"alt_U_L":72},{"date":"2027-12-11","hemoglobin_g_dL":12.4,"wbc_k_uL":8.0,"platelets_k_uL":193,"creatinine_mg_dL":0.84,"alt_U_L":28}]}
{"patient_id":"ANODE_SYNTH_2025_170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":74,"sex":"male","bmi":24.0,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-06-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-84},"pfs_months":37.65},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":61.1,"censored":false},"longitudinal_labs":[{"date":"2023-05-22","hemoglobin_g_dL":13.1,"wbc_k_uL":9.0,"platelets_k_uL":171,"creatinine_mg_dL":0.87,"alt_U_L":77},{"date":"2023-12-22","hemoglobin_g_dL":12.0,"wbc_k_uL":7.2,"platelets_k_uL":286,"creatinine_mg_dL":1.42,"alt_U_L":60},{"date":"2026-09-28","hemoglobin_g_dL":11.8,"wbc_k_uL":6.2,"platelets_k_uL":188,"creatinine_mg_dL":0.94,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":73,"sex":"female","bmi":29.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-85},"pfs_months":22.77},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.4,"censored":false},"longitudinal_labs":[{"date":"2022-09-01","hemoglobin_g_dL":14.5,"wbc_k_uL":7.6,"platelets_k_uL":343,"creatinine_mg_dL":0.87,"alt_U_L":59},{"date":"2023-04-26","hemoglobin_g_dL":12.3,"wbc_k_uL":6.2,"platelets_k_uL":236,"creatinine_mg_dL":1.35,"alt_U_L":83},{"date":"2024-11-01","hemoglobin_g_dL":11.2,"wbc_k_uL":4.8,"platelets_k_uL":262,"creatinine_mg_dL":0.96,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":71,"sex":"female","bmi":23.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-01-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-65},"pfs_months":14.0},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.9,"censored":true},"longitudinal_labs":[{"date":"2025-12-09","hemoglobin_g_dL":15.1,"wbc_k_uL":9.2,"platelets_k_uL":350,"creatinine_mg_dL":0.66,"alt_U_L":38},{"date":"2026-07-02","hemoglobin_g_dL":11.4,"wbc_k_uL":6.1,"platelets_k_uL":167,"creatinine_mg_dL":0.77,"alt_U_L":29},{"date":"2027-04-01","hemoglobin_g_dL":9.9,"wbc_k_uL":5.8,"platelets_k_uL":125,"creatinine_mg_dL":1.22,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_173","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":57,"sex":"female","bmi":34.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-07-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-60},"pfs_months":26.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.9,"censored":true},"longitudinal_labs":[{"date":"2021-07-08","hemoglobin_g_dL":12.8,"wbc_k_uL":8.1,"platelets_k_uL":281,"creatinine_mg_dL":1.24,"alt_U_L":29},{"date":"2022-01-23","hemoglobin_g_dL":13.2,"wbc_k_uL":5.4,"platelets_k_uL":147,"creatinine_mg_dL":1.38,"alt_U_L":60},{"date":"2023-10-25","hemoglobin_g_dL":10.2,"wbc_k_uL":4.5,"platelets_k_uL":297,"creatinine_mg_dL":0.93,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_174","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":54,"sex":"female","bmi":19.1,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-12-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-72},"pfs_months":27.17},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.6,"censored":true},"longitudinal_labs":[{"date":"2025-11-08","hemoglobin_g_dL":13.7,"wbc_k_uL":8.1,"platelets_k_uL":232,"creatinine_mg_dL":0.89,"alt_U_L":23},{"date":"2026-06-20","hemoglobin_g_dL":11.8,"wbc_k_uL":7.9,"platelets_k_uL":126,"creatinine_mg_dL":0.97,"alt_U_L":114},{"date":"2028-04-04","hemoglobin_g_dL":12.0,"wbc_k_uL":3.6,"platelets_k_uL":269,"creatinine_mg_dL":1.54,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":55,"sex":"male","bmi":29.6,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-04-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-56},"pfs_months":38.24},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.5,"censored":false},"longitudinal_labs":[{"date":"2024-02-07","hemoglobin_g_dL":12.1,"wbc_k_uL":10.6,"platelets_k_uL":401,"creatinine_mg_dL":0.71,"alt_U_L":40},{"date":"2024-09-28","hemoglobin_g_dL":11.9,"wbc_k_uL":7.6,"platelets_k_uL":215,"creatinine_mg_dL":1.22,"alt_U_L":30},{"date":"2027-06-23","hemoglobin_g_dL":10.2,"wbc_k_uL":5.0,"platelets_k_uL":265,"creatinine_mg_dL":1.63,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":63,"sex":"female","bmi":27.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-66},"pfs_months":28.71},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.7,"censored":true},"longitudinal_labs":[{"date":"2024-12-20","hemoglobin_g_dL":14.0,"wbc_k_uL":9.6,"platelets_k_uL":247,"creatinine_mg_dL":0.88,"alt_U_L":13},{"date":"2025-08-03","hemoglobin_g_dL":13.9,"wbc_k_uL":5.5,"platelets_k_uL":242,"creatinine_mg_dL":1.22,"alt_U_L":39},{"date":"2027-07-19","hemoglobin_g_dL":10.1,"wbc_k_uL":7.7,"platelets_k_uL":126,"creatinine_mg_dL":1.07,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":84,"sex":"female","bmi":37.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-49},"pfs_months":17.58},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.4,"censored":false},"longitudinal_labs":[{"date":"2020-05-18","hemoglobin_g_dL":12.0,"wbc_k_uL":8.5,"platelets_k_uL":198,"creatinine_mg_dL":1.15,"alt_U_L":52},{"date":"2020-12-15","hemoglobin_g_dL":10.2,"wbc_k_uL":5.5,"platelets_k_uL":380,"creatinine_mg_dL":1.4,"alt_U_L":65},{"date":"2022-01-03","hemoglobin_g_dL":12.9,"wbc_k_uL":5.7,"platelets_k_uL":281,"creatinine_mg_dL":1.62,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":70,"sex":"male","bmi":30.2,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-10-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-39},"pfs_months":6.01},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":10.0,"censored":true},"longitudinal_labs":[{"date":"2023-09-05","hemoglobin_g_dL":12.1,"wbc_k_uL":4.5,"platelets_k_uL":220,"creatinine_mg_dL":1.16,"alt_U_L":31},{"date":"2024-03-29","hemoglobin_g_dL":10.4,"wbc_k_uL":6.2,"platelets_k_uL":188,"creatinine_mg_dL":1.08,"alt_U_L":91},{"date":"2024-04-05","hemoglobin_g_dL":13.0,"wbc_k_uL":6.5,"platelets_k_uL":331,"creatinine_mg_dL":1.28,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":62,"sex":"female","bmi":26.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-76},"pfs_months":24.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.1,"censored":false},"longitudinal_labs":[{"date":"2022-08-06","hemoglobin_g_dL":14.2,"wbc_k_uL":7.1,"platelets_k_uL":314,"creatinine_mg_dL":0.85,"alt_U_L":63},{"date":"2023-03-11","hemoglobin_g_dL":13.6,"wbc_k_uL":6.4,"platelets_k_uL":277,"creatinine_mg_dL":1.45,"alt_U_L":37},{"date":"2024-11-02","hemoglobin_g_dL":9.5,"wbc_k_uL":7.8,"platelets_k_uL":176,"creatinine_mg_dL":1.22,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":60,"sex":"female","bmi":29.3,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-70},"pfs_months":13.86},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2025-06-05","hemoglobin_g_dL":13.4,"wbc_k_uL":6.2,"platelets_k_uL":264,"creatinine_mg_dL":1.19,"alt_U_L":12},{"date":"2025-12-26","hemoglobin_g_dL":10.5,"wbc_k_uL":8.0,"platelets_k_uL":184,"creatinine_mg_dL":1.47,"alt_U_L":76},{"date":"2026-09-27","hemoglobin_g_dL":11.2,"wbc_k_uL":3.0,"platelets_k_uL":175,"creatinine_mg_dL":1.53,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_181","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":55,"sex":"male","bmi":36.7,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-41},"pfs_months":14.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.6,"censored":false},"longitudinal_labs":[{"date":"2023-03-09","hemoglobin_g_dL":11.9,"wbc_k_uL":6.8,"platelets_k_uL":310,"creatinine_mg_dL":0.64,"alt_U_L":72},{"date":"2023-10-30","hemoglobin_g_dL":10.2,"wbc_k_uL":5.3,"platelets_k_uL":328,"creatinine_mg_dL":1.15,"alt_U_L":31},{"date":"2024-08-04","hemoglobin_g_dL":10.5,"wbc_k_uL":7.7,"platelets_k_uL":163,"creatinine_mg_dL":1.27,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":82,"sex":"female","bmi":23.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-50},"pfs_months":21.65},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.3,"censored":true},"longitudinal_labs":[{"date":"2020-10-27","hemoglobin_g_dL":13.4,"wbc_k_uL":9.6,"platelets_k_uL":440,"creatinine_mg_dL":0.91,"alt_U_L":29},{"date":"2021-06-05","hemoglobin_g_dL":11.7,"wbc_k_uL":7.2,"platelets_k_uL":205,"creatinine_mg_dL":0.98,"alt_U_L":80},{"date":"2022-10-26","hemoglobin_g_dL":11.7,"wbc_k_uL":5.2,"platelets_k_uL":343,"creatinine_mg_dL":1.63,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":81,"sex":"female","bmi":31.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-61},"pfs_months":23.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":true},"longitudinal_labs":[{"date":"2020-12-01","hemoglobin_g_dL":14.0,"wbc_k_uL":7.7,"platelets_k_uL":332,"creatinine_mg_dL":0.77,"alt_U_L":80},{"date":"2021-06-20","hemoglobin_g_dL":14.0,"wbc_k_uL":8.3,"platelets_k_uL":180,"creatinine_mg_dL":1.35,"alt_U_L":53},{"date":"2023-01-29","hemoglobin_g_dL":11.4,"wbc_k_uL":4.6,"platelets_k_uL":116,"creatinine_mg_dL":1.05,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":59,"sex":"male","bmi":34.6,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-10-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-63},"pfs_months":40.18},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-03-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":67.9,"censored":true},"longitudinal_labs":[{"date":"2025-10-03","hemoglobin_g_dL":13.5,"wbc_k_uL":5.9,"platelets_k_uL":171,"creatinine_mg_dL":1.22,"alt_U_L":79},{"date":"2026-04-22","hemoglobin_g_dL":13.0,"wbc_k_uL":6.4,"platelets_k_uL":180,"creatinine_mg_dL":1.52,"alt_U_L":78},{"date":"2029-03-07","hemoglobin_g_dL":11.4,"wbc_k_uL":3.6,"platelets_k_uL":217,"creatinine_mg_dL":1.39,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":80,"sex":"female","bmi":33.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-53},"pfs_months":32.0},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.2,"censored":false},"longitudinal_labs":[{"date":"2024-10-23","hemoglobin_g_dL":14.6,"wbc_k_uL":8.2,"platelets_k_uL":311,"creatinine_mg_dL":1.14,"alt_U_L":62},{"date":"2025-05-23","hemoglobin_g_dL":10.0,"wbc_k_uL":5.7,"platelets_k_uL":357,"creatinine_mg_dL":1.36,"alt_U_L":106},{"date":"2027-09-19","hemoglobin_g_dL":12.5,"wbc_k_uL":6.7,"platelets_k_uL":165,"creatinine_mg_dL":1.44,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":48,"sex":"female","bmi":21.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-53},"pfs_months":19.48},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.2,"censored":true},"longitudinal_labs":[{"date":"2025-06-07","hemoglobin_g_dL":12.6,"wbc_k_uL":10.2,"platelets_k_uL":405,"creatinine_mg_dL":1.29,"alt_U_L":33},{"date":"2026-01-09","hemoglobin_g_dL":12.0,"wbc_k_uL":4.9,"platelets_k_uL":302,"creatinine_mg_dL":1.37,"alt_U_L":15},{"date":"2027-03-26","hemoglobin_g_dL":12.8,"wbc_k_uL":7.1,"platelets_k_uL":340,"creatinine_mg_dL":1.59,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":88,"sex":"female","bmi":37.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-35},"pfs_months":30.59},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.2,"censored":false},"longitudinal_labs":[{"date":"2020-03-21","hemoglobin_g_dL":12.1,"wbc_k_uL":8.5,"platelets_k_uL":413,"creatinine_mg_dL":0.99,"alt_U_L":55},{"date":"2020-10-12","hemoglobin_g_dL":10.7,"wbc_k_uL":7.5,"platelets_k_uL":213,"creatinine_mg_dL":1.01,"alt_U_L":16},{"date":"2022-12-12","hemoglobin_g_dL":10.2,"wbc_k_uL":3.8,"platelets_k_uL":169,"creatinine_mg_dL":1.39,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_188","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":51,"sex":"female","bmi":25.1,"smoking_pack_years":16,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-02-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-56},"pfs_months":8.54},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":12.5,"censored":true},"longitudinal_labs":[{"date":"2021-01-07","hemoglobin_g_dL":15.2,"wbc_k_uL":8.2,"platelets_k_uL":186,"creatinine_mg_dL":0.99,"alt_U_L":77},{"date":"2021-08-03","hemoglobin_g_dL":12.9,"wbc_k_uL":5.7,"platelets_k_uL":196,"creatinine_mg_dL":0.72,"alt_U_L":101},{"date":"2021-12-02","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":203,"creatinine_mg_dL":0.86,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":82,"sex":"female","bmi":36.1,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-65},"pfs_months":23.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":false},"longitudinal_labs":[{"date":"2022-07-19","hemoglobin_g_dL":13.2,"wbc_k_uL":4.6,"platelets_k_uL":213,"creatinine_mg_dL":0.82,"alt_U_L":43},{"date":"2023-02-01","hemoglobin_g_dL":13.3,"wbc_k_uL":6.5,"platelets_k_uL":293,"creatinine_mg_dL":1.35,"alt_U_L":112},{"date":"2024-09-30","hemoglobin_g_dL":10.2,"wbc_k_uL":3.3,"platelets_k_uL":200,"creatinine_mg_dL":0.9,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":87,"sex":"female","bmi":34.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-57},"pfs_months":23.89},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":42.1,"censored":true},"longitudinal_labs":[{"date":"2024-04-19","hemoglobin_g_dL":11.8,"wbc_k_uL":4.6,"platelets_k_uL":307,"creatinine_mg_dL":0.94,"alt_U_L":45},{"date":"2024-11-03","hemoglobin_g_dL":12.9,"wbc_k_uL":6.3,"platelets_k_uL":339,"creatinine_mg_dL":1.51,"alt_U_L":56},{"date":"2026-06-18","hemoglobin_g_dL":10.2,"wbc_k_uL":7.2,"platelets_k_uL":236,"creatinine_mg_dL":1.14,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_191","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":51,"sex":"female","bmi":19.2,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-09-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-40},"pfs_months":32.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.2,"censored":false},"longitudinal_labs":[{"date":"2023-07-18","hemoglobin_g_dL":13.3,"wbc_k_uL":9.2,"platelets_k_uL":346,"creatinine_mg_dL":0.84,"alt_U_L":11},{"date":"2024-03-21","hemoglobin_g_dL":11.8,"wbc_k_uL":3.9,"platelets_k_uL":362,"creatinine_mg_dL":1.18,"alt_U_L":72},{"date":"2026-08-01","hemoglobin_g_dL":12.2,"wbc_k_uL":6.1,"platelets_k_uL":125,"creatinine_mg_dL":1.78,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_192","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":86,"sex":"male","bmi":32.8,"smoking_pack_years":21,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-06-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-42},"pfs_months":16.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.0,"censored":true},"longitudinal_labs":[{"date":"2025-05-21","hemoglobin_g_dL":13.2,"wbc_k_uL":7.7,"platelets_k_uL":317,"creatinine_mg_dL":1.06,"alt_U_L":33},{"date":"2025-12-23","hemoglobin_g_dL":14.0,"wbc_k_uL":5.1,"platelets_k_uL":362,"creatinine_mg_dL":1.48,"alt_U_L":56},{"date":"2026-11-20","hemoglobin_g_dL":10.1,"wbc_k_uL":7.9,"platelets_k_uL":287,"creatinine_mg_dL":1.63,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":65,"sex":"male","bmi":35.2,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-10-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-76},"pfs_months":39.89},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":65.8,"censored":false},"longitudinal_labs":[{"date":"2024-08-08","hemoglobin_g_dL":13.9,"wbc_k_uL":10.5,"platelets_k_uL":161,"creatinine_mg_dL":0.92,"alt_U_L":24},{"date":"2025-04-01","hemoglobin_g_dL":13.8,"wbc_k_uL":7.8,"platelets_k_uL":160,"creatinine_mg_dL":0.83,"alt_U_L":19},{"date":"2028-03-24","hemoglobin_g_dL":11.4,"wbc_k_uL":3.1,"platelets_k_uL":281,"creatinine_mg_dL":0.93,"alt_U_L":198}]}
{"patient_id":"ANODE_SYNTH_2025_194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":87,"sex":"female","bmi":37.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-35},"pfs_months":23.1},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.6,"censored":false},"longitudinal_labs":[{"date":"2023-11-22","hemoglobin_g_dL":14.2,"wbc_k_uL":5.3,"platelets_k_uL":154,"creatinine_mg_dL":0.87,"alt_U_L":23},{"date":"2024-06-03","hemoglobin_g_dL":10.1,"wbc_k_uL":4.4,"platelets_k_uL":379,"creatinine_mg_dL":0.88,"alt_U_L":42},{"date":"2025-12-17","hemoglobin_g_dL":11.1,"wbc_k_uL":4.1,"platelets_k_uL":203,"creatinine_mg_dL":1.42,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_195","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":55,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-41},"pfs_months":30.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":48.0,"censored":true},"longitudinal_labs":[{"date":"2025-02-27","hemoglobin_g_dL":12.6,"wbc_k_uL":7.7,"platelets_k_uL":424,"creatinine_mg_dL":1.24,"alt_U_L":28},{"date":"2025-10-23","hemoglobin_g_dL":12.7,"wbc_k_uL":8.2,"platelets_k_uL":348,"creatinine_mg_dL":0.77,"alt_U_L":78},{"date":"2027-12-29","hemoglobin_g_dL":10.7,"wbc_k_uL":4.1,"platelets_k_uL":287,"creatinine_mg_dL":1.85,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_196","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":83,"sex":"female","bmi":20.1,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-04-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-50},"pfs_months":37.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.4,"censored":true},"longitudinal_labs":[{"date":"2024-02-14","hemoglobin_g_dL":13.3,"wbc_k_uL":10.6,"platelets_k_uL":195,"creatinine_mg_dL":1.0,"alt_U_L":52},{"date":"2024-10-10","hemoglobin_g_dL":13.2,"wbc_k_uL":8.9,"platelets_k_uL":140,"creatinine_mg_dL":1.27,"alt_U_L":25},{"date":"2027-06-22","hemoglobin_g_dL":9.6,"wbc_k_uL":4.5,"platelets_k_uL":241,"creatinine_mg_dL":1.37,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":85,"sex":"female","bmi":25.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-78},"pfs_months":27.4},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":49.8,"censored":false},"longitudinal_labs":[{"date":"2023-08-22","hemoglobin_g_dL":12.0,"wbc_k_uL":9.0,"platelets_k_uL":193,"creatinine_mg_dL":1.2,"alt_U_L":42},{"date":"2024-04-03","hemoglobin_g_dL":10.1,"wbc_k_uL":4.6,"platelets_k_uL":275,"creatinine_mg_dL":1.34,"alt_U_L":19},{"date":"2026-02-04","hemoglobin_g_dL":9.6,"wbc_k_uL":5.2,"platelets_k_uL":138,"creatinine_mg_dL":0.95,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":51,"sex":"female","bmi":33.4,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-05-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-41},"pfs_months":11.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.4,"censored":false},"longitudinal_labs":[{"date":"2023-04-07","hemoglobin_g_dL":13.5,"wbc_k_uL":8.8,"platelets_k_uL":153,"creatinine_mg_dL":1.11,"alt_U_L":59},{"date":"2023-11-20","hemoglobin_g_dL":12.2,"wbc_k_uL":5.1,"platelets_k_uL":275,"creatinine_mg_dL":0.72,"alt_U_L":58},{"date":"2024-05-31","hemoglobin_g_dL":12.7,"wbc_k_uL":4.1,"platelets_k_uL":175,"creatinine_mg_dL":1.82,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":70,"sex":"female","bmi":25.0,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2021-08-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-47},"pfs_months":41.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":67.4,"censored":true},"longitudinal_labs":[{"date":"2021-07-13","hemoglobin_g_dL":11.6,"wbc_k_uL":8.6,"platelets_k_uL":289,"creatinine_mg_dL":1.14,"alt_U_L":72},{"date":"2022-02-03","hemoglobin_g_dL":10.9,"wbc_k_uL":7.8,"platelets_k_uL":376,"creatinine_mg_dL":1.36,"alt_U_L":105},{"date":"2025-03-04","hemoglobin_g_dL":11.1,"wbc_k_uL":5.7,"platelets_k_uL":200,"creatinine_mg_dL":1.79,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":82,"sex":"female","bmi":24.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-74},"pfs_months":15.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.1,"censored":true},"longitudinal_labs":[{"date":"2023-02-02","hemoglobin_g_dL":13.7,"wbc_k_uL":5.2,"platelets_k_uL":282,"creatinine_mg_dL":0.63,"alt_U_L":71},{"date":"2023-09-09","hemoglobin_g_dL":10.8,"wbc_k_uL":3.8,"platelets_k_uL":223,"creatinine_mg_dL":1.58,"alt_U_L":111},{"date":"2024-08-07","hemoglobin_g_dL":11.5,"wbc_k_uL":5.4,"platelets_k_uL":124,"creatinine_mg_dL":1.39,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_201","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":76,"sex":"male","bmi":24.9,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-06-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-79},"pfs_months":21.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":false},"longitudinal_labs":[{"date":"2020-05-02","hemoglobin_g_dL":11.8,"wbc_k_uL":6.6,"platelets_k_uL":449,"creatinine_mg_dL":0.9,"alt_U_L":57},{"date":"2020-12-14","hemoglobin_g_dL":12.7,"wbc_k_uL":7.8,"platelets_k_uL":206,"creatinine_mg_dL":1.37,"alt_U_L":32},{"date":"2022-04-27","hemoglobin_g_dL":9.9,"wbc_k_uL":3.9,"platelets_k_uL":114,"creatinine_mg_dL":1.02,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":84,"sex":"female","bmi":30.9,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-12-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-69},"pfs_months":40.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":61.4,"censored":true},"longitudinal_labs":[{"date":"2021-10-24","hemoglobin_g_dL":12.0,"wbc_k_uL":8.2,"platelets_k_uL":263,"creatinine_mg_dL":1.26,"alt_U_L":62},{"date":"2022-06-21","hemoglobin_g_dL":12.8,"wbc_k_uL":4.2,"platelets_k_uL":325,"creatinine_mg_dL":0.99,"alt_U_L":25},{"date":"2025-06-20","hemoglobin_g_dL":12.1,"wbc_k_uL":7.5,"platelets_k_uL":261,"creatinine_mg_dL":0.9,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":85,"sex":"female","bmi":25.7,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-09-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-55},"pfs_months":20.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2020-08-26","hemoglobin_g_dL":15.5,"wbc_k_uL":6.6,"platelets_k_uL":278,"creatinine_mg_dL":1.13,"alt_U_L":66},{"date":"2021-03-15","hemoglobin_g_dL":12.6,"wbc_k_uL":6.9,"platelets_k_uL":356,"creatinine_mg_dL":1.41,"alt_U_L":36},{"date":"2022-08-01","hemoglobin_g_dL":10.0,"wbc_k_uL":6.4,"platelets_k_uL":129,"creatinine_mg_dL":0.8,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":70,"sex":"male","bmi":21.8,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-12-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-41},"pfs_months":47.51},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.8,"censored":false},"longitudinal_labs":[{"date":"2021-10-19","hemoglobin_g_dL":13.7,"wbc_k_uL":8.0,"platelets_k_uL":290,"creatinine_mg_dL":0.94,"alt_U_L":67},{"date":"2022-06-03","hemoglobin_g_dL":13.2,"wbc_k_uL":6.6,"platelets_k_uL":184,"creatinine_mg_dL":0.89,"alt_U_L":106},{"date":"2025-11-25","hemoglobin_g_dL":11.1,"wbc_k_uL":4.5,"platelets_k_uL":102,"creatinine_mg_dL":1.48,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_205","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":70,"sex":"female","bmi":35.8,"smoking_pack_years":56,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-02-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-63},"pfs_months":12.09},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.1,"censored":false},"longitudinal_labs":[{"date":"2021-01-09","hemoglobin_g_dL":12.4,"wbc_k_uL":8.5,"platelets_k_uL":345,"creatinine_mg_dL":1.2,"alt_U_L":34},{"date":"2021-08-21","hemoglobin_g_dL":13.3,"wbc_k_uL":8.9,"platelets_k_uL":312,"creatinine_mg_dL":1.22,"alt_U_L":47},{"date":"2022-04-16","hemoglobin_g_dL":11.4,"wbc_k_uL":8.0,"platelets_k_uL":210,"creatinine_mg_dL":1.99,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":62,"sex":"female","bmi":30.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-62},"pfs_months":14.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":27.6,"censored":true},"longitudinal_labs":[{"date":"2021-01-26","hemoglobin_g_dL":11.8,"wbc_k_uL":10.4,"platelets_k_uL":435,"creatinine_mg_dL":1.01,"alt_U_L":66},{"date":"2021-09-29","hemoglobin_g_dL":11.5,"wbc_k_uL":5.2,"platelets_k_uL":141,"creatinine_mg_dL":1.0,"alt_U_L":75},{"date":"2022-07-13","hemoglobin_g_dL":9.9,"wbc_k_uL":4.5,"platelets_k_uL":254,"creatinine_mg_dL":1.8,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":60,"sex":"female","bmi":30.3,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-04-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-60},"pfs_months":14.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.2,"censored":false},"longitudinal_labs":[{"date":"2023-02-10","hemoglobin_g_dL":12.3,"wbc_k_uL":7.9,"platelets_k_uL":279,"creatinine_mg_dL":1.07,"alt_U_L":61},{"date":"2023-10-08","hemoglobin_g_dL":11.0,"wbc_k_uL":7.8,"platelets_k_uL":272,"creatinine_mg_dL":1.5,"alt_U_L":117},{"date":"2024-07-02","hemoglobin_g_dL":10.9,"wbc_k_uL":4.0,"platelets_k_uL":131,"creatinine_mg_dL":1.83,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":68,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-71},"pfs_months":28.94},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.7,"censored":false},"longitudinal_labs":[{"date":"2023-11-04","hemoglobin_g_dL":11.7,"wbc_k_uL":6.5,"platelets_k_uL":339,"creatinine_mg_dL":0.95,"alt_U_L":65},{"date":"2024-05-27","hemoglobin_g_dL":12.5,"wbc_k_uL":4.0,"platelets_k_uL":362,"creatinine_mg_dL":1.55,"alt_U_L":74},{"date":"2026-06-01","hemoglobin_g_dL":12.9,"wbc_k_uL":3.9,"platelets_k_uL":278,"creatinine_mg_dL":1.84,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":84,"sex":"female","bmi":27.2,"smoking_pack_years":13,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-08-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-52},"pfs_months":34.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.5,"censored":false},"longitudinal_labs":[{"date":"2025-06-22","hemoglobin_g_dL":14.9,"wbc_k_uL":8.3,"platelets_k_uL":213,"creatinine_mg_dL":0.6,"alt_U_L":63},{"date":"2026-02-08","hemoglobin_g_dL":13.8,"wbc_k_uL":8.9,"platelets_k_uL":271,"creatinine_mg_dL":0.89,"alt_U_L":100},{"date":"2028-07-06","hemoglobin_g_dL":11.1,"wbc_k_uL":6.5,"platelets_k_uL":195,"creatinine_mg_dL":0.82,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":61,"sex":"male","bmi":33.8,"smoking_pack_years":71,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2026-01-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-57},"pfs_months":11.76},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.2,"censored":false},"longitudinal_labs":[{"date":"2025-12-07","hemoglobin_g_dL":15.4,"wbc_k_uL":8.1,"platelets_k_uL":440,"creatinine_mg_dL":1.03,"alt_U_L":77},{"date":"2026-07-23","hemoglobin_g_dL":12.4,"wbc_k_uL":4.1,"platelets_k_uL":259,"creatinine_mg_dL":1.44,"alt_U_L":95},{"date":"2027-02-16","hemoglobin_g_dL":13.0,"wbc_k_uL":7.9,"platelets_k_uL":318,"creatinine_mg_dL":0.87,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":77,"sex":"female","bmi":23.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-68},"pfs_months":27.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":false},"longitudinal_labs":[{"date":"2023-12-12","hemoglobin_g_dL":13.0,"wbc_k_uL":10.4,"platelets_k_uL":436,"creatinine_mg_dL":0.99,"alt_U_L":37},{"date":"2024-07-16","hemoglobin_g_dL":10.6,"wbc_k_uL":8.9,"platelets_k_uL":267,"creatinine_mg_dL":0.86,"alt_U_L":89},{"date":"2026-06-12","hemoglobin_g_dL":11.4,"wbc_k_uL":3.4,"platelets_k_uL":329,"creatinine_mg_dL":1.47,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":63,"sex":"female","bmi":32.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["brain","pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-31},"pfs_months":24.71},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":false},"longitudinal_labs":[{"date":"2025-07-20","hemoglobin_g_dL":12.5,"wbc_k_uL":7.4,"platelets_k_uL":357,"creatinine_mg_dL":0.68,"alt_U_L":40},{"date":"2026-02-04","hemoglobin_g_dL":10.6,"wbc_k_uL":6.6,"platelets_k_uL":176,"creatinine_mg_dL":0.85,"alt_U_L":19},{"date":"2027-09-15","hemoglobin_g_dL":10.3,"wbc_k_uL":4.2,"platelets_k_uL":343,"creatinine_mg_dL":1.81,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":76,"sex":"male","bmi":29.5,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-08-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-76},"pfs_months":40.08},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":66.0,"censored":true},"longitudinal_labs":[{"date":"2020-06-15","hemoglobin_g_dL":13.7,"wbc_k_uL":9.3,"platelets_k_uL":217,"creatinine_mg_dL":1.27,"alt_U_L":23},{"date":"2021-02-11","hemoglobin_g_dL":12.5,"wbc_k_uL":5.9,"platelets_k_uL":356,"creatinine_mg_dL":1.29,"alt_U_L":108},{"date":"2024-02-09","hemoglobin_g_dL":10.0,"wbc_k_uL":3.6,"platelets_k_uL":281,"creatinine_mg_dL":1.92,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":83,"sex":"female","bmi":22.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-41},"pfs_months":30.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":48.6,"censored":false},"longitudinal_labs":[{"date":"2023-07-22","hemoglobin_g_dL":12.1,"wbc_k_uL":8.1,"platelets_k_uL":345,"creatinine_mg_dL":0.74,"alt_U_L":31},{"date":"2024-02-21","hemoglobin_g_dL":10.4,"wbc_k_uL":4.6,"platelets_k_uL":194,"creatinine_mg_dL":1.18,"alt_U_L":74},{"date":"2026-05-18","hemoglobin_g_dL":12.0,"wbc_k_uL":5.3,"platelets_k_uL":107,"creatinine_mg_dL":1.62,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_215","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":74,"sex":"male","bmi":35.9,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-07-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-31},"pfs_months":21.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.0,"censored":false},"longitudinal_labs":[{"date":"2021-06-17","hemoglobin_g_dL":12.9,"wbc_k_uL":5.9,"platelets_k_uL":224,"creatinine_mg_dL":0.85,"alt_U_L":52},{"date":"2022-01-13","hemoglobin_g_dL":13.3,"wbc_k_uL":5.1,"platelets_k_uL":313,"creatinine_mg_dL":1.19,"alt_U_L":119},{"date":"2023-06-02","hemoglobin_g_dL":10.3,"wbc_k_uL":4.3,"platelets_k_uL":109,"creatinine_mg_dL":1.04,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":78,"sex":"female","bmi":28.3,"smoking_pack_years":13,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-11-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-50},"pfs_months":4.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":11.7,"censored":true},"longitudinal_labs":[{"date":"2021-11-03","hemoglobin_g_dL":14.0,"wbc_k_uL":9.7,"platelets_k_uL":371,"creatinine_mg_dL":1.17,"alt_U_L":23},{"date":"2022-05-23","hemoglobin_g_dL":12.3,"wbc_k_uL":4.7,"platelets_k_uL":334,"creatinine_mg_dL":1.39,"alt_U_L":72},{"date":"2022-05-06","hemoglobin_g_dL":12.4,"wbc_k_uL":5.0,"platelets_k_uL":107,"creatinine_mg_dL":1.78,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":65,"sex":"female","bmi":37.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-68},"pfs_months":15.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.9,"censored":true},"longitudinal_labs":[{"date":"2024-12-06","hemoglobin_g_dL":14.0,"wbc_k_uL":10.1,"platelets_k_uL":407,"creatinine_mg_dL":0.92,"alt_U_L":10},{"date":"2025-07-19","hemoglobin_g_dL":12.1,"wbc_k_uL":6.6,"platelets_k_uL":141,"creatinine_mg_dL":1.29,"alt_U_L":29},{"date":"2026-06-15","hemoglobin_g_dL":12.3,"wbc_k_uL":4.4,"platelets_k_uL":117,"creatinine_mg_dL":1.59,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":57,"sex":"female","bmi":32.5,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-11-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-62},"pfs_months":39.33},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-04-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":68.7,"censored":false},"longitudinal_labs":[{"date":"2025-10-27","hemoglobin_g_dL":11.8,"wbc_k_uL":5.0,"platelets_k_uL":382,"creatinine_mg_dL":0.72,"alt_U_L":31},{"date":"2026-05-12","hemoglobin_g_dL":12.3,"wbc_k_uL":6.6,"platelets_k_uL":162,"creatinine_mg_dL":1.35,"alt_U_L":19},{"date":"2029-04-09","hemoglobin_g_dL":12.6,"wbc_k_uL":5.6,"platelets_k_uL":238,"creatinine_mg_dL":1.39,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":71,"sex":"female","bmi":19.3,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-07-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-77},"pfs_months":45.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":66.9,"censored":false},"longitudinal_labs":[{"date":"2022-05-16","hemoglobin_g_dL":13.9,"wbc_k_uL":8.0,"platelets_k_uL":163,"creatinine_mg_dL":0.99,"alt_U_L":12},{"date":"2023-01-18","hemoglobin_g_dL":10.9,"wbc_k_uL":5.0,"platelets_k_uL":370,"creatinine_mg_dL":1.38,"alt_U_L":16},{"date":"2026-06-27","hemoglobin_g_dL":10.2,"wbc_k_uL":7.8,"platelets_k_uL":349,"creatinine_mg_dL":1.29,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":81,"sex":"female","bmi":37.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-50},"pfs_months":23.2},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.9,"censored":false},"longitudinal_labs":[{"date":"2025-05-15","hemoglobin_g_dL":12.3,"wbc_k_uL":7.4,"platelets_k_uL":216,"creatinine_mg_dL":0.98,"alt_U_L":59},{"date":"2025-12-14","hemoglobin_g_dL":12.6,"wbc_k_uL":5.0,"platelets_k_uL":226,"creatinine_mg_dL":1.21,"alt_U_L":59},{"date":"2027-06-17","hemoglobin_g_dL":12.6,"wbc_k_uL":6.1,"platelets_k_uL":274,"creatinine_mg_dL":0.91,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":88,"sex":"female","bmi":36.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-68},"pfs_months":23.92},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.3,"censored":false},"longitudinal_labs":[{"date":"2025-05-27","hemoglobin_g_dL":15.5,"wbc_k_uL":7.3,"platelets_k_uL":188,"creatinine_mg_dL":0.97,"alt_U_L":18},{"date":"2025-12-07","hemoglobin_g_dL":10.4,"wbc_k_uL":7.7,"platelets_k_uL":273,"creatinine_mg_dL":1.13,"alt_U_L":58},{"date":"2027-06-13","hemoglobin_g_dL":12.6,"wbc_k_uL":5.0,"platelets_k_uL":220,"creatinine_mg_dL":1.68,"alt_U_L":166}]}
{"patient_id":"ANODE_SYNTH_2025_222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":87,"sex":"female","bmi":36.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-30},"pfs_months":18.56},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.9,"censored":true},"longitudinal_labs":[{"date":"2020-03-28","hemoglobin_g_dL":13.5,"wbc_k_uL":6.3,"platelets_k_uL":409,"creatinine_mg_dL":1.2,"alt_U_L":42},{"date":"2020-10-26","hemoglobin_g_dL":10.8,"wbc_k_uL":8.9,"platelets_k_uL":194,"creatinine_mg_dL":0.84,"alt_U_L":84},{"date":"2021-12-01","hemoglobin_g_dL":13.0,"wbc_k_uL":4.3,"platelets_k_uL":138,"creatinine_mg_dL":1.93,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":86,"sex":"female","bmi":23.0,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-64},"pfs_months":41.92},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":75.2,"censored":true},"longitudinal_labs":[{"date":"2021-04-18","hemoglobin_g_dL":14.7,"wbc_k_uL":7.3,"platelets_k_uL":201,"creatinine_mg_dL":0.79,"alt_U_L":25},{"date":"2021-12-23","hemoglobin_g_dL":10.1,"wbc_k_uL":4.6,"platelets_k_uL":333,"creatinine_mg_dL":0.97,"alt_U_L":100},{"date":"2025-02-19","hemoglobin_g_dL":12.4,"wbc_k_uL":4.2,"platelets_k_uL":106,"creatinine_mg_dL":1.57,"alt_U_L":149}]}
{"patient_id":"ANODE_SYNTH_2025_224","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":60,"sex":"male","bmi":28.3,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-09-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-37},"pfs_months":20.37},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":false},"longitudinal_labs":[{"date":"2025-08-14","hemoglobin_g_dL":11.5,"wbc_k_uL":9.2,"platelets_k_uL":257,"creatinine_mg_dL":1.0,"alt_U_L":30},{"date":"2026-03-15","hemoglobin_g_dL":10.2,"wbc_k_uL":8.1,"platelets_k_uL":349,"creatinine_mg_dL":1.55,"alt_U_L":92},{"date":"2027-07-16","hemoglobin_g_dL":12.1,"wbc_k_uL":5.8,"platelets_k_uL":339,"creatinine_mg_dL":1.58,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":85,"sex":"female","bmi":37.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-54},"pfs_months":29.34},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":49.0,"censored":false},"longitudinal_labs":[{"date":"2022-03-15","hemoglobin_g_dL":13.9,"wbc_k_uL":10.5,"platelets_k_uL":336,"creatinine_mg_dL":1.21,"alt_U_L":65},{"date":"2022-11-16","hemoglobin_g_dL":11.6,"wbc_k_uL":4.6,"platelets_k_uL":130,"creatinine_mg_dL":1.17,"alt_U_L":88},{"date":"2024-11-07","hemoglobin_g_dL":10.8,"wbc_k_uL":6.7,"platelets_k_uL":302,"creatinine_mg_dL":1.82,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":51,"sex":"female","bmi":22.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-72},"pfs_months":25.0},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.6,"censored":true},"longitudinal_labs":[{"date":"2025-01-08","hemoglobin_g_dL":15.0,"wbc_k_uL":7.3,"platelets_k_uL":178,"creatinine_mg_dL":1.09,"alt_U_L":10},{"date":"2025-07-31","hemoglobin_g_dL":11.2,"wbc_k_uL":5.2,"platelets_k_uL":373,"creatinine_mg_dL":1.0,"alt_U_L":19},{"date":"2027-03-28","hemoglobin_g_dL":11.2,"wbc_k_uL":4.0,"platelets_k_uL":233,"creatinine_mg_dL":1.06,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":84,"sex":"male","bmi":19.2,"smoking_pack_years":12,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-04-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-60},"pfs_months":39.1},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":66.5,"censored":false},"longitudinal_labs":[{"date":"2021-03-08","hemoglobin_g_dL":12.3,"wbc_k_uL":8.7,"platelets_k_uL":222,"creatinine_mg_dL":0.85,"alt_U_L":27},{"date":"2021-10-06","hemoglobin_g_dL":11.3,"wbc_k_uL":6.0,"platelets_k_uL":307,"creatinine_mg_dL":0.79,"alt_U_L":20},{"date":"2024-08-30","hemoglobin_g_dL":11.3,"wbc_k_uL":3.0,"platelets_k_uL":314,"creatinine_mg_dL":0.98,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_228","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":57,"sex":"female","bmi":28.3,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-52},"pfs_months":22.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":true},"longitudinal_labs":[{"date":"2023-05-17","hemoglobin_g_dL":13.9,"wbc_k_uL":9.6,"platelets_k_uL":349,"creatinine_mg_dL":0.82,"alt_U_L":31},{"date":"2024-01-20","hemoglobin_g_dL":12.8,"wbc_k_uL":4.6,"platelets_k_uL":204,"creatinine_mg_dL":1.05,"alt_U_L":87},{"date":"2025-06-21","hemoglobin_g_dL":11.6,"wbc_k_uL":4.4,"platelets_k_uL":275,"creatinine_mg_dL":1.08,"alt_U_L":125}]}
{"patient_id":"ANODE_SYNTH_2025_229","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":57,"sex":"male","bmi":26.3,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-04-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-84},"pfs_months":13.5},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.8,"censored":false},"longitudinal_labs":[{"date":"2024-03-12","hemoglobin_g_dL":13.9,"wbc_k_uL":10.3,"platelets_k_uL":331,"creatinine_mg_dL":0.89,"alt_U_L":17},{"date":"2024-10-12","hemoglobin_g_dL":10.1,"wbc_k_uL":5.0,"platelets_k_uL":157,"creatinine_mg_dL":0.85,"alt_U_L":94},{"date":"2025-07-29","hemoglobin_g_dL":12.5,"wbc_k_uL":6.3,"platelets_k_uL":282,"creatinine_mg_dL":1.63,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":62,"sex":"female","bmi":34.7,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-10-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-48},"pfs_months":38.37},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":60.3,"censored":false},"longitudinal_labs":[{"date":"2021-08-20","hemoglobin_g_dL":14.2,"wbc_k_uL":9.1,"platelets_k_uL":353,"creatinine_mg_dL":1.12,"alt_U_L":39},{"date":"2022-04-27","hemoglobin_g_dL":13.8,"wbc_k_uL":6.6,"platelets_k_uL":316,"creatinine_mg_dL":1.02,"alt_U_L":120},{"date":"2025-02-12","hemoglobin_g_dL":12.3,"wbc_k_uL":5.2,"platelets_k_uL":312,"creatinine_mg_dL":1.14,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":60,"sex":"female","bmi":20.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-46},"pfs_months":22.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.2,"censored":true},"longitudinal_labs":[{"date":"2025-11-01","hemoglobin_g_dL":11.9,"wbc_k_uL":6.1,"platelets_k_uL":399,"creatinine_mg_dL":0.86,"alt_U_L":38},{"date":"2026-05-28","hemoglobin_g_dL":12.0,"wbc_k_uL":7.4,"platelets_k_uL":298,"creatinine_mg_dL":1.24,"alt_U_L":112},{"date":"2027-12-01","hemoglobin_g_dL":10.6,"wbc_k_uL":6.6,"platelets_k_uL":135,"creatinine_mg_dL":1.71,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.2,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":52,"sex":"female","bmi":30.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-69},"pfs_months":20.53},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.8,"censored":false},"longitudinal_labs":[{"date":"2025-04-01","hemoglobin_g_dL":13.1,"wbc_k_uL":6.3,"platelets_k_uL":344,"creatinine_mg_dL":1.06,"alt_U_L":58},{"date":"2025-10-16","hemoglobin_g_dL":12.6,"wbc_k_uL":7.4,"platelets_k_uL":175,"creatinine_mg_dL":1.42,"alt_U_L":89},{"date":"2027-01-24","hemoglobin_g_dL":10.9,"wbc_k_uL":5.5,"platelets_k_uL":279,"creatinine_mg_dL":1.95,"alt_U_L":145}]}
{"patient_id":"ANODE_SYNTH_2025_233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":71,"sex":"male","bmi":30.4,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2020-12-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-55},"pfs_months":16.53},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":20.5,"censored":false},"longitudinal_labs":[{"date":"2020-10-06","hemoglobin_g_dL":15.4,"wbc_k_uL":8.3,"platelets_k_uL":395,"creatinine_mg_dL":0.75,"alt_U_L":29},{"date":"2021-05-31","hemoglobin_g_dL":13.8,"wbc_k_uL":6.8,"platelets_k_uL":190,"creatinine_mg_dL":1.26,"alt_U_L":105},{"date":"2022-04-29","hemoglobin_g_dL":10.8,"wbc_k_uL":7.5,"platelets_k_uL":246,"creatinine_mg_dL":1.21,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":76,"sex":"female","bmi":23.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-77},"pfs_months":22.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.0,"censored":true},"longitudinal_labs":[{"date":"2021-08-16","hemoglobin_g_dL":13.5,"wbc_k_uL":8.0,"platelets_k_uL":289,"creatinine_mg_dL":1.12,"alt_U_L":43},{"date":"2022-03-24","hemoglobin_g_dL":13.4,"wbc_k_uL":8.5,"platelets_k_uL":224,"creatinine_mg_dL":1.45,"alt_U_L":15},{"date":"2023-09-13","hemoglobin_g_dL":12.8,"wbc_k_uL":7.0,"platelets_k_uL":168,"creatinine_mg_dL":1.78,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":53,"sex":"female","bmi":32.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-75},"pfs_months":24.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.1,"censored":false},"longitudinal_labs":[{"date":"2025-07-14","hemoglobin_g_dL":14.4,"wbc_k_uL":9.0,"platelets_k_uL":289,"creatinine_mg_dL":0.69,"alt_U_L":45},{"date":"2026-03-16","hemoglobin_g_dL":12.3,"wbc_k_uL":5.7,"platelets_k_uL":134,"creatinine_mg_dL":0.75,"alt_U_L":68},{"date":"2027-12-04","hemoglobin_g_dL":11.6,"wbc_k_uL":5.0,"platelets_k_uL":312,"creatinine_mg_dL":1.72,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":76,"sex":"female","bmi":24.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-41},"pfs_months":26.87},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":false},"longitudinal_labs":[{"date":"2020-10-08","hemoglobin_g_dL":15.1,"wbc_k_uL":6.4,"platelets_k_uL":227,"creatinine_mg_dL":1.12,"alt_U_L":69},{"date":"2021-05-30","hemoglobin_g_dL":11.3,"wbc_k_uL":8.8,"platelets_k_uL":300,"creatinine_mg_dL":1.28,"alt_U_L":74},{"date":"2023-03-10","hemoglobin_g_dL":11.1,"wbc_k_uL":4.1,"platelets_k_uL":348,"creatinine_mg_dL":0.91,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":57,"sex":"female","bmi":36.1,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-01-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-31},"pfs_months":7.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.4,"censored":true},"longitudinal_labs":[{"date":"2022-11-17","hemoglobin_g_dL":11.6,"wbc_k_uL":4.6,"platelets_k_uL":289,"creatinine_mg_dL":1.02,"alt_U_L":29},{"date":"2023-07-22","hemoglobin_g_dL":12.6,"wbc_k_uL":8.2,"platelets_k_uL":341,"creatinine_mg_dL":1.53,"alt_U_L":99},{"date":"2023-09-22","hemoglobin_g_dL":11.1,"wbc_k_uL":4.4,"platelets_k_uL":244,"creatinine_mg_dL":0.89,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":53,"sex":"female","bmi":33.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-38},"pfs_months":11.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.5,"censored":false},"longitudinal_labs":[{"date":"2021-09-09","hemoglobin_g_dL":12.5,"wbc_k_uL":5.1,"platelets_k_uL":218,"creatinine_mg_dL":0.86,"alt_U_L":10},{"date":"2022-04-19","hemoglobin_g_dL":11.7,"wbc_k_uL":4.1,"platelets_k_uL":148,"creatinine_mg_dL":1.31,"alt_U_L":119},{"date":"2022-10-14","hemoglobin_g_dL":10.5,"wbc_k_uL":7.0,"platelets_k_uL":141,"creatinine_mg_dL":1.0,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_239","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":67,"sex":"female","bmi":30.8,"smoking_pack_years":74,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-43},"pfs_months":21.09},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.4,"censored":false},"longitudinal_labs":[{"date":"2020-01-13","hemoglobin_g_dL":14.4,"wbc_k_uL":10.4,"platelets_k_uL":419,"creatinine_mg_dL":0.86,"alt_U_L":61},{"date":"2020-09-14","hemoglobin_g_dL":12.0,"wbc_k_uL":8.8,"platelets_k_uL":187,"creatinine_mg_dL":0.97,"alt_U_L":72},{"date":"2022-02-05","hemoglobin_g_dL":10.6,"wbc_k_uL":5.4,"platelets_k_uL":182,"creatinine_mg_dL":1.8,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_240","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":78,"sex":"male","bmi":35.7,"smoking_pack_years":45,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-08-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-83},"pfs_months":16.59},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.3,"censored":false},"longitudinal_labs":[{"date":"2021-07-20","hemoglobin_g_dL":13.6,"wbc_k_uL":9.6,"platelets_k_uL":242,"creatinine_mg_dL":1.22,"alt_U_L":65},{"date":"2022-02-23","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":146,"creatinine_mg_dL":0.94,"alt_U_L":92},{"date":"2023-03-11","hemoglobin_g_dL":12.9,"wbc_k_uL":5.9,"platelets_k_uL":301,"creatinine_mg_dL":1.17,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":54,"sex":"male","bmi":21.4,"smoking_pack_years":13,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-75},"pfs_months":39.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.0,"censored":false},"longitudinal_labs":[{"date":"2022-12-02","hemoglobin_g_dL":14.0,"wbc_k_uL":8.4,"platelets_k_uL":188,"creatinine_mg_dL":1.19,"alt_U_L":46},{"date":"2023-06-16","hemoglobin_g_dL":10.6,"wbc_k_uL":6.2,"platelets_k_uL":335,"creatinine_mg_dL":0.72,"alt_U_L":28},{"date":"2026-05-12","hemoglobin_g_dL":12.6,"wbc_k_uL":6.1,"platelets_k_uL":196,"creatinine_mg_dL":1.87,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_242","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":83,"sex":"male","bmi":27.8,"smoking_pack_years":75,"ecog_performance_status":2,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-08-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-81},"pfs_months":22.18},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.6,"censored":true},"longitudinal_labs":[{"date":"2020-07-14","hemoglobin_g_dL":12.4,"wbc_k_uL":7.8,"platelets_k_uL":280,"creatinine_mg_dL":0.91,"alt_U_L":70},{"date":"2021-02-26","hemoglobin_g_dL":12.7,"wbc_k_uL":6.8,"platelets_k_uL":352,"creatinine_mg_dL":1.59,"alt_U_L":62},{"date":"2022-08-17","hemoglobin_g_dL":11.1,"wbc_k_uL":7.0,"platelets_k_uL":177,"creatinine_mg_dL":1.39,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":68,"sex":"female","bmi":28.8,"smoking_pack_years":56,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-03-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-56},"pfs_months":12.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.7,"censored":false},"longitudinal_labs":[{"date":"2025-02-04","hemoglobin_g_dL":11.8,"wbc_k_uL":5.7,"platelets_k_uL":409,"creatinine_mg_dL":1.1,"alt_U_L":79},{"date":"2025-09-08","hemoglobin_g_dL":13.1,"wbc_k_uL":4.2,"platelets_k_uL":238,"creatinine_mg_dL":1.13,"alt_U_L":16},{"date":"2026-05-01","hemoglobin_g_dL":11.9,"wbc_k_uL":4.5,"platelets_k_uL":301,"creatinine_mg_dL":1.79,"alt_U_L":90}]}
{"patient_id":"ANODE_SYNTH_2025_244","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":55,"sex":"male","bmi":26.5,"smoking_pack_years":54,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-06-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-50},"pfs_months":14.0},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.4,"censored":false},"longitudinal_labs":[{"date":"2024-05-20","hemoglobin_g_dL":12.7,"wbc_k_uL":9.4,"platelets_k_uL":431,"creatinine_mg_dL":0.72,"alt_U_L":23},{"date":"2024-12-03","hemoglobin_g_dL":11.8,"wbc_k_uL":7.1,"platelets_k_uL":147,"creatinine_mg_dL":0.95,"alt_U_L":98},{"date":"2025-09-09","hemoglobin_g_dL":12.4,"wbc_k_uL":7.3,"platelets_k_uL":208,"creatinine_mg_dL":1.04,"alt_U_L":108}]}
{"patient_id":"ANODE_SYNTH_2025_245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":70,"sex":"female","bmi":21.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-60},"pfs_months":24.44},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.3,"censored":false},"longitudinal_labs":[{"date":"2022-02-22","hemoglobin_g_dL":14.9,"wbc_k_uL":7.0,"platelets_k_uL":331,"creatinine_mg_dL":0.6,"alt_U_L":61},{"date":"2022-10-16","hemoglobin_g_dL":12.2,"wbc_k_uL":3.9,"platelets_k_uL":217,"creatinine_mg_dL":1.14,"alt_U_L":41},{"date":"2024-06-27","hemoglobin_g_dL":11.6,"wbc_k_uL":6.1,"platelets_k_uL":126,"creatinine_mg_dL":1.2,"alt_U_L":149}]}
{"patient_id":"ANODE_SYNTH_2025_246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":59,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-35},"pfs_months":23.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":true},"longitudinal_labs":[{"date":"2022-09-11","hemoglobin_g_dL":14.1,"wbc_k_uL":9.7,"platelets_k_uL":377,"creatinine_mg_dL":0.91,"alt_U_L":54},{"date":"2023-05-06","hemoglobin_g_dL":11.2,"wbc_k_uL":8.1,"platelets_k_uL":361,"creatinine_mg_dL":0.95,"alt_U_L":47},{"date":"2024-12-04","hemoglobin_g_dL":11.0,"wbc_k_uL":4.6,"platelets_k_uL":175,"creatinine_mg_dL":1.33,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":64,"sex":"female","bmi":19.6,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-54},"pfs_months":18.3},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.0,"censored":false},"longitudinal_labs":[{"date":"2025-05-26","hemoglobin_g_dL":12.1,"wbc_k_uL":6.7,"platelets_k_uL":425,"creatinine_mg_dL":1.01,"alt_U_L":23},{"date":"2026-01-28","hemoglobin_g_dL":13.9,"wbc_k_uL":4.2,"platelets_k_uL":259,"creatinine_mg_dL":1.31,"alt_U_L":67},{"date":"2027-02-22","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":288,"creatinine_mg_dL":1.36,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_248","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":79,"sex":"female","bmi":25.4,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-12-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-82},"pfs_months":23.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.4,"censored":false},"longitudinal_labs":[{"date":"2021-11-21","hemoglobin_g_dL":13.8,"wbc_k_uL":6.9,"platelets_k_uL":407,"creatinine_mg_dL":1.18,"alt_U_L":29},{"date":"2022-06-27","hemoglobin_g_dL":12.3,"wbc_k_uL":9.0,"platelets_k_uL":270,"creatinine_mg_dL":1.25,"alt_U_L":112},{"date":"2023-12-21","hemoglobin_g_dL":10.1,"wbc_k_uL":5.2,"platelets_k_uL":227,"creatinine_mg_dL":1.41,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":57,"sex":"female","bmi":29.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-72},"pfs_months":23.59},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.7,"censored":false},"longitudinal_labs":[{"date":"2024-08-04","hemoglobin_g_dL":15.2,"wbc_k_uL":7.2,"platelets_k_uL":217,"creatinine_mg_dL":1.04,"alt_U_L":43},{"date":"2025-04-08","hemoglobin_g_dL":11.9,"wbc_k_uL":6.0,"platelets_k_uL":314,"creatinine_mg_dL":1.1,"alt_U_L":97},{"date":"2026-10-10","hemoglobin_g_dL":10.8,"wbc_k_uL":6.7,"platelets_k_uL":196,"creatinine_mg_dL":1.53,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_250","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":55,"sex":"female","bmi":20.4,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-05-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-66},"pfs_months":22.44},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.0,"censored":false},"longitudinal_labs":[{"date":"2020-04-09","hemoglobin_g_dL":14.8,"wbc_k_uL":9.8,"platelets_k_uL":347,"creatinine_mg_dL":1.15,"alt_U_L":70},{"date":"2020-11-17","hemoglobin_g_dL":10.3,"wbc_k_uL":6.1,"platelets_k_uL":258,"creatinine_mg_dL":0.73,"alt_U_L":47},{"date":"2022-04-15","hemoglobin_g_dL":10.2,"wbc_k_uL":6.5,"platelets_k_uL":166,"creatinine_mg_dL":1.68,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":54,"sex":"female","bmi":18.9,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-10-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-83},"pfs_months":9.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":14.1,"censored":true},"longitudinal_labs":[{"date":"2023-09-11","hemoglobin_g_dL":11.8,"wbc_k_uL":6.8,"platelets_k_uL":170,"creatinine_mg_dL":0.66,"alt_U_L":34},{"date":"2024-04-06","hemoglobin_g_dL":14.0,"wbc_k_uL":6.7,"platelets_k_uL":132,"creatinine_mg_dL":0.76,"alt_U_L":67},{"date":"2024-08-23","hemoglobin_g_dL":11.0,"wbc_k_uL":7.9,"platelets_k_uL":205,"creatinine_mg_dL":0.89,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":83,"sex":"female","bmi":28.5,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-07-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-67},"pfs_months":35.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":58.2,"censored":false},"longitudinal_labs":[{"date":"2025-06-01","hemoglobin_g_dL":15.3,"wbc_k_uL":8.3,"platelets_k_uL":179,"creatinine_mg_dL":1.25,"alt_U_L":22},{"date":"2026-01-10","hemoglobin_g_dL":11.9,"wbc_k_uL":8.4,"platelets_k_uL":166,"creatinine_mg_dL":0.75,"alt_U_L":86},{"date":"2028-07-13","hemoglobin_g_dL":12.0,"wbc_k_uL":4.1,"platelets_k_uL":346,"creatinine_mg_dL":1.78,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_253","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":70,"sex":"female","bmi":30.3,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-12-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-58},"pfs_months":13.73},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":true},"longitudinal_labs":[{"date":"2025-11-22","hemoglobin_g_dL":12.5,"wbc_k_uL":5.7,"platelets_k_uL":439,"creatinine_mg_dL":0.75,"alt_U_L":12},{"date":"2026-06-11","hemoglobin_g_dL":10.5,"wbc_k_uL":6.5,"platelets_k_uL":210,"creatinine_mg_dL":1.16,"alt_U_L":104},{"date":"2027-03-06","hemoglobin_g_dL":11.6,"wbc_k_uL":3.6,"platelets_k_uL":319,"creatinine_mg_dL":0.98,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":79,"sex":"male","bmi":21.5,"smoking_pack_years":53,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-76},"pfs_months":29.31},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":55.3,"censored":false},"longitudinal_labs":[{"date":"2021-04-15","hemoglobin_g_dL":13.2,"wbc_k_uL":8.8,"platelets_k_uL":310,"creatinine_mg_dL":0.96,"alt_U_L":35},{"date":"2021-11-05","hemoglobin_g_dL":10.8,"wbc_k_uL":6.0,"platelets_k_uL":171,"creatinine_mg_dL":1.41,"alt_U_L":109},{"date":"2023-11-27","hemoglobin_g_dL":12.5,"wbc_k_uL":3.8,"platelets_k_uL":338,"creatinine_mg_dL":0.97,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":56,"sex":"female","bmi":35.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-68},"pfs_months":17.41},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.5,"censored":false},"longitudinal_labs":[{"date":"2021-08-02","hemoglobin_g_dL":12.2,"wbc_k_uL":6.5,"platelets_k_uL":189,"creatinine_mg_dL":0.64,"alt_U_L":50},{"date":"2022-03-21","hemoglobin_g_dL":10.6,"wbc_k_uL":5.0,"platelets_k_uL":223,"creatinine_mg_dL":1.43,"alt_U_L":67},{"date":"2023-04-11","hemoglobin_g_dL":9.9,"wbc_k_uL":3.1,"platelets_k_uL":227,"creatinine_mg_dL":1.74,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":71,"sex":"male","bmi":25.3,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-37},"pfs_months":33.51},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.4,"censored":true},"longitudinal_labs":[{"date":"2021-02-23","hemoglobin_g_dL":15.2,"wbc_k_uL":10.2,"platelets_k_uL":327,"creatinine_mg_dL":1.13,"alt_U_L":22},{"date":"2021-09-24","hemoglobin_g_dL":11.4,"wbc_k_uL":8.3,"platelets_k_uL":279,"creatinine_mg_dL":0.9,"alt_U_L":41},{"date":"2024-01-16","hemoglobin_g_dL":10.3,"wbc_k_uL":5.6,"platelets_k_uL":272,"creatinine_mg_dL":1.26,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":88,"sex":"male","bmi":37.9,"smoking_pack_years":79,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-10-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-41},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":11.0,"censored":false},"longitudinal_labs":[{"date":"2025-08-14","hemoglobin_g_dL":14.4,"wbc_k_uL":7.0,"platelets_k_uL":368,"creatinine_mg_dL":1.28,"alt_U_L":31},{"date":"2026-04-11","hemoglobin_g_dL":13.7,"wbc_k_uL":4.3,"platelets_k_uL":331,"creatinine_mg_dL":1.23,"alt_U_L":88},{"date":"2026-02-22","hemoglobin_g_dL":10.1,"wbc_k_uL":4.2,"platelets_k_uL":341,"creatinine_mg_dL":1.37,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":79,"sex":"female","bmi":31.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-78},"pfs_months":33.12},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.2,"censored":false},"longitudinal_labs":[{"date":"2025-03-03","hemoglobin_g_dL":12.8,"wbc_k_uL":5.6,"platelets_k_uL":337,"creatinine_mg_dL":1.07,"alt_U_L":32},{"date":"2025-11-06","hemoglobin_g_dL":10.8,"wbc_k_uL":6.5,"platelets_k_uL":343,"creatinine_mg_dL":0.95,"alt_U_L":58},{"date":"2028-03-11","hemoglobin_g_dL":9.7,"wbc_k_uL":7.6,"platelets_k_uL":149,"creatinine_mg_dL":1.01,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":77,"sex":"female","bmi":25.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-56},"pfs_months":25.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.3,"censored":false},"longitudinal_labs":[{"date":"2022-08-20","hemoglobin_g_dL":13.3,"wbc_k_uL":6.7,"platelets_k_uL":446,"creatinine_mg_dL":0.93,"alt_U_L":28},{"date":"2023-04-22","hemoglobin_g_dL":13.2,"wbc_k_uL":6.5,"platelets_k_uL":298,"creatinine_mg_dL":1.59,"alt_U_L":39},{"date":"2025-01-27","hemoglobin_g_dL":10.1,"wbc_k_uL":3.1,"platelets_k_uL":214,"creatinine_mg_dL":0.87,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":67,"sex":"male","bmi":36.7,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-66},"pfs_months":10.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":14.2,"censored":false},"longitudinal_labs":[{"date":"2022-04-14","hemoglobin_g_dL":11.6,"wbc_k_uL":10.4,"platelets_k_uL":254,"creatinine_mg_dL":1.29,"alt_U_L":49},{"date":"2022-12-05","hemoglobin_g_dL":13.1,"wbc_k_uL":4.2,"platelets_k_uL":128,"creatinine_mg_dL":1.51,"alt_U_L":76},{"date":"2023-04-20","hemoglobin_g_dL":12.5,"wbc_k_uL":7.7,"platelets_k_uL":305,"creatinine_mg_dL":1.06,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":57,"sex":"female","bmi":24.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-55},"pfs_months":21.19},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.0,"censored":false},"longitudinal_labs":[{"date":"2021-01-15","hemoglobin_g_dL":11.6,"wbc_k_uL":10.4,"platelets_k_uL":391,"creatinine_mg_dL":0.68,"alt_U_L":18},{"date":"2021-09-22","hemoglobin_g_dL":11.9,"wbc_k_uL":6.0,"platelets_k_uL":306,"creatinine_mg_dL":1.4,"alt_U_L":100},{"date":"2023-02-19","hemoglobin_g_dL":11.6,"wbc_k_uL":6.4,"platelets_k_uL":340,"creatinine_mg_dL":1.42,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":84,"sex":"female","bmi":30.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-81},"pfs_months":13.34},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":false},"longitudinal_labs":[{"date":"2024-12-16","hemoglobin_g_dL":12.2,"wbc_k_uL":5.3,"platelets_k_uL":430,"creatinine_mg_dL":0.93,"alt_U_L":28},{"date":"2025-08-02","hemoglobin_g_dL":10.7,"wbc_k_uL":4.8,"platelets_k_uL":177,"creatinine_mg_dL":1.19,"alt_U_L":96},{"date":"2026-05-14","hemoglobin_g_dL":12.1,"wbc_k_uL":7.9,"platelets_k_uL":324,"creatinine_mg_dL":0.82,"alt_U_L":58}]}
{"patient_id":"ANODE_SYNTH_2025_263","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":82,"sex":"female","bmi":32.2,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-04-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-70},"pfs_months":22.24},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.7,"censored":true},"longitudinal_labs":[{"date":"2022-04-05","hemoglobin_g_dL":14.8,"wbc_k_uL":6.2,"platelets_k_uL":178,"creatinine_mg_dL":0.99,"alt_U_L":38},{"date":"2022-10-24","hemoglobin_g_dL":10.4,"wbc_k_uL":8.7,"platelets_k_uL":270,"creatinine_mg_dL":0.72,"alt_U_L":29},{"date":"2024-04-16","hemoglobin_g_dL":10.7,"wbc_k_uL":7.1,"platelets_k_uL":253,"creatinine_mg_dL":1.03,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":59,"sex":"female","bmi":30.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-37},"pfs_months":35.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":57.1,"censored":false},"longitudinal_labs":[{"date":"2020-09-20","hemoglobin_g_dL":15.2,"wbc_k_uL":7.7,"platelets_k_uL":236,"creatinine_mg_dL":1.26,"alt_U_L":78},{"date":"2021-04-14","hemoglobin_g_dL":12.5,"wbc_k_uL":6.1,"platelets_k_uL":177,"creatinine_mg_dL":1.07,"alt_U_L":23},{"date":"2023-10-01","hemoglobin_g_dL":9.7,"wbc_k_uL":7.4,"platelets_k_uL":116,"creatinine_mg_dL":1.9,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":81,"sex":"male","bmi":31.9,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-11-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-82},"pfs_months":41.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":61.0,"censored":false},"longitudinal_labs":[{"date":"2024-10-18","hemoglobin_g_dL":13.6,"wbc_k_uL":5.8,"platelets_k_uL":349,"creatinine_mg_dL":0.91,"alt_U_L":70},{"date":"2025-05-20","hemoglobin_g_dL":11.8,"wbc_k_uL":4.2,"platelets_k_uL":273,"creatinine_mg_dL":1.4,"alt_U_L":41},{"date":"2028-06-30","hemoglobin_g_dL":9.6,"wbc_k_uL":6.6,"platelets_k_uL":219,"creatinine_mg_dL":0.88,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_266","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":78,"sex":"female","bmi":32.2,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2022-04-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-74},"pfs_months":21.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.0,"censored":false},"longitudinal_labs":[{"date":"2022-02-24","hemoglobin_g_dL":13.6,"wbc_k_uL":7.8,"platelets_k_uL":238,"creatinine_mg_dL":0.87,"alt_U_L":79},{"date":"2022-10-05","hemoglobin_g_dL":12.5,"wbc_k_uL":8.0,"platelets_k_uL":252,"creatinine_mg_dL":0.76,"alt_U_L":21},{"date":"2024-02-13","hemoglobin_g_dL":12.3,"wbc_k_uL":7.3,"platelets_k_uL":160,"creatinine_mg_dL":1.04,"alt_U_L":56}]}
{"patient_id":"ANODE_SYNTH_2025_267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":84,"sex":"female","bmi":34.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-85},"pfs_months":19.78},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.4,"censored":true},"longitudinal_labs":[{"date":"2020-06-16","hemoglobin_g_dL":12.8,"wbc_k_uL":7.0,"platelets_k_uL":236,"creatinine_mg_dL":1.11,"alt_U_L":23},{"date":"2021-02-12","hemoglobin_g_dL":10.4,"wbc_k_uL":5.3,"platelets_k_uL":265,"creatinine_mg_dL":1.11,"alt_U_L":78},{"date":"2022-06-06","hemoglobin_g_dL":11.2,"wbc_k_uL":3.5,"platelets_k_uL":299,"creatinine_mg_dL":1.84,"alt_U_L":198}]}
{"patient_id":"ANODE_SYNTH_2025_268","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":80,"sex":"female","bmi":26.8,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-11-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-37},"pfs_months":22.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":true},"longitudinal_labs":[{"date":"2024-10-15","hemoglobin_g_dL":11.5,"wbc_k_uL":8.4,"platelets_k_uL":179,"creatinine_mg_dL":1.24,"alt_U_L":30},{"date":"2025-04-30","hemoglobin_g_dL":11.4,"wbc_k_uL":7.7,"platelets_k_uL":143,"creatinine_mg_dL":1.39,"alt_U_L":73},{"date":"2026-09-27","hemoglobin_g_dL":11.1,"wbc_k_uL":3.2,"platelets_k_uL":259,"creatinine_mg_dL":0.88,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_269","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":76,"sex":"female","bmi":19.2,"smoking_pack_years":41,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-10-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-79},"pfs_months":19.81},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.0,"censored":true},"longitudinal_labs":[{"date":"2021-08-18","hemoglobin_g_dL":14.8,"wbc_k_uL":9.3,"platelets_k_uL":180,"creatinine_mg_dL":1.09,"alt_U_L":55},{"date":"2022-04-17","hemoglobin_g_dL":12.2,"wbc_k_uL":4.5,"platelets_k_uL":270,"creatinine_mg_dL":1.11,"alt_U_L":119},{"date":"2023-08-01","hemoglobin_g_dL":9.8,"wbc_k_uL":7.1,"platelets_k_uL":137,"creatinine_mg_dL":1.73,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":85,"sex":"male","bmi":30.3,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-07-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-80},"pfs_months":28.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":57.3,"censored":false},"longitudinal_labs":[{"date":"2025-06-15","hemoglobin_g_dL":13.8,"wbc_k_uL":9.7,"platelets_k_uL":232,"creatinine_mg_dL":0.94,"alt_U_L":20},{"date":"2026-01-03","hemoglobin_g_dL":13.0,"wbc_k_uL":5.7,"platelets_k_uL":214,"creatinine_mg_dL":0.88,"alt_U_L":77},{"date":"2027-12-19","hemoglobin_g_dL":12.4,"wbc_k_uL":7.0,"platelets_k_uL":191,"creatinine_mg_dL":0.84,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_271","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":53,"sex":"female","bmi":28.6,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-04-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-83},"pfs_months":31.01},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.9,"censored":false},"longitudinal_labs":[{"date":"2020-03-03","hemoglobin_g_dL":12.8,"wbc_k_uL":9.6,"platelets_k_uL":168,"creatinine_mg_dL":0.72,"alt_U_L":42},{"date":"2020-10-16","hemoglobin_g_dL":13.8,"wbc_k_uL":7.5,"platelets_k_uL":160,"creatinine_mg_dL":1.36,"alt_U_L":55},{"date":"2022-12-11","hemoglobin_g_dL":11.8,"wbc_k_uL":7.1,"platelets_k_uL":209,"creatinine_mg_dL":1.3,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":81,"sex":"male","bmi":30.6,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-04-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-60},"pfs_months":15.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":19.2,"censored":false},"longitudinal_labs":[{"date":"2025-02-27","hemoglobin_g_dL":13.6,"wbc_k_uL":9.5,"platelets_k_uL":333,"creatinine_mg_dL":0.62,"alt_U_L":37},{"date":"2025-10-01","hemoglobin_g_dL":14.0,"wbc_k_uL":7.6,"platelets_k_uL":147,"creatinine_mg_dL":1.11,"alt_U_L":42},{"date":"2026-07-18","hemoglobin_g_dL":9.9,"wbc_k_uL":5.2,"platelets_k_uL":244,"creatinine_mg_dL":1.76,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":83,"sex":"male","bmi":22.7,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-51},"pfs_months":7.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":16.3,"censored":false},"longitudinal_labs":[{"date":"2020-08-08","hemoglobin_g_dL":14.0,"wbc_k_uL":9.9,"platelets_k_uL":264,"creatinine_mg_dL":0.68,"alt_U_L":12},{"date":"2021-03-14","hemoglobin_g_dL":13.6,"wbc_k_uL":6.2,"platelets_k_uL":196,"creatinine_mg_dL":1.5,"alt_U_L":97},{"date":"2021-05-31","hemoglobin_g_dL":11.7,"wbc_k_uL":6.0,"platelets_k_uL":224,"creatinine_mg_dL":0.94,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":84,"sex":"female","bmi":30.3,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-04-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-73},"pfs_months":36.44},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":58.1,"censored":false},"longitudinal_labs":[{"date":"2021-02-17","hemoglobin_g_dL":15.3,"wbc_k_uL":8.7,"platelets_k_uL":264,"creatinine_mg_dL":1.11,"alt_U_L":69},{"date":"2021-10-21","hemoglobin_g_dL":13.4,"wbc_k_uL":8.9,"platelets_k_uL":356,"creatinine_mg_dL":1.03,"alt_U_L":108},{"date":"2024-06-08","hemoglobin_g_dL":10.9,"wbc_k_uL":4.7,"platelets_k_uL":319,"creatinine_mg_dL":1.42,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_275","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":83,"sex":"male","bmi":22.1,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-38},"pfs_months":21.65},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":false},"longitudinal_labs":[{"date":"2023-06-28","hemoglobin_g_dL":12.6,"wbc_k_uL":9.4,"platelets_k_uL":220,"creatinine_mg_dL":0.69,"alt_U_L":55},{"date":"2024-01-20","hemoglobin_g_dL":10.7,"wbc_k_uL":7.5,"platelets_k_uL":162,"creatinine_mg_dL":0.84,"alt_U_L":90},{"date":"2025-06-02","hemoglobin_g_dL":10.4,"wbc_k_uL":3.8,"platelets_k_uL":294,"creatinine_mg_dL":1.87,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_276","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":55,"sex":"female","bmi":29.6,"smoking_pack_years":52,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-08-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-65},"pfs_months":22.67},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.1,"censored":true},"longitudinal_labs":[{"date":"2023-07-21","hemoglobin_g_dL":14.4,"wbc_k_uL":8.7,"platelets_k_uL":277,"creatinine_mg_dL":1.29,"alt_U_L":53},{"date":"2024-02-21","hemoglobin_g_dL":12.9,"wbc_k_uL":5.8,"platelets_k_uL":279,"creatinine_mg_dL":1.42,"alt_U_L":103},{"date":"2025-08-13","hemoglobin_g_dL":10.4,"wbc_k_uL":7.9,"platelets_k_uL":342,"creatinine_mg_dL":1.07,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_277","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":74,"sex":"male","bmi":24.5,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-04-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-61},"pfs_months":17.15},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":27.5,"censored":true},"longitudinal_labs":[{"date":"2024-03-18","hemoglobin_g_dL":11.9,"wbc_k_uL":8.3,"platelets_k_uL":273,"creatinine_mg_dL":0.88,"alt_U_L":20},{"date":"2024-10-10","hemoglobin_g_dL":11.9,"wbc_k_uL":8.6,"platelets_k_uL":352,"creatinine_mg_dL":1.53,"alt_U_L":118},{"date":"2025-11-14","hemoglobin_g_dL":10.0,"wbc_k_uL":4.8,"platelets_k_uL":216,"creatinine_mg_dL":1.68,"alt_U_L":108}]}
{"patient_id":"ANODE_SYNTH_2025_278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":48,"sex":"female","bmi":25.8,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-01-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-30},"pfs_months":37.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":63.4,"censored":false},"longitudinal_labs":[{"date":"2021-12-05","hemoglobin_g_dL":12.0,"wbc_k_uL":4.6,"platelets_k_uL":301,"creatinine_mg_dL":0.78,"alt_U_L":31},{"date":"2022-07-30","hemoglobin_g_dL":12.8,"wbc_k_uL":3.9,"platelets_k_uL":253,"creatinine_mg_dL":1.56,"alt_U_L":92},{"date":"2025-03-28","hemoglobin_g_dL":12.8,"wbc_k_uL":3.2,"platelets_k_uL":280,"creatinine_mg_dL":1.14,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":70,"sex":"male","bmi":22.2,"smoking_pack_years":50,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-54},"pfs_months":27.24},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.0,"censored":false},"longitudinal_labs":[{"date":"2021-04-21","hemoglobin_g_dL":13.4,"wbc_k_uL":6.8,"platelets_k_uL":299,"creatinine_mg_dL":1.26,"alt_U_L":57},{"date":"2021-12-04","hemoglobin_g_dL":11.8,"wbc_k_uL":6.5,"platelets_k_uL":372,"creatinine_mg_dL":0.88,"alt_U_L":102},{"date":"2023-10-07","hemoglobin_g_dL":11.2,"wbc_k_uL":3.1,"platelets_k_uL":160,"creatinine_mg_dL":1.7,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":48,"sex":"female","bmi":24.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-83},"pfs_months":13.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":30.2,"censored":false},"longitudinal_labs":[{"date":"2024-03-26","hemoglobin_g_dL":13.5,"wbc_k_uL":9.7,"platelets_k_uL":177,"creatinine_mg_dL":1.27,"alt_U_L":29},{"date":"2024-11-24","hemoglobin_g_dL":12.7,"wbc_k_uL":6.1,"platelets_k_uL":126,"creatinine_mg_dL":1.27,"alt_U_L":53},{"date":"2025-07-31","hemoglobin_g_dL":12.6,"wbc_k_uL":5.8,"platelets_k_uL":312,"creatinine_mg_dL":1.12,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_281","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":62,"sex":"female","bmi":35.4,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-04-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-60},"pfs_months":29.73},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":false},"longitudinal_labs":[{"date":"2024-02-05","hemoglobin_g_dL":13.7,"wbc_k_uL":6.0,"platelets_k_uL":338,"creatinine_mg_dL":0.82,"alt_U_L":40},{"date":"2024-09-28","hemoglobin_g_dL":10.2,"wbc_k_uL":8.7,"platelets_k_uL":157,"creatinine_mg_dL":0.71,"alt_U_L":115},{"date":"2026-10-26","hemoglobin_g_dL":11.4,"wbc_k_uL":6.5,"platelets_k_uL":258,"creatinine_mg_dL":1.61,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":71,"sex":"male","bmi":19.6,"smoking_pack_years":55,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2022-12-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-77},"pfs_months":10.71},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.2,"censored":false},"longitudinal_labs":[{"date":"2022-11-20","hemoglobin_g_dL":15.2,"wbc_k_uL":6.2,"platelets_k_uL":287,"creatinine_mg_dL":0.77,"alt_U_L":43},{"date":"2023-06-18","hemoglobin_g_dL":11.6,"wbc_k_uL":5.2,"platelets_k_uL":350,"creatinine_mg_dL":1.08,"alt_U_L":80},{"date":"2023-11-28","hemoglobin_g_dL":10.7,"wbc_k_uL":3.5,"platelets_k_uL":245,"creatinine_mg_dL":1.05,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":58,"sex":"female","bmi":32.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-05-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-77},"pfs_months":21.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.0,"censored":true},"longitudinal_labs":[{"date":"2023-04-23","hemoglobin_g_dL":13.4,"wbc_k_uL":8.0,"platelets_k_uL":234,"creatinine_mg_dL":1.07,"alt_U_L":11},{"date":"2023-11-10","hemoglobin_g_dL":11.2,"wbc_k_uL":7.3,"platelets_k_uL":347,"creatinine_mg_dL":0.8,"alt_U_L":39},{"date":"2025-03-22","hemoglobin_g_dL":12.2,"wbc_k_uL":5.2,"platelets_k_uL":108,"creatinine_mg_dL":1.6,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":48,"sex":"female","bmi":23.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-57},"pfs_months":17.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":true},"longitudinal_labs":[{"date":"2022-10-16","hemoglobin_g_dL":13.1,"wbc_k_uL":9.8,"platelets_k_uL":448,"creatinine_mg_dL":1.01,"alt_U_L":60},{"date":"2023-05-09","hemoglobin_g_dL":11.1,"wbc_k_uL":8.7,"platelets_k_uL":188,"creatinine_mg_dL":1.38,"alt_U_L":82},{"date":"2024-06-06","hemoglobin_g_dL":12.9,"wbc_k_uL":7.7,"platelets_k_uL":229,"creatinine_mg_dL":0.83,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":52,"sex":"female","bmi":31.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-85},"pfs_months":13.37},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.8,"censored":true},"longitudinal_labs":[{"date":"2024-02-06","hemoglobin_g_dL":14.3,"wbc_k_uL":8.9,"platelets_k_uL":386,"creatinine_mg_dL":1.11,"alt_U_L":26},{"date":"2024-09-10","hemoglobin_g_dL":11.0,"wbc_k_uL":4.0,"platelets_k_uL":318,"creatinine_mg_dL":1.06,"alt_U_L":99},{"date":"2025-05-06","hemoglobin_g_dL":10.4,"wbc_k_uL":4.8,"platelets_k_uL":308,"creatinine_mg_dL":0.83,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_286","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":79,"sex":"female","bmi":34.9,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-01-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-51},"pfs_months":16.62},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":false},"longitudinal_labs":[{"date":"2025-11-20","hemoglobin_g_dL":15.5,"wbc_k_uL":8.9,"platelets_k_uL":373,"creatinine_mg_dL":0.93,"alt_U_L":38},{"date":"2026-07-15","hemoglobin_g_dL":11.2,"wbc_k_uL":5.4,"platelets_k_uL":188,"creatinine_mg_dL":1.52,"alt_U_L":116},{"date":"2027-07-30","hemoglobin_g_dL":13.0,"wbc_k_uL":6.2,"platelets_k_uL":344,"creatinine_mg_dL":1.21,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":56,"sex":"female","bmi":23.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-51},"pfs_months":21.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":false},"longitudinal_labs":[{"date":"2023-06-01","hemoglobin_g_dL":15.0,"wbc_k_uL":6.5,"platelets_k_uL":390,"creatinine_mg_dL":1.19,"alt_U_L":72},{"date":"2024-01-05","hemoglobin_g_dL":12.0,"wbc_k_uL":4.2,"platelets_k_uL":356,"creatinine_mg_dL":1.01,"alt_U_L":80},{"date":"2025-05-23","hemoglobin_g_dL":9.9,"wbc_k_uL":5.3,"platelets_k_uL":111,"creatinine_mg_dL":1.88,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_288","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":58,"sex":"female","bmi":36.7,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-07-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-75},"pfs_months":24.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.6,"censored":true},"longitudinal_labs":[{"date":"2022-06-26","hemoglobin_g_dL":13.7,"wbc_k_uL":9.8,"platelets_k_uL":349,"creatinine_mg_dL":0.93,"alt_U_L":30},{"date":"2023-01-07","hemoglobin_g_dL":10.4,"wbc_k_uL":6.7,"platelets_k_uL":231,"creatinine_mg_dL":1.37,"alt_U_L":35},{"date":"2024-08-11","hemoglobin_g_dL":9.6,"wbc_k_uL":5.0,"platelets_k_uL":155,"creatinine_mg_dL":1.66,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_289","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":49,"sex":"female","bmi":27.0,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-50},"pfs_months":17.87},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.5,"censored":false},"longitudinal_labs":[{"date":"2021-07-27","hemoglobin_g_dL":12.5,"wbc_k_uL":4.9,"platelets_k_uL":235,"creatinine_mg_dL":1.22,"alt_U_L":49},{"date":"2022-02-14","hemoglobin_g_dL":13.4,"wbc_k_uL":7.1,"platelets_k_uL":330,"creatinine_mg_dL":0.83,"alt_U_L":118},{"date":"2023-03-16","hemoglobin_g_dL":10.2,"wbc_k_uL":6.4,"platelets_k_uL":190,"creatinine_mg_dL":1.3,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":66,"sex":"female","bmi":30.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-75},"pfs_months":32.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.7,"censored":true},"longitudinal_labs":[{"date":"2021-03-25","hemoglobin_g_dL":11.5,"wbc_k_uL":5.3,"platelets_k_uL":447,"creatinine_mg_dL":0.65,"alt_U_L":39},{"date":"2021-11-15","hemoglobin_g_dL":13.6,"wbc_k_uL":6.9,"platelets_k_uL":217,"creatinine_mg_dL":0.74,"alt_U_L":119},{"date":"2024-02-27","hemoglobin_g_dL":11.3,"wbc_k_uL":3.9,"platelets_k_uL":183,"creatinine_mg_dL":1.4,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":65,"sex":"female","bmi":35.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-09-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-79},"pfs_months":24.8},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.8,"censored":false},"longitudinal_labs":[{"date":"2023-07-11","hemoglobin_g_dL":13.7,"wbc_k_uL":7.2,"platelets_k_uL":365,"creatinine_mg_dL":0.89,"alt_U_L":54},{"date":"2024-03-12","hemoglobin_g_dL":10.9,"wbc_k_uL":7.8,"platelets_k_uL":144,"creatinine_mg_dL":0.86,"alt_U_L":41},{"date":"2025-12-03","hemoglobin_g_dL":9.8,"wbc_k_uL":7.0,"platelets_k_uL":102,"creatinine_mg_dL":1.02,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":59,"sex":"female","bmi":22.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-83},"pfs_months":27.1},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.7,"censored":false},"longitudinal_labs":[{"date":"2024-04-21","hemoglobin_g_dL":13.4,"wbc_k_uL":8.5,"platelets_k_uL":263,"creatinine_mg_dL":0.88,"alt_U_L":49},{"date":"2024-11-01","hemoglobin_g_dL":13.9,"wbc_k_uL":5.1,"platelets_k_uL":147,"creatinine_mg_dL":0.86,"alt_U_L":119},{"date":"2026-09-11","hemoglobin_g_dL":11.3,"wbc_k_uL":6.5,"platelets_k_uL":227,"creatinine_mg_dL":1.12,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":62,"sex":"female","bmi":34.9,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2021-01-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-65},"pfs_months":34.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":49.8,"censored":false},"longitudinal_labs":[{"date":"2020-11-18","hemoglobin_g_dL":11.6,"wbc_k_uL":7.6,"platelets_k_uL":299,"creatinine_mg_dL":0.75,"alt_U_L":79},{"date":"2021-07-03","hemoglobin_g_dL":11.0,"wbc_k_uL":6.3,"platelets_k_uL":318,"creatinine_mg_dL":0.81,"alt_U_L":82},{"date":"2024-01-06","hemoglobin_g_dL":10.8,"wbc_k_uL":5.3,"platelets_k_uL":280,"creatinine_mg_dL":1.86,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":56,"sex":"male","bmi":28.9,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-09-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-75},"pfs_months":40.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":64.3,"censored":false},"longitudinal_labs":[{"date":"2022-07-15","hemoglobin_g_dL":14.4,"wbc_k_uL":6.9,"platelets_k_uL":326,"creatinine_mg_dL":1.25,"alt_U_L":70},{"date":"2023-03-04","hemoglobin_g_dL":11.1,"wbc_k_uL":7.4,"platelets_k_uL":245,"creatinine_mg_dL":1.33,"alt_U_L":114},{"date":"2026-03-15","hemoglobin_g_dL":11.7,"wbc_k_uL":4.0,"platelets_k_uL":282,"creatinine_mg_dL":1.21,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":71,"sex":"female","bmi":24.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-44},"pfs_months":15.74},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.0,"censored":false},"longitudinal_labs":[{"date":"2023-02-17","hemoglobin_g_dL":11.5,"wbc_k_uL":8.7,"platelets_k_uL":179,"creatinine_mg_dL":0.85,"alt_U_L":38},{"date":"2023-10-24","hemoglobin_g_dL":11.4,"wbc_k_uL":4.5,"platelets_k_uL":147,"creatinine_mg_dL":1.17,"alt_U_L":40},{"date":"2024-09-29","hemoglobin_g_dL":11.9,"wbc_k_uL":3.3,"platelets_k_uL":346,"creatinine_mg_dL":0.88,"alt_U_L":145}]}
{"patient_id":"ANODE_SYNTH_2025_296","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":59,"sex":"male","bmi":28.7,"smoking_pack_years":56,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-05-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-51},"pfs_months":21.39},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.0,"censored":true},"longitudinal_labs":[{"date":"2022-05-11","hemoglobin_g_dL":11.7,"wbc_k_uL":5.2,"platelets_k_uL":347,"creatinine_mg_dL":1.24,"alt_U_L":54},{"date":"2022-11-24","hemoglobin_g_dL":12.1,"wbc_k_uL":8.3,"platelets_k_uL":154,"creatinine_mg_dL":0.97,"alt_U_L":49},{"date":"2024-03-21","hemoglobin_g_dL":10.3,"wbc_k_uL":5.3,"platelets_k_uL":346,"creatinine_mg_dL":1.02,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":75,"sex":"male","bmi":35.9,"smoking_pack_years":33,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-02-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-62},"pfs_months":12.81},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":16.8,"censored":true},"longitudinal_labs":[{"date":"2025-02-01","hemoglobin_g_dL":14.4,"wbc_k_uL":8.8,"platelets_k_uL":181,"creatinine_mg_dL":0.66,"alt_U_L":52},{"date":"2025-08-16","hemoglobin_g_dL":11.0,"wbc_k_uL":7.9,"platelets_k_uL":295,"creatinine_mg_dL":1.16,"alt_U_L":115},{"date":"2026-05-12","hemoglobin_g_dL":10.3,"wbc_k_uL":8.0,"platelets_k_uL":249,"creatinine_mg_dL":1.06,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":60,"sex":"female","bmi":27.2,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-06-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-50},"pfs_months":9.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-04-18","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":18.1,"censored":false},"longitudinal_labs":[{"date":"2020-05-13","hemoglobin_g_dL":12.5,"wbc_k_uL":8.0,"platelets_k_uL":325,"creatinine_mg_dL":1.25,"alt_U_L":17},{"date":"2020-12-20","hemoglobin_g_dL":11.8,"wbc_k_uL":4.9,"platelets_k_uL":364,"creatinine_mg_dL":0.97,"alt_U_L":110},{"date":"2021-04-18","hemoglobin_g_dL":10.2,"wbc_k_uL":6.1,"platelets_k_uL":211,"creatinine_mg_dL":1.9,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":57,"sex":"male","bmi":31.7,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-12-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-61},"pfs_months":24.44},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.5,"censored":true},"longitudinal_labs":[{"date":"2024-11-11","hemoglobin_g_dL":13.4,"wbc_k_uL":5.4,"platelets_k_uL":283,"creatinine_mg_dL":1.08,"alt_U_L":57},{"date":"2025-06-09","hemoglobin_g_dL":12.6,"wbc_k_uL":8.2,"platelets_k_uL":157,"creatinine_mg_dL":1.15,"alt_U_L":36},{"date":"2027-02-14","hemoglobin_g_dL":10.2,"wbc_k_uL":5.8,"platelets_k_uL":117,"creatinine_mg_dL":1.38,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":68,"sex":"female","bmi":31.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-48},"pfs_months":19.58},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":true},"longitudinal_labs":[{"date":"2025-06-25","hemoglobin_g_dL":13.6,"wbc_k_uL":8.7,"platelets_k_uL":251,"creatinine_mg_dL":1.26,"alt_U_L":61},{"date":"2026-01-28","hemoglobin_g_dL":13.7,"wbc_k_uL":4.5,"platelets_k_uL":199,"creatinine_mg_dL":1.56,"alt_U_L":20},{"date":"2027-05-12","hemoglobin_g_dL":9.9,"wbc_k_uL":4.7,"platelets_k_uL":173,"creatinine_mg_dL":1.19,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":79,"sex":"male","bmi":18.6,"smoking_pack_years":32,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["brain","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-07-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-72},"pfs_months":39.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":57.8,"censored":false},"longitudinal_labs":[{"date":"2023-05-11","hemoglobin_g_dL":12.7,"wbc_k_uL":8.2,"platelets_k_uL":295,"creatinine_mg_dL":1.1,"alt_U_L":74},{"date":"2024-01-05","hemoglobin_g_dL":12.8,"wbc_k_uL":3.9,"platelets_k_uL":183,"creatinine_mg_dL":1.43,"alt_U_L":56},{"date":"2026-12-07","hemoglobin_g_dL":10.8,"wbc_k_uL":5.9,"platelets_k_uL":229,"creatinine_mg_dL":1.31,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":66,"sex":"female","bmi":34.3,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-08-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-36},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":7.1,"censored":false},"longitudinal_labs":[{"date":"2024-06-28","hemoglobin_g_dL":11.6,"wbc_k_uL":10.2,"platelets_k_uL":258,"creatinine_mg_dL":1.04,"alt_U_L":38},{"date":"2025-02-17","hemoglobin_g_dL":14.0,"wbc_k_uL":5.8,"platelets_k_uL":294,"creatinine_mg_dL":1.28,"alt_U_L":76},{"date":"2025-01-02","hemoglobin_g_dL":11.9,"wbc_k_uL":4.6,"platelets_k_uL":240,"creatinine_mg_dL":1.51,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":75,"sex":"female","bmi":21.0,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-02-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-57},"pfs_months":16.43},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.1,"censored":true},"longitudinal_labs":[{"date":"2025-12-21","hemoglobin_g_dL":14.6,"wbc_k_uL":8.2,"platelets_k_uL":157,"creatinine_mg_dL":1.3,"alt_U_L":55},{"date":"2026-08-20","hemoglobin_g_dL":10.2,"wbc_k_uL":7.4,"platelets_k_uL":314,"creatinine_mg_dL":1.24,"alt_U_L":118},{"date":"2027-08-21","hemoglobin_g_dL":10.6,"wbc_k_uL":3.2,"platelets_k_uL":319,"creatinine_mg_dL":1.15,"alt_U_L":198}]}
{"patient_id":"ANODE_SYNTH_2025_304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":78,"sex":"female","bmi":21.3,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-10-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-46},"pfs_months":10.15},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.1,"censored":false},"longitudinal_labs":[{"date":"2021-10-01","hemoglobin_g_dL":13.2,"wbc_k_uL":5.1,"platelets_k_uL":235,"creatinine_mg_dL":0.95,"alt_U_L":23},{"date":"2022-04-22","hemoglobin_g_dL":12.7,"wbc_k_uL":7.0,"platelets_k_uL":159,"creatinine_mg_dL":0.96,"alt_U_L":74},{"date":"2022-09-06","hemoglobin_g_dL":11.5,"wbc_k_uL":5.4,"platelets_k_uL":116,"creatinine_mg_dL":1.52,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":67,"sex":"female","bmi":29.9,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-06-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-48},"pfs_months":6.08},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":16.0,"censored":true},"longitudinal_labs":[{"date":"2022-05-10","hemoglobin_g_dL":14.3,"wbc_k_uL":8.5,"platelets_k_uL":215,"creatinine_mg_dL":1.12,"alt_U_L":48},{"date":"2022-12-04","hemoglobin_g_dL":13.6,"wbc_k_uL":4.6,"platelets_k_uL":349,"creatinine_mg_dL":0.77,"alt_U_L":113},{"date":"2022-12-30","hemoglobin_g_dL":11.4,"wbc_k_uL":4.1,"platelets_k_uL":218,"creatinine_mg_dL":1.2,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":69,"sex":"female","bmi":23.4,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-48},"pfs_months":9.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":18.7,"censored":false},"longitudinal_labs":[{"date":"2023-02-08","hemoglobin_g_dL":11.6,"wbc_k_uL":5.0,"platelets_k_uL":328,"creatinine_mg_dL":1.11,"alt_U_L":39},{"date":"2023-08-26","hemoglobin_g_dL":13.4,"wbc_k_uL":6.4,"platelets_k_uL":297,"creatinine_mg_dL":1.23,"alt_U_L":105},{"date":"2024-01-22","hemoglobin_g_dL":12.1,"wbc_k_uL":4.5,"platelets_k_uL":122,"creatinine_mg_dL":1.44,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":73,"sex":"female","bmi":24.3,"smoking_pack_years":24,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-04-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-57},"pfs_months":47.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-04-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.5,"censored":false},"longitudinal_labs":[{"date":"2025-01-28","hemoglobin_g_dL":15.0,"wbc_k_uL":7.5,"platelets_k_uL":356,"creatinine_mg_dL":0.92,"alt_U_L":79},{"date":"2025-10-05","hemoglobin_g_dL":12.9,"wbc_k_uL":7.2,"platelets_k_uL":377,"creatinine_mg_dL":1.35,"alt_U_L":80},{"date":"2029-04-27","hemoglobin_g_dL":12.3,"wbc_k_uL":3.5,"platelets_k_uL":199,"creatinine_mg_dL":1.58,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":68,"sex":"male","bmi":24.3,"smoking_pack_years":40,"ecog_performance_status":2,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-78},"pfs_months":7.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.1,"censored":false},"longitudinal_labs":[{"date":"2023-09-01","hemoglobin_g_dL":15.5,"wbc_k_uL":10.0,"platelets_k_uL":188,"creatinine_mg_dL":1.09,"alt_U_L":10},{"date":"2024-03-20","hemoglobin_g_dL":10.9,"wbc_k_uL":8.7,"platelets_k_uL":148,"creatinine_mg_dL":0.89,"alt_U_L":82},{"date":"2024-06-02","hemoglobin_g_dL":11.1,"wbc_k_uL":4.9,"platelets_k_uL":141,"creatinine_mg_dL":1.75,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":63,"sex":"female","bmi":26.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-57},"pfs_months":22.47},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.4,"censored":true},"longitudinal_labs":[{"date":"2021-04-25","hemoglobin_g_dL":12.9,"wbc_k_uL":7.0,"platelets_k_uL":431,"creatinine_mg_dL":0.8,"alt_U_L":67},{"date":"2021-11-21","hemoglobin_g_dL":10.6,"wbc_k_uL":7.7,"platelets_k_uL":235,"creatinine_mg_dL":1.42,"alt_U_L":71},{"date":"2023-05-09","hemoglobin_g_dL":9.8,"wbc_k_uL":4.2,"platelets_k_uL":244,"creatinine_mg_dL":0.96,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":53,"sex":"female","bmi":35.0,"smoking_pack_years":17,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-05-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-46},"pfs_months":44.45},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.5,"censored":false},"longitudinal_labs":[{"date":"2020-04-05","hemoglobin_g_dL":14.9,"wbc_k_uL":6.2,"platelets_k_uL":253,"creatinine_mg_dL":0.84,"alt_U_L":70},{"date":"2020-11-16","hemoglobin_g_dL":13.5,"wbc_k_uL":5.0,"platelets_k_uL":224,"creatinine_mg_dL":1.5,"alt_U_L":59},{"date":"2024-03-26","hemoglobin_g_dL":12.3,"wbc_k_uL":7.2,"platelets_k_uL":216,"creatinine_mg_dL":1.17,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_311","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":49,"sex":"female","bmi":31.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-55},"pfs_months":8.41},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":true},"longitudinal_labs":[{"date":"2024-09-12","hemoglobin_g_dL":14.3,"wbc_k_uL":8.2,"platelets_k_uL":219,"creatinine_mg_dL":1.08,"alt_U_L":52},{"date":"2025-04-14","hemoglobin_g_dL":13.4,"wbc_k_uL":5.6,"platelets_k_uL":317,"creatinine_mg_dL":1.08,"alt_U_L":113},{"date":"2025-08-15","hemoglobin_g_dL":10.9,"wbc_k_uL":3.2,"platelets_k_uL":117,"creatinine_mg_dL":1.44,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":67,"sex":"female","bmi":34.3,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-04-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-68},"pfs_months":17.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.5,"censored":false},"longitudinal_labs":[{"date":"2023-03-20","hemoglobin_g_dL":15.4,"wbc_k_uL":4.6,"platelets_k_uL":333,"creatinine_mg_dL":1.24,"alt_U_L":40},{"date":"2023-10-20","hemoglobin_g_dL":10.5,"wbc_k_uL":4.7,"platelets_k_uL":366,"creatinine_mg_dL":1.09,"alt_U_L":91},{"date":"2024-10-22","hemoglobin_g_dL":9.8,"wbc_k_uL":3.6,"platelets_k_uL":104,"creatinine_mg_dL":1.36,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":71,"sex":"female","bmi":36.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-33},"pfs_months":25.95},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.5,"censored":false},"longitudinal_labs":[{"date":"2025-03-16","hemoglobin_g_dL":11.6,"wbc_k_uL":10.4,"platelets_k_uL":273,"creatinine_mg_dL":1.01,"alt_U_L":74},{"date":"2025-09-26","hemoglobin_g_dL":11.0,"wbc_k_uL":4.3,"platelets_k_uL":230,"creatinine_mg_dL":1.09,"alt_U_L":48},{"date":"2027-07-25","hemoglobin_g_dL":12.1,"wbc_k_uL":6.7,"platelets_k_uL":167,"creatinine_mg_dL":0.92,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_314","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":86,"sex":"male","bmi":18.8,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-10-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-56},"pfs_months":16.69},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.9,"censored":true},"longitudinal_labs":[{"date":"2025-09-09","hemoglobin_g_dL":14.5,"wbc_k_uL":6.6,"platelets_k_uL":150,"creatinine_mg_dL":1.18,"alt_U_L":31},{"date":"2026-04-25","hemoglobin_g_dL":12.6,"wbc_k_uL":6.2,"platelets_k_uL":297,"creatinine_mg_dL":0.84,"alt_U_L":17},{"date":"2027-04-18","hemoglobin_g_dL":10.2,"wbc_k_uL":5.0,"platelets_k_uL":131,"creatinine_mg_dL":1.79,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":72,"sex":"female","bmi":20.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-52},"pfs_months":18.27},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":false},"longitudinal_labs":[{"date":"2025-04-25","hemoglobin_g_dL":14.4,"wbc_k_uL":10.0,"platelets_k_uL":418,"creatinine_mg_dL":0.92,"alt_U_L":24},{"date":"2025-12-21","hemoglobin_g_dL":10.6,"wbc_k_uL":5.2,"platelets_k_uL":326,"creatinine_mg_dL":0.9,"alt_U_L":38},{"date":"2027-01-27","hemoglobin_g_dL":11.9,"wbc_k_uL":5.1,"platelets_k_uL":347,"creatinine_mg_dL":0.88,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":56,"sex":"female","bmi":23.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-73},"pfs_months":22.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":false},"longitudinal_labs":[{"date":"2022-03-07","hemoglobin_g_dL":12.0,"wbc_k_uL":8.8,"platelets_k_uL":445,"creatinine_mg_dL":0.65,"alt_U_L":47},{"date":"2022-10-03","hemoglobin_g_dL":11.7,"wbc_k_uL":4.8,"platelets_k_uL":125,"creatinine_mg_dL":1.57,"alt_U_L":68},{"date":"2024-03-13","hemoglobin_g_dL":10.7,"wbc_k_uL":4.0,"platelets_k_uL":286,"creatinine_mg_dL":1.44,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":73,"sex":"female","bmi":33.5,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-11-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-37},"pfs_months":34.99},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":64.7,"censored":false},"longitudinal_labs":[{"date":"2020-09-09","hemoglobin_g_dL":15.2,"wbc_k_uL":5.8,"platelets_k_uL":246,"creatinine_mg_dL":0.65,"alt_U_L":50},{"date":"2021-05-07","hemoglobin_g_dL":13.3,"wbc_k_uL":8.9,"platelets_k_uL":328,"creatinine_mg_dL":0.75,"alt_U_L":63},{"date":"2023-12-06","hemoglobin_g_dL":12.9,"wbc_k_uL":3.8,"platelets_k_uL":322,"creatinine_mg_dL":1.51,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_318","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":67,"sex":"female","bmi":31.7,"smoking_pack_years":31,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-01-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-48},"pfs_months":25.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-10","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.9,"censored":false},"longitudinal_labs":[{"date":"2025-12-02","hemoglobin_g_dL":12.8,"wbc_k_uL":6.6,"platelets_k_uL":397,"creatinine_mg_dL":0.9,"alt_U_L":70},{"date":"2026-07-25","hemoglobin_g_dL":10.5,"wbc_k_uL":7.0,"platelets_k_uL":134,"creatinine_mg_dL":1.52,"alt_U_L":80},{"date":"2028-04-10","hemoglobin_g_dL":10.4,"wbc_k_uL":3.0,"platelets_k_uL":108,"creatinine_mg_dL":1.82,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_319","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":63,"sex":"male","bmi":18.9,"smoking_pack_years":77,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-10-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-53},"pfs_months":31.08},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":49.9,"censored":false},"longitudinal_labs":[{"date":"2025-09-21","hemoglobin_g_dL":11.7,"wbc_k_uL":6.8,"platelets_k_uL":343,"creatinine_mg_dL":0.95,"alt_U_L":80},{"date":"2026-04-06","hemoglobin_g_dL":13.1,"wbc_k_uL":7.0,"platelets_k_uL":182,"creatinine_mg_dL":1.0,"alt_U_L":57},{"date":"2028-07-09","hemoglobin_g_dL":9.8,"wbc_k_uL":7.5,"platelets_k_uL":163,"creatinine_mg_dL":1.51,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":88,"sex":"female","bmi":28.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-44},"pfs_months":15.24},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":true},"longitudinal_labs":[{"date":"2022-10-18","hemoglobin_g_dL":14.7,"wbc_k_uL":10.9,"platelets_k_uL":343,"creatinine_mg_dL":0.77,"alt_U_L":74},{"date":"2023-05-09","hemoglobin_g_dL":11.4,"wbc_k_uL":5.6,"platelets_k_uL":327,"creatinine_mg_dL":1.02,"alt_U_L":115},{"date":"2024-02-29","hemoglobin_g_dL":11.7,"wbc_k_uL":3.9,"platelets_k_uL":161,"creatinine_mg_dL":1.89,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_321","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":64,"sex":"female","bmi":22.1,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-10-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-42},"pfs_months":19.68},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-18","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.3,"censored":true},"longitudinal_labs":[{"date":"2022-09-01","hemoglobin_g_dL":14.1,"wbc_k_uL":6.6,"platelets_k_uL":448,"creatinine_mg_dL":0.79,"alt_U_L":38},{"date":"2023-04-05","hemoglobin_g_dL":13.3,"wbc_k_uL":8.6,"platelets_k_uL":165,"creatinine_mg_dL":0.71,"alt_U_L":57},{"date":"2024-07-18","hemoglobin_g_dL":10.4,"wbc_k_uL":4.0,"platelets_k_uL":241,"creatinine_mg_dL":0.83,"alt_U_L":145}]}
{"patient_id":"ANODE_SYNTH_2025_322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":58,"sex":"female","bmi":24.6,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-43},"pfs_months":14.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.0,"censored":false},"longitudinal_labs":[{"date":"2025-04-12","hemoglobin_g_dL":13.6,"wbc_k_uL":6.5,"platelets_k_uL":262,"creatinine_mg_dL":1.11,"alt_U_L":14},{"date":"2025-12-10","hemoglobin_g_dL":10.7,"wbc_k_uL":5.0,"platelets_k_uL":138,"creatinine_mg_dL":1.59,"alt_U_L":85},{"date":"2026-10-08","hemoglobin_g_dL":10.8,"wbc_k_uL":6.1,"platelets_k_uL":133,"creatinine_mg_dL":1.14,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":57,"sex":"male","bmi":37.8,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-10-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-30},"pfs_months":13.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.6,"censored":false},"longitudinal_labs":[{"date":"2023-08-14","hemoglobin_g_dL":12.3,"wbc_k_uL":7.2,"platelets_k_uL":182,"creatinine_mg_dL":1.1,"alt_U_L":58},{"date":"2024-04-09","hemoglobin_g_dL":10.4,"wbc_k_uL":5.2,"platelets_k_uL":378,"creatinine_mg_dL":1.15,"alt_U_L":24},{"date":"2025-01-06","hemoglobin_g_dL":11.9,"wbc_k_uL":6.3,"platelets_k_uL":264,"creatinine_mg_dL":1.62,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_324","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":49,"sex":"female","bmi":23.5,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-12-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-59},"pfs_months":18.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2021-11-08","hemoglobin_g_dL":12.5,"wbc_k_uL":8.1,"platelets_k_uL":397,"creatinine_mg_dL":0.83,"alt_U_L":40},{"date":"2022-06-19","hemoglobin_g_dL":12.5,"wbc_k_uL":4.6,"platelets_k_uL":235,"creatinine_mg_dL":1.52,"alt_U_L":38},{"date":"2023-09-07","hemoglobin_g_dL":12.1,"wbc_k_uL":5.7,"platelets_k_uL":266,"creatinine_mg_dL":1.72,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":73,"sex":"female","bmi":18.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-01-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-45},"pfs_months":18.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.2,"censored":true},"longitudinal_labs":[{"date":"2023-01-09","hemoglobin_g_dL":11.9,"wbc_k_uL":10.9,"platelets_k_uL":349,"creatinine_mg_dL":0.66,"alt_U_L":13},{"date":"2023-07-30","hemoglobin_g_dL":12.5,"wbc_k_uL":6.7,"platelets_k_uL":366,"creatinine_mg_dL":0.83,"alt_U_L":71},{"date":"2024-10-08","hemoglobin_g_dL":10.4,"wbc_k_uL":4.5,"platelets_k_uL":303,"creatinine_mg_dL":1.39,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_326","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":79,"sex":"male","bmi":34.5,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-08-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-69},"pfs_months":10.87},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.6,"censored":true},"longitudinal_labs":[{"date":"2020-07-20","hemoglobin_g_dL":15.1,"wbc_k_uL":5.4,"platelets_k_uL":285,"creatinine_mg_dL":1.18,"alt_U_L":72},{"date":"2021-02-08","hemoglobin_g_dL":11.1,"wbc_k_uL":7.6,"platelets_k_uL":198,"creatinine_mg_dL":1.07,"alt_U_L":65},{"date":"2021-07-15","hemoglobin_g_dL":10.6,"wbc_k_uL":7.6,"platelets_k_uL":278,"creatinine_mg_dL":1.76,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_327","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":52,"sex":"male","bmi":37.6,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-01-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-63},"pfs_months":17.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.1,"censored":true},"longitudinal_labs":[{"date":"2022-11-25","hemoglobin_g_dL":15.4,"wbc_k_uL":10.8,"platelets_k_uL":446,"creatinine_mg_dL":0.72,"alt_U_L":71},{"date":"2023-07-18","hemoglobin_g_dL":11.7,"wbc_k_uL":6.4,"platelets_k_uL":318,"creatinine_mg_dL":0.82,"alt_U_L":52},{"date":"2024-08-17","hemoglobin_g_dL":10.9,"wbc_k_uL":4.0,"platelets_k_uL":334,"creatinine_mg_dL":0.86,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":59,"sex":"female","bmi":29.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-02-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-66},"pfs_months":21.85},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.5,"censored":false},"longitudinal_labs":[{"date":"2025-12-24","hemoglobin_g_dL":14.7,"wbc_k_uL":7.1,"platelets_k_uL":389,"creatinine_mg_dL":1.19,"alt_U_L":40},{"date":"2026-08-14","hemoglobin_g_dL":10.1,"wbc_k_uL":5.9,"platelets_k_uL":379,"creatinine_mg_dL":1.14,"alt_U_L":83},{"date":"2028-01-08","hemoglobin_g_dL":11.0,"wbc_k_uL":5.4,"platelets_k_uL":143,"creatinine_mg_dL":1.11,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_329","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":76,"sex":"male","bmi":23.4,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-11-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-50},"pfs_months":28.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.7,"censored":false},"longitudinal_labs":[{"date":"2022-09-28","hemoglobin_g_dL":13.9,"wbc_k_uL":4.8,"platelets_k_uL":325,"creatinine_mg_dL":1.25,"alt_U_L":72},{"date":"2023-05-01","hemoglobin_g_dL":13.0,"wbc_k_uL":7.5,"platelets_k_uL":198,"creatinine_mg_dL":1.27,"alt_U_L":46},{"date":"2025-04-25","hemoglobin_g_dL":10.8,"wbc_k_uL":3.0,"platelets_k_uL":167,"creatinine_mg_dL":1.71,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":77,"sex":"female","bmi":31.1,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-01-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-45},"pfs_months":11.63},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":15.6,"censored":true},"longitudinal_labs":[{"date":"2022-11-05","hemoglobin_g_dL":13.4,"wbc_k_uL":6.6,"platelets_k_uL":369,"creatinine_mg_dL":1.16,"alt_U_L":46},{"date":"2023-07-01","hemoglobin_g_dL":12.9,"wbc_k_uL":6.0,"platelets_k_uL":285,"creatinine_mg_dL":0.73,"alt_U_L":73},{"date":"2024-01-14","hemoglobin_g_dL":11.4,"wbc_k_uL":4.8,"platelets_k_uL":159,"creatinine_mg_dL":1.8,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":72,"sex":"female","bmi":32.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-82},"pfs_months":22.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":true},"longitudinal_labs":[{"date":"2023-02-06","hemoglobin_g_dL":13.8,"wbc_k_uL":9.8,"platelets_k_uL":373,"creatinine_mg_dL":0.78,"alt_U_L":51},{"date":"2023-09-21","hemoglobin_g_dL":10.8,"wbc_k_uL":4.7,"platelets_k_uL":346,"creatinine_mg_dL":1.31,"alt_U_L":106},{"date":"2025-02-12","hemoglobin_g_dL":10.1,"wbc_k_uL":3.7,"platelets_k_uL":149,"creatinine_mg_dL":1.94,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":68,"sex":"female","bmi":22.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-57},"pfs_months":15.74},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":false},"longitudinal_labs":[{"date":"2022-07-04","hemoglobin_g_dL":12.0,"wbc_k_uL":7.9,"platelets_k_uL":291,"creatinine_mg_dL":1.23,"alt_U_L":21},{"date":"2023-02-22","hemoglobin_g_dL":10.1,"wbc_k_uL":5.8,"platelets_k_uL":343,"creatinine_mg_dL":1.12,"alt_U_L":64},{"date":"2024-01-20","hemoglobin_g_dL":11.0,"wbc_k_uL":5.1,"platelets_k_uL":276,"creatinine_mg_dL":1.28,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":64,"sex":"female","bmi":22.6,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-09-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-44},"pfs_months":15.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.6,"censored":false},"longitudinal_labs":[{"date":"2022-08-18","hemoglobin_g_dL":13.1,"wbc_k_uL":8.6,"platelets_k_uL":154,"creatinine_mg_dL":1.17,"alt_U_L":52},{"date":"2023-03-17","hemoglobin_g_dL":11.3,"wbc_k_uL":4.2,"platelets_k_uL":143,"creatinine_mg_dL":1.07,"alt_U_L":116},{"date":"2024-02-21","hemoglobin_g_dL":10.5,"wbc_k_uL":5.7,"platelets_k_uL":157,"creatinine_mg_dL":1.66,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":84,"sex":"female","bmi":34.4,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-62},"pfs_months":15.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.4,"censored":false},"longitudinal_labs":[{"date":"2025-02-21","hemoglobin_g_dL":11.7,"wbc_k_uL":9.5,"platelets_k_uL":222,"creatinine_mg_dL":0.84,"alt_U_L":70},{"date":"2025-09-14","hemoglobin_g_dL":12.5,"wbc_k_uL":7.2,"platelets_k_uL":237,"creatinine_mg_dL":1.36,"alt_U_L":91},{"date":"2026-08-15","hemoglobin_g_dL":11.1,"wbc_k_uL":5.9,"platelets_k_uL":268,"creatinine_mg_dL":1.71,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_335","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":78,"sex":"female","bmi":28.0,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-01-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-32},"pfs_months":16.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.4,"censored":false},"longitudinal_labs":[{"date":"2024-11-05","hemoglobin_g_dL":11.7,"wbc_k_uL":4.7,"platelets_k_uL":432,"creatinine_mg_dL":1.22,"alt_U_L":32},{"date":"2025-07-12","hemoglobin_g_dL":11.4,"wbc_k_uL":7.1,"platelets_k_uL":326,"creatinine_mg_dL":1.27,"alt_U_L":58},{"date":"2026-06-05","hemoglobin_g_dL":10.3,"wbc_k_uL":3.9,"platelets_k_uL":335,"creatinine_mg_dL":0.95,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_336","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":65,"sex":"female","bmi":37.8,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-01-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-65},"pfs_months":18.69},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":26.0,"censored":false},"longitudinal_labs":[{"date":"2022-11-19","hemoglobin_g_dL":13.2,"wbc_k_uL":8.7,"platelets_k_uL":287,"creatinine_mg_dL":1.28,"alt_U_L":52},{"date":"2023-07-02","hemoglobin_g_dL":10.7,"wbc_k_uL":6.5,"platelets_k_uL":198,"creatinine_mg_dL":1.24,"alt_U_L":53},{"date":"2024-09-09","hemoglobin_g_dL":9.8,"wbc_k_uL":4.0,"platelets_k_uL":322,"creatinine_mg_dL":0.9,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":64,"sex":"female","bmi":24.8,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-12-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-77},"pfs_months":6.21},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":10.4,"censored":true},"longitudinal_labs":[{"date":"2025-10-14","hemoglobin_g_dL":13.7,"wbc_k_uL":7.5,"platelets_k_uL":237,"creatinine_mg_dL":1.23,"alt_U_L":15},{"date":"2026-06-15","hemoglobin_g_dL":10.8,"wbc_k_uL":6.1,"platelets_k_uL":304,"creatinine_mg_dL":1.34,"alt_U_L":36},{"date":"2026-07-01","hemoglobin_g_dL":11.4,"wbc_k_uL":3.3,"platelets_k_uL":312,"creatinine_mg_dL":1.88,"alt_U_L":197}]}
{"patient_id":"ANODE_SYNTH_2025_338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":49,"sex":"male","bmi":21.1,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-09-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-70},"pfs_months":43.43},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":71.4,"censored":false},"longitudinal_labs":[{"date":"2020-08-28","hemoglobin_g_dL":14.8,"wbc_k_uL":7.5,"platelets_k_uL":270,"creatinine_mg_dL":0.94,"alt_U_L":40},{"date":"2021-03-28","hemoglobin_g_dL":11.4,"wbc_k_uL":7.5,"platelets_k_uL":205,"creatinine_mg_dL":1.6,"alt_U_L":88},{"date":"2024-06-29","hemoglobin_g_dL":12.6,"wbc_k_uL":6.1,"platelets_k_uL":123,"creatinine_mg_dL":1.16,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":65,"sex":"female","bmi":31.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-59},"pfs_months":14.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":26.6,"censored":false},"longitudinal_labs":[{"date":"2023-01-12","hemoglobin_g_dL":15.0,"wbc_k_uL":9.7,"platelets_k_uL":151,"creatinine_mg_dL":0.74,"alt_U_L":15},{"date":"2023-08-01","hemoglobin_g_dL":12.6,"wbc_k_uL":5.0,"platelets_k_uL":183,"creatinine_mg_dL":1.57,"alt_U_L":37},{"date":"2024-06-27","hemoglobin_g_dL":12.1,"wbc_k_uL":8.0,"platelets_k_uL":176,"creatinine_mg_dL":1.73,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":74,"sex":"male","bmi":19.7,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-56},"pfs_months":40.05},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":67.9,"censored":false},"longitudinal_labs":[{"date":"2021-03-08","hemoglobin_g_dL":15.5,"wbc_k_uL":6.8,"platelets_k_uL":229,"creatinine_mg_dL":0.75,"alt_U_L":41},{"date":"2021-11-05","hemoglobin_g_dL":10.3,"wbc_k_uL":8.3,"platelets_k_uL":352,"creatinine_mg_dL":1.48,"alt_U_L":81},{"date":"2024-10-13","hemoglobin_g_dL":12.1,"wbc_k_uL":6.5,"platelets_k_uL":324,"creatinine_mg_dL":1.67,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":59,"sex":"female","bmi":21.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-77},"pfs_months":28.65},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-31","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":47.2,"censored":false},"longitudinal_labs":[{"date":"2022-05-20","hemoglobin_g_dL":12.6,"wbc_k_uL":10.6,"platelets_k_uL":440,"creatinine_mg_dL":1.21,"alt_U_L":61},{"date":"2022-12-18","hemoglobin_g_dL":13.6,"wbc_k_uL":6.2,"platelets_k_uL":150,"creatinine_mg_dL":0.72,"alt_U_L":58},{"date":"2024-12-31","hemoglobin_g_dL":11.3,"wbc_k_uL":6.6,"platelets_k_uL":268,"creatinine_mg_dL":1.22,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":63,"sex":"female","bmi":29.5,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-07-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-66},"pfs_months":14.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.6,"censored":false},"longitudinal_labs":[{"date":"2022-05-19","hemoglobin_g_dL":13.7,"wbc_k_uL":10.9,"platelets_k_uL":227,"creatinine_mg_dL":1.06,"alt_U_L":61},{"date":"2022-12-29","hemoglobin_g_dL":10.1,"wbc_k_uL":6.6,"platelets_k_uL":270,"creatinine_mg_dL":1.43,"alt_U_L":74},{"date":"2023-10-14","hemoglobin_g_dL":11.1,"wbc_k_uL":5.1,"platelets_k_uL":210,"creatinine_mg_dL":1.81,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":55,"sex":"female","bmi":27.5,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-64},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":10.6,"censored":false},"longitudinal_labs":[{"date":"2021-08-14","hemoglobin_g_dL":14.7,"wbc_k_uL":5.2,"platelets_k_uL":196,"creatinine_mg_dL":0.68,"alt_U_L":74},{"date":"2022-03-22","hemoglobin_g_dL":11.5,"wbc_k_uL":5.5,"platelets_k_uL":364,"creatinine_mg_dL":1.36,"alt_U_L":41},{"date":"2022-02-13","hemoglobin_g_dL":11.1,"wbc_k_uL":7.0,"platelets_k_uL":240,"creatinine_mg_dL":1.99,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_344","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":86,"sex":"female","bmi":19.0,"smoking_pack_years":41,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-38},"pfs_months":19.71},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.2,"censored":false},"longitudinal_labs":[{"date":"2023-03-24","hemoglobin_g_dL":14.9,"wbc_k_uL":7.4,"platelets_k_uL":292,"creatinine_mg_dL":1.21,"alt_U_L":17},{"date":"2023-11-19","hemoglobin_g_dL":12.3,"wbc_k_uL":5.6,"platelets_k_uL":364,"creatinine_mg_dL":0.95,"alt_U_L":74},{"date":"2025-01-22","hemoglobin_g_dL":11.6,"wbc_k_uL":3.2,"platelets_k_uL":145,"creatinine_mg_dL":1.5,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":64,"sex":"female","bmi":32.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-61},"pfs_months":21.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-25","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.6,"censored":true},"longitudinal_labs":[{"date":"2025-05-20","hemoglobin_g_dL":11.8,"wbc_k_uL":9.2,"platelets_k_uL":315,"creatinine_mg_dL":1.29,"alt_U_L":55},{"date":"2026-01-14","hemoglobin_g_dL":10.3,"wbc_k_uL":8.4,"platelets_k_uL":304,"creatinine_mg_dL":0.74,"alt_U_L":83},{"date":"2027-05-25","hemoglobin_g_dL":10.4,"wbc_k_uL":4.9,"platelets_k_uL":122,"creatinine_mg_dL":0.81,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":76,"sex":"female","bmi":18.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-44},"pfs_months":28.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":false},"longitudinal_labs":[{"date":"2022-02-19","hemoglobin_g_dL":12.6,"wbc_k_uL":8.6,"platelets_k_uL":328,"creatinine_mg_dL":0.95,"alt_U_L":35},{"date":"2022-10-06","hemoglobin_g_dL":12.3,"wbc_k_uL":4.7,"platelets_k_uL":129,"creatinine_mg_dL":1.46,"alt_U_L":97},{"date":"2024-10-27","hemoglobin_g_dL":10.4,"wbc_k_uL":3.3,"platelets_k_uL":181,"creatinine_mg_dL":0.98,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_347","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":66,"sex":"male","bmi":26.4,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-05-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-65},"pfs_months":25.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.6,"censored":true},"longitudinal_labs":[{"date":"2021-03-14","hemoglobin_g_dL":12.2,"wbc_k_uL":10.2,"platelets_k_uL":313,"creatinine_mg_dL":0.73,"alt_U_L":11},{"date":"2021-11-15","hemoglobin_g_dL":10.5,"wbc_k_uL":3.9,"platelets_k_uL":226,"creatinine_mg_dL":1.32,"alt_U_L":93},{"date":"2023-07-10","hemoglobin_g_dL":10.8,"wbc_k_uL":3.6,"platelets_k_uL":300,"creatinine_mg_dL":1.1,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":62,"sex":"female","bmi":27.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-40},"pfs_months":20.86},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.8,"censored":true},"longitudinal_labs":[{"date":"2021-07-13","hemoglobin_g_dL":14.3,"wbc_k_uL":8.2,"platelets_k_uL":268,"creatinine_mg_dL":0.9,"alt_U_L":31},{"date":"2022-02-16","hemoglobin_g_dL":13.3,"wbc_k_uL":7.6,"platelets_k_uL":298,"creatinine_mg_dL":1.52,"alt_U_L":34},{"date":"2023-06-13","hemoglobin_g_dL":11.7,"wbc_k_uL":6.7,"platelets_k_uL":171,"creatinine_mg_dL":1.75,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":48,"sex":"female","bmi":20.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-39},"pfs_months":21.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.4,"censored":true},"longitudinal_labs":[{"date":"2021-07-18","hemoglobin_g_dL":11.8,"wbc_k_uL":10.6,"platelets_k_uL":295,"creatinine_mg_dL":0.87,"alt_U_L":18},{"date":"2022-02-12","hemoglobin_g_dL":11.4,"wbc_k_uL":5.4,"platelets_k_uL":312,"creatinine_mg_dL":1.59,"alt_U_L":56},{"date":"2023-06-09","hemoglobin_g_dL":9.8,"wbc_k_uL":7.9,"platelets_k_uL":249,"creatinine_mg_dL":1.58,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_350","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":70,"sex":"female","bmi":20.9,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-12-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-66},"pfs_months":35.65},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.0,"censored":true},"longitudinal_labs":[{"date":"2024-10-14","hemoglobin_g_dL":13.0,"wbc_k_uL":9.9,"platelets_k_uL":343,"creatinine_mg_dL":0.62,"alt_U_L":77},{"date":"2025-06-10","hemoglobin_g_dL":13.5,"wbc_k_uL":5.7,"platelets_k_uL":122,"creatinine_mg_dL":1.32,"alt_U_L":93},{"date":"2027-12-06","hemoglobin_g_dL":12.5,"wbc_k_uL":3.4,"platelets_k_uL":195,"creatinine_mg_dL":1.21,"alt_U_L":90}]}
{"patient_id":"ANODE_SYNTH_2025_351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":85,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-49},"pfs_months":16.99},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":true},"longitudinal_labs":[{"date":"2023-06-23","hemoglobin_g_dL":13.8,"wbc_k_uL":4.6,"platelets_k_uL":251,"creatinine_mg_dL":1.0,"alt_U_L":23},{"date":"2024-02-21","hemoglobin_g_dL":12.7,"wbc_k_uL":4.9,"platelets_k_uL":246,"creatinine_mg_dL":0.92,"alt_U_L":88},{"date":"2025-02-23","hemoglobin_g_dL":9.7,"wbc_k_uL":5.4,"platelets_k_uL":236,"creatinine_mg_dL":0.9,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":50,"sex":"female","bmi":18.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-32},"pfs_months":21.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.7,"censored":false},"longitudinal_labs":[{"date":"2024-10-07","hemoglobin_g_dL":12.2,"wbc_k_uL":6.1,"platelets_k_uL":280,"creatinine_mg_dL":1.22,"alt_U_L":59},{"date":"2025-05-07","hemoglobin_g_dL":10.2,"wbc_k_uL":4.0,"platelets_k_uL":256,"creatinine_mg_dL":0.88,"alt_U_L":108},{"date":"2026-09-18","hemoglobin_g_dL":10.7,"wbc_k_uL":6.8,"platelets_k_uL":316,"creatinine_mg_dL":0.98,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_353","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":72,"sex":"male","bmi":25.5,"smoking_pack_years":23,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-02-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-45},"pfs_months":29.17},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.5,"censored":false},"longitudinal_labs":[{"date":"2024-02-02","hemoglobin_g_dL":14.6,"wbc_k_uL":4.7,"platelets_k_uL":253,"creatinine_mg_dL":0.68,"alt_U_L":37},{"date":"2024-08-20","hemoglobin_g_dL":13.6,"wbc_k_uL":4.7,"platelets_k_uL":361,"creatinine_mg_dL":0.86,"alt_U_L":52},{"date":"2026-08-18","hemoglobin_g_dL":10.9,"wbc_k_uL":5.5,"platelets_k_uL":262,"creatinine_mg_dL":1.71,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":76,"sex":"male","bmi":24.1,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-71},"pfs_months":43.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":68.1,"censored":false},"longitudinal_labs":[{"date":"2021-03-14","hemoglobin_g_dL":12.1,"wbc_k_uL":10.4,"platelets_k_uL":431,"creatinine_mg_dL":0.92,"alt_U_L":32},{"date":"2021-11-06","hemoglobin_g_dL":10.2,"wbc_k_uL":5.8,"platelets_k_uL":214,"creatinine_mg_dL":0.94,"alt_U_L":41},{"date":"2025-01-30","hemoglobin_g_dL":11.8,"wbc_k_uL":7.5,"platelets_k_uL":161,"creatinine_mg_dL":1.22,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.2,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":84,"sex":"female","bmi":25.6,"smoking_pack_years":16,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2024-12-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-61},"pfs_months":18.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.6,"censored":true},"longitudinal_labs":[{"date":"2024-11-26","hemoglobin_g_dL":15.0,"wbc_k_uL":7.3,"platelets_k_uL":361,"creatinine_mg_dL":0.81,"alt_U_L":79},{"date":"2025-06-18","hemoglobin_g_dL":13.1,"wbc_k_uL":6.5,"platelets_k_uL":274,"creatinine_mg_dL":1.54,"alt_U_L":96},{"date":"2026-08-18","hemoglobin_g_dL":10.5,"wbc_k_uL":5.7,"platelets_k_uL":313,"creatinine_mg_dL":1.22,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":80,"sex":"female","bmi":26.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-02-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-61},"pfs_months":25.76},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":false},"longitudinal_labs":[{"date":"2020-01-17","hemoglobin_g_dL":11.7,"wbc_k_uL":8.9,"platelets_k_uL":227,"creatinine_mg_dL":0.82,"alt_U_L":53},{"date":"2020-08-11","hemoglobin_g_dL":12.4,"wbc_k_uL":3.8,"platelets_k_uL":295,"creatinine_mg_dL":0.89,"alt_U_L":51},{"date":"2022-05-29","hemoglobin_g_dL":10.1,"wbc_k_uL":7.7,"platelets_k_uL":344,"creatinine_mg_dL":0.91,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":79,"sex":"male","bmi":28.3,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-08-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-62},"pfs_months":38.05},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":60.2,"censored":false},"longitudinal_labs":[{"date":"2024-06-27","hemoglobin_g_dL":14.8,"wbc_k_uL":6.6,"platelets_k_uL":356,"creatinine_mg_dL":1.25,"alt_U_L":51},{"date":"2025-02-01","hemoglobin_g_dL":12.5,"wbc_k_uL":5.9,"platelets_k_uL":200,"creatinine_mg_dL":0.91,"alt_U_L":35},{"date":"2027-11-01","hemoglobin_g_dL":11.2,"wbc_k_uL":5.3,"platelets_k_uL":342,"creatinine_mg_dL":1.99,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":86,"sex":"female","bmi":27.3,"smoking_pack_years":41,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-04-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-60},"pfs_months":40.71},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":72.9,"censored":true},"longitudinal_labs":[{"date":"2020-02-22","hemoglobin_g_dL":12.8,"wbc_k_uL":5.5,"platelets_k_uL":203,"creatinine_mg_dL":0.89,"alt_U_L":47},{"date":"2020-10-27","hemoglobin_g_dL":12.8,"wbc_k_uL":8.6,"platelets_k_uL":129,"creatinine_mg_dL":1.08,"alt_U_L":107},{"date":"2023-10-06","hemoglobin_g_dL":10.2,"wbc_k_uL":7.8,"platelets_k_uL":179,"creatinine_mg_dL":1.49,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":75,"sex":"male","bmi":19.7,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2022-11-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-46},"pfs_months":33.35},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":50.5,"censored":false},"longitudinal_labs":[{"date":"2022-09-25","hemoglobin_g_dL":14.6,"wbc_k_uL":7.4,"platelets_k_uL":343,"creatinine_mg_dL":1.09,"alt_U_L":62},{"date":"2023-05-29","hemoglobin_g_dL":13.6,"wbc_k_uL":8.8,"platelets_k_uL":303,"creatinine_mg_dL":0.99,"alt_U_L":49},{"date":"2025-10-21","hemoglobin_g_dL":10.7,"wbc_k_uL":7.3,"platelets_k_uL":194,"creatinine_mg_dL":1.93,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":68,"sex":"female","bmi":30.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-40},"pfs_months":17.81},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":false},"longitudinal_labs":[{"date":"2021-10-21","hemoglobin_g_dL":13.2,"wbc_k_uL":9.8,"platelets_k_uL":187,"creatinine_mg_dL":1.15,"alt_U_L":32},{"date":"2022-05-13","hemoglobin_g_dL":13.2,"wbc_k_uL":8.1,"platelets_k_uL":350,"creatinine_mg_dL":1.07,"alt_U_L":23},{"date":"2023-06-17","hemoglobin_g_dL":10.1,"wbc_k_uL":5.6,"platelets_k_uL":102,"creatinine_mg_dL":0.84,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":79,"sex":"female","bmi":37.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-39},"pfs_months":10.32},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.7,"censored":true},"longitudinal_labs":[{"date":"2022-06-27","hemoglobin_g_dL":13.0,"wbc_k_uL":5.8,"platelets_k_uL":201,"creatinine_mg_dL":0.99,"alt_U_L":20},{"date":"2023-01-19","hemoglobin_g_dL":13.6,"wbc_k_uL":8.5,"platelets_k_uL":178,"creatinine_mg_dL":1.08,"alt_U_L":104},{"date":"2023-07-13","hemoglobin_g_dL":11.4,"wbc_k_uL":5.8,"platelets_k_uL":256,"creatinine_mg_dL":1.53,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":64,"sex":"female","bmi":27.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-36},"pfs_months":26.64},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.5,"censored":true},"longitudinal_labs":[{"date":"2020-12-28","hemoglobin_g_dL":14.4,"wbc_k_uL":8.0,"platelets_k_uL":253,"creatinine_mg_dL":1.24,"alt_U_L":73},{"date":"2021-08-02","hemoglobin_g_dL":11.4,"wbc_k_uL":7.3,"platelets_k_uL":236,"creatinine_mg_dL":1.08,"alt_U_L":100},{"date":"2023-05-31","hemoglobin_g_dL":11.2,"wbc_k_uL":4.1,"platelets_k_uL":125,"creatinine_mg_dL":1.68,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":85,"sex":"male","bmi":31.6,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-05-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-50},"pfs_months":33.94},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":56.0,"censored":false},"longitudinal_labs":[{"date":"2024-04-01","hemoglobin_g_dL":13.5,"wbc_k_uL":9.7,"platelets_k_uL":396,"creatinine_mg_dL":1.11,"alt_U_L":54},{"date":"2024-11-23","hemoglobin_g_dL":13.6,"wbc_k_uL":5.3,"platelets_k_uL":317,"creatinine_mg_dL":1.19,"alt_U_L":119},{"date":"2027-05-13","hemoglobin_g_dL":11.4,"wbc_k_uL":8.0,"platelets_k_uL":103,"creatinine_mg_dL":1.7,"alt_U_L":56}]}
{"patient_id":"ANODE_SYNTH_2025_364","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":60,"sex":"male","bmi":33.8,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-06-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-62},"pfs_months":17.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":true},"longitudinal_labs":[{"date":"2020-04-07","hemoglobin_g_dL":12.6,"wbc_k_uL":8.1,"platelets_k_uL":295,"creatinine_mg_dL":1.17,"alt_U_L":65},{"date":"2020-12-02","hemoglobin_g_dL":13.6,"wbc_k_uL":6.4,"platelets_k_uL":276,"creatinine_mg_dL":1.3,"alt_U_L":23},{"date":"2021-12-26","hemoglobin_g_dL":12.6,"wbc_k_uL":3.9,"platelets_k_uL":255,"creatinine_mg_dL":1.37,"alt_U_L":145}]}
{"patient_id":"ANODE_SYNTH_2025_365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":75,"sex":"female","bmi":31.0,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-11-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-54},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":10.7,"censored":false},"longitudinal_labs":[{"date":"2025-09-28","hemoglobin_g_dL":13.9,"wbc_k_uL":9.2,"platelets_k_uL":369,"creatinine_mg_dL":1.08,"alt_U_L":10},{"date":"2026-05-25","hemoglobin_g_dL":10.0,"wbc_k_uL":6.7,"platelets_k_uL":143,"creatinine_mg_dL":1.38,"alt_U_L":16},{"date":"2026-03-23","hemoglobin_g_dL":10.4,"wbc_k_uL":7.7,"platelets_k_uL":169,"creatinine_mg_dL":1.66,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":75,"sex":"male","bmi":19.8,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-07-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-69},"pfs_months":32.92},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":57.2,"censored":false},"longitudinal_labs":[{"date":"2023-06-08","hemoglobin_g_dL":12.4,"wbc_k_uL":5.9,"platelets_k_uL":317,"creatinine_mg_dL":0.74,"alt_U_L":75},{"date":"2024-01-27","hemoglobin_g_dL":13.0,"wbc_k_uL":4.9,"platelets_k_uL":131,"creatinine_mg_dL":0.8,"alt_U_L":89},{"date":"2026-06-25","hemoglobin_g_dL":11.5,"wbc_k_uL":5.3,"platelets_k_uL":119,"creatinine_mg_dL":1.7,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_367","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":65,"sex":"male","bmi":29.6,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-02-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-40},"pfs_months":25.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.5,"censored":false},"longitudinal_labs":[{"date":"2023-01-05","hemoglobin_g_dL":12.5,"wbc_k_uL":4.9,"platelets_k_uL":236,"creatinine_mg_dL":0.97,"alt_U_L":32},{"date":"2023-08-13","hemoglobin_g_dL":10.9,"wbc_k_uL":4.2,"platelets_k_uL":378,"creatinine_mg_dL":1.24,"alt_U_L":107},{"date":"2025-04-13","hemoglobin_g_dL":11.2,"wbc_k_uL":7.1,"platelets_k_uL":297,"creatinine_mg_dL":1.05,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_368","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":52,"sex":"male","bmi":28.6,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-08-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-73},"pfs_months":26.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.5,"censored":false},"longitudinal_labs":[{"date":"2023-06-27","hemoglobin_g_dL":14.6,"wbc_k_uL":4.9,"platelets_k_uL":312,"creatinine_mg_dL":0.7,"alt_U_L":22},{"date":"2024-02-03","hemoglobin_g_dL":11.5,"wbc_k_uL":6.9,"platelets_k_uL":311,"creatinine_mg_dL":0.77,"alt_U_L":18},{"date":"2025-11-03","hemoglobin_g_dL":11.9,"wbc_k_uL":7.8,"platelets_k_uL":181,"creatinine_mg_dL":1.18,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":55,"sex":"female","bmi":20.1,"smoking_pack_years":33,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-66},"pfs_months":7.92},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":11.9,"censored":false},"longitudinal_labs":[{"date":"2024-02-12","hemoglobin_g_dL":15.1,"wbc_k_uL":5.8,"platelets_k_uL":432,"creatinine_mg_dL":0.95,"alt_U_L":36},{"date":"2024-09-28","hemoglobin_g_dL":11.8,"wbc_k_uL":7.5,"platelets_k_uL":325,"creatinine_mg_dL":0.77,"alt_U_L":37},{"date":"2024-12-15","hemoglobin_g_dL":11.9,"wbc_k_uL":4.4,"platelets_k_uL":154,"creatinine_mg_dL":1.62,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":63,"sex":"male","bmi":25.6,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-05-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-80},"pfs_months":34.73},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":59.7,"censored":false},"longitudinal_labs":[{"date":"2025-03-25","hemoglobin_g_dL":15.1,"wbc_k_uL":6.1,"platelets_k_uL":268,"creatinine_mg_dL":0.98,"alt_U_L":64},{"date":"2025-10-28","hemoglobin_g_dL":12.8,"wbc_k_uL":6.9,"platelets_k_uL":362,"creatinine_mg_dL":1.6,"alt_U_L":100},{"date":"2028-05-09","hemoglobin_g_dL":12.9,"wbc_k_uL":6.5,"platelets_k_uL":151,"creatinine_mg_dL":1.55,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_371","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":63,"sex":"male","bmi":33.0,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-07-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-79},"pfs_months":15.93},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.1,"censored":false},"longitudinal_labs":[{"date":"2024-06-07","hemoglobin_g_dL":14.3,"wbc_k_uL":9.4,"platelets_k_uL":262,"creatinine_mg_dL":0.87,"alt_U_L":57},{"date":"2025-01-15","hemoglobin_g_dL":10.1,"wbc_k_uL":6.6,"platelets_k_uL":143,"creatinine_mg_dL":1.11,"alt_U_L":52},{"date":"2025-11-23","hemoglobin_g_dL":12.6,"wbc_k_uL":5.2,"platelets_k_uL":247,"creatinine_mg_dL":1.67,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":62,"sex":"female","bmi":34.7,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-02-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-53},"pfs_months":30.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":50.8,"censored":false},"longitudinal_labs":[{"date":"2020-12-19","hemoglobin_g_dL":12.7,"wbc_k_uL":7.4,"platelets_k_uL":227,"creatinine_mg_dL":1.18,"alt_U_L":72},{"date":"2021-08-16","hemoglobin_g_dL":12.2,"wbc_k_uL":5.4,"platelets_k_uL":143,"creatinine_mg_dL":0.88,"alt_U_L":46},{"date":"2023-09-12","hemoglobin_g_dL":13.0,"wbc_k_uL":3.7,"platelets_k_uL":148,"creatinine_mg_dL":1.2,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":75,"sex":"female","bmi":31.3,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-11-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-39},"pfs_months":27.37},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.3,"censored":false},"longitudinal_labs":[{"date":"2024-10-22","hemoglobin_g_dL":14.3,"wbc_k_uL":9.1,"platelets_k_uL":395,"creatinine_mg_dL":0.97,"alt_U_L":14},{"date":"2025-05-14","hemoglobin_g_dL":12.1,"wbc_k_uL":6.3,"platelets_k_uL":159,"creatinine_mg_dL":0.84,"alt_U_L":88},{"date":"2027-03-13","hemoglobin_g_dL":10.7,"wbc_k_uL":7.5,"platelets_k_uL":123,"creatinine_mg_dL":0.8,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":48,"sex":"female","bmi":28.3,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-38},"pfs_months":37.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":63.6,"censored":false},"longitudinal_labs":[{"date":"2024-01-05","hemoglobin_g_dL":12.4,"wbc_k_uL":8.0,"platelets_k_uL":404,"creatinine_mg_dL":1.22,"alt_U_L":78},{"date":"2024-08-31","hemoglobin_g_dL":11.0,"wbc_k_uL":4.1,"platelets_k_uL":372,"creatinine_mg_dL":1.52,"alt_U_L":56},{"date":"2027-05-11","hemoglobin_g_dL":10.8,"wbc_k_uL":3.0,"platelets_k_uL":232,"creatinine_mg_dL":1.16,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":63,"sex":"female","bmi":28.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-41},"pfs_months":22.74},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":false},"longitudinal_labs":[{"date":"2022-04-10","hemoglobin_g_dL":15.0,"wbc_k_uL":5.0,"platelets_k_uL":373,"creatinine_mg_dL":0.68,"alt_U_L":47},{"date":"2022-12-12","hemoglobin_g_dL":13.1,"wbc_k_uL":7.3,"platelets_k_uL":330,"creatinine_mg_dL":1.11,"alt_U_L":64},{"date":"2024-06-30","hemoglobin_g_dL":10.2,"wbc_k_uL":6.6,"platelets_k_uL":288,"creatinine_mg_dL":1.11,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_376","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":87,"sex":"male","bmi":20.6,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-12-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-66},"pfs_months":15.34},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2022-11-07","hemoglobin_g_dL":15.0,"wbc_k_uL":9.1,"platelets_k_uL":391,"creatinine_mg_dL":0.76,"alt_U_L":14},{"date":"2023-06-13","hemoglobin_g_dL":12.3,"wbc_k_uL":7.0,"platelets_k_uL":123,"creatinine_mg_dL":1.55,"alt_U_L":104},{"date":"2024-04-17","hemoglobin_g_dL":12.5,"wbc_k_uL":6.5,"platelets_k_uL":309,"creatinine_mg_dL":1.44,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_377","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":51,"sex":"female","bmi":22.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-02-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-77},"pfs_months":20.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":false},"longitudinal_labs":[{"date":"2023-12-10","hemoglobin_g_dL":13.0,"wbc_k_uL":8.4,"platelets_k_uL":419,"creatinine_mg_dL":0.6,"alt_U_L":49},{"date":"2024-08-06","hemoglobin_g_dL":11.0,"wbc_k_uL":3.8,"platelets_k_uL":232,"creatinine_mg_dL":0.98,"alt_U_L":70},{"date":"2025-11-19","hemoglobin_g_dL":12.5,"wbc_k_uL":7.2,"platelets_k_uL":298,"creatinine_mg_dL":0.83,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":82,"sex":"female","bmi":30.4,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-39},"pfs_months":18.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.2,"censored":true},"longitudinal_labs":[{"date":"2024-03-17","hemoglobin_g_dL":14.6,"wbc_k_uL":9.9,"platelets_k_uL":164,"creatinine_mg_dL":1.29,"alt_U_L":75},{"date":"2024-10-26","hemoglobin_g_dL":13.0,"wbc_k_uL":8.8,"platelets_k_uL":172,"creatinine_mg_dL":1.25,"alt_U_L":15},{"date":"2026-01-03","hemoglobin_g_dL":9.7,"wbc_k_uL":5.6,"platelets_k_uL":174,"creatinine_mg_dL":1.87,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_379","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":66,"sex":"female","bmi":37.2,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-67},"pfs_months":25.07},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":false},"longitudinal_labs":[{"date":"2023-12-10","hemoglobin_g_dL":12.8,"wbc_k_uL":6.7,"platelets_k_uL":406,"creatinine_mg_dL":1.14,"alt_U_L":18},{"date":"2024-06-21","hemoglobin_g_dL":13.6,"wbc_k_uL":4.0,"platelets_k_uL":145,"creatinine_mg_dL":0.83,"alt_U_L":28},{"date":"2026-02-11","hemoglobin_g_dL":10.9,"wbc_k_uL":4.7,"platelets_k_uL":244,"creatinine_mg_dL":1.28,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":55,"sex":"female","bmi":23.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-41},"pfs_months":17.15},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.4,"censored":true},"longitudinal_labs":[{"date":"2023-10-19","hemoglobin_g_dL":13.4,"wbc_k_uL":8.3,"platelets_k_uL":337,"creatinine_mg_dL":1.06,"alt_U_L":33},{"date":"2024-06-04","hemoglobin_g_dL":10.2,"wbc_k_uL":4.5,"platelets_k_uL":270,"creatinine_mg_dL":1.3,"alt_U_L":62},{"date":"2025-07-08","hemoglobin_g_dL":11.5,"wbc_k_uL":3.4,"platelets_k_uL":291,"creatinine_mg_dL":1.57,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":59,"sex":"male","bmi":32.8,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-49},"pfs_months":41.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":66.1,"censored":false},"longitudinal_labs":[{"date":"2021-04-24","hemoglobin_g_dL":14.2,"wbc_k_uL":10.1,"platelets_k_uL":247,"creatinine_mg_dL":0.73,"alt_U_L":39},{"date":"2021-12-25","hemoglobin_g_dL":10.9,"wbc_k_uL":6.6,"platelets_k_uL":211,"creatinine_mg_dL":0.81,"alt_U_L":81},{"date":"2025-01-08","hemoglobin_g_dL":12.4,"wbc_k_uL":5.8,"platelets_k_uL":339,"creatinine_mg_dL":1.34,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_382","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":57,"sex":"male","bmi":37.0,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-75},"pfs_months":41.49},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":64.6,"censored":false},"longitudinal_labs":[{"date":"2020-02-10","hemoglobin_g_dL":14.6,"wbc_k_uL":9.9,"platelets_k_uL":187,"creatinine_mg_dL":0.77,"alt_U_L":59},{"date":"2020-08-31","hemoglobin_g_dL":11.8,"wbc_k_uL":8.8,"platelets_k_uL":263,"creatinine_mg_dL":1.48,"alt_U_L":44},{"date":"2023-09-26","hemoglobin_g_dL":12.9,"wbc_k_uL":3.8,"platelets_k_uL":284,"creatinine_mg_dL":1.44,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":77,"sex":"female","bmi":34.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-54},"pfs_months":20.37},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.2,"censored":false},"longitudinal_labs":[{"date":"2024-03-04","hemoglobin_g_dL":13.3,"wbc_k_uL":6.2,"platelets_k_uL":409,"creatinine_mg_dL":1.17,"alt_U_L":74},{"date":"2024-10-23","hemoglobin_g_dL":13.7,"wbc_k_uL":5.6,"platelets_k_uL":255,"creatinine_mg_dL":1.23,"alt_U_L":35},{"date":"2026-02-15","hemoglobin_g_dL":12.1,"wbc_k_uL":7.0,"platelets_k_uL":104,"creatinine_mg_dL":1.83,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_384","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":77,"sex":"male","bmi":24.3,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-03-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-47},"pfs_months":17.15},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.3,"censored":false},"longitudinal_labs":[{"date":"2025-01-26","hemoglobin_g_dL":14.2,"wbc_k_uL":8.2,"platelets_k_uL":320,"creatinine_mg_dL":0.64,"alt_U_L":10},{"date":"2025-08-31","hemoglobin_g_dL":12.5,"wbc_k_uL":5.2,"platelets_k_uL":205,"creatinine_mg_dL":1.6,"alt_U_L":85},{"date":"2026-08-13","hemoglobin_g_dL":9.5,"wbc_k_uL":4.5,"platelets_k_uL":205,"creatinine_mg_dL":1.12,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":84,"sex":"female","bmi":24.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-54},"pfs_months":29.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":38.9,"censored":false},"longitudinal_labs":[{"date":"2025-06-13","hemoglobin_g_dL":12.2,"wbc_k_uL":7.1,"platelets_k_uL":400,"creatinine_mg_dL":1.25,"alt_U_L":51},{"date":"2026-01-08","hemoglobin_g_dL":10.5,"wbc_k_uL":7.5,"platelets_k_uL":279,"creatinine_mg_dL":1.26,"alt_U_L":70},{"date":"2028-02-03","hemoglobin_g_dL":11.3,"wbc_k_uL":7.6,"platelets_k_uL":136,"creatinine_mg_dL":1.36,"alt_U_L":166}]}
{"patient_id":"ANODE_SYNTH_2025_386","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":70,"sex":"male","bmi":34.6,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-05-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-75},"pfs_months":29.73},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.6,"censored":false},"longitudinal_labs":[{"date":"2020-04-08","hemoglobin_g_dL":15.2,"wbc_k_uL":7.7,"platelets_k_uL":376,"creatinine_mg_dL":1.19,"alt_U_L":10},{"date":"2020-10-29","hemoglobin_g_dL":13.3,"wbc_k_uL":6.7,"platelets_k_uL":140,"creatinine_mg_dL":1.01,"alt_U_L":72},{"date":"2022-11-04","hemoglobin_g_dL":9.7,"wbc_k_uL":3.8,"platelets_k_uL":232,"creatinine_mg_dL":1.54,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":70,"sex":"male","bmi":35.8,"smoking_pack_years":26,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-05-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-55},"pfs_months":41.69},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.7,"censored":false},"longitudinal_labs":[{"date":"2025-04-18","hemoglobin_g_dL":11.9,"wbc_k_uL":4.8,"platelets_k_uL":322,"creatinine_mg_dL":1.24,"alt_U_L":46},{"date":"2025-11-18","hemoglobin_g_dL":11.1,"wbc_k_uL":7.1,"platelets_k_uL":174,"creatinine_mg_dL":1.41,"alt_U_L":95},{"date":"2029-01-07","hemoglobin_g_dL":10.5,"wbc_k_uL":6.1,"platelets_k_uL":327,"creatinine_mg_dL":1.35,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":79,"sex":"female","bmi":33.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-02-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-67},"pfs_months":11.04},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":true},"longitudinal_labs":[{"date":"2021-12-16","hemoglobin_g_dL":12.4,"wbc_k_uL":9.6,"platelets_k_uL":268,"creatinine_mg_dL":0.62,"alt_U_L":26},{"date":"2022-08-15","hemoglobin_g_dL":10.6,"wbc_k_uL":6.5,"platelets_k_uL":290,"creatinine_mg_dL":0.99,"alt_U_L":19},{"date":"2023-02-05","hemoglobin_g_dL":12.0,"wbc_k_uL":4.1,"platelets_k_uL":182,"creatinine_mg_dL":1.77,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":50,"sex":"male","bmi":31.2,"smoking_pack_years":76,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-79},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-09-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":8.5,"censored":true},"longitudinal_labs":[{"date":"2020-04-11","hemoglobin_g_dL":15.1,"wbc_k_uL":9.4,"platelets_k_uL":320,"creatinine_mg_dL":0.89,"alt_U_L":62},{"date":"2020-12-08","hemoglobin_g_dL":11.3,"wbc_k_uL":4.4,"platelets_k_uL":255,"creatinine_mg_dL":1.39,"alt_U_L":30},{"date":"2020-09-28","hemoglobin_g_dL":9.8,"wbc_k_uL":6.9,"platelets_k_uL":338,"creatinine_mg_dL":1.21,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":64,"sex":"female","bmi":21.9,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-01-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-85},"pfs_months":9.49},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":13.4,"censored":true},"longitudinal_labs":[{"date":"2025-12-17","hemoglobin_g_dL":13.3,"wbc_k_uL":7.5,"platelets_k_uL":268,"creatinine_mg_dL":1.29,"alt_U_L":66},{"date":"2026-07-07","hemoglobin_g_dL":11.6,"wbc_k_uL":8.6,"platelets_k_uL":375,"creatinine_mg_dL":0.83,"alt_U_L":61},{"date":"2026-12-11","hemoglobin_g_dL":9.7,"wbc_k_uL":6.3,"platelets_k_uL":272,"creatinine_mg_dL":0.86,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":77,"sex":"female","bmi":27.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-38},"pfs_months":15.44},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":true},"longitudinal_labs":[{"date":"2020-08-22","hemoglobin_g_dL":14.3,"wbc_k_uL":7.9,"platelets_k_uL":295,"creatinine_mg_dL":0.64,"alt_U_L":41},{"date":"2021-03-25","hemoglobin_g_dL":11.8,"wbc_k_uL":5.7,"platelets_k_uL":318,"creatinine_mg_dL":0.91,"alt_U_L":120},{"date":"2022-01-22","hemoglobin_g_dL":12.9,"wbc_k_uL":4.7,"platelets_k_uL":271,"creatinine_mg_dL":0.93,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_392","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":86,"sex":"female","bmi":20.8,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-12-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-57},"pfs_months":26.58},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.3,"censored":false},"longitudinal_labs":[{"date":"2024-11-15","hemoglobin_g_dL":14.3,"wbc_k_uL":7.9,"platelets_k_uL":366,"creatinine_mg_dL":1.27,"alt_U_L":64},{"date":"2025-06-16","hemoglobin_g_dL":13.8,"wbc_k_uL":4.0,"platelets_k_uL":125,"creatinine_mg_dL":1.48,"alt_U_L":19},{"date":"2027-05-02","hemoglobin_g_dL":11.6,"wbc_k_uL":5.6,"platelets_k_uL":238,"creatinine_mg_dL":0.98,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":61,"sex":"female","bmi":30.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-73},"pfs_months":28.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":50.3,"censored":false},"longitudinal_labs":[{"date":"2025-03-03","hemoglobin_g_dL":12.1,"wbc_k_uL":5.4,"platelets_k_uL":358,"creatinine_mg_dL":1.29,"alt_U_L":76},{"date":"2025-10-13","hemoglobin_g_dL":12.1,"wbc_k_uL":4.6,"platelets_k_uL":188,"creatinine_mg_dL":1.23,"alt_U_L":118},{"date":"2027-09-28","hemoglobin_g_dL":12.6,"wbc_k_uL":4.9,"platelets_k_uL":210,"creatinine_mg_dL":1.19,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":86,"sex":"female","bmi":37.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-09-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-64},"pfs_months":29.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.6,"censored":false},"longitudinal_labs":[{"date":"2023-08-22","hemoglobin_g_dL":13.7,"wbc_k_uL":6.2,"platelets_k_uL":399,"creatinine_mg_dL":0.84,"alt_U_L":43},{"date":"2024-03-24","hemoglobin_g_dL":13.8,"wbc_k_uL":5.5,"platelets_k_uL":270,"creatinine_mg_dL":1.45,"alt_U_L":38},{"date":"2026-05-16","hemoglobin_g_dL":10.8,"wbc_k_uL":6.1,"platelets_k_uL":319,"creatinine_mg_dL":0.96,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":59,"sex":"female","bmi":21.6,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-65},"pfs_months":35.48},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":53.1,"censored":true},"longitudinal_labs":[{"date":"2023-09-12","hemoglobin_g_dL":14.6,"wbc_k_uL":4.8,"platelets_k_uL":325,"creatinine_mg_dL":1.25,"alt_U_L":70},{"date":"2024-05-08","hemoglobin_g_dL":10.1,"wbc_k_uL":3.9,"platelets_k_uL":217,"creatinine_mg_dL":0.8,"alt_U_L":76},{"date":"2026-12-04","hemoglobin_g_dL":11.3,"wbc_k_uL":7.3,"platelets_k_uL":254,"creatinine_mg_dL":1.46,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":48,"sex":"female","bmi":33.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-58},"pfs_months":19.81},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.5,"censored":false},"longitudinal_labs":[{"date":"2021-05-08","hemoglobin_g_dL":15.3,"wbc_k_uL":10.6,"platelets_k_uL":264,"creatinine_mg_dL":1.19,"alt_U_L":19},{"date":"2021-11-19","hemoglobin_g_dL":11.3,"wbc_k_uL":8.3,"platelets_k_uL":123,"creatinine_mg_dL":1.48,"alt_U_L":110},{"date":"2023-02-04","hemoglobin_g_dL":11.8,"wbc_k_uL":4.3,"platelets_k_uL":207,"creatinine_mg_dL":1.05,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":62,"sex":"female","bmi":19.9,"smoking_pack_years":16,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-63},"pfs_months":49.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-08-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":72.7,"censored":true},"longitudinal_labs":[{"date":"2025-05-14","hemoglobin_g_dL":13.0,"wbc_k_uL":9.0,"platelets_k_uL":400,"creatinine_mg_dL":0.7,"alt_U_L":67},{"date":"2025-12-30","hemoglobin_g_dL":12.0,"wbc_k_uL":6.9,"platelets_k_uL":154,"creatinine_mg_dL":0.84,"alt_U_L":96},{"date":"2029-08-11","hemoglobin_g_dL":10.0,"wbc_k_uL":5.6,"platelets_k_uL":151,"creatinine_mg_dL":1.2,"alt_U_L":145}]}
{"patient_id":"ANODE_SYNTH_2025_398","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":64,"sex":"female","bmi":24.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-56},"pfs_months":17.74},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.1,"censored":false},"longitudinal_labs":[{"date":"2025-01-28","hemoglobin_g_dL":15.0,"wbc_k_uL":8.1,"platelets_k_uL":417,"creatinine_mg_dL":0.65,"alt_U_L":75},{"date":"2025-09-18","hemoglobin_g_dL":13.5,"wbc_k_uL":7.7,"platelets_k_uL":155,"creatinine_mg_dL":1.35,"alt_U_L":27},{"date":"2026-09-27","hemoglobin_g_dL":11.0,"wbc_k_uL":3.3,"platelets_k_uL":220,"creatinine_mg_dL":1.33,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":62,"sex":"female","bmi":35.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-51},"pfs_months":20.73},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.0,"censored":true},"longitudinal_labs":[{"date":"2024-05-18","hemoglobin_g_dL":15.4,"wbc_k_uL":5.7,"platelets_k_uL":318,"creatinine_mg_dL":1.14,"alt_U_L":37},{"date":"2025-01-23","hemoglobin_g_dL":13.6,"wbc_k_uL":4.4,"platelets_k_uL":263,"creatinine_mg_dL":1.17,"alt_U_L":62},{"date":"2026-06-05","hemoglobin_g_dL":12.6,"wbc_k_uL":7.9,"platelets_k_uL":255,"creatinine_mg_dL":0.86,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":50,"sex":"female","bmi":27.1,"smoking_pack_years":25,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-02-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-34},"pfs_months":21.16},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.8,"censored":false},"longitudinal_labs":[{"date":"2021-01-14","hemoglobin_g_dL":11.6,"wbc_k_uL":6.7,"platelets_k_uL":396,"creatinine_mg_dL":1.05,"alt_U_L":47},{"date":"2021-08-19","hemoglobin_g_dL":10.6,"wbc_k_uL":5.4,"platelets_k_uL":378,"creatinine_mg_dL":1.02,"alt_U_L":105},{"date":"2022-12-10","hemoglobin_g_dL":11.8,"wbc_k_uL":5.0,"platelets_k_uL":113,"creatinine_mg_dL":0.82,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_401","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":63,"sex":"female","bmi":33.1,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-11-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-49},"pfs_months":11.04},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.5,"censored":true},"longitudinal_labs":[{"date":"2021-09-03","hemoglobin_g_dL":13.2,"wbc_k_uL":6.7,"platelets_k_uL":322,"creatinine_mg_dL":0.96,"alt_U_L":55},{"date":"2022-04-30","hemoglobin_g_dL":12.9,"wbc_k_uL":8.7,"platelets_k_uL":324,"creatinine_mg_dL":0.96,"alt_U_L":90},{"date":"2022-11-10","hemoglobin_g_dL":9.6,"wbc_k_uL":5.4,"platelets_k_uL":100,"creatinine_mg_dL":1.59,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":70,"sex":"female","bmi":27.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-62},"pfs_months":32.76},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.9,"censored":true},"longitudinal_labs":[{"date":"2024-03-28","hemoglobin_g_dL":11.6,"wbc_k_uL":4.6,"platelets_k_uL":267,"creatinine_mg_dL":0.99,"alt_U_L":53},{"date":"2024-12-03","hemoglobin_g_dL":12.2,"wbc_k_uL":6.2,"platelets_k_uL":251,"creatinine_mg_dL":1.16,"alt_U_L":94},{"date":"2027-03-11","hemoglobin_g_dL":12.3,"wbc_k_uL":4.8,"platelets_k_uL":121,"creatinine_mg_dL":1.41,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_403","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.0,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":70,"sex":"female","bmi":30.4,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-81},"pfs_months":24.8},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":47.3,"censored":true},"longitudinal_labs":[{"date":"2020-09-22","hemoglobin_g_dL":14.0,"wbc_k_uL":10.1,"platelets_k_uL":335,"creatinine_mg_dL":0.97,"alt_U_L":34},{"date":"2021-04-22","hemoglobin_g_dL":10.2,"wbc_k_uL":7.8,"platelets_k_uL":255,"creatinine_mg_dL":0.95,"alt_U_L":104},{"date":"2023-01-01","hemoglobin_g_dL":12.8,"wbc_k_uL":4.4,"platelets_k_uL":179,"creatinine_mg_dL":1.0,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":85,"sex":"female","bmi":19.3,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-05-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-68},"pfs_months":27.53},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":51.2,"censored":true},"longitudinal_labs":[{"date":"2024-04-14","hemoglobin_g_dL":11.6,"wbc_k_uL":6.5,"platelets_k_uL":433,"creatinine_mg_dL":1.09,"alt_U_L":27},{"date":"2024-11-09","hemoglobin_g_dL":13.8,"wbc_k_uL":8.7,"platelets_k_uL":124,"creatinine_mg_dL":0.73,"alt_U_L":117},{"date":"2026-10-14","hemoglobin_g_dL":11.0,"wbc_k_uL":7.6,"platelets_k_uL":227,"creatinine_mg_dL":1.69,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":52,"sex":"male","bmi":37.5,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-07-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-83},"pfs_months":43.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.5,"censored":false},"longitudinal_labs":[{"date":"2024-06-21","hemoglobin_g_dL":14.7,"wbc_k_uL":6.9,"platelets_k_uL":215,"creatinine_mg_dL":1.15,"alt_U_L":12},{"date":"2025-01-14","hemoglobin_g_dL":13.8,"wbc_k_uL":8.9,"platelets_k_uL":178,"creatinine_mg_dL":1.35,"alt_U_L":62},{"date":"2028-05-08","hemoglobin_g_dL":9.9,"wbc_k_uL":6.5,"platelets_k_uL":136,"creatinine_mg_dL":1.36,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_406","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":50,"sex":"female","bmi":20.6,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-10-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-64},"pfs_months":32.26},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":50.8,"censored":true},"longitudinal_labs":[{"date":"2020-09-16","hemoglobin_g_dL":11.5,"wbc_k_uL":4.8,"platelets_k_uL":278,"creatinine_mg_dL":1.25,"alt_U_L":47},{"date":"2021-04-22","hemoglobin_g_dL":13.1,"wbc_k_uL":5.9,"platelets_k_uL":342,"creatinine_mg_dL":0.76,"alt_U_L":76},{"date":"2023-08-06","hemoglobin_g_dL":10.0,"wbc_k_uL":4.3,"platelets_k_uL":130,"creatinine_mg_dL":1.96,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":65,"sex":"male","bmi":32.7,"smoking_pack_years":66,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-05-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-85},"pfs_months":24.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":56.5,"censored":false},"longitudinal_labs":[{"date":"2022-02-26","hemoglobin_g_dL":13.7,"wbc_k_uL":10.0,"platelets_k_uL":335,"creatinine_mg_dL":0.63,"alt_U_L":47},{"date":"2022-10-31","hemoglobin_g_dL":11.1,"wbc_k_uL":8.7,"platelets_k_uL":335,"creatinine_mg_dL":1.17,"alt_U_L":113},{"date":"2024-05-29","hemoglobin_g_dL":12.7,"wbc_k_uL":5.3,"platelets_k_uL":162,"creatinine_mg_dL":1.51,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":82,"sex":"female","bmi":20.1,"smoking_pack_years":55,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-05-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-79},"pfs_months":41.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":67.1,"censored":false},"longitudinal_labs":[{"date":"2022-03-24","hemoglobin_g_dL":12.9,"wbc_k_uL":6.1,"platelets_k_uL":283,"creatinine_mg_dL":0.73,"alt_U_L":69},{"date":"2022-11-27","hemoglobin_g_dL":13.1,"wbc_k_uL":8.6,"platelets_k_uL":234,"creatinine_mg_dL":0.94,"alt_U_L":90},{"date":"2025-12-09","hemoglobin_g_dL":12.5,"wbc_k_uL":7.0,"platelets_k_uL":229,"creatinine_mg_dL":0.95,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_409","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":54,"sex":"female","bmi":34.1,"smoking_pack_years":50,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-67},"pfs_months":21.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.4,"censored":false},"longitudinal_labs":[{"date":"2023-11-02","hemoglobin_g_dL":13.7,"wbc_k_uL":5.9,"platelets_k_uL":270,"creatinine_mg_dL":0.65,"alt_U_L":58},{"date":"2024-06-06","hemoglobin_g_dL":13.2,"wbc_k_uL":5.5,"platelets_k_uL":184,"creatinine_mg_dL":1.14,"alt_U_L":94},{"date":"2025-11-24","hemoglobin_g_dL":12.7,"wbc_k_uL":3.9,"platelets_k_uL":147,"creatinine_mg_dL":1.07,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":61,"sex":"female","bmi":29.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-01-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-70},"pfs_months":23.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.9,"censored":true},"longitudinal_labs":[{"date":"2025-11-28","hemoglobin_g_dL":14.8,"wbc_k_uL":6.1,"platelets_k_uL":321,"creatinine_mg_dL":1.24,"alt_U_L":16},{"date":"2026-06-30","hemoglobin_g_dL":13.7,"wbc_k_uL":7.2,"platelets_k_uL":320,"creatinine_mg_dL":1.47,"alt_U_L":96},{"date":"2028-01-23","hemoglobin_g_dL":12.5,"wbc_k_uL":5.5,"platelets_k_uL":218,"creatinine_mg_dL":1.82,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_411","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":66,"sex":"female","bmi":24.9,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-11-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-64},"pfs_months":20.99},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.3,"censored":false},"longitudinal_labs":[{"date":"2020-11-01","hemoglobin_g_dL":15.2,"wbc_k_uL":6.6,"platelets_k_uL":399,"creatinine_mg_dL":1.09,"alt_U_L":77},{"date":"2021-05-23","hemoglobin_g_dL":11.2,"wbc_k_uL":8.3,"platelets_k_uL":241,"creatinine_mg_dL":1.2,"alt_U_L":89},{"date":"2022-09-11","hemoglobin_g_dL":10.1,"wbc_k_uL":7.6,"platelets_k_uL":206,"creatinine_mg_dL":1.25,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":65,"sex":"female","bmi":28.4,"smoking_pack_years":19,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-12-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-74},"pfs_months":4.73},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":16.9,"censored":false},"longitudinal_labs":[{"date":"2021-10-03","hemoglobin_g_dL":14.2,"wbc_k_uL":5.7,"platelets_k_uL":309,"creatinine_mg_dL":0.68,"alt_U_L":36},{"date":"2022-05-30","hemoglobin_g_dL":11.6,"wbc_k_uL":4.1,"platelets_k_uL":160,"creatinine_mg_dL":1.1,"alt_U_L":25},{"date":"2022-05-21","hemoglobin_g_dL":12.5,"wbc_k_uL":7.8,"platelets_k_uL":118,"creatinine_mg_dL":1.37,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":69,"sex":"female","bmi":23.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-01-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-79},"pfs_months":24.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":28.9,"censored":true},"longitudinal_labs":[{"date":"2020-01-02","hemoglobin_g_dL":12.2,"wbc_k_uL":9.8,"platelets_k_uL":225,"creatinine_mg_dL":0.95,"alt_U_L":38},{"date":"2020-07-14","hemoglobin_g_dL":13.9,"wbc_k_uL":6.2,"platelets_k_uL":379,"creatinine_mg_dL":0.82,"alt_U_L":100},{"date":"2022-02-25","hemoglobin_g_dL":12.1,"wbc_k_uL":3.0,"platelets_k_uL":347,"creatinine_mg_dL":1.03,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_414","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":54,"sex":"female","bmi":30.0,"smoking_pack_years":37,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-02-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-53},"pfs_months":37.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":67.0,"censored":true},"longitudinal_labs":[{"date":"2020-01-25","hemoglobin_g_dL":12.5,"wbc_k_uL":5.8,"platelets_k_uL":422,"creatinine_mg_dL":0.61,"alt_U_L":69},{"date":"2020-08-06","hemoglobin_g_dL":12.8,"wbc_k_uL":8.7,"platelets_k_uL":238,"creatinine_mg_dL":0.88,"alt_U_L":62},{"date":"2023-04-09","hemoglobin_g_dL":11.2,"wbc_k_uL":3.2,"platelets_k_uL":114,"creatinine_mg_dL":1.14,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":76,"sex":"male","bmi":26.8,"smoking_pack_years":44,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-11-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-69},"pfs_months":44.78},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-10-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":77.3,"censored":true},"longitudinal_labs":[{"date":"2025-10-10","hemoglobin_g_dL":12.6,"wbc_k_uL":9.8,"platelets_k_uL":225,"creatinine_mg_dL":0.88,"alt_U_L":78},{"date":"2026-05-23","hemoglobin_g_dL":13.0,"wbc_k_uL":7.9,"platelets_k_uL":376,"creatinine_mg_dL":1.47,"alt_U_L":94},{"date":"2029-10-11","hemoglobin_g_dL":9.6,"wbc_k_uL":5.4,"platelets_k_uL":127,"creatinine_mg_dL":1.89,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":60,"sex":"female","bmi":29.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-70},"pfs_months":25.13},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.5,"censored":true},"longitudinal_labs":[{"date":"2020-06-06","hemoglobin_g_dL":12.3,"wbc_k_uL":8.6,"platelets_k_uL":345,"creatinine_mg_dL":1.2,"alt_U_L":42},{"date":"2021-01-14","hemoglobin_g_dL":11.4,"wbc_k_uL":8.2,"platelets_k_uL":255,"creatinine_mg_dL":0.95,"alt_U_L":36},{"date":"2022-10-03","hemoglobin_g_dL":9.6,"wbc_k_uL":4.8,"platelets_k_uL":330,"creatinine_mg_dL":1.53,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":81,"sex":"female","bmi":26.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-50},"pfs_months":17.12},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.3,"censored":false},"longitudinal_labs":[{"date":"2021-01-10","hemoglobin_g_dL":13.3,"wbc_k_uL":9.0,"platelets_k_uL":382,"creatinine_mg_dL":0.67,"alt_U_L":43},{"date":"2021-08-24","hemoglobin_g_dL":12.4,"wbc_k_uL":8.2,"platelets_k_uL":354,"creatinine_mg_dL":1.4,"alt_U_L":93},{"date":"2022-08-11","hemoglobin_g_dL":12.1,"wbc_k_uL":6.0,"platelets_k_uL":235,"creatinine_mg_dL":1.42,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":76,"sex":"female","bmi":26.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-33},"pfs_months":28.48},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-31","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.0,"censored":true},"longitudinal_labs":[{"date":"2024-10-13","hemoglobin_g_dL":13.4,"wbc_k_uL":7.9,"platelets_k_uL":450,"creatinine_mg_dL":1.12,"alt_U_L":29},{"date":"2025-05-05","hemoglobin_g_dL":12.1,"wbc_k_uL":6.4,"platelets_k_uL":307,"creatinine_mg_dL":1.48,"alt_U_L":49},{"date":"2027-03-31","hemoglobin_g_dL":10.3,"wbc_k_uL":3.4,"platelets_k_uL":198,"creatinine_mg_dL":1.41,"alt_U_L":28}]}
{"patient_id":"ANODE_SYNTH_2025_419","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":75,"sex":"female","bmi":20.2,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-09-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-30},"pfs_months":18.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":false},"longitudinal_labs":[{"date":"2022-09-03","hemoglobin_g_dL":12.4,"wbc_k_uL":8.3,"platelets_k_uL":315,"creatinine_mg_dL":0.66,"alt_U_L":38},{"date":"2023-03-27","hemoglobin_g_dL":10.1,"wbc_k_uL":5.2,"platelets_k_uL":261,"creatinine_mg_dL":1.01,"alt_U_L":91},{"date":"2024-06-09","hemoglobin_g_dL":12.1,"wbc_k_uL":3.0,"platelets_k_uL":342,"creatinine_mg_dL":1.45,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":86,"sex":"female","bmi":20.5,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-10-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-55},"pfs_months":13.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.4,"censored":true},"longitudinal_labs":[{"date":"2020-09-23","hemoglobin_g_dL":12.0,"wbc_k_uL":7.1,"platelets_k_uL":278,"creatinine_mg_dL":1.23,"alt_U_L":53},{"date":"2021-04-11","hemoglobin_g_dL":13.9,"wbc_k_uL":7.1,"platelets_k_uL":292,"creatinine_mg_dL":1.38,"alt_U_L":71},{"date":"2021-12-30","hemoglobin_g_dL":12.3,"wbc_k_uL":3.9,"platelets_k_uL":346,"creatinine_mg_dL":1.11,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_421","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":88,"sex":"male","bmi":28.9,"smoking_pack_years":62,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-09-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-35},"pfs_months":16.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.4,"censored":false},"longitudinal_labs":[{"date":"2025-08-21","hemoglobin_g_dL":12.5,"wbc_k_uL":7.6,"platelets_k_uL":377,"creatinine_mg_dL":0.62,"alt_U_L":13},{"date":"2026-03-25","hemoglobin_g_dL":11.9,"wbc_k_uL":8.7,"platelets_k_uL":273,"creatinine_mg_dL":1.24,"alt_U_L":29},{"date":"2027-03-19","hemoglobin_g_dL":10.1,"wbc_k_uL":3.4,"platelets_k_uL":280,"creatinine_mg_dL":1.67,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":84,"sex":"female","bmi":26.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-65},"pfs_months":17.77},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":true},"longitudinal_labs":[{"date":"2020-10-07","hemoglobin_g_dL":11.5,"wbc_k_uL":9.2,"platelets_k_uL":432,"creatinine_mg_dL":0.93,"alt_U_L":11},{"date":"2021-04-23","hemoglobin_g_dL":12.6,"wbc_k_uL":6.3,"platelets_k_uL":352,"creatinine_mg_dL":1.01,"alt_U_L":25},{"date":"2022-05-27","hemoglobin_g_dL":9.8,"wbc_k_uL":7.9,"platelets_k_uL":101,"creatinine_mg_dL":1.66,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":64,"sex":"male","bmi":18.8,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-07-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-51},"pfs_months":38.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":69.7,"censored":false},"longitudinal_labs":[{"date":"2021-07-10","hemoglobin_g_dL":12.7,"wbc_k_uL":4.7,"platelets_k_uL":245,"creatinine_mg_dL":1.14,"alt_U_L":22},{"date":"2022-01-24","hemoglobin_g_dL":11.8,"wbc_k_uL":8.2,"platelets_k_uL":368,"creatinine_mg_dL":1.41,"alt_U_L":43},{"date":"2024-11-29","hemoglobin_g_dL":12.4,"wbc_k_uL":5.4,"platelets_k_uL":216,"creatinine_mg_dL":1.22,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_424","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":60,"sex":"male","bmi":34.8,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-47},"pfs_months":23.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.9,"censored":false},"longitudinal_labs":[{"date":"2023-11-17","hemoglobin_g_dL":14.7,"wbc_k_uL":10.3,"platelets_k_uL":416,"creatinine_mg_dL":0.68,"alt_U_L":18},{"date":"2024-06-05","hemoglobin_g_dL":11.0,"wbc_k_uL":5.7,"platelets_k_uL":173,"creatinine_mg_dL":1.1,"alt_U_L":18},{"date":"2025-12-04","hemoglobin_g_dL":11.0,"wbc_k_uL":5.0,"platelets_k_uL":117,"creatinine_mg_dL":0.92,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":77,"sex":"male","bmi":31.2,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-34},"pfs_months":34.69},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":60.9,"censored":false},"longitudinal_labs":[{"date":"2021-04-28","hemoglobin_g_dL":12.9,"wbc_k_uL":4.5,"platelets_k_uL":384,"creatinine_mg_dL":0.83,"alt_U_L":12},{"date":"2021-12-26","hemoglobin_g_dL":13.8,"wbc_k_uL":5.8,"platelets_k_uL":171,"creatinine_mg_dL":1.01,"alt_U_L":76},{"date":"2024-06-08","hemoglobin_g_dL":10.3,"wbc_k_uL":6.3,"platelets_k_uL":201,"creatinine_mg_dL":0.84,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":57,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-83},"pfs_months":21.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.0,"censored":true},"longitudinal_labs":[{"date":"2021-01-25","hemoglobin_g_dL":14.1,"wbc_k_uL":8.8,"platelets_k_uL":396,"creatinine_mg_dL":1.12,"alt_U_L":40},{"date":"2021-08-17","hemoglobin_g_dL":11.2,"wbc_k_uL":6.1,"platelets_k_uL":239,"creatinine_mg_dL":1.0,"alt_U_L":43},{"date":"2023-01-09","hemoglobin_g_dL":11.1,"wbc_k_uL":4.9,"platelets_k_uL":177,"creatinine_mg_dL":1.42,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":66,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-78},"pfs_months":20.93},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.4,"censored":false},"longitudinal_labs":[{"date":"2020-08-09","hemoglobin_g_dL":13.1,"wbc_k_uL":9.8,"platelets_k_uL":235,"creatinine_mg_dL":0.89,"alt_U_L":41},{"date":"2021-02-27","hemoglobin_g_dL":13.8,"wbc_k_uL":4.2,"platelets_k_uL":369,"creatinine_mg_dL":0.9,"alt_U_L":46},{"date":"2022-07-16","hemoglobin_g_dL":11.7,"wbc_k_uL":3.2,"platelets_k_uL":264,"creatinine_mg_dL":1.79,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":58,"sex":"female","bmi":21.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-03-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-53},"pfs_months":25.1},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.6,"censored":false},"longitudinal_labs":[{"date":"2020-02-14","hemoglobin_g_dL":14.0,"wbc_k_uL":7.5,"platelets_k_uL":278,"creatinine_mg_dL":0.97,"alt_U_L":25},{"date":"2020-09-12","hemoglobin_g_dL":13.2,"wbc_k_uL":7.6,"platelets_k_uL":352,"creatinine_mg_dL":1.32,"alt_U_L":90},{"date":"2022-05-04","hemoglobin_g_dL":10.1,"wbc_k_uL":7.1,"platelets_k_uL":111,"creatinine_mg_dL":1.03,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_429","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":50,"sex":"female","bmi":32.8,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-11-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-35},"pfs_months":30.16},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.2,"censored":true},"longitudinal_labs":[{"date":"2025-10-09","hemoglobin_g_dL":15.0,"wbc_k_uL":5.4,"platelets_k_uL":231,"creatinine_mg_dL":1.18,"alt_U_L":78},{"date":"2026-05-18","hemoglobin_g_dL":13.9,"wbc_k_uL":8.7,"platelets_k_uL":251,"creatinine_mg_dL":1.09,"alt_U_L":50},{"date":"2028-06-20","hemoglobin_g_dL":11.3,"wbc_k_uL":7.6,"platelets_k_uL":285,"creatinine_mg_dL":1.02,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":59,"sex":"male","bmi":25.5,"smoking_pack_years":43,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-01-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-50},"pfs_months":17.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.8,"censored":true},"longitudinal_labs":[{"date":"2025-12-09","hemoglobin_g_dL":12.9,"wbc_k_uL":9.6,"platelets_k_uL":299,"creatinine_mg_dL":1.27,"alt_U_L":31},{"date":"2026-07-22","hemoglobin_g_dL":13.0,"wbc_k_uL":7.2,"platelets_k_uL":252,"creatinine_mg_dL":1.45,"alt_U_L":88},{"date":"2027-09-11","hemoglobin_g_dL":11.2,"wbc_k_uL":6.6,"platelets_k_uL":254,"creatinine_mg_dL":1.81,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":61,"sex":"female","bmi":33.3,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-11-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-57},"pfs_months":43.6},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.0,"censored":true},"longitudinal_labs":[{"date":"2020-10-01","hemoglobin_g_dL":15.0,"wbc_k_uL":5.7,"platelets_k_uL":226,"creatinine_mg_dL":0.76,"alt_U_L":37},{"date":"2021-05-02","hemoglobin_g_dL":10.9,"wbc_k_uL":4.2,"platelets_k_uL":351,"creatinine_mg_dL":0.86,"alt_U_L":111},{"date":"2024-08-16","hemoglobin_g_dL":12.2,"wbc_k_uL":3.4,"platelets_k_uL":184,"creatinine_mg_dL":1.65,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":56,"sex":"male","bmi":28.7,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-01-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-82},"pfs_months":11.89},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.0,"censored":false},"longitudinal_labs":[{"date":"2023-12-04","hemoglobin_g_dL":11.7,"wbc_k_uL":6.2,"platelets_k_uL":383,"creatinine_mg_dL":0.73,"alt_U_L":68},{"date":"2024-07-26","hemoglobin_g_dL":11.2,"wbc_k_uL":4.5,"platelets_k_uL":140,"creatinine_mg_dL":1.47,"alt_U_L":115},{"date":"2025-03-19","hemoglobin_g_dL":12.4,"wbc_k_uL":5.5,"platelets_k_uL":331,"creatinine_mg_dL":1.67,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":87,"sex":"female","bmi":23.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-49},"pfs_months":34.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.5,"censored":false},"longitudinal_labs":[{"date":"2021-01-05","hemoglobin_g_dL":15.3,"wbc_k_uL":9.9,"platelets_k_uL":207,"creatinine_mg_dL":0.7,"alt_U_L":48},{"date":"2021-07-31","hemoglobin_g_dL":11.9,"wbc_k_uL":8.0,"platelets_k_uL":169,"creatinine_mg_dL":1.21,"alt_U_L":61},{"date":"2024-01-22","hemoglobin_g_dL":11.5,"wbc_k_uL":4.0,"platelets_k_uL":173,"creatinine_mg_dL":1.22,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":77,"sex":"female","bmi":37.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-01-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-68},"pfs_months":25.69},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.5,"censored":true},"longitudinal_labs":[{"date":"2020-01-01","hemoglobin_g_dL":12.8,"wbc_k_uL":7.6,"platelets_k_uL":339,"creatinine_mg_dL":0.81,"alt_U_L":16},{"date":"2020-07-22","hemoglobin_g_dL":10.2,"wbc_k_uL":8.5,"platelets_k_uL":188,"creatinine_mg_dL":1.51,"alt_U_L":109},{"date":"2022-05-07","hemoglobin_g_dL":9.8,"wbc_k_uL":6.9,"platelets_k_uL":248,"creatinine_mg_dL":1.31,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":57,"sex":"male","bmi":35.7,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2026-01-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-84},"pfs_months":45.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-11-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":69.0,"censored":true},"longitudinal_labs":[{"date":"2025-12-19","hemoglobin_g_dL":12.4,"wbc_k_uL":7.3,"platelets_k_uL":188,"creatinine_mg_dL":1.21,"alt_U_L":58},{"date":"2026-07-14","hemoglobin_g_dL":11.3,"wbc_k_uL":4.4,"platelets_k_uL":273,"creatinine_mg_dL":1.42,"alt_U_L":20},{"date":"2029-11-15","hemoglobin_g_dL":9.7,"wbc_k_uL":4.6,"platelets_k_uL":124,"creatinine_mg_dL":1.9,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_436","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":74,"sex":"male","bmi":33.1,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["brain","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-12-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-79},"pfs_months":23.89},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2025-12-01","hemoglobin_g_dL":12.4,"wbc_k_uL":4.8,"platelets_k_uL":244,"creatinine_mg_dL":0.95,"alt_U_L":71},{"date":"2026-06-27","hemoglobin_g_dL":13.7,"wbc_k_uL":8.1,"platelets_k_uL":147,"creatinine_mg_dL":1.56,"alt_U_L":58},{"date":"2028-01-18","hemoglobin_g_dL":12.8,"wbc_k_uL":3.9,"platelets_k_uL":301,"creatinine_mg_dL":1.67,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":78,"sex":"male","bmi":30.6,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-03-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-56},"pfs_months":8.34},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.5,"censored":false},"longitudinal_labs":[{"date":"2023-01-01","hemoglobin_g_dL":14.1,"wbc_k_uL":7.8,"platelets_k_uL":399,"creatinine_mg_dL":0.82,"alt_U_L":67},{"date":"2023-08-28","hemoglobin_g_dL":13.7,"wbc_k_uL":8.3,"platelets_k_uL":246,"creatinine_mg_dL":0.77,"alt_U_L":17},{"date":"2023-11-28","hemoglobin_g_dL":10.1,"wbc_k_uL":6.7,"platelets_k_uL":139,"creatinine_mg_dL":1.39,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":58,"sex":"female","bmi":30.6,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-07-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-55},"pfs_months":15.74},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.7,"censored":false},"longitudinal_labs":[{"date":"2024-06-07","hemoglobin_g_dL":12.0,"wbc_k_uL":5.1,"platelets_k_uL":296,"creatinine_mg_dL":1.26,"alt_U_L":80},{"date":"2025-01-13","hemoglobin_g_dL":12.4,"wbc_k_uL":6.3,"platelets_k_uL":371,"creatinine_mg_dL":1.08,"alt_U_L":107},{"date":"2026-01-06","hemoglobin_g_dL":10.1,"wbc_k_uL":4.2,"platelets_k_uL":313,"creatinine_mg_dL":1.01,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":55,"sex":"female","bmi":22.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-51},"pfs_months":23.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.3,"censored":false},"longitudinal_labs":[{"date":"2020-12-11","hemoglobin_g_dL":12.8,"wbc_k_uL":7.0,"platelets_k_uL":343,"creatinine_mg_dL":0.86,"alt_U_L":72},{"date":"2021-07-29","hemoglobin_g_dL":12.2,"wbc_k_uL":7.8,"platelets_k_uL":317,"creatinine_mg_dL":1.51,"alt_U_L":88},{"date":"2023-01-20","hemoglobin_g_dL":9.9,"wbc_k_uL":8.0,"platelets_k_uL":342,"creatinine_mg_dL":1.65,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":64,"sex":"female","bmi":25.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-12-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-56},"pfs_months":17.81},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.8,"censored":false},"longitudinal_labs":[{"date":"2024-11-10","hemoglobin_g_dL":15.5,"wbc_k_uL":7.6,"platelets_k_uL":250,"creatinine_mg_dL":1.15,"alt_U_L":59},{"date":"2025-06-01","hemoglobin_g_dL":10.2,"wbc_k_uL":7.2,"platelets_k_uL":354,"creatinine_mg_dL":1.33,"alt_U_L":21},{"date":"2026-06-15","hemoglobin_g_dL":12.3,"wbc_k_uL":4.9,"platelets_k_uL":310,"creatinine_mg_dL":1.13,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":82,"sex":"female","bmi":33.3,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-38},"pfs_months":20.34},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.3,"censored":false},"longitudinal_labs":[{"date":"2020-04-12","hemoglobin_g_dL":13.3,"wbc_k_uL":7.3,"platelets_k_uL":195,"creatinine_mg_dL":1.05,"alt_U_L":80},{"date":"2020-11-23","hemoglobin_g_dL":11.4,"wbc_k_uL":4.0,"platelets_k_uL":242,"creatinine_mg_dL":1.54,"alt_U_L":99},{"date":"2022-02-14","hemoglobin_g_dL":11.2,"wbc_k_uL":7.9,"platelets_k_uL":306,"creatinine_mg_dL":1.7,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_442","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":77,"sex":"female","bmi":28.2,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-09-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-54},"pfs_months":22.05},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.8,"censored":false},"longitudinal_labs":[{"date":"2025-07-03","hemoglobin_g_dL":13.9,"wbc_k_uL":9.0,"platelets_k_uL":301,"creatinine_mg_dL":0.77,"alt_U_L":26},{"date":"2026-03-10","hemoglobin_g_dL":10.8,"wbc_k_uL":5.8,"platelets_k_uL":140,"creatinine_mg_dL":1.49,"alt_U_L":69},{"date":"2027-09-04","hemoglobin_g_dL":10.3,"wbc_k_uL":6.4,"platelets_k_uL":295,"creatinine_mg_dL":1.87,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":48,"sex":"female","bmi":24.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-39},"pfs_months":29.34},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.3,"censored":false},"longitudinal_labs":[{"date":"2021-03-04","hemoglobin_g_dL":12.1,"wbc_k_uL":9.7,"platelets_k_uL":356,"creatinine_mg_dL":1.03,"alt_U_L":63},{"date":"2021-10-10","hemoglobin_g_dL":13.9,"wbc_k_uL":8.5,"platelets_k_uL":292,"creatinine_mg_dL":1.18,"alt_U_L":83},{"date":"2023-10-20","hemoglobin_g_dL":11.6,"wbc_k_uL":5.1,"platelets_k_uL":306,"creatinine_mg_dL":1.02,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":74,"sex":"male","bmi":18.5,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-12-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-38},"pfs_months":9.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":17.6,"censored":true},"longitudinal_labs":[{"date":"2022-11-12","hemoglobin_g_dL":12.5,"wbc_k_uL":6.8,"platelets_k_uL":231,"creatinine_mg_dL":0.91,"alt_U_L":66},{"date":"2023-06-18","hemoglobin_g_dL":10.8,"wbc_k_uL":6.0,"platelets_k_uL":207,"creatinine_mg_dL":1.02,"alt_U_L":115},{"date":"2023-11-15","hemoglobin_g_dL":11.4,"wbc_k_uL":6.5,"platelets_k_uL":328,"creatinine_mg_dL":1.54,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_445","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":55,"sex":"male","bmi":34.5,"smoking_pack_years":30,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-37},"pfs_months":22.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":47.6,"censored":false},"longitudinal_labs":[{"date":"2021-04-14","hemoglobin_g_dL":12.7,"wbc_k_uL":7.3,"platelets_k_uL":326,"creatinine_mg_dL":0.86,"alt_U_L":63},{"date":"2021-12-05","hemoglobin_g_dL":10.0,"wbc_k_uL":5.9,"platelets_k_uL":147,"creatinine_mg_dL":1.03,"alt_U_L":58},{"date":"2023-05-09","hemoglobin_g_dL":10.2,"wbc_k_uL":5.1,"platelets_k_uL":338,"creatinine_mg_dL":1.04,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":69,"sex":"female","bmi":27.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-12-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-69},"pfs_months":15.61},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":28.4,"censored":false},"longitudinal_labs":[{"date":"2024-11-16","hemoglobin_g_dL":13.6,"wbc_k_uL":9.8,"platelets_k_uL":231,"creatinine_mg_dL":0.71,"alt_U_L":14},{"date":"2025-06-21","hemoglobin_g_dL":12.1,"wbc_k_uL":8.9,"platelets_k_uL":130,"creatinine_mg_dL":1.09,"alt_U_L":30},{"date":"2026-05-07","hemoglobin_g_dL":12.3,"wbc_k_uL":6.4,"platelets_k_uL":264,"creatinine_mg_dL":1.5,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":50,"sex":"female","bmi":21.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-82},"pfs_months":18.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.7,"censored":false},"longitudinal_labs":[{"date":"2022-02-16","hemoglobin_g_dL":15.1,"wbc_k_uL":10.7,"platelets_k_uL":151,"creatinine_mg_dL":0.87,"alt_U_L":39},{"date":"2022-10-24","hemoglobin_g_dL":10.3,"wbc_k_uL":4.8,"platelets_k_uL":329,"creatinine_mg_dL":0.79,"alt_U_L":32},{"date":"2023-12-19","hemoglobin_g_dL":12.0,"wbc_k_uL":4.5,"platelets_k_uL":293,"creatinine_mg_dL":1.14,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":54,"sex":"male","bmi":30.0,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-10-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-46},"pfs_months":3.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":10.0,"censored":true},"longitudinal_labs":[{"date":"2021-08-16","hemoglobin_g_dL":14.8,"wbc_k_uL":6.6,"platelets_k_uL":259,"creatinine_mg_dL":1.1,"alt_U_L":48},{"date":"2022-04-19","hemoglobin_g_dL":12.6,"wbc_k_uL":4.9,"platelets_k_uL":312,"creatinine_mg_dL":1.25,"alt_U_L":22},{"date":"2022-02-15","hemoglobin_g_dL":10.8,"wbc_k_uL":5.3,"platelets_k_uL":222,"creatinine_mg_dL":1.34,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":83,"sex":"male","bmi":35.7,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-05-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-65},"pfs_months":43.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":62.9,"censored":false},"longitudinal_labs":[{"date":"2023-04-20","hemoglobin_g_dL":14.5,"wbc_k_uL":10.5,"platelets_k_uL":366,"creatinine_mg_dL":1.14,"alt_U_L":43},{"date":"2023-11-16","hemoglobin_g_dL":11.3,"wbc_k_uL":5.9,"platelets_k_uL":270,"creatinine_mg_dL":0.98,"alt_U_L":103},{"date":"2027-02-13","hemoglobin_g_dL":11.1,"wbc_k_uL":6.7,"platelets_k_uL":332,"creatinine_mg_dL":1.16,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":56,"sex":"female","bmi":36.4,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-42},"pfs_months":41.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":68.0,"censored":false},"longitudinal_labs":[{"date":"2021-10-28","hemoglobin_g_dL":12.8,"wbc_k_uL":7.3,"platelets_k_uL":245,"creatinine_mg_dL":0.96,"alt_U_L":36},{"date":"2022-05-14","hemoglobin_g_dL":10.1,"wbc_k_uL":8.9,"platelets_k_uL":367,"creatinine_mg_dL":1.35,"alt_U_L":28},{"date":"2025-06-18","hemoglobin_g_dL":10.1,"wbc_k_uL":7.8,"platelets_k_uL":244,"creatinine_mg_dL":1.14,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":49,"sex":"male","bmi":27.3,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-01-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-53},"pfs_months":32.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":59.4,"censored":false},"longitudinal_labs":[{"date":"2020-12-09","hemoglobin_g_dL":13.5,"wbc_k_uL":7.4,"platelets_k_uL":160,"creatinine_mg_dL":1.1,"alt_U_L":55},{"date":"2021-07-18","hemoglobin_g_dL":11.7,"wbc_k_uL":5.5,"platelets_k_uL":143,"creatinine_mg_dL":1.31,"alt_U_L":118},{"date":"2023-10-21","hemoglobin_g_dL":12.5,"wbc_k_uL":6.8,"platelets_k_uL":254,"creatinine_mg_dL":1.33,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":73,"sex":"female","bmi":26.5,"smoking_pack_years":29,"ecog_performance_status":2,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-72},"pfs_months":43.27},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":67.4,"censored":false},"longitudinal_labs":[{"date":"2023-10-28","hemoglobin_g_dL":11.9,"wbc_k_uL":5.8,"platelets_k_uL":247,"creatinine_mg_dL":1.29,"alt_U_L":66},{"date":"2024-05-26","hemoglobin_g_dL":11.4,"wbc_k_uL":5.9,"platelets_k_uL":234,"creatinine_mg_dL":1.54,"alt_U_L":113},{"date":"2027-07-26","hemoglobin_g_dL":11.3,"wbc_k_uL":7.1,"platelets_k_uL":234,"creatinine_mg_dL":0.96,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":61,"sex":"male","bmi":34.7,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2026-02-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-47},"pfs_months":32.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-10-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":55.9,"censored":false},"longitudinal_labs":[{"date":"2025-12-22","hemoglobin_g_dL":15.0,"wbc_k_uL":8.7,"platelets_k_uL":440,"creatinine_mg_dL":1.11,"alt_U_L":49},{"date":"2026-08-04","hemoglobin_g_dL":13.4,"wbc_k_uL":6.6,"platelets_k_uL":277,"creatinine_mg_dL":1.33,"alt_U_L":102},{"date":"2028-10-19","hemoglobin_g_dL":10.2,"wbc_k_uL":7.1,"platelets_k_uL":185,"creatinine_mg_dL":1.63,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_454","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":84,"sex":"female","bmi":30.2,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-08-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-62},"pfs_months":34.3},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.6,"censored":true},"longitudinal_labs":[{"date":"2024-08-15","hemoglobin_g_dL":13.3,"wbc_k_uL":7.3,"platelets_k_uL":384,"creatinine_mg_dL":1.19,"alt_U_L":33},{"date":"2025-02-27","hemoglobin_g_dL":10.9,"wbc_k_uL":7.9,"platelets_k_uL":304,"creatinine_mg_dL":1.6,"alt_U_L":46},{"date":"2027-09-07","hemoglobin_g_dL":12.3,"wbc_k_uL":6.8,"platelets_k_uL":168,"creatinine_mg_dL":1.11,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":64,"sex":"female","bmi":24.3,"smoking_pack_years":33,"ecog_performance_status":0,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-06-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-71},"pfs_months":33.84},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.4,"censored":false},"longitudinal_labs":[{"date":"2023-04-21","hemoglobin_g_dL":11.6,"wbc_k_uL":5.4,"platelets_k_uL":389,"creatinine_mg_dL":1.03,"alt_U_L":23},{"date":"2023-12-19","hemoglobin_g_dL":11.3,"wbc_k_uL":6.1,"platelets_k_uL":283,"creatinine_mg_dL":0.91,"alt_U_L":19},{"date":"2026-06-15","hemoglobin_g_dL":11.8,"wbc_k_uL":6.7,"platelets_k_uL":171,"creatinine_mg_dL":1.01,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":79,"sex":"female","bmi":36.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-09-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-43},"pfs_months":16.36},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.1,"censored":false},"longitudinal_labs":[{"date":"2023-08-14","hemoglobin_g_dL":13.3,"wbc_k_uL":6.7,"platelets_k_uL":326,"creatinine_mg_dL":1.24,"alt_U_L":46},{"date":"2024-03-05","hemoglobin_g_dL":12.5,"wbc_k_uL":6.7,"platelets_k_uL":139,"creatinine_mg_dL":1.06,"alt_U_L":40},{"date":"2025-03-17","hemoglobin_g_dL":10.6,"wbc_k_uL":3.6,"platelets_k_uL":281,"creatinine_mg_dL":1.82,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":65,"sex":"female","bmi":29.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-79},"pfs_months":19.09},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.7,"censored":false},"longitudinal_labs":[{"date":"2020-11-05","hemoglobin_g_dL":13.8,"wbc_k_uL":8.3,"platelets_k_uL":214,"creatinine_mg_dL":0.95,"alt_U_L":20},{"date":"2021-06-17","hemoglobin_g_dL":10.1,"wbc_k_uL":7.2,"platelets_k_uL":354,"creatinine_mg_dL":1.25,"alt_U_L":34},{"date":"2022-09-11","hemoglobin_g_dL":11.7,"wbc_k_uL":5.5,"platelets_k_uL":318,"creatinine_mg_dL":1.73,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":87,"sex":"female","bmi":35.9,"smoking_pack_years":22,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-05-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-39},"pfs_months":42.05},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":66.2,"censored":true},"longitudinal_labs":[{"date":"2020-04-27","hemoglobin_g_dL":15.1,"wbc_k_uL":9.3,"platelets_k_uL":383,"creatinine_mg_dL":1.22,"alt_U_L":54},{"date":"2020-11-15","hemoglobin_g_dL":13.7,"wbc_k_uL":8.4,"platelets_k_uL":146,"creatinine_mg_dL":1.14,"alt_U_L":79},{"date":"2023-12-02","hemoglobin_g_dL":10.1,"wbc_k_uL":3.4,"platelets_k_uL":249,"creatinine_mg_dL":0.86,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":81,"sex":"female","bmi":22.4,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-06-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-71},"pfs_months":18.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.5,"censored":false},"longitudinal_labs":[{"date":"2021-05-08","hemoglobin_g_dL":11.8,"wbc_k_uL":9.9,"platelets_k_uL":334,"creatinine_mg_dL":1.05,"alt_U_L":67},{"date":"2021-11-29","hemoglobin_g_dL":13.6,"wbc_k_uL":3.9,"platelets_k_uL":377,"creatinine_mg_dL":1.58,"alt_U_L":71},{"date":"2022-12-22","hemoglobin_g_dL":10.1,"wbc_k_uL":5.2,"platelets_k_uL":111,"creatinine_mg_dL":1.11,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_460","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":64,"sex":"female","bmi":36.5,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-47},"pfs_months":24.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.2,"censored":true},"longitudinal_labs":[{"date":"2021-01-14","hemoglobin_g_dL":11.6,"wbc_k_uL":8.7,"platelets_k_uL":314,"creatinine_mg_dL":1.27,"alt_U_L":26},{"date":"2021-07-28","hemoglobin_g_dL":13.4,"wbc_k_uL":6.4,"platelets_k_uL":343,"creatinine_mg_dL":1.42,"alt_U_L":96},{"date":"2023-02-28","hemoglobin_g_dL":10.0,"wbc_k_uL":7.5,"platelets_k_uL":348,"creatinine_mg_dL":1.91,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":78,"sex":"male","bmi":26.7,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-04-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-30},"pfs_months":4.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":8.7,"censored":false},"longitudinal_labs":[{"date":"2022-03-13","hemoglobin_g_dL":14.5,"wbc_k_uL":10.3,"platelets_k_uL":394,"creatinine_mg_dL":0.63,"alt_U_L":15},{"date":"2022-10-21","hemoglobin_g_dL":10.1,"wbc_k_uL":4.1,"platelets_k_uL":378,"creatinine_mg_dL":0.86,"alt_U_L":63},{"date":"2022-11-08","hemoglobin_g_dL":10.3,"wbc_k_uL":7.0,"platelets_k_uL":251,"creatinine_mg_dL":0.91,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_462","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":73,"sex":"female","bmi":25.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-57},"pfs_months":22.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":false},"longitudinal_labs":[{"date":"2023-08-18","hemoglobin_g_dL":12.6,"wbc_k_uL":6.1,"platelets_k_uL":317,"creatinine_mg_dL":0.61,"alt_U_L":75},{"date":"2024-04-11","hemoglobin_g_dL":12.5,"wbc_k_uL":4.4,"platelets_k_uL":283,"creatinine_mg_dL":1.34,"alt_U_L":23},{"date":"2025-09-30","hemoglobin_g_dL":11.1,"wbc_k_uL":6.4,"platelets_k_uL":129,"creatinine_mg_dL":1.92,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":65,"sex":"female","bmi":22.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-66},"pfs_months":25.1},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.6,"censored":false},"longitudinal_labs":[{"date":"2023-03-16","hemoglobin_g_dL":11.6,"wbc_k_uL":6.5,"platelets_k_uL":439,"creatinine_mg_dL":0.69,"alt_U_L":24},{"date":"2023-10-16","hemoglobin_g_dL":12.0,"wbc_k_uL":5.1,"platelets_k_uL":303,"creatinine_mg_dL":1.03,"alt_U_L":65},{"date":"2025-06-08","hemoglobin_g_dL":12.4,"wbc_k_uL":5.9,"platelets_k_uL":186,"creatinine_mg_dL":1.14,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_464","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":66,"sex":"male","bmi":25.7,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-10-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-34},"pfs_months":16.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.6,"censored":false},"longitudinal_labs":[{"date":"2023-09-13","hemoglobin_g_dL":14.4,"wbc_k_uL":4.5,"platelets_k_uL":177,"creatinine_mg_dL":1.26,"alt_U_L":74},{"date":"2024-04-25","hemoglobin_g_dL":13.0,"wbc_k_uL":6.6,"platelets_k_uL":236,"creatinine_mg_dL":1.42,"alt_U_L":44},{"date":"2025-05-09","hemoglobin_g_dL":12.4,"wbc_k_uL":6.4,"platelets_k_uL":128,"creatinine_mg_dL":1.13,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.4,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":57,"sex":"male","bmi":22.5,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-47},"pfs_months":29.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":56.3,"censored":true},"longitudinal_labs":[{"date":"2020-02-13","hemoglobin_g_dL":14.9,"wbc_k_uL":10.7,"platelets_k_uL":319,"creatinine_mg_dL":1.18,"alt_U_L":57},{"date":"2020-09-07","hemoglobin_g_dL":12.9,"wbc_k_uL":8.0,"platelets_k_uL":335,"creatinine_mg_dL":0.83,"alt_U_L":22},{"date":"2022-10-07","hemoglobin_g_dL":10.3,"wbc_k_uL":5.4,"platelets_k_uL":273,"creatinine_mg_dL":1.74,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":60,"sex":"female","bmi":23.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-85},"pfs_months":18.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":true},"longitudinal_labs":[{"date":"2025-04-15","hemoglobin_g_dL":15.2,"wbc_k_uL":5.6,"platelets_k_uL":221,"creatinine_mg_dL":0.63,"alt_U_L":10},{"date":"2025-11-08","hemoglobin_g_dL":11.4,"wbc_k_uL":8.3,"platelets_k_uL":217,"creatinine_mg_dL":0.97,"alt_U_L":22},{"date":"2027-01-06","hemoglobin_g_dL":10.4,"wbc_k_uL":4.8,"platelets_k_uL":234,"creatinine_mg_dL":1.03,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_467","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":52,"sex":"male","bmi":20.1,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-12-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-71},"pfs_months":22.08},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":false},"longitudinal_labs":[{"date":"2021-09-28","hemoglobin_g_dL":14.8,"wbc_k_uL":10.7,"platelets_k_uL":303,"creatinine_mg_dL":1.26,"alt_U_L":49},{"date":"2022-06-05","hemoglobin_g_dL":11.7,"wbc_k_uL":5.7,"platelets_k_uL":143,"creatinine_mg_dL":1.29,"alt_U_L":91},{"date":"2023-11-05","hemoglobin_g_dL":11.2,"wbc_k_uL":5.7,"platelets_k_uL":319,"creatinine_mg_dL":1.73,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":80,"sex":"female","bmi":20.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-72},"pfs_months":29.21},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.0,"censored":true},"longitudinal_labs":[{"date":"2020-08-26","hemoglobin_g_dL":13.8,"wbc_k_uL":10.8,"platelets_k_uL":216,"creatinine_mg_dL":0.78,"alt_U_L":77},{"date":"2021-04-26","hemoglobin_g_dL":11.7,"wbc_k_uL":4.4,"platelets_k_uL":309,"creatinine_mg_dL":1.23,"alt_U_L":100},{"date":"2023-04-13","hemoglobin_g_dL":12.7,"wbc_k_uL":5.4,"platelets_k_uL":188,"creatinine_mg_dL":1.83,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":53,"sex":"male","bmi":33.9,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-69},"pfs_months":12.35},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.9,"censored":false},"longitudinal_labs":[{"date":"2021-01-26","hemoglobin_g_dL":14.7,"wbc_k_uL":8.7,"platelets_k_uL":392,"creatinine_mg_dL":0.83,"alt_U_L":17},{"date":"2021-09-01","hemoglobin_g_dL":11.6,"wbc_k_uL":4.7,"platelets_k_uL":311,"creatinine_mg_dL":0.74,"alt_U_L":64},{"date":"2022-04-30","hemoglobin_g_dL":9.5,"wbc_k_uL":4.5,"platelets_k_uL":209,"creatinine_mg_dL":1.54,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":70,"sex":"female","bmi":25.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-69},"pfs_months":18.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.5,"censored":false},"longitudinal_labs":[{"date":"2023-03-20","hemoglobin_g_dL":13.3,"wbc_k_uL":9.6,"platelets_k_uL":209,"creatinine_mg_dL":0.86,"alt_U_L":58},{"date":"2023-10-13","hemoglobin_g_dL":12.3,"wbc_k_uL":8.7,"platelets_k_uL":378,"creatinine_mg_dL":0.83,"alt_U_L":118},{"date":"2024-12-13","hemoglobin_g_dL":12.8,"wbc_k_uL":6.2,"platelets_k_uL":202,"creatinine_mg_dL":1.59,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":74,"sex":"female","bmi":21.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-61},"pfs_months":21.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.7,"censored":false},"longitudinal_labs":[{"date":"2022-10-22","hemoglobin_g_dL":12.2,"wbc_k_uL":9.9,"platelets_k_uL":404,"creatinine_mg_dL":0.93,"alt_U_L":63},{"date":"2023-06-19","hemoglobin_g_dL":13.6,"wbc_k_uL":8.2,"platelets_k_uL":222,"creatinine_mg_dL":0.9,"alt_U_L":21},{"date":"2024-10-29","hemoglobin_g_dL":11.2,"wbc_k_uL":3.6,"platelets_k_uL":240,"creatinine_mg_dL":1.98,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":81,"sex":"male","bmi":23.4,"smoking_pack_years":79,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-07-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-41},"pfs_months":45.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":78.2,"censored":true},"longitudinal_labs":[{"date":"2024-06-21","hemoglobin_g_dL":12.9,"wbc_k_uL":10.8,"platelets_k_uL":236,"creatinine_mg_dL":0.89,"alt_U_L":32},{"date":"2025-01-12","hemoglobin_g_dL":13.0,"wbc_k_uL":7.8,"platelets_k_uL":210,"creatinine_mg_dL":0.98,"alt_U_L":30},{"date":"2028-05-30","hemoglobin_g_dL":11.2,"wbc_k_uL":7.5,"platelets_k_uL":184,"creatinine_mg_dL":1.33,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":71,"sex":"female","bmi":26.8,"smoking_pack_years":26,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-08-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-73},"pfs_months":5.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":13.0,"censored":false},"longitudinal_labs":[{"date":"2024-06-09","hemoglobin_g_dL":11.6,"wbc_k_uL":6.7,"platelets_k_uL":427,"creatinine_mg_dL":1.1,"alt_U_L":54},{"date":"2025-02-13","hemoglobin_g_dL":11.9,"wbc_k_uL":8.4,"platelets_k_uL":293,"creatinine_mg_dL":1.05,"alt_U_L":54},{"date":"2025-03-20","hemoglobin_g_dL":11.2,"wbc_k_uL":4.7,"platelets_k_uL":209,"creatinine_mg_dL":1.15,"alt_U_L":108}]}
{"patient_id":"ANODE_SYNTH_2025_474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":74,"sex":"female","bmi":21.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-05-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-76},"pfs_months":22.31},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.4,"censored":true},"longitudinal_labs":[{"date":"2023-03-15","hemoglobin_g_dL":14.6,"wbc_k_uL":9.5,"platelets_k_uL":166,"creatinine_mg_dL":0.84,"alt_U_L":73},{"date":"2023-11-14","hemoglobin_g_dL":13.7,"wbc_k_uL":6.4,"platelets_k_uL":321,"creatinine_mg_dL":1.35,"alt_U_L":39},{"date":"2025-04-09","hemoglobin_g_dL":10.1,"wbc_k_uL":3.1,"platelets_k_uL":240,"creatinine_mg_dL":1.44,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":87,"sex":"female","bmi":31.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-01-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-58},"pfs_months":19.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.3,"censored":false},"longitudinal_labs":[{"date":"2025-11-16","hemoglobin_g_dL":15.3,"wbc_k_uL":4.8,"platelets_k_uL":228,"creatinine_mg_dL":0.81,"alt_U_L":27},{"date":"2026-07-14","hemoglobin_g_dL":12.6,"wbc_k_uL":8.5,"platelets_k_uL":171,"creatinine_mg_dL":0.73,"alt_U_L":82},{"date":"2027-09-21","hemoglobin_g_dL":11.5,"wbc_k_uL":6.1,"platelets_k_uL":104,"creatinine_mg_dL":1.22,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":78,"sex":"female","bmi":28.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-83},"pfs_months":35.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":51.1,"censored":true},"longitudinal_labs":[{"date":"2021-09-12","hemoglobin_g_dL":13.2,"wbc_k_uL":6.9,"platelets_k_uL":327,"creatinine_mg_dL":1.15,"alt_U_L":41},{"date":"2022-05-03","hemoglobin_g_dL":12.3,"wbc_k_uL":5.7,"platelets_k_uL":278,"creatinine_mg_dL":0.95,"alt_U_L":43},{"date":"2024-10-21","hemoglobin_g_dL":10.7,"wbc_k_uL":5.0,"platelets_k_uL":262,"creatinine_mg_dL":1.44,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":87,"sex":"female","bmi":33.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-82},"pfs_months":27.53},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.4,"censored":true},"longitudinal_labs":[{"date":"2023-05-05","hemoglobin_g_dL":11.7,"wbc_k_uL":6.7,"platelets_k_uL":195,"creatinine_mg_dL":1.11,"alt_U_L":25},{"date":"2023-12-30","hemoglobin_g_dL":12.3,"wbc_k_uL":6.2,"platelets_k_uL":312,"creatinine_mg_dL":1.05,"alt_U_L":21},{"date":"2025-11-20","hemoglobin_g_dL":10.0,"wbc_k_uL":6.8,"platelets_k_uL":163,"creatinine_mg_dL":1.67,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":60,"sex":"male","bmi":28.6,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-32},"pfs_months":38.14},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":64.5,"censored":false},"longitudinal_labs":[{"date":"2021-03-15","hemoglobin_g_dL":12.1,"wbc_k_uL":8.4,"platelets_k_uL":173,"creatinine_mg_dL":0.77,"alt_U_L":42},{"date":"2021-11-18","hemoglobin_g_dL":10.0,"wbc_k_uL":5.9,"platelets_k_uL":291,"creatinine_mg_dL":1.14,"alt_U_L":85},{"date":"2024-09-23","hemoglobin_g_dL":10.9,"wbc_k_uL":4.1,"platelets_k_uL":126,"creatinine_mg_dL":1.58,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":75,"sex":"female","bmi":19.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-35},"pfs_months":12.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.2,"censored":false},"longitudinal_labs":[{"date":"2020-07-06","hemoglobin_g_dL":12.0,"wbc_k_uL":5.8,"platelets_k_uL":259,"creatinine_mg_dL":1.16,"alt_U_L":38},{"date":"2021-02-18","hemoglobin_g_dL":12.6,"wbc_k_uL":3.8,"platelets_k_uL":347,"creatinine_mg_dL":0.78,"alt_U_L":49},{"date":"2021-10-31","hemoglobin_g_dL":10.0,"wbc_k_uL":3.2,"platelets_k_uL":168,"creatinine_mg_dL":1.21,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":71,"sex":"male","bmi":30.2,"smoking_pack_years":24,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-83},"pfs_months":36.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":61.2,"censored":false},"longitudinal_labs":[{"date":"2022-11-06","hemoglobin_g_dL":13.2,"wbc_k_uL":8.1,"platelets_k_uL":409,"creatinine_mg_dL":0.81,"alt_U_L":13},{"date":"2023-06-15","hemoglobin_g_dL":12.4,"wbc_k_uL":5.0,"platelets_k_uL":289,"creatinine_mg_dL":1.45,"alt_U_L":103},{"date":"2026-01-13","hemoglobin_g_dL":11.7,"wbc_k_uL":5.1,"platelets_k_uL":164,"creatinine_mg_dL":1.76,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":64,"sex":"female","bmi":28.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-40},"pfs_months":26.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.9,"censored":false},"longitudinal_labs":[{"date":"2024-08-28","hemoglobin_g_dL":14.4,"wbc_k_uL":5.3,"platelets_k_uL":190,"creatinine_mg_dL":0.85,"alt_U_L":14},{"date":"2025-04-09","hemoglobin_g_dL":12.8,"wbc_k_uL":6.3,"platelets_k_uL":207,"creatinine_mg_dL":1.12,"alt_U_L":52},{"date":"2027-01-27","hemoglobin_g_dL":12.9,"wbc_k_uL":7.5,"platelets_k_uL":327,"creatinine_mg_dL":1.84,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":66,"sex":"female","bmi":29.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-60},"pfs_months":19.48},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.2,"censored":false},"longitudinal_labs":[{"date":"2023-05-03","hemoglobin_g_dL":14.1,"wbc_k_uL":5.3,"platelets_k_uL":190,"creatinine_mg_dL":1.08,"alt_U_L":56},{"date":"2023-12-08","hemoglobin_g_dL":13.7,"wbc_k_uL":8.1,"platelets_k_uL":153,"creatinine_mg_dL":0.82,"alt_U_L":114},{"date":"2025-02-06","hemoglobin_g_dL":12.4,"wbc_k_uL":8.0,"platelets_k_uL":227,"creatinine_mg_dL":1.03,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_483","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":50,"sex":"male","bmi":34.3,"smoking_pack_years":35,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-32},"pfs_months":30.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":true},"longitudinal_labs":[{"date":"2023-04-04","hemoglobin_g_dL":13.2,"wbc_k_uL":8.3,"platelets_k_uL":339,"creatinine_mg_dL":1.21,"alt_U_L":43},{"date":"2023-11-30","hemoglobin_g_dL":11.9,"wbc_k_uL":6.3,"platelets_k_uL":155,"creatinine_mg_dL":0.79,"alt_U_L":30},{"date":"2026-02-03","hemoglobin_g_dL":11.1,"wbc_k_uL":6.8,"platelets_k_uL":129,"creatinine_mg_dL":1.25,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":59,"sex":"male","bmi":31.0,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-40},"pfs_months":26.41},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":51.6,"censored":false},"longitudinal_labs":[{"date":"2022-12-09","hemoglobin_g_dL":13.6,"wbc_k_uL":9.9,"platelets_k_uL":291,"creatinine_mg_dL":1.04,"alt_U_L":20},{"date":"2023-06-27","hemoglobin_g_dL":11.9,"wbc_k_uL":5.0,"platelets_k_uL":205,"creatinine_mg_dL":0.79,"alt_U_L":75},{"date":"2025-03-24","hemoglobin_g_dL":12.2,"wbc_k_uL":4.8,"platelets_k_uL":198,"creatinine_mg_dL":1.76,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":79,"sex":"male","bmi":31.9,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-05-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-30},"pfs_months":8.51},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":16.2,"censored":false},"longitudinal_labs":[{"date":"2021-03-15","hemoglobin_g_dL":12.3,"wbc_k_uL":7.5,"platelets_k_uL":188,"creatinine_mg_dL":1.2,"alt_U_L":52},{"date":"2021-11-15","hemoglobin_g_dL":10.9,"wbc_k_uL":8.1,"platelets_k_uL":143,"creatinine_mg_dL":0.83,"alt_U_L":29},{"date":"2022-03-20","hemoglobin_g_dL":10.8,"wbc_k_uL":8.0,"platelets_k_uL":224,"creatinine_mg_dL":1.3,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":48,"sex":"female","bmi":30.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-61},"pfs_months":29.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.7,"censored":false},"longitudinal_labs":[{"date":"2022-08-24","hemoglobin_g_dL":14.7,"wbc_k_uL":8.1,"platelets_k_uL":419,"creatinine_mg_dL":0.86,"alt_U_L":35},{"date":"2023-04-20","hemoglobin_g_dL":13.5,"wbc_k_uL":7.7,"platelets_k_uL":127,"creatinine_mg_dL":0.7,"alt_U_L":21},{"date":"2025-03-31","hemoglobin_g_dL":10.7,"wbc_k_uL":4.4,"platelets_k_uL":127,"creatinine_mg_dL":1.31,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_487","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":59,"sex":"female","bmi":25.8,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-01-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-75},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":false},"longitudinal_labs":[{"date":"2024-12-20","hemoglobin_g_dL":12.2,"wbc_k_uL":7.6,"platelets_k_uL":329,"creatinine_mg_dL":0.88,"alt_U_L":42},{"date":"2025-07-21","hemoglobin_g_dL":10.6,"wbc_k_uL":5.4,"platelets_k_uL":288,"creatinine_mg_dL":0.8,"alt_U_L":79},{"date":"2026-12-28","hemoglobin_g_dL":11.7,"wbc_k_uL":5.3,"platelets_k_uL":199,"creatinine_mg_dL":1.31,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":81,"sex":"male","bmi":22.2,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-02-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-40},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-06-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":6.9,"censored":false},"longitudinal_labs":[{"date":"2021-01-09","hemoglobin_g_dL":13.5,"wbc_k_uL":8.6,"platelets_k_uL":203,"creatinine_mg_dL":0.91,"alt_U_L":59},{"date":"2021-08-23","hemoglobin_g_dL":13.5,"wbc_k_uL":8.3,"platelets_k_uL":321,"creatinine_mg_dL":0.84,"alt_U_L":46},{"date":"2021-06-22","hemoglobin_g_dL":9.8,"wbc_k_uL":5.5,"platelets_k_uL":215,"creatinine_mg_dL":1.09,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":87,"sex":"female","bmi":18.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-73},"pfs_months":21.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.9,"censored":true},"longitudinal_labs":[{"date":"2023-02-27","hemoglobin_g_dL":12.4,"wbc_k_uL":6.9,"platelets_k_uL":265,"creatinine_mg_dL":1.29,"alt_U_L":56},{"date":"2023-09-27","hemoglobin_g_dL":11.5,"wbc_k_uL":8.9,"platelets_k_uL":333,"creatinine_mg_dL":1.13,"alt_U_L":22},{"date":"2025-01-29","hemoglobin_g_dL":9.8,"wbc_k_uL":7.8,"platelets_k_uL":111,"creatinine_mg_dL":0.84,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":49,"sex":"female","bmi":19.5,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-04-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-43},"pfs_months":37.39},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":53.9,"censored":false},"longitudinal_labs":[{"date":"2023-03-18","hemoglobin_g_dL":11.7,"wbc_k_uL":6.3,"platelets_k_uL":337,"creatinine_mg_dL":0.85,"alt_U_L":70},{"date":"2023-10-16","hemoglobin_g_dL":11.4,"wbc_k_uL":4.2,"platelets_k_uL":181,"creatinine_mg_dL":0.93,"alt_U_L":23},{"date":"2026-07-04","hemoglobin_g_dL":12.5,"wbc_k_uL":7.8,"platelets_k_uL":155,"creatinine_mg_dL":1.3,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":86,"sex":"male","bmi":31.5,"smoking_pack_years":49,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-04-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-47},"pfs_months":6.51},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":12.6,"censored":false},"longitudinal_labs":[{"date":"2022-03-04","hemoglobin_g_dL":14.9,"wbc_k_uL":9.8,"platelets_k_uL":355,"creatinine_mg_dL":0.73,"alt_U_L":45},{"date":"2022-10-15","hemoglobin_g_dL":11.7,"wbc_k_uL":6.4,"platelets_k_uL":186,"creatinine_mg_dL":0.99,"alt_U_L":25},{"date":"2022-12-08","hemoglobin_g_dL":12.6,"wbc_k_uL":7.9,"platelets_k_uL":294,"creatinine_mg_dL":1.79,"alt_U_L":166}]}
{"patient_id":"ANODE_SYNTH_2025_492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":64,"sex":"female","bmi":19.0,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-11-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-46},"pfs_months":43.73},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.1,"censored":false},"longitudinal_labs":[{"date":"2024-10-01","hemoglobin_g_dL":14.6,"wbc_k_uL":10.0,"platelets_k_uL":301,"creatinine_mg_dL":0.83,"alt_U_L":10},{"date":"2025-05-06","hemoglobin_g_dL":11.1,"wbc_k_uL":5.6,"platelets_k_uL":250,"creatinine_mg_dL":1.25,"alt_U_L":28},{"date":"2028-07-28","hemoglobin_g_dL":12.6,"wbc_k_uL":5.5,"platelets_k_uL":256,"creatinine_mg_dL":1.93,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":84,"sex":"female","bmi":24.4,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-06-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-38},"pfs_months":10.09},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":14.0,"censored":false},"longitudinal_labs":[{"date":"2023-05-08","hemoglobin_g_dL":12.0,"wbc_k_uL":5.3,"platelets_k_uL":371,"creatinine_mg_dL":1.04,"alt_U_L":76},{"date":"2023-12-01","hemoglobin_g_dL":13.2,"wbc_k_uL":7.1,"platelets_k_uL":347,"creatinine_mg_dL":0.72,"alt_U_L":31},{"date":"2024-05-12","hemoglobin_g_dL":12.2,"wbc_k_uL":6.4,"platelets_k_uL":240,"creatinine_mg_dL":0.97,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":66,"sex":"female","bmi":25.6,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-04-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-46},"pfs_months":10.28},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":17.3,"censored":false},"longitudinal_labs":[{"date":"2022-03-24","hemoglobin_g_dL":15.0,"wbc_k_uL":7.9,"platelets_k_uL":326,"creatinine_mg_dL":1.0,"alt_U_L":45},{"date":"2022-10-15","hemoglobin_g_dL":13.6,"wbc_k_uL":4.5,"platelets_k_uL":140,"creatinine_mg_dL":0.88,"alt_U_L":118},{"date":"2023-04-22","hemoglobin_g_dL":9.8,"wbc_k_uL":3.3,"platelets_k_uL":334,"creatinine_mg_dL":1.47,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":83,"sex":"female","bmi":27.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-61},"pfs_months":28.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.9,"censored":false},"longitudinal_labs":[{"date":"2024-06-12","hemoglobin_g_dL":13.5,"wbc_k_uL":10.3,"platelets_k_uL":176,"creatinine_mg_dL":0.93,"alt_U_L":46},{"date":"2025-02-08","hemoglobin_g_dL":11.5,"wbc_k_uL":7.3,"platelets_k_uL":156,"creatinine_mg_dL":0.77,"alt_U_L":100},{"date":"2027-01-24","hemoglobin_g_dL":10.7,"wbc_k_uL":7.6,"platelets_k_uL":214,"creatinine_mg_dL":0.98,"alt_U_L":56}]}
{"patient_id":"ANODE_SYNTH_2025_496","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":56,"sex":"female","bmi":29.6,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-84},"pfs_months":26.41},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.1,"censored":false},"longitudinal_labs":[{"date":"2022-04-26","hemoglobin_g_dL":12.5,"wbc_k_uL":10.2,"platelets_k_uL":276,"creatinine_mg_dL":0.99,"alt_U_L":71},{"date":"2022-12-09","hemoglobin_g_dL":10.3,"wbc_k_uL":6.2,"platelets_k_uL":248,"creatinine_mg_dL":1.16,"alt_U_L":100},{"date":"2024-10-03","hemoglobin_g_dL":12.0,"wbc_k_uL":3.7,"platelets_k_uL":251,"creatinine_mg_dL":0.83,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_497","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":77,"sex":"female","bmi":23.6,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-07-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-65},"pfs_months":17.61},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.0,"censored":false},"longitudinal_labs":[{"date":"2024-06-19","hemoglobin_g_dL":12.2,"wbc_k_uL":5.5,"platelets_k_uL":371,"creatinine_mg_dL":1.15,"alt_U_L":70},{"date":"2025-01-22","hemoglobin_g_dL":10.1,"wbc_k_uL":8.5,"platelets_k_uL":198,"creatinine_mg_dL":0.87,"alt_U_L":67},{"date":"2026-02-26","hemoglobin_g_dL":11.1,"wbc_k_uL":3.5,"platelets_k_uL":271,"creatinine_mg_dL":1.55,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":60,"sex":"male","bmi":33.2,"smoking_pack_years":25,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-81},"pfs_months":41.2},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":68.8,"censored":false},"longitudinal_labs":[{"date":"2024-02-22","hemoglobin_g_dL":12.5,"wbc_k_uL":9.6,"platelets_k_uL":361,"creatinine_mg_dL":0.77,"alt_U_L":32},{"date":"2024-09-14","hemoglobin_g_dL":10.6,"wbc_k_uL":4.0,"platelets_k_uL":232,"creatinine_mg_dL":1.59,"alt_U_L":47},{"date":"2027-09-08","hemoglobin_g_dL":12.1,"wbc_k_uL":5.3,"platelets_k_uL":113,"creatinine_mg_dL":1.1,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":82,"sex":"male","bmi":22.7,"smoking_pack_years":74,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-07-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-84},"pfs_months":34.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":64.1,"censored":false},"longitudinal_labs":[{"date":"2023-06-04","hemoglobin_g_dL":13.6,"wbc_k_uL":9.0,"platelets_k_uL":274,"creatinine_mg_dL":0.84,"alt_U_L":48},{"date":"2024-01-20","hemoglobin_g_dL":12.8,"wbc_k_uL":5.3,"platelets_k_uL":202,"creatinine_mg_dL":1.43,"alt_U_L":70},{"date":"2026-08-02","hemoglobin_g_dL":12.7,"wbc_k_uL":4.4,"platelets_k_uL":212,"creatinine_mg_dL":1.72,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":58,"sex":"female","bmi":26.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-62},"pfs_months":9.82},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.8,"censored":true},"longitudinal_labs":[{"date":"2025-10-13","hemoglobin_g_dL":14.4,"wbc_k_uL":8.9,"platelets_k_uL":223,"creatinine_mg_dL":1.07,"alt_U_L":75},{"date":"2026-05-13","hemoglobin_g_dL":13.9,"wbc_k_uL":4.9,"platelets_k_uL":373,"creatinine_mg_dL":1.39,"alt_U_L":27},{"date":"2026-11-01","hemoglobin_g_dL":12.9,"wbc_k_uL":4.3,"platelets_k_uL":178,"creatinine_mg_dL":0.96,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_501","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":69,"sex":"male","bmi":34.0,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-09-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-52},"pfs_months":27.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.8,"censored":false},"longitudinal_labs":[{"date":"2021-08-26","hemoglobin_g_dL":12.6,"wbc_k_uL":5.9,"platelets_k_uL":253,"creatinine_mg_dL":1.14,"alt_U_L":69},{"date":"2022-03-24","hemoglobin_g_dL":13.6,"wbc_k_uL":7.7,"platelets_k_uL":127,"creatinine_mg_dL":0.74,"alt_U_L":93},{"date":"2024-02-23","hemoglobin_g_dL":10.0,"wbc_k_uL":4.5,"platelets_k_uL":177,"creatinine_mg_dL":1.76,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":59,"sex":"male","bmi":32.7,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-07-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-75},"pfs_months":39.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.1,"censored":false},"longitudinal_labs":[{"date":"2021-06-01","hemoglobin_g_dL":12.4,"wbc_k_uL":11.0,"platelets_k_uL":352,"creatinine_mg_dL":0.72,"alt_U_L":53},{"date":"2022-01-12","hemoglobin_g_dL":11.5,"wbc_k_uL":7.3,"platelets_k_uL":152,"creatinine_mg_dL":1.2,"alt_U_L":49},{"date":"2024-11-27","hemoglobin_g_dL":10.8,"wbc_k_uL":5.5,"platelets_k_uL":167,"creatinine_mg_dL":1.87,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":55,"sex":"female","bmi":31.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-79},"pfs_months":20.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.1,"censored":false},"longitudinal_labs":[{"date":"2021-09-14","hemoglobin_g_dL":12.5,"wbc_k_uL":10.7,"platelets_k_uL":333,"creatinine_mg_dL":0.83,"alt_U_L":34},{"date":"2022-05-03","hemoglobin_g_dL":10.9,"wbc_k_uL":5.6,"platelets_k_uL":347,"creatinine_mg_dL":0.94,"alt_U_L":18},{"date":"2023-09-05","hemoglobin_g_dL":12.6,"wbc_k_uL":7.4,"platelets_k_uL":257,"creatinine_mg_dL":1.71,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":50,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-77},"pfs_months":17.64},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":false},"longitudinal_labs":[{"date":"2020-07-18","hemoglobin_g_dL":13.8,"wbc_k_uL":5.2,"platelets_k_uL":372,"creatinine_mg_dL":0.96,"alt_U_L":12},{"date":"2021-03-15","hemoglobin_g_dL":12.9,"wbc_k_uL":6.1,"platelets_k_uL":204,"creatinine_mg_dL":1.56,"alt_U_L":75},{"date":"2022-04-27","hemoglobin_g_dL":10.6,"wbc_k_uL":4.2,"platelets_k_uL":196,"creatinine_mg_dL":0.85,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":72,"sex":"male","bmi":26.7,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-31},"pfs_months":42.51},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":63.3,"censored":false},"longitudinal_labs":[{"date":"2021-05-28","hemoglobin_g_dL":13.4,"wbc_k_uL":6.7,"platelets_k_uL":162,"creatinine_mg_dL":0.75,"alt_U_L":47},{"date":"2021-12-30","hemoglobin_g_dL":10.9,"wbc_k_uL":5.3,"platelets_k_uL":132,"creatinine_mg_dL":1.2,"alt_U_L":47},{"date":"2025-03-16","hemoglobin_g_dL":9.6,"wbc_k_uL":5.4,"platelets_k_uL":149,"creatinine_mg_dL":1.61,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_506","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":67,"sex":"male","bmi":19.1,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-04-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-59},"pfs_months":25.3},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.8,"censored":false},"longitudinal_labs":[{"date":"2024-02-21","hemoglobin_g_dL":12.4,"wbc_k_uL":5.0,"platelets_k_uL":236,"creatinine_mg_dL":1.11,"alt_U_L":71},{"date":"2024-10-04","hemoglobin_g_dL":11.3,"wbc_k_uL":6.6,"platelets_k_uL":182,"creatinine_mg_dL":1.24,"alt_U_L":100},{"date":"2026-06-04","hemoglobin_g_dL":11.3,"wbc_k_uL":5.7,"platelets_k_uL":148,"creatinine_mg_dL":0.86,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":56,"sex":"female","bmi":26.7,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-38},"pfs_months":28.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":55.7,"censored":false},"longitudinal_labs":[{"date":"2023-10-02","hemoglobin_g_dL":15.1,"wbc_k_uL":7.2,"platelets_k_uL":420,"creatinine_mg_dL":1.22,"alt_U_L":67},{"date":"2024-05-22","hemoglobin_g_dL":12.7,"wbc_k_uL":4.4,"platelets_k_uL":208,"creatinine_mg_dL":1.05,"alt_U_L":85},{"date":"2026-05-03","hemoglobin_g_dL":11.7,"wbc_k_uL":5.4,"platelets_k_uL":233,"creatinine_mg_dL":1.12,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":49,"sex":"female","bmi":23.5,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-09-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-74},"pfs_months":17.58},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":true},"longitudinal_labs":[{"date":"2025-08-10","hemoglobin_g_dL":13.5,"wbc_k_uL":10.1,"platelets_k_uL":208,"creatinine_mg_dL":0.65,"alt_U_L":42},{"date":"2026-03-09","hemoglobin_g_dL":10.8,"wbc_k_uL":7.5,"platelets_k_uL":325,"creatinine_mg_dL":1.21,"alt_U_L":105},{"date":"2027-04-13","hemoglobin_g_dL":11.6,"wbc_k_uL":5.3,"platelets_k_uL":349,"creatinine_mg_dL":1.84,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":78,"sex":"female","bmi":19.6,"smoking_pack_years":37,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-01-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-57},"pfs_months":45.7},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":73.7,"censored":false},"longitudinal_labs":[{"date":"2021-11-21","hemoglobin_g_dL":13.4,"wbc_k_uL":9.3,"platelets_k_uL":180,"creatinine_mg_dL":0.96,"alt_U_L":46},{"date":"2022-07-25","hemoglobin_g_dL":13.2,"wbc_k_uL":5.7,"platelets_k_uL":121,"creatinine_mg_dL":1.24,"alt_U_L":111},{"date":"2025-12-25","hemoglobin_g_dL":12.5,"wbc_k_uL":3.5,"platelets_k_uL":111,"creatinine_mg_dL":1.91,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":50,"sex":"male","bmi":23.2,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-02-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-73},"pfs_months":21.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-16","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.5,"censored":false},"longitudinal_labs":[{"date":"2023-02-09","hemoglobin_g_dL":14.7,"wbc_k_uL":6.6,"platelets_k_uL":424,"creatinine_mg_dL":0.96,"alt_U_L":76},{"date":"2023-08-25","hemoglobin_g_dL":13.2,"wbc_k_uL":8.5,"platelets_k_uL":355,"creatinine_mg_dL":1.19,"alt_U_L":29},{"date":"2025-02-16","hemoglobin_g_dL":10.4,"wbc_k_uL":4.4,"platelets_k_uL":176,"creatinine_mg_dL":1.98,"alt_U_L":31}]}
{"patient_id":"ANODE_SYNTH_2025_511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":73,"sex":"male","bmi":36.3,"smoking_pack_years":45,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-38},"pfs_months":28.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":49.0,"censored":false},"longitudinal_labs":[{"date":"2021-09-24","hemoglobin_g_dL":14.1,"wbc_k_uL":7.2,"platelets_k_uL":329,"creatinine_mg_dL":0.66,"alt_U_L":69},{"date":"2022-05-20","hemoglobin_g_dL":12.7,"wbc_k_uL":6.7,"platelets_k_uL":238,"creatinine_mg_dL":0.85,"alt_U_L":117},{"date":"2024-05-07","hemoglobin_g_dL":10.8,"wbc_k_uL":7.7,"platelets_k_uL":253,"creatinine_mg_dL":1.08,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":67,"sex":"female","bmi":19.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-79},"pfs_months":25.72},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":false},"longitudinal_labs":[{"date":"2021-04-05","hemoglobin_g_dL":11.7,"wbc_k_uL":4.6,"platelets_k_uL":446,"creatinine_mg_dL":1.23,"alt_U_L":76},{"date":"2021-11-06","hemoglobin_g_dL":13.7,"wbc_k_uL":8.8,"platelets_k_uL":286,"creatinine_mg_dL":1.37,"alt_U_L":70},{"date":"2023-08-24","hemoglobin_g_dL":10.3,"wbc_k_uL":6.2,"platelets_k_uL":245,"creatinine_mg_dL":1.06,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":71,"sex":"female","bmi":29.5,"smoking_pack_years":45,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-43},"pfs_months":28.42},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":53.6,"censored":false},"longitudinal_labs":[{"date":"2024-03-05","hemoglobin_g_dL":11.8,"wbc_k_uL":8.9,"platelets_k_uL":446,"creatinine_mg_dL":1.04,"alt_U_L":19},{"date":"2024-09-27","hemoglobin_g_dL":10.3,"wbc_k_uL":6.3,"platelets_k_uL":326,"creatinine_mg_dL":1.03,"alt_U_L":105},{"date":"2026-09-30","hemoglobin_g_dL":11.9,"wbc_k_uL":4.8,"platelets_k_uL":349,"creatinine_mg_dL":1.98,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":56,"sex":"female","bmi":27.5,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-04-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-57},"pfs_months":11.14},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":15.1,"censored":true},"longitudinal_labs":[{"date":"2021-02-23","hemoglobin_g_dL":11.6,"wbc_k_uL":8.0,"platelets_k_uL":327,"creatinine_mg_dL":1.03,"alt_U_L":54},{"date":"2021-10-15","hemoglobin_g_dL":11.6,"wbc_k_uL":5.8,"platelets_k_uL":184,"creatinine_mg_dL":1.47,"alt_U_L":44},{"date":"2022-04-17","hemoglobin_g_dL":12.1,"wbc_k_uL":4.6,"platelets_k_uL":307,"creatinine_mg_dL":1.62,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":83,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-31},"pfs_months":24.51},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.4,"censored":false},"longitudinal_labs":[{"date":"2020-02-07","hemoglobin_g_dL":11.8,"wbc_k_uL":9.1,"platelets_k_uL":232,"creatinine_mg_dL":0.88,"alt_U_L":26},{"date":"2020-10-03","hemoglobin_g_dL":10.3,"wbc_k_uL":4.2,"platelets_k_uL":293,"creatinine_mg_dL":0.95,"alt_U_L":54},{"date":"2022-06-14","hemoglobin_g_dL":12.5,"wbc_k_uL":3.7,"platelets_k_uL":191,"creatinine_mg_dL":1.41,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":68,"sex":"female","bmi":28.1,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-06-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-54},"pfs_months":26.48},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":58.9,"censored":false},"longitudinal_labs":[{"date":"2022-04-13","hemoglobin_g_dL":13.2,"wbc_k_uL":4.8,"platelets_k_uL":304,"creatinine_mg_dL":0.65,"alt_U_L":25},{"date":"2022-12-07","hemoglobin_g_dL":13.9,"wbc_k_uL":5.5,"platelets_k_uL":150,"creatinine_mg_dL":0.78,"alt_U_L":69},{"date":"2024-08-28","hemoglobin_g_dL":12.4,"wbc_k_uL":5.5,"platelets_k_uL":261,"creatinine_mg_dL":1.81,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_517","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":54,"sex":"male","bmi":25.9,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-12-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-46},"pfs_months":25.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":47.9,"censored":true},"longitudinal_labs":[{"date":"2020-11-19","hemoglobin_g_dL":14.7,"wbc_k_uL":9.5,"platelets_k_uL":170,"creatinine_mg_dL":1.05,"alt_U_L":42},{"date":"2021-06-13","hemoglobin_g_dL":10.2,"wbc_k_uL":6.9,"platelets_k_uL":245,"creatinine_mg_dL":0.92,"alt_U_L":92},{"date":"2023-03-09","hemoglobin_g_dL":10.9,"wbc_k_uL":7.5,"platelets_k_uL":302,"creatinine_mg_dL":1.96,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":48,"sex":"male","bmi":31.6,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-41},"pfs_months":11.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":true},"longitudinal_labs":[{"date":"2020-11-02","hemoglobin_g_dL":13.9,"wbc_k_uL":5.7,"platelets_k_uL":156,"creatinine_mg_dL":0.81,"alt_U_L":39},{"date":"2021-05-29","hemoglobin_g_dL":12.2,"wbc_k_uL":4.7,"platelets_k_uL":357,"creatinine_mg_dL":1.28,"alt_U_L":94},{"date":"2021-12-22","hemoglobin_g_dL":12.4,"wbc_k_uL":6.6,"platelets_k_uL":179,"creatinine_mg_dL":1.29,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":64,"sex":"male","bmi":29.9,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-10-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-47},"pfs_months":6.08},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":15.7,"censored":false},"longitudinal_labs":[{"date":"2021-08-22","hemoglobin_g_dL":15.0,"wbc_k_uL":6.0,"platelets_k_uL":166,"creatinine_mg_dL":0.77,"alt_U_L":33},{"date":"2022-04-23","hemoglobin_g_dL":12.1,"wbc_k_uL":7.7,"platelets_k_uL":319,"creatinine_mg_dL":0.83,"alt_U_L":78},{"date":"2022-05-15","hemoglobin_g_dL":12.6,"wbc_k_uL":6.6,"platelets_k_uL":118,"creatinine_mg_dL":1.94,"alt_U_L":149}]}
{"patient_id":"ANODE_SYNTH_2025_520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":67,"sex":"female","bmi":24.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-64},"pfs_months":21.68},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.5,"censored":false},"longitudinal_labs":[{"date":"2024-11-17","hemoglobin_g_dL":11.9,"wbc_k_uL":10.5,"platelets_k_uL":432,"creatinine_mg_dL":1.3,"alt_U_L":22},{"date":"2025-07-14","hemoglobin_g_dL":12.6,"wbc_k_uL":7.5,"platelets_k_uL":179,"creatinine_mg_dL":1.49,"alt_U_L":88},{"date":"2026-12-09","hemoglobin_g_dL":10.9,"wbc_k_uL":6.5,"platelets_k_uL":329,"creatinine_mg_dL":0.92,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":50,"sex":"male","bmi":26.1,"smoking_pack_years":54,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-01-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-47},"pfs_months":17.77},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.6,"censored":false},"longitudinal_labs":[{"date":"2022-12-21","hemoglobin_g_dL":13.9,"wbc_k_uL":4.8,"platelets_k_uL":320,"creatinine_mg_dL":1.22,"alt_U_L":71},{"date":"2023-07-25","hemoglobin_g_dL":12.8,"wbc_k_uL":5.7,"platelets_k_uL":334,"creatinine_mg_dL":1.1,"alt_U_L":105},{"date":"2024-09-03","hemoglobin_g_dL":11.9,"wbc_k_uL":7.1,"platelets_k_uL":115,"creatinine_mg_dL":1.02,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":88,"sex":"female","bmi":19.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-65},"pfs_months":20.07},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.2,"censored":false},"longitudinal_labs":[{"date":"2022-07-23","hemoglobin_g_dL":12.9,"wbc_k_uL":4.5,"platelets_k_uL":321,"creatinine_mg_dL":1.11,"alt_U_L":20},{"date":"2023-02-17","hemoglobin_g_dL":11.2,"wbc_k_uL":4.3,"platelets_k_uL":327,"creatinine_mg_dL":0.95,"alt_U_L":87},{"date":"2024-06-07","hemoglobin_g_dL":11.8,"wbc_k_uL":6.7,"platelets_k_uL":209,"creatinine_mg_dL":0.92,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":75,"sex":"female","bmi":34.1,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-07-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-68},"pfs_months":48.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":68.3,"censored":true},"longitudinal_labs":[{"date":"2023-07-08","hemoglobin_g_dL":15.3,"wbc_k_uL":10.6,"platelets_k_uL":265,"creatinine_mg_dL":1.15,"alt_U_L":61},{"date":"2024-01-24","hemoglobin_g_dL":10.0,"wbc_k_uL":3.8,"platelets_k_uL":281,"creatinine_mg_dL":0.78,"alt_U_L":50},{"date":"2027-10-03","hemoglobin_g_dL":10.7,"wbc_k_uL":7.8,"platelets_k_uL":305,"creatinine_mg_dL":0.88,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":55,"sex":"female","bmi":19.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-42},"pfs_months":20.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-24","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.3,"censored":false},"longitudinal_labs":[{"date":"2025-05-02","hemoglobin_g_dL":14.5,"wbc_k_uL":5.1,"platelets_k_uL":298,"creatinine_mg_dL":0.81,"alt_U_L":24},{"date":"2025-12-05","hemoglobin_g_dL":12.1,"wbc_k_uL":5.4,"platelets_k_uL":328,"creatinine_mg_dL":0.9,"alt_U_L":53},{"date":"2027-03-24","hemoglobin_g_dL":11.6,"wbc_k_uL":5.3,"platelets_k_uL":342,"creatinine_mg_dL":1.58,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":55,"sex":"male","bmi":19.1,"smoking_pack_years":53,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-69},"pfs_months":41.92},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":60.8,"censored":false},"longitudinal_labs":[{"date":"2023-10-16","hemoglobin_g_dL":12.2,"wbc_k_uL":7.7,"platelets_k_uL":152,"creatinine_mg_dL":0.93,"alt_U_L":33},{"date":"2024-05-27","hemoglobin_g_dL":11.5,"wbc_k_uL":6.3,"platelets_k_uL":304,"creatinine_mg_dL":1.5,"alt_U_L":81},{"date":"2027-07-02","hemoglobin_g_dL":12.4,"wbc_k_uL":4.3,"platelets_k_uL":187,"creatinine_mg_dL":1.13,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":77,"sex":"female","bmi":20.5,"smoking_pack_years":18,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-05-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-81},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":12.6,"censored":false},"longitudinal_labs":[{"date":"2022-04-25","hemoglobin_g_dL":11.9,"wbc_k_uL":5.4,"platelets_k_uL":364,"creatinine_mg_dL":1.05,"alt_U_L":16},{"date":"2022-11-20","hemoglobin_g_dL":11.6,"wbc_k_uL":3.9,"platelets_k_uL":332,"creatinine_mg_dL":1.0,"alt_U_L":102},{"date":"2022-10-05","hemoglobin_g_dL":10.9,"wbc_k_uL":3.5,"platelets_k_uL":286,"creatinine_mg_dL":1.48,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":62,"sex":"female","bmi":31.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-31},"pfs_months":20.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":false},"longitudinal_labs":[{"date":"2021-08-02","hemoglobin_g_dL":11.8,"wbc_k_uL":8.9,"platelets_k_uL":387,"creatinine_mg_dL":1.2,"alt_U_L":33},{"date":"2022-03-28","hemoglobin_g_dL":11.9,"wbc_k_uL":6.7,"platelets_k_uL":329,"creatinine_mg_dL":1.27,"alt_U_L":36},{"date":"2023-07-25","hemoglobin_g_dL":10.5,"wbc_k_uL":8.0,"platelets_k_uL":329,"creatinine_mg_dL":0.82,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_528","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":66,"sex":"male","bmi":22.9,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-09-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-83},"pfs_months":29.63},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":false},"longitudinal_labs":[{"date":"2023-09-10","hemoglobin_g_dL":12.3,"wbc_k_uL":8.5,"platelets_k_uL":161,"creatinine_mg_dL":0.74,"alt_U_L":43},{"date":"2024-03-23","hemoglobin_g_dL":10.5,"wbc_k_uL":7.4,"platelets_k_uL":247,"creatinine_mg_dL":1.04,"alt_U_L":55},{"date":"2026-04-27","hemoglobin_g_dL":10.2,"wbc_k_uL":5.1,"platelets_k_uL":265,"creatinine_mg_dL":1.11,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":84,"sex":"female","bmi":26.3,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-36},"pfs_months":24.02},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.8,"censored":false},"longitudinal_labs":[{"date":"2024-12-08","hemoglobin_g_dL":12.2,"wbc_k_uL":9.9,"platelets_k_uL":448,"creatinine_mg_dL":1.29,"alt_U_L":65},{"date":"2025-07-02","hemoglobin_g_dL":11.2,"wbc_k_uL":8.8,"platelets_k_uL":199,"creatinine_mg_dL":0.98,"alt_U_L":118},{"date":"2027-01-08","hemoglobin_g_dL":12.2,"wbc_k_uL":7.4,"platelets_k_uL":319,"creatinine_mg_dL":1.95,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_530","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":68,"sex":"male","bmi":23.3,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-10-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-56},"pfs_months":10.61},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":21.8,"censored":false},"longitudinal_labs":[{"date":"2021-08-23","hemoglobin_g_dL":11.8,"wbc_k_uL":7.5,"platelets_k_uL":192,"creatinine_mg_dL":0.99,"alt_U_L":64},{"date":"2022-04-20","hemoglobin_g_dL":13.2,"wbc_k_uL":5.7,"platelets_k_uL":280,"creatinine_mg_dL":1.01,"alt_U_L":64},{"date":"2022-10-03","hemoglobin_g_dL":12.7,"wbc_k_uL":6.0,"platelets_k_uL":232,"creatinine_mg_dL":1.68,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":85,"sex":"female","bmi":22.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-70},"pfs_months":16.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.8,"censored":false},"longitudinal_labs":[{"date":"2024-07-22","hemoglobin_g_dL":11.8,"wbc_k_uL":8.4,"platelets_k_uL":186,"creatinine_mg_dL":0.87,"alt_U_L":11},{"date":"2025-02-06","hemoglobin_g_dL":10.2,"wbc_k_uL":4.6,"platelets_k_uL":124,"creatinine_mg_dL":0.8,"alt_U_L":60},{"date":"2026-01-24","hemoglobin_g_dL":12.0,"wbc_k_uL":5.4,"platelets_k_uL":183,"creatinine_mg_dL":1.12,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":60,"sex":"male","bmi":36.0,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-12-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-39},"pfs_months":15.8},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.8,"censored":false},"longitudinal_labs":[{"date":"2025-12-04","hemoglobin_g_dL":14.5,"wbc_k_uL":5.3,"platelets_k_uL":335,"creatinine_mg_dL":0.7,"alt_U_L":37},{"date":"2026-06-19","hemoglobin_g_dL":11.3,"wbc_k_uL":5.7,"platelets_k_uL":339,"creatinine_mg_dL":1.27,"alt_U_L":78},{"date":"2027-04-24","hemoglobin_g_dL":11.0,"wbc_k_uL":5.2,"platelets_k_uL":228,"creatinine_mg_dL":1.9,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":74,"sex":"female","bmi":32.5,"smoking_pack_years":14,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-68},"pfs_months":12.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-08-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":17.5,"censored":true},"longitudinal_labs":[{"date":"2020-06-15","hemoglobin_g_dL":14.5,"wbc_k_uL":10.0,"platelets_k_uL":275,"creatinine_mg_dL":1.1,"alt_U_L":15},{"date":"2020-12-28","hemoglobin_g_dL":11.1,"wbc_k_uL":5.6,"platelets_k_uL":315,"creatinine_mg_dL":1.45,"alt_U_L":22},{"date":"2021-08-17","hemoglobin_g_dL":10.2,"wbc_k_uL":3.5,"platelets_k_uL":170,"creatinine_mg_dL":1.73,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":88,"sex":"female","bmi":18.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-43},"pfs_months":12.65},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":16.6,"censored":false},"longitudinal_labs":[{"date":"2025-06-16","hemoglobin_g_dL":13.9,"wbc_k_uL":8.4,"platelets_k_uL":335,"creatinine_mg_dL":0.62,"alt_U_L":76},{"date":"2026-02-01","hemoglobin_g_dL":12.9,"wbc_k_uL":5.1,"platelets_k_uL":343,"creatinine_mg_dL":1.51,"alt_U_L":73},{"date":"2026-10-20","hemoglobin_g_dL":12.0,"wbc_k_uL":3.3,"platelets_k_uL":240,"creatinine_mg_dL":0.85,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":49,"sex":"female","bmi":32.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-42},"pfs_months":3.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":20.7,"censored":false},"longitudinal_labs":[{"date":"2021-06-24","hemoglobin_g_dL":11.7,"wbc_k_uL":10.1,"platelets_k_uL":236,"creatinine_mg_dL":1.08,"alt_U_L":53},{"date":"2022-02-13","hemoglobin_g_dL":10.2,"wbc_k_uL":5.8,"platelets_k_uL":186,"creatinine_mg_dL":1.44,"alt_U_L":44},{"date":"2022-01-25","hemoglobin_g_dL":11.0,"wbc_k_uL":8.0,"platelets_k_uL":289,"creatinine_mg_dL":1.49,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":55,"sex":"female","bmi":28.8,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-12-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-60},"pfs_months":13.47},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.6,"censored":false},"longitudinal_labs":[{"date":"2025-11-05","hemoglobin_g_dL":11.7,"wbc_k_uL":8.1,"platelets_k_uL":228,"creatinine_mg_dL":1.0,"alt_U_L":41},{"date":"2026-06-23","hemoglobin_g_dL":11.4,"wbc_k_uL":4.2,"platelets_k_uL":235,"creatinine_mg_dL":1.09,"alt_U_L":62},{"date":"2027-02-20","hemoglobin_g_dL":10.7,"wbc_k_uL":3.0,"platelets_k_uL":164,"creatinine_mg_dL":1.25,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":49,"sex":"female","bmi":35.1,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-02-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-77},"pfs_months":9.13},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":13.1,"censored":false},"longitudinal_labs":[{"date":"2023-12-22","hemoglobin_g_dL":13.7,"wbc_k_uL":7.8,"platelets_k_uL":358,"creatinine_mg_dL":1.3,"alt_U_L":46},{"date":"2024-08-19","hemoglobin_g_dL":10.3,"wbc_k_uL":5.2,"platelets_k_uL":134,"creatinine_mg_dL":0.76,"alt_U_L":46},{"date":"2025-01-23","hemoglobin_g_dL":10.7,"wbc_k_uL":5.5,"platelets_k_uL":131,"creatinine_mg_dL":1.4,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":79,"sex":"male","bmi":28.7,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-10-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-76},"pfs_months":6.24},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-23","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":10.2,"censored":false},"longitudinal_labs":[{"date":"2022-09-06","hemoglobin_g_dL":12.6,"wbc_k_uL":5.7,"platelets_k_uL":382,"creatinine_mg_dL":1.07,"alt_U_L":67},{"date":"2023-04-24","hemoglobin_g_dL":13.6,"wbc_k_uL":5.6,"platelets_k_uL":217,"creatinine_mg_dL":0.97,"alt_U_L":50},{"date":"2023-05-23","hemoglobin_g_dL":11.9,"wbc_k_uL":5.4,"platelets_k_uL":254,"creatinine_mg_dL":1.91,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":74,"sex":"male","bmi":26.5,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-05-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-68},"pfs_months":35.91},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":55.5,"censored":true},"longitudinal_labs":[{"date":"2025-04-07","hemoglobin_g_dL":14.0,"wbc_k_uL":4.9,"platelets_k_uL":186,"creatinine_mg_dL":1.01,"alt_U_L":40},{"date":"2025-11-27","hemoglobin_g_dL":11.6,"wbc_k_uL":6.8,"platelets_k_uL":216,"creatinine_mg_dL":1.34,"alt_U_L":109},{"date":"2028-06-23","hemoglobin_g_dL":11.9,"wbc_k_uL":5.8,"platelets_k_uL":279,"creatinine_mg_dL":1.24,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":61,"sex":"female","bmi":30.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-40},"pfs_months":16.76},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.5,"censored":false},"longitudinal_labs":[{"date":"2023-10-17","hemoglobin_g_dL":15.4,"wbc_k_uL":6.5,"platelets_k_uL":302,"creatinine_mg_dL":0.66,"alt_U_L":30},{"date":"2024-06-19","hemoglobin_g_dL":11.7,"wbc_k_uL":8.9,"platelets_k_uL":369,"creatinine_mg_dL":1.11,"alt_U_L":36},{"date":"2025-06-22","hemoglobin_g_dL":11.8,"wbc_k_uL":6.5,"platelets_k_uL":301,"creatinine_mg_dL":0.93,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_541","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":48,"sex":"female","bmi":28.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-52},"pfs_months":16.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":false},"longitudinal_labs":[{"date":"2023-06-21","hemoglobin_g_dL":13.3,"wbc_k_uL":5.1,"platelets_k_uL":216,"creatinine_mg_dL":0.98,"alt_U_L":49},{"date":"2024-01-14","hemoglobin_g_dL":11.5,"wbc_k_uL":8.1,"platelets_k_uL":129,"creatinine_mg_dL":1.11,"alt_U_L":79},{"date":"2025-01-04","hemoglobin_g_dL":12.3,"wbc_k_uL":3.9,"platelets_k_uL":204,"creatinine_mg_dL":1.15,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":58,"sex":"female","bmi":31.6,"smoking_pack_years":40,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-03-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-76},"pfs_months":48.13},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":77.5,"censored":false},"longitudinal_labs":[{"date":"2022-02-19","hemoglobin_g_dL":13.6,"wbc_k_uL":9.4,"platelets_k_uL":154,"creatinine_mg_dL":1.22,"alt_U_L":71},{"date":"2022-09-21","hemoglobin_g_dL":13.8,"wbc_k_uL":6.6,"platelets_k_uL":264,"creatinine_mg_dL":1.17,"alt_U_L":77},{"date":"2026-04-29","hemoglobin_g_dL":10.1,"wbc_k_uL":7.4,"platelets_k_uL":104,"creatinine_mg_dL":1.9,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_543","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":87,"sex":"female","bmi":27.0,"smoking_pack_years":28,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-80},"pfs_months":26.78},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":false},"longitudinal_labs":[{"date":"2023-06-05","hemoglobin_g_dL":13.5,"wbc_k_uL":4.6,"platelets_k_uL":328,"creatinine_mg_dL":1.0,"alt_U_L":51},{"date":"2023-12-16","hemoglobin_g_dL":11.5,"wbc_k_uL":4.5,"platelets_k_uL":272,"creatinine_mg_dL":1.11,"alt_U_L":27},{"date":"2025-10-10","hemoglobin_g_dL":11.0,"wbc_k_uL":4.4,"platelets_k_uL":307,"creatinine_mg_dL":1.01,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":68,"sex":"female","bmi":21.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-47},"pfs_months":27.76},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":49.9,"censored":false},"longitudinal_labs":[{"date":"2022-05-19","hemoglobin_g_dL":12.6,"wbc_k_uL":9.3,"platelets_k_uL":248,"creatinine_mg_dL":0.96,"alt_U_L":43},{"date":"2023-01-03","hemoglobin_g_dL":11.7,"wbc_k_uL":9.0,"platelets_k_uL":176,"creatinine_mg_dL":1.48,"alt_U_L":72},{"date":"2024-12-15","hemoglobin_g_dL":12.6,"wbc_k_uL":7.5,"platelets_k_uL":167,"creatinine_mg_dL":1.24,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":56,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-65},"pfs_months":11.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":28.4,"censored":false},"longitudinal_labs":[{"date":"2022-06-25","hemoglobin_g_dL":11.5,"wbc_k_uL":8.6,"platelets_k_uL":232,"creatinine_mg_dL":1.03,"alt_U_L":67},{"date":"2023-02-07","hemoglobin_g_dL":13.4,"wbc_k_uL":8.5,"platelets_k_uL":257,"creatinine_mg_dL":0.96,"alt_U_L":58},{"date":"2023-08-15","hemoglobin_g_dL":12.9,"wbc_k_uL":4.6,"platelets_k_uL":275,"creatinine_mg_dL":1.72,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_546","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":71,"sex":"female","bmi":18.8,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-11-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-31},"pfs_months":14.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":28.5,"censored":false},"longitudinal_labs":[{"date":"2022-10-10","hemoglobin_g_dL":14.9,"wbc_k_uL":9.7,"platelets_k_uL":266,"creatinine_mg_dL":0.74,"alt_U_L":23},{"date":"2023-05-03","hemoglobin_g_dL":12.9,"wbc_k_uL":8.8,"platelets_k_uL":140,"creatinine_mg_dL":1.09,"alt_U_L":83},{"date":"2024-03-08","hemoglobin_g_dL":12.0,"wbc_k_uL":7.8,"platelets_k_uL":232,"creatinine_mg_dL":1.56,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":56,"sex":"female","bmi":28.5,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-40},"pfs_months":15.7},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.9,"censored":false},"longitudinal_labs":[{"date":"2021-06-21","hemoglobin_g_dL":12.2,"wbc_k_uL":9.4,"platelets_k_uL":295,"creatinine_mg_dL":1.17,"alt_U_L":76},{"date":"2022-01-16","hemoglobin_g_dL":13.7,"wbc_k_uL":5.5,"platelets_k_uL":368,"creatinine_mg_dL":1.13,"alt_U_L":96},{"date":"2022-11-25","hemoglobin_g_dL":9.6,"wbc_k_uL":6.1,"platelets_k_uL":159,"creatinine_mg_dL":1.11,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":84,"sex":"female","bmi":28.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-59},"pfs_months":20.14},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":37.7,"censored":false},"longitudinal_labs":[{"date":"2021-07-17","hemoglobin_g_dL":11.9,"wbc_k_uL":5.3,"platelets_k_uL":239,"creatinine_mg_dL":1.28,"alt_U_L":72},{"date":"2022-02-04","hemoglobin_g_dL":11.9,"wbc_k_uL":5.8,"platelets_k_uL":190,"creatinine_mg_dL":0.9,"alt_U_L":120},{"date":"2023-04-27","hemoglobin_g_dL":10.5,"wbc_k_uL":3.3,"platelets_k_uL":349,"creatinine_mg_dL":1.15,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":63,"sex":"female","bmi":35.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-52},"pfs_months":21.26},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":false},"longitudinal_labs":[{"date":"2021-08-25","hemoglobin_g_dL":13.6,"wbc_k_uL":5.3,"platelets_k_uL":416,"creatinine_mg_dL":0.93,"alt_U_L":23},{"date":"2022-04-01","hemoglobin_g_dL":11.5,"wbc_k_uL":5.9,"platelets_k_uL":136,"creatinine_mg_dL":1.58,"alt_U_L":23},{"date":"2023-09-05","hemoglobin_g_dL":11.7,"wbc_k_uL":4.0,"platelets_k_uL":195,"creatinine_mg_dL":0.84,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":81,"sex":"female","bmi":25.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-62},"pfs_months":27.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":46.0,"censored":false},"longitudinal_labs":[{"date":"2022-09-24","hemoglobin_g_dL":13.8,"wbc_k_uL":7.6,"platelets_k_uL":370,"creatinine_mg_dL":0.65,"alt_U_L":69},{"date":"2023-05-30","hemoglobin_g_dL":10.2,"wbc_k_uL":6.2,"platelets_k_uL":380,"creatinine_mg_dL":0.85,"alt_U_L":107},{"date":"2025-04-02","hemoglobin_g_dL":9.6,"wbc_k_uL":3.6,"platelets_k_uL":302,"creatinine_mg_dL":1.85,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":63,"sex":"female","bmi":28.7,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-01-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-54},"pfs_months":10.74},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":15.9,"censored":false},"longitudinal_labs":[{"date":"2020-11-16","hemoglobin_g_dL":14.1,"wbc_k_uL":6.7,"platelets_k_uL":179,"creatinine_mg_dL":1.12,"alt_U_L":64},{"date":"2021-07-12","hemoglobin_g_dL":10.8,"wbc_k_uL":7.6,"platelets_k_uL":241,"creatinine_mg_dL":1.17,"alt_U_L":74},{"date":"2021-12-28","hemoglobin_g_dL":11.9,"wbc_k_uL":3.1,"platelets_k_uL":260,"creatinine_mg_dL":1.0,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":83,"sex":"female","bmi":31.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-38},"pfs_months":35.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":46.2,"censored":false},"longitudinal_labs":[{"date":"2024-04-10","hemoglobin_g_dL":14.2,"wbc_k_uL":5.7,"platelets_k_uL":417,"creatinine_mg_dL":1.07,"alt_U_L":35},{"date":"2024-10-25","hemoglobin_g_dL":11.1,"wbc_k_uL":6.4,"platelets_k_uL":203,"creatinine_mg_dL":0.77,"alt_U_L":38},{"date":"2027-04-16","hemoglobin_g_dL":12.2,"wbc_k_uL":5.5,"platelets_k_uL":159,"creatinine_mg_dL":0.88,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":60,"sex":"female","bmi":30.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-73},"pfs_months":15.08},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.9,"censored":true},"longitudinal_labs":[{"date":"2020-07-20","hemoglobin_g_dL":12.3,"wbc_k_uL":10.7,"platelets_k_uL":276,"creatinine_mg_dL":0.9,"alt_U_L":13},{"date":"2021-03-09","hemoglobin_g_dL":11.7,"wbc_k_uL":5.8,"platelets_k_uL":265,"creatinine_mg_dL":1.45,"alt_U_L":50},{"date":"2022-01-16","hemoglobin_g_dL":12.6,"wbc_k_uL":3.2,"platelets_k_uL":336,"creatinine_mg_dL":1.79,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":69,"sex":"female","bmi":20.7,"smoking_pack_years":68,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2023-09-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-42},"pfs_months":31.38},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":46.5,"censored":false},"longitudinal_labs":[{"date":"2023-07-15","hemoglobin_g_dL":15.2,"wbc_k_uL":8.6,"platelets_k_uL":437,"creatinine_mg_dL":1.29,"alt_U_L":80},{"date":"2024-03-04","hemoglobin_g_dL":11.4,"wbc_k_uL":8.4,"platelets_k_uL":125,"creatinine_mg_dL":1.35,"alt_U_L":89},{"date":"2026-05-24","hemoglobin_g_dL":10.8,"wbc_k_uL":3.2,"platelets_k_uL":121,"creatinine_mg_dL":1.02,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":53,"sex":"female","bmi":36.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-83},"pfs_months":31.97},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.7,"censored":true},"longitudinal_labs":[{"date":"2023-11-13","hemoglobin_g_dL":12.8,"wbc_k_uL":8.0,"platelets_k_uL":419,"creatinine_mg_dL":1.03,"alt_U_L":16},{"date":"2024-05-29","hemoglobin_g_dL":12.8,"wbc_k_uL":6.9,"platelets_k_uL":318,"creatinine_mg_dL":0.79,"alt_U_L":102},{"date":"2026-09-09","hemoglobin_g_dL":10.4,"wbc_k_uL":7.7,"platelets_k_uL":334,"creatinine_mg_dL":1.73,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":87,"sex":"female","bmi":26.3,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-70},"pfs_months":5.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-24","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":12.6,"censored":false},"longitudinal_labs":[{"date":"2023-06-27","hemoglobin_g_dL":13.8,"wbc_k_uL":9.3,"platelets_k_uL":280,"creatinine_mg_dL":1.21,"alt_U_L":46},{"date":"2024-03-01","hemoglobin_g_dL":10.1,"wbc_k_uL":8.8,"platelets_k_uL":300,"creatinine_mg_dL":1.25,"alt_U_L":86},{"date":"2024-02-24","hemoglobin_g_dL":10.5,"wbc_k_uL":5.9,"platelets_k_uL":209,"creatinine_mg_dL":1.25,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_557","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":62,"sex":"male","bmi":29.8,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-47},"pfs_months":19.84},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.9,"censored":true},"longitudinal_labs":[{"date":"2023-04-20","hemoglobin_g_dL":12.6,"wbc_k_uL":8.3,"platelets_k_uL":390,"creatinine_mg_dL":1.1,"alt_U_L":79},{"date":"2023-11-29","hemoglobin_g_dL":13.8,"wbc_k_uL":8.0,"platelets_k_uL":358,"creatinine_mg_dL":1.49,"alt_U_L":100},{"date":"2025-01-30","hemoglobin_g_dL":12.4,"wbc_k_uL":6.1,"platelets_k_uL":239,"creatinine_mg_dL":1.17,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_558","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":83,"sex":"male","bmi":20.0,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-06-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-57},"pfs_months":13.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":false},"longitudinal_labs":[{"date":"2024-04-17","hemoglobin_g_dL":14.9,"wbc_k_uL":6.7,"platelets_k_uL":238,"creatinine_mg_dL":0.64,"alt_U_L":18},{"date":"2024-12-11","hemoglobin_g_dL":10.5,"wbc_k_uL":8.8,"platelets_k_uL":175,"creatinine_mg_dL":0.8,"alt_U_L":16},{"date":"2025-09-28","hemoglobin_g_dL":12.6,"wbc_k_uL":4.6,"platelets_k_uL":138,"creatinine_mg_dL":0.91,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":60,"sex":"female","bmi":29.6,"smoking_pack_years":29,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-10-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-44},"pfs_months":44.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.7,"censored":false},"longitudinal_labs":[{"date":"2021-08-23","hemoglobin_g_dL":13.0,"wbc_k_uL":8.8,"platelets_k_uL":418,"creatinine_mg_dL":1.16,"alt_U_L":47},{"date":"2022-03-30","hemoglobin_g_dL":12.9,"wbc_k_uL":4.5,"platelets_k_uL":340,"creatinine_mg_dL":1.54,"alt_U_L":34},{"date":"2025-07-27","hemoglobin_g_dL":12.6,"wbc_k_uL":4.5,"platelets_k_uL":161,"creatinine_mg_dL":0.83,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":58,"sex":"female","bmi":31.2,"smoking_pack_years":67,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-08-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-61},"pfs_months":38.28},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-11-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":60.3,"censored":false},"longitudinal_labs":[{"date":"2025-07-01","hemoglobin_g_dL":15.4,"wbc_k_uL":6.5,"platelets_k_uL":320,"creatinine_mg_dL":0.98,"alt_U_L":67},{"date":"2026-02-21","hemoglobin_g_dL":10.9,"wbc_k_uL":7.2,"platelets_k_uL":302,"creatinine_mg_dL":0.84,"alt_U_L":40},{"date":"2028-11-16","hemoglobin_g_dL":10.2,"wbc_k_uL":3.2,"platelets_k_uL":286,"creatinine_mg_dL":1.42,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":59,"sex":"female","bmi":31.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-59},"pfs_months":24.74},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.1,"censored":true},"longitudinal_labs":[{"date":"2021-01-03","hemoglobin_g_dL":13.5,"wbc_k_uL":10.8,"platelets_k_uL":270,"creatinine_mg_dL":0.97,"alt_U_L":18},{"date":"2021-07-23","hemoglobin_g_dL":12.8,"wbc_k_uL":7.1,"platelets_k_uL":206,"creatinine_mg_dL":1.06,"alt_U_L":34},{"date":"2023-04-14","hemoglobin_g_dL":12.1,"wbc_k_uL":5.1,"platelets_k_uL":244,"creatinine_mg_dL":1.61,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_562","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":56,"sex":"female","bmi":31.0,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-06-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-69},"pfs_months":17.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":false},"longitudinal_labs":[{"date":"2021-05-04","hemoglobin_g_dL":11.7,"wbc_k_uL":5.5,"platelets_k_uL":333,"creatinine_mg_dL":0.71,"alt_U_L":76},{"date":"2021-12-10","hemoglobin_g_dL":11.8,"wbc_k_uL":8.0,"platelets_k_uL":295,"creatinine_mg_dL":0.98,"alt_U_L":107},{"date":"2023-01-15","hemoglobin_g_dL":10.0,"wbc_k_uL":6.0,"platelets_k_uL":163,"creatinine_mg_dL":1.24,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":60,"sex":"female","bmi":28.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-54},"pfs_months":22.87},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":40.2,"censored":true},"longitudinal_labs":[{"date":"2023-12-24","hemoglobin_g_dL":11.8,"wbc_k_uL":6.4,"platelets_k_uL":322,"creatinine_mg_dL":0.9,"alt_U_L":15},{"date":"2024-07-23","hemoglobin_g_dL":11.5,"wbc_k_uL":8.7,"platelets_k_uL":315,"creatinine_mg_dL":0.81,"alt_U_L":42},{"date":"2025-12-25","hemoglobin_g_dL":10.6,"wbc_k_uL":5.2,"platelets_k_uL":211,"creatinine_mg_dL":1.89,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":82,"sex":"male","bmi":28.7,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-31},"pfs_months":14.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.5,"censored":false},"longitudinal_labs":[{"date":"2020-11-18","hemoglobin_g_dL":14.2,"wbc_k_uL":4.6,"platelets_k_uL":421,"creatinine_mg_dL":1.18,"alt_U_L":68},{"date":"2021-06-23","hemoglobin_g_dL":12.4,"wbc_k_uL":4.2,"platelets_k_uL":311,"creatinine_mg_dL":0.98,"alt_U_L":57},{"date":"2022-04-13","hemoglobin_g_dL":10.0,"wbc_k_uL":5.1,"platelets_k_uL":285,"creatinine_mg_dL":1.06,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":79,"sex":"male","bmi":20.0,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-10-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-58},"pfs_months":8.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":13.8,"censored":false},"longitudinal_labs":[{"date":"2025-10-05","hemoglobin_g_dL":15.4,"wbc_k_uL":6.4,"platelets_k_uL":290,"creatinine_mg_dL":1.09,"alt_U_L":80},{"date":"2026-04-25","hemoglobin_g_dL":11.4,"wbc_k_uL":4.2,"platelets_k_uL":159,"creatinine_mg_dL":1.55,"alt_U_L":40},{"date":"2026-07-05","hemoglobin_g_dL":9.6,"wbc_k_uL":5.4,"platelets_k_uL":184,"creatinine_mg_dL":1.2,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_566","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":71,"sex":"male","bmi":32.9,"smoking_pack_years":58,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-12-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-39},"pfs_months":18.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":23.1,"censored":false},"longitudinal_labs":[{"date":"2020-10-01","hemoglobin_g_dL":13.2,"wbc_k_uL":5.2,"platelets_k_uL":251,"creatinine_mg_dL":1.23,"alt_U_L":19},{"date":"2021-06-02","hemoglobin_g_dL":11.4,"wbc_k_uL":5.9,"platelets_k_uL":321,"creatinine_mg_dL":1.05,"alt_U_L":66},{"date":"2022-08-27","hemoglobin_g_dL":10.6,"wbc_k_uL":3.4,"platelets_k_uL":250,"creatinine_mg_dL":1.58,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":72,"sex":"female","bmi":19.2,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-04-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-57},"pfs_months":8.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":13.0,"censored":true},"longitudinal_labs":[{"date":"2023-03-12","hemoglobin_g_dL":15.2,"wbc_k_uL":4.6,"platelets_k_uL":307,"creatinine_mg_dL":1.03,"alt_U_L":10},{"date":"2023-10-24","hemoglobin_g_dL":10.7,"wbc_k_uL":4.0,"platelets_k_uL":307,"creatinine_mg_dL":1.45,"alt_U_L":110},{"date":"2024-02-27","hemoglobin_g_dL":10.8,"wbc_k_uL":4.5,"platelets_k_uL":270,"creatinine_mg_dL":0.99,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":59,"sex":"male","bmi":33.3,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-10-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-41},"pfs_months":15.54},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":24.6,"censored":false},"longitudinal_labs":[{"date":"2021-09-02","hemoglobin_g_dL":13.9,"wbc_k_uL":5.8,"platelets_k_uL":355,"creatinine_mg_dL":0.83,"alt_U_L":69},{"date":"2022-04-20","hemoglobin_g_dL":12.7,"wbc_k_uL":4.6,"platelets_k_uL":189,"creatinine_mg_dL":1.54,"alt_U_L":73},{"date":"2023-02-26","hemoglobin_g_dL":9.8,"wbc_k_uL":3.3,"platelets_k_uL":248,"creatinine_mg_dL":1.26,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":56,"sex":"female","bmi":30.4,"smoking_pack_years":39,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-01-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-84},"pfs_months":43.47},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":64.0,"censored":false},"longitudinal_labs":[{"date":"2020-12-26","hemoglobin_g_dL":13.1,"wbc_k_uL":8.8,"platelets_k_uL":180,"creatinine_mg_dL":0.63,"alt_U_L":34},{"date":"2021-07-09","hemoglobin_g_dL":12.5,"wbc_k_uL":7.2,"platelets_k_uL":125,"creatinine_mg_dL":1.19,"alt_U_L":95},{"date":"2024-08-30","hemoglobin_g_dL":11.7,"wbc_k_uL":6.5,"platelets_k_uL":186,"creatinine_mg_dL":1.94,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":61,"sex":"female","bmi":28.1,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-02-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-66},"pfs_months":11.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":15.1,"censored":false},"longitudinal_labs":[{"date":"2024-01-04","hemoglobin_g_dL":15.2,"wbc_k_uL":9.8,"platelets_k_uL":283,"creatinine_mg_dL":0.71,"alt_U_L":54},{"date":"2024-08-07","hemoglobin_g_dL":11.6,"wbc_k_uL":6.6,"platelets_k_uL":225,"creatinine_mg_dL":0.91,"alt_U_L":90},{"date":"2025-02-11","hemoglobin_g_dL":12.7,"wbc_k_uL":6.4,"platelets_k_uL":173,"creatinine_mg_dL":0.97,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":67,"sex":"female","bmi":35.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-81},"pfs_months":11.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.0,"censored":false},"longitudinal_labs":[{"date":"2023-08-22","hemoglobin_g_dL":15.0,"wbc_k_uL":8.3,"platelets_k_uL":440,"creatinine_mg_dL":1.18,"alt_U_L":30},{"date":"2024-04-22","hemoglobin_g_dL":10.3,"wbc_k_uL":7.8,"platelets_k_uL":166,"creatinine_mg_dL":0.94,"alt_U_L":21},{"date":"2024-10-23","hemoglobin_g_dL":10.4,"wbc_k_uL":6.2,"platelets_k_uL":227,"creatinine_mg_dL":1.8,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":52,"sex":"male","bmi":28.2,"smoking_pack_years":41,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-03-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-62},"pfs_months":39.82},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":69.5,"censored":false},"longitudinal_labs":[{"date":"2022-01-23","hemoglobin_g_dL":14.4,"wbc_k_uL":5.5,"platelets_k_uL":390,"creatinine_mg_dL":0.67,"alt_U_L":76},{"date":"2022-08-28","hemoglobin_g_dL":13.2,"wbc_k_uL":6.0,"platelets_k_uL":348,"creatinine_mg_dL":1.28,"alt_U_L":42},{"date":"2025-07-30","hemoglobin_g_dL":9.7,"wbc_k_uL":4.8,"platelets_k_uL":320,"creatinine_mg_dL":1.67,"alt_U_L":108}]}
{"patient_id":"ANODE_SYNTH_2025_573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":70,"sex":"male","bmi":28.8,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-09-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-55},"pfs_months":17.77},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-24","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.8,"censored":true},"longitudinal_labs":[{"date":"2024-08-23","hemoglobin_g_dL":11.7,"wbc_k_uL":6.3,"platelets_k_uL":246,"creatinine_mg_dL":1.24,"alt_U_L":21},{"date":"2025-03-18","hemoglobin_g_dL":12.6,"wbc_k_uL":5.6,"platelets_k_uL":149,"creatinine_mg_dL":1.04,"alt_U_L":54},{"date":"2026-03-24","hemoglobin_g_dL":12.3,"wbc_k_uL":3.3,"platelets_k_uL":243,"creatinine_mg_dL":1.7,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":70,"sex":"female","bmi":30.4,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-01-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-81},"pfs_months":39.62},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":71.1,"censored":false},"longitudinal_labs":[{"date":"2023-11-16","hemoglobin_g_dL":12.1,"wbc_k_uL":5.7,"platelets_k_uL":199,"creatinine_mg_dL":0.87,"alt_U_L":63},{"date":"2024-07-22","hemoglobin_g_dL":12.4,"wbc_k_uL":8.9,"platelets_k_uL":301,"creatinine_mg_dL":1.35,"alt_U_L":111},{"date":"2027-06-02","hemoglobin_g_dL":10.7,"wbc_k_uL":4.9,"platelets_k_uL":308,"creatinine_mg_dL":1.14,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":77,"sex":"female","bmi":33.9,"smoking_pack_years":35,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-12-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-75},"pfs_months":42.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":66.3,"censored":false},"longitudinal_labs":[{"date":"2021-11-08","hemoglobin_g_dL":14.1,"wbc_k_uL":9.8,"platelets_k_uL":300,"creatinine_mg_dL":0.88,"alt_U_L":15},{"date":"2022-06-11","hemoglobin_g_dL":10.5,"wbc_k_uL":5.1,"platelets_k_uL":204,"creatinine_mg_dL":1.39,"alt_U_L":96},{"date":"2025-07-29","hemoglobin_g_dL":10.3,"wbc_k_uL":7.6,"platelets_k_uL":338,"creatinine_mg_dL":1.58,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":82,"sex":"female","bmi":31.8,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-08-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-83},"pfs_months":8.38},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":false},"longitudinal_labs":[{"date":"2023-06-23","hemoglobin_g_dL":13.1,"wbc_k_uL":8.6,"platelets_k_uL":294,"creatinine_mg_dL":0.67,"alt_U_L":35},{"date":"2024-02-27","hemoglobin_g_dL":10.6,"wbc_k_uL":7.0,"platelets_k_uL":320,"creatinine_mg_dL":0.89,"alt_U_L":112},{"date":"2024-07-04","hemoglobin_g_dL":10.0,"wbc_k_uL":6.1,"platelets_k_uL":288,"creatinine_mg_dL":1.54,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_577","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":76,"sex":"male","bmi":20.6,"smoking_pack_years":75,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-03-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-73},"pfs_months":23.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.6,"censored":false},"longitudinal_labs":[{"date":"2024-01-26","hemoglobin_g_dL":14.8,"wbc_k_uL":7.3,"platelets_k_uL":165,"creatinine_mg_dL":0.64,"alt_U_L":67},{"date":"2024-09-12","hemoglobin_g_dL":10.5,"wbc_k_uL":8.2,"platelets_k_uL":188,"creatinine_mg_dL":0.87,"alt_U_L":81},{"date":"2026-03-03","hemoglobin_g_dL":12.3,"wbc_k_uL":6.7,"platelets_k_uL":302,"creatinine_mg_dL":1.87,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":77,"sex":"female","bmi":24.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-58},"pfs_months":16.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":38.9,"censored":false},"longitudinal_labs":[{"date":"2020-04-24","hemoglobin_g_dL":12.4,"wbc_k_uL":8.2,"platelets_k_uL":230,"creatinine_mg_dL":0.62,"alt_U_L":73},{"date":"2020-12-05","hemoglobin_g_dL":11.4,"wbc_k_uL":8.4,"platelets_k_uL":253,"creatinine_mg_dL":1.17,"alt_U_L":24},{"date":"2021-11-03","hemoglobin_g_dL":10.6,"wbc_k_uL":3.6,"platelets_k_uL":134,"creatinine_mg_dL":0.98,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":61,"sex":"female","bmi":34.3,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-73},"pfs_months":6.14},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":10.1,"censored":false},"longitudinal_labs":[{"date":"2021-09-05","hemoglobin_g_dL":14.5,"wbc_k_uL":9.7,"platelets_k_uL":195,"creatinine_mg_dL":0.91,"alt_U_L":77},{"date":"2022-03-24","hemoglobin_g_dL":13.3,"wbc_k_uL":5.7,"platelets_k_uL":235,"creatinine_mg_dL":0.75,"alt_U_L":39},{"date":"2022-05-14","hemoglobin_g_dL":10.7,"wbc_k_uL":4.0,"platelets_k_uL":279,"creatinine_mg_dL":1.9,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":61,"sex":"male","bmi":26.1,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-05-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-49},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-09-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":10.9,"censored":false},"longitudinal_labs":[{"date":"2020-03-14","hemoglobin_g_dL":12.0,"wbc_k_uL":9.4,"platelets_k_uL":343,"creatinine_mg_dL":0.78,"alt_U_L":69},{"date":"2020-11-19","hemoglobin_g_dL":11.3,"wbc_k_uL":8.8,"platelets_k_uL":329,"creatinine_mg_dL":1.16,"alt_U_L":49},{"date":"2020-09-02","hemoglobin_g_dL":10.1,"wbc_k_uL":5.5,"platelets_k_uL":101,"creatinine_mg_dL":1.55,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":52,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-02-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-56},"pfs_months":19.71},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":false},"longitudinal_labs":[{"date":"2020-02-03","hemoglobin_g_dL":14.3,"wbc_k_uL":4.9,"platelets_k_uL":241,"creatinine_mg_dL":0.95,"alt_U_L":69},{"date":"2020-08-18","hemoglobin_g_dL":13.8,"wbc_k_uL":8.1,"platelets_k_uL":314,"creatinine_mg_dL":1.42,"alt_U_L":21},{"date":"2021-11-24","hemoglobin_g_dL":12.3,"wbc_k_uL":3.1,"platelets_k_uL":206,"creatinine_mg_dL":1.34,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_582","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":55,"sex":"female","bmi":25.6,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-05-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-43},"pfs_months":20.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.3,"censored":true},"longitudinal_labs":[{"date":"2025-05-03","hemoglobin_g_dL":14.1,"wbc_k_uL":7.0,"platelets_k_uL":231,"creatinine_mg_dL":1.24,"alt_U_L":64},{"date":"2025-11-24","hemoglobin_g_dL":13.0,"wbc_k_uL":8.5,"platelets_k_uL":215,"creatinine_mg_dL":1.12,"alt_U_L":69},{"date":"2027-03-16","hemoglobin_g_dL":10.6,"wbc_k_uL":3.9,"platelets_k_uL":153,"creatinine_mg_dL":0.92,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":84,"sex":"female","bmi":25.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-30},"pfs_months":10.94},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-04-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":26.5,"censored":false},"longitudinal_labs":[{"date":"2020-03-09","hemoglobin_g_dL":13.1,"wbc_k_uL":4.7,"platelets_k_uL":337,"creatinine_mg_dL":0.61,"alt_U_L":64},{"date":"2020-10-15","hemoglobin_g_dL":10.2,"wbc_k_uL":4.4,"platelets_k_uL":351,"creatinine_mg_dL":0.95,"alt_U_L":50},{"date":"2021-04-12","hemoglobin_g_dL":12.1,"wbc_k_uL":6.7,"platelets_k_uL":180,"creatinine_mg_dL":0.86,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":84,"sex":"female","bmi":22.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-79},"pfs_months":19.91},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":false},"longitudinal_labs":[{"date":"2020-12-01","hemoglobin_g_dL":11.8,"wbc_k_uL":9.3,"platelets_k_uL":430,"creatinine_mg_dL":0.88,"alt_U_L":66},{"date":"2021-07-31","hemoglobin_g_dL":13.5,"wbc_k_uL":5.3,"platelets_k_uL":264,"creatinine_mg_dL":1.26,"alt_U_L":64},{"date":"2022-10-05","hemoglobin_g_dL":10.4,"wbc_k_uL":4.9,"platelets_k_uL":179,"creatinine_mg_dL":1.74,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":66,"sex":"female","bmi":33.6,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2020-02-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-79},"pfs_months":11.83},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-02-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.7,"censored":false},"longitudinal_labs":[{"date":"2020-01-18","hemoglobin_g_dL":14.5,"wbc_k_uL":7.5,"platelets_k_uL":195,"creatinine_mg_dL":1.05,"alt_U_L":28},{"date":"2020-08-09","hemoglobin_g_dL":11.3,"wbc_k_uL":5.7,"platelets_k_uL":247,"creatinine_mg_dL":0.96,"alt_U_L":21},{"date":"2021-02-26","hemoglobin_g_dL":11.2,"wbc_k_uL":5.7,"platelets_k_uL":182,"creatinine_mg_dL":1.78,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":61,"sex":"female","bmi":37.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-74},"pfs_months":18.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.3,"censored":false},"longitudinal_labs":[{"date":"2020-10-01","hemoglobin_g_dL":11.7,"wbc_k_uL":9.6,"platelets_k_uL":220,"creatinine_mg_dL":0.93,"alt_U_L":21},{"date":"2021-05-26","hemoglobin_g_dL":12.0,"wbc_k_uL":5.8,"platelets_k_uL":331,"creatinine_mg_dL":1.2,"alt_U_L":20},{"date":"2022-07-29","hemoglobin_g_dL":11.2,"wbc_k_uL":4.5,"platelets_k_uL":180,"creatinine_mg_dL":0.98,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":67,"sex":"female","bmi":19.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-65},"pfs_months":27.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.3,"censored":true},"longitudinal_labs":[{"date":"2022-08-22","hemoglobin_g_dL":13.4,"wbc_k_uL":9.0,"platelets_k_uL":287,"creatinine_mg_dL":1.3,"alt_U_L":75},{"date":"2023-04-11","hemoglobin_g_dL":12.9,"wbc_k_uL":7.5,"platelets_k_uL":216,"creatinine_mg_dL":1.58,"alt_U_L":45},{"date":"2025-02-24","hemoglobin_g_dL":12.8,"wbc_k_uL":4.1,"platelets_k_uL":148,"creatinine_mg_dL":1.43,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_588","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":81,"sex":"male","bmi":26.8,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-10-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-42},"pfs_months":23.16},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":43.9,"censored":false},"longitudinal_labs":[{"date":"2021-09-01","hemoglobin_g_dL":13.8,"wbc_k_uL":7.5,"platelets_k_uL":292,"creatinine_mg_dL":1.12,"alt_U_L":43},{"date":"2022-04-03","hemoglobin_g_dL":13.0,"wbc_k_uL":6.4,"platelets_k_uL":241,"creatinine_mg_dL":1.31,"alt_U_L":59},{"date":"2023-10-23","hemoglobin_g_dL":11.6,"wbc_k_uL":6.0,"platelets_k_uL":151,"creatinine_mg_dL":1.38,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":74,"sex":"male","bmi":35.2,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-12-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-31},"pfs_months":9.72},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.6,"censored":false},"longitudinal_labs":[{"date":"2024-11-04","hemoglobin_g_dL":13.1,"wbc_k_uL":8.0,"platelets_k_uL":289,"creatinine_mg_dL":0.88,"alt_U_L":70},{"date":"2025-06-15","hemoglobin_g_dL":10.1,"wbc_k_uL":5.9,"platelets_k_uL":231,"creatinine_mg_dL":1.01,"alt_U_L":30},{"date":"2025-12-08","hemoglobin_g_dL":12.6,"wbc_k_uL":5.4,"platelets_k_uL":200,"creatinine_mg_dL":1.3,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":71,"sex":"female","bmi":37.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-61},"pfs_months":31.21},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.4,"censored":true},"longitudinal_labs":[{"date":"2025-08-23","hemoglobin_g_dL":14.5,"wbc_k_uL":9.8,"platelets_k_uL":270,"creatinine_mg_dL":0.97,"alt_U_L":78},{"date":"2026-03-11","hemoglobin_g_dL":12.9,"wbc_k_uL":4.1,"platelets_k_uL":368,"creatinine_mg_dL":1.08,"alt_U_L":31},{"date":"2028-06-14","hemoglobin_g_dL":12.5,"wbc_k_uL":7.4,"platelets_k_uL":175,"creatinine_mg_dL":1.73,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_591","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":52,"sex":"female","bmi":27.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-30},"pfs_months":23.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.3,"censored":true},"longitudinal_labs":[{"date":"2022-02-19","hemoglobin_g_dL":13.4,"wbc_k_uL":9.2,"platelets_k_uL":308,"creatinine_mg_dL":0.75,"alt_U_L":14},{"date":"2022-10-10","hemoglobin_g_dL":12.4,"wbc_k_uL":6.2,"platelets_k_uL":230,"creatinine_mg_dL":0.9,"alt_U_L":92},{"date":"2024-04-22","hemoglobin_g_dL":11.1,"wbc_k_uL":3.6,"platelets_k_uL":110,"creatinine_mg_dL":0.82,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":79,"sex":"female","bmi":22.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-50},"pfs_months":20.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":false},"longitudinal_labs":[{"date":"2020-10-04","hemoglobin_g_dL":13.5,"wbc_k_uL":5.4,"platelets_k_uL":448,"creatinine_mg_dL":1.11,"alt_U_L":68},{"date":"2021-05-09","hemoglobin_g_dL":10.4,"wbc_k_uL":7.9,"platelets_k_uL":367,"creatinine_mg_dL":0.92,"alt_U_L":45},{"date":"2022-08-18","hemoglobin_g_dL":10.2,"wbc_k_uL":7.1,"platelets_k_uL":309,"creatinine_mg_dL":1.77,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_593","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":88,"sex":"female","bmi":23.2,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-10-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-44},"pfs_months":36.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":57.3,"censored":false},"longitudinal_labs":[{"date":"2022-09-10","hemoglobin_g_dL":15.3,"wbc_k_uL":6.8,"platelets_k_uL":311,"creatinine_mg_dL":0.67,"alt_U_L":63},{"date":"2023-04-13","hemoglobin_g_dL":12.2,"wbc_k_uL":5.5,"platelets_k_uL":369,"creatinine_mg_dL":1.53,"alt_U_L":66},{"date":"2025-11-02","hemoglobin_g_dL":9.8,"wbc_k_uL":4.5,"platelets_k_uL":157,"creatinine_mg_dL":0.91,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_594","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":86,"sex":"female","bmi":34.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-49},"pfs_months":26.94},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.2,"censored":false},"longitudinal_labs":[{"date":"2020-04-22","hemoglobin_g_dL":12.9,"wbc_k_uL":6.2,"platelets_k_uL":255,"creatinine_mg_dL":0.65,"alt_U_L":49},{"date":"2020-11-16","hemoglobin_g_dL":10.3,"wbc_k_uL":5.5,"platelets_k_uL":135,"creatinine_mg_dL":0.95,"alt_U_L":70},{"date":"2022-08-26","hemoglobin_g_dL":11.4,"wbc_k_uL":7.3,"platelets_k_uL":288,"creatinine_mg_dL":0.94,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":70,"sex":"male","bmi":26.2,"smoking_pack_years":59,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-10-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-83},"pfs_months":37.82},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.4,"censored":false},"longitudinal_labs":[{"date":"2023-09-12","hemoglobin_g_dL":14.3,"wbc_k_uL":10.0,"platelets_k_uL":212,"creatinine_mg_dL":0.68,"alt_U_L":24},{"date":"2024-04-08","hemoglobin_g_dL":12.5,"wbc_k_uL":6.8,"platelets_k_uL":123,"creatinine_mg_dL":1.21,"alt_U_L":112},{"date":"2027-02-01","hemoglobin_g_dL":12.9,"wbc_k_uL":7.1,"platelets_k_uL":237,"creatinine_mg_dL":1.48,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":64,"sex":"female","bmi":26.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-72},"pfs_months":16.1},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.4,"censored":false},"longitudinal_labs":[{"date":"2025-04-02","hemoglobin_g_dL":14.8,"wbc_k_uL":8.3,"platelets_k_uL":388,"creatinine_mg_dL":0.72,"alt_U_L":21},{"date":"2025-11-26","hemoglobin_g_dL":13.8,"wbc_k_uL":8.6,"platelets_k_uL":179,"creatinine_mg_dL":1.29,"alt_U_L":30},{"date":"2026-10-31","hemoglobin_g_dL":9.8,"wbc_k_uL":5.3,"platelets_k_uL":159,"creatinine_mg_dL":0.99,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":82,"sex":"female","bmi":27.7,"smoking_pack_years":67,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-09-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-83},"pfs_months":39.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":64.2,"censored":false},"longitudinal_labs":[{"date":"2022-07-27","hemoglobin_g_dL":12.9,"wbc_k_uL":10.3,"platelets_k_uL":284,"creatinine_mg_dL":0.96,"alt_U_L":23},{"date":"2023-03-07","hemoglobin_g_dL":10.3,"wbc_k_uL":4.0,"platelets_k_uL":373,"creatinine_mg_dL":0.97,"alt_U_L":28},{"date":"2026-01-23","hemoglobin_g_dL":12.7,"wbc_k_uL":5.5,"platelets_k_uL":164,"creatinine_mg_dL":0.86,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_598","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":66,"sex":"female","bmi":19.7,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2023-08-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-85},"pfs_months":21.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.5,"censored":false},"longitudinal_labs":[{"date":"2023-06-26","hemoglobin_g_dL":15.2,"wbc_k_uL":8.9,"platelets_k_uL":200,"creatinine_mg_dL":0.67,"alt_U_L":20},{"date":"2024-02-16","hemoglobin_g_dL":10.4,"wbc_k_uL":4.8,"platelets_k_uL":272,"creatinine_mg_dL":0.93,"alt_U_L":41},{"date":"2025-07-08","hemoglobin_g_dL":11.3,"wbc_k_uL":4.1,"platelets_k_uL":262,"creatinine_mg_dL":1.19,"alt_U_L":56}]}
{"patient_id":"ANODE_SYNTH_2025_599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":79,"sex":"female","bmi":26.1,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-84},"pfs_months":11.89},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.6,"censored":true},"longitudinal_labs":[{"date":"2025-07-13","hemoglobin_g_dL":12.9,"wbc_k_uL":9.7,"platelets_k_uL":413,"creatinine_mg_dL":1.08,"alt_U_L":75},{"date":"2026-02-20","hemoglobin_g_dL":12.1,"wbc_k_uL":8.3,"platelets_k_uL":244,"creatinine_mg_dL":1.09,"alt_U_L":58},{"date":"2026-10-09","hemoglobin_g_dL":10.8,"wbc_k_uL":3.4,"platelets_k_uL":273,"creatinine_mg_dL":0.81,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":60,"sex":"female","bmi":23.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-57},"pfs_months":23.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.9,"censored":false},"longitudinal_labs":[{"date":"2023-05-13","hemoglobin_g_dL":14.0,"wbc_k_uL":8.1,"platelets_k_uL":273,"creatinine_mg_dL":0.78,"alt_U_L":11},{"date":"2024-01-18","hemoglobin_g_dL":10.6,"wbc_k_uL":6.0,"platelets_k_uL":282,"creatinine_mg_dL":1.03,"alt_U_L":93},{"date":"2025-08-25","hemoglobin_g_dL":9.5,"wbc_k_uL":6.8,"platelets_k_uL":243,"creatinine_mg_dL":1.98,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":52,"sex":"male","bmi":26.2,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-01-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-49},"pfs_months":30.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":60.5,"censored":false},"longitudinal_labs":[{"date":"2023-11-24","hemoglobin_g_dL":13.6,"wbc_k_uL":8.8,"platelets_k_uL":365,"creatinine_mg_dL":1.27,"alt_U_L":52},{"date":"2024-07-11","hemoglobin_g_dL":13.2,"wbc_k_uL":5.3,"platelets_k_uL":314,"creatinine_mg_dL":1.28,"alt_U_L":68},{"date":"2026-09-25","hemoglobin_g_dL":10.8,"wbc_k_uL":3.7,"platelets_k_uL":268,"creatinine_mg_dL":1.75,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":49,"sex":"female","bmi":31.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-05-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-40},"pfs_months":19.45},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2023-03-15","hemoglobin_g_dL":12.8,"wbc_k_uL":5.6,"platelets_k_uL":237,"creatinine_mg_dL":1.11,"alt_U_L":44},{"date":"2023-11-13","hemoglobin_g_dL":11.0,"wbc_k_uL":4.9,"platelets_k_uL":213,"creatinine_mg_dL":1.15,"alt_U_L":47},{"date":"2025-01-18","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":230,"creatinine_mg_dL":0.93,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":69,"sex":"female","bmi":35.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-40},"pfs_months":17.58},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":false},"longitudinal_labs":[{"date":"2021-08-03","hemoglobin_g_dL":14.2,"wbc_k_uL":4.5,"platelets_k_uL":347,"creatinine_mg_dL":0.99,"alt_U_L":20},{"date":"2022-03-25","hemoglobin_g_dL":12.3,"wbc_k_uL":5.7,"platelets_k_uL":376,"creatinine_mg_dL":0.91,"alt_U_L":98},{"date":"2023-04-24","hemoglobin_g_dL":10.6,"wbc_k_uL":6.6,"platelets_k_uL":162,"creatinine_mg_dL":1.36,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":68,"sex":"male","bmi":32.4,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-67},"pfs_months":30.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.1,"censored":false},"longitudinal_labs":[{"date":"2020-01-23","hemoglobin_g_dL":12.2,"wbc_k_uL":9.6,"platelets_k_uL":308,"creatinine_mg_dL":0.8,"alt_U_L":71},{"date":"2020-09-04","hemoglobin_g_dL":12.8,"wbc_k_uL":6.6,"platelets_k_uL":222,"creatinine_mg_dL":0.72,"alt_U_L":62},{"date":"2022-10-20","hemoglobin_g_dL":10.5,"wbc_k_uL":5.8,"platelets_k_uL":336,"creatinine_mg_dL":1.96,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":83,"sex":"female","bmi":31.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-12-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-49},"pfs_months":10.94},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.6,"censored":false},"longitudinal_labs":[{"date":"2024-10-12","hemoglobin_g_dL":12.7,"wbc_k_uL":9.5,"platelets_k_uL":437,"creatinine_mg_dL":0.8,"alt_U_L":14},{"date":"2025-06-12","hemoglobin_g_dL":11.6,"wbc_k_uL":8.4,"platelets_k_uL":263,"creatinine_mg_dL":1.25,"alt_U_L":99},{"date":"2025-12-19","hemoglobin_g_dL":9.8,"wbc_k_uL":4.9,"platelets_k_uL":166,"creatinine_mg_dL":1.55,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_606","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":83,"sex":"male","bmi":33.0,"smoking_pack_years":28,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-05-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-70},"pfs_months":31.77},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":46.7,"censored":false},"longitudinal_labs":[{"date":"2020-03-22","hemoglobin_g_dL":13.4,"wbc_k_uL":4.7,"platelets_k_uL":233,"creatinine_mg_dL":1.25,"alt_U_L":34},{"date":"2020-11-05","hemoglobin_g_dL":10.1,"wbc_k_uL":7.2,"platelets_k_uL":142,"creatinine_mg_dL":1.34,"alt_U_L":52},{"date":"2023-01-21","hemoglobin_g_dL":10.9,"wbc_k_uL":4.4,"platelets_k_uL":282,"creatinine_mg_dL":1.23,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":53,"sex":"female","bmi":24.8,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-11-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-44},"pfs_months":8.38},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":12.7,"censored":true},"longitudinal_labs":[{"date":"2024-09-04","hemoglobin_g_dL":13.3,"wbc_k_uL":6.8,"platelets_k_uL":305,"creatinine_mg_dL":1.12,"alt_U_L":64},{"date":"2025-05-10","hemoglobin_g_dL":10.6,"wbc_k_uL":8.2,"platelets_k_uL":134,"creatinine_mg_dL":1.11,"alt_U_L":86},{"date":"2025-08-22","hemoglobin_g_dL":10.8,"wbc_k_uL":4.2,"platelets_k_uL":291,"creatinine_mg_dL":1.33,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_608","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.4,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":58,"sex":"male","bmi":34.2,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-11-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-70},"pfs_months":18.6},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.5,"censored":false},"longitudinal_labs":[{"date":"2025-09-12","hemoglobin_g_dL":12.6,"wbc_k_uL":4.6,"platelets_k_uL":386,"creatinine_mg_dL":0.84,"alt_U_L":66},{"date":"2026-05-13","hemoglobin_g_dL":13.0,"wbc_k_uL":4.1,"platelets_k_uL":334,"creatinine_mg_dL":1.52,"alt_U_L":43},{"date":"2027-07-29","hemoglobin_g_dL":12.2,"wbc_k_uL":5.9,"platelets_k_uL":164,"creatinine_mg_dL":1.23,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_609","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":73,"sex":"male","bmi":21.8,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-11-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-54},"pfs_months":22.57},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.0,"censored":false},"longitudinal_labs":[{"date":"2021-10-20","hemoglobin_g_dL":13.2,"wbc_k_uL":5.7,"platelets_k_uL":407,"creatinine_mg_dL":1.22,"alt_U_L":14},{"date":"2022-05-15","hemoglobin_g_dL":10.4,"wbc_k_uL":4.3,"platelets_k_uL":219,"creatinine_mg_dL":1.53,"alt_U_L":75},{"date":"2023-10-26","hemoglobin_g_dL":12.2,"wbc_k_uL":4.4,"platelets_k_uL":199,"creatinine_mg_dL":1.17,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_610","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":61,"sex":"female","bmi":37.0,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-11-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-82},"pfs_months":23.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.5,"censored":false},"longitudinal_labs":[{"date":"2024-09-23","hemoglobin_g_dL":13.6,"wbc_k_uL":9.7,"platelets_k_uL":255,"creatinine_mg_dL":1.05,"alt_U_L":71},{"date":"2025-05-15","hemoglobin_g_dL":12.6,"wbc_k_uL":6.7,"platelets_k_uL":332,"creatinine_mg_dL":0.97,"alt_U_L":120},{"date":"2026-11-20","hemoglobin_g_dL":11.5,"wbc_k_uL":3.1,"platelets_k_uL":104,"creatinine_mg_dL":1.64,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":60,"sex":"female","bmi":28.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-38},"pfs_months":20.76},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":40.3,"censored":false},"longitudinal_labs":[{"date":"2021-05-14","hemoglobin_g_dL":12.8,"wbc_k_uL":9.6,"platelets_k_uL":323,"creatinine_mg_dL":0.68,"alt_U_L":76},{"date":"2021-12-10","hemoglobin_g_dL":14.0,"wbc_k_uL":6.7,"platelets_k_uL":162,"creatinine_mg_dL":1.2,"alt_U_L":49},{"date":"2023-04-12","hemoglobin_g_dL":11.8,"wbc_k_uL":3.2,"platelets_k_uL":274,"creatinine_mg_dL":1.12,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":85,"sex":"female","bmi":25.1,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-71},"pfs_months":3.35},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":7.3,"censored":true},"longitudinal_labs":[{"date":"2023-06-17","hemoglobin_g_dL":11.8,"wbc_k_uL":4.9,"platelets_k_uL":187,"creatinine_mg_dL":0.61,"alt_U_L":66},{"date":"2024-01-08","hemoglobin_g_dL":11.8,"wbc_k_uL":6.1,"platelets_k_uL":331,"creatinine_mg_dL":0.89,"alt_U_L":29},{"date":"2023-11-12","hemoglobin_g_dL":11.5,"wbc_k_uL":4.0,"platelets_k_uL":222,"creatinine_mg_dL":1.15,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":48,"sex":"female","bmi":29.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-65},"pfs_months":30.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.1,"censored":false},"longitudinal_labs":[{"date":"2020-05-17","hemoglobin_g_dL":12.1,"wbc_k_uL":10.9,"platelets_k_uL":299,"creatinine_mg_dL":1.22,"alt_U_L":19},{"date":"2020-12-13","hemoglobin_g_dL":11.2,"wbc_k_uL":7.5,"platelets_k_uL":347,"creatinine_mg_dL":0.82,"alt_U_L":33},{"date":"2023-02-04","hemoglobin_g_dL":12.8,"wbc_k_uL":4.4,"platelets_k_uL":160,"creatinine_mg_dL":1.61,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":86,"sex":"female","bmi":31.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-01-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-80},"pfs_months":20.6},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":28.7,"censored":true},"longitudinal_labs":[{"date":"2021-11-19","hemoglobin_g_dL":12.0,"wbc_k_uL":7.2,"platelets_k_uL":188,"creatinine_mg_dL":0.89,"alt_U_L":30},{"date":"2022-07-05","hemoglobin_g_dL":11.2,"wbc_k_uL":8.3,"platelets_k_uL":148,"creatinine_mg_dL":1.34,"alt_U_L":91},{"date":"2023-10-27","hemoglobin_g_dL":11.3,"wbc_k_uL":7.6,"platelets_k_uL":300,"creatinine_mg_dL":1.98,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":80,"sex":"female","bmi":20.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-67},"pfs_months":27.04},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":46.2,"censored":false},"longitudinal_labs":[{"date":"2022-12-01","hemoglobin_g_dL":14.0,"wbc_k_uL":7.3,"platelets_k_uL":393,"creatinine_mg_dL":1.0,"alt_U_L":19},{"date":"2023-06-15","hemoglobin_g_dL":13.6,"wbc_k_uL":6.0,"platelets_k_uL":348,"creatinine_mg_dL":1.27,"alt_U_L":74},{"date":"2025-04-19","hemoglobin_g_dL":12.3,"wbc_k_uL":5.8,"platelets_k_uL":159,"creatinine_mg_dL":1.42,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":80,"sex":"female","bmi":25.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-48},"pfs_months":19.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.0,"censored":false},"longitudinal_labs":[{"date":"2023-06-27","hemoglobin_g_dL":13.7,"wbc_k_uL":5.3,"platelets_k_uL":316,"creatinine_mg_dL":1.06,"alt_U_L":52},{"date":"2024-02-04","hemoglobin_g_dL":13.0,"wbc_k_uL":7.1,"platelets_k_uL":282,"creatinine_mg_dL":0.7,"alt_U_L":15},{"date":"2025-03-30","hemoglobin_g_dL":11.4,"wbc_k_uL":3.8,"platelets_k_uL":125,"creatinine_mg_dL":1.74,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":69,"sex":"female","bmi":22.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-77},"pfs_months":22.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.2,"censored":false},"longitudinal_labs":[{"date":"2024-05-19","hemoglobin_g_dL":13.3,"wbc_k_uL":5.3,"platelets_k_uL":208,"creatinine_mg_dL":0.64,"alt_U_L":10},{"date":"2024-12-30","hemoglobin_g_dL":11.1,"wbc_k_uL":4.8,"platelets_k_uL":151,"creatinine_mg_dL":1.19,"alt_U_L":16},{"date":"2026-05-20","hemoglobin_g_dL":11.1,"wbc_k_uL":7.0,"platelets_k_uL":271,"creatinine_mg_dL":1.15,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":80,"sex":"male","bmi":26.3,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-59},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-11-02","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":10.1,"censored":false},"longitudinal_labs":[{"date":"2020-06-13","hemoglobin_g_dL":13.2,"wbc_k_uL":8.4,"platelets_k_uL":272,"creatinine_mg_dL":1.05,"alt_U_L":54},{"date":"2021-01-19","hemoglobin_g_dL":10.2,"wbc_k_uL":5.6,"platelets_k_uL":275,"creatinine_mg_dL":0.8,"alt_U_L":35},{"date":"2020-11-02","hemoglobin_g_dL":10.2,"wbc_k_uL":6.8,"platelets_k_uL":200,"creatinine_mg_dL":1.72,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":58,"sex":"female","bmi":29.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-37},"pfs_months":11.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":18.2,"censored":false},"longitudinal_labs":[{"date":"2024-06-09","hemoglobin_g_dL":12.1,"wbc_k_uL":10.0,"platelets_k_uL":315,"creatinine_mg_dL":0.81,"alt_U_L":78},{"date":"2025-02-06","hemoglobin_g_dL":11.0,"wbc_k_uL":8.2,"platelets_k_uL":178,"creatinine_mg_dL":1.23,"alt_U_L":15},{"date":"2025-08-27","hemoglobin_g_dL":12.7,"wbc_k_uL":4.9,"platelets_k_uL":332,"creatinine_mg_dL":1.43,"alt_U_L":197}]}
{"patient_id":"ANODE_SYNTH_2025_620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":49,"sex":"male","bmi":23.6,"smoking_pack_years":11,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-04-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-80},"pfs_months":8.15},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.3,"censored":false},"longitudinal_labs":[{"date":"2021-03-22","hemoglobin_g_dL":15.1,"wbc_k_uL":7.2,"platelets_k_uL":405,"creatinine_mg_dL":0.85,"alt_U_L":15},{"date":"2021-10-18","hemoglobin_g_dL":11.8,"wbc_k_uL":7.8,"platelets_k_uL":134,"creatinine_mg_dL":1.31,"alt_U_L":21},{"date":"2022-02-22","hemoglobin_g_dL":12.9,"wbc_k_uL":6.0,"platelets_k_uL":271,"creatinine_mg_dL":1.38,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_621","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":66,"sex":"female","bmi":19.1,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-05-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-45},"pfs_months":21.65},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":false},"longitudinal_labs":[{"date":"2021-04-11","hemoglobin_g_dL":12.4,"wbc_k_uL":8.1,"platelets_k_uL":441,"creatinine_mg_dL":1.05,"alt_U_L":76},{"date":"2021-11-10","hemoglobin_g_dL":11.4,"wbc_k_uL":4.7,"platelets_k_uL":151,"creatinine_mg_dL":1.12,"alt_U_L":100},{"date":"2023-03-17","hemoglobin_g_dL":10.9,"wbc_k_uL":7.3,"platelets_k_uL":217,"creatinine_mg_dL":1.64,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_622","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":75,"sex":"female","bmi":37.8,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-05-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-42},"pfs_months":23.23},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.3,"censored":true},"longitudinal_labs":[{"date":"2021-03-27","hemoglobin_g_dL":15.1,"wbc_k_uL":7.5,"platelets_k_uL":215,"creatinine_mg_dL":0.66,"alt_U_L":18},{"date":"2021-10-31","hemoglobin_g_dL":12.3,"wbc_k_uL":4.5,"platelets_k_uL":152,"creatinine_mg_dL":1.23,"alt_U_L":45},{"date":"2023-05-15","hemoglobin_g_dL":12.3,"wbc_k_uL":5.3,"platelets_k_uL":152,"creatinine_mg_dL":1.47,"alt_U_L":197}]}
{"patient_id":"ANODE_SYNTH_2025_623","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":60,"sex":"male","bmi":37.1,"smoking_pack_years":20,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-07-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-36},"pfs_months":30.39},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":56.3,"censored":true},"longitudinal_labs":[{"date":"2023-07-02","hemoglobin_g_dL":15.5,"wbc_k_uL":8.1,"platelets_k_uL":202,"creatinine_mg_dL":0.85,"alt_U_L":67},{"date":"2024-01-17","hemoglobin_g_dL":13.3,"wbc_k_uL":8.0,"platelets_k_uL":291,"creatinine_mg_dL":0.76,"alt_U_L":63},{"date":"2026-03-20","hemoglobin_g_dL":9.7,"wbc_k_uL":7.9,"platelets_k_uL":101,"creatinine_mg_dL":1.28,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":67,"sex":"female","bmi":21.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-83},"pfs_months":15.34},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.3,"censored":false},"longitudinal_labs":[{"date":"2021-10-01","hemoglobin_g_dL":13.1,"wbc_k_uL":7.5,"platelets_k_uL":414,"creatinine_mg_dL":1.0,"alt_U_L":48},{"date":"2022-05-13","hemoglobin_g_dL":13.2,"wbc_k_uL":7.4,"platelets_k_uL":313,"creatinine_mg_dL":1.11,"alt_U_L":111},{"date":"2023-04-01","hemoglobin_g_dL":11.6,"wbc_k_uL":4.2,"platelets_k_uL":243,"creatinine_mg_dL":1.24,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":82,"sex":"female","bmi":20.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-57},"pfs_months":21.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.0,"censored":false},"longitudinal_labs":[{"date":"2021-04-10","hemoglobin_g_dL":12.2,"wbc_k_uL":5.6,"platelets_k_uL":401,"creatinine_mg_dL":0.67,"alt_U_L":47},{"date":"2021-11-08","hemoglobin_g_dL":11.6,"wbc_k_uL":4.8,"platelets_k_uL":160,"creatinine_mg_dL":1.2,"alt_U_L":57},{"date":"2023-03-15","hemoglobin_g_dL":10.4,"wbc_k_uL":5.3,"platelets_k_uL":254,"creatinine_mg_dL":1.46,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":84,"sex":"female","bmi":31.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-75},"pfs_months":16.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-10","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.6,"censored":true},"longitudinal_labs":[{"date":"2022-11-22","hemoglobin_g_dL":13.4,"wbc_k_uL":5.5,"platelets_k_uL":433,"creatinine_mg_dL":1.25,"alt_U_L":57},{"date":"2023-06-28","hemoglobin_g_dL":10.0,"wbc_k_uL":3.9,"platelets_k_uL":371,"creatinine_mg_dL":0.77,"alt_U_L":118},{"date":"2024-06-10","hemoglobin_g_dL":12.0,"wbc_k_uL":4.1,"platelets_k_uL":285,"creatinine_mg_dL":1.63,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":75,"sex":"male","bmi":23.0,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-04-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-51},"pfs_months":43.07},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":70.5,"censored":false},"longitudinal_labs":[{"date":"2025-03-10","hemoglobin_g_dL":11.9,"wbc_k_uL":7.3,"platelets_k_uL":383,"creatinine_mg_dL":0.68,"alt_U_L":22},{"date":"2025-10-25","hemoglobin_g_dL":13.4,"wbc_k_uL":7.5,"platelets_k_uL":176,"creatinine_mg_dL":0.73,"alt_U_L":52},{"date":"2029-01-12","hemoglobin_g_dL":10.9,"wbc_k_uL":4.9,"platelets_k_uL":241,"creatinine_mg_dL":1.65,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":64,"sex":"male","bmi":33.0,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-07-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-58},"pfs_months":40.38},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-12-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":67.7,"censored":false},"longitudinal_labs":[{"date":"2025-05-03","hemoglobin_g_dL":13.0,"wbc_k_uL":6.9,"platelets_k_uL":413,"creatinine_mg_dL":0.62,"alt_U_L":77},{"date":"2026-01-07","hemoglobin_g_dL":10.8,"wbc_k_uL":7.3,"platelets_k_uL":320,"creatinine_mg_dL":1.07,"alt_U_L":62},{"date":"2028-12-23","hemoglobin_g_dL":11.4,"wbc_k_uL":6.7,"platelets_k_uL":280,"creatinine_mg_dL":0.89,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":52,"sex":"male","bmi":28.7,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-33},"pfs_months":12.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":17.1,"censored":true},"longitudinal_labs":[{"date":"2025-06-15","hemoglobin_g_dL":13.1,"wbc_k_uL":9.8,"platelets_k_uL":154,"creatinine_mg_dL":1.2,"alt_U_L":73},{"date":"2026-01-10","hemoglobin_g_dL":12.1,"wbc_k_uL":6.4,"platelets_k_uL":127,"creatinine_mg_dL":1.09,"alt_U_L":48},{"date":"2026-09-14","hemoglobin_g_dL":11.3,"wbc_k_uL":7.6,"platelets_k_uL":201,"creatinine_mg_dL":0.82,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_630","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":80,"sex":"male","bmi":26.4,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-06-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-36},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":8.0,"censored":false},"longitudinal_labs":[{"date":"2021-05-11","hemoglobin_g_dL":12.4,"wbc_k_uL":8.7,"platelets_k_uL":238,"creatinine_mg_dL":0.87,"alt_U_L":40},{"date":"2021-12-21","hemoglobin_g_dL":10.4,"wbc_k_uL":8.4,"platelets_k_uL":145,"creatinine_mg_dL":1.07,"alt_U_L":85},{"date":"2021-11-15","hemoglobin_g_dL":10.0,"wbc_k_uL":7.6,"platelets_k_uL":337,"creatinine_mg_dL":1.6,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":74,"sex":"female","bmi":34.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-68},"pfs_months":25.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.0,"censored":true},"longitudinal_labs":[{"date":"2024-03-02","hemoglobin_g_dL":13.7,"wbc_k_uL":9.5,"platelets_k_uL":440,"creatinine_mg_dL":1.09,"alt_U_L":77},{"date":"2024-09-30","hemoglobin_g_dL":11.4,"wbc_k_uL":8.0,"platelets_k_uL":123,"creatinine_mg_dL":1.01,"alt_U_L":48},{"date":"2026-05-23","hemoglobin_g_dL":10.9,"wbc_k_uL":6.9,"platelets_k_uL":276,"creatinine_mg_dL":1.82,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_632","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":61,"sex":"female","bmi":36.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-38},"pfs_months":16.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.7,"censored":true},"longitudinal_labs":[{"date":"2024-12-07","hemoglobin_g_dL":14.9,"wbc_k_uL":6.3,"platelets_k_uL":353,"creatinine_mg_dL":0.82,"alt_U_L":65},{"date":"2025-07-22","hemoglobin_g_dL":10.6,"wbc_k_uL":5.9,"platelets_k_uL":351,"creatinine_mg_dL":1.3,"alt_U_L":52},{"date":"2026-07-24","hemoglobin_g_dL":9.7,"wbc_k_uL":3.6,"platelets_k_uL":224,"creatinine_mg_dL":1.08,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_633","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":84,"sex":"female","bmi":37.1,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-64},"pfs_months":23.39},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.5,"censored":false},"longitudinal_labs":[{"date":"2024-08-02","hemoglobin_g_dL":12.8,"wbc_k_uL":9.5,"platelets_k_uL":338,"creatinine_mg_dL":0.66,"alt_U_L":21},{"date":"2025-03-15","hemoglobin_g_dL":10.1,"wbc_k_uL":4.3,"platelets_k_uL":191,"creatinine_mg_dL":1.54,"alt_U_L":96},{"date":"2026-09-29","hemoglobin_g_dL":12.2,"wbc_k_uL":6.0,"platelets_k_uL":218,"creatinine_mg_dL":0.81,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":73,"sex":"female","bmi":22.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-55},"pfs_months":26.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.3,"censored":false},"longitudinal_labs":[{"date":"2024-02-03","hemoglobin_g_dL":11.7,"wbc_k_uL":7.8,"platelets_k_uL":406,"creatinine_mg_dL":0.63,"alt_U_L":19},{"date":"2024-10-10","hemoglobin_g_dL":10.2,"wbc_k_uL":4.0,"platelets_k_uL":207,"creatinine_mg_dL":1.03,"alt_U_L":73},{"date":"2026-06-20","hemoglobin_g_dL":11.4,"wbc_k_uL":4.0,"platelets_k_uL":141,"creatinine_mg_dL":1.28,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":65,"sex":"male","bmi":21.7,"smoking_pack_years":28,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-50},"pfs_months":8.18},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":12.1,"censored":false},"longitudinal_labs":[{"date":"2020-06-27","hemoglobin_g_dL":12.7,"wbc_k_uL":8.9,"platelets_k_uL":406,"creatinine_mg_dL":0.69,"alt_U_L":63},{"date":"2021-01-15","hemoglobin_g_dL":12.8,"wbc_k_uL":7.5,"platelets_k_uL":259,"creatinine_mg_dL":1.45,"alt_U_L":114},{"date":"2021-05-20","hemoglobin_g_dL":12.9,"wbc_k_uL":3.1,"platelets_k_uL":194,"creatinine_mg_dL":1.55,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":48,"sex":"female","bmi":36.3,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-07-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-74},"pfs_months":16.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.5,"censored":false},"longitudinal_labs":[{"date":"2024-05-10","hemoglobin_g_dL":13.1,"wbc_k_uL":7.8,"platelets_k_uL":389,"creatinine_mg_dL":0.77,"alt_U_L":37},{"date":"2024-12-28","hemoglobin_g_dL":12.4,"wbc_k_uL":7.6,"platelets_k_uL":185,"creatinine_mg_dL":0.79,"alt_U_L":39},{"date":"2025-12-07","hemoglobin_g_dL":11.3,"wbc_k_uL":4.1,"platelets_k_uL":237,"creatinine_mg_dL":1.95,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":63,"sex":"female","bmi":28.9,"smoking_pack_years":33,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-12-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-73},"pfs_months":55.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":78.9,"censored":true},"longitudinal_labs":[{"date":"2021-11-12","hemoglobin_g_dL":13.4,"wbc_k_uL":10.3,"platelets_k_uL":290,"creatinine_mg_dL":1.16,"alt_U_L":61},{"date":"2022-06-22","hemoglobin_g_dL":10.6,"wbc_k_uL":5.1,"platelets_k_uL":205,"creatinine_mg_dL":1.57,"alt_U_L":106},{"date":"2026-10-02","hemoglobin_g_dL":11.0,"wbc_k_uL":6.0,"platelets_k_uL":328,"creatinine_mg_dL":0.87,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":86,"sex":"male","bmi":18.6,"smoking_pack_years":64,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-54},"pfs_months":4.76},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":8.9,"censored":false},"longitudinal_labs":[{"date":"2025-06-22","hemoglobin_g_dL":13.0,"wbc_k_uL":5.3,"platelets_k_uL":161,"creatinine_mg_dL":0.74,"alt_U_L":31},{"date":"2026-02-04","hemoglobin_g_dL":13.2,"wbc_k_uL":5.8,"platelets_k_uL":276,"creatinine_mg_dL":1.3,"alt_U_L":61},{"date":"2026-01-14","hemoglobin_g_dL":10.7,"wbc_k_uL":6.9,"platelets_k_uL":189,"creatinine_mg_dL":0.9,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":62,"sex":"male","bmi":24.4,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-73},"pfs_months":34.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":59.9,"censored":true},"longitudinal_labs":[{"date":"2024-12-19","hemoglobin_g_dL":14.1,"wbc_k_uL":8.3,"platelets_k_uL":174,"creatinine_mg_dL":0.75,"alt_U_L":29},{"date":"2025-07-07","hemoglobin_g_dL":11.9,"wbc_k_uL":7.7,"platelets_k_uL":273,"creatinine_mg_dL":0.85,"alt_U_L":88},{"date":"2028-01-01","hemoglobin_g_dL":12.7,"wbc_k_uL":4.6,"platelets_k_uL":180,"creatinine_mg_dL":1.37,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":71,"sex":"female","bmi":35.0,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-44},"pfs_months":17.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":21.8,"censored":true},"longitudinal_labs":[{"date":"2023-01-06","hemoglobin_g_dL":15.2,"wbc_k_uL":7.3,"platelets_k_uL":346,"creatinine_mg_dL":0.7,"alt_U_L":20},{"date":"2023-08-05","hemoglobin_g_dL":12.0,"wbc_k_uL":6.3,"platelets_k_uL":283,"creatinine_mg_dL":1.39,"alt_U_L":108},{"date":"2024-09-10","hemoglobin_g_dL":11.5,"wbc_k_uL":5.3,"platelets_k_uL":119,"creatinine_mg_dL":0.99,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":53,"sex":"female","bmi":19.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-75},"pfs_months":13.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":23.3,"censored":false},"longitudinal_labs":[{"date":"2024-10-10","hemoglobin_g_dL":13.1,"wbc_k_uL":7.1,"platelets_k_uL":319,"creatinine_mg_dL":1.06,"alt_U_L":18},{"date":"2025-04-30","hemoglobin_g_dL":12.3,"wbc_k_uL":6.2,"platelets_k_uL":256,"creatinine_mg_dL":0.79,"alt_U_L":49},{"date":"2025-12-06","hemoglobin_g_dL":12.3,"wbc_k_uL":4.8,"platelets_k_uL":123,"creatinine_mg_dL":1.42,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_642","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":77,"sex":"female","bmi":27.6,"smoking_pack_years":35,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-06-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-54},"pfs_months":27.93},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.3,"censored":true},"longitudinal_labs":[{"date":"2021-06-09","hemoglobin_g_dL":13.0,"wbc_k_uL":9.9,"platelets_k_uL":373,"creatinine_mg_dL":1.08,"alt_U_L":61},{"date":"2021-12-26","hemoglobin_g_dL":11.1,"wbc_k_uL":4.1,"platelets_k_uL":316,"creatinine_mg_dL":0.96,"alt_U_L":119},{"date":"2023-10-31","hemoglobin_g_dL":11.4,"wbc_k_uL":5.8,"platelets_k_uL":123,"creatinine_mg_dL":1.15,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":88,"sex":"female","bmi":21.4,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-03-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-51},"pfs_months":26.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.5,"censored":true},"longitudinal_labs":[{"date":"2022-01-25","hemoglobin_g_dL":12.3,"wbc_k_uL":8.8,"platelets_k_uL":443,"creatinine_mg_dL":1.05,"alt_U_L":27},{"date":"2022-09-03","hemoglobin_g_dL":13.8,"wbc_k_uL":7.0,"platelets_k_uL":357,"creatinine_mg_dL":1.26,"alt_U_L":75},{"date":"2024-06-11","hemoglobin_g_dL":11.1,"wbc_k_uL":6.6,"platelets_k_uL":206,"creatinine_mg_dL":1.3,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":73,"sex":"female","bmi":30.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-56},"pfs_months":15.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.9,"censored":true},"longitudinal_labs":[{"date":"2021-07-17","hemoglobin_g_dL":12.3,"wbc_k_uL":4.8,"platelets_k_uL":204,"creatinine_mg_dL":0.87,"alt_U_L":19},{"date":"2022-03-11","hemoglobin_g_dL":10.3,"wbc_k_uL":8.3,"platelets_k_uL":238,"creatinine_mg_dL":0.83,"alt_U_L":57},{"date":"2023-02-08","hemoglobin_g_dL":11.8,"wbc_k_uL":4.4,"platelets_k_uL":283,"creatinine_mg_dL":1.56,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_645","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":55,"sex":"female","bmi":23.4,"smoking_pack_years":20,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-59},"pfs_months":17.58},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":24.8,"censored":false},"longitudinal_labs":[{"date":"2021-01-13","hemoglobin_g_dL":15.0,"wbc_k_uL":6.3,"platelets_k_uL":168,"creatinine_mg_dL":1.29,"alt_U_L":55},{"date":"2021-07-26","hemoglobin_g_dL":11.6,"wbc_k_uL":5.1,"platelets_k_uL":224,"creatinine_mg_dL":1.32,"alt_U_L":73},{"date":"2022-09-02","hemoglobin_g_dL":12.0,"wbc_k_uL":5.5,"platelets_k_uL":328,"creatinine_mg_dL":1.86,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_646","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":54,"sex":"female","bmi":19.1,"smoking_pack_years":10,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-09-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-64},"pfs_months":21.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":false},"longitudinal_labs":[{"date":"2021-08-05","hemoglobin_g_dL":12.3,"wbc_k_uL":9.1,"platelets_k_uL":257,"creatinine_mg_dL":1.21,"alt_U_L":57},{"date":"2022-03-08","hemoglobin_g_dL":13.4,"wbc_k_uL":5.4,"platelets_k_uL":200,"creatinine_mg_dL":0.76,"alt_U_L":68},{"date":"2023-07-21","hemoglobin_g_dL":12.2,"wbc_k_uL":4.7,"platelets_k_uL":253,"creatinine_mg_dL":1.71,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_647","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":84,"sex":"female","bmi":22.9,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-02-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-68},"pfs_months":25.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":46.5,"censored":false},"longitudinal_labs":[{"date":"2025-12-21","hemoglobin_g_dL":14.8,"wbc_k_uL":10.6,"platelets_k_uL":192,"creatinine_mg_dL":0.71,"alt_U_L":13},{"date":"2026-08-18","hemoglobin_g_dL":11.5,"wbc_k_uL":8.9,"platelets_k_uL":226,"creatinine_mg_dL":1.35,"alt_U_L":41},{"date":"2028-04-21","hemoglobin_g_dL":11.2,"wbc_k_uL":3.7,"platelets_k_uL":217,"creatinine_mg_dL":1.11,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":72,"sex":"female","bmi":37.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-61},"pfs_months":27.53},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.9,"censored":false},"longitudinal_labs":[{"date":"2024-10-07","hemoglobin_g_dL":11.5,"wbc_k_uL":10.2,"platelets_k_uL":242,"creatinine_mg_dL":1.23,"alt_U_L":13},{"date":"2025-05-11","hemoglobin_g_dL":10.4,"wbc_k_uL":5.6,"platelets_k_uL":170,"creatinine_mg_dL":1.41,"alt_U_L":29},{"date":"2027-04-18","hemoglobin_g_dL":10.5,"wbc_k_uL":3.6,"platelets_k_uL":177,"creatinine_mg_dL":1.3,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":48,"sex":"male","bmi":29.5,"smoking_pack_years":49,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-10-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-71},"pfs_months":15.84},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.8,"censored":false},"longitudinal_labs":[{"date":"2023-09-03","hemoglobin_g_dL":14.3,"wbc_k_uL":7.7,"platelets_k_uL":155,"creatinine_mg_dL":1.03,"alt_U_L":66},{"date":"2024-04-13","hemoglobin_g_dL":12.9,"wbc_k_uL":6.0,"platelets_k_uL":124,"creatinine_mg_dL":1.02,"alt_U_L":103},{"date":"2025-03-09","hemoglobin_g_dL":12.2,"wbc_k_uL":5.4,"platelets_k_uL":319,"creatinine_mg_dL":1.46,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":76,"sex":"female","bmi":23.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-75},"pfs_months":11.99},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.3,"censored":false},"longitudinal_labs":[{"date":"2021-03-03","hemoglobin_g_dL":14.6,"wbc_k_uL":6.5,"platelets_k_uL":324,"creatinine_mg_dL":0.99,"alt_U_L":72},{"date":"2021-11-04","hemoglobin_g_dL":10.2,"wbc_k_uL":4.1,"platelets_k_uL":163,"creatinine_mg_dL":1.49,"alt_U_L":78},{"date":"2022-05-14","hemoglobin_g_dL":12.2,"wbc_k_uL":7.6,"platelets_k_uL":325,"creatinine_mg_dL":0.87,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_651","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":69,"sex":"male","bmi":35.7,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-03-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-73},"pfs_months":19.68},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":true},"longitudinal_labs":[{"date":"2024-01-10","hemoglobin_g_dL":14.0,"wbc_k_uL":10.4,"platelets_k_uL":236,"creatinine_mg_dL":0.86,"alt_U_L":67},{"date":"2024-09-01","hemoglobin_g_dL":12.1,"wbc_k_uL":8.1,"platelets_k_uL":299,"creatinine_mg_dL":0.99,"alt_U_L":114},{"date":"2025-11-11","hemoglobin_g_dL":11.8,"wbc_k_uL":7.2,"platelets_k_uL":310,"creatinine_mg_dL":1.24,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":69,"sex":"female","bmi":34.6,"smoking_pack_years":75,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-01-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-63},"pfs_months":40.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":63.8,"censored":false},"longitudinal_labs":[{"date":"2023-12-18","hemoglobin_g_dL":14.3,"wbc_k_uL":5.4,"platelets_k_uL":191,"creatinine_mg_dL":0.98,"alt_U_L":14},{"date":"2024-07-19","hemoglobin_g_dL":10.6,"wbc_k_uL":4.1,"platelets_k_uL":254,"creatinine_mg_dL":1.11,"alt_U_L":80},{"date":"2027-07-20","hemoglobin_g_dL":10.7,"wbc_k_uL":7.6,"platelets_k_uL":103,"creatinine_mg_dL":1.91,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":60,"sex":"female","bmi":20.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-75},"pfs_months":23.56},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":false},"longitudinal_labs":[{"date":"2020-07-08","hemoglobin_g_dL":13.4,"wbc_k_uL":5.5,"platelets_k_uL":442,"creatinine_mg_dL":0.94,"alt_U_L":67},{"date":"2021-01-30","hemoglobin_g_dL":14.0,"wbc_k_uL":5.3,"platelets_k_uL":260,"creatinine_mg_dL":1.6,"alt_U_L":110},{"date":"2022-09-07","hemoglobin_g_dL":12.5,"wbc_k_uL":5.2,"platelets_k_uL":341,"creatinine_mg_dL":1.3,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":58,"sex":"female","bmi":34.8,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-54},"pfs_months":16.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":20.2,"censored":true},"longitudinal_labs":[{"date":"2021-05-21","hemoglobin_g_dL":15.3,"wbc_k_uL":8.4,"platelets_k_uL":286,"creatinine_mg_dL":0.99,"alt_U_L":73},{"date":"2022-01-24","hemoglobin_g_dL":10.1,"wbc_k_uL":7.9,"platelets_k_uL":123,"creatinine_mg_dL":1.6,"alt_U_L":66},{"date":"2022-12-21","hemoglobin_g_dL":12.7,"wbc_k_uL":7.7,"platelets_k_uL":313,"creatinine_mg_dL":1.66,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":55,"sex":"male","bmi":25.1,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-11-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-73},"pfs_months":11.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":22.3,"censored":false},"longitudinal_labs":[{"date":"2025-10-15","hemoglobin_g_dL":13.3,"wbc_k_uL":5.5,"platelets_k_uL":323,"creatinine_mg_dL":0.79,"alt_U_L":40},{"date":"2026-05-04","hemoglobin_g_dL":12.9,"wbc_k_uL":4.8,"platelets_k_uL":211,"creatinine_mg_dL":1.24,"alt_U_L":29},{"date":"2026-12-21","hemoglobin_g_dL":12.1,"wbc_k_uL":4.3,"platelets_k_uL":197,"creatinine_mg_dL":1.08,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":88,"sex":"female","bmi":29.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-49},"pfs_months":24.54},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.5,"censored":false},"longitudinal_labs":[{"date":"2025-07-01","hemoglobin_g_dL":13.9,"wbc_k_uL":7.7,"platelets_k_uL":213,"creatinine_mg_dL":0.97,"alt_U_L":24},{"date":"2026-02-15","hemoglobin_g_dL":11.5,"wbc_k_uL":6.7,"platelets_k_uL":171,"creatinine_mg_dL":1.14,"alt_U_L":95},{"date":"2027-09-17","hemoglobin_g_dL":11.3,"wbc_k_uL":6.8,"platelets_k_uL":255,"creatinine_mg_dL":1.86,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":51,"sex":"female","bmi":31.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-37},"pfs_months":30.26},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.2,"censored":false},"longitudinal_labs":[{"date":"2022-10-20","hemoglobin_g_dL":13.4,"wbc_k_uL":10.7,"platelets_k_uL":298,"creatinine_mg_dL":1.2,"alt_U_L":13},{"date":"2023-05-19","hemoglobin_g_dL":11.6,"wbc_k_uL":4.4,"platelets_k_uL":258,"creatinine_mg_dL":1.52,"alt_U_L":88},{"date":"2025-06-24","hemoglobin_g_dL":9.5,"wbc_k_uL":4.8,"platelets_k_uL":165,"creatinine_mg_dL":1.38,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":81,"sex":"male","bmi":35.2,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-72},"pfs_months":3.06},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-03-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":8.2,"censored":true},"longitudinal_labs":[{"date":"2020-10-27","hemoglobin_g_dL":11.7,"wbc_k_uL":8.0,"platelets_k_uL":312,"creatinine_mg_dL":1.13,"alt_U_L":57},{"date":"2021-05-13","hemoglobin_g_dL":10.5,"wbc_k_uL":8.3,"platelets_k_uL":265,"creatinine_mg_dL":1.32,"alt_U_L":108},{"date":"2021-03-24","hemoglobin_g_dL":12.4,"wbc_k_uL":7.6,"platelets_k_uL":277,"creatinine_mg_dL":1.07,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":80,"sex":"male","bmi":33.2,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-48},"pfs_months":32.89},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-23","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.2,"censored":false},"longitudinal_labs":[{"date":"2020-01-23","hemoglobin_g_dL":12.6,"wbc_k_uL":8.2,"platelets_k_uL":239,"creatinine_mg_dL":0.63,"alt_U_L":71},{"date":"2020-09-08","hemoglobin_g_dL":11.3,"wbc_k_uL":7.2,"platelets_k_uL":246,"creatinine_mg_dL":1.47,"alt_U_L":69},{"date":"2022-12-23","hemoglobin_g_dL":11.0,"wbc_k_uL":6.6,"platelets_k_uL":151,"creatinine_mg_dL":1.16,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":55,"sex":"male","bmi":36.8,"smoking_pack_years":18,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-08-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-38},"pfs_months":30.23},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":51.2,"censored":false},"longitudinal_labs":[{"date":"2025-07-16","hemoglobin_g_dL":13.2,"wbc_k_uL":11.0,"platelets_k_uL":321,"creatinine_mg_dL":0.86,"alt_U_L":11},{"date":"2026-02-22","hemoglobin_g_dL":13.4,"wbc_k_uL":4.9,"platelets_k_uL":226,"creatinine_mg_dL":1.29,"alt_U_L":56},{"date":"2028-03-15","hemoglobin_g_dL":12.1,"wbc_k_uL":4.4,"platelets_k_uL":244,"creatinine_mg_dL":1.08,"alt_U_L":31}]}
{"patient_id":"ANODE_SYNTH_2025_661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":78,"sex":"female","bmi":31.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-80},"pfs_months":18.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.1,"censored":true},"longitudinal_labs":[{"date":"2023-01-17","hemoglobin_g_dL":12.7,"wbc_k_uL":9.9,"platelets_k_uL":265,"creatinine_mg_dL":0.6,"alt_U_L":63},{"date":"2023-08-28","hemoglobin_g_dL":10.3,"wbc_k_uL":4.0,"platelets_k_uL":282,"creatinine_mg_dL":1.21,"alt_U_L":35},{"date":"2024-10-24","hemoglobin_g_dL":10.1,"wbc_k_uL":3.0,"platelets_k_uL":105,"creatinine_mg_dL":1.42,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":74,"sex":"female","bmi":32.0,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-09-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-38},"pfs_months":19.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.2,"censored":false},"longitudinal_labs":[{"date":"2022-09-04","hemoglobin_g_dL":11.9,"wbc_k_uL":7.5,"platelets_k_uL":320,"creatinine_mg_dL":1.18,"alt_U_L":13},{"date":"2023-03-21","hemoglobin_g_dL":11.4,"wbc_k_uL":7.5,"platelets_k_uL":185,"creatinine_mg_dL":1.08,"alt_U_L":60},{"date":"2024-05-25","hemoglobin_g_dL":12.3,"wbc_k_uL":3.1,"platelets_k_uL":113,"creatinine_mg_dL":1.25,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":83,"sex":"female","bmi":22.1,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-33},"pfs_months":24.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.5,"censored":false},"longitudinal_labs":[{"date":"2025-04-23","hemoglobin_g_dL":14.5,"wbc_k_uL":10.6,"platelets_k_uL":396,"creatinine_mg_dL":0.73,"alt_U_L":17},{"date":"2025-11-04","hemoglobin_g_dL":10.4,"wbc_k_uL":4.5,"platelets_k_uL":219,"creatinine_mg_dL":1.28,"alt_U_L":28},{"date":"2027-05-27","hemoglobin_g_dL":11.3,"wbc_k_uL":6.4,"platelets_k_uL":204,"creatinine_mg_dL":1.19,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":51,"sex":"female","bmi":34.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-84},"pfs_months":22.28},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.7,"censored":true},"longitudinal_labs":[{"date":"2024-05-09","hemoglobin_g_dL":14.0,"wbc_k_uL":6.4,"platelets_k_uL":265,"creatinine_mg_dL":1.29,"alt_U_L":26},{"date":"2024-12-22","hemoglobin_g_dL":12.6,"wbc_k_uL":6.0,"platelets_k_uL":226,"creatinine_mg_dL":1.1,"alt_U_L":68},{"date":"2026-06-02","hemoglobin_g_dL":11.5,"wbc_k_uL":7.6,"platelets_k_uL":268,"creatinine_mg_dL":1.64,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":61,"sex":"female","bmi":22.0,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-80},"pfs_months":40.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":69.4,"censored":false},"longitudinal_labs":[{"date":"2021-01-24","hemoglobin_g_dL":13.1,"wbc_k_uL":10.3,"platelets_k_uL":206,"creatinine_mg_dL":0.62,"alt_U_L":19},{"date":"2021-09-27","hemoglobin_g_dL":12.3,"wbc_k_uL":4.3,"platelets_k_uL":313,"creatinine_mg_dL":1.41,"alt_U_L":107},{"date":"2024-09-22","hemoglobin_g_dL":12.0,"wbc_k_uL":6.1,"platelets_k_uL":101,"creatinine_mg_dL":1.9,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":58,"sex":"female","bmi":31.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-63},"pfs_months":25.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":true},"longitudinal_labs":[{"date":"2022-12-01","hemoglobin_g_dL":15.1,"wbc_k_uL":9.5,"platelets_k_uL":297,"creatinine_mg_dL":0.99,"alt_U_L":37},{"date":"2023-08-07","hemoglobin_g_dL":12.3,"wbc_k_uL":6.2,"platelets_k_uL":126,"creatinine_mg_dL":1.03,"alt_U_L":48},{"date":"2025-04-26","hemoglobin_g_dL":11.0,"wbc_k_uL":3.1,"platelets_k_uL":105,"creatinine_mg_dL":1.28,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":64,"sex":"male","bmi":27.1,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-03-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-40},"pfs_months":35.19},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.7,"censored":false},"longitudinal_labs":[{"date":"2025-01-10","hemoglobin_g_dL":11.6,"wbc_k_uL":6.7,"platelets_k_uL":199,"creatinine_mg_dL":1.24,"alt_U_L":43},{"date":"2025-09-03","hemoglobin_g_dL":12.7,"wbc_k_uL":8.2,"platelets_k_uL":303,"creatinine_mg_dL":1.57,"alt_U_L":116},{"date":"2028-03-06","hemoglobin_g_dL":10.9,"wbc_k_uL":4.7,"platelets_k_uL":179,"creatinine_mg_dL":1.08,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_668","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":65,"sex":"female","bmi":22.2,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-03-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-45},"pfs_months":19.84},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":31.2,"censored":false},"longitudinal_labs":[{"date":"2021-02-01","hemoglobin_g_dL":13.3,"wbc_k_uL":7.9,"platelets_k_uL":183,"creatinine_mg_dL":1.04,"alt_U_L":75},{"date":"2021-09-01","hemoglobin_g_dL":11.7,"wbc_k_uL":5.9,"platelets_k_uL":278,"creatinine_mg_dL":1.07,"alt_U_L":32},{"date":"2022-11-04","hemoglobin_g_dL":12.2,"wbc_k_uL":6.0,"platelets_k_uL":242,"creatinine_mg_dL":1.45,"alt_U_L":166}]}
{"patient_id":"ANODE_SYNTH_2025_669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":76,"sex":"female","bmi":20.0,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-04-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-57},"pfs_months":37.85},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":60.0,"censored":false},"longitudinal_labs":[{"date":"2021-02-11","hemoglobin_g_dL":12.0,"wbc_k_uL":9.7,"platelets_k_uL":399,"creatinine_mg_dL":1.04,"alt_U_L":29},{"date":"2021-10-01","hemoglobin_g_dL":11.4,"wbc_k_uL":7.6,"platelets_k_uL":121,"creatinine_mg_dL":1.15,"alt_U_L":61},{"date":"2024-06-16","hemoglobin_g_dL":12.7,"wbc_k_uL":6.4,"platelets_k_uL":172,"creatinine_mg_dL":1.6,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":70,"sex":"female","bmi":26.4,"smoking_pack_years":68,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-45},"pfs_months":37.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.9,"censored":true},"longitudinal_labs":[{"date":"2025-01-19","hemoglobin_g_dL":13.1,"wbc_k_uL":10.8,"platelets_k_uL":287,"creatinine_mg_dL":0.92,"alt_U_L":55},{"date":"2025-08-14","hemoglobin_g_dL":10.8,"wbc_k_uL":6.5,"platelets_k_uL":197,"creatinine_mg_dL":0.73,"alt_U_L":116},{"date":"2028-06-04","hemoglobin_g_dL":12.3,"wbc_k_uL":6.8,"platelets_k_uL":137,"creatinine_mg_dL":1.12,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":80,"sex":"female","bmi":30.4,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-33},"pfs_months":42.38},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":59.9,"censored":true},"longitudinal_labs":[{"date":"2023-11-04","hemoglobin_g_dL":13.8,"wbc_k_uL":7.9,"platelets_k_uL":163,"creatinine_mg_dL":0.68,"alt_U_L":34},{"date":"2024-05-25","hemoglobin_g_dL":12.3,"wbc_k_uL":6.4,"platelets_k_uL":237,"creatinine_mg_dL":1.35,"alt_U_L":107},{"date":"2027-06-28","hemoglobin_g_dL":12.0,"wbc_k_uL":6.5,"platelets_k_uL":311,"creatinine_mg_dL":0.98,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_672","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":85,"sex":"male","bmi":37.6,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-02-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-76},"pfs_months":30.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.0,"censored":true},"longitudinal_labs":[{"date":"2023-12-20","hemoglobin_g_dL":14.8,"wbc_k_uL":4.8,"platelets_k_uL":442,"creatinine_mg_dL":1.17,"alt_U_L":34},{"date":"2024-08-20","hemoglobin_g_dL":10.1,"wbc_k_uL":8.3,"platelets_k_uL":325,"creatinine_mg_dL":0.73,"alt_U_L":29},{"date":"2026-09-14","hemoglobin_g_dL":12.8,"wbc_k_uL":3.6,"platelets_k_uL":173,"creatinine_mg_dL":1.89,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":63,"sex":"female","bmi":30.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-62},"pfs_months":14.88},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":24.6,"censored":true},"longitudinal_labs":[{"date":"2025-05-25","hemoglobin_g_dL":14.3,"wbc_k_uL":8.5,"platelets_k_uL":360,"creatinine_mg_dL":1.1,"alt_U_L":26},{"date":"2025-12-13","hemoglobin_g_dL":12.9,"wbc_k_uL":8.8,"platelets_k_uL":138,"creatinine_mg_dL":1.28,"alt_U_L":20},{"date":"2026-10-19","hemoglobin_g_dL":11.8,"wbc_k_uL":4.9,"platelets_k_uL":291,"creatinine_mg_dL":1.43,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":79,"sex":"male","bmi":23.8,"smoking_pack_years":71,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-04-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-42},"pfs_months":14.16},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.2,"censored":false},"longitudinal_labs":[{"date":"2025-02-24","hemoglobin_g_dL":12.4,"wbc_k_uL":10.2,"platelets_k_uL":167,"creatinine_mg_dL":0.8,"alt_U_L":41},{"date":"2025-10-14","hemoglobin_g_dL":10.2,"wbc_k_uL":4.1,"platelets_k_uL":326,"creatinine_mg_dL":0.92,"alt_U_L":54},{"date":"2026-07-20","hemoglobin_g_dL":12.4,"wbc_k_uL":5.0,"platelets_k_uL":282,"creatinine_mg_dL":1.64,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_675","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":87,"sex":"male","bmi":37.9,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-10-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-74},"pfs_months":28.58},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.5,"censored":false},"longitudinal_labs":[{"date":"2023-09-12","hemoglobin_g_dL":13.3,"wbc_k_uL":8.2,"platelets_k_uL":436,"creatinine_mg_dL":1.12,"alt_U_L":53},{"date":"2024-04-17","hemoglobin_g_dL":10.2,"wbc_k_uL":3.9,"platelets_k_uL":332,"creatinine_mg_dL":0.73,"alt_U_L":72},{"date":"2026-03-17","hemoglobin_g_dL":10.2,"wbc_k_uL":6.3,"platelets_k_uL":160,"creatinine_mg_dL":1.86,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":69,"sex":"female","bmi":18.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-61},"pfs_months":21.13},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":true},"longitudinal_labs":[{"date":"2022-10-22","hemoglobin_g_dL":12.6,"wbc_k_uL":8.2,"platelets_k_uL":332,"creatinine_mg_dL":1.08,"alt_U_L":64},{"date":"2023-06-16","hemoglobin_g_dL":12.3,"wbc_k_uL":8.1,"platelets_k_uL":175,"creatinine_mg_dL":1.27,"alt_U_L":52},{"date":"2024-10-02","hemoglobin_g_dL":12.2,"wbc_k_uL":7.2,"platelets_k_uL":170,"creatinine_mg_dL":1.04,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":86,"sex":"male","bmi":37.5,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-07-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-72},"pfs_months":36.99},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":59.1,"censored":false},"longitudinal_labs":[{"date":"2022-06-06","hemoglobin_g_dL":14.2,"wbc_k_uL":9.4,"platelets_k_uL":222,"creatinine_mg_dL":0.76,"alt_U_L":63},{"date":"2023-01-10","hemoglobin_g_dL":10.9,"wbc_k_uL":6.6,"platelets_k_uL":364,"creatinine_mg_dL":1.57,"alt_U_L":41},{"date":"2025-10-06","hemoglobin_g_dL":11.9,"wbc_k_uL":4.2,"platelets_k_uL":117,"creatinine_mg_dL":1.83,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_678","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":72,"sex":"female","bmi":34.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-35},"pfs_months":20.63},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.2,"censored":false},"longitudinal_labs":[{"date":"2021-03-07","hemoglobin_g_dL":13.7,"wbc_k_uL":6.0,"platelets_k_uL":356,"creatinine_mg_dL":0.78,"alt_U_L":10},{"date":"2021-10-10","hemoglobin_g_dL":11.9,"wbc_k_uL":4.8,"platelets_k_uL":244,"creatinine_mg_dL":1.33,"alt_U_L":33},{"date":"2023-01-12","hemoglobin_g_dL":11.6,"wbc_k_uL":7.7,"platelets_k_uL":303,"creatinine_mg_dL":1.4,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":50,"sex":"female","bmi":28.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-37},"pfs_months":19.45},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":false},"longitudinal_labs":[{"date":"2021-02-20","hemoglobin_g_dL":11.6,"wbc_k_uL":9.0,"platelets_k_uL":241,"creatinine_mg_dL":0.82,"alt_U_L":78},{"date":"2021-09-04","hemoglobin_g_dL":13.2,"wbc_k_uL":5.6,"platelets_k_uL":122,"creatinine_mg_dL":1.13,"alt_U_L":111},{"date":"2022-12-15","hemoglobin_g_dL":10.5,"wbc_k_uL":4.2,"platelets_k_uL":190,"creatinine_mg_dL":1.57,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":84,"sex":"female","bmi":28.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-82},"pfs_months":13.5},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.0,"censored":false},"longitudinal_labs":[{"date":"2024-05-06","hemoglobin_g_dL":13.8,"wbc_k_uL":8.4,"platelets_k_uL":266,"creatinine_mg_dL":1.16,"alt_U_L":63},{"date":"2024-12-06","hemoglobin_g_dL":10.1,"wbc_k_uL":4.9,"platelets_k_uL":190,"creatinine_mg_dL":0.84,"alt_U_L":25},{"date":"2025-08-01","hemoglobin_g_dL":10.8,"wbc_k_uL":6.4,"platelets_k_uL":253,"creatinine_mg_dL":1.33,"alt_U_L":112}]}
{"patient_id":"ANODE_SYNTH_2025_681","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":55,"sex":"female","bmi":28.0,"smoking_pack_years":45,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-06-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-78},"pfs_months":26.55},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":43.4,"censored":true},"longitudinal_labs":[{"date":"2024-04-23","hemoglobin_g_dL":13.0,"wbc_k_uL":8.3,"platelets_k_uL":189,"creatinine_mg_dL":1.05,"alt_U_L":37},{"date":"2024-12-09","hemoglobin_g_dL":10.5,"wbc_k_uL":4.2,"platelets_k_uL":372,"creatinine_mg_dL":1.24,"alt_U_L":78},{"date":"2026-10-25","hemoglobin_g_dL":11.8,"wbc_k_uL":6.5,"platelets_k_uL":336,"creatinine_mg_dL":1.4,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":63,"sex":"female","bmi":32.0,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-02-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-34},"pfs_months":39.33},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.4,"censored":false},"longitudinal_labs":[{"date":"2021-01-27","hemoglobin_g_dL":14.0,"wbc_k_uL":10.4,"platelets_k_uL":191,"creatinine_mg_dL":1.14,"alt_U_L":48},{"date":"2021-08-16","hemoglobin_g_dL":11.1,"wbc_k_uL":4.6,"platelets_k_uL":177,"creatinine_mg_dL":0.71,"alt_U_L":70},{"date":"2024-06-27","hemoglobin_g_dL":9.7,"wbc_k_uL":7.2,"platelets_k_uL":305,"creatinine_mg_dL":1.82,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":54,"sex":"female","bmi":25.0,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2021-02-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-43},"pfs_months":10.81},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.9,"censored":true},"longitudinal_labs":[{"date":"2021-01-17","hemoglobin_g_dL":13.0,"wbc_k_uL":8.2,"platelets_k_uL":432,"creatinine_mg_dL":0.6,"alt_U_L":36},{"date":"2021-08-22","hemoglobin_g_dL":11.9,"wbc_k_uL":6.5,"platelets_k_uL":208,"creatinine_mg_dL":1.54,"alt_U_L":106},{"date":"2022-02-11","hemoglobin_g_dL":10.2,"wbc_k_uL":4.8,"platelets_k_uL":208,"creatinine_mg_dL":1.68,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_684","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":49,"sex":"female","bmi":35.1,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-07-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-38},"pfs_months":27.43},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.4,"censored":false},"longitudinal_labs":[{"date":"2020-05-01","hemoglobin_g_dL":15.2,"wbc_k_uL":9.3,"platelets_k_uL":215,"creatinine_mg_dL":0.69,"alt_U_L":53},{"date":"2021-01-01","hemoglobin_g_dL":10.6,"wbc_k_uL":5.6,"platelets_k_uL":220,"creatinine_mg_dL":1.31,"alt_U_L":45},{"date":"2022-11-22","hemoglobin_g_dL":11.4,"wbc_k_uL":4.5,"platelets_k_uL":317,"creatinine_mg_dL":1.04,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":77,"sex":"female","bmi":21.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-68},"pfs_months":12.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.3,"censored":false},"longitudinal_labs":[{"date":"2023-06-27","hemoglobin_g_dL":13.5,"wbc_k_uL":8.2,"platelets_k_uL":384,"creatinine_mg_dL":0.65,"alt_U_L":11},{"date":"2024-02-09","hemoglobin_g_dL":10.2,"wbc_k_uL":5.6,"platelets_k_uL":259,"creatinine_mg_dL":1.46,"alt_U_L":91},{"date":"2024-10-24","hemoglobin_g_dL":11.3,"wbc_k_uL":6.0,"platelets_k_uL":137,"creatinine_mg_dL":1.84,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":62,"sex":"female","bmi":36.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-70},"pfs_months":22.47},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":false},"longitudinal_labs":[{"date":"2020-07-06","hemoglobin_g_dL":14.5,"wbc_k_uL":9.0,"platelets_k_uL":308,"creatinine_mg_dL":0.75,"alt_U_L":74},{"date":"2021-02-23","hemoglobin_g_dL":11.7,"wbc_k_uL":8.1,"platelets_k_uL":143,"creatinine_mg_dL":0.79,"alt_U_L":117},{"date":"2022-09-09","hemoglobin_g_dL":10.7,"wbc_k_uL":6.5,"platelets_k_uL":257,"creatinine_mg_dL":1.11,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":49,"sex":"female","bmi":27.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-01-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-74},"pfs_months":19.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":false},"longitudinal_labs":[{"date":"2022-11-12","hemoglobin_g_dL":11.9,"wbc_k_uL":10.9,"platelets_k_uL":259,"creatinine_mg_dL":0.76,"alt_U_L":18},{"date":"2023-07-09","hemoglobin_g_dL":10.4,"wbc_k_uL":7.1,"platelets_k_uL":210,"creatinine_mg_dL":1.25,"alt_U_L":120},{"date":"2024-09-11","hemoglobin_g_dL":9.9,"wbc_k_uL":5.0,"platelets_k_uL":274,"creatinine_mg_dL":1.2,"alt_U_L":31}]}
{"patient_id":"ANODE_SYNTH_2025_688","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":48,"sex":"female","bmi":20.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-74},"pfs_months":15.21},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.2,"censored":true},"longitudinal_labs":[{"date":"2021-01-15","hemoglobin_g_dL":13.8,"wbc_k_uL":4.8,"platelets_k_uL":300,"creatinine_mg_dL":0.98,"alt_U_L":52},{"date":"2021-08-22","hemoglobin_g_dL":13.9,"wbc_k_uL":4.5,"platelets_k_uL":284,"creatinine_mg_dL":0.7,"alt_U_L":83},{"date":"2022-07-10","hemoglobin_g_dL":12.7,"wbc_k_uL":4.4,"platelets_k_uL":251,"creatinine_mg_dL":1.68,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":75,"sex":"female","bmi":36.2,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-62},"pfs_months":53.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":78.9,"censored":true},"longitudinal_labs":[{"date":"2020-11-28","hemoglobin_g_dL":12.1,"wbc_k_uL":4.6,"platelets_k_uL":343,"creatinine_mg_dL":0.65,"alt_U_L":48},{"date":"2021-06-28","hemoglobin_g_dL":10.1,"wbc_k_uL":8.0,"platelets_k_uL":250,"creatinine_mg_dL":1.39,"alt_U_L":54},{"date":"2025-08-09","hemoglobin_g_dL":10.2,"wbc_k_uL":4.3,"platelets_k_uL":323,"creatinine_mg_dL":1.02,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":62,"sex":"male","bmi":34.7,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-05-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-39},"pfs_months":36.86},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.5,"censored":true},"longitudinal_labs":[{"date":"2025-05-03","hemoglobin_g_dL":15.4,"wbc_k_uL":8.6,"platelets_k_uL":408,"creatinine_mg_dL":0.9,"alt_U_L":64},{"date":"2025-11-18","hemoglobin_g_dL":11.8,"wbc_k_uL":8.5,"platelets_k_uL":204,"creatinine_mg_dL":1.17,"alt_U_L":32},{"date":"2028-07-27","hemoglobin_g_dL":10.0,"wbc_k_uL":3.3,"platelets_k_uL":239,"creatinine_mg_dL":1.89,"alt_U_L":139}]}
{"patient_id":"ANODE_SYNTH_2025_691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":52,"sex":"female","bmi":35.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-43},"pfs_months":19.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":25.4,"censored":true},"longitudinal_labs":[{"date":"2024-04-10","hemoglobin_g_dL":11.9,"wbc_k_uL":9.5,"platelets_k_uL":191,"creatinine_mg_dL":0.77,"alt_U_L":65},{"date":"2024-10-22","hemoglobin_g_dL":12.4,"wbc_k_uL":5.5,"platelets_k_uL":296,"creatinine_mg_dL":0.76,"alt_U_L":84},{"date":"2025-12-16","hemoglobin_g_dL":11.4,"wbc_k_uL":7.6,"platelets_k_uL":311,"creatinine_mg_dL":1.28,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_692","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":78,"sex":"female","bmi":19.8,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-04-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-36},"pfs_months":14.59},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.1,"censored":true},"longitudinal_labs":[{"date":"2021-03-21","hemoglobin_g_dL":11.9,"wbc_k_uL":10.3,"platelets_k_uL":281,"creatinine_mg_dL":0.62,"alt_U_L":68},{"date":"2021-10-16","hemoglobin_g_dL":11.8,"wbc_k_uL":8.4,"platelets_k_uL":139,"creatinine_mg_dL":1.34,"alt_U_L":117},{"date":"2022-08-24","hemoglobin_g_dL":12.8,"wbc_k_uL":5.3,"platelets_k_uL":349,"creatinine_mg_dL":1.91,"alt_U_L":125}]}
{"patient_id":"ANODE_SYNTH_2025_693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":84,"sex":"male","bmi":27.5,"smoking_pack_years":72,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-08-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-31},"pfs_months":37.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":63.1,"censored":false},"longitudinal_labs":[{"date":"2023-07-27","hemoglobin_g_dL":13.4,"wbc_k_uL":8.2,"platelets_k_uL":324,"creatinine_mg_dL":0.98,"alt_U_L":20},{"date":"2024-02-16","hemoglobin_g_dL":13.2,"wbc_k_uL":8.1,"platelets_k_uL":375,"creatinine_mg_dL":0.87,"alt_U_L":63},{"date":"2026-11-27","hemoglobin_g_dL":12.4,"wbc_k_uL":5.4,"platelets_k_uL":281,"creatinine_mg_dL":0.81,"alt_U_L":90}]}
{"patient_id":"ANODE_SYNTH_2025_694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":68,"sex":"female","bmi":25.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-64},"pfs_months":30.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.8,"censored":true},"longitudinal_labs":[{"date":"2023-02-07","hemoglobin_g_dL":13.7,"wbc_k_uL":8.9,"platelets_k_uL":270,"creatinine_mg_dL":0.63,"alt_U_L":18},{"date":"2023-08-27","hemoglobin_g_dL":11.5,"wbc_k_uL":5.8,"platelets_k_uL":234,"creatinine_mg_dL":0.98,"alt_U_L":58},{"date":"2025-09-18","hemoglobin_g_dL":9.6,"wbc_k_uL":4.7,"platelets_k_uL":337,"creatinine_mg_dL":1.76,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":71,"sex":"female","bmi":35.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-39},"pfs_months":13.5},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.1,"censored":true},"longitudinal_labs":[{"date":"2020-02-13","hemoglobin_g_dL":14.8,"wbc_k_uL":6.1,"platelets_k_uL":274,"creatinine_mg_dL":0.67,"alt_U_L":24},{"date":"2020-10-11","hemoglobin_g_dL":12.0,"wbc_k_uL":8.1,"platelets_k_uL":365,"creatinine_mg_dL":0.92,"alt_U_L":29},{"date":"2021-07-07","hemoglobin_g_dL":11.4,"wbc_k_uL":6.5,"platelets_k_uL":212,"creatinine_mg_dL":1.82,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":83,"sex":"female","bmi":20.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-48},"pfs_months":21.62},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":true},"longitudinal_labs":[{"date":"2020-04-12","hemoglobin_g_dL":13.9,"wbc_k_uL":7.6,"platelets_k_uL":222,"creatinine_mg_dL":1.0,"alt_U_L":39},{"date":"2020-10-23","hemoglobin_g_dL":13.6,"wbc_k_uL":8.5,"platelets_k_uL":316,"creatinine_mg_dL":1.57,"alt_U_L":63},{"date":"2022-04-05","hemoglobin_g_dL":11.0,"wbc_k_uL":6.0,"platelets_k_uL":119,"creatinine_mg_dL":1.26,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":75,"sex":"female","bmi":37.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-55},"pfs_months":9.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.0,"censored":false},"longitudinal_labs":[{"date":"2020-06-08","hemoglobin_g_dL":13.2,"wbc_k_uL":7.7,"platelets_k_uL":440,"creatinine_mg_dL":0.94,"alt_U_L":34},{"date":"2021-02-01","hemoglobin_g_dL":13.8,"wbc_k_uL":6.1,"platelets_k_uL":228,"creatinine_mg_dL":0.96,"alt_U_L":15},{"date":"2021-07-18","hemoglobin_g_dL":10.1,"wbc_k_uL":4.9,"platelets_k_uL":175,"creatinine_mg_dL":0.9,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":54,"sex":"female","bmi":28.2,"smoking_pack_years":17,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-47},"pfs_months":39.0},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":74.1,"censored":false},"longitudinal_labs":[{"date":"2024-02-25","hemoglobin_g_dL":15.5,"wbc_k_uL":9.3,"platelets_k_uL":280,"creatinine_mg_dL":1.24,"alt_U_L":11},{"date":"2024-09-20","hemoglobin_g_dL":13.3,"wbc_k_uL":4.2,"platelets_k_uL":237,"creatinine_mg_dL":1.29,"alt_U_L":58},{"date":"2027-07-06","hemoglobin_g_dL":10.2,"wbc_k_uL":3.1,"platelets_k_uL":212,"creatinine_mg_dL":1.21,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_699","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":68,"sex":"male","bmi":25.3,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-12-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-44},"pfs_months":18.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.5,"censored":false},"longitudinal_labs":[{"date":"2022-10-10","hemoglobin_g_dL":11.6,"wbc_k_uL":6.6,"platelets_k_uL":371,"creatinine_mg_dL":1.16,"alt_U_L":74},{"date":"2023-06-03","hemoglobin_g_dL":10.6,"wbc_k_uL":4.1,"platelets_k_uL":237,"creatinine_mg_dL":1.32,"alt_U_L":108},{"date":"2024-07-22","hemoglobin_g_dL":11.2,"wbc_k_uL":6.1,"platelets_k_uL":110,"creatinine_mg_dL":1.61,"alt_U_L":197}]}
{"patient_id":"ANODE_SYNTH_2025_700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":57,"sex":"male","bmi":24.3,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-12-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-65},"pfs_months":10.78},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":15.7,"censored":false},"longitudinal_labs":[{"date":"2020-11-18","hemoglobin_g_dL":14.5,"wbc_k_uL":9.0,"platelets_k_uL":224,"creatinine_mg_dL":1.18,"alt_U_L":77},{"date":"2021-06-22","hemoglobin_g_dL":12.3,"wbc_k_uL":5.6,"platelets_k_uL":222,"creatinine_mg_dL":1.29,"alt_U_L":98},{"date":"2021-12-21","hemoglobin_g_dL":12.9,"wbc_k_uL":3.3,"platelets_k_uL":306,"creatinine_mg_dL":1.65,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":67,"sex":"female","bmi":18.8,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-09-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-63},"pfs_months":34.92},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":64.4,"censored":true},"longitudinal_labs":[{"date":"2022-08-15","hemoglobin_g_dL":14.1,"wbc_k_uL":4.9,"platelets_k_uL":427,"creatinine_mg_dL":0.77,"alt_U_L":44},{"date":"2023-03-19","hemoglobin_g_dL":12.9,"wbc_k_uL":6.3,"platelets_k_uL":322,"creatinine_mg_dL":1.26,"alt_U_L":111},{"date":"2025-10-12","hemoglobin_g_dL":10.2,"wbc_k_uL":5.9,"platelets_k_uL":227,"creatinine_mg_dL":1.97,"alt_U_L":31}]}
{"patient_id":"ANODE_SYNTH_2025_702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":75,"sex":"male","bmi":28.7,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-52},"pfs_months":33.41},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":53.0,"censored":false},"longitudinal_labs":[{"date":"2022-11-26","hemoglobin_g_dL":14.1,"wbc_k_uL":9.1,"platelets_k_uL":309,"creatinine_mg_dL":0.83,"alt_U_L":34},{"date":"2023-06-23","hemoglobin_g_dL":12.3,"wbc_k_uL":6.4,"platelets_k_uL":255,"creatinine_mg_dL":1.08,"alt_U_L":19},{"date":"2025-11-24","hemoglobin_g_dL":11.2,"wbc_k_uL":6.6,"platelets_k_uL":247,"creatinine_mg_dL":1.68,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":76,"sex":"female","bmi":24.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-71},"pfs_months":28.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":47.7,"censored":true},"longitudinal_labs":[{"date":"2020-07-22","hemoglobin_g_dL":15.4,"wbc_k_uL":4.9,"platelets_k_uL":162,"creatinine_mg_dL":0.78,"alt_U_L":12},{"date":"2021-02-07","hemoglobin_g_dL":10.2,"wbc_k_uL":4.2,"platelets_k_uL":366,"creatinine_mg_dL":1.28,"alt_U_L":106},{"date":"2023-01-01","hemoglobin_g_dL":9.9,"wbc_k_uL":7.0,"platelets_k_uL":228,"creatinine_mg_dL":0.97,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_704","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":54,"sex":"female","bmi":23.7,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-07-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-58},"pfs_months":26.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.5,"censored":false},"longitudinal_labs":[{"date":"2025-06-06","hemoglobin_g_dL":14.5,"wbc_k_uL":9.5,"platelets_k_uL":378,"creatinine_mg_dL":0.87,"alt_U_L":15},{"date":"2026-01-03","hemoglobin_g_dL":11.4,"wbc_k_uL":6.4,"platelets_k_uL":182,"creatinine_mg_dL":1.55,"alt_U_L":105},{"date":"2027-09-30","hemoglobin_g_dL":10.0,"wbc_k_uL":4.5,"platelets_k_uL":344,"creatinine_mg_dL":1.59,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":61,"sex":"female","bmi":35.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-52},"pfs_months":15.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-10","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.4,"censored":false},"longitudinal_labs":[{"date":"2020-03-27","hemoglobin_g_dL":12.0,"wbc_k_uL":9.8,"platelets_k_uL":295,"creatinine_mg_dL":0.7,"alt_U_L":60},{"date":"2020-10-24","hemoglobin_g_dL":12.3,"wbc_k_uL":7.4,"platelets_k_uL":229,"creatinine_mg_dL":0.79,"alt_U_L":44},{"date":"2021-09-10","hemoglobin_g_dL":9.8,"wbc_k_uL":4.8,"platelets_k_uL":275,"creatinine_mg_dL":1.51,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":55,"sex":"female","bmi":24.2,"smoking_pack_years":11,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-48},"pfs_months":17.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":21.0,"censored":false},"longitudinal_labs":[{"date":"2020-10-11","hemoglobin_g_dL":12.3,"wbc_k_uL":5.5,"platelets_k_uL":442,"creatinine_mg_dL":1.22,"alt_U_L":29},{"date":"2021-05-03","hemoglobin_g_dL":10.0,"wbc_k_uL":5.8,"platelets_k_uL":255,"creatinine_mg_dL":0.72,"alt_U_L":17},{"date":"2022-04-10","hemoglobin_g_dL":10.3,"wbc_k_uL":4.0,"platelets_k_uL":324,"creatinine_mg_dL":1.77,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":69,"sex":"female","bmi":23.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-31},"pfs_months":21.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.6,"censored":false},"longitudinal_labs":[{"date":"2024-05-05","hemoglobin_g_dL":14.0,"wbc_k_uL":8.5,"platelets_k_uL":419,"creatinine_mg_dL":1.06,"alt_U_L":21},{"date":"2024-11-16","hemoglobin_g_dL":11.5,"wbc_k_uL":8.6,"platelets_k_uL":151,"creatinine_mg_dL":1.14,"alt_U_L":56},{"date":"2026-03-28","hemoglobin_g_dL":9.6,"wbc_k_uL":4.6,"platelets_k_uL":201,"creatinine_mg_dL":1.54,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":55,"sex":"female","bmi":25.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-32},"pfs_months":15.34},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":false},"longitudinal_labs":[{"date":"2022-01-16","hemoglobin_g_dL":15.3,"wbc_k_uL":5.2,"platelets_k_uL":258,"creatinine_mg_dL":0.77,"alt_U_L":78},{"date":"2022-09-18","hemoglobin_g_dL":13.4,"wbc_k_uL":7.3,"platelets_k_uL":318,"creatinine_mg_dL":0.94,"alt_U_L":52},{"date":"2023-08-29","hemoglobin_g_dL":10.7,"wbc_k_uL":5.6,"platelets_k_uL":181,"creatinine_mg_dL":0.93,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":85,"sex":"female","bmi":33.0,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-11-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-73},"pfs_months":36.57},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":65.2,"censored":true},"longitudinal_labs":[{"date":"2025-10-02","hemoglobin_g_dL":15.5,"wbc_k_uL":10.7,"platelets_k_uL":403,"creatinine_mg_dL":0.71,"alt_U_L":36},{"date":"2026-05-24","hemoglobin_g_dL":11.6,"wbc_k_uL":8.9,"platelets_k_uL":210,"creatinine_mg_dL":1.12,"alt_U_L":28},{"date":"2029-01-13","hemoglobin_g_dL":12.1,"wbc_k_uL":3.3,"platelets_k_uL":126,"creatinine_mg_dL":1.18,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":62,"sex":"female","bmi":35.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-44},"pfs_months":27.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.2,"censored":true},"longitudinal_labs":[{"date":"2022-09-14","hemoglobin_g_dL":14.7,"wbc_k_uL":8.8,"platelets_k_uL":245,"creatinine_mg_dL":0.74,"alt_U_L":56},{"date":"2023-04-19","hemoglobin_g_dL":13.6,"wbc_k_uL":4.5,"platelets_k_uL":250,"creatinine_mg_dL":1.6,"alt_U_L":51},{"date":"2025-02-06","hemoglobin_g_dL":10.1,"wbc_k_uL":4.8,"platelets_k_uL":113,"creatinine_mg_dL":1.64,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":64,"sex":"female","bmi":30.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-56},"pfs_months":15.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.3,"censored":false},"longitudinal_labs":[{"date":"2023-02-09","hemoglobin_g_dL":12.9,"wbc_k_uL":8.0,"platelets_k_uL":277,"creatinine_mg_dL":0.97,"alt_U_L":14},{"date":"2023-08-28","hemoglobin_g_dL":11.1,"wbc_k_uL":4.6,"platelets_k_uL":144,"creatinine_mg_dL":0.74,"alt_U_L":107},{"date":"2024-07-11","hemoglobin_g_dL":10.8,"wbc_k_uL":4.0,"platelets_k_uL":280,"creatinine_mg_dL":1.85,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":49,"sex":"female","bmi":34.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-07-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-70},"pfs_months":19.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.6,"censored":true},"longitudinal_labs":[{"date":"2021-05-16","hemoglobin_g_dL":11.9,"wbc_k_uL":9.8,"platelets_k_uL":393,"creatinine_mg_dL":1.14,"alt_U_L":60},{"date":"2022-01-16","hemoglobin_g_dL":11.1,"wbc_k_uL":4.7,"platelets_k_uL":157,"creatinine_mg_dL":1.08,"alt_U_L":55},{"date":"2023-04-17","hemoglobin_g_dL":11.6,"wbc_k_uL":4.8,"platelets_k_uL":151,"creatinine_mg_dL":1.99,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":56,"sex":"female","bmi":27.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-37},"pfs_months":22.6},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.4,"censored":true},"longitudinal_labs":[{"date":"2024-06-05","hemoglobin_g_dL":13.2,"wbc_k_uL":8.6,"platelets_k_uL":236,"creatinine_mg_dL":0.74,"alt_U_L":76},{"date":"2025-01-18","hemoglobin_g_dL":10.3,"wbc_k_uL":8.3,"platelets_k_uL":162,"creatinine_mg_dL":0.82,"alt_U_L":105},{"date":"2026-06-29","hemoglobin_g_dL":11.7,"wbc_k_uL":3.2,"platelets_k_uL":276,"creatinine_mg_dL":1.31,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":51,"sex":"male","bmi":29.0,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-12-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-83},"pfs_months":3.81},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":7.8,"censored":false},"longitudinal_labs":[{"date":"2020-10-13","hemoglobin_g_dL":12.6,"wbc_k_uL":9.2,"platelets_k_uL":287,"creatinine_mg_dL":0.79,"alt_U_L":55},{"date":"2021-06-03","hemoglobin_g_dL":10.7,"wbc_k_uL":6.5,"platelets_k_uL":373,"creatinine_mg_dL":0.92,"alt_U_L":104},{"date":"2021-05-13","hemoglobin_g_dL":10.3,"wbc_k_uL":7.4,"platelets_k_uL":138,"creatinine_mg_dL":1.16,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_715","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":83,"sex":"male","bmi":24.4,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-01-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-51},"pfs_months":21.75},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.5,"censored":false},"longitudinal_labs":[{"date":"2022-12-17","hemoglobin_g_dL":15.4,"wbc_k_uL":8.7,"platelets_k_uL":375,"creatinine_mg_dL":0.9,"alt_U_L":75},{"date":"2023-07-07","hemoglobin_g_dL":13.4,"wbc_k_uL":6.7,"platelets_k_uL":220,"creatinine_mg_dL":0.93,"alt_U_L":117},{"date":"2024-12-13","hemoglobin_g_dL":12.6,"wbc_k_uL":3.4,"platelets_k_uL":247,"creatinine_mg_dL":1.88,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":64,"sex":"female","bmi":34.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-57},"pfs_months":19.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.5,"censored":false},"longitudinal_labs":[{"date":"2020-08-10","hemoglobin_g_dL":11.6,"wbc_k_uL":8.8,"platelets_k_uL":294,"creatinine_mg_dL":0.8,"alt_U_L":67},{"date":"2021-04-16","hemoglobin_g_dL":12.6,"wbc_k_uL":8.9,"platelets_k_uL":266,"creatinine_mg_dL":0.93,"alt_U_L":36},{"date":"2022-07-25","hemoglobin_g_dL":9.8,"wbc_k_uL":6.7,"platelets_k_uL":315,"creatinine_mg_dL":0.9,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_717","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":74,"sex":"female","bmi":30.4,"smoking_pack_years":59,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-08-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-31},"pfs_months":19.19},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":false},"longitudinal_labs":[{"date":"2025-06-15","hemoglobin_g_dL":12.0,"wbc_k_uL":7.0,"platelets_k_uL":286,"creatinine_mg_dL":1.05,"alt_U_L":55},{"date":"2026-02-07","hemoglobin_g_dL":11.1,"wbc_k_uL":7.6,"platelets_k_uL":285,"creatinine_mg_dL":1.24,"alt_U_L":78},{"date":"2027-05-07","hemoglobin_g_dL":12.5,"wbc_k_uL":5.6,"platelets_k_uL":164,"creatinine_mg_dL":1.65,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":49,"sex":"female","bmi":31.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-30},"pfs_months":17.15},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.8,"censored":true},"longitudinal_labs":[{"date":"2022-05-23","hemoglobin_g_dL":12.5,"wbc_k_uL":5.1,"platelets_k_uL":446,"creatinine_mg_dL":0.85,"alt_U_L":13},{"date":"2023-01-12","hemoglobin_g_dL":11.5,"wbc_k_uL":3.9,"platelets_k_uL":163,"creatinine_mg_dL":1.38,"alt_U_L":26},{"date":"2024-01-02","hemoglobin_g_dL":12.9,"wbc_k_uL":5.9,"platelets_k_uL":294,"creatinine_mg_dL":1.45,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":86,"sex":"female","bmi":21.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-34},"pfs_months":30.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.5,"censored":true},"longitudinal_labs":[{"date":"2025-06-17","hemoglobin_g_dL":12.1,"wbc_k_uL":5.8,"platelets_k_uL":408,"creatinine_mg_dL":1.09,"alt_U_L":30},{"date":"2026-01-13","hemoglobin_g_dL":12.4,"wbc_k_uL":7.8,"platelets_k_uL":310,"creatinine_mg_dL":1.52,"alt_U_L":91},{"date":"2028-02-23","hemoglobin_g_dL":12.2,"wbc_k_uL":4.4,"platelets_k_uL":318,"creatinine_mg_dL":1.28,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":81,"sex":"female","bmi":29.2,"smoking_pack_years":51,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["brain","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2022-07-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-65},"pfs_months":18.63},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":true},"longitudinal_labs":[{"date":"2022-06-01","hemoglobin_g_dL":13.9,"wbc_k_uL":5.0,"platelets_k_uL":409,"creatinine_mg_dL":0.87,"alt_U_L":18},{"date":"2023-01-04","hemoglobin_g_dL":10.4,"wbc_k_uL":6.4,"platelets_k_uL":294,"creatinine_mg_dL":1.56,"alt_U_L":61},{"date":"2024-03-26","hemoglobin_g_dL":9.9,"wbc_k_uL":5.9,"platelets_k_uL":297,"creatinine_mg_dL":1.38,"alt_U_L":125}]}
{"patient_id":"ANODE_SYNTH_2025_721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":49,"sex":"female","bmi":26.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-55},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.5,"censored":false},"longitudinal_labs":[{"date":"2025-01-25","hemoglobin_g_dL":13.8,"wbc_k_uL":9.5,"platelets_k_uL":246,"creatinine_mg_dL":0.93,"alt_U_L":73},{"date":"2025-09-10","hemoglobin_g_dL":12.4,"wbc_k_uL":6.8,"platelets_k_uL":328,"creatinine_mg_dL":0.96,"alt_U_L":77},{"date":"2027-01-05","hemoglobin_g_dL":12.4,"wbc_k_uL":4.8,"platelets_k_uL":279,"creatinine_mg_dL":1.64,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":53,"sex":"female","bmi":24.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-69},"pfs_months":34.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.8,"censored":false},"longitudinal_labs":[{"date":"2025-03-04","hemoglobin_g_dL":14.4,"wbc_k_uL":9.9,"platelets_k_uL":442,"creatinine_mg_dL":1.19,"alt_U_L":79},{"date":"2025-11-09","hemoglobin_g_dL":13.0,"wbc_k_uL":7.7,"platelets_k_uL":306,"creatinine_mg_dL":1.1,"alt_U_L":18},{"date":"2028-05-01","hemoglobin_g_dL":12.4,"wbc_k_uL":5.4,"platelets_k_uL":136,"creatinine_mg_dL":1.26,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":65,"sex":"male","bmi":35.5,"smoking_pack_years":43,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-07-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-74},"pfs_months":3.88},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":7.8,"censored":false},"longitudinal_labs":[{"date":"2024-07-10","hemoglobin_g_dL":15.5,"wbc_k_uL":6.6,"platelets_k_uL":255,"creatinine_mg_dL":1.24,"alt_U_L":75},{"date":"2025-01-24","hemoglobin_g_dL":11.4,"wbc_k_uL":6.2,"platelets_k_uL":167,"creatinine_mg_dL":1.34,"alt_U_L":94},{"date":"2024-12-22","hemoglobin_g_dL":12.4,"wbc_k_uL":7.3,"platelets_k_uL":120,"creatinine_mg_dL":1.14,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_724","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":60,"sex":"female","bmi":24.4,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-07-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-65},"pfs_months":25.53},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.9,"censored":false},"longitudinal_labs":[{"date":"2021-06-24","hemoglobin_g_dL":12.8,"wbc_k_uL":6.1,"platelets_k_uL":155,"creatinine_mg_dL":0.73,"alt_U_L":53},{"date":"2022-01-11","hemoglobin_g_dL":10.3,"wbc_k_uL":4.6,"platelets_k_uL":172,"creatinine_mg_dL":1.46,"alt_U_L":91},{"date":"2023-10-26","hemoglobin_g_dL":12.9,"wbc_k_uL":4.2,"platelets_k_uL":262,"creatinine_mg_dL":1.51,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":57,"sex":"male","bmi":37.6,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-82},"pfs_months":19.42},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":false},"longitudinal_labs":[{"date":"2023-05-12","hemoglobin_g_dL":11.6,"wbc_k_uL":5.7,"platelets_k_uL":229,"creatinine_mg_dL":0.86,"alt_U_L":36},{"date":"2024-01-14","hemoglobin_g_dL":10.3,"wbc_k_uL":3.9,"platelets_k_uL":129,"creatinine_mg_dL":1.12,"alt_U_L":99},{"date":"2025-04-24","hemoglobin_g_dL":9.8,"wbc_k_uL":3.2,"platelets_k_uL":174,"creatinine_mg_dL":1.46,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":51,"sex":"female","bmi":31.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-68},"pfs_months":20.27},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":true},"longitudinal_labs":[{"date":"2020-11-03","hemoglobin_g_dL":14.2,"wbc_k_uL":6.8,"platelets_k_uL":171,"creatinine_mg_dL":1.02,"alt_U_L":36},{"date":"2021-05-19","hemoglobin_g_dL":13.3,"wbc_k_uL":8.7,"platelets_k_uL":237,"creatinine_mg_dL":1.42,"alt_U_L":66},{"date":"2022-08-21","hemoglobin_g_dL":9.8,"wbc_k_uL":7.5,"platelets_k_uL":293,"creatinine_mg_dL":0.81,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_727","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":76,"sex":"male","bmi":34.6,"smoking_pack_years":39,"ecog_performance_status":2,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-11-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-72},"pfs_months":28.81},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.8,"censored":true},"longitudinal_labs":[{"date":"2024-10-03","hemoglobin_g_dL":12.3,"wbc_k_uL":5.7,"platelets_k_uL":261,"creatinine_mg_dL":0.99,"alt_U_L":65},{"date":"2025-05-25","hemoglobin_g_dL":12.7,"wbc_k_uL":6.0,"platelets_k_uL":234,"creatinine_mg_dL":0.78,"alt_U_L":50},{"date":"2027-05-29","hemoglobin_g_dL":11.3,"wbc_k_uL":4.7,"platelets_k_uL":130,"creatinine_mg_dL":1.88,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":80,"sex":"female","bmi":24.7,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-12-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-62},"pfs_months":30.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":63.1,"censored":true},"longitudinal_labs":[{"date":"2024-11-17","hemoglobin_g_dL":11.7,"wbc_k_uL":6.0,"platelets_k_uL":177,"creatinine_mg_dL":1.25,"alt_U_L":68},{"date":"2025-06-08","hemoglobin_g_dL":12.8,"wbc_k_uL":8.7,"platelets_k_uL":310,"creatinine_mg_dL":0.72,"alt_U_L":42},{"date":"2027-07-31","hemoglobin_g_dL":10.5,"wbc_k_uL":4.9,"platelets_k_uL":333,"creatinine_mg_dL":1.61,"alt_U_L":58}]}
{"patient_id":"ANODE_SYNTH_2025_729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":56,"sex":"female","bmi":21.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-01-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-51},"pfs_months":25.0},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.4,"censored":false},"longitudinal_labs":[{"date":"2025-12-18","hemoglobin_g_dL":13.7,"wbc_k_uL":6.8,"platelets_k_uL":443,"creatinine_mg_dL":0.65,"alt_U_L":67},{"date":"2026-07-23","hemoglobin_g_dL":10.4,"wbc_k_uL":5.3,"platelets_k_uL":146,"creatinine_mg_dL":0.97,"alt_U_L":88},{"date":"2028-04-08","hemoglobin_g_dL":9.9,"wbc_k_uL":3.5,"platelets_k_uL":229,"creatinine_mg_dL":1.92,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":54,"sex":"male","bmi":36.0,"smoking_pack_years":47,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-10-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-84},"pfs_months":30.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":54.4,"censored":false},"longitudinal_labs":[{"date":"2022-07-28","hemoglobin_g_dL":12.7,"wbc_k_uL":4.8,"platelets_k_uL":358,"creatinine_mg_dL":0.81,"alt_U_L":34},{"date":"2023-04-04","hemoglobin_g_dL":10.3,"wbc_k_uL":4.3,"platelets_k_uL":132,"creatinine_mg_dL":1.54,"alt_U_L":75},{"date":"2025-06-05","hemoglobin_g_dL":12.6,"wbc_k_uL":6.6,"platelets_k_uL":162,"creatinine_mg_dL":1.11,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":51,"sex":"female","bmi":28.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-05-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-46},"pfs_months":16.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.7,"censored":true},"longitudinal_labs":[{"date":"2023-05-10","hemoglobin_g_dL":14.2,"wbc_k_uL":8.7,"platelets_k_uL":326,"creatinine_mg_dL":0.68,"alt_U_L":43},{"date":"2023-11-26","hemoglobin_g_dL":12.5,"wbc_k_uL":5.0,"platelets_k_uL":210,"creatinine_mg_dL":1.58,"alt_U_L":83},{"date":"2024-10-29","hemoglobin_g_dL":11.7,"wbc_k_uL":4.0,"platelets_k_uL":262,"creatinine_mg_dL":1.34,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":65,"sex":"female","bmi":38.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-65},"pfs_months":18.5},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":true},"longitudinal_labs":[{"date":"2021-01-04","hemoglobin_g_dL":14.0,"wbc_k_uL":10.7,"platelets_k_uL":310,"creatinine_mg_dL":0.96,"alt_U_L":28},{"date":"2021-07-23","hemoglobin_g_dL":12.0,"wbc_k_uL":3.9,"platelets_k_uL":294,"creatinine_mg_dL":0.87,"alt_U_L":16},{"date":"2022-09-18","hemoglobin_g_dL":12.8,"wbc_k_uL":5.0,"platelets_k_uL":273,"creatinine_mg_dL":1.58,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_733","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":70,"sex":"female","bmi":20.4,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-02-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-39},"pfs_months":25.95},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.2,"censored":true},"longitudinal_labs":[{"date":"2023-01-13","hemoglobin_g_dL":13.5,"wbc_k_uL":5.2,"platelets_k_uL":173,"creatinine_mg_dL":0.84,"alt_U_L":36},{"date":"2023-08-10","hemoglobin_g_dL":12.0,"wbc_k_uL":4.4,"platelets_k_uL":209,"creatinine_mg_dL":0.97,"alt_U_L":31},{"date":"2025-04-30","hemoglobin_g_dL":12.0,"wbc_k_uL":7.1,"platelets_k_uL":124,"creatinine_mg_dL":1.04,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":68,"sex":"female","bmi":25.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-62},"pfs_months":9.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.9,"censored":false},"longitudinal_labs":[{"date":"2023-06-02","hemoglobin_g_dL":13.3,"wbc_k_uL":7.0,"platelets_k_uL":405,"creatinine_mg_dL":0.99,"alt_U_L":70},{"date":"2024-01-04","hemoglobin_g_dL":13.1,"wbc_k_uL":4.3,"platelets_k_uL":266,"creatinine_mg_dL":1.1,"alt_U_L":66},{"date":"2024-04-23","hemoglobin_g_dL":10.9,"wbc_k_uL":4.9,"platelets_k_uL":279,"creatinine_mg_dL":1.88,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":51,"sex":"female","bmi":33.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-44},"pfs_months":26.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.5,"censored":false},"longitudinal_labs":[{"date":"2025-08-03","hemoglobin_g_dL":13.1,"wbc_k_uL":9.4,"platelets_k_uL":359,"creatinine_mg_dL":0.77,"alt_U_L":45},{"date":"2026-03-24","hemoglobin_g_dL":11.2,"wbc_k_uL":8.0,"platelets_k_uL":356,"creatinine_mg_dL":1.51,"alt_U_L":22},{"date":"2028-01-19","hemoglobin_g_dL":10.3,"wbc_k_uL":6.8,"platelets_k_uL":291,"creatinine_mg_dL":1.25,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":58,"sex":"female","bmi":20.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-05-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-69},"pfs_months":15.97},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.0,"censored":false},"longitudinal_labs":[{"date":"2023-03-25","hemoglobin_g_dL":13.8,"wbc_k_uL":10.0,"platelets_k_uL":394,"creatinine_mg_dL":0.78,"alt_U_L":55},{"date":"2023-11-24","hemoglobin_g_dL":11.9,"wbc_k_uL":4.2,"platelets_k_uL":206,"creatinine_mg_dL":1.31,"alt_U_L":97},{"date":"2024-10-15","hemoglobin_g_dL":10.0,"wbc_k_uL":4.1,"platelets_k_uL":293,"creatinine_mg_dL":1.98,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":55,"sex":"female","bmi":19.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-64},"pfs_months":19.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.2,"censored":false},"longitudinal_labs":[{"date":"2024-07-27","hemoglobin_g_dL":12.1,"wbc_k_uL":7.7,"platelets_k_uL":186,"creatinine_mg_dL":0.87,"alt_U_L":32},{"date":"2025-03-03","hemoglobin_g_dL":13.0,"wbc_k_uL":7.7,"platelets_k_uL":264,"creatinine_mg_dL":1.47,"alt_U_L":52},{"date":"2026-05-15","hemoglobin_g_dL":10.6,"wbc_k_uL":7.7,"platelets_k_uL":102,"creatinine_mg_dL":1.82,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_738","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":50,"sex":"female","bmi":26.7,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-12-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-30},"pfs_months":14.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.3,"censored":false},"longitudinal_labs":[{"date":"2021-11-26","hemoglobin_g_dL":12.6,"wbc_k_uL":8.0,"platelets_k_uL":208,"creatinine_mg_dL":0.89,"alt_U_L":73},{"date":"2022-06-22","hemoglobin_g_dL":10.4,"wbc_k_uL":6.0,"platelets_k_uL":236,"creatinine_mg_dL":1.41,"alt_U_L":58},{"date":"2023-04-30","hemoglobin_g_dL":10.8,"wbc_k_uL":5.0,"platelets_k_uL":296,"creatinine_mg_dL":1.27,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":54,"sex":"female","bmi":23.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-75},"pfs_months":19.71},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.8,"censored":false},"longitudinal_labs":[{"date":"2023-05-04","hemoglobin_g_dL":12.7,"wbc_k_uL":6.8,"platelets_k_uL":208,"creatinine_mg_dL":0.79,"alt_U_L":71},{"date":"2024-01-06","hemoglobin_g_dL":10.8,"wbc_k_uL":5.3,"platelets_k_uL":176,"creatinine_mg_dL":1.06,"alt_U_L":15},{"date":"2025-04-10","hemoglobin_g_dL":12.0,"wbc_k_uL":3.4,"platelets_k_uL":312,"creatinine_mg_dL":1.56,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":84,"sex":"female","bmi":34.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-68},"pfs_months":27.27},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.5,"censored":false},"longitudinal_labs":[{"date":"2025-09-11","hemoglobin_g_dL":13.0,"wbc_k_uL":5.4,"platelets_k_uL":283,"creatinine_mg_dL":0.63,"alt_U_L":44},{"date":"2026-05-05","hemoglobin_g_dL":11.1,"wbc_k_uL":5.5,"platelets_k_uL":243,"creatinine_mg_dL":1.22,"alt_U_L":23},{"date":"2028-03-25","hemoglobin_g_dL":11.7,"wbc_k_uL":7.4,"platelets_k_uL":257,"creatinine_mg_dL":1.18,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":84,"sex":"female","bmi":26.0,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-11-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-85},"pfs_months":39.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-03-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":61.7,"censored":false},"longitudinal_labs":[{"date":"2025-09-23","hemoglobin_g_dL":12.9,"wbc_k_uL":10.4,"platelets_k_uL":182,"creatinine_mg_dL":0.62,"alt_U_L":13},{"date":"2026-05-14","hemoglobin_g_dL":12.4,"wbc_k_uL":6.6,"platelets_k_uL":371,"creatinine_mg_dL":1.52,"alt_U_L":106},{"date":"2029-03-26","hemoglobin_g_dL":10.2,"wbc_k_uL":3.5,"platelets_k_uL":315,"creatinine_mg_dL":1.14,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_742","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":72,"sex":"female","bmi":24.9,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-31},"pfs_months":26.74},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.6,"censored":false},"longitudinal_labs":[{"date":"2023-05-09","hemoglobin_g_dL":13.5,"wbc_k_uL":6.2,"platelets_k_uL":394,"creatinine_mg_dL":1.16,"alt_U_L":16},{"date":"2023-12-30","hemoglobin_g_dL":13.5,"wbc_k_uL":5.3,"platelets_k_uL":285,"creatinine_mg_dL":1.22,"alt_U_L":80},{"date":"2025-10-22","hemoglobin_g_dL":11.5,"wbc_k_uL":6.7,"platelets_k_uL":215,"creatinine_mg_dL":1.3,"alt_U_L":56}]}
{"patient_id":"ANODE_SYNTH_2025_743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":60,"sex":"female","bmi":33.0,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-08-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-69},"pfs_months":18.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.9,"censored":false},"longitudinal_labs":[{"date":"2022-07-27","hemoglobin_g_dL":12.2,"wbc_k_uL":7.6,"platelets_k_uL":328,"creatinine_mg_dL":0.91,"alt_U_L":41},{"date":"2023-02-13","hemoglobin_g_dL":11.5,"wbc_k_uL":5.5,"platelets_k_uL":230,"creatinine_mg_dL":1.29,"alt_U_L":42},{"date":"2024-03-29","hemoglobin_g_dL":11.7,"wbc_k_uL":6.8,"platelets_k_uL":136,"creatinine_mg_dL":0.88,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_744","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":51,"sex":"female","bmi":34.5,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-05-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-78},"pfs_months":17.91},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.0,"censored":false},"longitudinal_labs":[{"date":"2021-03-12","hemoglobin_g_dL":14.1,"wbc_k_uL":6.6,"platelets_k_uL":292,"creatinine_mg_dL":0.64,"alt_U_L":27},{"date":"2021-11-09","hemoglobin_g_dL":12.8,"wbc_k_uL":8.3,"platelets_k_uL":356,"creatinine_mg_dL":1.45,"alt_U_L":26},{"date":"2022-12-20","hemoglobin_g_dL":12.0,"wbc_k_uL":4.7,"platelets_k_uL":221,"creatinine_mg_dL":1.63,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_745","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":73,"sex":"female","bmi":26.3,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-06-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-76},"pfs_months":35.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":57.7,"censored":false},"longitudinal_labs":[{"date":"2025-05-05","hemoglobin_g_dL":12.1,"wbc_k_uL":7.0,"platelets_k_uL":302,"creatinine_mg_dL":0.62,"alt_U_L":75},{"date":"2025-12-16","hemoglobin_g_dL":12.2,"wbc_k_uL":3.9,"platelets_k_uL":160,"creatinine_mg_dL":1.53,"alt_U_L":120},{"date":"2028-07-13","hemoglobin_g_dL":11.2,"wbc_k_uL":6.0,"platelets_k_uL":330,"creatinine_mg_dL":1.87,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":49,"sex":"female","bmi":28.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-09-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-79},"pfs_months":34.6},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":53.2,"censored":false},"longitudinal_labs":[{"date":"2023-08-12","hemoglobin_g_dL":13.6,"wbc_k_uL":9.8,"platelets_k_uL":336,"creatinine_mg_dL":0.81,"alt_U_L":52},{"date":"2024-03-22","hemoglobin_g_dL":11.8,"wbc_k_uL":7.0,"platelets_k_uL":317,"creatinine_mg_dL":1.5,"alt_U_L":55},{"date":"2026-09-21","hemoglobin_g_dL":10.1,"wbc_k_uL":4.4,"platelets_k_uL":328,"creatinine_mg_dL":1.98,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":62,"sex":"female","bmi":28.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-70},"pfs_months":19.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.2,"censored":false},"longitudinal_labs":[{"date":"2024-03-01","hemoglobin_g_dL":14.3,"wbc_k_uL":6.2,"platelets_k_uL":410,"creatinine_mg_dL":1.26,"alt_U_L":14},{"date":"2024-11-01","hemoglobin_g_dL":11.2,"wbc_k_uL":3.9,"platelets_k_uL":133,"creatinine_mg_dL":0.94,"alt_U_L":93},{"date":"2026-01-27","hemoglobin_g_dL":11.0,"wbc_k_uL":4.9,"platelets_k_uL":140,"creatinine_mg_dL":1.16,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":53,"sex":"female","bmi":19.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-50},"pfs_months":24.84},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.1,"censored":true},"longitudinal_labs":[{"date":"2021-05-07","hemoglobin_g_dL":12.4,"wbc_k_uL":9.5,"platelets_k_uL":258,"creatinine_mg_dL":0.69,"alt_U_L":16},{"date":"2021-12-07","hemoglobin_g_dL":10.4,"wbc_k_uL":4.9,"platelets_k_uL":188,"creatinine_mg_dL":0.74,"alt_U_L":111},{"date":"2023-07-16","hemoglobin_g_dL":12.0,"wbc_k_uL":3.8,"platelets_k_uL":164,"creatinine_mg_dL":1.74,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_749","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":61,"sex":"female","bmi":35.9,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-75},"pfs_months":49.64},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":82.2,"censored":false},"longitudinal_labs":[{"date":"2022-07-25","hemoglobin_g_dL":11.8,"wbc_k_uL":8.0,"platelets_k_uL":217,"creatinine_mg_dL":0.9,"alt_U_L":30},{"date":"2023-02-11","hemoglobin_g_dL":12.4,"wbc_k_uL":4.3,"platelets_k_uL":177,"creatinine_mg_dL":1.48,"alt_U_L":32},{"date":"2026-11-30","hemoglobin_g_dL":11.9,"wbc_k_uL":3.0,"platelets_k_uL":302,"creatinine_mg_dL":1.73,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":49,"sex":"female","bmi":29.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-54},"pfs_months":18.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":24.8,"censored":false},"longitudinal_labs":[{"date":"2025-10-04","hemoglobin_g_dL":12.2,"wbc_k_uL":4.9,"platelets_k_uL":345,"creatinine_mg_dL":0.94,"alt_U_L":33},{"date":"2026-05-10","hemoglobin_g_dL":13.8,"wbc_k_uL":8.4,"platelets_k_uL":137,"creatinine_mg_dL":1.28,"alt_U_L":50},{"date":"2027-07-06","hemoglobin_g_dL":11.0,"wbc_k_uL":6.7,"platelets_k_uL":310,"creatinine_mg_dL":1.98,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":80,"sex":"female","bmi":27.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["bone","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-62},"pfs_months":22.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.6,"censored":true},"longitudinal_labs":[{"date":"2024-04-26","hemoglobin_g_dL":11.8,"wbc_k_uL":10.5,"platelets_k_uL":305,"creatinine_mg_dL":0.74,"alt_U_L":30},{"date":"2024-11-25","hemoglobin_g_dL":11.3,"wbc_k_uL":8.1,"platelets_k_uL":349,"creatinine_mg_dL":1.0,"alt_U_L":118},{"date":"2026-04-13","hemoglobin_g_dL":10.0,"wbc_k_uL":5.6,"platelets_k_uL":101,"creatinine_mg_dL":1.96,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_752","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":82,"sex":"female","bmi":28.1,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-10-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-71},"pfs_months":35.19},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.2,"censored":false},"longitudinal_labs":[{"date":"2023-10-10","hemoglobin_g_dL":15.3,"wbc_k_uL":5.7,"platelets_k_uL":279,"creatinine_mg_dL":1.21,"alt_U_L":32},{"date":"2024-04-21","hemoglobin_g_dL":11.5,"wbc_k_uL":6.1,"platelets_k_uL":138,"creatinine_mg_dL":1.43,"alt_U_L":72},{"date":"2026-10-26","hemoglobin_g_dL":10.8,"wbc_k_uL":5.8,"platelets_k_uL":326,"creatinine_mg_dL":0.94,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.0,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":56,"sex":"female","bmi":19.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-33},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.7,"censored":false},"longitudinal_labs":[{"date":"2021-07-28","hemoglobin_g_dL":11.8,"wbc_k_uL":6.2,"platelets_k_uL":255,"creatinine_mg_dL":0.79,"alt_U_L":56},{"date":"2022-02-28","hemoglobin_g_dL":11.5,"wbc_k_uL":5.5,"platelets_k_uL":378,"creatinine_mg_dL":0.93,"alt_U_L":102},{"date":"2023-07-12","hemoglobin_g_dL":12.5,"wbc_k_uL":3.5,"platelets_k_uL":349,"creatinine_mg_dL":0.87,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_754","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":68,"sex":"male","bmi":20.6,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-42},"pfs_months":27.14},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.0,"censored":true},"longitudinal_labs":[{"date":"2023-10-06","hemoglobin_g_dL":11.9,"wbc_k_uL":7.1,"platelets_k_uL":222,"creatinine_mg_dL":1.11,"alt_U_L":45},{"date":"2024-06-09","hemoglobin_g_dL":10.4,"wbc_k_uL":4.8,"platelets_k_uL":269,"creatinine_mg_dL":1.33,"alt_U_L":42},{"date":"2026-05-16","hemoglobin_g_dL":10.4,"wbc_k_uL":7.6,"platelets_k_uL":306,"creatinine_mg_dL":1.66,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":54,"sex":"female","bmi":21.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-69},"pfs_months":20.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.4,"censored":true},"longitudinal_labs":[{"date":"2022-12-17","hemoglobin_g_dL":12.5,"wbc_k_uL":6.3,"platelets_k_uL":262,"creatinine_mg_dL":1.21,"alt_U_L":67},{"date":"2023-08-14","hemoglobin_g_dL":10.3,"wbc_k_uL":7.5,"platelets_k_uL":203,"creatinine_mg_dL":1.31,"alt_U_L":54},{"date":"2024-12-12","hemoglobin_g_dL":10.4,"wbc_k_uL":3.1,"platelets_k_uL":285,"creatinine_mg_dL":1.82,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":72,"sex":"female","bmi":37.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-82},"pfs_months":16.62},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.7,"censored":false},"longitudinal_labs":[{"date":"2024-03-18","hemoglobin_g_dL":12.8,"wbc_k_uL":10.2,"platelets_k_uL":220,"creatinine_mg_dL":0.87,"alt_U_L":47},{"date":"2024-11-06","hemoglobin_g_dL":10.9,"wbc_k_uL":5.0,"platelets_k_uL":154,"creatinine_mg_dL":1.19,"alt_U_L":72},{"date":"2025-10-12","hemoglobin_g_dL":9.8,"wbc_k_uL":7.6,"platelets_k_uL":226,"creatinine_mg_dL":1.42,"alt_U_L":145}]}
{"patient_id":"ANODE_SYNTH_2025_757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":65,"sex":"male","bmi":32.3,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-12-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-83},"pfs_months":36.7},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":56.7,"censored":false},"longitudinal_labs":[{"date":"2021-12-08","hemoglobin_g_dL":15.2,"wbc_k_uL":10.1,"platelets_k_uL":296,"creatinine_mg_dL":1.07,"alt_U_L":18},{"date":"2022-06-24","hemoglobin_g_dL":10.5,"wbc_k_uL":4.7,"platelets_k_uL":132,"creatinine_mg_dL":0.95,"alt_U_L":19},{"date":"2025-01-21","hemoglobin_g_dL":11.0,"wbc_k_uL":6.8,"platelets_k_uL":167,"creatinine_mg_dL":1.73,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":72,"sex":"female","bmi":25.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-47},"pfs_months":26.45},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.1,"censored":false},"longitudinal_labs":[{"date":"2024-05-23","hemoglobin_g_dL":14.6,"wbc_k_uL":9.9,"platelets_k_uL":439,"creatinine_mg_dL":1.17,"alt_U_L":14},{"date":"2024-12-20","hemoglobin_g_dL":13.9,"wbc_k_uL":6.6,"platelets_k_uL":319,"creatinine_mg_dL":0.98,"alt_U_L":74},{"date":"2026-10-03","hemoglobin_g_dL":11.0,"wbc_k_uL":6.3,"platelets_k_uL":292,"creatinine_mg_dL":1.85,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":58,"sex":"female","bmi":29.2,"smoking_pack_years":41,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-11-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-45},"pfs_months":39.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":57.0,"censored":true},"longitudinal_labs":[{"date":"2022-10-13","hemoglobin_g_dL":14.5,"wbc_k_uL":9.4,"platelets_k_uL":392,"creatinine_mg_dL":0.62,"alt_U_L":68},{"date":"2023-05-17","hemoglobin_g_dL":12.4,"wbc_k_uL":8.3,"platelets_k_uL":189,"creatinine_mg_dL":1.57,"alt_U_L":65},{"date":"2026-04-24","hemoglobin_g_dL":10.3,"wbc_k_uL":3.2,"platelets_k_uL":251,"creatinine_mg_dL":1.79,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":49,"sex":"female","bmi":30.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-84},"pfs_months":27.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.0,"censored":false},"longitudinal_labs":[{"date":"2023-05-06","hemoglobin_g_dL":12.6,"wbc_k_uL":5.1,"platelets_k_uL":391,"creatinine_mg_dL":0.95,"alt_U_L":46},{"date":"2023-12-15","hemoglobin_g_dL":10.0,"wbc_k_uL":4.0,"platelets_k_uL":256,"creatinine_mg_dL":1.59,"alt_U_L":103},{"date":"2025-12-01","hemoglobin_g_dL":12.0,"wbc_k_uL":3.1,"platelets_k_uL":151,"creatinine_mg_dL":1.72,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":49,"sex":"female","bmi":19.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-60},"pfs_months":16.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.0,"censored":true},"longitudinal_labs":[{"date":"2024-02-11","hemoglobin_g_dL":12.0,"wbc_k_uL":7.9,"platelets_k_uL":250,"creatinine_mg_dL":0.65,"alt_U_L":46},{"date":"2024-09-11","hemoglobin_g_dL":11.8,"wbc_k_uL":7.2,"platelets_k_uL":310,"creatinine_mg_dL":0.71,"alt_U_L":72},{"date":"2025-08-28","hemoglobin_g_dL":12.5,"wbc_k_uL":3.3,"platelets_k_uL":115,"creatinine_mg_dL":1.48,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":70,"sex":"male","bmi":20.2,"smoking_pack_years":77,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-04-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-53},"pfs_months":40.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":61.8,"censored":false},"longitudinal_labs":[{"date":"2024-02-17","hemoglobin_g_dL":15.5,"wbc_k_uL":10.1,"platelets_k_uL":327,"creatinine_mg_dL":1.2,"alt_U_L":11},{"date":"2024-10-08","hemoglobin_g_dL":13.1,"wbc_k_uL":8.4,"platelets_k_uL":363,"creatinine_mg_dL":1.21,"alt_U_L":18},{"date":"2027-09-05","hemoglobin_g_dL":9.9,"wbc_k_uL":5.8,"platelets_k_uL":107,"creatinine_mg_dL":1.58,"alt_U_L":112}]}
{"patient_id":"ANODE_SYNTH_2025_763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":79,"sex":"female","bmi":35.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-43},"pfs_months":2.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":18.1,"censored":false},"longitudinal_labs":[{"date":"2023-06-24","hemoglobin_g_dL":13.5,"wbc_k_uL":8.7,"platelets_k_uL":243,"creatinine_mg_dL":0.91,"alt_U_L":79},{"date":"2024-02-21","hemoglobin_g_dL":11.1,"wbc_k_uL":8.6,"platelets_k_uL":146,"creatinine_mg_dL":1.07,"alt_U_L":29},{"date":"2023-12-14","hemoglobin_g_dL":11.9,"wbc_k_uL":7.1,"platelets_k_uL":153,"creatinine_mg_dL":1.96,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":83,"sex":"female","bmi":19.0,"smoking_pack_years":16,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-08-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-44},"pfs_months":41.07},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":67.2,"censored":false},"longitudinal_labs":[{"date":"2020-07-10","hemoglobin_g_dL":14.7,"wbc_k_uL":7.4,"platelets_k_uL":289,"creatinine_mg_dL":1.09,"alt_U_L":60},{"date":"2021-01-28","hemoglobin_g_dL":12.5,"wbc_k_uL":6.1,"platelets_k_uL":196,"creatinine_mg_dL":1.26,"alt_U_L":98},{"date":"2024-01-12","hemoglobin_g_dL":13.0,"wbc_k_uL":4.2,"platelets_k_uL":109,"creatinine_mg_dL":1.85,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_765","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":66,"sex":"male","bmi":22.0,"smoking_pack_years":61,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-01-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-33},"pfs_months":19.32},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.5,"censored":false},"longitudinal_labs":[{"date":"2021-11-09","hemoglobin_g_dL":13.2,"wbc_k_uL":10.6,"platelets_k_uL":301,"creatinine_mg_dL":0.69,"alt_U_L":47},{"date":"2022-07-05","hemoglobin_g_dL":10.3,"wbc_k_uL":8.4,"platelets_k_uL":363,"creatinine_mg_dL":0.98,"alt_U_L":112},{"date":"2023-08-28","hemoglobin_g_dL":11.9,"wbc_k_uL":7.8,"platelets_k_uL":133,"creatinine_mg_dL":0.95,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":83,"sex":"female","bmi":27.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-43},"pfs_months":31.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.8,"censored":true},"longitudinal_labs":[{"date":"2023-07-06","hemoglobin_g_dL":14.8,"wbc_k_uL":4.8,"platelets_k_uL":244,"creatinine_mg_dL":0.99,"alt_U_L":32},{"date":"2024-01-30","hemoglobin_g_dL":13.3,"wbc_k_uL":7.4,"platelets_k_uL":259,"creatinine_mg_dL":1.12,"alt_U_L":98},{"date":"2026-05-14","hemoglobin_g_dL":11.1,"wbc_k_uL":7.5,"platelets_k_uL":144,"creatinine_mg_dL":1.86,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":79,"sex":"female","bmi":28.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-56},"pfs_months":19.68},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":false},"longitudinal_labs":[{"date":"2024-03-26","hemoglobin_g_dL":14.2,"wbc_k_uL":4.5,"platelets_k_uL":319,"creatinine_mg_dL":1.26,"alt_U_L":59},{"date":"2024-11-14","hemoglobin_g_dL":12.0,"wbc_k_uL":5.8,"platelets_k_uL":139,"creatinine_mg_dL":0.94,"alt_U_L":106},{"date":"2026-01-29","hemoglobin_g_dL":12.2,"wbc_k_uL":4.1,"platelets_k_uL":116,"creatinine_mg_dL":1.5,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":85,"sex":"female","bmi":21.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-78},"pfs_months":24.08},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":false},"longitudinal_labs":[{"date":"2022-06-08","hemoglobin_g_dL":15.5,"wbc_k_uL":9.0,"platelets_k_uL":373,"creatinine_mg_dL":0.9,"alt_U_L":28},{"date":"2022-12-29","hemoglobin_g_dL":13.5,"wbc_k_uL":5.0,"platelets_k_uL":374,"creatinine_mg_dL":1.37,"alt_U_L":74},{"date":"2024-08-14","hemoglobin_g_dL":12.6,"wbc_k_uL":3.2,"platelets_k_uL":122,"creatinine_mg_dL":1.56,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_769","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":87,"sex":"male","bmi":36.9,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-04-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-70},"pfs_months":21.95},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.1,"censored":false},"longitudinal_labs":[{"date":"2020-02-02","hemoglobin_g_dL":15.5,"wbc_k_uL":7.2,"platelets_k_uL":317,"creatinine_mg_dL":0.71,"alt_U_L":73},{"date":"2020-09-29","hemoglobin_g_dL":12.3,"wbc_k_uL":7.8,"platelets_k_uL":300,"creatinine_mg_dL":0.71,"alt_U_L":30},{"date":"2022-02-07","hemoglobin_g_dL":9.7,"wbc_k_uL":7.2,"platelets_k_uL":203,"creatinine_mg_dL":1.46,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":77,"sex":"female","bmi":27.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-74},"pfs_months":26.91},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.9,"censored":true},"longitudinal_labs":[{"date":"2021-08-02","hemoglobin_g_dL":12.7,"wbc_k_uL":8.6,"platelets_k_uL":313,"creatinine_mg_dL":0.8,"alt_U_L":31},{"date":"2022-02-13","hemoglobin_g_dL":11.2,"wbc_k_uL":7.1,"platelets_k_uL":349,"creatinine_mg_dL":0.95,"alt_U_L":25},{"date":"2023-11-22","hemoglobin_g_dL":11.3,"wbc_k_uL":4.2,"platelets_k_uL":144,"creatinine_mg_dL":1.27,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":81,"sex":"female","bmi":25.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-50},"pfs_months":32.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.6,"censored":true},"longitudinal_labs":[{"date":"2022-05-20","hemoglobin_g_dL":13.9,"wbc_k_uL":7.9,"platelets_k_uL":449,"creatinine_mg_dL":0.77,"alt_U_L":37},{"date":"2022-12-30","hemoglobin_g_dL":11.1,"wbc_k_uL":8.3,"platelets_k_uL":349,"creatinine_mg_dL":1.06,"alt_U_L":100},{"date":"2025-04-27","hemoglobin_g_dL":12.8,"wbc_k_uL":7.2,"platelets_k_uL":256,"creatinine_mg_dL":1.34,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":51,"sex":"female","bmi":31.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-51},"pfs_months":24.77},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.5,"censored":true},"longitudinal_labs":[{"date":"2023-01-04","hemoglobin_g_dL":13.0,"wbc_k_uL":6.9,"platelets_k_uL":155,"creatinine_mg_dL":0.73,"alt_U_L":23},{"date":"2023-08-22","hemoglobin_g_dL":13.0,"wbc_k_uL":5.2,"platelets_k_uL":362,"creatinine_mg_dL":0.78,"alt_U_L":33},{"date":"2025-04-23","hemoglobin_g_dL":12.4,"wbc_k_uL":5.4,"platelets_k_uL":166,"creatinine_mg_dL":1.25,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":54,"sex":"male","bmi":27.2,"smoking_pack_years":24,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-08-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-43},"pfs_months":13.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":23.0,"censored":false},"longitudinal_labs":[{"date":"2020-06-25","hemoglobin_g_dL":12.6,"wbc_k_uL":4.9,"platelets_k_uL":325,"creatinine_mg_dL":1.27,"alt_U_L":39},{"date":"2021-02-08","hemoglobin_g_dL":13.9,"wbc_k_uL":4.9,"platelets_k_uL":238,"creatinine_mg_dL":1.03,"alt_U_L":51},{"date":"2021-10-09","hemoglobin_g_dL":12.9,"wbc_k_uL":4.2,"platelets_k_uL":237,"creatinine_mg_dL":1.56,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":61,"sex":"female","bmi":31.2,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-53},"pfs_months":16.85},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.8,"censored":true},"longitudinal_labs":[{"date":"2025-11-03","hemoglobin_g_dL":15.1,"wbc_k_uL":10.8,"platelets_k_uL":258,"creatinine_mg_dL":0.89,"alt_U_L":70},{"date":"2026-06-23","hemoglobin_g_dL":11.3,"wbc_k_uL":8.3,"platelets_k_uL":257,"creatinine_mg_dL":0.94,"alt_U_L":34},{"date":"2027-06-25","hemoglobin_g_dL":10.9,"wbc_k_uL":3.5,"platelets_k_uL":294,"creatinine_mg_dL":1.99,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":55,"sex":"male","bmi":33.4,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-05-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-50},"pfs_months":36.76},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":58.8,"censored":false},"longitudinal_labs":[{"date":"2025-03-17","hemoglobin_g_dL":14.8,"wbc_k_uL":6.1,"platelets_k_uL":280,"creatinine_mg_dL":0.91,"alt_U_L":28},{"date":"2025-11-11","hemoglobin_g_dL":12.1,"wbc_k_uL":7.2,"platelets_k_uL":158,"creatinine_mg_dL":0.89,"alt_U_L":44},{"date":"2028-06-19","hemoglobin_g_dL":12.3,"wbc_k_uL":6.2,"platelets_k_uL":102,"creatinine_mg_dL":1.36,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":74,"sex":"female","bmi":36.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-69},"pfs_months":26.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.0,"censored":true},"longitudinal_labs":[{"date":"2022-03-24","hemoglobin_g_dL":11.9,"wbc_k_uL":10.8,"platelets_k_uL":363,"creatinine_mg_dL":0.79,"alt_U_L":28},{"date":"2022-11-16","hemoglobin_g_dL":11.5,"wbc_k_uL":8.5,"platelets_k_uL":279,"creatinine_mg_dL":0.88,"alt_U_L":61},{"date":"2024-09-19","hemoglobin_g_dL":9.9,"wbc_k_uL":3.6,"platelets_k_uL":309,"creatinine_mg_dL":1.18,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":64,"sex":"female","bmi":32.2,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-46},"pfs_months":15.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":24.4,"censored":false},"longitudinal_labs":[{"date":"2021-07-22","hemoglobin_g_dL":13.6,"wbc_k_uL":10.2,"platelets_k_uL":341,"creatinine_mg_dL":1.09,"alt_U_L":77},{"date":"2022-02-14","hemoglobin_g_dL":11.9,"wbc_k_uL":8.0,"platelets_k_uL":231,"creatinine_mg_dL":0.92,"alt_U_L":46},{"date":"2023-01-17","hemoglobin_g_dL":10.9,"wbc_k_uL":7.6,"platelets_k_uL":281,"creatinine_mg_dL":1.41,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":51,"sex":"female","bmi":27.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-75},"pfs_months":23.56},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.0,"censored":false},"longitudinal_labs":[{"date":"2023-01-18","hemoglobin_g_dL":11.7,"wbc_k_uL":9.5,"platelets_k_uL":442,"creatinine_mg_dL":0.66,"alt_U_L":37},{"date":"2023-08-04","hemoglobin_g_dL":11.9,"wbc_k_uL":5.9,"platelets_k_uL":192,"creatinine_mg_dL":1.33,"alt_U_L":109},{"date":"2025-02-05","hemoglobin_g_dL":12.6,"wbc_k_uL":6.4,"platelets_k_uL":235,"creatinine_mg_dL":1.09,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":67,"sex":"female","bmi":24.3,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-44},"pfs_months":28.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":false},"longitudinal_labs":[{"date":"2021-02-20","hemoglobin_g_dL":14.6,"wbc_k_uL":7.3,"platelets_k_uL":376,"creatinine_mg_dL":0.9,"alt_U_L":30},{"date":"2021-09-02","hemoglobin_g_dL":11.5,"wbc_k_uL":4.1,"platelets_k_uL":189,"creatinine_mg_dL":1.25,"alt_U_L":23},{"date":"2023-09-10","hemoglobin_g_dL":12.2,"wbc_k_uL":7.8,"platelets_k_uL":298,"creatinine_mg_dL":1.32,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_780","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":56,"sex":"female","bmi":33.3,"smoking_pack_years":30,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-05-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-81},"pfs_months":27.99},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-23","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.4,"censored":false},"longitudinal_labs":[{"date":"2024-04-02","hemoglobin_g_dL":13.3,"wbc_k_uL":10.4,"platelets_k_uL":410,"creatinine_mg_dL":1.04,"alt_U_L":71},{"date":"2024-11-09","hemoglobin_g_dL":10.8,"wbc_k_uL":7.8,"platelets_k_uL":144,"creatinine_mg_dL":1.37,"alt_U_L":51},{"date":"2026-10-23","hemoglobin_g_dL":10.2,"wbc_k_uL":6.8,"platelets_k_uL":176,"creatinine_mg_dL":1.42,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":78,"sex":"male","bmi":34.0,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-06-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-32},"pfs_months":31.38},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":51.8,"censored":true},"longitudinal_labs":[{"date":"2025-04-05","hemoglobin_g_dL":14.7,"wbc_k_uL":5.7,"platelets_k_uL":311,"creatinine_mg_dL":0.65,"alt_U_L":23},{"date":"2025-11-28","hemoglobin_g_dL":13.1,"wbc_k_uL":6.7,"platelets_k_uL":360,"creatinine_mg_dL":1.27,"alt_U_L":17},{"date":"2028-02-26","hemoglobin_g_dL":11.4,"wbc_k_uL":5.1,"platelets_k_uL":337,"creatinine_mg_dL":1.62,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":86,"sex":"female","bmi":22.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-83},"pfs_months":13.37},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":true},"longitudinal_labs":[{"date":"2021-04-09","hemoglobin_g_dL":14.4,"wbc_k_uL":6.8,"platelets_k_uL":329,"creatinine_mg_dL":0.61,"alt_U_L":49},{"date":"2021-10-24","hemoglobin_g_dL":10.9,"wbc_k_uL":8.4,"platelets_k_uL":160,"creatinine_mg_dL":1.5,"alt_U_L":98},{"date":"2022-08-03","hemoglobin_g_dL":11.7,"wbc_k_uL":7.6,"platelets_k_uL":343,"creatinine_mg_dL":1.23,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":50,"sex":"female","bmi":28.4,"smoking_pack_years":80,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-53},"pfs_months":40.51},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.1,"censored":false},"longitudinal_labs":[{"date":"2024-01-06","hemoglobin_g_dL":12.4,"wbc_k_uL":5.4,"platelets_k_uL":309,"creatinine_mg_dL":1.2,"alt_U_L":80},{"date":"2024-08-28","hemoglobin_g_dL":12.0,"wbc_k_uL":6.4,"platelets_k_uL":187,"creatinine_mg_dL":1.43,"alt_U_L":57},{"date":"2027-07-26","hemoglobin_g_dL":10.7,"wbc_k_uL":6.7,"platelets_k_uL":260,"creatinine_mg_dL":1.88,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_784","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":69,"sex":"female","bmi":19.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-02-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-42},"pfs_months":24.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":true},"longitudinal_labs":[{"date":"2022-01-11","hemoglobin_g_dL":13.0,"wbc_k_uL":5.6,"platelets_k_uL":260,"creatinine_mg_dL":1.0,"alt_U_L":53},{"date":"2022-08-18","hemoglobin_g_dL":12.6,"wbc_k_uL":5.1,"platelets_k_uL":321,"creatinine_mg_dL":1.45,"alt_U_L":26},{"date":"2024-04-10","hemoglobin_g_dL":12.2,"wbc_k_uL":3.7,"platelets_k_uL":344,"creatinine_mg_dL":1.36,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":53,"sex":"female","bmi":24.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-77},"pfs_months":24.44},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":true},"longitudinal_labs":[{"date":"2025-03-12","hemoglobin_g_dL":13.8,"wbc_k_uL":8.1,"platelets_k_uL":259,"creatinine_mg_dL":0.99,"alt_U_L":76},{"date":"2025-11-03","hemoglobin_g_dL":11.1,"wbc_k_uL":7.3,"platelets_k_uL":198,"creatinine_mg_dL":0.9,"alt_U_L":120},{"date":"2027-07-03","hemoglobin_g_dL":10.7,"wbc_k_uL":3.2,"platelets_k_uL":119,"creatinine_mg_dL":1.45,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":56,"sex":"female","bmi":19.6,"smoking_pack_years":22,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2026-01-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-73},"pfs_months":31.61},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-09-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":54.9,"censored":true},"longitudinal_labs":[{"date":"2025-12-23","hemoglobin_g_dL":13.1,"wbc_k_uL":8.8,"platelets_k_uL":235,"creatinine_mg_dL":1.07,"alt_U_L":25},{"date":"2026-07-07","hemoglobin_g_dL":13.4,"wbc_k_uL":8.4,"platelets_k_uL":375,"creatinine_mg_dL":0.95,"alt_U_L":24},{"date":"2028-09-04","hemoglobin_g_dL":12.6,"wbc_k_uL":3.2,"platelets_k_uL":265,"creatinine_mg_dL":1.84,"alt_U_L":87}]}
{"patient_id":"ANODE_SYNTH_2025_787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":75,"sex":"female","bmi":37.5,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-05-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-76},"pfs_months":10.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.7,"censored":false},"longitudinal_labs":[{"date":"2023-04-16","hemoglobin_g_dL":13.6,"wbc_k_uL":7.1,"platelets_k_uL":189,"creatinine_mg_dL":1.27,"alt_U_L":12},{"date":"2023-11-20","hemoglobin_g_dL":10.9,"wbc_k_uL":7.6,"platelets_k_uL":245,"creatinine_mg_dL":1.34,"alt_U_L":89},{"date":"2024-04-21","hemoglobin_g_dL":11.4,"wbc_k_uL":6.9,"platelets_k_uL":175,"creatinine_mg_dL":1.09,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_788","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":69,"sex":"male","bmi":21.8,"smoking_pack_years":76,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-10-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-85},"pfs_months":27.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.4,"censored":false},"longitudinal_labs":[{"date":"2021-07-25","hemoglobin_g_dL":12.1,"wbc_k_uL":6.1,"platelets_k_uL":197,"creatinine_mg_dL":1.03,"alt_U_L":74},{"date":"2022-03-30","hemoglobin_g_dL":13.6,"wbc_k_uL":5.9,"platelets_k_uL":311,"creatinine_mg_dL":1.38,"alt_U_L":42},{"date":"2024-03-22","hemoglobin_g_dL":9.8,"wbc_k_uL":7.0,"platelets_k_uL":126,"creatinine_mg_dL":0.94,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_789","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":82,"sex":"male","bmi":19.5,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-10-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-31},"pfs_months":23.16},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":50.2,"censored":false},"longitudinal_labs":[{"date":"2020-08-04","hemoglobin_g_dL":11.7,"wbc_k_uL":6.8,"platelets_k_uL":390,"creatinine_mg_dL":1.22,"alt_U_L":63},{"date":"2021-04-06","hemoglobin_g_dL":12.9,"wbc_k_uL":4.1,"platelets_k_uL":164,"creatinine_mg_dL":1.33,"alt_U_L":101},{"date":"2022-10-14","hemoglobin_g_dL":10.9,"wbc_k_uL":7.2,"platelets_k_uL":234,"creatinine_mg_dL":1.63,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":49,"sex":"female","bmi":20.5,"smoking_pack_years":19,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-69},"pfs_months":40.74},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":66.1,"censored":true},"longitudinal_labs":[{"date":"2022-11-14","hemoglobin_g_dL":13.4,"wbc_k_uL":9.4,"platelets_k_uL":369,"creatinine_mg_dL":0.65,"alt_U_L":78},{"date":"2023-06-17","hemoglobin_g_dL":13.7,"wbc_k_uL":8.5,"platelets_k_uL":181,"creatinine_mg_dL":1.2,"alt_U_L":34},{"date":"2026-06-17","hemoglobin_g_dL":10.2,"wbc_k_uL":5.9,"platelets_k_uL":192,"creatinine_mg_dL":1.44,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":79,"sex":"female","bmi":29.8,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-08-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-35},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.0,"censored":true},"longitudinal_labs":[{"date":"2024-07-02","hemoglobin_g_dL":14.1,"wbc_k_uL":10.0,"platelets_k_uL":205,"creatinine_mg_dL":0.89,"alt_U_L":35},{"date":"2025-02-10","hemoglobin_g_dL":13.0,"wbc_k_uL":6.9,"platelets_k_uL":187,"creatinine_mg_dL":1.38,"alt_U_L":16},{"date":"2024-12-15","hemoglobin_g_dL":9.8,"wbc_k_uL":7.3,"platelets_k_uL":193,"creatinine_mg_dL":1.55,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_792","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":78,"sex":"female","bmi":34.7,"smoking_pack_years":69,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-06-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-58},"pfs_months":20.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.9,"censored":false},"longitudinal_labs":[{"date":"2020-04-27","hemoglobin_g_dL":15.0,"wbc_k_uL":7.7,"platelets_k_uL":189,"creatinine_mg_dL":0.98,"alt_U_L":38},{"date":"2020-12-12","hemoglobin_g_dL":11.2,"wbc_k_uL":6.5,"platelets_k_uL":270,"creatinine_mg_dL":1.16,"alt_U_L":105},{"date":"2022-03-06","hemoglobin_g_dL":12.7,"wbc_k_uL":7.2,"platelets_k_uL":157,"creatinine_mg_dL":1.71,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_793","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":49,"sex":"male","bmi":27.4,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-08-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-40},"pfs_months":23.92},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.1,"censored":false},"longitudinal_labs":[{"date":"2022-07-26","hemoglobin_g_dL":15.0,"wbc_k_uL":7.9,"platelets_k_uL":290,"creatinine_mg_dL":1.05,"alt_U_L":66},{"date":"2023-02-12","hemoglobin_g_dL":10.7,"wbc_k_uL":8.5,"platelets_k_uL":162,"creatinine_mg_dL":1.1,"alt_U_L":78},{"date":"2024-09-03","hemoglobin_g_dL":12.6,"wbc_k_uL":4.5,"platelets_k_uL":282,"creatinine_mg_dL":1.82,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":63,"sex":"male","bmi":37.4,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-77},"pfs_months":42.22},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":63.7,"censored":true},"longitudinal_labs":[{"date":"2023-11-02","hemoglobin_g_dL":14.2,"wbc_k_uL":9.9,"platelets_k_uL":410,"creatinine_mg_dL":1.02,"alt_U_L":10},{"date":"2024-05-14","hemoglobin_g_dL":11.6,"wbc_k_uL":7.1,"platelets_k_uL":130,"creatinine_mg_dL":0.85,"alt_U_L":99},{"date":"2027-07-04","hemoglobin_g_dL":10.7,"wbc_k_uL":5.0,"platelets_k_uL":234,"creatinine_mg_dL":1.32,"alt_U_L":139}]}
{"patient_id":"ANODE_SYNTH_2025_795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":75,"sex":"female","bmi":37.4,"smoking_pack_years":21,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-49},"pfs_months":9.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.4,"censored":true},"longitudinal_labs":[{"date":"2020-10-18","hemoglobin_g_dL":14.6,"wbc_k_uL":8.6,"platelets_k_uL":216,"creatinine_mg_dL":1.26,"alt_U_L":78},{"date":"2021-05-14","hemoglobin_g_dL":11.1,"wbc_k_uL":5.4,"platelets_k_uL":342,"creatinine_mg_dL":0.82,"alt_U_L":115},{"date":"2021-10-26","hemoglobin_g_dL":11.4,"wbc_k_uL":5.6,"platelets_k_uL":229,"creatinine_mg_dL":1.22,"alt_U_L":198}]}
{"patient_id":"ANODE_SYNTH_2025_796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":75,"sex":"female","bmi":20.9,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-04-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-53},"pfs_months":32.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":53.4,"censored":false},"longitudinal_labs":[{"date":"2024-03-12","hemoglobin_g_dL":13.7,"wbc_k_uL":4.8,"platelets_k_uL":312,"creatinine_mg_dL":0.66,"alt_U_L":11},{"date":"2024-09-30","hemoglobin_g_dL":12.6,"wbc_k_uL":5.0,"platelets_k_uL":186,"creatinine_mg_dL":1.22,"alt_U_L":18},{"date":"2027-02-06","hemoglobin_g_dL":11.4,"wbc_k_uL":7.2,"platelets_k_uL":343,"creatinine_mg_dL":1.49,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":60,"sex":"female","bmi":29.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-69},"pfs_months":23.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":38.2,"censored":true},"longitudinal_labs":[{"date":"2023-09-07","hemoglobin_g_dL":12.0,"wbc_k_uL":9.1,"platelets_k_uL":421,"creatinine_mg_dL":1.06,"alt_U_L":43},{"date":"2024-04-06","hemoglobin_g_dL":11.5,"wbc_k_uL":8.6,"platelets_k_uL":286,"creatinine_mg_dL":1.22,"alt_U_L":99},{"date":"2025-10-13","hemoglobin_g_dL":10.0,"wbc_k_uL":4.2,"platelets_k_uL":125,"creatinine_mg_dL":0.92,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":50,"sex":"female","bmi":35.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-46},"pfs_months":16.03},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":false},"longitudinal_labs":[{"date":"2023-11-14","hemoglobin_g_dL":12.6,"wbc_k_uL":5.4,"platelets_k_uL":344,"creatinine_mg_dL":0.96,"alt_U_L":33},{"date":"2024-06-15","hemoglobin_g_dL":10.9,"wbc_k_uL":7.3,"platelets_k_uL":181,"creatinine_mg_dL":1.05,"alt_U_L":56},{"date":"2025-05-13","hemoglobin_g_dL":10.6,"wbc_k_uL":5.3,"platelets_k_uL":148,"creatinine_mg_dL":0.82,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_799","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":56,"sex":"female","bmi":37.2,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-09-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-51},"pfs_months":21.95},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.3,"censored":true},"longitudinal_labs":[{"date":"2022-09-10","hemoglobin_g_dL":14.5,"wbc_k_uL":5.3,"platelets_k_uL":419,"creatinine_mg_dL":1.28,"alt_U_L":39},{"date":"2023-03-27","hemoglobin_g_dL":13.3,"wbc_k_uL":4.8,"platelets_k_uL":276,"creatinine_mg_dL":0.89,"alt_U_L":20},{"date":"2024-08-18","hemoglobin_g_dL":12.8,"wbc_k_uL":5.4,"platelets_k_uL":188,"creatinine_mg_dL":1.96,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":53,"sex":"female","bmi":32.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-49},"pfs_months":20.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.7,"censored":true},"longitudinal_labs":[{"date":"2020-10-24","hemoglobin_g_dL":13.1,"wbc_k_uL":7.7,"platelets_k_uL":167,"creatinine_mg_dL":1.1,"alt_U_L":76},{"date":"2021-06-04","hemoglobin_g_dL":10.7,"wbc_k_uL":7.5,"platelets_k_uL":219,"creatinine_mg_dL":1.36,"alt_U_L":48},{"date":"2022-08-12","hemoglobin_g_dL":13.0,"wbc_k_uL":3.1,"platelets_k_uL":108,"creatinine_mg_dL":1.13,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":49,"sex":"female","bmi":31.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-44},"pfs_months":31.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.9,"censored":false},"longitudinal_labs":[{"date":"2025-09-01","hemoglobin_g_dL":13.9,"wbc_k_uL":4.8,"platelets_k_uL":332,"creatinine_mg_dL":0.75,"alt_U_L":78},{"date":"2026-03-17","hemoglobin_g_dL":10.0,"wbc_k_uL":8.0,"platelets_k_uL":374,"creatinine_mg_dL":0.89,"alt_U_L":50},{"date":"2028-06-11","hemoglobin_g_dL":11.7,"wbc_k_uL":6.7,"platelets_k_uL":212,"creatinine_mg_dL":1.69,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":56,"sex":"male","bmi":35.4,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-66},"pfs_months":32.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":56.3,"censored":false},"longitudinal_labs":[{"date":"2020-12-06","hemoglobin_g_dL":14.3,"wbc_k_uL":7.4,"platelets_k_uL":383,"creatinine_mg_dL":0.96,"alt_U_L":65},{"date":"2021-06-26","hemoglobin_g_dL":10.6,"wbc_k_uL":6.1,"platelets_k_uL":125,"creatinine_mg_dL":1.49,"alt_U_L":32},{"date":"2023-10-27","hemoglobin_g_dL":10.4,"wbc_k_uL":7.4,"platelets_k_uL":199,"creatinine_mg_dL":1.24,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":61,"sex":"female","bmi":28.1,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-06-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-81},"pfs_months":51.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-10-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":75.0,"censored":false},"longitudinal_labs":[{"date":"2024-04-17","hemoglobin_g_dL":13.0,"wbc_k_uL":7.0,"platelets_k_uL":301,"creatinine_mg_dL":0.7,"alt_U_L":32},{"date":"2024-12-12","hemoglobin_g_dL":10.6,"wbc_k_uL":6.0,"platelets_k_uL":306,"creatinine_mg_dL":1.24,"alt_U_L":36},{"date":"2028-10-20","hemoglobin_g_dL":10.1,"wbc_k_uL":3.1,"platelets_k_uL":265,"creatinine_mg_dL":1.68,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":61,"sex":"female","bmi":25.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-79},"pfs_months":22.87},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.5,"censored":true},"longitudinal_labs":[{"date":"2025-10-09","hemoglobin_g_dL":12.2,"wbc_k_uL":5.2,"platelets_k_uL":216,"creatinine_mg_dL":1.01,"alt_U_L":56},{"date":"2026-05-21","hemoglobin_g_dL":10.4,"wbc_k_uL":8.0,"platelets_k_uL":224,"creatinine_mg_dL":1.56,"alt_U_L":55},{"date":"2027-11-21","hemoglobin_g_dL":12.6,"wbc_k_uL":5.3,"platelets_k_uL":267,"creatinine_mg_dL":1.46,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_805","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":54,"sex":"female","bmi":24.3,"smoking_pack_years":67,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-85},"pfs_months":16.3},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":false},"longitudinal_labs":[{"date":"2021-04-03","hemoglobin_g_dL":12.2,"wbc_k_uL":8.8,"platelets_k_uL":187,"creatinine_mg_dL":1.29,"alt_U_L":63},{"date":"2021-12-08","hemoglobin_g_dL":11.9,"wbc_k_uL":4.6,"platelets_k_uL":262,"creatinine_mg_dL":1.29,"alt_U_L":65},{"date":"2022-12-04","hemoglobin_g_dL":10.0,"wbc_k_uL":6.9,"platelets_k_uL":277,"creatinine_mg_dL":1.86,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":86,"sex":"female","bmi":27.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-82},"pfs_months":12.09},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.4,"censored":true},"longitudinal_labs":[{"date":"2021-10-01","hemoglobin_g_dL":12.9,"wbc_k_uL":10.0,"platelets_k_uL":219,"creatinine_mg_dL":0.83,"alt_U_L":31},{"date":"2022-05-05","hemoglobin_g_dL":12.6,"wbc_k_uL":4.4,"platelets_k_uL":196,"creatinine_mg_dL":1.33,"alt_U_L":87},{"date":"2023-01-01","hemoglobin_g_dL":12.5,"wbc_k_uL":7.7,"platelets_k_uL":256,"creatinine_mg_dL":0.86,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":61,"sex":"female","bmi":32.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-56},"pfs_months":10.58},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":18.4,"censored":false},"longitudinal_labs":[{"date":"2024-02-07","hemoglobin_g_dL":12.3,"wbc_k_uL":5.6,"platelets_k_uL":376,"creatinine_mg_dL":0.7,"alt_U_L":14},{"date":"2024-10-06","hemoglobin_g_dL":10.8,"wbc_k_uL":5.7,"platelets_k_uL":193,"creatinine_mg_dL":1.47,"alt_U_L":91},{"date":"2025-04-09","hemoglobin_g_dL":10.9,"wbc_k_uL":4.3,"platelets_k_uL":117,"creatinine_mg_dL":1.81,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":65,"sex":"female","bmi":22.7,"smoking_pack_years":29,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-75},"pfs_months":3.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":10.1,"censored":false},"longitudinal_labs":[{"date":"2023-05-16","hemoglobin_g_dL":14.6,"wbc_k_uL":8.8,"platelets_k_uL":384,"creatinine_mg_dL":1.2,"alt_U_L":22},{"date":"2023-12-31","hemoglobin_g_dL":13.0,"wbc_k_uL":7.5,"platelets_k_uL":199,"creatinine_mg_dL":1.45,"alt_U_L":95},{"date":"2023-12-13","hemoglobin_g_dL":10.9,"wbc_k_uL":4.6,"platelets_k_uL":213,"creatinine_mg_dL":1.84,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":72,"sex":"female","bmi":28.9,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-02-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-69},"pfs_months":37.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":59.4,"censored":true},"longitudinal_labs":[{"date":"2024-01-19","hemoglobin_g_dL":13.4,"wbc_k_uL":9.0,"platelets_k_uL":400,"creatinine_mg_dL":1.15,"alt_U_L":72},{"date":"2024-08-12","hemoglobin_g_dL":13.7,"wbc_k_uL":9.0,"platelets_k_uL":263,"creatinine_mg_dL":0.89,"alt_U_L":106},{"date":"2027-04-03","hemoglobin_g_dL":12.5,"wbc_k_uL":4.2,"platelets_k_uL":229,"creatinine_mg_dL":1.94,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.2,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":75,"sex":"female","bmi":25.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-72},"pfs_months":16.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.8,"censored":false},"longitudinal_labs":[{"date":"2020-05-18","hemoglobin_g_dL":12.6,"wbc_k_uL":11.0,"platelets_k_uL":315,"creatinine_mg_dL":0.68,"alt_U_L":74},{"date":"2021-01-17","hemoglobin_g_dL":12.3,"wbc_k_uL":8.4,"platelets_k_uL":278,"creatinine_mg_dL":0.7,"alt_U_L":99},{"date":"2021-12-04","hemoglobin_g_dL":10.3,"wbc_k_uL":5.0,"platelets_k_uL":301,"creatinine_mg_dL":1.7,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_811","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":63,"sex":"female","bmi":35.9,"smoking_pack_years":41,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-12-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-75},"pfs_months":30.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":52.1,"censored":false},"longitudinal_labs":[{"date":"2025-10-20","hemoglobin_g_dL":12.1,"wbc_k_uL":5.6,"platelets_k_uL":284,"creatinine_mg_dL":0.74,"alt_U_L":34},{"date":"2026-06-04","hemoglobin_g_dL":12.8,"wbc_k_uL":7.5,"platelets_k_uL":369,"creatinine_mg_dL":1.46,"alt_U_L":119},{"date":"2028-07-12","hemoglobin_g_dL":11.8,"wbc_k_uL":7.0,"platelets_k_uL":127,"creatinine_mg_dL":1.37,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":70,"sex":"female","bmi":19.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-70},"pfs_months":32.03},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.5,"censored":true},"longitudinal_labs":[{"date":"2020-07-25","hemoglobin_g_dL":11.8,"wbc_k_uL":10.2,"platelets_k_uL":165,"creatinine_mg_dL":0.71,"alt_U_L":77},{"date":"2021-03-05","hemoglobin_g_dL":10.3,"wbc_k_uL":5.3,"platelets_k_uL":217,"creatinine_mg_dL":0.96,"alt_U_L":28},{"date":"2023-05-17","hemoglobin_g_dL":12.0,"wbc_k_uL":7.9,"platelets_k_uL":107,"creatinine_mg_dL":1.81,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_813","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":84,"sex":"female","bmi":23.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-61},"pfs_months":24.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":false},"longitudinal_labs":[{"date":"2020-11-22","hemoglobin_g_dL":14.2,"wbc_k_uL":7.2,"platelets_k_uL":423,"creatinine_mg_dL":0.78,"alt_U_L":37},{"date":"2021-06-30","hemoglobin_g_dL":13.5,"wbc_k_uL":8.7,"platelets_k_uL":166,"creatinine_mg_dL":1.03,"alt_U_L":56},{"date":"2023-02-04","hemoglobin_g_dL":13.0,"wbc_k_uL":7.5,"platelets_k_uL":211,"creatinine_mg_dL":0.97,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":65,"sex":"female","bmi":19.9,"smoking_pack_years":62,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-07-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-34},"pfs_months":6.6},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":19.1,"censored":false},"longitudinal_labs":[{"date":"2024-05-21","hemoglobin_g_dL":12.7,"wbc_k_uL":7.5,"platelets_k_uL":230,"creatinine_mg_dL":0.82,"alt_U_L":38},{"date":"2025-01-17","hemoglobin_g_dL":13.1,"wbc_k_uL":5.0,"platelets_k_uL":359,"creatinine_mg_dL":1.54,"alt_U_L":60},{"date":"2025-03-15","hemoglobin_g_dL":11.5,"wbc_k_uL":5.3,"platelets_k_uL":191,"creatinine_mg_dL":1.05,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":73,"sex":"female","bmi":32.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-10-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-72},"pfs_months":27.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.6,"censored":true},"longitudinal_labs":[{"date":"2025-09-12","hemoglobin_g_dL":13.9,"wbc_k_uL":7.0,"platelets_k_uL":193,"creatinine_mg_dL":0.78,"alt_U_L":29},{"date":"2026-04-17","hemoglobin_g_dL":11.1,"wbc_k_uL":6.2,"platelets_k_uL":375,"creatinine_mg_dL":1.34,"alt_U_L":104},{"date":"2028-02-25","hemoglobin_g_dL":11.8,"wbc_k_uL":4.0,"platelets_k_uL":264,"creatinine_mg_dL":1.54,"alt_U_L":125}]}
{"patient_id":"ANODE_SYNTH_2025_816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":80,"sex":"female","bmi":25.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-40},"pfs_months":22.7},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.0,"censored":false},"longitudinal_labs":[{"date":"2021-01-06","hemoglobin_g_dL":11.9,"wbc_k_uL":5.1,"platelets_k_uL":392,"creatinine_mg_dL":1.3,"alt_U_L":28},{"date":"2021-08-30","hemoglobin_g_dL":11.8,"wbc_k_uL":6.4,"platelets_k_uL":281,"creatinine_mg_dL":1.34,"alt_U_L":67},{"date":"2023-03-22","hemoglobin_g_dL":11.9,"wbc_k_uL":7.0,"platelets_k_uL":239,"creatinine_mg_dL":1.5,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_817","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":52,"sex":"female","bmi":18.7,"smoking_pack_years":58,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-06-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-50},"pfs_months":27.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.7,"censored":false},"longitudinal_labs":[{"date":"2021-04-26","hemoglobin_g_dL":13.3,"wbc_k_uL":8.7,"platelets_k_uL":356,"creatinine_mg_dL":0.66,"alt_U_L":22},{"date":"2021-12-24","hemoglobin_g_dL":13.1,"wbc_k_uL":4.9,"platelets_k_uL":345,"creatinine_mg_dL":1.14,"alt_U_L":59},{"date":"2023-11-25","hemoglobin_g_dL":9.6,"wbc_k_uL":4.8,"platelets_k_uL":313,"creatinine_mg_dL":0.85,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":81,"sex":"male","bmi":19.9,"smoking_pack_years":27,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-57},"pfs_months":19.81},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.5,"censored":false},"longitudinal_labs":[{"date":"2021-07-18","hemoglobin_g_dL":14.2,"wbc_k_uL":7.7,"platelets_k_uL":223,"creatinine_mg_dL":0.95,"alt_U_L":67},{"date":"2022-03-20","hemoglobin_g_dL":13.5,"wbc_k_uL":7.9,"platelets_k_uL":163,"creatinine_mg_dL":1.52,"alt_U_L":79},{"date":"2023-06-09","hemoglobin_g_dL":11.7,"wbc_k_uL":4.3,"platelets_k_uL":169,"creatinine_mg_dL":1.72,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_819","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":66,"sex":"female","bmi":30.5,"smoking_pack_years":34,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-49},"pfs_months":7.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.7,"censored":true},"longitudinal_labs":[{"date":"2025-11-01","hemoglobin_g_dL":15.0,"wbc_k_uL":10.5,"platelets_k_uL":319,"creatinine_mg_dL":0.65,"alt_U_L":18},{"date":"2026-06-23","hemoglobin_g_dL":11.0,"wbc_k_uL":6.7,"platelets_k_uL":314,"creatinine_mg_dL":1.33,"alt_U_L":49},{"date":"2026-08-18","hemoglobin_g_dL":13.0,"wbc_k_uL":3.8,"platelets_k_uL":295,"creatinine_mg_dL":1.68,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":62,"sex":"female","bmi":31.3,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-62},"pfs_months":23.72},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.1,"censored":true},"longitudinal_labs":[{"date":"2023-05-27","hemoglobin_g_dL":14.0,"wbc_k_uL":8.9,"platelets_k_uL":264,"creatinine_mg_dL":1.26,"alt_U_L":12},{"date":"2024-01-31","hemoglobin_g_dL":12.0,"wbc_k_uL":4.0,"platelets_k_uL":223,"creatinine_mg_dL":1.0,"alt_U_L":81},{"date":"2025-08-20","hemoglobin_g_dL":11.3,"wbc_k_uL":4.4,"platelets_k_uL":235,"creatinine_mg_dL":1.08,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":85,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-30},"pfs_months":26.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.7,"censored":false},"longitudinal_labs":[{"date":"2022-02-22","hemoglobin_g_dL":13.7,"wbc_k_uL":10.0,"platelets_k_uL":244,"creatinine_mg_dL":0.99,"alt_U_L":19},{"date":"2022-09-08","hemoglobin_g_dL":13.7,"wbc_k_uL":8.4,"platelets_k_uL":125,"creatinine_mg_dL":1.23,"alt_U_L":17},{"date":"2024-06-19","hemoglobin_g_dL":11.5,"wbc_k_uL":3.9,"platelets_k_uL":299,"creatinine_mg_dL":1.89,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":81,"sex":"female","bmi":27.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-02-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-54},"pfs_months":25.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":44.9,"censored":false},"longitudinal_labs":[{"date":"2023-12-20","hemoglobin_g_dL":11.7,"wbc_k_uL":4.5,"platelets_k_uL":378,"creatinine_mg_dL":0.69,"alt_U_L":38},{"date":"2024-08-21","hemoglobin_g_dL":13.2,"wbc_k_uL":8.3,"platelets_k_uL":136,"creatinine_mg_dL":1.32,"alt_U_L":119},{"date":"2026-05-31","hemoglobin_g_dL":12.7,"wbc_k_uL":6.2,"platelets_k_uL":120,"creatinine_mg_dL":1.42,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":73,"sex":"female","bmi":35.0,"smoking_pack_years":12,"ecog_performance_status":2,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-02-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-32},"pfs_months":11.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":22.6,"censored":false},"longitudinal_labs":[{"date":"2020-12-27","hemoglobin_g_dL":13.8,"wbc_k_uL":5.3,"platelets_k_uL":157,"creatinine_mg_dL":0.63,"alt_U_L":67},{"date":"2021-08-24","hemoglobin_g_dL":13.1,"wbc_k_uL":5.4,"platelets_k_uL":274,"creatinine_mg_dL":0.77,"alt_U_L":22},{"date":"2022-03-13","hemoglobin_g_dL":11.3,"wbc_k_uL":5.5,"platelets_k_uL":322,"creatinine_mg_dL":1.04,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":62,"sex":"male","bmi":34.5,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-03-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-53},"pfs_months":29.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.2,"censored":true},"longitudinal_labs":[{"date":"2023-02-14","hemoglobin_g_dL":14.7,"wbc_k_uL":10.1,"platelets_k_uL":239,"creatinine_mg_dL":0.76,"alt_U_L":44},{"date":"2023-08-31","hemoglobin_g_dL":10.8,"wbc_k_uL":7.0,"platelets_k_uL":369,"creatinine_mg_dL":1.42,"alt_U_L":49},{"date":"2025-10-01","hemoglobin_g_dL":10.8,"wbc_k_uL":5.6,"platelets_k_uL":231,"creatinine_mg_dL":1.61,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":49,"sex":"female","bmi":28.3,"smoking_pack_years":32,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-02-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-59},"pfs_months":35.19},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":58.2,"censored":false},"longitudinal_labs":[{"date":"2021-01-19","hemoglobin_g_dL":13.6,"wbc_k_uL":5.3,"platelets_k_uL":407,"creatinine_mg_dL":0.78,"alt_U_L":62},{"date":"2021-08-15","hemoglobin_g_dL":13.3,"wbc_k_uL":6.5,"platelets_k_uL":359,"creatinine_mg_dL":1.25,"alt_U_L":104},{"date":"2024-03-05","hemoglobin_g_dL":11.6,"wbc_k_uL":3.8,"platelets_k_uL":309,"creatinine_mg_dL":1.57,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":81,"sex":"female","bmi":33.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-74},"pfs_months":12.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":17.6,"censored":true},"longitudinal_labs":[{"date":"2022-11-21","hemoglobin_g_dL":14.6,"wbc_k_uL":6.3,"platelets_k_uL":353,"creatinine_mg_dL":1.25,"alt_U_L":51},{"date":"2023-06-15","hemoglobin_g_dL":10.3,"wbc_k_uL":5.3,"platelets_k_uL":308,"creatinine_mg_dL":0.74,"alt_U_L":47},{"date":"2024-01-03","hemoglobin_g_dL":10.6,"wbc_k_uL":4.1,"platelets_k_uL":101,"creatinine_mg_dL":0.91,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":53,"sex":"male","bmi":20.8,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-42},"pfs_months":41.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.3,"censored":true},"longitudinal_labs":[{"date":"2024-02-14","hemoglobin_g_dL":14.9,"wbc_k_uL":7.8,"platelets_k_uL":301,"creatinine_mg_dL":0.69,"alt_U_L":55},{"date":"2024-09-13","hemoglobin_g_dL":10.5,"wbc_k_uL":7.0,"platelets_k_uL":322,"creatinine_mg_dL":1.33,"alt_U_L":44},{"date":"2027-09-28","hemoglobin_g_dL":9.9,"wbc_k_uL":6.2,"platelets_k_uL":183,"creatinine_mg_dL":1.61,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_828","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":50,"sex":"female","bmi":30.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-56},"pfs_months":23.52},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.6,"censored":true},"longitudinal_labs":[{"date":"2022-10-01","hemoglobin_g_dL":12.4,"wbc_k_uL":9.3,"platelets_k_uL":381,"creatinine_mg_dL":1.15,"alt_U_L":58},{"date":"2023-04-20","hemoglobin_g_dL":11.7,"wbc_k_uL":4.1,"platelets_k_uL":233,"creatinine_mg_dL":1.03,"alt_U_L":64},{"date":"2024-10-27","hemoglobin_g_dL":12.7,"wbc_k_uL":3.9,"platelets_k_uL":116,"creatinine_mg_dL":1.42,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":80,"sex":"female","bmi":24.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-69},"pfs_months":21.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.8,"censored":false},"longitudinal_labs":[{"date":"2022-05-07","hemoglobin_g_dL":11.5,"wbc_k_uL":10.9,"platelets_k_uL":403,"creatinine_mg_dL":0.94,"alt_U_L":19},{"date":"2022-12-05","hemoglobin_g_dL":11.1,"wbc_k_uL":3.9,"platelets_k_uL":314,"creatinine_mg_dL":1.47,"alt_U_L":28},{"date":"2024-05-09","hemoglobin_g_dL":9.8,"wbc_k_uL":5.7,"platelets_k_uL":274,"creatinine_mg_dL":1.2,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":86,"sex":"female","bmi":21.9,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-06-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-62},"pfs_months":15.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":27.4,"censored":true},"longitudinal_labs":[{"date":"2023-05-07","hemoglobin_g_dL":11.6,"wbc_k_uL":9.9,"platelets_k_uL":420,"creatinine_mg_dL":0.8,"alt_U_L":54},{"date":"2023-12-01","hemoglobin_g_dL":13.3,"wbc_k_uL":4.4,"platelets_k_uL":323,"creatinine_mg_dL":1.27,"alt_U_L":46},{"date":"2024-10-21","hemoglobin_g_dL":10.7,"wbc_k_uL":5.5,"platelets_k_uL":175,"creatinine_mg_dL":1.48,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":53,"sex":"female","bmi":36.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-62},"pfs_months":18.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.6,"censored":false},"longitudinal_labs":[{"date":"2022-10-14","hemoglobin_g_dL":15.4,"wbc_k_uL":7.3,"platelets_k_uL":367,"creatinine_mg_dL":1.06,"alt_U_L":73},{"date":"2023-05-30","hemoglobin_g_dL":11.8,"wbc_k_uL":6.9,"platelets_k_uL":311,"creatinine_mg_dL":1.19,"alt_U_L":88},{"date":"2024-06-26","hemoglobin_g_dL":9.5,"wbc_k_uL":4.8,"platelets_k_uL":234,"creatinine_mg_dL":1.82,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":86,"sex":"female","bmi":25.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-46},"pfs_months":18.23},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.6,"censored":false},"longitudinal_labs":[{"date":"2020-06-21","hemoglobin_g_dL":14.7,"wbc_k_uL":8.7,"platelets_k_uL":363,"creatinine_mg_dL":0.99,"alt_U_L":74},{"date":"2021-02-23","hemoglobin_g_dL":12.0,"wbc_k_uL":4.3,"platelets_k_uL":371,"creatinine_mg_dL":1.4,"alt_U_L":50},{"date":"2022-03-24","hemoglobin_g_dL":12.4,"wbc_k_uL":7.7,"platelets_k_uL":236,"creatinine_mg_dL":1.2,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":84,"sex":"female","bmi":21.0,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-39},"pfs_months":18.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.1,"censored":false},"longitudinal_labs":[{"date":"2023-08-27","hemoglobin_g_dL":12.7,"wbc_k_uL":8.1,"platelets_k_uL":401,"creatinine_mg_dL":0.94,"alt_U_L":29},{"date":"2024-04-04","hemoglobin_g_dL":12.3,"wbc_k_uL":5.8,"platelets_k_uL":341,"creatinine_mg_dL":1.07,"alt_U_L":24},{"date":"2025-05-06","hemoglobin_g_dL":10.2,"wbc_k_uL":7.6,"platelets_k_uL":108,"creatinine_mg_dL":1.65,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":56,"sex":"female","bmi":22.3,"smoking_pack_years":13,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-01-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-73},"pfs_months":16.26},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.2,"censored":true},"longitudinal_labs":[{"date":"2022-11-16","hemoglobin_g_dL":14.6,"wbc_k_uL":5.1,"platelets_k_uL":289,"creatinine_mg_dL":0.61,"alt_U_L":73},{"date":"2023-07-17","hemoglobin_g_dL":11.4,"wbc_k_uL":9.0,"platelets_k_uL":302,"creatinine_mg_dL":1.56,"alt_U_L":87},{"date":"2024-07-25","hemoglobin_g_dL":10.1,"wbc_k_uL":3.8,"platelets_k_uL":227,"creatinine_mg_dL":0.85,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":68,"sex":"female","bmi":27.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-30},"pfs_months":14.82},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":true},"longitudinal_labs":[{"date":"2024-09-19","hemoglobin_g_dL":14.8,"wbc_k_uL":7.8,"platelets_k_uL":396,"creatinine_mg_dL":0.74,"alt_U_L":14},{"date":"2025-04-27","hemoglobin_g_dL":11.8,"wbc_k_uL":8.2,"platelets_k_uL":212,"creatinine_mg_dL":1.33,"alt_U_L":87},{"date":"2026-02-24","hemoglobin_g_dL":11.4,"wbc_k_uL":3.5,"platelets_k_uL":285,"creatinine_mg_dL":1.31,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":70,"sex":"female","bmi":27.1,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-06-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-43},"pfs_months":35.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.5,"censored":false},"longitudinal_labs":[{"date":"2024-04-03","hemoglobin_g_dL":15.2,"wbc_k_uL":7.5,"platelets_k_uL":201,"creatinine_mg_dL":0.78,"alt_U_L":78},{"date":"2024-12-04","hemoglobin_g_dL":12.0,"wbc_k_uL":5.4,"platelets_k_uL":174,"creatinine_mg_dL":1.27,"alt_U_L":80},{"date":"2027-06-14","hemoglobin_g_dL":13.0,"wbc_k_uL":7.7,"platelets_k_uL":204,"creatinine_mg_dL":1.95,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":88,"sex":"female","bmi":21.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-75},"pfs_months":26.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":false},"longitudinal_labs":[{"date":"2021-09-24","hemoglobin_g_dL":14.8,"wbc_k_uL":7.7,"platelets_k_uL":225,"creatinine_mg_dL":1.08,"alt_U_L":77},{"date":"2022-05-07","hemoglobin_g_dL":10.8,"wbc_k_uL":5.7,"platelets_k_uL":209,"creatinine_mg_dL":1.56,"alt_U_L":97},{"date":"2024-02-25","hemoglobin_g_dL":9.8,"wbc_k_uL":5.6,"platelets_k_uL":172,"creatinine_mg_dL":0.91,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_838","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":76,"sex":"male","bmi":24.8,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-07-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-44},"pfs_months":23.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.2,"censored":true},"longitudinal_labs":[{"date":"2025-06-09","hemoglobin_g_dL":12.9,"wbc_k_uL":4.9,"platelets_k_uL":407,"creatinine_mg_dL":0.62,"alt_U_L":52},{"date":"2026-01-23","hemoglobin_g_dL":10.9,"wbc_k_uL":7.3,"platelets_k_uL":351,"creatinine_mg_dL":1.41,"alt_U_L":28},{"date":"2027-07-25","hemoglobin_g_dL":11.4,"wbc_k_uL":5.7,"platelets_k_uL":233,"creatinine_mg_dL":1.14,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":63,"sex":"female","bmi":36.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-02-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-60},"pfs_months":24.84},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":false},"longitudinal_labs":[{"date":"2024-01-23","hemoglobin_g_dL":15.3,"wbc_k_uL":6.8,"platelets_k_uL":407,"creatinine_mg_dL":1.03,"alt_U_L":49},{"date":"2024-08-27","hemoglobin_g_dL":13.3,"wbc_k_uL":8.0,"platelets_k_uL":139,"creatinine_mg_dL":1.03,"alt_U_L":96},{"date":"2026-05-14","hemoglobin_g_dL":10.0,"wbc_k_uL":3.2,"platelets_k_uL":317,"creatinine_mg_dL":1.46,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":52,"sex":"female","bmi":30.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-77},"pfs_months":23.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-31","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":42.4,"censored":false},"longitudinal_labs":[{"date":"2020-08-25","hemoglobin_g_dL":12.1,"wbc_k_uL":5.2,"platelets_k_uL":224,"creatinine_mg_dL":1.21,"alt_U_L":77},{"date":"2021-03-26","hemoglobin_g_dL":11.5,"wbc_k_uL":5.0,"platelets_k_uL":330,"creatinine_mg_dL":1.33,"alt_U_L":102},{"date":"2022-10-31","hemoglobin_g_dL":11.0,"wbc_k_uL":6.8,"platelets_k_uL":316,"creatinine_mg_dL":1.99,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":79,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-56},"pfs_months":22.87},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":true},"longitudinal_labs":[{"date":"2020-07-25","hemoglobin_g_dL":14.5,"wbc_k_uL":8.4,"platelets_k_uL":355,"creatinine_mg_dL":0.73,"alt_U_L":47},{"date":"2021-03-04","hemoglobin_g_dL":12.3,"wbc_k_uL":7.6,"platelets_k_uL":133,"creatinine_mg_dL":1.51,"alt_U_L":89},{"date":"2022-09-24","hemoglobin_g_dL":9.9,"wbc_k_uL":7.8,"platelets_k_uL":221,"creatinine_mg_dL":1.68,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":79,"sex":"female","bmi":26.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-69},"pfs_months":26.15},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.9,"censored":false},"longitudinal_labs":[{"date":"2023-10-06","hemoglobin_g_dL":11.7,"wbc_k_uL":6.3,"platelets_k_uL":389,"creatinine_mg_dL":0.75,"alt_U_L":74},{"date":"2024-05-19","hemoglobin_g_dL":10.2,"wbc_k_uL":7.3,"platelets_k_uL":341,"creatinine_mg_dL":0.71,"alt_U_L":29},{"date":"2026-02-13","hemoglobin_g_dL":10.8,"wbc_k_uL":6.1,"platelets_k_uL":345,"creatinine_mg_dL":1.64,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":80,"sex":"female","bmi":34.8,"smoking_pack_years":24,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-09-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-79},"pfs_months":47.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":65.8,"censored":true},"longitudinal_labs":[{"date":"2020-09-14","hemoglobin_g_dL":14.7,"wbc_k_uL":6.5,"platelets_k_uL":425,"creatinine_mg_dL":1.22,"alt_U_L":22},{"date":"2021-03-29","hemoglobin_g_dL":10.5,"wbc_k_uL":8.6,"platelets_k_uL":192,"creatinine_mg_dL":1.29,"alt_U_L":112},{"date":"2024-10-23","hemoglobin_g_dL":11.4,"wbc_k_uL":3.3,"platelets_k_uL":140,"creatinine_mg_dL":0.93,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":60,"sex":"male","bmi":37.2,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-38},"pfs_months":39.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-05-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":64.6,"censored":false},"longitudinal_labs":[{"date":"2025-11-13","hemoglobin_g_dL":14.9,"wbc_k_uL":7.2,"platelets_k_uL":390,"creatinine_mg_dL":1.28,"alt_U_L":29},{"date":"2026-06-04","hemoglobin_g_dL":11.8,"wbc_k_uL":5.6,"platelets_k_uL":219,"creatinine_mg_dL":1.06,"alt_U_L":76},{"date":"2029-05-18","hemoglobin_g_dL":11.1,"wbc_k_uL":7.4,"platelets_k_uL":116,"creatinine_mg_dL":1.42,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":57,"sex":"male","bmi":36.2,"smoking_pack_years":80,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-05-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-44},"pfs_months":11.83},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.5,"censored":true},"longitudinal_labs":[{"date":"2024-04-08","hemoglobin_g_dL":12.0,"wbc_k_uL":6.1,"platelets_k_uL":180,"creatinine_mg_dL":1.05,"alt_U_L":74},{"date":"2024-11-16","hemoglobin_g_dL":11.4,"wbc_k_uL":4.4,"platelets_k_uL":207,"creatinine_mg_dL":1.23,"alt_U_L":15},{"date":"2025-06-22","hemoglobin_g_dL":11.8,"wbc_k_uL":3.8,"platelets_k_uL":153,"creatinine_mg_dL":1.41,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_846","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":84,"sex":"female","bmi":35.7,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-02-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-60},"pfs_months":12.02},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.3,"censored":false},"longitudinal_labs":[{"date":"2024-01-16","hemoglobin_g_dL":12.7,"wbc_k_uL":10.7,"platelets_k_uL":164,"creatinine_mg_dL":0.98,"alt_U_L":24},{"date":"2024-08-13","hemoglobin_g_dL":10.9,"wbc_k_uL":3.9,"platelets_k_uL":323,"creatinine_mg_dL":1.11,"alt_U_L":40},{"date":"2025-02-28","hemoglobin_g_dL":9.5,"wbc_k_uL":7.7,"platelets_k_uL":124,"creatinine_mg_dL":1.97,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":18.0,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":80,"sex":"female","bmi":36.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-76},"pfs_months":16.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.9,"censored":false},"longitudinal_labs":[{"date":"2023-03-21","hemoglobin_g_dL":12.9,"wbc_k_uL":6.5,"platelets_k_uL":414,"creatinine_mg_dL":1.03,"alt_U_L":28},{"date":"2023-10-24","hemoglobin_g_dL":12.2,"wbc_k_uL":5.4,"platelets_k_uL":337,"creatinine_mg_dL":1.35,"alt_U_L":34},{"date":"2024-10-08","hemoglobin_g_dL":12.3,"wbc_k_uL":3.6,"platelets_k_uL":272,"creatinine_mg_dL":1.61,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":68,"sex":"female","bmi":19.5,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-36},"pfs_months":4.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":11.2,"censored":false},"longitudinal_labs":[{"date":"2025-01-06","hemoglobin_g_dL":15.2,"wbc_k_uL":5.9,"platelets_k_uL":159,"creatinine_mg_dL":0.77,"alt_U_L":71},{"date":"2025-07-22","hemoglobin_g_dL":10.2,"wbc_k_uL":6.3,"platelets_k_uL":128,"creatinine_mg_dL":1.2,"alt_U_L":107},{"date":"2025-06-04","hemoglobin_g_dL":10.7,"wbc_k_uL":3.7,"platelets_k_uL":344,"creatinine_mg_dL":1.7,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":72,"sex":"male","bmi":34.7,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["bone","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-04-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-46},"pfs_months":32.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":52.9,"censored":false},"longitudinal_labs":[{"date":"2020-02-27","hemoglobin_g_dL":14.7,"wbc_k_uL":4.9,"platelets_k_uL":339,"creatinine_mg_dL":0.83,"alt_U_L":63},{"date":"2020-10-03","hemoglobin_g_dL":12.3,"wbc_k_uL":6.6,"platelets_k_uL":198,"creatinine_mg_dL":0.85,"alt_U_L":88},{"date":"2023-01-18","hemoglobin_g_dL":12.7,"wbc_k_uL":7.6,"platelets_k_uL":330,"creatinine_mg_dL":1.66,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_850","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":51,"sex":"male","bmi":21.0,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-08-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-53},"pfs_months":30.75},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":true},"longitudinal_labs":[{"date":"2020-07-26","hemoglobin_g_dL":14.1,"wbc_k_uL":10.6,"platelets_k_uL":283,"creatinine_mg_dL":0.63,"alt_U_L":46},{"date":"2021-02-08","hemoglobin_g_dL":11.1,"wbc_k_uL":7.0,"platelets_k_uL":281,"creatinine_mg_dL":1.11,"alt_U_L":104},{"date":"2023-04-08","hemoglobin_g_dL":11.8,"wbc_k_uL":4.7,"platelets_k_uL":336,"creatinine_mg_dL":1.0,"alt_U_L":71}]}
{"patient_id":"ANODE_SYNTH_2025_851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":81,"sex":"female","bmi":26.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-78},"pfs_months":19.19},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.4,"censored":false},"longitudinal_labs":[{"date":"2020-08-18","hemoglobin_g_dL":11.9,"wbc_k_uL":7.7,"platelets_k_uL":373,"creatinine_mg_dL":0.8,"alt_U_L":19},{"date":"2021-04-16","hemoglobin_g_dL":11.7,"wbc_k_uL":5.4,"platelets_k_uL":293,"creatinine_mg_dL":0.9,"alt_U_L":17},{"date":"2022-05-31","hemoglobin_g_dL":11.8,"wbc_k_uL":7.2,"platelets_k_uL":165,"creatinine_mg_dL":1.9,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":48,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-74},"pfs_months":15.31},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.7,"censored":true},"longitudinal_labs":[{"date":"2023-02-03","hemoglobin_g_dL":13.6,"wbc_k_uL":7.9,"platelets_k_uL":237,"creatinine_mg_dL":1.14,"alt_U_L":68},{"date":"2023-08-18","hemoglobin_g_dL":12.2,"wbc_k_uL":4.2,"platelets_k_uL":199,"creatinine_mg_dL":1.04,"alt_U_L":75},{"date":"2024-06-09","hemoglobin_g_dL":10.5,"wbc_k_uL":3.2,"platelets_k_uL":202,"creatinine_mg_dL":1.31,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":72,"sex":"female","bmi":34.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-78},"pfs_months":22.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.6,"censored":false},"longitudinal_labs":[{"date":"2025-11-22","hemoglobin_g_dL":12.4,"wbc_k_uL":5.4,"platelets_k_uL":233,"creatinine_mg_dL":1.22,"alt_U_L":76},{"date":"2026-06-04","hemoglobin_g_dL":10.0,"wbc_k_uL":8.9,"platelets_k_uL":325,"creatinine_mg_dL":1.24,"alt_U_L":96},{"date":"2027-11-21","hemoglobin_g_dL":9.9,"wbc_k_uL":7.5,"platelets_k_uL":192,"creatinine_mg_dL":1.53,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":60,"sex":"female","bmi":28.5,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-59},"pfs_months":31.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.6,"censored":false},"longitudinal_labs":[{"date":"2024-02-28","hemoglobin_g_dL":15.3,"wbc_k_uL":9.8,"platelets_k_uL":223,"creatinine_mg_dL":0.72,"alt_U_L":50},{"date":"2024-09-18","hemoglobin_g_dL":10.2,"wbc_k_uL":6.0,"platelets_k_uL":202,"creatinine_mg_dL":1.05,"alt_U_L":67},{"date":"2026-12-05","hemoglobin_g_dL":9.8,"wbc_k_uL":4.2,"platelets_k_uL":288,"creatinine_mg_dL":1.22,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":57,"sex":"male","bmi":23.8,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-81},"pfs_months":14.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.7,"censored":true},"longitudinal_labs":[{"date":"2025-07-08","hemoglobin_g_dL":15.3,"wbc_k_uL":10.9,"platelets_k_uL":356,"creatinine_mg_dL":0.71,"alt_U_L":60},{"date":"2026-02-18","hemoglobin_g_dL":10.0,"wbc_k_uL":7.9,"platelets_k_uL":165,"creatinine_mg_dL":1.26,"alt_U_L":99},{"date":"2027-01-04","hemoglobin_g_dL":11.0,"wbc_k_uL":4.0,"platelets_k_uL":300,"creatinine_mg_dL":1.01,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":88,"sex":"female","bmi":30.4,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-36},"pfs_months":28.65},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":48.4,"censored":true},"longitudinal_labs":[{"date":"2021-03-09","hemoglobin_g_dL":11.5,"wbc_k_uL":5.3,"platelets_k_uL":334,"creatinine_mg_dL":0.64,"alt_U_L":64},{"date":"2021-09-21","hemoglobin_g_dL":10.4,"wbc_k_uL":4.5,"platelets_k_uL":176,"creatinine_mg_dL":0.76,"alt_U_L":87},{"date":"2023-09-12","hemoglobin_g_dL":11.1,"wbc_k_uL":3.3,"platelets_k_uL":200,"creatinine_mg_dL":1.63,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_857","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":62,"sex":"female","bmi":26.8,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-07-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-55},"pfs_months":29.17},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":false},"longitudinal_labs":[{"date":"2020-07-05","hemoglobin_g_dL":12.9,"wbc_k_uL":9.3,"platelets_k_uL":447,"creatinine_mg_dL":1.08,"alt_U_L":62},{"date":"2021-01-21","hemoglobin_g_dL":13.0,"wbc_k_uL":4.2,"platelets_k_uL":273,"creatinine_mg_dL":0.96,"alt_U_L":113},{"date":"2023-01-06","hemoglobin_g_dL":10.9,"wbc_k_uL":3.1,"platelets_k_uL":347,"creatinine_mg_dL":1.35,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":76,"sex":"female","bmi":25.1,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-68},"pfs_months":15.15},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":19.1,"censored":false},"longitudinal_labs":[{"date":"2023-02-01","hemoglobin_g_dL":11.9,"wbc_k_uL":8.0,"platelets_k_uL":182,"creatinine_mg_dL":0.96,"alt_U_L":67},{"date":"2023-09-18","hemoglobin_g_dL":11.8,"wbc_k_uL":7.5,"platelets_k_uL":232,"creatinine_mg_dL":1.42,"alt_U_L":67},{"date":"2024-07-24","hemoglobin_g_dL":10.1,"wbc_k_uL":4.6,"platelets_k_uL":195,"creatinine_mg_dL":1.95,"alt_U_L":90}]}
{"patient_id":"ANODE_SYNTH_2025_859","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":80,"sex":"female","bmi":35.5,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-12-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-73},"pfs_months":25.59},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-10","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.5,"censored":false},"longitudinal_labs":[{"date":"2022-11-15","hemoglobin_g_dL":13.4,"wbc_k_uL":9.1,"platelets_k_uL":417,"creatinine_mg_dL":0.8,"alt_U_L":43},{"date":"2023-06-14","hemoglobin_g_dL":10.4,"wbc_k_uL":7.6,"platelets_k_uL":316,"creatinine_mg_dL":1.48,"alt_U_L":101},{"date":"2025-02-10","hemoglobin_g_dL":12.3,"wbc_k_uL":7.0,"platelets_k_uL":192,"creatinine_mg_dL":1.41,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_860","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":56,"sex":"male","bmi":26.9,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-10-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-72},"pfs_months":16.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":31.9,"censored":true},"longitudinal_labs":[{"date":"2023-09-02","hemoglobin_g_dL":15.4,"wbc_k_uL":9.3,"platelets_k_uL":384,"creatinine_mg_dL":0.66,"alt_U_L":16},{"date":"2024-04-26","hemoglobin_g_dL":13.0,"wbc_k_uL":7.8,"platelets_k_uL":125,"creatinine_mg_dL":1.37,"alt_U_L":99},{"date":"2025-04-15","hemoglobin_g_dL":10.5,"wbc_k_uL":6.6,"platelets_k_uL":309,"creatinine_mg_dL":1.4,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_861","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":57,"sex":"female","bmi":28.7,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-09-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-61},"pfs_months":30.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":41.2,"censored":true},"longitudinal_labs":[{"date":"2020-08-21","hemoglobin_g_dL":14.7,"wbc_k_uL":10.2,"platelets_k_uL":401,"creatinine_mg_dL":0.83,"alt_U_L":16},{"date":"2021-03-28","hemoglobin_g_dL":13.5,"wbc_k_uL":7.1,"platelets_k_uL":248,"creatinine_mg_dL":1.54,"alt_U_L":81},{"date":"2023-05-29","hemoglobin_g_dL":12.2,"wbc_k_uL":8.0,"platelets_k_uL":310,"creatinine_mg_dL":1.7,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":82,"sex":"female","bmi":33.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-34},"pfs_months":22.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.5,"censored":true},"longitudinal_labs":[{"date":"2025-09-28","hemoglobin_g_dL":11.8,"wbc_k_uL":7.6,"platelets_k_uL":422,"creatinine_mg_dL":0.81,"alt_U_L":34},{"date":"2026-05-19","hemoglobin_g_dL":10.0,"wbc_k_uL":4.9,"platelets_k_uL":204,"creatinine_mg_dL":1.19,"alt_U_L":30},{"date":"2027-10-27","hemoglobin_g_dL":12.7,"wbc_k_uL":3.8,"platelets_k_uL":168,"creatinine_mg_dL":0.94,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":75,"sex":"female","bmi":21.9,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-01-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-60},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":15.2,"censored":true},"longitudinal_labs":[{"date":"2021-12-01","hemoglobin_g_dL":14.1,"wbc_k_uL":4.8,"platelets_k_uL":313,"creatinine_mg_dL":0.89,"alt_U_L":20},{"date":"2022-07-13","hemoglobin_g_dL":11.9,"wbc_k_uL":5.3,"platelets_k_uL":187,"creatinine_mg_dL":1.09,"alt_U_L":98},{"date":"2022-06-12","hemoglobin_g_dL":11.4,"wbc_k_uL":6.3,"platelets_k_uL":339,"creatinine_mg_dL":1.01,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":61,"sex":"female","bmi":30.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-36},"pfs_months":28.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":false},"longitudinal_labs":[{"date":"2024-04-13","hemoglobin_g_dL":13.2,"wbc_k_uL":10.7,"platelets_k_uL":392,"creatinine_mg_dL":1.08,"alt_U_L":72},{"date":"2024-10-24","hemoglobin_g_dL":11.9,"wbc_k_uL":5.7,"platelets_k_uL":183,"creatinine_mg_dL":1.35,"alt_U_L":32},{"date":"2026-09-07","hemoglobin_g_dL":12.5,"wbc_k_uL":5.5,"platelets_k_uL":249,"creatinine_mg_dL":0.96,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":50,"sex":"male","bmi":37.9,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-74},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":6.9,"censored":true},"longitudinal_labs":[{"date":"2025-05-03","hemoglobin_g_dL":13.0,"wbc_k_uL":5.0,"platelets_k_uL":287,"creatinine_mg_dL":0.89,"alt_U_L":20},{"date":"2025-12-10","hemoglobin_g_dL":12.1,"wbc_k_uL":8.1,"platelets_k_uL":149,"creatinine_mg_dL":1.45,"alt_U_L":49},{"date":"2025-09-28","hemoglobin_g_dL":11.1,"wbc_k_uL":7.7,"platelets_k_uL":167,"creatinine_mg_dL":1.97,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_866","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":48,"sex":"female","bmi":23.9,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-04-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-51},"pfs_months":20.8},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.7,"censored":false},"longitudinal_labs":[{"date":"2024-03-11","hemoglobin_g_dL":13.1,"wbc_k_uL":5.0,"platelets_k_uL":252,"creatinine_mg_dL":0.77,"alt_U_L":79},{"date":"2024-10-22","hemoglobin_g_dL":11.3,"wbc_k_uL":7.7,"platelets_k_uL":286,"creatinine_mg_dL":1.08,"alt_U_L":30},{"date":"2026-02-22","hemoglobin_g_dL":10.6,"wbc_k_uL":7.0,"platelets_k_uL":240,"creatinine_mg_dL":1.51,"alt_U_L":125}]}
{"patient_id":"ANODE_SYNTH_2025_867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":76,"sex":"female","bmi":27.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-33},"pfs_months":22.97},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":false},"longitudinal_labs":[{"date":"2022-05-28","hemoglobin_g_dL":15.3,"wbc_k_uL":9.6,"platelets_k_uL":161,"creatinine_mg_dL":0.83,"alt_U_L":30},{"date":"2023-01-23","hemoglobin_g_dL":13.8,"wbc_k_uL":7.8,"platelets_k_uL":366,"creatinine_mg_dL":1.37,"alt_U_L":93},{"date":"2024-08-04","hemoglobin_g_dL":12.8,"wbc_k_uL":6.3,"platelets_k_uL":288,"creatinine_mg_dL":0.91,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":77,"sex":"male","bmi":32.8,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-30},"pfs_months":30.65},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":57.7,"censored":false},"longitudinal_labs":[{"date":"2022-03-16","hemoglobin_g_dL":11.9,"wbc_k_uL":10.3,"platelets_k_uL":379,"creatinine_mg_dL":0.85,"alt_U_L":73},{"date":"2022-10-23","hemoglobin_g_dL":10.3,"wbc_k_uL":8.2,"platelets_k_uL":136,"creatinine_mg_dL":1.37,"alt_U_L":117},{"date":"2024-11-28","hemoglobin_g_dL":10.8,"wbc_k_uL":5.4,"platelets_k_uL":256,"creatinine_mg_dL":1.23,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":62,"sex":"female","bmi":32.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-59},"pfs_months":18.73},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-31","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.7,"censored":true},"longitudinal_labs":[{"date":"2025-12-06","hemoglobin_g_dL":14.1,"wbc_k_uL":7.5,"platelets_k_uL":340,"creatinine_mg_dL":0.68,"alt_U_L":61},{"date":"2026-06-19","hemoglobin_g_dL":12.0,"wbc_k_uL":8.1,"platelets_k_uL":164,"creatinine_mg_dL":1.33,"alt_U_L":109},{"date":"2027-08-31","hemoglobin_g_dL":10.3,"wbc_k_uL":5.9,"platelets_k_uL":216,"creatinine_mg_dL":0.85,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":48,"sex":"female","bmi":24.7,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-55},"pfs_months":15.44},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.4,"censored":true},"longitudinal_labs":[{"date":"2020-10-04","hemoglobin_g_dL":13.6,"wbc_k_uL":8.7,"platelets_k_uL":365,"creatinine_mg_dL":1.03,"alt_U_L":68},{"date":"2021-05-06","hemoglobin_g_dL":12.3,"wbc_k_uL":5.8,"platelets_k_uL":320,"creatinine_mg_dL":1.54,"alt_U_L":70},{"date":"2022-03-09","hemoglobin_g_dL":11.3,"wbc_k_uL":3.3,"platelets_k_uL":216,"creatinine_mg_dL":1.75,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":67,"sex":"female","bmi":22.8,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-04-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-76},"pfs_months":41.99},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":61.2,"censored":true},"longitudinal_labs":[{"date":"2023-03-01","hemoglobin_g_dL":13.8,"wbc_k_uL":5.0,"platelets_k_uL":217,"creatinine_mg_dL":0.92,"alt_U_L":70},{"date":"2023-10-15","hemoglobin_g_dL":12.3,"wbc_k_uL":7.5,"platelets_k_uL":325,"creatinine_mg_dL":1.33,"alt_U_L":61},{"date":"2026-10-21","hemoglobin_g_dL":10.3,"wbc_k_uL":5.7,"platelets_k_uL":126,"creatinine_mg_dL":1.05,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":77,"sex":"female","bmi":32.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-49},"pfs_months":32.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":42.4,"censored":false},"longitudinal_labs":[{"date":"2022-07-19","hemoglobin_g_dL":15.3,"wbc_k_uL":9.7,"platelets_k_uL":201,"creatinine_mg_dL":0.6,"alt_U_L":29},{"date":"2023-02-19","hemoglobin_g_dL":11.1,"wbc_k_uL":6.7,"platelets_k_uL":181,"creatinine_mg_dL":1.22,"alt_U_L":22},{"date":"2025-05-15","hemoglobin_g_dL":12.1,"wbc_k_uL":3.8,"platelets_k_uL":240,"creatinine_mg_dL":1.25,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":76,"sex":"female","bmi":21.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-69},"pfs_months":15.31},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":23.9,"censored":false},"longitudinal_labs":[{"date":"2022-09-28","hemoglobin_g_dL":15.4,"wbc_k_uL":8.7,"platelets_k_uL":235,"creatinine_mg_dL":0.92,"alt_U_L":80},{"date":"2023-04-15","hemoglobin_g_dL":11.8,"wbc_k_uL":8.0,"platelets_k_uL":299,"creatinine_mg_dL":1.01,"alt_U_L":109},{"date":"2024-02-23","hemoglobin_g_dL":12.4,"wbc_k_uL":5.2,"platelets_k_uL":221,"creatinine_mg_dL":1.96,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":70,"sex":"female","bmi":19.7,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-02-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-43},"pfs_months":6.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":22.0,"censored":true},"longitudinal_labs":[{"date":"2024-02-01","hemoglobin_g_dL":15.3,"wbc_k_uL":7.3,"platelets_k_uL":371,"creatinine_mg_dL":0.83,"alt_U_L":53},{"date":"2024-08-19","hemoglobin_g_dL":13.3,"wbc_k_uL":8.6,"platelets_k_uL":362,"creatinine_mg_dL":0.77,"alt_U_L":75},{"date":"2024-10-06","hemoglobin_g_dL":12.5,"wbc_k_uL":4.2,"platelets_k_uL":225,"creatinine_mg_dL":1.17,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_875","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":49,"sex":"female","bmi":23.6,"smoking_pack_years":55,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-03-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-58},"pfs_months":25.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.4,"censored":false},"longitudinal_labs":[{"date":"2021-01-01","hemoglobin_g_dL":11.6,"wbc_k_uL":9.5,"platelets_k_uL":382,"creatinine_mg_dL":0.92,"alt_U_L":37},{"date":"2021-09-01","hemoglobin_g_dL":11.2,"wbc_k_uL":7.0,"platelets_k_uL":263,"creatinine_mg_dL":1.3,"alt_U_L":18},{"date":"2023-05-28","hemoglobin_g_dL":12.5,"wbc_k_uL":6.1,"platelets_k_uL":342,"creatinine_mg_dL":0.88,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_876","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":80,"sex":"female","bmi":25.6,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-08-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-75},"pfs_months":17.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":true},"longitudinal_labs":[{"date":"2020-07-05","hemoglobin_g_dL":14.7,"wbc_k_uL":6.6,"platelets_k_uL":423,"creatinine_mg_dL":0.78,"alt_U_L":49},{"date":"2021-02-19","hemoglobin_g_dL":12.2,"wbc_k_uL":4.0,"platelets_k_uL":239,"creatinine_mg_dL":0.97,"alt_U_L":102},{"date":"2022-02-27","hemoglobin_g_dL":12.4,"wbc_k_uL":7.6,"platelets_k_uL":112,"creatinine_mg_dL":1.47,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_877","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":62,"sex":"male","bmi":25.8,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-01-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-35},"pfs_months":15.44},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.5,"censored":true},"longitudinal_labs":[{"date":"2025-11-18","hemoglobin_g_dL":14.3,"wbc_k_uL":7.1,"platelets_k_uL":182,"creatinine_mg_dL":1.16,"alt_U_L":47},{"date":"2026-07-12","hemoglobin_g_dL":12.3,"wbc_k_uL":7.6,"platelets_k_uL":126,"creatinine_mg_dL":1.58,"alt_U_L":108},{"date":"2027-05-27","hemoglobin_g_dL":9.7,"wbc_k_uL":7.6,"platelets_k_uL":333,"creatinine_mg_dL":1.45,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":62,"sex":"male","bmi":26.0,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-07-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-53},"pfs_months":25.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.5,"censored":false},"longitudinal_labs":[{"date":"2022-07-06","hemoglobin_g_dL":13.2,"wbc_k_uL":10.4,"platelets_k_uL":198,"creatinine_mg_dL":1.16,"alt_U_L":79},{"date":"2023-01-21","hemoglobin_g_dL":12.9,"wbc_k_uL":7.6,"platelets_k_uL":136,"creatinine_mg_dL":1.43,"alt_U_L":27},{"date":"2024-10-19","hemoglobin_g_dL":12.5,"wbc_k_uL":7.5,"platelets_k_uL":133,"creatinine_mg_dL":1.38,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":68,"sex":"female","bmi":35.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-74},"pfs_months":18.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2021-02-13","hemoglobin_g_dL":11.5,"wbc_k_uL":7.7,"platelets_k_uL":178,"creatinine_mg_dL":0.63,"alt_U_L":58},{"date":"2021-09-27","hemoglobin_g_dL":12.8,"wbc_k_uL":5.9,"platelets_k_uL":351,"creatinine_mg_dL":0.81,"alt_U_L":54},{"date":"2022-11-01","hemoglobin_g_dL":12.0,"wbc_k_uL":5.7,"platelets_k_uL":335,"creatinine_mg_dL":1.43,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_880","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":82,"sex":"female","bmi":21.1,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-03-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-81},"pfs_months":23.46},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.7,"censored":false},"longitudinal_labs":[{"date":"2023-12-24","hemoglobin_g_dL":13.4,"wbc_k_uL":5.0,"platelets_k_uL":158,"creatinine_mg_dL":1.16,"alt_U_L":48},{"date":"2024-08-30","hemoglobin_g_dL":12.0,"wbc_k_uL":6.0,"platelets_k_uL":191,"creatinine_mg_dL":1.22,"alt_U_L":41},{"date":"2026-03-18","hemoglobin_g_dL":9.6,"wbc_k_uL":5.5,"platelets_k_uL":314,"creatinine_mg_dL":1.13,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":61,"sex":"female","bmi":20.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-72},"pfs_months":22.28},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.4,"censored":false},"longitudinal_labs":[{"date":"2025-02-19","hemoglobin_g_dL":14.3,"wbc_k_uL":10.2,"platelets_k_uL":221,"creatinine_mg_dL":0.63,"alt_U_L":27},{"date":"2025-09-15","hemoglobin_g_dL":10.3,"wbc_k_uL":6.5,"platelets_k_uL":302,"creatinine_mg_dL":1.5,"alt_U_L":105},{"date":"2027-02-27","hemoglobin_g_dL":12.6,"wbc_k_uL":4.0,"platelets_k_uL":127,"creatinine_mg_dL":1.22,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":63,"sex":"male","bmi":19.7,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-10-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-85},"pfs_months":21.09},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2025-09-16","hemoglobin_g_dL":15.1,"wbc_k_uL":7.9,"platelets_k_uL":442,"creatinine_mg_dL":0.91,"alt_U_L":32},{"date":"2026-03-30","hemoglobin_g_dL":10.8,"wbc_k_uL":8.6,"platelets_k_uL":341,"creatinine_mg_dL":0.89,"alt_U_L":20},{"date":"2027-07-21","hemoglobin_g_dL":11.7,"wbc_k_uL":5.1,"platelets_k_uL":160,"creatinine_mg_dL":1.84,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":66,"sex":"male","bmi":26.4,"smoking_pack_years":27,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-06-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-44},"pfs_months":7.82},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.6,"censored":false},"longitudinal_labs":[{"date":"2023-04-20","hemoglobin_g_dL":14.0,"wbc_k_uL":9.6,"platelets_k_uL":437,"creatinine_mg_dL":0.83,"alt_U_L":12},{"date":"2023-12-20","hemoglobin_g_dL":10.6,"wbc_k_uL":5.8,"platelets_k_uL":334,"creatinine_mg_dL":0.99,"alt_U_L":23},{"date":"2024-04-01","hemoglobin_g_dL":10.7,"wbc_k_uL":5.3,"platelets_k_uL":226,"creatinine_mg_dL":0.9,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":60,"sex":"female","bmi":19.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-69},"pfs_months":30.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.3,"censored":false},"longitudinal_labs":[{"date":"2020-12-14","hemoglobin_g_dL":14.7,"wbc_k_uL":5.2,"platelets_k_uL":404,"creatinine_mg_dL":0.88,"alt_U_L":57},{"date":"2021-06-26","hemoglobin_g_dL":12.4,"wbc_k_uL":6.9,"platelets_k_uL":279,"creatinine_mg_dL":0.97,"alt_U_L":87},{"date":"2023-08-30","hemoglobin_g_dL":12.5,"wbc_k_uL":6.7,"platelets_k_uL":210,"creatinine_mg_dL":1.99,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_885","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":88,"sex":"male","bmi":35.7,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-02-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-45},"pfs_months":22.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.5,"censored":false},"longitudinal_labs":[{"date":"2023-01-09","hemoglobin_g_dL":13.2,"wbc_k_uL":7.6,"platelets_k_uL":204,"creatinine_mg_dL":1.26,"alt_U_L":11},{"date":"2023-08-25","hemoglobin_g_dL":12.7,"wbc_k_uL":4.6,"platelets_k_uL":380,"creatinine_mg_dL":1.16,"alt_U_L":73},{"date":"2025-01-22","hemoglobin_g_dL":10.3,"wbc_k_uL":7.7,"platelets_k_uL":256,"creatinine_mg_dL":1.75,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_886","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":87,"sex":"male","bmi":25.9,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-12-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-71},"pfs_months":26.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.6,"censored":false},"longitudinal_labs":[{"date":"2022-12-02","hemoglobin_g_dL":11.9,"wbc_k_uL":9.5,"platelets_k_uL":246,"creatinine_mg_dL":1.08,"alt_U_L":23},{"date":"2023-06-28","hemoglobin_g_dL":11.3,"wbc_k_uL":7.7,"platelets_k_uL":275,"creatinine_mg_dL":1.53,"alt_U_L":92},{"date":"2025-05-01","hemoglobin_g_dL":11.0,"wbc_k_uL":6.1,"platelets_k_uL":179,"creatinine_mg_dL":1.49,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":75,"sex":"female","bmi":32.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-07-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-61},"pfs_months":27.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.3,"censored":false},"longitudinal_labs":[{"date":"2021-06-23","hemoglobin_g_dL":12.3,"wbc_k_uL":8.3,"platelets_k_uL":383,"creatinine_mg_dL":1.02,"alt_U_L":47},{"date":"2022-01-05","hemoglobin_g_dL":12.7,"wbc_k_uL":7.6,"platelets_k_uL":214,"creatinine_mg_dL":1.25,"alt_U_L":46},{"date":"2023-11-18","hemoglobin_g_dL":11.3,"wbc_k_uL":7.2,"platelets_k_uL":134,"creatinine_mg_dL":1.78,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.2,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":65,"sex":"female","bmi":22.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-65},"pfs_months":18.89},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":false},"longitudinal_labs":[{"date":"2021-04-21","hemoglobin_g_dL":11.5,"wbc_k_uL":10.7,"platelets_k_uL":394,"creatinine_mg_dL":0.84,"alt_U_L":76},{"date":"2021-12-27","hemoglobin_g_dL":10.6,"wbc_k_uL":4.8,"platelets_k_uL":121,"creatinine_mg_dL":1.32,"alt_U_L":84},{"date":"2023-02-19","hemoglobin_g_dL":11.6,"wbc_k_uL":3.1,"platelets_k_uL":333,"creatinine_mg_dL":1.47,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":52,"sex":"female","bmi":37.3,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-09-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-70},"pfs_months":8.44},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":14.9,"censored":false},"longitudinal_labs":[{"date":"2025-07-26","hemoglobin_g_dL":14.5,"wbc_k_uL":9.0,"platelets_k_uL":195,"creatinine_mg_dL":1.06,"alt_U_L":14},{"date":"2026-03-10","hemoglobin_g_dL":13.0,"wbc_k_uL":5.8,"platelets_k_uL":267,"creatinine_mg_dL":1.46,"alt_U_L":40},{"date":"2026-06-04","hemoglobin_g_dL":12.1,"wbc_k_uL":3.8,"platelets_k_uL":230,"creatinine_mg_dL":1.35,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":57,"sex":"male","bmi":20.0,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-10-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-68},"pfs_months":37.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":64.1,"censored":false},"longitudinal_labs":[{"date":"2021-08-28","hemoglobin_g_dL":14.6,"wbc_k_uL":10.0,"platelets_k_uL":392,"creatinine_mg_dL":0.75,"alt_U_L":74},{"date":"2022-04-10","hemoglobin_g_dL":13.4,"wbc_k_uL":4.2,"platelets_k_uL":140,"creatinine_mg_dL":0.91,"alt_U_L":91},{"date":"2024-12-22","hemoglobin_g_dL":10.7,"wbc_k_uL":7.2,"platelets_k_uL":342,"creatinine_mg_dL":1.35,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":83,"sex":"female","bmi":37.5,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-78},"pfs_months":9.82},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.8,"censored":true},"longitudinal_labs":[{"date":"2023-08-10","hemoglobin_g_dL":14.8,"wbc_k_uL":8.4,"platelets_k_uL":309,"creatinine_mg_dL":1.27,"alt_U_L":66},{"date":"2024-03-06","hemoglobin_g_dL":11.2,"wbc_k_uL":7.6,"platelets_k_uL":292,"creatinine_mg_dL":1.13,"alt_U_L":32},{"date":"2024-08-12","hemoglobin_g_dL":12.8,"wbc_k_uL":7.1,"platelets_k_uL":115,"creatinine_mg_dL":1.38,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":52,"sex":"male","bmi":35.4,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-10-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-49},"pfs_months":27.37},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":58.0,"censored":true},"longitudinal_labs":[{"date":"2020-09-12","hemoglobin_g_dL":13.7,"wbc_k_uL":5.0,"platelets_k_uL":318,"creatinine_mg_dL":0.7,"alt_U_L":63},{"date":"2021-04-10","hemoglobin_g_dL":10.6,"wbc_k_uL":8.9,"platelets_k_uL":317,"creatinine_mg_dL":1.29,"alt_U_L":65},{"date":"2023-02-16","hemoglobin_g_dL":10.9,"wbc_k_uL":6.1,"platelets_k_uL":195,"creatinine_mg_dL":1.93,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_893","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":67,"sex":"female","bmi":28.7,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-49},"pfs_months":24.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":false},"longitudinal_labs":[{"date":"2022-05-22","hemoglobin_g_dL":15.0,"wbc_k_uL":10.2,"platelets_k_uL":157,"creatinine_mg_dL":1.24,"alt_U_L":22},{"date":"2022-12-04","hemoglobin_g_dL":13.0,"wbc_k_uL":8.6,"platelets_k_uL":242,"creatinine_mg_dL":1.39,"alt_U_L":93},{"date":"2024-07-21","hemoglobin_g_dL":9.8,"wbc_k_uL":3.1,"platelets_k_uL":104,"creatinine_mg_dL":1.94,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_894","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":50,"sex":"male","bmi":37.0,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-07-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-64},"pfs_months":20.7},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.6,"censored":false},"longitudinal_labs":[{"date":"2022-05-25","hemoglobin_g_dL":15.2,"wbc_k_uL":10.5,"platelets_k_uL":386,"creatinine_mg_dL":1.28,"alt_U_L":67},{"date":"2023-01-01","hemoglobin_g_dL":13.2,"wbc_k_uL":8.7,"platelets_k_uL":180,"creatinine_mg_dL":0.93,"alt_U_L":31},{"date":"2024-04-15","hemoglobin_g_dL":11.6,"wbc_k_uL":3.3,"platelets_k_uL":213,"creatinine_mg_dL":1.92,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":67,"sex":"male","bmi":25.6,"smoking_pack_years":13,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-07-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-51},"pfs_months":37.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.0,"censored":false},"longitudinal_labs":[{"date":"2022-07-12","hemoglobin_g_dL":13.3,"wbc_k_uL":6.9,"platelets_k_uL":210,"creatinine_mg_dL":1.13,"alt_U_L":13},{"date":"2023-01-23","hemoglobin_g_dL":10.2,"wbc_k_uL":6.5,"platelets_k_uL":239,"creatinine_mg_dL":1.2,"alt_U_L":85},{"date":"2025-10-17","hemoglobin_g_dL":12.2,"wbc_k_uL":5.8,"platelets_k_uL":174,"creatinine_mg_dL":1.75,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_896","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":70,"sex":"male","bmi":27.8,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-06-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-62},"pfs_months":19.65},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":42.1,"censored":true},"longitudinal_labs":[{"date":"2025-04-23","hemoglobin_g_dL":11.6,"wbc_k_uL":10.2,"platelets_k_uL":294,"creatinine_mg_dL":0.69,"alt_U_L":53},{"date":"2025-12-24","hemoglobin_g_dL":11.1,"wbc_k_uL":4.5,"platelets_k_uL":149,"creatinine_mg_dL":1.25,"alt_U_L":67},{"date":"2027-03-21","hemoglobin_g_dL":10.9,"wbc_k_uL":7.2,"platelets_k_uL":186,"creatinine_mg_dL":1.15,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_897","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":51,"sex":"female","bmi":28.5,"smoking_pack_years":32,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-11-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-56},"pfs_months":24.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.0,"censored":false},"longitudinal_labs":[{"date":"2020-10-25","hemoglobin_g_dL":11.5,"wbc_k_uL":6.9,"platelets_k_uL":246,"creatinine_mg_dL":1.26,"alt_U_L":59},{"date":"2021-05-23","hemoglobin_g_dL":11.1,"wbc_k_uL":4.8,"platelets_k_uL":313,"creatinine_mg_dL":0.89,"alt_U_L":55},{"date":"2023-01-30","hemoglobin_g_dL":11.2,"wbc_k_uL":4.1,"platelets_k_uL":112,"creatinine_mg_dL":1.49,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":79,"sex":"female","bmi":34.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-12-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-40},"pfs_months":15.44},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.7,"censored":false},"longitudinal_labs":[{"date":"2021-11-23","hemoglobin_g_dL":13.4,"wbc_k_uL":5.5,"platelets_k_uL":407,"creatinine_mg_dL":1.21,"alt_U_L":30},{"date":"2022-06-27","hemoglobin_g_dL":13.2,"wbc_k_uL":4.5,"platelets_k_uL":308,"creatinine_mg_dL":1.04,"alt_U_L":33},{"date":"2023-05-26","hemoglobin_g_dL":11.3,"wbc_k_uL":5.0,"platelets_k_uL":142,"creatinine_mg_dL":1.68,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_899","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":67,"sex":"female","bmi":32.1,"smoking_pack_years":48,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["bone","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-38},"pfs_months":12.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.1,"censored":true},"longitudinal_labs":[{"date":"2020-12-24","hemoglobin_g_dL":14.1,"wbc_k_uL":10.6,"platelets_k_uL":389,"creatinine_mg_dL":1.12,"alt_U_L":23},{"date":"2021-07-20","hemoglobin_g_dL":12.9,"wbc_k_uL":5.7,"platelets_k_uL":200,"creatinine_mg_dL":1.45,"alt_U_L":81},{"date":"2022-02-24","hemoglobin_g_dL":13.0,"wbc_k_uL":3.4,"platelets_k_uL":316,"creatinine_mg_dL":1.43,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_900","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":62,"sex":"female","bmi":34.8,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-12-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-37},"pfs_months":18.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.7,"censored":false},"longitudinal_labs":[{"date":"2021-10-18","hemoglobin_g_dL":14.3,"wbc_k_uL":5.6,"platelets_k_uL":249,"creatinine_mg_dL":0.78,"alt_U_L":34},{"date":"2022-06-25","hemoglobin_g_dL":12.4,"wbc_k_uL":6.4,"platelets_k_uL":221,"creatinine_mg_dL":0.91,"alt_U_L":72},{"date":"2023-08-01","hemoglobin_g_dL":10.8,"wbc_k_uL":5.5,"platelets_k_uL":214,"creatinine_mg_dL":0.92,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":75,"sex":"male","bmi":33.7,"smoking_pack_years":19,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-03-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-68},"pfs_months":6.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":10.5,"censored":true},"longitudinal_labs":[{"date":"2022-01-25","hemoglobin_g_dL":12.5,"wbc_k_uL":5.1,"platelets_k_uL":223,"creatinine_mg_dL":0.68,"alt_U_L":35},{"date":"2022-09-03","hemoglobin_g_dL":13.7,"wbc_k_uL":3.9,"platelets_k_uL":124,"creatinine_mg_dL":0.84,"alt_U_L":37},{"date":"2022-10-20","hemoglobin_g_dL":10.4,"wbc_k_uL":7.7,"platelets_k_uL":165,"creatinine_mg_dL":1.26,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":79,"sex":"female","bmi":21.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-78},"pfs_months":31.01},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.8,"censored":true},"longitudinal_labs":[{"date":"2023-10-22","hemoglobin_g_dL":11.8,"wbc_k_uL":9.8,"platelets_k_uL":191,"creatinine_mg_dL":1.21,"alt_U_L":54},{"date":"2024-05-21","hemoglobin_g_dL":13.9,"wbc_k_uL":8.4,"platelets_k_uL":246,"creatinine_mg_dL":0.84,"alt_U_L":59},{"date":"2026-07-07","hemoglobin_g_dL":11.4,"wbc_k_uL":6.9,"platelets_k_uL":171,"creatinine_mg_dL":0.88,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":74,"sex":"female","bmi":20.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-41},"pfs_months":33.61},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":47.2,"censored":false},"longitudinal_labs":[{"date":"2022-06-10","hemoglobin_g_dL":12.4,"wbc_k_uL":8.5,"platelets_k_uL":206,"creatinine_mg_dL":0.8,"alt_U_L":22},{"date":"2023-02-12","hemoglobin_g_dL":13.9,"wbc_k_uL":8.8,"platelets_k_uL":158,"creatinine_mg_dL":1.15,"alt_U_L":61},{"date":"2025-06-17","hemoglobin_g_dL":11.1,"wbc_k_uL":5.0,"platelets_k_uL":235,"creatinine_mg_dL":1.37,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":81,"sex":"female","bmi":30.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-03-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-53},"pfs_months":24.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.9,"censored":false},"longitudinal_labs":[{"date":"2020-02-18","hemoglobin_g_dL":14.8,"wbc_k_uL":5.8,"platelets_k_uL":381,"creatinine_mg_dL":1.14,"alt_U_L":72},{"date":"2020-09-11","hemoglobin_g_dL":13.1,"wbc_k_uL":4.1,"platelets_k_uL":356,"creatinine_mg_dL":0.89,"alt_U_L":19},{"date":"2022-04-17","hemoglobin_g_dL":12.6,"wbc_k_uL":4.2,"platelets_k_uL":196,"creatinine_mg_dL":0.92,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":60,"sex":"female","bmi":25.3,"smoking_pack_years":78,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-85},"pfs_months":36.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":64.4,"censored":true},"longitudinal_labs":[{"date":"2024-12-25","hemoglobin_g_dL":12.2,"wbc_k_uL":10.3,"platelets_k_uL":165,"creatinine_mg_dL":1.27,"alt_U_L":50},{"date":"2025-07-13","hemoglobin_g_dL":11.5,"wbc_k_uL":6.2,"platelets_k_uL":374,"creatinine_mg_dL":0.97,"alt_U_L":73},{"date":"2028-03-03","hemoglobin_g_dL":11.6,"wbc_k_uL":6.1,"platelets_k_uL":118,"creatinine_mg_dL":0.93,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":66,"sex":"female","bmi":31.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-38},"pfs_months":26.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.0,"censored":false},"longitudinal_labs":[{"date":"2021-02-09","hemoglobin_g_dL":12.8,"wbc_k_uL":8.9,"platelets_k_uL":164,"creatinine_mg_dL":0.61,"alt_U_L":33},{"date":"2021-09-24","hemoglobin_g_dL":10.3,"wbc_k_uL":4.1,"platelets_k_uL":345,"creatinine_mg_dL":1.08,"alt_U_L":76},{"date":"2023-07-14","hemoglobin_g_dL":11.2,"wbc_k_uL":4.4,"platelets_k_uL":142,"creatinine_mg_dL":1.79,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":74,"sex":"female","bmi":21.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-02-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-83},"pfs_months":25.82},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.9,"censored":false},"longitudinal_labs":[{"date":"2020-01-15","hemoglobin_g_dL":14.0,"wbc_k_uL":6.9,"platelets_k_uL":367,"creatinine_mg_dL":0.89,"alt_U_L":42},{"date":"2020-08-03","hemoglobin_g_dL":12.9,"wbc_k_uL":5.2,"platelets_k_uL":289,"creatinine_mg_dL":0.93,"alt_U_L":49},{"date":"2022-04-15","hemoglobin_g_dL":12.9,"wbc_k_uL":3.5,"platelets_k_uL":279,"creatinine_mg_dL":1.41,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_908","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.9,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":49,"sex":"male","bmi":21.3,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-75},"pfs_months":41.86},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.6,"censored":false},"longitudinal_labs":[{"date":"2024-01-09","hemoglobin_g_dL":12.5,"wbc_k_uL":7.1,"platelets_k_uL":204,"creatinine_mg_dL":0.91,"alt_U_L":69},{"date":"2024-09-11","hemoglobin_g_dL":12.5,"wbc_k_uL":6.8,"platelets_k_uL":220,"creatinine_mg_dL":1.39,"alt_U_L":88},{"date":"2027-11-07","hemoglobin_g_dL":12.4,"wbc_k_uL":4.6,"platelets_k_uL":161,"creatinine_mg_dL":1.03,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":55,"sex":"female","bmi":34.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-79},"pfs_months":21.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":false},"longitudinal_labs":[{"date":"2021-08-27","hemoglobin_g_dL":12.6,"wbc_k_uL":7.9,"platelets_k_uL":382,"creatinine_mg_dL":0.89,"alt_U_L":21},{"date":"2022-03-26","hemoglobin_g_dL":10.9,"wbc_k_uL":4.2,"platelets_k_uL":279,"creatinine_mg_dL":0.86,"alt_U_L":61},{"date":"2023-08-09","hemoglobin_g_dL":11.9,"wbc_k_uL":5.0,"platelets_k_uL":200,"creatinine_mg_dL":1.07,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":51,"sex":"female","bmi":20.0,"smoking_pack_years":71,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-77},"pfs_months":11.89},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.5,"censored":true},"longitudinal_labs":[{"date":"2023-08-20","hemoglobin_g_dL":13.0,"wbc_k_uL":9.6,"platelets_k_uL":431,"creatinine_mg_dL":1.14,"alt_U_L":46},{"date":"2024-03-13","hemoglobin_g_dL":13.4,"wbc_k_uL":8.3,"platelets_k_uL":336,"creatinine_mg_dL":0.92,"alt_U_L":98},{"date":"2024-09-16","hemoglobin_g_dL":10.9,"wbc_k_uL":5.2,"platelets_k_uL":189,"creatinine_mg_dL":0.88,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_911","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":63,"sex":"female","bmi":25.4,"smoking_pack_years":38,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-36},"pfs_months":22.47},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":true},"longitudinal_labs":[{"date":"2022-07-02","hemoglobin_g_dL":12.8,"wbc_k_uL":8.6,"platelets_k_uL":170,"creatinine_mg_dL":0.8,"alt_U_L":44},{"date":"2023-02-14","hemoglobin_g_dL":11.1,"wbc_k_uL":5.8,"platelets_k_uL":234,"creatinine_mg_dL":0.89,"alt_U_L":56},{"date":"2024-07-31","hemoglobin_g_dL":10.8,"wbc_k_uL":7.0,"platelets_k_uL":135,"creatinine_mg_dL":1.1,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":58,"sex":"male","bmi":26.8,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-63},"pfs_months":43.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-06-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":70.6,"censored":true},"longitudinal_labs":[{"date":"2025-07-25","hemoglobin_g_dL":14.9,"wbc_k_uL":9.2,"platelets_k_uL":413,"creatinine_mg_dL":1.03,"alt_U_L":55},{"date":"2026-03-14","hemoglobin_g_dL":11.9,"wbc_k_uL":6.0,"platelets_k_uL":247,"creatinine_mg_dL":0.72,"alt_U_L":18},{"date":"2029-06-04","hemoglobin_g_dL":12.1,"wbc_k_uL":6.4,"platelets_k_uL":232,"creatinine_mg_dL":1.74,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":70,"sex":"female","bmi":30.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-12-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-73},"pfs_months":22.28},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.9,"censored":false},"longitudinal_labs":[{"date":"2024-11-25","hemoglobin_g_dL":13.9,"wbc_k_uL":9.9,"platelets_k_uL":284,"creatinine_mg_dL":1.22,"alt_U_L":21},{"date":"2025-06-22","hemoglobin_g_dL":10.9,"wbc_k_uL":4.6,"platelets_k_uL":366,"creatinine_mg_dL":1.38,"alt_U_L":97},{"date":"2026-12-08","hemoglobin_g_dL":11.1,"wbc_k_uL":5.3,"platelets_k_uL":119,"creatinine_mg_dL":1.03,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":57,"sex":"female","bmi":32.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-56},"pfs_months":8.84},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.6,"censored":false},"longitudinal_labs":[{"date":"2025-06-07","hemoglobin_g_dL":12.2,"wbc_k_uL":10.4,"platelets_k_uL":398,"creatinine_mg_dL":0.61,"alt_U_L":75},{"date":"2025-12-26","hemoglobin_g_dL":11.4,"wbc_k_uL":5.1,"platelets_k_uL":288,"creatinine_mg_dL":1.23,"alt_U_L":26},{"date":"2026-04-16","hemoglobin_g_dL":11.1,"wbc_k_uL":6.5,"platelets_k_uL":269,"creatinine_mg_dL":1.78,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":62,"sex":"female","bmi":28.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-59},"pfs_months":27.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.2,"censored":false},"longitudinal_labs":[{"date":"2022-07-26","hemoglobin_g_dL":14.9,"wbc_k_uL":9.6,"platelets_k_uL":311,"creatinine_mg_dL":0.84,"alt_U_L":71},{"date":"2023-03-26","hemoglobin_g_dL":11.5,"wbc_k_uL":8.3,"platelets_k_uL":256,"creatinine_mg_dL":1.36,"alt_U_L":53},{"date":"2025-02-03","hemoglobin_g_dL":11.9,"wbc_k_uL":6.1,"platelets_k_uL":298,"creatinine_mg_dL":0.88,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":86,"sex":"female","bmi":37.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-48},"pfs_months":15.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":false},"longitudinal_labs":[{"date":"2022-04-25","hemoglobin_g_dL":12.6,"wbc_k_uL":6.7,"platelets_k_uL":387,"creatinine_mg_dL":0.75,"alt_U_L":11},{"date":"2022-11-09","hemoglobin_g_dL":12.2,"wbc_k_uL":7.3,"platelets_k_uL":344,"creatinine_mg_dL":0.89,"alt_U_L":42},{"date":"2023-09-15","hemoglobin_g_dL":12.3,"wbc_k_uL":7.5,"platelets_k_uL":107,"creatinine_mg_dL":1.45,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_917","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":67,"sex":"female","bmi":32.8,"smoking_pack_years":15,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-08-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-83},"pfs_months":27.01},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":false},"longitudinal_labs":[{"date":"2025-07-03","hemoglobin_g_dL":14.1,"wbc_k_uL":10.7,"platelets_k_uL":234,"creatinine_mg_dL":0.92,"alt_U_L":69},{"date":"2026-02-17","hemoglobin_g_dL":12.6,"wbc_k_uL":4.7,"platelets_k_uL":358,"creatinine_mg_dL":1.26,"alt_U_L":108},{"date":"2027-12-28","hemoglobin_g_dL":10.5,"wbc_k_uL":6.9,"platelets_k_uL":101,"creatinine_mg_dL":1.28,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_918","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":87,"sex":"female","bmi":20.3,"smoking_pack_years":33,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-12-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-73},"pfs_months":35.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":47.1,"censored":false},"longitudinal_labs":[{"date":"2020-10-03","hemoglobin_g_dL":14.3,"wbc_k_uL":7.2,"platelets_k_uL":232,"creatinine_mg_dL":0.67,"alt_U_L":19},{"date":"2021-06-03","hemoglobin_g_dL":13.8,"wbc_k_uL":6.2,"platelets_k_uL":205,"creatinine_mg_dL":0.93,"alt_U_L":37},{"date":"2024-01-04","hemoglobin_g_dL":9.9,"wbc_k_uL":3.5,"platelets_k_uL":217,"creatinine_mg_dL":0.88,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_919","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":72,"sex":"male","bmi":33.7,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-10-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-77},"pfs_months":24.48},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":47.3,"censored":true},"longitudinal_labs":[{"date":"2020-09-02","hemoglobin_g_dL":14.1,"wbc_k_uL":7.9,"platelets_k_uL":280,"creatinine_mg_dL":0.74,"alt_U_L":64},{"date":"2021-04-16","hemoglobin_g_dL":12.1,"wbc_k_uL":6.4,"platelets_k_uL":262,"creatinine_mg_dL":1.07,"alt_U_L":31},{"date":"2022-11-07","hemoglobin_g_dL":9.6,"wbc_k_uL":6.9,"platelets_k_uL":333,"creatinine_mg_dL":1.2,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":63,"sex":"female","bmi":24.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-30},"pfs_months":21.36},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.2,"censored":false},"longitudinal_labs":[{"date":"2025-02-04","hemoglobin_g_dL":12.9,"wbc_k_uL":10.9,"platelets_k_uL":427,"creatinine_mg_dL":0.77,"alt_U_L":54},{"date":"2025-08-26","hemoglobin_g_dL":11.2,"wbc_k_uL":4.8,"platelets_k_uL":212,"creatinine_mg_dL":0.87,"alt_U_L":51},{"date":"2027-02-03","hemoglobin_g_dL":12.4,"wbc_k_uL":6.6,"platelets_k_uL":311,"creatinine_mg_dL":1.27,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_921","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":59,"sex":"male","bmi":26.4,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-04-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-42},"pfs_months":20.04},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.3,"censored":false},"longitudinal_labs":[{"date":"2022-02-21","hemoglobin_g_dL":15.1,"wbc_k_uL":9.2,"platelets_k_uL":294,"creatinine_mg_dL":0.79,"alt_U_L":45},{"date":"2022-09-28","hemoglobin_g_dL":12.4,"wbc_k_uL":5.9,"platelets_k_uL":302,"creatinine_mg_dL":0.95,"alt_U_L":103},{"date":"2024-01-25","hemoglobin_g_dL":11.4,"wbc_k_uL":5.5,"platelets_k_uL":187,"creatinine_mg_dL":1.93,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_922","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":49,"sex":"male","bmi":27.0,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-11-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-62},"pfs_months":19.68},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.4,"censored":false},"longitudinal_labs":[{"date":"2025-09-23","hemoglobin_g_dL":12.4,"wbc_k_uL":7.8,"platelets_k_uL":377,"creatinine_mg_dL":0.72,"alt_U_L":10},{"date":"2026-05-25","hemoglobin_g_dL":10.3,"wbc_k_uL":6.3,"platelets_k_uL":150,"creatinine_mg_dL":0.72,"alt_U_L":70},{"date":"2027-08-13","hemoglobin_g_dL":11.2,"wbc_k_uL":4.8,"platelets_k_uL":140,"creatinine_mg_dL":1.23,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":61,"sex":"male","bmi":34.4,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-10-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-63},"pfs_months":38.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.3,"censored":false},"longitudinal_labs":[{"date":"2023-08-02","hemoglobin_g_dL":14.7,"wbc_k_uL":10.0,"platelets_k_uL":243,"creatinine_mg_dL":1.1,"alt_U_L":61},{"date":"2024-04-05","hemoglobin_g_dL":11.4,"wbc_k_uL":4.6,"platelets_k_uL":336,"creatinine_mg_dL":1.5,"alt_U_L":38},{"date":"2027-01-28","hemoglobin_g_dL":12.0,"wbc_k_uL":7.2,"platelets_k_uL":158,"creatinine_mg_dL":1.72,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":48,"sex":"male","bmi":19.4,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-10-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-55},"pfs_months":34.27},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":53.8,"censored":false},"longitudinal_labs":[{"date":"2020-08-10","hemoglobin_g_dL":13.2,"wbc_k_uL":8.6,"platelets_k_uL":351,"creatinine_mg_dL":1.2,"alt_U_L":32},{"date":"2021-03-30","hemoglobin_g_dL":13.5,"wbc_k_uL":5.9,"platelets_k_uL":154,"creatinine_mg_dL":1.33,"alt_U_L":70},{"date":"2023-08-29","hemoglobin_g_dL":9.7,"wbc_k_uL":3.5,"platelets_k_uL":172,"creatinine_mg_dL":1.73,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_925","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":65,"sex":"female","bmi":23.9,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-11-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-33},"pfs_months":33.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.0,"censored":true},"longitudinal_labs":[{"date":"2024-09-23","hemoglobin_g_dL":12.4,"wbc_k_uL":9.1,"platelets_k_uL":433,"creatinine_mg_dL":0.84,"alt_U_L":72},{"date":"2025-05-12","hemoglobin_g_dL":12.5,"wbc_k_uL":4.6,"platelets_k_uL":341,"creatinine_mg_dL":1.54,"alt_U_L":26},{"date":"2027-09-19","hemoglobin_g_dL":12.1,"wbc_k_uL":4.6,"platelets_k_uL":166,"creatinine_mg_dL":1.47,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_926","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":52,"sex":"female","bmi":25.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-44},"pfs_months":32.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.0,"censored":false},"longitudinal_labs":[{"date":"2021-10-02","hemoglobin_g_dL":11.8,"wbc_k_uL":5.0,"platelets_k_uL":382,"creatinine_mg_dL":0.97,"alt_U_L":47},{"date":"2022-04-16","hemoglobin_g_dL":12.2,"wbc_k_uL":3.8,"platelets_k_uL":374,"creatinine_mg_dL":0.94,"alt_U_L":96},{"date":"2024-09-04","hemoglobin_g_dL":11.2,"wbc_k_uL":6.3,"platelets_k_uL":335,"creatinine_mg_dL":1.11,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":66,"sex":"female","bmi":19.6,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-01-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-74},"pfs_months":35.61},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":62.8,"censored":true},"longitudinal_labs":[{"date":"2021-11-12","hemoglobin_g_dL":13.4,"wbc_k_uL":7.0,"platelets_k_uL":279,"creatinine_mg_dL":1.24,"alt_U_L":71},{"date":"2022-07-08","hemoglobin_g_dL":10.6,"wbc_k_uL":5.8,"platelets_k_uL":336,"creatinine_mg_dL":1.28,"alt_U_L":107},{"date":"2025-01-26","hemoglobin_g_dL":10.9,"wbc_k_uL":3.3,"platelets_k_uL":113,"creatinine_mg_dL":1.39,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":59,"sex":"male","bmi":30.6,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-33},"pfs_months":12.35},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.4,"censored":false},"longitudinal_labs":[{"date":"2024-04-02","hemoglobin_g_dL":11.8,"wbc_k_uL":7.2,"platelets_k_uL":440,"creatinine_mg_dL":0.8,"alt_U_L":51},{"date":"2024-10-17","hemoglobin_g_dL":13.0,"wbc_k_uL":5.3,"platelets_k_uL":287,"creatinine_mg_dL":1.13,"alt_U_L":52},{"date":"2025-06-14","hemoglobin_g_dL":11.2,"wbc_k_uL":7.2,"platelets_k_uL":261,"creatinine_mg_dL":1.13,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":87,"sex":"male","bmi":36.5,"smoking_pack_years":33,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-01-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-36},"pfs_months":38.87},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":57.5,"censored":false},"longitudinal_labs":[{"date":"2021-11-22","hemoglobin_g_dL":14.9,"wbc_k_uL":5.0,"platelets_k_uL":167,"creatinine_mg_dL":1.02,"alt_U_L":76},{"date":"2022-07-01","hemoglobin_g_dL":11.4,"wbc_k_uL":4.0,"platelets_k_uL":242,"creatinine_mg_dL":0.91,"alt_U_L":36},{"date":"2025-04-22","hemoglobin_g_dL":12.4,"wbc_k_uL":4.7,"platelets_k_uL":183,"creatinine_mg_dL":1.09,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_930","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":59,"sex":"female","bmi":30.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-55},"pfs_months":24.84},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.8,"censored":false},"longitudinal_labs":[{"date":"2024-09-02","hemoglobin_g_dL":12.9,"wbc_k_uL":6.5,"platelets_k_uL":450,"creatinine_mg_dL":1.21,"alt_U_L":27},{"date":"2025-05-05","hemoglobin_g_dL":11.3,"wbc_k_uL":8.4,"platelets_k_uL":177,"creatinine_mg_dL":1.6,"alt_U_L":90},{"date":"2026-12-20","hemoglobin_g_dL":11.1,"wbc_k_uL":7.2,"platelets_k_uL":212,"creatinine_mg_dL":1.64,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":77,"sex":"female","bmi":21.1,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-01-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-34},"pfs_months":32.0},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-24","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":49.1,"censored":false},"longitudinal_labs":[{"date":"2020-11-09","hemoglobin_g_dL":15.2,"wbc_k_uL":8.2,"platelets_k_uL":189,"creatinine_mg_dL":0.62,"alt_U_L":69},{"date":"2021-07-17","hemoglobin_g_dL":10.8,"wbc_k_uL":4.5,"platelets_k_uL":219,"creatinine_mg_dL":1.13,"alt_U_L":107},{"date":"2023-09-24","hemoglobin_g_dL":10.2,"wbc_k_uL":4.5,"platelets_k_uL":153,"creatinine_mg_dL":1.38,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":50,"sex":"female","bmi":22.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-46},"pfs_months":35.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":49.1,"censored":true},"longitudinal_labs":[{"date":"2025-02-22","hemoglobin_g_dL":15.4,"wbc_k_uL":10.2,"platelets_k_uL":441,"creatinine_mg_dL":1.07,"alt_U_L":41},{"date":"2025-10-30","hemoglobin_g_dL":11.7,"wbc_k_uL":5.0,"platelets_k_uL":138,"creatinine_mg_dL":1.49,"alt_U_L":107},{"date":"2028-05-08","hemoglobin_g_dL":11.2,"wbc_k_uL":7.3,"platelets_k_uL":130,"creatinine_mg_dL":1.55,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":88,"sex":"female","bmi":35.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-40},"pfs_months":18.43},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.3,"censored":false},"longitudinal_labs":[{"date":"2024-09-12","hemoglobin_g_dL":11.5,"wbc_k_uL":8.1,"platelets_k_uL":326,"creatinine_mg_dL":1.01,"alt_U_L":73},{"date":"2025-05-19","hemoglobin_g_dL":12.3,"wbc_k_uL":6.4,"platelets_k_uL":249,"creatinine_mg_dL":1.41,"alt_U_L":76},{"date":"2026-06-14","hemoglobin_g_dL":9.8,"wbc_k_uL":7.0,"platelets_k_uL":236,"creatinine_mg_dL":1.32,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_934","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":49,"sex":"female","bmi":36.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-53},"pfs_months":25.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.9,"censored":true},"longitudinal_labs":[{"date":"2025-02-09","hemoglobin_g_dL":14.1,"wbc_k_uL":10.4,"platelets_k_uL":361,"creatinine_mg_dL":0.79,"alt_U_L":60},{"date":"2025-09-17","hemoglobin_g_dL":12.6,"wbc_k_uL":6.7,"platelets_k_uL":156,"creatinine_mg_dL":1.6,"alt_U_L":100},{"date":"2027-05-24","hemoglobin_g_dL":9.6,"wbc_k_uL":4.4,"platelets_k_uL":339,"creatinine_mg_dL":1.17,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":62,"sex":"female","bmi":31.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-79},"pfs_months":9.07},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.3,"censored":false},"longitudinal_labs":[{"date":"2024-09-05","hemoglobin_g_dL":13.7,"wbc_k_uL":11.0,"platelets_k_uL":243,"creatinine_mg_dL":0.72,"alt_U_L":59},{"date":"2025-05-09","hemoglobin_g_dL":13.9,"wbc_k_uL":6.5,"platelets_k_uL":298,"creatinine_mg_dL":1.16,"alt_U_L":17},{"date":"2025-09-29","hemoglobin_g_dL":12.0,"wbc_k_uL":3.1,"platelets_k_uL":306,"creatinine_mg_dL":1.87,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":77,"sex":"female","bmi":26.8,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-02-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-73},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-06-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":8.5,"censored":false},"longitudinal_labs":[{"date":"2021-01-08","hemoglobin_g_dL":15.4,"wbc_k_uL":9.7,"platelets_k_uL":171,"creatinine_mg_dL":1.3,"alt_U_L":29},{"date":"2021-08-02","hemoglobin_g_dL":13.7,"wbc_k_uL":7.4,"platelets_k_uL":282,"creatinine_mg_dL":1.11,"alt_U_L":114},{"date":"2021-06-15","hemoglobin_g_dL":10.0,"wbc_k_uL":6.9,"platelets_k_uL":169,"creatinine_mg_dL":1.94,"alt_U_L":112}]}
{"patient_id":"ANODE_SYNTH_2025_937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":53,"sex":"female","bmi":22.9,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-04-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-62},"pfs_months":41.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":57.7,"censored":true},"longitudinal_labs":[{"date":"2020-03-14","hemoglobin_g_dL":14.1,"wbc_k_uL":6.3,"platelets_k_uL":251,"creatinine_mg_dL":1.08,"alt_U_L":48},{"date":"2020-10-22","hemoglobin_g_dL":10.5,"wbc_k_uL":8.9,"platelets_k_uL":374,"creatinine_mg_dL":1.59,"alt_U_L":68},{"date":"2023-11-24","hemoglobin_g_dL":10.6,"wbc_k_uL":5.3,"platelets_k_uL":201,"creatinine_mg_dL":1.56,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.4,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":60,"sex":"male","bmi":26.9,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-85},"pfs_months":34.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":62.7,"censored":false},"longitudinal_labs":[{"date":"2021-11-03","hemoglobin_g_dL":14.5,"wbc_k_uL":8.4,"platelets_k_uL":206,"creatinine_mg_dL":1.13,"alt_U_L":47},{"date":"2022-05-20","hemoglobin_g_dL":10.7,"wbc_k_uL":9.0,"platelets_k_uL":128,"creatinine_mg_dL":1.53,"alt_U_L":52},{"date":"2024-11-15","hemoglobin_g_dL":10.6,"wbc_k_uL":5.9,"platelets_k_uL":134,"creatinine_mg_dL":1.07,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":61,"sex":"female","bmi":28.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-09-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-59},"pfs_months":14.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.1,"censored":true},"longitudinal_labs":[{"date":"2023-07-07","hemoglobin_g_dL":15.5,"wbc_k_uL":6.7,"platelets_k_uL":150,"creatinine_mg_dL":0.72,"alt_U_L":46},{"date":"2024-03-02","hemoglobin_g_dL":12.1,"wbc_k_uL":7.7,"platelets_k_uL":147,"creatinine_mg_dL":1.04,"alt_U_L":32},{"date":"2025-01-07","hemoglobin_g_dL":11.8,"wbc_k_uL":7.8,"platelets_k_uL":112,"creatinine_mg_dL":1.69,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":51,"sex":"female","bmi":29.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-85},"pfs_months":16.92},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.2,"censored":false},"longitudinal_labs":[{"date":"2023-02-04","hemoglobin_g_dL":15.3,"wbc_k_uL":10.5,"platelets_k_uL":325,"creatinine_mg_dL":0.62,"alt_U_L":72},{"date":"2023-09-21","hemoglobin_g_dL":14.0,"wbc_k_uL":4.7,"platelets_k_uL":153,"creatinine_mg_dL":1.04,"alt_U_L":66},{"date":"2024-10-16","hemoglobin_g_dL":12.3,"wbc_k_uL":6.6,"platelets_k_uL":286,"creatinine_mg_dL":1.88,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":85,"sex":"female","bmi":23.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-63},"pfs_months":17.12},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.4,"censored":false},"longitudinal_labs":[{"date":"2024-02-10","hemoglobin_g_dL":11.6,"wbc_k_uL":8.7,"platelets_k_uL":201,"creatinine_mg_dL":0.65,"alt_U_L":34},{"date":"2024-09-11","hemoglobin_g_dL":12.4,"wbc_k_uL":8.9,"platelets_k_uL":148,"creatinine_mg_dL":1.33,"alt_U_L":82},{"date":"2025-09-15","hemoglobin_g_dL":12.0,"wbc_k_uL":6.3,"platelets_k_uL":241,"creatinine_mg_dL":1.62,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_942","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":61,"sex":"female","bmi":36.7,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-03-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-66},"pfs_months":23.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.0,"censored":false},"longitudinal_labs":[{"date":"2024-03-07","hemoglobin_g_dL":14.0,"wbc_k_uL":4.7,"platelets_k_uL":212,"creatinine_mg_dL":0.91,"alt_U_L":53},{"date":"2024-09-17","hemoglobin_g_dL":12.5,"wbc_k_uL":4.2,"platelets_k_uL":157,"creatinine_mg_dL":0.78,"alt_U_L":68},{"date":"2026-04-03","hemoglobin_g_dL":10.3,"wbc_k_uL":3.0,"platelets_k_uL":287,"creatinine_mg_dL":1.79,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_943","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":68,"sex":"male","bmi":27.2,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-03-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-73},"pfs_months":20.47},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.1,"censored":false},"longitudinal_labs":[{"date":"2020-02-03","hemoglobin_g_dL":14.5,"wbc_k_uL":7.2,"platelets_k_uL":221,"creatinine_mg_dL":0.61,"alt_U_L":59},{"date":"2020-09-22","hemoglobin_g_dL":12.2,"wbc_k_uL":3.9,"platelets_k_uL":299,"creatinine_mg_dL":1.12,"alt_U_L":72},{"date":"2022-01-29","hemoglobin_g_dL":12.4,"wbc_k_uL":3.4,"platelets_k_uL":155,"creatinine_mg_dL":1.76,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":68,"sex":"female","bmi":22.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-38},"pfs_months":21.09},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.0,"censored":false},"longitudinal_labs":[{"date":"2024-02-18","hemoglobin_g_dL":13.0,"wbc_k_uL":5.8,"platelets_k_uL":280,"creatinine_mg_dL":0.83,"alt_U_L":52},{"date":"2024-10-21","hemoglobin_g_dL":10.9,"wbc_k_uL":7.7,"platelets_k_uL":370,"creatinine_mg_dL":0.74,"alt_U_L":63},{"date":"2026-02-16","hemoglobin_g_dL":12.8,"wbc_k_uL":4.6,"platelets_k_uL":325,"creatinine_mg_dL":1.88,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_945","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":75,"sex":"female","bmi":25.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-12-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-85},"pfs_months":23.26},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.6,"censored":true},"longitudinal_labs":[{"date":"2021-11-02","hemoglobin_g_dL":12.6,"wbc_k_uL":8.2,"platelets_k_uL":262,"creatinine_mg_dL":0.65,"alt_U_L":51},{"date":"2022-06-21","hemoglobin_g_dL":11.2,"wbc_k_uL":7.9,"platelets_k_uL":336,"creatinine_mg_dL":1.34,"alt_U_L":48},{"date":"2023-12-29","hemoglobin_g_dL":11.5,"wbc_k_uL":3.6,"platelets_k_uL":203,"creatinine_mg_dL":1.01,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_946","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":87,"sex":"male","bmi":36.3,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-04-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-57},"pfs_months":18.5},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.9,"censored":true},"longitudinal_labs":[{"date":"2021-03-03","hemoglobin_g_dL":15.3,"wbc_k_uL":6.8,"platelets_k_uL":405,"creatinine_mg_dL":1.24,"alt_U_L":40},{"date":"2021-10-14","hemoglobin_g_dL":13.6,"wbc_k_uL":5.6,"platelets_k_uL":191,"creatinine_mg_dL":1.09,"alt_U_L":39},{"date":"2022-12-18","hemoglobin_g_dL":10.4,"wbc_k_uL":5.4,"platelets_k_uL":195,"creatinine_mg_dL":0.85,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":79,"sex":"male","bmi":29.4,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-06-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-53},"pfs_months":9.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":16.1,"censored":false},"longitudinal_labs":[{"date":"2022-05-22","hemoglobin_g_dL":13.4,"wbc_k_uL":5.5,"platelets_k_uL":195,"creatinine_mg_dL":0.92,"alt_U_L":48},{"date":"2022-12-09","hemoglobin_g_dL":12.3,"wbc_k_uL":3.8,"platelets_k_uL":351,"creatinine_mg_dL":1.44,"alt_U_L":53},{"date":"2023-05-09","hemoglobin_g_dL":10.3,"wbc_k_uL":7.0,"platelets_k_uL":108,"creatinine_mg_dL":1.38,"alt_U_L":149}]}
{"patient_id":"ANODE_SYNTH_2025_948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":80,"sex":"female","bmi":21.0,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-76},"pfs_months":19.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-25","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.4,"censored":true},"longitudinal_labs":[{"date":"2025-07-14","hemoglobin_g_dL":12.7,"wbc_k_uL":8.2,"platelets_k_uL":230,"creatinine_mg_dL":0.96,"alt_U_L":62},{"date":"2026-02-06","hemoglobin_g_dL":12.0,"wbc_k_uL":6.7,"platelets_k_uL":358,"creatinine_mg_dL":0.97,"alt_U_L":54},{"date":"2027-03-25","hemoglobin_g_dL":12.8,"wbc_k_uL":3.8,"platelets_k_uL":210,"creatinine_mg_dL":1.86,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":65,"sex":"male","bmi":20.9,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-08-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-45},"pfs_months":12.39},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":26.1,"censored":false},"longitudinal_labs":[{"date":"2021-08-10","hemoglobin_g_dL":13.9,"wbc_k_uL":10.9,"platelets_k_uL":175,"creatinine_mg_dL":0.92,"alt_U_L":71},{"date":"2022-02-24","hemoglobin_g_dL":13.0,"wbc_k_uL":4.6,"platelets_k_uL":345,"creatinine_mg_dL":1.52,"alt_U_L":20},{"date":"2022-09-19","hemoglobin_g_dL":10.4,"wbc_k_uL":5.6,"platelets_k_uL":211,"creatinine_mg_dL":1.26,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":84,"sex":"female","bmi":25.8,"smoking_pack_years":19,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-07-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-36},"pfs_months":28.68},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":59.8,"censored":false},"longitudinal_labs":[{"date":"2023-06-07","hemoglobin_g_dL":13.2,"wbc_k_uL":5.5,"platelets_k_uL":204,"creatinine_mg_dL":0.86,"alt_U_L":34},{"date":"2024-01-05","hemoglobin_g_dL":13.9,"wbc_k_uL":7.1,"platelets_k_uL":173,"creatinine_mg_dL":1.27,"alt_U_L":21},{"date":"2026-01-06","hemoglobin_g_dL":10.5,"wbc_k_uL":5.7,"platelets_k_uL":163,"creatinine_mg_dL":0.85,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_951","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":76,"sex":"female","bmi":34.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-39},"pfs_months":27.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":47.8,"censored":false},"longitudinal_labs":[{"date":"2022-09-10","hemoglobin_g_dL":15.5,"wbc_k_uL":8.5,"platelets_k_uL":272,"creatinine_mg_dL":0.66,"alt_U_L":35},{"date":"2023-05-06","hemoglobin_g_dL":13.2,"wbc_k_uL":5.6,"platelets_k_uL":297,"creatinine_mg_dL":0.79,"alt_U_L":99},{"date":"2025-03-07","hemoglobin_g_dL":11.9,"wbc_k_uL":5.3,"platelets_k_uL":100,"creatinine_mg_dL":1.21,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":79,"sex":"male","bmi":19.6,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-05-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-44},"pfs_months":14.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.0,"censored":false},"longitudinal_labs":[{"date":"2022-04-20","hemoglobin_g_dL":12.2,"wbc_k_uL":7.2,"platelets_k_uL":405,"creatinine_mg_dL":1.08,"alt_U_L":18},{"date":"2022-11-19","hemoglobin_g_dL":10.2,"wbc_k_uL":8.4,"platelets_k_uL":185,"creatinine_mg_dL":1.45,"alt_U_L":94},{"date":"2023-08-19","hemoglobin_g_dL":12.8,"wbc_k_uL":7.5,"platelets_k_uL":181,"creatinine_mg_dL":0.89,"alt_U_L":87}]}
{"patient_id":"ANODE_SYNTH_2025_953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":51,"sex":"female","bmi":19.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-71},"pfs_months":8.8},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-02-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.4,"censored":false},"longitudinal_labs":[{"date":"2020-02-25","hemoglobin_g_dL":13.4,"wbc_k_uL":5.4,"platelets_k_uL":295,"creatinine_mg_dL":0.74,"alt_U_L":77},{"date":"2020-10-11","hemoglobin_g_dL":12.8,"wbc_k_uL":8.5,"platelets_k_uL":250,"creatinine_mg_dL":1.32,"alt_U_L":95},{"date":"2021-02-01","hemoglobin_g_dL":10.3,"wbc_k_uL":4.9,"platelets_k_uL":201,"creatinine_mg_dL":1.06,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":74,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-70},"pfs_months":16.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.8,"censored":false},"longitudinal_labs":[{"date":"2020-08-06","hemoglobin_g_dL":14.8,"wbc_k_uL":5.2,"platelets_k_uL":339,"creatinine_mg_dL":1.19,"alt_U_L":46},{"date":"2021-03-29","hemoglobin_g_dL":12.1,"wbc_k_uL":5.0,"platelets_k_uL":371,"creatinine_mg_dL":1.1,"alt_U_L":30},{"date":"2022-04-07","hemoglobin_g_dL":11.6,"wbc_k_uL":8.0,"platelets_k_uL":108,"creatinine_mg_dL":1.75,"alt_U_L":112}]}
{"patient_id":"ANODE_SYNTH_2025_955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":67,"sex":"female","bmi":18.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-76},"pfs_months":16.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.3,"censored":false},"longitudinal_labs":[{"date":"2021-03-20","hemoglobin_g_dL":13.8,"wbc_k_uL":9.8,"platelets_k_uL":275,"creatinine_mg_dL":1.29,"alt_U_L":42},{"date":"2021-10-02","hemoglobin_g_dL":10.2,"wbc_k_uL":7.2,"platelets_k_uL":238,"creatinine_mg_dL":1.43,"alt_U_L":48},{"date":"2022-09-02","hemoglobin_g_dL":12.6,"wbc_k_uL":4.1,"platelets_k_uL":130,"creatinine_mg_dL":1.46,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_956","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":72,"sex":"male","bmi":28.9,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-02-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-82},"pfs_months":13.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.0,"censored":false},"longitudinal_labs":[{"date":"2024-12-28","hemoglobin_g_dL":15.0,"wbc_k_uL":7.7,"platelets_k_uL":255,"creatinine_mg_dL":1.17,"alt_U_L":18},{"date":"2025-08-26","hemoglobin_g_dL":11.9,"wbc_k_uL":7.4,"platelets_k_uL":199,"creatinine_mg_dL":1.43,"alt_U_L":89},{"date":"2026-05-05","hemoglobin_g_dL":9.5,"wbc_k_uL":3.9,"platelets_k_uL":289,"creatinine_mg_dL":1.22,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":73,"sex":"female","bmi":37.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-31},"pfs_months":21.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.8,"censored":false},"longitudinal_labs":[{"date":"2020-11-02","hemoglobin_g_dL":13.5,"wbc_k_uL":7.4,"platelets_k_uL":335,"creatinine_mg_dL":1.02,"alt_U_L":46},{"date":"2021-06-05","hemoglobin_g_dL":11.8,"wbc_k_uL":7.9,"platelets_k_uL":310,"creatinine_mg_dL":1.54,"alt_U_L":64},{"date":"2022-09-27","hemoglobin_g_dL":11.5,"wbc_k_uL":6.8,"platelets_k_uL":322,"creatinine_mg_dL":1.43,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":65,"sex":"female","bmi":37.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-46},"pfs_months":26.74},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.8,"censored":true},"longitudinal_labs":[{"date":"2020-07-24","hemoglobin_g_dL":15.3,"wbc_k_uL":10.2,"platelets_k_uL":315,"creatinine_mg_dL":0.72,"alt_U_L":37},{"date":"2021-03-15","hemoglobin_g_dL":13.5,"wbc_k_uL":8.5,"platelets_k_uL":201,"creatinine_mg_dL":1.36,"alt_U_L":98},{"date":"2023-01-25","hemoglobin_g_dL":12.5,"wbc_k_uL":6.5,"platelets_k_uL":333,"creatinine_mg_dL":1.38,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_959","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":69,"sex":"female","bmi":35.9,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-08-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-51},"pfs_months":22.87},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":46.0,"censored":false},"longitudinal_labs":[{"date":"2021-07-20","hemoglobin_g_dL":15.4,"wbc_k_uL":11.0,"platelets_k_uL":287,"creatinine_mg_dL":1.26,"alt_U_L":21},{"date":"2022-02-15","hemoglobin_g_dL":13.1,"wbc_k_uL":8.7,"platelets_k_uL":200,"creatinine_mg_dL":1.52,"alt_U_L":63},{"date":"2023-08-13","hemoglobin_g_dL":10.7,"wbc_k_uL":7.1,"platelets_k_uL":109,"creatinine_mg_dL":1.72,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_960","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":67,"sex":"female","bmi":30.4,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-05-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-50},"pfs_months":27.07},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.6,"censored":false},"longitudinal_labs":[{"date":"2021-04-20","hemoglobin_g_dL":13.2,"wbc_k_uL":7.3,"platelets_k_uL":235,"creatinine_mg_dL":0.7,"alt_U_L":80},{"date":"2021-11-15","hemoglobin_g_dL":13.9,"wbc_k_uL":7.9,"platelets_k_uL":314,"creatinine_mg_dL":1.25,"alt_U_L":92},{"date":"2023-09-07","hemoglobin_g_dL":10.4,"wbc_k_uL":7.8,"platelets_k_uL":193,"creatinine_mg_dL":1.15,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_961","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":68,"sex":"female","bmi":38.0,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-01-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-59},"pfs_months":21.78},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.5,"censored":false},"longitudinal_labs":[{"date":"2024-12-14","hemoglobin_g_dL":14.9,"wbc_k_uL":9.1,"platelets_k_uL":212,"creatinine_mg_dL":0.69,"alt_U_L":51},{"date":"2025-07-21","hemoglobin_g_dL":13.1,"wbc_k_uL":5.0,"platelets_k_uL":226,"creatinine_mg_dL":1.33,"alt_U_L":92},{"date":"2026-11-20","hemoglobin_g_dL":10.0,"wbc_k_uL":3.6,"platelets_k_uL":215,"creatinine_mg_dL":0.85,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":58,"sex":"male","bmi":33.9,"smoking_pack_years":80,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-10-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-50},"pfs_months":9.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.6,"censored":true},"longitudinal_labs":[{"date":"2022-09-18","hemoglobin_g_dL":12.8,"wbc_k_uL":4.8,"platelets_k_uL":304,"creatinine_mg_dL":0.97,"alt_U_L":80},{"date":"2023-04-08","hemoglobin_g_dL":11.4,"wbc_k_uL":6.4,"platelets_k_uL":304,"creatinine_mg_dL":1.07,"alt_U_L":62},{"date":"2023-08-06","hemoglobin_g_dL":10.3,"wbc_k_uL":6.7,"platelets_k_uL":184,"creatinine_mg_dL":1.89,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":54,"sex":"female","bmi":20.4,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-63},"pfs_months":40.61},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":68.4,"censored":false},"longitudinal_labs":[{"date":"2021-10-23","hemoglobin_g_dL":12.0,"wbc_k_uL":5.5,"platelets_k_uL":374,"creatinine_mg_dL":0.62,"alt_U_L":50},{"date":"2022-05-29","hemoglobin_g_dL":10.2,"wbc_k_uL":4.1,"platelets_k_uL":294,"creatinine_mg_dL":0.85,"alt_U_L":96},{"date":"2025-05-17","hemoglobin_g_dL":9.9,"wbc_k_uL":5.6,"platelets_k_uL":298,"creatinine_mg_dL":1.84,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":67,"sex":"female","bmi":21.5,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-06-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-83},"pfs_months":13.5},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":30.5,"censored":true},"longitudinal_labs":[{"date":"2020-05-14","hemoglobin_g_dL":12.4,"wbc_k_uL":6.8,"platelets_k_uL":430,"creatinine_mg_dL":0.74,"alt_U_L":52},{"date":"2020-12-04","hemoglobin_g_dL":12.0,"wbc_k_uL":6.8,"platelets_k_uL":206,"creatinine_mg_dL":0.89,"alt_U_L":62},{"date":"2021-09-20","hemoglobin_g_dL":12.2,"wbc_k_uL":7.1,"platelets_k_uL":284,"creatinine_mg_dL":1.34,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_965","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":86,"sex":"female","bmi":26.2,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-05-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-71},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":9.0,"censored":false},"longitudinal_labs":[{"date":"2023-04-11","hemoglobin_g_dL":14.3,"wbc_k_uL":11.0,"platelets_k_uL":218,"creatinine_mg_dL":1.0,"alt_U_L":61},{"date":"2023-11-04","hemoglobin_g_dL":10.7,"wbc_k_uL":5.3,"platelets_k_uL":264,"creatinine_mg_dL":0.83,"alt_U_L":62},{"date":"2023-09-19","hemoglobin_g_dL":11.6,"wbc_k_uL":5.8,"platelets_k_uL":145,"creatinine_mg_dL":1.19,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_966","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.0,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":52,"sex":"male","bmi":35.5,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-08-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-68},"pfs_months":33.77},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":47.4,"censored":true},"longitudinal_labs":[{"date":"2021-07-03","hemoglobin_g_dL":12.4,"wbc_k_uL":5.7,"platelets_k_uL":307,"creatinine_mg_dL":0.92,"alt_U_L":11},{"date":"2022-02-16","hemoglobin_g_dL":11.3,"wbc_k_uL":8.5,"platelets_k_uL":184,"creatinine_mg_dL":1.28,"alt_U_L":68},{"date":"2024-07-04","hemoglobin_g_dL":11.2,"wbc_k_uL":4.4,"platelets_k_uL":159,"creatinine_mg_dL":1.83,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":76,"sex":"female","bmi":37.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-46},"pfs_months":26.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":false},"longitudinal_labs":[{"date":"2021-10-04","hemoglobin_g_dL":14.4,"wbc_k_uL":9.2,"platelets_k_uL":164,"creatinine_mg_dL":1.03,"alt_U_L":66},{"date":"2022-05-14","hemoglobin_g_dL":14.0,"wbc_k_uL":7.0,"platelets_k_uL":361,"creatinine_mg_dL":0.84,"alt_U_L":85},{"date":"2024-03-21","hemoglobin_g_dL":10.2,"wbc_k_uL":7.4,"platelets_k_uL":170,"creatinine_mg_dL":1.95,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":82,"sex":"female","bmi":31.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-56},"pfs_months":21.55},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":false},"longitudinal_labs":[{"date":"2020-05-16","hemoglobin_g_dL":14.5,"wbc_k_uL":5.6,"platelets_k_uL":251,"creatinine_mg_dL":0.74,"alt_U_L":45},{"date":"2021-01-21","hemoglobin_g_dL":10.6,"wbc_k_uL":6.4,"platelets_k_uL":161,"creatinine_mg_dL":1.49,"alt_U_L":107},{"date":"2022-05-28","hemoglobin_g_dL":12.0,"wbc_k_uL":3.3,"platelets_k_uL":328,"creatinine_mg_dL":1.17,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_969","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":58,"sex":"female","bmi":24.5,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-09-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-78},"pfs_months":39.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.2,"censored":false},"longitudinal_labs":[{"date":"2021-08-08","hemoglobin_g_dL":12.9,"wbc_k_uL":10.3,"platelets_k_uL":351,"creatinine_mg_dL":1.07,"alt_U_L":39},{"date":"2022-03-25","hemoglobin_g_dL":13.7,"wbc_k_uL":7.9,"platelets_k_uL":197,"creatinine_mg_dL":1.55,"alt_U_L":90},{"date":"2025-01-07","hemoglobin_g_dL":13.0,"wbc_k_uL":6.2,"platelets_k_uL":267,"creatinine_mg_dL":1.88,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_970","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":51,"sex":"female","bmi":23.2,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-35},"pfs_months":24.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.4,"censored":true},"longitudinal_labs":[{"date":"2022-04-13","hemoglobin_g_dL":12.8,"wbc_k_uL":6.1,"platelets_k_uL":416,"creatinine_mg_dL":1.13,"alt_U_L":70},{"date":"2022-11-28","hemoglobin_g_dL":12.8,"wbc_k_uL":5.9,"platelets_k_uL":160,"creatinine_mg_dL":0.84,"alt_U_L":28},{"date":"2024-06-24","hemoglobin_g_dL":10.1,"wbc_k_uL":3.6,"platelets_k_uL":129,"creatinine_mg_dL":0.88,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":60,"sex":"female","bmi":34.9,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-10-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-68},"pfs_months":46.39},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":76.3,"censored":true},"longitudinal_labs":[{"date":"2021-09-11","hemoglobin_g_dL":15.5,"wbc_k_uL":6.0,"platelets_k_uL":367,"creatinine_mg_dL":0.94,"alt_U_L":30},{"date":"2022-04-26","hemoglobin_g_dL":12.0,"wbc_k_uL":8.9,"platelets_k_uL":276,"creatinine_mg_dL":0.75,"alt_U_L":84},{"date":"2025-10-14","hemoglobin_g_dL":12.5,"wbc_k_uL":3.0,"platelets_k_uL":122,"creatinine_mg_dL":0.9,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":69,"sex":"male","bmi":31.5,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-05-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-74},"pfs_months":4.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":19.1,"censored":false},"longitudinal_labs":[{"date":"2023-04-03","hemoglobin_g_dL":12.7,"wbc_k_uL":6.4,"platelets_k_uL":422,"creatinine_mg_dL":1.16,"alt_U_L":38},{"date":"2023-11-14","hemoglobin_g_dL":13.6,"wbc_k_uL":7.8,"platelets_k_uL":379,"creatinine_mg_dL":1.51,"alt_U_L":96},{"date":"2023-09-30","hemoglobin_g_dL":10.0,"wbc_k_uL":4.2,"platelets_k_uL":273,"creatinine_mg_dL":1.78,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":87,"sex":"female","bmi":29.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-31},"pfs_months":21.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":true},"longitudinal_labs":[{"date":"2025-06-11","hemoglobin_g_dL":12.6,"wbc_k_uL":10.5,"platelets_k_uL":257,"creatinine_mg_dL":0.69,"alt_U_L":65},{"date":"2026-01-19","hemoglobin_g_dL":12.5,"wbc_k_uL":6.3,"platelets_k_uL":217,"creatinine_mg_dL":1.56,"alt_U_L":58},{"date":"2027-06-03","hemoglobin_g_dL":11.1,"wbc_k_uL":6.9,"platelets_k_uL":118,"creatinine_mg_dL":1.77,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":71,"sex":"female","bmi":37.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-53},"pfs_months":11.27},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":17.6,"censored":false},"longitudinal_labs":[{"date":"2025-07-15","hemoglobin_g_dL":14.9,"wbc_k_uL":6.5,"platelets_k_uL":398,"creatinine_mg_dL":0.89,"alt_U_L":69},{"date":"2026-01-29","hemoglobin_g_dL":11.7,"wbc_k_uL":5.2,"platelets_k_uL":320,"creatinine_mg_dL":1.41,"alt_U_L":29},{"date":"2026-07-30","hemoglobin_g_dL":12.7,"wbc_k_uL":5.9,"platelets_k_uL":248,"creatinine_mg_dL":1.68,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":79,"sex":"female","bmi":36.6,"smoking_pack_years":53,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2023-01-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-46},"pfs_months":5.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":15.9,"censored":false},"longitudinal_labs":[{"date":"2022-11-07","hemoglobin_g_dL":14.4,"wbc_k_uL":5.6,"platelets_k_uL":340,"creatinine_mg_dL":1.3,"alt_U_L":67},{"date":"2023-06-30","hemoglobin_g_dL":10.7,"wbc_k_uL":4.2,"platelets_k_uL":290,"creatinine_mg_dL":0.88,"alt_U_L":70},{"date":"2023-08-19","hemoglobin_g_dL":11.1,"wbc_k_uL":4.2,"platelets_k_uL":225,"creatinine_mg_dL":1.57,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":63,"sex":"female","bmi":22.2,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-79},"pfs_months":3.19},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":13.1,"censored":false},"longitudinal_labs":[{"date":"2021-02-13","hemoglobin_g_dL":11.7,"wbc_k_uL":8.3,"platelets_k_uL":234,"creatinine_mg_dL":0.96,"alt_U_L":34},{"date":"2021-09-14","hemoglobin_g_dL":11.7,"wbc_k_uL":4.4,"platelets_k_uL":134,"creatinine_mg_dL":1.16,"alt_U_L":70},{"date":"2021-07-28","hemoglobin_g_dL":10.7,"wbc_k_uL":3.9,"platelets_k_uL":324,"creatinine_mg_dL":1.96,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":55,"sex":"female","bmi":28.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-56},"pfs_months":24.84},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.3,"censored":false},"longitudinal_labs":[{"date":"2021-01-03","hemoglobin_g_dL":12.0,"wbc_k_uL":8.6,"platelets_k_uL":307,"creatinine_mg_dL":0.9,"alt_U_L":31},{"date":"2021-08-02","hemoglobin_g_dL":13.6,"wbc_k_uL":8.0,"platelets_k_uL":286,"creatinine_mg_dL":1.37,"alt_U_L":80},{"date":"2023-04-16","hemoglobin_g_dL":9.6,"wbc_k_uL":6.2,"platelets_k_uL":278,"creatinine_mg_dL":1.58,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_978","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":85,"sex":"male","bmi":24.1,"smoking_pack_years":27,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-10-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-68},"pfs_months":14.88},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2024-09-19","hemoglobin_g_dL":15.4,"wbc_k_uL":5.2,"platelets_k_uL":184,"creatinine_mg_dL":1.22,"alt_U_L":34},{"date":"2025-04-29","hemoglobin_g_dL":11.7,"wbc_k_uL":3.8,"platelets_k_uL":351,"creatinine_mg_dL":0.9,"alt_U_L":51},{"date":"2026-03-11","hemoglobin_g_dL":10.8,"wbc_k_uL":5.9,"platelets_k_uL":337,"creatinine_mg_dL":1.56,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_979","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":82,"sex":"female","bmi":25.9,"smoking_pack_years":76,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-03-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-37},"pfs_months":22.87},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.0,"censored":true},"longitudinal_labs":[{"date":"2024-03-01","hemoglobin_g_dL":14.5,"wbc_k_uL":9.7,"platelets_k_uL":302,"creatinine_mg_dL":0.86,"alt_U_L":38},{"date":"2024-09-23","hemoglobin_g_dL":13.6,"wbc_k_uL":4.8,"platelets_k_uL":204,"creatinine_mg_dL":1.46,"alt_U_L":103},{"date":"2026-03-19","hemoglobin_g_dL":9.7,"wbc_k_uL":3.7,"platelets_k_uL":248,"creatinine_mg_dL":1.85,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_980","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":56,"sex":"female","bmi":33.3,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-36},"pfs_months":27.4},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":false},"longitudinal_labs":[{"date":"2023-04-12","hemoglobin_g_dL":11.8,"wbc_k_uL":7.1,"platelets_k_uL":385,"creatinine_mg_dL":0.98,"alt_U_L":39},{"date":"2023-12-13","hemoglobin_g_dL":13.5,"wbc_k_uL":8.4,"platelets_k_uL":296,"creatinine_mg_dL":0.85,"alt_U_L":87},{"date":"2025-11-03","hemoglobin_g_dL":9.6,"wbc_k_uL":5.2,"platelets_k_uL":252,"creatinine_mg_dL":1.05,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":69,"sex":"male","bmi":34.9,"smoking_pack_years":25,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-01-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-82},"pfs_months":34.56},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":57.3,"censored":true},"longitudinal_labs":[{"date":"2023-11-28","hemoglobin_g_dL":13.1,"wbc_k_uL":4.7,"platelets_k_uL":344,"creatinine_mg_dL":0.8,"alt_U_L":49},{"date":"2024-07-23","hemoglobin_g_dL":12.5,"wbc_k_uL":8.5,"platelets_k_uL":286,"creatinine_mg_dL":1.1,"alt_U_L":90},{"date":"2027-01-29","hemoglobin_g_dL":11.6,"wbc_k_uL":3.4,"platelets_k_uL":180,"creatinine_mg_dL":1.45,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":74,"sex":"female","bmi":30.6,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-05-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-34},"pfs_months":14.59},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.1,"censored":false},"longitudinal_labs":[{"date":"2021-04-13","hemoglobin_g_dL":11.9,"wbc_k_uL":8.9,"platelets_k_uL":435,"creatinine_mg_dL":1.17,"alt_U_L":79},{"date":"2021-11-24","hemoglobin_g_dL":13.1,"wbc_k_uL":8.3,"platelets_k_uL":228,"creatinine_mg_dL":1.2,"alt_U_L":93},{"date":"2022-09-14","hemoglobin_g_dL":10.1,"wbc_k_uL":7.1,"platelets_k_uL":257,"creatinine_mg_dL":1.37,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":80,"sex":"female","bmi":37.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-72},"pfs_months":23.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":true},"longitudinal_labs":[{"date":"2020-05-19","hemoglobin_g_dL":13.1,"wbc_k_uL":5.5,"platelets_k_uL":195,"creatinine_mg_dL":1.23,"alt_U_L":16},{"date":"2021-01-07","hemoglobin_g_dL":13.0,"wbc_k_uL":5.8,"platelets_k_uL":196,"creatinine_mg_dL":1.09,"alt_U_L":117},{"date":"2022-08-18","hemoglobin_g_dL":12.2,"wbc_k_uL":7.5,"platelets_k_uL":267,"creatinine_mg_dL":1.34,"alt_U_L":58}]}
{"patient_id":"ANODE_SYNTH_2025_984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":88,"sex":"male","bmi":34.8,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-02-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-61},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":6.9,"censored":false},"longitudinal_labs":[{"date":"2021-01-19","hemoglobin_g_dL":14.1,"wbc_k_uL":7.5,"platelets_k_uL":363,"creatinine_mg_dL":0.9,"alt_U_L":34},{"date":"2021-08-20","hemoglobin_g_dL":11.8,"wbc_k_uL":5.4,"platelets_k_uL":161,"creatinine_mg_dL":1.1,"alt_U_L":36},{"date":"2021-07-14","hemoglobin_g_dL":10.4,"wbc_k_uL":6.9,"platelets_k_uL":174,"creatinine_mg_dL":1.96,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":69,"sex":"female","bmi":37.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-67},"pfs_months":27.04},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.1,"censored":false},"longitudinal_labs":[{"date":"2022-11-04","hemoglobin_g_dL":12.3,"wbc_k_uL":9.8,"platelets_k_uL":273,"creatinine_mg_dL":0.89,"alt_U_L":78},{"date":"2023-06-14","hemoglobin_g_dL":13.3,"wbc_k_uL":8.7,"platelets_k_uL":208,"creatinine_mg_dL":1.43,"alt_U_L":106},{"date":"2025-04-23","hemoglobin_g_dL":12.1,"wbc_k_uL":3.5,"platelets_k_uL":311,"creatinine_mg_dL":1.55,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":88,"sex":"female","bmi":24.7,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-04-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-65},"pfs_months":15.74},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":24.5,"censored":false},"longitudinal_labs":[{"date":"2023-02-15","hemoglobin_g_dL":12.6,"wbc_k_uL":7.1,"platelets_k_uL":185,"creatinine_mg_dL":0.98,"alt_U_L":39},{"date":"2023-10-23","hemoglobin_g_dL":11.9,"wbc_k_uL":3.8,"platelets_k_uL":217,"creatinine_mg_dL":1.53,"alt_U_L":59},{"date":"2024-09-16","hemoglobin_g_dL":11.9,"wbc_k_uL":3.2,"platelets_k_uL":180,"creatinine_mg_dL":1.0,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":65,"sex":"male","bmi":27.3,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-85},"pfs_months":3.91},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.9,"censored":false},"longitudinal_labs":[{"date":"2023-06-20","hemoglobin_g_dL":12.5,"wbc_k_uL":6.4,"platelets_k_uL":244,"creatinine_mg_dL":1.15,"alt_U_L":54},{"date":"2023-12-31","hemoglobin_g_dL":10.0,"wbc_k_uL":8.9,"platelets_k_uL":282,"creatinine_mg_dL":0.71,"alt_U_L":34},{"date":"2023-11-17","hemoglobin_g_dL":9.8,"wbc_k_uL":6.1,"platelets_k_uL":279,"creatinine_mg_dL":1.76,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_988","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":79,"sex":"female","bmi":25.4,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-12-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-32},"pfs_months":31.77},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.9,"censored":false},"longitudinal_labs":[{"date":"2021-11-02","hemoglobin_g_dL":12.6,"wbc_k_uL":8.4,"platelets_k_uL":395,"creatinine_mg_dL":1.07,"alt_U_L":72},{"date":"2022-06-03","hemoglobin_g_dL":12.0,"wbc_k_uL":4.2,"platelets_k_uL":121,"creatinine_mg_dL":1.52,"alt_U_L":42},{"date":"2024-09-16","hemoglobin_g_dL":12.5,"wbc_k_uL":3.3,"platelets_k_uL":226,"creatinine_mg_dL":1.37,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":51,"sex":"female","bmi":28.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-12-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-84},"pfs_months":25.59},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.1,"censored":false},"longitudinal_labs":[{"date":"2024-11-15","hemoglobin_g_dL":13.5,"wbc_k_uL":7.6,"platelets_k_uL":448,"creatinine_mg_dL":1.06,"alt_U_L":61},{"date":"2025-06-12","hemoglobin_g_dL":10.5,"wbc_k_uL":6.8,"platelets_k_uL":290,"creatinine_mg_dL":1.05,"alt_U_L":31},{"date":"2027-04-02","hemoglobin_g_dL":12.9,"wbc_k_uL":5.9,"platelets_k_uL":215,"creatinine_mg_dL":1.64,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":65,"sex":"female","bmi":19.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-54},"pfs_months":19.81},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.5,"censored":false},"longitudinal_labs":[{"date":"2024-04-08","hemoglobin_g_dL":13.6,"wbc_k_uL":10.4,"platelets_k_uL":330,"creatinine_mg_dL":0.99,"alt_U_L":29},{"date":"2024-11-07","hemoglobin_g_dL":11.7,"wbc_k_uL":7.0,"platelets_k_uL":165,"creatinine_mg_dL":0.81,"alt_U_L":113},{"date":"2026-01-29","hemoglobin_g_dL":12.8,"wbc_k_uL":3.1,"platelets_k_uL":324,"creatinine_mg_dL":1.61,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":77,"sex":"male","bmi":37.1,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-06-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-41},"pfs_months":13.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.9,"censored":false},"longitudinal_labs":[{"date":"2021-05-05","hemoglobin_g_dL":14.6,"wbc_k_uL":8.9,"platelets_k_uL":195,"creatinine_mg_dL":1.18,"alt_U_L":43},{"date":"2021-12-01","hemoglobin_g_dL":10.1,"wbc_k_uL":5.9,"platelets_k_uL":315,"creatinine_mg_dL":1.21,"alt_U_L":64},{"date":"2022-08-21","hemoglobin_g_dL":12.3,"wbc_k_uL":7.5,"platelets_k_uL":184,"creatinine_mg_dL":1.6,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":52,"sex":"female","bmi":33.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-30},"pfs_months":26.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.1,"censored":false},"longitudinal_labs":[{"date":"2023-03-18","hemoglobin_g_dL":13.3,"wbc_k_uL":4.6,"platelets_k_uL":218,"creatinine_mg_dL":1.04,"alt_U_L":37},{"date":"2023-10-11","hemoglobin_g_dL":10.5,"wbc_k_uL":6.3,"platelets_k_uL":279,"creatinine_mg_dL":1.23,"alt_U_L":40},{"date":"2025-07-12","hemoglobin_g_dL":12.5,"wbc_k_uL":4.3,"platelets_k_uL":281,"creatinine_mg_dL":1.78,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":62,"sex":"female","bmi":37.6,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-04-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-62},"pfs_months":14.88},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.7,"censored":false},"longitudinal_labs":[{"date":"2023-03-28","hemoglobin_g_dL":13.1,"wbc_k_uL":5.1,"platelets_k_uL":324,"creatinine_mg_dL":0.95,"alt_U_L":38},{"date":"2023-10-14","hemoglobin_g_dL":12.8,"wbc_k_uL":7.4,"platelets_k_uL":169,"creatinine_mg_dL":0.83,"alt_U_L":81},{"date":"2024-08-16","hemoglobin_g_dL":12.7,"wbc_k_uL":7.3,"platelets_k_uL":205,"creatinine_mg_dL":1.08,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":71,"sex":"female","bmi":33.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-48},"pfs_months":12.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":24.7,"censored":false},"longitudinal_labs":[{"date":"2023-02-12","hemoglobin_g_dL":14.4,"wbc_k_uL":6.5,"platelets_k_uL":230,"creatinine_mg_dL":0.79,"alt_U_L":24},{"date":"2023-09-07","hemoglobin_g_dL":10.6,"wbc_k_uL":4.5,"platelets_k_uL":273,"creatinine_mg_dL":1.54,"alt_U_L":91},{"date":"2024-04-21","hemoglobin_g_dL":11.6,"wbc_k_uL":8.0,"platelets_k_uL":224,"creatinine_mg_dL":0.96,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":69,"sex":"male","bmi":21.6,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-08-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-67},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":13.1,"censored":true},"longitudinal_labs":[{"date":"2023-06-23","hemoglobin_g_dL":11.7,"wbc_k_uL":8.0,"platelets_k_uL":262,"creatinine_mg_dL":0.78,"alt_U_L":10},{"date":"2024-02-01","hemoglobin_g_dL":12.5,"wbc_k_uL":5.6,"platelets_k_uL":306,"creatinine_mg_dL":1.32,"alt_U_L":66},{"date":"2023-11-21","hemoglobin_g_dL":12.1,"wbc_k_uL":4.3,"platelets_k_uL":251,"creatinine_mg_dL":1.57,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":85,"sex":"female","bmi":18.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-83},"pfs_months":17.41},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.0,"censored":false},"longitudinal_labs":[{"date":"2025-07-11","hemoglobin_g_dL":12.0,"wbc_k_uL":6.7,"platelets_k_uL":259,"creatinine_mg_dL":0.66,"alt_U_L":37},{"date":"2026-01-28","hemoglobin_g_dL":13.3,"wbc_k_uL":6.5,"platelets_k_uL":174,"creatinine_mg_dL":1.41,"alt_U_L":88},{"date":"2027-03-11","hemoglobin_g_dL":12.3,"wbc_k_uL":3.7,"platelets_k_uL":280,"creatinine_mg_dL":1.45,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":75,"sex":"male","bmi":35.8,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-03-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-51},"pfs_months":13.37},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.5,"censored":false},"longitudinal_labs":[{"date":"2020-01-20","hemoglobin_g_dL":12.8,"wbc_k_uL":11.0,"platelets_k_uL":233,"creatinine_mg_dL":0.65,"alt_U_L":38},{"date":"2020-09-24","hemoglobin_g_dL":10.3,"wbc_k_uL":7.7,"platelets_k_uL":211,"creatinine_mg_dL":0.76,"alt_U_L":39},{"date":"2021-07-01","hemoglobin_g_dL":10.1,"wbc_k_uL":6.7,"platelets_k_uL":235,"creatinine_mg_dL":0.9,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_998","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":86,"sex":"female","bmi":33.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-03-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-66},"pfs_months":32.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":47.0,"censored":false},"longitudinal_labs":[{"date":"2020-01-13","hemoglobin_g_dL":12.1,"wbc_k_uL":10.5,"platelets_k_uL":311,"creatinine_mg_dL":0.87,"alt_U_L":17},{"date":"2020-09-07","hemoglobin_g_dL":10.9,"wbc_k_uL":7.2,"platelets_k_uL":332,"creatinine_mg_dL":1.03,"alt_U_L":67},{"date":"2022-11-26","hemoglobin_g_dL":10.5,"wbc_k_uL":4.4,"platelets_k_uL":315,"creatinine_mg_dL":1.12,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":80,"sex":"female","bmi":19.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-39},"pfs_months":21.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":false},"longitudinal_labs":[{"date":"2023-10-27","hemoglobin_g_dL":13.2,"wbc_k_uL":4.9,"platelets_k_uL":312,"creatinine_mg_dL":1.05,"alt_U_L":47},{"date":"2024-06-27","hemoglobin_g_dL":13.1,"wbc_k_uL":4.4,"platelets_k_uL":178,"creatinine_mg_dL":1.48,"alt_U_L":37},{"date":"2025-11-26","hemoglobin_g_dL":11.3,"wbc_k_uL":7.2,"platelets_k_uL":143,"creatinine_mg_dL":1.92,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_1000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":88,"sex":"female","bmi":19.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-78},"pfs_months":21.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.7,"censored":false},"longitudinal_labs":[{"date":"2023-11-01","hemoglobin_g_dL":14.1,"wbc_k_uL":6.9,"platelets_k_uL":374,"creatinine_mg_dL":0.73,"alt_U_L":32},{"date":"2024-06-16","hemoglobin_g_dL":12.2,"wbc_k_uL":5.6,"platelets_k_uL":282,"creatinine_mg_dL":0.88,"alt_U_L":107},{"date":"2025-11-14","hemoglobin_g_dL":13.0,"wbc_k_uL":4.7,"platelets_k_uL":174,"creatinine_mg_dL":1.93,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_1001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":62,"sex":"female","bmi":31.0,"smoking_pack_years":44,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-08-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-45},"pfs_months":37.72},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":53.7,"censored":false},"longitudinal_labs":[{"date":"2021-08-17","hemoglobin_g_dL":12.9,"wbc_k_uL":9.6,"platelets_k_uL":165,"creatinine_mg_dL":0.79,"alt_U_L":59},{"date":"2022-02-27","hemoglobin_g_dL":13.2,"wbc_k_uL":8.0,"platelets_k_uL":264,"creatinine_mg_dL":1.39,"alt_U_L":110},{"date":"2024-11-22","hemoglobin_g_dL":9.5,"wbc_k_uL":4.3,"platelets_k_uL":323,"creatinine_mg_dL":1.07,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_1002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":87,"sex":"female","bmi":30.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-54},"pfs_months":23.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.9,"censored":true},"longitudinal_labs":[{"date":"2023-08-08","hemoglobin_g_dL":14.3,"wbc_k_uL":5.3,"platelets_k_uL":432,"creatinine_mg_dL":1.01,"alt_U_L":52},{"date":"2024-03-25","hemoglobin_g_dL":11.3,"wbc_k_uL":8.9,"platelets_k_uL":345,"creatinine_mg_dL":1.52,"alt_U_L":108},{"date":"2025-10-06","hemoglobin_g_dL":10.0,"wbc_k_uL":7.3,"platelets_k_uL":112,"creatinine_mg_dL":1.13,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_1003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":61,"sex":"female","bmi":29.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-79},"pfs_months":17.51},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.5,"censored":false},"longitudinal_labs":[{"date":"2025-02-21","hemoglobin_g_dL":14.0,"wbc_k_uL":6.0,"platelets_k_uL":338,"creatinine_mg_dL":0.95,"alt_U_L":66},{"date":"2025-10-27","hemoglobin_g_dL":12.9,"wbc_k_uL":7.7,"platelets_k_uL":205,"creatinine_mg_dL":1.04,"alt_U_L":44},{"date":"2026-12-01","hemoglobin_g_dL":12.8,"wbc_k_uL":5.7,"platelets_k_uL":156,"creatinine_mg_dL":1.25,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_1004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":51,"sex":"female","bmi":18.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-66},"pfs_months":25.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.3,"censored":true},"longitudinal_labs":[{"date":"2021-02-05","hemoglobin_g_dL":15.2,"wbc_k_uL":9.3,"platelets_k_uL":210,"creatinine_mg_dL":1.12,"alt_U_L":65},{"date":"2021-10-10","hemoglobin_g_dL":12.3,"wbc_k_uL":6.4,"platelets_k_uL":160,"creatinine_mg_dL":1.47,"alt_U_L":114},{"date":"2023-06-25","hemoglobin_g_dL":10.8,"wbc_k_uL":7.8,"platelets_k_uL":317,"creatinine_mg_dL":0.81,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_1005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":70,"sex":"male","bmi":35.9,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-12-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-73},"pfs_months":38.74},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.8,"censored":true},"longitudinal_labs":[{"date":"2024-10-17","hemoglobin_g_dL":15.2,"wbc_k_uL":5.1,"platelets_k_uL":316,"creatinine_mg_dL":0.72,"alt_U_L":78},{"date":"2025-06-04","hemoglobin_g_dL":12.5,"wbc_k_uL":8.2,"platelets_k_uL":376,"creatinine_mg_dL":1.56,"alt_U_L":61},{"date":"2028-04-05","hemoglobin_g_dL":10.9,"wbc_k_uL":7.7,"platelets_k_uL":260,"creatinine_mg_dL":1.11,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_1006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":48,"sex":"male","bmi":29.7,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-03-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-41},"pfs_months":43.4},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-12-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":70.6,"censored":false},"longitudinal_labs":[{"date":"2025-02-14","hemoglobin_g_dL":12.7,"wbc_k_uL":8.6,"platelets_k_uL":263,"creatinine_mg_dL":1.2,"alt_U_L":48},{"date":"2025-09-25","hemoglobin_g_dL":13.5,"wbc_k_uL":8.4,"platelets_k_uL":147,"creatinine_mg_dL":0.73,"alt_U_L":80},{"date":"2028-12-26","hemoglobin_g_dL":9.7,"wbc_k_uL":6.8,"platelets_k_uL":129,"creatinine_mg_dL":1.72,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_1007","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.8,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":57,"sex":"male","bmi":20.6,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-49},"pfs_months":32.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.8,"censored":true},"longitudinal_labs":[{"date":"2022-04-22","hemoglobin_g_dL":15.4,"wbc_k_uL":6.0,"platelets_k_uL":386,"creatinine_mg_dL":0.93,"alt_U_L":19},{"date":"2022-12-05","hemoglobin_g_dL":13.0,"wbc_k_uL":8.3,"platelets_k_uL":305,"creatinine_mg_dL":0.89,"alt_U_L":28},{"date":"2025-03-14","hemoglobin_g_dL":10.1,"wbc_k_uL":4.3,"platelets_k_uL":277,"creatinine_mg_dL":1.5,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_1008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":85,"sex":"female","bmi":23.4,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-01-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-54},"pfs_months":14.59},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.0,"censored":false},"longitudinal_labs":[{"date":"2023-10-26","hemoglobin_g_dL":12.3,"wbc_k_uL":6.6,"platelets_k_uL":397,"creatinine_mg_dL":0.64,"alt_U_L":32},{"date":"2024-07-01","hemoglobin_g_dL":13.3,"wbc_k_uL":5.4,"platelets_k_uL":281,"creatinine_mg_dL":1.4,"alt_U_L":32},{"date":"2025-04-05","hemoglobin_g_dL":11.0,"wbc_k_uL":4.2,"platelets_k_uL":300,"creatinine_mg_dL":1.47,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_1009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":85,"sex":"female","bmi":20.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-45},"pfs_months":22.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.4,"censored":false},"longitudinal_labs":[{"date":"2022-10-23","hemoglobin_g_dL":11.6,"wbc_k_uL":5.7,"platelets_k_uL":299,"creatinine_mg_dL":1.19,"alt_U_L":67},{"date":"2023-06-26","hemoglobin_g_dL":12.7,"wbc_k_uL":5.0,"platelets_k_uL":268,"creatinine_mg_dL":1.51,"alt_U_L":111},{"date":"2025-01-12","hemoglobin_g_dL":12.5,"wbc_k_uL":4.3,"platelets_k_uL":159,"creatinine_mg_dL":0.99,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_1010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":63,"sex":"female","bmi":21.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-49},"pfs_months":26.15},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.0,"censored":false},"longitudinal_labs":[{"date":"2021-07-23","hemoglobin_g_dL":11.9,"wbc_k_uL":5.8,"platelets_k_uL":243,"creatinine_mg_dL":0.7,"alt_U_L":55},{"date":"2022-03-28","hemoglobin_g_dL":11.3,"wbc_k_uL":4.5,"platelets_k_uL":306,"creatinine_mg_dL":1.04,"alt_U_L":92},{"date":"2023-12-16","hemoglobin_g_dL":11.8,"wbc_k_uL":5.4,"platelets_k_uL":295,"creatinine_mg_dL":1.92,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_1011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":69,"sex":"female","bmi":33.2,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-10-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-68},"pfs_months":4.21},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-03-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":8.1,"censored":false},"longitudinal_labs":[{"date":"2020-08-09","hemoglobin_g_dL":11.6,"wbc_k_uL":9.1,"platelets_k_uL":154,"creatinine_mg_dL":1.03,"alt_U_L":26},{"date":"2021-04-15","hemoglobin_g_dL":12.7,"wbc_k_uL":4.2,"platelets_k_uL":319,"creatinine_mg_dL":0.98,"alt_U_L":38},{"date":"2021-03-05","hemoglobin_g_dL":9.5,"wbc_k_uL":5.9,"platelets_k_uL":319,"creatinine_mg_dL":1.14,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_1012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":79,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-55},"pfs_months":19.22},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2024-08-16","hemoglobin_g_dL":15.1,"wbc_k_uL":9.7,"platelets_k_uL":338,"creatinine_mg_dL":0.87,"alt_U_L":31},{"date":"2025-04-14","hemoglobin_g_dL":11.3,"wbc_k_uL":5.7,"platelets_k_uL":218,"creatinine_mg_dL":0.94,"alt_U_L":66},{"date":"2026-07-02","hemoglobin_g_dL":10.1,"wbc_k_uL":7.4,"platelets_k_uL":280,"creatinine_mg_dL":1.36,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_1013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":76,"sex":"male","bmi":33.0,"smoking_pack_years":35,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-59},"pfs_months":3.81},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-04-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":13.1,"censored":false},"longitudinal_labs":[{"date":"2020-10-01","hemoglobin_g_dL":13.9,"wbc_k_uL":6.1,"platelets_k_uL":392,"creatinine_mg_dL":1.26,"alt_U_L":76},{"date":"2021-05-23","hemoglobin_g_dL":13.9,"wbc_k_uL":4.6,"platelets_k_uL":321,"creatinine_mg_dL":1.05,"alt_U_L":32},{"date":"2021-04-03","hemoglobin_g_dL":11.1,"wbc_k_uL":6.4,"platelets_k_uL":132,"creatinine_mg_dL":1.07,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_1014","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":72,"sex":"male","bmi":27.1,"smoking_pack_years":16,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-01-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-49},"pfs_months":18.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-08-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.8,"censored":true},"longitudinal_labs":[{"date":"2020-01-14","hemoglobin_g_dL":12.2,"wbc_k_uL":9.4,"platelets_k_uL":357,"creatinine_mg_dL":0.71,"alt_U_L":40},{"date":"2020-07-29","hemoglobin_g_dL":10.1,"wbc_k_uL":7.2,"platelets_k_uL":364,"creatinine_mg_dL":0.86,"alt_U_L":51},{"date":"2021-08-30","hemoglobin_g_dL":12.5,"wbc_k_uL":5.3,"platelets_k_uL":256,"creatinine_mg_dL":0.89,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_1015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":69,"sex":"female","bmi":35.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-47},"pfs_months":20.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.6,"censored":false},"longitudinal_labs":[{"date":"2020-10-03","hemoglobin_g_dL":12.5,"wbc_k_uL":6.3,"platelets_k_uL":428,"creatinine_mg_dL":0.79,"alt_U_L":22},{"date":"2021-05-16","hemoglobin_g_dL":12.8,"wbc_k_uL":6.4,"platelets_k_uL":225,"creatinine_mg_dL":1.6,"alt_U_L":35},{"date":"2022-09-26","hemoglobin_g_dL":12.0,"wbc_k_uL":3.1,"platelets_k_uL":183,"creatinine_mg_dL":1.67,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_1016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":60,"sex":"female","bmi":21.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-33},"pfs_months":22.11},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.4,"censored":false},"longitudinal_labs":[{"date":"2025-07-18","hemoglobin_g_dL":13.1,"wbc_k_uL":8.3,"platelets_k_uL":349,"creatinine_mg_dL":0.69,"alt_U_L":20},{"date":"2026-03-09","hemoglobin_g_dL":11.8,"wbc_k_uL":4.5,"platelets_k_uL":239,"creatinine_mg_dL":1.37,"alt_U_L":89},{"date":"2027-08-05","hemoglobin_g_dL":12.8,"wbc_k_uL":3.3,"platelets_k_uL":157,"creatinine_mg_dL":1.38,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_1017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":80,"sex":"female","bmi":35.9,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-70},"pfs_months":37.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":61.2,"censored":true},"longitudinal_labs":[{"date":"2022-06-14","hemoglobin_g_dL":12.8,"wbc_k_uL":8.6,"platelets_k_uL":440,"creatinine_mg_dL":0.95,"alt_U_L":62},{"date":"2023-02-14","hemoglobin_g_dL":13.5,"wbc_k_uL":4.7,"platelets_k_uL":216,"creatinine_mg_dL":1.24,"alt_U_L":46},{"date":"2025-10-24","hemoglobin_g_dL":12.2,"wbc_k_uL":7.3,"platelets_k_uL":185,"creatinine_mg_dL":1.6,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_1018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":64,"sex":"female","bmi":30.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-68},"pfs_months":20.53},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.2,"censored":false},"longitudinal_labs":[{"date":"2020-06-25","hemoglobin_g_dL":13.6,"wbc_k_uL":10.6,"platelets_k_uL":301,"creatinine_mg_dL":1.09,"alt_U_L":21},{"date":"2021-01-08","hemoglobin_g_dL":11.9,"wbc_k_uL":4.9,"platelets_k_uL":161,"creatinine_mg_dL":0.98,"alt_U_L":42},{"date":"2022-05-04","hemoglobin_g_dL":11.3,"wbc_k_uL":6.8,"platelets_k_uL":349,"creatinine_mg_dL":0.9,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_1019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":62,"sex":"female","bmi":21.9,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-05-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-42},"pfs_months":36.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":55.6,"censored":false},"longitudinal_labs":[{"date":"2025-03-21","hemoglobin_g_dL":12.9,"wbc_k_uL":7.7,"platelets_k_uL":430,"creatinine_mg_dL":1.15,"alt_U_L":18},{"date":"2025-11-22","hemoglobin_g_dL":10.3,"wbc_k_uL":8.8,"platelets_k_uL":258,"creatinine_mg_dL":1.45,"alt_U_L":49},{"date":"2028-07-13","hemoglobin_g_dL":10.6,"wbc_k_uL":4.8,"platelets_k_uL":232,"creatinine_mg_dL":1.34,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_1020","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":60,"sex":"male","bmi":35.5,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-04-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-70},"pfs_months":25.46},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.3,"censored":false},"longitudinal_labs":[{"date":"2023-03-02","hemoglobin_g_dL":12.0,"wbc_k_uL":10.4,"platelets_k_uL":350,"creatinine_mg_dL":0.83,"alt_U_L":12},{"date":"2023-10-06","hemoglobin_g_dL":10.5,"wbc_k_uL":4.0,"platelets_k_uL":231,"creatinine_mg_dL":1.15,"alt_U_L":46},{"date":"2025-07-13","hemoglobin_g_dL":11.7,"wbc_k_uL":3.9,"platelets_k_uL":312,"creatinine_mg_dL":1.11,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_1021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":54,"sex":"female","bmi":30.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-47},"pfs_months":16.39},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.1,"censored":false},"longitudinal_labs":[{"date":"2022-06-17","hemoglobin_g_dL":12.8,"wbc_k_uL":9.5,"platelets_k_uL":415,"creatinine_mg_dL":1.28,"alt_U_L":57},{"date":"2023-01-11","hemoglobin_g_dL":13.8,"wbc_k_uL":6.8,"platelets_k_uL":320,"creatinine_mg_dL":1.13,"alt_U_L":60},{"date":"2024-01-23","hemoglobin_g_dL":12.8,"wbc_k_uL":4.3,"platelets_k_uL":348,"creatinine_mg_dL":1.38,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_1022","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":53,"sex":"female","bmi":23.8,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-78},"pfs_months":10.94},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-04-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":16.7,"censored":true},"longitudinal_labs":[{"date":"2020-04-06","hemoglobin_g_dL":13.6,"wbc_k_uL":6.3,"platelets_k_uL":210,"creatinine_mg_dL":0.66,"alt_U_L":79},{"date":"2020-10-23","hemoglobin_g_dL":10.6,"wbc_k_uL":8.7,"platelets_k_uL":163,"creatinine_mg_dL":1.03,"alt_U_L":104},{"date":"2021-04-14","hemoglobin_g_dL":12.1,"wbc_k_uL":7.4,"platelets_k_uL":192,"creatinine_mg_dL":1.25,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_1023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":63,"sex":"female","bmi":21.5,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-02-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-46},"pfs_months":34.3},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":55.8,"censored":false},"longitudinal_labs":[{"date":"2021-12-27","hemoglobin_g_dL":12.8,"wbc_k_uL":4.9,"platelets_k_uL":376,"creatinine_mg_dL":0.7,"alt_U_L":16},{"date":"2022-08-03","hemoglobin_g_dL":11.1,"wbc_k_uL":5.9,"platelets_k_uL":333,"creatinine_mg_dL":0.99,"alt_U_L":95},{"date":"2025-01-21","hemoglobin_g_dL":11.2,"wbc_k_uL":6.1,"platelets_k_uL":190,"creatinine_mg_dL":1.24,"alt_U_L":99}]}
{"patient_id":"ANODE_SYNTH_2025_1024","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":71,"sex":"male","bmi":31.2,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-01-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-70},"pfs_months":19.58},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":false},"longitudinal_labs":[{"date":"2023-01-09","hemoglobin_g_dL":11.7,"wbc_k_uL":5.8,"platelets_k_uL":219,"creatinine_mg_dL":0.9,"alt_U_L":37},{"date":"2023-07-29","hemoglobin_g_dL":11.0,"wbc_k_uL":5.7,"platelets_k_uL":142,"creatinine_mg_dL":0.83,"alt_U_L":119},{"date":"2024-10-12","hemoglobin_g_dL":10.5,"wbc_k_uL":5.7,"platelets_k_uL":318,"creatinine_mg_dL":1.59,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_1025","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":78,"sex":"female","bmi":29.8,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-11-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-72},"pfs_months":21.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.1,"censored":false},"longitudinal_labs":[{"date":"2021-10-04","hemoglobin_g_dL":12.4,"wbc_k_uL":10.6,"platelets_k_uL":240,"creatinine_mg_dL":0.96,"alt_U_L":64},{"date":"2022-05-14","hemoglobin_g_dL":11.7,"wbc_k_uL":4.9,"platelets_k_uL":359,"creatinine_mg_dL":0.72,"alt_U_L":99},{"date":"2023-09-27","hemoglobin_g_dL":10.4,"wbc_k_uL":7.6,"platelets_k_uL":197,"creatinine_mg_dL":0.92,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_1026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":80,"sex":"female","bmi":29.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-45},"pfs_months":14.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.3,"censored":false},"longitudinal_labs":[{"date":"2025-02-01","hemoglobin_g_dL":15.2,"wbc_k_uL":9.6,"platelets_k_uL":245,"creatinine_mg_dL":0.7,"alt_U_L":39},{"date":"2025-10-06","hemoglobin_g_dL":10.1,"wbc_k_uL":8.0,"platelets_k_uL":173,"creatinine_mg_dL":1.2,"alt_U_L":32},{"date":"2026-08-13","hemoglobin_g_dL":12.6,"wbc_k_uL":7.8,"platelets_k_uL":156,"creatinine_mg_dL":1.28,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_1027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":74,"sex":"male","bmi":23.5,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-05-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-80},"pfs_months":13.17},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-02","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.4,"censored":true},"longitudinal_labs":[{"date":"2023-03-17","hemoglobin_g_dL":12.4,"wbc_k_uL":9.2,"platelets_k_uL":262,"creatinine_mg_dL":1.21,"alt_U_L":29},{"date":"2023-11-17","hemoglobin_g_dL":12.9,"wbc_k_uL":4.0,"platelets_k_uL":315,"creatinine_mg_dL":1.44,"alt_U_L":16},{"date":"2024-08-02","hemoglobin_g_dL":12.8,"wbc_k_uL":7.2,"platelets_k_uL":134,"creatinine_mg_dL":1.34,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_1028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":54,"sex":"male","bmi":35.8,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-04-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-69},"pfs_months":13.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-06-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":17.6,"censored":true},"longitudinal_labs":[{"date":"2020-03-21","hemoglobin_g_dL":11.8,"wbc_k_uL":9.6,"platelets_k_uL":310,"creatinine_mg_dL":1.07,"alt_U_L":40},{"date":"2020-10-05","hemoglobin_g_dL":11.0,"wbc_k_uL":4.1,"platelets_k_uL":275,"creatinine_mg_dL":0.83,"alt_U_L":74},{"date":"2021-06-07","hemoglobin_g_dL":11.5,"wbc_k_uL":4.4,"platelets_k_uL":196,"creatinine_mg_dL":1.76,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_1029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":84,"sex":"male","bmi":29.6,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-37},"pfs_months":3.02},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.9,"censored":true},"longitudinal_labs":[{"date":"2021-04-23","hemoglobin_g_dL":13.1,"wbc_k_uL":10.4,"platelets_k_uL":196,"creatinine_mg_dL":0.63,"alt_U_L":56},{"date":"2021-12-28","hemoglobin_g_dL":13.4,"wbc_k_uL":7.6,"platelets_k_uL":301,"creatinine_mg_dL":1.18,"alt_U_L":62},{"date":"2021-11-04","hemoglobin_g_dL":11.4,"wbc_k_uL":4.0,"platelets_k_uL":120,"creatinine_mg_dL":1.61,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_1030","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":87,"sex":"male","bmi":31.3,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-64},"pfs_months":17.81},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.8,"censored":false},"longitudinal_labs":[{"date":"2020-12-15","hemoglobin_g_dL":14.2,"wbc_k_uL":7.3,"platelets_k_uL":347,"creatinine_mg_dL":0.79,"alt_U_L":39},{"date":"2021-07-02","hemoglobin_g_dL":13.8,"wbc_k_uL":6.3,"platelets_k_uL":159,"creatinine_mg_dL":1.51,"alt_U_L":114},{"date":"2022-07-30","hemoglobin_g_dL":11.1,"wbc_k_uL":4.0,"platelets_k_uL":128,"creatinine_mg_dL":0.93,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_1031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":85,"sex":"male","bmi":32.2,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-01-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-48},"pfs_months":37.13},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":60.2,"censored":true},"longitudinal_labs":[{"date":"2020-12-01","hemoglobin_g_dL":14.1,"wbc_k_uL":9.7,"platelets_k_uL":224,"creatinine_mg_dL":1.12,"alt_U_L":57},{"date":"2021-07-22","hemoglobin_g_dL":12.1,"wbc_k_uL":7.0,"platelets_k_uL":236,"creatinine_mg_dL":1.35,"alt_U_L":33},{"date":"2024-03-08","hemoglobin_g_dL":10.9,"wbc_k_uL":3.4,"platelets_k_uL":183,"creatinine_mg_dL":1.53,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_1032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":59,"sex":"male","bmi":32.2,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-02-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-48},"pfs_months":14.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":18.6,"censored":true},"longitudinal_labs":[{"date":"2020-01-02","hemoglobin_g_dL":13.0,"wbc_k_uL":6.0,"platelets_k_uL":352,"creatinine_mg_dL":0.75,"alt_U_L":44},{"date":"2020-08-11","hemoglobin_g_dL":13.1,"wbc_k_uL":8.7,"platelets_k_uL":136,"creatinine_mg_dL":1.12,"alt_U_L":106},{"date":"2021-07-01","hemoglobin_g_dL":9.6,"wbc_k_uL":7.0,"platelets_k_uL":295,"creatinine_mg_dL":1.34,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_1033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":66,"sex":"male","bmi":33.4,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-40},"pfs_months":28.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":52.4,"censored":false},"longitudinal_labs":[{"date":"2020-01-24","hemoglobin_g_dL":11.7,"wbc_k_uL":10.3,"platelets_k_uL":437,"creatinine_mg_dL":0.91,"alt_U_L":63},{"date":"2020-09-02","hemoglobin_g_dL":10.5,"wbc_k_uL":6.8,"platelets_k_uL":210,"creatinine_mg_dL":1.19,"alt_U_L":83},{"date":"2022-08-18","hemoglobin_g_dL":10.4,"wbc_k_uL":6.4,"platelets_k_uL":165,"creatinine_mg_dL":1.74,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":88,"sex":"female","bmi":21.7,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-05-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-46},"pfs_months":33.35},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":62.1,"censored":false},"longitudinal_labs":[{"date":"2020-04-18","hemoglobin_g_dL":12.9,"wbc_k_uL":6.6,"platelets_k_uL":422,"creatinine_mg_dL":0.71,"alt_U_L":44},{"date":"2020-10-30","hemoglobin_g_dL":10.9,"wbc_k_uL":6.4,"platelets_k_uL":361,"creatinine_mg_dL":1.59,"alt_U_L":86},{"date":"2023-04-11","hemoglobin_g_dL":11.5,"wbc_k_uL":5.2,"platelets_k_uL":271,"creatinine_mg_dL":1.01,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_1035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":83,"sex":"male","bmi":30.8,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-57},"pfs_months":45.21},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-31","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.6,"censored":true},"longitudinal_labs":[{"date":"2021-04-28","hemoglobin_g_dL":12.8,"wbc_k_uL":8.1,"platelets_k_uL":160,"creatinine_mg_dL":0.75,"alt_U_L":76},{"date":"2021-11-25","hemoglobin_g_dL":11.3,"wbc_k_uL":8.9,"platelets_k_uL":232,"creatinine_mg_dL":1.04,"alt_U_L":21},{"date":"2025-03-31","hemoglobin_g_dL":12.8,"wbc_k_uL":6.9,"platelets_k_uL":149,"creatinine_mg_dL":1.19,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_1036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":58,"sex":"female","bmi":21.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-05-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-72},"pfs_months":26.68},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":46.4,"censored":false},"longitudinal_labs":[{"date":"2023-04-01","hemoglobin_g_dL":11.9,"wbc_k_uL":6.2,"platelets_k_uL":154,"creatinine_mg_dL":1.18,"alt_U_L":78},{"date":"2023-10-31","hemoglobin_g_dL":10.6,"wbc_k_uL":6.8,"platelets_k_uL":234,"creatinine_mg_dL":0.73,"alt_U_L":61},{"date":"2025-08-20","hemoglobin_g_dL":10.2,"wbc_k_uL":5.0,"platelets_k_uL":269,"creatinine_mg_dL":1.6,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_1037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":70,"sex":"female","bmi":19.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-12-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-84},"pfs_months":27.14},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.0,"censored":false},"longitudinal_labs":[{"date":"2021-10-21","hemoglobin_g_dL":13.3,"wbc_k_uL":8.1,"platelets_k_uL":439,"creatinine_mg_dL":0.74,"alt_U_L":25},{"date":"2022-06-07","hemoglobin_g_dL":13.1,"wbc_k_uL":6.7,"platelets_k_uL":188,"creatinine_mg_dL":1.43,"alt_U_L":30},{"date":"2024-05-04","hemoglobin_g_dL":11.4,"wbc_k_uL":6.0,"platelets_k_uL":227,"creatinine_mg_dL":1.33,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_1038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":83,"sex":"female","bmi":36.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-49},"pfs_months":23.2},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.0,"censored":true},"longitudinal_labs":[{"date":"2022-07-13","hemoglobin_g_dL":14.4,"wbc_k_uL":8.4,"platelets_k_uL":386,"creatinine_mg_dL":1.03,"alt_U_L":55},{"date":"2023-01-25","hemoglobin_g_dL":13.5,"wbc_k_uL":4.7,"platelets_k_uL":169,"creatinine_mg_dL":1.18,"alt_U_L":110},{"date":"2024-07-23","hemoglobin_g_dL":13.0,"wbc_k_uL":6.3,"platelets_k_uL":219,"creatinine_mg_dL":0.81,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_1039","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":65,"sex":"male","bmi":26.3,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-03-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-43},"pfs_months":17.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.2,"censored":false},"longitudinal_labs":[{"date":"2025-03-09","hemoglobin_g_dL":12.1,"wbc_k_uL":6.6,"platelets_k_uL":442,"creatinine_mg_dL":0.75,"alt_U_L":65},{"date":"2025-09-21","hemoglobin_g_dL":13.4,"wbc_k_uL":4.2,"platelets_k_uL":269,"creatinine_mg_dL":1.49,"alt_U_L":98},{"date":"2026-09-28","hemoglobin_g_dL":10.6,"wbc_k_uL":4.8,"platelets_k_uL":145,"creatinine_mg_dL":1.69,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_1040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":87,"sex":"female","bmi":25.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-38},"pfs_months":26.61},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":44.3,"censored":false},"longitudinal_labs":[{"date":"2025-05-23","hemoglobin_g_dL":13.8,"wbc_k_uL":8.2,"platelets_k_uL":316,"creatinine_mg_dL":1.06,"alt_U_L":78},{"date":"2025-12-08","hemoglobin_g_dL":11.3,"wbc_k_uL":7.9,"platelets_k_uL":303,"creatinine_mg_dL":1.53,"alt_U_L":25},{"date":"2027-10-26","hemoglobin_g_dL":11.3,"wbc_k_uL":3.5,"platelets_k_uL":107,"creatinine_mg_dL":1.7,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_1041","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":84,"sex":"female","bmi":22.5,"smoking_pack_years":76,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-08-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-84},"pfs_months":20.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.3,"censored":false},"longitudinal_labs":[{"date":"2021-07-14","hemoglobin_g_dL":12.9,"wbc_k_uL":4.6,"platelets_k_uL":249,"creatinine_mg_dL":0.9,"alt_U_L":74},{"date":"2022-02-09","hemoglobin_g_dL":12.5,"wbc_k_uL":7.1,"platelets_k_uL":125,"creatinine_mg_dL":1.55,"alt_U_L":20},{"date":"2023-05-22","hemoglobin_g_dL":10.3,"wbc_k_uL":6.3,"platelets_k_uL":144,"creatinine_mg_dL":1.31,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_1042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":75,"sex":"female","bmi":27.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-76},"pfs_months":29.7},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":true},"longitudinal_labs":[{"date":"2022-03-26","hemoglobin_g_dL":14.6,"wbc_k_uL":9.2,"platelets_k_uL":449,"creatinine_mg_dL":1.16,"alt_U_L":66},{"date":"2022-11-12","hemoglobin_g_dL":10.5,"wbc_k_uL":5.6,"platelets_k_uL":139,"creatinine_mg_dL":0.86,"alt_U_L":17},{"date":"2024-12-30","hemoglobin_g_dL":12.8,"wbc_k_uL":4.1,"platelets_k_uL":323,"creatinine_mg_dL":1.2,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_1043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":59,"sex":"female","bmi":24.9,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-04-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-84},"pfs_months":44.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-02-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":67.8,"censored":false},"longitudinal_labs":[{"date":"2025-02-27","hemoglobin_g_dL":11.9,"wbc_k_uL":8.8,"platelets_k_uL":398,"creatinine_mg_dL":0.78,"alt_U_L":39},{"date":"2025-10-12","hemoglobin_g_dL":12.1,"wbc_k_uL":5.1,"platelets_k_uL":370,"creatinine_mg_dL":1.51,"alt_U_L":27},{"date":"2029-02-05","hemoglobin_g_dL":11.4,"wbc_k_uL":7.7,"platelets_k_uL":327,"creatinine_mg_dL":1.96,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_1044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":77,"sex":"female","bmi":28.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-71},"pfs_months":33.51},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.9,"censored":false},"longitudinal_labs":[{"date":"2025-02-27","hemoglobin_g_dL":14.0,"wbc_k_uL":8.1,"platelets_k_uL":343,"creatinine_mg_dL":1.19,"alt_U_L":78},{"date":"2025-11-03","hemoglobin_g_dL":10.4,"wbc_k_uL":4.2,"platelets_k_uL":343,"creatinine_mg_dL":0.99,"alt_U_L":36},{"date":"2028-04-02","hemoglobin_g_dL":10.5,"wbc_k_uL":5.5,"platelets_k_uL":113,"creatinine_mg_dL":1.61,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_1045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":67,"sex":"female","bmi":19.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-70},"pfs_months":4.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":12.4,"censored":false},"longitudinal_labs":[{"date":"2020-10-18","hemoglobin_g_dL":13.3,"wbc_k_uL":8.5,"platelets_k_uL":360,"creatinine_mg_dL":1.24,"alt_U_L":28},{"date":"2021-06-22","hemoglobin_g_dL":13.6,"wbc_k_uL":8.6,"platelets_k_uL":278,"creatinine_mg_dL":0.82,"alt_U_L":42},{"date":"2021-05-28","hemoglobin_g_dL":12.8,"wbc_k_uL":7.7,"platelets_k_uL":135,"creatinine_mg_dL":1.35,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_1046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":51,"sex":"male","bmi":24.8,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-09-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-34},"pfs_months":8.31},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.2,"censored":false},"longitudinal_labs":[{"date":"2025-08-18","hemoglobin_g_dL":12.6,"wbc_k_uL":7.0,"platelets_k_uL":302,"creatinine_mg_dL":1.1,"alt_U_L":66},{"date":"2026-03-01","hemoglobin_g_dL":12.5,"wbc_k_uL":8.2,"platelets_k_uL":361,"creatinine_mg_dL":1.2,"alt_U_L":117},{"date":"2026-06-15","hemoglobin_g_dL":12.6,"wbc_k_uL":6.6,"platelets_k_uL":105,"creatinine_mg_dL":1.55,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_1047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":53,"sex":"female","bmi":19.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-44},"pfs_months":19.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.2,"censored":false},"longitudinal_labs":[{"date":"2025-02-06","hemoglobin_g_dL":14.5,"wbc_k_uL":9.0,"platelets_k_uL":369,"creatinine_mg_dL":1.29,"alt_U_L":53},{"date":"2025-10-01","hemoglobin_g_dL":10.1,"wbc_k_uL":3.8,"platelets_k_uL":148,"creatinine_mg_dL":1.28,"alt_U_L":34},{"date":"2027-01-04","hemoglobin_g_dL":10.3,"wbc_k_uL":6.1,"platelets_k_uL":324,"creatinine_mg_dL":1.3,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_1048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":69,"sex":"female","bmi":22.6,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-74},"pfs_months":42.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":64.5,"censored":true},"longitudinal_labs":[{"date":"2024-02-17","hemoglobin_g_dL":15.3,"wbc_k_uL":8.5,"platelets_k_uL":411,"creatinine_mg_dL":1.05,"alt_U_L":56},{"date":"2024-09-23","hemoglobin_g_dL":13.1,"wbc_k_uL":7.5,"platelets_k_uL":282,"creatinine_mg_dL":1.48,"alt_U_L":42},{"date":"2027-10-21","hemoglobin_g_dL":9.9,"wbc_k_uL":7.4,"platelets_k_uL":248,"creatinine_mg_dL":0.95,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_1049","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":85,"sex":"male","bmi":30.0,"smoking_pack_years":51,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-07-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-70},"pfs_months":20.86},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":false},"longitudinal_labs":[{"date":"2020-06-17","hemoglobin_g_dL":14.5,"wbc_k_uL":10.2,"platelets_k_uL":198,"creatinine_mg_dL":0.96,"alt_U_L":50},{"date":"2021-01-08","hemoglobin_g_dL":13.8,"wbc_k_uL":6.0,"platelets_k_uL":308,"creatinine_mg_dL":0.99,"alt_U_L":94},{"date":"2022-04-28","hemoglobin_g_dL":9.6,"wbc_k_uL":8.0,"platelets_k_uL":167,"creatinine_mg_dL":1.32,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_1050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":79,"sex":"female","bmi":30.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-63},"pfs_months":22.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.8,"censored":true},"longitudinal_labs":[{"date":"2022-02-04","hemoglobin_g_dL":12.4,"wbc_k_uL":9.6,"platelets_k_uL":187,"creatinine_mg_dL":1.21,"alt_U_L":46},{"date":"2022-10-12","hemoglobin_g_dL":12.1,"wbc_k_uL":4.0,"platelets_k_uL":357,"creatinine_mg_dL":1.1,"alt_U_L":47},{"date":"2024-03-23","hemoglobin_g_dL":12.7,"wbc_k_uL":7.9,"platelets_k_uL":190,"creatinine_mg_dL":1.42,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_1051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":81,"sex":"female","bmi":23.9,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-65},"pfs_months":6.67},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":10.6,"censored":true},"longitudinal_labs":[{"date":"2025-04-23","hemoglobin_g_dL":14.0,"wbc_k_uL":9.1,"platelets_k_uL":427,"creatinine_mg_dL":0.79,"alt_U_L":36},{"date":"2025-12-05","hemoglobin_g_dL":12.6,"wbc_k_uL":5.4,"platelets_k_uL":377,"creatinine_mg_dL":1.47,"alt_U_L":114},{"date":"2026-01-21","hemoglobin_g_dL":10.3,"wbc_k_uL":4.5,"platelets_k_uL":328,"creatinine_mg_dL":1.09,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_1052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":68,"sex":"female","bmi":27.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-48},"pfs_months":34.27},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.9,"censored":true},"longitudinal_labs":[{"date":"2020-08-03","hemoglobin_g_dL":13.4,"wbc_k_uL":8.8,"platelets_k_uL":295,"creatinine_mg_dL":0.78,"alt_U_L":80},{"date":"2021-04-03","hemoglobin_g_dL":13.4,"wbc_k_uL":7.3,"platelets_k_uL":292,"creatinine_mg_dL":1.58,"alt_U_L":88},{"date":"2023-10-10","hemoglobin_g_dL":10.9,"wbc_k_uL":5.1,"platelets_k_uL":109,"creatinine_mg_dL":1.01,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_1053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":79,"sex":"female","bmi":25.6,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-10-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-53},"pfs_months":41.13},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":62.3,"censored":false},"longitudinal_labs":[{"date":"2022-08-23","hemoglobin_g_dL":13.9,"wbc_k_uL":10.7,"platelets_k_uL":390,"creatinine_mg_dL":1.01,"alt_U_L":31},{"date":"2023-04-13","hemoglobin_g_dL":11.4,"wbc_k_uL":5.1,"platelets_k_uL":225,"creatinine_mg_dL":1.22,"alt_U_L":21},{"date":"2026-05-10","hemoglobin_g_dL":10.7,"wbc_k_uL":3.4,"platelets_k_uL":117,"creatinine_mg_dL":0.86,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_1054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":84,"sex":"female","bmi":26.9,"smoking_pack_years":79,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-10-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-49},"pfs_months":29.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":59.5,"censored":false},"longitudinal_labs":[{"date":"2024-09-09","hemoglobin_g_dL":12.0,"wbc_k_uL":7.8,"platelets_k_uL":267,"creatinine_mg_dL":0.97,"alt_U_L":28},{"date":"2025-04-11","hemoglobin_g_dL":12.8,"wbc_k_uL":6.2,"platelets_k_uL":236,"creatinine_mg_dL":0.98,"alt_U_L":120},{"date":"2027-05-31","hemoglobin_g_dL":12.6,"wbc_k_uL":5.8,"platelets_k_uL":199,"creatinine_mg_dL":1.58,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_1055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":59,"sex":"male","bmi":37.0,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-60},"pfs_months":15.87},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.7,"censored":false},"longitudinal_labs":[{"date":"2021-06-27","hemoglobin_g_dL":11.7,"wbc_k_uL":8.4,"platelets_k_uL":215,"creatinine_mg_dL":1.14,"alt_U_L":58},{"date":"2022-02-14","hemoglobin_g_dL":12.5,"wbc_k_uL":7.1,"platelets_k_uL":221,"creatinine_mg_dL":1.38,"alt_U_L":80},{"date":"2023-02-01","hemoglobin_g_dL":11.7,"wbc_k_uL":6.0,"platelets_k_uL":108,"creatinine_mg_dL":1.28,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_1056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":61,"sex":"female","bmi":32.6,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-01-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-46},"pfs_months":5.59},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":false},"longitudinal_labs":[{"date":"2022-12-13","hemoglobin_g_dL":12.9,"wbc_k_uL":7.0,"platelets_k_uL":417,"creatinine_mg_dL":0.72,"alt_U_L":80},{"date":"2023-07-17","hemoglobin_g_dL":13.7,"wbc_k_uL":5.0,"platelets_k_uL":144,"creatinine_mg_dL":1.48,"alt_U_L":41},{"date":"2023-07-29","hemoglobin_g_dL":11.5,"wbc_k_uL":5.9,"platelets_k_uL":254,"creatinine_mg_dL":0.89,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_1057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":55,"sex":"female","bmi":36.4,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-01-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-76},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":10.5,"censored":true},"longitudinal_labs":[{"date":"2022-12-13","hemoglobin_g_dL":11.8,"wbc_k_uL":8.1,"platelets_k_uL":321,"creatinine_mg_dL":1.11,"alt_U_L":41},{"date":"2023-07-14","hemoglobin_g_dL":11.8,"wbc_k_uL":5.9,"platelets_k_uL":344,"creatinine_mg_dL":1.21,"alt_U_L":54},{"date":"2023-05-13","hemoglobin_g_dL":12.3,"wbc_k_uL":6.8,"platelets_k_uL":120,"creatinine_mg_dL":1.83,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_1058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":51,"sex":"male","bmi":24.4,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-08-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-40},"pfs_months":6.37},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.7,"censored":false},"longitudinal_labs":[{"date":"2022-06-27","hemoglobin_g_dL":14.2,"wbc_k_uL":9.2,"platelets_k_uL":212,"creatinine_mg_dL":0.66,"alt_U_L":37},{"date":"2023-02-06","hemoglobin_g_dL":11.0,"wbc_k_uL":4.1,"platelets_k_uL":171,"creatinine_mg_dL":1.09,"alt_U_L":97},{"date":"2023-04-01","hemoglobin_g_dL":9.9,"wbc_k_uL":7.6,"platelets_k_uL":263,"creatinine_mg_dL":0.95,"alt_U_L":139}]}
{"patient_id":"ANODE_SYNTH_2025_1059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":85,"sex":"male","bmi":37.2,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-59},"pfs_months":6.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-02-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":12.1,"censored":false},"longitudinal_labs":[{"date":"2020-05-28","hemoglobin_g_dL":11.8,"wbc_k_uL":4.9,"platelets_k_uL":366,"creatinine_mg_dL":1.01,"alt_U_L":70},{"date":"2021-01-18","hemoglobin_g_dL":13.4,"wbc_k_uL":6.9,"platelets_k_uL":207,"creatinine_mg_dL":0.78,"alt_U_L":83},{"date":"2021-02-27","hemoglobin_g_dL":13.0,"wbc_k_uL":7.1,"platelets_k_uL":188,"creatinine_mg_dL":1.87,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_1060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":61,"sex":"male","bmi":34.6,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-07-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-79},"pfs_months":38.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":66.9,"censored":true},"longitudinal_labs":[{"date":"2023-05-06","hemoglobin_g_dL":14.8,"wbc_k_uL":9.1,"platelets_k_uL":261,"creatinine_mg_dL":0.84,"alt_U_L":25},{"date":"2024-01-03","hemoglobin_g_dL":11.8,"wbc_k_uL":5.5,"platelets_k_uL":311,"creatinine_mg_dL":1.13,"alt_U_L":78},{"date":"2026-09-28","hemoglobin_g_dL":12.0,"wbc_k_uL":6.9,"platelets_k_uL":157,"creatinine_mg_dL":1.35,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_1061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":84,"sex":"female","bmi":32.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-45},"pfs_months":26.41},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.0,"censored":true},"longitudinal_labs":[{"date":"2023-02-04","hemoglobin_g_dL":13.1,"wbc_k_uL":4.8,"platelets_k_uL":364,"creatinine_mg_dL":1.1,"alt_U_L":41},{"date":"2023-09-22","hemoglobin_g_dL":10.8,"wbc_k_uL":3.9,"platelets_k_uL":338,"creatinine_mg_dL":1.24,"alt_U_L":82},{"date":"2025-06-27","hemoglobin_g_dL":10.2,"wbc_k_uL":5.0,"platelets_k_uL":217,"creatinine_mg_dL":1.23,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_1062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":55,"sex":"male","bmi":31.1,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-05-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-68},"pfs_months":8.74},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.0,"censored":false},"longitudinal_labs":[{"date":"2024-04-08","hemoglobin_g_dL":15.4,"wbc_k_uL":7.1,"platelets_k_uL":233,"creatinine_mg_dL":1.08,"alt_U_L":55},{"date":"2024-11-06","hemoglobin_g_dL":10.7,"wbc_k_uL":4.1,"platelets_k_uL":275,"creatinine_mg_dL":1.59,"alt_U_L":117},{"date":"2025-03-27","hemoglobin_g_dL":12.9,"wbc_k_uL":4.6,"platelets_k_uL":336,"creatinine_mg_dL":0.81,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_1063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":48,"sex":"female","bmi":32.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-30},"pfs_months":20.27},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.7,"censored":false},"longitudinal_labs":[{"date":"2024-07-07","hemoglobin_g_dL":13.4,"wbc_k_uL":9.2,"platelets_k_uL":349,"creatinine_mg_dL":1.17,"alt_U_L":50},{"date":"2025-02-12","hemoglobin_g_dL":12.6,"wbc_k_uL":8.2,"platelets_k_uL":262,"creatinine_mg_dL":1.37,"alt_U_L":32},{"date":"2026-05-12","hemoglobin_g_dL":9.9,"wbc_k_uL":5.4,"platelets_k_uL":221,"creatinine_mg_dL":1.73,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_1064","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":55,"sex":"female","bmi":21.9,"smoking_pack_years":58,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-06-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-84},"pfs_months":25.17},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.6,"censored":false},"longitudinal_labs":[{"date":"2024-05-28","hemoglobin_g_dL":11.6,"wbc_k_uL":5.0,"platelets_k_uL":428,"creatinine_mg_dL":0.71,"alt_U_L":60},{"date":"2024-12-18","hemoglobin_g_dL":10.0,"wbc_k_uL":8.5,"platelets_k_uL":186,"creatinine_mg_dL":0.97,"alt_U_L":97},{"date":"2026-09-24","hemoglobin_g_dL":12.3,"wbc_k_uL":3.6,"platelets_k_uL":300,"creatinine_mg_dL":2.0,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_1065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":87,"sex":"female","bmi":22.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-85},"pfs_months":22.34},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.6,"censored":true},"longitudinal_labs":[{"date":"2022-11-09","hemoglobin_g_dL":14.2,"wbc_k_uL":6.2,"platelets_k_uL":150,"creatinine_mg_dL":0.98,"alt_U_L":33},{"date":"2023-06-24","hemoglobin_g_dL":13.5,"wbc_k_uL":6.4,"platelets_k_uL":336,"creatinine_mg_dL":1.0,"alt_U_L":77},{"date":"2024-12-17","hemoglobin_g_dL":10.0,"wbc_k_uL":3.7,"platelets_k_uL":240,"creatinine_mg_dL":0.96,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_1066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":83,"sex":"male","bmi":37.2,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-08-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-78},"pfs_months":41.23},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.1,"censored":false},"longitudinal_labs":[{"date":"2024-06-20","hemoglobin_g_dL":15.2,"wbc_k_uL":5.9,"platelets_k_uL":416,"creatinine_mg_dL":1.01,"alt_U_L":66},{"date":"2025-02-01","hemoglobin_g_dL":10.5,"wbc_k_uL":7.8,"platelets_k_uL":205,"creatinine_mg_dL":1.35,"alt_U_L":108},{"date":"2028-01-28","hemoglobin_g_dL":11.8,"wbc_k_uL":6.7,"platelets_k_uL":310,"creatinine_mg_dL":1.25,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_1067","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":70,"sex":"female","bmi":22.0,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-55},"pfs_months":21.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":40.0,"censored":true},"longitudinal_labs":[{"date":"2023-03-05","hemoglobin_g_dL":13.7,"wbc_k_uL":5.0,"platelets_k_uL":257,"creatinine_mg_dL":1.11,"alt_U_L":72},{"date":"2023-11-06","hemoglobin_g_dL":10.2,"wbc_k_uL":5.3,"platelets_k_uL":244,"creatinine_mg_dL":1.37,"alt_U_L":94},{"date":"2025-04-07","hemoglobin_g_dL":10.9,"wbc_k_uL":6.4,"platelets_k_uL":254,"creatinine_mg_dL":1.31,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_1068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":57,"sex":"female","bmi":33.0,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-33},"pfs_months":27.4},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":true},"longitudinal_labs":[{"date":"2022-09-13","hemoglobin_g_dL":11.6,"wbc_k_uL":8.1,"platelets_k_uL":262,"creatinine_mg_dL":0.66,"alt_U_L":17},{"date":"2023-03-26","hemoglobin_g_dL":13.1,"wbc_k_uL":7.0,"platelets_k_uL":157,"creatinine_mg_dL":0.88,"alt_U_L":82},{"date":"2025-01-30","hemoglobin_g_dL":11.5,"wbc_k_uL":4.2,"platelets_k_uL":343,"creatinine_mg_dL":1.11,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_1069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":55,"sex":"female","bmi":26.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-59},"pfs_months":28.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":46.1,"censored":true},"longitudinal_labs":[{"date":"2021-03-16","hemoglobin_g_dL":12.5,"wbc_k_uL":10.4,"platelets_k_uL":334,"creatinine_mg_dL":0.84,"alt_U_L":72},{"date":"2021-11-07","hemoglobin_g_dL":10.5,"wbc_k_uL":4.8,"platelets_k_uL":345,"creatinine_mg_dL":0.74,"alt_U_L":84},{"date":"2023-09-27","hemoglobin_g_dL":9.8,"wbc_k_uL":6.7,"platelets_k_uL":340,"creatinine_mg_dL":1.03,"alt_U_L":99}]}
{"patient_id":"ANODE_SYNTH_2025_1070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":72,"sex":"male","bmi":22.4,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-40},"pfs_months":32.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":63.3,"censored":false},"longitudinal_labs":[{"date":"2023-10-06","hemoglobin_g_dL":11.8,"wbc_k_uL":5.2,"platelets_k_uL":303,"creatinine_mg_dL":1.19,"alt_U_L":58},{"date":"2024-05-19","hemoglobin_g_dL":13.2,"wbc_k_uL":4.0,"platelets_k_uL":229,"creatinine_mg_dL":1.43,"alt_U_L":58},{"date":"2026-09-23","hemoglobin_g_dL":10.8,"wbc_k_uL":7.0,"platelets_k_uL":172,"creatinine_mg_dL":1.21,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_1071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":72,"sex":"female","bmi":28.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-44},"pfs_months":29.83},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.1,"censored":false},"longitudinal_labs":[{"date":"2025-08-03","hemoglobin_g_dL":11.6,"wbc_k_uL":6.5,"platelets_k_uL":210,"creatinine_mg_dL":0.93,"alt_U_L":26},{"date":"2026-03-07","hemoglobin_g_dL":12.5,"wbc_k_uL":6.9,"platelets_k_uL":236,"creatinine_mg_dL":1.49,"alt_U_L":83},{"date":"2028-03-23","hemoglobin_g_dL":10.1,"wbc_k_uL":5.3,"platelets_k_uL":154,"creatinine_mg_dL":1.85,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_1072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":76,"sex":"female","bmi":37.8,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-05-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-75},"pfs_months":33.61},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":46.2,"censored":true},"longitudinal_labs":[{"date":"2024-04-15","hemoglobin_g_dL":14.8,"wbc_k_uL":7.5,"platelets_k_uL":432,"creatinine_mg_dL":1.03,"alt_U_L":27},{"date":"2024-11-12","hemoglobin_g_dL":11.0,"wbc_k_uL":7.6,"platelets_k_uL":359,"creatinine_mg_dL":1.53,"alt_U_L":71},{"date":"2027-03-10","hemoglobin_g_dL":10.0,"wbc_k_uL":5.5,"platelets_k_uL":243,"creatinine_mg_dL":1.02,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_1073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":62,"sex":"female","bmi":25.6,"smoking_pack_years":53,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-64},"pfs_months":9.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":13.9,"censored":true},"longitudinal_labs":[{"date":"2020-05-16","hemoglobin_g_dL":14.4,"wbc_k_uL":6.6,"platelets_k_uL":408,"creatinine_mg_dL":1.18,"alt_U_L":70},{"date":"2021-01-14","hemoglobin_g_dL":12.7,"wbc_k_uL":5.6,"platelets_k_uL":361,"creatinine_mg_dL":0.94,"alt_U_L":16},{"date":"2021-07-01","hemoglobin_g_dL":10.1,"wbc_k_uL":6.4,"platelets_k_uL":321,"creatinine_mg_dL":1.18,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_1074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":75,"sex":"female","bmi":18.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-48},"pfs_months":23.23},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.7,"censored":false},"longitudinal_labs":[{"date":"2022-04-06","hemoglobin_g_dL":15.1,"wbc_k_uL":5.1,"platelets_k_uL":428,"creatinine_mg_dL":1.11,"alt_U_L":49},{"date":"2022-10-21","hemoglobin_g_dL":13.1,"wbc_k_uL":8.1,"platelets_k_uL":291,"creatinine_mg_dL":0.76,"alt_U_L":36},{"date":"2024-05-24","hemoglobin_g_dL":11.3,"wbc_k_uL":7.8,"platelets_k_uL":231,"creatinine_mg_dL":0.89,"alt_U_L":166}]}
{"patient_id":"ANODE_SYNTH_2025_1075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":86,"sex":"female","bmi":19.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-01-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-34},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.4,"censored":false},"longitudinal_labs":[{"date":"2021-12-12","hemoglobin_g_dL":12.9,"wbc_k_uL":5.8,"platelets_k_uL":361,"creatinine_mg_dL":0.76,"alt_U_L":42},{"date":"2022-07-18","hemoglobin_g_dL":12.9,"wbc_k_uL":4.2,"platelets_k_uL":229,"creatinine_mg_dL":0.85,"alt_U_L":29},{"date":"2023-12-07","hemoglobin_g_dL":12.2,"wbc_k_uL":4.7,"platelets_k_uL":255,"creatinine_mg_dL":1.0,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_1076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":61,"sex":"female","bmi":21.2,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-40},"pfs_months":38.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":58.3,"censored":false},"longitudinal_labs":[{"date":"2021-02-04","hemoglobin_g_dL":13.6,"wbc_k_uL":9.7,"platelets_k_uL":344,"creatinine_mg_dL":0.8,"alt_U_L":38},{"date":"2021-09-14","hemoglobin_g_dL":13.7,"wbc_k_uL":4.5,"platelets_k_uL":295,"creatinine_mg_dL":1.27,"alt_U_L":101},{"date":"2024-07-22","hemoglobin_g_dL":9.7,"wbc_k_uL":5.3,"platelets_k_uL":119,"creatinine_mg_dL":1.32,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_1077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":58,"sex":"female","bmi":27.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-82},"pfs_months":33.77},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":41.9,"censored":false},"longitudinal_labs":[{"date":"2023-09-18","hemoglobin_g_dL":13.9,"wbc_k_uL":9.8,"platelets_k_uL":412,"creatinine_mg_dL":1.09,"alt_U_L":75},{"date":"2024-05-12","hemoglobin_g_dL":13.8,"wbc_k_uL":3.9,"platelets_k_uL":277,"creatinine_mg_dL":0.89,"alt_U_L":105},{"date":"2026-10-16","hemoglobin_g_dL":10.0,"wbc_k_uL":6.8,"platelets_k_uL":215,"creatinine_mg_dL":1.01,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_1078","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":71,"sex":"female","bmi":28.3,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-42},"pfs_months":31.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":47.1,"censored":false},"longitudinal_labs":[{"date":"2023-05-14","hemoglobin_g_dL":15.2,"wbc_k_uL":7.4,"platelets_k_uL":366,"creatinine_mg_dL":1.3,"alt_U_L":77},{"date":"2023-12-10","hemoglobin_g_dL":10.4,"wbc_k_uL":6.9,"platelets_k_uL":156,"creatinine_mg_dL":1.39,"alt_U_L":101},{"date":"2026-03-09","hemoglobin_g_dL":10.8,"wbc_k_uL":6.7,"platelets_k_uL":254,"creatinine_mg_dL":1.42,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_1079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":50,"sex":"female","bmi":34.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-77},"pfs_months":24.54},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":false},"longitudinal_labs":[{"date":"2024-12-03","hemoglobin_g_dL":11.6,"wbc_k_uL":7.7,"platelets_k_uL":196,"creatinine_mg_dL":1.1,"alt_U_L":65},{"date":"2025-07-13","hemoglobin_g_dL":12.1,"wbc_k_uL":5.6,"platelets_k_uL":313,"creatinine_mg_dL":1.56,"alt_U_L":19},{"date":"2027-03-29","hemoglobin_g_dL":9.6,"wbc_k_uL":5.6,"platelets_k_uL":108,"creatinine_mg_dL":1.58,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1080","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":70,"sex":"female","bmi":28.1,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-66},"pfs_months":15.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.0,"censored":true},"longitudinal_labs":[{"date":"2020-01-19","hemoglobin_g_dL":12.9,"wbc_k_uL":4.6,"platelets_k_uL":307,"creatinine_mg_dL":0.63,"alt_U_L":29},{"date":"2020-09-04","hemoglobin_g_dL":12.9,"wbc_k_uL":8.1,"platelets_k_uL":224,"creatinine_mg_dL":0.86,"alt_U_L":61},{"date":"2021-07-08","hemoglobin_g_dL":10.8,"wbc_k_uL":5.7,"platelets_k_uL":239,"creatinine_mg_dL":1.88,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_1081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":84,"sex":"male","bmi":23.0,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-10-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-40},"pfs_months":51.61},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":71.2,"censored":true},"longitudinal_labs":[{"date":"2022-08-28","hemoglobin_g_dL":14.4,"wbc_k_uL":4.8,"platelets_k_uL":444,"creatinine_mg_dL":0.76,"alt_U_L":62},{"date":"2023-03-31","hemoglobin_g_dL":11.5,"wbc_k_uL":6.0,"platelets_k_uL":178,"creatinine_mg_dL":1.46,"alt_U_L":91},{"date":"2027-03-21","hemoglobin_g_dL":11.6,"wbc_k_uL":5.4,"platelets_k_uL":240,"creatinine_mg_dL":1.32,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_1082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":62,"sex":"female","bmi":20.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["brain","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-30},"pfs_months":33.08},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.6,"censored":false},"longitudinal_labs":[{"date":"2022-05-16","hemoglobin_g_dL":12.6,"wbc_k_uL":8.0,"platelets_k_uL":309,"creatinine_mg_dL":1.24,"alt_U_L":80},{"date":"2023-01-13","hemoglobin_g_dL":12.4,"wbc_k_uL":5.4,"platelets_k_uL":185,"creatinine_mg_dL":1.44,"alt_U_L":97},{"date":"2025-05-13","hemoglobin_g_dL":12.4,"wbc_k_uL":7.9,"platelets_k_uL":109,"creatinine_mg_dL":1.89,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_1083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":77,"sex":"female","bmi":30.6,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-11-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-76},"pfs_months":41.72},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":65.4,"censored":false},"longitudinal_labs":[{"date":"2020-09-17","hemoglobin_g_dL":14.5,"wbc_k_uL":6.5,"platelets_k_uL":436,"creatinine_mg_dL":0.78,"alt_U_L":36},{"date":"2021-05-14","hemoglobin_g_dL":12.1,"wbc_k_uL":8.1,"platelets_k_uL":194,"creatinine_mg_dL":0.87,"alt_U_L":30},{"date":"2024-06-10","hemoglobin_g_dL":10.4,"wbc_k_uL":5.2,"platelets_k_uL":192,"creatinine_mg_dL":1.93,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_1084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":65,"sex":"female","bmi":25.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-36},"pfs_months":23.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.2,"censored":true},"longitudinal_labs":[{"date":"2025-02-19","hemoglobin_g_dL":11.8,"wbc_k_uL":5.0,"platelets_k_uL":223,"creatinine_mg_dL":0.91,"alt_U_L":17},{"date":"2025-10-13","hemoglobin_g_dL":11.4,"wbc_k_uL":5.6,"platelets_k_uL":290,"creatinine_mg_dL":1.49,"alt_U_L":47},{"date":"2027-05-17","hemoglobin_g_dL":10.1,"wbc_k_uL":5.2,"platelets_k_uL":252,"creatinine_mg_dL":1.62,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_1085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":55,"sex":"male","bmi":24.6,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-03-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-42},"pfs_months":3.91},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-08-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.8,"censored":false},"longitudinal_labs":[{"date":"2020-01-11","hemoglobin_g_dL":15.0,"wbc_k_uL":8.7,"platelets_k_uL":262,"creatinine_mg_dL":0.93,"alt_U_L":64},{"date":"2020-08-29","hemoglobin_g_dL":12.5,"wbc_k_uL":7.8,"platelets_k_uL":206,"creatinine_mg_dL":1.52,"alt_U_L":27},{"date":"2020-08-05","hemoglobin_g_dL":12.9,"wbc_k_uL":3.6,"platelets_k_uL":126,"creatinine_mg_dL":1.61,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":50,"sex":"female","bmi":23.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-10-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-74},"pfs_months":16.13},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-10","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.3,"censored":false},"longitudinal_labs":[{"date":"2025-09-28","hemoglobin_g_dL":13.7,"wbc_k_uL":5.7,"platelets_k_uL":217,"creatinine_mg_dL":0.76,"alt_U_L":79},{"date":"2026-04-13","hemoglobin_g_dL":10.6,"wbc_k_uL":6.0,"platelets_k_uL":134,"creatinine_mg_dL":1.06,"alt_U_L":100},{"date":"2027-04-10","hemoglobin_g_dL":10.0,"wbc_k_uL":3.4,"platelets_k_uL":295,"creatinine_mg_dL":0.81,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_1087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":80,"sex":"female","bmi":25.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-65},"pfs_months":26.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":true},"longitudinal_labs":[{"date":"2021-10-18","hemoglobin_g_dL":12.6,"wbc_k_uL":10.0,"platelets_k_uL":158,"creatinine_mg_dL":1.08,"alt_U_L":80},{"date":"2022-05-29","hemoglobin_g_dL":10.6,"wbc_k_uL":4.1,"platelets_k_uL":148,"creatinine_mg_dL":1.0,"alt_U_L":70},{"date":"2024-03-17","hemoglobin_g_dL":9.6,"wbc_k_uL":5.9,"platelets_k_uL":276,"creatinine_mg_dL":1.47,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_1088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":76,"sex":"female","bmi":34.4,"smoking_pack_years":28,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-08-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-34},"pfs_months":11.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-31","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.9,"censored":true},"longitudinal_labs":[{"date":"2024-07-09","hemoglobin_g_dL":15.0,"wbc_k_uL":6.1,"platelets_k_uL":411,"creatinine_mg_dL":1.29,"alt_U_L":71},{"date":"2025-02-11","hemoglobin_g_dL":13.0,"wbc_k_uL":3.8,"platelets_k_uL":319,"creatinine_mg_dL":1.41,"alt_U_L":88},{"date":"2025-08-31","hemoglobin_g_dL":9.9,"wbc_k_uL":5.8,"platelets_k_uL":123,"creatinine_mg_dL":1.96,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_1089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":54,"sex":"male","bmi":21.7,"smoking_pack_years":43,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2025-03-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-81},"pfs_months":15.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":false},"longitudinal_labs":[{"date":"2025-03-03","hemoglobin_g_dL":12.4,"wbc_k_uL":4.8,"platelets_k_uL":429,"creatinine_mg_dL":1.15,"alt_U_L":38},{"date":"2025-09-13","hemoglobin_g_dL":10.1,"wbc_k_uL":7.1,"platelets_k_uL":343,"creatinine_mg_dL":1.34,"alt_U_L":71},{"date":"2026-09-01","hemoglobin_g_dL":11.2,"wbc_k_uL":4.6,"platelets_k_uL":261,"creatinine_mg_dL":1.82,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_1090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":76,"sex":"male","bmi":22.9,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-02-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-39},"pfs_months":37.09},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":67.1,"censored":false},"longitudinal_labs":[{"date":"2022-02-04","hemoglobin_g_dL":12.1,"wbc_k_uL":5.6,"platelets_k_uL":323,"creatinine_mg_dL":0.89,"alt_U_L":63},{"date":"2022-08-17","hemoglobin_g_dL":13.6,"wbc_k_uL":6.5,"platelets_k_uL":227,"creatinine_mg_dL":1.53,"alt_U_L":68},{"date":"2025-03-27","hemoglobin_g_dL":10.5,"wbc_k_uL":6.2,"platelets_k_uL":154,"creatinine_mg_dL":1.86,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_1091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":77,"sex":"female","bmi":37.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-75},"pfs_months":30.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.8,"censored":false},"longitudinal_labs":[{"date":"2023-01-09","hemoglobin_g_dL":14.7,"wbc_k_uL":4.6,"platelets_k_uL":355,"creatinine_mg_dL":0.72,"alt_U_L":15},{"date":"2023-09-02","hemoglobin_g_dL":14.0,"wbc_k_uL":4.4,"platelets_k_uL":272,"creatinine_mg_dL":0.93,"alt_U_L":109},{"date":"2025-10-13","hemoglobin_g_dL":12.4,"wbc_k_uL":5.9,"platelets_k_uL":142,"creatinine_mg_dL":1.79,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_1092","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":51,"sex":"male","bmi":32.7,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-07-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-74},"pfs_months":23.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":false},"longitudinal_labs":[{"date":"2022-04-25","hemoglobin_g_dL":15.2,"wbc_k_uL":4.6,"platelets_k_uL":197,"creatinine_mg_dL":0.79,"alt_U_L":33},{"date":"2022-12-30","hemoglobin_g_dL":13.8,"wbc_k_uL":7.1,"platelets_k_uL":237,"creatinine_mg_dL":1.47,"alt_U_L":89},{"date":"2024-07-27","hemoglobin_g_dL":9.8,"wbc_k_uL":6.0,"platelets_k_uL":329,"creatinine_mg_dL":1.81,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_1093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":72,"sex":"female","bmi":25.3,"smoking_pack_years":51,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-03-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-78},"pfs_months":8.84},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.4,"censored":false},"longitudinal_labs":[{"date":"2025-02-07","hemoglobin_g_dL":12.1,"wbc_k_uL":9.6,"platelets_k_uL":273,"creatinine_mg_dL":1.28,"alt_U_L":54},{"date":"2025-09-19","hemoglobin_g_dL":10.3,"wbc_k_uL":8.1,"platelets_k_uL":363,"creatinine_mg_dL":1.16,"alt_U_L":34},{"date":"2026-02-02","hemoglobin_g_dL":9.9,"wbc_k_uL":8.0,"platelets_k_uL":138,"creatinine_mg_dL":1.89,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_1094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":85,"sex":"male","bmi":33.7,"smoking_pack_years":25,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-07-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-83},"pfs_months":42.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":72.2,"censored":false},"longitudinal_labs":[{"date":"2024-05-16","hemoglobin_g_dL":13.9,"wbc_k_uL":6.3,"platelets_k_uL":408,"creatinine_mg_dL":1.08,"alt_U_L":27},{"date":"2025-01-09","hemoglobin_g_dL":10.6,"wbc_k_uL":7.3,"platelets_k_uL":285,"creatinine_mg_dL":0.76,"alt_U_L":85},{"date":"2028-01-24","hemoglobin_g_dL":12.1,"wbc_k_uL":3.6,"platelets_k_uL":213,"creatinine_mg_dL":0.82,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_1095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":62,"sex":"male","bmi":25.0,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-06-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-46},"pfs_months":13.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2022-04-05","hemoglobin_g_dL":12.2,"wbc_k_uL":4.9,"platelets_k_uL":246,"creatinine_mg_dL":1.2,"alt_U_L":38},{"date":"2022-12-06","hemoglobin_g_dL":12.7,"wbc_k_uL":7.9,"platelets_k_uL":197,"creatinine_mg_dL":0.98,"alt_U_L":74},{"date":"2023-08-18","hemoglobin_g_dL":10.3,"wbc_k_uL":7.4,"platelets_k_uL":168,"creatinine_mg_dL":1.81,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_1096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":49,"sex":"female","bmi":36.5,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-01-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-80},"pfs_months":5.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":10.3,"censored":true},"longitudinal_labs":[{"date":"2021-11-19","hemoglobin_g_dL":11.7,"wbc_k_uL":6.4,"platelets_k_uL":327,"creatinine_mg_dL":0.81,"alt_U_L":68},{"date":"2022-07-16","hemoglobin_g_dL":12.6,"wbc_k_uL":6.9,"platelets_k_uL":245,"creatinine_mg_dL":1.32,"alt_U_L":31},{"date":"2022-09-12","hemoglobin_g_dL":11.1,"wbc_k_uL":6.1,"platelets_k_uL":320,"creatinine_mg_dL":1.08,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_1097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":63,"sex":"female","bmi":26.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-56},"pfs_months":16.39},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.0,"censored":false},"longitudinal_labs":[{"date":"2025-04-05","hemoglobin_g_dL":14.6,"wbc_k_uL":10.3,"platelets_k_uL":303,"creatinine_mg_dL":0.62,"alt_U_L":20},{"date":"2025-11-09","hemoglobin_g_dL":13.1,"wbc_k_uL":5.6,"platelets_k_uL":146,"creatinine_mg_dL":1.2,"alt_U_L":95},{"date":"2026-11-01","hemoglobin_g_dL":9.8,"wbc_k_uL":4.2,"platelets_k_uL":215,"creatinine_mg_dL":1.48,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_1098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":64,"sex":"female","bmi":26.0,"smoking_pack_years":17,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-02-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-68},"pfs_months":46.62},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":67.9,"censored":true},"longitudinal_labs":[{"date":"2020-01-16","hemoglobin_g_dL":14.8,"wbc_k_uL":5.5,"platelets_k_uL":354,"creatinine_mg_dL":1.07,"alt_U_L":55},{"date":"2020-08-03","hemoglobin_g_dL":13.2,"wbc_k_uL":4.1,"platelets_k_uL":352,"creatinine_mg_dL":1.43,"alt_U_L":105},{"date":"2024-02-23","hemoglobin_g_dL":9.8,"wbc_k_uL":4.7,"platelets_k_uL":138,"creatinine_mg_dL":0.99,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_1099","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":55,"sex":"male","bmi":32.9,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-04-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-69},"pfs_months":19.22},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.2,"censored":true},"longitudinal_labs":[{"date":"2022-03-13","hemoglobin_g_dL":13.9,"wbc_k_uL":4.7,"platelets_k_uL":350,"creatinine_mg_dL":0.8,"alt_U_L":58},{"date":"2022-10-09","hemoglobin_g_dL":11.4,"wbc_k_uL":4.0,"platelets_k_uL":295,"creatinine_mg_dL":1.36,"alt_U_L":70},{"date":"2023-11-25","hemoglobin_g_dL":9.9,"wbc_k_uL":6.5,"platelets_k_uL":225,"creatinine_mg_dL":1.27,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_1100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":84,"sex":"female","bmi":26.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-77},"pfs_months":31.87},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.1,"censored":true},"longitudinal_labs":[{"date":"2020-05-20","hemoglobin_g_dL":13.3,"wbc_k_uL":6.6,"platelets_k_uL":303,"creatinine_mg_dL":0.69,"alt_U_L":71},{"date":"2020-12-02","hemoglobin_g_dL":10.8,"wbc_k_uL":6.2,"platelets_k_uL":328,"creatinine_mg_dL":0.81,"alt_U_L":110},{"date":"2023-02-28","hemoglobin_g_dL":10.4,"wbc_k_uL":7.0,"platelets_k_uL":274,"creatinine_mg_dL":1.0,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_1101","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":85,"sex":"male","bmi":32.7,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["bone","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-09-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-43},"pfs_months":42.15},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":59.8,"censored":false},"longitudinal_labs":[{"date":"2022-07-14","hemoglobin_g_dL":14.7,"wbc_k_uL":6.4,"platelets_k_uL":307,"creatinine_mg_dL":0.77,"alt_U_L":75},{"date":"2023-03-02","hemoglobin_g_dL":13.2,"wbc_k_uL":4.1,"platelets_k_uL":252,"creatinine_mg_dL":0.94,"alt_U_L":92},{"date":"2026-03-18","hemoglobin_g_dL":11.4,"wbc_k_uL":7.5,"platelets_k_uL":207,"creatinine_mg_dL":0.96,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_1102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":88,"sex":"female","bmi":27.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-40},"pfs_months":11.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.9,"censored":false},"longitudinal_labs":[{"date":"2021-08-01","hemoglobin_g_dL":13.9,"wbc_k_uL":7.6,"platelets_k_uL":420,"creatinine_mg_dL":0.7,"alt_U_L":52},{"date":"2022-03-26","hemoglobin_g_dL":11.3,"wbc_k_uL":5.0,"platelets_k_uL":201,"creatinine_mg_dL":0.96,"alt_U_L":105},{"date":"2022-10-25","hemoglobin_g_dL":12.6,"wbc_k_uL":7.1,"platelets_k_uL":345,"creatinine_mg_dL":1.3,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_1103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":82,"sex":"male","bmi":23.2,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-10-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-52},"pfs_months":36.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":65.5,"censored":false},"longitudinal_labs":[{"date":"2023-10-17","hemoglobin_g_dL":15.1,"wbc_k_uL":6.2,"platelets_k_uL":188,"creatinine_mg_dL":0.64,"alt_U_L":65},{"date":"2024-04-28","hemoglobin_g_dL":13.4,"wbc_k_uL":6.3,"platelets_k_uL":234,"creatinine_mg_dL":1.3,"alt_U_L":31},{"date":"2026-12-22","hemoglobin_g_dL":12.6,"wbc_k_uL":5.3,"platelets_k_uL":298,"creatinine_mg_dL":1.7,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_1104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":67,"sex":"female","bmi":29.0,"smoking_pack_years":24,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-08-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-71},"pfs_months":32.43},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":54.0,"censored":false},"longitudinal_labs":[{"date":"2020-07-24","hemoglobin_g_dL":13.4,"wbc_k_uL":10.2,"platelets_k_uL":154,"creatinine_mg_dL":0.91,"alt_U_L":17},{"date":"2021-02-20","hemoglobin_g_dL":13.6,"wbc_k_uL":8.9,"platelets_k_uL":207,"creatinine_mg_dL":0.7,"alt_U_L":82},{"date":"2023-06-13","hemoglobin_g_dL":10.5,"wbc_k_uL":7.2,"platelets_k_uL":317,"creatinine_mg_dL":1.05,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_1105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":85,"sex":"female","bmi":29.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-53},"pfs_months":26.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.8,"censored":false},"longitudinal_labs":[{"date":"2020-12-09","hemoglobin_g_dL":14.9,"wbc_k_uL":7.1,"platelets_k_uL":262,"creatinine_mg_dL":1.18,"alt_U_L":41},{"date":"2021-08-07","hemoglobin_g_dL":12.6,"wbc_k_uL":6.6,"platelets_k_uL":265,"creatinine_mg_dL":1.51,"alt_U_L":18},{"date":"2023-06-06","hemoglobin_g_dL":10.9,"wbc_k_uL":7.9,"platelets_k_uL":251,"creatinine_mg_dL":1.6,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_1106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":72,"sex":"female","bmi":23.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-65},"pfs_months":16.36},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.6,"censored":false},"longitudinal_labs":[{"date":"2023-02-04","hemoglobin_g_dL":12.1,"wbc_k_uL":7.2,"platelets_k_uL":294,"creatinine_mg_dL":0.98,"alt_U_L":62},{"date":"2023-08-18","hemoglobin_g_dL":12.5,"wbc_k_uL":8.4,"platelets_k_uL":306,"creatinine_mg_dL":0.84,"alt_U_L":59},{"date":"2024-07-30","hemoglobin_g_dL":10.4,"wbc_k_uL":4.9,"platelets_k_uL":319,"creatinine_mg_dL":1.09,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_1107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":57,"sex":"female","bmi":22.6,"smoking_pack_years":31,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-09-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-56},"pfs_months":24.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":53.8,"censored":false},"longitudinal_labs":[{"date":"2025-08-26","hemoglobin_g_dL":13.5,"wbc_k_uL":5.5,"platelets_k_uL":272,"creatinine_mg_dL":0.87,"alt_U_L":44},{"date":"2026-03-17","hemoglobin_g_dL":12.3,"wbc_k_uL":6.9,"platelets_k_uL":147,"creatinine_mg_dL":1.23,"alt_U_L":98},{"date":"2027-12-09","hemoglobin_g_dL":9.6,"wbc_k_uL":5.2,"platelets_k_uL":168,"creatinine_mg_dL":0.86,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_1108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":68,"sex":"female","bmi":22.6,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-61},"pfs_months":39.95},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":66.2,"censored":true},"longitudinal_labs":[{"date":"2022-07-27","hemoglobin_g_dL":13.6,"wbc_k_uL":5.9,"platelets_k_uL":247,"creatinine_mg_dL":1.14,"alt_U_L":44},{"date":"2023-02-17","hemoglobin_g_dL":11.3,"wbc_k_uL":4.5,"platelets_k_uL":289,"creatinine_mg_dL":0.83,"alt_U_L":94},{"date":"2026-01-09","hemoglobin_g_dL":10.3,"wbc_k_uL":4.1,"platelets_k_uL":331,"creatinine_mg_dL":1.41,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_1109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":63,"sex":"female","bmi":24.6,"smoking_pack_years":16,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-09-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-83},"pfs_months":12.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":24.7,"censored":true},"longitudinal_labs":[{"date":"2025-07-10","hemoglobin_g_dL":12.3,"wbc_k_uL":10.0,"platelets_k_uL":398,"creatinine_mg_dL":1.05,"alt_U_L":60},{"date":"2026-03-16","hemoglobin_g_dL":11.4,"wbc_k_uL":6.6,"platelets_k_uL":276,"creatinine_mg_dL":0.81,"alt_U_L":58},{"date":"2026-11-25","hemoglobin_g_dL":11.8,"wbc_k_uL":5.8,"platelets_k_uL":226,"creatinine_mg_dL":0.88,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_1110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":49,"sex":"male","bmi":31.1,"smoking_pack_years":32,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-05-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-56},"pfs_months":9.0},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":21.8,"censored":false},"longitudinal_labs":[{"date":"2022-03-13","hemoglobin_g_dL":13.7,"wbc_k_uL":5.1,"platelets_k_uL":254,"creatinine_mg_dL":1.2,"alt_U_L":63},{"date":"2022-10-30","hemoglobin_g_dL":13.6,"wbc_k_uL":6.0,"platelets_k_uL":177,"creatinine_mg_dL":0.95,"alt_U_L":46},{"date":"2023-02-27","hemoglobin_g_dL":11.0,"wbc_k_uL":6.3,"platelets_k_uL":346,"creatinine_mg_dL":0.95,"alt_U_L":125}]}
{"patient_id":"ANODE_SYNTH_2025_1111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":63,"sex":"female","bmi":20.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-32},"pfs_months":14.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.4,"censored":false},"longitudinal_labs":[{"date":"2021-02-15","hemoglobin_g_dL":11.8,"wbc_k_uL":5.6,"platelets_k_uL":358,"creatinine_mg_dL":0.93,"alt_U_L":77},{"date":"2021-09-19","hemoglobin_g_dL":11.9,"wbc_k_uL":7.4,"platelets_k_uL":161,"creatinine_mg_dL":0.99,"alt_U_L":96},{"date":"2022-06-17","hemoglobin_g_dL":9.9,"wbc_k_uL":4.2,"platelets_k_uL":110,"creatinine_mg_dL":1.69,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_1112","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":80,"sex":"male","bmi":21.3,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-10-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-61},"pfs_months":22.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.8,"censored":true},"longitudinal_labs":[{"date":"2022-09-12","hemoglobin_g_dL":12.2,"wbc_k_uL":6.2,"platelets_k_uL":395,"creatinine_mg_dL":1.16,"alt_U_L":39},{"date":"2023-04-11","hemoglobin_g_dL":12.6,"wbc_k_uL":4.5,"platelets_k_uL":211,"creatinine_mg_dL":1.33,"alt_U_L":109},{"date":"2024-10-27","hemoglobin_g_dL":10.2,"wbc_k_uL":5.6,"platelets_k_uL":291,"creatinine_mg_dL":1.67,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_1113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":80,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-67},"pfs_months":18.99},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.4,"censored":true},"longitudinal_labs":[{"date":"2025-01-10","hemoglobin_g_dL":12.1,"wbc_k_uL":10.6,"platelets_k_uL":356,"creatinine_mg_dL":1.19,"alt_U_L":26},{"date":"2025-08-18","hemoglobin_g_dL":10.6,"wbc_k_uL":5.6,"platelets_k_uL":156,"creatinine_mg_dL":0.95,"alt_U_L":77},{"date":"2026-11-14","hemoglobin_g_dL":9.6,"wbc_k_uL":4.8,"platelets_k_uL":214,"creatinine_mg_dL":1.71,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_1114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":52,"sex":"female","bmi":35.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-78},"pfs_months":21.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":false},"longitudinal_labs":[{"date":"2021-09-04","hemoglobin_g_dL":15.3,"wbc_k_uL":5.4,"platelets_k_uL":218,"creatinine_mg_dL":0.82,"alt_U_L":45},{"date":"2022-04-25","hemoglobin_g_dL":10.6,"wbc_k_uL":6.0,"platelets_k_uL":242,"creatinine_mg_dL":1.51,"alt_U_L":36},{"date":"2023-09-24","hemoglobin_g_dL":11.0,"wbc_k_uL":6.6,"platelets_k_uL":114,"creatinine_mg_dL":1.91,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_1115","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":57,"sex":"male","bmi":37.6,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-11-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-76},"pfs_months":13.21},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":false},"longitudinal_labs":[{"date":"2022-10-11","hemoglobin_g_dL":14.9,"wbc_k_uL":10.7,"platelets_k_uL":343,"creatinine_mg_dL":1.28,"alt_U_L":73},{"date":"2023-05-15","hemoglobin_g_dL":10.3,"wbc_k_uL":5.7,"platelets_k_uL":257,"creatinine_mg_dL":0.77,"alt_U_L":20},{"date":"2024-01-21","hemoglobin_g_dL":12.2,"wbc_k_uL":7.3,"platelets_k_uL":121,"creatinine_mg_dL":1.06,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_1116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":78,"sex":"female","bmi":36.3,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-09-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-30},"pfs_months":9.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":15.7,"censored":false},"longitudinal_labs":[{"date":"2024-08-14","hemoglobin_g_dL":11.8,"wbc_k_uL":7.5,"platelets_k_uL":443,"creatinine_mg_dL":0.69,"alt_U_L":43},{"date":"2025-03-18","hemoglobin_g_dL":10.3,"wbc_k_uL":6.7,"platelets_k_uL":128,"creatinine_mg_dL":1.09,"alt_U_L":53},{"date":"2025-07-15","hemoglobin_g_dL":11.0,"wbc_k_uL":4.0,"platelets_k_uL":236,"creatinine_mg_dL":0.96,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_1117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":63,"sex":"female","bmi":22.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-59},"pfs_months":26.68},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.6,"censored":false},"longitudinal_labs":[{"date":"2022-06-16","hemoglobin_g_dL":14.4,"wbc_k_uL":9.2,"platelets_k_uL":443,"creatinine_mg_dL":0.63,"alt_U_L":33},{"date":"2023-01-02","hemoglobin_g_dL":10.3,"wbc_k_uL":6.7,"platelets_k_uL":137,"creatinine_mg_dL":1.17,"alt_U_L":118},{"date":"2024-11-07","hemoglobin_g_dL":10.1,"wbc_k_uL":5.0,"platelets_k_uL":156,"creatinine_mg_dL":1.26,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_1118","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":60,"sex":"female","bmi":32.4,"smoking_pack_years":72,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-07-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-70},"pfs_months":39.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":52.7,"censored":false},"longitudinal_labs":[{"date":"2024-06-26","hemoglobin_g_dL":11.7,"wbc_k_uL":9.1,"platelets_k_uL":296,"creatinine_mg_dL":1.2,"alt_U_L":29},{"date":"2025-01-11","hemoglobin_g_dL":13.1,"wbc_k_uL":6.4,"platelets_k_uL":253,"creatinine_mg_dL":1.49,"alt_U_L":93},{"date":"2027-12-04","hemoglobin_g_dL":11.5,"wbc_k_uL":5.1,"platelets_k_uL":183,"creatinine_mg_dL":1.23,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_1119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":71,"sex":"female","bmi":25.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-69},"pfs_months":28.09},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.2,"censored":false},"longitudinal_labs":[{"date":"2020-11-21","hemoglobin_g_dL":11.5,"wbc_k_uL":7.0,"platelets_k_uL":434,"creatinine_mg_dL":1.09,"alt_U_L":20},{"date":"2021-06-03","hemoglobin_g_dL":11.2,"wbc_k_uL":5.8,"platelets_k_uL":370,"creatinine_mg_dL":0.86,"alt_U_L":61},{"date":"2023-05-23","hemoglobin_g_dL":12.3,"wbc_k_uL":4.3,"platelets_k_uL":350,"creatinine_mg_dL":1.05,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_1120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":58,"sex":"female","bmi":25.1,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-04-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-39},"pfs_months":12.02},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":16.0,"censored":false},"longitudinal_labs":[{"date":"2021-02-18","hemoglobin_g_dL":12.7,"wbc_k_uL":5.5,"platelets_k_uL":396,"creatinine_mg_dL":1.19,"alt_U_L":38},{"date":"2021-10-16","hemoglobin_g_dL":10.7,"wbc_k_uL":4.3,"platelets_k_uL":337,"creatinine_mg_dL":1.11,"alt_U_L":105},{"date":"2022-06-09","hemoglobin_g_dL":10.7,"wbc_k_uL":6.5,"platelets_k_uL":135,"creatinine_mg_dL":0.97,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_1121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":78,"sex":"male","bmi":28.0,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-01-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-72},"pfs_months":12.42},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-02","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.4,"censored":false},"longitudinal_labs":[{"date":"2023-11-12","hemoglobin_g_dL":11.9,"wbc_k_uL":5.4,"platelets_k_uL":267,"creatinine_mg_dL":1.24,"alt_U_L":35},{"date":"2024-07-10","hemoglobin_g_dL":11.5,"wbc_k_uL":5.8,"platelets_k_uL":218,"creatinine_mg_dL":0.86,"alt_U_L":115},{"date":"2025-03-02","hemoglobin_g_dL":10.1,"wbc_k_uL":7.0,"platelets_k_uL":305,"creatinine_mg_dL":1.94,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_1122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":78,"sex":"female","bmi":19.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-40},"pfs_months":20.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.9,"censored":false},"longitudinal_labs":[{"date":"2023-11-03","hemoglobin_g_dL":13.3,"wbc_k_uL":4.8,"platelets_k_uL":446,"creatinine_mg_dL":1.01,"alt_U_L":46},{"date":"2024-05-28","hemoglobin_g_dL":12.1,"wbc_k_uL":5.6,"platelets_k_uL":328,"creatinine_mg_dL":0.84,"alt_U_L":21},{"date":"2025-09-28","hemoglobin_g_dL":11.6,"wbc_k_uL":6.6,"platelets_k_uL":302,"creatinine_mg_dL":0.94,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_1123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":50,"sex":"male","bmi":22.9,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-02-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-75},"pfs_months":34.69},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":50.4,"censored":true},"longitudinal_labs":[{"date":"2022-02-05","hemoglobin_g_dL":12.5,"wbc_k_uL":10.0,"platelets_k_uL":279,"creatinine_mg_dL":1.05,"alt_U_L":70},{"date":"2022-08-26","hemoglobin_g_dL":13.0,"wbc_k_uL":4.8,"platelets_k_uL":221,"creatinine_mg_dL":1.58,"alt_U_L":24},{"date":"2025-02-22","hemoglobin_g_dL":12.8,"wbc_k_uL":5.6,"platelets_k_uL":274,"creatinine_mg_dL":1.59,"alt_U_L":149}]}
{"patient_id":"ANODE_SYNTH_2025_1124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":74,"sex":"male","bmi":32.3,"smoking_pack_years":58,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-09-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-51},"pfs_months":31.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.5,"censored":false},"longitudinal_labs":[{"date":"2024-07-25","hemoglobin_g_dL":15.3,"wbc_k_uL":4.7,"platelets_k_uL":252,"creatinine_mg_dL":1.05,"alt_U_L":26},{"date":"2025-03-03","hemoglobin_g_dL":11.4,"wbc_k_uL":8.7,"platelets_k_uL":279,"creatinine_mg_dL":0.75,"alt_U_L":66},{"date":"2027-05-13","hemoglobin_g_dL":9.5,"wbc_k_uL":5.8,"platelets_k_uL":319,"creatinine_mg_dL":1.95,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_1125","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":73,"sex":"female","bmi":21.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-37},"pfs_months":13.83},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.7,"censored":false},"longitudinal_labs":[{"date":"2021-09-04","hemoglobin_g_dL":14.0,"wbc_k_uL":10.7,"platelets_k_uL":381,"creatinine_mg_dL":1.03,"alt_U_L":46},{"date":"2022-04-03","hemoglobin_g_dL":10.8,"wbc_k_uL":6.5,"platelets_k_uL":272,"creatinine_mg_dL":0.85,"alt_U_L":47},{"date":"2023-01-13","hemoglobin_g_dL":11.3,"wbc_k_uL":7.9,"platelets_k_uL":274,"creatinine_mg_dL":1.28,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_1126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":62,"sex":"female","bmi":23.0,"smoking_pack_years":20,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-51},"pfs_months":4.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":8.6,"censored":false},"longitudinal_labs":[{"date":"2025-04-15","hemoglobin_g_dL":14.8,"wbc_k_uL":6.2,"platelets_k_uL":374,"creatinine_mg_dL":0.93,"alt_U_L":69},{"date":"2025-12-19","hemoglobin_g_dL":11.5,"wbc_k_uL":8.8,"platelets_k_uL":207,"creatinine_mg_dL":0.85,"alt_U_L":74},{"date":"2025-11-22","hemoglobin_g_dL":9.9,"wbc_k_uL":6.8,"platelets_k_uL":131,"creatinine_mg_dL":1.41,"alt_U_L":31}]}
{"patient_id":"ANODE_SYNTH_2025_1127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":57,"sex":"female","bmi":37.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-74},"pfs_months":27.53},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.9,"censored":false},"longitudinal_labs":[{"date":"2024-02-18","hemoglobin_g_dL":12.4,"wbc_k_uL":8.2,"platelets_k_uL":165,"creatinine_mg_dL":1.04,"alt_U_L":36},{"date":"2024-09-05","hemoglobin_g_dL":13.9,"wbc_k_uL":4.3,"platelets_k_uL":275,"creatinine_mg_dL":1.32,"alt_U_L":38},{"date":"2026-08-21","hemoglobin_g_dL":12.9,"wbc_k_uL":6.1,"platelets_k_uL":157,"creatinine_mg_dL":1.62,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_1128","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":80,"sex":"female","bmi":28.2,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-09-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-47},"pfs_months":21.19},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.1,"censored":false},"longitudinal_labs":[{"date":"2020-07-25","hemoglobin_g_dL":14.1,"wbc_k_uL":5.5,"platelets_k_uL":445,"creatinine_mg_dL":0.61,"alt_U_L":47},{"date":"2021-03-23","hemoglobin_g_dL":13.0,"wbc_k_uL":6.2,"platelets_k_uL":327,"creatinine_mg_dL":1.15,"alt_U_L":30},{"date":"2022-07-07","hemoglobin_g_dL":12.4,"wbc_k_uL":7.3,"platelets_k_uL":218,"creatinine_mg_dL":1.63,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_1129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":83,"sex":"male","bmi":32.5,"smoking_pack_years":31,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-08-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-46},"pfs_months":14.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":17.9,"censored":false},"longitudinal_labs":[{"date":"2020-07-20","hemoglobin_g_dL":14.3,"wbc_k_uL":5.3,"platelets_k_uL":418,"creatinine_mg_dL":0.98,"alt_U_L":35},{"date":"2021-02-12","hemoglobin_g_dL":12.1,"wbc_k_uL":5.3,"platelets_k_uL":287,"creatinine_mg_dL":0.89,"alt_U_L":73},{"date":"2021-12-02","hemoglobin_g_dL":10.9,"wbc_k_uL":4.9,"platelets_k_uL":271,"creatinine_mg_dL":1.2,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_1130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":70,"sex":"female","bmi":23.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-10-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-74},"pfs_months":21.55},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.2,"censored":false},"longitudinal_labs":[{"date":"2025-10-10","hemoglobin_g_dL":11.5,"wbc_k_uL":7.1,"platelets_k_uL":174,"creatinine_mg_dL":0.76,"alt_U_L":39},{"date":"2026-04-26","hemoglobin_g_dL":12.2,"wbc_k_uL":7.0,"platelets_k_uL":186,"creatinine_mg_dL":1.3,"alt_U_L":110},{"date":"2027-09-20","hemoglobin_g_dL":12.1,"wbc_k_uL":6.3,"platelets_k_uL":143,"creatinine_mg_dL":0.84,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_1131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":75,"sex":"male","bmi":23.1,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-04-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-60},"pfs_months":32.92},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.8,"censored":false},"longitudinal_labs":[{"date":"2024-03-23","hemoglobin_g_dL":14.1,"wbc_k_uL":6.6,"platelets_k_uL":265,"creatinine_mg_dL":0.78,"alt_U_L":67},{"date":"2024-10-05","hemoglobin_g_dL":11.8,"wbc_k_uL":7.2,"platelets_k_uL":283,"creatinine_mg_dL":1.2,"alt_U_L":116},{"date":"2027-02-09","hemoglobin_g_dL":9.9,"wbc_k_uL":3.2,"platelets_k_uL":347,"creatinine_mg_dL":1.84,"alt_U_L":58}]}
{"patient_id":"ANODE_SYNTH_2025_1132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":61,"sex":"female","bmi":26.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-84},"pfs_months":19.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.4,"censored":false},"longitudinal_labs":[{"date":"2023-06-05","hemoglobin_g_dL":13.6,"wbc_k_uL":9.9,"platelets_k_uL":197,"creatinine_mg_dL":0.78,"alt_U_L":38},{"date":"2024-01-13","hemoglobin_g_dL":10.2,"wbc_k_uL":6.5,"platelets_k_uL":278,"creatinine_mg_dL":0.89,"alt_U_L":15},{"date":"2025-04-23","hemoglobin_g_dL":10.9,"wbc_k_uL":5.2,"platelets_k_uL":205,"creatinine_mg_dL":1.38,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_1133","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.4,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":57,"sex":"male","bmi":34.3,"smoking_pack_years":78,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["bone","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-03-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-39},"pfs_months":18.4},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2023-03-02","hemoglobin_g_dL":15.5,"wbc_k_uL":9.7,"platelets_k_uL":313,"creatinine_mg_dL":1.18,"alt_U_L":54},{"date":"2023-09-13","hemoglobin_g_dL":13.0,"wbc_k_uL":6.6,"platelets_k_uL":129,"creatinine_mg_dL":0.85,"alt_U_L":33},{"date":"2024-11-16","hemoglobin_g_dL":12.9,"wbc_k_uL":6.9,"platelets_k_uL":116,"creatinine_mg_dL":1.43,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_1134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":57,"sex":"female","bmi":34.7,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-07-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-41},"pfs_months":33.94},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":49.6,"censored":false},"longitudinal_labs":[{"date":"2022-05-07","hemoglobin_g_dL":11.9,"wbc_k_uL":9.4,"platelets_k_uL":156,"creatinine_mg_dL":1.18,"alt_U_L":80},{"date":"2022-12-28","hemoglobin_g_dL":10.6,"wbc_k_uL":7.8,"platelets_k_uL":296,"creatinine_mg_dL":1.34,"alt_U_L":79},{"date":"2025-05-08","hemoglobin_g_dL":9.6,"wbc_k_uL":4.0,"platelets_k_uL":102,"creatinine_mg_dL":2.0,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_1135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":81,"sex":"male","bmi":22.2,"smoking_pack_years":64,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-10-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-60},"pfs_months":43.33},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.2,"censored":false},"longitudinal_labs":[{"date":"2020-08-07","hemoglobin_g_dL":12.1,"wbc_k_uL":6.3,"platelets_k_uL":343,"creatinine_mg_dL":0.82,"alt_U_L":21},{"date":"2021-04-02","hemoglobin_g_dL":10.2,"wbc_k_uL":6.5,"platelets_k_uL":173,"creatinine_mg_dL":0.72,"alt_U_L":93},{"date":"2024-07-07","hemoglobin_g_dL":12.2,"wbc_k_uL":7.6,"platelets_k_uL":161,"creatinine_mg_dL":1.1,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_1136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":72,"sex":"female","bmi":21.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-75},"pfs_months":24.08},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":37.8,"censored":true},"longitudinal_labs":[{"date":"2022-10-09","hemoglobin_g_dL":13.8,"wbc_k_uL":9.4,"platelets_k_uL":423,"creatinine_mg_dL":0.87,"alt_U_L":69},{"date":"2023-05-19","hemoglobin_g_dL":12.8,"wbc_k_uL":8.3,"platelets_k_uL":205,"creatinine_mg_dL":1.18,"alt_U_L":22},{"date":"2024-12-13","hemoglobin_g_dL":11.7,"wbc_k_uL":7.9,"platelets_k_uL":255,"creatinine_mg_dL":1.4,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_1137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":86,"sex":"male","bmi":22.8,"smoking_pack_years":12,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-12-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-63},"pfs_months":35.35},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":58.4,"censored":false},"longitudinal_labs":[{"date":"2023-10-15","hemoglobin_g_dL":13.3,"wbc_k_uL":9.3,"platelets_k_uL":351,"creatinine_mg_dL":0.7,"alt_U_L":57},{"date":"2024-06-07","hemoglobin_g_dL":12.9,"wbc_k_uL":5.5,"platelets_k_uL":173,"creatinine_mg_dL":1.1,"alt_U_L":107},{"date":"2026-11-24","hemoglobin_g_dL":9.9,"wbc_k_uL":4.4,"platelets_k_uL":179,"creatinine_mg_dL":1.76,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_1138","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.4,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":59,"sex":"male","bmi":18.6,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-07-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-31},"pfs_months":21.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.6,"censored":true},"longitudinal_labs":[{"date":"2025-06-23","hemoglobin_g_dL":14.0,"wbc_k_uL":5.2,"platelets_k_uL":331,"creatinine_mg_dL":1.21,"alt_U_L":25},{"date":"2026-01-08","hemoglobin_g_dL":13.4,"wbc_k_uL":5.2,"platelets_k_uL":279,"creatinine_mg_dL":1.25,"alt_U_L":55},{"date":"2027-05-23","hemoglobin_g_dL":10.2,"wbc_k_uL":3.8,"platelets_k_uL":325,"creatinine_mg_dL":1.19,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_1139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":83,"sex":"female","bmi":20.0,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-02-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-57},"pfs_months":17.71},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.9,"censored":false},"longitudinal_labs":[{"date":"2022-12-25","hemoglobin_g_dL":15.2,"wbc_k_uL":9.1,"platelets_k_uL":223,"creatinine_mg_dL":0.97,"alt_U_L":46},{"date":"2023-08-03","hemoglobin_g_dL":10.2,"wbc_k_uL":5.1,"platelets_k_uL":337,"creatinine_mg_dL":1.24,"alt_U_L":41},{"date":"2024-09-20","hemoglobin_g_dL":11.4,"wbc_k_uL":3.4,"platelets_k_uL":334,"creatinine_mg_dL":1.81,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_1140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":74,"sex":"male","bmi":21.9,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-09-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-75},"pfs_months":29.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.2,"censored":true},"longitudinal_labs":[{"date":"2025-06-27","hemoglobin_g_dL":12.1,"wbc_k_uL":10.0,"platelets_k_uL":343,"creatinine_mg_dL":1.14,"alt_U_L":74},{"date":"2026-03-01","hemoglobin_g_dL":12.0,"wbc_k_uL":4.4,"platelets_k_uL":121,"creatinine_mg_dL":0.82,"alt_U_L":56},{"date":"2028-04-05","hemoglobin_g_dL":12.5,"wbc_k_uL":4.7,"platelets_k_uL":298,"creatinine_mg_dL":1.98,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_1141","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":80,"sex":"female","bmi":31.5,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-02-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-82},"pfs_months":21.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.2,"censored":false},"longitudinal_labs":[{"date":"2021-01-11","hemoglobin_g_dL":13.3,"wbc_k_uL":9.4,"platelets_k_uL":422,"creatinine_mg_dL":0.7,"alt_U_L":50},{"date":"2021-08-02","hemoglobin_g_dL":12.0,"wbc_k_uL":5.8,"platelets_k_uL":265,"creatinine_mg_dL":1.57,"alt_U_L":53},{"date":"2022-12-10","hemoglobin_g_dL":10.9,"wbc_k_uL":8.0,"platelets_k_uL":207,"creatinine_mg_dL":1.91,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_1142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":68,"sex":"female","bmi":34.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-40},"pfs_months":23.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.4,"censored":true},"longitudinal_labs":[{"date":"2020-08-02","hemoglobin_g_dL":15.1,"wbc_k_uL":6.4,"platelets_k_uL":352,"creatinine_mg_dL":0.71,"alt_U_L":26},{"date":"2021-03-09","hemoglobin_g_dL":12.8,"wbc_k_uL":5.0,"platelets_k_uL":190,"creatinine_mg_dL":1.24,"alt_U_L":111},{"date":"2022-11-01","hemoglobin_g_dL":10.7,"wbc_k_uL":5.9,"platelets_k_uL":250,"creatinine_mg_dL":1.98,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_1143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":52,"sex":"male","bmi":18.7,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-02-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-84},"pfs_months":14.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-24","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.2,"censored":false},"longitudinal_labs":[{"date":"2025-01-03","hemoglobin_g_dL":14.7,"wbc_k_uL":6.1,"platelets_k_uL":344,"creatinine_mg_dL":0.91,"alt_U_L":65},{"date":"2025-08-13","hemoglobin_g_dL":13.2,"wbc_k_uL":5.6,"platelets_k_uL":376,"creatinine_mg_dL":0.75,"alt_U_L":25},{"date":"2026-04-24","hemoglobin_g_dL":9.6,"wbc_k_uL":6.0,"platelets_k_uL":292,"creatinine_mg_dL":1.33,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_1144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":65,"sex":"female","bmi":37.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-38},"pfs_months":25.89},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.0,"censored":false},"longitudinal_labs":[{"date":"2023-08-13","hemoglobin_g_dL":14.5,"wbc_k_uL":6.7,"platelets_k_uL":278,"creatinine_mg_dL":1.14,"alt_U_L":14},{"date":"2024-04-02","hemoglobin_g_dL":10.1,"wbc_k_uL":6.6,"platelets_k_uL":202,"creatinine_mg_dL":0.72,"alt_U_L":43},{"date":"2025-12-31","hemoglobin_g_dL":12.6,"wbc_k_uL":7.8,"platelets_k_uL":143,"creatinine_mg_dL":1.29,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_1145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.2,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":55,"sex":"female","bmi":20.6,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-12-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-60},"pfs_months":5.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":12.2,"censored":false},"longitudinal_labs":[{"date":"2021-10-14","hemoglobin_g_dL":11.6,"wbc_k_uL":5.5,"platelets_k_uL":379,"creatinine_mg_dL":1.12,"alt_U_L":38},{"date":"2022-06-21","hemoglobin_g_dL":11.7,"wbc_k_uL":6.2,"platelets_k_uL":244,"creatinine_mg_dL":1.39,"alt_U_L":105},{"date":"2022-06-29","hemoglobin_g_dL":11.6,"wbc_k_uL":4.4,"platelets_k_uL":335,"creatinine_mg_dL":1.4,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_1146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":74,"sex":"female","bmi":22.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-68},"pfs_months":10.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.6,"censored":false},"longitudinal_labs":[{"date":"2023-06-19","hemoglobin_g_dL":15.5,"wbc_k_uL":5.5,"platelets_k_uL":205,"creatinine_mg_dL":1.28,"alt_U_L":60},{"date":"2024-01-24","hemoglobin_g_dL":11.3,"wbc_k_uL":4.8,"platelets_k_uL":194,"creatinine_mg_dL":1.26,"alt_U_L":92},{"date":"2024-06-30","hemoglobin_g_dL":11.2,"wbc_k_uL":7.7,"platelets_k_uL":262,"creatinine_mg_dL":1.92,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_1147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":74,"sex":"female","bmi":22.9,"smoking_pack_years":62,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-01-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-48},"pfs_months":32.92},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":60.0,"censored":false},"longitudinal_labs":[{"date":"2020-12-19","hemoglobin_g_dL":11.6,"wbc_k_uL":8.7,"platelets_k_uL":422,"creatinine_mg_dL":0.64,"alt_U_L":19},{"date":"2021-07-02","hemoglobin_g_dL":11.6,"wbc_k_uL":6.1,"platelets_k_uL":200,"creatinine_mg_dL":1.32,"alt_U_L":75},{"date":"2023-10-22","hemoglobin_g_dL":10.8,"wbc_k_uL":5.1,"platelets_k_uL":244,"creatinine_mg_dL":1.16,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_1148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":62,"sex":"female","bmi":31.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-74},"pfs_months":28.94},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":46.0,"censored":true},"longitudinal_labs":[{"date":"2024-09-12","hemoglobin_g_dL":12.4,"wbc_k_uL":10.6,"platelets_k_uL":417,"creatinine_mg_dL":1.2,"alt_U_L":10},{"date":"2025-04-09","hemoglobin_g_dL":12.0,"wbc_k_uL":4.1,"platelets_k_uL":304,"creatinine_mg_dL":1.51,"alt_U_L":57},{"date":"2027-04-23","hemoglobin_g_dL":11.7,"wbc_k_uL":4.0,"platelets_k_uL":289,"creatinine_mg_dL":1.65,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_1149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":53,"sex":"female","bmi":21.4,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-03-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-66},"pfs_months":4.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":17.0,"censored":false},"longitudinal_labs":[{"date":"2025-02-22","hemoglobin_g_dL":13.0,"wbc_k_uL":8.3,"platelets_k_uL":368,"creatinine_mg_dL":0.63,"alt_U_L":21},{"date":"2025-09-08","hemoglobin_g_dL":11.1,"wbc_k_uL":5.8,"platelets_k_uL":192,"creatinine_mg_dL":1.5,"alt_U_L":20},{"date":"2025-09-12","hemoglobin_g_dL":11.5,"wbc_k_uL":4.1,"platelets_k_uL":225,"creatinine_mg_dL":0.94,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_1150","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":78,"sex":"female","bmi":35.2,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-11-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-59},"pfs_months":11.27},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":20.6,"censored":true},"longitudinal_labs":[{"date":"2023-10-08","hemoglobin_g_dL":14.5,"wbc_k_uL":6.3,"platelets_k_uL":417,"creatinine_mg_dL":0.72,"alt_U_L":33},{"date":"2024-05-19","hemoglobin_g_dL":13.6,"wbc_k_uL":6.2,"platelets_k_uL":199,"creatinine_mg_dL":1.28,"alt_U_L":23},{"date":"2024-12-26","hemoglobin_g_dL":12.4,"wbc_k_uL":7.0,"platelets_k_uL":183,"creatinine_mg_dL":1.88,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_1151","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":80,"sex":"male","bmi":37.7,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-08-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-33},"pfs_months":15.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.7,"censored":false},"longitudinal_labs":[{"date":"2022-07-19","hemoglobin_g_dL":13.8,"wbc_k_uL":8.4,"platelets_k_uL":288,"creatinine_mg_dL":1.24,"alt_U_L":27},{"date":"2023-02-23","hemoglobin_g_dL":11.4,"wbc_k_uL":8.3,"platelets_k_uL":208,"creatinine_mg_dL":0.95,"alt_U_L":20},{"date":"2024-01-01","hemoglobin_g_dL":9.9,"wbc_k_uL":4.6,"platelets_k_uL":140,"creatinine_mg_dL":1.8,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_1152","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":60,"sex":"male","bmi":33.8,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-11-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-38},"pfs_months":17.45},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.9,"censored":true},"longitudinal_labs":[{"date":"2023-09-18","hemoglobin_g_dL":11.6,"wbc_k_uL":8.4,"platelets_k_uL":311,"creatinine_mg_dL":1.21,"alt_U_L":33},{"date":"2024-04-29","hemoglobin_g_dL":10.8,"wbc_k_uL":6.6,"platelets_k_uL":344,"creatinine_mg_dL":1.27,"alt_U_L":67},{"date":"2025-05-19","hemoglobin_g_dL":11.2,"wbc_k_uL":4.1,"platelets_k_uL":128,"creatinine_mg_dL":1.5,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_1153","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":76,"sex":"male","bmi":23.7,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-11-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-66},"pfs_months":20.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2023-10-02","hemoglobin_g_dL":14.9,"wbc_k_uL":5.8,"platelets_k_uL":370,"creatinine_mg_dL":0.9,"alt_U_L":72},{"date":"2024-05-15","hemoglobin_g_dL":11.6,"wbc_k_uL":4.0,"platelets_k_uL":136,"creatinine_mg_dL":1.22,"alt_U_L":41},{"date":"2025-08-28","hemoglobin_g_dL":11.5,"wbc_k_uL":5.8,"platelets_k_uL":286,"creatinine_mg_dL":1.6,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_1154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":75,"sex":"male","bmi":18.9,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-12-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-76},"pfs_months":33.45},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":51.8,"censored":false},"longitudinal_labs":[{"date":"2023-11-04","hemoglobin_g_dL":14.3,"wbc_k_uL":4.9,"platelets_k_uL":172,"creatinine_mg_dL":1.2,"alt_U_L":74},{"date":"2024-06-07","hemoglobin_g_dL":11.7,"wbc_k_uL":5.2,"platelets_k_uL":368,"creatinine_mg_dL":1.24,"alt_U_L":57},{"date":"2026-10-21","hemoglobin_g_dL":10.7,"wbc_k_uL":5.2,"platelets_k_uL":102,"creatinine_mg_dL":1.95,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_1155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":80,"sex":"female","bmi":31.3,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-31},"pfs_months":32.82},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":50.2,"censored":true},"longitudinal_labs":[{"date":"2024-01-25","hemoglobin_g_dL":12.2,"wbc_k_uL":9.4,"platelets_k_uL":155,"creatinine_mg_dL":1.12,"alt_U_L":69},{"date":"2024-09-19","hemoglobin_g_dL":12.3,"wbc_k_uL":4.3,"platelets_k_uL":348,"creatinine_mg_dL":1.42,"alt_U_L":38},{"date":"2027-01-29","hemoglobin_g_dL":9.8,"wbc_k_uL":4.7,"platelets_k_uL":240,"creatinine_mg_dL":1.28,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_1156","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":88,"sex":"female","bmi":34.0,"smoking_pack_years":80,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-10-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-65},"pfs_months":31.51},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":true},"longitudinal_labs":[{"date":"2023-08-11","hemoglobin_g_dL":14.2,"wbc_k_uL":7.5,"platelets_k_uL":239,"creatinine_mg_dL":1.2,"alt_U_L":61},{"date":"2024-03-30","hemoglobin_g_dL":13.2,"wbc_k_uL":7.5,"platelets_k_uL":180,"creatinine_mg_dL":1.04,"alt_U_L":104},{"date":"2026-06-07","hemoglobin_g_dL":12.4,"wbc_k_uL":7.4,"platelets_k_uL":149,"creatinine_mg_dL":1.51,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_1157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":85,"sex":"female","bmi":35.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-78},"pfs_months":17.54},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":23.1,"censored":false},"longitudinal_labs":[{"date":"2024-06-26","hemoglobin_g_dL":13.2,"wbc_k_uL":10.9,"platelets_k_uL":444,"creatinine_mg_dL":0.98,"alt_U_L":63},{"date":"2025-01-13","hemoglobin_g_dL":13.7,"wbc_k_uL":8.7,"platelets_k_uL":370,"creatinine_mg_dL":1.38,"alt_U_L":99},{"date":"2026-01-15","hemoglobin_g_dL":10.7,"wbc_k_uL":4.2,"platelets_k_uL":180,"creatinine_mg_dL":1.95,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_1158","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":60,"sex":"female","bmi":26.8,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-72},"pfs_months":16.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-18","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.9,"censored":false},"longitudinal_labs":[{"date":"2023-05-07","hemoglobin_g_dL":13.8,"wbc_k_uL":4.9,"platelets_k_uL":169,"creatinine_mg_dL":0.76,"alt_U_L":17},{"date":"2023-11-27","hemoglobin_g_dL":10.7,"wbc_k_uL":4.0,"platelets_k_uL":273,"creatinine_mg_dL":0.86,"alt_U_L":101},{"date":"2024-11-18","hemoglobin_g_dL":11.1,"wbc_k_uL":7.0,"platelets_k_uL":277,"creatinine_mg_dL":1.04,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_1159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":82,"sex":"male","bmi":31.1,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-05-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-39},"pfs_months":16.59},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.5,"censored":false},"longitudinal_labs":[{"date":"2025-04-25","hemoglobin_g_dL":13.0,"wbc_k_uL":9.8,"platelets_k_uL":203,"creatinine_mg_dL":1.21,"alt_U_L":20},{"date":"2025-11-10","hemoglobin_g_dL":13.7,"wbc_k_uL":4.5,"platelets_k_uL":184,"creatinine_mg_dL":1.1,"alt_U_L":86},{"date":"2026-11-04","hemoglobin_g_dL":10.3,"wbc_k_uL":4.5,"platelets_k_uL":202,"creatinine_mg_dL":1.46,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_1160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":78,"sex":"female","bmi":18.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-12-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-68},"pfs_months":17.18},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.8,"censored":false},"longitudinal_labs":[{"date":"2024-11-12","hemoglobin_g_dL":13.2,"wbc_k_uL":11.0,"platelets_k_uL":351,"creatinine_mg_dL":0.7,"alt_U_L":18},{"date":"2025-06-17","hemoglobin_g_dL":10.6,"wbc_k_uL":7.6,"platelets_k_uL":184,"creatinine_mg_dL":1.16,"alt_U_L":30},{"date":"2026-06-20","hemoglobin_g_dL":11.1,"wbc_k_uL":4.2,"platelets_k_uL":235,"creatinine_mg_dL":0.94,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_1161","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":51,"sex":"female","bmi":26.7,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-07-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-31},"pfs_months":22.83},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.8,"censored":false},"longitudinal_labs":[{"date":"2024-06-03","hemoglobin_g_dL":15.4,"wbc_k_uL":5.6,"platelets_k_uL":368,"creatinine_mg_dL":0.8,"alt_U_L":31},{"date":"2025-01-07","hemoglobin_g_dL":12.8,"wbc_k_uL":4.9,"platelets_k_uL":150,"creatinine_mg_dL":0.79,"alt_U_L":55},{"date":"2026-06-25","hemoglobin_g_dL":11.1,"wbc_k_uL":5.8,"platelets_k_uL":317,"creatinine_mg_dL":1.96,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_1162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":74,"sex":"male","bmi":34.4,"smoking_pack_years":11,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-59},"pfs_months":38.05},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":67.0,"censored":false},"longitudinal_labs":[{"date":"2024-12-15","hemoglobin_g_dL":15.1,"wbc_k_uL":10.5,"platelets_k_uL":265,"creatinine_mg_dL":1.24,"alt_U_L":78},{"date":"2025-07-22","hemoglobin_g_dL":13.4,"wbc_k_uL":7.2,"platelets_k_uL":364,"creatinine_mg_dL":1.47,"alt_U_L":18},{"date":"2028-04-20","hemoglobin_g_dL":12.8,"wbc_k_uL":6.7,"platelets_k_uL":323,"creatinine_mg_dL":1.39,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_1163","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":49,"sex":"male","bmi":37.9,"smoking_pack_years":32,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-05-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-68},"pfs_months":23.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.6,"censored":true},"longitudinal_labs":[{"date":"2021-04-25","hemoglobin_g_dL":14.0,"wbc_k_uL":8.5,"platelets_k_uL":348,"creatinine_mg_dL":0.64,"alt_U_L":38},{"date":"2021-11-05","hemoglobin_g_dL":10.2,"wbc_k_uL":4.3,"platelets_k_uL":204,"creatinine_mg_dL":1.03,"alt_U_L":66},{"date":"2023-05-12","hemoglobin_g_dL":10.5,"wbc_k_uL":3.6,"platelets_k_uL":336,"creatinine_mg_dL":1.1,"alt_U_L":125}]}
{"patient_id":"ANODE_SYNTH_2025_1164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":61,"sex":"male","bmi":31.1,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-84},"pfs_months":42.71},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":72.2,"censored":false},"longitudinal_labs":[{"date":"2024-03-12","hemoglobin_g_dL":13.3,"wbc_k_uL":10.3,"platelets_k_uL":376,"creatinine_mg_dL":1.2,"alt_U_L":36},{"date":"2024-10-23","hemoglobin_g_dL":10.3,"wbc_k_uL":4.1,"platelets_k_uL":153,"creatinine_mg_dL":0.86,"alt_U_L":69},{"date":"2027-12-04","hemoglobin_g_dL":11.1,"wbc_k_uL":6.6,"platelets_k_uL":277,"creatinine_mg_dL":1.6,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_1165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":88,"sex":"female","bmi":21.1,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-02-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-51},"pfs_months":40.48},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":66.0,"censored":false},"longitudinal_labs":[{"date":"2020-12-26","hemoglobin_g_dL":15.0,"wbc_k_uL":7.1,"platelets_k_uL":313,"creatinine_mg_dL":0.75,"alt_U_L":13},{"date":"2021-08-26","hemoglobin_g_dL":11.8,"wbc_k_uL":6.3,"platelets_k_uL":298,"creatinine_mg_dL":0.93,"alt_U_L":92},{"date":"2024-08-19","hemoglobin_g_dL":9.5,"wbc_k_uL":7.7,"platelets_k_uL":283,"creatinine_mg_dL":0.96,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_1166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":55,"sex":"female","bmi":34.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-63},"pfs_months":27.33},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.3,"censored":true},"longitudinal_labs":[{"date":"2022-10-18","hemoglobin_g_dL":14.5,"wbc_k_uL":10.5,"platelets_k_uL":361,"creatinine_mg_dL":0.86,"alt_U_L":58},{"date":"2023-06-03","hemoglobin_g_dL":11.7,"wbc_k_uL":6.0,"platelets_k_uL":172,"creatinine_mg_dL":1.25,"alt_U_L":28},{"date":"2025-03-22","hemoglobin_g_dL":10.9,"wbc_k_uL":4.9,"platelets_k_uL":335,"creatinine_mg_dL":1.04,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_1167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":85,"sex":"female","bmi":20.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-78},"pfs_months":23.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.4,"censored":false},"longitudinal_labs":[{"date":"2022-05-17","hemoglobin_g_dL":11.6,"wbc_k_uL":10.9,"platelets_k_uL":276,"creatinine_mg_dL":1.24,"alt_U_L":62},{"date":"2022-12-20","hemoglobin_g_dL":13.7,"wbc_k_uL":6.8,"platelets_k_uL":196,"creatinine_mg_dL":1.08,"alt_U_L":47},{"date":"2024-07-17","hemoglobin_g_dL":11.1,"wbc_k_uL":5.6,"platelets_k_uL":292,"creatinine_mg_dL":1.42,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_1168","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":60,"sex":"male","bmi":30.3,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-33},"pfs_months":19.42},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.7,"censored":false},"longitudinal_labs":[{"date":"2023-05-03","hemoglobin_g_dL":14.5,"wbc_k_uL":9.9,"platelets_k_uL":199,"creatinine_mg_dL":0.97,"alt_U_L":76},{"date":"2023-12-21","hemoglobin_g_dL":12.7,"wbc_k_uL":4.4,"platelets_k_uL":176,"creatinine_mg_dL":1.09,"alt_U_L":65},{"date":"2025-03-19","hemoglobin_g_dL":10.7,"wbc_k_uL":4.1,"platelets_k_uL":262,"creatinine_mg_dL":1.12,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_1169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":76,"sex":"female","bmi":33.2,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-60},"pfs_months":42.12},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":69.0,"censored":true},"longitudinal_labs":[{"date":"2021-09-24","hemoglobin_g_dL":15.1,"wbc_k_uL":10.4,"platelets_k_uL":247,"creatinine_mg_dL":0.74,"alt_U_L":55},{"date":"2022-05-23","hemoglobin_g_dL":11.7,"wbc_k_uL":6.9,"platelets_k_uL":377,"creatinine_mg_dL":0.87,"alt_U_L":52},{"date":"2025-07-26","hemoglobin_g_dL":10.8,"wbc_k_uL":3.7,"platelets_k_uL":178,"creatinine_mg_dL":0.98,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_1170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":18.0,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":87,"sex":"male","bmi":36.1,"smoking_pack_years":32,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-09-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-36},"pfs_months":48.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":76.0,"censored":false},"longitudinal_labs":[{"date":"2023-08-17","hemoglobin_g_dL":12.5,"wbc_k_uL":9.8,"platelets_k_uL":273,"creatinine_mg_dL":0.72,"alt_U_L":78},{"date":"2024-03-01","hemoglobin_g_dL":11.1,"wbc_k_uL":6.6,"platelets_k_uL":257,"creatinine_mg_dL":1.1,"alt_U_L":34},{"date":"2027-11-07","hemoglobin_g_dL":12.1,"wbc_k_uL":7.0,"platelets_k_uL":204,"creatinine_mg_dL":1.63,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_1171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":68,"sex":"female","bmi":25.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-75},"pfs_months":20.34},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.7,"censored":true},"longitudinal_labs":[{"date":"2022-09-01","hemoglobin_g_dL":13.2,"wbc_k_uL":10.9,"platelets_k_uL":323,"creatinine_mg_dL":1.08,"alt_U_L":76},{"date":"2023-05-03","hemoglobin_g_dL":13.3,"wbc_k_uL":5.1,"platelets_k_uL":124,"creatinine_mg_dL":1.21,"alt_U_L":48},{"date":"2024-09-13","hemoglobin_g_dL":10.2,"wbc_k_uL":3.7,"platelets_k_uL":195,"creatinine_mg_dL":0.99,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_1172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":59,"sex":"female","bmi":36.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-40},"pfs_months":27.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":40.6,"censored":false},"longitudinal_labs":[{"date":"2020-06-05","hemoglobin_g_dL":12.4,"wbc_k_uL":8.9,"platelets_k_uL":429,"creatinine_mg_dL":0.88,"alt_U_L":58},{"date":"2020-12-29","hemoglobin_g_dL":13.0,"wbc_k_uL":5.5,"platelets_k_uL":206,"creatinine_mg_dL":1.32,"alt_U_L":80},{"date":"2022-11-24","hemoglobin_g_dL":12.6,"wbc_k_uL":3.0,"platelets_k_uL":161,"creatinine_mg_dL":1.18,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_1173","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":56,"sex":"male","bmi":33.8,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-10-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-62},"pfs_months":19.19},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.3,"censored":true},"longitudinal_labs":[{"date":"2023-09-07","hemoglobin_g_dL":15.4,"wbc_k_uL":6.9,"platelets_k_uL":394,"creatinine_mg_dL":0.83,"alt_U_L":58},{"date":"2024-04-02","hemoglobin_g_dL":11.7,"wbc_k_uL":7.7,"platelets_k_uL":162,"creatinine_mg_dL":0.93,"alt_U_L":80},{"date":"2025-06-29","hemoglobin_g_dL":11.6,"wbc_k_uL":6.4,"platelets_k_uL":112,"creatinine_mg_dL":1.17,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_1174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":76,"sex":"female","bmi":37.8,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-10-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-69},"pfs_months":27.27},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":31.2,"censored":false},"longitudinal_labs":[{"date":"2024-08-05","hemoglobin_g_dL":13.9,"wbc_k_uL":5.7,"platelets_k_uL":253,"creatinine_mg_dL":0.92,"alt_U_L":25},{"date":"2025-04-04","hemoglobin_g_dL":10.4,"wbc_k_uL":5.4,"platelets_k_uL":223,"creatinine_mg_dL":1.41,"alt_U_L":83},{"date":"2027-02-09","hemoglobin_g_dL":12.7,"wbc_k_uL":7.0,"platelets_k_uL":253,"creatinine_mg_dL":1.11,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_1175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":79,"sex":"male","bmi":31.0,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-12-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-35},"pfs_months":11.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.8,"censored":false},"longitudinal_labs":[{"date":"2021-12-05","hemoglobin_g_dL":15.2,"wbc_k_uL":5.0,"platelets_k_uL":217,"creatinine_mg_dL":0.68,"alt_U_L":22},{"date":"2022-06-19","hemoglobin_g_dL":12.6,"wbc_k_uL":5.7,"platelets_k_uL":205,"creatinine_mg_dL":1.51,"alt_U_L":99},{"date":"2023-01-07","hemoglobin_g_dL":11.2,"wbc_k_uL":4.6,"platelets_k_uL":291,"creatinine_mg_dL":1.14,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_1176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":75,"sex":"female","bmi":20.2,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-08-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-38},"pfs_months":13.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2024-07-23","hemoglobin_g_dL":13.2,"wbc_k_uL":7.0,"platelets_k_uL":391,"creatinine_mg_dL":1.06,"alt_U_L":56},{"date":"2025-02-14","hemoglobin_g_dL":12.0,"wbc_k_uL":4.6,"platelets_k_uL":241,"creatinine_mg_dL":1.52,"alt_U_L":50},{"date":"2025-11-30","hemoglobin_g_dL":11.3,"wbc_k_uL":6.6,"platelets_k_uL":114,"creatinine_mg_dL":1.4,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_1177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":77,"sex":"female","bmi":24.0,"smoking_pack_years":75,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-11-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-60},"pfs_months":27.93},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":47.5,"censored":false},"longitudinal_labs":[{"date":"2022-09-15","hemoglobin_g_dL":13.0,"wbc_k_uL":5.4,"platelets_k_uL":323,"creatinine_mg_dL":0.89,"alt_U_L":19},{"date":"2023-05-19","hemoglobin_g_dL":13.8,"wbc_k_uL":8.9,"platelets_k_uL":346,"creatinine_mg_dL":1.27,"alt_U_L":46},{"date":"2025-05-09","hemoglobin_g_dL":10.5,"wbc_k_uL":4.4,"platelets_k_uL":217,"creatinine_mg_dL":1.87,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_1178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":61,"sex":"female","bmi":19.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-34},"pfs_months":23.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":42.2,"censored":false},"longitudinal_labs":[{"date":"2025-10-02","hemoglobin_g_dL":14.9,"wbc_k_uL":9.8,"platelets_k_uL":263,"creatinine_mg_dL":1.13,"alt_U_L":27},{"date":"2026-04-30","hemoglobin_g_dL":12.0,"wbc_k_uL":7.2,"platelets_k_uL":310,"creatinine_mg_dL":0.92,"alt_U_L":15},{"date":"2027-10-21","hemoglobin_g_dL":13.0,"wbc_k_uL":6.5,"platelets_k_uL":149,"creatinine_mg_dL":1.42,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_1179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":55,"sex":"female","bmi":37.4,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-09-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-36},"pfs_months":42.58},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":69.1,"censored":false},"longitudinal_labs":[{"date":"2020-08-18","hemoglobin_g_dL":14.8,"wbc_k_uL":9.4,"platelets_k_uL":231,"creatinine_mg_dL":0.72,"alt_U_L":78},{"date":"2021-03-12","hemoglobin_g_dL":12.0,"wbc_k_uL":4.0,"platelets_k_uL":214,"creatinine_mg_dL":1.0,"alt_U_L":45},{"date":"2024-05-22","hemoglobin_g_dL":11.8,"wbc_k_uL":5.5,"platelets_k_uL":272,"creatinine_mg_dL":1.09,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_1180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":68,"sex":"female","bmi":20.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-41},"pfs_months":34.37},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.8,"censored":false},"longitudinal_labs":[{"date":"2022-02-14","hemoglobin_g_dL":12.4,"wbc_k_uL":7.4,"platelets_k_uL":369,"creatinine_mg_dL":0.87,"alt_U_L":21},{"date":"2022-10-03","hemoglobin_g_dL":11.3,"wbc_k_uL":4.7,"platelets_k_uL":199,"creatinine_mg_dL":1.0,"alt_U_L":94},{"date":"2025-04-09","hemoglobin_g_dL":10.1,"wbc_k_uL":6.8,"platelets_k_uL":257,"creatinine_mg_dL":1.19,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_1181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":79,"sex":"female","bmi":30.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-73},"pfs_months":30.19},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":59.5,"censored":false},"longitudinal_labs":[{"date":"2024-05-17","hemoglobin_g_dL":11.8,"wbc_k_uL":6.9,"platelets_k_uL":202,"creatinine_mg_dL":1.22,"alt_U_L":66},{"date":"2024-11-29","hemoglobin_g_dL":13.2,"wbc_k_uL":5.3,"platelets_k_uL":327,"creatinine_mg_dL":1.14,"alt_U_L":49},{"date":"2027-01-14","hemoglobin_g_dL":11.0,"wbc_k_uL":4.0,"platelets_k_uL":128,"creatinine_mg_dL":1.71,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_1182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":58,"sex":"male","bmi":35.0,"smoking_pack_years":15,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-09-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-76},"pfs_months":42.15},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":73.1,"censored":false},"longitudinal_labs":[{"date":"2022-08-10","hemoglobin_g_dL":11.9,"wbc_k_uL":9.0,"platelets_k_uL":400,"creatinine_mg_dL":1.23,"alt_U_L":51},{"date":"2023-03-23","hemoglobin_g_dL":13.7,"wbc_k_uL":6.9,"platelets_k_uL":241,"creatinine_mg_dL":1.42,"alt_U_L":50},{"date":"2026-04-09","hemoglobin_g_dL":12.7,"wbc_k_uL":5.4,"platelets_k_uL":202,"creatinine_mg_dL":2.0,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_1183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":60,"sex":"female","bmi":21.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-35},"pfs_months":13.44},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.3,"censored":false},"longitudinal_labs":[{"date":"2024-10-08","hemoglobin_g_dL":13.3,"wbc_k_uL":5.1,"platelets_k_uL":211,"creatinine_mg_dL":1.26,"alt_U_L":27},{"date":"2025-05-14","hemoglobin_g_dL":13.1,"wbc_k_uL":7.5,"platelets_k_uL":353,"creatinine_mg_dL":1.28,"alt_U_L":103},{"date":"2026-01-20","hemoglobin_g_dL":10.1,"wbc_k_uL":3.9,"platelets_k_uL":287,"creatinine_mg_dL":1.98,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_1184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":79,"sex":"male","bmi":26.0,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-57},"pfs_months":12.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.1,"censored":false},"longitudinal_labs":[{"date":"2021-06-16","hemoglobin_g_dL":15.3,"wbc_k_uL":7.6,"platelets_k_uL":183,"creatinine_mg_dL":0.84,"alt_U_L":17},{"date":"2022-01-01","hemoglobin_g_dL":13.7,"wbc_k_uL":4.5,"platelets_k_uL":140,"creatinine_mg_dL":0.89,"alt_U_L":28},{"date":"2022-09-08","hemoglobin_g_dL":10.9,"wbc_k_uL":7.6,"platelets_k_uL":163,"creatinine_mg_dL":1.77,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_1185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":84,"sex":"female","bmi":24.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-78},"pfs_months":22.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.9,"censored":false},"longitudinal_labs":[{"date":"2021-08-25","hemoglobin_g_dL":15.3,"wbc_k_uL":10.5,"platelets_k_uL":169,"creatinine_mg_dL":1.11,"alt_U_L":25},{"date":"2022-04-18","hemoglobin_g_dL":12.9,"wbc_k_uL":4.8,"platelets_k_uL":284,"creatinine_mg_dL":1.51,"alt_U_L":52},{"date":"2023-10-13","hemoglobin_g_dL":12.8,"wbc_k_uL":8.0,"platelets_k_uL":261,"creatinine_mg_dL":1.85,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_1186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":63,"sex":"male","bmi":29.2,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-09-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-37},"pfs_months":35.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":60.1,"censored":false},"longitudinal_labs":[{"date":"2021-07-14","hemoglobin_g_dL":12.4,"wbc_k_uL":7.5,"platelets_k_uL":378,"creatinine_mg_dL":1.17,"alt_U_L":75},{"date":"2022-03-13","hemoglobin_g_dL":12.4,"wbc_k_uL":5.5,"platelets_k_uL":121,"creatinine_mg_dL":1.21,"alt_U_L":87},{"date":"2024-09-21","hemoglobin_g_dL":9.6,"wbc_k_uL":4.1,"platelets_k_uL":148,"creatinine_mg_dL":1.65,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_1187","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":49,"sex":"female","bmi":28.3,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-38},"pfs_months":16.33},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.9,"censored":false},"longitudinal_labs":[{"date":"2023-05-13","hemoglobin_g_dL":12.5,"wbc_k_uL":10.2,"platelets_k_uL":381,"creatinine_mg_dL":0.9,"alt_U_L":10},{"date":"2024-01-09","hemoglobin_g_dL":10.6,"wbc_k_uL":6.6,"platelets_k_uL":211,"creatinine_mg_dL":1.35,"alt_U_L":93},{"date":"2024-12-22","hemoglobin_g_dL":9.9,"wbc_k_uL":7.9,"platelets_k_uL":171,"creatinine_mg_dL":1.29,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_1188","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":73,"sex":"female","bmi":32.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-77},"pfs_months":17.15},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-16","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":false},"longitudinal_labs":[{"date":"2023-07-16","hemoglobin_g_dL":14.4,"wbc_k_uL":8.0,"platelets_k_uL":334,"creatinine_mg_dL":1.29,"alt_U_L":56},{"date":"2024-02-12","hemoglobin_g_dL":12.9,"wbc_k_uL":7.2,"platelets_k_uL":249,"creatinine_mg_dL":1.24,"alt_U_L":98},{"date":"2025-03-16","hemoglobin_g_dL":11.5,"wbc_k_uL":5.0,"platelets_k_uL":151,"creatinine_mg_dL":1.2,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_1189","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":65,"sex":"female","bmi":21.9,"smoking_pack_years":74,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-03-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-40},"pfs_months":21.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":true},"longitudinal_labs":[{"date":"2025-01-18","hemoglobin_g_dL":12.9,"wbc_k_uL":10.3,"platelets_k_uL":207,"creatinine_mg_dL":0.64,"alt_U_L":74},{"date":"2025-09-07","hemoglobin_g_dL":10.7,"wbc_k_uL":4.2,"platelets_k_uL":357,"creatinine_mg_dL":0.71,"alt_U_L":85},{"date":"2027-01-14","hemoglobin_g_dL":10.0,"wbc_k_uL":6.0,"platelets_k_uL":305,"creatinine_mg_dL":1.97,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_1190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":59,"sex":"male","bmi":30.5,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-03-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-56},"pfs_months":16.85},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2023-02-07","hemoglobin_g_dL":12.3,"wbc_k_uL":7.3,"platelets_k_uL":391,"creatinine_mg_dL":1.11,"alt_U_L":51},{"date":"2023-09-06","hemoglobin_g_dL":11.8,"wbc_k_uL":5.4,"platelets_k_uL":343,"creatinine_mg_dL":0.78,"alt_U_L":41},{"date":"2024-08-15","hemoglobin_g_dL":12.3,"wbc_k_uL":3.3,"platelets_k_uL":272,"creatinine_mg_dL":1.06,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_1191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":85,"sex":"male","bmi":25.9,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-08-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-49},"pfs_months":15.93},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":true},"longitudinal_labs":[{"date":"2021-07-10","hemoglobin_g_dL":12.0,"wbc_k_uL":5.5,"platelets_k_uL":423,"creatinine_mg_dL":1.06,"alt_U_L":49},{"date":"2022-02-22","hemoglobin_g_dL":11.8,"wbc_k_uL":7.0,"platelets_k_uL":228,"creatinine_mg_dL":1.14,"alt_U_L":113},{"date":"2023-01-24","hemoglobin_g_dL":12.7,"wbc_k_uL":6.4,"platelets_k_uL":277,"creatinine_mg_dL":1.35,"alt_U_L":28}]}
{"patient_id":"ANODE_SYNTH_2025_1192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":85,"sex":"female","bmi":37.4,"smoking_pack_years":61,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["liver","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-02-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-57},"pfs_months":37.16},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.1,"censored":false},"longitudinal_labs":[{"date":"2021-12-17","hemoglobin_g_dL":14.5,"wbc_k_uL":10.9,"platelets_k_uL":268,"creatinine_mg_dL":1.09,"alt_U_L":75},{"date":"2022-08-14","hemoglobin_g_dL":12.8,"wbc_k_uL":3.9,"platelets_k_uL":317,"creatinine_mg_dL":1.08,"alt_U_L":90},{"date":"2025-04-05","hemoglobin_g_dL":9.6,"wbc_k_uL":6.6,"platelets_k_uL":330,"creatinine_mg_dL":0.85,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":51,"sex":"female","bmi":29.3,"smoking_pack_years":66,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-33},"pfs_months":35.88},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.7,"censored":false},"longitudinal_labs":[{"date":"2021-02-07","hemoglobin_g_dL":12.2,"wbc_k_uL":9.2,"platelets_k_uL":257,"creatinine_mg_dL":1.03,"alt_U_L":15},{"date":"2021-09-23","hemoglobin_g_dL":12.5,"wbc_k_uL":5.4,"platelets_k_uL":121,"creatinine_mg_dL":0.98,"alt_U_L":43},{"date":"2024-04-06","hemoglobin_g_dL":10.4,"wbc_k_uL":3.3,"platelets_k_uL":177,"creatinine_mg_dL":1.72,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_1194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":77,"sex":"female","bmi":20.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-01-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-72},"pfs_months":25.13},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.3,"censored":false},"longitudinal_labs":[{"date":"2023-01-10","hemoglobin_g_dL":14.7,"wbc_k_uL":7.1,"platelets_k_uL":278,"creatinine_mg_dL":0.9,"alt_U_L":20},{"date":"2023-07-25","hemoglobin_g_dL":12.0,"wbc_k_uL":5.1,"platelets_k_uL":161,"creatinine_mg_dL":1.52,"alt_U_L":27},{"date":"2025-03-06","hemoglobin_g_dL":12.6,"wbc_k_uL":5.4,"platelets_k_uL":141,"creatinine_mg_dL":0.84,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_1195","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":66,"sex":"female","bmi":24.3,"smoking_pack_years":21,"ecog_performance_status":0,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-52},"pfs_months":40.61},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.5,"censored":true},"longitudinal_labs":[{"date":"2022-11-14","hemoglobin_g_dL":15.0,"wbc_k_uL":9.3,"platelets_k_uL":398,"creatinine_mg_dL":1.14,"alt_U_L":15},{"date":"2023-06-12","hemoglobin_g_dL":11.0,"wbc_k_uL":8.8,"platelets_k_uL":168,"creatinine_mg_dL":0.92,"alt_U_L":64},{"date":"2026-06-17","hemoglobin_g_dL":12.7,"wbc_k_uL":6.7,"platelets_k_uL":282,"creatinine_mg_dL":1.23,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_1196","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":88,"sex":"male","bmi":35.1,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-44},"pfs_months":21.03},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":true},"longitudinal_labs":[{"date":"2023-03-12","hemoglobin_g_dL":13.0,"wbc_k_uL":5.8,"platelets_k_uL":181,"creatinine_mg_dL":1.17,"alt_U_L":43},{"date":"2023-11-08","hemoglobin_g_dL":13.5,"wbc_k_uL":5.1,"platelets_k_uL":280,"creatinine_mg_dL":1.27,"alt_U_L":91},{"date":"2025-03-16","hemoglobin_g_dL":12.7,"wbc_k_uL":3.9,"platelets_k_uL":106,"creatinine_mg_dL":1.05,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_1197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":73,"sex":"female","bmi":22.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-76},"pfs_months":24.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":false},"longitudinal_labs":[{"date":"2024-04-28","hemoglobin_g_dL":12.6,"wbc_k_uL":10.1,"platelets_k_uL":290,"creatinine_mg_dL":0.86,"alt_U_L":67},{"date":"2024-12-07","hemoglobin_g_dL":13.3,"wbc_k_uL":8.4,"platelets_k_uL":139,"creatinine_mg_dL":1.55,"alt_U_L":120},{"date":"2026-07-27","hemoglobin_g_dL":12.4,"wbc_k_uL":7.5,"platelets_k_uL":256,"creatinine_mg_dL":0.86,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_1198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.9,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":56,"sex":"male","bmi":28.3,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-08-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-68},"pfs_months":47.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-08-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":72.7,"censored":true},"longitudinal_labs":[{"date":"2025-06-19","hemoglobin_g_dL":13.7,"wbc_k_uL":6.9,"platelets_k_uL":224,"creatinine_mg_dL":0.75,"alt_U_L":57},{"date":"2026-01-30","hemoglobin_g_dL":13.2,"wbc_k_uL":8.2,"platelets_k_uL":197,"creatinine_mg_dL":1.03,"alt_U_L":15},{"date":"2029-08-12","hemoglobin_g_dL":10.2,"wbc_k_uL":4.1,"platelets_k_uL":321,"creatinine_mg_dL":1.65,"alt_U_L":149}]}
{"patient_id":"ANODE_SYNTH_2025_1199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":71,"sex":"female","bmi":35.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-55},"pfs_months":34.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":46.9,"censored":false},"longitudinal_labs":[{"date":"2022-10-28","hemoglobin_g_dL":11.9,"wbc_k_uL":7.2,"platelets_k_uL":272,"creatinine_mg_dL":0.63,"alt_U_L":39},{"date":"2023-06-23","hemoglobin_g_dL":13.4,"wbc_k_uL":7.7,"platelets_k_uL":326,"creatinine_mg_dL":1.43,"alt_U_L":69},{"date":"2025-12-01","hemoglobin_g_dL":12.2,"wbc_k_uL":3.7,"platelets_k_uL":312,"creatinine_mg_dL":1.56,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_1200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":58,"sex":"female","bmi":34.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-52},"pfs_months":20.44},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":false},"longitudinal_labs":[{"date":"2021-08-02","hemoglobin_g_dL":12.4,"wbc_k_uL":9.7,"platelets_k_uL":210,"creatinine_mg_dL":0.7,"alt_U_L":10},{"date":"2022-04-04","hemoglobin_g_dL":12.6,"wbc_k_uL":4.7,"platelets_k_uL":340,"creatinine_mg_dL":1.33,"alt_U_L":97},{"date":"2023-07-18","hemoglobin_g_dL":9.9,"wbc_k_uL":3.9,"platelets_k_uL":226,"creatinine_mg_dL":1.96,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_1201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":55,"sex":"female","bmi":29.3,"smoking_pack_years":28,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-58},"pfs_months":40.71},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.1,"censored":false},"longitudinal_labs":[{"date":"2020-02-23","hemoglobin_g_dL":15.1,"wbc_k_uL":10.7,"platelets_k_uL":362,"creatinine_mg_dL":1.09,"alt_U_L":44},{"date":"2020-09-16","hemoglobin_g_dL":10.2,"wbc_k_uL":7.8,"platelets_k_uL":365,"creatinine_mg_dL":1.36,"alt_U_L":106},{"date":"2023-08-27","hemoglobin_g_dL":10.4,"wbc_k_uL":3.1,"platelets_k_uL":276,"creatinine_mg_dL":1.67,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_1202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":72,"sex":"female","bmi":35.4,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-09-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-66},"pfs_months":40.44},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":62.4,"censored":false},"longitudinal_labs":[{"date":"2021-07-03","hemoglobin_g_dL":14.7,"wbc_k_uL":10.6,"platelets_k_uL":411,"creatinine_mg_dL":1.07,"alt_U_L":47},{"date":"2022-03-09","hemoglobin_g_dL":13.5,"wbc_k_uL":6.5,"platelets_k_uL":314,"creatinine_mg_dL":1.48,"alt_U_L":75},{"date":"2025-03-22","hemoglobin_g_dL":11.7,"wbc_k_uL":5.6,"platelets_k_uL":306,"creatinine_mg_dL":1.16,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_1203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":51,"sex":"female","bmi":37.2,"smoking_pack_years":53,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-49},"pfs_months":29.8},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.7,"censored":false},"longitudinal_labs":[{"date":"2021-03-22","hemoglobin_g_dL":12.6,"wbc_k_uL":6.3,"platelets_k_uL":448,"creatinine_mg_dL":0.98,"alt_U_L":50},{"date":"2021-11-08","hemoglobin_g_dL":11.0,"wbc_k_uL":8.7,"platelets_k_uL":282,"creatinine_mg_dL":1.09,"alt_U_L":42},{"date":"2023-12-01","hemoglobin_g_dL":12.8,"wbc_k_uL":5.7,"platelets_k_uL":159,"creatinine_mg_dL":1.83,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_1204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":77,"sex":"male","bmi":21.5,"smoking_pack_years":21,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-77},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-03-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":10.8,"censored":false},"longitudinal_labs":[{"date":"2020-10-10","hemoglobin_g_dL":12.4,"wbc_k_uL":9.6,"platelets_k_uL":427,"creatinine_mg_dL":1.11,"alt_U_L":39},{"date":"2021-05-18","hemoglobin_g_dL":12.5,"wbc_k_uL":3.9,"platelets_k_uL":282,"creatinine_mg_dL":1.19,"alt_U_L":72},{"date":"2021-03-26","hemoglobin_g_dL":12.6,"wbc_k_uL":6.9,"platelets_k_uL":114,"creatinine_mg_dL":1.87,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_1205","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":49,"sex":"female","bmi":25.7,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-08-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-71},"pfs_months":25.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":true},"longitudinal_labs":[{"date":"2025-08-13","hemoglobin_g_dL":13.6,"wbc_k_uL":7.6,"platelets_k_uL":408,"creatinine_mg_dL":1.3,"alt_U_L":42},{"date":"2026-02-24","hemoglobin_g_dL":10.8,"wbc_k_uL":4.2,"platelets_k_uL":269,"creatinine_mg_dL":0.79,"alt_U_L":77},{"date":"2027-10-19","hemoglobin_g_dL":11.1,"wbc_k_uL":6.2,"platelets_k_uL":274,"creatinine_mg_dL":1.83,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_1206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":48,"sex":"female","bmi":29.4,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-01-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-84},"pfs_months":39.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":64.1,"censored":false},"longitudinal_labs":[{"date":"2021-11-22","hemoglobin_g_dL":11.7,"wbc_k_uL":8.7,"platelets_k_uL":377,"creatinine_mg_dL":1.26,"alt_U_L":36},{"date":"2022-07-14","hemoglobin_g_dL":10.4,"wbc_k_uL":6.5,"platelets_k_uL":283,"creatinine_mg_dL":0.89,"alt_U_L":89},{"date":"2025-04-26","hemoglobin_g_dL":12.7,"wbc_k_uL":5.7,"platelets_k_uL":345,"creatinine_mg_dL":1.17,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_1207","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":50,"sex":"female","bmi":22.1,"smoking_pack_years":76,"ecog_performance_status":0,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-12-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-63},"pfs_months":36.67},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.5,"censored":true},"longitudinal_labs":[{"date":"2021-10-08","hemoglobin_g_dL":11.5,"wbc_k_uL":8.0,"platelets_k_uL":280,"creatinine_mg_dL":1.08,"alt_U_L":29},{"date":"2022-06-12","hemoglobin_g_dL":11.7,"wbc_k_uL":8.9,"platelets_k_uL":159,"creatinine_mg_dL":1.24,"alt_U_L":89},{"date":"2025-02-15","hemoglobin_g_dL":10.7,"wbc_k_uL":4.0,"platelets_k_uL":249,"creatinine_mg_dL":0.84,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_1208","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":64,"sex":"female","bmi":29.6,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-57},"pfs_months":16.72},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.8,"censored":false},"longitudinal_labs":[{"date":"2020-11-26","hemoglobin_g_dL":14.5,"wbc_k_uL":8.6,"platelets_k_uL":382,"creatinine_mg_dL":0.76,"alt_U_L":20},{"date":"2021-07-29","hemoglobin_g_dL":13.9,"wbc_k_uL":6.0,"platelets_k_uL":250,"creatinine_mg_dL":0.97,"alt_U_L":96},{"date":"2022-07-20","hemoglobin_g_dL":10.9,"wbc_k_uL":4.5,"platelets_k_uL":306,"creatinine_mg_dL":0.99,"alt_U_L":56}]}
{"patient_id":"ANODE_SYNTH_2025_1209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":50,"sex":"female","bmi":36.1,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-11-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-50},"pfs_months":38.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.4,"censored":true},"longitudinal_labs":[{"date":"2020-09-28","hemoglobin_g_dL":12.7,"wbc_k_uL":6.5,"platelets_k_uL":393,"creatinine_mg_dL":1.02,"alt_U_L":11},{"date":"2021-05-14","hemoglobin_g_dL":11.2,"wbc_k_uL":8.8,"platelets_k_uL":283,"creatinine_mg_dL":1.54,"alt_U_L":33},{"date":"2024-02-06","hemoglobin_g_dL":11.0,"wbc_k_uL":5.9,"platelets_k_uL":103,"creatinine_mg_dL":1.14,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_1210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":81,"sex":"male","bmi":35.8,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-01-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-33},"pfs_months":27.04},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.0,"censored":true},"longitudinal_labs":[{"date":"2021-11-23","hemoglobin_g_dL":11.7,"wbc_k_uL":6.1,"platelets_k_uL":274,"creatinine_mg_dL":0.92,"alt_U_L":30},{"date":"2022-07-14","hemoglobin_g_dL":10.3,"wbc_k_uL":7.5,"platelets_k_uL":210,"creatinine_mg_dL":1.47,"alt_U_L":88},{"date":"2024-05-12","hemoglobin_g_dL":11.2,"wbc_k_uL":7.3,"platelets_k_uL":294,"creatinine_mg_dL":1.61,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_1211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":64,"sex":"female","bmi":24.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-37},"pfs_months":28.81},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.8,"censored":true},"longitudinal_labs":[{"date":"2024-06-28","hemoglobin_g_dL":13.1,"wbc_k_uL":6.4,"platelets_k_uL":175,"creatinine_mg_dL":0.61,"alt_U_L":80},{"date":"2025-02-22","hemoglobin_g_dL":13.8,"wbc_k_uL":5.1,"platelets_k_uL":234,"creatinine_mg_dL":1.35,"alt_U_L":108},{"date":"2027-02-02","hemoglobin_g_dL":12.4,"wbc_k_uL":7.2,"platelets_k_uL":301,"creatinine_mg_dL":1.95,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_1212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":72,"sex":"female","bmi":21.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-64},"pfs_months":24.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.2,"censored":false},"longitudinal_labs":[{"date":"2020-04-13","hemoglobin_g_dL":12.9,"wbc_k_uL":10.3,"platelets_k_uL":431,"creatinine_mg_dL":1.26,"alt_U_L":18},{"date":"2020-12-06","hemoglobin_g_dL":12.0,"wbc_k_uL":5.1,"platelets_k_uL":269,"creatinine_mg_dL":1.21,"alt_U_L":83},{"date":"2022-07-15","hemoglobin_g_dL":10.1,"wbc_k_uL":3.7,"platelets_k_uL":161,"creatinine_mg_dL":1.04,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_1213","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":82,"sex":"female","bmi":36.0,"smoking_pack_years":49,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-42},"pfs_months":13.37},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2023-04-11","hemoglobin_g_dL":11.6,"wbc_k_uL":6.1,"platelets_k_uL":210,"creatinine_mg_dL":1.26,"alt_U_L":57},{"date":"2023-11-18","hemoglobin_g_dL":11.1,"wbc_k_uL":8.7,"platelets_k_uL":233,"creatinine_mg_dL":1.5,"alt_U_L":25},{"date":"2024-08-16","hemoglobin_g_dL":11.1,"wbc_k_uL":4.2,"platelets_k_uL":153,"creatinine_mg_dL":0.82,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_1214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":80,"sex":"male","bmi":33.1,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-58},"pfs_months":41.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.9,"censored":true},"longitudinal_labs":[{"date":"2022-07-23","hemoglobin_g_dL":15.4,"wbc_k_uL":5.1,"platelets_k_uL":439,"creatinine_mg_dL":1.01,"alt_U_L":66},{"date":"2023-02-23","hemoglobin_g_dL":13.7,"wbc_k_uL":7.3,"platelets_k_uL":181,"creatinine_mg_dL":1.23,"alt_U_L":83},{"date":"2026-04-17","hemoglobin_g_dL":11.8,"wbc_k_uL":4.0,"platelets_k_uL":248,"creatinine_mg_dL":1.99,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_1215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":64,"sex":"female","bmi":25.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-78},"pfs_months":20.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":true},"longitudinal_labs":[{"date":"2021-10-07","hemoglobin_g_dL":14.7,"wbc_k_uL":7.5,"platelets_k_uL":323,"creatinine_mg_dL":1.01,"alt_U_L":14},{"date":"2022-04-28","hemoglobin_g_dL":12.9,"wbc_k_uL":8.8,"platelets_k_uL":218,"creatinine_mg_dL":0.78,"alt_U_L":75},{"date":"2023-08-08","hemoglobin_g_dL":12.4,"wbc_k_uL":4.8,"platelets_k_uL":272,"creatinine_mg_dL":1.46,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_1216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":79,"sex":"female","bmi":32.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-57},"pfs_months":27.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.7,"censored":false},"longitudinal_labs":[{"date":"2020-12-14","hemoglobin_g_dL":12.9,"wbc_k_uL":7.4,"platelets_k_uL":391,"creatinine_mg_dL":0.85,"alt_U_L":38},{"date":"2021-08-05","hemoglobin_g_dL":10.8,"wbc_k_uL":8.9,"platelets_k_uL":253,"creatinine_mg_dL":1.09,"alt_U_L":55},{"date":"2023-05-18","hemoglobin_g_dL":10.1,"wbc_k_uL":5.4,"platelets_k_uL":175,"creatinine_mg_dL":1.26,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_1217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":87,"sex":"female","bmi":29.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-46},"pfs_months":16.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.4,"censored":false},"longitudinal_labs":[{"date":"2025-07-13","hemoglobin_g_dL":13.4,"wbc_k_uL":8.5,"platelets_k_uL":313,"creatinine_mg_dL":1.08,"alt_U_L":80},{"date":"2026-03-17","hemoglobin_g_dL":11.5,"wbc_k_uL":6.1,"platelets_k_uL":216,"creatinine_mg_dL":1.21,"alt_U_L":96},{"date":"2027-03-05","hemoglobin_g_dL":10.1,"wbc_k_uL":3.2,"platelets_k_uL":146,"creatinine_mg_dL":1.07,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_1218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":78,"sex":"female","bmi":27.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-49},"pfs_months":22.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":false},"longitudinal_labs":[{"date":"2023-01-12","hemoglobin_g_dL":13.4,"wbc_k_uL":5.9,"platelets_k_uL":425,"creatinine_mg_dL":1.17,"alt_U_L":25},{"date":"2023-09-06","hemoglobin_g_dL":11.6,"wbc_k_uL":5.2,"platelets_k_uL":196,"creatinine_mg_dL":1.22,"alt_U_L":16},{"date":"2025-02-09","hemoglobin_g_dL":10.9,"wbc_k_uL":5.2,"platelets_k_uL":100,"creatinine_mg_dL":1.31,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_1219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":75,"sex":"female","bmi":25.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-05-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-45},"pfs_months":25.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":true},"longitudinal_labs":[{"date":"2023-04-21","hemoglobin_g_dL":12.5,"wbc_k_uL":8.7,"platelets_k_uL":449,"creatinine_mg_dL":0.89,"alt_U_L":49},{"date":"2023-11-09","hemoglobin_g_dL":13.8,"wbc_k_uL":7.8,"platelets_k_uL":243,"creatinine_mg_dL":1.33,"alt_U_L":102},{"date":"2025-07-15","hemoglobin_g_dL":12.0,"wbc_k_uL":7.9,"platelets_k_uL":263,"creatinine_mg_dL":1.91,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_1220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":49,"sex":"female","bmi":34.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-78},"pfs_months":22.93},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.3,"censored":false},"longitudinal_labs":[{"date":"2023-05-16","hemoglobin_g_dL":15.3,"wbc_k_uL":6.8,"platelets_k_uL":238,"creatinine_mg_dL":1.23,"alt_U_L":36},{"date":"2024-01-13","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":298,"creatinine_mg_dL":1.01,"alt_U_L":55},{"date":"2025-07-26","hemoglobin_g_dL":10.8,"wbc_k_uL":5.3,"platelets_k_uL":149,"creatinine_mg_dL":0.9,"alt_U_L":99}]}
{"patient_id":"ANODE_SYNTH_2025_1221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.9,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":54,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-33},"pfs_months":14.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":true},"longitudinal_labs":[{"date":"2024-06-15","hemoglobin_g_dL":12.0,"wbc_k_uL":9.5,"platelets_k_uL":340,"creatinine_mg_dL":0.61,"alt_U_L":35},{"date":"2025-01-09","hemoglobin_g_dL":12.7,"wbc_k_uL":6.6,"platelets_k_uL":305,"creatinine_mg_dL":1.54,"alt_U_L":31},{"date":"2025-10-16","hemoglobin_g_dL":11.1,"wbc_k_uL":3.4,"platelets_k_uL":189,"creatinine_mg_dL":1.94,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_1222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":70,"sex":"female","bmi":34.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-34},"pfs_months":30.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.9,"censored":true},"longitudinal_labs":[{"date":"2023-07-03","hemoglobin_g_dL":15.5,"wbc_k_uL":8.7,"platelets_k_uL":231,"creatinine_mg_dL":0.63,"alt_U_L":46},{"date":"2024-01-21","hemoglobin_g_dL":11.3,"wbc_k_uL":4.5,"platelets_k_uL":331,"creatinine_mg_dL":1.07,"alt_U_L":23},{"date":"2026-03-02","hemoglobin_g_dL":10.2,"wbc_k_uL":3.5,"platelets_k_uL":292,"creatinine_mg_dL":0.98,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_1223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":72,"sex":"female","bmi":37.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-59},"pfs_months":27.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.8,"censored":true},"longitudinal_labs":[{"date":"2024-08-13","hemoglobin_g_dL":12.8,"wbc_k_uL":5.0,"platelets_k_uL":360,"creatinine_mg_dL":1.15,"alt_U_L":21},{"date":"2025-03-07","hemoglobin_g_dL":10.6,"wbc_k_uL":6.0,"platelets_k_uL":257,"creatinine_mg_dL":1.56,"alt_U_L":17},{"date":"2027-01-25","hemoglobin_g_dL":10.0,"wbc_k_uL":3.4,"platelets_k_uL":207,"creatinine_mg_dL":1.79,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_1224","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":86,"sex":"male","bmi":25.9,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-48},"pfs_months":16.36},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.3,"censored":false},"longitudinal_labs":[{"date":"2020-11-11","hemoglobin_g_dL":13.0,"wbc_k_uL":10.0,"platelets_k_uL":269,"creatinine_mg_dL":1.12,"alt_U_L":13},{"date":"2021-07-04","hemoglobin_g_dL":13.6,"wbc_k_uL":5.7,"platelets_k_uL":301,"creatinine_mg_dL":1.03,"alt_U_L":70},{"date":"2022-07-17","hemoglobin_g_dL":11.3,"wbc_k_uL":4.3,"platelets_k_uL":230,"creatinine_mg_dL":1.52,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_1225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":87,"sex":"female","bmi":35.9,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-04-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-78},"pfs_months":39.43},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":61.7,"censored":false},"longitudinal_labs":[{"date":"2020-02-01","hemoglobin_g_dL":12.5,"wbc_k_uL":10.5,"platelets_k_uL":401,"creatinine_mg_dL":0.84,"alt_U_L":25},{"date":"2020-10-03","hemoglobin_g_dL":13.0,"wbc_k_uL":6.0,"platelets_k_uL":304,"creatinine_mg_dL":1.22,"alt_U_L":43},{"date":"2023-09-02","hemoglobin_g_dL":9.9,"wbc_k_uL":4.9,"platelets_k_uL":262,"creatinine_mg_dL":1.16,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_1226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":85,"sex":"male","bmi":36.8,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-12-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-42},"pfs_months":13.21},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.1,"censored":false},"longitudinal_labs":[{"date":"2025-12-01","hemoglobin_g_dL":14.4,"wbc_k_uL":8.5,"platelets_k_uL":244,"creatinine_mg_dL":1.09,"alt_U_L":41},{"date":"2026-06-24","hemoglobin_g_dL":10.2,"wbc_k_uL":5.7,"platelets_k_uL":376,"creatinine_mg_dL":1.37,"alt_U_L":78},{"date":"2027-04-01","hemoglobin_g_dL":9.5,"wbc_k_uL":5.6,"platelets_k_uL":100,"creatinine_mg_dL":1.71,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_1227","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":87,"sex":"female","bmi":30.5,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-12-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-51},"pfs_months":30.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.3,"censored":true},"longitudinal_labs":[{"date":"2022-11-03","hemoglobin_g_dL":12.6,"wbc_k_uL":4.6,"platelets_k_uL":329,"creatinine_mg_dL":0.91,"alt_U_L":43},{"date":"2023-06-25","hemoglobin_g_dL":13.1,"wbc_k_uL":5.4,"platelets_k_uL":133,"creatinine_mg_dL":1.37,"alt_U_L":97},{"date":"2025-08-12","hemoglobin_g_dL":12.6,"wbc_k_uL":7.2,"platelets_k_uL":165,"creatinine_mg_dL":1.41,"alt_U_L":145}]}
{"patient_id":"ANODE_SYNTH_2025_1228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":73,"sex":"female","bmi":31.5,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-05-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-47},"pfs_months":28.91},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":53.7,"censored":true},"longitudinal_labs":[{"date":"2020-03-21","hemoglobin_g_dL":11.7,"wbc_k_uL":4.8,"platelets_k_uL":318,"creatinine_mg_dL":1.09,"alt_U_L":50},{"date":"2020-11-15","hemoglobin_g_dL":10.4,"wbc_k_uL":7.6,"platelets_k_uL":354,"creatinine_mg_dL":1.34,"alt_U_L":71},{"date":"2022-11-03","hemoglobin_g_dL":10.3,"wbc_k_uL":7.6,"platelets_k_uL":166,"creatinine_mg_dL":1.43,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_1229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":61,"sex":"female","bmi":23.9,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-57},"pfs_months":8.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":14.8,"censored":false},"longitudinal_labs":[{"date":"2024-12-10","hemoglobin_g_dL":12.7,"wbc_k_uL":7.6,"platelets_k_uL":276,"creatinine_mg_dL":0.85,"alt_U_L":28},{"date":"2025-07-24","hemoglobin_g_dL":10.9,"wbc_k_uL":7.8,"platelets_k_uL":144,"creatinine_mg_dL":1.47,"alt_U_L":71},{"date":"2025-10-22","hemoglobin_g_dL":10.8,"wbc_k_uL":7.6,"platelets_k_uL":171,"creatinine_mg_dL":1.79,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_1230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":65,"sex":"female","bmi":29.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-83},"pfs_months":20.83},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.1,"censored":true},"longitudinal_labs":[{"date":"2022-12-25","hemoglobin_g_dL":13.4,"wbc_k_uL":10.2,"platelets_k_uL":163,"creatinine_mg_dL":1.28,"alt_U_L":25},{"date":"2023-08-31","hemoglobin_g_dL":10.9,"wbc_k_uL":8.9,"platelets_k_uL":352,"creatinine_mg_dL":1.4,"alt_U_L":43},{"date":"2025-01-03","hemoglobin_g_dL":10.5,"wbc_k_uL":7.5,"platelets_k_uL":252,"creatinine_mg_dL":1.69,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_1231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":52,"sex":"male","bmi":25.4,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-09-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-33},"pfs_months":7.59},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":15.9,"censored":false},"longitudinal_labs":[{"date":"2024-08-10","hemoglobin_g_dL":14.3,"wbc_k_uL":9.5,"platelets_k_uL":254,"creatinine_mg_dL":0.72,"alt_U_L":79},{"date":"2025-03-15","hemoglobin_g_dL":12.5,"wbc_k_uL":3.9,"platelets_k_uL":271,"creatinine_mg_dL":1.45,"alt_U_L":47},{"date":"2025-05-09","hemoglobin_g_dL":11.3,"wbc_k_uL":4.8,"platelets_k_uL":194,"creatinine_mg_dL":1.69,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_1232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":73,"sex":"female","bmi":23.1,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-07-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-55},"pfs_months":31.15},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":52.1,"censored":false},"longitudinal_labs":[{"date":"2024-05-27","hemoglobin_g_dL":12.6,"wbc_k_uL":9.0,"platelets_k_uL":320,"creatinine_mg_dL":0.6,"alt_U_L":30},{"date":"2024-12-29","hemoglobin_g_dL":12.9,"wbc_k_uL":8.6,"platelets_k_uL":191,"creatinine_mg_dL":0.83,"alt_U_L":84},{"date":"2027-02-17","hemoglobin_g_dL":12.1,"wbc_k_uL":4.7,"platelets_k_uL":211,"creatinine_mg_dL":1.44,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_1233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":81,"sex":"female","bmi":31.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-69},"pfs_months":12.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.6,"censored":true},"longitudinal_labs":[{"date":"2021-02-26","hemoglobin_g_dL":15.4,"wbc_k_uL":5.6,"platelets_k_uL":245,"creatinine_mg_dL":0.61,"alt_U_L":36},{"date":"2021-10-16","hemoglobin_g_dL":14.0,"wbc_k_uL":8.4,"platelets_k_uL":228,"creatinine_mg_dL":0.86,"alt_U_L":120},{"date":"2022-05-09","hemoglobin_g_dL":10.4,"wbc_k_uL":5.2,"platelets_k_uL":269,"creatinine_mg_dL":1.79,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_1234","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":79,"sex":"female","bmi":25.9,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-07-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-44},"pfs_months":25.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.9,"censored":false},"longitudinal_labs":[{"date":"2021-05-05","hemoglobin_g_dL":11.6,"wbc_k_uL":7.1,"platelets_k_uL":335,"creatinine_mg_dL":1.2,"alt_U_L":64},{"date":"2022-01-01","hemoglobin_g_dL":11.9,"wbc_k_uL":4.5,"platelets_k_uL":378,"creatinine_mg_dL":1.02,"alt_U_L":52},{"date":"2023-08-24","hemoglobin_g_dL":10.9,"wbc_k_uL":7.8,"platelets_k_uL":184,"creatinine_mg_dL":0.89,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_1235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":78,"sex":"female","bmi":30.4,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-12-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-67},"pfs_months":7.92},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.2,"censored":false},"longitudinal_labs":[{"date":"2023-10-28","hemoglobin_g_dL":12.4,"wbc_k_uL":9.3,"platelets_k_uL":444,"creatinine_mg_dL":1.07,"alt_U_L":10},{"date":"2024-06-23","hemoglobin_g_dL":13.0,"wbc_k_uL":6.8,"platelets_k_uL":133,"creatinine_mg_dL":1.5,"alt_U_L":72},{"date":"2024-09-08","hemoglobin_g_dL":10.1,"wbc_k_uL":4.5,"platelets_k_uL":108,"creatinine_mg_dL":1.1,"alt_U_L":90}]}
{"patient_id":"ANODE_SYNTH_2025_1236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":69,"sex":"female","bmi":28.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-38},"pfs_months":21.13},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.3,"censored":false},"longitudinal_labs":[{"date":"2022-07-11","hemoglobin_g_dL":14.1,"wbc_k_uL":9.9,"platelets_k_uL":247,"creatinine_mg_dL":1.12,"alt_U_L":67},{"date":"2023-02-26","hemoglobin_g_dL":12.9,"wbc_k_uL":6.7,"platelets_k_uL":267,"creatinine_mg_dL":1.22,"alt_U_L":102},{"date":"2024-07-15","hemoglobin_g_dL":12.1,"wbc_k_uL":4.0,"platelets_k_uL":250,"creatinine_mg_dL":0.88,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_1237","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":86,"sex":"male","bmi":22.8,"smoking_pack_years":25,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-49},"pfs_months":29.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.9,"censored":true},"longitudinal_labs":[{"date":"2022-06-04","hemoglobin_g_dL":13.0,"wbc_k_uL":6.7,"platelets_k_uL":373,"creatinine_mg_dL":0.87,"alt_U_L":43},{"date":"2022-12-25","hemoglobin_g_dL":12.4,"wbc_k_uL":7.3,"platelets_k_uL":244,"creatinine_mg_dL":0.87,"alt_U_L":70},{"date":"2025-01-06","hemoglobin_g_dL":10.3,"wbc_k_uL":4.7,"platelets_k_uL":182,"creatinine_mg_dL":1.27,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_1238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":78,"sex":"female","bmi":37.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-81},"pfs_months":16.99},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":27.2,"censored":true},"longitudinal_labs":[{"date":"2020-11-11","hemoglobin_g_dL":14.5,"wbc_k_uL":7.1,"platelets_k_uL":449,"creatinine_mg_dL":0.93,"alt_U_L":38},{"date":"2021-06-01","hemoglobin_g_dL":10.1,"wbc_k_uL":6.2,"platelets_k_uL":145,"creatinine_mg_dL":1.04,"alt_U_L":118},{"date":"2022-06-19","hemoglobin_g_dL":12.9,"wbc_k_uL":5.3,"platelets_k_uL":196,"creatinine_mg_dL":1.15,"alt_U_L":87}]}
{"patient_id":"ANODE_SYNTH_2025_1239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":76,"sex":"female","bmi":32.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-02-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-72},"pfs_months":18.73},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.2,"censored":false},"longitudinal_labs":[{"date":"2025-12-05","hemoglobin_g_dL":15.2,"wbc_k_uL":7.4,"platelets_k_uL":265,"creatinine_mg_dL":0.64,"alt_U_L":36},{"date":"2026-08-09","hemoglobin_g_dL":13.6,"wbc_k_uL":5.5,"platelets_k_uL":170,"creatinine_mg_dL":1.21,"alt_U_L":115},{"date":"2027-09-12","hemoglobin_g_dL":12.0,"wbc_k_uL":6.0,"platelets_k_uL":165,"creatinine_mg_dL":1.66,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_1240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":66,"sex":"female","bmi":25.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-51},"pfs_months":13.21},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.5,"censored":false},"longitudinal_labs":[{"date":"2020-07-21","hemoglobin_g_dL":13.6,"wbc_k_uL":5.1,"platelets_k_uL":266,"creatinine_mg_dL":1.16,"alt_U_L":36},{"date":"2021-03-01","hemoglobin_g_dL":11.4,"wbc_k_uL":6.3,"platelets_k_uL":222,"creatinine_mg_dL":1.19,"alt_U_L":120},{"date":"2021-10-15","hemoglobin_g_dL":11.8,"wbc_k_uL":3.0,"platelets_k_uL":247,"creatinine_mg_dL":1.66,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_1241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":86,"sex":"male","bmi":31.7,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-08-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-53},"pfs_months":15.28},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.5,"censored":false},"longitudinal_labs":[{"date":"2021-07-20","hemoglobin_g_dL":13.6,"wbc_k_uL":6.7,"platelets_k_uL":428,"creatinine_mg_dL":0.76,"alt_U_L":75},{"date":"2022-02-13","hemoglobin_g_dL":12.4,"wbc_k_uL":6.0,"platelets_k_uL":379,"creatinine_mg_dL":1.33,"alt_U_L":30},{"date":"2022-12-25","hemoglobin_g_dL":11.4,"wbc_k_uL":6.9,"platelets_k_uL":218,"creatinine_mg_dL":1.17,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_1242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":49,"sex":"female","bmi":27.9,"smoking_pack_years":51,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-04-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-65},"pfs_months":34.37},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":52.6,"censored":false},"longitudinal_labs":[{"date":"2021-03-15","hemoglobin_g_dL":14.5,"wbc_k_uL":7.4,"platelets_k_uL":222,"creatinine_mg_dL":0.88,"alt_U_L":10},{"date":"2021-10-10","hemoglobin_g_dL":11.1,"wbc_k_uL":5.7,"platelets_k_uL":121,"creatinine_mg_dL":0.83,"alt_U_L":17},{"date":"2024-04-18","hemoglobin_g_dL":10.6,"wbc_k_uL":6.7,"platelets_k_uL":275,"creatinine_mg_dL":1.74,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_1243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":72,"sex":"female","bmi":27.1,"smoking_pack_years":60,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-12-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-60},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":9.4,"censored":true},"longitudinal_labs":[{"date":"2023-10-17","hemoglobin_g_dL":12.3,"wbc_k_uL":6.4,"platelets_k_uL":207,"creatinine_mg_dL":0.85,"alt_U_L":52},{"date":"2024-06-23","hemoglobin_g_dL":12.7,"wbc_k_uL":6.8,"platelets_k_uL":154,"creatinine_mg_dL":0.8,"alt_U_L":90},{"date":"2024-04-10","hemoglobin_g_dL":10.6,"wbc_k_uL":4.4,"platelets_k_uL":124,"creatinine_mg_dL":1.3,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_1244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":87,"sex":"female","bmi":34.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-85},"pfs_months":26.45},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.5,"censored":false},"longitudinal_labs":[{"date":"2024-09-13","hemoglobin_g_dL":11.9,"wbc_k_uL":8.8,"platelets_k_uL":252,"creatinine_mg_dL":1.04,"alt_U_L":56},{"date":"2025-03-27","hemoglobin_g_dL":10.5,"wbc_k_uL":6.6,"platelets_k_uL":172,"creatinine_mg_dL":0.75,"alt_U_L":80},{"date":"2027-01-29","hemoglobin_g_dL":9.6,"wbc_k_uL":4.4,"platelets_k_uL":295,"creatinine_mg_dL":1.48,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_1245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":52,"sex":"male","bmi":29.2,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-11-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-68},"pfs_months":18.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":true},"longitudinal_labs":[{"date":"2021-09-22","hemoglobin_g_dL":14.7,"wbc_k_uL":10.5,"platelets_k_uL":158,"creatinine_mg_dL":1.03,"alt_U_L":61},{"date":"2022-05-05","hemoglobin_g_dL":13.2,"wbc_k_uL":7.3,"platelets_k_uL":159,"creatinine_mg_dL":0.74,"alt_U_L":75},{"date":"2023-06-19","hemoglobin_g_dL":11.2,"wbc_k_uL":3.8,"platelets_k_uL":333,"creatinine_mg_dL":0.92,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_1246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":56,"sex":"female","bmi":32.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-02-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-65},"pfs_months":12.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-04-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.5,"censored":true},"longitudinal_labs":[{"date":"2020-01-02","hemoglobin_g_dL":13.5,"wbc_k_uL":10.8,"platelets_k_uL":253,"creatinine_mg_dL":0.93,"alt_U_L":15},{"date":"2020-08-13","hemoglobin_g_dL":10.5,"wbc_k_uL":6.7,"platelets_k_uL":267,"creatinine_mg_dL":0.95,"alt_U_L":54},{"date":"2021-04-15","hemoglobin_g_dL":11.4,"wbc_k_uL":7.1,"platelets_k_uL":168,"creatinine_mg_dL":1.88,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_1247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":75,"sex":"male","bmi":22.6,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-02-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-63},"pfs_months":35.02},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":57.5,"censored":false},"longitudinal_labs":[{"date":"2021-01-05","hemoglobin_g_dL":11.7,"wbc_k_uL":8.9,"platelets_k_uL":415,"creatinine_mg_dL":0.88,"alt_U_L":37},{"date":"2021-08-21","hemoglobin_g_dL":10.3,"wbc_k_uL":4.5,"platelets_k_uL":360,"creatinine_mg_dL":1.09,"alt_U_L":52},{"date":"2024-03-14","hemoglobin_g_dL":12.6,"wbc_k_uL":4.0,"platelets_k_uL":152,"creatinine_mg_dL":1.31,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_1248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":73,"sex":"female","bmi":26.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-45},"pfs_months":26.48},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.5,"censored":false},"longitudinal_labs":[{"date":"2020-07-19","hemoglobin_g_dL":12.9,"wbc_k_uL":10.4,"platelets_k_uL":411,"creatinine_mg_dL":1.27,"alt_U_L":16},{"date":"2021-02-27","hemoglobin_g_dL":12.7,"wbc_k_uL":6.0,"platelets_k_uL":312,"creatinine_mg_dL":1.02,"alt_U_L":83},{"date":"2022-12-12","hemoglobin_g_dL":10.8,"wbc_k_uL":5.5,"platelets_k_uL":322,"creatinine_mg_dL":1.3,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_1249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":84,"sex":"female","bmi":35.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-45},"pfs_months":9.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":25.0,"censored":false},"longitudinal_labs":[{"date":"2021-09-16","hemoglobin_g_dL":15.1,"wbc_k_uL":6.5,"platelets_k_uL":252,"creatinine_mg_dL":0.89,"alt_U_L":10},{"date":"2022-05-18","hemoglobin_g_dL":11.4,"wbc_k_uL":4.5,"platelets_k_uL":220,"creatinine_mg_dL":1.02,"alt_U_L":118},{"date":"2022-09-24","hemoglobin_g_dL":12.3,"wbc_k_uL":6.5,"platelets_k_uL":301,"creatinine_mg_dL":1.09,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_1250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":72,"sex":"male","bmi":35.0,"smoking_pack_years":22,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-07-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-73},"pfs_months":13.6},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.4,"censored":false},"longitudinal_labs":[{"date":"2022-06-15","hemoglobin_g_dL":14.1,"wbc_k_uL":5.2,"platelets_k_uL":293,"creatinine_mg_dL":1.15,"alt_U_L":63},{"date":"2023-01-22","hemoglobin_g_dL":12.1,"wbc_k_uL":7.0,"platelets_k_uL":326,"creatinine_mg_dL":1.03,"alt_U_L":46},{"date":"2023-11-06","hemoglobin_g_dL":10.4,"wbc_k_uL":4.6,"platelets_k_uL":335,"creatinine_mg_dL":1.28,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_1251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":67,"sex":"female","bmi":34.2,"smoking_pack_years":44,"ecog_performance_status":2,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-02-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-63},"pfs_months":22.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":26.8,"censored":false},"longitudinal_labs":[{"date":"2025-01-10","hemoglobin_g_dL":13.9,"wbc_k_uL":5.6,"platelets_k_uL":355,"creatinine_mg_dL":0.79,"alt_U_L":26},{"date":"2025-08-24","hemoglobin_g_dL":10.7,"wbc_k_uL":7.1,"platelets_k_uL":353,"creatinine_mg_dL":1.14,"alt_U_L":103},{"date":"2027-02-09","hemoglobin_g_dL":10.3,"wbc_k_uL":5.4,"platelets_k_uL":271,"creatinine_mg_dL":1.9,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_1252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":75,"sex":"male","bmi":20.2,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-33},"pfs_months":37.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":57.2,"censored":false},"longitudinal_labs":[{"date":"2023-09-01","hemoglobin_g_dL":14.1,"wbc_k_uL":9.5,"platelets_k_uL":368,"creatinine_mg_dL":0.66,"alt_U_L":32},{"date":"2024-03-13","hemoglobin_g_dL":12.7,"wbc_k_uL":7.6,"platelets_k_uL":161,"creatinine_mg_dL":1.03,"alt_U_L":30},{"date":"2026-11-15","hemoglobin_g_dL":12.8,"wbc_k_uL":3.1,"platelets_k_uL":164,"creatinine_mg_dL":1.56,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_1253","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":75,"sex":"female","bmi":24.0,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-68},"pfs_months":15.15},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.3,"censored":false},"longitudinal_labs":[{"date":"2024-08-10","hemoglobin_g_dL":13.0,"wbc_k_uL":5.4,"platelets_k_uL":174,"creatinine_mg_dL":1.06,"alt_U_L":33},{"date":"2025-03-15","hemoglobin_g_dL":10.0,"wbc_k_uL":7.8,"platelets_k_uL":183,"creatinine_mg_dL":1.22,"alt_U_L":113},{"date":"2026-02-17","hemoglobin_g_dL":10.6,"wbc_k_uL":5.4,"platelets_k_uL":289,"creatinine_mg_dL":1.24,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_1254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":75,"sex":"male","bmi":24.0,"smoking_pack_years":80,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-11-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-74},"pfs_months":30.85},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.1,"censored":false},"longitudinal_labs":[{"date":"2025-10-06","hemoglobin_g_dL":13.8,"wbc_k_uL":7.0,"platelets_k_uL":154,"creatinine_mg_dL":1.01,"alt_U_L":63},{"date":"2026-05-20","hemoglobin_g_dL":11.0,"wbc_k_uL":7.7,"platelets_k_uL":189,"creatinine_mg_dL":0.86,"alt_U_L":86},{"date":"2028-07-05","hemoglobin_g_dL":10.4,"wbc_k_uL":6.0,"platelets_k_uL":105,"creatinine_mg_dL":1.06,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_1255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":56,"sex":"male","bmi":23.4,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-09-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-54},"pfs_months":39.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":66.9,"censored":false},"longitudinal_labs":[{"date":"2022-08-10","hemoglobin_g_dL":13.8,"wbc_k_uL":6.8,"platelets_k_uL":403,"creatinine_mg_dL":0.68,"alt_U_L":70},{"date":"2023-03-07","hemoglobin_g_dL":11.2,"wbc_k_uL":4.9,"platelets_k_uL":256,"creatinine_mg_dL":0.89,"alt_U_L":108},{"date":"2026-01-06","hemoglobin_g_dL":10.5,"wbc_k_uL":5.6,"platelets_k_uL":320,"creatinine_mg_dL":1.52,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_1256","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":68,"sex":"female","bmi":29.9,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-50},"pfs_months":11.04},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.1,"censored":true},"longitudinal_labs":[{"date":"2025-01-03","hemoglobin_g_dL":14.9,"wbc_k_uL":10.7,"platelets_k_uL":303,"creatinine_mg_dL":0.75,"alt_U_L":11},{"date":"2025-07-30","hemoglobin_g_dL":11.1,"wbc_k_uL":7.2,"platelets_k_uL":272,"creatinine_mg_dL":1.38,"alt_U_L":37},{"date":"2026-01-06","hemoglobin_g_dL":12.8,"wbc_k_uL":3.3,"platelets_k_uL":165,"creatinine_mg_dL":1.36,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_1257","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":49,"sex":"female","bmi":29.6,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-04-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-72},"pfs_months":18.92},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.3,"censored":true},"longitudinal_labs":[{"date":"2023-02-23","hemoglobin_g_dL":14.1,"wbc_k_uL":5.3,"platelets_k_uL":260,"creatinine_mg_dL":0.68,"alt_U_L":25},{"date":"2023-10-27","hemoglobin_g_dL":10.2,"wbc_k_uL":7.9,"platelets_k_uL":188,"creatinine_mg_dL":1.06,"alt_U_L":65},{"date":"2024-12-04","hemoglobin_g_dL":9.6,"wbc_k_uL":3.5,"platelets_k_uL":203,"creatinine_mg_dL":1.96,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_1258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":58,"sex":"male","bmi":37.5,"smoking_pack_years":79,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-67},"pfs_months":39.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":55.0,"censored":false},"longitudinal_labs":[{"date":"2024-08-04","hemoglobin_g_dL":13.7,"wbc_k_uL":9.4,"platelets_k_uL":188,"creatinine_mg_dL":1.23,"alt_U_L":19},{"date":"2025-03-14","hemoglobin_g_dL":13.2,"wbc_k_uL":4.7,"platelets_k_uL":318,"creatinine_mg_dL":1.49,"alt_U_L":50},{"date":"2028-01-06","hemoglobin_g_dL":11.2,"wbc_k_uL":4.9,"platelets_k_uL":120,"creatinine_mg_dL":1.76,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_1259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":85,"sex":"female","bmi":36.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-55},"pfs_months":20.86},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.6,"censored":true},"longitudinal_labs":[{"date":"2023-01-20","hemoglobin_g_dL":12.1,"wbc_k_uL":7.7,"platelets_k_uL":286,"creatinine_mg_dL":1.12,"alt_U_L":16},{"date":"2023-08-31","hemoglobin_g_dL":10.9,"wbc_k_uL":8.4,"platelets_k_uL":193,"creatinine_mg_dL":1.18,"alt_U_L":71},{"date":"2024-12-24","hemoglobin_g_dL":12.1,"wbc_k_uL":6.2,"platelets_k_uL":237,"creatinine_mg_dL":0.95,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_1260","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":78,"sex":"female","bmi":34.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-35},"pfs_months":12.85},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-24","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":true},"longitudinal_labs":[{"date":"2022-03-18","hemoglobin_g_dL":11.6,"wbc_k_uL":4.7,"platelets_k_uL":157,"creatinine_mg_dL":1.0,"alt_U_L":75},{"date":"2022-10-13","hemoglobin_g_dL":13.7,"wbc_k_uL":5.9,"platelets_k_uL":277,"creatinine_mg_dL":1.27,"alt_U_L":79},{"date":"2023-06-24","hemoglobin_g_dL":13.0,"wbc_k_uL":7.1,"platelets_k_uL":223,"creatinine_mg_dL":1.87,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_1261","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":50,"sex":"female","bmi":33.7,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-69},"pfs_months":26.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":false},"longitudinal_labs":[{"date":"2023-05-09","hemoglobin_g_dL":13.4,"wbc_k_uL":9.0,"platelets_k_uL":234,"creatinine_mg_dL":1.01,"alt_U_L":63},{"date":"2023-12-07","hemoglobin_g_dL":13.5,"wbc_k_uL":5.8,"platelets_k_uL":238,"creatinine_mg_dL":1.17,"alt_U_L":77},{"date":"2025-09-20","hemoglobin_g_dL":11.7,"wbc_k_uL":7.5,"platelets_k_uL":298,"creatinine_mg_dL":1.52,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_1262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":79,"sex":"female","bmi":19.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-34},"pfs_months":17.15},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":true},"longitudinal_labs":[{"date":"2020-10-17","hemoglobin_g_dL":14.3,"wbc_k_uL":9.6,"platelets_k_uL":267,"creatinine_mg_dL":0.69,"alt_U_L":21},{"date":"2021-05-01","hemoglobin_g_dL":13.7,"wbc_k_uL":4.7,"platelets_k_uL":217,"creatinine_mg_dL":1.23,"alt_U_L":69},{"date":"2022-04-13","hemoglobin_g_dL":10.6,"wbc_k_uL":3.7,"platelets_k_uL":253,"creatinine_mg_dL":0.99,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_1263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":68,"sex":"female","bmi":20.1,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-02-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-39},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":9.7,"censored":false},"longitudinal_labs":[{"date":"2025-12-16","hemoglobin_g_dL":13.9,"wbc_k_uL":7.5,"platelets_k_uL":403,"creatinine_mg_dL":0.92,"alt_U_L":72},{"date":"2026-08-23","hemoglobin_g_dL":10.7,"wbc_k_uL":8.5,"platelets_k_uL":266,"creatinine_mg_dL":1.31,"alt_U_L":42},{"date":"2026-07-05","hemoglobin_g_dL":11.5,"wbc_k_uL":5.1,"platelets_k_uL":262,"creatinine_mg_dL":0.87,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_1264","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":69,"sex":"female","bmi":21.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-62},"pfs_months":14.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.1,"censored":false},"longitudinal_labs":[{"date":"2024-01-04","hemoglobin_g_dL":13.4,"wbc_k_uL":7.2,"platelets_k_uL":411,"creatinine_mg_dL":0.86,"alt_U_L":69},{"date":"2024-09-05","hemoglobin_g_dL":12.5,"wbc_k_uL":5.2,"platelets_k_uL":169,"creatinine_mg_dL":1.24,"alt_U_L":63},{"date":"2025-06-26","hemoglobin_g_dL":12.3,"wbc_k_uL":3.9,"platelets_k_uL":167,"creatinine_mg_dL":1.3,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_1265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":82,"sex":"female","bmi":18.6,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-11-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-45},"pfs_months":9.69},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":15.6,"censored":false},"longitudinal_labs":[{"date":"2022-10-26","hemoglobin_g_dL":13.7,"wbc_k_uL":5.9,"platelets_k_uL":349,"creatinine_mg_dL":1.29,"alt_U_L":18},{"date":"2023-05-08","hemoglobin_g_dL":11.3,"wbc_k_uL":7.7,"platelets_k_uL":146,"creatinine_mg_dL":1.08,"alt_U_L":42},{"date":"2023-10-24","hemoglobin_g_dL":12.2,"wbc_k_uL":6.7,"platelets_k_uL":101,"creatinine_mg_dL":1.66,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_1266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":57,"sex":"female","bmi":22.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-39},"pfs_months":16.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.4,"censored":false},"longitudinal_labs":[{"date":"2025-08-16","hemoglobin_g_dL":14.3,"wbc_k_uL":5.7,"platelets_k_uL":212,"creatinine_mg_dL":0.62,"alt_U_L":16},{"date":"2026-02-26","hemoglobin_g_dL":13.6,"wbc_k_uL":8.8,"platelets_k_uL":267,"creatinine_mg_dL":1.55,"alt_U_L":31},{"date":"2027-02-17","hemoglobin_g_dL":10.2,"wbc_k_uL":4.1,"platelets_k_uL":259,"creatinine_mg_dL":1.76,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_1267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":84,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-68},"pfs_months":29.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":false},"longitudinal_labs":[{"date":"2022-06-01","hemoglobin_g_dL":12.4,"wbc_k_uL":7.8,"platelets_k_uL":393,"creatinine_mg_dL":1.26,"alt_U_L":30},{"date":"2022-12-14","hemoglobin_g_dL":13.0,"wbc_k_uL":7.9,"platelets_k_uL":136,"creatinine_mg_dL":1.53,"alt_U_L":74},{"date":"2024-12-29","hemoglobin_g_dL":13.0,"wbc_k_uL":7.9,"platelets_k_uL":199,"creatinine_mg_dL":1.62,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_1268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":49,"sex":"female","bmi":22.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-49},"pfs_months":9.92},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.6,"censored":true},"longitudinal_labs":[{"date":"2025-07-03","hemoglobin_g_dL":11.7,"wbc_k_uL":6.5,"platelets_k_uL":223,"creatinine_mg_dL":1.08,"alt_U_L":28},{"date":"2026-02-07","hemoglobin_g_dL":10.1,"wbc_k_uL":7.4,"platelets_k_uL":362,"creatinine_mg_dL":1.13,"alt_U_L":74},{"date":"2026-08-02","hemoglobin_g_dL":11.5,"wbc_k_uL":5.8,"platelets_k_uL":193,"creatinine_mg_dL":1.0,"alt_U_L":145}]}
{"patient_id":"ANODE_SYNTH_2025_1269","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":84,"sex":"female","bmi":28.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-46},"pfs_months":20.93},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.6,"censored":false},"longitudinal_labs":[{"date":"2023-02-15","hemoglobin_g_dL":11.6,"wbc_k_uL":6.6,"platelets_k_uL":173,"creatinine_mg_dL":1.01,"alt_U_L":55},{"date":"2023-09-29","hemoglobin_g_dL":12.6,"wbc_k_uL":5.1,"platelets_k_uL":196,"creatinine_mg_dL":1.51,"alt_U_L":99},{"date":"2025-02-12","hemoglobin_g_dL":12.4,"wbc_k_uL":5.5,"platelets_k_uL":321,"creatinine_mg_dL":1.49,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_1270","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":80,"sex":"female","bmi":27.7,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-08-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-49},"pfs_months":32.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.8,"censored":false},"longitudinal_labs":[{"date":"2022-06-13","hemoglobin_g_dL":13.6,"wbc_k_uL":6.8,"platelets_k_uL":391,"creatinine_mg_dL":1.27,"alt_U_L":55},{"date":"2023-02-01","hemoglobin_g_dL":10.6,"wbc_k_uL":8.9,"platelets_k_uL":235,"creatinine_mg_dL":1.41,"alt_U_L":72},{"date":"2025-06-08","hemoglobin_g_dL":12.9,"wbc_k_uL":5.3,"platelets_k_uL":205,"creatinine_mg_dL":0.85,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_1271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":85,"sex":"male","bmi":30.3,"smoking_pack_years":28,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-07-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-79},"pfs_months":42.84},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.6,"censored":true},"longitudinal_labs":[{"date":"2024-06-25","hemoglobin_g_dL":13.4,"wbc_k_uL":5.8,"platelets_k_uL":297,"creatinine_mg_dL":0.99,"alt_U_L":20},{"date":"2025-01-17","hemoglobin_g_dL":13.7,"wbc_k_uL":8.0,"platelets_k_uL":190,"creatinine_mg_dL":1.09,"alt_U_L":24},{"date":"2028-04-01","hemoglobin_g_dL":12.5,"wbc_k_uL":5.2,"platelets_k_uL":165,"creatinine_mg_dL":1.71,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_1272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":66,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-39},"pfs_months":20.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.6,"censored":true},"longitudinal_labs":[{"date":"2024-12-10","hemoglobin_g_dL":11.9,"wbc_k_uL":10.1,"platelets_k_uL":431,"creatinine_mg_dL":0.61,"alt_U_L":64},{"date":"2025-08-03","hemoglobin_g_dL":13.4,"wbc_k_uL":7.3,"platelets_k_uL":366,"creatinine_mg_dL":1.19,"alt_U_L":39},{"date":"2026-10-29","hemoglobin_g_dL":11.4,"wbc_k_uL":3.7,"platelets_k_uL":298,"creatinine_mg_dL":1.9,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_1273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":79,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-12-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-42},"pfs_months":24.54},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.8,"censored":false},"longitudinal_labs":[{"date":"2021-11-22","hemoglobin_g_dL":11.9,"wbc_k_uL":10.9,"platelets_k_uL":273,"creatinine_mg_dL":0.94,"alt_U_L":12},{"date":"2022-06-08","hemoglobin_g_dL":12.5,"wbc_k_uL":6.7,"platelets_k_uL":347,"creatinine_mg_dL":0.88,"alt_U_L":100},{"date":"2024-01-11","hemoglobin_g_dL":10.2,"wbc_k_uL":6.9,"platelets_k_uL":328,"creatinine_mg_dL":1.12,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_1274","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":82,"sex":"female","bmi":37.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-37},"pfs_months":30.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":52.0,"censored":false},"longitudinal_labs":[{"date":"2021-01-28","hemoglobin_g_dL":15.4,"wbc_k_uL":6.4,"platelets_k_uL":253,"creatinine_mg_dL":1.18,"alt_U_L":75},{"date":"2021-09-18","hemoglobin_g_dL":13.7,"wbc_k_uL":7.4,"platelets_k_uL":262,"creatinine_mg_dL":0.9,"alt_U_L":86},{"date":"2023-10-28","hemoglobin_g_dL":11.2,"wbc_k_uL":3.5,"platelets_k_uL":188,"creatinine_mg_dL":1.3,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_1275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":77,"sex":"female","bmi":19.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-75},"pfs_months":23.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.5,"censored":false},"longitudinal_labs":[{"date":"2022-02-24","hemoglobin_g_dL":13.1,"wbc_k_uL":7.8,"platelets_k_uL":403,"creatinine_mg_dL":0.94,"alt_U_L":69},{"date":"2022-10-19","hemoglobin_g_dL":13.1,"wbc_k_uL":4.0,"platelets_k_uL":143,"creatinine_mg_dL":1.53,"alt_U_L":22},{"date":"2024-06-03","hemoglobin_g_dL":12.5,"wbc_k_uL":5.9,"platelets_k_uL":251,"creatinine_mg_dL":1.48,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_1276","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":83,"sex":"female","bmi":37.0,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-44},"pfs_months":18.37},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":true},"longitudinal_labs":[{"date":"2022-04-21","hemoglobin_g_dL":14.3,"wbc_k_uL":6.0,"platelets_k_uL":170,"creatinine_mg_dL":0.75,"alt_U_L":69},{"date":"2022-11-30","hemoglobin_g_dL":11.6,"wbc_k_uL":5.2,"platelets_k_uL":266,"creatinine_mg_dL":1.26,"alt_U_L":101},{"date":"2024-02-11","hemoglobin_g_dL":10.3,"wbc_k_uL":6.4,"platelets_k_uL":312,"creatinine_mg_dL":1.03,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_1277","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":18.0,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":68,"sex":"female","bmi":20.7,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-01-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-53},"pfs_months":27.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":45.5,"censored":false},"longitudinal_labs":[{"date":"2025-11-18","hemoglobin_g_dL":13.0,"wbc_k_uL":6.1,"platelets_k_uL":213,"creatinine_mg_dL":1.06,"alt_U_L":54},{"date":"2026-07-19","hemoglobin_g_dL":13.8,"wbc_k_uL":5.0,"platelets_k_uL":168,"creatinine_mg_dL":0.71,"alt_U_L":26},{"date":"2028-06-06","hemoglobin_g_dL":11.0,"wbc_k_uL":6.2,"platelets_k_uL":116,"creatinine_mg_dL":1.66,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_1278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":70,"sex":"female","bmi":31.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-52},"pfs_months":18.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.9,"censored":false},"longitudinal_labs":[{"date":"2024-08-12","hemoglobin_g_dL":14.7,"wbc_k_uL":8.9,"platelets_k_uL":205,"creatinine_mg_dL":1.15,"alt_U_L":45},{"date":"2025-02-27","hemoglobin_g_dL":12.6,"wbc_k_uL":7.9,"platelets_k_uL":195,"creatinine_mg_dL":1.56,"alt_U_L":89},{"date":"2026-05-01","hemoglobin_g_dL":9.7,"wbc_k_uL":4.0,"platelets_k_uL":265,"creatinine_mg_dL":1.89,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_1279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":68,"sex":"female","bmi":25.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-44},"pfs_months":18.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":true},"longitudinal_labs":[{"date":"2024-05-12","hemoglobin_g_dL":12.0,"wbc_k_uL":5.4,"platelets_k_uL":441,"creatinine_mg_dL":1.01,"alt_U_L":74},{"date":"2025-01-17","hemoglobin_g_dL":11.0,"wbc_k_uL":6.5,"platelets_k_uL":125,"creatinine_mg_dL":1.23,"alt_U_L":92},{"date":"2026-03-27","hemoglobin_g_dL":12.4,"wbc_k_uL":3.9,"platelets_k_uL":258,"creatinine_mg_dL":1.33,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_1280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":75,"sex":"male","bmi":35.2,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-11-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-55},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":15.4,"censored":true},"longitudinal_labs":[{"date":"2024-10-19","hemoglobin_g_dL":12.4,"wbc_k_uL":6.2,"platelets_k_uL":226,"creatinine_mg_dL":1.03,"alt_U_L":69},{"date":"2025-05-28","hemoglobin_g_dL":12.9,"wbc_k_uL":7.5,"platelets_k_uL":183,"creatinine_mg_dL":1.26,"alt_U_L":62},{"date":"2025-04-27","hemoglobin_g_dL":12.1,"wbc_k_uL":5.3,"platelets_k_uL":265,"creatinine_mg_dL":1.77,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_1281","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":82,"sex":"female","bmi":30.0,"smoking_pack_years":26,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-01-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-43},"pfs_months":19.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.7,"censored":true},"longitudinal_labs":[{"date":"2022-12-15","hemoglobin_g_dL":13.7,"wbc_k_uL":8.4,"platelets_k_uL":416,"creatinine_mg_dL":0.87,"alt_U_L":24},{"date":"2023-07-20","hemoglobin_g_dL":11.8,"wbc_k_uL":5.3,"platelets_k_uL":259,"creatinine_mg_dL":1.59,"alt_U_L":97},{"date":"2024-10-03","hemoglobin_g_dL":12.7,"wbc_k_uL":5.4,"platelets_k_uL":339,"creatinine_mg_dL":1.33,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_1282","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":63,"sex":"female","bmi":36.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-50},"pfs_months":19.75},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.0,"censored":false},"longitudinal_labs":[{"date":"2023-05-14","hemoglobin_g_dL":11.9,"wbc_k_uL":10.1,"platelets_k_uL":185,"creatinine_mg_dL":1.07,"alt_U_L":22},{"date":"2024-01-14","hemoglobin_g_dL":12.3,"wbc_k_uL":8.8,"platelets_k_uL":278,"creatinine_mg_dL":1.13,"alt_U_L":51},{"date":"2025-04-26","hemoglobin_g_dL":10.6,"wbc_k_uL":3.4,"platelets_k_uL":230,"creatinine_mg_dL":1.29,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_1283","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":72,"sex":"female","bmi":34.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-65},"pfs_months":24.05},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":true},"longitudinal_labs":[{"date":"2023-06-20","hemoglobin_g_dL":14.4,"wbc_k_uL":9.3,"platelets_k_uL":378,"creatinine_mg_dL":0.84,"alt_U_L":77},{"date":"2024-01-05","hemoglobin_g_dL":12.7,"wbc_k_uL":4.3,"platelets_k_uL":219,"creatinine_mg_dL":1.24,"alt_U_L":67},{"date":"2025-07-20","hemoglobin_g_dL":10.8,"wbc_k_uL":6.8,"platelets_k_uL":285,"creatinine_mg_dL":1.39,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_1284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":62,"sex":"female","bmi":35.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-83},"pfs_months":22.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.5,"censored":false},"longitudinal_labs":[{"date":"2022-04-18","hemoglobin_g_dL":14.2,"wbc_k_uL":4.9,"platelets_k_uL":220,"creatinine_mg_dL":0.63,"alt_U_L":43},{"date":"2022-11-25","hemoglobin_g_dL":12.0,"wbc_k_uL":6.8,"platelets_k_uL":126,"creatinine_mg_dL":0.97,"alt_U_L":88},{"date":"2024-05-20","hemoglobin_g_dL":12.4,"wbc_k_uL":4.4,"platelets_k_uL":159,"creatinine_mg_dL":1.88,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_1285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":60,"sex":"female","bmi":21.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-85},"pfs_months":27.56},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.0,"censored":true},"longitudinal_labs":[{"date":"2025-03-15","hemoglobin_g_dL":13.4,"wbc_k_uL":8.5,"platelets_k_uL":397,"creatinine_mg_dL":0.79,"alt_U_L":40},{"date":"2025-10-11","hemoglobin_g_dL":11.0,"wbc_k_uL":7.2,"platelets_k_uL":245,"creatinine_mg_dL":1.44,"alt_U_L":103},{"date":"2027-09-05","hemoglobin_g_dL":12.0,"wbc_k_uL":8.0,"platelets_k_uL":161,"creatinine_mg_dL":1.04,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_1286","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":72,"sex":"female","bmi":24.7,"smoking_pack_years":59,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-03-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-49},"pfs_months":18.04},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.7,"censored":false},"longitudinal_labs":[{"date":"2024-02-12","hemoglobin_g_dL":14.6,"wbc_k_uL":8.2,"platelets_k_uL":253,"creatinine_mg_dL":1.23,"alt_U_L":48},{"date":"2024-09-26","hemoglobin_g_dL":13.1,"wbc_k_uL":8.3,"platelets_k_uL":164,"creatinine_mg_dL":0.88,"alt_U_L":30},{"date":"2025-11-20","hemoglobin_g_dL":9.6,"wbc_k_uL":3.7,"platelets_k_uL":205,"creatinine_mg_dL":0.8,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_1287","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":66,"sex":"male","bmi":22.8,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-02-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-37},"pfs_months":7.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":11.7,"censored":false},"longitudinal_labs":[{"date":"2023-01-06","hemoglobin_g_dL":11.8,"wbc_k_uL":7.4,"platelets_k_uL":393,"creatinine_mg_dL":0.71,"alt_U_L":47},{"date":"2023-08-11","hemoglobin_g_dL":11.2,"wbc_k_uL":4.9,"platelets_k_uL":147,"creatinine_mg_dL":1.19,"alt_U_L":109},{"date":"2023-10-19","hemoglobin_g_dL":12.0,"wbc_k_uL":3.7,"platelets_k_uL":212,"creatinine_mg_dL":1.92,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_1288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":80,"sex":"female","bmi":29.9,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-70},"pfs_months":12.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.6,"censored":false},"longitudinal_labs":[{"date":"2024-11-20","hemoglobin_g_dL":13.9,"wbc_k_uL":9.1,"platelets_k_uL":222,"creatinine_mg_dL":1.22,"alt_U_L":56},{"date":"2025-07-17","hemoglobin_g_dL":10.1,"wbc_k_uL":7.5,"platelets_k_uL":371,"creatinine_mg_dL":1.19,"alt_U_L":58},{"date":"2026-03-25","hemoglobin_g_dL":11.6,"wbc_k_uL":6.6,"platelets_k_uL":110,"creatinine_mg_dL":1.86,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_1289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":64,"sex":"female","bmi":28.0,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-08-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-73},"pfs_months":11.3},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":16.1,"censored":false},"longitudinal_labs":[{"date":"2021-07-24","hemoglobin_g_dL":11.8,"wbc_k_uL":9.9,"platelets_k_uL":306,"creatinine_mg_dL":1.17,"alt_U_L":36},{"date":"2022-02-03","hemoglobin_g_dL":12.0,"wbc_k_uL":7.8,"platelets_k_uL":340,"creatinine_mg_dL":1.54,"alt_U_L":63},{"date":"2022-07-29","hemoglobin_g_dL":10.5,"wbc_k_uL":5.4,"platelets_k_uL":323,"creatinine_mg_dL":1.65,"alt_U_L":112}]}
{"patient_id":"ANODE_SYNTH_2025_1290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":81,"sex":"female","bmi":22.4,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-02-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-69},"pfs_months":22.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.9,"censored":true},"longitudinal_labs":[{"date":"2023-11-26","hemoglobin_g_dL":15.2,"wbc_k_uL":5.0,"platelets_k_uL":286,"creatinine_mg_dL":0.62,"alt_U_L":40},{"date":"2024-07-30","hemoglobin_g_dL":12.9,"wbc_k_uL":6.4,"platelets_k_uL":263,"creatinine_mg_dL":1.26,"alt_U_L":28},{"date":"2025-12-25","hemoglobin_g_dL":11.3,"wbc_k_uL":3.3,"platelets_k_uL":257,"creatinine_mg_dL":1.35,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_1291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":66,"sex":"female","bmi":31.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-07-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-38},"pfs_months":18.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":false},"longitudinal_labs":[{"date":"2021-06-03","hemoglobin_g_dL":13.3,"wbc_k_uL":6.0,"platelets_k_uL":332,"creatinine_mg_dL":1.17,"alt_U_L":73},{"date":"2022-01-06","hemoglobin_g_dL":11.2,"wbc_k_uL":4.6,"platelets_k_uL":186,"creatinine_mg_dL":1.26,"alt_U_L":78},{"date":"2023-03-26","hemoglobin_g_dL":9.7,"wbc_k_uL":5.8,"platelets_k_uL":148,"creatinine_mg_dL":1.77,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_1292","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":53,"sex":"female","bmi":21.2,"smoking_pack_years":41,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-02-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-79},"pfs_months":16.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":20.6,"censored":false},"longitudinal_labs":[{"date":"2022-02-03","hemoglobin_g_dL":14.6,"wbc_k_uL":9.2,"platelets_k_uL":352,"creatinine_mg_dL":1.3,"alt_U_L":80},{"date":"2022-08-16","hemoglobin_g_dL":13.4,"wbc_k_uL":7.9,"platelets_k_uL":344,"creatinine_mg_dL":1.59,"alt_U_L":20},{"date":"2023-07-29","hemoglobin_g_dL":12.6,"wbc_k_uL":5.8,"platelets_k_uL":293,"creatinine_mg_dL":1.06,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_1293","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":65,"sex":"male","bmi":21.5,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-51},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":9.6,"censored":true},"longitudinal_labs":[{"date":"2023-07-03","hemoglobin_g_dL":11.5,"wbc_k_uL":5.8,"platelets_k_uL":324,"creatinine_mg_dL":0.9,"alt_U_L":40},{"date":"2024-01-19","hemoglobin_g_dL":10.9,"wbc_k_uL":7.3,"platelets_k_uL":367,"creatinine_mg_dL":0.83,"alt_U_L":42},{"date":"2023-11-23","hemoglobin_g_dL":10.2,"wbc_k_uL":4.4,"platelets_k_uL":107,"creatinine_mg_dL":1.51,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_1294","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":49,"sex":"male","bmi":30.8,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-84},"pfs_months":4.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":8.2,"censored":true},"longitudinal_labs":[{"date":"2024-03-19","hemoglobin_g_dL":13.6,"wbc_k_uL":10.1,"platelets_k_uL":444,"creatinine_mg_dL":0.78,"alt_U_L":23},{"date":"2024-10-17","hemoglobin_g_dL":11.8,"wbc_k_uL":5.4,"platelets_k_uL":295,"creatinine_mg_dL":1.25,"alt_U_L":42},{"date":"2024-10-17","hemoglobin_g_dL":12.5,"wbc_k_uL":3.5,"platelets_k_uL":131,"creatinine_mg_dL":1.27,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_1295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":70,"sex":"female","bmi":25.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-77},"pfs_months":23.52},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.9,"censored":false},"longitudinal_labs":[{"date":"2025-01-21","hemoglobin_g_dL":13.3,"wbc_k_uL":4.5,"platelets_k_uL":367,"creatinine_mg_dL":0.9,"alt_U_L":67},{"date":"2025-09-10","hemoglobin_g_dL":10.4,"wbc_k_uL":7.4,"platelets_k_uL":367,"creatinine_mg_dL":0.85,"alt_U_L":93},{"date":"2027-04-08","hemoglobin_g_dL":12.4,"wbc_k_uL":5.7,"platelets_k_uL":181,"creatinine_mg_dL":1.65,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_1296","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":53,"sex":"male","bmi":23.0,"smoking_pack_years":42,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-11-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-43},"pfs_months":30.09},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.0,"censored":false},"longitudinal_labs":[{"date":"2024-09-24","hemoglobin_g_dL":13.2,"wbc_k_uL":4.7,"platelets_k_uL":278,"creatinine_mg_dL":1.25,"alt_U_L":53},{"date":"2025-05-21","hemoglobin_g_dL":13.2,"wbc_k_uL":5.2,"platelets_k_uL":227,"creatinine_mg_dL":1.51,"alt_U_L":25},{"date":"2027-06-14","hemoglobin_g_dL":9.6,"wbc_k_uL":7.7,"platelets_k_uL":149,"creatinine_mg_dL":1.16,"alt_U_L":28}]}
{"patient_id":"ANODE_SYNTH_2025_1297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":49,"sex":"female","bmi":19.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-47},"pfs_months":22.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.3,"censored":false},"longitudinal_labs":[{"date":"2020-03-27","hemoglobin_g_dL":14.1,"wbc_k_uL":8.8,"platelets_k_uL":150,"creatinine_mg_dL":0.87,"alt_U_L":28},{"date":"2020-11-05","hemoglobin_g_dL":10.7,"wbc_k_uL":5.2,"platelets_k_uL":313,"creatinine_mg_dL":1.27,"alt_U_L":104},{"date":"2022-04-06","hemoglobin_g_dL":11.9,"wbc_k_uL":7.0,"platelets_k_uL":101,"creatinine_mg_dL":1.69,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_1298","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":85,"sex":"female","bmi":24.0,"smoking_pack_years":53,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-42},"pfs_months":36.37},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.1,"censored":false},"longitudinal_labs":[{"date":"2021-03-22","hemoglobin_g_dL":12.9,"wbc_k_uL":7.1,"platelets_k_uL":339,"creatinine_mg_dL":0.89,"alt_U_L":11},{"date":"2021-11-03","hemoglobin_g_dL":11.4,"wbc_k_uL":4.1,"platelets_k_uL":307,"creatinine_mg_dL":1.28,"alt_U_L":79},{"date":"2024-06-03","hemoglobin_g_dL":12.2,"wbc_k_uL":7.8,"platelets_k_uL":123,"creatinine_mg_dL":1.47,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_1299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":71,"sex":"female","bmi":35.9,"smoking_pack_years":59,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-82},"pfs_months":33.35},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":70.2,"censored":false},"longitudinal_labs":[{"date":"2021-09-22","hemoglobin_g_dL":14.8,"wbc_k_uL":5.2,"platelets_k_uL":229,"creatinine_mg_dL":1.09,"alt_U_L":45},{"date":"2022-05-15","hemoglobin_g_dL":11.5,"wbc_k_uL":4.1,"platelets_k_uL":319,"creatinine_mg_dL":0.87,"alt_U_L":29},{"date":"2024-09-04","hemoglobin_g_dL":12.2,"wbc_k_uL":3.2,"platelets_k_uL":344,"creatinine_mg_dL":1.95,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_1300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":74,"sex":"male","bmi":26.6,"smoking_pack_years":22,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-03-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-45},"pfs_months":37.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":55.0,"censored":false},"longitudinal_labs":[{"date":"2023-02-04","hemoglobin_g_dL":12.0,"wbc_k_uL":5.2,"platelets_k_uL":361,"creatinine_mg_dL":0.92,"alt_U_L":48},{"date":"2023-09-06","hemoglobin_g_dL":13.6,"wbc_k_uL":7.8,"platelets_k_uL":223,"creatinine_mg_dL":0.84,"alt_U_L":42},{"date":"2026-05-12","hemoglobin_g_dL":12.3,"wbc_k_uL":3.8,"platelets_k_uL":266,"creatinine_mg_dL":1.82,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_1301","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":77,"sex":"female","bmi":20.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-53},"pfs_months":14.46},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.0,"censored":false},"longitudinal_labs":[{"date":"2020-07-01","hemoglobin_g_dL":15.1,"wbc_k_uL":6.7,"platelets_k_uL":196,"creatinine_mg_dL":0.66,"alt_U_L":41},{"date":"2021-01-14","hemoglobin_g_dL":12.2,"wbc_k_uL":5.1,"platelets_k_uL":263,"creatinine_mg_dL":1.25,"alt_U_L":103},{"date":"2021-11-15","hemoglobin_g_dL":12.7,"wbc_k_uL":3.7,"platelets_k_uL":238,"creatinine_mg_dL":0.84,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_1302","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":64,"sex":"male","bmi":24.1,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-02-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-44},"pfs_months":14.88},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.7,"censored":false},"longitudinal_labs":[{"date":"2024-12-17","hemoglobin_g_dL":14.5,"wbc_k_uL":7.1,"platelets_k_uL":316,"creatinine_mg_dL":1.1,"alt_U_L":13},{"date":"2025-08-18","hemoglobin_g_dL":13.9,"wbc_k_uL":7.7,"platelets_k_uL":127,"creatinine_mg_dL":1.29,"alt_U_L":69},{"date":"2026-05-26","hemoglobin_g_dL":9.8,"wbc_k_uL":4.6,"platelets_k_uL":326,"creatinine_mg_dL":1.61,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_1303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":82,"sex":"female","bmi":19.0,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-09-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-50},"pfs_months":19.78},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.7,"censored":false},"longitudinal_labs":[{"date":"2024-07-01","hemoglobin_g_dL":12.3,"wbc_k_uL":10.9,"platelets_k_uL":302,"creatinine_mg_dL":0.95,"alt_U_L":14},{"date":"2025-03-08","hemoglobin_g_dL":11.8,"wbc_k_uL":7.0,"platelets_k_uL":186,"creatinine_mg_dL":0.89,"alt_U_L":26},{"date":"2026-07-02","hemoglobin_g_dL":11.7,"wbc_k_uL":5.4,"platelets_k_uL":184,"creatinine_mg_dL":1.34,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_1304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":53,"sex":"male","bmi":28.7,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-05-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-30},"pfs_months":12.22},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.4,"censored":true},"longitudinal_labs":[{"date":"2024-03-25","hemoglobin_g_dL":13.6,"wbc_k_uL":7.8,"platelets_k_uL":369,"creatinine_mg_dL":0.84,"alt_U_L":75},{"date":"2024-10-31","hemoglobin_g_dL":10.5,"wbc_k_uL":4.2,"platelets_k_uL":219,"creatinine_mg_dL":1.23,"alt_U_L":81},{"date":"2025-06-27","hemoglobin_g_dL":12.4,"wbc_k_uL":5.9,"platelets_k_uL":239,"creatinine_mg_dL":1.34,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_1305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":84,"sex":"female","bmi":21.5,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-06-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-49},"pfs_months":10.84},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":14.9,"censored":false},"longitudinal_labs":[{"date":"2021-04-18","hemoglobin_g_dL":15.4,"wbc_k_uL":6.7,"platelets_k_uL":239,"creatinine_mg_dL":0.75,"alt_U_L":36},{"date":"2021-12-18","hemoglobin_g_dL":12.4,"wbc_k_uL":5.9,"platelets_k_uL":137,"creatinine_mg_dL":1.11,"alt_U_L":38},{"date":"2022-06-03","hemoglobin_g_dL":11.1,"wbc_k_uL":6.0,"platelets_k_uL":240,"creatinine_mg_dL":0.93,"alt_U_L":71}]}
{"patient_id":"ANODE_SYNTH_2025_1306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":87,"sex":"female","bmi":23.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-67},"pfs_months":22.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.5,"censored":true},"longitudinal_labs":[{"date":"2020-09-03","hemoglobin_g_dL":12.4,"wbc_k_uL":4.9,"platelets_k_uL":234,"creatinine_mg_dL":0.79,"alt_U_L":49},{"date":"2021-05-10","hemoglobin_g_dL":12.2,"wbc_k_uL":8.1,"platelets_k_uL":258,"creatinine_mg_dL":0.9,"alt_U_L":116},{"date":"2022-11-07","hemoglobin_g_dL":12.5,"wbc_k_uL":3.2,"platelets_k_uL":110,"creatinine_mg_dL":1.49,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_1307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":77,"sex":"male","bmi":23.1,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-07-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-76},"pfs_months":3.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":9.3,"censored":true},"longitudinal_labs":[{"date":"2024-05-17","hemoglobin_g_dL":15.2,"wbc_k_uL":5.1,"platelets_k_uL":365,"creatinine_mg_dL":0.84,"alt_U_L":37},{"date":"2024-12-29","hemoglobin_g_dL":12.7,"wbc_k_uL":5.6,"platelets_k_uL":194,"creatinine_mg_dL":1.2,"alt_U_L":91},{"date":"2024-11-16","hemoglobin_g_dL":11.0,"wbc_k_uL":4.9,"platelets_k_uL":335,"creatinine_mg_dL":1.95,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_1308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":65,"sex":"female","bmi":29.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-40},"pfs_months":31.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.2,"censored":false},"longitudinal_labs":[{"date":"2025-08-15","hemoglobin_g_dL":14.8,"wbc_k_uL":10.0,"platelets_k_uL":193,"creatinine_mg_dL":1.07,"alt_U_L":22},{"date":"2026-03-11","hemoglobin_g_dL":10.8,"wbc_k_uL":4.3,"platelets_k_uL":205,"creatinine_mg_dL":0.75,"alt_U_L":57},{"date":"2028-06-24","hemoglobin_g_dL":10.1,"wbc_k_uL":5.2,"platelets_k_uL":165,"creatinine_mg_dL":1.64,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_1309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":77,"sex":"female","bmi":23.7,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-12-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-57},"pfs_months":13.17},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-18","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.6,"censored":false},"longitudinal_labs":[{"date":"2021-10-10","hemoglobin_g_dL":14.4,"wbc_k_uL":9.9,"platelets_k_uL":251,"creatinine_mg_dL":0.72,"alt_U_L":31},{"date":"2022-06-09","hemoglobin_g_dL":11.1,"wbc_k_uL":7.0,"platelets_k_uL":222,"creatinine_mg_dL":0.76,"alt_U_L":24},{"date":"2023-02-18","hemoglobin_g_dL":11.9,"wbc_k_uL":5.8,"platelets_k_uL":191,"creatinine_mg_dL":1.65,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_1310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":84,"sex":"female","bmi":22.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-35},"pfs_months":20.17},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.3,"censored":false},"longitudinal_labs":[{"date":"2022-02-16","hemoglobin_g_dL":11.8,"wbc_k_uL":6.1,"platelets_k_uL":320,"creatinine_mg_dL":0.76,"alt_U_L":10},{"date":"2022-09-26","hemoglobin_g_dL":12.7,"wbc_k_uL":8.1,"platelets_k_uL":166,"creatinine_mg_dL":1.26,"alt_U_L":116},{"date":"2023-12-12","hemoglobin_g_dL":10.1,"wbc_k_uL":3.3,"platelets_k_uL":263,"creatinine_mg_dL":1.29,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_1311","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":56,"sex":"male","bmi":27.3,"smoking_pack_years":40,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-79},"pfs_months":26.97},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":false},"longitudinal_labs":[{"date":"2023-05-21","hemoglobin_g_dL":15.1,"wbc_k_uL":5.9,"platelets_k_uL":205,"creatinine_mg_dL":1.02,"alt_U_L":49},{"date":"2023-12-09","hemoglobin_g_dL":11.1,"wbc_k_uL":5.4,"platelets_k_uL":166,"creatinine_mg_dL":0.99,"alt_U_L":111},{"date":"2025-10-01","hemoglobin_g_dL":10.0,"wbc_k_uL":4.7,"platelets_k_uL":284,"creatinine_mg_dL":1.32,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_1312","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":84,"sex":"female","bmi":34.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-44},"pfs_months":20.8},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":30.3,"censored":false},"longitudinal_labs":[{"date":"2024-04-16","hemoglobin_g_dL":13.2,"wbc_k_uL":8.0,"platelets_k_uL":238,"creatinine_mg_dL":0.72,"alt_U_L":67},{"date":"2024-11-12","hemoglobin_g_dL":11.1,"wbc_k_uL":6.7,"platelets_k_uL":127,"creatinine_mg_dL":0.91,"alt_U_L":72},{"date":"2026-03-22","hemoglobin_g_dL":11.8,"wbc_k_uL":7.4,"platelets_k_uL":258,"creatinine_mg_dL":1.43,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_1313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":64,"sex":"male","bmi":35.7,"smoking_pack_years":60,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-05-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-62},"pfs_months":5.45},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":12.3,"censored":false},"longitudinal_labs":[{"date":"2023-03-21","hemoglobin_g_dL":12.4,"wbc_k_uL":8.5,"platelets_k_uL":201,"creatinine_mg_dL":0.79,"alt_U_L":75},{"date":"2023-11-24","hemoglobin_g_dL":13.8,"wbc_k_uL":5.8,"platelets_k_uL":351,"creatinine_mg_dL":1.02,"alt_U_L":78},{"date":"2023-11-22","hemoglobin_g_dL":10.8,"wbc_k_uL":4.5,"platelets_k_uL":151,"creatinine_mg_dL":1.52,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_1314","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":72,"sex":"female","bmi":22.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-31},"pfs_months":25.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":true},"longitudinal_labs":[{"date":"2021-08-06","hemoglobin_g_dL":13.5,"wbc_k_uL":7.6,"platelets_k_uL":248,"creatinine_mg_dL":1.08,"alt_U_L":11},{"date":"2022-02-16","hemoglobin_g_dL":12.3,"wbc_k_uL":4.7,"platelets_k_uL":341,"creatinine_mg_dL":1.41,"alt_U_L":79},{"date":"2023-12-02","hemoglobin_g_dL":12.0,"wbc_k_uL":4.7,"platelets_k_uL":320,"creatinine_mg_dL":1.38,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_1315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":58,"sex":"male","bmi":22.7,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-10-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-65},"pfs_months":35.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.3,"censored":true},"longitudinal_labs":[{"date":"2024-10-08","hemoglobin_g_dL":12.3,"wbc_k_uL":5.3,"platelets_k_uL":180,"creatinine_mg_dL":0.79,"alt_U_L":35},{"date":"2025-04-22","hemoglobin_g_dL":13.1,"wbc_k_uL":8.5,"platelets_k_uL":287,"creatinine_mg_dL":1.18,"alt_U_L":43},{"date":"2027-11-28","hemoglobin_g_dL":10.4,"wbc_k_uL":6.9,"platelets_k_uL":156,"creatinine_mg_dL":1.7,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_1316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":73,"sex":"female","bmi":29.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-56},"pfs_months":13.17},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.7,"censored":true},"longitudinal_labs":[{"date":"2025-06-05","hemoglobin_g_dL":11.9,"wbc_k_uL":9.8,"platelets_k_uL":444,"creatinine_mg_dL":0.86,"alt_U_L":28},{"date":"2026-01-12","hemoglobin_g_dL":11.4,"wbc_k_uL":4.6,"platelets_k_uL":303,"creatinine_mg_dL":1.25,"alt_U_L":44},{"date":"2026-10-08","hemoglobin_g_dL":10.9,"wbc_k_uL":4.2,"platelets_k_uL":329,"creatinine_mg_dL":1.89,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_1317","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":70,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-72},"pfs_months":27.53},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.8,"censored":false},"longitudinal_labs":[{"date":"2020-05-20","hemoglobin_g_dL":14.8,"wbc_k_uL":8.6,"platelets_k_uL":425,"creatinine_mg_dL":0.71,"alt_U_L":23},{"date":"2020-12-30","hemoglobin_g_dL":13.8,"wbc_k_uL":6.0,"platelets_k_uL":120,"creatinine_mg_dL":1.01,"alt_U_L":111},{"date":"2022-12-09","hemoglobin_g_dL":11.0,"wbc_k_uL":4.6,"platelets_k_uL":320,"creatinine_mg_dL":1.56,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_1318","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":88,"sex":"male","bmi":26.2,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-08-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-71},"pfs_months":20.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.1,"censored":false},"longitudinal_labs":[{"date":"2024-07-03","hemoglobin_g_dL":14.6,"wbc_k_uL":6.3,"platelets_k_uL":383,"creatinine_mg_dL":0.79,"alt_U_L":47},{"date":"2025-01-30","hemoglobin_g_dL":12.3,"wbc_k_uL":8.9,"platelets_k_uL":313,"creatinine_mg_dL":0.86,"alt_U_L":64},{"date":"2026-05-28","hemoglobin_g_dL":11.4,"wbc_k_uL":5.5,"platelets_k_uL":152,"creatinine_mg_dL":1.49,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_1319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":84,"sex":"male","bmi":26.4,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-56},"pfs_months":12.94},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.0,"censored":false},"longitudinal_labs":[{"date":"2020-10-05","hemoglobin_g_dL":12.7,"wbc_k_uL":9.0,"platelets_k_uL":179,"creatinine_mg_dL":0.99,"alt_U_L":61},{"date":"2021-05-17","hemoglobin_g_dL":13.9,"wbc_k_uL":4.5,"platelets_k_uL":273,"creatinine_mg_dL":1.25,"alt_U_L":39},{"date":"2022-01-24","hemoglobin_g_dL":9.5,"wbc_k_uL":6.4,"platelets_k_uL":339,"creatinine_mg_dL":1.63,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_1320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":80,"sex":"female","bmi":30.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-34},"pfs_months":15.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.4,"censored":true},"longitudinal_labs":[{"date":"2020-05-01","hemoglobin_g_dL":15.4,"wbc_k_uL":9.0,"platelets_k_uL":441,"creatinine_mg_dL":1.14,"alt_U_L":41},{"date":"2020-12-27","hemoglobin_g_dL":11.5,"wbc_k_uL":8.0,"platelets_k_uL":359,"creatinine_mg_dL":1.54,"alt_U_L":95},{"date":"2021-11-22","hemoglobin_g_dL":10.2,"wbc_k_uL":3.4,"platelets_k_uL":173,"creatinine_mg_dL":0.92,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_1321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.8,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":65,"sex":"male","bmi":35.9,"smoking_pack_years":75,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-07-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-57},"pfs_months":16.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":23.8,"censored":false},"longitudinal_labs":[{"date":"2022-05-02","hemoglobin_g_dL":14.2,"wbc_k_uL":8.1,"platelets_k_uL":201,"creatinine_mg_dL":0.75,"alt_U_L":11},{"date":"2023-01-04","hemoglobin_g_dL":13.2,"wbc_k_uL":8.8,"platelets_k_uL":230,"creatinine_mg_dL":1.14,"alt_U_L":42},{"date":"2024-01-03","hemoglobin_g_dL":10.6,"wbc_k_uL":6.0,"platelets_k_uL":218,"creatinine_mg_dL":1.09,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_1322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":67,"sex":"male","bmi":20.5,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-02-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-65},"pfs_months":7.92},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.8,"censored":true},"longitudinal_labs":[{"date":"2022-12-06","hemoglobin_g_dL":12.1,"wbc_k_uL":5.5,"platelets_k_uL":260,"creatinine_mg_dL":0.73,"alt_U_L":74},{"date":"2023-08-07","hemoglobin_g_dL":13.3,"wbc_k_uL":6.4,"platelets_k_uL":337,"creatinine_mg_dL":1.09,"alt_U_L":54},{"date":"2023-11-03","hemoglobin_g_dL":10.7,"wbc_k_uL":5.1,"platelets_k_uL":166,"creatinine_mg_dL":1.21,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_1323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":67,"sex":"female","bmi":22.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-39},"pfs_months":20.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.9,"censored":false},"longitudinal_labs":[{"date":"2022-02-21","hemoglobin_g_dL":13.8,"wbc_k_uL":5.3,"platelets_k_uL":280,"creatinine_mg_dL":0.83,"alt_U_L":67},{"date":"2022-09-15","hemoglobin_g_dL":13.8,"wbc_k_uL":8.0,"platelets_k_uL":207,"creatinine_mg_dL":1.37,"alt_U_L":59},{"date":"2023-12-12","hemoglobin_g_dL":10.0,"wbc_k_uL":4.0,"platelets_k_uL":346,"creatinine_mg_dL":1.95,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_1324","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":57,"sex":"female","bmi":35.8,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-05-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-60},"pfs_months":25.4},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.1,"censored":false},"longitudinal_labs":[{"date":"2022-04-11","hemoglobin_g_dL":15.0,"wbc_k_uL":5.5,"platelets_k_uL":327,"creatinine_mg_dL":0.64,"alt_U_L":37},{"date":"2022-11-22","hemoglobin_g_dL":13.3,"wbc_k_uL":6.0,"platelets_k_uL":121,"creatinine_mg_dL":1.4,"alt_U_L":102},{"date":"2024-08-11","hemoglobin_g_dL":11.4,"wbc_k_uL":3.0,"platelets_k_uL":218,"creatinine_mg_dL":0.92,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_1325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":64,"sex":"female","bmi":21.8,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-04-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-55},"pfs_months":36.14},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":68.3,"censored":false},"longitudinal_labs":[{"date":"2022-03-23","hemoglobin_g_dL":12.4,"wbc_k_uL":6.6,"platelets_k_uL":222,"creatinine_mg_dL":1.29,"alt_U_L":70},{"date":"2022-10-20","hemoglobin_g_dL":10.3,"wbc_k_uL":5.4,"platelets_k_uL":285,"creatinine_mg_dL":0.85,"alt_U_L":20},{"date":"2025-06-05","hemoglobin_g_dL":12.1,"wbc_k_uL":3.6,"platelets_k_uL":349,"creatinine_mg_dL":0.98,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_1326","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":76,"sex":"female","bmi":25.5,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-11-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-33},"pfs_months":47.93},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":72.4,"censored":false},"longitudinal_labs":[{"date":"2020-10-08","hemoglobin_g_dL":13.0,"wbc_k_uL":10.7,"platelets_k_uL":188,"creatinine_mg_dL":0.7,"alt_U_L":78},{"date":"2021-05-09","hemoglobin_g_dL":12.3,"wbc_k_uL":4.0,"platelets_k_uL":224,"creatinine_mg_dL":1.42,"alt_U_L":45},{"date":"2024-12-16","hemoglobin_g_dL":12.0,"wbc_k_uL":6.5,"platelets_k_uL":107,"creatinine_mg_dL":1.55,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_1327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":69,"sex":"female","bmi":29.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-37},"pfs_months":21.62},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":true},"longitudinal_labs":[{"date":"2024-08-20","hemoglobin_g_dL":12.2,"wbc_k_uL":10.3,"platelets_k_uL":218,"creatinine_mg_dL":0.65,"alt_U_L":65},{"date":"2025-04-07","hemoglobin_g_dL":13.3,"wbc_k_uL":5.4,"platelets_k_uL":123,"creatinine_mg_dL":1.19,"alt_U_L":93},{"date":"2026-08-22","hemoglobin_g_dL":12.1,"wbc_k_uL":5.9,"platelets_k_uL":154,"creatinine_mg_dL":1.26,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_1328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":67,"sex":"female","bmi":19.3,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-10-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-36},"pfs_months":47.97},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":73.7,"censored":false},"longitudinal_labs":[{"date":"2022-08-10","hemoglobin_g_dL":11.6,"wbc_k_uL":8.6,"platelets_k_uL":280,"creatinine_mg_dL":1.15,"alt_U_L":44},{"date":"2023-03-31","hemoglobin_g_dL":10.1,"wbc_k_uL":9.0,"platelets_k_uL":268,"creatinine_mg_dL":1.22,"alt_U_L":17},{"date":"2026-11-25","hemoglobin_g_dL":12.8,"wbc_k_uL":6.7,"platelets_k_uL":332,"creatinine_mg_dL":1.08,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_1329","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":63,"sex":"male","bmi":33.3,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-02-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-62},"pfs_months":18.76},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":false},"longitudinal_labs":[{"date":"2022-02-09","hemoglobin_g_dL":13.2,"wbc_k_uL":6.6,"platelets_k_uL":236,"creatinine_mg_dL":0.93,"alt_U_L":77},{"date":"2022-08-24","hemoglobin_g_dL":10.6,"wbc_k_uL":4.8,"platelets_k_uL":316,"creatinine_mg_dL":1.47,"alt_U_L":54},{"date":"2023-10-19","hemoglobin_g_dL":11.8,"wbc_k_uL":4.0,"platelets_k_uL":302,"creatinine_mg_dL":1.18,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_1330","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":87,"sex":"female","bmi":31.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-40},"pfs_months":22.41},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.6,"censored":true},"longitudinal_labs":[{"date":"2025-02-15","hemoglobin_g_dL":14.6,"wbc_k_uL":4.8,"platelets_k_uL":244,"creatinine_mg_dL":1.01,"alt_U_L":44},{"date":"2025-10-09","hemoglobin_g_dL":12.2,"wbc_k_uL":4.6,"platelets_k_uL":323,"creatinine_mg_dL":0.8,"alt_U_L":35},{"date":"2027-03-17","hemoglobin_g_dL":9.9,"wbc_k_uL":5.6,"platelets_k_uL":164,"creatinine_mg_dL":1.52,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_1331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":64,"sex":"male","bmi":36.9,"smoking_pack_years":62,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-05-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-42},"pfs_months":10.12},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":14.1,"censored":false},"longitudinal_labs":[{"date":"2023-03-20","hemoglobin_g_dL":11.9,"wbc_k_uL":4.6,"platelets_k_uL":344,"creatinine_mg_dL":0.9,"alt_U_L":38},{"date":"2023-11-08","hemoglobin_g_dL":11.5,"wbc_k_uL":4.9,"platelets_k_uL":257,"creatinine_mg_dL":0.8,"alt_U_L":104},{"date":"2024-04-06","hemoglobin_g_dL":10.5,"wbc_k_uL":5.7,"platelets_k_uL":301,"creatinine_mg_dL":1.39,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_1332","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":75,"sex":"female","bmi":23.3,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-06-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-35},"pfs_months":18.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.7,"censored":true},"longitudinal_labs":[{"date":"2024-05-20","hemoglobin_g_dL":15.3,"wbc_k_uL":7.1,"platelets_k_uL":248,"creatinine_mg_dL":0.93,"alt_U_L":64},{"date":"2024-12-04","hemoglobin_g_dL":11.2,"wbc_k_uL":8.2,"platelets_k_uL":322,"creatinine_mg_dL":1.08,"alt_U_L":110},{"date":"2026-01-29","hemoglobin_g_dL":9.7,"wbc_k_uL":4.3,"platelets_k_uL":170,"creatinine_mg_dL":1.09,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_1333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":58,"sex":"female","bmi":29.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-53},"pfs_months":30.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.1,"censored":true},"longitudinal_labs":[{"date":"2021-04-12","hemoglobin_g_dL":14.4,"wbc_k_uL":10.2,"platelets_k_uL":338,"creatinine_mg_dL":0.73,"alt_U_L":20},{"date":"2021-11-15","hemoglobin_g_dL":11.9,"wbc_k_uL":5.5,"platelets_k_uL":350,"creatinine_mg_dL":1.34,"alt_U_L":77},{"date":"2024-01-13","hemoglobin_g_dL":10.6,"wbc_k_uL":7.9,"platelets_k_uL":106,"creatinine_mg_dL":1.48,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_1334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":80,"sex":"male","bmi":37.3,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-02-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-48},"pfs_months":19.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":24.5,"censored":false},"longitudinal_labs":[{"date":"2023-01-01","hemoglobin_g_dL":14.1,"wbc_k_uL":7.2,"platelets_k_uL":411,"creatinine_mg_dL":1.29,"alt_U_L":41},{"date":"2023-08-20","hemoglobin_g_dL":10.3,"wbc_k_uL":5.5,"platelets_k_uL":153,"creatinine_mg_dL":1.6,"alt_U_L":76},{"date":"2024-11-29","hemoglobin_g_dL":11.3,"wbc_k_uL":3.8,"platelets_k_uL":133,"creatinine_mg_dL":1.26,"alt_U_L":58}]}
{"patient_id":"ANODE_SYNTH_2025_1335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":55,"sex":"female","bmi":34.6,"smoking_pack_years":11,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-43},"pfs_months":46.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-02-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":74.6,"censored":false},"longitudinal_labs":[{"date":"2025-01-12","hemoglobin_g_dL":13.2,"wbc_k_uL":10.9,"platelets_k_uL":210,"creatinine_mg_dL":1.29,"alt_U_L":55},{"date":"2025-08-18","hemoglobin_g_dL":13.4,"wbc_k_uL":5.8,"platelets_k_uL":273,"creatinine_mg_dL":0.88,"alt_U_L":92},{"date":"2029-02-16","hemoglobin_g_dL":12.3,"wbc_k_uL":3.1,"platelets_k_uL":291,"creatinine_mg_dL":1.28,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_1336","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":64,"sex":"male","bmi":34.1,"smoking_pack_years":35,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-06-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-70},"pfs_months":19.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.7,"censored":true},"longitudinal_labs":[{"date":"2020-04-22","hemoglobin_g_dL":15.3,"wbc_k_uL":4.9,"platelets_k_uL":350,"creatinine_mg_dL":0.77,"alt_U_L":27},{"date":"2020-12-02","hemoglobin_g_dL":13.0,"wbc_k_uL":6.2,"platelets_k_uL":340,"creatinine_mg_dL":1.37,"alt_U_L":102},{"date":"2022-02-27","hemoglobin_g_dL":10.3,"wbc_k_uL":4.2,"platelets_k_uL":332,"creatinine_mg_dL":1.86,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_1337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":56,"sex":"female","bmi":32.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-63},"pfs_months":28.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.0,"censored":false},"longitudinal_labs":[{"date":"2020-03-11","hemoglobin_g_dL":13.0,"wbc_k_uL":7.1,"platelets_k_uL":377,"creatinine_mg_dL":0.83,"alt_U_L":40},{"date":"2020-10-15","hemoglobin_g_dL":12.4,"wbc_k_uL":8.4,"platelets_k_uL":128,"creatinine_mg_dL":0.92,"alt_U_L":50},{"date":"2022-10-17","hemoglobin_g_dL":10.5,"wbc_k_uL":6.9,"platelets_k_uL":212,"creatinine_mg_dL":0.86,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_1338","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":87,"sex":"male","bmi":33.4,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-50},"pfs_months":16.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":false},"longitudinal_labs":[{"date":"2020-05-19","hemoglobin_g_dL":15.3,"wbc_k_uL":10.3,"platelets_k_uL":307,"creatinine_mg_dL":0.72,"alt_U_L":41},{"date":"2020-12-08","hemoglobin_g_dL":13.1,"wbc_k_uL":4.3,"platelets_k_uL":287,"creatinine_mg_dL":1.22,"alt_U_L":110},{"date":"2021-11-20","hemoglobin_g_dL":11.5,"wbc_k_uL":6.1,"platelets_k_uL":144,"creatinine_mg_dL":1.61,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_1339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":57,"sex":"female","bmi":25.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-64},"pfs_months":28.06},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":50.2,"censored":true},"longitudinal_labs":[{"date":"2023-11-19","hemoglobin_g_dL":14.6,"wbc_k_uL":10.1,"platelets_k_uL":347,"creatinine_mg_dL":0.61,"alt_U_L":46},{"date":"2024-07-07","hemoglobin_g_dL":11.1,"wbc_k_uL":6.2,"platelets_k_uL":213,"creatinine_mg_dL":1.38,"alt_U_L":107},{"date":"2026-06-08","hemoglobin_g_dL":10.0,"wbc_k_uL":5.3,"platelets_k_uL":121,"creatinine_mg_dL":1.35,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_1340","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":53,"sex":"female","bmi":30.1,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["liver","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-06-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-35},"pfs_months":22.31},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.9,"censored":false},"longitudinal_labs":[{"date":"2025-04-15","hemoglobin_g_dL":14.2,"wbc_k_uL":8.0,"platelets_k_uL":338,"creatinine_mg_dL":1.02,"alt_U_L":68},{"date":"2025-12-19","hemoglobin_g_dL":12.2,"wbc_k_uL":5.8,"platelets_k_uL":221,"creatinine_mg_dL":1.09,"alt_U_L":28},{"date":"2027-06-04","hemoglobin_g_dL":12.9,"wbc_k_uL":3.3,"platelets_k_uL":343,"creatinine_mg_dL":1.84,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_1341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":74,"sex":"female","bmi":26.2,"smoking_pack_years":62,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-03-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-50},"pfs_months":10.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.1,"censored":true},"longitudinal_labs":[{"date":"2025-02-25","hemoglobin_g_dL":12.1,"wbc_k_uL":7.1,"platelets_k_uL":419,"creatinine_mg_dL":1.29,"alt_U_L":68},{"date":"2025-09-09","hemoglobin_g_dL":11.4,"wbc_k_uL":4.2,"platelets_k_uL":368,"creatinine_mg_dL":0.83,"alt_U_L":15},{"date":"2026-03-12","hemoglobin_g_dL":12.6,"wbc_k_uL":5.2,"platelets_k_uL":293,"creatinine_mg_dL":1.94,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_1342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":84,"sex":"male","bmi":20.6,"smoking_pack_years":78,"ecog_performance_status":2,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-10-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-41},"pfs_months":9.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":23.3,"censored":false},"longitudinal_labs":[{"date":"2022-09-28","hemoglobin_g_dL":13.1,"wbc_k_uL":9.3,"platelets_k_uL":293,"creatinine_mg_dL":0.64,"alt_U_L":77},{"date":"2023-04-26","hemoglobin_g_dL":13.1,"wbc_k_uL":5.7,"platelets_k_uL":317,"creatinine_mg_dL":0.71,"alt_U_L":119},{"date":"2023-09-19","hemoglobin_g_dL":11.6,"wbc_k_uL":3.5,"platelets_k_uL":283,"creatinine_mg_dL":1.98,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_1343","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":70,"sex":"female","bmi":27.9,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-10-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-51},"pfs_months":21.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":28.0,"censored":false},"longitudinal_labs":[{"date":"2022-08-25","hemoglobin_g_dL":11.6,"wbc_k_uL":6.5,"platelets_k_uL":177,"creatinine_mg_dL":1.25,"alt_U_L":10},{"date":"2023-04-24","hemoglobin_g_dL":11.8,"wbc_k_uL":7.7,"platelets_k_uL":341,"creatinine_mg_dL":0.95,"alt_U_L":33},{"date":"2024-10-09","hemoglobin_g_dL":11.7,"wbc_k_uL":7.6,"platelets_k_uL":118,"creatinine_mg_dL":1.86,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_1344","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":59,"sex":"female","bmi":28.0,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-10-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-64},"pfs_months":26.18},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":false},"longitudinal_labs":[{"date":"2020-09-21","hemoglobin_g_dL":15.3,"wbc_k_uL":10.4,"platelets_k_uL":422,"creatinine_mg_dL":0.92,"alt_U_L":78},{"date":"2021-04-20","hemoglobin_g_dL":11.8,"wbc_k_uL":7.6,"platelets_k_uL":162,"creatinine_mg_dL":1.39,"alt_U_L":114},{"date":"2023-01-08","hemoglobin_g_dL":10.3,"wbc_k_uL":7.8,"platelets_k_uL":215,"creatinine_mg_dL":1.81,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_1345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":60,"sex":"male","bmi":28.4,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-06-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-45},"pfs_months":10.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.7,"censored":false},"longitudinal_labs":[{"date":"2023-04-19","hemoglobin_g_dL":15.3,"wbc_k_uL":8.4,"platelets_k_uL":322,"creatinine_mg_dL":1.05,"alt_U_L":77},{"date":"2023-12-16","hemoglobin_g_dL":10.9,"wbc_k_uL":8.5,"platelets_k_uL":138,"creatinine_mg_dL":1.2,"alt_U_L":65},{"date":"2024-06-16","hemoglobin_g_dL":9.8,"wbc_k_uL":6.8,"platelets_k_uL":324,"creatinine_mg_dL":1.52,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_1346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":60,"sex":"female","bmi":31.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-40},"pfs_months":29.11},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.6,"censored":false},"longitudinal_labs":[{"date":"2024-03-24","hemoglobin_g_dL":12.4,"wbc_k_uL":7.7,"platelets_k_uL":316,"creatinine_mg_dL":0.86,"alt_U_L":24},{"date":"2024-11-06","hemoglobin_g_dL":10.2,"wbc_k_uL":6.6,"platelets_k_uL":306,"creatinine_mg_dL":1.36,"alt_U_L":104},{"date":"2026-11-14","hemoglobin_g_dL":10.2,"wbc_k_uL":7.0,"platelets_k_uL":260,"creatinine_mg_dL":1.61,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_1347","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":81,"sex":"female","bmi":33.9,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-32},"pfs_months":32.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.1,"censored":true},"longitudinal_labs":[{"date":"2022-05-23","hemoglobin_g_dL":14.6,"wbc_k_uL":6.6,"platelets_k_uL":422,"creatinine_mg_dL":0.85,"alt_U_L":14},{"date":"2022-12-12","hemoglobin_g_dL":12.9,"wbc_k_uL":4.0,"platelets_k_uL":238,"creatinine_mg_dL":1.03,"alt_U_L":38},{"date":"2025-04-04","hemoglobin_g_dL":11.6,"wbc_k_uL":4.3,"platelets_k_uL":147,"creatinine_mg_dL":1.74,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_1348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":68,"sex":"female","bmi":21.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-60},"pfs_months":13.37},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":false},"longitudinal_labs":[{"date":"2021-05-13","hemoglobin_g_dL":14.4,"wbc_k_uL":8.1,"platelets_k_uL":342,"creatinine_mg_dL":1.06,"alt_U_L":28},{"date":"2021-11-27","hemoglobin_g_dL":12.1,"wbc_k_uL":6.1,"platelets_k_uL":163,"creatinine_mg_dL":0.71,"alt_U_L":101},{"date":"2022-08-09","hemoglobin_g_dL":11.3,"wbc_k_uL":6.0,"platelets_k_uL":101,"creatinine_mg_dL":1.3,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_1349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":84,"sex":"female","bmi":29.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-62},"pfs_months":14.23},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.1,"censored":true},"longitudinal_labs":[{"date":"2020-09-04","hemoglobin_g_dL":13.1,"wbc_k_uL":4.7,"platelets_k_uL":279,"creatinine_mg_dL":1.24,"alt_U_L":76},{"date":"2021-04-16","hemoglobin_g_dL":12.9,"wbc_k_uL":4.4,"platelets_k_uL":130,"creatinine_mg_dL":0.97,"alt_U_L":94},{"date":"2022-01-20","hemoglobin_g_dL":11.1,"wbc_k_uL":3.2,"platelets_k_uL":184,"creatinine_mg_dL":1.84,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_1350","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":86,"sex":"male","bmi":37.2,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-01-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-69},"pfs_months":27.07},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":47.4,"censored":true},"longitudinal_labs":[{"date":"2022-11-05","hemoglobin_g_dL":13.0,"wbc_k_uL":10.9,"platelets_k_uL":264,"creatinine_mg_dL":0.84,"alt_U_L":23},{"date":"2023-07-12","hemoglobin_g_dL":11.9,"wbc_k_uL":7.5,"platelets_k_uL":349,"creatinine_mg_dL":0.97,"alt_U_L":41},{"date":"2025-04-29","hemoglobin_g_dL":10.2,"wbc_k_uL":4.5,"platelets_k_uL":238,"creatinine_mg_dL":1.12,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_1351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":79,"sex":"female","bmi":20.1,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-12-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-57},"pfs_months":35.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":64.9,"censored":false},"longitudinal_labs":[{"date":"2023-11-13","hemoglobin_g_dL":12.9,"wbc_k_uL":7.0,"platelets_k_uL":371,"creatinine_mg_dL":0.87,"alt_U_L":12},{"date":"2024-05-30","hemoglobin_g_dL":10.6,"wbc_k_uL":4.6,"platelets_k_uL":359,"creatinine_mg_dL":1.02,"alt_U_L":59},{"date":"2026-11-14","hemoglobin_g_dL":11.8,"wbc_k_uL":4.0,"platelets_k_uL":275,"creatinine_mg_dL":0.83,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_1352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":80,"sex":"female","bmi":26.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-60},"pfs_months":22.74},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.3,"censored":true},"longitudinal_labs":[{"date":"2022-07-09","hemoglobin_g_dL":14.8,"wbc_k_uL":4.6,"platelets_k_uL":245,"creatinine_mg_dL":0.66,"alt_U_L":38},{"date":"2023-03-08","hemoglobin_g_dL":12.4,"wbc_k_uL":5.7,"platelets_k_uL":205,"creatinine_mg_dL":1.19,"alt_U_L":37},{"date":"2024-08-15","hemoglobin_g_dL":11.9,"wbc_k_uL":6.3,"platelets_k_uL":170,"creatinine_mg_dL":1.62,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_1353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":76,"sex":"female","bmi":20.8,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-57},"pfs_months":44.45},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-31","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":70.4,"censored":false},"longitudinal_labs":[{"date":"2021-04-13","hemoglobin_g_dL":14.5,"wbc_k_uL":6.0,"platelets_k_uL":290,"creatinine_mg_dL":0.77,"alt_U_L":70},{"date":"2021-11-25","hemoglobin_g_dL":13.1,"wbc_k_uL":5.1,"platelets_k_uL":136,"creatinine_mg_dL":1.28,"alt_U_L":33},{"date":"2025-03-31","hemoglobin_g_dL":10.8,"wbc_k_uL":5.4,"platelets_k_uL":302,"creatinine_mg_dL":1.01,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_1354","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":72,"sex":"male","bmi":29.1,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-03-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-40},"pfs_months":21.55},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.8,"censored":true},"longitudinal_labs":[{"date":"2023-02-15","hemoglobin_g_dL":12.6,"wbc_k_uL":10.5,"platelets_k_uL":425,"creatinine_mg_dL":1.11,"alt_U_L":31},{"date":"2023-09-27","hemoglobin_g_dL":12.3,"wbc_k_uL":5.7,"platelets_k_uL":326,"creatinine_mg_dL":1.04,"alt_U_L":61},{"date":"2025-02-04","hemoglobin_g_dL":12.7,"wbc_k_uL":4.7,"platelets_k_uL":248,"creatinine_mg_dL":1.6,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_1355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":76,"sex":"female","bmi":27.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-54},"pfs_months":18.07},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.0,"censored":false},"longitudinal_labs":[{"date":"2023-11-17","hemoglobin_g_dL":11.6,"wbc_k_uL":9.2,"platelets_k_uL":306,"creatinine_mg_dL":1.21,"alt_U_L":66},{"date":"2024-07-03","hemoglobin_g_dL":10.1,"wbc_k_uL":8.7,"platelets_k_uL":240,"creatinine_mg_dL":1.48,"alt_U_L":60},{"date":"2025-08-03","hemoglobin_g_dL":9.8,"wbc_k_uL":3.1,"platelets_k_uL":183,"creatinine_mg_dL":1.53,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_1356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":76,"sex":"female","bmi":28.6,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-01-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-82},"pfs_months":14.75},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":false},"longitudinal_labs":[{"date":"2020-01-07","hemoglobin_g_dL":12.2,"wbc_k_uL":10.4,"platelets_k_uL":320,"creatinine_mg_dL":1.22,"alt_U_L":62},{"date":"2020-07-22","hemoglobin_g_dL":10.1,"wbc_k_uL":4.9,"platelets_k_uL":351,"creatinine_mg_dL":1.6,"alt_U_L":45},{"date":"2021-05-14","hemoglobin_g_dL":10.7,"wbc_k_uL":7.1,"platelets_k_uL":267,"creatinine_mg_dL":1.12,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_1357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":64,"sex":"male","bmi":33.4,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-45},"pfs_months":12.16},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.4,"censored":false},"longitudinal_labs":[{"date":"2024-04-04","hemoglobin_g_dL":13.4,"wbc_k_uL":10.5,"platelets_k_uL":416,"creatinine_mg_dL":0.75,"alt_U_L":55},{"date":"2024-10-21","hemoglobin_g_dL":13.4,"wbc_k_uL":7.5,"platelets_k_uL":307,"creatinine_mg_dL":1.29,"alt_U_L":60},{"date":"2025-06-07","hemoglobin_g_dL":12.1,"wbc_k_uL":6.3,"platelets_k_uL":209,"creatinine_mg_dL":1.31,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_1358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":69,"sex":"male","bmi":36.2,"smoking_pack_years":68,"ecog_performance_status":2,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-07-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-79},"pfs_months":18.5},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.5,"censored":true},"longitudinal_labs":[{"date":"2022-06-08","hemoglobin_g_dL":13.1,"wbc_k_uL":5.7,"platelets_k_uL":332,"creatinine_mg_dL":0.7,"alt_U_L":64},{"date":"2023-01-25","hemoglobin_g_dL":11.5,"wbc_k_uL":4.6,"platelets_k_uL":126,"creatinine_mg_dL":1.51,"alt_U_L":64},{"date":"2024-03-05","hemoglobin_g_dL":12.3,"wbc_k_uL":4.9,"platelets_k_uL":159,"creatinine_mg_dL":1.04,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_1359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":60,"sex":"male","bmi":32.7,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-03-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-63},"pfs_months":10.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":16.5,"censored":true},"longitudinal_labs":[{"date":"2024-02-04","hemoglobin_g_dL":14.8,"wbc_k_uL":8.4,"platelets_k_uL":440,"creatinine_mg_dL":0.64,"alt_U_L":61},{"date":"2024-09-16","hemoglobin_g_dL":13.7,"wbc_k_uL":7.9,"platelets_k_uL":229,"creatinine_mg_dL":1.28,"alt_U_L":48},{"date":"2025-02-23","hemoglobin_g_dL":13.0,"wbc_k_uL":5.1,"platelets_k_uL":260,"creatinine_mg_dL":1.45,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_1360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":64,"sex":"female","bmi":35.7,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-11-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-75},"pfs_months":41.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":67.6,"censored":true},"longitudinal_labs":[{"date":"2022-09-02","hemoglobin_g_dL":14.1,"wbc_k_uL":9.8,"platelets_k_uL":339,"creatinine_mg_dL":1.13,"alt_U_L":31},{"date":"2023-05-02","hemoglobin_g_dL":13.1,"wbc_k_uL":4.6,"platelets_k_uL":125,"creatinine_mg_dL":1.34,"alt_U_L":120},{"date":"2026-05-12","hemoglobin_g_dL":9.8,"wbc_k_uL":4.7,"platelets_k_uL":158,"creatinine_mg_dL":1.51,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_1361","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":78,"sex":"female","bmi":31.2,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-08-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-34},"pfs_months":19.48},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.5,"censored":true},"longitudinal_labs":[{"date":"2024-06-19","hemoglobin_g_dL":12.6,"wbc_k_uL":8.0,"platelets_k_uL":260,"creatinine_mg_dL":1.19,"alt_U_L":25},{"date":"2025-02-18","hemoglobin_g_dL":12.8,"wbc_k_uL":6.5,"platelets_k_uL":349,"creatinine_mg_dL":1.58,"alt_U_L":73},{"date":"2026-04-21","hemoglobin_g_dL":10.7,"wbc_k_uL":6.2,"platelets_k_uL":346,"creatinine_mg_dL":0.94,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_1362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":87,"sex":"male","bmi":23.4,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-42},"pfs_months":45.31},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":70.5,"censored":false},"longitudinal_labs":[{"date":"2025-02-02","hemoglobin_g_dL":14.3,"wbc_k_uL":6.9,"platelets_k_uL":262,"creatinine_mg_dL":1.28,"alt_U_L":21},{"date":"2025-08-25","hemoglobin_g_dL":10.2,"wbc_k_uL":7.5,"platelets_k_uL":200,"creatinine_mg_dL":1.23,"alt_U_L":15},{"date":"2029-01-04","hemoglobin_g_dL":9.9,"wbc_k_uL":3.8,"platelets_k_uL":311,"creatinine_mg_dL":1.36,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_1363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":74,"sex":"male","bmi":21.1,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-39},"pfs_months":48.2},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-12-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":70.7,"censored":true},"longitudinal_labs":[{"date":"2025-10-20","hemoglobin_g_dL":14.3,"wbc_k_uL":10.6,"platelets_k_uL":282,"creatinine_mg_dL":1.16,"alt_U_L":33},{"date":"2026-06-07","hemoglobin_g_dL":13.0,"wbc_k_uL":6.8,"platelets_k_uL":268,"creatinine_mg_dL":1.14,"alt_U_L":67},{"date":"2029-12-20","hemoglobin_g_dL":12.7,"wbc_k_uL":6.7,"platelets_k_uL":227,"creatinine_mg_dL":1.01,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_1364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":50,"sex":"female","bmi":29.8,"smoking_pack_years":61,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-03-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-80},"pfs_months":16.69},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.6,"censored":true},"longitudinal_labs":[{"date":"2022-02-23","hemoglobin_g_dL":15.5,"wbc_k_uL":6.9,"platelets_k_uL":330,"creatinine_mg_dL":0.98,"alt_U_L":66},{"date":"2022-09-21","hemoglobin_g_dL":10.3,"wbc_k_uL":5.4,"platelets_k_uL":203,"creatinine_mg_dL":1.53,"alt_U_L":32},{"date":"2023-10-08","hemoglobin_g_dL":9.7,"wbc_k_uL":5.7,"platelets_k_uL":125,"creatinine_mg_dL":1.7,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_1365","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":49,"sex":"male","bmi":30.6,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-08-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-80},"pfs_months":27.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.7,"censored":false},"longitudinal_labs":[{"date":"2024-08-04","hemoglobin_g_dL":12.2,"wbc_k_uL":9.9,"platelets_k_uL":373,"creatinine_mg_dL":0.65,"alt_U_L":18},{"date":"2025-02-20","hemoglobin_g_dL":13.4,"wbc_k_uL":4.4,"platelets_k_uL":282,"creatinine_mg_dL":1.55,"alt_U_L":90},{"date":"2027-01-27","hemoglobin_g_dL":11.7,"wbc_k_uL":6.4,"platelets_k_uL":306,"creatinine_mg_dL":1.65,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_1366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":62,"sex":"male","bmi":34.6,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-01-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-75},"pfs_months":11.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.0,"censored":false},"longitudinal_labs":[{"date":"2021-11-14","hemoglobin_g_dL":14.9,"wbc_k_uL":7.7,"platelets_k_uL":418,"creatinine_mg_dL":0.87,"alt_U_L":51},{"date":"2022-07-04","hemoglobin_g_dL":11.2,"wbc_k_uL":8.9,"platelets_k_uL":311,"creatinine_mg_dL":1.15,"alt_U_L":64},{"date":"2023-01-22","hemoglobin_g_dL":9.9,"wbc_k_uL":5.7,"platelets_k_uL":136,"creatinine_mg_dL":1.76,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_1367","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":75,"sex":"female","bmi":27.9,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["liver","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-09-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-56},"pfs_months":13.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-31","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.9,"censored":false},"longitudinal_labs":[{"date":"2021-07-13","hemoglobin_g_dL":14.7,"wbc_k_uL":8.3,"platelets_k_uL":245,"creatinine_mg_dL":1.15,"alt_U_L":28},{"date":"2022-03-20","hemoglobin_g_dL":12.2,"wbc_k_uL":6.0,"platelets_k_uL":206,"creatinine_mg_dL":1.5,"alt_U_L":86},{"date":"2022-12-31","hemoglobin_g_dL":9.5,"wbc_k_uL":6.7,"platelets_k_uL":247,"creatinine_mg_dL":1.97,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_1368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":68,"sex":"female","bmi":31.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["bone","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-84},"pfs_months":20.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":false},"longitudinal_labs":[{"date":"2025-10-21","hemoglobin_g_dL":13.6,"wbc_k_uL":5.7,"platelets_k_uL":441,"creatinine_mg_dL":1.05,"alt_U_L":50},{"date":"2026-05-12","hemoglobin_g_dL":12.3,"wbc_k_uL":5.4,"platelets_k_uL":234,"creatinine_mg_dL":1.36,"alt_U_L":17},{"date":"2027-08-17","hemoglobin_g_dL":10.4,"wbc_k_uL":3.6,"platelets_k_uL":291,"creatinine_mg_dL":1.91,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_1369","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.9,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":55,"sex":"female","bmi":37.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-77},"pfs_months":25.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.3,"censored":false},"longitudinal_labs":[{"date":"2025-02-15","hemoglobin_g_dL":11.8,"wbc_k_uL":7.8,"platelets_k_uL":361,"creatinine_mg_dL":0.97,"alt_U_L":74},{"date":"2025-09-29","hemoglobin_g_dL":11.9,"wbc_k_uL":7.9,"platelets_k_uL":261,"creatinine_mg_dL":0.89,"alt_U_L":105},{"date":"2027-06-17","hemoglobin_g_dL":11.1,"wbc_k_uL":6.5,"platelets_k_uL":181,"creatinine_mg_dL":1.33,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_1370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":65,"sex":"female","bmi":21.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-64},"pfs_months":29.01},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":false},"longitudinal_labs":[{"date":"2021-06-24","hemoglobin_g_dL":12.9,"wbc_k_uL":7.9,"platelets_k_uL":360,"creatinine_mg_dL":0.87,"alt_U_L":11},{"date":"2022-03-01","hemoglobin_g_dL":11.5,"wbc_k_uL":6.8,"platelets_k_uL":185,"creatinine_mg_dL":0.82,"alt_U_L":20},{"date":"2024-03-28","hemoglobin_g_dL":12.2,"wbc_k_uL":3.0,"platelets_k_uL":289,"creatinine_mg_dL":1.98,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_1371","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":66,"sex":"female","bmi":22.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-63},"pfs_months":23.0},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.0,"censored":false},"longitudinal_labs":[{"date":"2023-12-04","hemoglobin_g_dL":14.6,"wbc_k_uL":8.8,"platelets_k_uL":362,"creatinine_mg_dL":0.63,"alt_U_L":31},{"date":"2024-07-19","hemoglobin_g_dL":11.2,"wbc_k_uL":7.3,"platelets_k_uL":363,"creatinine_mg_dL":1.1,"alt_U_L":25},{"date":"2026-01-08","hemoglobin_g_dL":10.9,"wbc_k_uL":4.7,"platelets_k_uL":139,"creatinine_mg_dL":1.64,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_1372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":60,"sex":"male","bmi":34.6,"smoking_pack_years":10,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-67},"pfs_months":32.95},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":59.4,"censored":false},"longitudinal_labs":[{"date":"2020-11-11","hemoglobin_g_dL":12.1,"wbc_k_uL":6.4,"platelets_k_uL":175,"creatinine_mg_dL":1.15,"alt_U_L":42},{"date":"2021-06-25","hemoglobin_g_dL":13.3,"wbc_k_uL":5.1,"platelets_k_uL":243,"creatinine_mg_dL":1.56,"alt_U_L":92},{"date":"2023-10-28","hemoglobin_g_dL":9.8,"wbc_k_uL":7.6,"platelets_k_uL":274,"creatinine_mg_dL":1.66,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_1373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":51,"sex":"male","bmi":33.8,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-06-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-47},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-11-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":16.0,"censored":false},"longitudinal_labs":[{"date":"2020-05-19","hemoglobin_g_dL":12.3,"wbc_k_uL":8.9,"platelets_k_uL":378,"creatinine_mg_dL":0.71,"alt_U_L":25},{"date":"2020-12-20","hemoglobin_g_dL":12.4,"wbc_k_uL":8.2,"platelets_k_uL":229,"creatinine_mg_dL":1.05,"alt_U_L":23},{"date":"2020-11-06","hemoglobin_g_dL":12.8,"wbc_k_uL":3.8,"platelets_k_uL":251,"creatinine_mg_dL":1.91,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_1374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":87,"sex":"female","bmi":30.5,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-58},"pfs_months":31.05},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.9,"censored":false},"longitudinal_labs":[{"date":"2025-04-11","hemoglobin_g_dL":14.9,"wbc_k_uL":6.0,"platelets_k_uL":366,"creatinine_mg_dL":1.16,"alt_U_L":40},{"date":"2025-12-05","hemoglobin_g_dL":10.1,"wbc_k_uL":3.9,"platelets_k_uL":165,"creatinine_mg_dL":0.78,"alt_U_L":59},{"date":"2028-03-06","hemoglobin_g_dL":12.7,"wbc_k_uL":4.1,"platelets_k_uL":123,"creatinine_mg_dL":0.92,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_1375","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":49,"sex":"female","bmi":23.5,"smoking_pack_years":38,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-03-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-54},"pfs_months":21.13},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.7,"censored":true},"longitudinal_labs":[{"date":"2025-02-04","hemoglobin_g_dL":15.4,"wbc_k_uL":6.1,"platelets_k_uL":270,"creatinine_mg_dL":0.92,"alt_U_L":26},{"date":"2025-08-30","hemoglobin_g_dL":10.4,"wbc_k_uL":5.5,"platelets_k_uL":311,"creatinine_mg_dL":1.53,"alt_U_L":49},{"date":"2026-12-11","hemoglobin_g_dL":12.7,"wbc_k_uL":4.6,"platelets_k_uL":344,"creatinine_mg_dL":1.71,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_1376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":83,"sex":"female","bmi":32.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-56},"pfs_months":14.39},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.7,"censored":false},"longitudinal_labs":[{"date":"2024-08-26","hemoglobin_g_dL":13.6,"wbc_k_uL":8.5,"platelets_k_uL":218,"creatinine_mg_dL":0.68,"alt_U_L":11},{"date":"2025-05-01","hemoglobin_g_dL":11.9,"wbc_k_uL":4.3,"platelets_k_uL":270,"creatinine_mg_dL":1.19,"alt_U_L":76},{"date":"2026-02-24","hemoglobin_g_dL":12.4,"wbc_k_uL":4.8,"platelets_k_uL":270,"creatinine_mg_dL":1.17,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_1377","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":84,"sex":"female","bmi":25.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-49},"pfs_months":34.6},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":50.2,"censored":true},"longitudinal_labs":[{"date":"2025-03-23","hemoglobin_g_dL":11.6,"wbc_k_uL":5.1,"platelets_k_uL":291,"creatinine_mg_dL":0.73,"alt_U_L":20},{"date":"2025-11-23","hemoglobin_g_dL":12.2,"wbc_k_uL":5.5,"platelets_k_uL":149,"creatinine_mg_dL":1.23,"alt_U_L":67},{"date":"2028-05-29","hemoglobin_g_dL":9.8,"wbc_k_uL":5.7,"platelets_k_uL":162,"creatinine_mg_dL":1.88,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_1378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":82,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-38},"pfs_months":19.42},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.5,"censored":false},"longitudinal_labs":[{"date":"2020-05-18","hemoglobin_g_dL":11.6,"wbc_k_uL":10.5,"platelets_k_uL":442,"creatinine_mg_dL":1.13,"alt_U_L":12},{"date":"2020-12-31","hemoglobin_g_dL":10.5,"wbc_k_uL":5.2,"platelets_k_uL":318,"creatinine_mg_dL":0.71,"alt_U_L":39},{"date":"2022-03-16","hemoglobin_g_dL":11.7,"wbc_k_uL":5.1,"platelets_k_uL":262,"creatinine_mg_dL":0.86,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_1379","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":61,"sex":"male","bmi":26.5,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-31},"pfs_months":18.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.4,"censored":false},"longitudinal_labs":[{"date":"2020-12-21","hemoglobin_g_dL":14.5,"wbc_k_uL":8.2,"platelets_k_uL":385,"creatinine_mg_dL":1.17,"alt_U_L":79},{"date":"2021-07-15","hemoglobin_g_dL":10.3,"wbc_k_uL":4.8,"platelets_k_uL":167,"creatinine_mg_dL":0.7,"alt_U_L":47},{"date":"2022-09-29","hemoglobin_g_dL":12.0,"wbc_k_uL":6.9,"platelets_k_uL":128,"creatinine_mg_dL":1.02,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_1380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":78,"sex":"male","bmi":30.6,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-02-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-60},"pfs_months":38.57},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.7,"censored":true},"longitudinal_labs":[{"date":"2020-11-28","hemoglobin_g_dL":11.7,"wbc_k_uL":10.7,"platelets_k_uL":166,"creatinine_mg_dL":1.24,"alt_U_L":62},{"date":"2021-08-02","hemoglobin_g_dL":10.9,"wbc_k_uL":4.2,"platelets_k_uL":257,"creatinine_mg_dL":1.3,"alt_U_L":101},{"date":"2024-06-03","hemoglobin_g_dL":10.4,"wbc_k_uL":4.4,"platelets_k_uL":109,"creatinine_mg_dL":1.04,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_1381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":79,"sex":"male","bmi":33.6,"smoking_pack_years":11,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-12-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-74},"pfs_months":27.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.7,"censored":false},"longitudinal_labs":[{"date":"2021-10-06","hemoglobin_g_dL":15.5,"wbc_k_uL":6.6,"platelets_k_uL":172,"creatinine_mg_dL":0.68,"alt_U_L":31},{"date":"2022-06-10","hemoglobin_g_dL":11.9,"wbc_k_uL":8.4,"platelets_k_uL":291,"creatinine_mg_dL":0.89,"alt_U_L":44},{"date":"2024-04-13","hemoglobin_g_dL":10.1,"wbc_k_uL":3.1,"platelets_k_uL":293,"creatinine_mg_dL":2.0,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_1382","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":63,"sex":"female","bmi":36.9,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-07-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-79},"pfs_months":36.44},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":51.0,"censored":false},"longitudinal_labs":[{"date":"2022-06-22","hemoglobin_g_dL":14.8,"wbc_k_uL":4.5,"platelets_k_uL":420,"creatinine_mg_dL":0.79,"alt_U_L":62},{"date":"2023-01-20","hemoglobin_g_dL":11.7,"wbc_k_uL":3.9,"platelets_k_uL":184,"creatinine_mg_dL":0.91,"alt_U_L":38},{"date":"2025-09-13","hemoglobin_g_dL":11.5,"wbc_k_uL":3.2,"platelets_k_uL":129,"creatinine_mg_dL":1.33,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_1383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":71,"sex":"male","bmi":30.1,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-11-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-40},"pfs_months":11.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":15.6,"censored":false},"longitudinal_labs":[{"date":"2023-10-06","hemoglobin_g_dL":12.9,"wbc_k_uL":9.0,"platelets_k_uL":236,"creatinine_mg_dL":0.88,"alt_U_L":47},{"date":"2024-05-02","hemoglobin_g_dL":10.9,"wbc_k_uL":8.0,"platelets_k_uL":238,"creatinine_mg_dL":1.11,"alt_U_L":16},{"date":"2024-11-12","hemoglobin_g_dL":11.5,"wbc_k_uL":7.7,"platelets_k_uL":118,"creatinine_mg_dL":1.34,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_1384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":86,"sex":"female","bmi":22.3,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-58},"pfs_months":19.15},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.9,"censored":false},"longitudinal_labs":[{"date":"2021-01-05","hemoglobin_g_dL":13.3,"wbc_k_uL":6.2,"platelets_k_uL":444,"creatinine_mg_dL":0.81,"alt_U_L":28},{"date":"2021-09-05","hemoglobin_g_dL":13.8,"wbc_k_uL":8.5,"platelets_k_uL":192,"creatinine_mg_dL":1.37,"alt_U_L":77},{"date":"2022-11-13","hemoglobin_g_dL":10.0,"wbc_k_uL":4.9,"platelets_k_uL":316,"creatinine_mg_dL":1.82,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_1385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":77,"sex":"female","bmi":37.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-81},"pfs_months":14.65},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.5,"censored":true},"longitudinal_labs":[{"date":"2021-05-20","hemoglobin_g_dL":13.4,"wbc_k_uL":9.5,"platelets_k_uL":192,"creatinine_mg_dL":1.29,"alt_U_L":43},{"date":"2021-12-27","hemoglobin_g_dL":13.4,"wbc_k_uL":7.1,"platelets_k_uL":264,"creatinine_mg_dL":1.38,"alt_U_L":111},{"date":"2022-11-15","hemoglobin_g_dL":10.8,"wbc_k_uL":7.1,"platelets_k_uL":265,"creatinine_mg_dL":1.36,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_1386","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":49,"sex":"female","bmi":18.6,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-10-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-31},"pfs_months":18.46},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.9,"censored":false},"longitudinal_labs":[{"date":"2024-09-04","hemoglobin_g_dL":13.6,"wbc_k_uL":9.3,"platelets_k_uL":211,"creatinine_mg_dL":1.06,"alt_U_L":26},{"date":"2025-04-04","hemoglobin_g_dL":10.4,"wbc_k_uL":4.1,"platelets_k_uL":314,"creatinine_mg_dL":1.14,"alt_U_L":120},{"date":"2026-05-03","hemoglobin_g_dL":11.9,"wbc_k_uL":5.3,"platelets_k_uL":328,"creatinine_mg_dL":1.23,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_1387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":54,"sex":"female","bmi":24.0,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-80},"pfs_months":13.37},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":17.8,"censored":false},"longitudinal_labs":[{"date":"2023-07-06","hemoglobin_g_dL":12.0,"wbc_k_uL":6.4,"platelets_k_uL":248,"creatinine_mg_dL":0.62,"alt_U_L":10},{"date":"2024-03-01","hemoglobin_g_dL":12.5,"wbc_k_uL":6.3,"platelets_k_uL":183,"creatinine_mg_dL":1.44,"alt_U_L":117},{"date":"2024-11-21","hemoglobin_g_dL":9.7,"wbc_k_uL":5.1,"platelets_k_uL":197,"creatinine_mg_dL":1.82,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_1388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":85,"sex":"female","bmi":19.7,"smoking_pack_years":21,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-10-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-32},"pfs_months":38.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.9,"censored":false},"longitudinal_labs":[{"date":"2025-09-04","hemoglobin_g_dL":12.5,"wbc_k_uL":5.8,"platelets_k_uL":289,"creatinine_mg_dL":0.99,"alt_U_L":71},{"date":"2026-04-20","hemoglobin_g_dL":13.0,"wbc_k_uL":3.9,"platelets_k_uL":213,"creatinine_mg_dL":1.42,"alt_U_L":89},{"date":"2029-01-21","hemoglobin_g_dL":12.7,"wbc_k_uL":3.4,"platelets_k_uL":254,"creatinine_mg_dL":1.33,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_1389","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":88,"sex":"male","bmi":36.6,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-74},"pfs_months":26.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.2,"censored":false},"longitudinal_labs":[{"date":"2023-11-19","hemoglobin_g_dL":11.8,"wbc_k_uL":8.3,"platelets_k_uL":194,"creatinine_mg_dL":1.08,"alt_U_L":34},{"date":"2024-06-28","hemoglobin_g_dL":10.7,"wbc_k_uL":7.5,"platelets_k_uL":366,"creatinine_mg_dL":0.77,"alt_U_L":66},{"date":"2026-05-26","hemoglobin_g_dL":12.1,"wbc_k_uL":7.6,"platelets_k_uL":220,"creatinine_mg_dL":1.2,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_1390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":82,"sex":"female","bmi":26.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-01-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-40},"pfs_months":22.74},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.8,"censored":false},"longitudinal_labs":[{"date":"2025-11-22","hemoglobin_g_dL":14.3,"wbc_k_uL":9.0,"platelets_k_uL":213,"creatinine_mg_dL":1.29,"alt_U_L":36},{"date":"2026-07-12","hemoglobin_g_dL":12.2,"wbc_k_uL":7.1,"platelets_k_uL":179,"creatinine_mg_dL":1.29,"alt_U_L":17},{"date":"2027-12-22","hemoglobin_g_dL":11.9,"wbc_k_uL":4.0,"platelets_k_uL":298,"creatinine_mg_dL":0.88,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_1391","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":77,"sex":"female","bmi":23.0,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-11-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-70},"pfs_months":6.77},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.5,"censored":false},"longitudinal_labs":[{"date":"2023-10-07","hemoglobin_g_dL":12.0,"wbc_k_uL":6.4,"platelets_k_uL":393,"creatinine_mg_dL":1.0,"alt_U_L":33},{"date":"2024-05-27","hemoglobin_g_dL":12.0,"wbc_k_uL":8.2,"platelets_k_uL":302,"creatinine_mg_dL":0.88,"alt_U_L":70},{"date":"2024-08-08","hemoglobin_g_dL":10.0,"wbc_k_uL":4.9,"platelets_k_uL":185,"creatinine_mg_dL":0.92,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_1392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":54,"sex":"female","bmi":29.5,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-06-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-67},"pfs_months":18.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":false},"longitudinal_labs":[{"date":"2022-06-13","hemoglobin_g_dL":11.8,"wbc_k_uL":4.9,"platelets_k_uL":296,"creatinine_mg_dL":1.0,"alt_U_L":49},{"date":"2022-12-25","hemoglobin_g_dL":11.6,"wbc_k_uL":8.0,"platelets_k_uL":183,"creatinine_mg_dL":1.58,"alt_U_L":110},{"date":"2024-02-19","hemoglobin_g_dL":12.0,"wbc_k_uL":8.0,"platelets_k_uL":281,"creatinine_mg_dL":1.21,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_1393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":59,"sex":"female","bmi":24.6,"smoking_pack_years":63,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-09-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-63},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":false},"longitudinal_labs":[{"date":"2025-08-02","hemoglobin_g_dL":14.8,"wbc_k_uL":5.8,"platelets_k_uL":269,"creatinine_mg_dL":1.21,"alt_U_L":30},{"date":"2026-03-09","hemoglobin_g_dL":13.1,"wbc_k_uL":7.7,"platelets_k_uL":250,"creatinine_mg_dL":1.39,"alt_U_L":107},{"date":"2026-01-07","hemoglobin_g_dL":10.2,"wbc_k_uL":3.5,"platelets_k_uL":140,"creatinine_mg_dL":1.79,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_1394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":55,"sex":"male","bmi":35.5,"smoking_pack_years":19,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-04-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-65},"pfs_months":43.6},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":69.2,"censored":false},"longitudinal_labs":[{"date":"2023-03-07","hemoglobin_g_dL":15.4,"wbc_k_uL":7.7,"platelets_k_uL":279,"creatinine_mg_dL":1.12,"alt_U_L":12},{"date":"2023-10-19","hemoglobin_g_dL":13.7,"wbc_k_uL":5.6,"platelets_k_uL":322,"creatinine_mg_dL":1.09,"alt_U_L":115},{"date":"2027-02-03","hemoglobin_g_dL":11.4,"wbc_k_uL":6.9,"platelets_k_uL":229,"creatinine_mg_dL":1.27,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_1395","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":72,"sex":"male","bmi":28.7,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-08-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-67},"pfs_months":23.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.2,"censored":true},"longitudinal_labs":[{"date":"2024-06-03","hemoglobin_g_dL":14.0,"wbc_k_uL":5.6,"platelets_k_uL":339,"creatinine_mg_dL":0.96,"alt_U_L":63},{"date":"2025-02-08","hemoglobin_g_dL":13.1,"wbc_k_uL":4.2,"platelets_k_uL":120,"creatinine_mg_dL":1.39,"alt_U_L":107},{"date":"2026-09-01","hemoglobin_g_dL":11.0,"wbc_k_uL":5.8,"platelets_k_uL":209,"creatinine_mg_dL":0.91,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_1396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":68,"sex":"female","bmi":37.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-44},"pfs_months":30.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-23","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.9,"censored":true},"longitudinal_labs":[{"date":"2024-09-09","hemoglobin_g_dL":14.9,"wbc_k_uL":9.1,"platelets_k_uL":197,"creatinine_mg_dL":0.63,"alt_U_L":17},{"date":"2025-04-01","hemoglobin_g_dL":12.5,"wbc_k_uL":8.7,"platelets_k_uL":213,"creatinine_mg_dL":1.39,"alt_U_L":17},{"date":"2027-05-23","hemoglobin_g_dL":9.9,"wbc_k_uL":6.3,"platelets_k_uL":178,"creatinine_mg_dL":1.84,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_1397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":76,"sex":"female","bmi":30.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-75},"pfs_months":18.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.2,"censored":true},"longitudinal_labs":[{"date":"2023-11-18","hemoglobin_g_dL":11.9,"wbc_k_uL":11.0,"platelets_k_uL":428,"creatinine_mg_dL":1.27,"alt_U_L":80},{"date":"2024-06-06","hemoglobin_g_dL":11.3,"wbc_k_uL":3.8,"platelets_k_uL":260,"creatinine_mg_dL":1.33,"alt_U_L":112},{"date":"2025-08-05","hemoglobin_g_dL":12.4,"wbc_k_uL":6.8,"platelets_k_uL":350,"creatinine_mg_dL":1.93,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_1398","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":58,"sex":"female","bmi":34.1,"smoking_pack_years":41,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-09-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-83},"pfs_months":13.31},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":20.7,"censored":false},"longitudinal_labs":[{"date":"2023-07-24","hemoglobin_g_dL":15.4,"wbc_k_uL":10.2,"platelets_k_uL":180,"creatinine_mg_dL":1.09,"alt_U_L":40},{"date":"2024-03-08","hemoglobin_g_dL":13.6,"wbc_k_uL":4.0,"platelets_k_uL":215,"creatinine_mg_dL":1.34,"alt_U_L":61},{"date":"2024-10-25","hemoglobin_g_dL":12.9,"wbc_k_uL":5.0,"platelets_k_uL":101,"creatinine_mg_dL":1.21,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":51,"sex":"male","bmi":34.8,"smoking_pack_years":10,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-05-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-39},"pfs_months":42.58},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":65.8,"censored":true},"longitudinal_labs":[{"date":"2024-03-12","hemoglobin_g_dL":15.0,"wbc_k_uL":9.9,"platelets_k_uL":401,"creatinine_mg_dL":1.28,"alt_U_L":61},{"date":"2024-11-12","hemoglobin_g_dL":13.0,"wbc_k_uL":8.5,"platelets_k_uL":365,"creatinine_mg_dL":1.08,"alt_U_L":69},{"date":"2028-01-12","hemoglobin_g_dL":12.2,"wbc_k_uL":4.5,"platelets_k_uL":331,"creatinine_mg_dL":1.99,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":87,"sex":"male","bmi":34.7,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2022-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-74},"pfs_months":13.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":25.9,"censored":true},"longitudinal_labs":[{"date":"2022-11-25","hemoglobin_g_dL":15.3,"wbc_k_uL":10.5,"platelets_k_uL":244,"creatinine_mg_dL":0.91,"alt_U_L":37},{"date":"2023-06-23","hemoglobin_g_dL":13.2,"wbc_k_uL":4.6,"platelets_k_uL":348,"creatinine_mg_dL":0.75,"alt_U_L":94},{"date":"2024-02-19","hemoglobin_g_dL":11.0,"wbc_k_uL":6.8,"platelets_k_uL":274,"creatinine_mg_dL":1.61,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_1401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":83,"sex":"male","bmi":34.5,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-07-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-58},"pfs_months":34.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":61.1,"censored":false},"longitudinal_labs":[{"date":"2021-06-24","hemoglobin_g_dL":13.3,"wbc_k_uL":7.1,"platelets_k_uL":190,"creatinine_mg_dL":1.12,"alt_U_L":67},{"date":"2022-01-10","hemoglobin_g_dL":10.7,"wbc_k_uL":8.3,"platelets_k_uL":247,"creatinine_mg_dL":1.58,"alt_U_L":49},{"date":"2024-06-30","hemoglobin_g_dL":9.7,"wbc_k_uL":4.1,"platelets_k_uL":253,"creatinine_mg_dL":1.42,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_1402","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":48,"sex":"female","bmi":25.6,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-10-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-35},"pfs_months":9.56},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":18.6,"censored":true},"longitudinal_labs":[{"date":"2021-08-24","hemoglobin_g_dL":14.3,"wbc_k_uL":9.7,"platelets_k_uL":445,"creatinine_mg_dL":1.3,"alt_U_L":10},{"date":"2022-04-22","hemoglobin_g_dL":11.5,"wbc_k_uL":7.9,"platelets_k_uL":195,"creatinine_mg_dL":0.81,"alt_U_L":75},{"date":"2022-08-25","hemoglobin_g_dL":9.8,"wbc_k_uL":4.1,"platelets_k_uL":158,"creatinine_mg_dL":1.29,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_1403","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":50,"sex":"male","bmi":29.6,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-09-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-44},"pfs_months":24.67},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.4,"censored":true},"longitudinal_labs":[{"date":"2025-07-27","hemoglobin_g_dL":12.1,"wbc_k_uL":6.2,"platelets_k_uL":417,"creatinine_mg_dL":1.26,"alt_U_L":25},{"date":"2026-03-08","hemoglobin_g_dL":10.7,"wbc_k_uL":5.7,"platelets_k_uL":202,"creatinine_mg_dL":1.59,"alt_U_L":43},{"date":"2027-10-29","hemoglobin_g_dL":9.7,"wbc_k_uL":7.2,"platelets_k_uL":123,"creatinine_mg_dL":1.25,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_1404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":81,"sex":"male","bmi":28.2,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-09-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-83},"pfs_months":41.1},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":71.6,"censored":false},"longitudinal_labs":[{"date":"2020-08-10","hemoglobin_g_dL":14.1,"wbc_k_uL":10.9,"platelets_k_uL":331,"creatinine_mg_dL":0.72,"alt_U_L":24},{"date":"2021-03-20","hemoglobin_g_dL":12.1,"wbc_k_uL":6.0,"platelets_k_uL":338,"creatinine_mg_dL":0.75,"alt_U_L":29},{"date":"2024-04-17","hemoglobin_g_dL":11.1,"wbc_k_uL":6.0,"platelets_k_uL":114,"creatinine_mg_dL":0.81,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_1405","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":72,"sex":"female","bmi":32.7,"smoking_pack_years":73,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-12-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-77},"pfs_months":27.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.8,"censored":false},"longitudinal_labs":[{"date":"2024-10-23","hemoglobin_g_dL":14.1,"wbc_k_uL":5.5,"platelets_k_uL":350,"creatinine_mg_dL":1.17,"alt_U_L":37},{"date":"2025-06-05","hemoglobin_g_dL":13.3,"wbc_k_uL":6.9,"platelets_k_uL":130,"creatinine_mg_dL":0.9,"alt_U_L":105},{"date":"2027-04-07","hemoglobin_g_dL":9.6,"wbc_k_uL":5.5,"platelets_k_uL":350,"creatinine_mg_dL":1.46,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_1406","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":77,"sex":"male","bmi":23.3,"smoking_pack_years":40,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-03-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-50},"pfs_months":16.89},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.8,"censored":false},"longitudinal_labs":[{"date":"2020-01-25","hemoglobin_g_dL":13.1,"wbc_k_uL":6.6,"platelets_k_uL":282,"creatinine_mg_dL":0.79,"alt_U_L":64},{"date":"2020-08-29","hemoglobin_g_dL":13.5,"wbc_k_uL":4.9,"platelets_k_uL":359,"creatinine_mg_dL":0.83,"alt_U_L":70},{"date":"2021-09-01","hemoglobin_g_dL":12.3,"wbc_k_uL":3.6,"platelets_k_uL":296,"creatinine_mg_dL":1.86,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_1407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":71,"sex":"female","bmi":32.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-78},"pfs_months":21.45},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.8,"censored":true},"longitudinal_labs":[{"date":"2020-08-27","hemoglobin_g_dL":14.6,"wbc_k_uL":6.8,"platelets_k_uL":340,"creatinine_mg_dL":1.21,"alt_U_L":43},{"date":"2021-04-24","hemoglobin_g_dL":13.6,"wbc_k_uL":6.7,"platelets_k_uL":130,"creatinine_mg_dL":0.96,"alt_U_L":20},{"date":"2022-09-24","hemoglobin_g_dL":12.3,"wbc_k_uL":3.6,"platelets_k_uL":171,"creatinine_mg_dL":1.83,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_1408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":55,"sex":"female","bmi":33.6,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-34},"pfs_months":42.12},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.2,"censored":false},"longitudinal_labs":[{"date":"2020-02-24","hemoglobin_g_dL":14.4,"wbc_k_uL":10.2,"platelets_k_uL":434,"creatinine_mg_dL":0.74,"alt_U_L":39},{"date":"2020-10-23","hemoglobin_g_dL":11.5,"wbc_k_uL":6.8,"platelets_k_uL":200,"creatinine_mg_dL":1.48,"alt_U_L":48},{"date":"2023-11-03","hemoglobin_g_dL":11.3,"wbc_k_uL":6.0,"platelets_k_uL":106,"creatinine_mg_dL":1.45,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_1409","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":66,"sex":"male","bmi":33.5,"smoking_pack_years":14,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-10-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-83},"pfs_months":18.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.5,"censored":false},"longitudinal_labs":[{"date":"2024-08-04","hemoglobin_g_dL":13.8,"wbc_k_uL":4.6,"platelets_k_uL":408,"creatinine_mg_dL":1.17,"alt_U_L":31},{"date":"2025-04-07","hemoglobin_g_dL":12.7,"wbc_k_uL":6.2,"platelets_k_uL":353,"creatinine_mg_dL":1.36,"alt_U_L":21},{"date":"2026-06-28","hemoglobin_g_dL":11.2,"wbc_k_uL":3.1,"platelets_k_uL":290,"creatinine_mg_dL":1.35,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_1410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":49,"sex":"female","bmi":21.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-49},"pfs_months":23.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":false},"longitudinal_labs":[{"date":"2022-06-01","hemoglobin_g_dL":15.2,"wbc_k_uL":5.9,"platelets_k_uL":442,"creatinine_mg_dL":1.02,"alt_U_L":19},{"date":"2022-12-23","hemoglobin_g_dL":12.6,"wbc_k_uL":4.9,"platelets_k_uL":364,"creatinine_mg_dL":1.34,"alt_U_L":64},{"date":"2024-07-24","hemoglobin_g_dL":13.0,"wbc_k_uL":7.0,"platelets_k_uL":252,"creatinine_mg_dL":1.15,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_1411","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":59,"sex":"male","bmi":22.6,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-01-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-77},"pfs_months":26.94},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":false},"longitudinal_labs":[{"date":"2023-12-24","hemoglobin_g_dL":13.3,"wbc_k_uL":9.1,"platelets_k_uL":278,"creatinine_mg_dL":0.91,"alt_U_L":49},{"date":"2024-07-21","hemoglobin_g_dL":11.2,"wbc_k_uL":6.7,"platelets_k_uL":351,"creatinine_mg_dL":1.47,"alt_U_L":50},{"date":"2026-06-20","hemoglobin_g_dL":12.1,"wbc_k_uL":7.6,"platelets_k_uL":332,"creatinine_mg_dL":0.96,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_1412","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":71,"sex":"female","bmi":26.5,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-12-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-55},"pfs_months":34.66},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":48.0,"censored":false},"longitudinal_labs":[{"date":"2020-11-16","hemoglobin_g_dL":14.5,"wbc_k_uL":4.9,"platelets_k_uL":158,"creatinine_mg_dL":1.17,"alt_U_L":10},{"date":"2021-06-20","hemoglobin_g_dL":10.2,"wbc_k_uL":9.0,"platelets_k_uL":283,"creatinine_mg_dL":1.49,"alt_U_L":20},{"date":"2023-12-26","hemoglobin_g_dL":10.8,"wbc_k_uL":3.3,"platelets_k_uL":275,"creatinine_mg_dL":1.73,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_1413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":50,"sex":"female","bmi":33.1,"smoking_pack_years":61,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-08-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-34},"pfs_months":6.87},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":15.0,"censored":false},"longitudinal_labs":[{"date":"2021-08-04","hemoglobin_g_dL":12.2,"wbc_k_uL":4.9,"platelets_k_uL":405,"creatinine_mg_dL":0.9,"alt_U_L":26},{"date":"2022-02-24","hemoglobin_g_dL":13.5,"wbc_k_uL":8.3,"platelets_k_uL":160,"creatinine_mg_dL":1.3,"alt_U_L":37},{"date":"2022-04-02","hemoglobin_g_dL":9.8,"wbc_k_uL":7.5,"platelets_k_uL":226,"creatinine_mg_dL":1.54,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_1414","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":83,"sex":"male","bmi":19.0,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-06-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-35},"pfs_months":19.06},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.4,"censored":false},"longitudinal_labs":[{"date":"2025-04-07","hemoglobin_g_dL":15.1,"wbc_k_uL":5.9,"platelets_k_uL":239,"creatinine_mg_dL":1.22,"alt_U_L":13},{"date":"2025-11-29","hemoglobin_g_dL":11.6,"wbc_k_uL":4.5,"platelets_k_uL":359,"creatinine_mg_dL":0.75,"alt_U_L":69},{"date":"2027-01-18","hemoglobin_g_dL":12.8,"wbc_k_uL":4.1,"platelets_k_uL":278,"creatinine_mg_dL":0.8,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_1415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":58,"sex":"female","bmi":21.5,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-62},"pfs_months":15.18},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":24.8,"censored":false},"longitudinal_labs":[{"date":"2021-07-06","hemoglobin_g_dL":14.6,"wbc_k_uL":5.4,"platelets_k_uL":349,"creatinine_mg_dL":0.87,"alt_U_L":17},{"date":"2022-03-02","hemoglobin_g_dL":11.7,"wbc_k_uL":6.9,"platelets_k_uL":298,"creatinine_mg_dL":0.96,"alt_U_L":23},{"date":"2023-01-27","hemoglobin_g_dL":10.0,"wbc_k_uL":5.2,"platelets_k_uL":288,"creatinine_mg_dL":1.98,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_1416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":59,"sex":"female","bmi":27.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-66},"pfs_months":18.43},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":false},"longitudinal_labs":[{"date":"2025-09-02","hemoglobin_g_dL":12.3,"wbc_k_uL":10.5,"platelets_k_uL":219,"creatinine_mg_dL":0.83,"alt_U_L":63},{"date":"2026-05-01","hemoglobin_g_dL":10.6,"wbc_k_uL":8.7,"platelets_k_uL":225,"creatinine_mg_dL":0.87,"alt_U_L":98},{"date":"2027-06-18","hemoglobin_g_dL":12.4,"wbc_k_uL":4.7,"platelets_k_uL":271,"creatinine_mg_dL":1.18,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_1417","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":60,"sex":"female","bmi":28.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-38},"pfs_months":31.61},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.7,"censored":false},"longitudinal_labs":[{"date":"2020-06-04","hemoglobin_g_dL":13.1,"wbc_k_uL":8.6,"platelets_k_uL":360,"creatinine_mg_dL":0.98,"alt_U_L":67},{"date":"2021-01-14","hemoglobin_g_dL":13.5,"wbc_k_uL":7.4,"platelets_k_uL":240,"creatinine_mg_dL":1.35,"alt_U_L":102},{"date":"2023-03-30","hemoglobin_g_dL":11.7,"wbc_k_uL":6.7,"platelets_k_uL":345,"creatinine_mg_dL":0.88,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_1418","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":60,"sex":"female","bmi":30.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-44},"pfs_months":25.89},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":false},"longitudinal_labs":[{"date":"2020-11-22","hemoglobin_g_dL":15.0,"wbc_k_uL":7.5,"platelets_k_uL":207,"creatinine_mg_dL":1.18,"alt_U_L":51},{"date":"2021-06-18","hemoglobin_g_dL":12.5,"wbc_k_uL":4.6,"platelets_k_uL":368,"creatinine_mg_dL":1.46,"alt_U_L":19},{"date":"2023-04-11","hemoglobin_g_dL":10.5,"wbc_k_uL":6.5,"platelets_k_uL":199,"creatinine_mg_dL":1.28,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_1419","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":74,"sex":"female","bmi":37.4,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-85},"pfs_months":39.56},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.7,"censored":false},"longitudinal_labs":[{"date":"2023-08-25","hemoglobin_g_dL":11.7,"wbc_k_uL":7.3,"platelets_k_uL":334,"creatinine_mg_dL":0.64,"alt_U_L":39},{"date":"2024-04-30","hemoglobin_g_dL":11.4,"wbc_k_uL":4.2,"platelets_k_uL":142,"creatinine_mg_dL":0.9,"alt_U_L":49},{"date":"2027-04-12","hemoglobin_g_dL":10.7,"wbc_k_uL":4.3,"platelets_k_uL":299,"creatinine_mg_dL":1.58,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_1420","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":63,"sex":"male","bmi":37.9,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-10-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-61},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-01-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":6.9,"censored":false},"longitudinal_labs":[{"date":"2020-08-24","hemoglobin_g_dL":14.1,"wbc_k_uL":4.7,"platelets_k_uL":169,"creatinine_mg_dL":0.85,"alt_U_L":13},{"date":"2021-04-17","hemoglobin_g_dL":13.5,"wbc_k_uL":6.8,"platelets_k_uL":179,"creatinine_mg_dL":0.95,"alt_U_L":72},{"date":"2021-01-26","hemoglobin_g_dL":10.5,"wbc_k_uL":7.3,"platelets_k_uL":242,"creatinine_mg_dL":1.13,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_1421","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":61,"sex":"male","bmi":29.2,"smoking_pack_years":24,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-05-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-30},"pfs_months":13.34},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.6,"censored":false},"longitudinal_labs":[{"date":"2025-03-15","hemoglobin_g_dL":14.6,"wbc_k_uL":7.3,"platelets_k_uL":168,"creatinine_mg_dL":0.74,"alt_U_L":56},{"date":"2025-11-18","hemoglobin_g_dL":11.8,"wbc_k_uL":7.6,"platelets_k_uL":265,"creatinine_mg_dL":1.49,"alt_U_L":15},{"date":"2026-07-24","hemoglobin_g_dL":11.6,"wbc_k_uL":3.2,"platelets_k_uL":321,"creatinine_mg_dL":1.68,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_1422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":82,"sex":"female","bmi":29.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-38},"pfs_months":31.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.0,"censored":false},"longitudinal_labs":[{"date":"2024-03-24","hemoglobin_g_dL":11.6,"wbc_k_uL":5.2,"platelets_k_uL":289,"creatinine_mg_dL":1.29,"alt_U_L":59},{"date":"2024-11-13","hemoglobin_g_dL":11.2,"wbc_k_uL":4.3,"platelets_k_uL":241,"creatinine_mg_dL":1.33,"alt_U_L":109},{"date":"2027-01-02","hemoglobin_g_dL":10.6,"wbc_k_uL":4.4,"platelets_k_uL":329,"creatinine_mg_dL":1.22,"alt_U_L":166}]}
{"patient_id":"ANODE_SYNTH_2025_1423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":66,"sex":"male","bmi":19.7,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-04-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-83},"pfs_months":40.34},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":67.8,"censored":true},"longitudinal_labs":[{"date":"2021-03-10","hemoglobin_g_dL":13.8,"wbc_k_uL":8.6,"platelets_k_uL":191,"creatinine_mg_dL":1.06,"alt_U_L":66},{"date":"2021-10-09","hemoglobin_g_dL":11.1,"wbc_k_uL":5.6,"platelets_k_uL":295,"creatinine_mg_dL":1.15,"alt_U_L":51},{"date":"2024-08-27","hemoglobin_g_dL":9.8,"wbc_k_uL":5.8,"platelets_k_uL":258,"creatinine_mg_dL":1.89,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_1424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":53,"sex":"male","bmi":20.4,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-06-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-33},"pfs_months":37.45},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":55.0,"censored":false},"longitudinal_labs":[{"date":"2023-04-12","hemoglobin_g_dL":12.3,"wbc_k_uL":7.3,"platelets_k_uL":361,"creatinine_mg_dL":0.95,"alt_U_L":73},{"date":"2023-12-18","hemoglobin_g_dL":13.4,"wbc_k_uL":5.4,"platelets_k_uL":304,"creatinine_mg_dL":0.98,"alt_U_L":20},{"date":"2026-09-02","hemoglobin_g_dL":10.7,"wbc_k_uL":5.6,"platelets_k_uL":195,"creatinine_mg_dL":1.1,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_1425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":82,"sex":"male","bmi":28.2,"smoking_pack_years":60,"ecog_performance_status":2,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-12-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-80},"pfs_months":18.99},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.1,"censored":false},"longitudinal_labs":[{"date":"2023-11-11","hemoglobin_g_dL":13.9,"wbc_k_uL":10.3,"platelets_k_uL":415,"creatinine_mg_dL":0.73,"alt_U_L":32},{"date":"2024-06-21","hemoglobin_g_dL":10.3,"wbc_k_uL":5.5,"platelets_k_uL":331,"creatinine_mg_dL":0.74,"alt_U_L":74},{"date":"2025-08-06","hemoglobin_g_dL":9.7,"wbc_k_uL":3.1,"platelets_k_uL":224,"creatinine_mg_dL":1.71,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_1426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":80,"sex":"female","bmi":22.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-60},"pfs_months":19.19},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":true},"longitudinal_labs":[{"date":"2023-06-15","hemoglobin_g_dL":15.0,"wbc_k_uL":8.3,"platelets_k_uL":299,"creatinine_mg_dL":1.14,"alt_U_L":50},{"date":"2024-01-25","hemoglobin_g_dL":10.2,"wbc_k_uL":7.2,"platelets_k_uL":296,"creatinine_mg_dL":0.74,"alt_U_L":64},{"date":"2025-04-08","hemoglobin_g_dL":10.0,"wbc_k_uL":6.0,"platelets_k_uL":251,"creatinine_mg_dL":1.12,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_1427","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":66,"sex":"male","bmi":28.6,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-02-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-64},"pfs_months":10.05},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2022-12-11","hemoglobin_g_dL":12.6,"wbc_k_uL":6.3,"platelets_k_uL":259,"creatinine_mg_dL":1.2,"alt_U_L":35},{"date":"2023-08-04","hemoglobin_g_dL":10.7,"wbc_k_uL":7.5,"platelets_k_uL":223,"creatinine_mg_dL":0.72,"alt_U_L":69},{"date":"2024-01-18","hemoglobin_g_dL":12.3,"wbc_k_uL":4.2,"platelets_k_uL":213,"creatinine_mg_dL":1.26,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_1428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":71,"sex":"female","bmi":22.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-59},"pfs_months":27.37},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.3,"censored":false},"longitudinal_labs":[{"date":"2022-04-05","hemoglobin_g_dL":13.8,"wbc_k_uL":9.6,"platelets_k_uL":281,"creatinine_mg_dL":1.23,"alt_U_L":54},{"date":"2022-12-03","hemoglobin_g_dL":10.8,"wbc_k_uL":6.9,"platelets_k_uL":170,"creatinine_mg_dL":1.02,"alt_U_L":84},{"date":"2024-11-06","hemoglobin_g_dL":11.0,"wbc_k_uL":4.1,"platelets_k_uL":216,"creatinine_mg_dL":1.84,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_1429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":87,"sex":"male","bmi":28.1,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-05-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-33},"pfs_months":40.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":64.9,"censored":false},"longitudinal_labs":[{"date":"2024-04-16","hemoglobin_g_dL":14.4,"wbc_k_uL":8.8,"platelets_k_uL":367,"creatinine_mg_dL":1.03,"alt_U_L":42},{"date":"2024-10-31","hemoglobin_g_dL":10.9,"wbc_k_uL":7.4,"platelets_k_uL":240,"creatinine_mg_dL":1.38,"alt_U_L":60},{"date":"2027-11-01","hemoglobin_g_dL":11.3,"wbc_k_uL":7.9,"platelets_k_uL":199,"creatinine_mg_dL":0.83,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_1430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":70,"sex":"female","bmi":26.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-33},"pfs_months":25.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.2,"censored":false},"longitudinal_labs":[{"date":"2022-05-09","hemoglobin_g_dL":12.9,"wbc_k_uL":8.4,"platelets_k_uL":166,"creatinine_mg_dL":0.76,"alt_U_L":59},{"date":"2022-12-10","hemoglobin_g_dL":11.6,"wbc_k_uL":5.1,"platelets_k_uL":351,"creatinine_mg_dL":1.22,"alt_U_L":53},{"date":"2024-08-26","hemoglobin_g_dL":11.1,"wbc_k_uL":4.8,"platelets_k_uL":127,"creatinine_mg_dL":1.92,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_1431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":84,"sex":"female","bmi":22.9,"smoking_pack_years":56,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-03-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-53},"pfs_months":9.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":false},"longitudinal_labs":[{"date":"2024-02-11","hemoglobin_g_dL":15.2,"wbc_k_uL":11.0,"platelets_k_uL":279,"creatinine_mg_dL":0.78,"alt_U_L":74},{"date":"2024-09-26","hemoglobin_g_dL":13.7,"wbc_k_uL":6.6,"platelets_k_uL":137,"creatinine_mg_dL":1.01,"alt_U_L":44},{"date":"2025-02-10","hemoglobin_g_dL":12.7,"wbc_k_uL":3.4,"platelets_k_uL":133,"creatinine_mg_dL":1.62,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_1432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":61,"sex":"female","bmi":25.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-46},"pfs_months":15.61},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":false},"longitudinal_labs":[{"date":"2021-04-21","hemoglobin_g_dL":15.0,"wbc_k_uL":9.3,"platelets_k_uL":215,"creatinine_mg_dL":1.26,"alt_U_L":68},{"date":"2021-12-07","hemoglobin_g_dL":13.8,"wbc_k_uL":8.8,"platelets_k_uL":261,"creatinine_mg_dL":1.41,"alt_U_L":73},{"date":"2022-11-15","hemoglobin_g_dL":11.0,"wbc_k_uL":7.4,"platelets_k_uL":285,"creatinine_mg_dL":1.9,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_1433","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":63,"sex":"male","bmi":26.0,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-04-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-83},"pfs_months":18.27},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.8,"censored":false},"longitudinal_labs":[{"date":"2022-02-25","hemoglobin_g_dL":15.2,"wbc_k_uL":7.7,"platelets_k_uL":188,"creatinine_mg_dL":1.16,"alt_U_L":43},{"date":"2022-10-18","hemoglobin_g_dL":12.4,"wbc_k_uL":7.2,"platelets_k_uL":264,"creatinine_mg_dL":1.6,"alt_U_L":107},{"date":"2023-12-23","hemoglobin_g_dL":13.0,"wbc_k_uL":4.3,"platelets_k_uL":321,"creatinine_mg_dL":1.34,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_1434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":52,"sex":"female","bmi":24.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-59},"pfs_months":25.4},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.3,"censored":true},"longitudinal_labs":[{"date":"2023-02-27","hemoglobin_g_dL":11.9,"wbc_k_uL":6.0,"platelets_k_uL":179,"creatinine_mg_dL":0.76,"alt_U_L":21},{"date":"2023-10-22","hemoglobin_g_dL":10.2,"wbc_k_uL":6.5,"platelets_k_uL":287,"creatinine_mg_dL":1.58,"alt_U_L":75},{"date":"2025-08-04","hemoglobin_g_dL":12.8,"wbc_k_uL":5.3,"platelets_k_uL":305,"creatinine_mg_dL":1.45,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_1435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":57,"sex":"female","bmi":25.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-07-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-55},"pfs_months":22.37},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.0,"censored":false},"longitudinal_labs":[{"date":"2021-06-20","hemoglobin_g_dL":11.8,"wbc_k_uL":9.2,"platelets_k_uL":164,"creatinine_mg_dL":0.67,"alt_U_L":42},{"date":"2022-01-26","hemoglobin_g_dL":11.3,"wbc_k_uL":7.0,"platelets_k_uL":309,"creatinine_mg_dL":0.81,"alt_U_L":64},{"date":"2023-07-30","hemoglobin_g_dL":10.6,"wbc_k_uL":6.8,"platelets_k_uL":183,"creatinine_mg_dL":1.74,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_1436","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":68,"sex":"female","bmi":25.0,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-08-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-42},"pfs_months":25.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.2,"censored":true},"longitudinal_labs":[{"date":"2023-07-13","hemoglobin_g_dL":13.8,"wbc_k_uL":9.8,"platelets_k_uL":412,"creatinine_mg_dL":1.0,"alt_U_L":44},{"date":"2024-01-29","hemoglobin_g_dL":10.1,"wbc_k_uL":8.8,"platelets_k_uL":348,"creatinine_mg_dL":1.49,"alt_U_L":43},{"date":"2025-10-18","hemoglobin_g_dL":10.8,"wbc_k_uL":4.1,"platelets_k_uL":106,"creatinine_mg_dL":1.71,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_1437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":80,"sex":"female","bmi":26.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-47},"pfs_months":26.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.2,"censored":false},"longitudinal_labs":[{"date":"2022-09-23","hemoglobin_g_dL":14.4,"wbc_k_uL":7.7,"platelets_k_uL":342,"creatinine_mg_dL":1.04,"alt_U_L":54},{"date":"2023-04-06","hemoglobin_g_dL":11.9,"wbc_k_uL":3.9,"platelets_k_uL":191,"creatinine_mg_dL":0.75,"alt_U_L":33},{"date":"2025-02-12","hemoglobin_g_dL":10.5,"wbc_k_uL":4.8,"platelets_k_uL":285,"creatinine_mg_dL":1.6,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_1438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":79,"sex":"female","bmi":31.7,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-05-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-32},"pfs_months":33.77},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":57.0,"censored":false},"longitudinal_labs":[{"date":"2023-04-28","hemoglobin_g_dL":13.3,"wbc_k_uL":10.7,"platelets_k_uL":391,"creatinine_mg_dL":1.24,"alt_U_L":30},{"date":"2023-11-21","hemoglobin_g_dL":10.6,"wbc_k_uL":4.2,"platelets_k_uL":122,"creatinine_mg_dL":0.8,"alt_U_L":27},{"date":"2026-04-18","hemoglobin_g_dL":11.0,"wbc_k_uL":5.1,"platelets_k_uL":217,"creatinine_mg_dL":1.09,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_1439","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":83,"sex":"female","bmi":26.2,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-09-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-44},"pfs_months":18.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2020-09-01","hemoglobin_g_dL":13.9,"wbc_k_uL":7.4,"platelets_k_uL":209,"creatinine_mg_dL":0.64,"alt_U_L":49},{"date":"2021-03-16","hemoglobin_g_dL":10.2,"wbc_k_uL":8.2,"platelets_k_uL":366,"creatinine_mg_dL":1.13,"alt_U_L":15},{"date":"2022-04-25","hemoglobin_g_dL":12.9,"wbc_k_uL":3.2,"platelets_k_uL":267,"creatinine_mg_dL":1.65,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_1440","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":84,"sex":"male","bmi":35.9,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-05-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-50},"pfs_months":16.16},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":false},"longitudinal_labs":[{"date":"2020-03-27","hemoglobin_g_dL":11.6,"wbc_k_uL":4.9,"platelets_k_uL":363,"creatinine_mg_dL":1.06,"alt_U_L":71},{"date":"2020-10-29","hemoglobin_g_dL":13.8,"wbc_k_uL":6.2,"platelets_k_uL":135,"creatinine_mg_dL":0.75,"alt_U_L":87},{"date":"2021-10-16","hemoglobin_g_dL":12.2,"wbc_k_uL":4.2,"platelets_k_uL":350,"creatinine_mg_dL":1.44,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_1441","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":64,"sex":"female","bmi":21.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-60},"pfs_months":19.35},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.2,"censored":true},"longitudinal_labs":[{"date":"2023-10-19","hemoglobin_g_dL":13.0,"wbc_k_uL":9.7,"platelets_k_uL":206,"creatinine_mg_dL":0.97,"alt_U_L":59},{"date":"2024-05-03","hemoglobin_g_dL":11.9,"wbc_k_uL":3.8,"platelets_k_uL":235,"creatinine_mg_dL":1.05,"alt_U_L":29},{"date":"2025-07-15","hemoglobin_g_dL":12.3,"wbc_k_uL":6.2,"platelets_k_uL":237,"creatinine_mg_dL":1.5,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_1442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":62,"sex":"male","bmi":26.2,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-02-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-66},"pfs_months":3.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-07-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":13.4,"censored":false},"longitudinal_labs":[{"date":"2020-01-19","hemoglobin_g_dL":13.0,"wbc_k_uL":7.9,"platelets_k_uL":274,"creatinine_mg_dL":0.86,"alt_U_L":33},{"date":"2020-08-08","hemoglobin_g_dL":11.2,"wbc_k_uL":4.3,"platelets_k_uL":340,"creatinine_mg_dL":1.1,"alt_U_L":34},{"date":"2020-07-11","hemoglobin_g_dL":12.8,"wbc_k_uL":7.5,"platelets_k_uL":198,"creatinine_mg_dL":1.89,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_1443","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":52,"sex":"male","bmi":33.6,"smoking_pack_years":21,"ecog_performance_status":2,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-04-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-51},"pfs_months":8.74},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-02-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.7,"censored":false},"longitudinal_labs":[{"date":"2020-03-07","hemoglobin_g_dL":12.7,"wbc_k_uL":7.9,"platelets_k_uL":274,"creatinine_mg_dL":1.29,"alt_U_L":69},{"date":"2020-10-13","hemoglobin_g_dL":12.7,"wbc_k_uL":7.6,"platelets_k_uL":172,"creatinine_mg_dL":1.35,"alt_U_L":45},{"date":"2021-02-09","hemoglobin_g_dL":10.8,"wbc_k_uL":6.6,"platelets_k_uL":293,"creatinine_mg_dL":1.36,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_1444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":51,"sex":"male","bmi":30.4,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-09-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-42},"pfs_months":45.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.8,"censored":false},"longitudinal_labs":[{"date":"2023-08-22","hemoglobin_g_dL":13.5,"wbc_k_uL":7.6,"platelets_k_uL":252,"creatinine_mg_dL":1.15,"alt_U_L":13},{"date":"2024-03-14","hemoglobin_g_dL":13.9,"wbc_k_uL":8.4,"platelets_k_uL":378,"creatinine_mg_dL":1.06,"alt_U_L":106},{"date":"2027-07-21","hemoglobin_g_dL":10.2,"wbc_k_uL":7.6,"platelets_k_uL":129,"creatinine_mg_dL":1.46,"alt_U_L":112}]}
{"patient_id":"ANODE_SYNTH_2025_1445","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":79,"sex":"female","bmi":27.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-56},"pfs_months":26.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.9,"censored":false},"longitudinal_labs":[{"date":"2025-10-26","hemoglobin_g_dL":12.1,"wbc_k_uL":7.0,"platelets_k_uL":174,"creatinine_mg_dL":1.04,"alt_U_L":38},{"date":"2026-06-25","hemoglobin_g_dL":12.2,"wbc_k_uL":8.2,"platelets_k_uL":175,"creatinine_mg_dL":1.04,"alt_U_L":52},{"date":"2028-03-26","hemoglobin_g_dL":10.7,"wbc_k_uL":7.2,"platelets_k_uL":246,"creatinine_mg_dL":0.96,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_1446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":73,"sex":"female","bmi":27.3,"smoking_pack_years":78,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-04-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-79},"pfs_months":45.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-03-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":59.1,"censored":true},"longitudinal_labs":[{"date":"2025-04-03","hemoglobin_g_dL":12.1,"wbc_k_uL":9.3,"platelets_k_uL":254,"creatinine_mg_dL":1.26,"alt_U_L":20},{"date":"2025-10-20","hemoglobin_g_dL":13.4,"wbc_k_uL":4.0,"platelets_k_uL":275,"creatinine_mg_dL":0.91,"alt_U_L":48},{"date":"2029-03-20","hemoglobin_g_dL":12.8,"wbc_k_uL":7.5,"platelets_k_uL":200,"creatinine_mg_dL":0.92,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_1447","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.2,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":81,"sex":"male","bmi":37.6,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-01-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-60},"pfs_months":16.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.5,"censored":false},"longitudinal_labs":[{"date":"2023-11-17","hemoglobin_g_dL":12.1,"wbc_k_uL":11.0,"platelets_k_uL":242,"creatinine_mg_dL":1.03,"alt_U_L":55},{"date":"2024-07-04","hemoglobin_g_dL":11.4,"wbc_k_uL":4.5,"platelets_k_uL":236,"creatinine_mg_dL":0.86,"alt_U_L":51},{"date":"2025-06-02","hemoglobin_g_dL":12.1,"wbc_k_uL":7.1,"platelets_k_uL":283,"creatinine_mg_dL":0.85,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_1448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":57,"sex":"female","bmi":18.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-30},"pfs_months":18.04},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2025-06-14","hemoglobin_g_dL":12.5,"wbc_k_uL":9.6,"platelets_k_uL":433,"creatinine_mg_dL":0.94,"alt_U_L":80},{"date":"2026-02-02","hemoglobin_g_dL":13.9,"wbc_k_uL":7.8,"platelets_k_uL":253,"creatinine_mg_dL":1.37,"alt_U_L":41},{"date":"2027-03-04","hemoglobin_g_dL":9.8,"wbc_k_uL":6.1,"platelets_k_uL":231,"creatinine_mg_dL":1.63,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_1449","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":76,"sex":"female","bmi":20.4,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-05-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-53},"pfs_months":17.77},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.3,"censored":true},"longitudinal_labs":[{"date":"2020-04-18","hemoglobin_g_dL":12.6,"wbc_k_uL":10.2,"platelets_k_uL":177,"creatinine_mg_dL":0.87,"alt_U_L":41},{"date":"2020-11-13","hemoglobin_g_dL":13.2,"wbc_k_uL":3.9,"platelets_k_uL":254,"creatinine_mg_dL":1.59,"alt_U_L":114},{"date":"2021-12-26","hemoglobin_g_dL":11.5,"wbc_k_uL":6.3,"platelets_k_uL":321,"creatinine_mg_dL":0.99,"alt_U_L":31}]}
{"patient_id":"ANODE_SYNTH_2025_1450","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":74,"sex":"male","bmi":35.0,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-02-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-62},"pfs_months":23.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.4,"censored":true},"longitudinal_labs":[{"date":"2020-12-27","hemoglobin_g_dL":13.4,"wbc_k_uL":7.9,"platelets_k_uL":441,"creatinine_mg_dL":1.04,"alt_U_L":24},{"date":"2021-08-24","hemoglobin_g_dL":10.5,"wbc_k_uL":5.0,"platelets_k_uL":176,"creatinine_mg_dL":1.37,"alt_U_L":84},{"date":"2023-02-23","hemoglobin_g_dL":11.3,"wbc_k_uL":7.1,"platelets_k_uL":270,"creatinine_mg_dL":1.37,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_1451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":63,"sex":"female","bmi":37.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-38},"pfs_months":23.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.2,"censored":false},"longitudinal_labs":[{"date":"2023-05-22","hemoglobin_g_dL":12.7,"wbc_k_uL":8.4,"platelets_k_uL":378,"creatinine_mg_dL":1.14,"alt_U_L":23},{"date":"2024-01-25","hemoglobin_g_dL":12.6,"wbc_k_uL":6.8,"platelets_k_uL":166,"creatinine_mg_dL":0.88,"alt_U_L":91},{"date":"2025-07-21","hemoglobin_g_dL":12.6,"wbc_k_uL":5.5,"platelets_k_uL":323,"creatinine_mg_dL":1.47,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1452","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":85,"sex":"male","bmi":24.6,"smoking_pack_years":48,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-07-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-81},"pfs_months":20.04},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":false},"longitudinal_labs":[{"date":"2025-05-10","hemoglobin_g_dL":13.7,"wbc_k_uL":8.6,"platelets_k_uL":184,"creatinine_mg_dL":0.71,"alt_U_L":44},{"date":"2025-12-30","hemoglobin_g_dL":10.8,"wbc_k_uL":8.7,"platelets_k_uL":188,"creatinine_mg_dL":0.86,"alt_U_L":94},{"date":"2027-04-28","hemoglobin_g_dL":9.7,"wbc_k_uL":7.2,"platelets_k_uL":332,"creatinine_mg_dL":1.09,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_1453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":56,"sex":"male","bmi":20.4,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-04-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-67},"pfs_months":25.4},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":49.8,"censored":false},"longitudinal_labs":[{"date":"2022-03-04","hemoglobin_g_dL":13.3,"wbc_k_uL":9.4,"platelets_k_uL":438,"creatinine_mg_dL":1.12,"alt_U_L":50},{"date":"2022-10-09","hemoglobin_g_dL":13.1,"wbc_k_uL":4.1,"platelets_k_uL":341,"creatinine_mg_dL":1.36,"alt_U_L":35},{"date":"2024-06-10","hemoglobin_g_dL":11.0,"wbc_k_uL":5.2,"platelets_k_uL":159,"creatinine_mg_dL":1.09,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_1454","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":63,"sex":"female","bmi":32.5,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-11-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-74},"pfs_months":30.69},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":48.8,"censored":false},"longitudinal_labs":[{"date":"2021-09-24","hemoglobin_g_dL":14.1,"wbc_k_uL":5.9,"platelets_k_uL":373,"creatinine_mg_dL":1.12,"alt_U_L":13},{"date":"2022-05-05","hemoglobin_g_dL":10.1,"wbc_k_uL":7.3,"platelets_k_uL":156,"creatinine_mg_dL":1.18,"alt_U_L":89},{"date":"2024-07-25","hemoglobin_g_dL":10.1,"wbc_k_uL":7.4,"platelets_k_uL":311,"creatinine_mg_dL":1.55,"alt_U_L":99}]}
{"patient_id":"ANODE_SYNTH_2025_1455","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":60,"sex":"female","bmi":19.4,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-05-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-53},"pfs_months":9.13},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-03-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":21.5,"censored":false},"longitudinal_labs":[{"date":"2020-04-27","hemoglobin_g_dL":15.4,"wbc_k_uL":7.6,"platelets_k_uL":267,"creatinine_mg_dL":1.21,"alt_U_L":10},{"date":"2020-11-19","hemoglobin_g_dL":13.3,"wbc_k_uL":3.8,"platelets_k_uL":180,"creatinine_mg_dL":1.46,"alt_U_L":43},{"date":"2021-03-05","hemoglobin_g_dL":10.2,"wbc_k_uL":6.9,"platelets_k_uL":211,"creatinine_mg_dL":0.96,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_1456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":62,"sex":"female","bmi":22.9,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-04-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-65},"pfs_months":47.05},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":70.7,"censored":true},"longitudinal_labs":[{"date":"2020-02-28","hemoglobin_g_dL":13.3,"wbc_k_uL":9.4,"platelets_k_uL":290,"creatinine_mg_dL":1.0,"alt_U_L":10},{"date":"2020-10-25","hemoglobin_g_dL":10.6,"wbc_k_uL":6.2,"platelets_k_uL":297,"creatinine_mg_dL":0.74,"alt_U_L":90},{"date":"2024-04-04","hemoglobin_g_dL":12.2,"wbc_k_uL":3.1,"platelets_k_uL":219,"creatinine_mg_dL":1.04,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_1457","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":67,"sex":"female","bmi":24.9,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-10-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-85},"pfs_months":22.7},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":false},"longitudinal_labs":[{"date":"2020-09-20","hemoglobin_g_dL":14.0,"wbc_k_uL":10.7,"platelets_k_uL":203,"creatinine_mg_dL":0.99,"alt_U_L":72},{"date":"2021-04-15","hemoglobin_g_dL":11.8,"wbc_k_uL":5.8,"platelets_k_uL":327,"creatinine_mg_dL":1.59,"alt_U_L":42},{"date":"2022-11-03","hemoglobin_g_dL":12.4,"wbc_k_uL":6.8,"platelets_k_uL":129,"creatinine_mg_dL":1.74,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_1458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":56,"sex":"male","bmi":20.6,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-01-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-52},"pfs_months":3.35},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":10.0,"censored":true},"longitudinal_labs":[{"date":"2023-12-06","hemoglobin_g_dL":12.8,"wbc_k_uL":6.1,"platelets_k_uL":328,"creatinine_mg_dL":0.65,"alt_U_L":15},{"date":"2024-06-30","hemoglobin_g_dL":13.6,"wbc_k_uL":6.5,"platelets_k_uL":273,"creatinine_mg_dL":1.22,"alt_U_L":105},{"date":"2024-05-15","hemoglobin_g_dL":12.1,"wbc_k_uL":6.7,"platelets_k_uL":128,"creatinine_mg_dL":1.87,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_1459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":55,"sex":"male","bmi":21.3,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-77},"pfs_months":34.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.3,"censored":false},"longitudinal_labs":[{"date":"2024-02-22","hemoglobin_g_dL":14.4,"wbc_k_uL":9.9,"platelets_k_uL":394,"creatinine_mg_dL":1.2,"alt_U_L":70},{"date":"2024-09-25","hemoglobin_g_dL":10.9,"wbc_k_uL":4.0,"platelets_k_uL":333,"creatinine_mg_dL":1.2,"alt_U_L":68},{"date":"2027-02-07","hemoglobin_g_dL":9.6,"wbc_k_uL":7.8,"platelets_k_uL":226,"creatinine_mg_dL":1.15,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_1460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":51,"sex":"male","bmi":35.8,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-47},"pfs_months":20.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":25.9,"censored":false},"longitudinal_labs":[{"date":"2021-01-13","hemoglobin_g_dL":15.2,"wbc_k_uL":6.2,"platelets_k_uL":387,"creatinine_mg_dL":0.98,"alt_U_L":27},{"date":"2021-09-14","hemoglobin_g_dL":10.6,"wbc_k_uL":5.3,"platelets_k_uL":324,"creatinine_mg_dL":1.18,"alt_U_L":82},{"date":"2022-12-10","hemoglobin_g_dL":9.6,"wbc_k_uL":7.9,"platelets_k_uL":247,"creatinine_mg_dL":1.32,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_1461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":50,"sex":"female","bmi":29.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-75},"pfs_months":8.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.1,"censored":false},"longitudinal_labs":[{"date":"2020-06-02","hemoglobin_g_dL":14.5,"wbc_k_uL":9.7,"platelets_k_uL":198,"creatinine_mg_dL":0.91,"alt_U_L":58},{"date":"2021-01-07","hemoglobin_g_dL":13.5,"wbc_k_uL":4.0,"platelets_k_uL":162,"creatinine_mg_dL":1.12,"alt_U_L":120},{"date":"2021-05-04","hemoglobin_g_dL":10.8,"wbc_k_uL":5.8,"platelets_k_uL":152,"creatinine_mg_dL":1.14,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_1462","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":74,"sex":"female","bmi":32.2,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-10-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-57},"pfs_months":13.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":17.4,"censored":false},"longitudinal_labs":[{"date":"2024-09-02","hemoglobin_g_dL":12.6,"wbc_k_uL":9.4,"platelets_k_uL":219,"creatinine_mg_dL":0.99,"alt_U_L":28},{"date":"2025-04-11","hemoglobin_g_dL":11.7,"wbc_k_uL":7.1,"platelets_k_uL":221,"creatinine_mg_dL":0.89,"alt_U_L":54},{"date":"2026-01-10","hemoglobin_g_dL":9.7,"wbc_k_uL":4.0,"platelets_k_uL":225,"creatinine_mg_dL":2.0,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_1463","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":63,"sex":"male","bmi":21.0,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-05-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-85},"pfs_months":15.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.1,"censored":true},"longitudinal_labs":[{"date":"2024-05-01","hemoglobin_g_dL":14.6,"wbc_k_uL":7.1,"platelets_k_uL":266,"creatinine_mg_dL":1.18,"alt_U_L":40},{"date":"2024-11-21","hemoglobin_g_dL":12.3,"wbc_k_uL":7.3,"platelets_k_uL":235,"creatinine_mg_dL":1.09,"alt_U_L":34},{"date":"2025-10-03","hemoglobin_g_dL":11.5,"wbc_k_uL":4.8,"platelets_k_uL":299,"creatinine_mg_dL":0.88,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_1464","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":64,"sex":"male","bmi":19.5,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["bone","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-02-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-63},"pfs_months":13.86},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-04-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.5,"censored":false},"longitudinal_labs":[{"date":"2020-01-13","hemoglobin_g_dL":12.9,"wbc_k_uL":6.9,"platelets_k_uL":374,"creatinine_mg_dL":1.11,"alt_U_L":17},{"date":"2020-08-06","hemoglobin_g_dL":12.1,"wbc_k_uL":5.4,"platelets_k_uL":330,"creatinine_mg_dL":0.84,"alt_U_L":93},{"date":"2021-04-29","hemoglobin_g_dL":9.7,"wbc_k_uL":4.6,"platelets_k_uL":246,"creatinine_mg_dL":1.74,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_1465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":54,"sex":"male","bmi":19.8,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-70},"pfs_months":12.85},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":16.8,"censored":false},"longitudinal_labs":[{"date":"2025-08-01","hemoglobin_g_dL":14.1,"wbc_k_uL":10.2,"platelets_k_uL":358,"creatinine_mg_dL":1.12,"alt_U_L":52},{"date":"2026-03-26","hemoglobin_g_dL":12.6,"wbc_k_uL":4.2,"platelets_k_uL":168,"creatinine_mg_dL":0.71,"alt_U_L":71},{"date":"2026-11-08","hemoglobin_g_dL":12.3,"wbc_k_uL":3.5,"platelets_k_uL":137,"creatinine_mg_dL":1.31,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_1466","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":63,"sex":"female","bmi":33.9,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-11-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-63},"pfs_months":23.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.8,"censored":false},"longitudinal_labs":[{"date":"2024-10-06","hemoglobin_g_dL":13.6,"wbc_k_uL":4.7,"platelets_k_uL":171,"creatinine_mg_dL":0.91,"alt_U_L":41},{"date":"2025-05-01","hemoglobin_g_dL":12.8,"wbc_k_uL":5.9,"platelets_k_uL":374,"creatinine_mg_dL":1.36,"alt_U_L":32},{"date":"2026-11-13","hemoglobin_g_dL":12.3,"wbc_k_uL":7.4,"platelets_k_uL":279,"creatinine_mg_dL":1.82,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_1467","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":55,"sex":"male","bmi":29.4,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-04-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-46},"pfs_months":31.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.0,"censored":true},"longitudinal_labs":[{"date":"2023-03-13","hemoglobin_g_dL":14.7,"wbc_k_uL":5.5,"platelets_k_uL":415,"creatinine_mg_dL":1.23,"alt_U_L":61},{"date":"2023-10-03","hemoglobin_g_dL":11.3,"wbc_k_uL":5.1,"platelets_k_uL":259,"creatinine_mg_dL":0.87,"alt_U_L":31},{"date":"2025-11-22","hemoglobin_g_dL":11.1,"wbc_k_uL":5.2,"platelets_k_uL":304,"creatinine_mg_dL":1.52,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_1468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":54,"sex":"female","bmi":31.4,"smoking_pack_years":77,"ecog_performance_status":2,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-02-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-55},"pfs_months":8.77},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":12.7,"censored":true},"longitudinal_labs":[{"date":"2021-12-22","hemoglobin_g_dL":15.2,"wbc_k_uL":6.2,"platelets_k_uL":395,"creatinine_mg_dL":1.19,"alt_U_L":31},{"date":"2022-08-23","hemoglobin_g_dL":13.1,"wbc_k_uL":5.9,"platelets_k_uL":133,"creatinine_mg_dL":1.31,"alt_U_L":55},{"date":"2022-11-30","hemoglobin_g_dL":12.8,"wbc_k_uL":3.8,"platelets_k_uL":303,"creatinine_mg_dL":1.34,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_1469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":86,"sex":"female","bmi":36.6,"smoking_pack_years":26,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-54},"pfs_months":12.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.2,"censored":true},"longitudinal_labs":[{"date":"2021-07-13","hemoglobin_g_dL":11.5,"wbc_k_uL":4.8,"platelets_k_uL":160,"creatinine_mg_dL":0.77,"alt_U_L":18},{"date":"2022-03-12","hemoglobin_g_dL":10.1,"wbc_k_uL":4.0,"platelets_k_uL":379,"creatinine_mg_dL":1.53,"alt_U_L":65},{"date":"2022-10-14","hemoglobin_g_dL":11.3,"wbc_k_uL":3.3,"platelets_k_uL":119,"creatinine_mg_dL":1.17,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_1470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":57,"sex":"male","bmi":32.9,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-04-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-52},"pfs_months":29.77},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.6,"censored":false},"longitudinal_labs":[{"date":"2023-02-28","hemoglobin_g_dL":12.7,"wbc_k_uL":5.2,"platelets_k_uL":377,"creatinine_mg_dL":0.66,"alt_U_L":13},{"date":"2023-10-15","hemoglobin_g_dL":13.2,"wbc_k_uL":3.9,"platelets_k_uL":169,"creatinine_mg_dL":1.33,"alt_U_L":44},{"date":"2025-10-16","hemoglobin_g_dL":11.4,"wbc_k_uL":5.8,"platelets_k_uL":193,"creatinine_mg_dL":1.47,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_1471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":81,"sex":"female","bmi":22.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-51},"pfs_months":27.07},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":41.9,"censored":false},"longitudinal_labs":[{"date":"2022-05-16","hemoglobin_g_dL":11.6,"wbc_k_uL":7.5,"platelets_k_uL":249,"creatinine_mg_dL":1.14,"alt_U_L":80},{"date":"2023-01-12","hemoglobin_g_dL":11.3,"wbc_k_uL":8.7,"platelets_k_uL":199,"creatinine_mg_dL":1.59,"alt_U_L":100},{"date":"2024-12-03","hemoglobin_g_dL":12.6,"wbc_k_uL":6.1,"platelets_k_uL":267,"creatinine_mg_dL":1.81,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_1472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":82,"sex":"male","bmi":28.0,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-02-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-80},"pfs_months":53.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":74.5,"censored":false},"longitudinal_labs":[{"date":"2021-12-26","hemoglobin_g_dL":12.3,"wbc_k_uL":6.3,"platelets_k_uL":203,"creatinine_mg_dL":1.05,"alt_U_L":53},{"date":"2022-08-11","hemoglobin_g_dL":11.1,"wbc_k_uL":8.2,"platelets_k_uL":268,"creatinine_mg_dL":1.57,"alt_U_L":52},{"date":"2026-08-18","hemoglobin_g_dL":10.9,"wbc_k_uL":6.8,"platelets_k_uL":183,"creatinine_mg_dL":1.06,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_1473","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":85,"sex":"female","bmi":34.1,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["liver","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-10-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-52},"pfs_months":36.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.0,"censored":false},"longitudinal_labs":[{"date":"2022-09-22","hemoglobin_g_dL":12.1,"wbc_k_uL":9.5,"platelets_k_uL":205,"creatinine_mg_dL":0.62,"alt_U_L":49},{"date":"2023-04-19","hemoglobin_g_dL":12.0,"wbc_k_uL":6.6,"platelets_k_uL":226,"creatinine_mg_dL":1.41,"alt_U_L":38},{"date":"2025-11-24","hemoglobin_g_dL":11.7,"wbc_k_uL":5.8,"platelets_k_uL":204,"creatinine_mg_dL":1.46,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_1474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":66,"sex":"female","bmi":21.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-41},"pfs_months":22.6},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.8,"censored":false},"longitudinal_labs":[{"date":"2024-01-25","hemoglobin_g_dL":15.3,"wbc_k_uL":7.6,"platelets_k_uL":362,"creatinine_mg_dL":1.08,"alt_U_L":18},{"date":"2024-09-15","hemoglobin_g_dL":10.5,"wbc_k_uL":8.2,"platelets_k_uL":202,"creatinine_mg_dL":0.71,"alt_U_L":19},{"date":"2026-03-11","hemoglobin_g_dL":12.7,"wbc_k_uL":4.3,"platelets_k_uL":103,"creatinine_mg_dL":1.36,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_1475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":71,"sex":"female","bmi":25.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-73},"pfs_months":16.82},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":true},"longitudinal_labs":[{"date":"2025-02-07","hemoglobin_g_dL":13.6,"wbc_k_uL":9.5,"platelets_k_uL":328,"creatinine_mg_dL":0.78,"alt_U_L":37},{"date":"2025-08-31","hemoglobin_g_dL":13.5,"wbc_k_uL":5.0,"platelets_k_uL":346,"creatinine_mg_dL":1.49,"alt_U_L":62},{"date":"2026-09-06","hemoglobin_g_dL":12.7,"wbc_k_uL":7.2,"platelets_k_uL":155,"creatinine_mg_dL":1.05,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_1476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":74,"sex":"female","bmi":37.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-40},"pfs_months":26.09},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":false},"longitudinal_labs":[{"date":"2023-09-04","hemoglobin_g_dL":13.9,"wbc_k_uL":5.6,"platelets_k_uL":337,"creatinine_mg_dL":0.8,"alt_U_L":26},{"date":"2024-04-12","hemoglobin_g_dL":11.8,"wbc_k_uL":8.0,"platelets_k_uL":356,"creatinine_mg_dL":0.84,"alt_U_L":66},{"date":"2026-01-06","hemoglobin_g_dL":11.1,"wbc_k_uL":7.3,"platelets_k_uL":345,"creatinine_mg_dL":1.44,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_1477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":87,"sex":"female","bmi":20.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-52},"pfs_months":19.52},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.3,"censored":true},"longitudinal_labs":[{"date":"2022-08-11","hemoglobin_g_dL":12.9,"wbc_k_uL":8.9,"platelets_k_uL":321,"creatinine_mg_dL":1.17,"alt_U_L":13},{"date":"2023-03-07","hemoglobin_g_dL":13.7,"wbc_k_uL":4.2,"platelets_k_uL":319,"creatinine_mg_dL":1.11,"alt_U_L":29},{"date":"2024-06-13","hemoglobin_g_dL":12.9,"wbc_k_uL":4.7,"platelets_k_uL":104,"creatinine_mg_dL":1.16,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_1478","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":55,"sex":"female","bmi":37.1,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-59},"pfs_months":20.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.9,"censored":false},"longitudinal_labs":[{"date":"2021-08-24","hemoglobin_g_dL":12.8,"wbc_k_uL":8.6,"platelets_k_uL":424,"creatinine_mg_dL":1.14,"alt_U_L":58},{"date":"2022-03-26","hemoglobin_g_dL":12.7,"wbc_k_uL":5.1,"platelets_k_uL":169,"creatinine_mg_dL":0.82,"alt_U_L":61},{"date":"2023-08-08","hemoglobin_g_dL":10.4,"wbc_k_uL":4.4,"platelets_k_uL":197,"creatinine_mg_dL":1.46,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_1479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":49,"sex":"female","bmi":25.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-67},"pfs_months":10.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.3,"censored":false},"longitudinal_labs":[{"date":"2020-09-01","hemoglobin_g_dL":13.1,"wbc_k_uL":9.8,"platelets_k_uL":366,"creatinine_mg_dL":1.19,"alt_U_L":50},{"date":"2021-04-15","hemoglobin_g_dL":11.2,"wbc_k_uL":7.8,"platelets_k_uL":342,"creatinine_mg_dL":0.87,"alt_U_L":98},{"date":"2021-10-01","hemoglobin_g_dL":11.6,"wbc_k_uL":8.0,"platelets_k_uL":159,"creatinine_mg_dL":0.98,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_1480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":51,"sex":"female","bmi":19.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-77},"pfs_months":29.27},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":50.5,"censored":true},"longitudinal_labs":[{"date":"2020-06-16","hemoglobin_g_dL":12.4,"wbc_k_uL":9.7,"platelets_k_uL":248,"creatinine_mg_dL":0.85,"alt_U_L":10},{"date":"2021-01-31","hemoglobin_g_dL":10.6,"wbc_k_uL":7.6,"platelets_k_uL":234,"creatinine_mg_dL":1.34,"alt_U_L":51},{"date":"2023-02-27","hemoglobin_g_dL":11.1,"wbc_k_uL":3.9,"platelets_k_uL":217,"creatinine_mg_dL":1.92,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_1481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":88,"sex":"female","bmi":37.2,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-44},"pfs_months":38.14},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":63.7,"censored":false},"longitudinal_labs":[{"date":"2022-05-12","hemoglobin_g_dL":15.3,"wbc_k_uL":6.1,"platelets_k_uL":391,"creatinine_mg_dL":1.08,"alt_U_L":47},{"date":"2022-12-30","hemoglobin_g_dL":12.9,"wbc_k_uL":7.0,"platelets_k_uL":371,"creatinine_mg_dL":1.2,"alt_U_L":45},{"date":"2025-10-13","hemoglobin_g_dL":11.8,"wbc_k_uL":4.5,"platelets_k_uL":269,"creatinine_mg_dL":1.33,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_1482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":79,"sex":"male","bmi":20.4,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2021-05-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-31},"pfs_months":19.12},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.2,"censored":false},"longitudinal_labs":[{"date":"2021-04-05","hemoglobin_g_dL":12.9,"wbc_k_uL":7.1,"platelets_k_uL":332,"creatinine_mg_dL":1.11,"alt_U_L":74},{"date":"2021-11-02","hemoglobin_g_dL":10.7,"wbc_k_uL":5.0,"platelets_k_uL":327,"creatinine_mg_dL":1.24,"alt_U_L":67},{"date":"2023-01-27","hemoglobin_g_dL":12.2,"wbc_k_uL":3.3,"platelets_k_uL":224,"creatinine_mg_dL":1.45,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_1483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":51,"sex":"male","bmi":21.9,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-10-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-56},"pfs_months":51.81},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-04-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":72.0,"censored":false},"longitudinal_labs":[{"date":"2024-09-24","hemoglobin_g_dL":11.9,"wbc_k_uL":9.9,"platelets_k_uL":382,"creatinine_mg_dL":0.71,"alt_U_L":10},{"date":"2025-04-25","hemoglobin_g_dL":12.7,"wbc_k_uL":7.8,"platelets_k_uL":178,"creatinine_mg_dL":1.3,"alt_U_L":74},{"date":"2029-04-16","hemoglobin_g_dL":9.8,"wbc_k_uL":5.8,"platelets_k_uL":108,"creatinine_mg_dL":1.0,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_1484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":84,"sex":"female","bmi":20.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-54},"pfs_months":19.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.1,"censored":false},"longitudinal_labs":[{"date":"2023-02-17","hemoglobin_g_dL":11.9,"wbc_k_uL":7.6,"platelets_k_uL":251,"creatinine_mg_dL":1.18,"alt_U_L":23},{"date":"2023-10-06","hemoglobin_g_dL":10.2,"wbc_k_uL":6.2,"platelets_k_uL":191,"creatinine_mg_dL":1.49,"alt_U_L":87},{"date":"2024-12-20","hemoglobin_g_dL":11.5,"wbc_k_uL":4.1,"platelets_k_uL":105,"creatinine_mg_dL":1.83,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_1485","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":88,"sex":"male","bmi":28.5,"smoking_pack_years":39,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-08-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-40},"pfs_months":28.16},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":41.3,"censored":false},"longitudinal_labs":[{"date":"2025-06-28","hemoglobin_g_dL":14.8,"wbc_k_uL":10.3,"platelets_k_uL":334,"creatinine_mg_dL":1.02,"alt_U_L":53},{"date":"2026-02-12","hemoglobin_g_dL":11.6,"wbc_k_uL":8.5,"platelets_k_uL":311,"creatinine_mg_dL":1.37,"alt_U_L":84},{"date":"2027-12-30","hemoglobin_g_dL":10.5,"wbc_k_uL":7.2,"platelets_k_uL":348,"creatinine_mg_dL":1.43,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_1486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":79,"sex":"female","bmi":21.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-32},"pfs_months":14.95},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.3,"censored":false},"longitudinal_labs":[{"date":"2025-03-04","hemoglobin_g_dL":13.2,"wbc_k_uL":6.0,"platelets_k_uL":277,"creatinine_mg_dL":1.23,"alt_U_L":26},{"date":"2025-09-17","hemoglobin_g_dL":12.6,"wbc_k_uL":7.6,"platelets_k_uL":246,"creatinine_mg_dL":0.97,"alt_U_L":70},{"date":"2026-08-13","hemoglobin_g_dL":9.9,"wbc_k_uL":4.3,"platelets_k_uL":142,"creatinine_mg_dL":1.25,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_1487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":57,"sex":"male","bmi":33.3,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-11-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-42},"pfs_months":42.78},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.3,"censored":false},"longitudinal_labs":[{"date":"2020-10-04","hemoglobin_g_dL":14.1,"wbc_k_uL":8.3,"platelets_k_uL":363,"creatinine_mg_dL":1.23,"alt_U_L":44},{"date":"2021-05-01","hemoglobin_g_dL":13.3,"wbc_k_uL":5.8,"platelets_k_uL":157,"creatinine_mg_dL":1.21,"alt_U_L":26},{"date":"2024-07-04","hemoglobin_g_dL":10.2,"wbc_k_uL":4.1,"platelets_k_uL":139,"creatinine_mg_dL":1.8,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_1488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":55,"sex":"female","bmi":36.3,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-01-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-37},"pfs_months":44.94},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.4,"censored":true},"longitudinal_labs":[{"date":"2023-12-19","hemoglobin_g_dL":13.1,"wbc_k_uL":9.2,"platelets_k_uL":437,"creatinine_mg_dL":0.96,"alt_U_L":71},{"date":"2024-07-24","hemoglobin_g_dL":13.8,"wbc_k_uL":8.2,"platelets_k_uL":289,"creatinine_mg_dL":0.8,"alt_U_L":25},{"date":"2027-12-01","hemoglobin_g_dL":10.2,"wbc_k_uL":5.3,"platelets_k_uL":289,"creatinine_mg_dL":1.32,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_1489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":77,"sex":"female","bmi":30.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-32},"pfs_months":22.31},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":false},"longitudinal_labs":[{"date":"2024-05-24","hemoglobin_g_dL":14.8,"wbc_k_uL":7.6,"platelets_k_uL":378,"creatinine_mg_dL":1.27,"alt_U_L":70},{"date":"2024-12-15","hemoglobin_g_dL":13.6,"wbc_k_uL":4.4,"platelets_k_uL":152,"creatinine_mg_dL":0.95,"alt_U_L":44},{"date":"2026-05-28","hemoglobin_g_dL":10.8,"wbc_k_uL":6.2,"platelets_k_uL":205,"creatinine_mg_dL":1.05,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_1490","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":88,"sex":"female","bmi":23.3,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-03-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-38},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-07-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":10.0,"censored":false},"longitudinal_labs":[{"date":"2020-03-06","hemoglobin_g_dL":13.4,"wbc_k_uL":10.5,"platelets_k_uL":321,"creatinine_mg_dL":0.84,"alt_U_L":22},{"date":"2020-09-26","hemoglobin_g_dL":13.4,"wbc_k_uL":6.5,"platelets_k_uL":158,"creatinine_mg_dL":1.31,"alt_U_L":104},{"date":"2020-07-31","hemoglobin_g_dL":11.4,"wbc_k_uL":5.2,"platelets_k_uL":315,"creatinine_mg_dL":1.29,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_1491","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":70,"sex":"female","bmi":36.7,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-03-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-78},"pfs_months":13.4},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":true},"longitudinal_labs":[{"date":"2024-01-01","hemoglobin_g_dL":12.9,"wbc_k_uL":6.7,"platelets_k_uL":279,"creatinine_mg_dL":0.84,"alt_U_L":49},{"date":"2024-08-30","hemoglobin_g_dL":13.4,"wbc_k_uL":4.9,"platelets_k_uL":231,"creatinine_mg_dL":1.32,"alt_U_L":50},{"date":"2025-05-30","hemoglobin_g_dL":12.3,"wbc_k_uL":4.2,"platelets_k_uL":280,"creatinine_mg_dL":1.43,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_1492","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":79,"sex":"female","bmi":36.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-78},"pfs_months":26.55},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.0,"censored":false},"longitudinal_labs":[{"date":"2024-08-28","hemoglobin_g_dL":14.6,"wbc_k_uL":9.4,"platelets_k_uL":445,"creatinine_mg_dL":0.9,"alt_U_L":54},{"date":"2025-04-28","hemoglobin_g_dL":12.1,"wbc_k_uL":7.4,"platelets_k_uL":344,"creatinine_mg_dL":0.92,"alt_U_L":17},{"date":"2027-01-22","hemoglobin_g_dL":10.0,"wbc_k_uL":7.4,"platelets_k_uL":308,"creatinine_mg_dL":1.08,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_1493","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":53,"sex":"female","bmi":29.6,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-10-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-68},"pfs_months":29.44},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-02","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.6,"censored":false},"longitudinal_labs":[{"date":"2021-08-19","hemoglobin_g_dL":14.2,"wbc_k_uL":7.2,"platelets_k_uL":346,"creatinine_mg_dL":1.12,"alt_U_L":62},{"date":"2022-03-30","hemoglobin_g_dL":11.7,"wbc_k_uL":6.1,"platelets_k_uL":121,"creatinine_mg_dL":0.7,"alt_U_L":92},{"date":"2024-05-02","hemoglobin_g_dL":12.7,"wbc_k_uL":7.9,"platelets_k_uL":267,"creatinine_mg_dL":1.66,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_1494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":87,"sex":"female","bmi":29.4,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-37},"pfs_months":47.34},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-10-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":76.2,"censored":false},"longitudinal_labs":[{"date":"2024-08-13","hemoglobin_g_dL":11.6,"wbc_k_uL":11.0,"platelets_k_uL":408,"creatinine_mg_dL":0.97,"alt_U_L":35},{"date":"2025-03-26","hemoglobin_g_dL":12.5,"wbc_k_uL":6.1,"platelets_k_uL":339,"creatinine_mg_dL":0.84,"alt_U_L":73},{"date":"2028-10-22","hemoglobin_g_dL":12.5,"wbc_k_uL":3.8,"platelets_k_uL":298,"creatinine_mg_dL":0.88,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_1495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":61,"sex":"female","bmi":37.1,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-02-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-78},"pfs_months":42.02},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.3,"censored":false},"longitudinal_labs":[{"date":"2020-02-01","hemoglobin_g_dL":13.7,"wbc_k_uL":8.7,"platelets_k_uL":296,"creatinine_mg_dL":1.28,"alt_U_L":12},{"date":"2020-08-16","hemoglobin_g_dL":11.7,"wbc_k_uL":6.5,"platelets_k_uL":305,"creatinine_mg_dL":1.23,"alt_U_L":24},{"date":"2023-09-27","hemoglobin_g_dL":12.4,"wbc_k_uL":7.4,"platelets_k_uL":225,"creatinine_mg_dL":1.88,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_1496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":51,"sex":"male","bmi":19.4,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-09-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-33},"pfs_months":12.55},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.1,"censored":true},"longitudinal_labs":[{"date":"2024-08-20","hemoglobin_g_dL":13.7,"wbc_k_uL":4.6,"platelets_k_uL":306,"creatinine_mg_dL":1.12,"alt_U_L":52},{"date":"2025-03-20","hemoglobin_g_dL":12.0,"wbc_k_uL":7.2,"platelets_k_uL":363,"creatinine_mg_dL":0.91,"alt_U_L":38},{"date":"2025-11-06","hemoglobin_g_dL":10.5,"wbc_k_uL":7.8,"platelets_k_uL":106,"creatinine_mg_dL":1.83,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_1497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":84,"sex":"female","bmi":36.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-41},"pfs_months":11.99},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.1,"censored":false},"longitudinal_labs":[{"date":"2023-02-07","hemoglobin_g_dL":15.1,"wbc_k_uL":8.7,"platelets_k_uL":213,"creatinine_mg_dL":0.76,"alt_U_L":60},{"date":"2023-09-07","hemoglobin_g_dL":12.4,"wbc_k_uL":9.0,"platelets_k_uL":149,"creatinine_mg_dL":1.41,"alt_U_L":112},{"date":"2024-03-19","hemoglobin_g_dL":9.7,"wbc_k_uL":5.8,"platelets_k_uL":261,"creatinine_mg_dL":1.49,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_1498","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.2,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":81,"sex":"male","bmi":21.3,"smoking_pack_years":24,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-01-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-57},"pfs_months":17.15},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":true},"longitudinal_labs":[{"date":"2021-12-28","hemoglobin_g_dL":11.9,"wbc_k_uL":9.2,"platelets_k_uL":189,"creatinine_mg_dL":0.82,"alt_U_L":29},{"date":"2022-07-21","hemoglobin_g_dL":10.6,"wbc_k_uL":5.0,"platelets_k_uL":121,"creatinine_mg_dL":1.47,"alt_U_L":51},{"date":"2023-07-10","hemoglobin_g_dL":11.2,"wbc_k_uL":4.1,"platelets_k_uL":105,"creatinine_mg_dL":1.6,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_1499","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":78,"sex":"male","bmi":29.3,"smoking_pack_years":24,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-52},"pfs_months":31.77},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":61.1,"censored":false},"longitudinal_labs":[{"date":"2024-12-23","hemoglobin_g_dL":12.1,"wbc_k_uL":5.7,"platelets_k_uL":364,"creatinine_mg_dL":1.19,"alt_U_L":71},{"date":"2025-08-15","hemoglobin_g_dL":10.4,"wbc_k_uL":8.7,"platelets_k_uL":358,"creatinine_mg_dL":0.8,"alt_U_L":110},{"date":"2027-12-04","hemoglobin_g_dL":11.1,"wbc_k_uL":5.9,"platelets_k_uL":206,"creatinine_mg_dL":1.47,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_1500","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":54,"sex":"male","bmi":29.5,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-83},"pfs_months":11.76},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":15.7,"censored":false},"longitudinal_labs":[{"date":"2025-06-22","hemoglobin_g_dL":11.9,"wbc_k_uL":10.3,"platelets_k_uL":277,"creatinine_mg_dL":1.22,"alt_U_L":44},{"date":"2026-02-03","hemoglobin_g_dL":12.3,"wbc_k_uL":7.6,"platelets_k_uL":215,"creatinine_mg_dL":0.91,"alt_U_L":68},{"date":"2026-09-11","hemoglobin_g_dL":11.8,"wbc_k_uL":5.8,"platelets_k_uL":129,"creatinine_mg_dL":1.66,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_1501","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":67,"sex":"male","bmi":37.1,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2025-08-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-64},"pfs_months":26.51},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":48.2,"censored":true},"longitudinal_labs":[{"date":"2025-06-27","hemoglobin_g_dL":14.1,"wbc_k_uL":6.3,"platelets_k_uL":283,"creatinine_mg_dL":0.86,"alt_U_L":32},{"date":"2026-02-07","hemoglobin_g_dL":13.6,"wbc_k_uL":6.5,"platelets_k_uL":180,"creatinine_mg_dL":1.55,"alt_U_L":77},{"date":"2027-11-09","hemoglobin_g_dL":11.7,"wbc_k_uL":4.1,"platelets_k_uL":103,"creatinine_mg_dL":1.41,"alt_U_L":71}]}
{"patient_id":"ANODE_SYNTH_2025_1502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":71,"sex":"female","bmi":37.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-56},"pfs_months":24.84},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.1,"censored":false},"longitudinal_labs":[{"date":"2020-05-19","hemoglobin_g_dL":13.9,"wbc_k_uL":8.2,"platelets_k_uL":214,"creatinine_mg_dL":0.82,"alt_U_L":32},{"date":"2021-01-07","hemoglobin_g_dL":11.8,"wbc_k_uL":3.9,"platelets_k_uL":240,"creatinine_mg_dL":1.06,"alt_U_L":95},{"date":"2022-09-12","hemoglobin_g_dL":12.7,"wbc_k_uL":3.3,"platelets_k_uL":244,"creatinine_mg_dL":0.95,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_1503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":75,"sex":"female","bmi":25.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-50},"pfs_months":26.35},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":38.6,"censored":true},"longitudinal_labs":[{"date":"2021-03-04","hemoglobin_g_dL":15.4,"wbc_k_uL":8.1,"platelets_k_uL":206,"creatinine_mg_dL":0.97,"alt_U_L":28},{"date":"2021-10-29","hemoglobin_g_dL":13.4,"wbc_k_uL":6.6,"platelets_k_uL":299,"creatinine_mg_dL":1.24,"alt_U_L":68},{"date":"2023-08-05","hemoglobin_g_dL":9.9,"wbc_k_uL":4.0,"platelets_k_uL":330,"creatinine_mg_dL":1.81,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_1504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":83,"sex":"female","bmi":23.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-35},"pfs_months":30.55},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":51.6,"censored":true},"longitudinal_labs":[{"date":"2025-07-20","hemoglobin_g_dL":12.0,"wbc_k_uL":9.9,"platelets_k_uL":449,"creatinine_mg_dL":0.66,"alt_U_L":58},{"date":"2026-03-03","hemoglobin_g_dL":10.1,"wbc_k_uL":6.5,"platelets_k_uL":216,"creatinine_mg_dL":1.33,"alt_U_L":46},{"date":"2028-05-14","hemoglobin_g_dL":12.5,"wbc_k_uL":3.8,"platelets_k_uL":276,"creatinine_mg_dL":1.27,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_1505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":63,"sex":"female","bmi":35.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-57},"pfs_months":22.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.4,"censored":false},"longitudinal_labs":[{"date":"2025-01-21","hemoglobin_g_dL":13.4,"wbc_k_uL":5.4,"platelets_k_uL":227,"creatinine_mg_dL":0.74,"alt_U_L":46},{"date":"2025-09-09","hemoglobin_g_dL":11.8,"wbc_k_uL":7.4,"platelets_k_uL":229,"creatinine_mg_dL":1.01,"alt_U_L":91},{"date":"2027-02-05","hemoglobin_g_dL":12.9,"wbc_k_uL":5.1,"platelets_k_uL":323,"creatinine_mg_dL":1.29,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_1506","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":72,"sex":"male","bmi":29.7,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-09-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-38},"pfs_months":15.61},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.5,"censored":false},"longitudinal_labs":[{"date":"2020-07-08","hemoglobin_g_dL":11.9,"wbc_k_uL":4.9,"platelets_k_uL":351,"creatinine_mg_dL":0.77,"alt_U_L":38},{"date":"2021-03-01","hemoglobin_g_dL":10.6,"wbc_k_uL":4.1,"platelets_k_uL":254,"creatinine_mg_dL":0.79,"alt_U_L":46},{"date":"2022-01-18","hemoglobin_g_dL":13.0,"wbc_k_uL":6.3,"platelets_k_uL":242,"creatinine_mg_dL":1.54,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_1507","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":81,"sex":"female","bmi":30.3,"smoking_pack_years":53,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-01-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-48},"pfs_months":5.13},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":14.5,"censored":false},"longitudinal_labs":[{"date":"2022-12-21","hemoglobin_g_dL":13.8,"wbc_k_uL":6.3,"platelets_k_uL":235,"creatinine_mg_dL":0.71,"alt_U_L":52},{"date":"2023-07-23","hemoglobin_g_dL":12.9,"wbc_k_uL":5.8,"platelets_k_uL":162,"creatinine_mg_dL":0.73,"alt_U_L":63},{"date":"2023-08-22","hemoglobin_g_dL":12.1,"wbc_k_uL":6.7,"platelets_k_uL":316,"creatinine_mg_dL":1.59,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_1508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":48,"sex":"male","bmi":29.9,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-01-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-72},"pfs_months":13.44},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":17.4,"censored":true},"longitudinal_labs":[{"date":"2021-11-20","hemoglobin_g_dL":15.3,"wbc_k_uL":6.2,"platelets_k_uL":241,"creatinine_mg_dL":1.27,"alt_U_L":41},{"date":"2022-07-06","hemoglobin_g_dL":10.7,"wbc_k_uL":4.2,"platelets_k_uL":186,"creatinine_mg_dL":1.57,"alt_U_L":34},{"date":"2023-03-27","hemoglobin_g_dL":10.7,"wbc_k_uL":3.6,"platelets_k_uL":312,"creatinine_mg_dL":1.43,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_1509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":67,"sex":"female","bmi":30.8,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-41},"pfs_months":31.24},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.9,"censored":true},"longitudinal_labs":[{"date":"2021-07-25","hemoglobin_g_dL":11.7,"wbc_k_uL":5.2,"platelets_k_uL":281,"creatinine_mg_dL":0.67,"alt_U_L":59},{"date":"2022-03-26","hemoglobin_g_dL":12.9,"wbc_k_uL":4.0,"platelets_k_uL":290,"creatinine_mg_dL":1.43,"alt_U_L":15},{"date":"2024-05-15","hemoglobin_g_dL":9.8,"wbc_k_uL":6.1,"platelets_k_uL":254,"creatinine_mg_dL":1.67,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_1510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":18.0,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":65,"sex":"female","bmi":22.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-33},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.1,"censored":false},"longitudinal_labs":[{"date":"2021-07-12","hemoglobin_g_dL":15.5,"wbc_k_uL":6.2,"platelets_k_uL":404,"creatinine_mg_dL":1.28,"alt_U_L":39},{"date":"2022-03-01","hemoglobin_g_dL":13.5,"wbc_k_uL":6.3,"platelets_k_uL":331,"creatinine_mg_dL":1.32,"alt_U_L":15},{"date":"2023-08-05","hemoglobin_g_dL":13.0,"wbc_k_uL":5.2,"platelets_k_uL":188,"creatinine_mg_dL":0.99,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_1511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":53,"sex":"female","bmi":29.3,"smoking_pack_years":11,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-63},"pfs_months":10.97},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":22.1,"censored":false},"longitudinal_labs":[{"date":"2021-01-05","hemoglobin_g_dL":14.5,"wbc_k_uL":5.0,"platelets_k_uL":170,"creatinine_mg_dL":1.12,"alt_U_L":29},{"date":"2021-09-04","hemoglobin_g_dL":10.2,"wbc_k_uL":7.5,"platelets_k_uL":264,"creatinine_mg_dL":1.19,"alt_U_L":20},{"date":"2022-03-23","hemoglobin_g_dL":10.6,"wbc_k_uL":5.0,"platelets_k_uL":296,"creatinine_mg_dL":1.63,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_1512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":77,"sex":"male","bmi":24.0,"smoking_pack_years":12,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-05-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-50},"pfs_months":6.93},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":10.9,"censored":false},"longitudinal_labs":[{"date":"2024-03-01","hemoglobin_g_dL":14.5,"wbc_k_uL":8.7,"platelets_k_uL":412,"creatinine_mg_dL":0.8,"alt_U_L":32},{"date":"2024-11-02","hemoglobin_g_dL":11.9,"wbc_k_uL":6.8,"platelets_k_uL":195,"creatinine_mg_dL":1.27,"alt_U_L":16},{"date":"2025-01-25","hemoglobin_g_dL":10.6,"wbc_k_uL":7.9,"platelets_k_uL":260,"creatinine_mg_dL":1.93,"alt_U_L":197}]}
{"patient_id":"ANODE_SYNTH_2025_1513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":53,"sex":"female","bmi":19.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-53},"pfs_months":21.62},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.5,"censored":true},"longitudinal_labs":[{"date":"2023-01-02","hemoglobin_g_dL":15.4,"wbc_k_uL":7.4,"platelets_k_uL":258,"creatinine_mg_dL":0.76,"alt_U_L":34},{"date":"2023-09-01","hemoglobin_g_dL":12.9,"wbc_k_uL":4.3,"platelets_k_uL":283,"creatinine_mg_dL":1.38,"alt_U_L":93},{"date":"2025-01-15","hemoglobin_g_dL":11.5,"wbc_k_uL":5.4,"platelets_k_uL":169,"creatinine_mg_dL":1.11,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_1514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":48,"sex":"female","bmi":25.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-30},"pfs_months":24.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.0,"censored":false},"longitudinal_labs":[{"date":"2022-07-14","hemoglobin_g_dL":13.4,"wbc_k_uL":6.4,"platelets_k_uL":223,"creatinine_mg_dL":0.61,"alt_U_L":45},{"date":"2023-01-30","hemoglobin_g_dL":13.1,"wbc_k_uL":6.2,"platelets_k_uL":266,"creatinine_mg_dL":0.76,"alt_U_L":37},{"date":"2024-09-23","hemoglobin_g_dL":12.0,"wbc_k_uL":4.8,"platelets_k_uL":148,"creatinine_mg_dL":1.85,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_1515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":63,"sex":"female","bmi":34.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-73},"pfs_months":17.05},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.9,"censored":false},"longitudinal_labs":[{"date":"2020-03-28","hemoglobin_g_dL":15.1,"wbc_k_uL":5.8,"platelets_k_uL":215,"creatinine_mg_dL":0.71,"alt_U_L":68},{"date":"2020-10-08","hemoglobin_g_dL":10.3,"wbc_k_uL":6.8,"platelets_k_uL":377,"creatinine_mg_dL":0.89,"alt_U_L":107},{"date":"2021-10-12","hemoglobin_g_dL":12.3,"wbc_k_uL":4.3,"platelets_k_uL":260,"creatinine_mg_dL":1.78,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_1516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":85,"sex":"female","bmi":24.6,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-45},"pfs_months":34.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-12-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.6,"censored":false},"longitudinal_labs":[{"date":"2025-10-24","hemoglobin_g_dL":15.3,"wbc_k_uL":5.7,"platelets_k_uL":192,"creatinine_mg_dL":1.03,"alt_U_L":13},{"date":"2026-06-08","hemoglobin_g_dL":10.2,"wbc_k_uL":6.1,"platelets_k_uL":212,"creatinine_mg_dL":1.49,"alt_U_L":87},{"date":"2028-12-13","hemoglobin_g_dL":11.2,"wbc_k_uL":3.1,"platelets_k_uL":148,"creatinine_mg_dL":1.77,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_1517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":74,"sex":"female","bmi":26.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-53},"pfs_months":16.82},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.6,"censored":false},"longitudinal_labs":[{"date":"2022-05-22","hemoglobin_g_dL":12.5,"wbc_k_uL":7.8,"platelets_k_uL":165,"creatinine_mg_dL":1.13,"alt_U_L":29},{"date":"2023-01-06","hemoglobin_g_dL":10.7,"wbc_k_uL":7.7,"platelets_k_uL":179,"creatinine_mg_dL":1.21,"alt_U_L":93},{"date":"2023-12-14","hemoglobin_g_dL":12.2,"wbc_k_uL":5.2,"platelets_k_uL":304,"creatinine_mg_dL":1.51,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_1518","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":81,"sex":"female","bmi":28.8,"smoking_pack_years":11,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-70},"pfs_months":29.17},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":false},"longitudinal_labs":[{"date":"2025-07-10","hemoglobin_g_dL":12.5,"wbc_k_uL":10.2,"platelets_k_uL":236,"creatinine_mg_dL":0.82,"alt_U_L":34},{"date":"2026-02-14","hemoglobin_g_dL":12.4,"wbc_k_uL":4.8,"platelets_k_uL":219,"creatinine_mg_dL":0.97,"alt_U_L":83},{"date":"2028-03-04","hemoglobin_g_dL":11.0,"wbc_k_uL":3.4,"platelets_k_uL":258,"creatinine_mg_dL":1.27,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_1519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":72,"sex":"male","bmi":30.7,"smoking_pack_years":52,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-12-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-41},"pfs_months":8.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":12.4,"censored":false},"longitudinal_labs":[{"date":"2025-10-06","hemoglobin_g_dL":13.4,"wbc_k_uL":5.0,"platelets_k_uL":429,"creatinine_mg_dL":0.64,"alt_U_L":27},{"date":"2026-06-03","hemoglobin_g_dL":11.4,"wbc_k_uL":7.9,"platelets_k_uL":209,"creatinine_mg_dL":1.47,"alt_U_L":91},{"date":"2026-09-04","hemoglobin_g_dL":11.5,"wbc_k_uL":4.3,"platelets_k_uL":259,"creatinine_mg_dL":1.84,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_1520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":53,"sex":"female","bmi":27.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-47},"pfs_months":18.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.5,"censored":true},"longitudinal_labs":[{"date":"2025-01-22","hemoglobin_g_dL":15.3,"wbc_k_uL":9.6,"platelets_k_uL":349,"creatinine_mg_dL":0.66,"alt_U_L":43},{"date":"2025-09-11","hemoglobin_g_dL":12.0,"wbc_k_uL":5.3,"platelets_k_uL":373,"creatinine_mg_dL":0.92,"alt_U_L":109},{"date":"2026-10-05","hemoglobin_g_dL":11.4,"wbc_k_uL":7.3,"platelets_k_uL":108,"creatinine_mg_dL":1.31,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_1521","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":50,"sex":"female","bmi":20.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-35},"pfs_months":8.08},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-06-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.3,"censored":false},"longitudinal_labs":[{"date":"2020-08-19","hemoglobin_g_dL":14.1,"wbc_k_uL":5.0,"platelets_k_uL":371,"creatinine_mg_dL":1.09,"alt_U_L":65},{"date":"2021-03-30","hemoglobin_g_dL":12.7,"wbc_k_uL":6.1,"platelets_k_uL":316,"creatinine_mg_dL":0.81,"alt_U_L":99},{"date":"2021-06-19","hemoglobin_g_dL":11.5,"wbc_k_uL":4.8,"platelets_k_uL":350,"creatinine_mg_dL":1.91,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_1522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":66,"sex":"female","bmi":21.1,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-05-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-53},"pfs_months":34.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":56.0,"censored":false},"longitudinal_labs":[{"date":"2023-04-11","hemoglobin_g_dL":14.7,"wbc_k_uL":10.9,"platelets_k_uL":278,"creatinine_mg_dL":1.06,"alt_U_L":26},{"date":"2023-11-24","hemoglobin_g_dL":10.2,"wbc_k_uL":5.3,"platelets_k_uL":200,"creatinine_mg_dL":1.22,"alt_U_L":37},{"date":"2026-05-09","hemoglobin_g_dL":11.8,"wbc_k_uL":7.1,"platelets_k_uL":283,"creatinine_mg_dL":1.24,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_1523","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":53,"sex":"female","bmi":34.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-72},"pfs_months":25.1},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.4,"censored":false},"longitudinal_labs":[{"date":"2021-08-18","hemoglobin_g_dL":14.7,"wbc_k_uL":9.5,"platelets_k_uL":311,"creatinine_mg_dL":0.93,"alt_U_L":72},{"date":"2022-04-05","hemoglobin_g_dL":10.1,"wbc_k_uL":4.2,"platelets_k_uL":270,"creatinine_mg_dL":1.2,"alt_U_L":52},{"date":"2023-12-22","hemoglobin_g_dL":12.6,"wbc_k_uL":4.9,"platelets_k_uL":330,"creatinine_mg_dL":1.37,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_1524","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":81,"sex":"female","bmi":29.0,"smoking_pack_years":53,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-12-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-39},"pfs_months":29.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":48.6,"censored":false},"longitudinal_labs":[{"date":"2025-11-12","hemoglobin_g_dL":12.6,"wbc_k_uL":7.1,"platelets_k_uL":428,"creatinine_mg_dL":0.74,"alt_U_L":44},{"date":"2026-06-09","hemoglobin_g_dL":12.7,"wbc_k_uL":7.5,"platelets_k_uL":284,"creatinine_mg_dL":0.93,"alt_U_L":68},{"date":"2028-07-15","hemoglobin_g_dL":9.8,"wbc_k_uL":3.8,"platelets_k_uL":124,"creatinine_mg_dL":1.8,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_1525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":71,"sex":"female","bmi":22.6,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-07-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-60},"pfs_months":42.87},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":69.5,"censored":false},"longitudinal_labs":[{"date":"2021-07-02","hemoglobin_g_dL":14.1,"wbc_k_uL":5.0,"platelets_k_uL":252,"creatinine_mg_dL":1.28,"alt_U_L":20},{"date":"2022-01-16","hemoglobin_g_dL":10.9,"wbc_k_uL":4.5,"platelets_k_uL":322,"creatinine_mg_dL":1.08,"alt_U_L":90},{"date":"2025-02-26","hemoglobin_g_dL":10.0,"wbc_k_uL":7.8,"platelets_k_uL":212,"creatinine_mg_dL":1.03,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_1526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":73,"sex":"female","bmi":25.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-42},"pfs_months":27.73},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":false},"longitudinal_labs":[{"date":"2021-04-01","hemoglobin_g_dL":12.6,"wbc_k_uL":6.9,"platelets_k_uL":357,"creatinine_mg_dL":0.71,"alt_U_L":50},{"date":"2021-11-20","hemoglobin_g_dL":12.3,"wbc_k_uL":4.7,"platelets_k_uL":214,"creatinine_mg_dL":1.46,"alt_U_L":90},{"date":"2023-10-08","hemoglobin_g_dL":10.2,"wbc_k_uL":5.7,"platelets_k_uL":333,"creatinine_mg_dL":1.47,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_1527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":86,"sex":"female","bmi":24.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-78},"pfs_months":20.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":false},"longitudinal_labs":[{"date":"2021-01-17","hemoglobin_g_dL":12.9,"wbc_k_uL":6.4,"platelets_k_uL":370,"creatinine_mg_dL":0.77,"alt_U_L":77},{"date":"2021-09-05","hemoglobin_g_dL":13.8,"wbc_k_uL":5.5,"platelets_k_uL":324,"creatinine_mg_dL":1.5,"alt_U_L":36},{"date":"2022-12-04","hemoglobin_g_dL":9.6,"wbc_k_uL":6.9,"platelets_k_uL":120,"creatinine_mg_dL":1.76,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_1528","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":52,"sex":"female","bmi":30.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-59},"pfs_months":26.71},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":false},"longitudinal_labs":[{"date":"2024-11-25","hemoglobin_g_dL":14.9,"wbc_k_uL":9.8,"platelets_k_uL":406,"creatinine_mg_dL":1.3,"alt_U_L":70},{"date":"2025-07-19","hemoglobin_g_dL":10.2,"wbc_k_uL":4.0,"platelets_k_uL":278,"creatinine_mg_dL":1.23,"alt_U_L":50},{"date":"2027-05-09","hemoglobin_g_dL":10.9,"wbc_k_uL":6.8,"platelets_k_uL":325,"creatinine_mg_dL":1.88,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_1529","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":82,"sex":"male","bmi":29.4,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-66},"pfs_months":11.5},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.0,"censored":false},"longitudinal_labs":[{"date":"2021-04-26","hemoglobin_g_dL":13.0,"wbc_k_uL":5.8,"platelets_k_uL":156,"creatinine_mg_dL":0.83,"alt_U_L":43},{"date":"2021-12-30","hemoglobin_g_dL":11.7,"wbc_k_uL":4.6,"platelets_k_uL":267,"creatinine_mg_dL":0.85,"alt_U_L":32},{"date":"2022-07-13","hemoglobin_g_dL":11.0,"wbc_k_uL":3.1,"platelets_k_uL":265,"creatinine_mg_dL":1.93,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_1530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":52,"sex":"female","bmi":20.1,"smoking_pack_years":59,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2026-02-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-61},"pfs_months":51.12},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2030-06-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":81.5,"censored":false},"longitudinal_labs":[{"date":"2025-12-18","hemoglobin_g_dL":15.5,"wbc_k_uL":9.9,"platelets_k_uL":169,"creatinine_mg_dL":1.09,"alt_U_L":51},{"date":"2026-08-21","hemoglobin_g_dL":11.5,"wbc_k_uL":5.7,"platelets_k_uL":234,"creatinine_mg_dL":1.33,"alt_U_L":104},{"date":"2030-06-01","hemoglobin_g_dL":11.1,"wbc_k_uL":3.4,"platelets_k_uL":258,"creatinine_mg_dL":1.66,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_1531","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":81,"sex":"female","bmi":25.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-80},"pfs_months":22.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":true},"longitudinal_labs":[{"date":"2023-10-20","hemoglobin_g_dL":12.2,"wbc_k_uL":7.1,"platelets_k_uL":155,"creatinine_mg_dL":1.15,"alt_U_L":17},{"date":"2024-06-21","hemoglobin_g_dL":12.2,"wbc_k_uL":5.7,"platelets_k_uL":288,"creatinine_mg_dL":1.33,"alt_U_L":67},{"date":"2026-01-06","hemoglobin_g_dL":12.7,"wbc_k_uL":3.9,"platelets_k_uL":294,"creatinine_mg_dL":1.75,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_1532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":69,"sex":"male","bmi":23.4,"smoking_pack_years":66,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-11-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-67},"pfs_months":4.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":8.9,"censored":false},"longitudinal_labs":[{"date":"2023-09-20","hemoglobin_g_dL":12.0,"wbc_k_uL":5.6,"platelets_k_uL":419,"creatinine_mg_dL":1.26,"alt_U_L":35},{"date":"2024-05-21","hemoglobin_g_dL":12.8,"wbc_k_uL":7.4,"platelets_k_uL":188,"creatinine_mg_dL":1.06,"alt_U_L":112},{"date":"2024-05-02","hemoglobin_g_dL":12.9,"wbc_k_uL":3.6,"platelets_k_uL":240,"creatinine_mg_dL":1.41,"alt_U_L":90}]}
{"patient_id":"ANODE_SYNTH_2025_1533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":82,"sex":"female","bmi":26.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-59},"pfs_months":18.99},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-16","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":true},"longitudinal_labs":[{"date":"2024-04-27","hemoglobin_g_dL":13.4,"wbc_k_uL":7.4,"platelets_k_uL":251,"creatinine_mg_dL":0.77,"alt_U_L":61},{"date":"2024-11-16","hemoglobin_g_dL":10.5,"wbc_k_uL":5.2,"platelets_k_uL":234,"creatinine_mg_dL":1.3,"alt_U_L":40},{"date":"2026-01-16","hemoglobin_g_dL":12.0,"wbc_k_uL":3.1,"platelets_k_uL":178,"creatinine_mg_dL":0.88,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_1534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":81,"sex":"female","bmi":35.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-73},"pfs_months":21.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.3,"censored":false},"longitudinal_labs":[{"date":"2023-06-25","hemoglobin_g_dL":14.8,"wbc_k_uL":7.0,"platelets_k_uL":286,"creatinine_mg_dL":0.67,"alt_U_L":20},{"date":"2024-01-23","hemoglobin_g_dL":12.7,"wbc_k_uL":5.5,"platelets_k_uL":308,"creatinine_mg_dL":0.84,"alt_U_L":115},{"date":"2025-07-03","hemoglobin_g_dL":9.8,"wbc_k_uL":5.7,"platelets_k_uL":172,"creatinine_mg_dL":0.98,"alt_U_L":71}]}
{"patient_id":"ANODE_SYNTH_2025_1535","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":81,"sex":"male","bmi":26.5,"smoking_pack_years":53,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-02-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-52},"pfs_months":19.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-10","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.3,"censored":false},"longitudinal_labs":[{"date":"2024-12-20","hemoglobin_g_dL":12.7,"wbc_k_uL":8.2,"platelets_k_uL":207,"creatinine_mg_dL":0.9,"alt_U_L":22},{"date":"2025-08-26","hemoglobin_g_dL":13.7,"wbc_k_uL":7.2,"platelets_k_uL":343,"creatinine_mg_dL":0.95,"alt_U_L":87},{"date":"2026-12-10","hemoglobin_g_dL":9.5,"wbc_k_uL":6.1,"platelets_k_uL":345,"creatinine_mg_dL":1.53,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_1536","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":60,"sex":"male","bmi":27.5,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-11-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-79},"pfs_months":17.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":false},"longitudinal_labs":[{"date":"2024-10-09","hemoglobin_g_dL":12.0,"wbc_k_uL":10.6,"platelets_k_uL":358,"creatinine_mg_dL":0.99,"alt_U_L":72},{"date":"2025-05-12","hemoglobin_g_dL":11.0,"wbc_k_uL":8.8,"platelets_k_uL":375,"creatinine_mg_dL":1.33,"alt_U_L":32},{"date":"2026-05-18","hemoglobin_g_dL":12.2,"wbc_k_uL":7.4,"platelets_k_uL":139,"creatinine_mg_dL":1.53,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_1537","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":63,"sex":"female","bmi":25.4,"smoking_pack_years":17,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-67},"pfs_months":30.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":53.8,"censored":false},"longitudinal_labs":[{"date":"2024-10-25","hemoglobin_g_dL":12.6,"wbc_k_uL":5.7,"platelets_k_uL":191,"creatinine_mg_dL":0.74,"alt_U_L":60},{"date":"2025-07-01","hemoglobin_g_dL":12.0,"wbc_k_uL":5.1,"platelets_k_uL":358,"creatinine_mg_dL":1.48,"alt_U_L":22},{"date":"2027-09-14","hemoglobin_g_dL":10.9,"wbc_k_uL":6.7,"platelets_k_uL":278,"creatinine_mg_dL":0.91,"alt_U_L":71}]}
{"patient_id":"ANODE_SYNTH_2025_1538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":85,"sex":"female","bmi":27.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-74},"pfs_months":25.4},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.1,"censored":false},"longitudinal_labs":[{"date":"2024-04-25","hemoglobin_g_dL":13.3,"wbc_k_uL":10.0,"platelets_k_uL":342,"creatinine_mg_dL":0.97,"alt_U_L":11},{"date":"2024-11-07","hemoglobin_g_dL":11.8,"wbc_k_uL":6.5,"platelets_k_uL":375,"creatinine_mg_dL":0.76,"alt_U_L":33},{"date":"2026-08-18","hemoglobin_g_dL":12.1,"wbc_k_uL":6.2,"platelets_k_uL":240,"creatinine_mg_dL":0.81,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_1539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":87,"sex":"female","bmi":19.2,"smoking_pack_years":12,"ecog_performance_status":0,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-71},"pfs_months":4.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-04-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":13.0,"censored":false},"longitudinal_labs":[{"date":"2020-10-19","hemoglobin_g_dL":13.1,"wbc_k_uL":8.8,"platelets_k_uL":440,"creatinine_mg_dL":0.7,"alt_U_L":49},{"date":"2021-05-03","hemoglobin_g_dL":13.2,"wbc_k_uL":4.2,"platelets_k_uL":322,"creatinine_mg_dL":1.07,"alt_U_L":64},{"date":"2021-04-25","hemoglobin_g_dL":12.2,"wbc_k_uL":5.1,"platelets_k_uL":288,"creatinine_mg_dL":1.62,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_1540","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":49,"sex":"male","bmi":33.1,"smoking_pack_years":15,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-30},"pfs_months":6.97},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.8,"censored":false},"longitudinal_labs":[{"date":"2023-08-20","hemoglobin_g_dL":11.8,"wbc_k_uL":9.3,"platelets_k_uL":220,"creatinine_mg_dL":0.65,"alt_U_L":18},{"date":"2024-03-20","hemoglobin_g_dL":13.9,"wbc_k_uL":5.8,"platelets_k_uL":354,"creatinine_mg_dL":0.99,"alt_U_L":15},{"date":"2024-06-01","hemoglobin_g_dL":9.8,"wbc_k_uL":4.5,"platelets_k_uL":312,"creatinine_mg_dL":1.63,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_1541","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":76,"sex":"female","bmi":34.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-38},"pfs_months":23.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.5,"censored":true},"longitudinal_labs":[{"date":"2025-04-12","hemoglobin_g_dL":15.2,"wbc_k_uL":6.3,"platelets_k_uL":186,"creatinine_mg_dL":1.22,"alt_U_L":77},{"date":"2025-10-27","hemoglobin_g_dL":11.1,"wbc_k_uL":8.1,"platelets_k_uL":346,"creatinine_mg_dL":0.97,"alt_U_L":29},{"date":"2027-05-27","hemoglobin_g_dL":12.6,"wbc_k_uL":3.8,"platelets_k_uL":311,"creatinine_mg_dL":1.38,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_1542","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":76,"sex":"female","bmi":29.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-03-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-75},"pfs_months":23.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":45.7,"censored":false},"longitudinal_labs":[{"date":"2020-02-08","hemoglobin_g_dL":11.6,"wbc_k_uL":9.3,"platelets_k_uL":307,"creatinine_mg_dL":1.22,"alt_U_L":70},{"date":"2020-09-10","hemoglobin_g_dL":11.2,"wbc_k_uL":7.8,"platelets_k_uL":139,"creatinine_mg_dL":0.84,"alt_U_L":17},{"date":"2022-03-18","hemoglobin_g_dL":10.3,"wbc_k_uL":3.3,"platelets_k_uL":331,"creatinine_mg_dL":1.8,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_1543","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":66,"sex":"female","bmi":27.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-38},"pfs_months":22.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.1,"censored":false},"longitudinal_labs":[{"date":"2025-11-23","hemoglobin_g_dL":12.8,"wbc_k_uL":5.1,"platelets_k_uL":381,"creatinine_mg_dL":1.12,"alt_U_L":42},{"date":"2026-06-14","hemoglobin_g_dL":12.1,"wbc_k_uL":4.8,"platelets_k_uL":217,"creatinine_mg_dL":1.2,"alt_U_L":107},{"date":"2027-12-26","hemoglobin_g_dL":11.4,"wbc_k_uL":5.5,"platelets_k_uL":135,"creatinine_mg_dL":1.01,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_1544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":18.0,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":53,"sex":"female","bmi":30.6,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-02-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-34},"pfs_months":18.99},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":false},"longitudinal_labs":[{"date":"2021-11-28","hemoglobin_g_dL":13.5,"wbc_k_uL":5.7,"platelets_k_uL":181,"creatinine_mg_dL":0.87,"alt_U_L":23},{"date":"2022-07-31","hemoglobin_g_dL":11.0,"wbc_k_uL":7.2,"platelets_k_uL":150,"creatinine_mg_dL":1.13,"alt_U_L":85},{"date":"2023-09-08","hemoglobin_g_dL":11.4,"wbc_k_uL":6.6,"platelets_k_uL":258,"creatinine_mg_dL":1.39,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_1545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":58,"sex":"female","bmi":30.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-64},"pfs_months":24.51},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.3,"censored":false},"longitudinal_labs":[{"date":"2025-01-10","hemoglobin_g_dL":12.0,"wbc_k_uL":9.3,"platelets_k_uL":232,"creatinine_mg_dL":0.75,"alt_U_L":33},{"date":"2025-09-12","hemoglobin_g_dL":11.9,"wbc_k_uL":6.2,"platelets_k_uL":361,"creatinine_mg_dL":0.93,"alt_U_L":57},{"date":"2027-05-03","hemoglobin_g_dL":10.9,"wbc_k_uL":3.7,"platelets_k_uL":234,"creatinine_mg_dL":1.1,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_1546","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":77,"sex":"female","bmi":32.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-38},"pfs_months":24.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":false},"longitudinal_labs":[{"date":"2020-08-26","hemoglobin_g_dL":12.0,"wbc_k_uL":5.7,"platelets_k_uL":294,"creatinine_mg_dL":0.85,"alt_U_L":68},{"date":"2021-04-09","hemoglobin_g_dL":13.4,"wbc_k_uL":3.8,"platelets_k_uL":158,"creatinine_mg_dL":1.28,"alt_U_L":82},{"date":"2022-12-05","hemoglobin_g_dL":9.7,"wbc_k_uL":7.9,"platelets_k_uL":297,"creatinine_mg_dL":1.91,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_1547","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":81,"sex":"male","bmi":35.6,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-09-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-44},"pfs_months":30.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.9,"censored":true},"longitudinal_labs":[{"date":"2022-07-26","hemoglobin_g_dL":13.9,"wbc_k_uL":6.3,"platelets_k_uL":163,"creatinine_mg_dL":1.13,"alt_U_L":79},{"date":"2023-03-03","hemoglobin_g_dL":13.6,"wbc_k_uL":5.4,"platelets_k_uL":259,"creatinine_mg_dL":1.32,"alt_U_L":58},{"date":"2025-04-16","hemoglobin_g_dL":12.2,"wbc_k_uL":7.8,"platelets_k_uL":114,"creatinine_mg_dL":1.65,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_1548","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":82,"sex":"male","bmi":19.1,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-10-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-61},"pfs_months":25.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.4,"censored":true},"longitudinal_labs":[{"date":"2024-09-20","hemoglobin_g_dL":15.5,"wbc_k_uL":10.8,"platelets_k_uL":255,"creatinine_mg_dL":0.82,"alt_U_L":60},{"date":"2025-04-13","hemoglobin_g_dL":10.0,"wbc_k_uL":6.7,"platelets_k_uL":362,"creatinine_mg_dL":0.88,"alt_U_L":35},{"date":"2027-01-07","hemoglobin_g_dL":10.0,"wbc_k_uL":3.6,"platelets_k_uL":220,"creatinine_mg_dL":0.86,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_1549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":82,"sex":"male","bmi":27.6,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-08-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-76},"pfs_months":42.61},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":70.4,"censored":true},"longitudinal_labs":[{"date":"2020-05-27","hemoglobin_g_dL":12.4,"wbc_k_uL":8.4,"platelets_k_uL":334,"creatinine_mg_dL":0.9,"alt_U_L":42},{"date":"2021-01-31","hemoglobin_g_dL":13.2,"wbc_k_uL":8.6,"platelets_k_uL":337,"creatinine_mg_dL":1.17,"alt_U_L":55},{"date":"2024-03-09","hemoglobin_g_dL":12.7,"wbc_k_uL":6.5,"platelets_k_uL":211,"creatinine_mg_dL":1.24,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_1550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":77,"sex":"female","bmi":35.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-01-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-64},"pfs_months":14.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.7,"censored":true},"longitudinal_labs":[{"date":"2025-12-17","hemoglobin_g_dL":12.8,"wbc_k_uL":5.0,"platelets_k_uL":186,"creatinine_mg_dL":1.0,"alt_U_L":52},{"date":"2026-07-10","hemoglobin_g_dL":11.9,"wbc_k_uL":8.4,"platelets_k_uL":142,"creatinine_mg_dL":1.1,"alt_U_L":53},{"date":"2027-04-30","hemoglobin_g_dL":9.5,"wbc_k_uL":7.3,"platelets_k_uL":138,"creatinine_mg_dL":1.67,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_1551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":78,"sex":"female","bmi":29.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-58},"pfs_months":30.92},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.7,"censored":true},"longitudinal_labs":[{"date":"2021-06-05","hemoglobin_g_dL":13.3,"wbc_k_uL":8.4,"platelets_k_uL":314,"creatinine_mg_dL":0.78,"alt_U_L":16},{"date":"2022-01-31","hemoglobin_g_dL":13.6,"wbc_k_uL":5.4,"platelets_k_uL":262,"creatinine_mg_dL":1.34,"alt_U_L":93},{"date":"2024-03-11","hemoglobin_g_dL":12.1,"wbc_k_uL":3.1,"platelets_k_uL":245,"creatinine_mg_dL":1.8,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_1552","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":52,"sex":"male","bmi":32.3,"smoking_pack_years":56,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-07-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-67},"pfs_months":31.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.9,"censored":false},"longitudinal_labs":[{"date":"2024-06-20","hemoglobin_g_dL":15.1,"wbc_k_uL":8.4,"platelets_k_uL":404,"creatinine_mg_dL":0.68,"alt_U_L":24},{"date":"2025-01-15","hemoglobin_g_dL":10.6,"wbc_k_uL":4.2,"platelets_k_uL":175,"creatinine_mg_dL":1.16,"alt_U_L":75},{"date":"2027-05-09","hemoglobin_g_dL":12.0,"wbc_k_uL":6.2,"platelets_k_uL":328,"creatinine_mg_dL":1.85,"alt_U_L":176}]}
{"patient_id":"ANODE_SYNTH_2025_1553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":53,"sex":"female","bmi":32.2,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-11-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-40},"pfs_months":19.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.9,"censored":true},"longitudinal_labs":[{"date":"2022-10-16","hemoglobin_g_dL":15.1,"wbc_k_uL":4.7,"platelets_k_uL":344,"creatinine_mg_dL":0.88,"alt_U_L":31},{"date":"2023-05-01","hemoglobin_g_dL":13.4,"wbc_k_uL":4.3,"platelets_k_uL":271,"creatinine_mg_dL":0.84,"alt_U_L":26},{"date":"2024-07-18","hemoglobin_g_dL":11.4,"wbc_k_uL":6.7,"platelets_k_uL":249,"creatinine_mg_dL":1.89,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_1554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":63,"sex":"male","bmi":28.3,"smoking_pack_years":39,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-01-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-60},"pfs_months":8.61},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":13.5,"censored":true},"longitudinal_labs":[{"date":"2021-11-09","hemoglobin_g_dL":14.6,"wbc_k_uL":9.7,"platelets_k_uL":186,"creatinine_mg_dL":1.27,"alt_U_L":66},{"date":"2022-07-12","hemoglobin_g_dL":11.4,"wbc_k_uL":6.7,"platelets_k_uL":243,"creatinine_mg_dL":1.44,"alt_U_L":99},{"date":"2022-11-10","hemoglobin_g_dL":11.8,"wbc_k_uL":4.6,"platelets_k_uL":129,"creatinine_mg_dL":1.47,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_1555","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":68,"sex":"male","bmi":34.3,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-09-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-62},"pfs_months":14.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.6,"censored":false},"longitudinal_labs":[{"date":"2023-08-07","hemoglobin_g_dL":14.2,"wbc_k_uL":10.6,"platelets_k_uL":398,"creatinine_mg_dL":0.99,"alt_U_L":80},{"date":"2024-03-22","hemoglobin_g_dL":10.4,"wbc_k_uL":4.9,"platelets_k_uL":274,"creatinine_mg_dL":1.19,"alt_U_L":72},{"date":"2024-12-30","hemoglobin_g_dL":10.2,"wbc_k_uL":7.5,"platelets_k_uL":284,"creatinine_mg_dL":1.77,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_1556","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":79,"sex":"female","bmi":19.2,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-12-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-77},"pfs_months":21.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.3,"censored":true},"longitudinal_labs":[{"date":"2021-10-04","hemoglobin_g_dL":15.1,"wbc_k_uL":5.8,"platelets_k_uL":258,"creatinine_mg_dL":0.97,"alt_U_L":47},{"date":"2022-05-31","hemoglobin_g_dL":11.4,"wbc_k_uL":8.4,"platelets_k_uL":141,"creatinine_mg_dL":0.77,"alt_U_L":100},{"date":"2023-11-17","hemoglobin_g_dL":10.5,"wbc_k_uL":5.3,"platelets_k_uL":149,"creatinine_mg_dL":1.02,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_1557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":54,"sex":"male","bmi":19.2,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-11-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-52},"pfs_months":41.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":64.7,"censored":false},"longitudinal_labs":[{"date":"2024-09-17","hemoglobin_g_dL":13.3,"wbc_k_uL":8.7,"platelets_k_uL":384,"creatinine_mg_dL":0.82,"alt_U_L":72},{"date":"2025-05-10","hemoglobin_g_dL":14.0,"wbc_k_uL":4.2,"platelets_k_uL":368,"creatinine_mg_dL":1.34,"alt_U_L":44},{"date":"2028-05-27","hemoglobin_g_dL":10.7,"wbc_k_uL":6.2,"platelets_k_uL":150,"creatinine_mg_dL":1.55,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_1558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":70,"sex":"female","bmi":32.9,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-06-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-85},"pfs_months":46.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":78.7,"censored":false},"longitudinal_labs":[{"date":"2022-04-04","hemoglobin_g_dL":14.2,"wbc_k_uL":7.4,"platelets_k_uL":449,"creatinine_mg_dL":1.25,"alt_U_L":55},{"date":"2022-12-09","hemoglobin_g_dL":12.4,"wbc_k_uL":8.8,"platelets_k_uL":230,"creatinine_mg_dL":0.86,"alt_U_L":103},{"date":"2026-05-06","hemoglobin_g_dL":11.5,"wbc_k_uL":5.0,"platelets_k_uL":338,"creatinine_mg_dL":1.35,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_1559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":88,"sex":"male","bmi":31.7,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-55},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.0,"censored":false},"longitudinal_labs":[{"date":"2025-06-09","hemoglobin_g_dL":14.8,"wbc_k_uL":8.0,"platelets_k_uL":355,"creatinine_mg_dL":1.26,"alt_U_L":70},{"date":"2026-01-11","hemoglobin_g_dL":13.2,"wbc_k_uL":7.4,"platelets_k_uL":270,"creatinine_mg_dL":1.54,"alt_U_L":21},{"date":"2025-12-11","hemoglobin_g_dL":10.5,"wbc_k_uL":7.6,"platelets_k_uL":275,"creatinine_mg_dL":1.08,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_1560","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":83,"sex":"male","bmi":36.9,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-04-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-73},"pfs_months":25.07},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":47.0,"censored":false},"longitudinal_labs":[{"date":"2020-03-16","hemoglobin_g_dL":14.4,"wbc_k_uL":10.3,"platelets_k_uL":228,"creatinine_mg_dL":1.06,"alt_U_L":73},{"date":"2020-10-23","hemoglobin_g_dL":12.9,"wbc_k_uL":8.1,"platelets_k_uL":324,"creatinine_mg_dL":0.92,"alt_U_L":41},{"date":"2022-06-07","hemoglobin_g_dL":11.2,"wbc_k_uL":4.3,"platelets_k_uL":144,"creatinine_mg_dL":1.63,"alt_U_L":112}]}
{"patient_id":"ANODE_SYNTH_2025_1561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":69,"sex":"male","bmi":30.9,"smoking_pack_years":48,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-08-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-73},"pfs_months":37.03},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":51.4,"censored":true},"longitudinal_labs":[{"date":"2021-08-08","hemoglobin_g_dL":13.5,"wbc_k_uL":6.9,"platelets_k_uL":378,"creatinine_mg_dL":0.86,"alt_U_L":21},{"date":"2022-02-21","hemoglobin_g_dL":11.8,"wbc_k_uL":5.2,"platelets_k_uL":263,"creatinine_mg_dL":0.83,"alt_U_L":58},{"date":"2024-11-01","hemoglobin_g_dL":9.9,"wbc_k_uL":4.2,"platelets_k_uL":257,"creatinine_mg_dL":1.17,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_1562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":71,"sex":"female","bmi":22.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-64},"pfs_months":19.38},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.6,"censored":false},"longitudinal_labs":[{"date":"2024-09-06","hemoglobin_g_dL":12.7,"wbc_k_uL":9.0,"platelets_k_uL":205,"creatinine_mg_dL":1.05,"alt_U_L":26},{"date":"2025-03-23","hemoglobin_g_dL":10.5,"wbc_k_uL":3.8,"platelets_k_uL":229,"creatinine_mg_dL":0.95,"alt_U_L":62},{"date":"2026-07-06","hemoglobin_g_dL":10.3,"wbc_k_uL":4.1,"platelets_k_uL":144,"creatinine_mg_dL":1.96,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_1563","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":54,"sex":"female","bmi":33.6,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-65},"pfs_months":11.04},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.3,"censored":false},"longitudinal_labs":[{"date":"2023-05-15","hemoglobin_g_dL":15.4,"wbc_k_uL":5.2,"platelets_k_uL":334,"creatinine_mg_dL":0.79,"alt_U_L":46},{"date":"2024-01-17","hemoglobin_g_dL":11.1,"wbc_k_uL":8.3,"platelets_k_uL":264,"creatinine_mg_dL":1.53,"alt_U_L":19},{"date":"2024-07-04","hemoglobin_g_dL":10.8,"wbc_k_uL":7.8,"platelets_k_uL":201,"creatinine_mg_dL":1.91,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_1564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":61,"sex":"female","bmi":21.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-56},"pfs_months":13.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":false},"longitudinal_labs":[{"date":"2024-05-17","hemoglobin_g_dL":12.5,"wbc_k_uL":7.4,"platelets_k_uL":213,"creatinine_mg_dL":1.28,"alt_U_L":15},{"date":"2024-11-28","hemoglobin_g_dL":10.3,"wbc_k_uL":8.0,"platelets_k_uL":206,"creatinine_mg_dL":1.21,"alt_U_L":40},{"date":"2025-09-25","hemoglobin_g_dL":12.7,"wbc_k_uL":4.1,"platelets_k_uL":121,"creatinine_mg_dL":1.88,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_1565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":58,"sex":"female","bmi":28.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-38},"pfs_months":19.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":true},"longitudinal_labs":[{"date":"2024-05-09","hemoglobin_g_dL":11.8,"wbc_k_uL":7.3,"platelets_k_uL":164,"creatinine_mg_dL":1.04,"alt_U_L":68},{"date":"2024-12-11","hemoglobin_g_dL":12.2,"wbc_k_uL":5.2,"platelets_k_uL":218,"creatinine_mg_dL":0.84,"alt_U_L":74},{"date":"2026-03-16","hemoglobin_g_dL":12.9,"wbc_k_uL":6.9,"platelets_k_uL":248,"creatinine_mg_dL":1.06,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_1566","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":74,"sex":"female","bmi":27.8,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-49},"pfs_months":26.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.2,"censored":false},"longitudinal_labs":[{"date":"2021-02-25","hemoglobin_g_dL":14.1,"wbc_k_uL":7.3,"platelets_k_uL":165,"creatinine_mg_dL":1.02,"alt_U_L":46},{"date":"2021-09-18","hemoglobin_g_dL":11.7,"wbc_k_uL":5.0,"platelets_k_uL":359,"creatinine_mg_dL":1.3,"alt_U_L":64},{"date":"2023-06-14","hemoglobin_g_dL":10.4,"wbc_k_uL":5.5,"platelets_k_uL":246,"creatinine_mg_dL":1.36,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_1567","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":87,"sex":"female","bmi":21.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-84},"pfs_months":16.33},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.5,"censored":true},"longitudinal_labs":[{"date":"2023-01-19","hemoglobin_g_dL":12.0,"wbc_k_uL":4.6,"platelets_k_uL":199,"creatinine_mg_dL":0.83,"alt_U_L":33},{"date":"2023-08-23","hemoglobin_g_dL":11.2,"wbc_k_uL":5.3,"platelets_k_uL":270,"creatinine_mg_dL":0.88,"alt_U_L":111},{"date":"2024-08-17","hemoglobin_g_dL":10.3,"wbc_k_uL":3.1,"platelets_k_uL":117,"creatinine_mg_dL":2.0,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_1568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":63,"sex":"male","bmi":34.4,"smoking_pack_years":55,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-10-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-32},"pfs_months":8.97},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.1,"censored":false},"longitudinal_labs":[{"date":"2024-09-19","hemoglobin_g_dL":12.3,"wbc_k_uL":7.5,"platelets_k_uL":354,"creatinine_mg_dL":0.91,"alt_U_L":24},{"date":"2025-04-02","hemoglobin_g_dL":11.5,"wbc_k_uL":4.3,"platelets_k_uL":203,"creatinine_mg_dL":1.47,"alt_U_L":102},{"date":"2025-07-21","hemoglobin_g_dL":12.8,"wbc_k_uL":5.4,"platelets_k_uL":267,"creatinine_mg_dL":1.58,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_1569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":88,"sex":"female","bmi":26.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-33},"pfs_months":25.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.5,"censored":false},"longitudinal_labs":[{"date":"2024-07-12","hemoglobin_g_dL":13.0,"wbc_k_uL":4.9,"platelets_k_uL":242,"creatinine_mg_dL":0.77,"alt_U_L":62},{"date":"2025-01-24","hemoglobin_g_dL":10.7,"wbc_k_uL":4.8,"platelets_k_uL":313,"creatinine_mg_dL":0.75,"alt_U_L":63},{"date":"2026-10-08","hemoglobin_g_dL":10.6,"wbc_k_uL":3.7,"platelets_k_uL":225,"creatinine_mg_dL":0.86,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_1570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":53,"sex":"female","bmi":22.5,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-12-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-50},"pfs_months":40.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.9,"censored":false},"longitudinal_labs":[{"date":"2023-11-07","hemoglobin_g_dL":14.6,"wbc_k_uL":9.1,"platelets_k_uL":385,"creatinine_mg_dL":0.84,"alt_U_L":62},{"date":"2024-06-15","hemoglobin_g_dL":10.9,"wbc_k_uL":8.1,"platelets_k_uL":139,"creatinine_mg_dL":1.06,"alt_U_L":107},{"date":"2027-05-28","hemoglobin_g_dL":12.7,"wbc_k_uL":7.1,"platelets_k_uL":112,"creatinine_mg_dL":1.85,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_1571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":49,"sex":"male","bmi":30.6,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-11-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-31},"pfs_months":46.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":60.1,"censored":false},"longitudinal_labs":[{"date":"2022-10-10","hemoglobin_g_dL":15.1,"wbc_k_uL":5.6,"platelets_k_uL":330,"creatinine_mg_dL":0.96,"alt_U_L":16},{"date":"2023-05-28","hemoglobin_g_dL":12.9,"wbc_k_uL":8.9,"platelets_k_uL":226,"creatinine_mg_dL":0.98,"alt_U_L":108},{"date":"2026-10-21","hemoglobin_g_dL":10.6,"wbc_k_uL":7.5,"platelets_k_uL":187,"creatinine_mg_dL":1.72,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_1572","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":75,"sex":"female","bmi":21.3,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-48},"pfs_months":30.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.3,"censored":true},"longitudinal_labs":[{"date":"2024-04-15","hemoglobin_g_dL":14.1,"wbc_k_uL":8.1,"platelets_k_uL":319,"creatinine_mg_dL":0.83,"alt_U_L":13},{"date":"2024-12-14","hemoglobin_g_dL":13.2,"wbc_k_uL":4.0,"platelets_k_uL":186,"creatinine_mg_dL":0.98,"alt_U_L":110},{"date":"2026-12-25","hemoglobin_g_dL":11.4,"wbc_k_uL":5.2,"platelets_k_uL":209,"creatinine_mg_dL":1.48,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_1573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":76,"sex":"male","bmi":27.9,"smoking_pack_years":46,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-30},"pfs_months":13.44},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.0,"censored":false},"longitudinal_labs":[{"date":"2021-06-12","hemoglobin_g_dL":13.1,"wbc_k_uL":4.6,"platelets_k_uL":400,"creatinine_mg_dL":0.82,"alt_U_L":11},{"date":"2022-02-14","hemoglobin_g_dL":13.8,"wbc_k_uL":4.7,"platelets_k_uL":368,"creatinine_mg_dL":1.48,"alt_U_L":52},{"date":"2022-11-21","hemoglobin_g_dL":11.2,"wbc_k_uL":5.3,"platelets_k_uL":225,"creatinine_mg_dL":0.88,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_1574","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":51,"sex":"male","bmi":38.0,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-06-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-30},"pfs_months":20.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.3,"censored":false},"longitudinal_labs":[{"date":"2024-05-21","hemoglobin_g_dL":14.7,"wbc_k_uL":7.0,"platelets_k_uL":287,"creatinine_mg_dL":1.09,"alt_U_L":45},{"date":"2024-12-15","hemoglobin_g_dL":13.5,"wbc_k_uL":7.8,"platelets_k_uL":261,"creatinine_mg_dL":0.78,"alt_U_L":115},{"date":"2026-04-13","hemoglobin_g_dL":10.4,"wbc_k_uL":5.7,"platelets_k_uL":343,"creatinine_mg_dL":1.21,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_1575","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":87,"sex":"male","bmi":25.4,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-08-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-32},"pfs_months":26.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.1,"censored":false},"longitudinal_labs":[{"date":"2020-06-28","hemoglobin_g_dL":14.6,"wbc_k_uL":6.9,"platelets_k_uL":358,"creatinine_mg_dL":1.04,"alt_U_L":32},{"date":"2021-02-09","hemoglobin_g_dL":12.9,"wbc_k_uL":4.5,"platelets_k_uL":262,"creatinine_mg_dL":0.75,"alt_U_L":28},{"date":"2022-11-18","hemoglobin_g_dL":11.3,"wbc_k_uL":4.5,"platelets_k_uL":344,"creatinine_mg_dL":0.89,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_1576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":88,"sex":"female","bmi":18.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-30},"pfs_months":23.75},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.8,"censored":false},"longitudinal_labs":[{"date":"2023-07-08","hemoglobin_g_dL":12.5,"wbc_k_uL":9.6,"platelets_k_uL":314,"creatinine_mg_dL":1.21,"alt_U_L":74},{"date":"2024-02-03","hemoglobin_g_dL":13.4,"wbc_k_uL":7.1,"platelets_k_uL":300,"creatinine_mg_dL":1.55,"alt_U_L":70},{"date":"2025-09-13","hemoglobin_g_dL":10.3,"wbc_k_uL":5.0,"platelets_k_uL":212,"creatinine_mg_dL":1.99,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_1577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":65,"sex":"male","bmi":28.9,"smoking_pack_years":32,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-12-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-67},"pfs_months":10.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":14.9,"censored":false},"longitudinal_labs":[{"date":"2020-10-25","hemoglobin_g_dL":14.0,"wbc_k_uL":10.9,"platelets_k_uL":352,"creatinine_mg_dL":1.11,"alt_U_L":23},{"date":"2021-06-27","hemoglobin_g_dL":13.7,"wbc_k_uL":7.4,"platelets_k_uL":167,"creatinine_mg_dL":1.6,"alt_U_L":91},{"date":"2021-12-13","hemoglobin_g_dL":11.3,"wbc_k_uL":6.9,"platelets_k_uL":229,"creatinine_mg_dL":0.8,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_1578","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":86,"sex":"male","bmi":36.5,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-08-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-77},"pfs_months":16.1},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":28.8,"censored":false},"longitudinal_labs":[{"date":"2023-07-19","hemoglobin_g_dL":14.1,"wbc_k_uL":9.9,"platelets_k_uL":164,"creatinine_mg_dL":0.91,"alt_U_L":59},{"date":"2024-02-01","hemoglobin_g_dL":13.7,"wbc_k_uL":7.8,"platelets_k_uL":343,"creatinine_mg_dL":1.33,"alt_U_L":96},{"date":"2024-12-22","hemoglobin_g_dL":9.9,"wbc_k_uL":5.9,"platelets_k_uL":291,"creatinine_mg_dL":0.93,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_1579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":65,"sex":"female","bmi":21.6,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-06-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-82},"pfs_months":37.65},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":61.3,"censored":false},"longitudinal_labs":[{"date":"2020-05-18","hemoglobin_g_dL":11.9,"wbc_k_uL":8.2,"platelets_k_uL":248,"creatinine_mg_dL":1.09,"alt_U_L":24},{"date":"2020-12-22","hemoglobin_g_dL":12.2,"wbc_k_uL":4.2,"platelets_k_uL":307,"creatinine_mg_dL":1.11,"alt_U_L":25},{"date":"2023-09-25","hemoglobin_g_dL":9.9,"wbc_k_uL":6.2,"platelets_k_uL":186,"creatinine_mg_dL":1.3,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_1580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":68,"sex":"female","bmi":31.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-39},"pfs_months":18.17},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.9,"censored":true},"longitudinal_labs":[{"date":"2024-09-18","hemoglobin_g_dL":13.2,"wbc_k_uL":5.3,"platelets_k_uL":332,"creatinine_mg_dL":0.62,"alt_U_L":56},{"date":"2025-05-05","hemoglobin_g_dL":12.6,"wbc_k_uL":8.9,"platelets_k_uL":207,"creatinine_mg_dL":0.79,"alt_U_L":17},{"date":"2026-06-15","hemoglobin_g_dL":10.6,"wbc_k_uL":4.0,"platelets_k_uL":197,"creatinine_mg_dL":1.07,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_1581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":79,"sex":"female","bmi":33.2,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-80},"pfs_months":9.59},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.9,"censored":false},"longitudinal_labs":[{"date":"2024-12-26","hemoglobin_g_dL":13.6,"wbc_k_uL":5.6,"platelets_k_uL":213,"creatinine_mg_dL":0.82,"alt_U_L":18},{"date":"2025-07-15","hemoglobin_g_dL":10.1,"wbc_k_uL":4.7,"platelets_k_uL":266,"creatinine_mg_dL":1.46,"alt_U_L":75},{"date":"2025-12-03","hemoglobin_g_dL":12.9,"wbc_k_uL":6.4,"platelets_k_uL":141,"creatinine_mg_dL":1.1,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_1582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":71,"sex":"male","bmi":36.8,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-75},"pfs_months":8.21},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":12.3,"censored":false},"longitudinal_labs":[{"date":"2021-05-04","hemoglobin_g_dL":13.3,"wbc_k_uL":5.2,"platelets_k_uL":212,"creatinine_mg_dL":1.08,"alt_U_L":56},{"date":"2022-01-02","hemoglobin_g_dL":14.0,"wbc_k_uL":8.6,"platelets_k_uL":379,"creatinine_mg_dL":0.8,"alt_U_L":38},{"date":"2022-05-04","hemoglobin_g_dL":10.7,"wbc_k_uL":7.6,"platelets_k_uL":105,"creatinine_mg_dL":1.98,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_1583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":71,"sex":"female","bmi":32.3,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-01-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-76},"pfs_months":8.77},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":15.4,"censored":false},"longitudinal_labs":[{"date":"2023-12-01","hemoglobin_g_dL":14.0,"wbc_k_uL":7.2,"platelets_k_uL":247,"creatinine_mg_dL":1.16,"alt_U_L":77},{"date":"2024-07-08","hemoglobin_g_dL":10.1,"wbc_k_uL":4.6,"platelets_k_uL":367,"creatinine_mg_dL":1.03,"alt_U_L":44},{"date":"2024-10-23","hemoglobin_g_dL":11.3,"wbc_k_uL":7.2,"platelets_k_uL":330,"creatinine_mg_dL":1.12,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_1584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":59,"sex":"female","bmi":37.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-64},"pfs_months":15.84},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.7,"censored":true},"longitudinal_labs":[{"date":"2023-04-01","hemoglobin_g_dL":13.6,"wbc_k_uL":6.5,"platelets_k_uL":206,"creatinine_mg_dL":0.67,"alt_U_L":17},{"date":"2023-10-17","hemoglobin_g_dL":10.2,"wbc_k_uL":5.6,"platelets_k_uL":360,"creatinine_mg_dL":1.28,"alt_U_L":40},{"date":"2024-10-04","hemoglobin_g_dL":11.4,"wbc_k_uL":7.1,"platelets_k_uL":326,"creatinine_mg_dL":1.19,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_1585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":85,"sex":"male","bmi":25.7,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-52},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":9.2,"censored":false},"longitudinal_labs":[{"date":"2023-03-02","hemoglobin_g_dL":13.9,"wbc_k_uL":9.5,"platelets_k_uL":254,"creatinine_mg_dL":1.04,"alt_U_L":70},{"date":"2023-09-14","hemoglobin_g_dL":13.6,"wbc_k_uL":6.5,"platelets_k_uL":232,"creatinine_mg_dL":1.55,"alt_U_L":100},{"date":"2023-07-29","hemoglobin_g_dL":9.7,"wbc_k_uL":6.6,"platelets_k_uL":260,"creatinine_mg_dL":1.84,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_1586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":75,"sex":"female","bmi":31.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-12-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-53},"pfs_months":11.6},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.2,"censored":true},"longitudinal_labs":[{"date":"2021-11-10","hemoglobin_g_dL":14.3,"wbc_k_uL":8.9,"platelets_k_uL":230,"creatinine_mg_dL":0.87,"alt_U_L":11},{"date":"2022-06-20","hemoglobin_g_dL":10.0,"wbc_k_uL":7.7,"platelets_k_uL":351,"creatinine_mg_dL":0.79,"alt_U_L":34},{"date":"2022-12-22","hemoglobin_g_dL":10.9,"wbc_k_uL":5.7,"platelets_k_uL":134,"creatinine_mg_dL":1.73,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_1587","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":84,"sex":"male","bmi":23.2,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-02-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-43},"pfs_months":26.38},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":false},"longitudinal_labs":[{"date":"2023-12-24","hemoglobin_g_dL":14.7,"wbc_k_uL":8.5,"platelets_k_uL":200,"creatinine_mg_dL":1.23,"alt_U_L":49},{"date":"2024-08-24","hemoglobin_g_dL":12.6,"wbc_k_uL":6.2,"platelets_k_uL":178,"creatinine_mg_dL":1.52,"alt_U_L":42},{"date":"2026-05-27","hemoglobin_g_dL":11.9,"wbc_k_uL":4.1,"platelets_k_uL":278,"creatinine_mg_dL":1.01,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_1588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":77,"sex":"female","bmi":18.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-49},"pfs_months":21.22},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.3,"censored":false},"longitudinal_labs":[{"date":"2025-10-12","hemoglobin_g_dL":14.0,"wbc_k_uL":7.7,"platelets_k_uL":296,"creatinine_mg_dL":0.97,"alt_U_L":12},{"date":"2026-05-20","hemoglobin_g_dL":10.9,"wbc_k_uL":5.1,"platelets_k_uL":280,"creatinine_mg_dL":1.11,"alt_U_L":99},{"date":"2027-09-18","hemoglobin_g_dL":11.2,"wbc_k_uL":4.9,"platelets_k_uL":349,"creatinine_mg_dL":1.08,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_1589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":80,"sex":"female","bmi":21.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-46},"pfs_months":23.56},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.9,"censored":false},"longitudinal_labs":[{"date":"2024-08-28","hemoglobin_g_dL":13.8,"wbc_k_uL":10.0,"platelets_k_uL":169,"creatinine_mg_dL":1.02,"alt_U_L":77},{"date":"2025-04-19","hemoglobin_g_dL":10.4,"wbc_k_uL":7.4,"platelets_k_uL":369,"creatinine_mg_dL":1.48,"alt_U_L":43},{"date":"2026-11-14","hemoglobin_g_dL":9.6,"wbc_k_uL":3.6,"platelets_k_uL":281,"creatinine_mg_dL":1.28,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_1590","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":87,"sex":"female","bmi":26.3,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-12-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-80},"pfs_months":42.12},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-16","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":57.0,"censored":false},"longitudinal_labs":[{"date":"2021-10-01","hemoglobin_g_dL":15.4,"wbc_k_uL":6.2,"platelets_k_uL":161,"creatinine_mg_dL":1.3,"alt_U_L":19},{"date":"2022-06-06","hemoglobin_g_dL":10.8,"wbc_k_uL":6.7,"platelets_k_uL":272,"creatinine_mg_dL":1.35,"alt_U_L":30},{"date":"2025-06-16","hemoglobin_g_dL":10.8,"wbc_k_uL":5.5,"platelets_k_uL":292,"creatinine_mg_dL":1.95,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_1591","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":70,"sex":"female","bmi":35.7,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-02-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-61},"pfs_months":20.07},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":true},"longitudinal_labs":[{"date":"2021-01-08","hemoglobin_g_dL":14.1,"wbc_k_uL":5.1,"platelets_k_uL":232,"creatinine_mg_dL":1.04,"alt_U_L":53},{"date":"2021-08-21","hemoglobin_g_dL":13.7,"wbc_k_uL":5.7,"platelets_k_uL":215,"creatinine_mg_dL":1.05,"alt_U_L":61},{"date":"2022-11-26","hemoglobin_g_dL":12.1,"wbc_k_uL":7.4,"platelets_k_uL":278,"creatinine_mg_dL":1.96,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_1592","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":54,"sex":"female","bmi":20.4,"smoking_pack_years":51,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-04-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-81},"pfs_months":40.34},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":72.9,"censored":true},"longitudinal_labs":[{"date":"2020-02-13","hemoglobin_g_dL":11.6,"wbc_k_uL":10.7,"platelets_k_uL":154,"creatinine_mg_dL":0.79,"alt_U_L":18},{"date":"2020-10-07","hemoglobin_g_dL":13.6,"wbc_k_uL":3.8,"platelets_k_uL":204,"creatinine_mg_dL":1.26,"alt_U_L":73},{"date":"2023-10-09","hemoglobin_g_dL":9.9,"wbc_k_uL":7.9,"platelets_k_uL":185,"creatinine_mg_dL":1.04,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_1593","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":64,"sex":"male","bmi":25.8,"smoking_pack_years":67,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-10-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-42},"pfs_months":19.71},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-31","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.2,"censored":true},"longitudinal_labs":[{"date":"2025-09-20","hemoglobin_g_dL":12.2,"wbc_k_uL":5.6,"platelets_k_uL":276,"creatinine_mg_dL":1.05,"alt_U_L":45},{"date":"2026-04-16","hemoglobin_g_dL":13.1,"wbc_k_uL":7.3,"platelets_k_uL":274,"creatinine_mg_dL":0.8,"alt_U_L":16},{"date":"2027-07-31","hemoglobin_g_dL":11.0,"wbc_k_uL":5.4,"platelets_k_uL":186,"creatinine_mg_dL":1.86,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_1594","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":65,"sex":"female","bmi":24.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-54},"pfs_months":9.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.0,"censored":false},"longitudinal_labs":[{"date":"2020-07-01","hemoglobin_g_dL":12.1,"wbc_k_uL":4.8,"platelets_k_uL":177,"creatinine_mg_dL":1.28,"alt_U_L":12},{"date":"2021-02-01","hemoglobin_g_dL":12.9,"wbc_k_uL":8.7,"platelets_k_uL":312,"creatinine_mg_dL":1.21,"alt_U_L":42},{"date":"2021-05-19","hemoglobin_g_dL":10.8,"wbc_k_uL":4.4,"platelets_k_uL":103,"creatinine_mg_dL":0.85,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_1595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":80,"sex":"female","bmi":33.2,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-37},"pfs_months":3.88},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":11.3,"censored":false},"longitudinal_labs":[{"date":"2021-08-06","hemoglobin_g_dL":11.9,"wbc_k_uL":7.4,"platelets_k_uL":357,"creatinine_mg_dL":1.25,"alt_U_L":27},{"date":"2022-03-27","hemoglobin_g_dL":11.5,"wbc_k_uL":4.5,"platelets_k_uL":376,"creatinine_mg_dL":1.14,"alt_U_L":109},{"date":"2022-02-20","hemoglobin_g_dL":12.6,"wbc_k_uL":6.1,"platelets_k_uL":243,"creatinine_mg_dL":0.88,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_1596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":60,"sex":"male","bmi":27.9,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-05-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-80},"pfs_months":14.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":false},"longitudinal_labs":[{"date":"2022-03-02","hemoglobin_g_dL":11.6,"wbc_k_uL":8.7,"platelets_k_uL":384,"creatinine_mg_dL":0.94,"alt_U_L":34},{"date":"2022-11-07","hemoglobin_g_dL":10.9,"wbc_k_uL":7.5,"platelets_k_uL":379,"creatinine_mg_dL":0.79,"alt_U_L":17},{"date":"2023-09-13","hemoglobin_g_dL":12.7,"wbc_k_uL":3.8,"platelets_k_uL":189,"creatinine_mg_dL":1.13,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_1597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":59,"sex":"female","bmi":23.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-01-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-76},"pfs_months":25.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":false},"longitudinal_labs":[{"date":"2021-12-25","hemoglobin_g_dL":13.0,"wbc_k_uL":5.5,"platelets_k_uL":311,"creatinine_mg_dL":0.72,"alt_U_L":36},{"date":"2022-07-25","hemoglobin_g_dL":10.0,"wbc_k_uL":8.8,"platelets_k_uL":234,"creatinine_mg_dL":1.19,"alt_U_L":37},{"date":"2024-03-16","hemoglobin_g_dL":11.1,"wbc_k_uL":7.0,"platelets_k_uL":127,"creatinine_mg_dL":1.73,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_1598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":74,"sex":"male","bmi":36.7,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-10-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-60},"pfs_months":35.75},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":59.9,"censored":true},"longitudinal_labs":[{"date":"2024-09-03","hemoglobin_g_dL":14.2,"wbc_k_uL":8.7,"platelets_k_uL":240,"creatinine_mg_dL":0.72,"alt_U_L":52},{"date":"2025-04-27","hemoglobin_g_dL":11.7,"wbc_k_uL":7.2,"platelets_k_uL":307,"creatinine_mg_dL":1.16,"alt_U_L":92},{"date":"2027-12-16","hemoglobin_g_dL":12.6,"wbc_k_uL":5.7,"platelets_k_uL":202,"creatinine_mg_dL":1.65,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_1599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":81,"sex":"female","bmi":29.0,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-08-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-61},"pfs_months":34.6},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.3,"censored":false},"longitudinal_labs":[{"date":"2021-07-16","hemoglobin_g_dL":12.3,"wbc_k_uL":9.1,"platelets_k_uL":441,"creatinine_mg_dL":1.22,"alt_U_L":41},{"date":"2022-02-01","hemoglobin_g_dL":11.0,"wbc_k_uL":4.6,"platelets_k_uL":313,"creatinine_mg_dL":0.85,"alt_U_L":64},{"date":"2024-08-07","hemoglobin_g_dL":10.8,"wbc_k_uL":7.0,"platelets_k_uL":180,"creatinine_mg_dL":1.32,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_1600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":51,"sex":"female","bmi":28.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-42},"pfs_months":17.87},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.0,"censored":false},"longitudinal_labs":[{"date":"2021-08-03","hemoglobin_g_dL":12.9,"wbc_k_uL":9.6,"platelets_k_uL":263,"creatinine_mg_dL":0.78,"alt_U_L":29},{"date":"2022-03-11","hemoglobin_g_dL":12.4,"wbc_k_uL":5.5,"platelets_k_uL":186,"creatinine_mg_dL":1.14,"alt_U_L":43},{"date":"2023-04-13","hemoglobin_g_dL":9.9,"wbc_k_uL":5.1,"platelets_k_uL":199,"creatinine_mg_dL":1.38,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_1601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":67,"sex":"female","bmi":22.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-60},"pfs_months":21.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":true},"longitudinal_labs":[{"date":"2024-08-14","hemoglobin_g_dL":13.6,"wbc_k_uL":8.2,"platelets_k_uL":246,"creatinine_mg_dL":1.03,"alt_U_L":54},{"date":"2025-04-15","hemoglobin_g_dL":12.2,"wbc_k_uL":7.4,"platelets_k_uL":153,"creatinine_mg_dL":0.95,"alt_U_L":69},{"date":"2026-07-23","hemoglobin_g_dL":11.1,"wbc_k_uL":3.9,"platelets_k_uL":144,"creatinine_mg_dL":0.8,"alt_U_L":28}]}
{"patient_id":"ANODE_SYNTH_2025_1602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":72,"sex":"female","bmi":23.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-63},"pfs_months":10.45},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.1,"censored":false},"longitudinal_labs":[{"date":"2023-11-04","hemoglobin_g_dL":13.1,"wbc_k_uL":10.2,"platelets_k_uL":185,"creatinine_mg_dL":0.74,"alt_U_L":56},{"date":"2024-05-30","hemoglobin_g_dL":12.2,"wbc_k_uL":6.7,"platelets_k_uL":191,"creatinine_mg_dL":0.89,"alt_U_L":31},{"date":"2024-11-11","hemoglobin_g_dL":10.0,"wbc_k_uL":4.9,"platelets_k_uL":102,"creatinine_mg_dL":0.97,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_1603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":75,"sex":"female","bmi":37.8,"smoking_pack_years":47,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-11-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-80},"pfs_months":5.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":13.5,"censored":false},"longitudinal_labs":[{"date":"2022-10-07","hemoglobin_g_dL":15.2,"wbc_k_uL":8.7,"platelets_k_uL":375,"creatinine_mg_dL":1.02,"alt_U_L":28},{"date":"2023-05-13","hemoglobin_g_dL":12.3,"wbc_k_uL":7.3,"platelets_k_uL":233,"creatinine_mg_dL":1.48,"alt_U_L":37},{"date":"2023-05-01","hemoglobin_g_dL":11.7,"wbc_k_uL":4.5,"platelets_k_uL":132,"creatinine_mg_dL":1.91,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_1604","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":88,"sex":"male","bmi":29.8,"smoking_pack_years":30,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-09-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-72},"pfs_months":16.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":true},"longitudinal_labs":[{"date":"2021-07-28","hemoglobin_g_dL":13.5,"wbc_k_uL":9.7,"platelets_k_uL":274,"creatinine_mg_dL":0.8,"alt_U_L":74},{"date":"2022-03-20","hemoglobin_g_dL":13.1,"wbc_k_uL":7.5,"platelets_k_uL":306,"creatinine_mg_dL":1.47,"alt_U_L":91},{"date":"2023-03-18","hemoglobin_g_dL":10.3,"wbc_k_uL":7.3,"platelets_k_uL":122,"creatinine_mg_dL":1.23,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_1605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":70,"sex":"male","bmi":34.2,"smoking_pack_years":76,"ecog_performance_status":0,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-03-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-83},"pfs_months":15.15},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.6,"censored":true},"longitudinal_labs":[{"date":"2022-01-12","hemoglobin_g_dL":12.5,"wbc_k_uL":9.8,"platelets_k_uL":290,"creatinine_mg_dL":1.09,"alt_U_L":34},{"date":"2022-09-19","hemoglobin_g_dL":13.6,"wbc_k_uL":5.9,"platelets_k_uL":324,"creatinine_mg_dL":1.59,"alt_U_L":60},{"date":"2023-08-06","hemoglobin_g_dL":12.8,"wbc_k_uL":6.4,"platelets_k_uL":178,"creatinine_mg_dL":0.87,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_1606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.4,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":55,"sex":"female","bmi":37.2,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-71},"pfs_months":18.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.5,"censored":false},"longitudinal_labs":[{"date":"2021-06-05","hemoglobin_g_dL":14.2,"wbc_k_uL":10.3,"platelets_k_uL":294,"creatinine_mg_dL":0.66,"alt_U_L":15},{"date":"2022-01-14","hemoglobin_g_dL":12.0,"wbc_k_uL":7.4,"platelets_k_uL":184,"creatinine_mg_dL":0.95,"alt_U_L":99},{"date":"2023-01-28","hemoglobin_g_dL":10.0,"wbc_k_uL":5.3,"platelets_k_uL":133,"creatinine_mg_dL":1.04,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_1607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":59,"sex":"female","bmi":32.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-63},"pfs_months":15.51},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.7,"censored":false},"longitudinal_labs":[{"date":"2024-02-11","hemoglobin_g_dL":11.8,"wbc_k_uL":7.0,"platelets_k_uL":207,"creatinine_mg_dL":0.78,"alt_U_L":25},{"date":"2024-09-16","hemoglobin_g_dL":11.8,"wbc_k_uL":8.9,"platelets_k_uL":376,"creatinine_mg_dL":0.98,"alt_U_L":112},{"date":"2025-08-24","hemoglobin_g_dL":12.1,"wbc_k_uL":3.7,"platelets_k_uL":318,"creatinine_mg_dL":1.81,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_1608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":72,"sex":"male","bmi":32.0,"smoking_pack_years":72,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-04-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-58},"pfs_months":40.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":60.7,"censored":true},"longitudinal_labs":[{"date":"2024-02-08","hemoglobin_g_dL":13.0,"wbc_k_uL":10.0,"platelets_k_uL":291,"creatinine_mg_dL":0.71,"alt_U_L":12},{"date":"2024-10-15","hemoglobin_g_dL":13.6,"wbc_k_uL":7.6,"platelets_k_uL":178,"creatinine_mg_dL":0.81,"alt_U_L":89},{"date":"2027-10-13","hemoglobin_g_dL":10.5,"wbc_k_uL":5.8,"platelets_k_uL":266,"creatinine_mg_dL":1.67,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_1609","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":86,"sex":"male","bmi":29.9,"smoking_pack_years":62,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-39},"pfs_months":18.56},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.0,"censored":true},"longitudinal_labs":[{"date":"2024-08-26","hemoglobin_g_dL":12.4,"wbc_k_uL":9.3,"platelets_k_uL":326,"creatinine_mg_dL":0.76,"alt_U_L":70},{"date":"2025-03-15","hemoglobin_g_dL":11.3,"wbc_k_uL":5.7,"platelets_k_uL":373,"creatinine_mg_dL":0.73,"alt_U_L":33},{"date":"2026-05-05","hemoglobin_g_dL":12.3,"wbc_k_uL":5.0,"platelets_k_uL":160,"creatinine_mg_dL":1.4,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_1610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":59,"sex":"male","bmi":36.3,"smoking_pack_years":15,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-30},"pfs_months":31.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":58.3,"censored":false},"longitudinal_labs":[{"date":"2020-03-07","hemoglobin_g_dL":14.5,"wbc_k_uL":8.1,"platelets_k_uL":199,"creatinine_mg_dL":1.19,"alt_U_L":79},{"date":"2020-09-17","hemoglobin_g_dL":11.5,"wbc_k_uL":5.6,"platelets_k_uL":198,"creatinine_mg_dL":1.27,"alt_U_L":74},{"date":"2022-12-02","hemoglobin_g_dL":12.4,"wbc_k_uL":5.2,"platelets_k_uL":250,"creatinine_mg_dL":1.5,"alt_U_L":139}]}
{"patient_id":"ANODE_SYNTH_2025_1611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":63,"sex":"male","bmi":36.1,"smoking_pack_years":79,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-31},"pfs_months":13.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":17.2,"censored":true},"longitudinal_labs":[{"date":"2021-05-23","hemoglobin_g_dL":12.2,"wbc_k_uL":5.0,"platelets_k_uL":417,"creatinine_mg_dL":0.94,"alt_U_L":49},{"date":"2022-01-07","hemoglobin_g_dL":12.2,"wbc_k_uL":4.1,"platelets_k_uL":250,"creatinine_mg_dL":1.58,"alt_U_L":42},{"date":"2022-09-16","hemoglobin_g_dL":12.4,"wbc_k_uL":7.0,"platelets_k_uL":178,"creatinine_mg_dL":0.93,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_1612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":82,"sex":"female","bmi":36.3,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-05-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-34},"pfs_months":18.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.6,"censored":false},"longitudinal_labs":[{"date":"2023-04-03","hemoglobin_g_dL":13.7,"wbc_k_uL":5.9,"platelets_k_uL":349,"creatinine_mg_dL":1.28,"alt_U_L":63},{"date":"2023-10-31","hemoglobin_g_dL":11.5,"wbc_k_uL":7.1,"platelets_k_uL":274,"creatinine_mg_dL":1.06,"alt_U_L":53},{"date":"2024-12-27","hemoglobin_g_dL":12.6,"wbc_k_uL":3.4,"platelets_k_uL":200,"creatinine_mg_dL":1.85,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_1613","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":56,"sex":"male","bmi":26.1,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-12-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-50},"pfs_months":30.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.1,"censored":true},"longitudinal_labs":[{"date":"2020-11-14","hemoglobin_g_dL":11.6,"wbc_k_uL":7.3,"platelets_k_uL":230,"creatinine_mg_dL":1.02,"alt_U_L":47},{"date":"2021-06-02","hemoglobin_g_dL":13.3,"wbc_k_uL":8.1,"platelets_k_uL":311,"creatinine_mg_dL":1.58,"alt_U_L":38},{"date":"2023-06-20","hemoglobin_g_dL":11.5,"wbc_k_uL":6.5,"platelets_k_uL":310,"creatinine_mg_dL":1.19,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_1614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":83,"sex":"female","bmi":34.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-10-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-67},"pfs_months":18.69},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.3,"censored":false},"longitudinal_labs":[{"date":"2025-09-20","hemoglobin_g_dL":13.7,"wbc_k_uL":8.6,"platelets_k_uL":346,"creatinine_mg_dL":0.8,"alt_U_L":75},{"date":"2026-04-20","hemoglobin_g_dL":13.6,"wbc_k_uL":6.4,"platelets_k_uL":257,"creatinine_mg_dL":0.78,"alt_U_L":28},{"date":"2027-05-23","hemoglobin_g_dL":12.0,"wbc_k_uL":3.5,"platelets_k_uL":231,"creatinine_mg_dL":1.28,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_1615","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":65,"sex":"female","bmi":34.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-10-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-50},"pfs_months":17.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.5,"censored":false},"longitudinal_labs":[{"date":"2025-09-15","hemoglobin_g_dL":13.6,"wbc_k_uL":6.9,"platelets_k_uL":364,"creatinine_mg_dL":1.03,"alt_U_L":49},{"date":"2026-04-10","hemoglobin_g_dL":13.4,"wbc_k_uL":8.9,"platelets_k_uL":338,"creatinine_mg_dL":1.47,"alt_U_L":59},{"date":"2027-04-22","hemoglobin_g_dL":9.8,"wbc_k_uL":5.7,"platelets_k_uL":200,"creatinine_mg_dL":0.87,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_1616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":50,"sex":"female","bmi":37.3,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-05-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-75},"pfs_months":12.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2025-03-10","hemoglobin_g_dL":15.2,"wbc_k_uL":9.9,"platelets_k_uL":339,"creatinine_mg_dL":1.0,"alt_U_L":17},{"date":"2025-11-15","hemoglobin_g_dL":10.9,"wbc_k_uL":4.4,"platelets_k_uL":295,"creatinine_mg_dL":1.34,"alt_U_L":115},{"date":"2026-06-06","hemoglobin_g_dL":11.2,"wbc_k_uL":5.5,"platelets_k_uL":168,"creatinine_mg_dL":1.89,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_1617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":50,"sex":"female","bmi":33.4,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-12-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-36},"pfs_months":13.5},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":23.6,"censored":true},"longitudinal_labs":[{"date":"2023-11-27","hemoglobin_g_dL":14.5,"wbc_k_uL":11.0,"platelets_k_uL":162,"creatinine_mg_dL":0.64,"alt_U_L":74},{"date":"2024-06-20","hemoglobin_g_dL":10.3,"wbc_k_uL":8.3,"platelets_k_uL":131,"creatinine_mg_dL":1.22,"alt_U_L":66},{"date":"2025-02-14","hemoglobin_g_dL":10.5,"wbc_k_uL":3.1,"platelets_k_uL":228,"creatinine_mg_dL":1.7,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_1618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":87,"sex":"female","bmi":34.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-05-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-40},"pfs_months":20.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.6,"censored":false},"longitudinal_labs":[{"date":"2023-04-14","hemoglobin_g_dL":11.9,"wbc_k_uL":6.0,"platelets_k_uL":389,"creatinine_mg_dL":0.9,"alt_U_L":18},{"date":"2023-11-02","hemoglobin_g_dL":13.6,"wbc_k_uL":6.3,"platelets_k_uL":353,"creatinine_mg_dL":1.19,"alt_U_L":115},{"date":"2025-01-29","hemoglobin_g_dL":9.7,"wbc_k_uL":3.3,"platelets_k_uL":136,"creatinine_mg_dL":0.94,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_1619","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":88,"sex":"female","bmi":18.8,"smoking_pack_years":32,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-10-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-30},"pfs_months":20.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.9,"censored":false},"longitudinal_labs":[{"date":"2021-09-18","hemoglobin_g_dL":11.9,"wbc_k_uL":9.5,"platelets_k_uL":185,"creatinine_mg_dL":0.83,"alt_U_L":30},{"date":"2022-04-16","hemoglobin_g_dL":11.0,"wbc_k_uL":7.2,"platelets_k_uL":233,"creatinine_mg_dL":1.53,"alt_U_L":58},{"date":"2023-07-24","hemoglobin_g_dL":10.1,"wbc_k_uL":5.0,"platelets_k_uL":184,"creatinine_mg_dL":1.38,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_1620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":56,"sex":"male","bmi":36.5,"smoking_pack_years":14,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-47},"pfs_months":16.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.7,"censored":true},"longitudinal_labs":[{"date":"2025-01-14","hemoglobin_g_dL":13.6,"wbc_k_uL":10.6,"platelets_k_uL":270,"creatinine_mg_dL":1.2,"alt_U_L":75},{"date":"2025-07-27","hemoglobin_g_dL":13.7,"wbc_k_uL":6.2,"platelets_k_uL":131,"creatinine_mg_dL":1.47,"alt_U_L":68},{"date":"2026-07-15","hemoglobin_g_dL":10.3,"wbc_k_uL":5.3,"platelets_k_uL":211,"creatinine_mg_dL":1.7,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_1621","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":53,"sex":"female","bmi":21.1,"smoking_pack_years":70,"ecog_performance_status":2,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-02-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-84},"pfs_months":25.82},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.7,"censored":false},"longitudinal_labs":[{"date":"2024-02-06","hemoglobin_g_dL":13.6,"wbc_k_uL":5.9,"platelets_k_uL":212,"creatinine_mg_dL":1.16,"alt_U_L":51},{"date":"2024-08-27","hemoglobin_g_dL":11.4,"wbc_k_uL":6.4,"platelets_k_uL":192,"creatinine_mg_dL":0.9,"alt_U_L":109},{"date":"2026-05-18","hemoglobin_g_dL":11.4,"wbc_k_uL":7.1,"platelets_k_uL":268,"creatinine_mg_dL":1.18,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_1622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":59,"sex":"female","bmi":35.0,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-03-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-57},"pfs_months":32.72},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":52.2,"censored":true},"longitudinal_labs":[{"date":"2022-02-11","hemoglobin_g_dL":12.0,"wbc_k_uL":9.3,"platelets_k_uL":328,"creatinine_mg_dL":0.71,"alt_U_L":76},{"date":"2022-09-26","hemoglobin_g_dL":12.9,"wbc_k_uL":5.7,"platelets_k_uL":332,"creatinine_mg_dL":0.77,"alt_U_L":54},{"date":"2025-01-26","hemoglobin_g_dL":12.4,"wbc_k_uL":5.7,"platelets_k_uL":302,"creatinine_mg_dL":1.59,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_1623","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":82,"sex":"female","bmi":38.0,"smoking_pack_years":21,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-05-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-35},"pfs_months":19.06},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.4,"censored":false},"longitudinal_labs":[{"date":"2022-04-03","hemoglobin_g_dL":12.9,"wbc_k_uL":10.5,"platelets_k_uL":255,"creatinine_mg_dL":1.02,"alt_U_L":60},{"date":"2022-10-29","hemoglobin_g_dL":12.1,"wbc_k_uL":5.7,"platelets_k_uL":142,"creatinine_mg_dL":1.21,"alt_U_L":81},{"date":"2024-01-21","hemoglobin_g_dL":12.5,"wbc_k_uL":4.3,"platelets_k_uL":186,"creatinine_mg_dL":1.31,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_1624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":74,"sex":"female","bmi":30.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-72},"pfs_months":18.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.4,"censored":true},"longitudinal_labs":[{"date":"2021-01-24","hemoglobin_g_dL":13.3,"wbc_k_uL":10.5,"platelets_k_uL":158,"creatinine_mg_dL":0.63,"alt_U_L":13},{"date":"2021-08-30","hemoglobin_g_dL":12.7,"wbc_k_uL":7.2,"platelets_k_uL":131,"creatinine_mg_dL":1.32,"alt_U_L":99},{"date":"2022-11-30","hemoglobin_g_dL":12.1,"wbc_k_uL":4.7,"platelets_k_uL":237,"creatinine_mg_dL":0.83,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_1625","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":76,"sex":"female","bmi":28.5,"smoking_pack_years":72,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-10-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-66},"pfs_months":36.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":56.5,"censored":false},"longitudinal_labs":[{"date":"2024-08-23","hemoglobin_g_dL":14.3,"wbc_k_uL":8.6,"platelets_k_uL":260,"creatinine_mg_dL":1.02,"alt_U_L":19},{"date":"2025-04-24","hemoglobin_g_dL":12.3,"wbc_k_uL":5.5,"platelets_k_uL":137,"creatinine_mg_dL":1.13,"alt_U_L":104},{"date":"2027-12-03","hemoglobin_g_dL":10.6,"wbc_k_uL":7.3,"platelets_k_uL":207,"creatinine_mg_dL":1.16,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_1626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":77,"sex":"male","bmi":25.9,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-09-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-47},"pfs_months":6.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.6,"censored":false},"longitudinal_labs":[{"date":"2024-07-27","hemoglobin_g_dL":14.3,"wbc_k_uL":10.7,"platelets_k_uL":285,"creatinine_mg_dL":1.01,"alt_U_L":13},{"date":"2025-03-23","hemoglobin_g_dL":12.5,"wbc_k_uL":8.7,"platelets_k_uL":197,"creatinine_mg_dL":1.07,"alt_U_L":37},{"date":"2025-05-27","hemoglobin_g_dL":11.1,"wbc_k_uL":5.7,"platelets_k_uL":134,"creatinine_mg_dL":0.82,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_1627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":53,"sex":"female","bmi":27.4,"smoking_pack_years":69,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-75},"pfs_months":46.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":72.4,"censored":false},"longitudinal_labs":[{"date":"2021-04-18","hemoglobin_g_dL":15.3,"wbc_k_uL":10.8,"platelets_k_uL":385,"creatinine_mg_dL":1.25,"alt_U_L":65},{"date":"2021-12-22","hemoglobin_g_dL":12.4,"wbc_k_uL":4.0,"platelets_k_uL":213,"creatinine_mg_dL":1.28,"alt_U_L":58},{"date":"2025-05-17","hemoglobin_g_dL":12.0,"wbc_k_uL":6.2,"platelets_k_uL":349,"creatinine_mg_dL":1.77,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_1628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":64,"sex":"female","bmi":24.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-83},"pfs_months":25.53},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.1,"censored":false},"longitudinal_labs":[{"date":"2024-02-05","hemoglobin_g_dL":11.5,"wbc_k_uL":9.6,"platelets_k_uL":382,"creatinine_mg_dL":0.8,"alt_U_L":30},{"date":"2024-09-08","hemoglobin_g_dL":10.8,"wbc_k_uL":6.7,"platelets_k_uL":335,"creatinine_mg_dL":1.18,"alt_U_L":37},{"date":"2026-05-25","hemoglobin_g_dL":11.5,"wbc_k_uL":7.6,"platelets_k_uL":339,"creatinine_mg_dL":1.35,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_1629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":86,"sex":"female","bmi":36.7,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-12-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-70},"pfs_months":4.83},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":8.8,"censored":false},"longitudinal_labs":[{"date":"2023-10-16","hemoglobin_g_dL":13.2,"wbc_k_uL":8.0,"platelets_k_uL":269,"creatinine_mg_dL":1.14,"alt_U_L":40},{"date":"2024-06-21","hemoglobin_g_dL":12.7,"wbc_k_uL":6.7,"platelets_k_uL":337,"creatinine_mg_dL":0.87,"alt_U_L":47},{"date":"2024-06-21","hemoglobin_g_dL":10.3,"wbc_k_uL":7.9,"platelets_k_uL":112,"creatinine_mg_dL":1.5,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_1630","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":88,"sex":"female","bmi":35.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-52},"pfs_months":36.21},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.4,"censored":false},"longitudinal_labs":[{"date":"2023-02-04","hemoglobin_g_dL":13.3,"wbc_k_uL":8.8,"platelets_k_uL":209,"creatinine_mg_dL":0.61,"alt_U_L":50},{"date":"2023-09-18","hemoglobin_g_dL":10.6,"wbc_k_uL":4.8,"platelets_k_uL":377,"creatinine_mg_dL":1.48,"alt_U_L":53},{"date":"2026-05-19","hemoglobin_g_dL":10.3,"wbc_k_uL":4.5,"platelets_k_uL":223,"creatinine_mg_dL":0.95,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_1631","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":77,"sex":"male","bmi":28.7,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-03-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-68},"pfs_months":28.22},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.4,"censored":false},"longitudinal_labs":[{"date":"2021-01-22","hemoglobin_g_dL":12.1,"wbc_k_uL":9.8,"platelets_k_uL":261,"creatinine_mg_dL":1.18,"alt_U_L":66},{"date":"2021-09-09","hemoglobin_g_dL":13.7,"wbc_k_uL":8.8,"platelets_k_uL":191,"creatinine_mg_dL":1.17,"alt_U_L":46},{"date":"2023-08-21","hemoglobin_g_dL":12.6,"wbc_k_uL":3.7,"platelets_k_uL":236,"creatinine_mg_dL":1.48,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_1632","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":55,"sex":"female","bmi":20.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-75},"pfs_months":19.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":false},"longitudinal_labs":[{"date":"2022-05-21","hemoglobin_g_dL":15.1,"wbc_k_uL":4.9,"platelets_k_uL":370,"creatinine_mg_dL":1.3,"alt_U_L":10},{"date":"2023-01-11","hemoglobin_g_dL":10.7,"wbc_k_uL":6.1,"platelets_k_uL":156,"creatinine_mg_dL":0.98,"alt_U_L":62},{"date":"2024-04-06","hemoglobin_g_dL":11.2,"wbc_k_uL":4.8,"platelets_k_uL":276,"creatinine_mg_dL":1.52,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_1633","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":79,"sex":"male","bmi":35.0,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-05-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-35},"pfs_months":28.02},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.9,"censored":false},"longitudinal_labs":[{"date":"2025-03-11","hemoglobin_g_dL":15.4,"wbc_k_uL":8.1,"platelets_k_uL":204,"creatinine_mg_dL":0.93,"alt_U_L":11},{"date":"2025-10-28","hemoglobin_g_dL":13.7,"wbc_k_uL":4.5,"platelets_k_uL":191,"creatinine_mg_dL":0.75,"alt_U_L":21},{"date":"2027-10-19","hemoglobin_g_dL":11.3,"wbc_k_uL":4.8,"platelets_k_uL":107,"creatinine_mg_dL":0.92,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_1634","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":59,"sex":"female","bmi":21.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-48},"pfs_months":25.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.8,"censored":false},"longitudinal_labs":[{"date":"2025-03-03","hemoglobin_g_dL":13.8,"wbc_k_uL":9.0,"platelets_k_uL":244,"creatinine_mg_dL":1.25,"alt_U_L":57},{"date":"2025-09-25","hemoglobin_g_dL":11.5,"wbc_k_uL":5.0,"platelets_k_uL":336,"creatinine_mg_dL":1.43,"alt_U_L":33},{"date":"2027-07-13","hemoglobin_g_dL":11.9,"wbc_k_uL":6.7,"platelets_k_uL":147,"creatinine_mg_dL":1.01,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_1635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":18.0,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":86,"sex":"female","bmi":27.3,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-43},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.2,"censored":false},"longitudinal_labs":[{"date":"2021-08-20","hemoglobin_g_dL":15.3,"wbc_k_uL":6.6,"platelets_k_uL":365,"creatinine_mg_dL":0.95,"alt_U_L":32},{"date":"2022-03-10","hemoglobin_g_dL":10.5,"wbc_k_uL":7.2,"platelets_k_uL":295,"creatinine_mg_dL":0.97,"alt_U_L":41},{"date":"2022-01-08","hemoglobin_g_dL":10.2,"wbc_k_uL":3.3,"platelets_k_uL":223,"creatinine_mg_dL":0.85,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_1636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":49,"sex":"female","bmi":27.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-57},"pfs_months":25.3},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.1,"censored":false},"longitudinal_labs":[{"date":"2022-02-07","hemoglobin_g_dL":11.9,"wbc_k_uL":10.6,"platelets_k_uL":236,"creatinine_mg_dL":1.11,"alt_U_L":54},{"date":"2022-09-20","hemoglobin_g_dL":10.0,"wbc_k_uL":7.6,"platelets_k_uL":291,"creatinine_mg_dL":0.81,"alt_U_L":107},{"date":"2024-06-14","hemoglobin_g_dL":11.1,"wbc_k_uL":3.1,"platelets_k_uL":121,"creatinine_mg_dL":1.37,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_1637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":62,"sex":"male","bmi":22.8,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-12-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-83},"pfs_months":32.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":55.6,"censored":false},"longitudinal_labs":[{"date":"2023-12-01","hemoglobin_g_dL":12.5,"wbc_k_uL":10.2,"platelets_k_uL":323,"creatinine_mg_dL":0.62,"alt_U_L":15},{"date":"2024-06-12","hemoglobin_g_dL":10.9,"wbc_k_uL":4.0,"platelets_k_uL":139,"creatinine_mg_dL":1.3,"alt_U_L":46},{"date":"2026-10-19","hemoglobin_g_dL":11.3,"wbc_k_uL":5.3,"platelets_k_uL":338,"creatinine_mg_dL":1.81,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_1638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":69,"sex":"male","bmi":33.1,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-03-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-70},"pfs_months":10.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.4,"censored":false},"longitudinal_labs":[{"date":"2022-01-06","hemoglobin_g_dL":14.7,"wbc_k_uL":5.0,"platelets_k_uL":268,"creatinine_mg_dL":1.14,"alt_U_L":18},{"date":"2022-09-11","hemoglobin_g_dL":13.9,"wbc_k_uL":4.9,"platelets_k_uL":243,"creatinine_mg_dL":1.24,"alt_U_L":52},{"date":"2023-02-03","hemoglobin_g_dL":11.4,"wbc_k_uL":3.6,"platelets_k_uL":344,"creatinine_mg_dL":1.83,"alt_U_L":99}]}
{"patient_id":"ANODE_SYNTH_2025_1639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":63,"sex":"male","bmi":23.2,"smoking_pack_years":61,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-37},"pfs_months":4.53},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.0,"censored":true},"longitudinal_labs":[{"date":"2023-06-12","hemoglobin_g_dL":12.5,"wbc_k_uL":9.5,"platelets_k_uL":232,"creatinine_mg_dL":1.2,"alt_U_L":46},{"date":"2023-12-28","hemoglobin_g_dL":11.8,"wbc_k_uL":7.5,"platelets_k_uL":132,"creatinine_mg_dL":1.44,"alt_U_L":57},{"date":"2023-12-14","hemoglobin_g_dL":12.9,"wbc_k_uL":5.4,"platelets_k_uL":304,"creatinine_mg_dL":1.6,"alt_U_L":87}]}
{"patient_id":"ANODE_SYNTH_2025_1640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":85,"sex":"male","bmi":19.3,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-75},"pfs_months":14.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.6,"censored":true},"longitudinal_labs":[{"date":"2024-02-25","hemoglobin_g_dL":12.8,"wbc_k_uL":10.3,"platelets_k_uL":193,"creatinine_mg_dL":1.2,"alt_U_L":44},{"date":"2024-10-24","hemoglobin_g_dL":10.1,"wbc_k_uL":7.6,"platelets_k_uL":137,"creatinine_mg_dL":1.51,"alt_U_L":37},{"date":"2025-07-17","hemoglobin_g_dL":11.5,"wbc_k_uL":7.6,"platelets_k_uL":344,"creatinine_mg_dL":1.79,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_1641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":55,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-79},"pfs_months":13.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.3,"censored":false},"longitudinal_labs":[{"date":"2023-01-19","hemoglobin_g_dL":14.5,"wbc_k_uL":9.0,"platelets_k_uL":305,"creatinine_mg_dL":0.93,"alt_U_L":51},{"date":"2023-09-23","hemoglobin_g_dL":11.0,"wbc_k_uL":4.4,"platelets_k_uL":130,"creatinine_mg_dL":0.91,"alt_U_L":115},{"date":"2024-06-29","hemoglobin_g_dL":12.5,"wbc_k_uL":6.2,"platelets_k_uL":247,"creatinine_mg_dL":1.29,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_1642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":63,"sex":"female","bmi":27.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-32},"pfs_months":23.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.3,"censored":false},"longitudinal_labs":[{"date":"2022-06-13","hemoglobin_g_dL":13.5,"wbc_k_uL":9.0,"platelets_k_uL":282,"creatinine_mg_dL":1.06,"alt_U_L":65},{"date":"2023-01-02","hemoglobin_g_dL":13.7,"wbc_k_uL":6.2,"platelets_k_uL":179,"creatinine_mg_dL":1.43,"alt_U_L":59},{"date":"2024-08-04","hemoglobin_g_dL":10.9,"wbc_k_uL":5.2,"platelets_k_uL":309,"creatinine_mg_dL":1.56,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_1643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":85,"sex":"female","bmi":34.2,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-43},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":13.8,"censored":false},"longitudinal_labs":[{"date":"2024-02-02","hemoglobin_g_dL":12.8,"wbc_k_uL":6.1,"platelets_k_uL":251,"creatinine_mg_dL":1.08,"alt_U_L":59},{"date":"2024-10-06","hemoglobin_g_dL":10.4,"wbc_k_uL":6.5,"platelets_k_uL":376,"creatinine_mg_dL":0.89,"alt_U_L":109},{"date":"2024-09-03","hemoglobin_g_dL":11.7,"wbc_k_uL":3.4,"platelets_k_uL":275,"creatinine_mg_dL":1.52,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_1644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":53,"sex":"male","bmi":27.6,"smoking_pack_years":18,"ecog_performance_status":2,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-10-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-70},"pfs_months":12.35},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.4,"censored":false},"longitudinal_labs":[{"date":"2024-08-26","hemoglobin_g_dL":13.6,"wbc_k_uL":6.2,"platelets_k_uL":315,"creatinine_mg_dL":1.25,"alt_U_L":26},{"date":"2025-04-21","hemoglobin_g_dL":12.8,"wbc_k_uL":5.9,"platelets_k_uL":192,"creatinine_mg_dL":0.74,"alt_U_L":98},{"date":"2025-12-22","hemoglobin_g_dL":12.3,"wbc_k_uL":6.3,"platelets_k_uL":280,"creatinine_mg_dL":1.59,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_1645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":52,"sex":"male","bmi":24.7,"smoking_pack_years":49,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-06-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-57},"pfs_months":17.71},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":false},"longitudinal_labs":[{"date":"2021-05-17","hemoglobin_g_dL":14.2,"wbc_k_uL":7.7,"platelets_k_uL":390,"creatinine_mg_dL":1.04,"alt_U_L":75},{"date":"2021-12-27","hemoglobin_g_dL":13.0,"wbc_k_uL":5.9,"platelets_k_uL":201,"creatinine_mg_dL":1.4,"alt_U_L":51},{"date":"2022-12-26","hemoglobin_g_dL":12.0,"wbc_k_uL":4.0,"platelets_k_uL":165,"creatinine_mg_dL":0.81,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_1646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":68,"sex":"female","bmi":23.5,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-79},"pfs_months":40.97},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":69.0,"censored":false},"longitudinal_labs":[{"date":"2021-01-26","hemoglobin_g_dL":14.8,"wbc_k_uL":9.0,"platelets_k_uL":266,"creatinine_mg_dL":1.21,"alt_U_L":10},{"date":"2021-09-09","hemoglobin_g_dL":11.6,"wbc_k_uL":6.8,"platelets_k_uL":330,"creatinine_mg_dL":1.52,"alt_U_L":40},{"date":"2024-09-14","hemoglobin_g_dL":12.7,"wbc_k_uL":5.9,"platelets_k_uL":252,"creatinine_mg_dL":0.84,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_1647","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":77,"sex":"female","bmi":27.5,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-12-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-84},"pfs_months":23.75},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.9,"censored":false},"longitudinal_labs":[{"date":"2025-11-23","hemoglobin_g_dL":12.2,"wbc_k_uL":9.0,"platelets_k_uL":431,"creatinine_mg_dL":1.19,"alt_U_L":13},{"date":"2026-06-17","hemoglobin_g_dL":11.8,"wbc_k_uL":8.9,"platelets_k_uL":283,"creatinine_mg_dL":0.96,"alt_U_L":108},{"date":"2028-01-28","hemoglobin_g_dL":11.3,"wbc_k_uL":6.1,"platelets_k_uL":256,"creatinine_mg_dL":0.87,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_1648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":86,"sex":"female","bmi":35.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-38},"pfs_months":29.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-10","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.9,"censored":true},"longitudinal_labs":[{"date":"2023-02-09","hemoglobin_g_dL":11.6,"wbc_k_uL":9.2,"platelets_k_uL":421,"creatinine_mg_dL":0.71,"alt_U_L":14},{"date":"2023-08-24","hemoglobin_g_dL":10.1,"wbc_k_uL":5.3,"platelets_k_uL":208,"creatinine_mg_dL":0.9,"alt_U_L":52},{"date":"2025-10-10","hemoglobin_g_dL":11.8,"wbc_k_uL":4.3,"platelets_k_uL":340,"creatinine_mg_dL":1.47,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_1649","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":65,"sex":"female","bmi":25.2,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2020-11-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-49},"pfs_months":23.66},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":false},"longitudinal_labs":[{"date":"2020-11-14","hemoglobin_g_dL":14.7,"wbc_k_uL":7.0,"platelets_k_uL":170,"creatinine_mg_dL":0.68,"alt_U_L":66},{"date":"2021-05-27","hemoglobin_g_dL":12.1,"wbc_k_uL":6.2,"platelets_k_uL":201,"creatinine_mg_dL":1.43,"alt_U_L":59},{"date":"2022-12-27","hemoglobin_g_dL":10.7,"wbc_k_uL":6.5,"platelets_k_uL":258,"creatinine_mg_dL":1.03,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_1650","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":74,"sex":"male","bmi":22.7,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-03-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-62},"pfs_months":12.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.6,"censored":false},"longitudinal_labs":[{"date":"2023-01-12","hemoglobin_g_dL":14.0,"wbc_k_uL":10.9,"platelets_k_uL":258,"creatinine_mg_dL":0.89,"alt_U_L":63},{"date":"2023-09-02","hemoglobin_g_dL":13.9,"wbc_k_uL":6.2,"platelets_k_uL":144,"creatinine_mg_dL":0.77,"alt_U_L":60},{"date":"2024-03-16","hemoglobin_g_dL":11.7,"wbc_k_uL":5.4,"platelets_k_uL":174,"creatinine_mg_dL":1.01,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1651","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":48,"sex":"male","bmi":21.7,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-11-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-76},"pfs_months":52.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":77.4,"censored":true},"longitudinal_labs":[{"date":"2022-10-07","hemoglobin_g_dL":14.3,"wbc_k_uL":10.2,"platelets_k_uL":254,"creatinine_mg_dL":0.78,"alt_U_L":22},{"date":"2023-05-03","hemoglobin_g_dL":12.2,"wbc_k_uL":6.9,"platelets_k_uL":269,"creatinine_mg_dL":1.54,"alt_U_L":18},{"date":"2027-04-07","hemoglobin_g_dL":11.9,"wbc_k_uL":3.8,"platelets_k_uL":294,"creatinine_mg_dL":1.94,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_1652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":78,"sex":"female","bmi":34.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-31},"pfs_months":22.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.3,"censored":false},"longitudinal_labs":[{"date":"2024-12-05","hemoglobin_g_dL":13.1,"wbc_k_uL":10.8,"platelets_k_uL":160,"creatinine_mg_dL":1.02,"alt_U_L":64},{"date":"2025-07-14","hemoglobin_g_dL":12.3,"wbc_k_uL":8.5,"platelets_k_uL":321,"creatinine_mg_dL":1.27,"alt_U_L":18},{"date":"2027-01-12","hemoglobin_g_dL":11.5,"wbc_k_uL":5.1,"platelets_k_uL":283,"creatinine_mg_dL":1.03,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_1653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":51,"sex":"male","bmi":36.8,"smoking_pack_years":38,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2026-01-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-55},"pfs_months":37.06},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-04-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.2,"censored":false},"longitudinal_labs":[{"date":"2025-11-25","hemoglobin_g_dL":13.8,"wbc_k_uL":10.5,"platelets_k_uL":196,"creatinine_mg_dL":0.61,"alt_U_L":26},{"date":"2026-07-28","hemoglobin_g_dL":13.4,"wbc_k_uL":8.5,"platelets_k_uL":256,"creatinine_mg_dL":0.93,"alt_U_L":35},{"date":"2029-04-11","hemoglobin_g_dL":10.4,"wbc_k_uL":4.4,"platelets_k_uL":175,"creatinine_mg_dL":1.65,"alt_U_L":176}]}
{"patient_id":"ANODE_SYNTH_2025_1654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":85,"sex":"female","bmi":19.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-74},"pfs_months":11.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.4,"censored":false},"longitudinal_labs":[{"date":"2023-03-02","hemoglobin_g_dL":13.4,"wbc_k_uL":9.3,"platelets_k_uL":339,"creatinine_mg_dL":1.2,"alt_U_L":62},{"date":"2023-09-19","hemoglobin_g_dL":13.2,"wbc_k_uL":8.3,"platelets_k_uL":199,"creatinine_mg_dL":1.31,"alt_U_L":68},{"date":"2024-05-04","hemoglobin_g_dL":10.3,"wbc_k_uL":4.7,"platelets_k_uL":339,"creatinine_mg_dL":1.76,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_1655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":52,"sex":"female","bmi":25.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-42},"pfs_months":32.53},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.6,"censored":false},"longitudinal_labs":[{"date":"2021-04-23","hemoglobin_g_dL":14.7,"wbc_k_uL":8.4,"platelets_k_uL":241,"creatinine_mg_dL":1.21,"alt_U_L":54},{"date":"2021-12-09","hemoglobin_g_dL":10.8,"wbc_k_uL":8.5,"platelets_k_uL":158,"creatinine_mg_dL":1.55,"alt_U_L":90},{"date":"2024-04-20","hemoglobin_g_dL":12.5,"wbc_k_uL":3.2,"platelets_k_uL":301,"creatinine_mg_dL":1.17,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_1656","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":53,"sex":"female","bmi":27.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-50},"pfs_months":19.61},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.0,"censored":true},"longitudinal_labs":[{"date":"2025-07-03","hemoglobin_g_dL":13.0,"wbc_k_uL":9.7,"platelets_k_uL":410,"creatinine_mg_dL":1.06,"alt_U_L":17},{"date":"2026-03-10","hemoglobin_g_dL":12.4,"wbc_k_uL":5.4,"platelets_k_uL":283,"creatinine_mg_dL":1.44,"alt_U_L":89},{"date":"2027-06-21","hemoglobin_g_dL":12.2,"wbc_k_uL":3.7,"platelets_k_uL":136,"creatinine_mg_dL":1.64,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_1657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":84,"sex":"female","bmi":29.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-69},"pfs_months":22.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":false},"longitudinal_labs":[{"date":"2020-11-26","hemoglobin_g_dL":13.6,"wbc_k_uL":4.7,"platelets_k_uL":445,"creatinine_mg_dL":0.92,"alt_U_L":52},{"date":"2021-07-11","hemoglobin_g_dL":10.7,"wbc_k_uL":3.9,"platelets_k_uL":375,"creatinine_mg_dL":1.46,"alt_U_L":28},{"date":"2023-01-11","hemoglobin_g_dL":12.3,"wbc_k_uL":6.3,"platelets_k_uL":279,"creatinine_mg_dL":1.52,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_1658","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":83,"sex":"female","bmi":29.7,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-10-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-71},"pfs_months":15.15},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.3,"censored":false},"longitudinal_labs":[{"date":"2022-09-15","hemoglobin_g_dL":14.9,"wbc_k_uL":6.4,"platelets_k_uL":192,"creatinine_mg_dL":1.29,"alt_U_L":48},{"date":"2023-03-30","hemoglobin_g_dL":13.1,"wbc_k_uL":7.3,"platelets_k_uL":236,"creatinine_mg_dL":1.17,"alt_U_L":77},{"date":"2024-02-26","hemoglobin_g_dL":10.4,"wbc_k_uL":7.5,"platelets_k_uL":185,"creatinine_mg_dL":1.04,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_1659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":72,"sex":"male","bmi":32.2,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-70},"pfs_months":27.53},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.9,"censored":false},"longitudinal_labs":[{"date":"2021-02-13","hemoglobin_g_dL":14.9,"wbc_k_uL":6.5,"platelets_k_uL":311,"creatinine_mg_dL":0.63,"alt_U_L":73},{"date":"2021-09-01","hemoglobin_g_dL":12.4,"wbc_k_uL":4.6,"platelets_k_uL":378,"creatinine_mg_dL":1.01,"alt_U_L":76},{"date":"2023-08-20","hemoglobin_g_dL":9.8,"wbc_k_uL":7.1,"platelets_k_uL":251,"creatinine_mg_dL":1.75,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_1660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":57,"sex":"female","bmi":22.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-69},"pfs_months":20.93},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.1,"censored":false},"longitudinal_labs":[{"date":"2024-08-03","hemoglobin_g_dL":13.7,"wbc_k_uL":10.6,"platelets_k_uL":395,"creatinine_mg_dL":1.17,"alt_U_L":71},{"date":"2025-03-13","hemoglobin_g_dL":12.0,"wbc_k_uL":8.8,"platelets_k_uL":350,"creatinine_mg_dL":0.95,"alt_U_L":85},{"date":"2026-07-14","hemoglobin_g_dL":10.1,"wbc_k_uL":3.9,"platelets_k_uL":248,"creatinine_mg_dL":1.99,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_1661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":60,"sex":"female","bmi":35.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-59},"pfs_months":30.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.5,"censored":false},"longitudinal_labs":[{"date":"2024-08-10","hemoglobin_g_dL":12.9,"wbc_k_uL":6.7,"platelets_k_uL":205,"creatinine_mg_dL":1.03,"alt_U_L":47},{"date":"2025-03-27","hemoglobin_g_dL":11.0,"wbc_k_uL":8.8,"platelets_k_uL":313,"creatinine_mg_dL":1.37,"alt_U_L":84},{"date":"2027-05-29","hemoglobin_g_dL":11.4,"wbc_k_uL":3.5,"platelets_k_uL":241,"creatinine_mg_dL":1.26,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_1662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":59,"sex":"female","bmi":32.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-68},"pfs_months":29.08},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.6,"censored":false},"longitudinal_labs":[{"date":"2020-08-05","hemoglobin_g_dL":13.5,"wbc_k_uL":4.7,"platelets_k_uL":366,"creatinine_mg_dL":0.84,"alt_U_L":64},{"date":"2021-04-10","hemoglobin_g_dL":11.2,"wbc_k_uL":8.5,"platelets_k_uL":155,"creatinine_mg_dL":1.52,"alt_U_L":77},{"date":"2023-04-27","hemoglobin_g_dL":10.5,"wbc_k_uL":5.1,"platelets_k_uL":107,"creatinine_mg_dL":1.54,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_1663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":57,"sex":"male","bmi":31.0,"smoking_pack_years":57,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-10-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-78},"pfs_months":3.22},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":10.0,"censored":false},"longitudinal_labs":[{"date":"2024-08-01","hemoglobin_g_dL":13.8,"wbc_k_uL":6.0,"platelets_k_uL":414,"creatinine_mg_dL":1.28,"alt_U_L":60},{"date":"2025-04-08","hemoglobin_g_dL":13.8,"wbc_k_uL":8.0,"platelets_k_uL":323,"creatinine_mg_dL":1.38,"alt_U_L":87},{"date":"2025-03-01","hemoglobin_g_dL":12.1,"wbc_k_uL":4.1,"platelets_k_uL":112,"creatinine_mg_dL":0.9,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_1664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":56,"sex":"female","bmi":31.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-39},"pfs_months":30.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":false},"longitudinal_labs":[{"date":"2020-11-11","hemoglobin_g_dL":13.1,"wbc_k_uL":9.4,"platelets_k_uL":339,"creatinine_mg_dL":0.68,"alt_U_L":57},{"date":"2021-06-02","hemoglobin_g_dL":10.2,"wbc_k_uL":6.9,"platelets_k_uL":339,"creatinine_mg_dL":1.15,"alt_U_L":115},{"date":"2023-07-07","hemoglobin_g_dL":10.0,"wbc_k_uL":6.2,"platelets_k_uL":157,"creatinine_mg_dL":1.9,"alt_U_L":56}]}
{"patient_id":"ANODE_SYNTH_2025_1665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":48,"sex":"female","bmi":19.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-56},"pfs_months":24.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.1,"censored":false},"longitudinal_labs":[{"date":"2022-03-19","hemoglobin_g_dL":14.3,"wbc_k_uL":10.8,"platelets_k_uL":215,"creatinine_mg_dL":0.7,"alt_U_L":48},{"date":"2022-10-16","hemoglobin_g_dL":13.9,"wbc_k_uL":5.2,"platelets_k_uL":358,"creatinine_mg_dL":1.13,"alt_U_L":66},{"date":"2024-05-12","hemoglobin_g_dL":10.1,"wbc_k_uL":4.0,"platelets_k_uL":272,"creatinine_mg_dL":1.39,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_1666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":85,"sex":"female","bmi":36.4,"smoking_pack_years":60,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-03-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-37},"pfs_months":9.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":13.9,"censored":false},"longitudinal_labs":[{"date":"2023-03-13","hemoglobin_g_dL":15.2,"wbc_k_uL":7.7,"platelets_k_uL":274,"creatinine_mg_dL":1.24,"alt_U_L":53},{"date":"2023-09-25","hemoglobin_g_dL":12.5,"wbc_k_uL":6.6,"platelets_k_uL":175,"creatinine_mg_dL":1.43,"alt_U_L":112},{"date":"2024-02-04","hemoglobin_g_dL":11.4,"wbc_k_uL":5.9,"platelets_k_uL":148,"creatinine_mg_dL":0.86,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_1667","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":57,"sex":"female","bmi":37.9,"smoking_pack_years":47,"ecog_performance_status":2,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-55},"pfs_months":14.65},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.7,"censored":false},"longitudinal_labs":[{"date":"2021-04-26","hemoglobin_g_dL":15.3,"wbc_k_uL":4.8,"platelets_k_uL":230,"creatinine_mg_dL":0.8,"alt_U_L":28},{"date":"2021-12-08","hemoglobin_g_dL":10.5,"wbc_k_uL":4.2,"platelets_k_uL":124,"creatinine_mg_dL":1.34,"alt_U_L":25},{"date":"2022-10-17","hemoglobin_g_dL":11.5,"wbc_k_uL":6.1,"platelets_k_uL":290,"creatinine_mg_dL":0.87,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_1668","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":87,"sex":"male","bmi":36.1,"smoking_pack_years":36,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2024-12-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-68},"pfs_months":18.69},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":37.7,"censored":true},"longitudinal_labs":[{"date":"2024-10-25","hemoglobin_g_dL":14.4,"wbc_k_uL":8.9,"platelets_k_uL":364,"creatinine_mg_dL":1.13,"alt_U_L":30},{"date":"2025-06-14","hemoglobin_g_dL":10.9,"wbc_k_uL":5.6,"platelets_k_uL":161,"creatinine_mg_dL":1.04,"alt_U_L":107},{"date":"2026-08-15","hemoglobin_g_dL":11.9,"wbc_k_uL":5.3,"platelets_k_uL":313,"creatinine_mg_dL":1.03,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_1669","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":82,"sex":"female","bmi":33.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-65},"pfs_months":23.26},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.6,"censored":true},"longitudinal_labs":[{"date":"2022-04-21","hemoglobin_g_dL":13.0,"wbc_k_uL":8.4,"platelets_k_uL":373,"creatinine_mg_dL":0.76,"alt_U_L":77},{"date":"2022-11-11","hemoglobin_g_dL":13.5,"wbc_k_uL":5.8,"platelets_k_uL":193,"creatinine_mg_dL":1.54,"alt_U_L":67},{"date":"2024-05-02","hemoglobin_g_dL":12.0,"wbc_k_uL":5.8,"platelets_k_uL":285,"creatinine_mg_dL":1.5,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_1670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":71,"sex":"female","bmi":30.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-55},"pfs_months":27.37},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.6,"censored":false},"longitudinal_labs":[{"date":"2025-01-22","hemoglobin_g_dL":12.3,"wbc_k_uL":4.8,"platelets_k_uL":155,"creatinine_mg_dL":0.74,"alt_U_L":57},{"date":"2025-09-13","hemoglobin_g_dL":10.7,"wbc_k_uL":5.5,"platelets_k_uL":370,"creatinine_mg_dL":1.06,"alt_U_L":71},{"date":"2027-08-01","hemoglobin_g_dL":12.5,"wbc_k_uL":5.3,"platelets_k_uL":329,"creatinine_mg_dL":1.63,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_1671","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":75,"sex":"female","bmi":35.1,"smoking_pack_years":38,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-04-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-45},"pfs_months":17.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.4,"censored":false},"longitudinal_labs":[{"date":"2022-04-15","hemoglobin_g_dL":13.9,"wbc_k_uL":9.6,"platelets_k_uL":321,"creatinine_mg_dL":0.73,"alt_U_L":58},{"date":"2022-10-26","hemoglobin_g_dL":13.1,"wbc_k_uL":8.8,"platelets_k_uL":192,"creatinine_mg_dL":0.97,"alt_U_L":41},{"date":"2023-11-18","hemoglobin_g_dL":10.0,"wbc_k_uL":5.6,"platelets_k_uL":197,"creatinine_mg_dL":1.09,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_1672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":53,"sex":"female","bmi":19.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-33},"pfs_months":18.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.8,"censored":true},"longitudinal_labs":[{"date":"2024-09-23","hemoglobin_g_dL":15.4,"wbc_k_uL":9.2,"platelets_k_uL":153,"creatinine_mg_dL":0.88,"alt_U_L":47},{"date":"2025-05-08","hemoglobin_g_dL":12.5,"wbc_k_uL":7.9,"platelets_k_uL":329,"creatinine_mg_dL":1.54,"alt_U_L":108},{"date":"2026-08-02","hemoglobin_g_dL":10.2,"wbc_k_uL":6.6,"platelets_k_uL":116,"creatinine_mg_dL":1.9,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_1673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":73,"sex":"male","bmi":29.9,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-05-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-76},"pfs_months":14.52},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":18.5,"censored":false},"longitudinal_labs":[{"date":"2023-04-12","hemoglobin_g_dL":14.6,"wbc_k_uL":9.1,"platelets_k_uL":413,"creatinine_mg_dL":1.02,"alt_U_L":58},{"date":"2023-11-07","hemoglobin_g_dL":11.9,"wbc_k_uL":5.9,"platelets_k_uL":230,"creatinine_mg_dL":0.94,"alt_U_L":43},{"date":"2024-09-06","hemoglobin_g_dL":12.0,"wbc_k_uL":6.0,"platelets_k_uL":347,"creatinine_mg_dL":1.42,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_1674","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":52,"sex":"female","bmi":20.8,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-08-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-84},"pfs_months":17.12},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.1,"censored":false},"longitudinal_labs":[{"date":"2024-08-04","hemoglobin_g_dL":14.2,"wbc_k_uL":10.1,"platelets_k_uL":295,"creatinine_mg_dL":0.8,"alt_U_L":29},{"date":"2025-02-20","hemoglobin_g_dL":11.9,"wbc_k_uL":4.5,"platelets_k_uL":164,"creatinine_mg_dL":1.45,"alt_U_L":107},{"date":"2026-03-12","hemoglobin_g_dL":11.3,"wbc_k_uL":4.3,"platelets_k_uL":118,"creatinine_mg_dL":0.96,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_1675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.2,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":57,"sex":"male","bmi":35.0,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-05-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-68},"pfs_months":36.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":56.8,"censored":false},"longitudinal_labs":[{"date":"2020-03-06","hemoglobin_g_dL":11.9,"wbc_k_uL":4.8,"platelets_k_uL":184,"creatinine_mg_dL":0.6,"alt_U_L":58},{"date":"2020-11-06","hemoglobin_g_dL":12.3,"wbc_k_uL":7.8,"platelets_k_uL":182,"creatinine_mg_dL":1.54,"alt_U_L":119},{"date":"2023-07-25","hemoglobin_g_dL":9.9,"wbc_k_uL":5.3,"platelets_k_uL":127,"creatinine_mg_dL":0.93,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_1676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":64,"sex":"female","bmi":22.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-44},"pfs_months":31.44},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":45.7,"censored":false},"longitudinal_labs":[{"date":"2023-01-15","hemoglobin_g_dL":14.5,"wbc_k_uL":10.0,"platelets_k_uL":161,"creatinine_mg_dL":0.91,"alt_U_L":20},{"date":"2023-08-01","hemoglobin_g_dL":13.5,"wbc_k_uL":4.9,"platelets_k_uL":184,"creatinine_mg_dL":1.2,"alt_U_L":39},{"date":"2025-10-14","hemoglobin_g_dL":12.1,"wbc_k_uL":5.1,"platelets_k_uL":140,"creatinine_mg_dL":1.59,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_1677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":48,"sex":"female","bmi":37.4,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-11-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-33},"pfs_months":9.36},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":13.3,"censored":false},"longitudinal_labs":[{"date":"2023-09-09","hemoglobin_g_dL":12.5,"wbc_k_uL":7.9,"platelets_k_uL":409,"creatinine_mg_dL":1.06,"alt_U_L":27},{"date":"2024-05-10","hemoglobin_g_dL":11.8,"wbc_k_uL":4.0,"platelets_k_uL":378,"creatinine_mg_dL":1.06,"alt_U_L":115},{"date":"2024-09-25","hemoglobin_g_dL":11.9,"wbc_k_uL":5.6,"platelets_k_uL":274,"creatinine_mg_dL":1.7,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_1678","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":61,"sex":"male","bmi":22.9,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-03-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-64},"pfs_months":32.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":56.1,"censored":true},"longitudinal_labs":[{"date":"2023-01-26","hemoglobin_g_dL":13.2,"wbc_k_uL":6.1,"platelets_k_uL":398,"creatinine_mg_dL":0.65,"alt_U_L":43},{"date":"2023-09-17","hemoglobin_g_dL":12.4,"wbc_k_uL":7.8,"platelets_k_uL":229,"creatinine_mg_dL":1.55,"alt_U_L":73},{"date":"2025-12-24","hemoglobin_g_dL":12.5,"wbc_k_uL":7.8,"platelets_k_uL":126,"creatinine_mg_dL":1.1,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_1679","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":75,"sex":"male","bmi":36.2,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-68},"pfs_months":21.52},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.1,"censored":false},"longitudinal_labs":[{"date":"2023-02-14","hemoglobin_g_dL":13.5,"wbc_k_uL":5.1,"platelets_k_uL":330,"creatinine_mg_dL":0.67,"alt_U_L":22},{"date":"2023-09-14","hemoglobin_g_dL":12.5,"wbc_k_uL":7.3,"platelets_k_uL":175,"creatinine_mg_dL":1.26,"alt_U_L":84},{"date":"2025-02-17","hemoglobin_g_dL":11.9,"wbc_k_uL":7.9,"platelets_k_uL":280,"creatinine_mg_dL":1.73,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_1680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":68,"sex":"male","bmi":35.1,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-02-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-52},"pfs_months":14.42},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":18.4,"censored":false},"longitudinal_labs":[{"date":"2024-12-22","hemoglobin_g_dL":13.5,"wbc_k_uL":8.4,"platelets_k_uL":219,"creatinine_mg_dL":1.23,"alt_U_L":59},{"date":"2025-08-27","hemoglobin_g_dL":11.1,"wbc_k_uL":6.9,"platelets_k_uL":332,"creatinine_mg_dL":1.3,"alt_U_L":92},{"date":"2026-06-18","hemoglobin_g_dL":9.5,"wbc_k_uL":4.2,"platelets_k_uL":265,"creatinine_mg_dL":1.57,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_1681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":63,"sex":"female","bmi":22.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-02-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-62},"pfs_months":23.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":true},"longitudinal_labs":[{"date":"2022-01-18","hemoglobin_g_dL":12.8,"wbc_k_uL":8.0,"platelets_k_uL":361,"creatinine_mg_dL":1.23,"alt_U_L":19},{"date":"2022-08-06","hemoglobin_g_dL":11.4,"wbc_k_uL":6.7,"platelets_k_uL":315,"creatinine_mg_dL":0.79,"alt_U_L":77},{"date":"2024-03-28","hemoglobin_g_dL":9.7,"wbc_k_uL":6.8,"platelets_k_uL":215,"creatinine_mg_dL":1.59,"alt_U_L":58}]}
{"patient_id":"ANODE_SYNTH_2025_1682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":88,"sex":"female","bmi":26.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-45},"pfs_months":28.94},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.4,"censored":false},"longitudinal_labs":[{"date":"2023-07-05","hemoglobin_g_dL":13.6,"wbc_k_uL":6.0,"platelets_k_uL":209,"creatinine_mg_dL":1.25,"alt_U_L":62},{"date":"2024-02-16","hemoglobin_g_dL":13.1,"wbc_k_uL":4.3,"platelets_k_uL":280,"creatinine_mg_dL":0.87,"alt_U_L":73},{"date":"2026-03-09","hemoglobin_g_dL":9.6,"wbc_k_uL":7.0,"platelets_k_uL":248,"creatinine_mg_dL":1.32,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_1683","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":48,"sex":"male","bmi":36.4,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-10-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-41},"pfs_months":25.92},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.0,"censored":false},"longitudinal_labs":[{"date":"2020-08-18","hemoglobin_g_dL":13.2,"wbc_k_uL":4.8,"platelets_k_uL":276,"creatinine_mg_dL":0.79,"alt_U_L":15},{"date":"2021-04-20","hemoglobin_g_dL":13.4,"wbc_k_uL":6.6,"platelets_k_uL":262,"creatinine_mg_dL":0.7,"alt_U_L":81},{"date":"2023-02-04","hemoglobin_g_dL":11.4,"wbc_k_uL":5.2,"platelets_k_uL":222,"creatinine_mg_dL":1.69,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_1684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":70,"sex":"male","bmi":19.6,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-32},"pfs_months":11.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.1,"censored":true},"longitudinal_labs":[{"date":"2024-03-09","hemoglobin_g_dL":12.2,"wbc_k_uL":10.2,"platelets_k_uL":388,"creatinine_mg_dL":1.19,"alt_U_L":63},{"date":"2024-10-09","hemoglobin_g_dL":13.6,"wbc_k_uL":7.4,"platelets_k_uL":313,"creatinine_mg_dL":1.35,"alt_U_L":102},{"date":"2025-05-26","hemoglobin_g_dL":12.1,"wbc_k_uL":5.2,"platelets_k_uL":266,"creatinine_mg_dL":1.25,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_1685","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":57,"sex":"female","bmi":29.8,"smoking_pack_years":58,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-12-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-48},"pfs_months":19.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.5,"censored":false},"longitudinal_labs":[{"date":"2022-10-24","hemoglobin_g_dL":12.3,"wbc_k_uL":9.5,"platelets_k_uL":336,"creatinine_mg_dL":0.8,"alt_U_L":79},{"date":"2023-06-06","hemoglobin_g_dL":10.2,"wbc_k_uL":7.5,"platelets_k_uL":146,"creatinine_mg_dL":1.49,"alt_U_L":39},{"date":"2024-07-19","hemoglobin_g_dL":9.9,"wbc_k_uL":4.7,"platelets_k_uL":181,"creatinine_mg_dL":1.46,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_1686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":55,"sex":"female","bmi":34.0,"smoking_pack_years":54,"ecog_performance_status":2,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-06-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-55},"pfs_months":24.18},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":49.7,"censored":false},"longitudinal_labs":[{"date":"2023-05-26","hemoglobin_g_dL":11.8,"wbc_k_uL":9.1,"platelets_k_uL":376,"creatinine_mg_dL":0.62,"alt_U_L":60},{"date":"2023-12-07","hemoglobin_g_dL":11.5,"wbc_k_uL":5.3,"platelets_k_uL":317,"creatinine_mg_dL":1.17,"alt_U_L":39},{"date":"2025-08-06","hemoglobin_g_dL":11.8,"wbc_k_uL":3.2,"platelets_k_uL":330,"creatinine_mg_dL":1.34,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1687","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":50,"sex":"male","bmi":20.0,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-08-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-48},"pfs_months":17.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.1,"censored":false},"longitudinal_labs":[{"date":"2023-07-23","hemoglobin_g_dL":14.2,"wbc_k_uL":9.5,"platelets_k_uL":197,"creatinine_mg_dL":0.75,"alt_U_L":17},{"date":"2024-02-09","hemoglobin_g_dL":12.6,"wbc_k_uL":7.9,"platelets_k_uL":132,"creatinine_mg_dL":1.2,"alt_U_L":82},{"date":"2025-02-09","hemoglobin_g_dL":12.5,"wbc_k_uL":5.0,"platelets_k_uL":249,"creatinine_mg_dL":1.29,"alt_U_L":198}]}
{"patient_id":"ANODE_SYNTH_2025_1688","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":77,"sex":"female","bmi":22.2,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-02-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-80},"pfs_months":24.71},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":44.7,"censored":false},"longitudinal_labs":[{"date":"2022-12-16","hemoglobin_g_dL":12.1,"wbc_k_uL":9.1,"platelets_k_uL":153,"creatinine_mg_dL":0.78,"alt_U_L":49},{"date":"2023-08-07","hemoglobin_g_dL":10.2,"wbc_k_uL":5.0,"platelets_k_uL":321,"creatinine_mg_dL":0.97,"alt_U_L":95},{"date":"2025-03-23","hemoglobin_g_dL":12.9,"wbc_k_uL":4.5,"platelets_k_uL":207,"creatinine_mg_dL":0.97,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_1689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":71,"sex":"female","bmi":34.9,"smoking_pack_years":74,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-04-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-69},"pfs_months":27.93},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":58.0,"censored":false},"longitudinal_labs":[{"date":"2024-02-07","hemoglobin_g_dL":13.4,"wbc_k_uL":8.1,"platelets_k_uL":353,"creatinine_mg_dL":0.76,"alt_U_L":72},{"date":"2024-10-06","hemoglobin_g_dL":13.1,"wbc_k_uL":6.2,"platelets_k_uL":342,"creatinine_mg_dL":1.57,"alt_U_L":60},{"date":"2026-09-14","hemoglobin_g_dL":12.3,"wbc_k_uL":3.5,"platelets_k_uL":223,"creatinine_mg_dL":1.87,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_1690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":52,"sex":"female","bmi":32.6,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-02-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-45},"pfs_months":21.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.1,"censored":false},"longitudinal_labs":[{"date":"2021-01-07","hemoglobin_g_dL":11.6,"wbc_k_uL":4.7,"platelets_k_uL":222,"creatinine_mg_dL":0.85,"alt_U_L":68},{"date":"2021-08-12","hemoglobin_g_dL":10.9,"wbc_k_uL":8.8,"platelets_k_uL":287,"creatinine_mg_dL":1.55,"alt_U_L":75},{"date":"2023-01-01","hemoglobin_g_dL":13.0,"wbc_k_uL":6.7,"platelets_k_uL":265,"creatinine_mg_dL":1.09,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_1691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":54,"sex":"female","bmi":36.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-78},"pfs_months":21.59},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.3,"censored":false},"longitudinal_labs":[{"date":"2025-05-10","hemoglobin_g_dL":13.5,"wbc_k_uL":10.2,"platelets_k_uL":159,"creatinine_mg_dL":0.98,"alt_U_L":19},{"date":"2025-12-04","hemoglobin_g_dL":12.8,"wbc_k_uL":8.8,"platelets_k_uL":360,"creatinine_mg_dL":1.27,"alt_U_L":74},{"date":"2027-05-21","hemoglobin_g_dL":10.9,"wbc_k_uL":3.3,"platelets_k_uL":322,"creatinine_mg_dL":1.99,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_1692","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":54,"sex":"male","bmi":37.8,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-03-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-45},"pfs_months":23.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":false},"longitudinal_labs":[{"date":"2021-02-17","hemoglobin_g_dL":12.8,"wbc_k_uL":10.8,"platelets_k_uL":163,"creatinine_mg_dL":0.74,"alt_U_L":44},{"date":"2021-09-01","hemoglobin_g_dL":11.6,"wbc_k_uL":9.0,"platelets_k_uL":128,"creatinine_mg_dL":1.59,"alt_U_L":74},{"date":"2023-03-22","hemoglobin_g_dL":9.8,"wbc_k_uL":3.1,"platelets_k_uL":136,"creatinine_mg_dL":1.76,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_1693","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":80,"sex":"female","bmi":34.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-53},"pfs_months":20.93},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.8,"censored":true},"longitudinal_labs":[{"date":"2022-04-09","hemoglobin_g_dL":13.0,"wbc_k_uL":9.4,"platelets_k_uL":334,"creatinine_mg_dL":0.93,"alt_U_L":51},{"date":"2022-11-18","hemoglobin_g_dL":10.9,"wbc_k_uL":7.1,"platelets_k_uL":270,"creatinine_mg_dL":1.58,"alt_U_L":83},{"date":"2024-03-30","hemoglobin_g_dL":12.7,"wbc_k_uL":6.1,"platelets_k_uL":209,"creatinine_mg_dL":1.85,"alt_U_L":197}]}
{"patient_id":"ANODE_SYNTH_2025_1694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":51,"sex":"female","bmi":32.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-73},"pfs_months":22.51},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.2,"censored":false},"longitudinal_labs":[{"date":"2022-04-26","hemoglobin_g_dL":14.2,"wbc_k_uL":6.5,"platelets_k_uL":439,"creatinine_mg_dL":1.05,"alt_U_L":61},{"date":"2022-11-28","hemoglobin_g_dL":13.4,"wbc_k_uL":7.7,"platelets_k_uL":351,"creatinine_mg_dL":1.48,"alt_U_L":102},{"date":"2024-05-17","hemoglobin_g_dL":12.2,"wbc_k_uL":5.7,"platelets_k_uL":327,"creatinine_mg_dL":1.51,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_1695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":56,"sex":"female","bmi":22.3,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-10-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-71},"pfs_months":6.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.8,"censored":false},"longitudinal_labs":[{"date":"2024-10-02","hemoglobin_g_dL":12.2,"wbc_k_uL":5.4,"platelets_k_uL":218,"creatinine_mg_dL":1.24,"alt_U_L":61},{"date":"2025-04-14","hemoglobin_g_dL":12.0,"wbc_k_uL":8.3,"platelets_k_uL":304,"creatinine_mg_dL":0.95,"alt_U_L":37},{"date":"2025-06-07","hemoglobin_g_dL":11.1,"wbc_k_uL":6.6,"platelets_k_uL":110,"creatinine_mg_dL":1.54,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_1696","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":83,"sex":"female","bmi":32.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-33},"pfs_months":16.56},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.1,"censored":false},"longitudinal_labs":[{"date":"2024-01-12","hemoglobin_g_dL":14.9,"wbc_k_uL":6.5,"platelets_k_uL":315,"creatinine_mg_dL":0.84,"alt_U_L":14},{"date":"2024-09-01","hemoglobin_g_dL":13.8,"wbc_k_uL":4.7,"platelets_k_uL":171,"creatinine_mg_dL":1.23,"alt_U_L":51},{"date":"2025-08-07","hemoglobin_g_dL":12.1,"wbc_k_uL":5.0,"platelets_k_uL":315,"creatinine_mg_dL":0.84,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_1697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":83,"sex":"male","bmi":31.0,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-01-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-75},"pfs_months":31.21},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.7,"censored":true},"longitudinal_labs":[{"date":"2023-11-18","hemoglobin_g_dL":12.5,"wbc_k_uL":10.5,"platelets_k_uL":426,"creatinine_mg_dL":1.12,"alt_U_L":37},{"date":"2024-07-01","hemoglobin_g_dL":10.9,"wbc_k_uL":7.9,"platelets_k_uL":313,"creatinine_mg_dL":1.32,"alt_U_L":61},{"date":"2026-10-06","hemoglobin_g_dL":12.0,"wbc_k_uL":6.0,"platelets_k_uL":236,"creatinine_mg_dL":1.55,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_1698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":65,"sex":"female","bmi":33.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-75},"pfs_months":25.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.8,"censored":false},"longitudinal_labs":[{"date":"2020-06-07","hemoglobin_g_dL":12.5,"wbc_k_uL":8.8,"platelets_k_uL":334,"creatinine_mg_dL":0.73,"alt_U_L":36},{"date":"2021-01-05","hemoglobin_g_dL":11.3,"wbc_k_uL":4.1,"platelets_k_uL":365,"creatinine_mg_dL":1.48,"alt_U_L":84},{"date":"2022-09-19","hemoglobin_g_dL":11.0,"wbc_k_uL":5.9,"platelets_k_uL":226,"creatinine_mg_dL":1.2,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_1699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":67,"sex":"female","bmi":18.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-35},"pfs_months":20.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":false},"longitudinal_labs":[{"date":"2020-10-09","hemoglobin_g_dL":13.5,"wbc_k_uL":9.4,"platelets_k_uL":383,"creatinine_mg_dL":0.65,"alt_U_L":36},{"date":"2021-06-04","hemoglobin_g_dL":13.2,"wbc_k_uL":6.4,"platelets_k_uL":247,"creatinine_mg_dL":1.31,"alt_U_L":38},{"date":"2022-09-30","hemoglobin_g_dL":10.5,"wbc_k_uL":5.5,"platelets_k_uL":171,"creatinine_mg_dL":1.33,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_1700","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":65,"sex":"male","bmi":34.3,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-10-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-50},"pfs_months":29.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":50.2,"censored":false},"longitudinal_labs":[{"date":"2024-09-05","hemoglobin_g_dL":11.7,"wbc_k_uL":7.3,"platelets_k_uL":278,"creatinine_mg_dL":1.07,"alt_U_L":11},{"date":"2025-04-20","hemoglobin_g_dL":12.1,"wbc_k_uL":7.5,"platelets_k_uL":297,"creatinine_mg_dL":1.23,"alt_U_L":97},{"date":"2027-05-27","hemoglobin_g_dL":11.3,"wbc_k_uL":6.6,"platelets_k_uL":292,"creatinine_mg_dL":1.39,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_1701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":87,"sex":"female","bmi":24.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-48},"pfs_months":25.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.4,"censored":false},"longitudinal_labs":[{"date":"2022-08-07","hemoglobin_g_dL":12.1,"wbc_k_uL":9.9,"platelets_k_uL":219,"creatinine_mg_dL":1.28,"alt_U_L":31},{"date":"2023-03-03","hemoglobin_g_dL":12.3,"wbc_k_uL":7.8,"platelets_k_uL":134,"creatinine_mg_dL":1.29,"alt_U_L":82},{"date":"2024-12-13","hemoglobin_g_dL":12.4,"wbc_k_uL":5.4,"platelets_k_uL":166,"creatinine_mg_dL":1.61,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_1702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":76,"sex":"female","bmi":24.5,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-06-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-35},"pfs_months":52.5},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-12-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":75.6,"censored":false},"longitudinal_labs":[{"date":"2025-05-07","hemoglobin_g_dL":12.8,"wbc_k_uL":8.6,"platelets_k_uL":205,"creatinine_mg_dL":0.66,"alt_U_L":67},{"date":"2025-12-22","hemoglobin_g_dL":13.2,"wbc_k_uL":6.4,"platelets_k_uL":187,"creatinine_mg_dL":1.21,"alt_U_L":85},{"date":"2029-12-26","hemoglobin_g_dL":9.8,"wbc_k_uL":7.5,"platelets_k_uL":297,"creatinine_mg_dL":1.23,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_1703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":48,"sex":"male","bmi":36.4,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-05-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-70},"pfs_months":3.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":13.7,"censored":false},"longitudinal_labs":[{"date":"2021-03-02","hemoglobin_g_dL":13.6,"wbc_k_uL":7.4,"platelets_k_uL":261,"creatinine_mg_dL":0.95,"alt_U_L":22},{"date":"2021-11-03","hemoglobin_g_dL":11.9,"wbc_k_uL":6.9,"platelets_k_uL":255,"creatinine_mg_dL":1.19,"alt_U_L":87},{"date":"2021-09-19","hemoglobin_g_dL":13.0,"wbc_k_uL":6.7,"platelets_k_uL":212,"creatinine_mg_dL":1.18,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1704","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":80,"sex":"female","bmi":32.5,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-11-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-60},"pfs_months":32.59},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.1,"censored":true},"longitudinal_labs":[{"date":"2021-11-04","hemoglobin_g_dL":14.2,"wbc_k_uL":6.5,"platelets_k_uL":320,"creatinine_mg_dL":1.01,"alt_U_L":49},{"date":"2022-05-22","hemoglobin_g_dL":11.8,"wbc_k_uL":4.6,"platelets_k_uL":148,"creatinine_mg_dL":0.83,"alt_U_L":38},{"date":"2024-08-19","hemoglobin_g_dL":9.8,"wbc_k_uL":4.3,"platelets_k_uL":295,"creatinine_mg_dL":0.81,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_1705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":55,"sex":"female","bmi":30.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-33},"pfs_months":12.55},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.5,"censored":true},"longitudinal_labs":[{"date":"2024-05-06","hemoglobin_g_dL":12.3,"wbc_k_uL":6.1,"platelets_k_uL":244,"creatinine_mg_dL":1.03,"alt_U_L":30},{"date":"2024-12-02","hemoglobin_g_dL":10.9,"wbc_k_uL":8.0,"platelets_k_uL":271,"creatinine_mg_dL":1.57,"alt_U_L":42},{"date":"2025-07-20","hemoglobin_g_dL":10.8,"wbc_k_uL":6.0,"platelets_k_uL":151,"creatinine_mg_dL":1.65,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_1706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":48,"sex":"male","bmi":32.1,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-02-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-81},"pfs_months":36.07},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":64.6,"censored":false},"longitudinal_labs":[{"date":"2022-01-17","hemoglobin_g_dL":14.6,"wbc_k_uL":9.0,"platelets_k_uL":319,"creatinine_mg_dL":1.27,"alt_U_L":77},{"date":"2022-08-03","hemoglobin_g_dL":11.0,"wbc_k_uL":7.6,"platelets_k_uL":300,"creatinine_mg_dL":0.88,"alt_U_L":60},{"date":"2025-03-25","hemoglobin_g_dL":11.6,"wbc_k_uL":7.1,"platelets_k_uL":343,"creatinine_mg_dL":1.97,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_1707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":61,"sex":"female","bmi":22.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-72},"pfs_months":31.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.4,"censored":true},"longitudinal_labs":[{"date":"2022-06-04","hemoglobin_g_dL":12.5,"wbc_k_uL":8.4,"platelets_k_uL":385,"creatinine_mg_dL":0.68,"alt_U_L":31},{"date":"2022-12-31","hemoglobin_g_dL":13.5,"wbc_k_uL":6.3,"platelets_k_uL":357,"creatinine_mg_dL":1.0,"alt_U_L":101},{"date":"2025-03-01","hemoglobin_g_dL":12.1,"wbc_k_uL":5.6,"platelets_k_uL":219,"creatinine_mg_dL":1.94,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_1708","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":61,"sex":"male","bmi":21.5,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-06-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-34},"pfs_months":24.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":true},"longitudinal_labs":[{"date":"2025-04-04","hemoglobin_g_dL":15.3,"wbc_k_uL":10.0,"platelets_k_uL":383,"creatinine_mg_dL":0.76,"alt_U_L":12},{"date":"2025-12-02","hemoglobin_g_dL":11.2,"wbc_k_uL":7.7,"platelets_k_uL":153,"creatinine_mg_dL":1.35,"alt_U_L":18},{"date":"2027-06-22","hemoglobin_g_dL":11.8,"wbc_k_uL":7.1,"platelets_k_uL":249,"creatinine_mg_dL":1.32,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_1709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":48,"sex":"male","bmi":37.3,"smoking_pack_years":15,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2022-12-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-42},"pfs_months":31.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.3,"censored":false},"longitudinal_labs":[{"date":"2022-11-15","hemoglobin_g_dL":13.5,"wbc_k_uL":6.6,"platelets_k_uL":214,"creatinine_mg_dL":0.72,"alt_U_L":53},{"date":"2023-06-11","hemoglobin_g_dL":10.7,"wbc_k_uL":4.9,"platelets_k_uL":240,"creatinine_mg_dL":1.07,"alt_U_L":16},{"date":"2025-09-22","hemoglobin_g_dL":11.8,"wbc_k_uL":6.9,"platelets_k_uL":323,"creatinine_mg_dL":1.46,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_1710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":59,"sex":"female","bmi":25.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-02-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-69},"pfs_months":24.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.4,"censored":false},"longitudinal_labs":[{"date":"2025-12-15","hemoglobin_g_dL":13.5,"wbc_k_uL":9.0,"platelets_k_uL":154,"creatinine_mg_dL":0.9,"alt_U_L":42},{"date":"2026-08-21","hemoglobin_g_dL":12.4,"wbc_k_uL":6.4,"platelets_k_uL":284,"creatinine_mg_dL":1.47,"alt_U_L":66},{"date":"2028-04-15","hemoglobin_g_dL":10.4,"wbc_k_uL":4.2,"platelets_k_uL":175,"creatinine_mg_dL":0.85,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_1711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":53,"sex":"male","bmi":28.0,"smoking_pack_years":15,"ecog_performance_status":2,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-08-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-54},"pfs_months":43.47},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":64.2,"censored":false},"longitudinal_labs":[{"date":"2024-06-22","hemoglobin_g_dL":14.0,"wbc_k_uL":6.1,"platelets_k_uL":280,"creatinine_mg_dL":0.63,"alt_U_L":79},{"date":"2025-02-09","hemoglobin_g_dL":10.2,"wbc_k_uL":5.4,"platelets_k_uL":286,"creatinine_mg_dL":0.93,"alt_U_L":75},{"date":"2028-04-16","hemoglobin_g_dL":12.5,"wbc_k_uL":5.0,"platelets_k_uL":180,"creatinine_mg_dL":1.99,"alt_U_L":28}]}
{"patient_id":"ANODE_SYNTH_2025_1712","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":87,"sex":"female","bmi":36.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-73},"pfs_months":22.08},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":false},"longitudinal_labs":[{"date":"2020-12-04","hemoglobin_g_dL":12.6,"wbc_k_uL":6.0,"platelets_k_uL":222,"creatinine_mg_dL":0.63,"alt_U_L":30},{"date":"2021-07-05","hemoglobin_g_dL":12.4,"wbc_k_uL":6.5,"platelets_k_uL":270,"creatinine_mg_dL":1.48,"alt_U_L":92},{"date":"2022-11-30","hemoglobin_g_dL":12.8,"wbc_k_uL":4.8,"platelets_k_uL":216,"creatinine_mg_dL":1.48,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_1713","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":62,"sex":"female","bmi":29.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-33},"pfs_months":19.48},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.2,"censored":true},"longitudinal_labs":[{"date":"2023-11-08","hemoglobin_g_dL":14.9,"wbc_k_uL":10.9,"platelets_k_uL":366,"creatinine_mg_dL":1.21,"alt_U_L":75},{"date":"2024-06-14","hemoglobin_g_dL":13.8,"wbc_k_uL":5.7,"platelets_k_uL":342,"creatinine_mg_dL":0.84,"alt_U_L":99},{"date":"2025-08-13","hemoglobin_g_dL":10.0,"wbc_k_uL":3.3,"platelets_k_uL":286,"creatinine_mg_dL":1.98,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_1714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":86,"sex":"female","bmi":26.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-39},"pfs_months":13.54},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-08-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":false},"longitudinal_labs":[{"date":"2020-04-05","hemoglobin_g_dL":12.3,"wbc_k_uL":4.7,"platelets_k_uL":164,"creatinine_mg_dL":1.16,"alt_U_L":72},{"date":"2020-11-10","hemoglobin_g_dL":12.5,"wbc_k_uL":6.9,"platelets_k_uL":283,"creatinine_mg_dL":0.73,"alt_U_L":42},{"date":"2021-08-18","hemoglobin_g_dL":12.4,"wbc_k_uL":4.0,"platelets_k_uL":229,"creatinine_mg_dL":1.57,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_1715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":58,"sex":"female","bmi":20.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-51},"pfs_months":17.94},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.7,"censored":true},"longitudinal_labs":[{"date":"2022-06-11","hemoglobin_g_dL":13.4,"wbc_k_uL":7.0,"platelets_k_uL":249,"creatinine_mg_dL":0.8,"alt_U_L":61},{"date":"2022-12-22","hemoglobin_g_dL":10.7,"wbc_k_uL":6.8,"platelets_k_uL":362,"creatinine_mg_dL":1.1,"alt_U_L":40},{"date":"2024-01-16","hemoglobin_g_dL":11.5,"wbc_k_uL":7.2,"platelets_k_uL":120,"creatinine_mg_dL":0.99,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_1716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.2,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":82,"sex":"female","bmi":30.1,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-72},"pfs_months":11.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.3,"censored":false},"longitudinal_labs":[{"date":"2025-02-27","hemoglobin_g_dL":11.7,"wbc_k_uL":5.6,"platelets_k_uL":291,"creatinine_mg_dL":1.2,"alt_U_L":28},{"date":"2025-09-18","hemoglobin_g_dL":13.8,"wbc_k_uL":4.0,"platelets_k_uL":356,"creatinine_mg_dL":1.57,"alt_U_L":104},{"date":"2026-03-27","hemoglobin_g_dL":10.0,"wbc_k_uL":3.2,"platelets_k_uL":283,"creatinine_mg_dL":1.25,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_1717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":49,"sex":"female","bmi":25.8,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-12-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-70},"pfs_months":43.17},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-08-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":68.1,"censored":false},"longitudinal_labs":[{"date":"2024-11-07","hemoglobin_g_dL":14.6,"wbc_k_uL":10.3,"platelets_k_uL":170,"creatinine_mg_dL":1.21,"alt_U_L":79},{"date":"2025-06-25","hemoglobin_g_dL":12.8,"wbc_k_uL":7.0,"platelets_k_uL":320,"creatinine_mg_dL":0.84,"alt_U_L":49},{"date":"2028-08-09","hemoglobin_g_dL":12.4,"wbc_k_uL":7.8,"platelets_k_uL":116,"creatinine_mg_dL":1.82,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_1718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":74,"sex":"female","bmi":25.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-79},"pfs_months":21.85},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":true},"longitudinal_labs":[{"date":"2025-10-28","hemoglobin_g_dL":13.4,"wbc_k_uL":7.8,"platelets_k_uL":254,"creatinine_mg_dL":0.98,"alt_U_L":30},{"date":"2026-06-01","hemoglobin_g_dL":10.5,"wbc_k_uL":5.2,"platelets_k_uL":241,"creatinine_mg_dL":0.89,"alt_U_L":46},{"date":"2027-11-22","hemoglobin_g_dL":10.4,"wbc_k_uL":7.7,"platelets_k_uL":121,"creatinine_mg_dL":1.7,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_1719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":64,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-44},"pfs_months":27.3},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.7,"censored":false},"longitudinal_labs":[{"date":"2023-05-19","hemoglobin_g_dL":13.9,"wbc_k_uL":5.0,"platelets_k_uL":263,"creatinine_mg_dL":0.89,"alt_U_L":24},{"date":"2024-01-16","hemoglobin_g_dL":11.1,"wbc_k_uL":6.1,"platelets_k_uL":173,"creatinine_mg_dL":1.34,"alt_U_L":35},{"date":"2025-12-15","hemoglobin_g_dL":10.8,"wbc_k_uL":3.3,"platelets_k_uL":318,"creatinine_mg_dL":1.58,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_1720","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":76,"sex":"female","bmi":24.5,"smoking_pack_years":38,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-61},"pfs_months":19.22},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.2,"censored":false},"longitudinal_labs":[{"date":"2023-05-18","hemoglobin_g_dL":13.9,"wbc_k_uL":7.3,"platelets_k_uL":227,"creatinine_mg_dL":0.93,"alt_U_L":31},{"date":"2023-12-29","hemoglobin_g_dL":10.5,"wbc_k_uL":8.4,"platelets_k_uL":248,"creatinine_mg_dL":1.41,"alt_U_L":69},{"date":"2025-03-13","hemoglobin_g_dL":9.7,"wbc_k_uL":4.2,"platelets_k_uL":194,"creatinine_mg_dL":1.11,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_1721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":63,"sex":"female","bmi":28.4,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-12-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-59},"pfs_months":11.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.7,"censored":false},"longitudinal_labs":[{"date":"2022-11-09","hemoglobin_g_dL":11.7,"wbc_k_uL":5.6,"platelets_k_uL":277,"creatinine_mg_dL":1.19,"alt_U_L":34},{"date":"2023-06-04","hemoglobin_g_dL":10.0,"wbc_k_uL":6.9,"platelets_k_uL":379,"creatinine_mg_dL":1.19,"alt_U_L":113},{"date":"2023-12-15","hemoglobin_g_dL":9.8,"wbc_k_uL":5.8,"platelets_k_uL":161,"creatinine_mg_dL":0.9,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_1722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":87,"sex":"female","bmi":24.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-82},"pfs_months":19.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.3,"censored":true},"longitudinal_labs":[{"date":"2024-03-26","hemoglobin_g_dL":14.4,"wbc_k_uL":10.7,"platelets_k_uL":272,"creatinine_mg_dL":0.63,"alt_U_L":77},{"date":"2024-10-12","hemoglobin_g_dL":10.7,"wbc_k_uL":6.4,"platelets_k_uL":218,"creatinine_mg_dL":1.0,"alt_U_L":96},{"date":"2026-01-17","hemoglobin_g_dL":11.8,"wbc_k_uL":4.9,"platelets_k_uL":129,"creatinine_mg_dL":1.41,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_1723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":85,"sex":"female","bmi":23.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-61},"pfs_months":15.21},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":true},"longitudinal_labs":[{"date":"2022-10-09","hemoglobin_g_dL":12.5,"wbc_k_uL":5.2,"platelets_k_uL":374,"creatinine_mg_dL":0.74,"alt_U_L":10},{"date":"2023-05-06","hemoglobin_g_dL":12.3,"wbc_k_uL":7.1,"platelets_k_uL":246,"creatinine_mg_dL":1.0,"alt_U_L":106},{"date":"2024-03-19","hemoglobin_g_dL":13.0,"wbc_k_uL":7.9,"platelets_k_uL":168,"creatinine_mg_dL":1.52,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1724","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":50,"sex":"female","bmi":32.7,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-11-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-34},"pfs_months":27.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":true},"longitudinal_labs":[{"date":"2023-09-25","hemoglobin_g_dL":12.6,"wbc_k_uL":6.9,"platelets_k_uL":418,"creatinine_mg_dL":0.76,"alt_U_L":53},{"date":"2024-05-15","hemoglobin_g_dL":10.3,"wbc_k_uL":4.0,"platelets_k_uL":125,"creatinine_mg_dL":0.77,"alt_U_L":105},{"date":"2026-03-16","hemoglobin_g_dL":12.5,"wbc_k_uL":5.8,"platelets_k_uL":178,"creatinine_mg_dL":1.58,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_1725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":52,"sex":"female","bmi":23.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-78},"pfs_months":22.31},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.5,"censored":false},"longitudinal_labs":[{"date":"2020-12-18","hemoglobin_g_dL":13.4,"wbc_k_uL":7.2,"platelets_k_uL":192,"creatinine_mg_dL":0.88,"alt_U_L":30},{"date":"2021-08-25","hemoglobin_g_dL":10.1,"wbc_k_uL":8.1,"platelets_k_uL":371,"creatinine_mg_dL":1.15,"alt_U_L":43},{"date":"2023-02-01","hemoglobin_g_dL":11.9,"wbc_k_uL":5.2,"platelets_k_uL":171,"creatinine_mg_dL":1.05,"alt_U_L":198}]}
{"patient_id":"ANODE_SYNTH_2025_1726","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":82,"sex":"female","bmi":20.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-52},"pfs_months":27.73},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":38.1,"censored":false},"longitudinal_labs":[{"date":"2023-09-15","hemoglobin_g_dL":12.7,"wbc_k_uL":7.1,"platelets_k_uL":344,"creatinine_mg_dL":0.94,"alt_U_L":60},{"date":"2024-04-04","hemoglobin_g_dL":12.8,"wbc_k_uL":6.5,"platelets_k_uL":264,"creatinine_mg_dL":1.38,"alt_U_L":32},{"date":"2026-03-10","hemoglobin_g_dL":10.5,"wbc_k_uL":5.8,"platelets_k_uL":327,"creatinine_mg_dL":1.82,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_1727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":70,"sex":"female","bmi":35.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-47},"pfs_months":31.87},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":52.7,"censored":false},"longitudinal_labs":[{"date":"2024-12-17","hemoglobin_g_dL":14.9,"wbc_k_uL":9.3,"platelets_k_uL":338,"creatinine_mg_dL":0.77,"alt_U_L":10},{"date":"2025-07-07","hemoglobin_g_dL":10.0,"wbc_k_uL":7.2,"platelets_k_uL":193,"creatinine_mg_dL":1.38,"alt_U_L":94},{"date":"2027-10-05","hemoglobin_g_dL":11.0,"wbc_k_uL":6.5,"platelets_k_uL":240,"creatinine_mg_dL":1.34,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_1728","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":83,"sex":"female","bmi":31.0,"smoking_pack_years":79,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-08-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-72},"pfs_months":26.28},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":48.6,"censored":false},"longitudinal_labs":[{"date":"2022-07-16","hemoglobin_g_dL":13.1,"wbc_k_uL":6.7,"platelets_k_uL":439,"creatinine_mg_dL":0.82,"alt_U_L":52},{"date":"2023-02-15","hemoglobin_g_dL":13.7,"wbc_k_uL":7.4,"platelets_k_uL":295,"creatinine_mg_dL":1.02,"alt_U_L":50},{"date":"2024-12-13","hemoglobin_g_dL":11.8,"wbc_k_uL":7.3,"platelets_k_uL":231,"creatinine_mg_dL":1.81,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_1729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":48,"sex":"male","bmi":19.8,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-07-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-71},"pfs_months":39.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":57.9,"censored":true},"longitudinal_labs":[{"date":"2022-06-06","hemoglobin_g_dL":13.9,"wbc_k_uL":10.1,"platelets_k_uL":242,"creatinine_mg_dL":0.96,"alt_U_L":49},{"date":"2023-01-27","hemoglobin_g_dL":13.1,"wbc_k_uL":5.4,"platelets_k_uL":246,"creatinine_mg_dL":0.7,"alt_U_L":58},{"date":"2026-01-15","hemoglobin_g_dL":12.0,"wbc_k_uL":8.0,"platelets_k_uL":272,"creatinine_mg_dL":1.39,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_1730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":72,"sex":"male","bmi":28.0,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-09-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-62},"pfs_months":6.74},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":18.3,"censored":false},"longitudinal_labs":[{"date":"2022-08-07","hemoglobin_g_dL":14.3,"wbc_k_uL":4.7,"platelets_k_uL":370,"creatinine_mg_dL":1.08,"alt_U_L":41},{"date":"2023-03-03","hemoglobin_g_dL":12.2,"wbc_k_uL":5.4,"platelets_k_uL":304,"creatinine_mg_dL":0.74,"alt_U_L":83},{"date":"2023-04-06","hemoglobin_g_dL":11.9,"wbc_k_uL":6.7,"platelets_k_uL":125,"creatinine_mg_dL":1.19,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_1731","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":61,"sex":"female","bmi":34.0,"smoking_pack_years":48,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-07-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-48},"pfs_months":26.81},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.9,"censored":false},"longitudinal_labs":[{"date":"2021-06-20","hemoglobin_g_dL":14.0,"wbc_k_uL":4.9,"platelets_k_uL":193,"creatinine_mg_dL":1.08,"alt_U_L":30},{"date":"2022-01-05","hemoglobin_g_dL":10.1,"wbc_k_uL":5.5,"platelets_k_uL":346,"creatinine_mg_dL":1.5,"alt_U_L":109},{"date":"2023-11-04","hemoglobin_g_dL":12.6,"wbc_k_uL":5.6,"platelets_k_uL":203,"creatinine_mg_dL":0.84,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_1732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":68,"sex":"female","bmi":26.0,"smoking_pack_years":29,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-35},"pfs_months":4.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.6,"censored":true},"longitudinal_labs":[{"date":"2023-09-07","hemoglobin_g_dL":15.3,"wbc_k_uL":6.3,"platelets_k_uL":396,"creatinine_mg_dL":0.7,"alt_U_L":34},{"date":"2024-03-25","hemoglobin_g_dL":13.2,"wbc_k_uL":8.0,"platelets_k_uL":137,"creatinine_mg_dL":1.47,"alt_U_L":73},{"date":"2024-04-01","hemoglobin_g_dL":11.2,"wbc_k_uL":4.5,"platelets_k_uL":257,"creatinine_mg_dL":1.4,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_1733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":61,"sex":"female","bmi":33.3,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-02-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-41},"pfs_months":11.53},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.1,"censored":false},"longitudinal_labs":[{"date":"2023-12-06","hemoglobin_g_dL":14.9,"wbc_k_uL":10.5,"platelets_k_uL":251,"creatinine_mg_dL":0.83,"alt_U_L":16},{"date":"2024-08-07","hemoglobin_g_dL":13.1,"wbc_k_uL":3.8,"platelets_k_uL":250,"creatinine_mg_dL":1.53,"alt_U_L":26},{"date":"2025-03-14","hemoglobin_g_dL":12.0,"wbc_k_uL":6.7,"platelets_k_uL":210,"creatinine_mg_dL":1.09,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_1734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":56,"sex":"male","bmi":28.2,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-78},"pfs_months":13.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":21.8,"censored":true},"longitudinal_labs":[{"date":"2025-07-07","hemoglobin_g_dL":13.2,"wbc_k_uL":4.6,"platelets_k_uL":349,"creatinine_mg_dL":1.04,"alt_U_L":40},{"date":"2026-01-29","hemoglobin_g_dL":11.9,"wbc_k_uL":7.6,"platelets_k_uL":135,"creatinine_mg_dL":1.41,"alt_U_L":90},{"date":"2026-10-30","hemoglobin_g_dL":10.9,"wbc_k_uL":6.3,"platelets_k_uL":200,"creatinine_mg_dL":1.62,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_1735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":73,"sex":"female","bmi":20.5,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-43},"pfs_months":34.89},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":57.7,"censored":false},"longitudinal_labs":[{"date":"2025-01-21","hemoglobin_g_dL":14.8,"wbc_k_uL":9.9,"platelets_k_uL":254,"creatinine_mg_dL":0.79,"alt_U_L":37},{"date":"2025-08-27","hemoglobin_g_dL":13.8,"wbc_k_uL":7.7,"platelets_k_uL":129,"creatinine_mg_dL":1.15,"alt_U_L":15},{"date":"2028-02-07","hemoglobin_g_dL":11.0,"wbc_k_uL":5.4,"platelets_k_uL":155,"creatinine_mg_dL":1.8,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_1736","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":61,"sex":"female","bmi":22.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-75},"pfs_months":18.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.2,"censored":false},"longitudinal_labs":[{"date":"2020-09-14","hemoglobin_g_dL":13.2,"wbc_k_uL":9.9,"platelets_k_uL":177,"creatinine_mg_dL":1.29,"alt_U_L":18},{"date":"2021-05-03","hemoglobin_g_dL":13.8,"wbc_k_uL":5.4,"platelets_k_uL":332,"creatinine_mg_dL":0.93,"alt_U_L":72},{"date":"2022-05-27","hemoglobin_g_dL":12.8,"wbc_k_uL":6.9,"platelets_k_uL":301,"creatinine_mg_dL":1.4,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_1737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":68,"sex":"male","bmi":35.2,"smoking_pack_years":52,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-47},"pfs_months":26.02},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.2,"censored":false},"longitudinal_labs":[{"date":"2021-05-28","hemoglobin_g_dL":14.5,"wbc_k_uL":6.8,"platelets_k_uL":413,"creatinine_mg_dL":1.27,"alt_U_L":12},{"date":"2021-12-22","hemoglobin_g_dL":13.9,"wbc_k_uL":6.0,"platelets_k_uL":338,"creatinine_mg_dL":0.99,"alt_U_L":91},{"date":"2023-10-12","hemoglobin_g_dL":11.1,"wbc_k_uL":3.4,"platelets_k_uL":201,"creatinine_mg_dL":0.92,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_1738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":58,"sex":"female","bmi":36.5,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-10-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-73},"pfs_months":15.87},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.6,"censored":false},"longitudinal_labs":[{"date":"2021-09-23","hemoglobin_g_dL":12.0,"wbc_k_uL":6.5,"platelets_k_uL":409,"creatinine_mg_dL":0.64,"alt_U_L":62},{"date":"2022-04-26","hemoglobin_g_dL":10.9,"wbc_k_uL":7.2,"platelets_k_uL":262,"creatinine_mg_dL":1.55,"alt_U_L":28},{"date":"2023-04-03","hemoglobin_g_dL":11.8,"wbc_k_uL":6.4,"platelets_k_uL":210,"creatinine_mg_dL":0.91,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_1739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":61,"sex":"female","bmi":36.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-65},"pfs_months":27.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.5,"censored":false},"longitudinal_labs":[{"date":"2025-07-15","hemoglobin_g_dL":14.7,"wbc_k_uL":8.2,"platelets_k_uL":243,"creatinine_mg_dL":0.78,"alt_U_L":27},{"date":"2026-01-29","hemoglobin_g_dL":13.4,"wbc_k_uL":5.1,"platelets_k_uL":330,"creatinine_mg_dL":0.71,"alt_U_L":67},{"date":"2027-12-08","hemoglobin_g_dL":12.8,"wbc_k_uL":4.1,"platelets_k_uL":335,"creatinine_mg_dL":1.41,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_1740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":55,"sex":"female","bmi":19.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-63},"pfs_months":18.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.4,"censored":true},"longitudinal_labs":[{"date":"2025-01-19","hemoglobin_g_dL":12.4,"wbc_k_uL":10.8,"platelets_k_uL":308,"creatinine_mg_dL":1.29,"alt_U_L":46},{"date":"2025-08-01","hemoglobin_g_dL":11.6,"wbc_k_uL":7.2,"platelets_k_uL":280,"creatinine_mg_dL":1.54,"alt_U_L":44},{"date":"2026-10-27","hemoglobin_g_dL":10.5,"wbc_k_uL":4.1,"platelets_k_uL":224,"creatinine_mg_dL":1.32,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_1741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":68,"sex":"female","bmi":23.7,"smoking_pack_years":64,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-12-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-82},"pfs_months":53.65},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":83.2,"censored":false},"longitudinal_labs":[{"date":"2021-10-20","hemoglobin_g_dL":12.6,"wbc_k_uL":6.5,"platelets_k_uL":174,"creatinine_mg_dL":0.99,"alt_U_L":51},{"date":"2022-06-05","hemoglobin_g_dL":11.5,"wbc_k_uL":6.2,"platelets_k_uL":257,"creatinine_mg_dL":0.8,"alt_U_L":25},{"date":"2026-07-27","hemoglobin_g_dL":12.6,"wbc_k_uL":4.8,"platelets_k_uL":212,"creatinine_mg_dL":1.07,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_1742","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":59,"sex":"female","bmi":32.1,"smoking_pack_years":52,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-36},"pfs_months":14.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":23.3,"censored":false},"longitudinal_labs":[{"date":"2023-10-27","hemoglobin_g_dL":14.4,"wbc_k_uL":7.1,"platelets_k_uL":165,"creatinine_mg_dL":1.08,"alt_U_L":70},{"date":"2024-06-20","hemoglobin_g_dL":12.4,"wbc_k_uL":7.8,"platelets_k_uL":340,"creatinine_mg_dL":1.23,"alt_U_L":113},{"date":"2025-04-18","hemoglobin_g_dL":10.0,"wbc_k_uL":3.3,"platelets_k_uL":175,"creatinine_mg_dL":0.99,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_1743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.2,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":58,"sex":"female","bmi":36.4,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-06-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-54},"pfs_months":45.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":66.5,"censored":false},"longitudinal_labs":[{"date":"2024-05-14","hemoglobin_g_dL":13.2,"wbc_k_uL":10.5,"platelets_k_uL":184,"creatinine_mg_dL":0.81,"alt_U_L":62},{"date":"2024-12-25","hemoglobin_g_dL":12.8,"wbc_k_uL":4.3,"platelets_k_uL":312,"creatinine_mg_dL":1.11,"alt_U_L":104},{"date":"2028-06-14","hemoglobin_g_dL":9.7,"wbc_k_uL":3.3,"platelets_k_uL":301,"creatinine_mg_dL":1.21,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_1744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.8,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":54,"sex":"female","bmi":24.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-51},"pfs_months":20.01},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.1,"censored":false},"longitudinal_labs":[{"date":"2023-06-20","hemoglobin_g_dL":14.1,"wbc_k_uL":8.1,"platelets_k_uL":240,"creatinine_mg_dL":1.28,"alt_U_L":24},{"date":"2024-01-16","hemoglobin_g_dL":11.2,"wbc_k_uL":6.7,"platelets_k_uL":357,"creatinine_mg_dL":1.05,"alt_U_L":39},{"date":"2025-05-15","hemoglobin_g_dL":10.4,"wbc_k_uL":4.5,"platelets_k_uL":201,"creatinine_mg_dL":1.39,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_1745","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":81,"sex":"male","bmi":32.9,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-08-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-43},"pfs_months":14.69},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":false},"longitudinal_labs":[{"date":"2024-07-19","hemoglobin_g_dL":11.6,"wbc_k_uL":10.3,"platelets_k_uL":272,"creatinine_mg_dL":1.01,"alt_U_L":25},{"date":"2025-02-05","hemoglobin_g_dL":11.0,"wbc_k_uL":6.4,"platelets_k_uL":346,"creatinine_mg_dL":1.24,"alt_U_L":22},{"date":"2025-12-24","hemoglobin_g_dL":10.4,"wbc_k_uL":4.1,"platelets_k_uL":112,"creatinine_mg_dL":1.84,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_1746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":55,"sex":"male","bmi":33.4,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-07-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-44},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":6.9,"censored":false},"longitudinal_labs":[{"date":"2024-07-12","hemoglobin_g_dL":11.8,"wbc_k_uL":8.0,"platelets_k_uL":409,"creatinine_mg_dL":1.09,"alt_U_L":45},{"date":"2025-01-23","hemoglobin_g_dL":13.8,"wbc_k_uL":4.3,"platelets_k_uL":250,"creatinine_mg_dL":1.28,"alt_U_L":110},{"date":"2024-11-03","hemoglobin_g_dL":12.2,"wbc_k_uL":6.5,"platelets_k_uL":158,"creatinine_mg_dL":1.44,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_1747","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":57,"sex":"male","bmi":34.8,"smoking_pack_years":76,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-51},"pfs_months":13.4},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.4,"censored":false},"longitudinal_labs":[{"date":"2025-05-05","hemoglobin_g_dL":14.7,"wbc_k_uL":9.8,"platelets_k_uL":307,"creatinine_mg_dL":0.74,"alt_U_L":26},{"date":"2025-12-03","hemoglobin_g_dL":11.6,"wbc_k_uL":7.7,"platelets_k_uL":179,"creatinine_mg_dL":1.41,"alt_U_L":44},{"date":"2026-09-11","hemoglobin_g_dL":11.2,"wbc_k_uL":5.4,"platelets_k_uL":110,"creatinine_mg_dL":1.61,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_1748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":59,"sex":"female","bmi":35.8,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-02-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-75},"pfs_months":3.12},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":7.1,"censored":true},"longitudinal_labs":[{"date":"2024-12-24","hemoglobin_g_dL":15.3,"wbc_k_uL":8.1,"platelets_k_uL":398,"creatinine_mg_dL":0.8,"alt_U_L":20},{"date":"2025-08-23","hemoglobin_g_dL":11.7,"wbc_k_uL":3.9,"platelets_k_uL":175,"creatinine_mg_dL":1.37,"alt_U_L":33},{"date":"2025-06-13","hemoglobin_g_dL":11.8,"wbc_k_uL":6.9,"platelets_k_uL":189,"creatinine_mg_dL":1.42,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_1749","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":74,"sex":"female","bmi":35.0,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-03-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-77},"pfs_months":26.87},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":false},"longitudinal_labs":[{"date":"2025-01-17","hemoglobin_g_dL":15.2,"wbc_k_uL":7.1,"platelets_k_uL":330,"creatinine_mg_dL":0.7,"alt_U_L":74},{"date":"2025-08-31","hemoglobin_g_dL":12.5,"wbc_k_uL":8.3,"platelets_k_uL":242,"creatinine_mg_dL":1.33,"alt_U_L":90},{"date":"2027-06-17","hemoglobin_g_dL":11.2,"wbc_k_uL":6.9,"platelets_k_uL":111,"creatinine_mg_dL":1.73,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_1750","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":64,"sex":"female","bmi":26.2,"smoking_pack_years":16,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-71},"pfs_months":27.76},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.7,"censored":false},"longitudinal_labs":[{"date":"2025-06-03","hemoglobin_g_dL":12.9,"wbc_k_uL":6.2,"platelets_k_uL":448,"creatinine_mg_dL":0.96,"alt_U_L":72},{"date":"2026-01-15","hemoglobin_g_dL":10.5,"wbc_k_uL":6.2,"platelets_k_uL":345,"creatinine_mg_dL":1.32,"alt_U_L":29},{"date":"2027-12-29","hemoglobin_g_dL":12.2,"wbc_k_uL":3.7,"platelets_k_uL":272,"creatinine_mg_dL":1.85,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_1751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":48,"sex":"male","bmi":34.8,"smoking_pack_years":64,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-08-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-40},"pfs_months":36.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-10-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":65.6,"censored":false},"longitudinal_labs":[{"date":"2025-07-18","hemoglobin_g_dL":15.3,"wbc_k_uL":7.7,"platelets_k_uL":410,"creatinine_mg_dL":1.25,"alt_U_L":74},{"date":"2026-02-19","hemoglobin_g_dL":10.4,"wbc_k_uL":4.8,"platelets_k_uL":311,"creatinine_mg_dL":1.22,"alt_U_L":93},{"date":"2028-10-08","hemoglobin_g_dL":10.8,"wbc_k_uL":7.9,"platelets_k_uL":293,"creatinine_mg_dL":1.31,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_1752","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":85,"sex":"female","bmi":30.4,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-31},"pfs_months":41.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-08-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":67.2,"censored":false},"longitudinal_labs":[{"date":"2025-01-17","hemoglobin_g_dL":14.6,"wbc_k_uL":4.7,"platelets_k_uL":425,"creatinine_mg_dL":0.97,"alt_U_L":36},{"date":"2025-08-16","hemoglobin_g_dL":12.1,"wbc_k_uL":5.7,"platelets_k_uL":177,"creatinine_mg_dL":1.18,"alt_U_L":96},{"date":"2028-08-08","hemoglobin_g_dL":12.0,"wbc_k_uL":5.8,"platelets_k_uL":299,"creatinine_mg_dL":0.87,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_1753","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":55,"sex":"female","bmi":29.5,"smoking_pack_years":72,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-04-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-54},"pfs_months":22.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.8,"censored":false},"longitudinal_labs":[{"date":"2023-02-24","hemoglobin_g_dL":14.1,"wbc_k_uL":8.8,"platelets_k_uL":263,"creatinine_mg_dL":0.68,"alt_U_L":67},{"date":"2023-10-22","hemoglobin_g_dL":12.6,"wbc_k_uL":5.5,"platelets_k_uL":227,"creatinine_mg_dL":1.23,"alt_U_L":84},{"date":"2025-04-05","hemoglobin_g_dL":11.0,"wbc_k_uL":4.1,"platelets_k_uL":260,"creatinine_mg_dL":2.0,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_1754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":51,"sex":"male","bmi":26.8,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2021-09-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-72},"pfs_months":25.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":true},"longitudinal_labs":[{"date":"2021-08-05","hemoglobin_g_dL":13.3,"wbc_k_uL":9.5,"platelets_k_uL":206,"creatinine_mg_dL":0.79,"alt_U_L":10},{"date":"2022-03-03","hemoglobin_g_dL":10.3,"wbc_k_uL":6.7,"platelets_k_uL":139,"creatinine_mg_dL":1.19,"alt_U_L":93},{"date":"2023-12-02","hemoglobin_g_dL":10.1,"wbc_k_uL":4.8,"platelets_k_uL":175,"creatinine_mg_dL":0.83,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_1755","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":88,"sex":"male","bmi":22.1,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-04-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-48},"pfs_months":21.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.7,"censored":false},"longitudinal_labs":[{"date":"2025-02-17","hemoglobin_g_dL":12.7,"wbc_k_uL":8.0,"platelets_k_uL":365,"creatinine_mg_dL":0.89,"alt_U_L":72},{"date":"2025-10-24","hemoglobin_g_dL":12.8,"wbc_k_uL":5.9,"platelets_k_uL":148,"creatinine_mg_dL":1.39,"alt_U_L":62},{"date":"2027-02-22","hemoglobin_g_dL":10.6,"wbc_k_uL":5.2,"platelets_k_uL":249,"creatinine_mg_dL":1.43,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_1756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":79,"sex":"male","bmi":33.3,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-06-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-54},"pfs_months":8.38},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.8,"censored":false},"longitudinal_labs":[{"date":"2023-04-21","hemoglobin_g_dL":12.6,"wbc_k_uL":8.2,"platelets_k_uL":427,"creatinine_mg_dL":0.92,"alt_U_L":36},{"date":"2023-12-11","hemoglobin_g_dL":11.0,"wbc_k_uL":8.4,"platelets_k_uL":210,"creatinine_mg_dL":1.03,"alt_U_L":85},{"date":"2024-03-19","hemoglobin_g_dL":10.1,"wbc_k_uL":7.0,"platelets_k_uL":331,"creatinine_mg_dL":1.52,"alt_U_L":31}]}
{"patient_id":"ANODE_SYNTH_2025_1757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":55,"sex":"male","bmi":27.4,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-02-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-38},"pfs_months":29.6},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":54.3,"censored":true},"longitudinal_labs":[{"date":"2022-01-19","hemoglobin_g_dL":12.1,"wbc_k_uL":6.6,"platelets_k_uL":413,"creatinine_mg_dL":0.86,"alt_U_L":64},{"date":"2022-08-23","hemoglobin_g_dL":12.2,"wbc_k_uL":4.7,"platelets_k_uL":377,"creatinine_mg_dL":0.84,"alt_U_L":114},{"date":"2024-08-19","hemoglobin_g_dL":9.6,"wbc_k_uL":4.5,"platelets_k_uL":184,"creatinine_mg_dL":0.97,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_1758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":75,"sex":"male","bmi":37.2,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-03-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-51},"pfs_months":39.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-08-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":71.6,"censored":false},"longitudinal_labs":[{"date":"2025-01-07","hemoglobin_g_dL":13.4,"wbc_k_uL":10.0,"platelets_k_uL":185,"creatinine_mg_dL":1.15,"alt_U_L":14},{"date":"2025-08-29","hemoglobin_g_dL":13.6,"wbc_k_uL":4.1,"platelets_k_uL":122,"creatinine_mg_dL":1.3,"alt_U_L":73},{"date":"2028-08-04","hemoglobin_g_dL":11.9,"wbc_k_uL":7.5,"platelets_k_uL":254,"creatinine_mg_dL":1.46,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_1759","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":61,"sex":"female","bmi":22.3,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-03-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-72},"pfs_months":15.87},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.5,"censored":false},"longitudinal_labs":[{"date":"2025-01-13","hemoglobin_g_dL":15.0,"wbc_k_uL":5.5,"platelets_k_uL":235,"creatinine_mg_dL":0.85,"alt_U_L":10},{"date":"2025-09-05","hemoglobin_g_dL":12.2,"wbc_k_uL":6.0,"platelets_k_uL":240,"creatinine_mg_dL":1.32,"alt_U_L":30},{"date":"2026-08-22","hemoglobin_g_dL":11.8,"wbc_k_uL":4.8,"platelets_k_uL":328,"creatinine_mg_dL":1.06,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_1760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":78,"sex":"female","bmi":37.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-02-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-33},"pfs_months":8.71},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.7,"censored":false},"longitudinal_labs":[{"date":"2021-12-07","hemoglobin_g_dL":11.7,"wbc_k_uL":10.2,"platelets_k_uL":398,"creatinine_mg_dL":0.91,"alt_U_L":42},{"date":"2022-08-09","hemoglobin_g_dL":11.2,"wbc_k_uL":4.0,"platelets_k_uL":206,"creatinine_mg_dL":0.8,"alt_U_L":21},{"date":"2022-11-12","hemoglobin_g_dL":11.6,"wbc_k_uL":6.1,"platelets_k_uL":266,"creatinine_mg_dL":1.81,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_1761","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":51,"sex":"female","bmi":19.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-45},"pfs_months":19.35},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.8,"censored":false},"longitudinal_labs":[{"date":"2022-02-28","hemoglobin_g_dL":12.5,"wbc_k_uL":8.7,"platelets_k_uL":278,"creatinine_mg_dL":1.05,"alt_U_L":36},{"date":"2022-09-11","hemoglobin_g_dL":11.5,"wbc_k_uL":8.5,"platelets_k_uL":326,"creatinine_mg_dL":1.42,"alt_U_L":61},{"date":"2023-12-01","hemoglobin_g_dL":12.4,"wbc_k_uL":5.6,"platelets_k_uL":247,"creatinine_mg_dL":1.69,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_1762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":57,"sex":"male","bmi":30.6,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-44},"pfs_months":42.61},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":71.0,"censored":false},"longitudinal_labs":[{"date":"2022-11-06","hemoglobin_g_dL":15.4,"wbc_k_uL":8.0,"platelets_k_uL":409,"creatinine_mg_dL":1.0,"alt_U_L":39},{"date":"2023-06-02","hemoglobin_g_dL":11.1,"wbc_k_uL":4.3,"platelets_k_uL":142,"creatinine_mg_dL":0.91,"alt_U_L":47},{"date":"2026-07-15","hemoglobin_g_dL":11.8,"wbc_k_uL":3.2,"platelets_k_uL":157,"creatinine_mg_dL":0.85,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_1763","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":82,"sex":"female","bmi":18.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-38},"pfs_months":21.55},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":true},"longitudinal_labs":[{"date":"2023-10-21","hemoglobin_g_dL":13.9,"wbc_k_uL":7.0,"platelets_k_uL":360,"creatinine_mg_dL":1.01,"alt_U_L":56},{"date":"2024-06-15","hemoglobin_g_dL":14.0,"wbc_k_uL":7.6,"platelets_k_uL":234,"creatinine_mg_dL":1.56,"alt_U_L":111},{"date":"2025-12-03","hemoglobin_g_dL":9.6,"wbc_k_uL":6.4,"platelets_k_uL":325,"creatinine_mg_dL":1.87,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_1764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":62,"sex":"female","bmi":35.9,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-56},"pfs_months":10.81},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":false},"longitudinal_labs":[{"date":"2024-03-26","hemoglobin_g_dL":13.7,"wbc_k_uL":8.5,"platelets_k_uL":287,"creatinine_mg_dL":1.1,"alt_U_L":17},{"date":"2024-10-26","hemoglobin_g_dL":12.4,"wbc_k_uL":5.9,"platelets_k_uL":132,"creatinine_mg_dL":0.94,"alt_U_L":15},{"date":"2025-05-05","hemoglobin_g_dL":9.9,"wbc_k_uL":5.2,"platelets_k_uL":147,"creatinine_mg_dL":1.34,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_1765","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":71,"sex":"female","bmi":27.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-48},"pfs_months":24.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-25","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":true},"longitudinal_labs":[{"date":"2021-08-14","hemoglobin_g_dL":13.1,"wbc_k_uL":7.0,"platelets_k_uL":446,"creatinine_mg_dL":0.73,"alt_U_L":22},{"date":"2022-04-06","hemoglobin_g_dL":13.2,"wbc_k_uL":8.1,"platelets_k_uL":273,"creatinine_mg_dL":1.07,"alt_U_L":26},{"date":"2023-11-25","hemoglobin_g_dL":12.8,"wbc_k_uL":3.1,"platelets_k_uL":331,"creatinine_mg_dL":1.72,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_1766","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":53,"sex":"male","bmi":18.8,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["brain","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-76},"pfs_months":15.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.6,"censored":true},"longitudinal_labs":[{"date":"2024-02-24","hemoglobin_g_dL":11.9,"wbc_k_uL":5.7,"platelets_k_uL":440,"creatinine_mg_dL":0.69,"alt_U_L":17},{"date":"2024-09-18","hemoglobin_g_dL":12.7,"wbc_k_uL":7.4,"platelets_k_uL":334,"creatinine_mg_dL":1.24,"alt_U_L":109},{"date":"2025-08-11","hemoglobin_g_dL":9.6,"wbc_k_uL":7.0,"platelets_k_uL":134,"creatinine_mg_dL":1.64,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_1767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":80,"sex":"female","bmi":36.5,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-07-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-32},"pfs_months":31.64},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":61.9,"censored":false},"longitudinal_labs":[{"date":"2020-06-05","hemoglobin_g_dL":12.2,"wbc_k_uL":7.0,"platelets_k_uL":364,"creatinine_mg_dL":1.08,"alt_U_L":74},{"date":"2021-01-13","hemoglobin_g_dL":11.0,"wbc_k_uL":8.2,"platelets_k_uL":193,"creatinine_mg_dL":0.82,"alt_U_L":88},{"date":"2023-04-14","hemoglobin_g_dL":12.7,"wbc_k_uL":7.3,"platelets_k_uL":150,"creatinine_mg_dL":1.29,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_1768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":51,"sex":"female","bmi":31.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-68},"pfs_months":18.0},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.1,"censored":false},"longitudinal_labs":[{"date":"2022-05-04","hemoglobin_g_dL":12.4,"wbc_k_uL":7.4,"platelets_k_uL":166,"creatinine_mg_dL":1.08,"alt_U_L":40},{"date":"2022-12-30","hemoglobin_g_dL":12.5,"wbc_k_uL":8.5,"platelets_k_uL":173,"creatinine_mg_dL":0.7,"alt_U_L":109},{"date":"2024-02-04","hemoglobin_g_dL":11.3,"wbc_k_uL":7.9,"platelets_k_uL":320,"creatinine_mg_dL":1.59,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_1769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":87,"sex":"female","bmi":19.6,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-11-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-52},"pfs_months":7.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":13.2,"censored":false},"longitudinal_labs":[{"date":"2025-10-02","hemoglobin_g_dL":12.0,"wbc_k_uL":9.2,"platelets_k_uL":434,"creatinine_mg_dL":1.09,"alt_U_L":40},{"date":"2026-05-03","hemoglobin_g_dL":12.6,"wbc_k_uL":7.1,"platelets_k_uL":212,"creatinine_mg_dL":0.71,"alt_U_L":82},{"date":"2026-07-11","hemoglobin_g_dL":11.9,"wbc_k_uL":6.9,"platelets_k_uL":184,"creatinine_mg_dL":1.6,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_1770","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":70,"sex":"male","bmi":20.7,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2023-05-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-76},"pfs_months":29.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.9,"censored":false},"longitudinal_labs":[{"date":"2023-03-16","hemoglobin_g_dL":12.2,"wbc_k_uL":6.9,"platelets_k_uL":393,"creatinine_mg_dL":0.73,"alt_U_L":54},{"date":"2023-11-16","hemoglobin_g_dL":12.8,"wbc_k_uL":6.7,"platelets_k_uL":290,"creatinine_mg_dL":1.23,"alt_U_L":49},{"date":"2025-11-19","hemoglobin_g_dL":10.2,"wbc_k_uL":3.3,"platelets_k_uL":295,"creatinine_mg_dL":0.98,"alt_U_L":139}]}
{"patient_id":"ANODE_SYNTH_2025_1771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":81,"sex":"female","bmi":21.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-74},"pfs_months":17.45},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.0,"censored":false},"longitudinal_labs":[{"date":"2020-10-05","hemoglobin_g_dL":12.3,"wbc_k_uL":6.4,"platelets_k_uL":356,"creatinine_mg_dL":0.89,"alt_U_L":48},{"date":"2021-04-27","hemoglobin_g_dL":12.1,"wbc_k_uL":7.6,"platelets_k_uL":259,"creatinine_mg_dL":1.18,"alt_U_L":49},{"date":"2022-04-26","hemoglobin_g_dL":11.8,"wbc_k_uL":3.1,"platelets_k_uL":220,"creatinine_mg_dL":1.86,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_1772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":76,"sex":"female","bmi":20.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-46},"pfs_months":21.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":37.2,"censored":false},"longitudinal_labs":[{"date":"2021-02-13","hemoglobin_g_dL":14.1,"wbc_k_uL":8.2,"platelets_k_uL":156,"creatinine_mg_dL":1.21,"alt_U_L":26},{"date":"2021-09-02","hemoglobin_g_dL":11.2,"wbc_k_uL":8.1,"platelets_k_uL":232,"creatinine_mg_dL":0.85,"alt_U_L":31},{"date":"2023-02-08","hemoglobin_g_dL":11.0,"wbc_k_uL":4.4,"platelets_k_uL":289,"creatinine_mg_dL":1.57,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_1773","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":70,"sex":"female","bmi":34.5,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-04-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-63},"pfs_months":18.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.7,"censored":false},"longitudinal_labs":[{"date":"2022-03-06","hemoglobin_g_dL":12.3,"wbc_k_uL":6.3,"platelets_k_uL":436,"creatinine_mg_dL":0.67,"alt_U_L":20},{"date":"2022-10-08","hemoglobin_g_dL":10.3,"wbc_k_uL":4.3,"platelets_k_uL":198,"creatinine_mg_dL":1.19,"alt_U_L":83},{"date":"2023-11-02","hemoglobin_g_dL":12.0,"wbc_k_uL":4.1,"platelets_k_uL":283,"creatinine_mg_dL":1.45,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_1774","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":85,"sex":"female","bmi":19.9,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-10-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-32},"pfs_months":46.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-11-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":67.9,"censored":false},"longitudinal_labs":[{"date":"2025-10-06","hemoglobin_g_dL":15.1,"wbc_k_uL":8.0,"platelets_k_uL":328,"creatinine_mg_dL":1.19,"alt_U_L":25},{"date":"2026-04-21","hemoglobin_g_dL":10.6,"wbc_k_uL":6.1,"platelets_k_uL":343,"creatinine_mg_dL":1.44,"alt_U_L":45},{"date":"2029-11-04","hemoglobin_g_dL":12.8,"wbc_k_uL":4.9,"platelets_k_uL":326,"creatinine_mg_dL":1.34,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_1775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":79,"sex":"female","bmi":19.1,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-51},"pfs_months":18.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":true},"longitudinal_labs":[{"date":"2021-09-11","hemoglobin_g_dL":13.8,"wbc_k_uL":9.9,"platelets_k_uL":344,"creatinine_mg_dL":1.17,"alt_U_L":10},{"date":"2022-05-01","hemoglobin_g_dL":10.3,"wbc_k_uL":5.4,"platelets_k_uL":215,"creatinine_mg_dL":1.16,"alt_U_L":56},{"date":"2023-06-27","hemoglobin_g_dL":11.9,"wbc_k_uL":3.2,"platelets_k_uL":270,"creatinine_mg_dL":1.28,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_1776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.4,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":60,"sex":"female","bmi":23.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-67},"pfs_months":15.11},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.8,"censored":false},"longitudinal_labs":[{"date":"2024-04-06","hemoglobin_g_dL":14.3,"wbc_k_uL":5.9,"platelets_k_uL":179,"creatinine_mg_dL":0.89,"alt_U_L":10},{"date":"2024-12-01","hemoglobin_g_dL":13.4,"wbc_k_uL":7.6,"platelets_k_uL":142,"creatinine_mg_dL":0.8,"alt_U_L":44},{"date":"2025-09-17","hemoglobin_g_dL":11.1,"wbc_k_uL":7.2,"platelets_k_uL":317,"creatinine_mg_dL":1.91,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_1777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":58,"sex":"male","bmi":20.4,"smoking_pack_years":54,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-79},"pfs_months":45.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":67.4,"censored":true},"longitudinal_labs":[{"date":"2021-09-21","hemoglobin_g_dL":12.0,"wbc_k_uL":10.8,"platelets_k_uL":198,"creatinine_mg_dL":0.66,"alt_U_L":70},{"date":"2022-05-26","hemoglobin_g_dL":13.5,"wbc_k_uL":5.7,"platelets_k_uL":180,"creatinine_mg_dL":1.24,"alt_U_L":86},{"date":"2025-10-26","hemoglobin_g_dL":11.4,"wbc_k_uL":3.7,"platelets_k_uL":113,"creatinine_mg_dL":1.06,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_1778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":65,"sex":"female","bmi":29.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-81},"pfs_months":28.85},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.4,"censored":true},"longitudinal_labs":[{"date":"2020-04-14","hemoglobin_g_dL":12.8,"wbc_k_uL":8.8,"platelets_k_uL":281,"creatinine_mg_dL":1.01,"alt_U_L":53},{"date":"2020-11-21","hemoglobin_g_dL":11.3,"wbc_k_uL":8.3,"platelets_k_uL":304,"creatinine_mg_dL":0.92,"alt_U_L":82},{"date":"2022-11-29","hemoglobin_g_dL":11.3,"wbc_k_uL":5.2,"platelets_k_uL":254,"creatinine_mg_dL":0.81,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_1779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":69,"sex":"female","bmi":24.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-33},"pfs_months":20.27},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.4,"censored":false},"longitudinal_labs":[{"date":"2024-07-07","hemoglobin_g_dL":12.2,"wbc_k_uL":9.2,"platelets_k_uL":172,"creatinine_mg_dL":0.69,"alt_U_L":80},{"date":"2025-03-14","hemoglobin_g_dL":12.8,"wbc_k_uL":7.4,"platelets_k_uL":132,"creatinine_mg_dL":1.6,"alt_U_L":115},{"date":"2026-07-20","hemoglobin_g_dL":10.9,"wbc_k_uL":4.5,"platelets_k_uL":242,"creatinine_mg_dL":1.88,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_1780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":55,"sex":"female","bmi":23.9,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-12-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-73},"pfs_months":31.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":60.5,"censored":true},"longitudinal_labs":[{"date":"2024-10-18","hemoglobin_g_dL":11.7,"wbc_k_uL":6.1,"platelets_k_uL":440,"creatinine_mg_dL":1.02,"alt_U_L":31},{"date":"2025-06-13","hemoglobin_g_dL":11.1,"wbc_k_uL":8.5,"platelets_k_uL":300,"creatinine_mg_dL":0.89,"alt_U_L":21},{"date":"2027-09-26","hemoglobin_g_dL":11.3,"wbc_k_uL":4.3,"platelets_k_uL":137,"creatinine_mg_dL":1.9,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_1781","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":82,"sex":"female","bmi":32.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-30},"pfs_months":22.7},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":true},"longitudinal_labs":[{"date":"2022-07-13","hemoglobin_g_dL":14.6,"wbc_k_uL":5.1,"platelets_k_uL":376,"creatinine_mg_dL":0.74,"alt_U_L":15},{"date":"2023-03-09","hemoglobin_g_dL":12.0,"wbc_k_uL":6.0,"platelets_k_uL":290,"creatinine_mg_dL":0.77,"alt_U_L":93},{"date":"2024-08-26","hemoglobin_g_dL":12.4,"wbc_k_uL":6.1,"platelets_k_uL":277,"creatinine_mg_dL":1.17,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_1782","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":65,"sex":"female","bmi":26.4,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-66},"pfs_months":25.76},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.5,"censored":false},"longitudinal_labs":[{"date":"2020-12-26","hemoglobin_g_dL":12.9,"wbc_k_uL":10.5,"platelets_k_uL":297,"creatinine_mg_dL":0.74,"alt_U_L":74},{"date":"2021-07-20","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":192,"creatinine_mg_dL":1.35,"alt_U_L":33},{"date":"2023-04-21","hemoglobin_g_dL":11.8,"wbc_k_uL":6.4,"platelets_k_uL":120,"creatinine_mg_dL":0.98,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_1783","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":52,"sex":"female","bmi":36.0,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-61},"pfs_months":47.61},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":81.9,"censored":false},"longitudinal_labs":[{"date":"2021-04-04","hemoglobin_g_dL":12.5,"wbc_k_uL":9.4,"platelets_k_uL":253,"creatinine_mg_dL":1.05,"alt_U_L":50},{"date":"2021-11-03","hemoglobin_g_dL":13.6,"wbc_k_uL":4.0,"platelets_k_uL":347,"creatinine_mg_dL":1.2,"alt_U_L":113},{"date":"2025-06-03","hemoglobin_g_dL":11.0,"wbc_k_uL":7.0,"platelets_k_uL":272,"creatinine_mg_dL":1.73,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_1784","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":68,"sex":"female","bmi":19.5,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-10-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-79},"pfs_months":25.63},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.7,"censored":true},"longitudinal_labs":[{"date":"2023-09-24","hemoglobin_g_dL":15.1,"wbc_k_uL":4.7,"platelets_k_uL":155,"creatinine_mg_dL":1.26,"alt_U_L":10},{"date":"2024-04-15","hemoglobin_g_dL":10.9,"wbc_k_uL":6.5,"platelets_k_uL":291,"creatinine_mg_dL":0.86,"alt_U_L":41},{"date":"2026-01-30","hemoglobin_g_dL":12.6,"wbc_k_uL":3.2,"platelets_k_uL":219,"creatinine_mg_dL":0.96,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_1785","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":68,"sex":"female","bmi":33.8,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-01-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-56},"pfs_months":21.42},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.8,"censored":false},"longitudinal_labs":[{"date":"2024-12-22","hemoglobin_g_dL":12.6,"wbc_k_uL":8.0,"platelets_k_uL":295,"creatinine_mg_dL":1.26,"alt_U_L":78},{"date":"2025-07-23","hemoglobin_g_dL":13.7,"wbc_k_uL":5.7,"platelets_k_uL":214,"creatinine_mg_dL":1.52,"alt_U_L":16},{"date":"2026-11-18","hemoglobin_g_dL":12.2,"wbc_k_uL":4.5,"platelets_k_uL":120,"creatinine_mg_dL":1.26,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_1786","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":61,"sex":"male","bmi":34.6,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-01-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-68},"pfs_months":21.26},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.6,"censored":true},"longitudinal_labs":[{"date":"2022-12-03","hemoglobin_g_dL":11.6,"wbc_k_uL":9.1,"platelets_k_uL":389,"creatinine_mg_dL":1.17,"alt_U_L":29},{"date":"2023-07-13","hemoglobin_g_dL":10.3,"wbc_k_uL":4.0,"platelets_k_uL":144,"creatinine_mg_dL":1.4,"alt_U_L":36},{"date":"2024-12-17","hemoglobin_g_dL":11.9,"wbc_k_uL":6.3,"platelets_k_uL":176,"creatinine_mg_dL":0.92,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_1787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":64,"sex":"female","bmi":18.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-52},"pfs_months":20.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.4,"censored":false},"longitudinal_labs":[{"date":"2021-03-07","hemoglobin_g_dL":12.1,"wbc_k_uL":6.0,"platelets_k_uL":237,"creatinine_mg_dL":1.21,"alt_U_L":47},{"date":"2021-09-18","hemoglobin_g_dL":13.7,"wbc_k_uL":8.5,"platelets_k_uL":332,"creatinine_mg_dL":1.09,"alt_U_L":96},{"date":"2022-12-14","hemoglobin_g_dL":12.4,"wbc_k_uL":3.2,"platelets_k_uL":277,"creatinine_mg_dL":1.8,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_1788","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":48,"sex":"female","bmi":22.1,"smoking_pack_years":54,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-05-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-30},"pfs_months":23.75},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.4,"censored":false},"longitudinal_labs":[{"date":"2021-04-06","hemoglobin_g_dL":14.1,"wbc_k_uL":10.2,"platelets_k_uL":155,"creatinine_mg_dL":0.62,"alt_U_L":16},{"date":"2021-11-20","hemoglobin_g_dL":13.0,"wbc_k_uL":4.7,"platelets_k_uL":302,"creatinine_mg_dL":1.21,"alt_U_L":105},{"date":"2023-06-05","hemoglobin_g_dL":9.6,"wbc_k_uL":3.3,"platelets_k_uL":176,"creatinine_mg_dL":1.07,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_1789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":56,"sex":"male","bmi":19.7,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2023-12-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-51},"pfs_months":28.58},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.2,"censored":false},"longitudinal_labs":[{"date":"2023-12-15","hemoglobin_g_dL":15.0,"wbc_k_uL":9.2,"platelets_k_uL":388,"creatinine_mg_dL":0.69,"alt_U_L":66},{"date":"2024-06-28","hemoglobin_g_dL":12.8,"wbc_k_uL":6.3,"platelets_k_uL":181,"creatinine_mg_dL":1.46,"alt_U_L":51},{"date":"2026-05-30","hemoglobin_g_dL":10.3,"wbc_k_uL":5.8,"platelets_k_uL":337,"creatinine_mg_dL":0.87,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_1790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":74,"sex":"female","bmi":20.4,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-49},"pfs_months":26.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.0,"censored":false},"longitudinal_labs":[{"date":"2024-03-21","hemoglobin_g_dL":15.2,"wbc_k_uL":9.4,"platelets_k_uL":350,"creatinine_mg_dL":1.22,"alt_U_L":68},{"date":"2024-10-10","hemoglobin_g_dL":10.3,"wbc_k_uL":5.1,"platelets_k_uL":350,"creatinine_mg_dL":0.91,"alt_U_L":48},{"date":"2026-08-05","hemoglobin_g_dL":11.8,"wbc_k_uL":4.3,"platelets_k_uL":136,"creatinine_mg_dL":1.11,"alt_U_L":71}]}
{"patient_id":"ANODE_SYNTH_2025_1791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":87,"sex":"female","bmi":31.5,"smoking_pack_years":32,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-05-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-66},"pfs_months":8.05},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":14.5,"censored":false},"longitudinal_labs":[{"date":"2022-03-27","hemoglobin_g_dL":13.9,"wbc_k_uL":10.2,"platelets_k_uL":159,"creatinine_mg_dL":1.27,"alt_U_L":64},{"date":"2022-11-05","hemoglobin_g_dL":10.2,"wbc_k_uL":6.7,"platelets_k_uL":212,"creatinine_mg_dL":1.55,"alt_U_L":99},{"date":"2023-01-15","hemoglobin_g_dL":10.4,"wbc_k_uL":7.8,"platelets_k_uL":208,"creatinine_mg_dL":0.9,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_1792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":67,"sex":"male","bmi":37.6,"smoking_pack_years":48,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-04-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-34},"pfs_months":15.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":false},"longitudinal_labs":[{"date":"2025-03-22","hemoglobin_g_dL":14.1,"wbc_k_uL":9.4,"platelets_k_uL":186,"creatinine_mg_dL":0.76,"alt_U_L":65},{"date":"2025-10-04","hemoglobin_g_dL":11.8,"wbc_k_uL":7.2,"platelets_k_uL":280,"creatinine_mg_dL":1.44,"alt_U_L":26},{"date":"2026-07-17","hemoglobin_g_dL":11.6,"wbc_k_uL":3.4,"platelets_k_uL":254,"creatinine_mg_dL":1.65,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_1793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":76,"sex":"male","bmi":27.0,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-01-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-57},"pfs_months":48.46},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":74.4,"censored":false},"longitudinal_labs":[{"date":"2020-12-11","hemoglobin_g_dL":12.4,"wbc_k_uL":7.9,"platelets_k_uL":235,"creatinine_mg_dL":1.29,"alt_U_L":31},{"date":"2021-07-03","hemoglobin_g_dL":11.1,"wbc_k_uL":8.3,"platelets_k_uL":295,"creatinine_mg_dL":0.79,"alt_U_L":98},{"date":"2025-03-12","hemoglobin_g_dL":9.7,"wbc_k_uL":5.4,"platelets_k_uL":224,"creatinine_mg_dL":1.0,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_1794","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":70,"sex":"male","bmi":33.7,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-04-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-56},"pfs_months":25.92},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.0,"censored":false},"longitudinal_labs":[{"date":"2022-04-03","hemoglobin_g_dL":13.9,"wbc_k_uL":9.1,"platelets_k_uL":302,"creatinine_mg_dL":1.09,"alt_U_L":51},{"date":"2022-10-14","hemoglobin_g_dL":10.3,"wbc_k_uL":6.7,"platelets_k_uL":330,"creatinine_mg_dL":1.58,"alt_U_L":40},{"date":"2024-07-06","hemoglobin_g_dL":11.6,"wbc_k_uL":4.7,"platelets_k_uL":125,"creatinine_mg_dL":1.78,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1795","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":57,"sex":"female","bmi":30.4,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-06-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-31},"pfs_months":17.74},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.4,"censored":false},"longitudinal_labs":[{"date":"2023-05-05","hemoglobin_g_dL":15.5,"wbc_k_uL":4.7,"platelets_k_uL":404,"creatinine_mg_dL":1.19,"alt_U_L":19},{"date":"2023-12-06","hemoglobin_g_dL":11.0,"wbc_k_uL":4.9,"platelets_k_uL":365,"creatinine_mg_dL":0.79,"alt_U_L":66},{"date":"2024-12-15","hemoglobin_g_dL":12.8,"wbc_k_uL":6.2,"platelets_k_uL":316,"creatinine_mg_dL":1.59,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_1796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":79,"sex":"male","bmi":32.1,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-01-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-68},"pfs_months":12.02},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.0,"censored":false},"longitudinal_labs":[{"date":"2025-12-09","hemoglobin_g_dL":13.6,"wbc_k_uL":8.9,"platelets_k_uL":219,"creatinine_mg_dL":1.16,"alt_U_L":22},{"date":"2026-07-24","hemoglobin_g_dL":13.7,"wbc_k_uL":4.7,"platelets_k_uL":285,"creatinine_mg_dL":1.41,"alt_U_L":27},{"date":"2027-03-07","hemoglobin_g_dL":12.3,"wbc_k_uL":7.8,"platelets_k_uL":327,"creatinine_mg_dL":1.44,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_1797","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":70,"sex":"female","bmi":19.7,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-07-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-56},"pfs_months":26.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":false},"longitudinal_labs":[{"date":"2022-06-18","hemoglobin_g_dL":11.8,"wbc_k_uL":7.2,"platelets_k_uL":180,"creatinine_mg_dL":0.86,"alt_U_L":80},{"date":"2023-01-06","hemoglobin_g_dL":12.3,"wbc_k_uL":7.9,"platelets_k_uL":136,"creatinine_mg_dL":1.06,"alt_U_L":69},{"date":"2024-09-21","hemoglobin_g_dL":11.4,"wbc_k_uL":7.9,"platelets_k_uL":335,"creatinine_mg_dL":0.9,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_1798","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":54,"sex":"female","bmi":35.7,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-01-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-51},"pfs_months":6.93},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":17.9,"censored":false},"longitudinal_labs":[{"date":"2025-12-09","hemoglobin_g_dL":13.2,"wbc_k_uL":6.6,"platelets_k_uL":314,"creatinine_mg_dL":0.85,"alt_U_L":77},{"date":"2026-07-29","hemoglobin_g_dL":12.0,"wbc_k_uL":8.7,"platelets_k_uL":272,"creatinine_mg_dL":1.18,"alt_U_L":46},{"date":"2026-09-20","hemoglobin_g_dL":10.0,"wbc_k_uL":4.3,"platelets_k_uL":114,"creatinine_mg_dL":1.04,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_1799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":84,"sex":"female","bmi":34.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-84},"pfs_months":10.81},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.5,"censored":true},"longitudinal_labs":[{"date":"2024-05-28","hemoglobin_g_dL":13.2,"wbc_k_uL":7.3,"platelets_k_uL":268,"creatinine_mg_dL":0.86,"alt_U_L":64},{"date":"2024-12-29","hemoglobin_g_dL":12.2,"wbc_k_uL":9.0,"platelets_k_uL":359,"creatinine_mg_dL":1.06,"alt_U_L":99},{"date":"2025-07-24","hemoglobin_g_dL":9.6,"wbc_k_uL":5.0,"platelets_k_uL":110,"creatinine_mg_dL":1.33,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_1800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":88,"sex":"female","bmi":19.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-43},"pfs_months":25.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":46.0,"censored":false},"longitudinal_labs":[{"date":"2023-05-22","hemoglobin_g_dL":13.3,"wbc_k_uL":10.0,"platelets_k_uL":387,"creatinine_mg_dL":1.14,"alt_U_L":73},{"date":"2024-01-07","hemoglobin_g_dL":13.0,"wbc_k_uL":4.1,"platelets_k_uL":283,"creatinine_mg_dL":1.24,"alt_U_L":117},{"date":"2025-09-26","hemoglobin_g_dL":12.8,"wbc_k_uL":3.1,"platelets_k_uL":284,"creatinine_mg_dL":1.86,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_1801","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":60,"sex":"male","bmi":36.0,"smoking_pack_years":46,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-03-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-85},"pfs_months":21.03},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.1,"censored":true},"longitudinal_labs":[{"date":"2022-01-24","hemoglobin_g_dL":11.6,"wbc_k_uL":9.0,"platelets_k_uL":367,"creatinine_mg_dL":1.16,"alt_U_L":44},{"date":"2022-09-09","hemoglobin_g_dL":11.3,"wbc_k_uL":6.7,"platelets_k_uL":273,"creatinine_mg_dL":1.16,"alt_U_L":108},{"date":"2024-02-08","hemoglobin_g_dL":11.6,"wbc_k_uL":6.0,"platelets_k_uL":101,"creatinine_mg_dL":1.95,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_1802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":81,"sex":"female","bmi":29.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-65},"pfs_months":21.88},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.5,"censored":true},"longitudinal_labs":[{"date":"2024-06-04","hemoglobin_g_dL":11.6,"wbc_k_uL":7.4,"platelets_k_uL":345,"creatinine_mg_dL":1.28,"alt_U_L":25},{"date":"2025-01-23","hemoglobin_g_dL":13.1,"wbc_k_uL":5.2,"platelets_k_uL":352,"creatinine_mg_dL":1.06,"alt_U_L":97},{"date":"2026-06-08","hemoglobin_g_dL":11.4,"wbc_k_uL":5.1,"platelets_k_uL":112,"creatinine_mg_dL":1.82,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_1803","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":50,"sex":"female","bmi":30.8,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-09-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-58},"pfs_months":22.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":false},"longitudinal_labs":[{"date":"2025-08-25","hemoglobin_g_dL":11.5,"wbc_k_uL":6.1,"platelets_k_uL":161,"creatinine_mg_dL":1.16,"alt_U_L":54},{"date":"2026-03-25","hemoglobin_g_dL":10.7,"wbc_k_uL":7.7,"platelets_k_uL":198,"creatinine_mg_dL":0.87,"alt_U_L":112},{"date":"2027-09-09","hemoglobin_g_dL":11.5,"wbc_k_uL":4.9,"platelets_k_uL":154,"creatinine_mg_dL":0.9,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_1804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":53,"sex":"female","bmi":33.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-73},"pfs_months":19.35},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.2,"censored":false},"longitudinal_labs":[{"date":"2025-08-21","hemoglobin_g_dL":11.6,"wbc_k_uL":8.7,"platelets_k_uL":374,"creatinine_mg_dL":0.64,"alt_U_L":24},{"date":"2026-03-26","hemoglobin_g_dL":12.8,"wbc_k_uL":7.8,"platelets_k_uL":243,"creatinine_mg_dL":0.83,"alt_U_L":83},{"date":"2027-06-22","hemoglobin_g_dL":12.8,"wbc_k_uL":3.3,"platelets_k_uL":291,"creatinine_mg_dL":1.17,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_1805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":76,"sex":"female","bmi":30.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-78},"pfs_months":20.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.7,"censored":true},"longitudinal_labs":[{"date":"2024-03-25","hemoglobin_g_dL":13.9,"wbc_k_uL":5.8,"platelets_k_uL":209,"creatinine_mg_dL":1.14,"alt_U_L":36},{"date":"2024-10-08","hemoglobin_g_dL":12.1,"wbc_k_uL":4.8,"platelets_k_uL":170,"creatinine_mg_dL":1.03,"alt_U_L":88},{"date":"2026-01-08","hemoglobin_g_dL":11.8,"wbc_k_uL":3.7,"platelets_k_uL":295,"creatinine_mg_dL":1.48,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_1806","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":51,"sex":"female","bmi":36.4,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-08-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-37},"pfs_months":22.93},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.3,"censored":true},"longitudinal_labs":[{"date":"2022-08-01","hemoglobin_g_dL":14.5,"wbc_k_uL":9.3,"platelets_k_uL":356,"creatinine_mg_dL":0.64,"alt_U_L":54},{"date":"2023-02-27","hemoglobin_g_dL":11.8,"wbc_k_uL":6.5,"platelets_k_uL":297,"creatinine_mg_dL":1.34,"alt_U_L":101},{"date":"2024-08-19","hemoglobin_g_dL":10.9,"wbc_k_uL":5.1,"platelets_k_uL":290,"creatinine_mg_dL":0.88,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_1807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":56,"sex":"male","bmi":37.4,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-12-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-68},"pfs_months":10.35},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.9,"censored":false},"longitudinal_labs":[{"date":"2020-11-05","hemoglobin_g_dL":15.1,"wbc_k_uL":10.7,"platelets_k_uL":268,"creatinine_mg_dL":0.9,"alt_U_L":64},{"date":"2021-06-28","hemoglobin_g_dL":11.8,"wbc_k_uL":4.8,"platelets_k_uL":353,"creatinine_mg_dL":1.54,"alt_U_L":24},{"date":"2022-01-08","hemoglobin_g_dL":12.7,"wbc_k_uL":6.1,"platelets_k_uL":343,"creatinine_mg_dL":0.84,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_1808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":18.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":76,"sex":"male","bmi":27.8,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-65},"pfs_months":22.44},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.4,"censored":false},"longitudinal_labs":[{"date":"2025-06-05","hemoglobin_g_dL":13.3,"wbc_k_uL":7.5,"platelets_k_uL":210,"creatinine_mg_dL":0.68,"alt_U_L":42},{"date":"2026-01-12","hemoglobin_g_dL":13.2,"wbc_k_uL":8.3,"platelets_k_uL":273,"creatinine_mg_dL":0.83,"alt_U_L":81},{"date":"2027-06-13","hemoglobin_g_dL":10.7,"wbc_k_uL":6.6,"platelets_k_uL":232,"creatinine_mg_dL":1.0,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_1809","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":57,"sex":"female","bmi":29.0,"smoking_pack_years":64,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-04-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-44},"pfs_months":18.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":28.8,"censored":false},"longitudinal_labs":[{"date":"2024-02-11","hemoglobin_g_dL":15.4,"wbc_k_uL":9.2,"platelets_k_uL":216,"creatinine_mg_dL":1.12,"alt_U_L":55},{"date":"2024-10-14","hemoglobin_g_dL":13.2,"wbc_k_uL":8.9,"platelets_k_uL":248,"creatinine_mg_dL":1.14,"alt_U_L":63},{"date":"2025-11-11","hemoglobin_g_dL":12.3,"wbc_k_uL":3.5,"platelets_k_uL":207,"creatinine_mg_dL":0.97,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_1810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":56,"sex":"female","bmi":24.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-50},"pfs_months":25.66},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.4,"censored":false},"longitudinal_labs":[{"date":"2020-11-03","hemoglobin_g_dL":14.5,"wbc_k_uL":5.1,"platelets_k_uL":201,"creatinine_mg_dL":1.17,"alt_U_L":48},{"date":"2021-06-17","hemoglobin_g_dL":11.5,"wbc_k_uL":4.4,"platelets_k_uL":275,"creatinine_mg_dL":1.3,"alt_U_L":87},{"date":"2023-02-24","hemoglobin_g_dL":12.2,"wbc_k_uL":6.8,"platelets_k_uL":186,"creatinine_mg_dL":1.02,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_1811","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":79,"sex":"male","bmi":33.3,"smoking_pack_years":68,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["bone","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-04-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-36},"pfs_months":40.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":62.3,"censored":false},"longitudinal_labs":[{"date":"2023-03-09","hemoglobin_g_dL":12.3,"wbc_k_uL":7.9,"platelets_k_uL":213,"creatinine_mg_dL":1.11,"alt_U_L":33},{"date":"2023-10-04","hemoglobin_g_dL":12.0,"wbc_k_uL":6.3,"platelets_k_uL":253,"creatinine_mg_dL":0.74,"alt_U_L":33},{"date":"2026-09-16","hemoglobin_g_dL":12.7,"wbc_k_uL":3.1,"platelets_k_uL":206,"creatinine_mg_dL":1.51,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_1812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":78,"sex":"female","bmi":34.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-41},"pfs_months":25.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.9,"censored":false},"longitudinal_labs":[{"date":"2022-03-13","hemoglobin_g_dL":13.8,"wbc_k_uL":10.9,"platelets_k_uL":370,"creatinine_mg_dL":1.18,"alt_U_L":41},{"date":"2022-11-13","hemoglobin_g_dL":11.5,"wbc_k_uL":8.5,"platelets_k_uL":304,"creatinine_mg_dL":1.03,"alt_U_L":59},{"date":"2024-08-18","hemoglobin_g_dL":12.6,"wbc_k_uL":6.0,"platelets_k_uL":194,"creatinine_mg_dL":1.91,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_1813","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":67,"sex":"male","bmi":21.3,"smoking_pack_years":11,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-02-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-62},"pfs_months":16.72},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":31.7,"censored":false},"longitudinal_labs":[{"date":"2025-12-24","hemoglobin_g_dL":14.0,"wbc_k_uL":10.7,"platelets_k_uL":408,"creatinine_mg_dL":1.13,"alt_U_L":61},{"date":"2026-07-31","hemoglobin_g_dL":11.4,"wbc_k_uL":4.7,"platelets_k_uL":165,"creatinine_mg_dL":1.03,"alt_U_L":93},{"date":"2027-07-11","hemoglobin_g_dL":9.7,"wbc_k_uL":7.7,"platelets_k_uL":270,"creatinine_mg_dL":1.37,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_1814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":58,"sex":"female","bmi":30.9,"smoking_pack_years":17,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-09-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-63},"pfs_months":10.71},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.3,"censored":false},"longitudinal_labs":[{"date":"2024-07-28","hemoglobin_g_dL":11.7,"wbc_k_uL":4.6,"platelets_k_uL":406,"creatinine_mg_dL":1.18,"alt_U_L":50},{"date":"2025-03-04","hemoglobin_g_dL":12.8,"wbc_k_uL":6.8,"platelets_k_uL":193,"creatinine_mg_dL":0.95,"alt_U_L":31},{"date":"2025-09-08","hemoglobin_g_dL":10.5,"wbc_k_uL":3.4,"platelets_k_uL":135,"creatinine_mg_dL":1.77,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_1815","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":70,"sex":"male","bmi":22.3,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-12-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-51},"pfs_months":23.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.3,"censored":true},"longitudinal_labs":[{"date":"2025-11-08","hemoglobin_g_dL":12.8,"wbc_k_uL":7.0,"platelets_k_uL":156,"creatinine_mg_dL":1.24,"alt_U_L":18},{"date":"2026-06-07","hemoglobin_g_dL":12.0,"wbc_k_uL":6.5,"platelets_k_uL":244,"creatinine_mg_dL":1.02,"alt_U_L":120},{"date":"2027-12-29","hemoglobin_g_dL":12.1,"wbc_k_uL":6.5,"platelets_k_uL":223,"creatinine_mg_dL":1.62,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_1816","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":57,"sex":"male","bmi":19.8,"smoking_pack_years":39,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-47},"pfs_months":16.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.0,"censored":false},"longitudinal_labs":[{"date":"2023-05-16","hemoglobin_g_dL":12.1,"wbc_k_uL":7.0,"platelets_k_uL":246,"creatinine_mg_dL":0.99,"alt_U_L":14},{"date":"2023-11-28","hemoglobin_g_dL":12.7,"wbc_k_uL":6.1,"platelets_k_uL":273,"creatinine_mg_dL":0.96,"alt_U_L":116},{"date":"2024-12-09","hemoglobin_g_dL":10.0,"wbc_k_uL":4.1,"platelets_k_uL":314,"creatinine_mg_dL":1.52,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_1817","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":62,"sex":"female","bmi":28.4,"smoking_pack_years":56,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-63},"pfs_months":9.26},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-23","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.9,"censored":false},"longitudinal_labs":[{"date":"2021-09-04","hemoglobin_g_dL":14.5,"wbc_k_uL":8.7,"platelets_k_uL":224,"creatinine_mg_dL":0.92,"alt_U_L":53},{"date":"2022-03-27","hemoglobin_g_dL":12.0,"wbc_k_uL":8.3,"platelets_k_uL":367,"creatinine_mg_dL":1.38,"alt_U_L":70},{"date":"2022-07-23","hemoglobin_g_dL":12.5,"wbc_k_uL":5.5,"platelets_k_uL":206,"creatinine_mg_dL":1.88,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_1818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":63,"sex":"male","bmi":29.4,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-04-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-34},"pfs_months":31.44},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":57.9,"censored":true},"longitudinal_labs":[{"date":"2021-03-08","hemoglobin_g_dL":13.1,"wbc_k_uL":4.9,"platelets_k_uL":338,"creatinine_mg_dL":1.1,"alt_U_L":66},{"date":"2021-10-16","hemoglobin_g_dL":11.7,"wbc_k_uL":4.9,"platelets_k_uL":238,"creatinine_mg_dL":0.92,"alt_U_L":107},{"date":"2023-12-26","hemoglobin_g_dL":11.0,"wbc_k_uL":3.8,"platelets_k_uL":191,"creatinine_mg_dL":1.53,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_1819","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":48,"sex":"female","bmi":32.7,"smoking_pack_years":68,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-11-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-80},"pfs_months":13.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.9,"censored":false},"longitudinal_labs":[{"date":"2020-09-07","hemoglobin_g_dL":12.5,"wbc_k_uL":9.4,"platelets_k_uL":312,"creatinine_mg_dL":1.27,"alt_U_L":16},{"date":"2021-04-30","hemoglobin_g_dL":10.6,"wbc_k_uL":8.1,"platelets_k_uL":360,"creatinine_mg_dL":0.73,"alt_U_L":22},{"date":"2022-01-20","hemoglobin_g_dL":9.8,"wbc_k_uL":7.6,"platelets_k_uL":211,"creatinine_mg_dL":1.52,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_1820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.2,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":59,"sex":"female","bmi":28.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-80},"pfs_months":17.31},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.4,"censored":false},"longitudinal_labs":[{"date":"2025-04-13","hemoglobin_g_dL":15.0,"wbc_k_uL":8.9,"platelets_k_uL":415,"creatinine_mg_dL":0.83,"alt_U_L":43},{"date":"2025-12-13","hemoglobin_g_dL":11.0,"wbc_k_uL":4.7,"platelets_k_uL":165,"creatinine_mg_dL":0.82,"alt_U_L":41},{"date":"2026-12-28","hemoglobin_g_dL":10.1,"wbc_k_uL":3.8,"platelets_k_uL":233,"creatinine_mg_dL":1.48,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_1821","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":78,"sex":"male","bmi":32.8,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-09-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-69},"pfs_months":6.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.3,"censored":false},"longitudinal_labs":[{"date":"2022-07-09","hemoglobin_g_dL":13.7,"wbc_k_uL":9.1,"platelets_k_uL":154,"creatinine_mg_dL":0.63,"alt_U_L":14},{"date":"2023-03-10","hemoglobin_g_dL":13.0,"wbc_k_uL":3.9,"platelets_k_uL":183,"creatinine_mg_dL":1.57,"alt_U_L":110},{"date":"2023-04-07","hemoglobin_g_dL":12.6,"wbc_k_uL":5.3,"platelets_k_uL":111,"creatinine_mg_dL":1.25,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_1822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":76,"sex":"male","bmi":26.8,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-02-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-47},"pfs_months":37.55},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":59.9,"censored":false},"longitudinal_labs":[{"date":"2022-01-20","hemoglobin_g_dL":12.4,"wbc_k_uL":8.6,"platelets_k_uL":360,"creatinine_mg_dL":0.9,"alt_U_L":72},{"date":"2022-08-24","hemoglobin_g_dL":10.5,"wbc_k_uL":6.6,"platelets_k_uL":233,"creatinine_mg_dL":1.14,"alt_U_L":50},{"date":"2025-04-26","hemoglobin_g_dL":11.4,"wbc_k_uL":7.7,"platelets_k_uL":186,"creatinine_mg_dL":1.52,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_1823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":81,"sex":"male","bmi":36.4,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-01-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-38},"pfs_months":5.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":13.9,"censored":true},"longitudinal_labs":[{"date":"2025-11-24","hemoglobin_g_dL":12.7,"wbc_k_uL":10.8,"platelets_k_uL":190,"creatinine_mg_dL":1.02,"alt_U_L":43},{"date":"2026-07-21","hemoglobin_g_dL":13.2,"wbc_k_uL":8.8,"platelets_k_uL":362,"creatinine_mg_dL":1.45,"alt_U_L":78},{"date":"2026-08-02","hemoglobin_g_dL":12.4,"wbc_k_uL":4.7,"platelets_k_uL":151,"creatinine_mg_dL":1.44,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_1824","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":60,"sex":"male","bmi":25.4,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-07-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-56},"pfs_months":36.93},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":61.0,"censored":false},"longitudinal_labs":[{"date":"2024-06-08","hemoglobin_g_dL":12.4,"wbc_k_uL":8.2,"platelets_k_uL":340,"creatinine_mg_dL":0.61,"alt_U_L":60},{"date":"2025-01-14","hemoglobin_g_dL":13.8,"wbc_k_uL":5.7,"platelets_k_uL":315,"creatinine_mg_dL":1.25,"alt_U_L":77},{"date":"2027-10-15","hemoglobin_g_dL":9.8,"wbc_k_uL":3.4,"platelets_k_uL":100,"creatinine_mg_dL":1.52,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_1825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":87,"sex":"female","bmi":24.1,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-06-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-67},"pfs_months":32.39},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":55.8,"censored":false},"longitudinal_labs":[{"date":"2024-04-19","hemoglobin_g_dL":13.1,"wbc_k_uL":8.3,"platelets_k_uL":363,"creatinine_mg_dL":1.18,"alt_U_L":53},{"date":"2024-12-18","hemoglobin_g_dL":13.4,"wbc_k_uL":4.4,"platelets_k_uL":136,"creatinine_mg_dL":1.5,"alt_U_L":116},{"date":"2027-03-23","hemoglobin_g_dL":10.6,"wbc_k_uL":6.9,"platelets_k_uL":198,"creatinine_mg_dL":0.97,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_1826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":63,"sex":"female","bmi":25.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-67},"pfs_months":18.3},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.0,"censored":false},"longitudinal_labs":[{"date":"2020-06-12","hemoglobin_g_dL":12.4,"wbc_k_uL":10.4,"platelets_k_uL":315,"creatinine_mg_dL":1.01,"alt_U_L":18},{"date":"2021-01-07","hemoglobin_g_dL":11.3,"wbc_k_uL":4.3,"platelets_k_uL":324,"creatinine_mg_dL":1.2,"alt_U_L":25},{"date":"2022-03-04","hemoglobin_g_dL":12.9,"wbc_k_uL":5.6,"platelets_k_uL":299,"creatinine_mg_dL":1.46,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_1827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":51,"sex":"female","bmi":36.5,"smoking_pack_years":45,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-05-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-45},"pfs_months":34.1},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":55.7,"censored":false},"longitudinal_labs":[{"date":"2022-03-17","hemoglobin_g_dL":11.7,"wbc_k_uL":8.3,"platelets_k_uL":392,"creatinine_mg_dL":1.29,"alt_U_L":58},{"date":"2022-11-02","hemoglobin_g_dL":12.0,"wbc_k_uL":6.6,"platelets_k_uL":371,"creatinine_mg_dL":1.28,"alt_U_L":16},{"date":"2025-04-07","hemoglobin_g_dL":10.7,"wbc_k_uL":7.6,"platelets_k_uL":350,"creatinine_mg_dL":1.39,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_1828","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":57,"sex":"female","bmi":20.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-66},"pfs_months":13.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.3,"censored":true},"longitudinal_labs":[{"date":"2023-07-28","hemoglobin_g_dL":13.6,"wbc_k_uL":4.9,"platelets_k_uL":273,"creatinine_mg_dL":1.02,"alt_U_L":44},{"date":"2024-04-02","hemoglobin_g_dL":12.7,"wbc_k_uL":4.5,"platelets_k_uL":188,"creatinine_mg_dL":1.44,"alt_U_L":101},{"date":"2025-01-15","hemoglobin_g_dL":10.3,"wbc_k_uL":6.8,"platelets_k_uL":162,"creatinine_mg_dL":1.39,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_1829","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":76,"sex":"female","bmi":21.2,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-05-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-30},"pfs_months":24.71},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.2,"censored":true},"longitudinal_labs":[{"date":"2022-05-09","hemoglobin_g_dL":11.8,"wbc_k_uL":6.4,"platelets_k_uL":315,"creatinine_mg_dL":0.61,"alt_U_L":16},{"date":"2022-11-27","hemoglobin_g_dL":11.2,"wbc_k_uL":5.2,"platelets_k_uL":377,"creatinine_mg_dL":1.44,"alt_U_L":75},{"date":"2024-07-21","hemoglobin_g_dL":10.0,"wbc_k_uL":5.0,"platelets_k_uL":181,"creatinine_mg_dL":2.0,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_1830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":53,"sex":"female","bmi":28.2,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-49},"pfs_months":7.59},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":11.5,"censored":false},"longitudinal_labs":[{"date":"2023-06-10","hemoglobin_g_dL":15.1,"wbc_k_uL":7.9,"platelets_k_uL":386,"creatinine_mg_dL":1.18,"alt_U_L":40},{"date":"2024-01-20","hemoglobin_g_dL":13.5,"wbc_k_uL":6.9,"platelets_k_uL":185,"creatinine_mg_dL":1.11,"alt_U_L":35},{"date":"2024-03-23","hemoglobin_g_dL":10.9,"wbc_k_uL":4.6,"platelets_k_uL":321,"creatinine_mg_dL":1.68,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_1831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":87,"sex":"male","bmi":33.9,"smoking_pack_years":26,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-12-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-55},"pfs_months":14.85},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":18.8,"censored":true},"longitudinal_labs":[{"date":"2021-11-06","hemoglobin_g_dL":11.6,"wbc_k_uL":5.1,"platelets_k_uL":262,"creatinine_mg_dL":0.64,"alt_U_L":62},{"date":"2022-06-26","hemoglobin_g_dL":10.7,"wbc_k_uL":7.5,"platelets_k_uL":206,"creatinine_mg_dL":1.49,"alt_U_L":19},{"date":"2023-04-23","hemoglobin_g_dL":11.0,"wbc_k_uL":7.0,"platelets_k_uL":305,"creatinine_mg_dL":1.29,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_1832","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":53,"sex":"male","bmi":25.0,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-01-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-41},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":6.9,"censored":false},"longitudinal_labs":[{"date":"2021-12-07","hemoglobin_g_dL":15.4,"wbc_k_uL":6.7,"platelets_k_uL":181,"creatinine_mg_dL":0.81,"alt_U_L":55},{"date":"2022-07-15","hemoglobin_g_dL":12.7,"wbc_k_uL":4.2,"platelets_k_uL":238,"creatinine_mg_dL":1.19,"alt_U_L":91},{"date":"2022-05-06","hemoglobin_g_dL":11.0,"wbc_k_uL":4.1,"platelets_k_uL":255,"creatinine_mg_dL":0.8,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_1833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":51,"sex":"female","bmi":28.8,"smoking_pack_years":16,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-12-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-76},"pfs_months":40.61},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":61.8,"censored":false},"longitudinal_labs":[{"date":"2023-11-13","hemoglobin_g_dL":13.9,"wbc_k_uL":6.0,"platelets_k_uL":301,"creatinine_mg_dL":1.29,"alt_U_L":47},{"date":"2024-06-20","hemoglobin_g_dL":12.2,"wbc_k_uL":6.4,"platelets_k_uL":376,"creatinine_mg_dL":0.95,"alt_U_L":72},{"date":"2027-06-22","hemoglobin_g_dL":10.8,"wbc_k_uL":7.4,"platelets_k_uL":137,"creatinine_mg_dL":1.72,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_1834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":53,"sex":"female","bmi":34.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-56},"pfs_months":21.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.3,"censored":false},"longitudinal_labs":[{"date":"2020-02-09","hemoglobin_g_dL":12.5,"wbc_k_uL":7.9,"platelets_k_uL":443,"creatinine_mg_dL":0.78,"alt_U_L":54},{"date":"2020-10-02","hemoglobin_g_dL":13.3,"wbc_k_uL":5.8,"platelets_k_uL":376,"creatinine_mg_dL":1.3,"alt_U_L":19},{"date":"2022-02-21","hemoglobin_g_dL":10.5,"wbc_k_uL":4.9,"platelets_k_uL":298,"creatinine_mg_dL":1.61,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_1835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":51,"sex":"female","bmi":25.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-68},"pfs_months":27.1},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":false},"longitudinal_labs":[{"date":"2020-11-10","hemoglobin_g_dL":14.2,"wbc_k_uL":6.8,"platelets_k_uL":177,"creatinine_mg_dL":0.85,"alt_U_L":63},{"date":"2021-05-23","hemoglobin_g_dL":13.5,"wbc_k_uL":8.8,"platelets_k_uL":120,"creatinine_mg_dL":1.43,"alt_U_L":103},{"date":"2023-03-26","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":119,"creatinine_mg_dL":1.04,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_1836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":49,"sex":"female","bmi":32.1,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-64},"pfs_months":25.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.2,"censored":true},"longitudinal_labs":[{"date":"2022-07-07","hemoglobin_g_dL":13.3,"wbc_k_uL":9.3,"platelets_k_uL":390,"creatinine_mg_dL":1.21,"alt_U_L":56},{"date":"2023-03-06","hemoglobin_g_dL":11.2,"wbc_k_uL":7.1,"platelets_k_uL":373,"creatinine_mg_dL":1.14,"alt_U_L":48},{"date":"2024-10-26","hemoglobin_g_dL":9.6,"wbc_k_uL":6.8,"platelets_k_uL":107,"creatinine_mg_dL":1.23,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_1837","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":58,"sex":"female","bmi":27.1,"smoking_pack_years":49,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-56},"pfs_months":15.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.9,"censored":true},"longitudinal_labs":[{"date":"2025-07-23","hemoglobin_g_dL":12.0,"wbc_k_uL":5.1,"platelets_k_uL":268,"creatinine_mg_dL":0.85,"alt_U_L":53},{"date":"2026-03-14","hemoglobin_g_dL":13.7,"wbc_k_uL":8.5,"platelets_k_uL":287,"creatinine_mg_dL":0.75,"alt_U_L":31},{"date":"2027-02-08","hemoglobin_g_dL":12.5,"wbc_k_uL":4.1,"platelets_k_uL":273,"creatinine_mg_dL":1.73,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_1838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":72,"sex":"female","bmi":27.1,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-07-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-43},"pfs_months":30.23},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":55.7,"censored":false},"longitudinal_labs":[{"date":"2023-06-10","hemoglobin_g_dL":12.8,"wbc_k_uL":9.1,"platelets_k_uL":238,"creatinine_mg_dL":1.27,"alt_U_L":76},{"date":"2024-01-01","hemoglobin_g_dL":10.9,"wbc_k_uL":8.7,"platelets_k_uL":251,"creatinine_mg_dL":1.48,"alt_U_L":47},{"date":"2026-01-20","hemoglobin_g_dL":11.5,"wbc_k_uL":5.2,"platelets_k_uL":313,"creatinine_mg_dL":1.42,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_1839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":65,"sex":"female","bmi":30.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-82},"pfs_months":29.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.1,"censored":true},"longitudinal_labs":[{"date":"2024-03-19","hemoglobin_g_dL":13.6,"wbc_k_uL":7.3,"platelets_k_uL":331,"creatinine_mg_dL":0.95,"alt_U_L":69},{"date":"2024-11-07","hemoglobin_g_dL":14.0,"wbc_k_uL":3.9,"platelets_k_uL":312,"creatinine_mg_dL":1.1,"alt_U_L":85},{"date":"2026-11-03","hemoglobin_g_dL":12.3,"wbc_k_uL":4.2,"platelets_k_uL":247,"creatinine_mg_dL":1.78,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_1840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":59,"sex":"female","bmi":33.1,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-01-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-71},"pfs_months":7.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-02","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.4,"censored":false},"longitudinal_labs":[{"date":"2020-12-28","hemoglobin_g_dL":12.9,"wbc_k_uL":9.5,"platelets_k_uL":229,"creatinine_mg_dL":1.17,"alt_U_L":66},{"date":"2021-07-26","hemoglobin_g_dL":10.3,"wbc_k_uL":9.0,"platelets_k_uL":334,"creatinine_mg_dL":1.23,"alt_U_L":98},{"date":"2021-10-02","hemoglobin_g_dL":10.8,"wbc_k_uL":4.9,"platelets_k_uL":109,"creatinine_mg_dL":1.64,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_1841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":62,"sex":"female","bmi":26.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-07-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-83},"pfs_months":21.42},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.6,"censored":false},"longitudinal_labs":[{"date":"2021-05-14","hemoglobin_g_dL":13.3,"wbc_k_uL":5.4,"platelets_k_uL":244,"creatinine_mg_dL":0.86,"alt_U_L":48},{"date":"2022-01-15","hemoglobin_g_dL":13.4,"wbc_k_uL":5.4,"platelets_k_uL":331,"creatinine_mg_dL":1.11,"alt_U_L":41},{"date":"2023-06-12","hemoglobin_g_dL":10.1,"wbc_k_uL":5.3,"platelets_k_uL":309,"creatinine_mg_dL":1.21,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_1842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":60,"sex":"female","bmi":19.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-12-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-53},"pfs_months":17.38},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":true},"longitudinal_labs":[{"date":"2021-10-26","hemoglobin_g_dL":15.3,"wbc_k_uL":6.2,"platelets_k_uL":418,"creatinine_mg_dL":1.03,"alt_U_L":78},{"date":"2022-06-01","hemoglobin_g_dL":11.1,"wbc_k_uL":8.7,"platelets_k_uL":363,"creatinine_mg_dL":1.48,"alt_U_L":83},{"date":"2023-06-11","hemoglobin_g_dL":11.6,"wbc_k_uL":6.6,"platelets_k_uL":180,"creatinine_mg_dL":1.62,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_1843","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":65,"sex":"female","bmi":19.7,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-11-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-76},"pfs_months":43.3},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":75.1,"censored":false},"longitudinal_labs":[{"date":"2022-10-20","hemoglobin_g_dL":13.4,"wbc_k_uL":8.0,"platelets_k_uL":298,"creatinine_mg_dL":1.06,"alt_U_L":18},{"date":"2023-05-22","hemoglobin_g_dL":12.3,"wbc_k_uL":8.9,"platelets_k_uL":288,"creatinine_mg_dL":1.26,"alt_U_L":21},{"date":"2026-08-21","hemoglobin_g_dL":10.7,"wbc_k_uL":7.1,"platelets_k_uL":315,"creatinine_mg_dL":1.16,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_1844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":71,"sex":"male","bmi":30.6,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-07-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-67},"pfs_months":38.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-10-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.0,"censored":true},"longitudinal_labs":[{"date":"2025-06-21","hemoglobin_g_dL":15.1,"wbc_k_uL":9.7,"platelets_k_uL":203,"creatinine_mg_dL":0.89,"alt_U_L":64},{"date":"2026-01-20","hemoglobin_g_dL":11.1,"wbc_k_uL":8.1,"platelets_k_uL":270,"creatinine_mg_dL":1.16,"alt_U_L":77},{"date":"2028-10-04","hemoglobin_g_dL":12.2,"wbc_k_uL":7.2,"platelets_k_uL":266,"creatinine_mg_dL":0.97,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_1845","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":54,"sex":"male","bmi":21.6,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-02-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-62},"pfs_months":23.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.0,"censored":true},"longitudinal_labs":[{"date":"2025-01-25","hemoglobin_g_dL":14.9,"wbc_k_uL":8.9,"platelets_k_uL":250,"creatinine_mg_dL":1.06,"alt_U_L":69},{"date":"2025-08-26","hemoglobin_g_dL":10.7,"wbc_k_uL":6.4,"platelets_k_uL":140,"creatinine_mg_dL":1.24,"alt_U_L":92},{"date":"2027-03-28","hemoglobin_g_dL":11.4,"wbc_k_uL":6.9,"platelets_k_uL":246,"creatinine_mg_dL":0.86,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_1846","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.4,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":74,"sex":"female","bmi":34.0,"smoking_pack_years":66,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-03-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-73},"pfs_months":12.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.2,"censored":true},"longitudinal_labs":[{"date":"2025-01-18","hemoglobin_g_dL":14.3,"wbc_k_uL":4.6,"platelets_k_uL":194,"creatinine_mg_dL":1.01,"alt_U_L":38},{"date":"2025-08-29","hemoglobin_g_dL":12.5,"wbc_k_uL":6.7,"platelets_k_uL":320,"creatinine_mg_dL":1.08,"alt_U_L":36},{"date":"2026-04-18","hemoglobin_g_dL":12.7,"wbc_k_uL":3.3,"platelets_k_uL":198,"creatinine_mg_dL":1.42,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_1847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":73,"sex":"female","bmi":28.0,"smoking_pack_years":70,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-03-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-33},"pfs_months":3.68},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":12.0,"censored":false},"longitudinal_labs":[{"date":"2024-02-27","hemoglobin_g_dL":15.1,"wbc_k_uL":9.3,"platelets_k_uL":429,"creatinine_mg_dL":0.71,"alt_U_L":20},{"date":"2024-09-10","hemoglobin_g_dL":10.8,"wbc_k_uL":5.5,"platelets_k_uL":377,"creatinine_mg_dL":1.31,"alt_U_L":44},{"date":"2024-08-13","hemoglobin_g_dL":12.0,"wbc_k_uL":4.0,"platelets_k_uL":350,"creatinine_mg_dL":1.59,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_1848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":55,"sex":"female","bmi":29.1,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-08-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-68},"pfs_months":45.54},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.2,"censored":true},"longitudinal_labs":[{"date":"2020-06-06","hemoglobin_g_dL":11.7,"wbc_k_uL":10.8,"platelets_k_uL":229,"creatinine_mg_dL":0.74,"alt_U_L":42},{"date":"2021-02-02","hemoglobin_g_dL":13.0,"wbc_k_uL":5.3,"platelets_k_uL":319,"creatinine_mg_dL":1.16,"alt_U_L":58},{"date":"2024-06-01","hemoglobin_g_dL":9.9,"wbc_k_uL":4.3,"platelets_k_uL":295,"creatinine_mg_dL":1.32,"alt_U_L":198}]}
{"patient_id":"ANODE_SYNTH_2025_1849","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":68,"sex":"male","bmi":23.4,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-46},"pfs_months":50.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":80.2,"censored":false},"longitudinal_labs":[{"date":"2021-04-24","hemoglobin_g_dL":14.0,"wbc_k_uL":10.7,"platelets_k_uL":414,"creatinine_mg_dL":0.71,"alt_U_L":18},{"date":"2021-11-07","hemoglobin_g_dL":11.5,"wbc_k_uL":8.3,"platelets_k_uL":215,"creatinine_mg_dL":0.73,"alt_U_L":23},{"date":"2025-08-30","hemoglobin_g_dL":11.9,"wbc_k_uL":4.8,"platelets_k_uL":350,"creatinine_mg_dL":0.85,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_1850","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":56,"sex":"female","bmi":19.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-48},"pfs_months":23.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.6,"censored":true},"longitudinal_labs":[{"date":"2020-05-19","hemoglobin_g_dL":12.4,"wbc_k_uL":7.7,"platelets_k_uL":288,"creatinine_mg_dL":0.64,"alt_U_L":26},{"date":"2020-12-22","hemoglobin_g_dL":12.2,"wbc_k_uL":6.5,"platelets_k_uL":204,"creatinine_mg_dL":0.78,"alt_U_L":67},{"date":"2022-08-07","hemoglobin_g_dL":12.4,"wbc_k_uL":6.4,"platelets_k_uL":166,"creatinine_mg_dL":0.83,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_1851","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":57,"sex":"female","bmi":23.0,"smoking_pack_years":40,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-05-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-59},"pfs_months":30.52},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.9,"censored":false},"longitudinal_labs":[{"date":"2025-04-09","hemoglobin_g_dL":12.9,"wbc_k_uL":4.7,"platelets_k_uL":388,"creatinine_mg_dL":1.24,"alt_U_L":54},{"date":"2025-11-02","hemoglobin_g_dL":13.5,"wbc_k_uL":6.0,"platelets_k_uL":194,"creatinine_mg_dL":0.76,"alt_U_L":71},{"date":"2027-11-28","hemoglobin_g_dL":12.4,"wbc_k_uL":4.2,"platelets_k_uL":196,"creatinine_mg_dL":1.56,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_1852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":80,"sex":"female","bmi":21.4,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-08-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-68},"pfs_months":12.85},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.0,"censored":false},"longitudinal_labs":[{"date":"2021-06-16","hemoglobin_g_dL":15.1,"wbc_k_uL":9.3,"platelets_k_uL":296,"creatinine_mg_dL":1.1,"alt_U_L":54},{"date":"2022-02-11","hemoglobin_g_dL":10.3,"wbc_k_uL":7.2,"platelets_k_uL":273,"creatinine_mg_dL":0.81,"alt_U_L":93},{"date":"2022-09-27","hemoglobin_g_dL":12.0,"wbc_k_uL":3.4,"platelets_k_uL":210,"creatinine_mg_dL":1.25,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_1853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":72,"sex":"female","bmi":36.9,"smoking_pack_years":64,"ecog_performance_status":2,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-02-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-44},"pfs_months":4.47},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":12.6,"censored":false},"longitudinal_labs":[{"date":"2023-12-04","hemoglobin_g_dL":12.7,"wbc_k_uL":8.6,"platelets_k_uL":175,"creatinine_mg_dL":0.68,"alt_U_L":44},{"date":"2024-08-05","hemoglobin_g_dL":12.1,"wbc_k_uL":8.5,"platelets_k_uL":258,"creatinine_mg_dL":0.85,"alt_U_L":72},{"date":"2024-06-26","hemoglobin_g_dL":9.6,"wbc_k_uL":3.5,"platelets_k_uL":341,"creatinine_mg_dL":0.94,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_1854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":72,"sex":"male","bmi":32.3,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-59},"pfs_months":18.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2021-04-06","hemoglobin_g_dL":13.8,"wbc_k_uL":9.7,"platelets_k_uL":370,"creatinine_mg_dL":0.95,"alt_U_L":50},{"date":"2021-10-23","hemoglobin_g_dL":11.3,"wbc_k_uL":7.6,"platelets_k_uL":277,"creatinine_mg_dL":1.2,"alt_U_L":23},{"date":"2022-12-01","hemoglobin_g_dL":9.7,"wbc_k_uL":3.8,"platelets_k_uL":198,"creatinine_mg_dL":1.05,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_1855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":73,"sex":"male","bmi":25.2,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-10-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-52},"pfs_months":37.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":64.0,"censored":true},"longitudinal_labs":[{"date":"2023-09-17","hemoglobin_g_dL":15.3,"wbc_k_uL":8.1,"platelets_k_uL":427,"creatinine_mg_dL":0.95,"alt_U_L":80},{"date":"2024-04-04","hemoglobin_g_dL":13.3,"wbc_k_uL":6.8,"platelets_k_uL":347,"creatinine_mg_dL":1.55,"alt_U_L":85},{"date":"2027-01-17","hemoglobin_g_dL":10.0,"wbc_k_uL":3.4,"platelets_k_uL":181,"creatinine_mg_dL":1.49,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_1856","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":50,"sex":"female","bmi":21.6,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-12-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-62},"pfs_months":29.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":41.1,"censored":false},"longitudinal_labs":[{"date":"2025-10-08","hemoglobin_g_dL":14.6,"wbc_k_uL":9.9,"platelets_k_uL":211,"creatinine_mg_dL":0.89,"alt_U_L":59},{"date":"2026-06-13","hemoglobin_g_dL":12.4,"wbc_k_uL":6.7,"platelets_k_uL":211,"creatinine_mg_dL":1.29,"alt_U_L":73},{"date":"2028-07-12","hemoglobin_g_dL":12.9,"wbc_k_uL":7.0,"platelets_k_uL":161,"creatinine_mg_dL":1.7,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_1857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":68,"sex":"female","bmi":19.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-43},"pfs_months":26.45},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":false},"longitudinal_labs":[{"date":"2022-07-28","hemoglobin_g_dL":14.1,"wbc_k_uL":8.5,"platelets_k_uL":431,"creatinine_mg_dL":0.8,"alt_U_L":12},{"date":"2023-03-11","hemoglobin_g_dL":10.8,"wbc_k_uL":5.3,"platelets_k_uL":310,"creatinine_mg_dL":1.17,"alt_U_L":112},{"date":"2025-01-15","hemoglobin_g_dL":10.7,"wbc_k_uL":7.7,"platelets_k_uL":307,"creatinine_mg_dL":1.02,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_1858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":86,"sex":"female","bmi":27.7,"smoking_pack_years":49,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-07-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-34},"pfs_months":30.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":47.5,"censored":true},"longitudinal_labs":[{"date":"2024-05-07","hemoglobin_g_dL":15.0,"wbc_k_uL":5.2,"platelets_k_uL":386,"creatinine_mg_dL":1.03,"alt_U_L":78},{"date":"2025-01-11","hemoglobin_g_dL":13.2,"wbc_k_uL":8.6,"platelets_k_uL":341,"creatinine_mg_dL":0.75,"alt_U_L":99},{"date":"2027-02-27","hemoglobin_g_dL":12.0,"wbc_k_uL":5.5,"platelets_k_uL":227,"creatinine_mg_dL":1.21,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_1859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":76,"sex":"female","bmi":30.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-57},"pfs_months":18.89},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":true},"longitudinal_labs":[{"date":"2020-06-27","hemoglobin_g_dL":12.0,"wbc_k_uL":4.7,"platelets_k_uL":283,"creatinine_mg_dL":0.9,"alt_U_L":16},{"date":"2021-02-21","hemoglobin_g_dL":10.6,"wbc_k_uL":5.3,"platelets_k_uL":232,"creatinine_mg_dL":0.82,"alt_U_L":31},{"date":"2022-05-17","hemoglobin_g_dL":10.0,"wbc_k_uL":7.5,"platelets_k_uL":221,"creatinine_mg_dL":1.13,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_1860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":51,"sex":"male","bmi":23.8,"smoking_pack_years":17,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-02-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-73},"pfs_months":13.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.9,"censored":false},"longitudinal_labs":[{"date":"2025-01-04","hemoglobin_g_dL":13.9,"wbc_k_uL":6.5,"platelets_k_uL":437,"creatinine_mg_dL":1.21,"alt_U_L":70},{"date":"2025-08-27","hemoglobin_g_dL":12.9,"wbc_k_uL":4.6,"platelets_k_uL":361,"creatinine_mg_dL":1.49,"alt_U_L":113},{"date":"2026-05-14","hemoglobin_g_dL":10.8,"wbc_k_uL":5.8,"platelets_k_uL":218,"creatinine_mg_dL":1.0,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_1861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":51,"sex":"male","bmi":31.7,"smoking_pack_years":33,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-09-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-71},"pfs_months":33.18},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":64.0,"censored":false},"longitudinal_labs":[{"date":"2025-07-24","hemoglobin_g_dL":12.9,"wbc_k_uL":7.3,"platelets_k_uL":203,"creatinine_mg_dL":0.64,"alt_U_L":53},{"date":"2026-03-04","hemoglobin_g_dL":13.0,"wbc_k_uL":4.5,"platelets_k_uL":328,"creatinine_mg_dL":1.31,"alt_U_L":32},{"date":"2028-07-15","hemoglobin_g_dL":10.9,"wbc_k_uL":6.3,"platelets_k_uL":198,"creatinine_mg_dL":0.9,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_1862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":63,"sex":"male","bmi":28.7,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-08-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-65},"pfs_months":12.19},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":21.5,"censored":false},"longitudinal_labs":[{"date":"2024-07-14","hemoglobin_g_dL":13.0,"wbc_k_uL":10.8,"platelets_k_uL":371,"creatinine_mg_dL":1.08,"alt_U_L":14},{"date":"2025-02-07","hemoglobin_g_dL":10.4,"wbc_k_uL":6.2,"platelets_k_uL":344,"creatinine_mg_dL":0.89,"alt_U_L":55},{"date":"2025-09-18","hemoglobin_g_dL":10.1,"wbc_k_uL":8.0,"platelets_k_uL":232,"creatinine_mg_dL":0.89,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_1863","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":62,"sex":"male","bmi":24.3,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-11-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-84},"pfs_months":4.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":14.2,"censored":false},"longitudinal_labs":[{"date":"2021-10-24","hemoglobin_g_dL":13.6,"wbc_k_uL":9.3,"platelets_k_uL":343,"creatinine_mg_dL":1.02,"alt_U_L":65},{"date":"2022-05-10","hemoglobin_g_dL":10.1,"wbc_k_uL":5.1,"platelets_k_uL":134,"creatinine_mg_dL":1.19,"alt_U_L":112},{"date":"2022-06-02","hemoglobin_g_dL":11.1,"wbc_k_uL":5.5,"platelets_k_uL":107,"creatinine_mg_dL":1.74,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_1864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":62,"sex":"female","bmi":20.5,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-68},"pfs_months":22.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.7,"censored":false},"longitudinal_labs":[{"date":"2021-08-23","hemoglobin_g_dL":15.2,"wbc_k_uL":9.9,"platelets_k_uL":239,"creatinine_mg_dL":0.93,"alt_U_L":56},{"date":"2022-03-14","hemoglobin_g_dL":11.4,"wbc_k_uL":4.6,"platelets_k_uL":229,"creatinine_mg_dL":0.99,"alt_U_L":117},{"date":"2023-09-29","hemoglobin_g_dL":11.6,"wbc_k_uL":3.0,"platelets_k_uL":223,"creatinine_mg_dL":1.61,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_1865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":53,"sex":"female","bmi":26.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-45},"pfs_months":14.75},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.7,"censored":false},"longitudinal_labs":[{"date":"2022-07-19","hemoglobin_g_dL":12.6,"wbc_k_uL":6.4,"platelets_k_uL":258,"creatinine_mg_dL":0.66,"alt_U_L":58},{"date":"2023-02-03","hemoglobin_g_dL":11.6,"wbc_k_uL":4.6,"platelets_k_uL":376,"creatinine_mg_dL":1.13,"alt_U_L":51},{"date":"2023-11-26","hemoglobin_g_dL":12.8,"wbc_k_uL":7.9,"platelets_k_uL":252,"creatinine_mg_dL":0.84,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_1866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":84,"sex":"female","bmi":26.1,"smoking_pack_years":54,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-03-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-77},"pfs_months":7.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":13.0,"censored":false},"longitudinal_labs":[{"date":"2023-01-26","hemoglobin_g_dL":13.9,"wbc_k_uL":7.1,"platelets_k_uL":450,"creatinine_mg_dL":0.95,"alt_U_L":47},{"date":"2023-08-30","hemoglobin_g_dL":12.3,"wbc_k_uL":5.2,"platelets_k_uL":325,"creatinine_mg_dL":1.07,"alt_U_L":18},{"date":"2023-12-03","hemoglobin_g_dL":10.0,"wbc_k_uL":3.7,"platelets_k_uL":305,"creatinine_mg_dL":1.1,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_1867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":48,"sex":"female","bmi":28.1,"smoking_pack_years":15,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-80},"pfs_months":39.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.6,"censored":false},"longitudinal_labs":[{"date":"2021-01-18","hemoglobin_g_dL":11.5,"wbc_k_uL":8.6,"platelets_k_uL":170,"creatinine_mg_dL":0.89,"alt_U_L":54},{"date":"2021-09-19","hemoglobin_g_dL":11.4,"wbc_k_uL":7.4,"platelets_k_uL":217,"creatinine_mg_dL":1.44,"alt_U_L":60},{"date":"2024-07-18","hemoglobin_g_dL":11.8,"wbc_k_uL":7.6,"platelets_k_uL":278,"creatinine_mg_dL":1.36,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_1868","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":84,"sex":"male","bmi":30.3,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-56},"pfs_months":19.65},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.1,"censored":false},"longitudinal_labs":[{"date":"2024-08-23","hemoglobin_g_dL":13.9,"wbc_k_uL":7.0,"platelets_k_uL":274,"creatinine_mg_dL":1.14,"alt_U_L":77},{"date":"2025-03-12","hemoglobin_g_dL":12.6,"wbc_k_uL":7.8,"platelets_k_uL":193,"creatinine_mg_dL":1.18,"alt_U_L":107},{"date":"2026-05-26","hemoglobin_g_dL":11.0,"wbc_k_uL":7.8,"platelets_k_uL":251,"creatinine_mg_dL":1.5,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_1869","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":58,"sex":"male","bmi":32.1,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-03-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-64},"pfs_months":21.72},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":false},"longitudinal_labs":[{"date":"2025-01-25","hemoglobin_g_dL":12.3,"wbc_k_uL":4.8,"platelets_k_uL":450,"creatinine_mg_dL":1.14,"alt_U_L":70},{"date":"2025-09-23","hemoglobin_g_dL":13.6,"wbc_k_uL":6.4,"platelets_k_uL":246,"creatinine_mg_dL":1.23,"alt_U_L":100},{"date":"2027-02-06","hemoglobin_g_dL":10.5,"wbc_k_uL":5.9,"platelets_k_uL":141,"creatinine_mg_dL":1.12,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_1870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":88,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-02-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-84},"pfs_months":12.35},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.3,"censored":false},"longitudinal_labs":[{"date":"2024-01-01","hemoglobin_g_dL":11.7,"wbc_k_uL":5.4,"platelets_k_uL":376,"creatinine_mg_dL":0.68,"alt_U_L":60},{"date":"2024-08-03","hemoglobin_g_dL":11.6,"wbc_k_uL":4.3,"platelets_k_uL":315,"creatinine_mg_dL":1.24,"alt_U_L":118},{"date":"2025-03-18","hemoglobin_g_dL":11.1,"wbc_k_uL":4.5,"platelets_k_uL":322,"creatinine_mg_dL":1.94,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_1871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":60,"sex":"female","bmi":36.7,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-07-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-64},"pfs_months":39.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":65.3,"censored":false},"longitudinal_labs":[{"date":"2024-05-06","hemoglobin_g_dL":12.1,"wbc_k_uL":4.7,"platelets_k_uL":173,"creatinine_mg_dL":0.82,"alt_U_L":67},{"date":"2025-01-07","hemoglobin_g_dL":13.2,"wbc_k_uL":5.6,"platelets_k_uL":269,"creatinine_mg_dL":0.76,"alt_U_L":92},{"date":"2027-12-10","hemoglobin_g_dL":10.8,"wbc_k_uL":5.9,"platelets_k_uL":225,"creatinine_mg_dL":1.9,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_1872","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":83,"sex":"male","bmi":31.5,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-09-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-30},"pfs_months":28.65},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":true},"longitudinal_labs":[{"date":"2020-08-08","hemoglobin_g_dL":14.6,"wbc_k_uL":6.6,"platelets_k_uL":225,"creatinine_mg_dL":0.93,"alt_U_L":71},{"date":"2021-03-10","hemoglobin_g_dL":13.3,"wbc_k_uL":9.0,"platelets_k_uL":323,"creatinine_mg_dL":1.13,"alt_U_L":29},{"date":"2023-02-13","hemoglobin_g_dL":11.2,"wbc_k_uL":3.1,"platelets_k_uL":279,"creatinine_mg_dL":1.64,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_1873","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":52,"sex":"female","bmi":27.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-70},"pfs_months":15.87},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-10","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":true},"longitudinal_labs":[{"date":"2022-04-23","hemoglobin_g_dL":13.3,"wbc_k_uL":5.3,"platelets_k_uL":172,"creatinine_mg_dL":0.64,"alt_U_L":49},{"date":"2022-12-12","hemoglobin_g_dL":11.2,"wbc_k_uL":8.6,"platelets_k_uL":178,"creatinine_mg_dL":0.75,"alt_U_L":98},{"date":"2023-12-10","hemoglobin_g_dL":12.5,"wbc_k_uL":3.3,"platelets_k_uL":313,"creatinine_mg_dL":1.27,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_1874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":58,"sex":"female","bmi":32.8,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-08-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-58},"pfs_months":13.77},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.2,"censored":true},"longitudinal_labs":[{"date":"2023-06-27","hemoglobin_g_dL":14.8,"wbc_k_uL":5.9,"platelets_k_uL":162,"creatinine_mg_dL":1.14,"alt_U_L":33},{"date":"2024-02-02","hemoglobin_g_dL":11.2,"wbc_k_uL":4.9,"platelets_k_uL":319,"creatinine_mg_dL":1.25,"alt_U_L":40},{"date":"2024-11-13","hemoglobin_g_dL":12.4,"wbc_k_uL":6.3,"platelets_k_uL":216,"creatinine_mg_dL":1.26,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_1875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":84,"sex":"male","bmi":37.8,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-05-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-74},"pfs_months":14.06},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-08-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.6,"censored":false},"longitudinal_labs":[{"date":"2020-04-11","hemoglobin_g_dL":13.4,"wbc_k_uL":7.9,"platelets_k_uL":259,"creatinine_mg_dL":0.68,"alt_U_L":37},{"date":"2020-11-04","hemoglobin_g_dL":13.3,"wbc_k_uL":5.2,"platelets_k_uL":348,"creatinine_mg_dL":1.07,"alt_U_L":47},{"date":"2021-08-29","hemoglobin_g_dL":12.8,"wbc_k_uL":6.8,"platelets_k_uL":334,"creatinine_mg_dL":1.26,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_1876","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":50,"sex":"female","bmi":37.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-62},"pfs_months":36.04},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":59.2,"censored":false},"longitudinal_labs":[{"date":"2023-07-04","hemoglobin_g_dL":14.4,"wbc_k_uL":4.6,"platelets_k_uL":203,"creatinine_mg_dL":1.08,"alt_U_L":78},{"date":"2024-02-15","hemoglobin_g_dL":12.6,"wbc_k_uL":5.1,"platelets_k_uL":322,"creatinine_mg_dL":1.29,"alt_U_L":72},{"date":"2026-08-24","hemoglobin_g_dL":11.4,"wbc_k_uL":7.8,"platelets_k_uL":253,"creatinine_mg_dL":1.05,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_1877","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":84,"sex":"male","bmi":30.8,"smoking_pack_years":66,"ecog_performance_status":0,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-03-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-79},"pfs_months":25.72},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.1,"censored":false},"longitudinal_labs":[{"date":"2025-01-22","hemoglobin_g_dL":13.6,"wbc_k_uL":7.6,"platelets_k_uL":175,"creatinine_mg_dL":1.0,"alt_U_L":38},{"date":"2025-09-15","hemoglobin_g_dL":12.0,"wbc_k_uL":8.5,"platelets_k_uL":369,"creatinine_mg_dL":1.01,"alt_U_L":101},{"date":"2027-07-03","hemoglobin_g_dL":10.2,"wbc_k_uL":6.8,"platelets_k_uL":167,"creatinine_mg_dL":1.77,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_1878","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":69,"sex":"female","bmi":30.0,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-11-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-65},"pfs_months":30.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.7,"censored":false},"longitudinal_labs":[{"date":"2020-09-20","hemoglobin_g_dL":13.1,"wbc_k_uL":10.4,"platelets_k_uL":417,"creatinine_mg_dL":0.62,"alt_U_L":40},{"date":"2021-05-23","hemoglobin_g_dL":11.4,"wbc_k_uL":4.4,"platelets_k_uL":291,"creatinine_mg_dL":1.28,"alt_U_L":119},{"date":"2023-07-01","hemoglobin_g_dL":12.0,"wbc_k_uL":6.5,"platelets_k_uL":124,"creatinine_mg_dL":0.95,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_1879","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":66,"sex":"male","bmi":23.3,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-12-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-69},"pfs_months":21.59},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":false},"longitudinal_labs":[{"date":"2024-10-16","hemoglobin_g_dL":14.7,"wbc_k_uL":9.5,"platelets_k_uL":349,"creatinine_mg_dL":0.86,"alt_U_L":43},{"date":"2025-06-16","hemoglobin_g_dL":10.6,"wbc_k_uL":4.5,"platelets_k_uL":375,"creatinine_mg_dL":1.18,"alt_U_L":86},{"date":"2026-10-17","hemoglobin_g_dL":12.0,"wbc_k_uL":4.8,"platelets_k_uL":273,"creatinine_mg_dL":1.36,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_1880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":51,"sex":"female","bmi":23.5,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-08-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-53},"pfs_months":38.51},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":62.3,"censored":false},"longitudinal_labs":[{"date":"2023-07-15","hemoglobin_g_dL":13.0,"wbc_k_uL":7.7,"platelets_k_uL":168,"creatinine_mg_dL":1.02,"alt_U_L":66},{"date":"2024-02-26","hemoglobin_g_dL":10.7,"wbc_k_uL":7.6,"platelets_k_uL":121,"creatinine_mg_dL":0.95,"alt_U_L":77},{"date":"2026-12-04","hemoglobin_g_dL":12.4,"wbc_k_uL":6.9,"platelets_k_uL":350,"creatinine_mg_dL":1.69,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_1881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":57,"sex":"female","bmi":20.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-61},"pfs_months":15.61},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.2,"censored":false},"longitudinal_labs":[{"date":"2024-04-19","hemoglobin_g_dL":12.6,"wbc_k_uL":9.2,"platelets_k_uL":335,"creatinine_mg_dL":0.65,"alt_U_L":69},{"date":"2024-11-25","hemoglobin_g_dL":14.0,"wbc_k_uL":7.2,"platelets_k_uL":243,"creatinine_mg_dL":0.87,"alt_U_L":118},{"date":"2025-10-26","hemoglobin_g_dL":10.8,"wbc_k_uL":5.2,"platelets_k_uL":333,"creatinine_mg_dL":0.92,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_1882","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":63,"sex":"male","bmi":25.8,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-82},"pfs_months":16.43},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.4,"censored":false},"longitudinal_labs":[{"date":"2020-10-13","hemoglobin_g_dL":12.7,"wbc_k_uL":8.9,"platelets_k_uL":398,"creatinine_mg_dL":0.99,"alt_U_L":30},{"date":"2021-05-27","hemoglobin_g_dL":13.5,"wbc_k_uL":5.6,"platelets_k_uL":184,"creatinine_mg_dL":1.52,"alt_U_L":116},{"date":"2022-05-12","hemoglobin_g_dL":12.0,"wbc_k_uL":5.5,"platelets_k_uL":190,"creatinine_mg_dL":1.02,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_1883","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":87,"sex":"female","bmi":28.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-01-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-78},"pfs_months":21.45},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":true},"longitudinal_labs":[{"date":"2022-11-16","hemoglobin_g_dL":11.5,"wbc_k_uL":9.1,"platelets_k_uL":307,"creatinine_mg_dL":0.66,"alt_U_L":79},{"date":"2023-07-04","hemoglobin_g_dL":13.0,"wbc_k_uL":6.4,"platelets_k_uL":243,"creatinine_mg_dL":1.43,"alt_U_L":66},{"date":"2024-12-03","hemoglobin_g_dL":12.6,"wbc_k_uL":3.4,"platelets_k_uL":104,"creatinine_mg_dL":1.74,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_1884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":71,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-47},"pfs_months":26.71},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.3,"censored":false},"longitudinal_labs":[{"date":"2023-05-13","hemoglobin_g_dL":13.5,"wbc_k_uL":6.1,"platelets_k_uL":312,"creatinine_mg_dL":1.01,"alt_U_L":62},{"date":"2023-12-13","hemoglobin_g_dL":13.6,"wbc_k_uL":5.0,"platelets_k_uL":290,"creatinine_mg_dL":0.79,"alt_U_L":92},{"date":"2025-10-27","hemoglobin_g_dL":11.1,"wbc_k_uL":4.1,"platelets_k_uL":191,"creatinine_mg_dL":1.91,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_1885","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":88,"sex":"male","bmi":32.7,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-11-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-43},"pfs_months":12.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":false},"longitudinal_labs":[{"date":"2021-10-18","hemoglobin_g_dL":13.8,"wbc_k_uL":8.2,"platelets_k_uL":289,"creatinine_mg_dL":0.79,"alt_U_L":18},{"date":"2022-05-23","hemoglobin_g_dL":10.0,"wbc_k_uL":7.8,"platelets_k_uL":158,"creatinine_mg_dL":1.03,"alt_U_L":32},{"date":"2023-01-19","hemoglobin_g_dL":11.5,"wbc_k_uL":5.3,"platelets_k_uL":254,"creatinine_mg_dL":1.55,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_1886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":86,"sex":"female","bmi":34.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-68},"pfs_months":14.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.8,"censored":false},"longitudinal_labs":[{"date":"2021-02-08","hemoglobin_g_dL":15.1,"wbc_k_uL":5.7,"platelets_k_uL":308,"creatinine_mg_dL":1.19,"alt_U_L":50},{"date":"2021-09-18","hemoglobin_g_dL":13.7,"wbc_k_uL":7.7,"platelets_k_uL":303,"creatinine_mg_dL":1.26,"alt_U_L":86},{"date":"2022-08-09","hemoglobin_g_dL":11.8,"wbc_k_uL":6.1,"platelets_k_uL":199,"creatinine_mg_dL":1.54,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_1887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":56,"sex":"female","bmi":29.5,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2025-05-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-58},"pfs_months":26.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.8,"censored":false},"longitudinal_labs":[{"date":"2025-04-17","hemoglobin_g_dL":12.4,"wbc_k_uL":6.8,"platelets_k_uL":228,"creatinine_mg_dL":1.23,"alt_U_L":80},{"date":"2025-11-18","hemoglobin_g_dL":13.6,"wbc_k_uL":3.9,"platelets_k_uL":315,"creatinine_mg_dL":0.85,"alt_U_L":119},{"date":"2027-08-24","hemoglobin_g_dL":10.0,"wbc_k_uL":5.5,"platelets_k_uL":165,"creatinine_mg_dL":1.98,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_1888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":70,"sex":"male","bmi":18.6,"smoking_pack_years":28,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-05-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-36},"pfs_months":13.93},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.7,"censored":false},"longitudinal_labs":[{"date":"2021-04-04","hemoglobin_g_dL":13.2,"wbc_k_uL":9.3,"platelets_k_uL":170,"creatinine_mg_dL":1.07,"alt_U_L":27},{"date":"2021-11-15","hemoglobin_g_dL":10.2,"wbc_k_uL":8.0,"platelets_k_uL":131,"creatinine_mg_dL":0.78,"alt_U_L":111},{"date":"2022-09-12","hemoglobin_g_dL":11.2,"wbc_k_uL":6.4,"platelets_k_uL":200,"creatinine_mg_dL":1.87,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_1889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":63,"sex":"female","bmi":20.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-85},"pfs_months":29.31},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.4,"censored":false},"longitudinal_labs":[{"date":"2022-09-28","hemoglobin_g_dL":12.4,"wbc_k_uL":5.7,"platelets_k_uL":317,"creatinine_mg_dL":0.69,"alt_U_L":29},{"date":"2023-05-31","hemoglobin_g_dL":13.2,"wbc_k_uL":4.4,"platelets_k_uL":371,"creatinine_mg_dL":0.73,"alt_U_L":81},{"date":"2025-07-01","hemoglobin_g_dL":10.1,"wbc_k_uL":5.2,"platelets_k_uL":284,"creatinine_mg_dL":1.05,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_1890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":48,"sex":"male","bmi":32.1,"smoking_pack_years":53,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-04-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-45},"pfs_months":9.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":22.1,"censored":false},"longitudinal_labs":[{"date":"2021-03-04","hemoglobin_g_dL":15.4,"wbc_k_uL":6.4,"platelets_k_uL":396,"creatinine_mg_dL":0.62,"alt_U_L":21},{"date":"2021-09-30","hemoglobin_g_dL":14.0,"wbc_k_uL":5.4,"platelets_k_uL":380,"creatinine_mg_dL":1.43,"alt_U_L":64},{"date":"2022-02-03","hemoglobin_g_dL":12.9,"wbc_k_uL":6.8,"platelets_k_uL":287,"creatinine_mg_dL":1.07,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_1891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":86,"sex":"female","bmi":33.1,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-06-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-43},"pfs_months":42.87},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":67.7,"censored":false},"longitudinal_labs":[{"date":"2020-04-14","hemoglobin_g_dL":13.5,"wbc_k_uL":5.1,"platelets_k_uL":331,"creatinine_mg_dL":1.09,"alt_U_L":67},{"date":"2020-12-16","hemoglobin_g_dL":11.0,"wbc_k_uL":4.2,"platelets_k_uL":157,"creatinine_mg_dL":0.85,"alt_U_L":116},{"date":"2024-02-10","hemoglobin_g_dL":10.7,"wbc_k_uL":5.4,"platelets_k_uL":120,"creatinine_mg_dL":1.36,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_1892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":69,"sex":"female","bmi":22.4,"smoking_pack_years":79,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-02-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-38},"pfs_months":5.39},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":11.8,"censored":false},"longitudinal_labs":[{"date":"2023-01-11","hemoglobin_g_dL":13.4,"wbc_k_uL":8.3,"platelets_k_uL":268,"creatinine_mg_dL":0.64,"alt_U_L":38},{"date":"2023-08-07","hemoglobin_g_dL":11.7,"wbc_k_uL":6.8,"platelets_k_uL":376,"creatinine_mg_dL":1.22,"alt_U_L":20},{"date":"2023-07-30","hemoglobin_g_dL":11.2,"wbc_k_uL":5.3,"platelets_k_uL":239,"creatinine_mg_dL":1.62,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_1893","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":57,"sex":"male","bmi":34.7,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-09-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-54},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-01-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":6.9,"censored":false},"longitudinal_labs":[{"date":"2020-09-13","hemoglobin_g_dL":15.0,"wbc_k_uL":5.5,"platelets_k_uL":330,"creatinine_mg_dL":1.04,"alt_U_L":19},{"date":"2021-03-28","hemoglobin_g_dL":11.9,"wbc_k_uL":8.1,"platelets_k_uL":169,"creatinine_mg_dL":1.32,"alt_U_L":64},{"date":"2021-01-10","hemoglobin_g_dL":12.9,"wbc_k_uL":7.4,"platelets_k_uL":255,"creatinine_mg_dL":1.01,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_1894","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":76,"sex":"male","bmi":36.2,"smoking_pack_years":35,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-47},"pfs_months":45.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":72.5,"censored":false},"longitudinal_labs":[{"date":"2021-05-02","hemoglobin_g_dL":11.6,"wbc_k_uL":7.3,"platelets_k_uL":388,"creatinine_mg_dL":1.24,"alt_U_L":39},{"date":"2021-12-21","hemoglobin_g_dL":12.0,"wbc_k_uL":4.6,"platelets_k_uL":146,"creatinine_mg_dL":0.73,"alt_U_L":30},{"date":"2025-05-13","hemoglobin_g_dL":11.6,"wbc_k_uL":6.2,"platelets_k_uL":117,"creatinine_mg_dL":1.88,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_1895","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":85,"sex":"male","bmi":30.5,"smoking_pack_years":17,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-08-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-81},"pfs_months":12.78},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-31","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.7,"censored":false},"longitudinal_labs":[{"date":"2022-06-22","hemoglobin_g_dL":12.2,"wbc_k_uL":10.8,"platelets_k_uL":324,"creatinine_mg_dL":1.0,"alt_U_L":41},{"date":"2023-02-21","hemoglobin_g_dL":11.4,"wbc_k_uL":7.1,"platelets_k_uL":366,"creatinine_mg_dL":1.45,"alt_U_L":30},{"date":"2023-10-31","hemoglobin_g_dL":10.6,"wbc_k_uL":5.8,"platelets_k_uL":266,"creatinine_mg_dL":1.4,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_1896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":78,"sex":"female","bmi":35.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-84},"pfs_months":28.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.6,"censored":false},"longitudinal_labs":[{"date":"2024-07-21","hemoglobin_g_dL":14.4,"wbc_k_uL":6.8,"platelets_k_uL":229,"creatinine_mg_dL":0.99,"alt_U_L":79},{"date":"2025-03-16","hemoglobin_g_dL":13.6,"wbc_k_uL":4.0,"platelets_k_uL":286,"creatinine_mg_dL":0.79,"alt_U_L":78},{"date":"2027-03-31","hemoglobin_g_dL":11.3,"wbc_k_uL":6.3,"platelets_k_uL":227,"creatinine_mg_dL":1.03,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_1897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":57,"sex":"female","bmi":22.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-03-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-32},"pfs_months":14.52},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":true},"longitudinal_labs":[{"date":"2020-02-09","hemoglobin_g_dL":12.8,"wbc_k_uL":6.5,"platelets_k_uL":427,"creatinine_mg_dL":0.64,"alt_U_L":22},{"date":"2020-09-11","hemoglobin_g_dL":13.1,"wbc_k_uL":4.4,"platelets_k_uL":269,"creatinine_mg_dL":0.72,"alt_U_L":105},{"date":"2021-07-08","hemoglobin_g_dL":11.3,"wbc_k_uL":4.0,"platelets_k_uL":298,"creatinine_mg_dL":1.24,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_1898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":85,"sex":"female","bmi":35.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-39},"pfs_months":26.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":48.9,"censored":true},"longitudinal_labs":[{"date":"2025-01-14","hemoglobin_g_dL":13.5,"wbc_k_uL":8.0,"platelets_k_uL":403,"creatinine_mg_dL":1.04,"alt_U_L":30},{"date":"2025-09-16","hemoglobin_g_dL":13.8,"wbc_k_uL":7.3,"platelets_k_uL":141,"creatinine_mg_dL":1.0,"alt_U_L":34},{"date":"2027-06-09","hemoglobin_g_dL":10.3,"wbc_k_uL":6.3,"platelets_k_uL":212,"creatinine_mg_dL":1.31,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_1899","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":70,"sex":"male","bmi":36.9,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-12-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-60},"pfs_months":29.5},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.9,"censored":false},"longitudinal_labs":[{"date":"2025-10-08","hemoglobin_g_dL":11.6,"wbc_k_uL":7.3,"platelets_k_uL":187,"creatinine_mg_dL":0.9,"alt_U_L":65},{"date":"2026-06-04","hemoglobin_g_dL":12.4,"wbc_k_uL":5.3,"platelets_k_uL":246,"creatinine_mg_dL":0.93,"alt_U_L":20},{"date":"2028-07-05","hemoglobin_g_dL":11.8,"wbc_k_uL":6.8,"platelets_k_uL":235,"creatinine_mg_dL":1.68,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_1900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":55,"sex":"female","bmi":35.2,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-11-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-79},"pfs_months":6.01},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.5,"censored":true},"longitudinal_labs":[{"date":"2023-10-11","hemoglobin_g_dL":14.2,"wbc_k_uL":6.6,"platelets_k_uL":187,"creatinine_mg_dL":0.67,"alt_U_L":34},{"date":"2024-05-21","hemoglobin_g_dL":10.6,"wbc_k_uL":7.5,"platelets_k_uL":163,"creatinine_mg_dL":1.33,"alt_U_L":82},{"date":"2024-06-15","hemoglobin_g_dL":11.6,"wbc_k_uL":5.9,"platelets_k_uL":179,"creatinine_mg_dL":1.93,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_1901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":61,"sex":"female","bmi":24.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-44},"pfs_months":18.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.6,"censored":false},"longitudinal_labs":[{"date":"2020-04-14","hemoglobin_g_dL":12.2,"wbc_k_uL":4.7,"platelets_k_uL":404,"creatinine_mg_dL":0.83,"alt_U_L":63},{"date":"2020-11-26","hemoglobin_g_dL":11.9,"wbc_k_uL":8.3,"platelets_k_uL":324,"creatinine_mg_dL":1.36,"alt_U_L":29},{"date":"2022-02-09","hemoglobin_g_dL":10.2,"wbc_k_uL":4.1,"platelets_k_uL":230,"creatinine_mg_dL":1.07,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_1902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":77,"sex":"male","bmi":24.8,"smoking_pack_years":33,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-68},"pfs_months":18.76},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":24.6,"censored":true},"longitudinal_labs":[{"date":"2025-07-16","hemoglobin_g_dL":11.6,"wbc_k_uL":10.6,"platelets_k_uL":419,"creatinine_mg_dL":1.22,"alt_U_L":28},{"date":"2026-02-25","hemoglobin_g_dL":13.4,"wbc_k_uL":4.1,"platelets_k_uL":367,"creatinine_mg_dL":1.19,"alt_U_L":61},{"date":"2027-03-27","hemoglobin_g_dL":11.4,"wbc_k_uL":4.2,"platelets_k_uL":194,"creatinine_mg_dL":1.78,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_1903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.2,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":78,"sex":"female","bmi":34.8,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-43},"pfs_months":17.74},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":28.1,"censored":false},"longitudinal_labs":[{"date":"2020-06-07","hemoglobin_g_dL":11.7,"wbc_k_uL":8.7,"platelets_k_uL":301,"creatinine_mg_dL":0.82,"alt_U_L":73},{"date":"2021-01-04","hemoglobin_g_dL":13.1,"wbc_k_uL":6.9,"platelets_k_uL":182,"creatinine_mg_dL":1.14,"alt_U_L":46},{"date":"2022-01-30","hemoglobin_g_dL":12.9,"wbc_k_uL":3.2,"platelets_k_uL":273,"creatinine_mg_dL":1.89,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_1904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":73,"sex":"female","bmi":36.5,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-53},"pfs_months":33.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.2,"censored":false},"longitudinal_labs":[{"date":"2022-05-25","hemoglobin_g_dL":14.0,"wbc_k_uL":9.2,"platelets_k_uL":290,"creatinine_mg_dL":0.93,"alt_U_L":67},{"date":"2023-01-28","hemoglobin_g_dL":12.7,"wbc_k_uL":8.6,"platelets_k_uL":226,"creatinine_mg_dL":0.97,"alt_U_L":94},{"date":"2025-07-19","hemoglobin_g_dL":11.8,"wbc_k_uL":3.2,"platelets_k_uL":274,"creatinine_mg_dL":1.86,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_1905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":60,"sex":"female","bmi":28.6,"smoking_pack_years":56,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-03-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-33},"pfs_months":13.73},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":18.6,"censored":true},"longitudinal_labs":[{"date":"2022-02-18","hemoglobin_g_dL":12.3,"wbc_k_uL":6.6,"platelets_k_uL":396,"creatinine_mg_dL":0.72,"alt_U_L":34},{"date":"2022-09-09","hemoglobin_g_dL":12.2,"wbc_k_uL":6.4,"platelets_k_uL":326,"creatinine_mg_dL":1.44,"alt_U_L":113},{"date":"2023-06-09","hemoglobin_g_dL":11.1,"wbc_k_uL":6.5,"platelets_k_uL":315,"creatinine_mg_dL":1.6,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_1906","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":58,"sex":"female","bmi":31.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-51},"pfs_months":23.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.2,"censored":false},"longitudinal_labs":[{"date":"2024-04-23","hemoglobin_g_dL":15.2,"wbc_k_uL":7.6,"platelets_k_uL":202,"creatinine_mg_dL":0.89,"alt_U_L":68},{"date":"2024-11-14","hemoglobin_g_dL":10.0,"wbc_k_uL":7.5,"platelets_k_uL":317,"creatinine_mg_dL":1.17,"alt_U_L":19},{"date":"2026-06-21","hemoglobin_g_dL":10.9,"wbc_k_uL":5.5,"platelets_k_uL":208,"creatinine_mg_dL":1.61,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_1907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":80,"sex":"female","bmi":26.3,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-12-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-81},"pfs_months":25.2},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.9,"censored":true},"longitudinal_labs":[{"date":"2021-12-05","hemoglobin_g_dL":15.4,"wbc_k_uL":6.9,"platelets_k_uL":424,"creatinine_mg_dL":1.19,"alt_U_L":13},{"date":"2022-06-29","hemoglobin_g_dL":12.8,"wbc_k_uL":7.9,"platelets_k_uL":178,"creatinine_mg_dL":1.39,"alt_U_L":15},{"date":"2024-03-15","hemoglobin_g_dL":12.1,"wbc_k_uL":3.4,"platelets_k_uL":157,"creatinine_mg_dL":1.96,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_1908","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":78,"sex":"female","bmi":31.9,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-11-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-74},"pfs_months":30.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":49.8,"censored":false},"longitudinal_labs":[{"date":"2021-09-03","hemoglobin_g_dL":12.0,"wbc_k_uL":4.9,"platelets_k_uL":345,"creatinine_mg_dL":0.65,"alt_U_L":46},{"date":"2022-05-02","hemoglobin_g_dL":12.7,"wbc_k_uL":6.0,"platelets_k_uL":361,"creatinine_mg_dL":1.25,"alt_U_L":120},{"date":"2024-05-10","hemoglobin_g_dL":10.6,"wbc_k_uL":7.5,"platelets_k_uL":228,"creatinine_mg_dL":1.86,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_1909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":52,"sex":"female","bmi":33.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-12-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-65},"pfs_months":31.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":47.9,"censored":false},"longitudinal_labs":[{"date":"2024-11-27","hemoglobin_g_dL":12.4,"wbc_k_uL":7.3,"platelets_k_uL":171,"creatinine_mg_dL":0.76,"alt_U_L":64},{"date":"2025-06-14","hemoglobin_g_dL":13.0,"wbc_k_uL":8.7,"platelets_k_uL":201,"creatinine_mg_dL":1.33,"alt_U_L":76},{"date":"2027-09-21","hemoglobin_g_dL":10.9,"wbc_k_uL":7.0,"platelets_k_uL":298,"creatinine_mg_dL":1.85,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_1910","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":51,"sex":"female","bmi":36.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-34},"pfs_months":24.84},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.0,"censored":true},"longitudinal_labs":[{"date":"2022-09-22","hemoglobin_g_dL":15.4,"wbc_k_uL":11.0,"platelets_k_uL":222,"creatinine_mg_dL":1.29,"alt_U_L":16},{"date":"2023-05-02","hemoglobin_g_dL":13.6,"wbc_k_uL":7.3,"platelets_k_uL":348,"creatinine_mg_dL":1.35,"alt_U_L":76},{"date":"2024-12-19","hemoglobin_g_dL":10.6,"wbc_k_uL":5.3,"platelets_k_uL":275,"creatinine_mg_dL":0.89,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_1911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":84,"sex":"female","bmi":29.6,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-45},"pfs_months":10.35},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-06-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":21.0,"censored":true},"longitudinal_labs":[{"date":"2020-06-21","hemoglobin_g_dL":14.7,"wbc_k_uL":5.5,"platelets_k_uL":151,"creatinine_mg_dL":0.72,"alt_U_L":78},{"date":"2021-01-07","hemoglobin_g_dL":10.9,"wbc_k_uL":4.0,"platelets_k_uL":123,"creatinine_mg_dL":0.93,"alt_U_L":90},{"date":"2021-06-30","hemoglobin_g_dL":10.1,"wbc_k_uL":7.0,"platelets_k_uL":201,"creatinine_mg_dL":1.94,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_1912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":74,"sex":"female","bmi":24.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-49},"pfs_months":25.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":false},"longitudinal_labs":[{"date":"2020-11-22","hemoglobin_g_dL":13.7,"wbc_k_uL":8.7,"platelets_k_uL":166,"creatinine_mg_dL":0.86,"alt_U_L":24},{"date":"2021-06-16","hemoglobin_g_dL":12.7,"wbc_k_uL":8.1,"platelets_k_uL":322,"creatinine_mg_dL":1.05,"alt_U_L":90},{"date":"2023-03-19","hemoglobin_g_dL":9.5,"wbc_k_uL":4.0,"platelets_k_uL":106,"creatinine_mg_dL":1.93,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_1913","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":62,"sex":"female","bmi":21.5,"smoking_pack_years":79,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-49},"pfs_months":24.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.8,"censored":true},"longitudinal_labs":[{"date":"2024-08-14","hemoglobin_g_dL":12.5,"wbc_k_uL":10.1,"platelets_k_uL":203,"creatinine_mg_dL":1.16,"alt_U_L":27},{"date":"2025-03-28","hemoglobin_g_dL":12.8,"wbc_k_uL":4.6,"platelets_k_uL":169,"creatinine_mg_dL":1.58,"alt_U_L":75},{"date":"2026-12-04","hemoglobin_g_dL":11.5,"wbc_k_uL":6.2,"platelets_k_uL":340,"creatinine_mg_dL":1.77,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_1914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":84,"sex":"female","bmi":26.8,"smoking_pack_years":12,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-06-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-36},"pfs_months":25.59},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.6,"censored":false},"longitudinal_labs":[{"date":"2020-04-19","hemoglobin_g_dL":11.9,"wbc_k_uL":6.4,"platelets_k_uL":294,"creatinine_mg_dL":0.72,"alt_U_L":29},{"date":"2020-12-07","hemoglobin_g_dL":12.4,"wbc_k_uL":8.1,"platelets_k_uL":297,"creatinine_mg_dL":0.97,"alt_U_L":43},{"date":"2022-08-12","hemoglobin_g_dL":10.7,"wbc_k_uL":3.3,"platelets_k_uL":350,"creatinine_mg_dL":1.67,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_1915","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":60,"sex":"female","bmi":23.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-32},"pfs_months":21.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":37.9,"censored":true},"longitudinal_labs":[{"date":"2025-05-04","hemoglobin_g_dL":11.7,"wbc_k_uL":7.6,"platelets_k_uL":186,"creatinine_mg_dL":0.64,"alt_U_L":28},{"date":"2026-01-04","hemoglobin_g_dL":13.5,"wbc_k_uL":7.1,"platelets_k_uL":184,"creatinine_mg_dL":1.3,"alt_U_L":92},{"date":"2027-05-18","hemoglobin_g_dL":12.2,"wbc_k_uL":3.3,"platelets_k_uL":112,"creatinine_mg_dL":1.65,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_1916","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":80,"sex":"male","bmi":31.1,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-06-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-39},"pfs_months":8.38},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":18.5,"censored":false},"longitudinal_labs":[{"date":"2023-04-15","hemoglobin_g_dL":12.2,"wbc_k_uL":6.2,"platelets_k_uL":444,"creatinine_mg_dL":0.85,"alt_U_L":19},{"date":"2023-12-02","hemoglobin_g_dL":12.5,"wbc_k_uL":5.1,"platelets_k_uL":368,"creatinine_mg_dL":1.44,"alt_U_L":39},{"date":"2024-03-01","hemoglobin_g_dL":10.9,"wbc_k_uL":5.7,"platelets_k_uL":161,"creatinine_mg_dL":0.98,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_1917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":80,"sex":"female","bmi":28.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-58},"pfs_months":18.53},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":true},"longitudinal_labs":[{"date":"2022-11-27","hemoglobin_g_dL":14.7,"wbc_k_uL":8.3,"platelets_k_uL":427,"creatinine_mg_dL":1.06,"alt_U_L":39},{"date":"2023-06-19","hemoglobin_g_dL":13.3,"wbc_k_uL":5.6,"platelets_k_uL":357,"creatinine_mg_dL":1.17,"alt_U_L":18},{"date":"2024-09-02","hemoglobin_g_dL":12.2,"wbc_k_uL":4.7,"platelets_k_uL":153,"creatinine_mg_dL":1.34,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_1918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":68,"sex":"female","bmi":31.6,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-05-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-61},"pfs_months":40.51},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":63.0,"censored":false},"longitudinal_labs":[{"date":"2023-05-04","hemoglobin_g_dL":13.1,"wbc_k_uL":5.3,"platelets_k_uL":178,"creatinine_mg_dL":0.83,"alt_U_L":72},{"date":"2023-11-17","hemoglobin_g_dL":13.1,"wbc_k_uL":6.2,"platelets_k_uL":247,"creatinine_mg_dL":1.19,"alt_U_L":24},{"date":"2026-11-24","hemoglobin_g_dL":10.7,"wbc_k_uL":3.4,"platelets_k_uL":286,"creatinine_mg_dL":1.57,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_1919","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":58,"sex":"female","bmi":32.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-40},"pfs_months":17.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":true},"longitudinal_labs":[{"date":"2023-03-26","hemoglobin_g_dL":14.9,"wbc_k_uL":9.0,"platelets_k_uL":347,"creatinine_mg_dL":1.14,"alt_U_L":40},{"date":"2023-10-21","hemoglobin_g_dL":12.4,"wbc_k_uL":5.0,"platelets_k_uL":357,"creatinine_mg_dL":1.23,"alt_U_L":77},{"date":"2024-10-22","hemoglobin_g_dL":12.8,"wbc_k_uL":5.4,"platelets_k_uL":127,"creatinine_mg_dL":1.98,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_1920","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":62,"sex":"female","bmi":24.6,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-09-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-49},"pfs_months":19.71},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.4,"censored":false},"longitudinal_labs":[{"date":"2025-07-18","hemoglobin_g_dL":14.2,"wbc_k_uL":9.9,"platelets_k_uL":325,"creatinine_mg_dL":0.98,"alt_U_L":72},{"date":"2026-03-19","hemoglobin_g_dL":11.3,"wbc_k_uL":5.3,"platelets_k_uL":141,"creatinine_mg_dL":1.05,"alt_U_L":116},{"date":"2027-06-10","hemoglobin_g_dL":11.9,"wbc_k_uL":7.7,"platelets_k_uL":232,"creatinine_mg_dL":0.89,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_1921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":80,"sex":"female","bmi":35.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-42},"pfs_months":20.14},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.7,"censored":true},"longitudinal_labs":[{"date":"2024-08-20","hemoglobin_g_dL":11.6,"wbc_k_uL":6.4,"platelets_k_uL":341,"creatinine_mg_dL":0.98,"alt_U_L":61},{"date":"2025-03-21","hemoglobin_g_dL":12.3,"wbc_k_uL":4.6,"platelets_k_uL":169,"creatinine_mg_dL":1.32,"alt_U_L":17},{"date":"2026-06-15","hemoglobin_g_dL":10.1,"wbc_k_uL":3.2,"platelets_k_uL":334,"creatinine_mg_dL":1.35,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_1922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":71,"sex":"female","bmi":27.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-02-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-84},"pfs_months":18.99},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":28.1,"censored":false},"longitudinal_labs":[{"date":"2025-12-16","hemoglobin_g_dL":11.9,"wbc_k_uL":9.3,"platelets_k_uL":274,"creatinine_mg_dL":0.96,"alt_U_L":69},{"date":"2026-08-03","hemoglobin_g_dL":12.6,"wbc_k_uL":4.5,"platelets_k_uL":239,"creatinine_mg_dL":1.02,"alt_U_L":49},{"date":"2027-10-24","hemoglobin_g_dL":11.5,"wbc_k_uL":5.1,"platelets_k_uL":241,"creatinine_mg_dL":1.03,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_1923","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":75,"sex":"female","bmi":31.4,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-06-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-47},"pfs_months":24.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":50.9,"censored":false},"longitudinal_labs":[{"date":"2020-04-18","hemoglobin_g_dL":12.3,"wbc_k_uL":7.6,"platelets_k_uL":258,"creatinine_mg_dL":0.8,"alt_U_L":51},{"date":"2020-12-19","hemoglobin_g_dL":13.3,"wbc_k_uL":7.7,"platelets_k_uL":132,"creatinine_mg_dL":1.02,"alt_U_L":108},{"date":"2022-07-20","hemoglobin_g_dL":11.5,"wbc_k_uL":5.2,"platelets_k_uL":238,"creatinine_mg_dL":0.87,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_1924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":76,"sex":"male","bmi":20.3,"smoking_pack_years":57,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-04-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-45},"pfs_months":35.81},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":61.0,"censored":false},"longitudinal_labs":[{"date":"2025-02-12","hemoglobin_g_dL":11.6,"wbc_k_uL":6.8,"platelets_k_uL":242,"creatinine_mg_dL":1.17,"alt_U_L":24},{"date":"2025-10-13","hemoglobin_g_dL":13.5,"wbc_k_uL":7.8,"platelets_k_uL":254,"creatinine_mg_dL":1.42,"alt_U_L":39},{"date":"2028-06-06","hemoglobin_g_dL":13.0,"wbc_k_uL":3.9,"platelets_k_uL":274,"creatinine_mg_dL":1.46,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_1925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":83,"sex":"male","bmi":33.2,"smoking_pack_years":80,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-63},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":10.1,"censored":true},"longitudinal_labs":[{"date":"2021-01-25","hemoglobin_g_dL":11.6,"wbc_k_uL":5.9,"platelets_k_uL":164,"creatinine_mg_dL":0.62,"alt_U_L":42},{"date":"2021-09-05","hemoglobin_g_dL":13.7,"wbc_k_uL":4.4,"platelets_k_uL":126,"creatinine_mg_dL":1.35,"alt_U_L":81},{"date":"2021-07-28","hemoglobin_g_dL":10.2,"wbc_k_uL":3.3,"platelets_k_uL":146,"creatinine_mg_dL":1.33,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_1926","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":53,"sex":"male","bmi":28.2,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-11-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-56},"pfs_months":37.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":53.8,"censored":false},"longitudinal_labs":[{"date":"2024-10-08","hemoglobin_g_dL":14.7,"wbc_k_uL":10.5,"platelets_k_uL":239,"creatinine_mg_dL":1.0,"alt_U_L":15},{"date":"2025-05-10","hemoglobin_g_dL":10.1,"wbc_k_uL":7.1,"platelets_k_uL":137,"creatinine_mg_dL":1.5,"alt_U_L":50},{"date":"2028-02-18","hemoglobin_g_dL":10.4,"wbc_k_uL":6.3,"platelets_k_uL":168,"creatinine_mg_dL":0.85,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_1927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":87,"sex":"female","bmi":29.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-64},"pfs_months":22.37},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.7,"censored":false},"longitudinal_labs":[{"date":"2020-12-16","hemoglobin_g_dL":14.4,"wbc_k_uL":7.5,"platelets_k_uL":315,"creatinine_mg_dL":1.03,"alt_U_L":56},{"date":"2021-08-14","hemoglobin_g_dL":13.0,"wbc_k_uL":5.1,"platelets_k_uL":128,"creatinine_mg_dL":0.96,"alt_U_L":48},{"date":"2023-01-08","hemoglobin_g_dL":11.3,"wbc_k_uL":5.8,"platelets_k_uL":301,"creatinine_mg_dL":1.0,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_1928","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":60,"sex":"female","bmi":20.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-41},"pfs_months":20.73},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.1,"censored":false},"longitudinal_labs":[{"date":"2023-10-17","hemoglobin_g_dL":12.6,"wbc_k_uL":5.9,"platelets_k_uL":285,"creatinine_mg_dL":1.25,"alt_U_L":51},{"date":"2024-05-23","hemoglobin_g_dL":13.1,"wbc_k_uL":7.9,"platelets_k_uL":338,"creatinine_mg_dL":0.9,"alt_U_L":74},{"date":"2025-08-27","hemoglobin_g_dL":10.3,"wbc_k_uL":6.3,"platelets_k_uL":207,"creatinine_mg_dL":1.28,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_1929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":65,"sex":"female","bmi":28.3,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-67},"pfs_months":12.12},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":18.6,"censored":false},"longitudinal_labs":[{"date":"2024-12-21","hemoglobin_g_dL":12.6,"wbc_k_uL":5.1,"platelets_k_uL":215,"creatinine_mg_dL":0.76,"alt_U_L":62},{"date":"2025-07-18","hemoglobin_g_dL":12.8,"wbc_k_uL":4.4,"platelets_k_uL":201,"creatinine_mg_dL":1.51,"alt_U_L":116},{"date":"2026-03-21","hemoglobin_g_dL":12.8,"wbc_k_uL":7.5,"platelets_k_uL":190,"creatinine_mg_dL":1.37,"alt_U_L":108}]}
{"patient_id":"ANODE_SYNTH_2025_1930","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":66,"sex":"male","bmi":19.6,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-02-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-33},"pfs_months":20.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.6,"censored":true},"longitudinal_labs":[{"date":"2024-11-25","hemoglobin_g_dL":12.8,"wbc_k_uL":4.9,"platelets_k_uL":255,"creatinine_mg_dL":1.19,"alt_U_L":79},{"date":"2025-07-31","hemoglobin_g_dL":11.4,"wbc_k_uL":5.4,"platelets_k_uL":289,"creatinine_mg_dL":0.99,"alt_U_L":88},{"date":"2026-11-14","hemoglobin_g_dL":12.8,"wbc_k_uL":7.0,"platelets_k_uL":331,"creatinine_mg_dL":1.24,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_1931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":82,"sex":"female","bmi":37.3,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-06-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-83},"pfs_months":16.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":28.7,"censored":true},"longitudinal_labs":[{"date":"2022-04-23","hemoglobin_g_dL":15.2,"wbc_k_uL":7.4,"platelets_k_uL":292,"creatinine_mg_dL":0.64,"alt_U_L":37},{"date":"2022-12-18","hemoglobin_g_dL":12.6,"wbc_k_uL":5.4,"platelets_k_uL":270,"creatinine_mg_dL":1.46,"alt_U_L":58},{"date":"2023-12-03","hemoglobin_g_dL":12.6,"wbc_k_uL":6.9,"platelets_k_uL":231,"creatinine_mg_dL":0.92,"alt_U_L":197}]}
{"patient_id":"ANODE_SYNTH_2025_1932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":71,"sex":"male","bmi":36.0,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-01-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-81},"pfs_months":32.72},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":56.3,"censored":true},"longitudinal_labs":[{"date":"2023-11-05","hemoglobin_g_dL":15.3,"wbc_k_uL":4.9,"platelets_k_uL":186,"creatinine_mg_dL":0.76,"alt_U_L":24},{"date":"2024-07-03","hemoglobin_g_dL":12.5,"wbc_k_uL":8.2,"platelets_k_uL":297,"creatinine_mg_dL":1.6,"alt_U_L":98},{"date":"2026-11-14","hemoglobin_g_dL":10.2,"wbc_k_uL":4.1,"platelets_k_uL":128,"creatinine_mg_dL":1.12,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_1933","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":74,"sex":"female","bmi":24.5,"smoking_pack_years":76,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-12-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-71},"pfs_months":8.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":12.5,"censored":false},"longitudinal_labs":[{"date":"2025-10-25","hemoglobin_g_dL":14.3,"wbc_k_uL":7.6,"platelets_k_uL":400,"creatinine_mg_dL":0.71,"alt_U_L":62},{"date":"2026-06-29","hemoglobin_g_dL":11.6,"wbc_k_uL":6.8,"platelets_k_uL":166,"creatinine_mg_dL":0.78,"alt_U_L":103},{"date":"2026-10-29","hemoglobin_g_dL":10.9,"wbc_k_uL":4.7,"platelets_k_uL":188,"creatinine_mg_dL":1.49,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_1934","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":77,"sex":"male","bmi":31.1,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-12-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-55},"pfs_months":14.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.9,"censored":false},"longitudinal_labs":[{"date":"2024-12-01","hemoglobin_g_dL":12.6,"wbc_k_uL":6.7,"platelets_k_uL":238,"creatinine_mg_dL":0.64,"alt_U_L":27},{"date":"2025-06-14","hemoglobin_g_dL":10.8,"wbc_k_uL":4.0,"platelets_k_uL":253,"creatinine_mg_dL":1.59,"alt_U_L":119},{"date":"2026-04-03","hemoglobin_g_dL":9.7,"wbc_k_uL":5.2,"platelets_k_uL":329,"creatinine_mg_dL":1.75,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_1935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":67,"sex":"male","bmi":33.3,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-02-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-80},"pfs_months":12.78},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":16.7,"censored":false},"longitudinal_labs":[{"date":"2023-12-01","hemoglobin_g_dL":15.0,"wbc_k_uL":8.7,"platelets_k_uL":225,"creatinine_mg_dL":0.75,"alt_U_L":13},{"date":"2024-08-03","hemoglobin_g_dL":10.7,"wbc_k_uL":3.9,"platelets_k_uL":252,"creatinine_mg_dL":1.44,"alt_U_L":107},{"date":"2025-04-19","hemoglobin_g_dL":10.1,"wbc_k_uL":6.0,"platelets_k_uL":298,"creatinine_mg_dL":1.57,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_1936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":63,"sex":"male","bmi":33.3,"smoking_pack_years":49,"ecog_performance_status":2,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-34},"pfs_months":36.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":57.0,"censored":false},"longitudinal_labs":[{"date":"2021-05-05","hemoglobin_g_dL":12.6,"wbc_k_uL":9.0,"platelets_k_uL":158,"creatinine_mg_dL":1.2,"alt_U_L":39},{"date":"2021-12-26","hemoglobin_g_dL":11.8,"wbc_k_uL":4.1,"platelets_k_uL":203,"creatinine_mg_dL":0.95,"alt_U_L":91},{"date":"2024-08-14","hemoglobin_g_dL":10.7,"wbc_k_uL":4.6,"platelets_k_uL":228,"creatinine_mg_dL":0.9,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_1937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":84,"sex":"female","bmi":37.9,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-08-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-82},"pfs_months":30.09},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":54.6,"censored":false},"longitudinal_labs":[{"date":"2025-07-20","hemoglobin_g_dL":13.0,"wbc_k_uL":4.9,"platelets_k_uL":226,"creatinine_mg_dL":0.64,"alt_U_L":14},{"date":"2026-01-31","hemoglobin_g_dL":13.3,"wbc_k_uL":7.2,"platelets_k_uL":237,"creatinine_mg_dL":0.92,"alt_U_L":78},{"date":"2028-03-11","hemoglobin_g_dL":10.8,"wbc_k_uL":6.7,"platelets_k_uL":324,"creatinine_mg_dL":1.53,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_1938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":80,"sex":"male","bmi":22.3,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-81},"pfs_months":4.73},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-10-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":8.7,"censored":false},"longitudinal_labs":[{"date":"2020-04-08","hemoglobin_g_dL":11.6,"wbc_k_uL":4.8,"platelets_k_uL":423,"creatinine_mg_dL":1.16,"alt_U_L":39},{"date":"2020-10-23","hemoglobin_g_dL":13.9,"wbc_k_uL":7.1,"platelets_k_uL":190,"creatinine_mg_dL":1.44,"alt_U_L":116},{"date":"2020-10-08","hemoglobin_g_dL":12.9,"wbc_k_uL":5.9,"platelets_k_uL":261,"creatinine_mg_dL":1.87,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_1939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":73,"sex":"female","bmi":37.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-64},"pfs_months":27.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":false},"longitudinal_labs":[{"date":"2020-08-24","hemoglobin_g_dL":15.1,"wbc_k_uL":10.2,"platelets_k_uL":443,"creatinine_mg_dL":1.17,"alt_U_L":66},{"date":"2021-04-25","hemoglobin_g_dL":12.5,"wbc_k_uL":7.3,"platelets_k_uL":365,"creatinine_mg_dL":1.29,"alt_U_L":89},{"date":"2023-03-11","hemoglobin_g_dL":11.6,"wbc_k_uL":7.3,"platelets_k_uL":338,"creatinine_mg_dL":1.26,"alt_U_L":71}]}
{"patient_id":"ANODE_SYNTH_2025_1940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":51,"sex":"female","bmi":23.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-55},"pfs_months":19.65},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.0,"censored":false},"longitudinal_labs":[{"date":"2023-10-02","hemoglobin_g_dL":14.2,"wbc_k_uL":4.6,"platelets_k_uL":348,"creatinine_mg_dL":0.83,"alt_U_L":51},{"date":"2024-04-29","hemoglobin_g_dL":13.0,"wbc_k_uL":6.4,"platelets_k_uL":305,"creatinine_mg_dL":1.05,"alt_U_L":77},{"date":"2025-07-08","hemoglobin_g_dL":11.1,"wbc_k_uL":6.2,"platelets_k_uL":134,"creatinine_mg_dL":1.72,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_1941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":75,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-40},"pfs_months":19.15},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.9,"censored":false},"longitudinal_labs":[{"date":"2025-02-05","hemoglobin_g_dL":14.7,"wbc_k_uL":6.5,"platelets_k_uL":181,"creatinine_mg_dL":0.7,"alt_U_L":44},{"date":"2025-09-19","hemoglobin_g_dL":11.9,"wbc_k_uL":8.6,"platelets_k_uL":356,"creatinine_mg_dL":1.08,"alt_U_L":48},{"date":"2026-12-22","hemoglobin_g_dL":12.2,"wbc_k_uL":3.2,"platelets_k_uL":206,"creatinine_mg_dL":1.03,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_1942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":72,"sex":"female","bmi":20.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-50},"pfs_months":13.11},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-06-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.1,"censored":true},"longitudinal_labs":[{"date":"2020-02-15","hemoglobin_g_dL":11.6,"wbc_k_uL":8.2,"platelets_k_uL":438,"creatinine_mg_dL":1.05,"alt_U_L":37},{"date":"2020-09-28","hemoglobin_g_dL":11.4,"wbc_k_uL":6.8,"platelets_k_uL":325,"creatinine_mg_dL":1.34,"alt_U_L":32},{"date":"2021-06-03","hemoglobin_g_dL":11.9,"wbc_k_uL":6.2,"platelets_k_uL":117,"creatinine_mg_dL":1.55,"alt_U_L":197}]}
{"patient_id":"ANODE_SYNTH_2025_1943","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":79,"sex":"female","bmi":31.1,"smoking_pack_years":50,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-08-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-75},"pfs_months":28.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":true},"longitudinal_labs":[{"date":"2024-06-10","hemoglobin_g_dL":14.9,"wbc_k_uL":8.9,"platelets_k_uL":195,"creatinine_mg_dL":1.0,"alt_U_L":17},{"date":"2025-02-11","hemoglobin_g_dL":13.2,"wbc_k_uL":5.1,"platelets_k_uL":242,"creatinine_mg_dL":0.8,"alt_U_L":51},{"date":"2027-01-31","hemoglobin_g_dL":9.9,"wbc_k_uL":3.5,"platelets_k_uL":208,"creatinine_mg_dL":1.46,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_1944","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":61,"sex":"male","bmi":26.5,"smoking_pack_years":42,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-60},"pfs_months":28.75},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.3,"censored":false},"longitudinal_labs":[{"date":"2023-04-05","hemoglobin_g_dL":11.7,"wbc_k_uL":10.8,"platelets_k_uL":393,"creatinine_mg_dL":0.68,"alt_U_L":68},{"date":"2023-11-17","hemoglobin_g_dL":11.7,"wbc_k_uL":6.0,"platelets_k_uL":196,"creatinine_mg_dL":1.05,"alt_U_L":81},{"date":"2025-12-11","hemoglobin_g_dL":12.1,"wbc_k_uL":5.4,"platelets_k_uL":237,"creatinine_mg_dL":0.96,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_1945","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":82,"sex":"female","bmi":22.2,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-01-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-78},"pfs_months":27.76},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.6,"censored":true},"longitudinal_labs":[{"date":"2025-01-11","hemoglobin_g_dL":12.6,"wbc_k_uL":10.6,"platelets_k_uL":197,"creatinine_mg_dL":0.88,"alt_U_L":73},{"date":"2025-07-26","hemoglobin_g_dL":13.8,"wbc_k_uL":4.3,"platelets_k_uL":221,"creatinine_mg_dL":0.78,"alt_U_L":92},{"date":"2027-07-10","hemoglobin_g_dL":10.3,"wbc_k_uL":3.7,"platelets_k_uL":259,"creatinine_mg_dL":1.43,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_1946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":61,"sex":"male","bmi":28.6,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-51},"pfs_months":30.42},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":57.2,"censored":false},"longitudinal_labs":[{"date":"2020-02-02","hemoglobin_g_dL":12.7,"wbc_k_uL":11.0,"platelets_k_uL":165,"creatinine_mg_dL":0.6,"alt_U_L":68},{"date":"2020-08-29","hemoglobin_g_dL":10.3,"wbc_k_uL":5.2,"platelets_k_uL":309,"creatinine_mg_dL":1.56,"alt_U_L":92},{"date":"2022-10-31","hemoglobin_g_dL":11.0,"wbc_k_uL":5.0,"platelets_k_uL":210,"creatinine_mg_dL":1.63,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_1947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":75,"sex":"female","bmi":24.6,"smoking_pack_years":21,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-10-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-82},"pfs_months":42.97},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":68.0,"censored":false},"longitudinal_labs":[{"date":"2023-10-01","hemoglobin_g_dL":14.8,"wbc_k_uL":5.1,"platelets_k_uL":390,"creatinine_mg_dL":0.89,"alt_U_L":13},{"date":"2024-04-14","hemoglobin_g_dL":12.0,"wbc_k_uL":5.2,"platelets_k_uL":302,"creatinine_mg_dL":1.53,"alt_U_L":116},{"date":"2027-06-20","hemoglobin_g_dL":11.7,"wbc_k_uL":5.0,"platelets_k_uL":246,"creatinine_mg_dL":1.69,"alt_U_L":28}]}
{"patient_id":"ANODE_SYNTH_2025_1948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":57,"sex":"female","bmi":35.0,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-11-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-72},"pfs_months":6.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-16","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.5,"censored":false},"longitudinal_labs":[{"date":"2021-10-19","hemoglobin_g_dL":12.8,"wbc_k_uL":10.4,"platelets_k_uL":285,"creatinine_mg_dL":1.06,"alt_U_L":20},{"date":"2022-05-26","hemoglobin_g_dL":12.6,"wbc_k_uL":8.4,"platelets_k_uL":333,"creatinine_mg_dL":0.81,"alt_U_L":55},{"date":"2022-08-16","hemoglobin_g_dL":12.2,"wbc_k_uL":4.7,"platelets_k_uL":296,"creatinine_mg_dL":1.57,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_1949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":53,"sex":"female","bmi":36.3,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-63},"pfs_months":37.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":59.5,"censored":true},"longitudinal_labs":[{"date":"2022-11-22","hemoglobin_g_dL":14.0,"wbc_k_uL":9.5,"platelets_k_uL":377,"creatinine_mg_dL":1.25,"alt_U_L":56},{"date":"2023-06-29","hemoglobin_g_dL":12.8,"wbc_k_uL":8.3,"platelets_k_uL":252,"creatinine_mg_dL":1.48,"alt_U_L":39},{"date":"2026-03-24","hemoglobin_g_dL":10.5,"wbc_k_uL":3.8,"platelets_k_uL":321,"creatinine_mg_dL":1.04,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_1950","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":64,"sex":"female","bmi":33.5,"smoking_pack_years":66,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-09-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-59},"pfs_months":17.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.1,"censored":true},"longitudinal_labs":[{"date":"2022-09-09","hemoglobin_g_dL":12.8,"wbc_k_uL":10.8,"platelets_k_uL":274,"creatinine_mg_dL":0.82,"alt_U_L":51},{"date":"2023-03-29","hemoglobin_g_dL":13.2,"wbc_k_uL":8.7,"platelets_k_uL":180,"creatinine_mg_dL":1.37,"alt_U_L":85},{"date":"2024-03-07","hemoglobin_g_dL":9.9,"wbc_k_uL":6.0,"platelets_k_uL":253,"creatinine_mg_dL":1.52,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_1951","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":86,"sex":"male","bmi":33.9,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-08-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-67},"pfs_months":19.48},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-25","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.6,"censored":true},"longitudinal_labs":[{"date":"2020-06-11","hemoglobin_g_dL":15.4,"wbc_k_uL":6.0,"platelets_k_uL":273,"creatinine_mg_dL":1.12,"alt_U_L":52},{"date":"2021-02-10","hemoglobin_g_dL":10.0,"wbc_k_uL":7.0,"platelets_k_uL":208,"creatinine_mg_dL":1.0,"alt_U_L":85},{"date":"2022-05-25","hemoglobin_g_dL":12.5,"wbc_k_uL":6.9,"platelets_k_uL":250,"creatinine_mg_dL":0.99,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_1952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":77,"sex":"female","bmi":28.9,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-05-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-54},"pfs_months":5.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":17.1,"censored":true},"longitudinal_labs":[{"date":"2024-03-10","hemoglobin_g_dL":15.2,"wbc_k_uL":6.6,"platelets_k_uL":183,"creatinine_mg_dL":0.77,"alt_U_L":47},{"date":"2024-11-06","hemoglobin_g_dL":13.7,"wbc_k_uL":4.0,"platelets_k_uL":337,"creatinine_mg_dL":1.57,"alt_U_L":98},{"date":"2024-10-30","hemoglobin_g_dL":10.9,"wbc_k_uL":5.5,"platelets_k_uL":116,"creatinine_mg_dL":1.65,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_1953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":88,"sex":"female","bmi":32.4,"smoking_pack_years":51,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-01-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-48},"pfs_months":24.97},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.4,"censored":false},"longitudinal_labs":[{"date":"2022-11-01","hemoglobin_g_dL":15.2,"wbc_k_uL":7.5,"platelets_k_uL":389,"creatinine_mg_dL":1.02,"alt_U_L":10},{"date":"2023-07-01","hemoglobin_g_dL":11.4,"wbc_k_uL":6.1,"platelets_k_uL":136,"creatinine_mg_dL":0.84,"alt_U_L":113},{"date":"2025-02-10","hemoglobin_g_dL":11.2,"wbc_k_uL":6.7,"platelets_k_uL":183,"creatinine_mg_dL":1.83,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_1954","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":63,"sex":"female","bmi":31.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-30},"pfs_months":10.78},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":37.2,"censored":false},"longitudinal_labs":[{"date":"2025-11-15","hemoglobin_g_dL":11.8,"wbc_k_uL":5.4,"platelets_k_uL":178,"creatinine_mg_dL":1.3,"alt_U_L":46},{"date":"2026-06-04","hemoglobin_g_dL":10.5,"wbc_k_uL":8.0,"platelets_k_uL":183,"creatinine_mg_dL":1.27,"alt_U_L":74},{"date":"2026-12-18","hemoglobin_g_dL":11.2,"wbc_k_uL":3.2,"platelets_k_uL":118,"creatinine_mg_dL":1.98,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_1955","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":64,"sex":"male","bmi":18.7,"smoking_pack_years":61,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-09-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-45},"pfs_months":19.12},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.2,"censored":true},"longitudinal_labs":[{"date":"2025-08-24","hemoglobin_g_dL":13.3,"wbc_k_uL":5.5,"platelets_k_uL":239,"creatinine_mg_dL":1.17,"alt_U_L":14},{"date":"2026-03-20","hemoglobin_g_dL":11.7,"wbc_k_uL":5.9,"platelets_k_uL":348,"creatinine_mg_dL":0.87,"alt_U_L":94},{"date":"2027-05-30","hemoglobin_g_dL":13.0,"wbc_k_uL":4.0,"platelets_k_uL":125,"creatinine_mg_dL":1.19,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_1956","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":78,"sex":"female","bmi":31.6,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-12-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-64},"pfs_months":32.89},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":52.0,"censored":true},"longitudinal_labs":[{"date":"2021-11-10","hemoglobin_g_dL":13.3,"wbc_k_uL":9.8,"platelets_k_uL":360,"creatinine_mg_dL":1.16,"alt_U_L":44},{"date":"2022-06-28","hemoglobin_g_dL":11.4,"wbc_k_uL":3.9,"platelets_k_uL":326,"creatinine_mg_dL":0.93,"alt_U_L":102},{"date":"2024-10-18","hemoglobin_g_dL":12.3,"wbc_k_uL":5.7,"platelets_k_uL":248,"creatinine_mg_dL":0.99,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_1957","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":68,"sex":"female","bmi":28.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-32},"pfs_months":21.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.1,"censored":false},"longitudinal_labs":[{"date":"2021-03-10","hemoglobin_g_dL":13.0,"wbc_k_uL":6.4,"platelets_k_uL":422,"creatinine_mg_dL":0.95,"alt_U_L":55},{"date":"2021-10-08","hemoglobin_g_dL":13.9,"wbc_k_uL":7.3,"platelets_k_uL":233,"creatinine_mg_dL":1.4,"alt_U_L":89},{"date":"2023-03-12","hemoglobin_g_dL":12.8,"wbc_k_uL":7.1,"platelets_k_uL":123,"creatinine_mg_dL":0.96,"alt_U_L":139}]}
{"patient_id":"ANODE_SYNTH_2025_1958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":57,"sex":"male","bmi":37.0,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-11-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-59},"pfs_months":36.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":67.4,"censored":false},"longitudinal_labs":[{"date":"2022-09-12","hemoglobin_g_dL":14.6,"wbc_k_uL":6.7,"platelets_k_uL":219,"creatinine_mg_dL":1.21,"alt_U_L":72},{"date":"2023-05-09","hemoglobin_g_dL":11.1,"wbc_k_uL":5.1,"platelets_k_uL":307,"creatinine_mg_dL":1.55,"alt_U_L":73},{"date":"2026-01-11","hemoglobin_g_dL":10.0,"wbc_k_uL":5.4,"platelets_k_uL":179,"creatinine_mg_dL":0.92,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_1959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":73,"sex":"female","bmi":31.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-85},"pfs_months":13.77},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":18.3,"censored":true},"longitudinal_labs":[{"date":"2023-03-02","hemoglobin_g_dL":13.3,"wbc_k_uL":5.2,"platelets_k_uL":413,"creatinine_mg_dL":0.96,"alt_U_L":25},{"date":"2023-10-24","hemoglobin_g_dL":11.3,"wbc_k_uL":8.7,"platelets_k_uL":292,"creatinine_mg_dL":1.47,"alt_U_L":65},{"date":"2024-08-18","hemoglobin_g_dL":9.6,"wbc_k_uL":5.3,"platelets_k_uL":298,"creatinine_mg_dL":1.5,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_1960","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":68,"sex":"male","bmi":25.0,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-57},"pfs_months":17.54},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.5,"censored":false},"longitudinal_labs":[{"date":"2023-05-14","hemoglobin_g_dL":12.2,"wbc_k_uL":10.9,"platelets_k_uL":293,"creatinine_mg_dL":0.64,"alt_U_L":11},{"date":"2023-12-20","hemoglobin_g_dL":11.2,"wbc_k_uL":6.5,"platelets_k_uL":136,"creatinine_mg_dL":1.33,"alt_U_L":71},{"date":"2025-01-24","hemoglobin_g_dL":10.1,"wbc_k_uL":8.0,"platelets_k_uL":120,"creatinine_mg_dL":1.01,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_1961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":80,"sex":"female","bmi":27.9,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-02-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-61},"pfs_months":16.39},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":true},"longitudinal_labs":[{"date":"2020-01-10","hemoglobin_g_dL":12.5,"wbc_k_uL":5.7,"platelets_k_uL":187,"creatinine_mg_dL":0.7,"alt_U_L":44},{"date":"2020-08-13","hemoglobin_g_dL":10.3,"wbc_k_uL":5.3,"platelets_k_uL":342,"creatinine_mg_dL":1.4,"alt_U_L":56},{"date":"2021-07-28","hemoglobin_g_dL":10.8,"wbc_k_uL":5.6,"platelets_k_uL":223,"creatinine_mg_dL":1.37,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_1962","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":77,"sex":"female","bmi":20.0,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-71},"pfs_months":36.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":53.8,"censored":true},"longitudinal_labs":[{"date":"2025-01-09","hemoglobin_g_dL":14.5,"wbc_k_uL":9.5,"platelets_k_uL":297,"creatinine_mg_dL":0.72,"alt_U_L":59},{"date":"2025-08-07","hemoglobin_g_dL":13.0,"wbc_k_uL":7.2,"platelets_k_uL":317,"creatinine_mg_dL":0.74,"alt_U_L":79},{"date":"2028-04-27","hemoglobin_g_dL":10.6,"wbc_k_uL":3.3,"platelets_k_uL":141,"creatinine_mg_dL":1.69,"alt_U_L":198}]}
{"patient_id":"ANODE_SYNTH_2025_1963","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":56,"sex":"male","bmi":36.4,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-04-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-57},"pfs_months":36.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":58.3,"censored":false},"longitudinal_labs":[{"date":"2021-02-08","hemoglobin_g_dL":13.0,"wbc_k_uL":6.9,"platelets_k_uL":201,"creatinine_mg_dL":1.14,"alt_U_L":11},{"date":"2021-09-30","hemoglobin_g_dL":12.1,"wbc_k_uL":4.7,"platelets_k_uL":228,"creatinine_mg_dL":0.94,"alt_U_L":104},{"date":"2024-06-09","hemoglobin_g_dL":9.7,"wbc_k_uL":3.5,"platelets_k_uL":158,"creatinine_mg_dL":1.56,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_1964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":60,"sex":"female","bmi":31.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-51},"pfs_months":19.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.8,"censored":false},"longitudinal_labs":[{"date":"2025-01-13","hemoglobin_g_dL":12.7,"wbc_k_uL":5.2,"platelets_k_uL":349,"creatinine_mg_dL":1.17,"alt_U_L":39},{"date":"2025-08-01","hemoglobin_g_dL":11.0,"wbc_k_uL":6.6,"platelets_k_uL":132,"creatinine_mg_dL":0.93,"alt_U_L":23},{"date":"2026-10-05","hemoglobin_g_dL":10.7,"wbc_k_uL":5.5,"platelets_k_uL":219,"creatinine_mg_dL":0.9,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_1965","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":73,"sex":"female","bmi":28.4,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-11-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-58},"pfs_months":27.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.1,"censored":true},"longitudinal_labs":[{"date":"2020-10-02","hemoglobin_g_dL":14.3,"wbc_k_uL":10.7,"platelets_k_uL":282,"creatinine_mg_dL":0.61,"alt_U_L":10},{"date":"2021-05-23","hemoglobin_g_dL":10.0,"wbc_k_uL":4.9,"platelets_k_uL":220,"creatinine_mg_dL":0.87,"alt_U_L":107},{"date":"2023-05-13","hemoglobin_g_dL":10.8,"wbc_k_uL":6.2,"platelets_k_uL":224,"creatinine_mg_dL":1.05,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_1966","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":63,"sex":"female","bmi":34.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-44},"pfs_months":18.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.3,"censored":true},"longitudinal_labs":[{"date":"2020-02-01","hemoglobin_g_dL":12.4,"wbc_k_uL":5.8,"platelets_k_uL":173,"creatinine_mg_dL":0.8,"alt_U_L":53},{"date":"2020-10-03","hemoglobin_g_dL":12.7,"wbc_k_uL":7.8,"platelets_k_uL":311,"creatinine_mg_dL":1.34,"alt_U_L":29},{"date":"2021-10-26","hemoglobin_g_dL":11.8,"wbc_k_uL":4.2,"platelets_k_uL":207,"creatinine_mg_dL":1.1,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_1967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":80,"sex":"male","bmi":18.7,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-11-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-81},"pfs_months":25.07},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":false},"longitudinal_labs":[{"date":"2025-09-22","hemoglobin_g_dL":13.3,"wbc_k_uL":6.5,"platelets_k_uL":245,"creatinine_mg_dL":1.29,"alt_U_L":10},{"date":"2026-05-16","hemoglobin_g_dL":10.0,"wbc_k_uL":8.1,"platelets_k_uL":163,"creatinine_mg_dL":1.05,"alt_U_L":118},{"date":"2028-01-13","hemoglobin_g_dL":11.3,"wbc_k_uL":4.3,"platelets_k_uL":287,"creatinine_mg_dL":1.17,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_1968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":78,"sex":"female","bmi":27.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-72},"pfs_months":18.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":false},"longitudinal_labs":[{"date":"2024-04-10","hemoglobin_g_dL":13.8,"wbc_k_uL":8.5,"platelets_k_uL":247,"creatinine_mg_dL":1.21,"alt_U_L":62},{"date":"2024-12-13","hemoglobin_g_dL":13.3,"wbc_k_uL":5.9,"platelets_k_uL":170,"creatinine_mg_dL":0.74,"alt_U_L":53},{"date":"2026-01-08","hemoglobin_g_dL":12.7,"wbc_k_uL":4.0,"platelets_k_uL":190,"creatinine_mg_dL":1.72,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_1969","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":79,"sex":"female","bmi":32.2,"smoking_pack_years":55,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-09-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-52},"pfs_months":21.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.6,"censored":false},"longitudinal_labs":[{"date":"2020-07-28","hemoglobin_g_dL":13.5,"wbc_k_uL":10.4,"platelets_k_uL":190,"creatinine_mg_dL":1.0,"alt_U_L":38},{"date":"2021-03-22","hemoglobin_g_dL":13.8,"wbc_k_uL":7.3,"platelets_k_uL":154,"creatinine_mg_dL":1.5,"alt_U_L":34},{"date":"2022-07-29","hemoglobin_g_dL":9.8,"wbc_k_uL":6.1,"platelets_k_uL":275,"creatinine_mg_dL":1.53,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_1970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":75,"sex":"female","bmi":31.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-52},"pfs_months":24.94},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":47.1,"censored":true},"longitudinal_labs":[{"date":"2022-02-06","hemoglobin_g_dL":14.9,"wbc_k_uL":9.7,"platelets_k_uL":213,"creatinine_mg_dL":1.28,"alt_U_L":10},{"date":"2022-10-14","hemoglobin_g_dL":11.2,"wbc_k_uL":5.1,"platelets_k_uL":364,"creatinine_mg_dL":0.95,"alt_U_L":111},{"date":"2024-06-09","hemoglobin_g_dL":11.3,"wbc_k_uL":3.4,"platelets_k_uL":119,"creatinine_mg_dL":1.7,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_1971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":59,"sex":"female","bmi":26.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-72},"pfs_months":20.27},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.0,"censored":false},"longitudinal_labs":[{"date":"2021-05-22","hemoglobin_g_dL":14.1,"wbc_k_uL":8.1,"platelets_k_uL":259,"creatinine_mg_dL":1.17,"alt_U_L":75},{"date":"2021-12-04","hemoglobin_g_dL":13.3,"wbc_k_uL":6.2,"platelets_k_uL":242,"creatinine_mg_dL":0.91,"alt_U_L":73},{"date":"2023-04-08","hemoglobin_g_dL":10.7,"wbc_k_uL":6.4,"platelets_k_uL":341,"creatinine_mg_dL":1.11,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_1972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":86,"sex":"female","bmi":26.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-01-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-41},"pfs_months":23.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.8,"censored":false},"longitudinal_labs":[{"date":"2022-01-02","hemoglobin_g_dL":15.3,"wbc_k_uL":8.4,"platelets_k_uL":408,"creatinine_mg_dL":0.96,"alt_U_L":61},{"date":"2022-07-25","hemoglobin_g_dL":11.5,"wbc_k_uL":4.7,"platelets_k_uL":357,"creatinine_mg_dL":1.58,"alt_U_L":18},{"date":"2024-01-29","hemoglobin_g_dL":12.5,"wbc_k_uL":3.2,"platelets_k_uL":259,"creatinine_mg_dL":1.12,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_1973","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":65,"sex":"female","bmi":27.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-44},"pfs_months":20.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.6,"censored":false},"longitudinal_labs":[{"date":"2025-01-20","hemoglobin_g_dL":13.3,"wbc_k_uL":9.3,"platelets_k_uL":204,"creatinine_mg_dL":0.92,"alt_U_L":15},{"date":"2025-09-07","hemoglobin_g_dL":11.3,"wbc_k_uL":3.9,"platelets_k_uL":248,"creatinine_mg_dL":1.57,"alt_U_L":99},{"date":"2027-01-11","hemoglobin_g_dL":11.5,"wbc_k_uL":6.8,"platelets_k_uL":180,"creatinine_mg_dL":1.96,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_1974","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":86,"sex":"female","bmi":21.0,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-32},"pfs_months":10.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.0,"censored":false},"longitudinal_labs":[{"date":"2025-05-23","hemoglobin_g_dL":13.0,"wbc_k_uL":9.1,"platelets_k_uL":259,"creatinine_mg_dL":1.1,"alt_U_L":76},{"date":"2026-01-23","hemoglobin_g_dL":13.8,"wbc_k_uL":8.6,"platelets_k_uL":277,"creatinine_mg_dL":0.94,"alt_U_L":49},{"date":"2026-06-29","hemoglobin_g_dL":9.9,"wbc_k_uL":3.2,"platelets_k_uL":296,"creatinine_mg_dL":1.47,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_1975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":70,"sex":"female","bmi":28.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-01-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-45},"pfs_months":20.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.2,"censored":true},"longitudinal_labs":[{"date":"2022-12-16","hemoglobin_g_dL":12.0,"wbc_k_uL":7.9,"platelets_k_uL":405,"creatinine_mg_dL":0.99,"alt_U_L":18},{"date":"2023-07-20","hemoglobin_g_dL":12.8,"wbc_k_uL":7.8,"platelets_k_uL":281,"creatinine_mg_dL":1.26,"alt_U_L":88},{"date":"2024-10-23","hemoglobin_g_dL":12.9,"wbc_k_uL":5.0,"platelets_k_uL":305,"creatinine_mg_dL":1.34,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_1976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":67,"sex":"female","bmi":33.1,"smoking_pack_years":13,"ecog_performance_status":2,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-45},"pfs_months":11.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":19.8,"censored":false},"longitudinal_labs":[{"date":"2023-05-25","hemoglobin_g_dL":13.7,"wbc_k_uL":11.0,"platelets_k_uL":183,"creatinine_mg_dL":0.9,"alt_U_L":14},{"date":"2024-01-27","hemoglobin_g_dL":11.4,"wbc_k_uL":8.3,"platelets_k_uL":329,"creatinine_mg_dL":0.93,"alt_U_L":94},{"date":"2024-08-03","hemoglobin_g_dL":11.8,"wbc_k_uL":5.6,"platelets_k_uL":284,"creatinine_mg_dL":1.3,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_1977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":61,"sex":"male","bmi":35.5,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-05-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-84},"pfs_months":5.65},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":10.2,"censored":false},"longitudinal_labs":[{"date":"2023-04-11","hemoglobin_g_dL":14.6,"wbc_k_uL":9.7,"platelets_k_uL":340,"creatinine_mg_dL":1.01,"alt_U_L":13},{"date":"2023-10-30","hemoglobin_g_dL":10.2,"wbc_k_uL":5.5,"platelets_k_uL":355,"creatinine_mg_dL":0.89,"alt_U_L":43},{"date":"2023-11-22","hemoglobin_g_dL":12.9,"wbc_k_uL":3.9,"platelets_k_uL":130,"creatinine_mg_dL":1.06,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_1978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":52,"sex":"male","bmi":25.4,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-10-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-47},"pfs_months":43.01},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-06-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":67.5,"censored":true},"longitudinal_labs":[{"date":"2025-08-12","hemoglobin_g_dL":11.8,"wbc_k_uL":10.5,"platelets_k_uL":168,"creatinine_mg_dL":0.99,"alt_U_L":48},{"date":"2026-04-03","hemoglobin_g_dL":12.5,"wbc_k_uL":8.4,"platelets_k_uL":230,"creatinine_mg_dL":1.46,"alt_U_L":62},{"date":"2029-06-15","hemoglobin_g_dL":10.3,"wbc_k_uL":7.0,"platelets_k_uL":327,"creatinine_mg_dL":1.34,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_1979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":59,"sex":"male","bmi":25.6,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-05-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-75},"pfs_months":37.75},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-08-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":55.8,"censored":false},"longitudinal_labs":[{"date":"2025-03-21","hemoglobin_g_dL":14.3,"wbc_k_uL":6.9,"platelets_k_uL":164,"creatinine_mg_dL":1.08,"alt_U_L":70},{"date":"2025-11-25","hemoglobin_g_dL":11.7,"wbc_k_uL":4.7,"platelets_k_uL":126,"creatinine_mg_dL":1.14,"alt_U_L":106},{"date":"2028-08-16","hemoglobin_g_dL":12.2,"wbc_k_uL":6.2,"platelets_k_uL":281,"creatinine_mg_dL":1.21,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_1980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":51,"sex":"female","bmi":19.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-80},"pfs_months":29.44},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.8,"censored":true},"longitudinal_labs":[{"date":"2022-09-04","hemoglobin_g_dL":15.0,"wbc_k_uL":8.8,"platelets_k_uL":290,"creatinine_mg_dL":1.0,"alt_U_L":30},{"date":"2023-05-06","hemoglobin_g_dL":13.9,"wbc_k_uL":5.9,"platelets_k_uL":215,"creatinine_mg_dL":1.12,"alt_U_L":102},{"date":"2025-05-26","hemoglobin_g_dL":10.7,"wbc_k_uL":6.4,"platelets_k_uL":161,"creatinine_mg_dL":1.1,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_1981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":62,"sex":"female","bmi":24.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-57},"pfs_months":23.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":false},"longitudinal_labs":[{"date":"2020-12-15","hemoglobin_g_dL":13.2,"wbc_k_uL":5.8,"platelets_k_uL":276,"creatinine_mg_dL":0.95,"alt_U_L":18},{"date":"2021-08-19","hemoglobin_g_dL":10.6,"wbc_k_uL":7.8,"platelets_k_uL":226,"creatinine_mg_dL":1.49,"alt_U_L":25},{"date":"2023-02-22","hemoglobin_g_dL":10.8,"wbc_k_uL":7.2,"platelets_k_uL":213,"creatinine_mg_dL":0.94,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_1982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":71,"sex":"female","bmi":35.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-74},"pfs_months":24.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":false},"longitudinal_labs":[{"date":"2022-10-16","hemoglobin_g_dL":14.2,"wbc_k_uL":5.6,"platelets_k_uL":175,"creatinine_mg_dL":0.6,"alt_U_L":56},{"date":"2023-06-09","hemoglobin_g_dL":11.1,"wbc_k_uL":4.7,"platelets_k_uL":284,"creatinine_mg_dL":1.09,"alt_U_L":107},{"date":"2025-01-03","hemoglobin_g_dL":11.4,"wbc_k_uL":4.6,"platelets_k_uL":126,"creatinine_mg_dL":0.86,"alt_U_L":31}]}
{"patient_id":"ANODE_SYNTH_2025_1983","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":49,"sex":"female","bmi":37.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-79},"pfs_months":23.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.6,"censored":false},"longitudinal_labs":[{"date":"2022-01-23","hemoglobin_g_dL":15.2,"wbc_k_uL":7.9,"platelets_k_uL":358,"creatinine_mg_dL":1.25,"alt_U_L":75},{"date":"2022-09-29","hemoglobin_g_dL":11.2,"wbc_k_uL":8.6,"platelets_k_uL":333,"creatinine_mg_dL":1.09,"alt_U_L":16},{"date":"2024-04-30","hemoglobin_g_dL":9.6,"wbc_k_uL":7.7,"platelets_k_uL":310,"creatinine_mg_dL":1.0,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_1984","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":69,"sex":"male","bmi":32.7,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-04-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-50},"pfs_months":6.54},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":18.3,"censored":true},"longitudinal_labs":[{"date":"2023-03-06","hemoglobin_g_dL":14.8,"wbc_k_uL":8.8,"platelets_k_uL":298,"creatinine_mg_dL":0.76,"alt_U_L":24},{"date":"2023-10-19","hemoglobin_g_dL":13.3,"wbc_k_uL":5.4,"platelets_k_uL":313,"creatinine_mg_dL":0.79,"alt_U_L":69},{"date":"2023-12-28","hemoglobin_g_dL":11.1,"wbc_k_uL":3.2,"platelets_k_uL":152,"creatinine_mg_dL":1.01,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_1985","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":85,"sex":"male","bmi":34.4,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-45},"pfs_months":41.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":61.1,"censored":false},"longitudinal_labs":[{"date":"2021-04-18","hemoglobin_g_dL":14.7,"wbc_k_uL":6.5,"platelets_k_uL":430,"creatinine_mg_dL":0.75,"alt_U_L":42},{"date":"2021-11-14","hemoglobin_g_dL":10.9,"wbc_k_uL":6.2,"platelets_k_uL":285,"creatinine_mg_dL":1.32,"alt_U_L":61},{"date":"2024-11-16","hemoglobin_g_dL":10.1,"wbc_k_uL":5.0,"platelets_k_uL":154,"creatinine_mg_dL":1.85,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_1986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":49,"sex":"female","bmi":19.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-44},"pfs_months":27.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":false},"longitudinal_labs":[{"date":"2025-01-12","hemoglobin_g_dL":14.3,"wbc_k_uL":7.3,"platelets_k_uL":275,"creatinine_mg_dL":0.91,"alt_U_L":24},{"date":"2025-08-23","hemoglobin_g_dL":10.5,"wbc_k_uL":7.3,"platelets_k_uL":200,"creatinine_mg_dL":0.9,"alt_U_L":70},{"date":"2027-07-27","hemoglobin_g_dL":12.1,"wbc_k_uL":5.1,"platelets_k_uL":301,"creatinine_mg_dL":1.47,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_1987","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":83,"sex":"female","bmi":33.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-68},"pfs_months":17.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":27.2,"censored":false},"longitudinal_labs":[{"date":"2022-07-16","hemoglobin_g_dL":14.6,"wbc_k_uL":9.6,"platelets_k_uL":444,"creatinine_mg_dL":0.92,"alt_U_L":79},{"date":"2023-03-14","hemoglobin_g_dL":11.5,"wbc_k_uL":7.0,"platelets_k_uL":195,"creatinine_mg_dL":1.01,"alt_U_L":80},{"date":"2024-04-27","hemoglobin_g_dL":9.9,"wbc_k_uL":5.0,"platelets_k_uL":344,"creatinine_mg_dL":1.16,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_1988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":69,"sex":"female","bmi":19.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-75},"pfs_months":21.36},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.1,"censored":true},"longitudinal_labs":[{"date":"2023-01-12","hemoglobin_g_dL":13.9,"wbc_k_uL":5.6,"platelets_k_uL":221,"creatinine_mg_dL":1.15,"alt_U_L":53},{"date":"2023-08-12","hemoglobin_g_dL":10.3,"wbc_k_uL":5.0,"platelets_k_uL":294,"creatinine_mg_dL":1.39,"alt_U_L":81},{"date":"2025-01-16","hemoglobin_g_dL":10.7,"wbc_k_uL":4.1,"platelets_k_uL":173,"creatinine_mg_dL":0.85,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_1989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":56,"sex":"female","bmi":35.2,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-12-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-30},"pfs_months":19.02},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.0,"censored":false},"longitudinal_labs":[{"date":"2025-12-07","hemoglobin_g_dL":12.9,"wbc_k_uL":5.6,"platelets_k_uL":247,"creatinine_mg_dL":0.83,"alt_U_L":19},{"date":"2026-06-29","hemoglobin_g_dL":12.5,"wbc_k_uL":4.7,"platelets_k_uL":331,"creatinine_mg_dL":1.57,"alt_U_L":117},{"date":"2027-09-18","hemoglobin_g_dL":11.5,"wbc_k_uL":4.0,"platelets_k_uL":146,"creatinine_mg_dL":1.55,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_1990","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":73,"sex":"female","bmi":28.2,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-05-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-41},"pfs_months":17.41},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.4,"censored":true},"longitudinal_labs":[{"date":"2020-04-14","hemoglobin_g_dL":12.3,"wbc_k_uL":7.7,"platelets_k_uL":231,"creatinine_mg_dL":1.28,"alt_U_L":24},{"date":"2020-11-23","hemoglobin_g_dL":11.5,"wbc_k_uL":7.7,"platelets_k_uL":249,"creatinine_mg_dL":1.08,"alt_U_L":53},{"date":"2021-12-08","hemoglobin_g_dL":11.7,"wbc_k_uL":4.1,"platelets_k_uL":182,"creatinine_mg_dL":1.04,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_1991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":76,"sex":"male","bmi":30.2,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-12-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-83},"pfs_months":47.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":68.6,"censored":false},"longitudinal_labs":[{"date":"2024-10-10","hemoglobin_g_dL":14.8,"wbc_k_uL":9.0,"platelets_k_uL":187,"creatinine_mg_dL":1.2,"alt_U_L":10},{"date":"2025-06-15","hemoglobin_g_dL":12.9,"wbc_k_uL":7.3,"platelets_k_uL":252,"creatinine_mg_dL":1.17,"alt_U_L":68},{"date":"2029-01-25","hemoglobin_g_dL":10.6,"wbc_k_uL":4.8,"platelets_k_uL":331,"creatinine_mg_dL":1.06,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_1992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":65,"sex":"female","bmi":35.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-84},"pfs_months":19.22},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":26.7,"censored":false},"longitudinal_labs":[{"date":"2020-04-23","hemoglobin_g_dL":13.8,"wbc_k_uL":7.3,"platelets_k_uL":362,"creatinine_mg_dL":1.11,"alt_U_L":57},{"date":"2020-12-10","hemoglobin_g_dL":11.1,"wbc_k_uL":4.3,"platelets_k_uL":186,"creatinine_mg_dL":1.47,"alt_U_L":17},{"date":"2022-02-06","hemoglobin_g_dL":11.9,"wbc_k_uL":7.5,"platelets_k_uL":111,"creatinine_mg_dL":1.54,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_1993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":88,"sex":"male","bmi":29.5,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-02-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-63},"pfs_months":15.01},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.3,"censored":false},"longitudinal_labs":[{"date":"2020-01-25","hemoglobin_g_dL":13.6,"wbc_k_uL":9.9,"platelets_k_uL":403,"creatinine_mg_dL":0.66,"alt_U_L":44},{"date":"2020-08-17","hemoglobin_g_dL":12.7,"wbc_k_uL":5.9,"platelets_k_uL":339,"creatinine_mg_dL":0.87,"alt_U_L":116},{"date":"2021-07-04","hemoglobin_g_dL":12.9,"wbc_k_uL":4.6,"platelets_k_uL":239,"creatinine_mg_dL":1.01,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_1994","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":77,"sex":"female","bmi":23.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-39},"pfs_months":25.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.7,"censored":false},"longitudinal_labs":[{"date":"2025-02-06","hemoglobin_g_dL":12.9,"wbc_k_uL":8.2,"platelets_k_uL":426,"creatinine_mg_dL":1.15,"alt_U_L":10},{"date":"2025-08-21","hemoglobin_g_dL":12.3,"wbc_k_uL":7.0,"platelets_k_uL":201,"creatinine_mg_dL":1.18,"alt_U_L":39},{"date":"2027-05-11","hemoglobin_g_dL":9.7,"wbc_k_uL":3.3,"platelets_k_uL":297,"creatinine_mg_dL":1.76,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_1995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":88,"sex":"female","bmi":21.0,"smoking_pack_years":51,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-11-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-62},"pfs_months":39.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":64.0,"censored":true},"longitudinal_labs":[{"date":"2022-10-26","hemoglobin_g_dL":14.1,"wbc_k_uL":8.5,"platelets_k_uL":167,"creatinine_mg_dL":1.14,"alt_U_L":48},{"date":"2023-05-08","hemoglobin_g_dL":13.7,"wbc_k_uL":5.4,"platelets_k_uL":172,"creatinine_mg_dL":1.36,"alt_U_L":108},{"date":"2026-04-09","hemoglobin_g_dL":12.4,"wbc_k_uL":5.8,"platelets_k_uL":152,"creatinine_mg_dL":1.62,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_1996","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":71,"sex":"female","bmi":24.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-68},"pfs_months":25.95},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.3,"censored":true},"longitudinal_labs":[{"date":"2025-03-27","hemoglobin_g_dL":11.8,"wbc_k_uL":6.1,"platelets_k_uL":158,"creatinine_mg_dL":0.8,"alt_U_L":46},{"date":"2025-10-08","hemoglobin_g_dL":12.8,"wbc_k_uL":8.5,"platelets_k_uL":179,"creatinine_mg_dL":0.82,"alt_U_L":117},{"date":"2027-06-24","hemoglobin_g_dL":10.1,"wbc_k_uL":5.0,"platelets_k_uL":236,"creatinine_mg_dL":1.11,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_1997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":87,"sex":"female","bmi":32.4,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-09-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-52},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-02-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":7.2,"censored":false},"longitudinal_labs":[{"date":"2020-07-27","hemoglobin_g_dL":14.6,"wbc_k_uL":8.6,"platelets_k_uL":301,"creatinine_mg_dL":1.04,"alt_U_L":43},{"date":"2021-03-23","hemoglobin_g_dL":13.7,"wbc_k_uL":4.9,"platelets_k_uL":323,"creatinine_mg_dL":1.1,"alt_U_L":38},{"date":"2021-02-17","hemoglobin_g_dL":9.9,"wbc_k_uL":6.1,"platelets_k_uL":324,"creatinine_mg_dL":1.16,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_1998","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":76,"sex":"female","bmi":35.5,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-76},"pfs_months":28.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.0,"censored":true},"longitudinal_labs":[{"date":"2020-11-18","hemoglobin_g_dL":14.3,"wbc_k_uL":8.1,"platelets_k_uL":280,"creatinine_mg_dL":1.28,"alt_U_L":26},{"date":"2021-07-19","hemoglobin_g_dL":11.2,"wbc_k_uL":9.0,"platelets_k_uL":306,"creatinine_mg_dL":1.21,"alt_U_L":62},{"date":"2023-07-31","hemoglobin_g_dL":9.5,"wbc_k_uL":6.0,"platelets_k_uL":112,"creatinine_mg_dL":1.0,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_1999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":55,"sex":"female","bmi":31.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-83},"pfs_months":25.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.6,"censored":false},"longitudinal_labs":[{"date":"2021-01-13","hemoglobin_g_dL":13.3,"wbc_k_uL":5.3,"platelets_k_uL":304,"creatinine_mg_dL":0.61,"alt_U_L":35},{"date":"2021-08-17","hemoglobin_g_dL":11.5,"wbc_k_uL":6.2,"platelets_k_uL":184,"creatinine_mg_dL":0.96,"alt_U_L":114},{"date":"2023-04-27","hemoglobin_g_dL":12.7,"wbc_k_uL":3.6,"platelets_k_uL":340,"creatinine_mg_dL":1.69,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_2000","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":76,"sex":"female","bmi":24.6,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-01-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-73},"pfs_months":11.04},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":15.0,"censored":false},"longitudinal_labs":[{"date":"2023-12-03","hemoglobin_g_dL":14.9,"wbc_k_uL":9.6,"platelets_k_uL":242,"creatinine_mg_dL":0.72,"alt_U_L":53},{"date":"2024-07-11","hemoglobin_g_dL":13.4,"wbc_k_uL":9.0,"platelets_k_uL":172,"creatinine_mg_dL":0.96,"alt_U_L":116},{"date":"2025-01-08","hemoglobin_g_dL":10.0,"wbc_k_uL":4.2,"platelets_k_uL":280,"creatinine_mg_dL":1.55,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_2001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":74,"sex":"male","bmi":26.7,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-08-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-36},"pfs_months":46.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":75.3,"censored":true},"longitudinal_labs":[{"date":"2021-06-15","hemoglobin_g_dL":14.1,"wbc_k_uL":6.0,"platelets_k_uL":280,"creatinine_mg_dL":0.63,"alt_U_L":33},{"date":"2022-02-01","hemoglobin_g_dL":11.9,"wbc_k_uL":8.2,"platelets_k_uL":368,"creatinine_mg_dL":0.8,"alt_U_L":19},{"date":"2025-07-17","hemoglobin_g_dL":10.2,"wbc_k_uL":6.9,"platelets_k_uL":291,"creatinine_mg_dL":0.98,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_2002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":71,"sex":"female","bmi":29.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-58},"pfs_months":25.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":false},"longitudinal_labs":[{"date":"2022-10-15","hemoglobin_g_dL":14.7,"wbc_k_uL":7.0,"platelets_k_uL":409,"creatinine_mg_dL":1.25,"alt_U_L":64},{"date":"2023-06-07","hemoglobin_g_dL":12.4,"wbc_k_uL":6.8,"platelets_k_uL":163,"creatinine_mg_dL":0.96,"alt_U_L":89},{"date":"2025-02-19","hemoglobin_g_dL":11.4,"wbc_k_uL":4.2,"platelets_k_uL":255,"creatinine_mg_dL":1.0,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_2003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":77,"sex":"female","bmi":34.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-45},"pfs_months":38.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.4,"censored":false},"longitudinal_labs":[{"date":"2021-04-11","hemoglobin_g_dL":12.2,"wbc_k_uL":5.0,"platelets_k_uL":252,"creatinine_mg_dL":0.71,"alt_U_L":67},{"date":"2021-10-30","hemoglobin_g_dL":10.8,"wbc_k_uL":6.1,"platelets_k_uL":337,"creatinine_mg_dL":1.4,"alt_U_L":94},{"date":"2024-07-30","hemoglobin_g_dL":13.0,"wbc_k_uL":6.3,"platelets_k_uL":193,"creatinine_mg_dL":1.33,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_2004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.9,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":63,"sex":"female","bmi":22.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-55},"pfs_months":26.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.8,"censored":false},"longitudinal_labs":[{"date":"2025-08-05","hemoglobin_g_dL":13.4,"wbc_k_uL":6.2,"platelets_k_uL":348,"creatinine_mg_dL":1.28,"alt_U_L":68},{"date":"2026-03-27","hemoglobin_g_dL":11.7,"wbc_k_uL":6.6,"platelets_k_uL":191,"creatinine_mg_dL":1.13,"alt_U_L":48},{"date":"2028-02-12","hemoglobin_g_dL":10.0,"wbc_k_uL":6.1,"platelets_k_uL":298,"creatinine_mg_dL":1.81,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_2005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":84,"sex":"female","bmi":21.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-09-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-45},"pfs_months":19.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":false},"longitudinal_labs":[{"date":"2023-08-01","hemoglobin_g_dL":15.3,"wbc_k_uL":9.6,"platelets_k_uL":186,"creatinine_mg_dL":1.02,"alt_U_L":27},{"date":"2024-03-24","hemoglobin_g_dL":13.7,"wbc_k_uL":8.6,"platelets_k_uL":343,"creatinine_mg_dL":1.02,"alt_U_L":51},{"date":"2025-06-02","hemoglobin_g_dL":10.4,"wbc_k_uL":5.2,"platelets_k_uL":115,"creatinine_mg_dL":1.75,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_2006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":86,"sex":"female","bmi":23.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-42},"pfs_months":23.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":false},"longitudinal_labs":[{"date":"2021-05-15","hemoglobin_g_dL":13.3,"wbc_k_uL":7.7,"platelets_k_uL":200,"creatinine_mg_dL":1.16,"alt_U_L":76},{"date":"2021-12-07","hemoglobin_g_dL":11.1,"wbc_k_uL":5.4,"platelets_k_uL":170,"creatinine_mg_dL":1.06,"alt_U_L":43},{"date":"2023-06-03","hemoglobin_g_dL":12.1,"wbc_k_uL":4.3,"platelets_k_uL":129,"creatinine_mg_dL":0.83,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_2007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":60,"sex":"female","bmi":31.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-51},"pfs_months":31.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.8,"censored":false},"longitudinal_labs":[{"date":"2024-12-15","hemoglobin_g_dL":12.9,"wbc_k_uL":6.6,"platelets_k_uL":390,"creatinine_mg_dL":1.19,"alt_U_L":34},{"date":"2025-08-19","hemoglobin_g_dL":12.8,"wbc_k_uL":7.9,"platelets_k_uL":356,"creatinine_mg_dL":1.0,"alt_U_L":83},{"date":"2027-10-17","hemoglobin_g_dL":11.5,"wbc_k_uL":7.1,"platelets_k_uL":331,"creatinine_mg_dL":1.61,"alt_U_L":112}]}
{"patient_id":"ANODE_SYNTH_2025_2008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":88,"sex":"female","bmi":23.0,"smoking_pack_years":26,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2026-02-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-56},"pfs_months":34.37},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.6,"censored":true},"longitudinal_labs":[{"date":"2025-12-27","hemoglobin_g_dL":11.8,"wbc_k_uL":10.8,"platelets_k_uL":194,"creatinine_mg_dL":1.19,"alt_U_L":38},{"date":"2026-07-31","hemoglobin_g_dL":12.3,"wbc_k_uL":4.2,"platelets_k_uL":219,"creatinine_mg_dL":1.07,"alt_U_L":101},{"date":"2029-01-26","hemoglobin_g_dL":10.2,"wbc_k_uL":5.5,"platelets_k_uL":270,"creatinine_mg_dL":1.53,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_2009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":65,"sex":"female","bmi":20.2,"smoking_pack_years":79,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-07-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-53},"pfs_months":44.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":64.8,"censored":true},"longitudinal_labs":[{"date":"2024-06-10","hemoglobin_g_dL":14.3,"wbc_k_uL":5.0,"platelets_k_uL":426,"creatinine_mg_dL":0.67,"alt_U_L":68},{"date":"2025-01-06","hemoglobin_g_dL":12.3,"wbc_k_uL":7.0,"platelets_k_uL":233,"creatinine_mg_dL":1.46,"alt_U_L":108},{"date":"2028-04-30","hemoglobin_g_dL":10.2,"wbc_k_uL":3.5,"platelets_k_uL":163,"creatinine_mg_dL":1.12,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_2010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":49,"sex":"female","bmi":25.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-64},"pfs_months":25.33},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.4,"censored":false},"longitudinal_labs":[{"date":"2022-10-03","hemoglobin_g_dL":13.4,"wbc_k_uL":7.7,"platelets_k_uL":268,"creatinine_mg_dL":0.63,"alt_U_L":73},{"date":"2023-04-26","hemoglobin_g_dL":11.1,"wbc_k_uL":5.5,"platelets_k_uL":166,"creatinine_mg_dL":1.03,"alt_U_L":17},{"date":"2025-01-06","hemoglobin_g_dL":11.2,"wbc_k_uL":7.0,"platelets_k_uL":347,"creatinine_mg_dL":1.79,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_2011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":63,"sex":"female","bmi":37.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-81},"pfs_months":20.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.3,"censored":false},"longitudinal_labs":[{"date":"2021-10-15","hemoglobin_g_dL":12.1,"wbc_k_uL":7.1,"platelets_k_uL":158,"creatinine_mg_dL":1.08,"alt_U_L":14},{"date":"2022-05-12","hemoglobin_g_dL":12.5,"wbc_k_uL":6.0,"platelets_k_uL":272,"creatinine_mg_dL":1.58,"alt_U_L":119},{"date":"2023-09-06","hemoglobin_g_dL":11.4,"wbc_k_uL":7.5,"platelets_k_uL":109,"creatinine_mg_dL":1.45,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_2012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":62,"sex":"female","bmi":21.8,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-06-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-30},"pfs_months":7.23},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":11.4,"censored":true},"longitudinal_labs":[{"date":"2021-04-20","hemoglobin_g_dL":12.4,"wbc_k_uL":9.5,"platelets_k_uL":222,"creatinine_mg_dL":0.89,"alt_U_L":34},{"date":"2021-12-07","hemoglobin_g_dL":13.9,"wbc_k_uL":5.4,"platelets_k_uL":214,"creatinine_mg_dL":0.85,"alt_U_L":60},{"date":"2022-01-24","hemoglobin_g_dL":12.3,"wbc_k_uL":4.8,"platelets_k_uL":129,"creatinine_mg_dL":1.14,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":87,"sex":"female","bmi":29.8,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2026-01-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-84},"pfs_months":33.94},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-11-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":64.1,"censored":true},"longitudinal_labs":[{"date":"2025-11-17","hemoglobin_g_dL":11.8,"wbc_k_uL":10.1,"platelets_k_uL":246,"creatinine_mg_dL":0.86,"alt_U_L":74},{"date":"2026-07-02","hemoglobin_g_dL":12.2,"wbc_k_uL":7.4,"platelets_k_uL":130,"creatinine_mg_dL":0.81,"alt_U_L":114},{"date":"2028-11-12","hemoglobin_g_dL":10.9,"wbc_k_uL":4.6,"platelets_k_uL":281,"creatinine_mg_dL":1.25,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_2014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":73,"sex":"female","bmi":18.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-43},"pfs_months":17.91},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":false},"longitudinal_labs":[{"date":"2022-06-24","hemoglobin_g_dL":11.8,"wbc_k_uL":7.9,"platelets_k_uL":221,"creatinine_mg_dL":0.94,"alt_U_L":64},{"date":"2023-02-25","hemoglobin_g_dL":12.4,"wbc_k_uL":7.6,"platelets_k_uL":323,"creatinine_mg_dL":0.98,"alt_U_L":24},{"date":"2024-04-02","hemoglobin_g_dL":11.8,"wbc_k_uL":5.2,"platelets_k_uL":314,"creatinine_mg_dL":1.37,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_2015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":82,"sex":"female","bmi":32.1,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-03-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-45},"pfs_months":44.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":74.9,"censored":false},"longitudinal_labs":[{"date":"2022-01-14","hemoglobin_g_dL":14.5,"wbc_k_uL":6.2,"platelets_k_uL":393,"creatinine_mg_dL":1.13,"alt_U_L":63},{"date":"2022-09-12","hemoglobin_g_dL":12.5,"wbc_k_uL":5.2,"platelets_k_uL":224,"creatinine_mg_dL":1.2,"alt_U_L":108},{"date":"2025-12-04","hemoglobin_g_dL":11.8,"wbc_k_uL":5.3,"platelets_k_uL":116,"creatinine_mg_dL":1.22,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_2016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":49,"sex":"female","bmi":28.9,"smoking_pack_years":66,"ecog_performance_status":0,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-01-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-76},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.4,"censored":false},"longitudinal_labs":[{"date":"2023-11-16","hemoglobin_g_dL":12.4,"wbc_k_uL":9.7,"platelets_k_uL":362,"creatinine_mg_dL":1.06,"alt_U_L":14},{"date":"2024-07-04","hemoglobin_g_dL":13.4,"wbc_k_uL":8.9,"platelets_k_uL":315,"creatinine_mg_dL":1.13,"alt_U_L":106},{"date":"2024-04-22","hemoglobin_g_dL":10.5,"wbc_k_uL":3.9,"platelets_k_uL":264,"creatinine_mg_dL":1.34,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_2017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":73,"sex":"male","bmi":18.9,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-08-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-80},"pfs_months":39.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":73.8,"censored":false},"longitudinal_labs":[{"date":"2023-06-24","hemoglobin_g_dL":12.7,"wbc_k_uL":7.8,"platelets_k_uL":270,"creatinine_mg_dL":0.71,"alt_U_L":63},{"date":"2024-02-09","hemoglobin_g_dL":12.0,"wbc_k_uL":6.9,"platelets_k_uL":165,"creatinine_mg_dL":0.88,"alt_U_L":15},{"date":"2027-01-25","hemoglobin_g_dL":11.9,"wbc_k_uL":5.7,"platelets_k_uL":107,"creatinine_mg_dL":1.58,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_2018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":79,"sex":"female","bmi":31.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-36},"pfs_months":22.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.9,"censored":false},"longitudinal_labs":[{"date":"2020-03-21","hemoglobin_g_dL":11.6,"wbc_k_uL":7.6,"platelets_k_uL":201,"creatinine_mg_dL":1.03,"alt_U_L":48},{"date":"2020-11-04","hemoglobin_g_dL":13.2,"wbc_k_uL":7.9,"platelets_k_uL":143,"creatinine_mg_dL":1.17,"alt_U_L":90},{"date":"2022-05-06","hemoglobin_g_dL":10.9,"wbc_k_uL":7.8,"platelets_k_uL":330,"creatinine_mg_dL":1.08,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_2019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.0,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":88,"sex":"female","bmi":33.4,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-02-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-40},"pfs_months":7.92},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":17.5,"censored":false},"longitudinal_labs":[{"date":"2024-01-06","hemoglobin_g_dL":13.0,"wbc_k_uL":4.5,"platelets_k_uL":176,"creatinine_mg_dL":1.21,"alt_U_L":63},{"date":"2024-08-04","hemoglobin_g_dL":10.3,"wbc_k_uL":8.8,"platelets_k_uL":376,"creatinine_mg_dL":1.5,"alt_U_L":25},{"date":"2024-10-31","hemoglobin_g_dL":12.2,"wbc_k_uL":3.1,"platelets_k_uL":191,"creatinine_mg_dL":1.83,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_2020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":53,"sex":"female","bmi":33.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-78},"pfs_months":20.3},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":41.0,"censored":false},"longitudinal_labs":[{"date":"2023-10-03","hemoglobin_g_dL":15.4,"wbc_k_uL":7.3,"platelets_k_uL":402,"creatinine_mg_dL":0.83,"alt_U_L":40},{"date":"2024-06-03","hemoglobin_g_dL":13.4,"wbc_k_uL":5.0,"platelets_k_uL":362,"creatinine_mg_dL":1.55,"alt_U_L":119},{"date":"2025-09-16","hemoglobin_g_dL":11.0,"wbc_k_uL":7.3,"platelets_k_uL":323,"creatinine_mg_dL":1.0,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_2021","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":61,"sex":"male","bmi":27.0,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-10-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-30},"pfs_months":28.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.1,"censored":false},"longitudinal_labs":[{"date":"2022-09-26","hemoglobin_g_dL":11.6,"wbc_k_uL":6.9,"platelets_k_uL":348,"creatinine_mg_dL":0.78,"alt_U_L":23},{"date":"2023-04-10","hemoglobin_g_dL":11.9,"wbc_k_uL":4.0,"platelets_k_uL":153,"creatinine_mg_dL":1.04,"alt_U_L":17},{"date":"2025-04-04","hemoglobin_g_dL":11.4,"wbc_k_uL":7.5,"platelets_k_uL":263,"creatinine_mg_dL":1.29,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_2022","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":54,"sex":"female","bmi":27.2,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-05-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-69},"pfs_months":21.91},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":true},"longitudinal_labs":[{"date":"2020-03-13","hemoglobin_g_dL":11.7,"wbc_k_uL":8.9,"platelets_k_uL":384,"creatinine_mg_dL":1.16,"alt_U_L":24},{"date":"2020-11-05","hemoglobin_g_dL":13.6,"wbc_k_uL":7.2,"platelets_k_uL":376,"creatinine_mg_dL":1.35,"alt_U_L":67},{"date":"2022-03-22","hemoglobin_g_dL":11.1,"wbc_k_uL":6.1,"platelets_k_uL":223,"creatinine_mg_dL":1.14,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_2023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":85,"sex":"female","bmi":37.8,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-10-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-31},"pfs_months":48.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-11-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":72.3,"censored":false},"longitudinal_labs":[{"date":"2025-08-21","hemoglobin_g_dL":15.1,"wbc_k_uL":8.9,"platelets_k_uL":167,"creatinine_mg_dL":0.76,"alt_U_L":53},{"date":"2026-03-30","hemoglobin_g_dL":11.6,"wbc_k_uL":4.4,"platelets_k_uL":254,"creatinine_mg_dL":1.35,"alt_U_L":98},{"date":"2029-11-16","hemoglobin_g_dL":11.2,"wbc_k_uL":5.2,"platelets_k_uL":270,"creatinine_mg_dL":1.9,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_2024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":51,"sex":"female","bmi":32.7,"smoking_pack_years":65,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-36},"pfs_months":42.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":72.0,"censored":false},"longitudinal_labs":[{"date":"2024-01-13","hemoglobin_g_dL":11.6,"wbc_k_uL":10.1,"platelets_k_uL":288,"creatinine_mg_dL":1.12,"alt_U_L":18},{"date":"2024-09-18","hemoglobin_g_dL":10.3,"wbc_k_uL":5.9,"platelets_k_uL":282,"creatinine_mg_dL":1.1,"alt_U_L":65},{"date":"2027-11-03","hemoglobin_g_dL":10.9,"wbc_k_uL":7.4,"platelets_k_uL":168,"creatinine_mg_dL":1.29,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_2025","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":55,"sex":"female","bmi":22.1,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-10-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-49},"pfs_months":33.58},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.6,"censored":true},"longitudinal_labs":[{"date":"2023-09-18","hemoglobin_g_dL":13.8,"wbc_k_uL":6.4,"platelets_k_uL":377,"creatinine_mg_dL":0.82,"alt_U_L":18},{"date":"2024-04-08","hemoglobin_g_dL":11.4,"wbc_k_uL":6.6,"platelets_k_uL":229,"creatinine_mg_dL":1.12,"alt_U_L":33},{"date":"2026-08-08","hemoglobin_g_dL":10.0,"wbc_k_uL":5.6,"platelets_k_uL":207,"creatinine_mg_dL":1.11,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_2026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":83,"sex":"male","bmi":37.5,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-44},"pfs_months":39.39},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.2,"censored":true},"longitudinal_labs":[{"date":"2021-04-21","hemoglobin_g_dL":14.5,"wbc_k_uL":4.8,"platelets_k_uL":439,"creatinine_mg_dL":0.91,"alt_U_L":47},{"date":"2021-12-23","hemoglobin_g_dL":12.1,"wbc_k_uL":7.0,"platelets_k_uL":201,"creatinine_mg_dL":1.02,"alt_U_L":76},{"date":"2024-11-20","hemoglobin_g_dL":10.1,"wbc_k_uL":6.8,"platelets_k_uL":290,"creatinine_mg_dL":1.39,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_2027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":67,"sex":"female","bmi":25.0,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-31},"pfs_months":27.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":false},"longitudinal_labs":[{"date":"2021-01-21","hemoglobin_g_dL":13.9,"wbc_k_uL":6.9,"platelets_k_uL":155,"creatinine_mg_dL":0.8,"alt_U_L":75},{"date":"2021-09-16","hemoglobin_g_dL":10.5,"wbc_k_uL":6.6,"platelets_k_uL":200,"creatinine_mg_dL":1.34,"alt_U_L":29},{"date":"2023-09-12","hemoglobin_g_dL":10.7,"wbc_k_uL":6.4,"platelets_k_uL":133,"creatinine_mg_dL":1.84,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_2028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":84,"sex":"male","bmi":28.3,"smoking_pack_years":23,"ecog_performance_status":2,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-09-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-35},"pfs_months":32.76},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.1,"censored":true},"longitudinal_labs":[{"date":"2021-08-13","hemoglobin_g_dL":12.7,"wbc_k_uL":7.8,"platelets_k_uL":243,"creatinine_mg_dL":0.66,"alt_U_L":39},{"date":"2022-03-11","hemoglobin_g_dL":10.0,"wbc_k_uL":7.4,"platelets_k_uL":377,"creatinine_mg_dL":0.87,"alt_U_L":49},{"date":"2024-06-16","hemoglobin_g_dL":10.7,"wbc_k_uL":6.2,"platelets_k_uL":283,"creatinine_mg_dL":1.97,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_2029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":57,"sex":"female","bmi":34.5,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-05-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-71},"pfs_months":6.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-01-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":13.0,"censored":false},"longitudinal_labs":[{"date":"2020-04-19","hemoglobin_g_dL":14.4,"wbc_k_uL":7.4,"platelets_k_uL":158,"creatinine_mg_dL":0.66,"alt_U_L":61},{"date":"2020-11-15","hemoglobin_g_dL":10.2,"wbc_k_uL":7.9,"platelets_k_uL":158,"creatinine_mg_dL":1.12,"alt_U_L":71},{"date":"2021-01-14","hemoglobin_g_dL":9.6,"wbc_k_uL":7.3,"platelets_k_uL":132,"creatinine_mg_dL":1.05,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_2030","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":68,"sex":"female","bmi":30.4,"smoking_pack_years":67,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-09-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-36},"pfs_months":32.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.1,"censored":false},"longitudinal_labs":[{"date":"2020-08-07","hemoglobin_g_dL":14.2,"wbc_k_uL":6.0,"platelets_k_uL":173,"creatinine_mg_dL":0.73,"alt_U_L":76},{"date":"2021-03-07","hemoglobin_g_dL":12.5,"wbc_k_uL":8.2,"platelets_k_uL":368,"creatinine_mg_dL":1.22,"alt_U_L":118},{"date":"2023-07-08","hemoglobin_g_dL":11.8,"wbc_k_uL":5.6,"platelets_k_uL":350,"creatinine_mg_dL":1.56,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_2031","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":68,"sex":"female","bmi":30.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-74},"pfs_months":12.45},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.6,"censored":false},"longitudinal_labs":[{"date":"2024-07-19","hemoglobin_g_dL":15.3,"wbc_k_uL":9.4,"platelets_k_uL":189,"creatinine_mg_dL":1.1,"alt_U_L":24},{"date":"2025-03-15","hemoglobin_g_dL":10.6,"wbc_k_uL":7.5,"platelets_k_uL":290,"creatinine_mg_dL":1.58,"alt_U_L":95},{"date":"2025-11-12","hemoglobin_g_dL":12.8,"wbc_k_uL":3.5,"platelets_k_uL":282,"creatinine_mg_dL":1.48,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_2032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":62,"sex":"female","bmi":34.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-45},"pfs_months":23.13},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.3,"censored":false},"longitudinal_labs":[{"date":"2025-10-17","hemoglobin_g_dL":12.7,"wbc_k_uL":9.2,"platelets_k_uL":195,"creatinine_mg_dL":1.21,"alt_U_L":46},{"date":"2026-06-02","hemoglobin_g_dL":11.6,"wbc_k_uL":4.0,"platelets_k_uL":378,"creatinine_mg_dL":1.39,"alt_U_L":25},{"date":"2027-12-16","hemoglobin_g_dL":11.1,"wbc_k_uL":6.4,"platelets_k_uL":199,"creatinine_mg_dL":1.4,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_2033","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":55,"sex":"female","bmi":34.4,"smoking_pack_years":15,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-11-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-77},"pfs_months":25.1},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.1,"censored":false},"longitudinal_labs":[{"date":"2021-11-06","hemoglobin_g_dL":14.9,"wbc_k_uL":10.6,"platelets_k_uL":268,"creatinine_mg_dL":0.74,"alt_U_L":31},{"date":"2022-05-28","hemoglobin_g_dL":11.8,"wbc_k_uL":5.1,"platelets_k_uL":249,"creatinine_mg_dL":1.13,"alt_U_L":67},{"date":"2024-02-05","hemoglobin_g_dL":11.6,"wbc_k_uL":7.7,"platelets_k_uL":153,"creatinine_mg_dL":1.91,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2034","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":59,"sex":"male","bmi":34.9,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2025-04-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-41},"pfs_months":24.15},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":true},"longitudinal_labs":[{"date":"2025-03-02","hemoglobin_g_dL":13.1,"wbc_k_uL":8.2,"platelets_k_uL":295,"creatinine_mg_dL":0.92,"alt_U_L":12},{"date":"2025-09-28","hemoglobin_g_dL":13.7,"wbc_k_uL":7.9,"platelets_k_uL":378,"creatinine_mg_dL":0.98,"alt_U_L":113},{"date":"2027-04-16","hemoglobin_g_dL":11.9,"wbc_k_uL":5.2,"platelets_k_uL":273,"creatinine_mg_dL":1.64,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_2035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":61,"sex":"female","bmi":19.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-10-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-79},"pfs_months":16.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.7,"censored":false},"longitudinal_labs":[{"date":"2025-08-22","hemoglobin_g_dL":15.4,"wbc_k_uL":10.9,"platelets_k_uL":353,"creatinine_mg_dL":1.19,"alt_U_L":69},{"date":"2026-04-16","hemoglobin_g_dL":13.4,"wbc_k_uL":7.5,"platelets_k_uL":340,"creatinine_mg_dL":1.1,"alt_U_L":61},{"date":"2027-04-11","hemoglobin_g_dL":11.2,"wbc_k_uL":4.9,"platelets_k_uL":102,"creatinine_mg_dL":0.91,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_2036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":48,"sex":"female","bmi":22.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-34},"pfs_months":20.7},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.9,"censored":true},"longitudinal_labs":[{"date":"2020-03-25","hemoglobin_g_dL":11.5,"wbc_k_uL":8.9,"platelets_k_uL":247,"creatinine_mg_dL":0.99,"alt_U_L":12},{"date":"2020-11-27","hemoglobin_g_dL":11.4,"wbc_k_uL":7.5,"platelets_k_uL":330,"creatinine_mg_dL":0.77,"alt_U_L":75},{"date":"2022-04-09","hemoglobin_g_dL":9.8,"wbc_k_uL":7.1,"platelets_k_uL":237,"creatinine_mg_dL":1.72,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_2037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":53,"sex":"female","bmi":19.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-37},"pfs_months":26.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":false},"longitudinal_labs":[{"date":"2024-04-08","hemoglobin_g_dL":13.4,"wbc_k_uL":4.9,"platelets_k_uL":246,"creatinine_mg_dL":1.24,"alt_U_L":47},{"date":"2024-10-19","hemoglobin_g_dL":12.7,"wbc_k_uL":4.0,"platelets_k_uL":272,"creatinine_mg_dL":1.15,"alt_U_L":75},{"date":"2026-08-13","hemoglobin_g_dL":10.7,"wbc_k_uL":3.3,"platelets_k_uL":264,"creatinine_mg_dL":0.99,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_2038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":88,"sex":"female","bmi":27.2,"smoking_pack_years":38,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-02-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-55},"pfs_months":9.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.8,"censored":false},"longitudinal_labs":[{"date":"2024-12-23","hemoglobin_g_dL":13.3,"wbc_k_uL":10.9,"platelets_k_uL":333,"creatinine_mg_dL":1.0,"alt_U_L":22},{"date":"2025-08-23","hemoglobin_g_dL":10.1,"wbc_k_uL":8.6,"platelets_k_uL":280,"creatinine_mg_dL":1.11,"alt_U_L":45},{"date":"2025-12-18","hemoglobin_g_dL":11.8,"wbc_k_uL":7.4,"platelets_k_uL":249,"creatinine_mg_dL":1.37,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_2039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":76,"sex":"male","bmi":29.0,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-79},"pfs_months":33.68},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":67.1,"censored":false},"longitudinal_labs":[{"date":"2021-01-21","hemoglobin_g_dL":13.6,"wbc_k_uL":4.8,"platelets_k_uL":366,"creatinine_mg_dL":0.99,"alt_U_L":14},{"date":"2021-09-14","hemoglobin_g_dL":10.8,"wbc_k_uL":4.5,"platelets_k_uL":359,"creatinine_mg_dL":1.33,"alt_U_L":50},{"date":"2024-01-23","hemoglobin_g_dL":11.9,"wbc_k_uL":7.1,"platelets_k_uL":224,"creatinine_mg_dL":0.9,"alt_U_L":145}]}
{"patient_id":"ANODE_SYNTH_2025_2040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":62,"sex":"female","bmi":29.2,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-11-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-59},"pfs_months":39.26},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":61.4,"censored":false},"longitudinal_labs":[{"date":"2022-09-11","hemoglobin_g_dL":13.0,"wbc_k_uL":9.7,"platelets_k_uL":289,"creatinine_mg_dL":0.84,"alt_U_L":25},{"date":"2023-05-01","hemoglobin_g_dL":13.4,"wbc_k_uL":4.0,"platelets_k_uL":273,"creatinine_mg_dL":1.28,"alt_U_L":34},{"date":"2026-02-16","hemoglobin_g_dL":12.4,"wbc_k_uL":5.1,"platelets_k_uL":329,"creatinine_mg_dL":1.29,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_2041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":77,"sex":"male","bmi":32.4,"smoking_pack_years":16,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-11-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-75},"pfs_months":14.75},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.1,"censored":false},"longitudinal_labs":[{"date":"2024-09-24","hemoglobin_g_dL":12.5,"wbc_k_uL":5.7,"platelets_k_uL":426,"creatinine_mg_dL":0.95,"alt_U_L":46},{"date":"2025-05-25","hemoglobin_g_dL":11.1,"wbc_k_uL":5.8,"platelets_k_uL":279,"creatinine_mg_dL":0.95,"alt_U_L":110},{"date":"2026-03-10","hemoglobin_g_dL":10.5,"wbc_k_uL":5.1,"platelets_k_uL":309,"creatinine_mg_dL":1.35,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_2042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":70,"sex":"male","bmi":29.3,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-05-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-74},"pfs_months":21.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.9,"censored":false},"longitudinal_labs":[{"date":"2021-03-08","hemoglobin_g_dL":12.4,"wbc_k_uL":6.7,"platelets_k_uL":171,"creatinine_mg_dL":1.11,"alt_U_L":67},{"date":"2021-11-01","hemoglobin_g_dL":12.8,"wbc_k_uL":4.6,"platelets_k_uL":373,"creatinine_mg_dL":1.54,"alt_U_L":17},{"date":"2023-03-29","hemoglobin_g_dL":11.4,"wbc_k_uL":7.1,"platelets_k_uL":293,"creatinine_mg_dL":0.93,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_2043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":67,"sex":"male","bmi":28.2,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-08-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-33},"pfs_months":40.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.9,"censored":true},"longitudinal_labs":[{"date":"2024-07-09","hemoglobin_g_dL":11.6,"wbc_k_uL":10.8,"platelets_k_uL":178,"creatinine_mg_dL":0.91,"alt_U_L":34},{"date":"2025-01-31","hemoglobin_g_dL":11.8,"wbc_k_uL":6.3,"platelets_k_uL":358,"creatinine_mg_dL":0.86,"alt_U_L":96},{"date":"2028-02-21","hemoglobin_g_dL":11.7,"wbc_k_uL":5.9,"platelets_k_uL":213,"creatinine_mg_dL":1.38,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_2044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.2,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":60,"sex":"female","bmi":31.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-52},"pfs_months":16.07},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":20.8,"censored":false},"longitudinal_labs":[{"date":"2025-04-11","hemoglobin_g_dL":12.5,"wbc_k_uL":5.6,"platelets_k_uL":346,"creatinine_mg_dL":0.93,"alt_U_L":42},{"date":"2025-12-08","hemoglobin_g_dL":10.2,"wbc_k_uL":7.4,"platelets_k_uL":217,"creatinine_mg_dL":0.73,"alt_U_L":47},{"date":"2026-11-05","hemoglobin_g_dL":10.3,"wbc_k_uL":3.9,"platelets_k_uL":112,"creatinine_mg_dL":1.71,"alt_U_L":71}]}
{"patient_id":"ANODE_SYNTH_2025_2045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":52,"sex":"female","bmi":31.5,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-09-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-57},"pfs_months":38.28},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.6,"censored":false},"longitudinal_labs":[{"date":"2023-08-19","hemoglobin_g_dL":12.5,"wbc_k_uL":5.5,"platelets_k_uL":374,"creatinine_mg_dL":1.02,"alt_U_L":66},{"date":"2024-03-11","hemoglobin_g_dL":13.1,"wbc_k_uL":5.6,"platelets_k_uL":168,"creatinine_mg_dL":1.59,"alt_U_L":24},{"date":"2026-11-26","hemoglobin_g_dL":9.5,"wbc_k_uL":4.2,"platelets_k_uL":170,"creatinine_mg_dL":1.88,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_2046","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":54,"sex":"female","bmi":24.6,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-01-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-36},"pfs_months":13.77},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.9,"censored":true},"longitudinal_labs":[{"date":"2023-11-12","hemoglobin_g_dL":13.7,"wbc_k_uL":8.2,"platelets_k_uL":431,"creatinine_mg_dL":0.77,"alt_U_L":49},{"date":"2024-07-03","hemoglobin_g_dL":13.3,"wbc_k_uL":5.3,"platelets_k_uL":138,"creatinine_mg_dL":0.79,"alt_U_L":116},{"date":"2025-04-02","hemoglobin_g_dL":10.2,"wbc_k_uL":3.6,"platelets_k_uL":273,"creatinine_mg_dL":1.13,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_2047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":83,"sex":"female","bmi":34.2,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-11-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-60},"pfs_months":34.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-11-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":60.9,"censored":true},"longitudinal_labs":[{"date":"2025-10-11","hemoglobin_g_dL":14.7,"wbc_k_uL":7.9,"platelets_k_uL":254,"creatinine_mg_dL":0.82,"alt_U_L":14},{"date":"2026-05-12","hemoglobin_g_dL":13.1,"wbc_k_uL":7.9,"platelets_k_uL":335,"creatinine_mg_dL":1.6,"alt_U_L":20},{"date":"2028-11-13","hemoglobin_g_dL":10.2,"wbc_k_uL":6.9,"platelets_k_uL":281,"creatinine_mg_dL":1.4,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_2048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":55,"sex":"female","bmi":27.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-05-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-60},"pfs_months":23.23},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.0,"censored":true},"longitudinal_labs":[{"date":"2023-04-05","hemoglobin_g_dL":12.0,"wbc_k_uL":4.9,"platelets_k_uL":403,"creatinine_mg_dL":1.05,"alt_U_L":20},{"date":"2023-11-19","hemoglobin_g_dL":11.5,"wbc_k_uL":4.8,"platelets_k_uL":303,"creatinine_mg_dL":1.47,"alt_U_L":64},{"date":"2025-05-14","hemoglobin_g_dL":11.5,"wbc_k_uL":3.5,"platelets_k_uL":350,"creatinine_mg_dL":1.62,"alt_U_L":112}]}
{"patient_id":"ANODE_SYNTH_2025_2049","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":62,"sex":"female","bmi":24.3,"smoking_pack_years":23,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-02-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-43},"pfs_months":12.91},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.8,"censored":false},"longitudinal_labs":[{"date":"2021-01-20","hemoglobin_g_dL":15.4,"wbc_k_uL":10.4,"platelets_k_uL":214,"creatinine_mg_dL":0.99,"alt_U_L":20},{"date":"2021-08-16","hemoglobin_g_dL":10.7,"wbc_k_uL":4.1,"platelets_k_uL":132,"creatinine_mg_dL":1.51,"alt_U_L":40},{"date":"2022-04-24","hemoglobin_g_dL":12.1,"wbc_k_uL":6.2,"platelets_k_uL":233,"creatinine_mg_dL":1.54,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_2050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":51,"sex":"male","bmi":22.9,"smoking_pack_years":58,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-12-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-34},"pfs_months":18.6},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":true},"longitudinal_labs":[{"date":"2024-11-04","hemoglobin_g_dL":13.6,"wbc_k_uL":8.4,"platelets_k_uL":233,"creatinine_mg_dL":0.72,"alt_U_L":33},{"date":"2025-06-11","hemoglobin_g_dL":13.1,"wbc_k_uL":7.6,"platelets_k_uL":265,"creatinine_mg_dL":1.18,"alt_U_L":31},{"date":"2026-08-27","hemoglobin_g_dL":9.8,"wbc_k_uL":7.7,"platelets_k_uL":254,"creatinine_mg_dL":0.92,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_2051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":62,"sex":"female","bmi":33.6,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-52},"pfs_months":15.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.3,"censored":false},"longitudinal_labs":[{"date":"2024-02-25","hemoglobin_g_dL":12.4,"wbc_k_uL":4.9,"platelets_k_uL":437,"creatinine_mg_dL":0.89,"alt_U_L":38},{"date":"2024-10-21","hemoglobin_g_dL":11.1,"wbc_k_uL":4.3,"platelets_k_uL":316,"creatinine_mg_dL":1.59,"alt_U_L":79},{"date":"2025-08-14","hemoglobin_g_dL":11.9,"wbc_k_uL":4.0,"platelets_k_uL":156,"creatinine_mg_dL":1.25,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_2052","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":83,"sex":"female","bmi":21.1,"smoking_pack_years":19,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-12-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-69},"pfs_months":16.99},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.5,"censored":true},"longitudinal_labs":[{"date":"2022-10-23","hemoglobin_g_dL":15.1,"wbc_k_uL":5.7,"platelets_k_uL":183,"creatinine_mg_dL":0.66,"alt_U_L":43},{"date":"2023-06-27","hemoglobin_g_dL":11.6,"wbc_k_uL":5.5,"platelets_k_uL":365,"creatinine_mg_dL":1.16,"alt_U_L":70},{"date":"2024-07-10","hemoglobin_g_dL":9.7,"wbc_k_uL":7.2,"platelets_k_uL":188,"creatinine_mg_dL":1.01,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_2053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":61,"sex":"male","bmi":19.3,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-12-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-61},"pfs_months":6.34},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":13.0,"censored":true},"longitudinal_labs":[{"date":"2021-10-21","hemoglobin_g_dL":13.2,"wbc_k_uL":7.0,"platelets_k_uL":220,"creatinine_mg_dL":1.03,"alt_U_L":27},{"date":"2022-06-09","hemoglobin_g_dL":12.6,"wbc_k_uL":5.6,"platelets_k_uL":201,"creatinine_mg_dL":1.42,"alt_U_L":104},{"date":"2022-08-12","hemoglobin_g_dL":11.5,"wbc_k_uL":3.9,"platelets_k_uL":170,"creatinine_mg_dL":0.97,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_2054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":79,"sex":"female","bmi":21.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-34},"pfs_months":24.51},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-18","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":true},"longitudinal_labs":[{"date":"2022-08-14","hemoglobin_g_dL":14.9,"wbc_k_uL":9.1,"platelets_k_uL":228,"creatinine_mg_dL":1.21,"alt_U_L":38},{"date":"2023-03-06","hemoglobin_g_dL":10.2,"wbc_k_uL":5.3,"platelets_k_uL":166,"creatinine_mg_dL":0.79,"alt_U_L":50},{"date":"2024-10-18","hemoglobin_g_dL":10.9,"wbc_k_uL":6.5,"platelets_k_uL":288,"creatinine_mg_dL":1.7,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_2055","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":81,"sex":"male","bmi":37.8,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2023-03-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-72},"pfs_months":28.45},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.9,"censored":true},"longitudinal_labs":[{"date":"2023-01-11","hemoglobin_g_dL":12.6,"wbc_k_uL":4.9,"platelets_k_uL":328,"creatinine_mg_dL":0.74,"alt_U_L":28},{"date":"2023-09-10","hemoglobin_g_dL":11.2,"wbc_k_uL":5.2,"platelets_k_uL":243,"creatinine_mg_dL":1.21,"alt_U_L":106},{"date":"2025-09-20","hemoglobin_g_dL":10.9,"wbc_k_uL":6.7,"platelets_k_uL":227,"creatinine_mg_dL":1.07,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_2056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":70,"sex":"female","bmi":33.4,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-02-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-72},"pfs_months":5.75},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":15.1,"censored":false},"longitudinal_labs":[{"date":"2025-02-06","hemoglobin_g_dL":11.5,"wbc_k_uL":6.6,"platelets_k_uL":199,"creatinine_mg_dL":1.27,"alt_U_L":72},{"date":"2025-08-23","hemoglobin_g_dL":12.8,"wbc_k_uL":8.0,"platelets_k_uL":243,"creatinine_mg_dL":1.08,"alt_U_L":114},{"date":"2025-09-13","hemoglobin_g_dL":12.1,"wbc_k_uL":6.1,"platelets_k_uL":263,"creatinine_mg_dL":1.85,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_2057","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":59,"sex":"female","bmi":34.9,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-08-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-81},"pfs_months":18.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":true},"longitudinal_labs":[{"date":"2020-07-10","hemoglobin_g_dL":13.3,"wbc_k_uL":9.7,"platelets_k_uL":300,"creatinine_mg_dL":0.95,"alt_U_L":65},{"date":"2021-02-24","hemoglobin_g_dL":11.3,"wbc_k_uL":5.5,"platelets_k_uL":214,"creatinine_mg_dL":1.15,"alt_U_L":88},{"date":"2022-05-05","hemoglobin_g_dL":9.6,"wbc_k_uL":3.2,"platelets_k_uL":248,"creatinine_mg_dL":1.72,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_2058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":50,"sex":"female","bmi":22.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-80},"pfs_months":32.26},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.6,"censored":false},"longitudinal_labs":[{"date":"2022-04-15","hemoglobin_g_dL":14.7,"wbc_k_uL":10.8,"platelets_k_uL":419,"creatinine_mg_dL":0.83,"alt_U_L":45},{"date":"2022-11-28","hemoglobin_g_dL":10.9,"wbc_k_uL":5.0,"platelets_k_uL":351,"creatinine_mg_dL":0.9,"alt_U_L":28},{"date":"2025-02-23","hemoglobin_g_dL":11.1,"wbc_k_uL":7.7,"platelets_k_uL":174,"creatinine_mg_dL":1.02,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_2059","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":87,"sex":"female","bmi":26.7,"smoking_pack_years":74,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-30},"pfs_months":34.04},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":47.8,"censored":true},"longitudinal_labs":[{"date":"2022-07-10","hemoglobin_g_dL":11.6,"wbc_k_uL":5.9,"platelets_k_uL":346,"creatinine_mg_dL":1.18,"alt_U_L":26},{"date":"2023-02-14","hemoglobin_g_dL":13.0,"wbc_k_uL":8.6,"platelets_k_uL":237,"creatinine_mg_dL":1.03,"alt_U_L":106},{"date":"2025-07-28","hemoglobin_g_dL":10.1,"wbc_k_uL":5.3,"platelets_k_uL":348,"creatinine_mg_dL":1.54,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_2060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":88,"sex":"female","bmi":21.3,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-09-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-58},"pfs_months":41.89},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":62.2,"censored":true},"longitudinal_labs":[{"date":"2024-08-16","hemoglobin_g_dL":12.4,"wbc_k_uL":11.0,"platelets_k_uL":282,"creatinine_mg_dL":1.2,"alt_U_L":51},{"date":"2025-03-01","hemoglobin_g_dL":10.5,"wbc_k_uL":8.9,"platelets_k_uL":257,"creatinine_mg_dL":1.45,"alt_U_L":97},{"date":"2028-04-06","hemoglobin_g_dL":10.0,"wbc_k_uL":4.2,"platelets_k_uL":108,"creatinine_mg_dL":0.82,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_2061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":88,"sex":"male","bmi":34.0,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2024-05-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-31},"pfs_months":20.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":false},"longitudinal_labs":[{"date":"2024-03-17","hemoglobin_g_dL":12.2,"wbc_k_uL":7.4,"platelets_k_uL":425,"creatinine_mg_dL":1.28,"alt_U_L":20},{"date":"2024-11-16","hemoglobin_g_dL":11.2,"wbc_k_uL":3.9,"platelets_k_uL":218,"creatinine_mg_dL":1.02,"alt_U_L":27},{"date":"2026-02-16","hemoglobin_g_dL":10.6,"wbc_k_uL":5.4,"platelets_k_uL":341,"creatinine_mg_dL":1.48,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_2062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":87,"sex":"female","bmi":24.7,"smoking_pack_years":60,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-11-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-44},"pfs_months":9.23},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":13.2,"censored":false},"longitudinal_labs":[{"date":"2025-09-08","hemoglobin_g_dL":11.9,"wbc_k_uL":6.9,"platelets_k_uL":371,"creatinine_mg_dL":1.01,"alt_U_L":56},{"date":"2026-05-10","hemoglobin_g_dL":12.6,"wbc_k_uL":7.2,"platelets_k_uL":332,"creatinine_mg_dL":0.82,"alt_U_L":19},{"date":"2026-10-02","hemoglobin_g_dL":12.7,"wbc_k_uL":6.6,"platelets_k_uL":318,"creatinine_mg_dL":1.06,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_2063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":64,"sex":"female","bmi":20.3,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-30},"pfs_months":43.6},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-09-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":74.7,"censored":false},"longitudinal_labs":[{"date":"2025-01-14","hemoglobin_g_dL":12.1,"wbc_k_uL":9.2,"platelets_k_uL":309,"creatinine_mg_dL":0.71,"alt_U_L":67},{"date":"2025-08-02","hemoglobin_g_dL":10.0,"wbc_k_uL":5.4,"platelets_k_uL":310,"creatinine_mg_dL":1.33,"alt_U_L":95},{"date":"2028-09-26","hemoglobin_g_dL":10.6,"wbc_k_uL":4.9,"platelets_k_uL":332,"creatinine_mg_dL":0.91,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_2064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":86,"sex":"female","bmi":23.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-61},"pfs_months":23.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.7,"censored":true},"longitudinal_labs":[{"date":"2021-07-13","hemoglobin_g_dL":14.9,"wbc_k_uL":7.2,"platelets_k_uL":432,"creatinine_mg_dL":1.14,"alt_U_L":26},{"date":"2022-02-20","hemoglobin_g_dL":11.4,"wbc_k_uL":6.3,"platelets_k_uL":279,"creatinine_mg_dL":1.02,"alt_U_L":22},{"date":"2023-08-17","hemoglobin_g_dL":12.5,"wbc_k_uL":4.9,"platelets_k_uL":161,"creatinine_mg_dL":1.71,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":68,"sex":"female","bmi":19.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-37},"pfs_months":3.71},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.2,"censored":true},"longitudinal_labs":[{"date":"2024-11-26","hemoglobin_g_dL":14.4,"wbc_k_uL":6.1,"platelets_k_uL":424,"creatinine_mg_dL":0.78,"alt_U_L":13},{"date":"2025-07-04","hemoglobin_g_dL":11.4,"wbc_k_uL":8.9,"platelets_k_uL":351,"creatinine_mg_dL":0.91,"alt_U_L":60},{"date":"2025-05-10","hemoglobin_g_dL":10.2,"wbc_k_uL":6.6,"platelets_k_uL":337,"creatinine_mg_dL":1.98,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_2066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":69,"sex":"female","bmi":19.7,"smoking_pack_years":25,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-56},"pfs_months":46.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-03-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":69.0,"censored":false},"longitudinal_labs":[{"date":"2025-01-25","hemoglobin_g_dL":11.9,"wbc_k_uL":10.3,"platelets_k_uL":157,"creatinine_mg_dL":0.65,"alt_U_L":75},{"date":"2025-09-04","hemoglobin_g_dL":10.5,"wbc_k_uL":6.8,"platelets_k_uL":136,"creatinine_mg_dL":1.4,"alt_U_L":40},{"date":"2029-03-02","hemoglobin_g_dL":12.3,"wbc_k_uL":3.3,"platelets_k_uL":321,"creatinine_mg_dL":1.57,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_2067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":59,"sex":"male","bmi":35.2,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-10-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-53},"pfs_months":35.91},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":65.2,"censored":false},"longitudinal_labs":[{"date":"2020-09-13","hemoglobin_g_dL":14.7,"wbc_k_uL":7.6,"platelets_k_uL":171,"creatinine_mg_dL":0.87,"alt_U_L":75},{"date":"2021-04-26","hemoglobin_g_dL":10.7,"wbc_k_uL":5.3,"platelets_k_uL":191,"creatinine_mg_dL":1.5,"alt_U_L":109},{"date":"2023-12-15","hemoglobin_g_dL":11.5,"wbc_k_uL":6.3,"platelets_k_uL":311,"creatinine_mg_dL":1.54,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_2068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":66,"sex":"female","bmi":19.1,"smoking_pack_years":62,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-08-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-53},"pfs_months":42.71},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":68.6,"censored":false},"longitudinal_labs":[{"date":"2023-07-26","hemoglobin_g_dL":12.9,"wbc_k_uL":4.7,"platelets_k_uL":384,"creatinine_mg_dL":1.15,"alt_U_L":74},{"date":"2024-02-25","hemoglobin_g_dL":13.9,"wbc_k_uL":6.9,"platelets_k_uL":174,"creatinine_mg_dL":0.77,"alt_U_L":28},{"date":"2027-05-16","hemoglobin_g_dL":12.8,"wbc_k_uL":4.4,"platelets_k_uL":212,"creatinine_mg_dL":1.41,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_2069","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":65,"sex":"female","bmi":30.3,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-81},"pfs_months":16.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":false},"longitudinal_labs":[{"date":"2021-02-02","hemoglobin_g_dL":13.1,"wbc_k_uL":6.1,"platelets_k_uL":395,"creatinine_mg_dL":0.65,"alt_U_L":10},{"date":"2021-09-04","hemoglobin_g_dL":11.8,"wbc_k_uL":8.9,"platelets_k_uL":336,"creatinine_mg_dL":1.02,"alt_U_L":25},{"date":"2022-08-22","hemoglobin_g_dL":12.8,"wbc_k_uL":5.3,"platelets_k_uL":203,"creatinine_mg_dL":1.64,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_2070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":55,"sex":"female","bmi":35.1,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-68},"pfs_months":10.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2021-05-15","hemoglobin_g_dL":12.3,"wbc_k_uL":5.9,"platelets_k_uL":443,"creatinine_mg_dL":0.92,"alt_U_L":20},{"date":"2021-12-31","hemoglobin_g_dL":11.4,"wbc_k_uL":6.9,"platelets_k_uL":141,"creatinine_mg_dL":0.92,"alt_U_L":29},{"date":"2022-07-08","hemoglobin_g_dL":11.9,"wbc_k_uL":3.6,"platelets_k_uL":203,"creatinine_mg_dL":1.9,"alt_U_L":87}]}
{"patient_id":"ANODE_SYNTH_2025_2071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":82,"sex":"female","bmi":29.8,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-09-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-57},"pfs_months":44.81},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":76.9,"censored":true},"longitudinal_labs":[{"date":"2023-07-22","hemoglobin_g_dL":12.1,"wbc_k_uL":8.4,"platelets_k_uL":282,"creatinine_mg_dL":0.89,"alt_U_L":62},{"date":"2024-03-24","hemoglobin_g_dL":11.3,"wbc_k_uL":4.9,"platelets_k_uL":146,"creatinine_mg_dL":0.85,"alt_U_L":47},{"date":"2027-07-20","hemoglobin_g_dL":11.7,"wbc_k_uL":7.0,"platelets_k_uL":340,"creatinine_mg_dL":0.91,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_2072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":71,"sex":"male","bmi":30.3,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-07-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-67},"pfs_months":37.45},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":64.2,"censored":true},"longitudinal_labs":[{"date":"2023-06-25","hemoglobin_g_dL":13.7,"wbc_k_uL":9.1,"platelets_k_uL":400,"creatinine_mg_dL":0.95,"alt_U_L":41},{"date":"2024-01-08","hemoglobin_g_dL":12.4,"wbc_k_uL":8.8,"platelets_k_uL":289,"creatinine_mg_dL":1.09,"alt_U_L":69},{"date":"2026-10-15","hemoglobin_g_dL":9.6,"wbc_k_uL":7.1,"platelets_k_uL":142,"creatinine_mg_dL":1.45,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_2073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":49,"sex":"female","bmi":32.9,"smoking_pack_years":35,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-34},"pfs_months":6.47},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":21.0,"censored":false},"longitudinal_labs":[{"date":"2022-08-12","hemoglobin_g_dL":13.0,"wbc_k_uL":8.5,"platelets_k_uL":190,"creatinine_mg_dL":0.9,"alt_U_L":17},{"date":"2023-03-26","hemoglobin_g_dL":13.6,"wbc_k_uL":8.4,"platelets_k_uL":293,"creatinine_mg_dL":1.17,"alt_U_L":62},{"date":"2023-05-26","hemoglobin_g_dL":12.5,"wbc_k_uL":6.1,"platelets_k_uL":235,"creatinine_mg_dL":1.19,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_2074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":49,"sex":"female","bmi":32.4,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-04-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-51},"pfs_months":37.78},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.4,"censored":false},"longitudinal_labs":[{"date":"2022-03-12","hemoglobin_g_dL":12.5,"wbc_k_uL":9.4,"platelets_k_uL":373,"creatinine_mg_dL":1.08,"alt_U_L":72},{"date":"2022-10-21","hemoglobin_g_dL":12.5,"wbc_k_uL":6.7,"platelets_k_uL":246,"creatinine_mg_dL":1.02,"alt_U_L":109},{"date":"2025-07-14","hemoglobin_g_dL":12.4,"wbc_k_uL":7.0,"platelets_k_uL":117,"creatinine_mg_dL":1.22,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_2075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":83,"sex":"female","bmi":28.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-66},"pfs_months":12.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":true},"longitudinal_labs":[{"date":"2025-03-05","hemoglobin_g_dL":14.2,"wbc_k_uL":9.5,"platelets_k_uL":355,"creatinine_mg_dL":1.28,"alt_U_L":20},{"date":"2025-11-03","hemoglobin_g_dL":13.2,"wbc_k_uL":4.5,"platelets_k_uL":369,"creatinine_mg_dL":1.01,"alt_U_L":102},{"date":"2026-06-19","hemoglobin_g_dL":11.4,"wbc_k_uL":3.8,"platelets_k_uL":142,"creatinine_mg_dL":1.16,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_2076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":62,"sex":"male","bmi":34.8,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-43},"pfs_months":43.89},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":65.4,"censored":true},"longitudinal_labs":[{"date":"2020-10-27","hemoglobin_g_dL":12.1,"wbc_k_uL":10.4,"platelets_k_uL":448,"creatinine_mg_dL":1.14,"alt_U_L":26},{"date":"2021-06-27","hemoglobin_g_dL":11.4,"wbc_k_uL":6.3,"platelets_k_uL":183,"creatinine_mg_dL":1.12,"alt_U_L":42},{"date":"2024-09-10","hemoglobin_g_dL":12.3,"wbc_k_uL":6.9,"platelets_k_uL":255,"creatinine_mg_dL":1.38,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":52,"sex":"female","bmi":25.8,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-04-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-54},"pfs_months":6.77},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":16.1,"censored":false},"longitudinal_labs":[{"date":"2022-03-25","hemoglobin_g_dL":13.4,"wbc_k_uL":6.0,"platelets_k_uL":296,"creatinine_mg_dL":0.9,"alt_U_L":33},{"date":"2022-10-07","hemoglobin_g_dL":11.6,"wbc_k_uL":5.9,"platelets_k_uL":133,"creatinine_mg_dL":1.51,"alt_U_L":104},{"date":"2022-11-27","hemoglobin_g_dL":9.5,"wbc_k_uL":5.6,"platelets_k_uL":158,"creatinine_mg_dL":1.82,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":58,"sex":"female","bmi":27.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-66},"pfs_months":17.31},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.4,"censored":false},"longitudinal_labs":[{"date":"2021-06-14","hemoglobin_g_dL":12.0,"wbc_k_uL":7.5,"platelets_k_uL":389,"creatinine_mg_dL":1.06,"alt_U_L":72},{"date":"2022-01-31","hemoglobin_g_dL":10.3,"wbc_k_uL":5.5,"platelets_k_uL":152,"creatinine_mg_dL":1.31,"alt_U_L":78},{"date":"2023-02-07","hemoglobin_g_dL":12.5,"wbc_k_uL":5.4,"platelets_k_uL":184,"creatinine_mg_dL":1.34,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_2079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":86,"sex":"female","bmi":36.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-72},"pfs_months":29.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.3,"censored":false},"longitudinal_labs":[{"date":"2021-05-24","hemoglobin_g_dL":13.7,"wbc_k_uL":7.8,"platelets_k_uL":346,"creatinine_mg_dL":1.03,"alt_U_L":36},{"date":"2021-12-07","hemoglobin_g_dL":12.0,"wbc_k_uL":5.7,"platelets_k_uL":297,"creatinine_mg_dL":1.17,"alt_U_L":75},{"date":"2024-01-19","hemoglobin_g_dL":10.6,"wbc_k_uL":6.2,"platelets_k_uL":147,"creatinine_mg_dL":1.03,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_2080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":83,"sex":"male","bmi":28.8,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-51},"pfs_months":13.08},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":17.0,"censored":false},"longitudinal_labs":[{"date":"2025-05-09","hemoglobin_g_dL":14.2,"wbc_k_uL":10.8,"platelets_k_uL":422,"creatinine_mg_dL":0.69,"alt_U_L":41},{"date":"2025-12-30","hemoglobin_g_dL":10.8,"wbc_k_uL":4.6,"platelets_k_uL":332,"creatinine_mg_dL":1.41,"alt_U_L":96},{"date":"2026-10-01","hemoglobin_g_dL":11.5,"wbc_k_uL":3.2,"platelets_k_uL":141,"creatinine_mg_dL":1.63,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_2081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":48,"sex":"female","bmi":22.2,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-75},"pfs_months":38.51},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":59.7,"censored":false},"longitudinal_labs":[{"date":"2021-10-15","hemoglobin_g_dL":11.7,"wbc_k_uL":4.9,"platelets_k_uL":165,"creatinine_mg_dL":1.25,"alt_U_L":54},{"date":"2022-05-16","hemoglobin_g_dL":12.9,"wbc_k_uL":5.2,"platelets_k_uL":166,"creatinine_mg_dL":1.08,"alt_U_L":26},{"date":"2025-03-24","hemoglobin_g_dL":11.4,"wbc_k_uL":4.9,"platelets_k_uL":302,"creatinine_mg_dL":1.5,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_2082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":61,"sex":"male","bmi":27.6,"smoking_pack_years":24,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-61},"pfs_months":41.92},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-08-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":64.7,"censored":true},"longitudinal_labs":[{"date":"2024-12-19","hemoglobin_g_dL":13.4,"wbc_k_uL":7.5,"platelets_k_uL":376,"creatinine_mg_dL":1.19,"alt_U_L":50},{"date":"2025-07-05","hemoglobin_g_dL":11.9,"wbc_k_uL":5.0,"platelets_k_uL":360,"creatinine_mg_dL":1.22,"alt_U_L":53},{"date":"2028-08-22","hemoglobin_g_dL":10.6,"wbc_k_uL":4.9,"platelets_k_uL":338,"creatinine_mg_dL":0.81,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_2083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":53,"sex":"male","bmi":24.5,"smoking_pack_years":10,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-04-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-39},"pfs_months":39.75},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":56.9,"censored":false},"longitudinal_labs":[{"date":"2020-03-21","hemoglobin_g_dL":13.1,"wbc_k_uL":6.5,"platelets_k_uL":388,"creatinine_mg_dL":0.83,"alt_U_L":44},{"date":"2020-10-02","hemoglobin_g_dL":11.7,"wbc_k_uL":5.8,"platelets_k_uL":256,"creatinine_mg_dL":1.49,"alt_U_L":63},{"date":"2023-08-17","hemoglobin_g_dL":10.7,"wbc_k_uL":6.1,"platelets_k_uL":103,"creatinine_mg_dL":1.67,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_2084","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":87,"sex":"male","bmi":26.7,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-02-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-84},"pfs_months":19.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.0,"censored":false},"longitudinal_labs":[{"date":"2020-12-05","hemoglobin_g_dL":15.1,"wbc_k_uL":8.1,"platelets_k_uL":181,"creatinine_mg_dL":0.93,"alt_U_L":53},{"date":"2021-08-03","hemoglobin_g_dL":13.8,"wbc_k_uL":4.0,"platelets_k_uL":256,"creatinine_mg_dL":1.56,"alt_U_L":117},{"date":"2022-09-28","hemoglobin_g_dL":10.6,"wbc_k_uL":3.5,"platelets_k_uL":270,"creatinine_mg_dL":1.32,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_2085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":81,"sex":"female","bmi":23.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-76},"pfs_months":18.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":true},"longitudinal_labs":[{"date":"2024-02-07","hemoglobin_g_dL":13.5,"wbc_k_uL":7.8,"platelets_k_uL":398,"creatinine_mg_dL":0.66,"alt_U_L":71},{"date":"2024-09-24","hemoglobin_g_dL":11.6,"wbc_k_uL":4.1,"platelets_k_uL":168,"creatinine_mg_dL":1.47,"alt_U_L":57},{"date":"2025-10-12","hemoglobin_g_dL":10.3,"wbc_k_uL":4.5,"platelets_k_uL":329,"creatinine_mg_dL":1.74,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_2086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":67,"sex":"female","bmi":21.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-60},"pfs_months":26.09},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.1,"censored":true},"longitudinal_labs":[{"date":"2021-09-22","hemoglobin_g_dL":12.0,"wbc_k_uL":6.0,"platelets_k_uL":225,"creatinine_mg_dL":0.88,"alt_U_L":70},{"date":"2022-05-24","hemoglobin_g_dL":11.8,"wbc_k_uL":6.5,"platelets_k_uL":231,"creatinine_mg_dL":1.32,"alt_U_L":57},{"date":"2024-02-01","hemoglobin_g_dL":9.7,"wbc_k_uL":3.2,"platelets_k_uL":100,"creatinine_mg_dL":1.36,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_2087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":86,"sex":"female","bmi":27.2,"smoking_pack_years":34,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-55},"pfs_months":8.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":12.9,"censored":false},"longitudinal_labs":[{"date":"2024-02-24","hemoglobin_g_dL":13.2,"wbc_k_uL":10.1,"platelets_k_uL":360,"creatinine_mg_dL":0.62,"alt_U_L":54},{"date":"2024-10-15","hemoglobin_g_dL":10.2,"wbc_k_uL":5.3,"platelets_k_uL":376,"creatinine_mg_dL":1.25,"alt_U_L":25},{"date":"2025-02-09","hemoglobin_g_dL":10.8,"wbc_k_uL":7.9,"platelets_k_uL":272,"creatinine_mg_dL":1.28,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_2088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":87,"sex":"female","bmi":20.6,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-03-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-61},"pfs_months":18.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.7,"censored":false},"longitudinal_labs":[{"date":"2020-01-27","hemoglobin_g_dL":12.1,"wbc_k_uL":9.8,"platelets_k_uL":435,"creatinine_mg_dL":0.71,"alt_U_L":28},{"date":"2020-09-21","hemoglobin_g_dL":11.4,"wbc_k_uL":5.7,"platelets_k_uL":221,"creatinine_mg_dL":1.42,"alt_U_L":53},{"date":"2021-11-01","hemoglobin_g_dL":11.3,"wbc_k_uL":3.3,"platelets_k_uL":320,"creatinine_mg_dL":1.06,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_2089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":63,"sex":"male","bmi":37.3,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-09-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-37},"pfs_months":14.85},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.9,"censored":true},"longitudinal_labs":[{"date":"2024-07-24","hemoglobin_g_dL":11.8,"wbc_k_uL":6.0,"platelets_k_uL":392,"creatinine_mg_dL":1.14,"alt_U_L":54},{"date":"2025-03-29","hemoglobin_g_dL":13.1,"wbc_k_uL":5.9,"platelets_k_uL":302,"creatinine_mg_dL":1.26,"alt_U_L":49},{"date":"2026-02-14","hemoglobin_g_dL":10.7,"wbc_k_uL":6.8,"platelets_k_uL":142,"creatinine_mg_dL":1.5,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_2090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":59,"sex":"female","bmi":20.8,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-01-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-82},"pfs_months":9.17},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":13.1,"censored":false},"longitudinal_labs":[{"date":"2021-12-16","hemoglobin_g_dL":14.2,"wbc_k_uL":7.1,"platelets_k_uL":355,"creatinine_mg_dL":1.19,"alt_U_L":77},{"date":"2022-07-03","hemoglobin_g_dL":11.4,"wbc_k_uL":5.1,"platelets_k_uL":164,"creatinine_mg_dL":1.2,"alt_U_L":40},{"date":"2022-11-20","hemoglobin_g_dL":12.3,"wbc_k_uL":7.1,"platelets_k_uL":131,"creatinine_mg_dL":1.16,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_2091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":55,"sex":"female","bmi":36.2,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-68},"pfs_months":21.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":false},"longitudinal_labs":[{"date":"2025-05-12","hemoglobin_g_dL":13.7,"wbc_k_uL":8.7,"platelets_k_uL":379,"creatinine_mg_dL":0.98,"alt_U_L":30},{"date":"2026-01-17","hemoglobin_g_dL":10.2,"wbc_k_uL":4.1,"platelets_k_uL":194,"creatinine_mg_dL":0.92,"alt_U_L":21},{"date":"2027-05-30","hemoglobin_g_dL":12.5,"wbc_k_uL":3.8,"platelets_k_uL":321,"creatinine_mg_dL":1.65,"alt_U_L":198}]}
{"patient_id":"ANODE_SYNTH_2025_2092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":62,"sex":"female","bmi":23.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-79},"pfs_months":31.08},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.4,"censored":false},"longitudinal_labs":[{"date":"2024-02-17","hemoglobin_g_dL":14.0,"wbc_k_uL":4.9,"platelets_k_uL":163,"creatinine_mg_dL":1.15,"alt_U_L":55},{"date":"2024-09-29","hemoglobin_g_dL":11.0,"wbc_k_uL":6.8,"platelets_k_uL":249,"creatinine_mg_dL":1.44,"alt_U_L":78},{"date":"2026-11-28","hemoglobin_g_dL":12.1,"wbc_k_uL":4.2,"platelets_k_uL":239,"creatinine_mg_dL":1.32,"alt_U_L":166}]}
{"patient_id":"ANODE_SYNTH_2025_2093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":76,"sex":"female","bmi":36.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-66},"pfs_months":27.76},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.0,"censored":true},"longitudinal_labs":[{"date":"2021-04-14","hemoglobin_g_dL":12.8,"wbc_k_uL":8.0,"platelets_k_uL":370,"creatinine_mg_dL":1.0,"alt_U_L":32},{"date":"2021-12-08","hemoglobin_g_dL":11.0,"wbc_k_uL":4.3,"platelets_k_uL":223,"creatinine_mg_dL":0.95,"alt_U_L":57},{"date":"2023-11-30","hemoglobin_g_dL":12.8,"wbc_k_uL":4.8,"platelets_k_uL":333,"creatinine_mg_dL":1.89,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":66,"sex":"female","bmi":34.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-75},"pfs_months":31.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.5,"censored":true},"longitudinal_labs":[{"date":"2023-06-20","hemoglobin_g_dL":11.6,"wbc_k_uL":6.0,"platelets_k_uL":361,"creatinine_mg_dL":1.28,"alt_U_L":58},{"date":"2024-02-07","hemoglobin_g_dL":10.0,"wbc_k_uL":6.6,"platelets_k_uL":328,"creatinine_mg_dL":0.84,"alt_U_L":94},{"date":"2026-04-23","hemoglobin_g_dL":11.0,"wbc_k_uL":4.7,"platelets_k_uL":136,"creatinine_mg_dL":1.81,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_2095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":81,"sex":"male","bmi":28.5,"smoking_pack_years":16,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-12-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-37},"pfs_months":3.42},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.1,"censored":true},"longitudinal_labs":[{"date":"2025-11-21","hemoglobin_g_dL":12.0,"wbc_k_uL":9.0,"platelets_k_uL":376,"creatinine_mg_dL":1.02,"alt_U_L":69},{"date":"2026-06-10","hemoglobin_g_dL":12.3,"wbc_k_uL":4.0,"platelets_k_uL":285,"creatinine_mg_dL":0.72,"alt_U_L":45},{"date":"2026-05-09","hemoglobin_g_dL":10.0,"wbc_k_uL":6.8,"platelets_k_uL":178,"creatinine_mg_dL":1.64,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_2096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":80,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-77},"pfs_months":12.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":false},"longitudinal_labs":[{"date":"2024-09-07","hemoglobin_g_dL":13.2,"wbc_k_uL":10.2,"platelets_k_uL":271,"creatinine_mg_dL":1.07,"alt_U_L":56},{"date":"2025-05-15","hemoglobin_g_dL":13.2,"wbc_k_uL":5.0,"platelets_k_uL":330,"creatinine_mg_dL":0.88,"alt_U_L":87},{"date":"2026-01-03","hemoglobin_g_dL":11.1,"wbc_k_uL":3.5,"platelets_k_uL":105,"creatinine_mg_dL":1.2,"alt_U_L":176}]}
{"patient_id":"ANODE_SYNTH_2025_2097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":52,"sex":"female","bmi":19.7,"smoking_pack_years":13,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-36},"pfs_months":14.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.4,"censored":false},"longitudinal_labs":[{"date":"2023-09-12","hemoglobin_g_dL":14.6,"wbc_k_uL":7.8,"platelets_k_uL":259,"creatinine_mg_dL":1.0,"alt_U_L":38},{"date":"2024-03-27","hemoglobin_g_dL":12.2,"wbc_k_uL":4.3,"platelets_k_uL":305,"creatinine_mg_dL":1.44,"alt_U_L":41},{"date":"2024-12-20","hemoglobin_g_dL":9.9,"wbc_k_uL":3.3,"platelets_k_uL":250,"creatinine_mg_dL":1.89,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_2098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":69,"sex":"female","bmi":18.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-72},"pfs_months":20.8},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.6,"censored":true},"longitudinal_labs":[{"date":"2023-08-07","hemoglobin_g_dL":14.5,"wbc_k_uL":10.6,"platelets_k_uL":435,"creatinine_mg_dL":1.27,"alt_U_L":55},{"date":"2024-04-01","hemoglobin_g_dL":13.4,"wbc_k_uL":5.2,"platelets_k_uL":127,"creatinine_mg_dL":0.86,"alt_U_L":23},{"date":"2025-07-22","hemoglobin_g_dL":11.8,"wbc_k_uL":7.4,"platelets_k_uL":183,"creatinine_mg_dL":1.01,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_2099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":82,"sex":"male","bmi":22.3,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-03-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-41},"pfs_months":15.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.4,"censored":true},"longitudinal_labs":[{"date":"2023-02-09","hemoglobin_g_dL":12.1,"wbc_k_uL":9.4,"platelets_k_uL":236,"creatinine_mg_dL":1.26,"alt_U_L":14},{"date":"2023-08-28","hemoglobin_g_dL":12.1,"wbc_k_uL":6.2,"platelets_k_uL":266,"creatinine_mg_dL":1.03,"alt_U_L":95},{"date":"2024-08-28","hemoglobin_g_dL":10.2,"wbc_k_uL":6.6,"platelets_k_uL":116,"creatinine_mg_dL":0.87,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_2100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":74,"sex":"female","bmi":35.7,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-12-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-42},"pfs_months":15.61},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":true},"longitudinal_labs":[{"date":"2021-11-12","hemoglobin_g_dL":12.0,"wbc_k_uL":10.2,"platelets_k_uL":236,"creatinine_mg_dL":1.25,"alt_U_L":11},{"date":"2022-06-17","hemoglobin_g_dL":12.4,"wbc_k_uL":7.7,"platelets_k_uL":198,"creatinine_mg_dL":1.22,"alt_U_L":69},{"date":"2023-04-20","hemoglobin_g_dL":10.9,"wbc_k_uL":4.8,"platelets_k_uL":245,"creatinine_mg_dL":0.92,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_2101","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":83,"sex":"male","bmi":24.7,"smoking_pack_years":51,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-10-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-48},"pfs_months":26.22},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.8,"censored":false},"longitudinal_labs":[{"date":"2021-08-16","hemoglobin_g_dL":13.3,"wbc_k_uL":10.4,"platelets_k_uL":402,"creatinine_mg_dL":1.18,"alt_U_L":59},{"date":"2022-04-10","hemoglobin_g_dL":13.3,"wbc_k_uL":7.0,"platelets_k_uL":154,"creatinine_mg_dL":1.33,"alt_U_L":30},{"date":"2024-02-03","hemoglobin_g_dL":12.5,"wbc_k_uL":6.9,"platelets_k_uL":271,"creatinine_mg_dL":0.9,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_2102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":54,"sex":"female","bmi":27.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-73},"pfs_months":17.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.6,"censored":false},"longitudinal_labs":[{"date":"2024-01-19","hemoglobin_g_dL":14.7,"wbc_k_uL":5.9,"platelets_k_uL":154,"creatinine_mg_dL":1.2,"alt_U_L":32},{"date":"2024-09-16","hemoglobin_g_dL":11.8,"wbc_k_uL":5.3,"platelets_k_uL":168,"creatinine_mg_dL":0.85,"alt_U_L":91},{"date":"2025-10-28","hemoglobin_g_dL":9.8,"wbc_k_uL":5.9,"platelets_k_uL":127,"creatinine_mg_dL":1.09,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_2103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":81,"sex":"female","bmi":24.3,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-66},"pfs_months":29.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.6,"censored":false},"longitudinal_labs":[{"date":"2021-02-28","hemoglobin_g_dL":11.9,"wbc_k_uL":8.0,"platelets_k_uL":214,"creatinine_mg_dL":0.83,"alt_U_L":26},{"date":"2021-10-31","hemoglobin_g_dL":12.7,"wbc_k_uL":8.0,"platelets_k_uL":191,"creatinine_mg_dL":1.16,"alt_U_L":107},{"date":"2023-10-26","hemoglobin_g_dL":10.1,"wbc_k_uL":6.7,"platelets_k_uL":184,"creatinine_mg_dL":1.27,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_2104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":85,"sex":"female","bmi":23.4,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-50},"pfs_months":34.23},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":59.3,"censored":false},"longitudinal_labs":[{"date":"2021-05-12","hemoglobin_g_dL":12.6,"wbc_k_uL":9.2,"platelets_k_uL":279,"creatinine_mg_dL":1.0,"alt_U_L":66},{"date":"2021-12-22","hemoglobin_g_dL":13.8,"wbc_k_uL":7.7,"platelets_k_uL":197,"creatinine_mg_dL":1.39,"alt_U_L":66},{"date":"2024-05-28","hemoglobin_g_dL":10.7,"wbc_k_uL":7.3,"platelets_k_uL":305,"creatinine_mg_dL":0.83,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_2105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":77,"sex":"male","bmi":23.9,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-06-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-47},"pfs_months":39.39},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":64.2,"censored":false},"longitudinal_labs":[{"date":"2023-05-22","hemoglobin_g_dL":11.8,"wbc_k_uL":9.8,"platelets_k_uL":191,"creatinine_mg_dL":0.63,"alt_U_L":77},{"date":"2023-12-18","hemoglobin_g_dL":13.3,"wbc_k_uL":6.6,"platelets_k_uL":371,"creatinine_mg_dL":1.24,"alt_U_L":101},{"date":"2026-11-15","hemoglobin_g_dL":12.9,"wbc_k_uL":4.8,"platelets_k_uL":114,"creatinine_mg_dL":1.83,"alt_U_L":90}]}
{"patient_id":"ANODE_SYNTH_2025_2106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":75,"sex":"male","bmi":31.1,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-01-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-81},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":10.9,"censored":true},"longitudinal_labs":[{"date":"2020-12-23","hemoglobin_g_dL":12.7,"wbc_k_uL":8.1,"platelets_k_uL":232,"creatinine_mg_dL":0.83,"alt_U_L":74},{"date":"2021-07-19","hemoglobin_g_dL":10.3,"wbc_k_uL":6.4,"platelets_k_uL":308,"creatinine_mg_dL":1.59,"alt_U_L":72},{"date":"2021-05-09","hemoglobin_g_dL":11.6,"wbc_k_uL":6.1,"platelets_k_uL":191,"creatinine_mg_dL":1.28,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_2107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":86,"sex":"male","bmi":33.1,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-04-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-63},"pfs_months":29.93},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.1,"censored":false},"longitudinal_labs":[{"date":"2023-02-05","hemoglobin_g_dL":12.0,"wbc_k_uL":8.1,"platelets_k_uL":232,"creatinine_mg_dL":1.17,"alt_U_L":42},{"date":"2023-10-08","hemoglobin_g_dL":11.8,"wbc_k_uL":4.1,"platelets_k_uL":254,"creatinine_mg_dL":1.02,"alt_U_L":39},{"date":"2025-11-19","hemoglobin_g_dL":11.4,"wbc_k_uL":5.3,"platelets_k_uL":199,"creatinine_mg_dL":1.81,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_2108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":86,"sex":"female","bmi":31.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-53},"pfs_months":23.0},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-25","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.9,"censored":false},"longitudinal_labs":[{"date":"2020-08-19","hemoglobin_g_dL":14.8,"wbc_k_uL":5.6,"platelets_k_uL":273,"creatinine_mg_dL":0.81,"alt_U_L":30},{"date":"2021-04-07","hemoglobin_g_dL":11.2,"wbc_k_uL":5.0,"platelets_k_uL":236,"creatinine_mg_dL":1.27,"alt_U_L":59},{"date":"2022-09-25","hemoglobin_g_dL":12.0,"wbc_k_uL":4.0,"platelets_k_uL":150,"creatinine_mg_dL":1.31,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_2109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":55,"sex":"male","bmi":33.1,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-84},"pfs_months":41.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-06-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":61.6,"censored":false},"longitudinal_labs":[{"date":"2025-10-25","hemoglobin_g_dL":12.1,"wbc_k_uL":6.4,"platelets_k_uL":203,"creatinine_mg_dL":0.76,"alt_U_L":31},{"date":"2026-06-12","hemoglobin_g_dL":11.5,"wbc_k_uL":8.1,"platelets_k_uL":333,"creatinine_mg_dL":1.05,"alt_U_L":96},{"date":"2029-06-13","hemoglobin_g_dL":10.4,"wbc_k_uL":5.3,"platelets_k_uL":200,"creatinine_mg_dL":0.89,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_2110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":86,"sex":"female","bmi":22.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-71},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.4,"censored":false},"longitudinal_labs":[{"date":"2023-03-01","hemoglobin_g_dL":13.3,"wbc_k_uL":10.4,"platelets_k_uL":353,"creatinine_mg_dL":0.69,"alt_U_L":19},{"date":"2023-10-23","hemoglobin_g_dL":13.7,"wbc_k_uL":5.4,"platelets_k_uL":253,"creatinine_mg_dL":1.18,"alt_U_L":118},{"date":"2025-02-23","hemoglobin_g_dL":10.4,"wbc_k_uL":3.7,"platelets_k_uL":244,"creatinine_mg_dL":1.58,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":49,"sex":"female","bmi":29.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-46},"pfs_months":17.71},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.2,"censored":false},"longitudinal_labs":[{"date":"2020-07-26","hemoglobin_g_dL":14.7,"wbc_k_uL":7.2,"platelets_k_uL":172,"creatinine_mg_dL":0.97,"alt_U_L":59},{"date":"2021-02-26","hemoglobin_g_dL":11.3,"wbc_k_uL":7.7,"platelets_k_uL":353,"creatinine_mg_dL":1.0,"alt_U_L":23},{"date":"2022-03-12","hemoglobin_g_dL":10.6,"wbc_k_uL":5.9,"platelets_k_uL":158,"creatinine_mg_dL":1.76,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_2112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":83,"sex":"male","bmi":28.3,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-10-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-60},"pfs_months":12.35},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":false},"longitudinal_labs":[{"date":"2024-08-11","hemoglobin_g_dL":15.5,"wbc_k_uL":4.9,"platelets_k_uL":443,"creatinine_mg_dL":0.77,"alt_U_L":74},{"date":"2025-04-16","hemoglobin_g_dL":10.1,"wbc_k_uL":8.4,"platelets_k_uL":154,"creatinine_mg_dL":1.46,"alt_U_L":41},{"date":"2025-12-11","hemoglobin_g_dL":11.2,"wbc_k_uL":3.5,"platelets_k_uL":186,"creatinine_mg_dL":1.15,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_2113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":75,"sex":"male","bmi":34.8,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-02-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-39},"pfs_months":12.16},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":18.1,"censored":false},"longitudinal_labs":[{"date":"2023-12-28","hemoglobin_g_dL":12.7,"wbc_k_uL":9.3,"platelets_k_uL":280,"creatinine_mg_dL":0.77,"alt_U_L":45},{"date":"2024-08-02","hemoglobin_g_dL":13.5,"wbc_k_uL":5.5,"platelets_k_uL":288,"creatinine_mg_dL":1.01,"alt_U_L":49},{"date":"2025-03-24","hemoglobin_g_dL":10.6,"wbc_k_uL":4.6,"platelets_k_uL":143,"creatinine_mg_dL":1.64,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_2114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":56,"sex":"male","bmi":22.6,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-65},"pfs_months":37.65},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":59.3,"censored":false},"longitudinal_labs":[{"date":"2021-04-06","hemoglobin_g_dL":12.6,"wbc_k_uL":4.8,"platelets_k_uL":308,"creatinine_mg_dL":1.17,"alt_U_L":64},{"date":"2021-11-12","hemoglobin_g_dL":12.0,"wbc_k_uL":8.7,"platelets_k_uL":319,"creatinine_mg_dL":0.88,"alt_U_L":18},{"date":"2024-08-13","hemoglobin_g_dL":11.3,"wbc_k_uL":6.8,"platelets_k_uL":334,"creatinine_mg_dL":0.88,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_2115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":84,"sex":"female","bmi":22.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-53},"pfs_months":19.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":false},"longitudinal_labs":[{"date":"2022-08-25","hemoglobin_g_dL":14.5,"wbc_k_uL":8.6,"platelets_k_uL":180,"creatinine_mg_dL":0.66,"alt_U_L":34},{"date":"2023-03-12","hemoglobin_g_dL":13.2,"wbc_k_uL":5.7,"platelets_k_uL":372,"creatinine_mg_dL":1.59,"alt_U_L":29},{"date":"2024-06-10","hemoglobin_g_dL":12.6,"wbc_k_uL":6.9,"platelets_k_uL":260,"creatinine_mg_dL":1.32,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_2116","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":50,"sex":"female","bmi":36.0,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-03-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-74},"pfs_months":21.45},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.0,"censored":true},"longitudinal_labs":[{"date":"2022-01-18","hemoglobin_g_dL":12.5,"wbc_k_uL":5.9,"platelets_k_uL":394,"creatinine_mg_dL":1.28,"alt_U_L":43},{"date":"2022-09-13","hemoglobin_g_dL":13.3,"wbc_k_uL":5.1,"platelets_k_uL":303,"creatinine_mg_dL":1.06,"alt_U_L":36},{"date":"2024-01-04","hemoglobin_g_dL":11.8,"wbc_k_uL":6.9,"platelets_k_uL":335,"creatinine_mg_dL":0.97,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_2117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":85,"sex":"female","bmi":32.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-48},"pfs_months":24.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.4,"censored":true},"longitudinal_labs":[{"date":"2021-07-22","hemoglobin_g_dL":14.1,"wbc_k_uL":8.4,"platelets_k_uL":349,"creatinine_mg_dL":0.88,"alt_U_L":22},{"date":"2022-02-17","hemoglobin_g_dL":11.2,"wbc_k_uL":7.2,"platelets_k_uL":131,"creatinine_mg_dL":0.82,"alt_U_L":77},{"date":"2023-10-15","hemoglobin_g_dL":12.6,"wbc_k_uL":7.9,"platelets_k_uL":182,"creatinine_mg_dL":1.81,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_2118","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":68,"sex":"male","bmi":29.5,"smoking_pack_years":79,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-58},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.1,"censored":false},"longitudinal_labs":[{"date":"2023-03-04","hemoglobin_g_dL":13.0,"wbc_k_uL":7.5,"platelets_k_uL":417,"creatinine_mg_dL":0.71,"alt_U_L":37},{"date":"2023-11-02","hemoglobin_g_dL":11.3,"wbc_k_uL":8.4,"platelets_k_uL":163,"creatinine_mg_dL":1.42,"alt_U_L":73},{"date":"2025-03-20","hemoglobin_g_dL":10.6,"wbc_k_uL":5.1,"platelets_k_uL":146,"creatinine_mg_dL":1.18,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_2119","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":83,"sex":"male","bmi":19.8,"smoking_pack_years":61,"ecog_performance_status":2,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-02-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-38},"pfs_months":16.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":27.4,"censored":false},"longitudinal_labs":[{"date":"2024-01-10","hemoglobin_g_dL":12.0,"wbc_k_uL":8.6,"platelets_k_uL":287,"creatinine_mg_dL":1.21,"alt_U_L":24},{"date":"2024-08-06","hemoglobin_g_dL":11.8,"wbc_k_uL":8.0,"platelets_k_uL":241,"creatinine_mg_dL":1.26,"alt_U_L":113},{"date":"2025-07-23","hemoglobin_g_dL":10.3,"wbc_k_uL":7.4,"platelets_k_uL":196,"creatinine_mg_dL":1.48,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_2120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":50,"sex":"male","bmi":25.1,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-09-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-55},"pfs_months":44.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":68.9,"censored":false},"longitudinal_labs":[{"date":"2021-08-15","hemoglobin_g_dL":15.0,"wbc_k_uL":10.3,"platelets_k_uL":310,"creatinine_mg_dL":1.29,"alt_U_L":54},{"date":"2022-03-18","hemoglobin_g_dL":12.0,"wbc_k_uL":6.1,"platelets_k_uL":141,"creatinine_mg_dL":0.82,"alt_U_L":82},{"date":"2025-06-06","hemoglobin_g_dL":11.1,"wbc_k_uL":5.6,"platelets_k_uL":101,"creatinine_mg_dL":1.76,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_2121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":71,"sex":"male","bmi":22.0,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-78},"pfs_months":41.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":63.6,"censored":false},"longitudinal_labs":[{"date":"2024-02-09","hemoglobin_g_dL":13.8,"wbc_k_uL":6.6,"platelets_k_uL":280,"creatinine_mg_dL":1.23,"alt_U_L":57},{"date":"2024-09-09","hemoglobin_g_dL":12.1,"wbc_k_uL":7.0,"platelets_k_uL":373,"creatinine_mg_dL":1.16,"alt_U_L":53},{"date":"2027-09-19","hemoglobin_g_dL":12.5,"wbc_k_uL":6.2,"platelets_k_uL":280,"creatinine_mg_dL":0.88,"alt_U_L":90}]}
{"patient_id":"ANODE_SYNTH_2025_2122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":61,"sex":"female","bmi":19.0,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-05-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-70},"pfs_months":9.46},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-03-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":13.4,"censored":true},"longitudinal_labs":[{"date":"2020-04-21","hemoglobin_g_dL":14.1,"wbc_k_uL":8.4,"platelets_k_uL":197,"creatinine_mg_dL":1.11,"alt_U_L":33},{"date":"2020-11-06","hemoglobin_g_dL":14.0,"wbc_k_uL":7.0,"platelets_k_uL":224,"creatinine_mg_dL":0.8,"alt_U_L":86},{"date":"2021-03-31","hemoglobin_g_dL":11.2,"wbc_k_uL":3.6,"platelets_k_uL":211,"creatinine_mg_dL":1.64,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_2123","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":84,"sex":"female","bmi":26.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-46},"pfs_months":17.45},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":false},"longitudinal_labs":[{"date":"2021-05-15","hemoglobin_g_dL":12.4,"wbc_k_uL":4.9,"platelets_k_uL":225,"creatinine_mg_dL":1.18,"alt_U_L":11},{"date":"2021-12-09","hemoglobin_g_dL":13.5,"wbc_k_uL":7.7,"platelets_k_uL":150,"creatinine_mg_dL":1.58,"alt_U_L":45},{"date":"2022-12-25","hemoglobin_g_dL":11.9,"wbc_k_uL":5.3,"platelets_k_uL":139,"creatinine_mg_dL":1.79,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_2124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.0,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":65,"sex":"male","bmi":31.9,"smoking_pack_years":16,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-04-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-50},"pfs_months":43.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":78.1,"censored":false},"longitudinal_labs":[{"date":"2020-04-02","hemoglobin_g_dL":12.5,"wbc_k_uL":6.4,"platelets_k_uL":421,"creatinine_mg_dL":0.79,"alt_U_L":40},{"date":"2020-10-20","hemoglobin_g_dL":11.9,"wbc_k_uL":7.9,"platelets_k_uL":365,"creatinine_mg_dL":1.26,"alt_U_L":53},{"date":"2024-01-23","hemoglobin_g_dL":11.2,"wbc_k_uL":3.1,"platelets_k_uL":254,"creatinine_mg_dL":1.93,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_2125","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":54,"sex":"female","bmi":36.9,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-01-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-34},"pfs_months":29.7},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":48.6,"censored":false},"longitudinal_labs":[{"date":"2022-12-04","hemoglobin_g_dL":14.7,"wbc_k_uL":6.8,"platelets_k_uL":163,"creatinine_mg_dL":0.66,"alt_U_L":17},{"date":"2023-07-18","hemoglobin_g_dL":13.1,"wbc_k_uL":7.5,"platelets_k_uL":159,"creatinine_mg_dL":0.92,"alt_U_L":15},{"date":"2025-08-15","hemoglobin_g_dL":12.1,"wbc_k_uL":5.5,"platelets_k_uL":318,"creatinine_mg_dL":1.44,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_2126","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":53,"sex":"female","bmi":30.2,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-11-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-81},"pfs_months":35.52},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":47.5,"censored":true},"longitudinal_labs":[{"date":"2020-09-14","hemoglobin_g_dL":14.3,"wbc_k_uL":9.9,"platelets_k_uL":269,"creatinine_mg_dL":1.22,"alt_U_L":75},{"date":"2021-05-09","hemoglobin_g_dL":11.9,"wbc_k_uL":6.1,"platelets_k_uL":269,"creatinine_mg_dL":1.07,"alt_U_L":64},{"date":"2023-11-18","hemoglobin_g_dL":12.2,"wbc_k_uL":4.3,"platelets_k_uL":280,"creatinine_mg_dL":0.89,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_2127","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":81,"sex":"female","bmi":19.8,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-10-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-43},"pfs_months":20.44},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.5,"censored":false},"longitudinal_labs":[{"date":"2024-09-08","hemoglobin_g_dL":13.8,"wbc_k_uL":6.9,"platelets_k_uL":344,"creatinine_mg_dL":0.83,"alt_U_L":58},{"date":"2025-04-06","hemoglobin_g_dL":13.0,"wbc_k_uL":4.3,"platelets_k_uL":340,"creatinine_mg_dL":1.0,"alt_U_L":24},{"date":"2026-08-01","hemoglobin_g_dL":10.9,"wbc_k_uL":6.7,"platelets_k_uL":292,"creatinine_mg_dL":1.39,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_2128","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":64,"sex":"female","bmi":26.6,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-02-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-51},"pfs_months":30.85},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-31","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.6,"censored":true},"longitudinal_labs":[{"date":"2021-01-28","hemoglobin_g_dL":11.8,"wbc_k_uL":9.4,"platelets_k_uL":415,"creatinine_mg_dL":0.73,"alt_U_L":52},{"date":"2021-08-24","hemoglobin_g_dL":10.3,"wbc_k_uL":4.0,"platelets_k_uL":289,"creatinine_mg_dL":1.23,"alt_U_L":114},{"date":"2023-10-31","hemoglobin_g_dL":9.9,"wbc_k_uL":6.5,"platelets_k_uL":294,"creatinine_mg_dL":1.55,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_2129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":64,"sex":"male","bmi":25.1,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-09-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-80},"pfs_months":38.83},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":66.6,"censored":false},"longitudinal_labs":[{"date":"2021-07-18","hemoglobin_g_dL":14.6,"wbc_k_uL":9.5,"platelets_k_uL":209,"creatinine_mg_dL":1.22,"alt_U_L":55},{"date":"2022-03-08","hemoglobin_g_dL":13.8,"wbc_k_uL":6.3,"platelets_k_uL":323,"creatinine_mg_dL":1.59,"alt_U_L":106},{"date":"2024-12-31","hemoglobin_g_dL":9.8,"wbc_k_uL":4.4,"platelets_k_uL":118,"creatinine_mg_dL":1.33,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_2130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":87,"sex":"male","bmi":23.8,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-11-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-47},"pfs_months":52.44},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-04-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":71.4,"censored":false},"longitudinal_labs":[{"date":"2024-10-04","hemoglobin_g_dL":13.4,"wbc_k_uL":10.5,"platelets_k_uL":340,"creatinine_mg_dL":1.26,"alt_U_L":64},{"date":"2025-05-15","hemoglobin_g_dL":12.8,"wbc_k_uL":6.6,"platelets_k_uL":230,"creatinine_mg_dL":0.79,"alt_U_L":18},{"date":"2029-04-24","hemoglobin_g_dL":12.9,"wbc_k_uL":6.5,"platelets_k_uL":171,"creatinine_mg_dL":1.26,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_2131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":57,"sex":"male","bmi":26.1,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-05-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-51},"pfs_months":31.38},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":57.8,"censored":false},"longitudinal_labs":[{"date":"2025-04-23","hemoglobin_g_dL":14.0,"wbc_k_uL":8.4,"platelets_k_uL":215,"creatinine_mg_dL":1.02,"alt_U_L":26},{"date":"2025-11-22","hemoglobin_g_dL":12.8,"wbc_k_uL":6.8,"platelets_k_uL":353,"creatinine_mg_dL":1.49,"alt_U_L":98},{"date":"2028-01-11","hemoglobin_g_dL":11.1,"wbc_k_uL":7.8,"platelets_k_uL":127,"creatinine_mg_dL":1.94,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_2132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":48,"sex":"female","bmi":35.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-36},"pfs_months":27.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.1,"censored":false},"longitudinal_labs":[{"date":"2024-04-16","hemoglobin_g_dL":15.1,"wbc_k_uL":8.9,"platelets_k_uL":225,"creatinine_mg_dL":0.78,"alt_U_L":54},{"date":"2024-12-03","hemoglobin_g_dL":14.0,"wbc_k_uL":8.8,"platelets_k_uL":208,"creatinine_mg_dL":1.11,"alt_U_L":80},{"date":"2026-10-01","hemoglobin_g_dL":10.3,"wbc_k_uL":3.1,"platelets_k_uL":270,"creatinine_mg_dL":0.93,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_2133","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":48,"sex":"female","bmi":21.8,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-09-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-77},"pfs_months":17.74},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.7,"censored":true},"longitudinal_labs":[{"date":"2020-08-19","hemoglobin_g_dL":14.1,"wbc_k_uL":10.7,"platelets_k_uL":350,"creatinine_mg_dL":0.75,"alt_U_L":18},{"date":"2021-03-06","hemoglobin_g_dL":10.4,"wbc_k_uL":3.9,"platelets_k_uL":244,"creatinine_mg_dL":1.56,"alt_U_L":99},{"date":"2022-04-03","hemoglobin_g_dL":12.3,"wbc_k_uL":6.5,"platelets_k_uL":257,"creatinine_mg_dL":1.62,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_2134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":79,"sex":"male","bmi":29.2,"smoking_pack_years":33,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-05-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-69},"pfs_months":32.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":52.0,"censored":false},"longitudinal_labs":[{"date":"2020-04-01","hemoglobin_g_dL":15.2,"wbc_k_uL":9.0,"platelets_k_uL":240,"creatinine_mg_dL":1.24,"alt_U_L":60},{"date":"2020-10-28","hemoglobin_g_dL":12.3,"wbc_k_uL":7.7,"platelets_k_uL":213,"creatinine_mg_dL":1.48,"alt_U_L":29},{"date":"2023-02-04","hemoglobin_g_dL":12.9,"wbc_k_uL":6.7,"platelets_k_uL":264,"creatinine_mg_dL":1.69,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_2135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":60,"sex":"female","bmi":27.1,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-36},"pfs_months":35.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":51.1,"censored":false},"longitudinal_labs":[{"date":"2025-03-18","hemoglobin_g_dL":13.6,"wbc_k_uL":4.5,"platelets_k_uL":340,"creatinine_mg_dL":0.92,"alt_U_L":69},{"date":"2025-10-03","hemoglobin_g_dL":10.6,"wbc_k_uL":7.1,"platelets_k_uL":120,"creatinine_mg_dL":1.28,"alt_U_L":33},{"date":"2028-04-15","hemoglobin_g_dL":10.2,"wbc_k_uL":7.1,"platelets_k_uL":287,"creatinine_mg_dL":1.95,"alt_U_L":197}]}
{"patient_id":"ANODE_SYNTH_2025_2136","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":80,"sex":"female","bmi":33.4,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-04-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-43},"pfs_months":21.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.9,"censored":true},"longitudinal_labs":[{"date":"2020-03-12","hemoglobin_g_dL":14.5,"wbc_k_uL":10.9,"platelets_k_uL":349,"creatinine_mg_dL":0.66,"alt_U_L":23},{"date":"2020-09-28","hemoglobin_g_dL":12.5,"wbc_k_uL":8.6,"platelets_k_uL":163,"creatinine_mg_dL":0.77,"alt_U_L":28},{"date":"2022-03-25","hemoglobin_g_dL":9.9,"wbc_k_uL":6.4,"platelets_k_uL":251,"creatinine_mg_dL":1.07,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_2137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":59,"sex":"female","bmi":20.2,"smoking_pack_years":61,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-76},"pfs_months":16.85},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.8,"censored":false},"longitudinal_labs":[{"date":"2024-03-03","hemoglobin_g_dL":12.5,"wbc_k_uL":9.3,"platelets_k_uL":406,"creatinine_mg_dL":0.68,"alt_U_L":47},{"date":"2024-10-13","hemoglobin_g_dL":11.5,"wbc_k_uL":6.6,"platelets_k_uL":334,"creatinine_mg_dL":1.35,"alt_U_L":24},{"date":"2025-09-29","hemoglobin_g_dL":12.2,"wbc_k_uL":6.9,"platelets_k_uL":264,"creatinine_mg_dL":1.58,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_2138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":84,"sex":"female","bmi":21.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-46},"pfs_months":18.5},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.7,"censored":true},"longitudinal_labs":[{"date":"2024-06-13","hemoglobin_g_dL":12.0,"wbc_k_uL":10.4,"platelets_k_uL":278,"creatinine_mg_dL":0.67,"alt_U_L":32},{"date":"2025-01-26","hemoglobin_g_dL":10.2,"wbc_k_uL":5.8,"platelets_k_uL":319,"creatinine_mg_dL":1.28,"alt_U_L":55},{"date":"2026-02-24","hemoglobin_g_dL":11.2,"wbc_k_uL":5.7,"platelets_k_uL":222,"creatinine_mg_dL":1.23,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_2139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":59,"sex":"female","bmi":25.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-01-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-34},"pfs_months":18.27},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.1,"censored":true},"longitudinal_labs":[{"date":"2022-11-16","hemoglobin_g_dL":11.6,"wbc_k_uL":8.1,"platelets_k_uL":323,"creatinine_mg_dL":0.94,"alt_U_L":36},{"date":"2023-07-03","hemoglobin_g_dL":12.1,"wbc_k_uL":6.2,"platelets_k_uL":331,"creatinine_mg_dL":0.88,"alt_U_L":45},{"date":"2024-08-16","hemoglobin_g_dL":12.6,"wbc_k_uL":5.5,"platelets_k_uL":164,"creatinine_mg_dL":1.2,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_2140","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":72,"sex":"male","bmi":29.8,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-60},"pfs_months":19.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":false},"longitudinal_labs":[{"date":"2024-08-06","hemoglobin_g_dL":11.6,"wbc_k_uL":7.7,"platelets_k_uL":285,"creatinine_mg_dL":1.12,"alt_U_L":61},{"date":"2025-03-23","hemoglobin_g_dL":11.5,"wbc_k_uL":8.3,"platelets_k_uL":256,"creatinine_mg_dL":1.28,"alt_U_L":28},{"date":"2026-05-26","hemoglobin_g_dL":11.6,"wbc_k_uL":7.7,"platelets_k_uL":327,"creatinine_mg_dL":1.65,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_2141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":59,"sex":"female","bmi":24.1,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-05-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-56},"pfs_months":28.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":52.5,"censored":false},"longitudinal_labs":[{"date":"2022-04-26","hemoglobin_g_dL":12.4,"wbc_k_uL":9.1,"platelets_k_uL":263,"creatinine_mg_dL":1.28,"alt_U_L":42},{"date":"2022-11-27","hemoglobin_g_dL":11.7,"wbc_k_uL":8.8,"platelets_k_uL":339,"creatinine_mg_dL":0.88,"alt_U_L":63},{"date":"2024-12-22","hemoglobin_g_dL":10.4,"wbc_k_uL":5.6,"platelets_k_uL":143,"creatinine_mg_dL":1.31,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_2142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":84,"sex":"female","bmi":32.0,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-02-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-72},"pfs_months":14.85},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-06-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.8,"censored":false},"longitudinal_labs":[{"date":"2020-01-11","hemoglobin_g_dL":15.2,"wbc_k_uL":6.4,"platelets_k_uL":395,"creatinine_mg_dL":1.29,"alt_U_L":59},{"date":"2020-08-16","hemoglobin_g_dL":12.9,"wbc_k_uL":7.6,"platelets_k_uL":149,"creatinine_mg_dL":1.09,"alt_U_L":67},{"date":"2021-06-12","hemoglobin_g_dL":12.3,"wbc_k_uL":4.0,"platelets_k_uL":281,"creatinine_mg_dL":1.23,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_2143","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":55,"sex":"male","bmi":26.4,"smoking_pack_years":50,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-65},"pfs_months":23.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.3,"censored":true},"longitudinal_labs":[{"date":"2020-12-13","hemoglobin_g_dL":13.0,"wbc_k_uL":9.0,"platelets_k_uL":171,"creatinine_mg_dL":1.14,"alt_U_L":10},{"date":"2021-07-12","hemoglobin_g_dL":12.2,"wbc_k_uL":7.3,"platelets_k_uL":143,"creatinine_mg_dL":0.78,"alt_U_L":118},{"date":"2023-01-06","hemoglobin_g_dL":9.9,"wbc_k_uL":6.9,"platelets_k_uL":315,"creatinine_mg_dL":1.89,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_2144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":73,"sex":"female","bmi":23.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-36},"pfs_months":15.15},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.2,"censored":false},"longitudinal_labs":[{"date":"2022-04-09","hemoglobin_g_dL":12.8,"wbc_k_uL":6.6,"platelets_k_uL":442,"creatinine_mg_dL":0.92,"alt_U_L":58},{"date":"2022-11-22","hemoglobin_g_dL":13.9,"wbc_k_uL":8.3,"platelets_k_uL":304,"creatinine_mg_dL":1.56,"alt_U_L":94},{"date":"2023-09-30","hemoglobin_g_dL":11.3,"wbc_k_uL":4.4,"platelets_k_uL":250,"creatinine_mg_dL":1.57,"alt_U_L":108}]}
{"patient_id":"ANODE_SYNTH_2025_2145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":84,"sex":"female","bmi":28.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-52},"pfs_months":21.39},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":false},"longitudinal_labs":[{"date":"2024-10-05","hemoglobin_g_dL":12.7,"wbc_k_uL":8.7,"platelets_k_uL":274,"creatinine_mg_dL":1.25,"alt_U_L":38},{"date":"2025-05-01","hemoglobin_g_dL":12.7,"wbc_k_uL":7.4,"platelets_k_uL":356,"creatinine_mg_dL":1.23,"alt_U_L":87},{"date":"2026-09-05","hemoglobin_g_dL":11.1,"wbc_k_uL":4.9,"platelets_k_uL":231,"creatinine_mg_dL":0.9,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_2146","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":83,"sex":"female","bmi":23.0,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-34},"pfs_months":30.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.7,"censored":false},"longitudinal_labs":[{"date":"2022-09-18","hemoglobin_g_dL":11.9,"wbc_k_uL":10.2,"platelets_k_uL":205,"creatinine_mg_dL":0.96,"alt_U_L":21},{"date":"2023-05-10","hemoglobin_g_dL":12.8,"wbc_k_uL":5.4,"platelets_k_uL":294,"creatinine_mg_dL":0.76,"alt_U_L":98},{"date":"2025-06-11","hemoglobin_g_dL":12.1,"wbc_k_uL":6.9,"platelets_k_uL":301,"creatinine_mg_dL":1.0,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_2147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":75,"sex":"female","bmi":25.4,"smoking_pack_years":75,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-01-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-56},"pfs_months":11.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":19.9,"censored":false},"longitudinal_labs":[{"date":"2020-11-15","hemoglobin_g_dL":12.2,"wbc_k_uL":10.6,"platelets_k_uL":354,"creatinine_mg_dL":0.84,"alt_U_L":19},{"date":"2021-07-13","hemoglobin_g_dL":11.4,"wbc_k_uL":5.4,"platelets_k_uL":316,"creatinine_mg_dL":1.44,"alt_U_L":38},{"date":"2021-12-27","hemoglobin_g_dL":9.9,"wbc_k_uL":7.3,"platelets_k_uL":235,"creatinine_mg_dL":1.52,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_2148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":56,"sex":"female","bmi":34.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-40},"pfs_months":33.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":51.4,"censored":true},"longitudinal_labs":[{"date":"2020-08-20","hemoglobin_g_dL":13.6,"wbc_k_uL":5.1,"platelets_k_uL":402,"creatinine_mg_dL":0.76,"alt_U_L":59},{"date":"2021-03-24","hemoglobin_g_dL":10.6,"wbc_k_uL":5.5,"platelets_k_uL":263,"creatinine_mg_dL":0.95,"alt_U_L":47},{"date":"2023-07-24","hemoglobin_g_dL":9.5,"wbc_k_uL":3.3,"platelets_k_uL":106,"creatinine_mg_dL":1.09,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_2149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":72,"sex":"male","bmi":29.2,"smoking_pack_years":35,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-05-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-47},"pfs_months":6.28},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":10.2,"censored":false},"longitudinal_labs":[{"date":"2024-04-11","hemoglobin_g_dL":14.8,"wbc_k_uL":5.9,"platelets_k_uL":448,"creatinine_mg_dL":0.91,"alt_U_L":78},{"date":"2024-11-17","hemoglobin_g_dL":11.5,"wbc_k_uL":7.4,"platelets_k_uL":357,"creatinine_mg_dL":1.13,"alt_U_L":118},{"date":"2025-01-21","hemoglobin_g_dL":11.6,"wbc_k_uL":6.2,"platelets_k_uL":187,"creatinine_mg_dL":1.94,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_2150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":87,"sex":"female","bmi":37.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-66},"pfs_months":8.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":22.6,"censored":true},"longitudinal_labs":[{"date":"2020-07-25","hemoglobin_g_dL":12.2,"wbc_k_uL":9.4,"platelets_k_uL":254,"creatinine_mg_dL":0.66,"alt_U_L":14},{"date":"2021-02-28","hemoglobin_g_dL":12.0,"wbc_k_uL":6.9,"platelets_k_uL":286,"creatinine_mg_dL":0.82,"alt_U_L":107},{"date":"2021-07-20","hemoglobin_g_dL":11.3,"wbc_k_uL":3.9,"platelets_k_uL":105,"creatinine_mg_dL":1.87,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_2151","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":77,"sex":"female","bmi":31.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-31},"pfs_months":34.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.8,"censored":true},"longitudinal_labs":[{"date":"2024-07-03","hemoglobin_g_dL":11.9,"wbc_k_uL":9.7,"platelets_k_uL":360,"creatinine_mg_dL":1.23,"alt_U_L":14},{"date":"2025-02-22","hemoglobin_g_dL":11.7,"wbc_k_uL":4.2,"platelets_k_uL":226,"creatinine_mg_dL":0.86,"alt_U_L":98},{"date":"2027-07-31","hemoglobin_g_dL":10.4,"wbc_k_uL":6.9,"platelets_k_uL":215,"creatinine_mg_dL":0.86,"alt_U_L":99}]}
{"patient_id":"ANODE_SYNTH_2025_2152","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":48,"sex":"female","bmi":24.1,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-07-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-79},"pfs_months":25.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":52.7,"censored":true},"longitudinal_labs":[{"date":"2024-05-14","hemoglobin_g_dL":14.7,"wbc_k_uL":10.9,"platelets_k_uL":417,"creatinine_mg_dL":0.75,"alt_U_L":31},{"date":"2025-01-08","hemoglobin_g_dL":13.9,"wbc_k_uL":6.7,"platelets_k_uL":242,"creatinine_mg_dL":0.98,"alt_U_L":57},{"date":"2026-09-30","hemoglobin_g_dL":11.9,"wbc_k_uL":7.0,"platelets_k_uL":313,"creatinine_mg_dL":0.96,"alt_U_L":87}]}
{"patient_id":"ANODE_SYNTH_2025_2153","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":53,"sex":"male","bmi":32.7,"smoking_pack_years":18,"ecog_performance_status":2,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-04-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-38},"pfs_months":10.12},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.3,"censored":true},"longitudinal_labs":[{"date":"2021-03-09","hemoglobin_g_dL":14.1,"wbc_k_uL":4.7,"platelets_k_uL":435,"creatinine_mg_dL":0.69,"alt_U_L":24},{"date":"2021-10-03","hemoglobin_g_dL":10.5,"wbc_k_uL":5.5,"platelets_k_uL":191,"creatinine_mg_dL":1.11,"alt_U_L":63},{"date":"2022-02-16","hemoglobin_g_dL":10.6,"wbc_k_uL":5.4,"platelets_k_uL":279,"creatinine_mg_dL":1.46,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_2154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":51,"sex":"male","bmi":30.8,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-05-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-46},"pfs_months":20.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.9,"censored":false},"longitudinal_labs":[{"date":"2021-03-03","hemoglobin_g_dL":15.0,"wbc_k_uL":7.5,"platelets_k_uL":250,"creatinine_mg_dL":0.77,"alt_U_L":14},{"date":"2021-11-04","hemoglobin_g_dL":10.4,"wbc_k_uL":8.9,"platelets_k_uL":364,"creatinine_mg_dL":0.84,"alt_U_L":59},{"date":"2023-01-26","hemoglobin_g_dL":12.6,"wbc_k_uL":4.1,"platelets_k_uL":132,"creatinine_mg_dL":1.78,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_2155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":66,"sex":"female","bmi":37.4,"smoking_pack_years":71,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-02-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-65},"pfs_months":5.22},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":12.4,"censored":false},"longitudinal_labs":[{"date":"2022-01-11","hemoglobin_g_dL":15.0,"wbc_k_uL":5.7,"platelets_k_uL":393,"creatinine_mg_dL":1.13,"alt_U_L":29},{"date":"2022-08-06","hemoglobin_g_dL":13.5,"wbc_k_uL":4.1,"platelets_k_uL":312,"creatinine_mg_dL":0.94,"alt_U_L":114},{"date":"2022-08-02","hemoglobin_g_dL":11.0,"wbc_k_uL":5.6,"platelets_k_uL":129,"creatinine_mg_dL":0.89,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_2156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":77,"sex":"male","bmi":27.5,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-09-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-58},"pfs_months":43.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":62.3,"censored":true},"longitudinal_labs":[{"date":"2024-09-04","hemoglobin_g_dL":12.6,"wbc_k_uL":5.2,"platelets_k_uL":185,"creatinine_mg_dL":1.3,"alt_U_L":14},{"date":"2025-03-24","hemoglobin_g_dL":10.8,"wbc_k_uL":7.0,"platelets_k_uL":301,"creatinine_mg_dL":1.19,"alt_U_L":32},{"date":"2028-05-20","hemoglobin_g_dL":10.4,"wbc_k_uL":6.4,"platelets_k_uL":294,"creatinine_mg_dL":0.98,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_2157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":72,"sex":"male","bmi":26.0,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-69},"pfs_months":39.56},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.9,"censored":true},"longitudinal_labs":[{"date":"2020-10-19","hemoglobin_g_dL":14.2,"wbc_k_uL":7.9,"platelets_k_uL":278,"creatinine_mg_dL":0.9,"alt_U_L":36},{"date":"2021-06-16","hemoglobin_g_dL":11.9,"wbc_k_uL":5.5,"platelets_k_uL":162,"creatinine_mg_dL":0.87,"alt_U_L":52},{"date":"2024-05-07","hemoglobin_g_dL":12.5,"wbc_k_uL":7.1,"platelets_k_uL":116,"creatinine_mg_dL":0.94,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_2158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":68,"sex":"female","bmi":23.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-02-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-35},"pfs_months":20.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.9,"censored":false},"longitudinal_labs":[{"date":"2020-01-01","hemoglobin_g_dL":12.4,"wbc_k_uL":7.9,"platelets_k_uL":320,"creatinine_mg_dL":1.14,"alt_U_L":53},{"date":"2020-08-15","hemoglobin_g_dL":11.6,"wbc_k_uL":3.9,"platelets_k_uL":143,"creatinine_mg_dL":0.84,"alt_U_L":57},{"date":"2022-01-02","hemoglobin_g_dL":9.8,"wbc_k_uL":3.8,"platelets_k_uL":281,"creatinine_mg_dL":1.09,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_2159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":64,"sex":"female","bmi":28.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-71},"pfs_months":20.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":true},"longitudinal_labs":[{"date":"2021-08-24","hemoglobin_g_dL":14.3,"wbc_k_uL":8.3,"platelets_k_uL":403,"creatinine_mg_dL":0.71,"alt_U_L":27},{"date":"2022-04-22","hemoglobin_g_dL":13.1,"wbc_k_uL":6.8,"platelets_k_uL":342,"creatinine_mg_dL":1.49,"alt_U_L":77},{"date":"2023-07-28","hemoglobin_g_dL":11.1,"wbc_k_uL":8.0,"platelets_k_uL":203,"creatinine_mg_dL":1.01,"alt_U_L":197}]}
{"patient_id":"ANODE_SYNTH_2025_2160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":53,"sex":"male","bmi":30.2,"smoking_pack_years":23,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-09-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-75},"pfs_months":19.22},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.0,"censored":true},"longitudinal_labs":[{"date":"2024-08-13","hemoglobin_g_dL":13.3,"wbc_k_uL":9.2,"platelets_k_uL":159,"creatinine_mg_dL":0.94,"alt_U_L":76},{"date":"2025-03-18","hemoglobin_g_dL":10.7,"wbc_k_uL":5.9,"platelets_k_uL":257,"creatinine_mg_dL":1.25,"alt_U_L":81},{"date":"2026-06-08","hemoglobin_g_dL":10.1,"wbc_k_uL":5.3,"platelets_k_uL":299,"creatinine_mg_dL":0.8,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_2161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":54,"sex":"female","bmi":18.8,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-08-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-55},"pfs_months":30.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.0,"censored":false},"longitudinal_labs":[{"date":"2021-07-07","hemoglobin_g_dL":12.9,"wbc_k_uL":10.6,"platelets_k_uL":187,"creatinine_mg_dL":0.7,"alt_U_L":33},{"date":"2022-02-07","hemoglobin_g_dL":13.4,"wbc_k_uL":5.2,"platelets_k_uL":224,"creatinine_mg_dL":1.46,"alt_U_L":41},{"date":"2024-03-19","hemoglobin_g_dL":10.9,"wbc_k_uL":4.6,"platelets_k_uL":286,"creatinine_mg_dL":1.7,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_2162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":83,"sex":"female","bmi":37.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-09-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-70},"pfs_months":25.86},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.4,"censored":false},"longitudinal_labs":[{"date":"2023-08-13","hemoglobin_g_dL":15.0,"wbc_k_uL":4.8,"platelets_k_uL":305,"creatinine_mg_dL":1.23,"alt_U_L":78},{"date":"2024-02-29","hemoglobin_g_dL":11.1,"wbc_k_uL":4.7,"platelets_k_uL":175,"creatinine_mg_dL":0.97,"alt_U_L":100},{"date":"2025-11-20","hemoglobin_g_dL":12.4,"wbc_k_uL":5.8,"platelets_k_uL":182,"creatinine_mg_dL":1.35,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_2163","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":73,"sex":"female","bmi":37.5,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-57},"pfs_months":14.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":false},"longitudinal_labs":[{"date":"2020-12-21","hemoglobin_g_dL":13.8,"wbc_k_uL":9.7,"platelets_k_uL":355,"creatinine_mg_dL":1.07,"alt_U_L":46},{"date":"2021-07-08","hemoglobin_g_dL":13.0,"wbc_k_uL":7.8,"platelets_k_uL":297,"creatinine_mg_dL":1.23,"alt_U_L":112},{"date":"2022-05-22","hemoglobin_g_dL":11.4,"wbc_k_uL":4.7,"platelets_k_uL":214,"creatinine_mg_dL":1.78,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_2164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":67,"sex":"female","bmi":21.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-02-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-58},"pfs_months":24.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":false},"longitudinal_labs":[{"date":"2020-01-21","hemoglobin_g_dL":14.4,"wbc_k_uL":9.7,"platelets_k_uL":283,"creatinine_mg_dL":0.61,"alt_U_L":53},{"date":"2020-08-14","hemoglobin_g_dL":10.6,"wbc_k_uL":8.1,"platelets_k_uL":223,"creatinine_mg_dL":1.14,"alt_U_L":101},{"date":"2022-03-13","hemoglobin_g_dL":11.1,"wbc_k_uL":3.9,"platelets_k_uL":269,"creatinine_mg_dL":1.78,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_2165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":59,"sex":"female","bmi":29.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-39},"pfs_months":19.61},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.4,"censored":true},"longitudinal_labs":[{"date":"2021-02-04","hemoglobin_g_dL":14.0,"wbc_k_uL":9.7,"platelets_k_uL":412,"creatinine_mg_dL":0.89,"alt_U_L":67},{"date":"2021-09-07","hemoglobin_g_dL":11.0,"wbc_k_uL":4.5,"platelets_k_uL":246,"creatinine_mg_dL":0.75,"alt_U_L":88},{"date":"2022-12-13","hemoglobin_g_dL":11.2,"wbc_k_uL":4.9,"platelets_k_uL":267,"creatinine_mg_dL":1.06,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_2166","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":54,"sex":"male","bmi":30.7,"smoking_pack_years":48,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-68},"pfs_months":22.97},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-24","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.3,"censored":false},"longitudinal_labs":[{"date":"2022-02-01","hemoglobin_g_dL":14.3,"wbc_k_uL":8.5,"platelets_k_uL":396,"creatinine_mg_dL":1.16,"alt_U_L":18},{"date":"2022-09-14","hemoglobin_g_dL":13.1,"wbc_k_uL":5.4,"platelets_k_uL":243,"creatinine_mg_dL":1.46,"alt_U_L":31},{"date":"2024-03-24","hemoglobin_g_dL":12.5,"wbc_k_uL":4.3,"platelets_k_uL":186,"creatinine_mg_dL":1.13,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_2167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":72,"sex":"female","bmi":36.1,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-36},"pfs_months":27.7},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.9,"censored":true},"longitudinal_labs":[{"date":"2024-09-03","hemoglobin_g_dL":11.6,"wbc_k_uL":7.7,"platelets_k_uL":397,"creatinine_mg_dL":1.07,"alt_U_L":73},{"date":"2025-03-31","hemoglobin_g_dL":11.9,"wbc_k_uL":7.4,"platelets_k_uL":286,"creatinine_mg_dL":1.46,"alt_U_L":24},{"date":"2027-03-17","hemoglobin_g_dL":11.4,"wbc_k_uL":4.1,"platelets_k_uL":293,"creatinine_mg_dL":1.26,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_2168","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":53,"sex":"female","bmi":31.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-59},"pfs_months":22.77},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.3,"censored":false},"longitudinal_labs":[{"date":"2022-10-14","hemoglobin_g_dL":13.4,"wbc_k_uL":5.3,"platelets_k_uL":155,"creatinine_mg_dL":1.18,"alt_U_L":37},{"date":"2023-05-12","hemoglobin_g_dL":11.0,"wbc_k_uL":8.5,"platelets_k_uL":188,"creatinine_mg_dL":1.12,"alt_U_L":64},{"date":"2024-11-22","hemoglobin_g_dL":12.2,"wbc_k_uL":6.6,"platelets_k_uL":137,"creatinine_mg_dL":1.93,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_2169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":83,"sex":"male","bmi":24.8,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2026-01-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-56},"pfs_months":32.76},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-11-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.8,"censored":false},"longitudinal_labs":[{"date":"2025-12-05","hemoglobin_g_dL":13.8,"wbc_k_uL":6.1,"platelets_k_uL":405,"creatinine_mg_dL":0.81,"alt_U_L":67},{"date":"2026-07-19","hemoglobin_g_dL":10.3,"wbc_k_uL":8.8,"platelets_k_uL":165,"creatinine_mg_dL":1.57,"alt_U_L":43},{"date":"2028-11-08","hemoglobin_g_dL":10.3,"wbc_k_uL":3.3,"platelets_k_uL":347,"creatinine_mg_dL":1.43,"alt_U_L":166}]}
{"patient_id":"ANODE_SYNTH_2025_2170","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":66,"sex":"male","bmi":30.5,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-06-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-63},"pfs_months":6.05},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.6,"censored":true},"longitudinal_labs":[{"date":"2021-04-22","hemoglobin_g_dL":12.9,"wbc_k_uL":8.8,"platelets_k_uL":173,"creatinine_mg_dL":0.76,"alt_U_L":62},{"date":"2021-12-11","hemoglobin_g_dL":12.9,"wbc_k_uL":6.7,"platelets_k_uL":147,"creatinine_mg_dL":0.72,"alt_U_L":76},{"date":"2021-12-28","hemoglobin_g_dL":11.1,"wbc_k_uL":3.8,"platelets_k_uL":236,"creatinine_mg_dL":1.98,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_2171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":74,"sex":"female","bmi":35.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-85},"pfs_months":33.12},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.1,"censored":false},"longitudinal_labs":[{"date":"2023-12-01","hemoglobin_g_dL":14.2,"wbc_k_uL":6.0,"platelets_k_uL":273,"creatinine_mg_dL":0.74,"alt_U_L":43},{"date":"2024-06-26","hemoglobin_g_dL":11.4,"wbc_k_uL":7.4,"platelets_k_uL":286,"creatinine_mg_dL":0.74,"alt_U_L":119},{"date":"2026-10-21","hemoglobin_g_dL":12.5,"wbc_k_uL":4.7,"platelets_k_uL":285,"creatinine_mg_dL":1.74,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_2172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":84,"sex":"female","bmi":26.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-42},"pfs_months":12.65},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":16.6,"censored":true},"longitudinal_labs":[{"date":"2020-10-08","hemoglobin_g_dL":12.5,"wbc_k_uL":10.7,"platelets_k_uL":176,"creatinine_mg_dL":1.16,"alt_U_L":42},{"date":"2021-05-09","hemoglobin_g_dL":12.8,"wbc_k_uL":7.6,"platelets_k_uL":360,"creatinine_mg_dL":1.04,"alt_U_L":35},{"date":"2021-12-28","hemoglobin_g_dL":11.7,"wbc_k_uL":6.1,"platelets_k_uL":187,"creatinine_mg_dL":1.14,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_2173","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":72,"sex":"male","bmi":30.7,"smoking_pack_years":79,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-11-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-68},"pfs_months":23.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":28.7,"censored":false},"longitudinal_labs":[{"date":"2022-10-10","hemoglobin_g_dL":11.5,"wbc_k_uL":5.9,"platelets_k_uL":289,"creatinine_mg_dL":1.13,"alt_U_L":64},{"date":"2023-05-02","hemoglobin_g_dL":10.9,"wbc_k_uL":3.9,"platelets_k_uL":207,"creatinine_mg_dL":1.27,"alt_U_L":83},{"date":"2024-10-27","hemoglobin_g_dL":10.7,"wbc_k_uL":4.4,"platelets_k_uL":233,"creatinine_mg_dL":1.22,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_2174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":49,"sex":"female","bmi":33.2,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-83},"pfs_months":31.84},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":56.4,"censored":true},"longitudinal_labs":[{"date":"2023-03-05","hemoglobin_g_dL":14.1,"wbc_k_uL":5.4,"platelets_k_uL":285,"creatinine_mg_dL":0.75,"alt_U_L":58},{"date":"2023-09-18","hemoglobin_g_dL":13.3,"wbc_k_uL":8.9,"platelets_k_uL":120,"creatinine_mg_dL":1.52,"alt_U_L":72},{"date":"2026-01-13","hemoglobin_g_dL":11.5,"wbc_k_uL":5.2,"platelets_k_uL":219,"creatinine_mg_dL":1.18,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_2175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":78,"sex":"male","bmi":30.9,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-54},"pfs_months":33.54},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":53.3,"censored":false},"longitudinal_labs":[{"date":"2020-10-13","hemoglobin_g_dL":11.8,"wbc_k_uL":6.9,"platelets_k_uL":346,"creatinine_mg_dL":0.76,"alt_U_L":77},{"date":"2021-06-07","hemoglobin_g_dL":13.8,"wbc_k_uL":7.3,"platelets_k_uL":313,"creatinine_mg_dL":0.88,"alt_U_L":69},{"date":"2023-10-28","hemoglobin_g_dL":10.0,"wbc_k_uL":7.6,"platelets_k_uL":340,"creatinine_mg_dL":1.66,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_2176","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":88,"sex":"female","bmi":26.9,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-10-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-69},"pfs_months":18.76},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.3,"censored":false},"longitudinal_labs":[{"date":"2021-08-28","hemoglobin_g_dL":12.7,"wbc_k_uL":6.6,"platelets_k_uL":405,"creatinine_mg_dL":0.7,"alt_U_L":31},{"date":"2022-04-21","hemoglobin_g_dL":12.1,"wbc_k_uL":4.1,"platelets_k_uL":357,"creatinine_mg_dL":1.33,"alt_U_L":66},{"date":"2023-06-08","hemoglobin_g_dL":10.7,"wbc_k_uL":3.4,"platelets_k_uL":276,"creatinine_mg_dL":1.86,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_2177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":77,"sex":"female","bmi":30.6,"smoking_pack_years":10,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2026-01-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-53},"pfs_months":35.52},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":58.3,"censored":true},"longitudinal_labs":[{"date":"2025-11-18","hemoglobin_g_dL":13.7,"wbc_k_uL":10.0,"platelets_k_uL":300,"creatinine_mg_dL":1.03,"alt_U_L":46},{"date":"2026-07-26","hemoglobin_g_dL":13.8,"wbc_k_uL":6.0,"platelets_k_uL":146,"creatinine_mg_dL":1.52,"alt_U_L":80},{"date":"2029-01-27","hemoglobin_g_dL":10.6,"wbc_k_uL":3.6,"platelets_k_uL":220,"creatinine_mg_dL":1.62,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_2178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":48,"sex":"male","bmi":26.5,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-02-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-31},"pfs_months":35.88},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":62.6,"censored":true},"longitudinal_labs":[{"date":"2023-12-22","hemoglobin_g_dL":14.2,"wbc_k_uL":4.7,"platelets_k_uL":317,"creatinine_mg_dL":1.19,"alt_U_L":76},{"date":"2024-08-06","hemoglobin_g_dL":13.1,"wbc_k_uL":6.9,"platelets_k_uL":344,"creatinine_mg_dL":1.05,"alt_U_L":71},{"date":"2027-03-22","hemoglobin_g_dL":12.9,"wbc_k_uL":4.4,"platelets_k_uL":239,"creatinine_mg_dL":1.71,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_2179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":70,"sex":"female","bmi":32.0,"smoking_pack_years":75,"ecog_performance_status":2,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-02-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-80},"pfs_months":17.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.5,"censored":false},"longitudinal_labs":[{"date":"2023-02-07","hemoglobin_g_dL":12.3,"wbc_k_uL":10.9,"platelets_k_uL":256,"creatinine_mg_dL":1.21,"alt_U_L":70},{"date":"2023-08-22","hemoglobin_g_dL":13.0,"wbc_k_uL":6.4,"platelets_k_uL":192,"creatinine_mg_dL":1.39,"alt_U_L":62},{"date":"2024-10-02","hemoglobin_g_dL":12.1,"wbc_k_uL":3.7,"platelets_k_uL":175,"creatinine_mg_dL":1.92,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_2180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":76,"sex":"female","bmi":27.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-67},"pfs_months":21.36},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":false},"longitudinal_labs":[{"date":"2025-11-06","hemoglobin_g_dL":15.1,"wbc_k_uL":8.0,"platelets_k_uL":277,"creatinine_mg_dL":0.65,"alt_U_L":74},{"date":"2026-06-05","hemoglobin_g_dL":12.4,"wbc_k_uL":3.9,"platelets_k_uL":151,"creatinine_mg_dL":1.12,"alt_U_L":64},{"date":"2027-10-01","hemoglobin_g_dL":12.2,"wbc_k_uL":3.9,"platelets_k_uL":288,"creatinine_mg_dL":1.31,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_2181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":81,"sex":"female","bmi":22.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-47},"pfs_months":16.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":true},"longitudinal_labs":[{"date":"2024-06-11","hemoglobin_g_dL":12.2,"wbc_k_uL":7.2,"platelets_k_uL":402,"creatinine_mg_dL":0.8,"alt_U_L":73},{"date":"2025-01-13","hemoglobin_g_dL":10.4,"wbc_k_uL":5.0,"platelets_k_uL":349,"creatinine_mg_dL":0.87,"alt_U_L":39},{"date":"2025-12-19","hemoglobin_g_dL":12.9,"wbc_k_uL":7.8,"platelets_k_uL":205,"creatinine_mg_dL":0.94,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_2182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":74,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-30},"pfs_months":23.33},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":false},"longitudinal_labs":[{"date":"2022-11-06","hemoglobin_g_dL":14.7,"wbc_k_uL":5.7,"platelets_k_uL":271,"creatinine_mg_dL":0.77,"alt_U_L":65},{"date":"2023-05-19","hemoglobin_g_dL":11.4,"wbc_k_uL":6.1,"platelets_k_uL":227,"creatinine_mg_dL":1.33,"alt_U_L":119},{"date":"2024-12-01","hemoglobin_g_dL":12.6,"wbc_k_uL":6.5,"platelets_k_uL":159,"creatinine_mg_dL":1.83,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_2183","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":52,"sex":"male","bmi":24.9,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-57},"pfs_months":19.12},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":false},"longitudinal_labs":[{"date":"2023-05-15","hemoglobin_g_dL":11.6,"wbc_k_uL":5.3,"platelets_k_uL":246,"creatinine_mg_dL":0.93,"alt_U_L":75},{"date":"2023-12-19","hemoglobin_g_dL":10.7,"wbc_k_uL":6.6,"platelets_k_uL":138,"creatinine_mg_dL":0.73,"alt_U_L":57},{"date":"2025-03-11","hemoglobin_g_dL":10.0,"wbc_k_uL":4.3,"platelets_k_uL":288,"creatinine_mg_dL":1.26,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_2184","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":64,"sex":"female","bmi":30.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-60},"pfs_months":23.52},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.7,"censored":false},"longitudinal_labs":[{"date":"2022-05-11","hemoglobin_g_dL":13.9,"wbc_k_uL":9.8,"platelets_k_uL":283,"creatinine_mg_dL":1.1,"alt_U_L":56},{"date":"2022-12-23","hemoglobin_g_dL":12.0,"wbc_k_uL":6.7,"platelets_k_uL":361,"creatinine_mg_dL":0.79,"alt_U_L":81},{"date":"2024-08-06","hemoglobin_g_dL":11.2,"wbc_k_uL":6.2,"platelets_k_uL":294,"creatinine_mg_dL":1.48,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_2185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":53,"sex":"female","bmi":37.9,"smoking_pack_years":52,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-53},"pfs_months":50.14},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-04-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":73.6,"censored":true},"longitudinal_labs":[{"date":"2024-12-07","hemoglobin_g_dL":13.4,"wbc_k_uL":9.3,"platelets_k_uL":365,"creatinine_mg_dL":0.99,"alt_U_L":43},{"date":"2025-06-30","hemoglobin_g_dL":10.9,"wbc_k_uL":8.0,"platelets_k_uL":217,"creatinine_mg_dL":1.23,"alt_U_L":112},{"date":"2029-04-30","hemoglobin_g_dL":10.3,"wbc_k_uL":5.6,"platelets_k_uL":110,"creatinine_mg_dL":1.72,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_2186","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":83,"sex":"female","bmi":34.2,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-09-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-45},"pfs_months":25.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.9,"censored":false},"longitudinal_labs":[{"date":"2021-07-09","hemoglobin_g_dL":11.5,"wbc_k_uL":10.9,"platelets_k_uL":205,"creatinine_mg_dL":0.9,"alt_U_L":17},{"date":"2022-03-01","hemoglobin_g_dL":12.6,"wbc_k_uL":6.3,"platelets_k_uL":253,"creatinine_mg_dL":0.83,"alt_U_L":55},{"date":"2023-12-09","hemoglobin_g_dL":12.4,"wbc_k_uL":6.6,"platelets_k_uL":176,"creatinine_mg_dL":1.13,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_2187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":87,"sex":"female","bmi":24.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-49},"pfs_months":18.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.1,"censored":false},"longitudinal_labs":[{"date":"2022-02-11","hemoglobin_g_dL":14.1,"wbc_k_uL":4.9,"platelets_k_uL":396,"creatinine_mg_dL":1.05,"alt_U_L":61},{"date":"2022-08-31","hemoglobin_g_dL":13.9,"wbc_k_uL":5.8,"platelets_k_uL":272,"creatinine_mg_dL":1.06,"alt_U_L":99},{"date":"2023-10-10","hemoglobin_g_dL":10.2,"wbc_k_uL":4.8,"platelets_k_uL":125,"creatinine_mg_dL":1.63,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_2188","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":61,"sex":"male","bmi":27.6,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-08-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-74},"pfs_months":24.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.7,"censored":false},"longitudinal_labs":[{"date":"2022-06-01","hemoglobin_g_dL":12.2,"wbc_k_uL":9.6,"platelets_k_uL":306,"creatinine_mg_dL":0.87,"alt_U_L":66},{"date":"2023-01-29","hemoglobin_g_dL":10.8,"wbc_k_uL":4.7,"platelets_k_uL":198,"creatinine_mg_dL":1.6,"alt_U_L":72},{"date":"2024-09-12","hemoglobin_g_dL":11.4,"wbc_k_uL":6.6,"platelets_k_uL":233,"creatinine_mg_dL":1.69,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_2189","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":87,"sex":"female","bmi":19.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-82},"pfs_months":28.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.2,"censored":false},"longitudinal_labs":[{"date":"2023-01-19","hemoglobin_g_dL":13.6,"wbc_k_uL":4.5,"platelets_k_uL":217,"creatinine_mg_dL":1.07,"alt_U_L":40},{"date":"2023-09-11","hemoglobin_g_dL":13.2,"wbc_k_uL":6.7,"platelets_k_uL":276,"creatinine_mg_dL":1.13,"alt_U_L":117},{"date":"2025-09-28","hemoglobin_g_dL":10.8,"wbc_k_uL":4.0,"platelets_k_uL":277,"creatinine_mg_dL":1.5,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2190","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":69,"sex":"female","bmi":34.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-79},"pfs_months":15.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":false},"longitudinal_labs":[{"date":"2025-01-26","hemoglobin_g_dL":14.4,"wbc_k_uL":9.2,"platelets_k_uL":398,"creatinine_mg_dL":1.16,"alt_U_L":47},{"date":"2025-08-16","hemoglobin_g_dL":10.5,"wbc_k_uL":5.2,"platelets_k_uL":300,"creatinine_mg_dL":1.19,"alt_U_L":38},{"date":"2026-07-23","hemoglobin_g_dL":10.3,"wbc_k_uL":4.5,"platelets_k_uL":236,"creatinine_mg_dL":1.01,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_2191","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":76,"sex":"female","bmi":26.9,"smoking_pack_years":72,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-06-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-51},"pfs_months":28.22},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.3,"censored":false},"longitudinal_labs":[{"date":"2021-06-05","hemoglobin_g_dL":14.7,"wbc_k_uL":8.5,"platelets_k_uL":348,"creatinine_mg_dL":0.62,"alt_U_L":27},{"date":"2021-12-17","hemoglobin_g_dL":12.2,"wbc_k_uL":4.3,"platelets_k_uL":295,"creatinine_mg_dL":1.57,"alt_U_L":94},{"date":"2023-12-23","hemoglobin_g_dL":11.4,"wbc_k_uL":4.8,"platelets_k_uL":179,"creatinine_mg_dL":0.99,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_2192","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":57,"sex":"female","bmi":31.6,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-05-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-47},"pfs_months":21.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":false},"longitudinal_labs":[{"date":"2025-03-13","hemoglobin_g_dL":13.1,"wbc_k_uL":5.5,"platelets_k_uL":221,"creatinine_mg_dL":0.94,"alt_U_L":31},{"date":"2025-11-07","hemoglobin_g_dL":12.5,"wbc_k_uL":7.6,"platelets_k_uL":202,"creatinine_mg_dL":1.09,"alt_U_L":79},{"date":"2027-03-13","hemoglobin_g_dL":9.7,"wbc_k_uL":7.0,"platelets_k_uL":318,"creatinine_mg_dL":1.68,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_2193","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":55,"sex":"female","bmi":33.4,"smoking_pack_years":79,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-65},"pfs_months":27.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.4,"censored":true},"longitudinal_labs":[{"date":"2023-07-24","hemoglobin_g_dL":11.5,"wbc_k_uL":10.2,"platelets_k_uL":450,"creatinine_mg_dL":1.04,"alt_U_L":59},{"date":"2024-03-13","hemoglobin_g_dL":13.0,"wbc_k_uL":6.6,"platelets_k_uL":355,"creatinine_mg_dL":1.36,"alt_U_L":87},{"date":"2025-12-29","hemoglobin_g_dL":10.2,"wbc_k_uL":4.4,"platelets_k_uL":301,"creatinine_mg_dL":1.93,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_2194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":62,"sex":"male","bmi":33.6,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-42},"pfs_months":7.92},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.2,"censored":false},"longitudinal_labs":[{"date":"2021-07-15","hemoglobin_g_dL":11.7,"wbc_k_uL":10.4,"platelets_k_uL":311,"creatinine_mg_dL":0.74,"alt_U_L":71},{"date":"2022-01-25","hemoglobin_g_dL":13.0,"wbc_k_uL":6.4,"platelets_k_uL":220,"creatinine_mg_dL":0.88,"alt_U_L":93},{"date":"2022-05-22","hemoglobin_g_dL":10.4,"wbc_k_uL":6.9,"platelets_k_uL":241,"creatinine_mg_dL":0.9,"alt_U_L":56}]}
{"patient_id":"ANODE_SYNTH_2025_2195","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":79,"sex":"female","bmi":22.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-51},"pfs_months":22.97},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.2,"censored":true},"longitudinal_labs":[{"date":"2022-07-14","hemoglobin_g_dL":14.6,"wbc_k_uL":10.2,"platelets_k_uL":332,"creatinine_mg_dL":0.69,"alt_U_L":74},{"date":"2023-03-14","hemoglobin_g_dL":11.8,"wbc_k_uL":5.9,"platelets_k_uL":220,"creatinine_mg_dL":0.84,"alt_U_L":45},{"date":"2024-09-22","hemoglobin_g_dL":10.7,"wbc_k_uL":4.8,"platelets_k_uL":141,"creatinine_mg_dL":1.78,"alt_U_L":99}]}
{"patient_id":"ANODE_SYNTH_2025_2196","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":77,"sex":"female","bmi":35.4,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-01-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-50},"pfs_months":21.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":false},"longitudinal_labs":[{"date":"2021-11-14","hemoglobin_g_dL":15.1,"wbc_k_uL":9.8,"platelets_k_uL":260,"creatinine_mg_dL":1.11,"alt_U_L":52},{"date":"2022-07-05","hemoglobin_g_dL":14.0,"wbc_k_uL":7.8,"platelets_k_uL":347,"creatinine_mg_dL":1.49,"alt_U_L":108},{"date":"2023-11-21","hemoglobin_g_dL":10.7,"wbc_k_uL":3.5,"platelets_k_uL":292,"creatinine_mg_dL":1.75,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_2197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":88,"sex":"female","bmi":26.1,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-66},"pfs_months":23.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.8,"censored":false},"longitudinal_labs":[{"date":"2021-05-14","hemoglobin_g_dL":13.7,"wbc_k_uL":6.1,"platelets_k_uL":320,"creatinine_mg_dL":1.08,"alt_U_L":73},{"date":"2021-12-27","hemoglobin_g_dL":10.4,"wbc_k_uL":6.4,"platelets_k_uL":200,"creatinine_mg_dL":1.31,"alt_U_L":86},{"date":"2023-08-14","hemoglobin_g_dL":11.3,"wbc_k_uL":4.2,"platelets_k_uL":230,"creatinine_mg_dL":0.84,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_2198","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":87,"sex":"female","bmi":29.5,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-04-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-34},"pfs_months":23.1},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.7,"censored":false},"longitudinal_labs":[{"date":"2022-03-20","hemoglobin_g_dL":15.1,"wbc_k_uL":5.0,"platelets_k_uL":436,"creatinine_mg_dL":0.92,"alt_U_L":39},{"date":"2022-10-12","hemoglobin_g_dL":13.8,"wbc_k_uL":4.7,"platelets_k_uL":126,"creatinine_mg_dL":0.78,"alt_U_L":63},{"date":"2024-03-30","hemoglobin_g_dL":12.2,"wbc_k_uL":3.2,"platelets_k_uL":174,"creatinine_mg_dL":1.73,"alt_U_L":166}]}
{"patient_id":"ANODE_SYNTH_2025_2199","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":64,"sex":"male","bmi":26.0,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-11-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-61},"pfs_months":22.83},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.1,"censored":false},"longitudinal_labs":[{"date":"2021-09-11","hemoglobin_g_dL":14.7,"wbc_k_uL":4.8,"platelets_k_uL":418,"creatinine_mg_dL":0.68,"alt_U_L":21},{"date":"2022-05-02","hemoglobin_g_dL":10.0,"wbc_k_uL":4.1,"platelets_k_uL":375,"creatinine_mg_dL":1.27,"alt_U_L":61},{"date":"2023-10-12","hemoglobin_g_dL":11.2,"wbc_k_uL":4.1,"platelets_k_uL":297,"creatinine_mg_dL":1.48,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_2200","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":61,"sex":"female","bmi":27.2,"smoking_pack_years":78,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-10-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-41},"pfs_months":20.7},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.0,"censored":false},"longitudinal_labs":[{"date":"2025-10-02","hemoglobin_g_dL":12.2,"wbc_k_uL":8.8,"platelets_k_uL":432,"creatinine_mg_dL":1.03,"alt_U_L":74},{"date":"2026-04-19","hemoglobin_g_dL":10.9,"wbc_k_uL":4.6,"platelets_k_uL":179,"creatinine_mg_dL":0.82,"alt_U_L":36},{"date":"2027-09-08","hemoglobin_g_dL":9.5,"wbc_k_uL":7.0,"platelets_k_uL":232,"creatinine_mg_dL":1.0,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_2201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":73,"sex":"female","bmi":37.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-51},"pfs_months":14.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.9,"censored":false},"longitudinal_labs":[{"date":"2020-07-06","hemoglobin_g_dL":11.7,"wbc_k_uL":5.4,"platelets_k_uL":230,"creatinine_mg_dL":0.71,"alt_U_L":12},{"date":"2021-01-31","hemoglobin_g_dL":12.1,"wbc_k_uL":3.9,"platelets_k_uL":184,"creatinine_mg_dL":1.53,"alt_U_L":28},{"date":"2021-11-28","hemoglobin_g_dL":10.1,"wbc_k_uL":3.6,"platelets_k_uL":318,"creatinine_mg_dL":0.89,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_2202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":82,"sex":"female","bmi":20.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-10-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-66},"pfs_months":9.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.6,"censored":false},"longitudinal_labs":[{"date":"2025-10-06","hemoglobin_g_dL":13.4,"wbc_k_uL":9.1,"platelets_k_uL":165,"creatinine_mg_dL":0.81,"alt_U_L":31},{"date":"2026-04-28","hemoglobin_g_dL":13.1,"wbc_k_uL":8.1,"platelets_k_uL":312,"creatinine_mg_dL":1.04,"alt_U_L":117},{"date":"2026-09-28","hemoglobin_g_dL":12.6,"wbc_k_uL":6.5,"platelets_k_uL":269,"creatinine_mg_dL":1.98,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_2203","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":57,"sex":"male","bmi":19.8,"smoking_pack_years":58,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-05-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-34},"pfs_months":14.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.7,"censored":false},"longitudinal_labs":[{"date":"2021-04-11","hemoglobin_g_dL":12.3,"wbc_k_uL":6.7,"platelets_k_uL":151,"creatinine_mg_dL":0.78,"alt_U_L":50},{"date":"2021-11-09","hemoglobin_g_dL":13.1,"wbc_k_uL":7.9,"platelets_k_uL":264,"creatinine_mg_dL":1.13,"alt_U_L":33},{"date":"2022-08-16","hemoglobin_g_dL":11.9,"wbc_k_uL":4.7,"platelets_k_uL":183,"creatinine_mg_dL":1.78,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_2204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":60,"sex":"female","bmi":36.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-80},"pfs_months":32.99},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":false},"longitudinal_labs":[{"date":"2025-05-28","hemoglobin_g_dL":12.0,"wbc_k_uL":10.9,"platelets_k_uL":285,"creatinine_mg_dL":0.96,"alt_U_L":55},{"date":"2025-12-21","hemoglobin_g_dL":10.1,"wbc_k_uL":5.4,"platelets_k_uL":192,"creatinine_mg_dL":1.49,"alt_U_L":58},{"date":"2028-04-06","hemoglobin_g_dL":11.9,"wbc_k_uL":3.6,"platelets_k_uL":137,"creatinine_mg_dL":1.31,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_2205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":59,"sex":"male","bmi":22.3,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-07-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-35},"pfs_months":36.44},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":57.7,"censored":false},"longitudinal_labs":[{"date":"2023-06-14","hemoglobin_g_dL":11.9,"wbc_k_uL":7.8,"platelets_k_uL":380,"creatinine_mg_dL":0.72,"alt_U_L":43},{"date":"2023-12-31","hemoglobin_g_dL":13.2,"wbc_k_uL":6.4,"platelets_k_uL":297,"creatinine_mg_dL":1.36,"alt_U_L":38},{"date":"2026-08-09","hemoglobin_g_dL":11.6,"wbc_k_uL":3.3,"platelets_k_uL":302,"creatinine_mg_dL":1.17,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_2206","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":75,"sex":"male","bmi":19.1,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-12-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-69},"pfs_months":28.02},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.0,"censored":true},"longitudinal_labs":[{"date":"2020-11-06","hemoglobin_g_dL":13.7,"wbc_k_uL":4.9,"platelets_k_uL":383,"creatinine_mg_dL":0.76,"alt_U_L":61},{"date":"2021-06-26","hemoglobin_g_dL":10.5,"wbc_k_uL":5.2,"platelets_k_uL":127,"creatinine_mg_dL":1.52,"alt_U_L":17},{"date":"2023-05-28","hemoglobin_g_dL":9.6,"wbc_k_uL":6.0,"platelets_k_uL":211,"creatinine_mg_dL":1.37,"alt_U_L":112}]}
{"patient_id":"ANODE_SYNTH_2025_2207","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":87,"sex":"female","bmi":23.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-64},"pfs_months":15.64},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.7,"censored":false},"longitudinal_labs":[{"date":"2024-09-24","hemoglobin_g_dL":15.3,"wbc_k_uL":9.4,"platelets_k_uL":281,"creatinine_mg_dL":1.1,"alt_U_L":20},{"date":"2025-05-21","hemoglobin_g_dL":11.5,"wbc_k_uL":6.3,"platelets_k_uL":307,"creatinine_mg_dL":0.74,"alt_U_L":94},{"date":"2026-05-07","hemoglobin_g_dL":11.9,"wbc_k_uL":3.2,"platelets_k_uL":263,"creatinine_mg_dL":1.77,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_2208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":67,"sex":"male","bmi":27.1,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-74},"pfs_months":45.08},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.8,"censored":false},"longitudinal_labs":[{"date":"2024-06-12","hemoglobin_g_dL":13.8,"wbc_k_uL":4.5,"platelets_k_uL":391,"creatinine_mg_dL":0.61,"alt_U_L":65},{"date":"2024-12-30","hemoglobin_g_dL":13.5,"wbc_k_uL":4.7,"platelets_k_uL":352,"creatinine_mg_dL":1.07,"alt_U_L":24},{"date":"2028-04-21","hemoglobin_g_dL":9.6,"wbc_k_uL":4.1,"platelets_k_uL":321,"creatinine_mg_dL":1.4,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_2209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":50,"sex":"male","bmi":25.6,"smoking_pack_years":73,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-36},"pfs_months":37.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":53.6,"censored":false},"longitudinal_labs":[{"date":"2022-10-10","hemoglobin_g_dL":13.6,"wbc_k_uL":8.5,"platelets_k_uL":160,"creatinine_mg_dL":1.17,"alt_U_L":74},{"date":"2023-05-30","hemoglobin_g_dL":11.0,"wbc_k_uL":5.4,"platelets_k_uL":301,"creatinine_mg_dL":1.42,"alt_U_L":41},{"date":"2026-02-22","hemoglobin_g_dL":11.9,"wbc_k_uL":7.7,"platelets_k_uL":342,"creatinine_mg_dL":1.2,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_2210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":61,"sex":"female","bmi":23.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-31},"pfs_months":21.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.9,"censored":false},"longitudinal_labs":[{"date":"2020-04-18","hemoglobin_g_dL":14.5,"wbc_k_uL":7.2,"platelets_k_uL":404,"creatinine_mg_dL":1.06,"alt_U_L":52},{"date":"2020-11-30","hemoglobin_g_dL":10.4,"wbc_k_uL":4.8,"platelets_k_uL":362,"creatinine_mg_dL":0.83,"alt_U_L":105},{"date":"2022-04-25","hemoglobin_g_dL":10.4,"wbc_k_uL":4.8,"platelets_k_uL":317,"creatinine_mg_dL":1.79,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_2211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":85,"sex":"female","bmi":36.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-48},"pfs_months":24.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-10","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":true},"longitudinal_labs":[{"date":"2021-08-08","hemoglobin_g_dL":13.0,"wbc_k_uL":8.1,"platelets_k_uL":182,"creatinine_mg_dL":0.61,"alt_U_L":72},{"date":"2022-02-26","hemoglobin_g_dL":10.1,"wbc_k_uL":5.0,"platelets_k_uL":154,"creatinine_mg_dL":1.13,"alt_U_L":56},{"date":"2023-10-10","hemoglobin_g_dL":10.1,"wbc_k_uL":6.5,"platelets_k_uL":261,"creatinine_mg_dL":1.55,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_2212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":49,"sex":"female","bmi":26.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-33},"pfs_months":20.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.4,"censored":false},"longitudinal_labs":[{"date":"2024-08-17","hemoglobin_g_dL":13.7,"wbc_k_uL":9.4,"platelets_k_uL":319,"creatinine_mg_dL":1.06,"alt_U_L":66},{"date":"2025-03-25","hemoglobin_g_dL":11.8,"wbc_k_uL":7.4,"platelets_k_uL":140,"creatinine_mg_dL":1.41,"alt_U_L":101},{"date":"2026-07-30","hemoglobin_g_dL":12.1,"wbc_k_uL":4.9,"platelets_k_uL":178,"creatinine_mg_dL":1.03,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_2213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":58,"sex":"female","bmi":29.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-70},"pfs_months":19.06},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":false},"longitudinal_labs":[{"date":"2025-05-24","hemoglobin_g_dL":13.5,"wbc_k_uL":9.5,"platelets_k_uL":369,"creatinine_mg_dL":1.12,"alt_U_L":19},{"date":"2025-12-11","hemoglobin_g_dL":10.8,"wbc_k_uL":7.9,"platelets_k_uL":331,"creatinine_mg_dL":1.16,"alt_U_L":89},{"date":"2027-01-21","hemoglobin_g_dL":12.8,"wbc_k_uL":3.3,"platelets_k_uL":336,"creatinine_mg_dL":1.12,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_2214","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":48,"sex":"male","bmi":21.2,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-03-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-77},"pfs_months":20.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.1,"censored":true},"longitudinal_labs":[{"date":"2023-01-02","hemoglobin_g_dL":13.7,"wbc_k_uL":9.0,"platelets_k_uL":390,"creatinine_mg_dL":0.85,"alt_U_L":55},{"date":"2023-09-06","hemoglobin_g_dL":12.7,"wbc_k_uL":6.1,"platelets_k_uL":151,"creatinine_mg_dL":1.36,"alt_U_L":49},{"date":"2024-12-16","hemoglobin_g_dL":11.9,"wbc_k_uL":5.6,"platelets_k_uL":348,"creatinine_mg_dL":1.39,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_2215","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":70,"sex":"male","bmi":28.5,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-02-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-74},"pfs_months":11.66},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.7,"censored":false},"longitudinal_labs":[{"date":"2023-12-17","hemoglobin_g_dL":14.0,"wbc_k_uL":6.3,"platelets_k_uL":327,"creatinine_mg_dL":0.95,"alt_U_L":64},{"date":"2024-08-12","hemoglobin_g_dL":13.1,"wbc_k_uL":6.2,"platelets_k_uL":337,"creatinine_mg_dL":0.89,"alt_U_L":98},{"date":"2025-03-03","hemoglobin_g_dL":10.3,"wbc_k_uL":6.3,"platelets_k_uL":229,"creatinine_mg_dL":1.09,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_2216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":59,"sex":"female","bmi":32.4,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-04-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-73},"pfs_months":36.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":69.2,"censored":false},"longitudinal_labs":[{"date":"2020-01-27","hemoglobin_g_dL":14.0,"wbc_k_uL":5.2,"platelets_k_uL":320,"creatinine_mg_dL":0.98,"alt_U_L":79},{"date":"2020-09-28","hemoglobin_g_dL":13.0,"wbc_k_uL":8.5,"platelets_k_uL":230,"creatinine_mg_dL":0.81,"alt_U_L":109},{"date":"2023-06-05","hemoglobin_g_dL":10.4,"wbc_k_uL":5.1,"platelets_k_uL":187,"creatinine_mg_dL":1.09,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_2217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":73,"sex":"female","bmi":33.5,"smoking_pack_years":47,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-10-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-67},"pfs_months":37.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":57.4,"censored":false},"longitudinal_labs":[{"date":"2024-08-20","hemoglobin_g_dL":11.5,"wbc_k_uL":7.7,"platelets_k_uL":234,"creatinine_mg_dL":1.3,"alt_U_L":29},{"date":"2025-04-05","hemoglobin_g_dL":10.8,"wbc_k_uL":3.9,"platelets_k_uL":319,"creatinine_mg_dL":0.7,"alt_U_L":20},{"date":"2027-12-17","hemoglobin_g_dL":12.4,"wbc_k_uL":7.6,"platelets_k_uL":170,"creatinine_mg_dL":1.24,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_2218","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":50,"sex":"male","bmi":37.1,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-76},"pfs_months":7.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.7,"censored":false},"longitudinal_labs":[{"date":"2023-05-05","hemoglobin_g_dL":13.3,"wbc_k_uL":7.3,"platelets_k_uL":439,"creatinine_mg_dL":0.78,"alt_U_L":76},{"date":"2023-12-08","hemoglobin_g_dL":11.8,"wbc_k_uL":6.7,"platelets_k_uL":139,"creatinine_mg_dL":1.03,"alt_U_L":38},{"date":"2024-03-08","hemoglobin_g_dL":9.6,"wbc_k_uL":4.9,"platelets_k_uL":242,"creatinine_mg_dL":1.16,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_2219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":52,"sex":"female","bmi":31.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-78},"pfs_months":18.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":false},"longitudinal_labs":[{"date":"2023-06-03","hemoglobin_g_dL":13.9,"wbc_k_uL":4.7,"platelets_k_uL":396,"creatinine_mg_dL":1.05,"alt_U_L":40},{"date":"2024-01-24","hemoglobin_g_dL":10.8,"wbc_k_uL":8.3,"platelets_k_uL":320,"creatinine_mg_dL":1.06,"alt_U_L":77},{"date":"2025-03-15","hemoglobin_g_dL":11.3,"wbc_k_uL":7.1,"platelets_k_uL":197,"creatinine_mg_dL":1.35,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2220","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":83,"sex":"female","bmi":30.6,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-54},"pfs_months":42.71},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-08-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":64.4,"censored":false},"longitudinal_labs":[{"date":"2025-12-15","hemoglobin_g_dL":11.6,"wbc_k_uL":9.5,"platelets_k_uL":344,"creatinine_mg_dL":0.78,"alt_U_L":50},{"date":"2026-06-29","hemoglobin_g_dL":11.8,"wbc_k_uL":4.5,"platelets_k_uL":353,"creatinine_mg_dL":1.08,"alt_U_L":119},{"date":"2029-08-06","hemoglobin_g_dL":10.9,"wbc_k_uL":6.3,"platelets_k_uL":165,"creatinine_mg_dL":1.57,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_2221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":60,"sex":"female","bmi":35.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-60},"pfs_months":31.7},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":49.4,"censored":false},"longitudinal_labs":[{"date":"2022-02-25","hemoglobin_g_dL":14.8,"wbc_k_uL":7.6,"platelets_k_uL":212,"creatinine_mg_dL":0.83,"alt_U_L":43},{"date":"2022-09-14","hemoglobin_g_dL":12.8,"wbc_k_uL":8.6,"platelets_k_uL":200,"creatinine_mg_dL":1.13,"alt_U_L":28},{"date":"2024-12-01","hemoglobin_g_dL":12.1,"wbc_k_uL":4.5,"platelets_k_uL":153,"creatinine_mg_dL":1.87,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_2222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":59,"sex":"female","bmi":32.4,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-03-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-42},"pfs_months":22.05},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.3,"censored":false},"longitudinal_labs":[{"date":"2020-02-03","hemoglobin_g_dL":13.3,"wbc_k_uL":7.7,"platelets_k_uL":427,"creatinine_mg_dL":0.63,"alt_U_L":15},{"date":"2020-09-17","hemoglobin_g_dL":13.3,"wbc_k_uL":5.7,"platelets_k_uL":334,"creatinine_mg_dL":1.24,"alt_U_L":94},{"date":"2022-03-19","hemoglobin_g_dL":9.6,"wbc_k_uL":5.9,"platelets_k_uL":332,"creatinine_mg_dL":1.76,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_2223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":79,"sex":"female","bmi":37.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-39},"pfs_months":26.41},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":47.2,"censored":false},"longitudinal_labs":[{"date":"2024-12-10","hemoglobin_g_dL":14.2,"wbc_k_uL":5.2,"platelets_k_uL":449,"creatinine_mg_dL":0.69,"alt_U_L":38},{"date":"2025-07-24","hemoglobin_g_dL":10.2,"wbc_k_uL":4.8,"platelets_k_uL":192,"creatinine_mg_dL":1.48,"alt_U_L":36},{"date":"2027-05-25","hemoglobin_g_dL":9.5,"wbc_k_uL":6.4,"platelets_k_uL":143,"creatinine_mg_dL":1.09,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_2224","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":83,"sex":"female","bmi":37.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-81},"pfs_months":17.05},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.6,"censored":false},"longitudinal_labs":[{"date":"2023-10-05","hemoglobin_g_dL":13.6,"wbc_k_uL":5.8,"platelets_k_uL":446,"creatinine_mg_dL":1.2,"alt_U_L":61},{"date":"2024-04-25","hemoglobin_g_dL":10.2,"wbc_k_uL":7.9,"platelets_k_uL":173,"creatinine_mg_dL":1.33,"alt_U_L":48},{"date":"2025-04-11","hemoglobin_g_dL":12.5,"wbc_k_uL":4.8,"platelets_k_uL":252,"creatinine_mg_dL":1.63,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_2225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":84,"sex":"female","bmi":22.5,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-05-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-83},"pfs_months":10.28},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-04-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.5,"censored":false},"longitudinal_labs":[{"date":"2020-03-24","hemoglobin_g_dL":14.0,"wbc_k_uL":8.0,"platelets_k_uL":432,"creatinine_mg_dL":0.98,"alt_U_L":32},{"date":"2020-11-10","hemoglobin_g_dL":11.7,"wbc_k_uL":8.1,"platelets_k_uL":319,"creatinine_mg_dL":0.77,"alt_U_L":88},{"date":"2021-04-22","hemoglobin_g_dL":9.5,"wbc_k_uL":5.7,"platelets_k_uL":312,"creatinine_mg_dL":0.99,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_2226","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":61,"sex":"male","bmi":34.8,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-01-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-77},"pfs_months":15.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":false},"longitudinal_labs":[{"date":"2023-12-11","hemoglobin_g_dL":12.0,"wbc_k_uL":10.0,"platelets_k_uL":237,"creatinine_mg_dL":0.82,"alt_U_L":72},{"date":"2024-07-06","hemoglobin_g_dL":10.9,"wbc_k_uL":5.4,"platelets_k_uL":232,"creatinine_mg_dL":0.88,"alt_U_L":47},{"date":"2025-05-02","hemoglobin_g_dL":12.0,"wbc_k_uL":5.9,"platelets_k_uL":180,"creatinine_mg_dL":1.02,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_2227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":68,"sex":"female","bmi":25.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-79},"pfs_months":14.88},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.3,"censored":false},"longitudinal_labs":[{"date":"2021-03-25","hemoglobin_g_dL":14.8,"wbc_k_uL":6.6,"platelets_k_uL":193,"creatinine_mg_dL":1.27,"alt_U_L":50},{"date":"2021-10-20","hemoglobin_g_dL":10.3,"wbc_k_uL":4.2,"platelets_k_uL":215,"creatinine_mg_dL":1.28,"alt_U_L":110},{"date":"2022-08-13","hemoglobin_g_dL":11.3,"wbc_k_uL":3.2,"platelets_k_uL":266,"creatinine_mg_dL":1.85,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_2228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":73,"sex":"female","bmi":33.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-41},"pfs_months":27.89},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.8,"censored":false},"longitudinal_labs":[{"date":"2024-05-26","hemoglobin_g_dL":12.9,"wbc_k_uL":6.3,"platelets_k_uL":239,"creatinine_mg_dL":0.91,"alt_U_L":55},{"date":"2025-01-25","hemoglobin_g_dL":11.7,"wbc_k_uL":8.4,"platelets_k_uL":342,"creatinine_mg_dL":0.95,"alt_U_L":93},{"date":"2026-12-04","hemoglobin_g_dL":11.4,"wbc_k_uL":3.5,"platelets_k_uL":155,"creatinine_mg_dL":1.41,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_2229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":49,"sex":"female","bmi":20.7,"smoking_pack_years":55,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-83},"pfs_months":19.84},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":23.8,"censored":false},"longitudinal_labs":[{"date":"2024-11-21","hemoglobin_g_dL":12.5,"wbc_k_uL":5.8,"platelets_k_uL":425,"creatinine_mg_dL":1.01,"alt_U_L":26},{"date":"2025-07-27","hemoglobin_g_dL":12.5,"wbc_k_uL":4.0,"platelets_k_uL":373,"creatinine_mg_dL":1.43,"alt_U_L":115},{"date":"2026-10-23","hemoglobin_g_dL":12.4,"wbc_k_uL":3.7,"platelets_k_uL":117,"creatinine_mg_dL":1.27,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_2230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":88,"sex":"female","bmi":34.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-35},"pfs_months":31.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.3,"censored":true},"longitudinal_labs":[{"date":"2023-04-25","hemoglobin_g_dL":15.3,"wbc_k_uL":8.9,"platelets_k_uL":367,"creatinine_mg_dL":0.74,"alt_U_L":67},{"date":"2023-12-21","hemoglobin_g_dL":11.2,"wbc_k_uL":8.3,"platelets_k_uL":380,"creatinine_mg_dL":1.23,"alt_U_L":70},{"date":"2026-03-09","hemoglobin_g_dL":11.0,"wbc_k_uL":6.4,"platelets_k_uL":172,"creatinine_mg_dL":1.43,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_2231","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":75,"sex":"female","bmi":26.1,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-03-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-54},"pfs_months":23.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":49.2,"censored":false},"longitudinal_labs":[{"date":"2023-02-27","hemoglobin_g_dL":15.3,"wbc_k_uL":4.7,"platelets_k_uL":447,"creatinine_mg_dL":1.1,"alt_U_L":35},{"date":"2023-09-23","hemoglobin_g_dL":10.1,"wbc_k_uL":7.6,"platelets_k_uL":370,"creatinine_mg_dL":1.3,"alt_U_L":43},{"date":"2025-04-26","hemoglobin_g_dL":10.4,"wbc_k_uL":5.5,"platelets_k_uL":322,"creatinine_mg_dL":1.83,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_2232","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":50,"sex":"female","bmi":25.2,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-12-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-45},"pfs_months":20.34},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.7,"censored":false},"longitudinal_labs":[{"date":"2021-11-11","hemoglobin_g_dL":13.4,"wbc_k_uL":7.2,"platelets_k_uL":236,"creatinine_mg_dL":0.8,"alt_U_L":32},{"date":"2022-06-04","hemoglobin_g_dL":11.9,"wbc_k_uL":5.2,"platelets_k_uL":251,"creatinine_mg_dL":0.76,"alt_U_L":53},{"date":"2023-09-13","hemoglobin_g_dL":12.8,"wbc_k_uL":7.8,"platelets_k_uL":133,"creatinine_mg_dL":1.2,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_2233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":65,"sex":"female","bmi":19.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-65},"pfs_months":18.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.2,"censored":true},"longitudinal_labs":[{"date":"2020-06-03","hemoglobin_g_dL":13.9,"wbc_k_uL":7.5,"platelets_k_uL":177,"creatinine_mg_dL":1.27,"alt_U_L":25},{"date":"2021-01-02","hemoglobin_g_dL":12.3,"wbc_k_uL":4.4,"platelets_k_uL":295,"creatinine_mg_dL":0.8,"alt_U_L":112},{"date":"2022-02-20","hemoglobin_g_dL":10.7,"wbc_k_uL":3.5,"platelets_k_uL":196,"creatinine_mg_dL":1.74,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_2234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":75,"sex":"female","bmi":23.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-55},"pfs_months":25.4},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.1,"censored":true},"longitudinal_labs":[{"date":"2020-05-22","hemoglobin_g_dL":15.0,"wbc_k_uL":6.1,"platelets_k_uL":390,"creatinine_mg_dL":1.05,"alt_U_L":29},{"date":"2020-12-15","hemoglobin_g_dL":12.9,"wbc_k_uL":8.8,"platelets_k_uL":298,"creatinine_mg_dL":0.99,"alt_U_L":29},{"date":"2022-09-09","hemoglobin_g_dL":12.2,"wbc_k_uL":6.8,"platelets_k_uL":256,"creatinine_mg_dL":1.22,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_2235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":67,"sex":"female","bmi":36.4,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-07-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-64},"pfs_months":43.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.6,"censored":false},"longitudinal_labs":[{"date":"2024-05-28","hemoglobin_g_dL":13.7,"wbc_k_uL":7.2,"platelets_k_uL":224,"creatinine_mg_dL":1.11,"alt_U_L":20},{"date":"2025-01-02","hemoglobin_g_dL":11.1,"wbc_k_uL":6.4,"platelets_k_uL":208,"creatinine_mg_dL":0.87,"alt_U_L":56},{"date":"2028-03-05","hemoglobin_g_dL":11.9,"wbc_k_uL":8.0,"platelets_k_uL":197,"creatinine_mg_dL":1.47,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_2236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":81,"sex":"male","bmi":28.2,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-10-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-53},"pfs_months":15.51},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":26.5,"censored":true},"longitudinal_labs":[{"date":"2022-09-17","hemoglobin_g_dL":13.9,"wbc_k_uL":5.4,"platelets_k_uL":274,"creatinine_mg_dL":0.76,"alt_U_L":58},{"date":"2023-04-05","hemoglobin_g_dL":11.6,"wbc_k_uL":7.3,"platelets_k_uL":303,"creatinine_mg_dL":1.07,"alt_U_L":51},{"date":"2024-02-10","hemoglobin_g_dL":12.3,"wbc_k_uL":3.9,"platelets_k_uL":165,"creatinine_mg_dL":1.13,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_2237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":52,"sex":"male","bmi":37.9,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-12-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-78},"pfs_months":13.83},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.1,"censored":false},"longitudinal_labs":[{"date":"2024-11-09","hemoglobin_g_dL":15.0,"wbc_k_uL":10.8,"platelets_k_uL":410,"creatinine_mg_dL":0.65,"alt_U_L":24},{"date":"2025-05-30","hemoglobin_g_dL":12.3,"wbc_k_uL":5.7,"platelets_k_uL":180,"creatinine_mg_dL":1.47,"alt_U_L":52},{"date":"2026-03-03","hemoglobin_g_dL":10.9,"wbc_k_uL":4.9,"platelets_k_uL":142,"creatinine_mg_dL":1.31,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_2238","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":50,"sex":"male","bmi":30.1,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-11-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-79},"pfs_months":23.43},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.5,"censored":false},"longitudinal_labs":[{"date":"2025-10-20","hemoglobin_g_dL":11.5,"wbc_k_uL":5.2,"platelets_k_uL":218,"creatinine_mg_dL":0.81,"alt_U_L":75},{"date":"2026-05-09","hemoglobin_g_dL":11.9,"wbc_k_uL":7.4,"platelets_k_uL":372,"creatinine_mg_dL":1.42,"alt_U_L":100},{"date":"2027-12-17","hemoglobin_g_dL":9.8,"wbc_k_uL":3.7,"platelets_k_uL":221,"creatinine_mg_dL":1.31,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_2239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":65,"sex":"female","bmi":35.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-43},"pfs_months":22.24},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.5,"censored":false},"longitudinal_labs":[{"date":"2025-02-07","hemoglobin_g_dL":11.6,"wbc_k_uL":7.3,"platelets_k_uL":215,"creatinine_mg_dL":0.69,"alt_U_L":35},{"date":"2025-09-07","hemoglobin_g_dL":10.1,"wbc_k_uL":5.8,"platelets_k_uL":195,"creatinine_mg_dL":0.75,"alt_U_L":71},{"date":"2027-02-22","hemoglobin_g_dL":12.2,"wbc_k_uL":6.4,"platelets_k_uL":274,"creatinine_mg_dL":1.97,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_2240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":68,"sex":"female","bmi":30.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-79},"pfs_months":16.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.9,"censored":true},"longitudinal_labs":[{"date":"2023-05-12","hemoglobin_g_dL":14.2,"wbc_k_uL":5.6,"platelets_k_uL":437,"creatinine_mg_dL":1.26,"alt_U_L":15},{"date":"2024-01-13","hemoglobin_g_dL":12.5,"wbc_k_uL":7.2,"platelets_k_uL":371,"creatinine_mg_dL":1.11,"alt_U_L":79},{"date":"2025-01-05","hemoglobin_g_dL":12.8,"wbc_k_uL":3.0,"platelets_k_uL":132,"creatinine_mg_dL":1.53,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_2241","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":82,"sex":"female","bmi":19.2,"smoking_pack_years":72,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-04-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-46},"pfs_months":24.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.3,"censored":false},"longitudinal_labs":[{"date":"2022-04-14","hemoglobin_g_dL":13.0,"wbc_k_uL":10.9,"platelets_k_uL":202,"creatinine_mg_dL":1.2,"alt_U_L":11},{"date":"2022-10-25","hemoglobin_g_dL":11.3,"wbc_k_uL":5.0,"platelets_k_uL":225,"creatinine_mg_dL":1.55,"alt_U_L":117},{"date":"2024-06-10","hemoglobin_g_dL":11.0,"wbc_k_uL":5.7,"platelets_k_uL":311,"creatinine_mg_dL":1.71,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_2242","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":68,"sex":"female","bmi":19.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-10-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-52},"pfs_months":23.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.5,"censored":false},"longitudinal_labs":[{"date":"2025-08-17","hemoglobin_g_dL":14.5,"wbc_k_uL":5.5,"platelets_k_uL":433,"creatinine_mg_dL":1.05,"alt_U_L":71},{"date":"2026-04-24","hemoglobin_g_dL":13.3,"wbc_k_uL":8.8,"platelets_k_uL":359,"creatinine_mg_dL":1.04,"alt_U_L":38},{"date":"2027-10-29","hemoglobin_g_dL":9.7,"wbc_k_uL":7.8,"platelets_k_uL":182,"creatinine_mg_dL":1.5,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_2243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":49,"sex":"female","bmi":31.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-02-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-49},"pfs_months":31.44},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":51.4,"censored":false},"longitudinal_labs":[{"date":"2022-01-02","hemoglobin_g_dL":12.6,"wbc_k_uL":8.2,"platelets_k_uL":344,"creatinine_mg_dL":1.06,"alt_U_L":26},{"date":"2022-08-19","hemoglobin_g_dL":13.4,"wbc_k_uL":9.0,"platelets_k_uL":253,"creatinine_mg_dL":1.14,"alt_U_L":104},{"date":"2024-11-11","hemoglobin_g_dL":10.8,"wbc_k_uL":4.3,"platelets_k_uL":112,"creatinine_mg_dL":1.15,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_2244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":78,"sex":"female","bmi":26.2,"smoking_pack_years":18,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-06-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-84},"pfs_months":3.78},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-12-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.7,"censored":false},"longitudinal_labs":[{"date":"2020-05-09","hemoglobin_g_dL":14.3,"wbc_k_uL":8.2,"platelets_k_uL":376,"creatinine_mg_dL":0.81,"alt_U_L":26},{"date":"2020-12-25","hemoglobin_g_dL":11.0,"wbc_k_uL":8.5,"platelets_k_uL":203,"creatinine_mg_dL":0.84,"alt_U_L":17},{"date":"2020-12-20","hemoglobin_g_dL":11.5,"wbc_k_uL":3.3,"platelets_k_uL":159,"creatinine_mg_dL":1.99,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_2245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":49,"sex":"male","bmi":21.2,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-09-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-72},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":7.0,"censored":false},"longitudinal_labs":[{"date":"2025-07-28","hemoglobin_g_dL":14.8,"wbc_k_uL":8.2,"platelets_k_uL":422,"creatinine_mg_dL":0.99,"alt_U_L":65},{"date":"2026-03-18","hemoglobin_g_dL":11.2,"wbc_k_uL":4.0,"platelets_k_uL":218,"creatinine_mg_dL":0.86,"alt_U_L":93},{"date":"2026-01-09","hemoglobin_g_dL":12.3,"wbc_k_uL":5.4,"platelets_k_uL":174,"creatinine_mg_dL":1.83,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_2246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":66,"sex":"female","bmi":21.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-75},"pfs_months":17.87},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.8,"censored":false},"longitudinal_labs":[{"date":"2021-07-26","hemoglobin_g_dL":13.4,"wbc_k_uL":6.0,"platelets_k_uL":248,"creatinine_mg_dL":1.25,"alt_U_L":28},{"date":"2022-02-10","hemoglobin_g_dL":10.2,"wbc_k_uL":7.3,"platelets_k_uL":266,"creatinine_mg_dL":1.08,"alt_U_L":111},{"date":"2023-02-17","hemoglobin_g_dL":11.4,"wbc_k_uL":6.5,"platelets_k_uL":298,"creatinine_mg_dL":1.06,"alt_U_L":28}]}
{"patient_id":"ANODE_SYNTH_2025_2247","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":83,"sex":"female","bmi":32.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-33},"pfs_months":21.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.0,"censored":true},"longitudinal_labs":[{"date":"2020-08-23","hemoglobin_g_dL":13.7,"wbc_k_uL":5.0,"platelets_k_uL":195,"creatinine_mg_dL":0.64,"alt_U_L":60},{"date":"2021-03-27","hemoglobin_g_dL":11.3,"wbc_k_uL":8.7,"platelets_k_uL":236,"creatinine_mg_dL":1.36,"alt_U_L":72},{"date":"2022-08-13","hemoglobin_g_dL":11.7,"wbc_k_uL":6.2,"platelets_k_uL":109,"creatinine_mg_dL":1.64,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_2248","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":84,"sex":"female","bmi":19.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-85},"pfs_months":28.75},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.5,"censored":false},"longitudinal_labs":[{"date":"2021-03-28","hemoglobin_g_dL":13.1,"wbc_k_uL":5.9,"platelets_k_uL":441,"creatinine_mg_dL":0.86,"alt_U_L":80},{"date":"2021-11-12","hemoglobin_g_dL":12.7,"wbc_k_uL":3.8,"platelets_k_uL":308,"creatinine_mg_dL":1.58,"alt_U_L":67},{"date":"2023-11-02","hemoglobin_g_dL":10.9,"wbc_k_uL":5.7,"platelets_k_uL":294,"creatinine_mg_dL":1.13,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_2249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":56,"sex":"female","bmi":29.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-62},"pfs_months":16.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":false},"longitudinal_labs":[{"date":"2025-02-26","hemoglobin_g_dL":15.3,"wbc_k_uL":5.1,"platelets_k_uL":356,"creatinine_mg_dL":1.09,"alt_U_L":67},{"date":"2025-10-19","hemoglobin_g_dL":10.4,"wbc_k_uL":7.7,"platelets_k_uL":368,"creatinine_mg_dL":1.32,"alt_U_L":105},{"date":"2026-09-09","hemoglobin_g_dL":11.6,"wbc_k_uL":4.1,"platelets_k_uL":160,"creatinine_mg_dL":1.82,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_2250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":66,"sex":"female","bmi":35.7,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-34},"pfs_months":36.47},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.3,"censored":false},"longitudinal_labs":[{"date":"2021-01-20","hemoglobin_g_dL":13.6,"wbc_k_uL":6.4,"platelets_k_uL":404,"creatinine_mg_dL":0.7,"alt_U_L":65},{"date":"2021-09-01","hemoglobin_g_dL":10.7,"wbc_k_uL":4.9,"platelets_k_uL":151,"creatinine_mg_dL":0.86,"alt_U_L":104},{"date":"2024-03-27","hemoglobin_g_dL":10.6,"wbc_k_uL":3.4,"platelets_k_uL":283,"creatinine_mg_dL":1.31,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_2251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":70,"sex":"male","bmi":20.4,"smoking_pack_years":77,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-11-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-45},"pfs_months":6.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":10.8,"censored":false},"longitudinal_labs":[{"date":"2023-10-11","hemoglobin_g_dL":13.9,"wbc_k_uL":9.5,"platelets_k_uL":347,"creatinine_mg_dL":1.14,"alt_U_L":65},{"date":"2024-05-15","hemoglobin_g_dL":12.2,"wbc_k_uL":6.8,"platelets_k_uL":260,"creatinine_mg_dL":1.3,"alt_U_L":65},{"date":"2024-07-04","hemoglobin_g_dL":12.5,"wbc_k_uL":3.6,"platelets_k_uL":295,"creatinine_mg_dL":1.7,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_2252","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":88,"sex":"male","bmi":28.0,"smoking_pack_years":76,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-51},"pfs_months":23.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":37.8,"censored":false},"longitudinal_labs":[{"date":"2024-07-05","hemoglobin_g_dL":14.1,"wbc_k_uL":10.0,"platelets_k_uL":398,"creatinine_mg_dL":0.72,"alt_U_L":45},{"date":"2025-03-08","hemoglobin_g_dL":10.0,"wbc_k_uL":4.5,"platelets_k_uL":120,"creatinine_mg_dL":1.36,"alt_U_L":62},{"date":"2026-09-03","hemoglobin_g_dL":10.5,"wbc_k_uL":5.0,"platelets_k_uL":232,"creatinine_mg_dL":1.23,"alt_U_L":176}]}
{"patient_id":"ANODE_SYNTH_2025_2253","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":68,"sex":"female","bmi":30.0,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-09-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-48},"pfs_months":15.47},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.4,"censored":true},"longitudinal_labs":[{"date":"2022-07-21","hemoglobin_g_dL":14.4,"wbc_k_uL":9.1,"platelets_k_uL":405,"creatinine_mg_dL":1.15,"alt_U_L":46},{"date":"2023-03-11","hemoglobin_g_dL":12.7,"wbc_k_uL":8.8,"platelets_k_uL":369,"creatinine_mg_dL":1.07,"alt_U_L":83},{"date":"2024-02-21","hemoglobin_g_dL":10.7,"wbc_k_uL":4.7,"platelets_k_uL":345,"creatinine_mg_dL":0.83,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_2254","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":53,"sex":"female","bmi":32.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-05-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-72},"pfs_months":19.71},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.7,"censored":true},"longitudinal_labs":[{"date":"2023-03-17","hemoglobin_g_dL":13.4,"wbc_k_uL":6.2,"platelets_k_uL":317,"creatinine_mg_dL":1.21,"alt_U_L":36},{"date":"2023-10-30","hemoglobin_g_dL":11.6,"wbc_k_uL":8.1,"platelets_k_uL":140,"creatinine_mg_dL":1.29,"alt_U_L":70},{"date":"2025-02-03","hemoglobin_g_dL":12.5,"wbc_k_uL":4.4,"platelets_k_uL":154,"creatinine_mg_dL":0.99,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_2255","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":83,"sex":"male","bmi":23.3,"smoking_pack_years":70,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-01-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-53},"pfs_months":15.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.0,"censored":false},"longitudinal_labs":[{"date":"2020-12-25","hemoglobin_g_dL":11.8,"wbc_k_uL":10.8,"platelets_k_uL":195,"creatinine_mg_dL":1.03,"alt_U_L":46},{"date":"2021-07-20","hemoglobin_g_dL":10.5,"wbc_k_uL":5.2,"platelets_k_uL":259,"creatinine_mg_dL":1.43,"alt_U_L":47},{"date":"2022-06-19","hemoglobin_g_dL":12.9,"wbc_k_uL":4.0,"platelets_k_uL":313,"creatinine_mg_dL":1.3,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_2256","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":65,"sex":"male","bmi":29.2,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-08-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-79},"pfs_months":18.04},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.9,"censored":false},"longitudinal_labs":[{"date":"2023-06-21","hemoglobin_g_dL":12.2,"wbc_k_uL":5.8,"platelets_k_uL":161,"creatinine_mg_dL":1.11,"alt_U_L":32},{"date":"2024-02-01","hemoglobin_g_dL":11.8,"wbc_k_uL":7.2,"platelets_k_uL":186,"creatinine_mg_dL":1.54,"alt_U_L":90},{"date":"2025-02-21","hemoglobin_g_dL":10.5,"wbc_k_uL":5.4,"platelets_k_uL":292,"creatinine_mg_dL":1.81,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_2257","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":86,"sex":"female","bmi":24.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-42},"pfs_months":17.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.0,"censored":false},"longitudinal_labs":[{"date":"2023-06-11","hemoglobin_g_dL":12.8,"wbc_k_uL":6.2,"platelets_k_uL":206,"creatinine_mg_dL":1.25,"alt_U_L":61},{"date":"2024-01-18","hemoglobin_g_dL":13.8,"wbc_k_uL":8.9,"platelets_k_uL":197,"creatinine_mg_dL":0.83,"alt_U_L":108},{"date":"2025-02-09","hemoglobin_g_dL":11.9,"wbc_k_uL":6.4,"platelets_k_uL":168,"creatinine_mg_dL":1.04,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_2258","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":61,"sex":"male","bmi":25.1,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-05-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-31},"pfs_months":41.76},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":68.0,"censored":true},"longitudinal_labs":[{"date":"2020-03-13","hemoglobin_g_dL":13.3,"wbc_k_uL":4.7,"platelets_k_uL":312,"creatinine_mg_dL":1.13,"alt_U_L":56},{"date":"2020-10-28","hemoglobin_g_dL":12.4,"wbc_k_uL":4.2,"platelets_k_uL":177,"creatinine_mg_dL":1.24,"alt_U_L":92},{"date":"2023-12-10","hemoglobin_g_dL":11.5,"wbc_k_uL":6.5,"platelets_k_uL":195,"creatinine_mg_dL":1.94,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_2259","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":74,"sex":"female","bmi":21.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-81},"pfs_months":25.69},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":49.6,"censored":false},"longitudinal_labs":[{"date":"2023-01-25","hemoglobin_g_dL":12.8,"wbc_k_uL":10.9,"platelets_k_uL":306,"creatinine_mg_dL":0.84,"alt_U_L":25},{"date":"2023-08-17","hemoglobin_g_dL":10.7,"wbc_k_uL":8.1,"platelets_k_uL":174,"creatinine_mg_dL":1.05,"alt_U_L":52},{"date":"2025-05-24","hemoglobin_g_dL":11.2,"wbc_k_uL":6.1,"platelets_k_uL":277,"creatinine_mg_dL":1.13,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_2260","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":80,"sex":"male","bmi":34.5,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-08-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-75},"pfs_months":30.13},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":true},"longitudinal_labs":[{"date":"2022-07-13","hemoglobin_g_dL":15.0,"wbc_k_uL":6.4,"platelets_k_uL":210,"creatinine_mg_dL":0.65,"alt_U_L":47},{"date":"2023-01-28","hemoglobin_g_dL":10.6,"wbc_k_uL":4.0,"platelets_k_uL":125,"creatinine_mg_dL":1.31,"alt_U_L":63},{"date":"2025-02-18","hemoglobin_g_dL":12.4,"wbc_k_uL":6.0,"platelets_k_uL":132,"creatinine_mg_dL":1.04,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_2261","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":82,"sex":"male","bmi":34.6,"smoking_pack_years":11,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-07-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-62},"pfs_months":11.04},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.9,"censored":false},"longitudinal_labs":[{"date":"2022-05-27","hemoglobin_g_dL":14.4,"wbc_k_uL":6.7,"platelets_k_uL":382,"creatinine_mg_dL":0.89,"alt_U_L":78},{"date":"2023-01-15","hemoglobin_g_dL":12.5,"wbc_k_uL":8.2,"platelets_k_uL":371,"creatinine_mg_dL":1.38,"alt_U_L":39},{"date":"2023-08-13","hemoglobin_g_dL":11.7,"wbc_k_uL":6.7,"platelets_k_uL":350,"creatinine_mg_dL":1.95,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2262","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":64,"sex":"male","bmi":30.6,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-04-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-53},"pfs_months":30.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":57.6,"censored":false},"longitudinal_labs":[{"date":"2024-04-13","hemoglobin_g_dL":14.2,"wbc_k_uL":7.4,"platelets_k_uL":212,"creatinine_mg_dL":0.97,"alt_U_L":22},{"date":"2024-10-26","hemoglobin_g_dL":10.3,"wbc_k_uL":4.2,"platelets_k_uL":295,"creatinine_mg_dL":1.14,"alt_U_L":104},{"date":"2026-12-15","hemoglobin_g_dL":9.9,"wbc_k_uL":4.0,"platelets_k_uL":267,"creatinine_mg_dL":1.27,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_2263","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":49,"sex":"male","bmi":35.4,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-07-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-46},"pfs_months":38.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":59.7,"censored":false},"longitudinal_labs":[{"date":"2022-05-10","hemoglobin_g_dL":12.1,"wbc_k_uL":5.0,"platelets_k_uL":267,"creatinine_mg_dL":1.13,"alt_U_L":80},{"date":"2023-01-11","hemoglobin_g_dL":12.3,"wbc_k_uL":7.5,"platelets_k_uL":161,"creatinine_mg_dL":0.85,"alt_U_L":29},{"date":"2025-10-13","hemoglobin_g_dL":9.6,"wbc_k_uL":5.7,"platelets_k_uL":159,"creatinine_mg_dL":0.84,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_2264","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":84,"sex":"female","bmi":32.9,"smoking_pack_years":32,"ecog_performance_status":2,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-03-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-71},"pfs_months":13.47},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":false},"longitudinal_labs":[{"date":"2024-01-06","hemoglobin_g_dL":14.7,"wbc_k_uL":9.2,"platelets_k_uL":341,"creatinine_mg_dL":1.22,"alt_U_L":68},{"date":"2024-09-03","hemoglobin_g_dL":12.0,"wbc_k_uL":5.2,"platelets_k_uL":222,"creatinine_mg_dL":0.74,"alt_U_L":38},{"date":"2025-05-26","hemoglobin_g_dL":12.8,"wbc_k_uL":4.9,"platelets_k_uL":164,"creatinine_mg_dL":0.89,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_2265","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":63,"sex":"female","bmi":30.9,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-37},"pfs_months":39.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":63.7,"censored":false},"longitudinal_labs":[{"date":"2022-06-16","hemoglobin_g_dL":11.7,"wbc_k_uL":5.9,"platelets_k_uL":318,"creatinine_mg_dL":0.78,"alt_U_L":21},{"date":"2023-01-29","hemoglobin_g_dL":11.4,"wbc_k_uL":7.6,"platelets_k_uL":332,"creatinine_mg_dL":1.43,"alt_U_L":73},{"date":"2025-12-21","hemoglobin_g_dL":9.9,"wbc_k_uL":3.2,"platelets_k_uL":341,"creatinine_mg_dL":1.68,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_2266","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":60,"sex":"female","bmi":23.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-74},"pfs_months":27.37},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":42.9,"censored":true},"longitudinal_labs":[{"date":"2022-08-24","hemoglobin_g_dL":13.9,"wbc_k_uL":7.6,"platelets_k_uL":363,"creatinine_mg_dL":0.8,"alt_U_L":78},{"date":"2023-04-12","hemoglobin_g_dL":10.5,"wbc_k_uL":8.3,"platelets_k_uL":144,"creatinine_mg_dL":0.97,"alt_U_L":83},{"date":"2025-03-14","hemoglobin_g_dL":9.7,"wbc_k_uL":5.9,"platelets_k_uL":235,"creatinine_mg_dL":1.69,"alt_U_L":58}]}
{"patient_id":"ANODE_SYNTH_2025_2267","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":57,"sex":"female","bmi":29.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-01-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-56},"pfs_months":15.61},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.8,"censored":false},"longitudinal_labs":[{"date":"2022-12-21","hemoglobin_g_dL":15.0,"wbc_k_uL":6.3,"platelets_k_uL":316,"creatinine_mg_dL":0.98,"alt_U_L":79},{"date":"2023-07-20","hemoglobin_g_dL":13.4,"wbc_k_uL":8.1,"platelets_k_uL":205,"creatinine_mg_dL":0.85,"alt_U_L":96},{"date":"2024-05-20","hemoglobin_g_dL":11.9,"wbc_k_uL":3.6,"platelets_k_uL":317,"creatinine_mg_dL":1.01,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_2268","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":84,"sex":"female","bmi":23.6,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-02-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-81},"pfs_months":43.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.6,"censored":false},"longitudinal_labs":[{"date":"2023-01-06","hemoglobin_g_dL":14.9,"wbc_k_uL":5.1,"platelets_k_uL":382,"creatinine_mg_dL":1.0,"alt_U_L":49},{"date":"2023-08-16","hemoglobin_g_dL":12.5,"wbc_k_uL":6.4,"platelets_k_uL":314,"creatinine_mg_dL":1.22,"alt_U_L":48},{"date":"2026-11-17","hemoglobin_g_dL":10.4,"wbc_k_uL":4.3,"platelets_k_uL":119,"creatinine_mg_dL":1.65,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_2269","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":78,"sex":"male","bmi":22.0,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-35},"pfs_months":23.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.0,"censored":false},"longitudinal_labs":[{"date":"2022-05-14","hemoglobin_g_dL":13.9,"wbc_k_uL":5.1,"platelets_k_uL":178,"creatinine_mg_dL":1.01,"alt_U_L":80},{"date":"2022-12-20","hemoglobin_g_dL":11.3,"wbc_k_uL":7.9,"platelets_k_uL":334,"creatinine_mg_dL":1.54,"alt_U_L":35},{"date":"2024-08-13","hemoglobin_g_dL":12.7,"wbc_k_uL":4.5,"platelets_k_uL":251,"creatinine_mg_dL":1.79,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_2270","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":76,"sex":"male","bmi":30.8,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-33},"pfs_months":9.89},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":17.3,"censored":true},"longitudinal_labs":[{"date":"2023-08-04","hemoglobin_g_dL":15.0,"wbc_k_uL":9.7,"platelets_k_uL":198,"creatinine_mg_dL":0.9,"alt_U_L":63},{"date":"2024-03-17","hemoglobin_g_dL":11.1,"wbc_k_uL":4.7,"platelets_k_uL":272,"creatinine_mg_dL":1.18,"alt_U_L":97},{"date":"2024-09-05","hemoglobin_g_dL":10.2,"wbc_k_uL":3.2,"platelets_k_uL":303,"creatinine_mg_dL":1.58,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_2271","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":66,"sex":"female","bmi":36.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-57},"pfs_months":19.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":31.7,"censored":true},"longitudinal_labs":[{"date":"2022-04-19","hemoglobin_g_dL":14.1,"wbc_k_uL":10.8,"platelets_k_uL":422,"creatinine_mg_dL":0.67,"alt_U_L":61},{"date":"2022-12-16","hemoglobin_g_dL":12.3,"wbc_k_uL":4.0,"platelets_k_uL":332,"creatinine_mg_dL":1.31,"alt_U_L":102},{"date":"2024-03-22","hemoglobin_g_dL":11.6,"wbc_k_uL":7.7,"platelets_k_uL":277,"creatinine_mg_dL":1.25,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_2272","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":84,"sex":"female","bmi":20.7,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-03-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-42},"pfs_months":9.92},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":13.9,"censored":false},"longitudinal_labs":[{"date":"2022-02-09","hemoglobin_g_dL":12.6,"wbc_k_uL":6.9,"platelets_k_uL":342,"creatinine_mg_dL":0.68,"alt_U_L":29},{"date":"2022-08-28","hemoglobin_g_dL":13.1,"wbc_k_uL":8.0,"platelets_k_uL":155,"creatinine_mg_dL":1.4,"alt_U_L":32},{"date":"2023-02-17","hemoglobin_g_dL":12.8,"wbc_k_uL":7.1,"platelets_k_uL":238,"creatinine_mg_dL":1.3,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_2273","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":64,"sex":"female","bmi":27.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-72},"pfs_months":12.94},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":22.3,"censored":true},"longitudinal_labs":[{"date":"2023-04-24","hemoglobin_g_dL":11.9,"wbc_k_uL":5.1,"platelets_k_uL":211,"creatinine_mg_dL":1.17,"alt_U_L":25},{"date":"2023-12-23","hemoglobin_g_dL":11.2,"wbc_k_uL":7.6,"platelets_k_uL":183,"creatinine_mg_dL":1.56,"alt_U_L":20},{"date":"2024-08-13","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":317,"creatinine_mg_dL":0.9,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_2274","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":68,"sex":"female","bmi":27.2,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-66},"pfs_months":24.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":true},"longitudinal_labs":[{"date":"2023-11-03","hemoglobin_g_dL":11.9,"wbc_k_uL":9.2,"platelets_k_uL":447,"creatinine_mg_dL":1.19,"alt_U_L":24},{"date":"2024-06-07","hemoglobin_g_dL":13.0,"wbc_k_uL":6.6,"platelets_k_uL":157,"creatinine_mg_dL":0.91,"alt_U_L":32},{"date":"2026-01-29","hemoglobin_g_dL":9.8,"wbc_k_uL":6.5,"platelets_k_uL":212,"creatinine_mg_dL":1.01,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_2275","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":54,"sex":"male","bmi":36.4,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-08-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-67},"pfs_months":15.38},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.4,"censored":true},"longitudinal_labs":[{"date":"2023-06-15","hemoglobin_g_dL":13.6,"wbc_k_uL":4.6,"platelets_k_uL":237,"creatinine_mg_dL":0.65,"alt_U_L":33},{"date":"2024-02-11","hemoglobin_g_dL":10.8,"wbc_k_uL":7.4,"platelets_k_uL":345,"creatinine_mg_dL":0.84,"alt_U_L":70},{"date":"2025-01-20","hemoglobin_g_dL":10.0,"wbc_k_uL":4.5,"platelets_k_uL":343,"creatinine_mg_dL":1.59,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_2276","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":84,"sex":"female","bmi":28.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-46},"pfs_months":17.12},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":false},"longitudinal_labs":[{"date":"2024-11-26","hemoglobin_g_dL":15.5,"wbc_k_uL":8.1,"platelets_k_uL":427,"creatinine_mg_dL":1.1,"alt_U_L":14},{"date":"2025-07-18","hemoglobin_g_dL":11.0,"wbc_k_uL":5.7,"platelets_k_uL":231,"creatinine_mg_dL":1.17,"alt_U_L":84},{"date":"2026-08-01","hemoglobin_g_dL":10.5,"wbc_k_uL":6.6,"platelets_k_uL":163,"creatinine_mg_dL":1.84,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_2277","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":80,"sex":"female","bmi":28.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-84},"pfs_months":24.74},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":false},"longitudinal_labs":[{"date":"2024-11-06","hemoglobin_g_dL":11.5,"wbc_k_uL":8.9,"platelets_k_uL":241,"creatinine_mg_dL":1.14,"alt_U_L":40},{"date":"2025-07-03","hemoglobin_g_dL":11.4,"wbc_k_uL":7.6,"platelets_k_uL":367,"creatinine_mg_dL":1.38,"alt_U_L":81},{"date":"2027-03-26","hemoglobin_g_dL":10.7,"wbc_k_uL":3.3,"platelets_k_uL":119,"creatinine_mg_dL":1.14,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_2278","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":56,"sex":"female","bmi":28.1,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-01-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-43},"pfs_months":12.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.6,"censored":false},"longitudinal_labs":[{"date":"2023-12-10","hemoglobin_g_dL":12.5,"wbc_k_uL":9.6,"platelets_k_uL":444,"creatinine_mg_dL":0.66,"alt_U_L":58},{"date":"2024-06-29","hemoglobin_g_dL":13.8,"wbc_k_uL":4.9,"platelets_k_uL":175,"creatinine_mg_dL":1.37,"alt_U_L":88},{"date":"2025-01-27","hemoglobin_g_dL":11.7,"wbc_k_uL":6.2,"platelets_k_uL":300,"creatinine_mg_dL":1.57,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_2279","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":79,"sex":"female","bmi":25.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-01-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-70},"pfs_months":22.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":false},"longitudinal_labs":[{"date":"2021-11-17","hemoglobin_g_dL":12.7,"wbc_k_uL":4.8,"platelets_k_uL":233,"creatinine_mg_dL":0.83,"alt_U_L":44},{"date":"2022-07-08","hemoglobin_g_dL":12.1,"wbc_k_uL":4.0,"platelets_k_uL":207,"creatinine_mg_dL":1.33,"alt_U_L":68},{"date":"2024-01-01","hemoglobin_g_dL":9.6,"wbc_k_uL":7.2,"platelets_k_uL":251,"creatinine_mg_dL":1.69,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_2280","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":48,"sex":"female","bmi":36.5,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-11-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-47},"pfs_months":32.59},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-09-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":56.9,"censored":true},"longitudinal_labs":[{"date":"2025-09-10","hemoglobin_g_dL":13.6,"wbc_k_uL":7.0,"platelets_k_uL":415,"creatinine_mg_dL":0.65,"alt_U_L":78},{"date":"2026-05-07","hemoglobin_g_dL":10.2,"wbc_k_uL":7.1,"platelets_k_uL":142,"creatinine_mg_dL":0.87,"alt_U_L":70},{"date":"2028-09-25","hemoglobin_g_dL":12.2,"wbc_k_uL":3.8,"platelets_k_uL":293,"creatinine_mg_dL":1.34,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_2281","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":78,"sex":"female","bmi":18.7,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-01-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-70},"pfs_months":21.68},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.3,"censored":false},"longitudinal_labs":[{"date":"2021-11-15","hemoglobin_g_dL":13.3,"wbc_k_uL":6.1,"platelets_k_uL":322,"creatinine_mg_dL":1.15,"alt_U_L":21},{"date":"2022-07-17","hemoglobin_g_dL":13.0,"wbc_k_uL":6.6,"platelets_k_uL":127,"creatinine_mg_dL":1.46,"alt_U_L":78},{"date":"2023-11-16","hemoglobin_g_dL":10.1,"wbc_k_uL":4.3,"platelets_k_uL":325,"creatinine_mg_dL":1.17,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_2282","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":54,"sex":"female","bmi":20.3,"smoking_pack_years":45,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-09-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-34},"pfs_months":22.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-31","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.4,"censored":false},"longitudinal_labs":[{"date":"2022-07-06","hemoglobin_g_dL":14.7,"wbc_k_uL":7.3,"platelets_k_uL":434,"creatinine_mg_dL":0.96,"alt_U_L":19},{"date":"2023-03-13","hemoglobin_g_dL":10.2,"wbc_k_uL":7.2,"platelets_k_uL":329,"creatinine_mg_dL":0.77,"alt_U_L":19},{"date":"2024-07-31","hemoglobin_g_dL":10.7,"wbc_k_uL":5.4,"platelets_k_uL":196,"creatinine_mg_dL":1.49,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_2283","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":80,"sex":"female","bmi":21.8,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-63},"pfs_months":24.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.9,"censored":false},"longitudinal_labs":[{"date":"2021-10-21","hemoglobin_g_dL":13.7,"wbc_k_uL":9.9,"platelets_k_uL":157,"creatinine_mg_dL":0.81,"alt_U_L":25},{"date":"2022-06-23","hemoglobin_g_dL":10.3,"wbc_k_uL":8.3,"platelets_k_uL":155,"creatinine_mg_dL":1.22,"alt_U_L":31},{"date":"2024-02-28","hemoglobin_g_dL":12.1,"wbc_k_uL":3.9,"platelets_k_uL":206,"creatinine_mg_dL":1.53,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_2284","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":63,"sex":"female","bmi":24.3,"smoking_pack_years":24,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-09-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-39},"pfs_months":31.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":49.2,"censored":true},"longitudinal_labs":[{"date":"2025-08-13","hemoglobin_g_dL":12.4,"wbc_k_uL":7.7,"platelets_k_uL":320,"creatinine_mg_dL":0.85,"alt_U_L":21},{"date":"2026-03-01","hemoglobin_g_dL":13.5,"wbc_k_uL":6.4,"platelets_k_uL":377,"creatinine_mg_dL":1.54,"alt_U_L":66},{"date":"2028-04-16","hemoglobin_g_dL":10.7,"wbc_k_uL":3.5,"platelets_k_uL":322,"creatinine_mg_dL":1.3,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_2285","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":70,"sex":"female","bmi":35.9,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-09-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-45},"pfs_months":37.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":69.9,"censored":true},"longitudinal_labs":[{"date":"2023-07-24","hemoglobin_g_dL":12.9,"wbc_k_uL":8.5,"platelets_k_uL":270,"creatinine_mg_dL":0.8,"alt_U_L":79},{"date":"2024-03-14","hemoglobin_g_dL":11.5,"wbc_k_uL":4.1,"platelets_k_uL":135,"creatinine_mg_dL":0.93,"alt_U_L":72},{"date":"2026-11-16","hemoglobin_g_dL":11.4,"wbc_k_uL":5.5,"platelets_k_uL":129,"creatinine_mg_dL":1.73,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_2286","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":65,"sex":"female","bmi":21.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-63},"pfs_months":22.37},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.3,"censored":false},"longitudinal_labs":[{"date":"2022-05-27","hemoglobin_g_dL":12.2,"wbc_k_uL":10.7,"platelets_k_uL":160,"creatinine_mg_dL":0.82,"alt_U_L":29},{"date":"2022-12-25","hemoglobin_g_dL":10.7,"wbc_k_uL":5.3,"platelets_k_uL":369,"creatinine_mg_dL":1.54,"alt_U_L":81},{"date":"2024-06-26","hemoglobin_g_dL":9.6,"wbc_k_uL":5.0,"platelets_k_uL":279,"creatinine_mg_dL":1.17,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_2287","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":58,"sex":"male","bmi":24.2,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-69},"pfs_months":25.56},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.7,"censored":false},"longitudinal_labs":[{"date":"2020-01-23","hemoglobin_g_dL":11.8,"wbc_k_uL":7.4,"platelets_k_uL":339,"creatinine_mg_dL":0.72,"alt_U_L":50},{"date":"2020-09-04","hemoglobin_g_dL":11.3,"wbc_k_uL":4.9,"platelets_k_uL":197,"creatinine_mg_dL":1.59,"alt_U_L":82},{"date":"2022-05-23","hemoglobin_g_dL":9.6,"wbc_k_uL":5.8,"platelets_k_uL":116,"creatinine_mg_dL":1.53,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_2288","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":55,"sex":"male","bmi":33.2,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-08-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-42},"pfs_months":30.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":47.9,"censored":true},"longitudinal_labs":[{"date":"2024-07-12","hemoglobin_g_dL":11.9,"wbc_k_uL":4.5,"platelets_k_uL":170,"creatinine_mg_dL":1.02,"alt_U_L":56},{"date":"2025-02-18","hemoglobin_g_dL":12.6,"wbc_k_uL":7.3,"platelets_k_uL":336,"creatinine_mg_dL":0.96,"alt_U_L":83},{"date":"2027-04-29","hemoglobin_g_dL":10.7,"wbc_k_uL":5.4,"platelets_k_uL":151,"creatinine_mg_dL":0.94,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_2289","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":69,"sex":"male","bmi":19.8,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-02-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-31},"pfs_months":7.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.7,"censored":true},"longitudinal_labs":[{"date":"2025-01-04","hemoglobin_g_dL":15.1,"wbc_k_uL":7.8,"platelets_k_uL":231,"creatinine_mg_dL":1.08,"alt_U_L":16},{"date":"2025-08-11","hemoglobin_g_dL":12.2,"wbc_k_uL":6.4,"platelets_k_uL":197,"creatinine_mg_dL":0.94,"alt_U_L":27},{"date":"2025-10-13","hemoglobin_g_dL":11.1,"wbc_k_uL":6.1,"platelets_k_uL":239,"creatinine_mg_dL":1.7,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_2290","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":52,"sex":"female","bmi":21.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-30},"pfs_months":17.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":false},"longitudinal_labs":[{"date":"2020-03-15","hemoglobin_g_dL":11.8,"wbc_k_uL":7.2,"platelets_k_uL":246,"creatinine_mg_dL":1.05,"alt_U_L":29},{"date":"2020-11-10","hemoglobin_g_dL":10.6,"wbc_k_uL":7.7,"platelets_k_uL":236,"creatinine_mg_dL":0.78,"alt_U_L":31},{"date":"2021-11-10","hemoglobin_g_dL":12.0,"wbc_k_uL":7.5,"platelets_k_uL":349,"creatinine_mg_dL":1.07,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_2291","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":74,"sex":"male","bmi":37.7,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-71},"pfs_months":5.16},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":16.4,"censored":false},"longitudinal_labs":[{"date":"2021-02-13","hemoglobin_g_dL":14.6,"wbc_k_uL":8.6,"platelets_k_uL":325,"creatinine_mg_dL":1.22,"alt_U_L":35},{"date":"2021-09-17","hemoglobin_g_dL":10.7,"wbc_k_uL":4.8,"platelets_k_uL":261,"creatinine_mg_dL":1.49,"alt_U_L":72},{"date":"2021-09-28","hemoglobin_g_dL":12.4,"wbc_k_uL":5.6,"platelets_k_uL":208,"creatinine_mg_dL":1.67,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_2292","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":48,"sex":"female","bmi":33.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-40},"pfs_months":23.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.3,"censored":false},"longitudinal_labs":[{"date":"2022-08-03","hemoglobin_g_dL":14.8,"wbc_k_uL":6.9,"platelets_k_uL":356,"creatinine_mg_dL":0.86,"alt_U_L":21},{"date":"2023-02-13","hemoglobin_g_dL":12.2,"wbc_k_uL":5.8,"platelets_k_uL":249,"creatinine_mg_dL":1.19,"alt_U_L":68},{"date":"2024-09-21","hemoglobin_g_dL":10.3,"wbc_k_uL":4.9,"platelets_k_uL":241,"creatinine_mg_dL":1.86,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_2293","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":68,"sex":"female","bmi":27.4,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-07-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-40},"pfs_months":26.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.6,"censored":true},"longitudinal_labs":[{"date":"2025-07-10","hemoglobin_g_dL":14.4,"wbc_k_uL":9.8,"platelets_k_uL":289,"creatinine_mg_dL":0.98,"alt_U_L":64},{"date":"2026-01-22","hemoglobin_g_dL":12.9,"wbc_k_uL":5.1,"platelets_k_uL":319,"creatinine_mg_dL":0.85,"alt_U_L":36},{"date":"2027-10-06","hemoglobin_g_dL":10.6,"wbc_k_uL":7.8,"platelets_k_uL":294,"creatinine_mg_dL":1.2,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_2294","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":86,"sex":"male","bmi":24.0,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-01-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-39},"pfs_months":13.54},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.8,"censored":true},"longitudinal_labs":[{"date":"2022-12-02","hemoglobin_g_dL":13.8,"wbc_k_uL":8.6,"platelets_k_uL":390,"creatinine_mg_dL":1.11,"alt_U_L":56},{"date":"2023-07-09","hemoglobin_g_dL":13.0,"wbc_k_uL":5.1,"platelets_k_uL":198,"creatinine_mg_dL":1.55,"alt_U_L":17},{"date":"2024-04-13","hemoglobin_g_dL":9.6,"wbc_k_uL":6.5,"platelets_k_uL":336,"creatinine_mg_dL":1.69,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_2295","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":64,"sex":"female","bmi":28.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-73},"pfs_months":27.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.2,"censored":false},"longitudinal_labs":[{"date":"2023-11-22","hemoglobin_g_dL":12.0,"wbc_k_uL":5.7,"platelets_k_uL":412,"creatinine_mg_dL":1.26,"alt_U_L":18},{"date":"2024-07-12","hemoglobin_g_dL":13.2,"wbc_k_uL":6.8,"platelets_k_uL":229,"creatinine_mg_dL":0.9,"alt_U_L":56},{"date":"2026-06-07","hemoglobin_g_dL":9.5,"wbc_k_uL":7.3,"platelets_k_uL":176,"creatinine_mg_dL":1.37,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_2296","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":66,"sex":"female","bmi":31.8,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-01-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-63},"pfs_months":37.13},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":51.8,"censored":false},"longitudinal_labs":[{"date":"2022-11-27","hemoglobin_g_dL":12.8,"wbc_k_uL":7.5,"platelets_k_uL":417,"creatinine_mg_dL":0.73,"alt_U_L":70},{"date":"2023-07-22","hemoglobin_g_dL":10.6,"wbc_k_uL":7.8,"platelets_k_uL":349,"creatinine_mg_dL":0.94,"alt_U_L":80},{"date":"2026-03-09","hemoglobin_g_dL":10.2,"wbc_k_uL":4.9,"platelets_k_uL":263,"creatinine_mg_dL":0.85,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_2297","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":65,"sex":"female","bmi":25.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-48},"pfs_months":31.51},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":43.9,"censored":false},"longitudinal_labs":[{"date":"2023-06-01","hemoglobin_g_dL":13.5,"wbc_k_uL":5.6,"platelets_k_uL":414,"creatinine_mg_dL":1.05,"alt_U_L":70},{"date":"2024-02-06","hemoglobin_g_dL":13.8,"wbc_k_uL":7.3,"platelets_k_uL":190,"creatinine_mg_dL":1.59,"alt_U_L":57},{"date":"2026-05-09","hemoglobin_g_dL":10.4,"wbc_k_uL":5.3,"platelets_k_uL":188,"creatinine_mg_dL":1.9,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_2298","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":50,"sex":"female","bmi":23.1,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-10-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-83},"pfs_months":25.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.4,"censored":false},"longitudinal_labs":[{"date":"2020-09-23","hemoglobin_g_dL":12.2,"wbc_k_uL":9.8,"platelets_k_uL":277,"creatinine_mg_dL":0.93,"alt_U_L":42},{"date":"2021-04-19","hemoglobin_g_dL":10.0,"wbc_k_uL":5.7,"platelets_k_uL":128,"creatinine_mg_dL":0.97,"alt_U_L":117},{"date":"2023-02-04","hemoglobin_g_dL":11.7,"wbc_k_uL":5.2,"platelets_k_uL":292,"creatinine_mg_dL":1.62,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_2299","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":84,"sex":"female","bmi":22.5,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-44},"pfs_months":11.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.7,"censored":false},"longitudinal_labs":[{"date":"2025-06-02","hemoglobin_g_dL":12.5,"wbc_k_uL":9.0,"platelets_k_uL":406,"creatinine_mg_dL":0.89,"alt_U_L":11},{"date":"2026-02-07","hemoglobin_g_dL":11.7,"wbc_k_uL":7.0,"platelets_k_uL":172,"creatinine_mg_dL":1.18,"alt_U_L":54},{"date":"2026-08-06","hemoglobin_g_dL":10.8,"wbc_k_uL":5.7,"platelets_k_uL":270,"creatinine_mg_dL":0.93,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_2300","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":55,"sex":"male","bmi":32.9,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-06-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-63},"pfs_months":13.73},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":17.7,"censored":false},"longitudinal_labs":[{"date":"2024-04-28","hemoglobin_g_dL":12.4,"wbc_k_uL":6.4,"platelets_k_uL":422,"creatinine_mg_dL":1.03,"alt_U_L":12},{"date":"2024-12-17","hemoglobin_g_dL":12.7,"wbc_k_uL":6.9,"platelets_k_uL":268,"creatinine_mg_dL":1.01,"alt_U_L":45},{"date":"2025-09-25","hemoglobin_g_dL":11.8,"wbc_k_uL":6.1,"platelets_k_uL":190,"creatinine_mg_dL":0.88,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_2301","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":82,"sex":"female","bmi":36.3,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["liver","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-05-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-59},"pfs_months":19.81},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.7,"censored":false},"longitudinal_labs":[{"date":"2024-03-22","hemoglobin_g_dL":13.6,"wbc_k_uL":9.5,"platelets_k_uL":430,"creatinine_mg_dL":1.14,"alt_U_L":77},{"date":"2024-11-25","hemoglobin_g_dL":14.0,"wbc_k_uL":8.8,"platelets_k_uL":301,"creatinine_mg_dL":0.98,"alt_U_L":21},{"date":"2026-02-18","hemoglobin_g_dL":10.4,"wbc_k_uL":4.3,"platelets_k_uL":259,"creatinine_mg_dL":1.5,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_2302","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":81,"sex":"female","bmi":28.5,"smoking_pack_years":67,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2020-10-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-65},"pfs_months":20.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.3,"censored":false},"longitudinal_labs":[{"date":"2020-09-17","hemoglobin_g_dL":14.9,"wbc_k_uL":7.2,"platelets_k_uL":419,"creatinine_mg_dL":0.81,"alt_U_L":62},{"date":"2021-04-26","hemoglobin_g_dL":12.9,"wbc_k_uL":4.3,"platelets_k_uL":287,"creatinine_mg_dL":1.23,"alt_U_L":34},{"date":"2022-07-30","hemoglobin_g_dL":11.8,"wbc_k_uL":6.9,"platelets_k_uL":273,"creatinine_mg_dL":1.47,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_2303","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":78,"sex":"female","bmi":36.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-59},"pfs_months":26.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.9,"censored":false},"longitudinal_labs":[{"date":"2022-04-04","hemoglobin_g_dL":12.6,"wbc_k_uL":7.9,"platelets_k_uL":185,"creatinine_mg_dL":0.65,"alt_U_L":35},{"date":"2022-11-29","hemoglobin_g_dL":10.9,"wbc_k_uL":6.1,"platelets_k_uL":305,"creatinine_mg_dL":0.85,"alt_U_L":66},{"date":"2024-09-27","hemoglobin_g_dL":10.9,"wbc_k_uL":3.3,"platelets_k_uL":257,"creatinine_mg_dL":0.89,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_2304","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":61,"sex":"female","bmi":24.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-63},"pfs_months":25.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.1,"censored":false},"longitudinal_labs":[{"date":"2024-09-19","hemoglobin_g_dL":12.5,"wbc_k_uL":8.5,"platelets_k_uL":241,"creatinine_mg_dL":1.04,"alt_U_L":27},{"date":"2025-05-14","hemoglobin_g_dL":12.7,"wbc_k_uL":6.3,"platelets_k_uL":218,"creatinine_mg_dL":1.12,"alt_U_L":65},{"date":"2027-01-22","hemoglobin_g_dL":11.2,"wbc_k_uL":4.8,"platelets_k_uL":190,"creatinine_mg_dL":1.05,"alt_U_L":112}]}
{"patient_id":"ANODE_SYNTH_2025_2305","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":50,"sex":"female","bmi":29.0,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-08-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-33},"pfs_months":15.18},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.1,"censored":true},"longitudinal_labs":[{"date":"2020-06-16","hemoglobin_g_dL":14.6,"wbc_k_uL":7.9,"platelets_k_uL":399,"creatinine_mg_dL":0.8,"alt_U_L":55},{"date":"2021-02-03","hemoglobin_g_dL":11.6,"wbc_k_uL":6.8,"platelets_k_uL":274,"creatinine_mg_dL":0.78,"alt_U_L":68},{"date":"2021-11-22","hemoglobin_g_dL":12.9,"wbc_k_uL":6.4,"platelets_k_uL":107,"creatinine_mg_dL":1.25,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_2306","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":71,"sex":"male","bmi":37.7,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-01-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-64},"pfs_months":12.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.9,"censored":false},"longitudinal_labs":[{"date":"2021-12-21","hemoglobin_g_dL":12.2,"wbc_k_uL":8.2,"platelets_k_uL":151,"creatinine_mg_dL":0.85,"alt_U_L":43},{"date":"2022-07-12","hemoglobin_g_dL":10.6,"wbc_k_uL":5.5,"platelets_k_uL":375,"creatinine_mg_dL":1.06,"alt_U_L":69},{"date":"2023-03-15","hemoglobin_g_dL":12.3,"wbc_k_uL":3.1,"platelets_k_uL":323,"creatinine_mg_dL":1.04,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_2307","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":79,"sex":"female","bmi":32.1,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-01-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-52},"pfs_months":34.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":43.1,"censored":true},"longitudinal_labs":[{"date":"2025-11-21","hemoglobin_g_dL":11.9,"wbc_k_uL":8.1,"platelets_k_uL":237,"creatinine_mg_dL":0.74,"alt_U_L":59},{"date":"2026-07-18","hemoglobin_g_dL":12.3,"wbc_k_uL":7.9,"platelets_k_uL":285,"creatinine_mg_dL":1.45,"alt_U_L":65},{"date":"2029-01-29","hemoglobin_g_dL":9.9,"wbc_k_uL":7.5,"platelets_k_uL":265,"creatinine_mg_dL":0.81,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_2308","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":75,"sex":"male","bmi":20.5,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-10-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-40},"pfs_months":5.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":9.9,"censored":false},"longitudinal_labs":[{"date":"2024-08-10","hemoglobin_g_dL":14.7,"wbc_k_uL":5.5,"platelets_k_uL":210,"creatinine_mg_dL":0.89,"alt_U_L":22},{"date":"2025-04-13","hemoglobin_g_dL":11.2,"wbc_k_uL":5.3,"platelets_k_uL":160,"creatinine_mg_dL":0.83,"alt_U_L":46},{"date":"2025-06-01","hemoglobin_g_dL":11.5,"wbc_k_uL":6.4,"platelets_k_uL":232,"creatinine_mg_dL":1.41,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_2309","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":61,"sex":"female","bmi":25.2,"smoking_pack_years":37,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-50},"pfs_months":51.02},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2030-04-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.1,"censored":false},"longitudinal_labs":[{"date":"2025-12-02","hemoglobin_g_dL":12.9,"wbc_k_uL":4.8,"platelets_k_uL":175,"creatinine_mg_dL":0.78,"alt_U_L":37},{"date":"2026-06-28","hemoglobin_g_dL":11.2,"wbc_k_uL":7.6,"platelets_k_uL":144,"creatinine_mg_dL":0.78,"alt_U_L":19},{"date":"2030-04-26","hemoglobin_g_dL":10.3,"wbc_k_uL":4.1,"platelets_k_uL":333,"creatinine_mg_dL":1.45,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_2310","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":73,"sex":"female","bmi":18.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-34},"pfs_months":29.54},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.9,"censored":true},"longitudinal_labs":[{"date":"2020-07-09","hemoglobin_g_dL":14.3,"wbc_k_uL":10.1,"platelets_k_uL":378,"creatinine_mg_dL":0.64,"alt_U_L":75},{"date":"2021-02-15","hemoglobin_g_dL":12.7,"wbc_k_uL":8.0,"platelets_k_uL":314,"creatinine_mg_dL":1.11,"alt_U_L":56},{"date":"2023-03-24","hemoglobin_g_dL":9.7,"wbc_k_uL":7.5,"platelets_k_uL":165,"creatinine_mg_dL":0.87,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_2311","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":83,"sex":"female","bmi":37.7,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-08-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-50},"pfs_months":13.63},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.5,"censored":true},"longitudinal_labs":[{"date":"2025-06-23","hemoglobin_g_dL":13.4,"wbc_k_uL":8.1,"platelets_k_uL":251,"creatinine_mg_dL":0.72,"alt_U_L":40},{"date":"2026-02-21","hemoglobin_g_dL":12.4,"wbc_k_uL":4.4,"platelets_k_uL":237,"creatinine_mg_dL":1.19,"alt_U_L":48},{"date":"2026-11-25","hemoglobin_g_dL":9.5,"wbc_k_uL":6.2,"platelets_k_uL":175,"creatinine_mg_dL":0.83,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_2312","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":55,"sex":"male","bmi":34.6,"smoking_pack_years":28,"ecog_performance_status":2,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-31},"pfs_months":27.7},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":48.1,"censored":false},"longitudinal_labs":[{"date":"2024-07-16","hemoglobin_g_dL":12.8,"wbc_k_uL":7.9,"platelets_k_uL":288,"creatinine_mg_dL":0.84,"alt_U_L":71},{"date":"2025-03-11","hemoglobin_g_dL":10.7,"wbc_k_uL":5.4,"platelets_k_uL":320,"creatinine_mg_dL":0.92,"alt_U_L":110},{"date":"2027-01-23","hemoglobin_g_dL":12.2,"wbc_k_uL":5.6,"platelets_k_uL":294,"creatinine_mg_dL":1.97,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2313","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":77,"sex":"female","bmi":37.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-76},"pfs_months":30.85},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-10","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":false},"longitudinal_labs":[{"date":"2024-05-14","hemoglobin_g_dL":15.0,"wbc_k_uL":5.4,"platelets_k_uL":252,"creatinine_mg_dL":1.12,"alt_U_L":36},{"date":"2024-12-15","hemoglobin_g_dL":12.8,"wbc_k_uL":6.1,"platelets_k_uL":298,"creatinine_mg_dL":1.15,"alt_U_L":34},{"date":"2027-03-10","hemoglobin_g_dL":12.4,"wbc_k_uL":6.5,"platelets_k_uL":300,"creatinine_mg_dL":1.13,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_2314","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":66,"sex":"male","bmi":34.7,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-49},"pfs_months":28.16},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.2,"censored":false},"longitudinal_labs":[{"date":"2023-04-12","hemoglobin_g_dL":13.8,"wbc_k_uL":7.4,"platelets_k_uL":436,"creatinine_mg_dL":1.24,"alt_U_L":13},{"date":"2023-12-03","hemoglobin_g_dL":11.1,"wbc_k_uL":6.1,"platelets_k_uL":233,"creatinine_mg_dL":1.52,"alt_U_L":71},{"date":"2025-11-07","hemoglobin_g_dL":11.4,"wbc_k_uL":5.5,"platelets_k_uL":284,"creatinine_mg_dL":1.24,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_2315","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":55,"sex":"female","bmi":22.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-07-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-66},"pfs_months":22.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.6,"censored":false},"longitudinal_labs":[{"date":"2021-06-25","hemoglobin_g_dL":12.9,"wbc_k_uL":8.7,"platelets_k_uL":317,"creatinine_mg_dL":0.62,"alt_U_L":56},{"date":"2022-01-13","hemoglobin_g_dL":13.9,"wbc_k_uL":6.4,"platelets_k_uL":295,"creatinine_mg_dL":0.84,"alt_U_L":46},{"date":"2023-06-19","hemoglobin_g_dL":12.5,"wbc_k_uL":6.8,"platelets_k_uL":324,"creatinine_mg_dL":0.87,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_2316","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":75,"sex":"female","bmi":21.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-41},"pfs_months":19.75},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.2,"censored":true},"longitudinal_labs":[{"date":"2021-07-04","hemoglobin_g_dL":13.6,"wbc_k_uL":5.9,"platelets_k_uL":172,"creatinine_mg_dL":0.6,"alt_U_L":40},{"date":"2022-02-19","hemoglobin_g_dL":13.7,"wbc_k_uL":5.1,"platelets_k_uL":346,"creatinine_mg_dL":0.75,"alt_U_L":100},{"date":"2023-06-11","hemoglobin_g_dL":12.6,"wbc_k_uL":7.7,"platelets_k_uL":303,"creatinine_mg_dL":0.82,"alt_U_L":176}]}
{"patient_id":"ANODE_SYNTH_2025_2317","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":63,"sex":"male","bmi":23.6,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-03-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-69},"pfs_months":23.0},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.8,"censored":false},"longitudinal_labs":[{"date":"2020-02-09","hemoglobin_g_dL":15.4,"wbc_k_uL":7.8,"platelets_k_uL":449,"creatinine_mg_dL":0.87,"alt_U_L":10},{"date":"2020-09-24","hemoglobin_g_dL":10.1,"wbc_k_uL":7.5,"platelets_k_uL":319,"creatinine_mg_dL":0.72,"alt_U_L":106},{"date":"2022-03-15","hemoglobin_g_dL":10.1,"wbc_k_uL":4.8,"platelets_k_uL":285,"creatinine_mg_dL":1.2,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_2318","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":72,"sex":"female","bmi":33.0,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-06-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-62},"pfs_months":44.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-16","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":63.8,"censored":false},"longitudinal_labs":[{"date":"2022-04-24","hemoglobin_g_dL":15.2,"wbc_k_uL":7.1,"platelets_k_uL":266,"creatinine_mg_dL":0.78,"alt_U_L":50},{"date":"2022-12-18","hemoglobin_g_dL":12.5,"wbc_k_uL":4.4,"platelets_k_uL":164,"creatinine_mg_dL":0.81,"alt_U_L":23},{"date":"2026-04-16","hemoglobin_g_dL":12.9,"wbc_k_uL":5.2,"platelets_k_uL":108,"creatinine_mg_dL":1.14,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_2319","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":58,"sex":"female","bmi":37.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-80},"pfs_months":23.06},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.7,"censored":false},"longitudinal_labs":[{"date":"2020-04-08","hemoglobin_g_dL":13.4,"wbc_k_uL":11.0,"platelets_k_uL":444,"creatinine_mg_dL":0.61,"alt_U_L":15},{"date":"2020-12-05","hemoglobin_g_dL":11.9,"wbc_k_uL":7.5,"platelets_k_uL":121,"creatinine_mg_dL":0.79,"alt_U_L":29},{"date":"2022-05-18","hemoglobin_g_dL":11.5,"wbc_k_uL":5.0,"platelets_k_uL":184,"creatinine_mg_dL":1.43,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_2320","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.2,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":86,"sex":"male","bmi":34.0,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-40},"pfs_months":31.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-09-18","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.0,"censored":false},"longitudinal_labs":[{"date":"2025-11-23","hemoglobin_g_dL":14.7,"wbc_k_uL":5.9,"platelets_k_uL":166,"creatinine_mg_dL":0.78,"alt_U_L":55},{"date":"2026-06-25","hemoglobin_g_dL":10.6,"wbc_k_uL":5.9,"platelets_k_uL":355,"creatinine_mg_dL":1.08,"alt_U_L":74},{"date":"2028-09-18","hemoglobin_g_dL":9.8,"wbc_k_uL":3.5,"platelets_k_uL":285,"creatinine_mg_dL":0.89,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_2321","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":51,"sex":"female","bmi":21.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-35},"pfs_months":18.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.7,"censored":false},"longitudinal_labs":[{"date":"2021-06-13","hemoglobin_g_dL":12.2,"wbc_k_uL":10.0,"platelets_k_uL":245,"creatinine_mg_dL":1.0,"alt_U_L":67},{"date":"2021-12-30","hemoglobin_g_dL":11.0,"wbc_k_uL":4.6,"platelets_k_uL":368,"creatinine_mg_dL":0.81,"alt_U_L":66},{"date":"2023-02-09","hemoglobin_g_dL":9.6,"wbc_k_uL":4.9,"platelets_k_uL":132,"creatinine_mg_dL":1.17,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_2322","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":66,"sex":"male","bmi":27.1,"smoking_pack_years":11,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-50},"pfs_months":11.17},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.9,"censored":false},"longitudinal_labs":[{"date":"2023-08-02","hemoglobin_g_dL":14.6,"wbc_k_uL":8.2,"platelets_k_uL":224,"creatinine_mg_dL":0.82,"alt_U_L":53},{"date":"2024-02-29","hemoglobin_g_dL":12.5,"wbc_k_uL":5.2,"platelets_k_uL":313,"creatinine_mg_dL":1.38,"alt_U_L":32},{"date":"2024-09-30","hemoglobin_g_dL":9.5,"wbc_k_uL":3.2,"platelets_k_uL":294,"creatinine_mg_dL":1.71,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_2323","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":58,"sex":"female","bmi":19.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-47},"pfs_months":11.7},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-04-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":20.3,"censored":false},"longitudinal_labs":[{"date":"2020-04-11","hemoglobin_g_dL":14.0,"wbc_k_uL":8.3,"platelets_k_uL":213,"creatinine_mg_dL":1.08,"alt_U_L":10},{"date":"2020-10-26","hemoglobin_g_dL":10.9,"wbc_k_uL":4.3,"platelets_k_uL":364,"creatinine_mg_dL":1.01,"alt_U_L":107},{"date":"2021-04-29","hemoglobin_g_dL":10.1,"wbc_k_uL":3.1,"platelets_k_uL":226,"creatinine_mg_dL":1.73,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_2324","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":51,"sex":"male","bmi":19.9,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-04-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-50},"pfs_months":23.95},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":49.8,"censored":false},"longitudinal_labs":[{"date":"2025-02-09","hemoglobin_g_dL":13.8,"wbc_k_uL":4.7,"platelets_k_uL":204,"creatinine_mg_dL":0.65,"alt_U_L":26},{"date":"2025-10-13","hemoglobin_g_dL":10.7,"wbc_k_uL":5.7,"platelets_k_uL":222,"creatinine_mg_dL":1.21,"alt_U_L":81},{"date":"2027-06-01","hemoglobin_g_dL":10.5,"wbc_k_uL":6.6,"platelets_k_uL":345,"creatinine_mg_dL":1.0,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_2325","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":74,"sex":"male","bmi":36.1,"smoking_pack_years":21,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-03-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-76},"pfs_months":12.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":30.0,"censored":false},"longitudinal_labs":[{"date":"2020-02-07","hemoglobin_g_dL":11.8,"wbc_k_uL":7.4,"platelets_k_uL":187,"creatinine_mg_dL":1.27,"alt_U_L":52},{"date":"2020-09-20","hemoglobin_g_dL":10.3,"wbc_k_uL":5.1,"platelets_k_uL":211,"creatinine_mg_dL":0.83,"alt_U_L":61},{"date":"2021-05-08","hemoglobin_g_dL":12.8,"wbc_k_uL":4.4,"platelets_k_uL":270,"creatinine_mg_dL":1.17,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_2326","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":58,"sex":"male","bmi":35.5,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-04-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-38},"pfs_months":30.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":53.7,"censored":false},"longitudinal_labs":[{"date":"2020-03-28","hemoglobin_g_dL":11.5,"wbc_k_uL":9.4,"platelets_k_uL":290,"creatinine_mg_dL":0.78,"alt_U_L":62},{"date":"2020-10-11","hemoglobin_g_dL":10.6,"wbc_k_uL":8.9,"platelets_k_uL":147,"creatinine_mg_dL":1.26,"alt_U_L":38},{"date":"2022-12-04","hemoglobin_g_dL":12.3,"wbc_k_uL":6.3,"platelets_k_uL":216,"creatinine_mg_dL":1.92,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_2327","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":76,"sex":"female","bmi":20.3,"smoking_pack_years":12,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-01-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-32},"pfs_months":14.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.3,"censored":false},"longitudinal_labs":[{"date":"2025-12-12","hemoglobin_g_dL":14.3,"wbc_k_uL":6.9,"platelets_k_uL":309,"creatinine_mg_dL":0.93,"alt_U_L":40},{"date":"2026-07-08","hemoglobin_g_dL":13.8,"wbc_k_uL":8.8,"platelets_k_uL":218,"creatinine_mg_dL":1.16,"alt_U_L":84},{"date":"2027-05-19","hemoglobin_g_dL":10.7,"wbc_k_uL":4.0,"platelets_k_uL":138,"creatinine_mg_dL":1.92,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_2328","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":49,"sex":"female","bmi":35.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-03-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-70},"pfs_months":19.19},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":28.2,"censored":false},"longitudinal_labs":[{"date":"2020-02-04","hemoglobin_g_dL":13.5,"wbc_k_uL":10.8,"platelets_k_uL":292,"creatinine_mg_dL":1.13,"alt_U_L":48},{"date":"2020-09-04","hemoglobin_g_dL":12.7,"wbc_k_uL":6.3,"platelets_k_uL":216,"creatinine_mg_dL":1.06,"alt_U_L":101},{"date":"2021-12-06","hemoglobin_g_dL":11.9,"wbc_k_uL":3.6,"platelets_k_uL":146,"creatinine_mg_dL":1.0,"alt_U_L":87}]}
{"patient_id":"ANODE_SYNTH_2025_2329","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":55,"sex":"female","bmi":31.3,"smoking_pack_years":49,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-12-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-67},"pfs_months":15.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.0,"censored":true},"longitudinal_labs":[{"date":"2025-11-14","hemoglobin_g_dL":12.2,"wbc_k_uL":6.1,"platelets_k_uL":424,"creatinine_mg_dL":0.74,"alt_U_L":65},{"date":"2026-06-22","hemoglobin_g_dL":12.8,"wbc_k_uL":5.6,"platelets_k_uL":324,"creatinine_mg_dL":1.06,"alt_U_L":56},{"date":"2027-05-27","hemoglobin_g_dL":9.9,"wbc_k_uL":4.2,"platelets_k_uL":239,"creatinine_mg_dL":1.06,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_2330","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":82,"sex":"male","bmi":23.6,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-02-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-60},"pfs_months":16.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.4,"censored":false},"longitudinal_labs":[{"date":"2021-02-04","hemoglobin_g_dL":13.1,"wbc_k_uL":4.6,"platelets_k_uL":445,"creatinine_mg_dL":1.1,"alt_U_L":50},{"date":"2021-08-26","hemoglobin_g_dL":10.8,"wbc_k_uL":4.1,"platelets_k_uL":147,"creatinine_mg_dL":1.02,"alt_U_L":52},{"date":"2022-08-15","hemoglobin_g_dL":11.8,"wbc_k_uL":4.6,"platelets_k_uL":273,"creatinine_mg_dL":1.09,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_2331","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":63,"sex":"female","bmi":24.3,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-12-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-32},"pfs_months":35.61},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":54.8,"censored":false},"longitudinal_labs":[{"date":"2023-11-17","hemoglobin_g_dL":11.6,"wbc_k_uL":9.4,"platelets_k_uL":211,"creatinine_mg_dL":1.15,"alt_U_L":14},{"date":"2024-06-13","hemoglobin_g_dL":12.5,"wbc_k_uL":7.4,"platelets_k_uL":299,"creatinine_mg_dL":1.24,"alt_U_L":16},{"date":"2027-01-03","hemoglobin_g_dL":12.5,"wbc_k_uL":7.6,"platelets_k_uL":189,"creatinine_mg_dL":1.28,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_2332","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":64,"sex":"female","bmi":20.3,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-05-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-53},"pfs_months":40.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":68.5,"censored":false},"longitudinal_labs":[{"date":"2024-04-11","hemoglobin_g_dL":14.7,"wbc_k_uL":9.0,"platelets_k_uL":273,"creatinine_mg_dL":0.77,"alt_U_L":18},{"date":"2024-11-18","hemoglobin_g_dL":12.7,"wbc_k_uL":7.6,"platelets_k_uL":186,"creatinine_mg_dL":1.13,"alt_U_L":28},{"date":"2027-11-19","hemoglobin_g_dL":11.1,"wbc_k_uL":8.0,"platelets_k_uL":180,"creatinine_mg_dL":1.59,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_2333","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":86,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-32},"pfs_months":25.0},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.8,"censored":true},"longitudinal_labs":[{"date":"2024-11-23","hemoglobin_g_dL":14.1,"wbc_k_uL":8.2,"platelets_k_uL":227,"creatinine_mg_dL":0.81,"alt_U_L":58},{"date":"2025-07-01","hemoglobin_g_dL":11.2,"wbc_k_uL":4.9,"platelets_k_uL":350,"creatinine_mg_dL":1.31,"alt_U_L":80},{"date":"2027-03-26","hemoglobin_g_dL":9.7,"wbc_k_uL":4.2,"platelets_k_uL":232,"creatinine_mg_dL":1.16,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_2334","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":63,"sex":"male","bmi":30.5,"smoking_pack_years":68,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-05-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-41},"pfs_months":3.91},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":9.8,"censored":false},"longitudinal_labs":[{"date":"2024-05-01","hemoglobin_g_dL":13.6,"wbc_k_uL":7.6,"platelets_k_uL":450,"creatinine_mg_dL":0.91,"alt_U_L":20},{"date":"2024-11-15","hemoglobin_g_dL":11.0,"wbc_k_uL":4.8,"platelets_k_uL":260,"creatinine_mg_dL":1.11,"alt_U_L":20},{"date":"2024-09-19","hemoglobin_g_dL":10.9,"wbc_k_uL":6.3,"platelets_k_uL":325,"creatinine_mg_dL":0.94,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_2335","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":82,"sex":"female","bmi":30.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-43},"pfs_months":23.85},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.6,"censored":false},"longitudinal_labs":[{"date":"2021-03-16","hemoglobin_g_dL":12.2,"wbc_k_uL":6.7,"platelets_k_uL":252,"creatinine_mg_dL":0.81,"alt_U_L":73},{"date":"2021-11-19","hemoglobin_g_dL":11.6,"wbc_k_uL":5.0,"platelets_k_uL":317,"creatinine_mg_dL":1.57,"alt_U_L":15},{"date":"2023-06-13","hemoglobin_g_dL":12.2,"wbc_k_uL":5.3,"platelets_k_uL":277,"creatinine_mg_dL":1.11,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_2336","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":50,"sex":"female","bmi":29.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-55},"pfs_months":17.45},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.3,"censored":false},"longitudinal_labs":[{"date":"2020-09-09","hemoglobin_g_dL":14.7,"wbc_k_uL":5.7,"platelets_k_uL":169,"creatinine_mg_dL":0.79,"alt_U_L":40},{"date":"2021-04-12","hemoglobin_g_dL":11.6,"wbc_k_uL":7.7,"platelets_k_uL":158,"creatinine_mg_dL":1.24,"alt_U_L":19},{"date":"2022-05-25","hemoglobin_g_dL":10.2,"wbc_k_uL":7.8,"platelets_k_uL":164,"creatinine_mg_dL":0.82,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_2337","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":81,"sex":"female","bmi":34.8,"smoking_pack_years":53,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-06-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-32},"pfs_months":34.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":52.0,"censored":false},"longitudinal_labs":[{"date":"2022-04-23","hemoglobin_g_dL":15.4,"wbc_k_uL":9.9,"platelets_k_uL":294,"creatinine_mg_dL":0.91,"alt_U_L":14},{"date":"2022-12-11","hemoglobin_g_dL":13.2,"wbc_k_uL":8.9,"platelets_k_uL":346,"creatinine_mg_dL":1.14,"alt_U_L":39},{"date":"2025-05-30","hemoglobin_g_dL":11.5,"wbc_k_uL":3.1,"platelets_k_uL":160,"creatinine_mg_dL":1.43,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_2338","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":71,"sex":"female","bmi":35.7,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-01-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-75},"pfs_months":50.4},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":74.6,"censored":true},"longitudinal_labs":[{"date":"2021-01-07","hemoglobin_g_dL":11.5,"wbc_k_uL":8.1,"platelets_k_uL":400,"creatinine_mg_dL":1.15,"alt_U_L":30},{"date":"2021-07-20","hemoglobin_g_dL":10.9,"wbc_k_uL":8.5,"platelets_k_uL":291,"creatinine_mg_dL":0.8,"alt_U_L":15},{"date":"2025-04-13","hemoglobin_g_dL":9.6,"wbc_k_uL":4.4,"platelets_k_uL":183,"creatinine_mg_dL":0.86,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_2339","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":66,"sex":"male","bmi":34.6,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-09-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-42},"pfs_months":45.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":69.7,"censored":false},"longitudinal_labs":[{"date":"2020-08-17","hemoglobin_g_dL":11.7,"wbc_k_uL":8.5,"platelets_k_uL":164,"creatinine_mg_dL":1.27,"alt_U_L":35},{"date":"2021-03-13","hemoglobin_g_dL":12.6,"wbc_k_uL":4.0,"platelets_k_uL":127,"creatinine_mg_dL":0.79,"alt_U_L":54},{"date":"2024-07-06","hemoglobin_g_dL":11.4,"wbc_k_uL":4.9,"platelets_k_uL":346,"creatinine_mg_dL":1.18,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_2340","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":76,"sex":"female","bmi":22.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-76},"pfs_months":15.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2021-04-10","hemoglobin_g_dL":14.1,"wbc_k_uL":6.7,"platelets_k_uL":327,"creatinine_mg_dL":1.24,"alt_U_L":10},{"date":"2021-10-27","hemoglobin_g_dL":12.1,"wbc_k_uL":6.5,"platelets_k_uL":174,"creatinine_mg_dL":1.38,"alt_U_L":63},{"date":"2022-10-05","hemoglobin_g_dL":12.5,"wbc_k_uL":5.3,"platelets_k_uL":207,"creatinine_mg_dL":1.04,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_2341","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":72,"sex":"female","bmi":26.5,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-09-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-61},"pfs_months":36.8},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":68.8,"censored":true},"longitudinal_labs":[{"date":"2024-09-10","hemoglobin_g_dL":11.8,"wbc_k_uL":7.7,"platelets_k_uL":297,"creatinine_mg_dL":1.18,"alt_U_L":23},{"date":"2025-03-25","hemoglobin_g_dL":13.0,"wbc_k_uL":7.2,"platelets_k_uL":315,"creatinine_mg_dL":1.58,"alt_U_L":76},{"date":"2027-11-24","hemoglobin_g_dL":12.0,"wbc_k_uL":4.1,"platelets_k_uL":271,"creatinine_mg_dL":1.22,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_2342","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":81,"sex":"male","bmi":23.2,"smoking_pack_years":16,"ecog_performance_status":2,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-05-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-56},"pfs_months":14.78},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.2,"censored":false},"longitudinal_labs":[{"date":"2020-03-17","hemoglobin_g_dL":14.0,"wbc_k_uL":6.6,"platelets_k_uL":386,"creatinine_mg_dL":0.66,"alt_U_L":56},{"date":"2020-11-21","hemoglobin_g_dL":11.0,"wbc_k_uL":8.0,"platelets_k_uL":379,"creatinine_mg_dL":1.45,"alt_U_L":64},{"date":"2021-10-12","hemoglobin_g_dL":10.1,"wbc_k_uL":7.9,"platelets_k_uL":316,"creatinine_mg_dL":0.87,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_2343","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":66,"sex":"female","bmi":35.6,"smoking_pack_years":51,"ecog_performance_status":2,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-01-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-58},"pfs_months":43.86},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":72.2,"censored":false},"longitudinal_labs":[{"date":"2023-11-17","hemoglobin_g_dL":12.7,"wbc_k_uL":4.5,"platelets_k_uL":238,"creatinine_mg_dL":1.13,"alt_U_L":33},{"date":"2024-07-05","hemoglobin_g_dL":10.0,"wbc_k_uL":7.8,"platelets_k_uL":169,"creatinine_mg_dL":1.09,"alt_U_L":118},{"date":"2027-09-19","hemoglobin_g_dL":10.0,"wbc_k_uL":3.9,"platelets_k_uL":246,"creatinine_mg_dL":1.53,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_2344","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":68,"sex":"female","bmi":36.6,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-06-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-53},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.6,"censored":false},"longitudinal_labs":[{"date":"2025-05-27","hemoglobin_g_dL":14.2,"wbc_k_uL":7.1,"platelets_k_uL":436,"creatinine_mg_dL":1.04,"alt_U_L":11},{"date":"2025-12-18","hemoglobin_g_dL":10.7,"wbc_k_uL":8.4,"platelets_k_uL":218,"creatinine_mg_dL":1.19,"alt_U_L":34},{"date":"2027-05-25","hemoglobin_g_dL":9.9,"wbc_k_uL":4.8,"platelets_k_uL":150,"creatinine_mg_dL":0.86,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_2345","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":86,"sex":"female","bmi":28.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-50},"pfs_months":18.43},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.2,"censored":false},"longitudinal_labs":[{"date":"2023-02-16","hemoglobin_g_dL":13.5,"wbc_k_uL":6.4,"platelets_k_uL":354,"creatinine_mg_dL":0.66,"alt_U_L":31},{"date":"2023-09-06","hemoglobin_g_dL":12.7,"wbc_k_uL":4.9,"platelets_k_uL":261,"creatinine_mg_dL":0.96,"alt_U_L":60},{"date":"2024-10-29","hemoglobin_g_dL":12.2,"wbc_k_uL":5.4,"platelets_k_uL":278,"creatinine_mg_dL":1.27,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_2346","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":51,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-38},"pfs_months":18.53},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.6,"censored":false},"longitudinal_labs":[{"date":"2022-09-18","hemoglobin_g_dL":12.3,"wbc_k_uL":6.3,"platelets_k_uL":259,"creatinine_mg_dL":0.9,"alt_U_L":13},{"date":"2023-04-25","hemoglobin_g_dL":13.9,"wbc_k_uL":3.9,"platelets_k_uL":221,"creatinine_mg_dL":1.41,"alt_U_L":36},{"date":"2024-06-21","hemoglobin_g_dL":12.9,"wbc_k_uL":7.4,"platelets_k_uL":304,"creatinine_mg_dL":1.53,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_2347","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":64,"sex":"female","bmi":34.4,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-05-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-47},"pfs_months":23.26},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.1,"censored":true},"longitudinal_labs":[{"date":"2024-04-06","hemoglobin_g_dL":13.8,"wbc_k_uL":7.3,"platelets_k_uL":263,"creatinine_mg_dL":0.7,"alt_U_L":39},{"date":"2024-11-14","hemoglobin_g_dL":13.8,"wbc_k_uL":8.8,"platelets_k_uL":322,"creatinine_mg_dL":1.14,"alt_U_L":74},{"date":"2026-05-22","hemoglobin_g_dL":12.0,"wbc_k_uL":3.3,"platelets_k_uL":120,"creatinine_mg_dL":1.47,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_2348","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":86,"sex":"female","bmi":22.2,"smoking_pack_years":12,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-06-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-49},"pfs_months":20.37},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.2,"censored":true},"longitudinal_labs":[{"date":"2022-05-06","hemoglobin_g_dL":14.6,"wbc_k_uL":9.6,"platelets_k_uL":417,"creatinine_mg_dL":1.09,"alt_U_L":51},{"date":"2022-12-03","hemoglobin_g_dL":12.3,"wbc_k_uL":4.5,"platelets_k_uL":361,"creatinine_mg_dL":1.58,"alt_U_L":41},{"date":"2024-04-10","hemoglobin_g_dL":11.1,"wbc_k_uL":5.6,"platelets_k_uL":289,"creatinine_mg_dL":1.33,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_2349","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":50,"sex":"female","bmi":32.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-51},"pfs_months":14.95},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.8,"censored":false},"longitudinal_labs":[{"date":"2025-01-15","hemoglobin_g_dL":13.3,"wbc_k_uL":6.7,"platelets_k_uL":212,"creatinine_mg_dL":0.78,"alt_U_L":70},{"date":"2025-08-16","hemoglobin_g_dL":13.2,"wbc_k_uL":3.8,"platelets_k_uL":359,"creatinine_mg_dL":1.26,"alt_U_L":113},{"date":"2026-05-29","hemoglobin_g_dL":9.9,"wbc_k_uL":8.0,"platelets_k_uL":262,"creatinine_mg_dL":1.91,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_2350","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":56,"sex":"female","bmi":33.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-59},"pfs_months":14.62},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":true},"longitudinal_labs":[{"date":"2021-08-13","hemoglobin_g_dL":12.4,"wbc_k_uL":7.3,"platelets_k_uL":191,"creatinine_mg_dL":0.82,"alt_U_L":16},{"date":"2022-02-23","hemoglobin_g_dL":11.1,"wbc_k_uL":8.9,"platelets_k_uL":282,"creatinine_mg_dL":1.59,"alt_U_L":73},{"date":"2022-12-13","hemoglobin_g_dL":11.5,"wbc_k_uL":5.2,"platelets_k_uL":329,"creatinine_mg_dL":1.45,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_2351","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":79,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-53},"pfs_months":20.37},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":false},"longitudinal_labs":[{"date":"2023-02-17","hemoglobin_g_dL":15.4,"wbc_k_uL":9.4,"platelets_k_uL":393,"creatinine_mg_dL":0.64,"alt_U_L":55},{"date":"2023-10-13","hemoglobin_g_dL":10.7,"wbc_k_uL":3.9,"platelets_k_uL":377,"creatinine_mg_dL":1.2,"alt_U_L":65},{"date":"2025-01-21","hemoglobin_g_dL":10.6,"wbc_k_uL":5.2,"platelets_k_uL":335,"creatinine_mg_dL":0.87,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_2352","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":62,"sex":"male","bmi":25.6,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-06-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-51},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-10-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":12.1,"censored":false},"longitudinal_labs":[{"date":"2020-05-04","hemoglobin_g_dL":13.0,"wbc_k_uL":10.6,"platelets_k_uL":271,"creatinine_mg_dL":1.06,"alt_U_L":34},{"date":"2020-12-05","hemoglobin_g_dL":11.9,"wbc_k_uL":4.7,"platelets_k_uL":231,"creatinine_mg_dL":0.9,"alt_U_L":22},{"date":"2020-10-03","hemoglobin_g_dL":12.6,"wbc_k_uL":3.6,"platelets_k_uL":102,"creatinine_mg_dL":0.81,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_2353","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":83,"sex":"female","bmi":34.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-69},"pfs_months":14.88},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":24.7,"censored":true},"longitudinal_labs":[{"date":"2025-07-03","hemoglobin_g_dL":14.0,"wbc_k_uL":7.8,"platelets_k_uL":426,"creatinine_mg_dL":0.64,"alt_U_L":63},{"date":"2026-02-06","hemoglobin_g_dL":11.4,"wbc_k_uL":4.3,"platelets_k_uL":199,"creatinine_mg_dL":0.75,"alt_U_L":95},{"date":"2026-12-14","hemoglobin_g_dL":9.9,"wbc_k_uL":4.9,"platelets_k_uL":201,"creatinine_mg_dL":0.92,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_2354","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":58,"sex":"female","bmi":34.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-73},"pfs_months":23.2},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.0,"censored":true},"longitudinal_labs":[{"date":"2020-09-12","hemoglobin_g_dL":11.8,"wbc_k_uL":8.6,"platelets_k_uL":295,"creatinine_mg_dL":0.86,"alt_U_L":52},{"date":"2021-04-21","hemoglobin_g_dL":13.0,"wbc_k_uL":5.5,"platelets_k_uL":173,"creatinine_mg_dL":1.17,"alt_U_L":23},{"date":"2022-11-17","hemoglobin_g_dL":11.2,"wbc_k_uL":5.7,"platelets_k_uL":158,"creatinine_mg_dL":1.61,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2355","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":83,"sex":"female","bmi":30.3,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-10-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-61},"pfs_months":36.6},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.8,"censored":false},"longitudinal_labs":[{"date":"2021-10-03","hemoglobin_g_dL":11.6,"wbc_k_uL":4.8,"platelets_k_uL":255,"creatinine_mg_dL":0.73,"alt_U_L":36},{"date":"2022-04-27","hemoglobin_g_dL":13.9,"wbc_k_uL":8.1,"platelets_k_uL":199,"creatinine_mg_dL":0.87,"alt_U_L":45},{"date":"2024-12-09","hemoglobin_g_dL":10.3,"wbc_k_uL":5.2,"platelets_k_uL":103,"creatinine_mg_dL":1.92,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_2356","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":68,"sex":"female","bmi":18.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-77},"pfs_months":17.87},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.2,"censored":false},"longitudinal_labs":[{"date":"2022-03-21","hemoglobin_g_dL":14.2,"wbc_k_uL":5.3,"platelets_k_uL":414,"creatinine_mg_dL":1.2,"alt_U_L":64},{"date":"2022-10-17","hemoglobin_g_dL":12.9,"wbc_k_uL":6.6,"platelets_k_uL":360,"creatinine_mg_dL":1.56,"alt_U_L":83},{"date":"2023-11-22","hemoglobin_g_dL":9.6,"wbc_k_uL":3.4,"platelets_k_uL":192,"creatinine_mg_dL":1.37,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_2357","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":85,"sex":"male","bmi":28.4,"smoking_pack_years":40,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-53},"pfs_months":7.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":15.8,"censored":false},"longitudinal_labs":[{"date":"2023-06-19","hemoglobin_g_dL":11.6,"wbc_k_uL":4.6,"platelets_k_uL":158,"creatinine_mg_dL":1.09,"alt_U_L":36},{"date":"2024-01-11","hemoglobin_g_dL":13.5,"wbc_k_uL":5.1,"platelets_k_uL":313,"creatinine_mg_dL":0.99,"alt_U_L":17},{"date":"2024-03-14","hemoglobin_g_dL":9.6,"wbc_k_uL":3.5,"platelets_k_uL":293,"creatinine_mg_dL":1.43,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_2358","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":61,"sex":"male","bmi":19.8,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-32},"pfs_months":8.31},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":17.8,"censored":true},"longitudinal_labs":[{"date":"2024-12-10","hemoglobin_g_dL":15.3,"wbc_k_uL":5.9,"platelets_k_uL":184,"creatinine_mg_dL":1.05,"alt_U_L":32},{"date":"2025-07-10","hemoglobin_g_dL":10.1,"wbc_k_uL":7.2,"platelets_k_uL":302,"creatinine_mg_dL":1.11,"alt_U_L":84},{"date":"2025-10-06","hemoglobin_g_dL":11.2,"wbc_k_uL":4.1,"platelets_k_uL":196,"creatinine_mg_dL":1.46,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_2359","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":84,"sex":"female","bmi":30.5,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-05-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-47},"pfs_months":45.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":57.6,"censored":true},"longitudinal_labs":[{"date":"2020-04-17","hemoglobin_g_dL":13.0,"wbc_k_uL":6.8,"platelets_k_uL":363,"creatinine_mg_dL":0.92,"alt_U_L":55},{"date":"2020-11-03","hemoglobin_g_dL":13.1,"wbc_k_uL":8.4,"platelets_k_uL":292,"creatinine_mg_dL":1.38,"alt_U_L":41},{"date":"2024-03-02","hemoglobin_g_dL":11.2,"wbc_k_uL":3.2,"platelets_k_uL":173,"creatinine_mg_dL":1.95,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_2360","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":53,"sex":"male","bmi":23.8,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-07-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-46},"pfs_months":48.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":59.9,"censored":true},"longitudinal_labs":[{"date":"2020-05-11","hemoglobin_g_dL":14.4,"wbc_k_uL":5.3,"platelets_k_uL":272,"creatinine_mg_dL":1.29,"alt_U_L":44},{"date":"2020-12-29","hemoglobin_g_dL":12.0,"wbc_k_uL":4.8,"platelets_k_uL":129,"creatinine_mg_dL":0.8,"alt_U_L":15},{"date":"2024-07-10","hemoglobin_g_dL":10.1,"wbc_k_uL":4.6,"platelets_k_uL":156,"creatinine_mg_dL":1.64,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_2361","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":88,"sex":"male","bmi":19.3,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-44},"pfs_months":36.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":56.5,"censored":true},"longitudinal_labs":[{"date":"2025-10-28","hemoglobin_g_dL":15.1,"wbc_k_uL":8.0,"platelets_k_uL":277,"creatinine_mg_dL":1.17,"alt_U_L":72},{"date":"2026-06-16","hemoglobin_g_dL":11.1,"wbc_k_uL":8.5,"platelets_k_uL":306,"creatinine_mg_dL":1.24,"alt_U_L":107},{"date":"2029-01-01","hemoglobin_g_dL":12.9,"wbc_k_uL":4.0,"platelets_k_uL":154,"creatinine_mg_dL":1.49,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_2362","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":75,"sex":"female","bmi":18.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-34},"pfs_months":16.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":false},"longitudinal_labs":[{"date":"2021-03-19","hemoglobin_g_dL":14.8,"wbc_k_uL":10.4,"platelets_k_uL":181,"creatinine_mg_dL":0.94,"alt_U_L":70},{"date":"2021-11-11","hemoglobin_g_dL":14.0,"wbc_k_uL":6.7,"platelets_k_uL":359,"creatinine_mg_dL":1.18,"alt_U_L":69},{"date":"2022-09-26","hemoglobin_g_dL":10.2,"wbc_k_uL":7.9,"platelets_k_uL":235,"creatinine_mg_dL":1.7,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_2363","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":66,"sex":"female","bmi":34.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-51},"pfs_months":32.07},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.2,"censored":false},"longitudinal_labs":[{"date":"2022-10-01","hemoglobin_g_dL":13.4,"wbc_k_uL":6.2,"platelets_k_uL":257,"creatinine_mg_dL":0.99,"alt_U_L":18},{"date":"2023-06-05","hemoglobin_g_dL":10.4,"wbc_k_uL":4.2,"platelets_k_uL":178,"creatinine_mg_dL":1.12,"alt_U_L":102},{"date":"2025-08-24","hemoglobin_g_dL":10.4,"wbc_k_uL":6.6,"platelets_k_uL":157,"creatinine_mg_dL":0.87,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_2364","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":72,"sex":"female","bmi":31.3,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-10-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-73},"pfs_months":44.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":70.9,"censored":false},"longitudinal_labs":[{"date":"2021-10-06","hemoglobin_g_dL":15.3,"wbc_k_uL":7.7,"platelets_k_uL":415,"creatinine_mg_dL":1.03,"alt_U_L":41},{"date":"2022-04-18","hemoglobin_g_dL":10.2,"wbc_k_uL":6.4,"platelets_k_uL":307,"creatinine_mg_dL":0.89,"alt_U_L":20},{"date":"2025-07-30","hemoglobin_g_dL":13.0,"wbc_k_uL":4.7,"platelets_k_uL":214,"creatinine_mg_dL":0.81,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_2365","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":82,"sex":"female","bmi":33.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-12-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-54},"pfs_months":12.12},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":22.3,"censored":false},"longitudinal_labs":[{"date":"2021-10-17","hemoglobin_g_dL":12.4,"wbc_k_uL":9.5,"platelets_k_uL":377,"creatinine_mg_dL":0.75,"alt_U_L":34},{"date":"2022-06-12","hemoglobin_g_dL":13.9,"wbc_k_uL":8.7,"platelets_k_uL":132,"creatinine_mg_dL":1.5,"alt_U_L":95},{"date":"2023-02-11","hemoglobin_g_dL":12.7,"wbc_k_uL":3.8,"platelets_k_uL":164,"creatinine_mg_dL":1.09,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_2366","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":55,"sex":"male","bmi":19.8,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-03-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-62},"pfs_months":12.06},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":false},"longitudinal_labs":[{"date":"2025-02-09","hemoglobin_g_dL":13.3,"wbc_k_uL":8.7,"platelets_k_uL":288,"creatinine_mg_dL":0.84,"alt_U_L":32},{"date":"2025-09-23","hemoglobin_g_dL":12.8,"wbc_k_uL":5.8,"platelets_k_uL":137,"creatinine_mg_dL":0.7,"alt_U_L":108},{"date":"2026-04-23","hemoglobin_g_dL":12.9,"wbc_k_uL":3.7,"platelets_k_uL":185,"creatinine_mg_dL":1.99,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_2367","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":74,"sex":"male","bmi":18.5,"smoking_pack_years":45,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-11-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-40},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":6.9,"censored":true},"longitudinal_labs":[{"date":"2024-09-13","hemoglobin_g_dL":13.2,"wbc_k_uL":7.1,"platelets_k_uL":257,"creatinine_mg_dL":1.08,"alt_U_L":18},{"date":"2025-05-06","hemoglobin_g_dL":11.5,"wbc_k_uL":4.9,"platelets_k_uL":378,"creatinine_mg_dL":1.04,"alt_U_L":100},{"date":"2025-04-03","hemoglobin_g_dL":9.8,"wbc_k_uL":6.6,"platelets_k_uL":130,"creatinine_mg_dL":1.37,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_2368","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":73,"sex":"male","bmi":24.1,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-08-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-67},"pfs_months":8.97},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.8,"censored":false},"longitudinal_labs":[{"date":"2024-08-08","hemoglobin_g_dL":13.3,"wbc_k_uL":4.6,"platelets_k_uL":347,"creatinine_mg_dL":0.92,"alt_U_L":20},{"date":"2025-02-26","hemoglobin_g_dL":10.1,"wbc_k_uL":5.0,"platelets_k_uL":129,"creatinine_mg_dL":0.98,"alt_U_L":108},{"date":"2025-07-20","hemoglobin_g_dL":12.3,"wbc_k_uL":5.4,"platelets_k_uL":146,"creatinine_mg_dL":1.62,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_2369","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":79,"sex":"female","bmi":30.9,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-51},"pfs_months":30.78},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.7,"censored":true},"longitudinal_labs":[{"date":"2024-07-24","hemoglobin_g_dL":11.9,"wbc_k_uL":7.1,"platelets_k_uL":275,"creatinine_mg_dL":0.77,"alt_U_L":61},{"date":"2025-03-19","hemoglobin_g_dL":12.3,"wbc_k_uL":8.7,"platelets_k_uL":199,"creatinine_mg_dL":1.25,"alt_U_L":26},{"date":"2027-05-10","hemoglobin_g_dL":10.5,"wbc_k_uL":5.9,"platelets_k_uL":235,"creatinine_mg_dL":1.35,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_2370","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":53,"sex":"female","bmi":34.3,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-12-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-75},"pfs_months":14.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.3,"censored":false},"longitudinal_labs":[{"date":"2022-12-01","hemoglobin_g_dL":14.7,"wbc_k_uL":8.9,"platelets_k_uL":309,"creatinine_mg_dL":0.99,"alt_U_L":50},{"date":"2023-06-18","hemoglobin_g_dL":11.3,"wbc_k_uL":8.0,"platelets_k_uL":351,"creatinine_mg_dL":1.47,"alt_U_L":15},{"date":"2024-03-13","hemoglobin_g_dL":9.5,"wbc_k_uL":8.0,"platelets_k_uL":330,"creatinine_mg_dL":1.76,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_2371","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":57,"sex":"male","bmi":21.1,"smoking_pack_years":33,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-08-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-74},"pfs_months":28.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.6,"censored":false},"longitudinal_labs":[{"date":"2024-07-13","hemoglobin_g_dL":12.5,"wbc_k_uL":9.6,"platelets_k_uL":449,"creatinine_mg_dL":0.68,"alt_U_L":22},{"date":"2025-02-25","hemoglobin_g_dL":13.7,"wbc_k_uL":4.5,"platelets_k_uL":358,"creatinine_mg_dL":1.27,"alt_U_L":59},{"date":"2027-02-13","hemoglobin_g_dL":12.7,"wbc_k_uL":4.8,"platelets_k_uL":276,"creatinine_mg_dL":1.64,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_2372","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":88,"sex":"male","bmi":27.6,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-02-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-34},"pfs_months":35.81},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":50.6,"censored":true},"longitudinal_labs":[{"date":"2021-12-05","hemoglobin_g_dL":13.6,"wbc_k_uL":9.6,"platelets_k_uL":371,"creatinine_mg_dL":1.02,"alt_U_L":25},{"date":"2022-08-05","hemoglobin_g_dL":12.6,"wbc_k_uL":5.8,"platelets_k_uL":176,"creatinine_mg_dL":0.99,"alt_U_L":83},{"date":"2025-03-24","hemoglobin_g_dL":10.4,"wbc_k_uL":3.4,"platelets_k_uL":148,"creatinine_mg_dL":1.84,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_2373","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":49,"sex":"female","bmi":31.3,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2024-08-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-47},"pfs_months":21.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.9,"censored":false},"longitudinal_labs":[{"date":"2024-06-12","hemoglobin_g_dL":12.0,"wbc_k_uL":4.8,"platelets_k_uL":232,"creatinine_mg_dL":0.93,"alt_U_L":21},{"date":"2025-02-02","hemoglobin_g_dL":13.5,"wbc_k_uL":6.6,"platelets_k_uL":309,"creatinine_mg_dL":1.05,"alt_U_L":87},{"date":"2026-07-07","hemoglobin_g_dL":9.6,"wbc_k_uL":5.0,"platelets_k_uL":194,"creatinine_mg_dL":1.78,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_2374","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":74,"sex":"female","bmi":25.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-43},"pfs_months":24.31},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.7,"censored":false},"longitudinal_labs":[{"date":"2020-04-06","hemoglobin_g_dL":12.7,"wbc_k_uL":7.4,"platelets_k_uL":444,"creatinine_mg_dL":0.7,"alt_U_L":76},{"date":"2020-12-08","hemoglobin_g_dL":12.5,"wbc_k_uL":8.3,"platelets_k_uL":208,"creatinine_mg_dL":0.72,"alt_U_L":27},{"date":"2022-07-16","hemoglobin_g_dL":12.6,"wbc_k_uL":5.5,"platelets_k_uL":321,"creatinine_mg_dL":1.59,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_2375","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":87,"sex":"female","bmi":26.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-37},"pfs_months":13.47},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.9,"censored":false},"longitudinal_labs":[{"date":"2025-02-16","hemoglobin_g_dL":14.0,"wbc_k_uL":7.8,"platelets_k_uL":383,"creatinine_mg_dL":1.06,"alt_U_L":44},{"date":"2025-10-08","hemoglobin_g_dL":11.0,"wbc_k_uL":6.0,"platelets_k_uL":312,"creatinine_mg_dL":0.93,"alt_U_L":78},{"date":"2026-07-04","hemoglobin_g_dL":10.0,"wbc_k_uL":5.2,"platelets_k_uL":199,"creatinine_mg_dL":1.16,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_2376","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":56,"sex":"female","bmi":21.8,"smoking_pack_years":79,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-72},"pfs_months":38.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":58.5,"censored":false},"longitudinal_labs":[{"date":"2021-04-03","hemoglobin_g_dL":14.5,"wbc_k_uL":5.1,"platelets_k_uL":412,"creatinine_mg_dL":0.74,"alt_U_L":12},{"date":"2021-12-06","hemoglobin_g_dL":13.7,"wbc_k_uL":4.4,"platelets_k_uL":304,"creatinine_mg_dL":1.37,"alt_U_L":74},{"date":"2024-10-09","hemoglobin_g_dL":9.9,"wbc_k_uL":5.2,"platelets_k_uL":316,"creatinine_mg_dL":1.23,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_2377","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":79,"sex":"male","bmi":22.6,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-78},"pfs_months":22.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.6,"censored":false},"longitudinal_labs":[{"date":"2023-05-25","hemoglobin_g_dL":15.2,"wbc_k_uL":6.3,"platelets_k_uL":241,"creatinine_mg_dL":0.63,"alt_U_L":19},{"date":"2024-01-03","hemoglobin_g_dL":13.7,"wbc_k_uL":4.6,"platelets_k_uL":138,"creatinine_mg_dL":1.2,"alt_U_L":100},{"date":"2025-06-23","hemoglobin_g_dL":10.9,"wbc_k_uL":6.1,"platelets_k_uL":188,"creatinine_mg_dL":1.65,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_2378","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":54,"sex":"female","bmi":34.5,"smoking_pack_years":20,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-07-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-60},"pfs_months":40.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.1,"censored":false},"longitudinal_labs":[{"date":"2025-05-19","hemoglobin_g_dL":12.9,"wbc_k_uL":10.0,"platelets_k_uL":342,"creatinine_mg_dL":1.08,"alt_U_L":24},{"date":"2026-01-19","hemoglobin_g_dL":11.6,"wbc_k_uL":7.5,"platelets_k_uL":373,"creatinine_mg_dL":1.14,"alt_U_L":65},{"date":"2029-01-28","hemoglobin_g_dL":12.4,"wbc_k_uL":5.1,"platelets_k_uL":127,"creatinine_mg_dL":1.03,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_2379","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":57,"sex":"female","bmi":32.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-65},"pfs_months":28.12},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":false},"longitudinal_labs":[{"date":"2022-10-18","hemoglobin_g_dL":12.2,"wbc_k_uL":10.1,"platelets_k_uL":443,"creatinine_mg_dL":0.89,"alt_U_L":76},{"date":"2023-05-24","hemoglobin_g_dL":10.9,"wbc_k_uL":7.3,"platelets_k_uL":241,"creatinine_mg_dL":1.36,"alt_U_L":93},{"date":"2025-05-12","hemoglobin_g_dL":10.7,"wbc_k_uL":6.4,"platelets_k_uL":185,"creatinine_mg_dL":1.72,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_2380","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":59,"sex":"male","bmi":23.4,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-35},"pfs_months":33.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.5,"censored":true},"longitudinal_labs":[{"date":"2023-08-18","hemoglobin_g_dL":13.6,"wbc_k_uL":9.3,"platelets_k_uL":310,"creatinine_mg_dL":1.12,"alt_U_L":30},{"date":"2024-03-13","hemoglobin_g_dL":13.3,"wbc_k_uL":4.2,"platelets_k_uL":299,"creatinine_mg_dL":1.33,"alt_U_L":44},{"date":"2026-08-13","hemoglobin_g_dL":11.5,"wbc_k_uL":5.1,"platelets_k_uL":273,"creatinine_mg_dL":1.25,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_2381","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":49,"sex":"female","bmi":30.6,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["bone","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-12-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-34},"pfs_months":38.37},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":59.5,"censored":false},"longitudinal_labs":[{"date":"2021-11-05","hemoglobin_g_dL":14.8,"wbc_k_uL":10.7,"platelets_k_uL":186,"creatinine_mg_dL":1.23,"alt_U_L":49},{"date":"2022-06-06","hemoglobin_g_dL":10.4,"wbc_k_uL":8.4,"platelets_k_uL":303,"creatinine_mg_dL":1.11,"alt_U_L":98},{"date":"2025-03-25","hemoglobin_g_dL":11.8,"wbc_k_uL":7.7,"platelets_k_uL":137,"creatinine_mg_dL":1.81,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_2382","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":54,"sex":"male","bmi":35.6,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-47},"pfs_months":21.13},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.2,"censored":false},"longitudinal_labs":[{"date":"2023-03-02","hemoglobin_g_dL":12.0,"wbc_k_uL":6.6,"platelets_k_uL":197,"creatinine_mg_dL":0.64,"alt_U_L":74},{"date":"2023-11-02","hemoglobin_g_dL":11.0,"wbc_k_uL":6.0,"platelets_k_uL":336,"creatinine_mg_dL":1.32,"alt_U_L":43},{"date":"2025-03-21","hemoglobin_g_dL":12.0,"wbc_k_uL":3.9,"platelets_k_uL":173,"creatinine_mg_dL":1.72,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_2383","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":82,"sex":"female","bmi":31.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-52},"pfs_months":23.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.1,"censored":true},"longitudinal_labs":[{"date":"2021-10-26","hemoglobin_g_dL":13.7,"wbc_k_uL":7.2,"platelets_k_uL":429,"creatinine_mg_dL":0.65,"alt_U_L":50},{"date":"2022-05-21","hemoglobin_g_dL":11.5,"wbc_k_uL":4.0,"platelets_k_uL":253,"creatinine_mg_dL":1.16,"alt_U_L":78},{"date":"2023-11-28","hemoglobin_g_dL":12.9,"wbc_k_uL":7.6,"platelets_k_uL":100,"creatinine_mg_dL":1.29,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_2384","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.8,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":83,"sex":"female","bmi":32.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-80},"pfs_months":28.45},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":49.1,"censored":false},"longitudinal_labs":[{"date":"2024-03-10","hemoglobin_g_dL":12.5,"wbc_k_uL":9.8,"platelets_k_uL":254,"creatinine_mg_dL":1.26,"alt_U_L":15},{"date":"2024-10-24","hemoglobin_g_dL":12.8,"wbc_k_uL":7.7,"platelets_k_uL":294,"creatinine_mg_dL":1.37,"alt_U_L":94},{"date":"2026-10-05","hemoglobin_g_dL":11.5,"wbc_k_uL":6.5,"platelets_k_uL":239,"creatinine_mg_dL":1.0,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_2385","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":52,"sex":"female","bmi":19.5,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-62},"pfs_months":14.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":23.1,"censored":false},"longitudinal_labs":[{"date":"2020-06-21","hemoglobin_g_dL":12.8,"wbc_k_uL":7.1,"platelets_k_uL":321,"creatinine_mg_dL":1.01,"alt_U_L":18},{"date":"2021-01-10","hemoglobin_g_dL":11.2,"wbc_k_uL":8.6,"platelets_k_uL":365,"creatinine_mg_dL":1.47,"alt_U_L":80},{"date":"2021-09-29","hemoglobin_g_dL":9.7,"wbc_k_uL":7.0,"platelets_k_uL":116,"creatinine_mg_dL":1.58,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_2386","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":86,"sex":"male","bmi":37.5,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-09-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-55},"pfs_months":19.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.5,"censored":false},"longitudinal_labs":[{"date":"2023-08-28","hemoglobin_g_dL":12.2,"wbc_k_uL":10.0,"platelets_k_uL":311,"creatinine_mg_dL":0.71,"alt_U_L":66},{"date":"2024-03-19","hemoglobin_g_dL":10.2,"wbc_k_uL":4.2,"platelets_k_uL":171,"creatinine_mg_dL":0.72,"alt_U_L":105},{"date":"2025-05-17","hemoglobin_g_dL":11.6,"wbc_k_uL":5.2,"platelets_k_uL":253,"creatinine_mg_dL":0.95,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_2387","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":84,"sex":"female","bmi":31.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-03-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-31},"pfs_months":22.6},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.8,"censored":true},"longitudinal_labs":[{"date":"2020-02-13","hemoglobin_g_dL":14.6,"wbc_k_uL":6.7,"platelets_k_uL":432,"creatinine_mg_dL":0.9,"alt_U_L":76},{"date":"2020-09-25","hemoglobin_g_dL":13.2,"wbc_k_uL":4.2,"platelets_k_uL":192,"creatinine_mg_dL":1.54,"alt_U_L":87},{"date":"2022-03-11","hemoglobin_g_dL":10.7,"wbc_k_uL":6.0,"platelets_k_uL":287,"creatinine_mg_dL":1.79,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_2388","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":48,"sex":"male","bmi":24.6,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-01-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-47},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":12.1,"censored":true},"longitudinal_labs":[{"date":"2022-12-25","hemoglobin_g_dL":11.5,"wbc_k_uL":6.8,"platelets_k_uL":181,"creatinine_mg_dL":1.14,"alt_U_L":54},{"date":"2023-07-18","hemoglobin_g_dL":12.9,"wbc_k_uL":6.8,"platelets_k_uL":340,"creatinine_mg_dL":1.6,"alt_U_L":34},{"date":"2023-05-30","hemoglobin_g_dL":9.8,"wbc_k_uL":7.9,"platelets_k_uL":158,"creatinine_mg_dL":0.99,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_2389","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":76,"sex":"female","bmi":32.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-83},"pfs_months":24.31},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.2,"censored":false},"longitudinal_labs":[{"date":"2021-01-09","hemoglobin_g_dL":15.2,"wbc_k_uL":10.6,"platelets_k_uL":266,"creatinine_mg_dL":0.8,"alt_U_L":46},{"date":"2021-08-14","hemoglobin_g_dL":10.0,"wbc_k_uL":5.6,"platelets_k_uL":244,"creatinine_mg_dL":1.36,"alt_U_L":92},{"date":"2023-03-05","hemoglobin_g_dL":11.1,"wbc_k_uL":6.6,"platelets_k_uL":261,"creatinine_mg_dL":1.91,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_2390","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":86,"sex":"male","bmi":35.2,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-04-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-53},"pfs_months":39.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":57.4,"censored":true},"longitudinal_labs":[{"date":"2024-03-07","hemoglobin_g_dL":14.0,"wbc_k_uL":10.4,"platelets_k_uL":313,"creatinine_mg_dL":1.26,"alt_U_L":36},{"date":"2024-10-21","hemoglobin_g_dL":12.9,"wbc_k_uL":4.5,"platelets_k_uL":201,"creatinine_mg_dL":1.29,"alt_U_L":66},{"date":"2027-10-15","hemoglobin_g_dL":11.5,"wbc_k_uL":5.6,"platelets_k_uL":117,"creatinine_mg_dL":0.84,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_2391","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":55,"sex":"female","bmi":28.1,"smoking_pack_years":29,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-10-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-54},"pfs_months":42.87},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":66.7,"censored":false},"longitudinal_labs":[{"date":"2020-08-27","hemoglobin_g_dL":15.3,"wbc_k_uL":5.2,"platelets_k_uL":213,"creatinine_mg_dL":0.69,"alt_U_L":64},{"date":"2021-04-29","hemoglobin_g_dL":12.8,"wbc_k_uL":5.9,"platelets_k_uL":303,"creatinine_mg_dL":1.21,"alt_U_L":90},{"date":"2024-06-19","hemoglobin_g_dL":11.6,"wbc_k_uL":5.1,"platelets_k_uL":170,"creatinine_mg_dL":1.73,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_2392","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":61,"sex":"male","bmi":33.8,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-68},"pfs_months":6.54},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.5,"censored":false},"longitudinal_labs":[{"date":"2025-01-12","hemoglobin_g_dL":13.1,"wbc_k_uL":9.8,"platelets_k_uL":255,"creatinine_mg_dL":0.81,"alt_U_L":32},{"date":"2025-09-14","hemoglobin_g_dL":11.9,"wbc_k_uL":6.9,"platelets_k_uL":345,"creatinine_mg_dL":0.84,"alt_U_L":89},{"date":"2025-10-25","hemoglobin_g_dL":11.8,"wbc_k_uL":3.2,"platelets_k_uL":308,"creatinine_mg_dL":0.91,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_2393","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":65,"sex":"male","bmi":33.9,"smoking_pack_years":37,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-04-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-64},"pfs_months":15.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.5,"censored":true},"longitudinal_labs":[{"date":"2022-02-15","hemoglobin_g_dL":15.5,"wbc_k_uL":9.9,"platelets_k_uL":211,"creatinine_mg_dL":0.65,"alt_U_L":43},{"date":"2022-10-19","hemoglobin_g_dL":13.2,"wbc_k_uL":7.2,"platelets_k_uL":332,"creatinine_mg_dL":0.77,"alt_U_L":65},{"date":"2023-09-18","hemoglobin_g_dL":11.8,"wbc_k_uL":3.1,"platelets_k_uL":124,"creatinine_mg_dL":0.91,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_2394","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":61,"sex":"male","bmi":34.0,"smoking_pack_years":63,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-32},"pfs_months":16.3},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.5,"censored":false},"longitudinal_labs":[{"date":"2020-05-02","hemoglobin_g_dL":12.2,"wbc_k_uL":4.9,"platelets_k_uL":427,"creatinine_mg_dL":0.95,"alt_U_L":55},{"date":"2021-01-05","hemoglobin_g_dL":13.7,"wbc_k_uL":7.4,"platelets_k_uL":378,"creatinine_mg_dL":1.45,"alt_U_L":107},{"date":"2021-12-25","hemoglobin_g_dL":12.6,"wbc_k_uL":3.1,"platelets_k_uL":319,"creatinine_mg_dL":1.64,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_2395","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":50,"sex":"female","bmi":19.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-76},"pfs_months":11.66},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":15.6,"censored":false},"longitudinal_labs":[{"date":"2022-08-11","hemoglobin_g_dL":12.4,"wbc_k_uL":10.8,"platelets_k_uL":151,"creatinine_mg_dL":0.61,"alt_U_L":12},{"date":"2023-04-05","hemoglobin_g_dL":13.6,"wbc_k_uL":6.7,"platelets_k_uL":370,"creatinine_mg_dL":1.33,"alt_U_L":16},{"date":"2023-11-24","hemoglobin_g_dL":12.1,"wbc_k_uL":3.2,"platelets_k_uL":243,"creatinine_mg_dL":1.69,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_2396","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":81,"sex":"female","bmi":25.1,"smoking_pack_years":63,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-10-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-70},"pfs_months":42.48},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.5,"censored":false},"longitudinal_labs":[{"date":"2023-08-01","hemoglobin_g_dL":11.8,"wbc_k_uL":5.3,"platelets_k_uL":386,"creatinine_mg_dL":1.3,"alt_U_L":24},{"date":"2024-04-03","hemoglobin_g_dL":10.1,"wbc_k_uL":7.6,"platelets_k_uL":277,"creatinine_mg_dL":1.4,"alt_U_L":48},{"date":"2027-05-09","hemoglobin_g_dL":9.6,"wbc_k_uL":5.6,"platelets_k_uL":228,"creatinine_mg_dL":1.54,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_2397","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":77,"sex":"female","bmi":29.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-02-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-51},"pfs_months":27.14},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.4,"censored":true},"longitudinal_labs":[{"date":"2022-01-12","hemoglobin_g_dL":15.1,"wbc_k_uL":8.1,"platelets_k_uL":335,"creatinine_mg_dL":1.12,"alt_U_L":56},{"date":"2022-08-17","hemoglobin_g_dL":10.5,"wbc_k_uL":4.4,"platelets_k_uL":361,"creatinine_mg_dL":0.77,"alt_U_L":118},{"date":"2024-06-08","hemoglobin_g_dL":12.2,"wbc_k_uL":3.4,"platelets_k_uL":197,"creatinine_mg_dL":1.65,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_2398","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":82,"sex":"female","bmi":22.5,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-04-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-48},"pfs_months":27.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":51.8,"censored":false},"longitudinal_labs":[{"date":"2023-02-18","hemoglobin_g_dL":13.6,"wbc_k_uL":7.7,"platelets_k_uL":428,"creatinine_mg_dL":1.06,"alt_U_L":52},{"date":"2023-10-03","hemoglobin_g_dL":13.4,"wbc_k_uL":7.1,"platelets_k_uL":223,"creatinine_mg_dL":0.75,"alt_U_L":81},{"date":"2025-08-28","hemoglobin_g_dL":11.9,"wbc_k_uL":4.4,"platelets_k_uL":145,"creatinine_mg_dL":0.84,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_2399","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":69,"sex":"male","bmi":29.2,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-38},"pfs_months":9.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":13.7,"censored":false},"longitudinal_labs":[{"date":"2024-03-24","hemoglobin_g_dL":14.7,"wbc_k_uL":9.6,"platelets_k_uL":174,"creatinine_mg_dL":0.98,"alt_U_L":71},{"date":"2024-10-08","hemoglobin_g_dL":10.7,"wbc_k_uL":8.1,"platelets_k_uL":302,"creatinine_mg_dL":1.5,"alt_U_L":34},{"date":"2025-03-20","hemoglobin_g_dL":11.9,"wbc_k_uL":7.6,"platelets_k_uL":137,"creatinine_mg_dL":1.02,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_2400","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":85,"sex":"female","bmi":27.6,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-09-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-33},"pfs_months":12.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":false},"longitudinal_labs":[{"date":"2024-07-23","hemoglobin_g_dL":13.2,"wbc_k_uL":5.0,"platelets_k_uL":168,"creatinine_mg_dL":0.85,"alt_U_L":61},{"date":"2025-03-10","hemoglobin_g_dL":11.8,"wbc_k_uL":5.8,"platelets_k_uL":228,"creatinine_mg_dL":1.57,"alt_U_L":119},{"date":"2025-10-23","hemoglobin_g_dL":10.6,"wbc_k_uL":4.5,"platelets_k_uL":338,"creatinine_mg_dL":1.12,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_2401","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":84,"sex":"female","bmi":34.5,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-36},"pfs_months":33.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":52.6,"censored":true},"longitudinal_labs":[{"date":"2023-09-27","hemoglobin_g_dL":11.7,"wbc_k_uL":9.3,"platelets_k_uL":170,"creatinine_mg_dL":1.29,"alt_U_L":19},{"date":"2024-05-09","hemoglobin_g_dL":13.6,"wbc_k_uL":9.0,"platelets_k_uL":133,"creatinine_mg_dL":1.23,"alt_U_L":113},{"date":"2026-09-14","hemoglobin_g_dL":9.6,"wbc_k_uL":3.3,"platelets_k_uL":301,"creatinine_mg_dL":0.94,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_2402","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":85,"sex":"female","bmi":21.1,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-10-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-38},"pfs_months":20.6},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.4,"censored":false},"longitudinal_labs":[{"date":"2025-08-19","hemoglobin_g_dL":12.1,"wbc_k_uL":10.6,"platelets_k_uL":437,"creatinine_mg_dL":1.3,"alt_U_L":15},{"date":"2026-04-25","hemoglobin_g_dL":12.1,"wbc_k_uL":6.7,"platelets_k_uL":301,"creatinine_mg_dL":1.37,"alt_U_L":33},{"date":"2027-08-29","hemoglobin_g_dL":11.4,"wbc_k_uL":5.3,"platelets_k_uL":196,"creatinine_mg_dL":1.51,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_2403","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":73,"sex":"female","bmi":22.5,"smoking_pack_years":79,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-01-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-84},"pfs_months":19.71},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.3,"censored":false},"longitudinal_labs":[{"date":"2024-12-02","hemoglobin_g_dL":14.9,"wbc_k_uL":6.9,"platelets_k_uL":196,"creatinine_mg_dL":1.29,"alt_U_L":26},{"date":"2025-07-18","hemoglobin_g_dL":10.7,"wbc_k_uL":8.2,"platelets_k_uL":321,"creatinine_mg_dL":1.43,"alt_U_L":62},{"date":"2026-09-26","hemoglobin_g_dL":11.8,"wbc_k_uL":4.7,"platelets_k_uL":107,"creatinine_mg_dL":1.34,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_2404","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":62,"sex":"male","bmi":31.6,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-06-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-47},"pfs_months":42.78},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":64.0,"censored":false},"longitudinal_labs":[{"date":"2025-04-22","hemoglobin_g_dL":14.6,"wbc_k_uL":9.1,"platelets_k_uL":424,"creatinine_mg_dL":0.97,"alt_U_L":50},{"date":"2025-12-12","hemoglobin_g_dL":12.4,"wbc_k_uL":8.8,"platelets_k_uL":202,"creatinine_mg_dL":0.97,"alt_U_L":15},{"date":"2029-01-27","hemoglobin_g_dL":11.5,"wbc_k_uL":5.3,"platelets_k_uL":151,"creatinine_mg_dL":1.16,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_2405","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":85,"sex":"female","bmi":30.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-69},"pfs_months":27.14},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.8,"censored":false},"longitudinal_labs":[{"date":"2022-05-14","hemoglobin_g_dL":14.5,"wbc_k_uL":9.7,"platelets_k_uL":319,"creatinine_mg_dL":0.74,"alt_U_L":49},{"date":"2023-01-01","hemoglobin_g_dL":13.5,"wbc_k_uL":5.5,"platelets_k_uL":354,"creatinine_mg_dL":1.45,"alt_U_L":112},{"date":"2024-12-03","hemoglobin_g_dL":10.2,"wbc_k_uL":3.0,"platelets_k_uL":272,"creatinine_mg_dL":1.53,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_2406","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":80,"sex":"male","bmi":29.9,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-08-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-32},"pfs_months":36.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":59.2,"censored":false},"longitudinal_labs":[{"date":"2021-06-24","hemoglobin_g_dL":12.0,"wbc_k_uL":8.7,"platelets_k_uL":195,"creatinine_mg_dL":0.84,"alt_U_L":13},{"date":"2022-02-10","hemoglobin_g_dL":11.7,"wbc_k_uL":7.4,"platelets_k_uL":267,"creatinine_mg_dL":1.57,"alt_U_L":39},{"date":"2024-10-26","hemoglobin_g_dL":11.2,"wbc_k_uL":4.9,"platelets_k_uL":344,"creatinine_mg_dL":1.99,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_2407","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":67,"sex":"female","bmi":29.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-04-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-82},"pfs_months":14.19},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.7,"censored":false},"longitudinal_labs":[{"date":"2022-02-22","hemoglobin_g_dL":14.0,"wbc_k_uL":7.2,"platelets_k_uL":272,"creatinine_mg_dL":1.09,"alt_U_L":42},{"date":"2022-10-01","hemoglobin_g_dL":11.2,"wbc_k_uL":6.6,"platelets_k_uL":239,"creatinine_mg_dL":1.24,"alt_U_L":105},{"date":"2023-06-26","hemoglobin_g_dL":11.6,"wbc_k_uL":3.2,"platelets_k_uL":219,"creatinine_mg_dL":1.67,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_2408","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":48,"sex":"female","bmi":32.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-83},"pfs_months":24.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.5,"censored":true},"longitudinal_labs":[{"date":"2025-11-11","hemoglobin_g_dL":12.4,"wbc_k_uL":8.5,"platelets_k_uL":272,"creatinine_mg_dL":0.69,"alt_U_L":71},{"date":"2026-06-20","hemoglobin_g_dL":13.6,"wbc_k_uL":7.1,"platelets_k_uL":230,"creatinine_mg_dL":1.53,"alt_U_L":45},{"date":"2028-02-08","hemoglobin_g_dL":11.2,"wbc_k_uL":6.6,"platelets_k_uL":319,"creatinine_mg_dL":1.11,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_2409","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":68,"sex":"female","bmi":28.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-38},"pfs_months":12.42},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.8,"censored":false},"longitudinal_labs":[{"date":"2021-02-17","hemoglobin_g_dL":15.5,"wbc_k_uL":6.7,"platelets_k_uL":227,"creatinine_mg_dL":0.95,"alt_U_L":80},{"date":"2021-08-31","hemoglobin_g_dL":12.7,"wbc_k_uL":4.2,"platelets_k_uL":172,"creatinine_mg_dL":1.0,"alt_U_L":36},{"date":"2022-05-05","hemoglobin_g_dL":12.5,"wbc_k_uL":5.5,"platelets_k_uL":257,"creatinine_mg_dL":1.18,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_2410","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":56,"sex":"female","bmi":37.4,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-82},"pfs_months":17.15},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.4,"censored":false},"longitudinal_labs":[{"date":"2023-01-20","hemoglobin_g_dL":13.7,"wbc_k_uL":7.5,"platelets_k_uL":353,"creatinine_mg_dL":1.02,"alt_U_L":28},{"date":"2023-08-22","hemoglobin_g_dL":11.2,"wbc_k_uL":8.0,"platelets_k_uL":360,"creatinine_mg_dL":0.86,"alt_U_L":43},{"date":"2024-08-12","hemoglobin_g_dL":11.3,"wbc_k_uL":7.4,"platelets_k_uL":197,"creatinine_mg_dL":1.12,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_2411","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":69,"sex":"female","bmi":19.1,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-01-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-51},"pfs_months":19.65},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.6,"censored":true},"longitudinal_labs":[{"date":"2022-11-20","hemoglobin_g_dL":13.3,"wbc_k_uL":6.0,"platelets_k_uL":283,"creatinine_mg_dL":0.87,"alt_U_L":34},{"date":"2023-07-01","hemoglobin_g_dL":12.0,"wbc_k_uL":4.4,"platelets_k_uL":229,"creatinine_mg_dL":0.95,"alt_U_L":90},{"date":"2024-09-06","hemoglobin_g_dL":12.0,"wbc_k_uL":3.4,"platelets_k_uL":209,"creatinine_mg_dL":0.92,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_2412","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":65,"sex":"female","bmi":35.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-53},"pfs_months":30.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.9,"censored":false},"longitudinal_labs":[{"date":"2021-09-15","hemoglobin_g_dL":14.1,"wbc_k_uL":9.2,"platelets_k_uL":446,"creatinine_mg_dL":0.81,"alt_U_L":12},{"date":"2022-04-23","hemoglobin_g_dL":10.8,"wbc_k_uL":6.6,"platelets_k_uL":318,"creatinine_mg_dL":1.01,"alt_U_L":113},{"date":"2024-06-16","hemoglobin_g_dL":11.4,"wbc_k_uL":6.4,"platelets_k_uL":282,"creatinine_mg_dL":1.83,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_2413","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":64,"sex":"male","bmi":20.1,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-32},"pfs_months":15.34},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":20.9,"censored":false},"longitudinal_labs":[{"date":"2025-06-05","hemoglobin_g_dL":12.1,"wbc_k_uL":4.8,"platelets_k_uL":280,"creatinine_mg_dL":0.83,"alt_U_L":41},{"date":"2026-01-27","hemoglobin_g_dL":11.9,"wbc_k_uL":5.4,"platelets_k_uL":138,"creatinine_mg_dL":1.21,"alt_U_L":111},{"date":"2026-11-25","hemoglobin_g_dL":12.5,"wbc_k_uL":5.9,"platelets_k_uL":299,"creatinine_mg_dL":1.26,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_2414","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":88,"sex":"male","bmi":30.5,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-01-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-33},"pfs_months":23.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.5,"censored":true},"longitudinal_labs":[{"date":"2021-12-14","hemoglobin_g_dL":12.0,"wbc_k_uL":8.2,"platelets_k_uL":382,"creatinine_mg_dL":1.11,"alt_U_L":20},{"date":"2022-07-11","hemoglobin_g_dL":12.0,"wbc_k_uL":4.1,"platelets_k_uL":179,"creatinine_mg_dL":1.01,"alt_U_L":117},{"date":"2024-01-04","hemoglobin_g_dL":9.5,"wbc_k_uL":4.8,"platelets_k_uL":298,"creatinine_mg_dL":1.13,"alt_U_L":34}]}
{"patient_id":"ANODE_SYNTH_2025_2415","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":52,"sex":"female","bmi":34.0,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-10-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-78},"pfs_months":33.31},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":53.8,"censored":true},"longitudinal_labs":[{"date":"2020-09-03","hemoglobin_g_dL":15.3,"wbc_k_uL":6.0,"platelets_k_uL":398,"creatinine_mg_dL":0.99,"alt_U_L":12},{"date":"2021-04-04","hemoglobin_g_dL":12.9,"wbc_k_uL":4.9,"platelets_k_uL":356,"creatinine_mg_dL":1.23,"alt_U_L":53},{"date":"2023-08-20","hemoglobin_g_dL":12.2,"wbc_k_uL":6.8,"platelets_k_uL":281,"creatinine_mg_dL":1.45,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_2416","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":60,"sex":"female","bmi":19.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-45},"pfs_months":21.09},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.7,"censored":false},"longitudinal_labs":[{"date":"2021-09-22","hemoglobin_g_dL":13.2,"wbc_k_uL":10.7,"platelets_k_uL":275,"creatinine_mg_dL":1.26,"alt_U_L":47},{"date":"2022-05-17","hemoglobin_g_dL":10.9,"wbc_k_uL":6.0,"platelets_k_uL":228,"creatinine_mg_dL":1.19,"alt_U_L":79},{"date":"2023-09-04","hemoglobin_g_dL":10.9,"wbc_k_uL":6.7,"platelets_k_uL":315,"creatinine_mg_dL":1.78,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_2417","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":64,"sex":"male","bmi":27.9,"smoking_pack_years":26,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-12-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-32},"pfs_months":31.7},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.7,"censored":true},"longitudinal_labs":[{"date":"2024-12-04","hemoglobin_g_dL":14.7,"wbc_k_uL":10.1,"platelets_k_uL":384,"creatinine_mg_dL":0.78,"alt_U_L":75},{"date":"2025-06-27","hemoglobin_g_dL":11.0,"wbc_k_uL":7.2,"platelets_k_uL":170,"creatinine_mg_dL":0.81,"alt_U_L":94},{"date":"2027-09-08","hemoglobin_g_dL":12.0,"wbc_k_uL":5.3,"platelets_k_uL":155,"creatinine_mg_dL":1.56,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_2418","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":54,"sex":"female","bmi":27.7,"smoking_pack_years":51,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-05-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-66},"pfs_months":27.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.6,"censored":true},"longitudinal_labs":[{"date":"2025-04-23","hemoglobin_g_dL":14.4,"wbc_k_uL":7.4,"platelets_k_uL":237,"creatinine_mg_dL":1.27,"alt_U_L":39},{"date":"2025-11-22","hemoglobin_g_dL":13.3,"wbc_k_uL":6.2,"platelets_k_uL":207,"creatinine_mg_dL":1.55,"alt_U_L":40},{"date":"2027-09-28","hemoglobin_g_dL":12.1,"wbc_k_uL":6.7,"platelets_k_uL":106,"creatinine_mg_dL":1.54,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_2419","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":18.0,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":86,"sex":"female","bmi":25.9,"smoking_pack_years":65,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-80},"pfs_months":28.58},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.3,"censored":false},"longitudinal_labs":[{"date":"2023-10-26","hemoglobin_g_dL":12.3,"wbc_k_uL":7.1,"platelets_k_uL":215,"creatinine_mg_dL":0.82,"alt_U_L":66},{"date":"2024-06-06","hemoglobin_g_dL":12.7,"wbc_k_uL":4.5,"platelets_k_uL":245,"creatinine_mg_dL":0.91,"alt_U_L":50},{"date":"2026-05-12","hemoglobin_g_dL":11.2,"wbc_k_uL":7.7,"platelets_k_uL":189,"creatinine_mg_dL":0.82,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_2420","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":52,"sex":"male","bmi":31.5,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-09-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-47},"pfs_months":21.19},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.6,"censored":false},"longitudinal_labs":[{"date":"2022-08-09","hemoglobin_g_dL":13.4,"wbc_k_uL":8.3,"platelets_k_uL":429,"creatinine_mg_dL":0.92,"alt_U_L":49},{"date":"2023-03-23","hemoglobin_g_dL":12.4,"wbc_k_uL":8.8,"platelets_k_uL":191,"creatinine_mg_dL":1.54,"alt_U_L":76},{"date":"2024-08-15","hemoglobin_g_dL":12.5,"wbc_k_uL":6.6,"platelets_k_uL":349,"creatinine_mg_dL":1.54,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_2421","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":78,"sex":"female","bmi":33.4,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-12-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-67},"pfs_months":11.56},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":false},"longitudinal_labs":[{"date":"2022-10-04","hemoglobin_g_dL":12.1,"wbc_k_uL":7.1,"platelets_k_uL":446,"creatinine_mg_dL":0.67,"alt_U_L":35},{"date":"2023-06-10","hemoglobin_g_dL":12.3,"wbc_k_uL":4.9,"platelets_k_uL":369,"creatinine_mg_dL":1.43,"alt_U_L":81},{"date":"2024-01-06","hemoglobin_g_dL":10.4,"wbc_k_uL":5.9,"platelets_k_uL":285,"creatinine_mg_dL":1.55,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2422","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":49,"sex":"female","bmi":23.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-36},"pfs_months":21.59},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":false},"longitudinal_labs":[{"date":"2021-03-25","hemoglobin_g_dL":15.2,"wbc_k_uL":8.2,"platelets_k_uL":216,"creatinine_mg_dL":0.71,"alt_U_L":39},{"date":"2021-11-24","hemoglobin_g_dL":11.0,"wbc_k_uL":6.4,"platelets_k_uL":346,"creatinine_mg_dL":1.45,"alt_U_L":84},{"date":"2023-04-07","hemoglobin_g_dL":12.0,"wbc_k_uL":6.1,"platelets_k_uL":238,"creatinine_mg_dL":1.11,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_2423","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":65,"sex":"female","bmi":34.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-02-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-66},"pfs_months":27.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.6,"censored":true},"longitudinal_labs":[{"date":"2020-01-07","hemoglobin_g_dL":12.8,"wbc_k_uL":4.8,"platelets_k_uL":219,"creatinine_mg_dL":1.12,"alt_U_L":23},{"date":"2020-08-11","hemoglobin_g_dL":11.7,"wbc_k_uL":3.9,"platelets_k_uL":313,"creatinine_mg_dL":0.77,"alt_U_L":110},{"date":"2022-07-29","hemoglobin_g_dL":10.8,"wbc_k_uL":4.0,"platelets_k_uL":284,"creatinine_mg_dL":0.87,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2424","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":72,"sex":"male","bmi":34.4,"smoking_pack_years":67,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-01-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-41},"pfs_months":36.11},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":61.3,"censored":false},"longitudinal_labs":[{"date":"2022-11-21","hemoglobin_g_dL":12.8,"wbc_k_uL":8.5,"platelets_k_uL":163,"creatinine_mg_dL":0.66,"alt_U_L":46},{"date":"2023-07-11","hemoglobin_g_dL":11.4,"wbc_k_uL":4.5,"platelets_k_uL":175,"creatinine_mg_dL":0.88,"alt_U_L":116},{"date":"2026-01-30","hemoglobin_g_dL":10.6,"wbc_k_uL":5.3,"platelets_k_uL":203,"creatinine_mg_dL":1.83,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_2425","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":50,"sex":"male","bmi":35.4,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-80},"pfs_months":51.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":77.0,"censored":false},"longitudinal_labs":[{"date":"2023-09-18","hemoglobin_g_dL":12.0,"wbc_k_uL":5.1,"platelets_k_uL":444,"creatinine_mg_dL":1.23,"alt_U_L":71},{"date":"2024-05-13","hemoglobin_g_dL":13.8,"wbc_k_uL":8.9,"platelets_k_uL":210,"creatinine_mg_dL":1.01,"alt_U_L":86},{"date":"2028-04-09","hemoglobin_g_dL":10.2,"wbc_k_uL":3.7,"platelets_k_uL":279,"creatinine_mg_dL":1.98,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_2426","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":87,"sex":"male","bmi":19.4,"smoking_pack_years":62,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-32},"pfs_months":14.06},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.3,"censored":false},"longitudinal_labs":[{"date":"2020-09-04","hemoglobin_g_dL":12.4,"wbc_k_uL":7.0,"platelets_k_uL":241,"creatinine_mg_dL":0.94,"alt_U_L":49},{"date":"2021-05-10","hemoglobin_g_dL":10.3,"wbc_k_uL":4.3,"platelets_k_uL":298,"creatinine_mg_dL":0.89,"alt_U_L":19},{"date":"2022-01-29","hemoglobin_g_dL":10.9,"wbc_k_uL":6.7,"platelets_k_uL":233,"creatinine_mg_dL":1.77,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_2427","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":59,"sex":"female","bmi":27.0,"smoking_pack_years":53,"ecog_performance_status":2,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-04-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-39},"pfs_months":23.95},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.8,"censored":false},"longitudinal_labs":[{"date":"2023-03-01","hemoglobin_g_dL":13.5,"wbc_k_uL":7.7,"platelets_k_uL":281,"creatinine_mg_dL":1.24,"alt_U_L":17},{"date":"2023-10-12","hemoglobin_g_dL":12.9,"wbc_k_uL":7.8,"platelets_k_uL":168,"creatinine_mg_dL":1.19,"alt_U_L":33},{"date":"2025-05-22","hemoglobin_g_dL":11.4,"wbc_k_uL":6.6,"platelets_k_uL":189,"creatinine_mg_dL":1.04,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_2428","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":59,"sex":"female","bmi":35.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-02-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-30},"pfs_months":20.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.0,"censored":true},"longitudinal_labs":[{"date":"2022-01-11","hemoglobin_g_dL":13.1,"wbc_k_uL":7.5,"platelets_k_uL":173,"creatinine_mg_dL":1.22,"alt_U_L":44},{"date":"2022-08-26","hemoglobin_g_dL":12.0,"wbc_k_uL":4.5,"platelets_k_uL":238,"creatinine_mg_dL":1.0,"alt_U_L":67},{"date":"2023-12-26","hemoglobin_g_dL":11.0,"wbc_k_uL":4.6,"platelets_k_uL":173,"creatinine_mg_dL":1.1,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_2429","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":66,"sex":"female","bmi":27.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-70},"pfs_months":21.26},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.6,"censored":false},"longitudinal_labs":[{"date":"2020-12-21","hemoglobin_g_dL":13.8,"wbc_k_uL":9.7,"platelets_k_uL":348,"creatinine_mg_dL":1.12,"alt_U_L":14},{"date":"2021-07-23","hemoglobin_g_dL":10.7,"wbc_k_uL":6.3,"platelets_k_uL":156,"creatinine_mg_dL":1.38,"alt_U_L":35},{"date":"2022-11-17","hemoglobin_g_dL":12.0,"wbc_k_uL":5.8,"platelets_k_uL":316,"creatinine_mg_dL":0.9,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_2430","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":70,"sex":"male","bmi":31.0,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-01-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-74},"pfs_months":11.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.0,"censored":false},"longitudinal_labs":[{"date":"2020-12-16","hemoglobin_g_dL":13.5,"wbc_k_uL":10.3,"platelets_k_uL":180,"creatinine_mg_dL":0.95,"alt_U_L":40},{"date":"2021-07-17","hemoglobin_g_dL":13.2,"wbc_k_uL":6.9,"platelets_k_uL":247,"creatinine_mg_dL":0.74,"alt_U_L":30},{"date":"2022-02-09","hemoglobin_g_dL":10.1,"wbc_k_uL":4.4,"platelets_k_uL":350,"creatinine_mg_dL":1.49,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_2431","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":56,"sex":"female","bmi":35.8,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-05-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-36},"pfs_months":42.12},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":64.6,"censored":false},"longitudinal_labs":[{"date":"2023-04-15","hemoglobin_g_dL":12.6,"wbc_k_uL":5.0,"platelets_k_uL":213,"creatinine_mg_dL":1.03,"alt_U_L":13},{"date":"2023-11-19","hemoglobin_g_dL":12.3,"wbc_k_uL":4.4,"platelets_k_uL":172,"creatinine_mg_dL":1.07,"alt_U_L":57},{"date":"2026-12-25","hemoglobin_g_dL":12.9,"wbc_k_uL":5.2,"platelets_k_uL":253,"creatinine_mg_dL":0.83,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_2432","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":86,"sex":"female","bmi":36.7,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-09-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-51},"pfs_months":8.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":17.9,"censored":true},"longitudinal_labs":[{"date":"2022-08-28","hemoglobin_g_dL":14.4,"wbc_k_uL":6.2,"platelets_k_uL":320,"creatinine_mg_dL":0.91,"alt_U_L":37},{"date":"2023-03-16","hemoglobin_g_dL":10.8,"wbc_k_uL":8.4,"platelets_k_uL":326,"creatinine_mg_dL":0.94,"alt_U_L":69},{"date":"2023-07-01","hemoglobin_g_dL":10.6,"wbc_k_uL":7.4,"platelets_k_uL":143,"creatinine_mg_dL":1.94,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_2433","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":53,"sex":"female","bmi":21.4,"smoking_pack_years":48,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-75},"pfs_months":44.19},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.6,"censored":false},"longitudinal_labs":[{"date":"2022-07-14","hemoglobin_g_dL":13.2,"wbc_k_uL":6.5,"platelets_k_uL":318,"creatinine_mg_dL":0.62,"alt_U_L":74},{"date":"2023-02-02","hemoglobin_g_dL":11.7,"wbc_k_uL":6.7,"platelets_k_uL":170,"creatinine_mg_dL":1.14,"alt_U_L":51},{"date":"2026-04-28","hemoglobin_g_dL":9.9,"wbc_k_uL":3.6,"platelets_k_uL":285,"creatinine_mg_dL":1.4,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_2434","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":72,"sex":"female","bmi":34.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-83},"pfs_months":27.5},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.2,"censored":false},"longitudinal_labs":[{"date":"2020-04-25","hemoglobin_g_dL":12.1,"wbc_k_uL":8.5,"platelets_k_uL":213,"creatinine_mg_dL":1.23,"alt_U_L":50},{"date":"2020-12-09","hemoglobin_g_dL":13.6,"wbc_k_uL":4.3,"platelets_k_uL":179,"creatinine_mg_dL":1.06,"alt_U_L":15},{"date":"2022-11-19","hemoglobin_g_dL":10.2,"wbc_k_uL":7.2,"platelets_k_uL":264,"creatinine_mg_dL":1.62,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_2435","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":70,"sex":"female","bmi":29.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-44},"pfs_months":19.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.4,"censored":false},"longitudinal_labs":[{"date":"2022-12-27","hemoglobin_g_dL":14.2,"wbc_k_uL":8.9,"platelets_k_uL":324,"creatinine_mg_dL":1.21,"alt_U_L":62},{"date":"2023-08-05","hemoglobin_g_dL":10.3,"wbc_k_uL":5.5,"platelets_k_uL":197,"creatinine_mg_dL":0.77,"alt_U_L":51},{"date":"2024-11-20","hemoglobin_g_dL":12.4,"wbc_k_uL":3.6,"platelets_k_uL":236,"creatinine_mg_dL":1.23,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_2436","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":87,"sex":"female","bmi":22.4,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-42},"pfs_months":27.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.7,"censored":false},"longitudinal_labs":[{"date":"2023-04-11","hemoglobin_g_dL":11.8,"wbc_k_uL":7.9,"platelets_k_uL":430,"creatinine_mg_dL":1.2,"alt_U_L":29},{"date":"2023-12-02","hemoglobin_g_dL":10.2,"wbc_k_uL":4.2,"platelets_k_uL":356,"creatinine_mg_dL":0.79,"alt_U_L":113},{"date":"2025-10-03","hemoglobin_g_dL":12.7,"wbc_k_uL":6.9,"platelets_k_uL":219,"creatinine_mg_dL":1.45,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_2437","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":72,"sex":"female","bmi":26.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-40},"pfs_months":18.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.6,"censored":false},"longitudinal_labs":[{"date":"2023-11-24","hemoglobin_g_dL":12.3,"wbc_k_uL":5.1,"platelets_k_uL":326,"creatinine_mg_dL":1.16,"alt_U_L":38},{"date":"2024-06-23","hemoglobin_g_dL":12.1,"wbc_k_uL":6.4,"platelets_k_uL":214,"creatinine_mg_dL":1.32,"alt_U_L":88},{"date":"2025-09-11","hemoglobin_g_dL":10.6,"wbc_k_uL":6.4,"platelets_k_uL":321,"creatinine_mg_dL":0.9,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_2438","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":64,"sex":"male","bmi":33.1,"smoking_pack_years":11,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-05-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-56},"pfs_months":9.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":14.9,"censored":true},"longitudinal_labs":[{"date":"2025-05-02","hemoglobin_g_dL":13.4,"wbc_k_uL":6.7,"platelets_k_uL":362,"creatinine_mg_dL":1.22,"alt_U_L":44},{"date":"2025-11-13","hemoglobin_g_dL":12.5,"wbc_k_uL":5.8,"platelets_k_uL":309,"creatinine_mg_dL":0.8,"alt_U_L":111},{"date":"2026-03-14","hemoglobin_g_dL":12.6,"wbc_k_uL":7.1,"platelets_k_uL":243,"creatinine_mg_dL":1.61,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_2439","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":68,"sex":"female","bmi":23.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-37},"pfs_months":14.65},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.7,"censored":true},"longitudinal_labs":[{"date":"2021-08-18","hemoglobin_g_dL":15.3,"wbc_k_uL":9.7,"platelets_k_uL":444,"creatinine_mg_dL":1.17,"alt_U_L":67},{"date":"2022-03-12","hemoglobin_g_dL":10.6,"wbc_k_uL":4.9,"platelets_k_uL":292,"creatinine_mg_dL":0.91,"alt_U_L":36},{"date":"2023-01-30","hemoglobin_g_dL":10.3,"wbc_k_uL":5.9,"platelets_k_uL":308,"creatinine_mg_dL":1.3,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_2440","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":70,"sex":"male","bmi":34.7,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-46},"pfs_months":10.48},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.0,"censored":false},"longitudinal_labs":[{"date":"2021-04-27","hemoglobin_g_dL":12.3,"wbc_k_uL":6.2,"platelets_k_uL":222,"creatinine_mg_dL":0.66,"alt_U_L":52},{"date":"2021-12-08","hemoglobin_g_dL":10.1,"wbc_k_uL":8.5,"platelets_k_uL":313,"creatinine_mg_dL":1.43,"alt_U_L":77},{"date":"2022-05-17","hemoglobin_g_dL":11.6,"wbc_k_uL":7.0,"platelets_k_uL":236,"creatinine_mg_dL":1.46,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_2441","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":55,"sex":"female","bmi":28.1,"smoking_pack_years":43,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-07-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-58},"pfs_months":23.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.2,"censored":false},"longitudinal_labs":[{"date":"2024-05-18","hemoglobin_g_dL":12.2,"wbc_k_uL":8.7,"platelets_k_uL":198,"creatinine_mg_dL":0.76,"alt_U_L":36},{"date":"2025-01-09","hemoglobin_g_dL":11.8,"wbc_k_uL":7.3,"platelets_k_uL":318,"creatinine_mg_dL":1.17,"alt_U_L":105},{"date":"2026-08-07","hemoglobin_g_dL":11.2,"wbc_k_uL":6.7,"platelets_k_uL":322,"creatinine_mg_dL":1.3,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_2442","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":68,"sex":"female","bmi":33.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-85},"pfs_months":26.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.5,"censored":true},"longitudinal_labs":[{"date":"2021-04-28","hemoglobin_g_dL":14.3,"wbc_k_uL":9.8,"platelets_k_uL":403,"creatinine_mg_dL":0.8,"alt_U_L":67},{"date":"2021-12-21","hemoglobin_g_dL":12.7,"wbc_k_uL":5.2,"platelets_k_uL":242,"creatinine_mg_dL":1.46,"alt_U_L":71},{"date":"2023-09-21","hemoglobin_g_dL":12.4,"wbc_k_uL":5.4,"platelets_k_uL":227,"creatinine_mg_dL":1.17,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_2443","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":77,"sex":"female","bmi":21.4,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-01-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-72},"pfs_months":19.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":true},"longitudinal_labs":[{"date":"2025-12-20","hemoglobin_g_dL":12.0,"wbc_k_uL":6.3,"platelets_k_uL":316,"creatinine_mg_dL":0.63,"alt_U_L":69},{"date":"2026-07-29","hemoglobin_g_dL":10.9,"wbc_k_uL":6.5,"platelets_k_uL":153,"creatinine_mg_dL":1.27,"alt_U_L":104},{"date":"2027-09-28","hemoglobin_g_dL":12.7,"wbc_k_uL":4.0,"platelets_k_uL":278,"creatinine_mg_dL":0.94,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_2444","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":72,"sex":"male","bmi":31.7,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-02-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-30},"pfs_months":45.4},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":75.4,"censored":false},"longitudinal_labs":[{"date":"2023-01-25","hemoglobin_g_dL":15.1,"wbc_k_uL":5.5,"platelets_k_uL":439,"creatinine_mg_dL":0.99,"alt_U_L":13},{"date":"2023-08-27","hemoglobin_g_dL":12.1,"wbc_k_uL":8.0,"platelets_k_uL":228,"creatinine_mg_dL":1.26,"alt_U_L":76},{"date":"2026-12-24","hemoglobin_g_dL":12.3,"wbc_k_uL":4.9,"platelets_k_uL":238,"creatinine_mg_dL":1.15,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_2445","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":73,"sex":"male","bmi":34.0,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-01-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-65},"pfs_months":18.27},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.4,"censored":false},"longitudinal_labs":[{"date":"2025-12-04","hemoglobin_g_dL":14.1,"wbc_k_uL":9.5,"platelets_k_uL":324,"creatinine_mg_dL":0.7,"alt_U_L":16},{"date":"2026-07-18","hemoglobin_g_dL":12.2,"wbc_k_uL":7.6,"platelets_k_uL":122,"creatinine_mg_dL":0.79,"alt_U_L":120},{"date":"2027-09-27","hemoglobin_g_dL":12.0,"wbc_k_uL":4.0,"platelets_k_uL":300,"creatinine_mg_dL":0.95,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_2446","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":75,"sex":"female","bmi":31.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-50},"pfs_months":24.02},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.1,"censored":false},"longitudinal_labs":[{"date":"2025-03-15","hemoglobin_g_dL":14.5,"wbc_k_uL":6.1,"platelets_k_uL":347,"creatinine_mg_dL":0.89,"alt_U_L":46},{"date":"2025-11-15","hemoglobin_g_dL":13.6,"wbc_k_uL":6.2,"platelets_k_uL":213,"creatinine_mg_dL":0.83,"alt_U_L":53},{"date":"2027-07-16","hemoglobin_g_dL":10.8,"wbc_k_uL":3.6,"platelets_k_uL":176,"creatinine_mg_dL":1.11,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_2447","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":48,"sex":"female","bmi":20.2,"smoking_pack_years":62,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-12-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-40},"pfs_months":11.89},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-25","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":15.8,"censored":true},"longitudinal_labs":[{"date":"2021-11-01","hemoglobin_g_dL":13.2,"wbc_k_uL":9.9,"platelets_k_uL":387,"creatinine_mg_dL":1.04,"alt_U_L":47},{"date":"2022-06-12","hemoglobin_g_dL":12.0,"wbc_k_uL":4.8,"platelets_k_uL":327,"creatinine_mg_dL":0.98,"alt_U_L":104},{"date":"2022-12-25","hemoglobin_g_dL":9.7,"wbc_k_uL":4.1,"platelets_k_uL":132,"creatinine_mg_dL":1.9,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_2448","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":77,"sex":"female","bmi":24.5,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-11-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-35},"pfs_months":14.59},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.2,"censored":true},"longitudinal_labs":[{"date":"2024-10-27","hemoglobin_g_dL":12.8,"wbc_k_uL":9.0,"platelets_k_uL":275,"creatinine_mg_dL":0.91,"alt_U_L":75},{"date":"2025-05-11","hemoglobin_g_dL":11.7,"wbc_k_uL":6.6,"platelets_k_uL":182,"creatinine_mg_dL":0.81,"alt_U_L":117},{"date":"2026-03-24","hemoglobin_g_dL":12.7,"wbc_k_uL":3.4,"platelets_k_uL":187,"creatinine_mg_dL":1.29,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_2449","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":50,"sex":"female","bmi":21.6,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-01-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-45},"pfs_months":26.22},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.7,"censored":false},"longitudinal_labs":[{"date":"2022-11-25","hemoglobin_g_dL":13.8,"wbc_k_uL":10.3,"platelets_k_uL":310,"creatinine_mg_dL":0.83,"alt_U_L":79},{"date":"2023-07-27","hemoglobin_g_dL":11.6,"wbc_k_uL":6.7,"platelets_k_uL":232,"creatinine_mg_dL":1.08,"alt_U_L":96},{"date":"2025-04-17","hemoglobin_g_dL":11.3,"wbc_k_uL":4.9,"platelets_k_uL":279,"creatinine_mg_dL":1.34,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_2450","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":86,"sex":"female","bmi":31.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-68},"pfs_months":21.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":false},"longitudinal_labs":[{"date":"2025-04-27","hemoglobin_g_dL":14.3,"wbc_k_uL":10.8,"platelets_k_uL":336,"creatinine_mg_dL":1.03,"alt_U_L":39},{"date":"2025-12-18","hemoglobin_g_dL":10.9,"wbc_k_uL":6.5,"platelets_k_uL":327,"creatinine_mg_dL":1.47,"alt_U_L":71},{"date":"2027-04-11","hemoglobin_g_dL":9.9,"wbc_k_uL":3.8,"platelets_k_uL":224,"creatinine_mg_dL":0.89,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_2451","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":74,"sex":"male","bmi":20.9,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-06-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-56},"pfs_months":37.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":63.2,"censored":true},"longitudinal_labs":[{"date":"2022-04-21","hemoglobin_g_dL":14.8,"wbc_k_uL":6.4,"platelets_k_uL":253,"creatinine_mg_dL":0.72,"alt_U_L":60},{"date":"2022-12-12","hemoglobin_g_dL":13.3,"wbc_k_uL":5.6,"platelets_k_uL":292,"creatinine_mg_dL":1.18,"alt_U_L":90},{"date":"2025-08-13","hemoglobin_g_dL":9.7,"wbc_k_uL":3.9,"platelets_k_uL":189,"creatinine_mg_dL":1.15,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_2452","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.8,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":88,"sex":"female","bmi":20.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-11-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-59},"pfs_months":21.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.7,"censored":false},"longitudinal_labs":[{"date":"2024-10-17","hemoglobin_g_dL":12.2,"wbc_k_uL":4.8,"platelets_k_uL":314,"creatinine_mg_dL":0.78,"alt_U_L":38},{"date":"2025-05-26","hemoglobin_g_dL":11.2,"wbc_k_uL":8.3,"platelets_k_uL":135,"creatinine_mg_dL":1.12,"alt_U_L":65},{"date":"2026-10-31","hemoglobin_g_dL":10.0,"wbc_k_uL":3.5,"platelets_k_uL":195,"creatinine_mg_dL":0.96,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_2453","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":52,"sex":"male","bmi":23.1,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-10-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-67},"pfs_months":25.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":46.4,"censored":false},"longitudinal_labs":[{"date":"2021-09-19","hemoglobin_g_dL":13.8,"wbc_k_uL":8.5,"platelets_k_uL":428,"creatinine_mg_dL":0.83,"alt_U_L":22},{"date":"2022-04-09","hemoglobin_g_dL":10.2,"wbc_k_uL":5.7,"platelets_k_uL":272,"creatinine_mg_dL":1.51,"alt_U_L":64},{"date":"2023-12-01","hemoglobin_g_dL":9.8,"wbc_k_uL":4.5,"platelets_k_uL":335,"creatinine_mg_dL":1.36,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_2454","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":79,"sex":"male","bmi":30.4,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-07-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-39},"pfs_months":33.58},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":67.7,"censored":true},"longitudinal_labs":[{"date":"2022-05-25","hemoglobin_g_dL":14.9,"wbc_k_uL":10.0,"platelets_k_uL":279,"creatinine_mg_dL":1.0,"alt_U_L":80},{"date":"2023-01-12","hemoglobin_g_dL":12.0,"wbc_k_uL":6.1,"platelets_k_uL":321,"creatinine_mg_dL":1.24,"alt_U_L":85},{"date":"2025-06-04","hemoglobin_g_dL":10.7,"wbc_k_uL":6.8,"platelets_k_uL":116,"creatinine_mg_dL":1.02,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_2455","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":80,"sex":"female","bmi":28.1,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-10-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-46},"pfs_months":16.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.6,"censored":false},"longitudinal_labs":[{"date":"2021-09-04","hemoglobin_g_dL":13.9,"wbc_k_uL":8.9,"platelets_k_uL":232,"creatinine_mg_dL":1.08,"alt_U_L":38},{"date":"2022-04-08","hemoglobin_g_dL":12.1,"wbc_k_uL":6.1,"platelets_k_uL":306,"creatinine_mg_dL":0.97,"alt_U_L":102},{"date":"2023-03-19","hemoglobin_g_dL":10.7,"wbc_k_uL":4.7,"platelets_k_uL":299,"creatinine_mg_dL":1.5,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_2456","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":63,"sex":"male","bmi":22.0,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-04-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-65},"pfs_months":40.05},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.9,"censored":false},"longitudinal_labs":[{"date":"2024-02-18","hemoglobin_g_dL":12.1,"wbc_k_uL":10.1,"platelets_k_uL":346,"creatinine_mg_dL":0.78,"alt_U_L":62},{"date":"2024-10-14","hemoglobin_g_dL":13.9,"wbc_k_uL":5.9,"platelets_k_uL":195,"creatinine_mg_dL":1.05,"alt_U_L":72},{"date":"2027-10-17","hemoglobin_g_dL":10.7,"wbc_k_uL":4.2,"platelets_k_uL":186,"creatinine_mg_dL":1.82,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_2457","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":81,"sex":"female","bmi":34.1,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-05-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-61},"pfs_months":48.76},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":74.8,"censored":false},"longitudinal_labs":[{"date":"2024-03-24","hemoglobin_g_dL":12.5,"wbc_k_uL":6.1,"platelets_k_uL":173,"creatinine_mg_dL":1.18,"alt_U_L":48},{"date":"2024-11-08","hemoglobin_g_dL":13.2,"wbc_k_uL":5.2,"platelets_k_uL":300,"creatinine_mg_dL":0.87,"alt_U_L":104},{"date":"2028-07-14","hemoglobin_g_dL":12.2,"wbc_k_uL":6.3,"platelets_k_uL":156,"creatinine_mg_dL":1.54,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_2458","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":62,"sex":"female","bmi":33.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-71},"pfs_months":29.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":true},"longitudinal_labs":[{"date":"2020-05-03","hemoglobin_g_dL":15.0,"wbc_k_uL":8.3,"platelets_k_uL":153,"creatinine_mg_dL":0.98,"alt_U_L":14},{"date":"2020-11-14","hemoglobin_g_dL":13.4,"wbc_k_uL":5.8,"platelets_k_uL":374,"creatinine_mg_dL":1.37,"alt_U_L":29},{"date":"2022-10-30","hemoglobin_g_dL":11.2,"wbc_k_uL":3.3,"platelets_k_uL":239,"creatinine_mg_dL":1.09,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_2459","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":48,"sex":"male","bmi":20.8,"smoking_pack_years":11,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-03-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-50},"pfs_months":32.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":54.1,"censored":false},"longitudinal_labs":[{"date":"2022-03-11","hemoglobin_g_dL":14.7,"wbc_k_uL":7.8,"platelets_k_uL":200,"creatinine_mg_dL":0.99,"alt_U_L":16},{"date":"2022-09-27","hemoglobin_g_dL":10.5,"wbc_k_uL":5.8,"platelets_k_uL":296,"creatinine_mg_dL":1.46,"alt_U_L":47},{"date":"2025-01-27","hemoglobin_g_dL":10.8,"wbc_k_uL":6.3,"platelets_k_uL":234,"creatinine_mg_dL":1.5,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_2460","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":65,"sex":"female","bmi":30.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-59},"pfs_months":19.12},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.1,"censored":false},"longitudinal_labs":[{"date":"2023-11-16","hemoglobin_g_dL":14.3,"wbc_k_uL":5.2,"platelets_k_uL":416,"creatinine_mg_dL":0.68,"alt_U_L":78},{"date":"2024-07-06","hemoglobin_g_dL":13.0,"wbc_k_uL":4.0,"platelets_k_uL":334,"creatinine_mg_dL":0.92,"alt_U_L":103},{"date":"2025-10-10","hemoglobin_g_dL":11.4,"wbc_k_uL":7.1,"platelets_k_uL":258,"creatinine_mg_dL":1.21,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_2461","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":76,"sex":"female","bmi":30.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-35},"pfs_months":16.99},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-10","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.9,"censored":false},"longitudinal_labs":[{"date":"2022-07-04","hemoglobin_g_dL":12.1,"wbc_k_uL":7.3,"platelets_k_uL":208,"creatinine_mg_dL":1.11,"alt_U_L":71},{"date":"2023-01-31","hemoglobin_g_dL":11.8,"wbc_k_uL":4.5,"platelets_k_uL":309,"creatinine_mg_dL":1.43,"alt_U_L":31},{"date":"2024-02-10","hemoglobin_g_dL":11.0,"wbc_k_uL":7.9,"platelets_k_uL":311,"creatinine_mg_dL":1.26,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2462","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":67,"sex":"male","bmi":27.7,"smoking_pack_years":19,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-01-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-80},"pfs_months":28.22},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":true},"longitudinal_labs":[{"date":"2021-12-01","hemoglobin_g_dL":14.8,"wbc_k_uL":8.0,"platelets_k_uL":298,"creatinine_mg_dL":0.96,"alt_U_L":11},{"date":"2022-07-14","hemoglobin_g_dL":12.8,"wbc_k_uL":8.6,"platelets_k_uL":286,"creatinine_mg_dL":1.11,"alt_U_L":111},{"date":"2024-06-29","hemoglobin_g_dL":11.3,"wbc_k_uL":5.5,"platelets_k_uL":314,"creatinine_mg_dL":1.88,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_2463","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":48,"sex":"female","bmi":31.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-84},"pfs_months":12.09},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":18.6,"censored":true},"longitudinal_labs":[{"date":"2024-07-25","hemoglobin_g_dL":14.5,"wbc_k_uL":10.7,"platelets_k_uL":261,"creatinine_mg_dL":1.09,"alt_U_L":42},{"date":"2025-02-22","hemoglobin_g_dL":11.8,"wbc_k_uL":4.6,"platelets_k_uL":319,"creatinine_mg_dL":1.37,"alt_U_L":60},{"date":"2025-09-02","hemoglobin_g_dL":10.1,"wbc_k_uL":5.7,"platelets_k_uL":248,"creatinine_mg_dL":1.67,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_2464","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":77,"sex":"female","bmi":32.1,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-77},"pfs_months":34.14},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":61.5,"censored":false},"longitudinal_labs":[{"date":"2022-01-24","hemoglobin_g_dL":13.1,"wbc_k_uL":9.7,"platelets_k_uL":302,"creatinine_mg_dL":0.95,"alt_U_L":27},{"date":"2022-09-14","hemoglobin_g_dL":13.5,"wbc_k_uL":7.3,"platelets_k_uL":306,"creatinine_mg_dL":0.76,"alt_U_L":82},{"date":"2025-03-02","hemoglobin_g_dL":11.4,"wbc_k_uL":5.2,"platelets_k_uL":322,"creatinine_mg_dL":1.38,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_2465","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":66,"sex":"female","bmi":25.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-79},"pfs_months":16.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.7,"censored":false},"longitudinal_labs":[{"date":"2025-07-20","hemoglobin_g_dL":12.1,"wbc_k_uL":9.1,"platelets_k_uL":396,"creatinine_mg_dL":0.93,"alt_U_L":62},{"date":"2026-03-01","hemoglobin_g_dL":12.3,"wbc_k_uL":4.6,"platelets_k_uL":212,"creatinine_mg_dL":0.74,"alt_U_L":71},{"date":"2027-02-20","hemoglobin_g_dL":9.6,"wbc_k_uL":4.6,"platelets_k_uL":254,"creatinine_mg_dL":0.92,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_2466","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":83,"sex":"female","bmi":33.4,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-07-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-64},"pfs_months":39.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":68.9,"censored":false},"longitudinal_labs":[{"date":"2020-05-22","hemoglobin_g_dL":14.4,"wbc_k_uL":5.9,"platelets_k_uL":279,"creatinine_mg_dL":0.68,"alt_U_L":57},{"date":"2021-01-27","hemoglobin_g_dL":13.4,"wbc_k_uL":8.7,"platelets_k_uL":326,"creatinine_mg_dL":0.81,"alt_U_L":36},{"date":"2023-11-08","hemoglobin_g_dL":10.3,"wbc_k_uL":3.4,"platelets_k_uL":336,"creatinine_mg_dL":1.52,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_2467","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":65,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-75},"pfs_months":32.89},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.8,"censored":false},"longitudinal_labs":[{"date":"2024-06-28","hemoglobin_g_dL":15.3,"wbc_k_uL":9.2,"platelets_k_uL":219,"creatinine_mg_dL":1.22,"alt_U_L":50},{"date":"2025-02-05","hemoglobin_g_dL":13.2,"wbc_k_uL":4.2,"platelets_k_uL":326,"creatinine_mg_dL":0.95,"alt_U_L":38},{"date":"2027-06-13","hemoglobin_g_dL":10.4,"wbc_k_uL":7.1,"platelets_k_uL":102,"creatinine_mg_dL":1.21,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_2468","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":78,"sex":"female","bmi":29.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-66},"pfs_months":32.03},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":45.0,"censored":true},"longitudinal_labs":[{"date":"2020-12-27","hemoglobin_g_dL":14.7,"wbc_k_uL":9.5,"platelets_k_uL":228,"creatinine_mg_dL":0.86,"alt_U_L":36},{"date":"2021-07-19","hemoglobin_g_dL":11.1,"wbc_k_uL":3.9,"platelets_k_uL":233,"creatinine_mg_dL":1.28,"alt_U_L":60},{"date":"2023-11-15","hemoglobin_g_dL":11.2,"wbc_k_uL":5.5,"platelets_k_uL":283,"creatinine_mg_dL":1.3,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_2469","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":66,"sex":"male","bmi":37.0,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-40},"pfs_months":49.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":70.7,"censored":true},"longitudinal_labs":[{"date":"2021-10-02","hemoglobin_g_dL":12.0,"wbc_k_uL":6.3,"platelets_k_uL":174,"creatinine_mg_dL":0.71,"alt_U_L":53},{"date":"2022-05-12","hemoglobin_g_dL":10.4,"wbc_k_uL":7.4,"platelets_k_uL":272,"creatinine_mg_dL":1.29,"alt_U_L":58},{"date":"2026-02-19","hemoglobin_g_dL":11.8,"wbc_k_uL":3.9,"platelets_k_uL":105,"creatinine_mg_dL":1.38,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_2470","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":64,"sex":"female","bmi":34.0,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-85},"pfs_months":47.41},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":79.6,"censored":false},"longitudinal_labs":[{"date":"2021-04-23","hemoglobin_g_dL":15.2,"wbc_k_uL":10.6,"platelets_k_uL":319,"creatinine_mg_dL":0.93,"alt_U_L":45},{"date":"2021-12-04","hemoglobin_g_dL":11.9,"wbc_k_uL":8.2,"platelets_k_uL":274,"creatinine_mg_dL":1.17,"alt_U_L":102},{"date":"2025-05-26","hemoglobin_g_dL":10.5,"wbc_k_uL":4.8,"platelets_k_uL":236,"creatinine_mg_dL":0.87,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_2471","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":51,"sex":"female","bmi":36.6,"smoking_pack_years":59,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-07-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-63},"pfs_months":47.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":81.2,"censored":false},"longitudinal_labs":[{"date":"2020-05-17","hemoglobin_g_dL":13.9,"wbc_k_uL":5.3,"platelets_k_uL":157,"creatinine_mg_dL":0.8,"alt_U_L":75},{"date":"2021-01-09","hemoglobin_g_dL":12.8,"wbc_k_uL":7.0,"platelets_k_uL":228,"creatinine_mg_dL":1.17,"alt_U_L":107},{"date":"2024-07-17","hemoglobin_g_dL":12.7,"wbc_k_uL":5.6,"platelets_k_uL":286,"creatinine_mg_dL":1.55,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_2472","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":71,"sex":"male","bmi":19.1,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-05-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-53},"pfs_months":41.69},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-18","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.3,"censored":true},"longitudinal_labs":[{"date":"2024-03-24","hemoglobin_g_dL":13.6,"wbc_k_uL":8.6,"platelets_k_uL":390,"creatinine_mg_dL":0.62,"alt_U_L":21},{"date":"2024-11-18","hemoglobin_g_dL":13.4,"wbc_k_uL":5.5,"platelets_k_uL":120,"creatinine_mg_dL":1.4,"alt_U_L":17},{"date":"2027-11-18","hemoglobin_g_dL":11.3,"wbc_k_uL":7.9,"platelets_k_uL":189,"creatinine_mg_dL":1.25,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_2473","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":57,"sex":"male","bmi":37.0,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-40},"pfs_months":45.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":63.8,"censored":false},"longitudinal_labs":[{"date":"2020-10-14","hemoglobin_g_dL":12.0,"wbc_k_uL":8.2,"platelets_k_uL":234,"creatinine_mg_dL":1.19,"alt_U_L":57},{"date":"2021-06-01","hemoglobin_g_dL":11.4,"wbc_k_uL":6.1,"platelets_k_uL":197,"creatinine_mg_dL":1.18,"alt_U_L":87},{"date":"2024-10-25","hemoglobin_g_dL":11.6,"wbc_k_uL":4.2,"platelets_k_uL":191,"creatinine_mg_dL":0.92,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_2474","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":76,"sex":"female","bmi":23.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-02-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-66},"pfs_months":20.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.8,"censored":false},"longitudinal_labs":[{"date":"2025-12-03","hemoglobin_g_dL":15.1,"wbc_k_uL":7.7,"platelets_k_uL":363,"creatinine_mg_dL":0.82,"alt_U_L":63},{"date":"2026-08-03","hemoglobin_g_dL":10.5,"wbc_k_uL":5.8,"platelets_k_uL":154,"creatinine_mg_dL":0.8,"alt_U_L":61},{"date":"2027-11-03","hemoglobin_g_dL":12.5,"wbc_k_uL":4.8,"platelets_k_uL":142,"creatinine_mg_dL":1.04,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_2475","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":50,"sex":"male","bmi":29.4,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-08-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-49},"pfs_months":33.18},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.6,"censored":true},"longitudinal_labs":[{"date":"2021-07-21","hemoglobin_g_dL":12.4,"wbc_k_uL":10.9,"platelets_k_uL":434,"creatinine_mg_dL":0.8,"alt_U_L":70},{"date":"2022-02-13","hemoglobin_g_dL":10.5,"wbc_k_uL":6.7,"platelets_k_uL":195,"creatinine_mg_dL":1.51,"alt_U_L":17},{"date":"2024-06-09","hemoglobin_g_dL":11.3,"wbc_k_uL":4.4,"platelets_k_uL":296,"creatinine_mg_dL":1.74,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_2476","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":76,"sex":"male","bmi":30.0,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2021-06-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-78},"pfs_months":17.08},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":false},"longitudinal_labs":[{"date":"2021-05-05","hemoglobin_g_dL":13.4,"wbc_k_uL":5.2,"platelets_k_uL":182,"creatinine_mg_dL":0.76,"alt_U_L":47},{"date":"2021-12-07","hemoglobin_g_dL":11.3,"wbc_k_uL":8.8,"platelets_k_uL":202,"creatinine_mg_dL":1.32,"alt_U_L":29},{"date":"2022-12-27","hemoglobin_g_dL":10.3,"wbc_k_uL":6.9,"platelets_k_uL":233,"creatinine_mg_dL":1.13,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_2477","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":65,"sex":"female","bmi":22.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["liver","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-36},"pfs_months":22.21},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.8,"censored":false},"longitudinal_labs":[{"date":"2020-02-22","hemoglobin_g_dL":15.0,"wbc_k_uL":6.3,"platelets_k_uL":370,"creatinine_mg_dL":0.85,"alt_U_L":29},{"date":"2020-10-23","hemoglobin_g_dL":10.9,"wbc_k_uL":6.2,"platelets_k_uL":178,"creatinine_mg_dL":1.11,"alt_U_L":38},{"date":"2022-03-29","hemoglobin_g_dL":12.8,"wbc_k_uL":7.4,"platelets_k_uL":296,"creatinine_mg_dL":1.06,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_2478","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":54,"sex":"female","bmi":19.6,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-53},"pfs_months":40.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-06-18","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.3,"censored":false},"longitudinal_labs":[{"date":"2025-11-23","hemoglobin_g_dL":13.1,"wbc_k_uL":7.2,"platelets_k_uL":272,"creatinine_mg_dL":0.87,"alt_U_L":20},{"date":"2026-06-10","hemoglobin_g_dL":11.4,"wbc_k_uL":7.1,"platelets_k_uL":355,"creatinine_mg_dL":1.4,"alt_U_L":116},{"date":"2029-06-18","hemoglobin_g_dL":9.9,"wbc_k_uL":6.1,"platelets_k_uL":125,"creatinine_mg_dL":1.39,"alt_U_L":31}]}
{"patient_id":"ANODE_SYNTH_2025_2479","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":79,"sex":"male","bmi":24.0,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-10-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-61},"pfs_months":32.3},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":50.4,"censored":true},"longitudinal_labs":[{"date":"2021-09-12","hemoglobin_g_dL":14.8,"wbc_k_uL":6.1,"platelets_k_uL":309,"creatinine_mg_dL":0.86,"alt_U_L":16},{"date":"2022-04-27","hemoglobin_g_dL":13.4,"wbc_k_uL":6.8,"platelets_k_uL":296,"creatinine_mg_dL":0.83,"alt_U_L":69},{"date":"2024-08-03","hemoglobin_g_dL":10.5,"wbc_k_uL":3.9,"platelets_k_uL":124,"creatinine_mg_dL":1.37,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_2480","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":69,"sex":"female","bmi":36.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-41},"pfs_months":27.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.9,"censored":false},"longitudinal_labs":[{"date":"2021-07-23","hemoglobin_g_dL":13.4,"wbc_k_uL":6.7,"platelets_k_uL":286,"creatinine_mg_dL":0.67,"alt_U_L":62},{"date":"2022-03-29","hemoglobin_g_dL":12.9,"wbc_k_uL":7.3,"platelets_k_uL":263,"creatinine_mg_dL":0.94,"alt_U_L":46},{"date":"2024-03-19","hemoglobin_g_dL":10.1,"wbc_k_uL":7.6,"platelets_k_uL":246,"creatinine_mg_dL":1.57,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_2481","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":75,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-69},"pfs_months":19.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.3,"censored":false},"longitudinal_labs":[{"date":"2023-02-01","hemoglobin_g_dL":14.1,"wbc_k_uL":4.8,"platelets_k_uL":406,"creatinine_mg_dL":1.21,"alt_U_L":36},{"date":"2023-10-08","hemoglobin_g_dL":12.1,"wbc_k_uL":6.5,"platelets_k_uL":363,"creatinine_mg_dL":0.86,"alt_U_L":31},{"date":"2024-12-27","hemoglobin_g_dL":11.0,"wbc_k_uL":7.1,"platelets_k_uL":309,"creatinine_mg_dL":1.85,"alt_U_L":87}]}
{"patient_id":"ANODE_SYNTH_2025_2482","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":52,"sex":"female","bmi":20.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-81},"pfs_months":20.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":38.1,"censored":false},"longitudinal_labs":[{"date":"2023-06-04","hemoglobin_g_dL":12.3,"wbc_k_uL":5.3,"platelets_k_uL":235,"creatinine_mg_dL":0.64,"alt_U_L":46},{"date":"2024-01-28","hemoglobin_g_dL":13.1,"wbc_k_uL":7.2,"platelets_k_uL":247,"creatinine_mg_dL":1.46,"alt_U_L":49},{"date":"2025-05-24","hemoglobin_g_dL":11.8,"wbc_k_uL":3.1,"platelets_k_uL":345,"creatinine_mg_dL":1.15,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_2483","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":80,"sex":"female","bmi":30.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-59},"pfs_months":22.21},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":false},"longitudinal_labs":[{"date":"2022-05-23","hemoglobin_g_dL":12.5,"wbc_k_uL":8.2,"platelets_k_uL":446,"creatinine_mg_dL":1.16,"alt_U_L":76},{"date":"2022-12-12","hemoglobin_g_dL":13.7,"wbc_k_uL":7.8,"platelets_k_uL":285,"creatinine_mg_dL":1.45,"alt_U_L":101},{"date":"2024-05-30","hemoglobin_g_dL":10.6,"wbc_k_uL":4.3,"platelets_k_uL":162,"creatinine_mg_dL":1.44,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_2484","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":70,"sex":"female","bmi":28.8,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-06-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-77},"pfs_months":35.15},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.3,"censored":false},"longitudinal_labs":[{"date":"2024-04-13","hemoglobin_g_dL":14.8,"wbc_k_uL":8.7,"platelets_k_uL":305,"creatinine_mg_dL":1.13,"alt_U_L":14},{"date":"2024-12-13","hemoglobin_g_dL":12.7,"wbc_k_uL":7.3,"platelets_k_uL":323,"creatinine_mg_dL":0.95,"alt_U_L":118},{"date":"2027-06-20","hemoglobin_g_dL":10.6,"wbc_k_uL":6.4,"platelets_k_uL":269,"creatinine_mg_dL":1.55,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_2485","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":67,"sex":"female","bmi":18.6,"smoking_pack_years":32,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-48},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-10","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.0,"censored":false},"longitudinal_labs":[{"date":"2021-08-23","hemoglobin_g_dL":15.5,"wbc_k_uL":4.5,"platelets_k_uL":335,"creatinine_mg_dL":0.61,"alt_U_L":64},{"date":"2022-03-25","hemoglobin_g_dL":13.4,"wbc_k_uL":7.4,"platelets_k_uL":290,"creatinine_mg_dL":1.15,"alt_U_L":110},{"date":"2022-02-10","hemoglobin_g_dL":10.4,"wbc_k_uL":4.3,"platelets_k_uL":221,"creatinine_mg_dL":1.46,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_2486","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":63,"sex":"male","bmi":21.3,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-03-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-46},"pfs_months":8.64},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-01-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":14.9,"censored":false},"longitudinal_labs":[{"date":"2020-02-16","hemoglobin_g_dL":12.1,"wbc_k_uL":9.4,"platelets_k_uL":224,"creatinine_mg_dL":0.68,"alt_U_L":15},{"date":"2020-09-08","hemoglobin_g_dL":10.8,"wbc_k_uL":8.4,"platelets_k_uL":322,"creatinine_mg_dL":0.8,"alt_U_L":86},{"date":"2021-01-01","hemoglobin_g_dL":10.6,"wbc_k_uL":4.3,"platelets_k_uL":347,"creatinine_mg_dL":0.92,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_2487","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":57,"sex":"female","bmi":31.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-59},"pfs_months":26.15},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":false},"longitudinal_labs":[{"date":"2020-09-17","hemoglobin_g_dL":12.1,"wbc_k_uL":8.2,"platelets_k_uL":395,"creatinine_mg_dL":0.73,"alt_U_L":23},{"date":"2021-05-22","hemoglobin_g_dL":10.5,"wbc_k_uL":6.3,"platelets_k_uL":364,"creatinine_mg_dL":1.42,"alt_U_L":47},{"date":"2023-03-06","hemoglobin_g_dL":10.8,"wbc_k_uL":6.2,"platelets_k_uL":260,"creatinine_mg_dL":0.98,"alt_U_L":108}]}
{"patient_id":"ANODE_SYNTH_2025_2488","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":52,"sex":"female","bmi":20.4,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["bone","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-05-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-31},"pfs_months":48.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":64.2,"censored":false},"longitudinal_labs":[{"date":"2022-05-11","hemoglobin_g_dL":15.1,"wbc_k_uL":9.1,"platelets_k_uL":383,"creatinine_mg_dL":0.69,"alt_U_L":67},{"date":"2022-11-27","hemoglobin_g_dL":13.6,"wbc_k_uL":7.9,"platelets_k_uL":354,"creatinine_mg_dL":0.99,"alt_U_L":81},{"date":"2026-08-07","hemoglobin_g_dL":12.7,"wbc_k_uL":5.5,"platelets_k_uL":147,"creatinine_mg_dL":1.68,"alt_U_L":176}]}
{"patient_id":"ANODE_SYNTH_2025_2489","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":53,"sex":"female","bmi":27.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-47},"pfs_months":33.45},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":58.2,"censored":false},"longitudinal_labs":[{"date":"2020-07-12","hemoglobin_g_dL":13.3,"wbc_k_uL":8.0,"platelets_k_uL":169,"creatinine_mg_dL":0.94,"alt_U_L":14},{"date":"2021-02-10","hemoglobin_g_dL":11.1,"wbc_k_uL":8.4,"platelets_k_uL":343,"creatinine_mg_dL":1.24,"alt_U_L":18},{"date":"2023-06-30","hemoglobin_g_dL":10.6,"wbc_k_uL":4.7,"platelets_k_uL":237,"creatinine_mg_dL":1.19,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_2490","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":70,"sex":"male","bmi":23.5,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-76},"pfs_months":20.17},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.8,"censored":true},"longitudinal_labs":[{"date":"2023-06-03","hemoglobin_g_dL":15.2,"wbc_k_uL":6.2,"platelets_k_uL":238,"creatinine_mg_dL":1.3,"alt_U_L":43},{"date":"2024-01-15","hemoglobin_g_dL":10.7,"wbc_k_uL":6.7,"platelets_k_uL":248,"creatinine_mg_dL":0.76,"alt_U_L":81},{"date":"2025-05-21","hemoglobin_g_dL":9.7,"wbc_k_uL":7.6,"platelets_k_uL":334,"creatinine_mg_dL":1.12,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_2491","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":51,"sex":"male","bmi":35.9,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-03-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-34},"pfs_months":31.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.6,"censored":false},"longitudinal_labs":[{"date":"2021-02-24","hemoglobin_g_dL":14.1,"wbc_k_uL":10.4,"platelets_k_uL":442,"creatinine_mg_dL":1.21,"alt_U_L":75},{"date":"2021-09-18","hemoglobin_g_dL":11.7,"wbc_k_uL":9.0,"platelets_k_uL":304,"creatinine_mg_dL":0.81,"alt_U_L":41},{"date":"2023-11-19","hemoglobin_g_dL":11.9,"wbc_k_uL":4.4,"platelets_k_uL":256,"creatinine_mg_dL":1.29,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_2492","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":77,"sex":"male","bmi":23.8,"smoking_pack_years":58,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-02-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-62},"pfs_months":17.35},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.3,"censored":false},"longitudinal_labs":[{"date":"2022-01-03","hemoglobin_g_dL":15.0,"wbc_k_uL":7.5,"platelets_k_uL":274,"creatinine_mg_dL":0.97,"alt_U_L":29},{"date":"2022-08-27","hemoglobin_g_dL":12.6,"wbc_k_uL":6.2,"platelets_k_uL":209,"creatinine_mg_dL":1.25,"alt_U_L":101},{"date":"2023-09-11","hemoglobin_g_dL":12.8,"wbc_k_uL":3.2,"platelets_k_uL":259,"creatinine_mg_dL":1.03,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_2493","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.4,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":51,"sex":"female","bmi":27.7,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-08-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-82},"pfs_months":41.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":71.8,"censored":false},"longitudinal_labs":[{"date":"2024-07-01","hemoglobin_g_dL":14.9,"wbc_k_uL":9.8,"platelets_k_uL":427,"creatinine_mg_dL":0.76,"alt_U_L":25},{"date":"2025-01-29","hemoglobin_g_dL":10.2,"wbc_k_uL":8.0,"platelets_k_uL":360,"creatinine_mg_dL":0.81,"alt_U_L":96},{"date":"2028-02-11","hemoglobin_g_dL":10.4,"wbc_k_uL":4.2,"platelets_k_uL":219,"creatinine_mg_dL":1.85,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_2494","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":60,"sex":"female","bmi":35.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-76},"pfs_months":17.81},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.4,"censored":false},"longitudinal_labs":[{"date":"2022-09-02","hemoglobin_g_dL":14.5,"wbc_k_uL":10.0,"platelets_k_uL":315,"creatinine_mg_dL":0.64,"alt_U_L":74},{"date":"2023-04-02","hemoglobin_g_dL":10.3,"wbc_k_uL":5.1,"platelets_k_uL":247,"creatinine_mg_dL":1.36,"alt_U_L":61},{"date":"2024-05-12","hemoglobin_g_dL":11.8,"wbc_k_uL":5.7,"platelets_k_uL":189,"creatinine_mg_dL":1.44,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_2495","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":83,"sex":"female","bmi":23.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-70},"pfs_months":14.82},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":28.3,"censored":false},"longitudinal_labs":[{"date":"2020-01-25","hemoglobin_g_dL":14.5,"wbc_k_uL":4.6,"platelets_k_uL":186,"creatinine_mg_dL":1.22,"alt_U_L":70},{"date":"2020-09-28","hemoglobin_g_dL":11.7,"wbc_k_uL":6.6,"platelets_k_uL":151,"creatinine_mg_dL":1.49,"alt_U_L":17},{"date":"2021-07-28","hemoglobin_g_dL":9.8,"wbc_k_uL":5.0,"platelets_k_uL":272,"creatinine_mg_dL":1.18,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_2496","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":80,"sex":"male","bmi":34.8,"smoking_pack_years":59,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-02-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-53},"pfs_months":13.54},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.5,"censored":false},"longitudinal_labs":[{"date":"2021-12-15","hemoglobin_g_dL":15.3,"wbc_k_uL":6.4,"platelets_k_uL":312,"creatinine_mg_dL":1.09,"alt_U_L":16},{"date":"2022-08-04","hemoglobin_g_dL":12.1,"wbc_k_uL":7.8,"platelets_k_uL":339,"creatinine_mg_dL":0.8,"alt_U_L":82},{"date":"2023-05-04","hemoglobin_g_dL":11.0,"wbc_k_uL":5.8,"platelets_k_uL":316,"creatinine_mg_dL":1.53,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_2497","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":83,"sex":"female","bmi":31.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-76},"pfs_months":23.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.2,"censored":true},"longitudinal_labs":[{"date":"2021-03-14","hemoglobin_g_dL":12.8,"wbc_k_uL":4.8,"platelets_k_uL":158,"creatinine_mg_dL":1.07,"alt_U_L":24},{"date":"2021-10-09","hemoglobin_g_dL":11.4,"wbc_k_uL":6.1,"platelets_k_uL":353,"creatinine_mg_dL":1.36,"alt_U_L":105},{"date":"2023-05-05","hemoglobin_g_dL":11.9,"wbc_k_uL":5.3,"platelets_k_uL":265,"creatinine_mg_dL":0.89,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_2498","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":59,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-82},"pfs_months":27.43},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-10","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.8,"censored":false},"longitudinal_labs":[{"date":"2022-05-16","hemoglobin_g_dL":13.1,"wbc_k_uL":6.8,"platelets_k_uL":412,"creatinine_mg_dL":1.01,"alt_U_L":66},{"date":"2022-12-16","hemoglobin_g_dL":12.1,"wbc_k_uL":8.0,"platelets_k_uL":136,"creatinine_mg_dL":0.79,"alt_U_L":50},{"date":"2024-10-10","hemoglobin_g_dL":12.4,"wbc_k_uL":3.1,"platelets_k_uL":283,"creatinine_mg_dL":1.84,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_2499","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":54,"sex":"female","bmi":22.4,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-06-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-51},"pfs_months":22.24},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.5,"censored":true},"longitudinal_labs":[{"date":"2020-04-14","hemoglobin_g_dL":14.7,"wbc_k_uL":6.0,"platelets_k_uL":369,"creatinine_mg_dL":0.66,"alt_U_L":53},{"date":"2020-12-02","hemoglobin_g_dL":11.3,"wbc_k_uL":5.5,"platelets_k_uL":163,"creatinine_mg_dL":1.54,"alt_U_L":90},{"date":"2022-04-28","hemoglobin_g_dL":12.3,"wbc_k_uL":5.9,"platelets_k_uL":321,"creatinine_mg_dL":1.41,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_2500","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":66,"sex":"female","bmi":27.3,"smoking_pack_years":16,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-03-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-58},"pfs_months":7.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":22.9,"censored":true},"longitudinal_labs":[{"date":"2024-01-28","hemoglobin_g_dL":14.7,"wbc_k_uL":6.8,"platelets_k_uL":182,"creatinine_mg_dL":1.25,"alt_U_L":78},{"date":"2024-09-08","hemoglobin_g_dL":11.1,"wbc_k_uL":5.3,"platelets_k_uL":153,"creatinine_mg_dL":1.16,"alt_U_L":67},{"date":"2024-11-30","hemoglobin_g_dL":10.7,"wbc_k_uL":7.1,"platelets_k_uL":253,"creatinine_mg_dL":0.89,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_2501","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":68,"sex":"female","bmi":37.3,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-10-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-78},"pfs_months":8.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":12.4,"censored":false},"longitudinal_labs":[{"date":"2024-08-25","hemoglobin_g_dL":13.1,"wbc_k_uL":5.6,"platelets_k_uL":271,"creatinine_mg_dL":0.69,"alt_U_L":74},{"date":"2025-04-21","hemoglobin_g_dL":12.2,"wbc_k_uL":5.4,"platelets_k_uL":365,"creatinine_mg_dL":1.18,"alt_U_L":52},{"date":"2025-08-22","hemoglobin_g_dL":10.4,"wbc_k_uL":7.0,"platelets_k_uL":338,"creatinine_mg_dL":1.41,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_2502","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":60,"sex":"female","bmi":34.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-54},"pfs_months":21.95},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":40.5,"censored":false},"longitudinal_labs":[{"date":"2022-11-11","hemoglobin_g_dL":12.9,"wbc_k_uL":5.2,"platelets_k_uL":297,"creatinine_mg_dL":1.22,"alt_U_L":70},{"date":"2023-06-01","hemoglobin_g_dL":12.8,"wbc_k_uL":6.8,"platelets_k_uL":131,"creatinine_mg_dL":1.34,"alt_U_L":73},{"date":"2024-11-01","hemoglobin_g_dL":12.1,"wbc_k_uL":3.7,"platelets_k_uL":201,"creatinine_mg_dL":0.86,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_2503","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":56,"sex":"female","bmi":19.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-32},"pfs_months":19.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.6,"censored":false},"longitudinal_labs":[{"date":"2025-01-24","hemoglobin_g_dL":14.6,"wbc_k_uL":5.8,"platelets_k_uL":192,"creatinine_mg_dL":0.99,"alt_U_L":37},{"date":"2025-08-23","hemoglobin_g_dL":13.4,"wbc_k_uL":6.7,"platelets_k_uL":225,"creatinine_mg_dL":1.31,"alt_U_L":91},{"date":"2026-11-07","hemoglobin_g_dL":9.8,"wbc_k_uL":7.3,"platelets_k_uL":129,"creatinine_mg_dL":1.43,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_2504","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":60,"sex":"female","bmi":36.2,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-05-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-49},"pfs_months":39.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":58.5,"censored":false},"longitudinal_labs":[{"date":"2022-04-23","hemoglobin_g_dL":12.6,"wbc_k_uL":9.1,"platelets_k_uL":367,"creatinine_mg_dL":1.11,"alt_U_L":56},{"date":"2022-11-14","hemoglobin_g_dL":13.2,"wbc_k_uL":8.8,"platelets_k_uL":353,"creatinine_mg_dL":1.52,"alt_U_L":21},{"date":"2025-09-10","hemoglobin_g_dL":12.2,"wbc_k_uL":4.6,"platelets_k_uL":268,"creatinine_mg_dL":1.72,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_2505","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":86,"sex":"female","bmi":33.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-67},"pfs_months":28.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":true},"longitudinal_labs":[{"date":"2022-11-12","hemoglobin_g_dL":15.4,"wbc_k_uL":10.5,"platelets_k_uL":177,"creatinine_mg_dL":0.77,"alt_U_L":41},{"date":"2023-06-11","hemoglobin_g_dL":12.1,"wbc_k_uL":6.1,"platelets_k_uL":311,"creatinine_mg_dL":0.74,"alt_U_L":94},{"date":"2025-05-14","hemoglobin_g_dL":12.7,"wbc_k_uL":4.4,"platelets_k_uL":230,"creatinine_mg_dL":1.43,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_2506","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":85,"sex":"female","bmi":24.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-74},"pfs_months":14.85},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":false},"longitudinal_labs":[{"date":"2022-01-20","hemoglobin_g_dL":12.1,"wbc_k_uL":5.4,"platelets_k_uL":203,"creatinine_mg_dL":1.09,"alt_U_L":77},{"date":"2022-09-09","hemoglobin_g_dL":10.3,"wbc_k_uL":5.4,"platelets_k_uL":125,"creatinine_mg_dL":1.54,"alt_U_L":97},{"date":"2023-08-04","hemoglobin_g_dL":12.2,"wbc_k_uL":6.0,"platelets_k_uL":253,"creatinine_mg_dL":1.83,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_2507","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":83,"sex":"male","bmi":30.8,"smoking_pack_years":43,"ecog_performance_status":2,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-10-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-58},"pfs_months":23.92},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":42.0,"censored":false},"longitudinal_labs":[{"date":"2022-08-14","hemoglobin_g_dL":12.0,"wbc_k_uL":8.4,"platelets_k_uL":302,"creatinine_mg_dL":0.66,"alt_U_L":68},{"date":"2023-04-13","hemoglobin_g_dL":13.8,"wbc_k_uL":8.6,"platelets_k_uL":286,"creatinine_mg_dL":1.0,"alt_U_L":28},{"date":"2024-10-16","hemoglobin_g_dL":10.3,"wbc_k_uL":5.5,"platelets_k_uL":120,"creatinine_mg_dL":1.43,"alt_U_L":90}]}
{"patient_id":"ANODE_SYNTH_2025_2508","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":52,"sex":"female","bmi":24.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-60},"pfs_months":13.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.3,"censored":false},"longitudinal_labs":[{"date":"2021-02-21","hemoglobin_g_dL":11.5,"wbc_k_uL":7.6,"platelets_k_uL":267,"creatinine_mg_dL":1.0,"alt_U_L":61},{"date":"2021-10-06","hemoglobin_g_dL":12.8,"wbc_k_uL":6.5,"platelets_k_uL":179,"creatinine_mg_dL":1.05,"alt_U_L":42},{"date":"2022-06-18","hemoglobin_g_dL":9.9,"wbc_k_uL":5.4,"platelets_k_uL":156,"creatinine_mg_dL":1.5,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2509","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":60,"sex":"male","bmi":22.8,"smoking_pack_years":77,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-10-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-65},"pfs_months":40.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":71.7,"censored":false},"longitudinal_labs":[{"date":"2022-08-24","hemoglobin_g_dL":13.9,"wbc_k_uL":4.6,"platelets_k_uL":267,"creatinine_mg_dL":0.93,"alt_U_L":53},{"date":"2023-04-15","hemoglobin_g_dL":12.1,"wbc_k_uL":4.4,"platelets_k_uL":301,"creatinine_mg_dL":1.03,"alt_U_L":41},{"date":"2026-03-21","hemoglobin_g_dL":10.1,"wbc_k_uL":4.7,"platelets_k_uL":321,"creatinine_mg_dL":1.71,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_2510","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":51,"sex":"male","bmi":28.9,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-07-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-68},"pfs_months":42.55},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":66.2,"censored":false},"longitudinal_labs":[{"date":"2025-06-13","hemoglobin_g_dL":13.2,"wbc_k_uL":8.2,"platelets_k_uL":280,"creatinine_mg_dL":0.79,"alt_U_L":72},{"date":"2026-01-03","hemoglobin_g_dL":13.8,"wbc_k_uL":8.5,"platelets_k_uL":351,"creatinine_mg_dL":0.92,"alt_U_L":83},{"date":"2029-01-28","hemoglobin_g_dL":11.2,"wbc_k_uL":6.6,"platelets_k_uL":166,"creatinine_mg_dL":0.96,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_2511","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":71,"sex":"female","bmi":22.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-01-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-59},"pfs_months":17.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":23.5,"censored":true},"longitudinal_labs":[{"date":"2025-12-03","hemoglobin_g_dL":14.3,"wbc_k_uL":6.5,"platelets_k_uL":380,"creatinine_mg_dL":0.67,"alt_U_L":34},{"date":"2026-07-01","hemoglobin_g_dL":13.7,"wbc_k_uL":5.9,"platelets_k_uL":336,"creatinine_mg_dL":0.88,"alt_U_L":41},{"date":"2027-06-19","hemoglobin_g_dL":12.4,"wbc_k_uL":6.2,"platelets_k_uL":310,"creatinine_mg_dL":1.13,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_2512","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":76,"sex":"female","bmi":20.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-85},"pfs_months":20.04},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-16","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.8,"censored":false},"longitudinal_labs":[{"date":"2022-10-16","hemoglobin_g_dL":12.2,"wbc_k_uL":8.2,"platelets_k_uL":439,"creatinine_mg_dL":0.7,"alt_U_L":67},{"date":"2023-05-17","hemoglobin_g_dL":13.2,"wbc_k_uL":6.1,"platelets_k_uL":359,"creatinine_mg_dL":0.85,"alt_U_L":93},{"date":"2024-09-16","hemoglobin_g_dL":10.9,"wbc_k_uL":4.2,"platelets_k_uL":340,"creatinine_mg_dL":1.0,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_2513","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":64,"sex":"female","bmi":21.6,"smoking_pack_years":18,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-01-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-83},"pfs_months":21.03},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.0,"censored":true},"longitudinal_labs":[{"date":"2023-11-10","hemoglobin_g_dL":12.3,"wbc_k_uL":6.9,"platelets_k_uL":233,"creatinine_mg_dL":0.65,"alt_U_L":16},{"date":"2024-07-03","hemoglobin_g_dL":13.6,"wbc_k_uL":7.1,"platelets_k_uL":371,"creatinine_mg_dL":0.71,"alt_U_L":111},{"date":"2025-10-20","hemoglobin_g_dL":10.8,"wbc_k_uL":4.9,"platelets_k_uL":218,"creatinine_mg_dL":1.58,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_2514","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":68,"sex":"female","bmi":30.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-01-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-54},"pfs_months":23.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":false},"longitudinal_labs":[{"date":"2025-11-21","hemoglobin_g_dL":14.0,"wbc_k_uL":5.5,"platelets_k_uL":438,"creatinine_mg_dL":1.05,"alt_U_L":25},{"date":"2026-07-21","hemoglobin_g_dL":10.4,"wbc_k_uL":5.1,"platelets_k_uL":183,"creatinine_mg_dL":1.08,"alt_U_L":48},{"date":"2028-02-16","hemoglobin_g_dL":9.7,"wbc_k_uL":7.1,"platelets_k_uL":196,"creatinine_mg_dL":1.99,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_2515","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":57,"sex":"female","bmi":30.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-58},"pfs_months":26.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.1,"censored":false},"longitudinal_labs":[{"date":"2023-09-15","hemoglobin_g_dL":14.1,"wbc_k_uL":10.4,"platelets_k_uL":208,"creatinine_mg_dL":1.26,"alt_U_L":46},{"date":"2024-05-07","hemoglobin_g_dL":11.8,"wbc_k_uL":6.7,"platelets_k_uL":176,"creatinine_mg_dL":1.26,"alt_U_L":92},{"date":"2026-02-26","hemoglobin_g_dL":10.2,"wbc_k_uL":3.7,"platelets_k_uL":248,"creatinine_mg_dL":1.73,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_2516","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":55,"sex":"female","bmi":24.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-02-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-75},"pfs_months":26.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.8,"censored":true},"longitudinal_labs":[{"date":"2020-01-15","hemoglobin_g_dL":15.3,"wbc_k_uL":8.3,"platelets_k_uL":176,"creatinine_mg_dL":1.17,"alt_U_L":61},{"date":"2020-08-19","hemoglobin_g_dL":10.7,"wbc_k_uL":4.7,"platelets_k_uL":319,"creatinine_mg_dL":1.36,"alt_U_L":47},{"date":"2022-07-15","hemoglobin_g_dL":12.3,"wbc_k_uL":7.9,"platelets_k_uL":116,"creatinine_mg_dL":1.36,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_2517","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":80,"sex":"female","bmi":33.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-69},"pfs_months":20.73},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-10","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.3,"censored":true},"longitudinal_labs":[{"date":"2024-09-02","hemoglobin_g_dL":12.9,"wbc_k_uL":9.1,"platelets_k_uL":269,"creatinine_mg_dL":0.78,"alt_U_L":20},{"date":"2025-03-17","hemoglobin_g_dL":12.0,"wbc_k_uL":6.5,"platelets_k_uL":149,"creatinine_mg_dL":0.91,"alt_U_L":62},{"date":"2026-07-10","hemoglobin_g_dL":9.6,"wbc_k_uL":6.4,"platelets_k_uL":284,"creatinine_mg_dL":1.93,"alt_U_L":87}]}
{"patient_id":"ANODE_SYNTH_2025_2518","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":72,"sex":"female","bmi":25.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-44},"pfs_months":20.73},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.5,"censored":false},"longitudinal_labs":[{"date":"2024-01-11","hemoglobin_g_dL":12.2,"wbc_k_uL":9.0,"platelets_k_uL":360,"creatinine_mg_dL":0.85,"alt_U_L":36},{"date":"2024-09-07","hemoglobin_g_dL":11.5,"wbc_k_uL":4.6,"platelets_k_uL":188,"creatinine_mg_dL":1.0,"alt_U_L":66},{"date":"2026-01-17","hemoglobin_g_dL":11.0,"wbc_k_uL":7.7,"platelets_k_uL":102,"creatinine_mg_dL":1.1,"alt_U_L":166}]}
{"patient_id":"ANODE_SYNTH_2025_2519","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":70,"sex":"female","bmi":22.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-69},"pfs_months":23.59},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.9,"censored":false},"longitudinal_labs":[{"date":"2020-03-03","hemoglobin_g_dL":12.3,"wbc_k_uL":9.2,"platelets_k_uL":274,"creatinine_mg_dL":0.9,"alt_U_L":12},{"date":"2020-10-07","hemoglobin_g_dL":11.5,"wbc_k_uL":6.9,"platelets_k_uL":302,"creatinine_mg_dL":1.04,"alt_U_L":78},{"date":"2022-04-17","hemoglobin_g_dL":11.6,"wbc_k_uL":7.2,"platelets_k_uL":309,"creatinine_mg_dL":1.83,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_2520","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":85,"sex":"female","bmi":35.6,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-11-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-64},"pfs_months":7.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.5,"censored":false},"longitudinal_labs":[{"date":"2022-09-27","hemoglobin_g_dL":13.8,"wbc_k_uL":9.9,"platelets_k_uL":291,"creatinine_mg_dL":1.19,"alt_U_L":65},{"date":"2023-05-01","hemoglobin_g_dL":10.1,"wbc_k_uL":4.3,"platelets_k_uL":320,"creatinine_mg_dL":1.59,"alt_U_L":93},{"date":"2023-08-26","hemoglobin_g_dL":9.6,"wbc_k_uL":4.0,"platelets_k_uL":334,"creatinine_mg_dL":1.09,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_2521","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":88,"sex":"male","bmi":32.5,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-43},"pfs_months":39.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.9,"censored":true},"longitudinal_labs":[{"date":"2020-11-22","hemoglobin_g_dL":14.3,"wbc_k_uL":10.9,"platelets_k_uL":344,"creatinine_mg_dL":1.1,"alt_U_L":13},{"date":"2021-07-15","hemoglobin_g_dL":12.1,"wbc_k_uL":6.7,"platelets_k_uL":330,"creatinine_mg_dL":1.32,"alt_U_L":112},{"date":"2024-04-30","hemoglobin_g_dL":9.7,"wbc_k_uL":3.2,"platelets_k_uL":286,"creatinine_mg_dL":0.93,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_2522","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":64,"sex":"male","bmi":20.3,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-12-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-55},"pfs_months":7.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.0,"censored":true},"longitudinal_labs":[{"date":"2024-10-11","hemoglobin_g_dL":13.6,"wbc_k_uL":9.7,"platelets_k_uL":440,"creatinine_mg_dL":1.02,"alt_U_L":61},{"date":"2025-06-11","hemoglobin_g_dL":12.8,"wbc_k_uL":4.3,"platelets_k_uL":223,"creatinine_mg_dL":1.33,"alt_U_L":84},{"date":"2025-08-03","hemoglobin_g_dL":9.6,"wbc_k_uL":5.6,"platelets_k_uL":122,"creatinine_mg_dL":0.82,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_2523","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":67,"sex":"male","bmi":23.6,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-05-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-30},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.0,"censored":false},"longitudinal_labs":[{"date":"2024-04-07","hemoglobin_g_dL":12.9,"wbc_k_uL":5.3,"platelets_k_uL":309,"creatinine_mg_dL":0.72,"alt_U_L":66},{"date":"2024-11-21","hemoglobin_g_dL":10.2,"wbc_k_uL":7.4,"platelets_k_uL":185,"creatinine_mg_dL":1.27,"alt_U_L":90},{"date":"2026-05-01","hemoglobin_g_dL":10.8,"wbc_k_uL":4.2,"platelets_k_uL":324,"creatinine_mg_dL":0.91,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_2524","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":71,"sex":"male","bmi":21.4,"smoking_pack_years":42,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-04-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-35},"pfs_months":10.22},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":15.1,"censored":true},"longitudinal_labs":[{"date":"2021-01-28","hemoglobin_g_dL":14.4,"wbc_k_uL":10.3,"platelets_k_uL":294,"creatinine_mg_dL":0.98,"alt_U_L":38},{"date":"2021-10-03","hemoglobin_g_dL":12.1,"wbc_k_uL":4.4,"platelets_k_uL":214,"creatinine_mg_dL":1.57,"alt_U_L":49},{"date":"2022-02-16","hemoglobin_g_dL":12.2,"wbc_k_uL":3.4,"platelets_k_uL":317,"creatinine_mg_dL":0.81,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_2525","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":49,"sex":"male","bmi":29.3,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-10-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-43},"pfs_months":8.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":12.5,"censored":false},"longitudinal_labs":[{"date":"2023-10-05","hemoglobin_g_dL":13.1,"wbc_k_uL":6.6,"platelets_k_uL":260,"creatinine_mg_dL":0.61,"alt_U_L":48},{"date":"2024-04-22","hemoglobin_g_dL":11.7,"wbc_k_uL":7.8,"platelets_k_uL":249,"creatinine_mg_dL":1.59,"alt_U_L":45},{"date":"2024-08-27","hemoglobin_g_dL":10.8,"wbc_k_uL":7.5,"platelets_k_uL":114,"creatinine_mg_dL":1.74,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_2526","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":85,"sex":"male","bmi":28.9,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-07-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-38},"pfs_months":35.48},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":57.9,"censored":false},"longitudinal_labs":[{"date":"2021-04-25","hemoglobin_g_dL":14.9,"wbc_k_uL":10.5,"platelets_k_uL":270,"creatinine_mg_dL":0.6,"alt_U_L":44},{"date":"2021-12-28","hemoglobin_g_dL":13.1,"wbc_k_uL":5.0,"platelets_k_uL":178,"creatinine_mg_dL":1.04,"alt_U_L":29},{"date":"2024-08-03","hemoglobin_g_dL":12.1,"wbc_k_uL":6.2,"platelets_k_uL":177,"creatinine_mg_dL":1.83,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_2527","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":85,"sex":"male","bmi":23.4,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-05-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-40},"pfs_months":16.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":false},"longitudinal_labs":[{"date":"2025-03-21","hemoglobin_g_dL":11.6,"wbc_k_uL":5.7,"platelets_k_uL":346,"creatinine_mg_dL":0.7,"alt_U_L":58},{"date":"2025-11-12","hemoglobin_g_dL":10.7,"wbc_k_uL":8.8,"platelets_k_uL":201,"creatinine_mg_dL":1.27,"alt_U_L":54},{"date":"2026-10-03","hemoglobin_g_dL":12.3,"wbc_k_uL":7.0,"platelets_k_uL":137,"creatinine_mg_dL":0.93,"alt_U_L":108}]}
{"patient_id":"ANODE_SYNTH_2025_2528","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":75,"sex":"female","bmi":32.9,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-03-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-36},"pfs_months":25.4},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.1,"censored":false},"longitudinal_labs":[{"date":"2023-01-23","hemoglobin_g_dL":11.6,"wbc_k_uL":9.5,"platelets_k_uL":240,"creatinine_mg_dL":0.71,"alt_U_L":10},{"date":"2023-09-17","hemoglobin_g_dL":12.6,"wbc_k_uL":5.6,"platelets_k_uL":176,"creatinine_mg_dL":1.33,"alt_U_L":46},{"date":"2025-05-19","hemoglobin_g_dL":13.0,"wbc_k_uL":4.6,"platelets_k_uL":150,"creatinine_mg_dL":1.95,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_2529","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":72,"sex":"female","bmi":27.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-50},"pfs_months":18.99},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":false},"longitudinal_labs":[{"date":"2025-03-20","hemoglobin_g_dL":12.8,"wbc_k_uL":9.7,"platelets_k_uL":309,"creatinine_mg_dL":1.04,"alt_U_L":25},{"date":"2025-10-23","hemoglobin_g_dL":11.7,"wbc_k_uL":5.4,"platelets_k_uL":244,"creatinine_mg_dL":1.35,"alt_U_L":106},{"date":"2026-12-11","hemoglobin_g_dL":12.1,"wbc_k_uL":5.5,"platelets_k_uL":130,"creatinine_mg_dL":1.12,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_2530","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":63,"sex":"female","bmi":29.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-01-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-80},"pfs_months":28.94},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.5,"censored":false},"longitudinal_labs":[{"date":"2022-01-11","hemoglobin_g_dL":12.6,"wbc_k_uL":5.5,"platelets_k_uL":222,"creatinine_mg_dL":1.15,"alt_U_L":27},{"date":"2022-07-30","hemoglobin_g_dL":12.1,"wbc_k_uL":6.3,"platelets_k_uL":334,"creatinine_mg_dL":0.91,"alt_U_L":67},{"date":"2024-07-22","hemoglobin_g_dL":10.3,"wbc_k_uL":7.0,"platelets_k_uL":255,"creatinine_mg_dL":0.81,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_2531","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":80,"sex":"male","bmi":25.2,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-67},"pfs_months":23.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":42.5,"censored":true},"longitudinal_labs":[{"date":"2023-04-23","hemoglobin_g_dL":12.3,"wbc_k_uL":6.3,"platelets_k_uL":255,"creatinine_mg_dL":0.86,"alt_U_L":24},{"date":"2023-11-22","hemoglobin_g_dL":13.2,"wbc_k_uL":8.9,"platelets_k_uL":207,"creatinine_mg_dL":1.02,"alt_U_L":22},{"date":"2025-05-14","hemoglobin_g_dL":13.0,"wbc_k_uL":6.4,"platelets_k_uL":131,"creatinine_mg_dL":0.94,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_2532","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":61,"sex":"male","bmi":27.7,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-12-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-32},"pfs_months":33.97},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-21","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":53.6,"censored":true},"longitudinal_labs":[{"date":"2024-11-19","hemoglobin_g_dL":13.7,"wbc_k_uL":8.3,"platelets_k_uL":162,"creatinine_mg_dL":0.82,"alt_U_L":20},{"date":"2025-06-20","hemoglobin_g_dL":10.3,"wbc_k_uL":5.3,"platelets_k_uL":318,"creatinine_mg_dL":1.32,"alt_U_L":93},{"date":"2027-11-21","hemoglobin_g_dL":11.5,"wbc_k_uL":4.1,"platelets_k_uL":231,"creatinine_mg_dL":1.0,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_2533","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":77,"sex":"female","bmi":25.6,"smoking_pack_years":67,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-34},"pfs_months":25.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":55.5,"censored":false},"longitudinal_labs":[{"date":"2025-01-20","hemoglobin_g_dL":13.2,"wbc_k_uL":5.0,"platelets_k_uL":407,"creatinine_mg_dL":1.07,"alt_U_L":11},{"date":"2025-08-02","hemoglobin_g_dL":11.5,"wbc_k_uL":5.3,"platelets_k_uL":256,"creatinine_mg_dL":1.32,"alt_U_L":94},{"date":"2027-03-26","hemoglobin_g_dL":11.2,"wbc_k_uL":6.2,"platelets_k_uL":191,"creatinine_mg_dL":1.75,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2534","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":77,"sex":"female","bmi":30.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-35},"pfs_months":14.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-16","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.9,"censored":false},"longitudinal_labs":[{"date":"2020-06-01","hemoglobin_g_dL":14.7,"wbc_k_uL":5.2,"platelets_k_uL":342,"creatinine_mg_dL":0.63,"alt_U_L":69},{"date":"2020-12-13","hemoglobin_g_dL":10.1,"wbc_k_uL":3.9,"platelets_k_uL":215,"creatinine_mg_dL":1.59,"alt_U_L":23},{"date":"2021-10-16","hemoglobin_g_dL":11.3,"wbc_k_uL":6.9,"platelets_k_uL":320,"creatinine_mg_dL":0.92,"alt_U_L":198}]}
{"patient_id":"ANODE_SYNTH_2025_2535","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":60,"sex":"female","bmi":35.8,"smoking_pack_years":20,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-06-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-60},"pfs_months":14.23},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.8,"censored":false},"longitudinal_labs":[{"date":"2020-05-15","hemoglobin_g_dL":12.3,"wbc_k_uL":7.6,"platelets_k_uL":365,"creatinine_mg_dL":1.25,"alt_U_L":24},{"date":"2020-11-30","hemoglobin_g_dL":13.2,"wbc_k_uL":4.8,"platelets_k_uL":225,"creatinine_mg_dL":0.76,"alt_U_L":63},{"date":"2021-09-18","hemoglobin_g_dL":10.0,"wbc_k_uL":5.9,"platelets_k_uL":190,"creatinine_mg_dL":1.57,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_2536","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":55,"sex":"female","bmi":35.0,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-02-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-65},"pfs_months":23.62},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.2,"censored":false},"longitudinal_labs":[{"date":"2024-01-28","hemoglobin_g_dL":12.7,"wbc_k_uL":10.2,"platelets_k_uL":337,"creatinine_mg_dL":1.1,"alt_U_L":20},{"date":"2024-08-16","hemoglobin_g_dL":13.9,"wbc_k_uL":8.2,"platelets_k_uL":291,"creatinine_mg_dL":1.45,"alt_U_L":15},{"date":"2026-03-16","hemoglobin_g_dL":11.2,"wbc_k_uL":3.9,"platelets_k_uL":273,"creatinine_mg_dL":1.05,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_2537","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":69,"sex":"male","bmi":18.9,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-02-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-35},"pfs_months":30.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.5,"censored":true},"longitudinal_labs":[{"date":"2022-01-25","hemoglobin_g_dL":14.5,"wbc_k_uL":4.6,"platelets_k_uL":150,"creatinine_mg_dL":0.76,"alt_U_L":55},{"date":"2022-08-22","hemoglobin_g_dL":12.1,"wbc_k_uL":4.9,"platelets_k_uL":145,"creatinine_mg_dL":0.97,"alt_U_L":86},{"date":"2024-10-18","hemoglobin_g_dL":10.6,"wbc_k_uL":5.3,"platelets_k_uL":163,"creatinine_mg_dL":1.84,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_2538","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":65,"sex":"male","bmi":36.3,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-40},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":10.7,"censored":false},"longitudinal_labs":[{"date":"2025-07-14","hemoglobin_g_dL":13.8,"wbc_k_uL":7.0,"platelets_k_uL":367,"creatinine_mg_dL":1.24,"alt_U_L":43},{"date":"2026-01-27","hemoglobin_g_dL":11.5,"wbc_k_uL":6.2,"platelets_k_uL":316,"creatinine_mg_dL":1.23,"alt_U_L":20},{"date":"2025-12-27","hemoglobin_g_dL":11.7,"wbc_k_uL":7.7,"platelets_k_uL":188,"creatinine_mg_dL":0.95,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_2539","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":60,"sex":"male","bmi":29.0,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-06-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-61},"pfs_months":39.62},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":62.2,"censored":false},"longitudinal_labs":[{"date":"2024-05-25","hemoglobin_g_dL":15.4,"wbc_k_uL":6.4,"platelets_k_uL":314,"creatinine_mg_dL":0.65,"alt_U_L":68},{"date":"2024-12-21","hemoglobin_g_dL":13.3,"wbc_k_uL":5.2,"platelets_k_uL":122,"creatinine_mg_dL":1.39,"alt_U_L":63},{"date":"2027-11-30","hemoglobin_g_dL":9.7,"wbc_k_uL":7.5,"platelets_k_uL":232,"creatinine_mg_dL":1.05,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_2540","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":74,"sex":"male","bmi":19.4,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-02-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-34},"pfs_months":24.51},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.4,"censored":true},"longitudinal_labs":[{"date":"2025-01-26","hemoglobin_g_dL":11.5,"wbc_k_uL":5.6,"platelets_k_uL":311,"creatinine_mg_dL":1.0,"alt_U_L":17},{"date":"2025-08-12","hemoglobin_g_dL":10.1,"wbc_k_uL":4.0,"platelets_k_uL":183,"creatinine_mg_dL":1.57,"alt_U_L":83},{"date":"2027-04-11","hemoglobin_g_dL":10.6,"wbc_k_uL":7.2,"platelets_k_uL":228,"creatinine_mg_dL":1.26,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_2541","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":71,"sex":"female","bmi":37.1,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-06-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-44},"pfs_months":27.73},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.4,"censored":false},"longitudinal_labs":[{"date":"2020-05-16","hemoglobin_g_dL":13.5,"wbc_k_uL":5.8,"platelets_k_uL":427,"creatinine_mg_dL":0.62,"alt_U_L":38},{"date":"2020-12-02","hemoglobin_g_dL":11.3,"wbc_k_uL":8.7,"platelets_k_uL":122,"creatinine_mg_dL":1.29,"alt_U_L":52},{"date":"2022-10-23","hemoglobin_g_dL":12.8,"wbc_k_uL":5.3,"platelets_k_uL":341,"creatinine_mg_dL":1.41,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_2542","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":48,"sex":"male","bmi":21.5,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-06-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-51},"pfs_months":28.35},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.1,"censored":false},"longitudinal_labs":[{"date":"2025-06-01","hemoglobin_g_dL":13.0,"wbc_k_uL":8.0,"platelets_k_uL":328,"creatinine_mg_dL":0.68,"alt_U_L":69},{"date":"2025-12-18","hemoglobin_g_dL":11.5,"wbc_k_uL":6.8,"platelets_k_uL":369,"creatinine_mg_dL":0.83,"alt_U_L":16},{"date":"2027-11-10","hemoglobin_g_dL":10.5,"wbc_k_uL":5.3,"platelets_k_uL":140,"creatinine_mg_dL":1.79,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_2543","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":50,"sex":"female","bmi":29.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-65},"pfs_months":22.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.1,"censored":false},"longitudinal_labs":[{"date":"2025-04-23","hemoglobin_g_dL":14.7,"wbc_k_uL":6.3,"platelets_k_uL":250,"creatinine_mg_dL":1.25,"alt_U_L":58},{"date":"2025-11-05","hemoglobin_g_dL":10.0,"wbc_k_uL":6.0,"platelets_k_uL":212,"creatinine_mg_dL":0.73,"alt_U_L":32},{"date":"2027-03-30","hemoglobin_g_dL":11.8,"wbc_k_uL":4.5,"platelets_k_uL":192,"creatinine_mg_dL":1.55,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_2544","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":81,"sex":"female","bmi":20.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-66},"pfs_months":15.97},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.2,"censored":true},"longitudinal_labs":[{"date":"2025-03-19","hemoglobin_g_dL":13.8,"wbc_k_uL":8.6,"platelets_k_uL":430,"creatinine_mg_dL":0.91,"alt_U_L":74},{"date":"2025-10-27","hemoglobin_g_dL":11.5,"wbc_k_uL":4.3,"platelets_k_uL":266,"creatinine_mg_dL":1.41,"alt_U_L":100},{"date":"2026-09-03","hemoglobin_g_dL":9.8,"wbc_k_uL":7.2,"platelets_k_uL":185,"creatinine_mg_dL":1.82,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_2545","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":63,"sex":"female","bmi":36.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-31},"pfs_months":15.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.5,"censored":true},"longitudinal_labs":[{"date":"2025-10-10","hemoglobin_g_dL":15.0,"wbc_k_uL":8.5,"platelets_k_uL":345,"creatinine_mg_dL":0.79,"alt_U_L":46},{"date":"2026-05-07","hemoglobin_g_dL":11.6,"wbc_k_uL":7.3,"platelets_k_uL":142,"creatinine_mg_dL":1.1,"alt_U_L":120},{"date":"2027-03-24","hemoglobin_g_dL":10.8,"wbc_k_uL":3.1,"platelets_k_uL":180,"creatinine_mg_dL":0.84,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_2546","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":51,"sex":"female","bmi":24.3,"smoking_pack_years":61,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-02-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-37},"pfs_months":21.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.0,"censored":true},"longitudinal_labs":[{"date":"2020-02-10","hemoglobin_g_dL":13.5,"wbc_k_uL":10.0,"platelets_k_uL":388,"creatinine_mg_dL":1.04,"alt_U_L":15},{"date":"2020-08-23","hemoglobin_g_dL":13.4,"wbc_k_uL":4.6,"platelets_k_uL":339,"creatinine_mg_dL":1.59,"alt_U_L":22},{"date":"2021-12-14","hemoglobin_g_dL":12.9,"wbc_k_uL":5.4,"platelets_k_uL":281,"creatinine_mg_dL":1.74,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_2547","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":77,"sex":"female","bmi":34.2,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-04-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-70},"pfs_months":13.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":18.5,"censored":false},"longitudinal_labs":[{"date":"2023-02-26","hemoglobin_g_dL":14.2,"wbc_k_uL":7.3,"platelets_k_uL":284,"creatinine_mg_dL":1.28,"alt_U_L":27},{"date":"2023-10-14","hemoglobin_g_dL":12.6,"wbc_k_uL":7.9,"platelets_k_uL":297,"creatinine_mg_dL":1.49,"alt_U_L":34},{"date":"2024-06-18","hemoglobin_g_dL":12.3,"wbc_k_uL":4.6,"platelets_k_uL":343,"creatinine_mg_dL":1.08,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_2548","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":85,"sex":"female","bmi":30.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-60},"pfs_months":21.82},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.7,"censored":true},"longitudinal_labs":[{"date":"2021-02-27","hemoglobin_g_dL":13.7,"wbc_k_uL":4.6,"platelets_k_uL":387,"creatinine_mg_dL":0.76,"alt_U_L":37},{"date":"2021-09-15","hemoglobin_g_dL":12.2,"wbc_k_uL":4.6,"platelets_k_uL":279,"creatinine_mg_dL":0.97,"alt_U_L":48},{"date":"2023-03-06","hemoglobin_g_dL":12.6,"wbc_k_uL":4.8,"platelets_k_uL":241,"creatinine_mg_dL":1.16,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_2549","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":53,"sex":"female","bmi":34.1,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-37},"pfs_months":45.24},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":73.2,"censored":false},"longitudinal_labs":[{"date":"2021-04-21","hemoglobin_g_dL":11.6,"wbc_k_uL":7.1,"platelets_k_uL":337,"creatinine_mg_dL":0.92,"alt_U_L":65},{"date":"2021-12-27","hemoglobin_g_dL":11.5,"wbc_k_uL":6.5,"platelets_k_uL":376,"creatinine_mg_dL":1.57,"alt_U_L":21},{"date":"2025-06-03","hemoglobin_g_dL":9.8,"wbc_k_uL":6.6,"platelets_k_uL":126,"creatinine_mg_dL":0.84,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_2550","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":55,"sex":"female","bmi":25.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-82},"pfs_months":18.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":true},"longitudinal_labs":[{"date":"2020-07-03","hemoglobin_g_dL":13.0,"wbc_k_uL":8.1,"platelets_k_uL":361,"creatinine_mg_dL":1.09,"alt_U_L":64},{"date":"2021-02-14","hemoglobin_g_dL":11.5,"wbc_k_uL":6.6,"platelets_k_uL":231,"creatinine_mg_dL":0.95,"alt_U_L":20},{"date":"2022-04-11","hemoglobin_g_dL":11.1,"wbc_k_uL":6.3,"platelets_k_uL":178,"creatinine_mg_dL":1.16,"alt_U_L":56}]}
{"patient_id":"ANODE_SYNTH_2025_2551","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":71,"sex":"female","bmi":27.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-71},"pfs_months":11.93},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-06-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.3,"censored":false},"longitudinal_labs":[{"date":"2020-03-05","hemoglobin_g_dL":12.5,"wbc_k_uL":9.9,"platelets_k_uL":270,"creatinine_mg_dL":0.96,"alt_U_L":64},{"date":"2020-10-21","hemoglobin_g_dL":13.8,"wbc_k_uL":8.6,"platelets_k_uL":220,"creatinine_mg_dL":1.59,"alt_U_L":106},{"date":"2021-06-19","hemoglobin_g_dL":11.6,"wbc_k_uL":7.3,"platelets_k_uL":124,"creatinine_mg_dL":1.87,"alt_U_L":73}]}
{"patient_id":"ANODE_SYNTH_2025_2552","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":72,"sex":"female","bmi":36.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-59},"pfs_months":26.51},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.0,"censored":true},"longitudinal_labs":[{"date":"2024-04-03","hemoglobin_g_dL":14.5,"wbc_k_uL":5.7,"platelets_k_uL":245,"creatinine_mg_dL":0.86,"alt_U_L":65},{"date":"2024-12-01","hemoglobin_g_dL":13.8,"wbc_k_uL":7.1,"platelets_k_uL":135,"creatinine_mg_dL":1.43,"alt_U_L":48},{"date":"2026-10-15","hemoglobin_g_dL":11.2,"wbc_k_uL":8.0,"platelets_k_uL":302,"creatinine_mg_dL":0.95,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_2553","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":66,"sex":"male","bmi":32.0,"smoking_pack_years":79,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-05-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-53},"pfs_months":37.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.4,"censored":false},"longitudinal_labs":[{"date":"2020-04-09","hemoglobin_g_dL":12.8,"wbc_k_uL":5.9,"platelets_k_uL":389,"creatinine_mg_dL":0.88,"alt_U_L":75},{"date":"2020-11-08","hemoglobin_g_dL":11.9,"wbc_k_uL":7.5,"platelets_k_uL":188,"creatinine_mg_dL":1.08,"alt_U_L":18},{"date":"2023-07-02","hemoglobin_g_dL":11.2,"wbc_k_uL":6.3,"platelets_k_uL":219,"creatinine_mg_dL":1.61,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_2554","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":78,"sex":"female","bmi":22.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-74},"pfs_months":13.11},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-06-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.4,"censored":false},"longitudinal_labs":[{"date":"2020-04-23","hemoglobin_g_dL":12.4,"wbc_k_uL":6.4,"platelets_k_uL":330,"creatinine_mg_dL":1.13,"alt_U_L":48},{"date":"2020-11-04","hemoglobin_g_dL":12.6,"wbc_k_uL":7.3,"platelets_k_uL":318,"creatinine_mg_dL":0.84,"alt_U_L":15},{"date":"2021-06-26","hemoglobin_g_dL":11.9,"wbc_k_uL":4.5,"platelets_k_uL":202,"creatinine_mg_dL":1.44,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_2555","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":61,"sex":"female","bmi":34.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-63},"pfs_months":25.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.7,"censored":true},"longitudinal_labs":[{"date":"2023-10-16","hemoglobin_g_dL":15.1,"wbc_k_uL":9.0,"platelets_k_uL":349,"creatinine_mg_dL":1.15,"alt_U_L":58},{"date":"2024-05-02","hemoglobin_g_dL":10.9,"wbc_k_uL":6.7,"platelets_k_uL":184,"creatinine_mg_dL":1.38,"alt_U_L":89},{"date":"2026-02-27","hemoglobin_g_dL":13.0,"wbc_k_uL":6.9,"platelets_k_uL":205,"creatinine_mg_dL":1.13,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_2556","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":88,"sex":"female","bmi":22.7,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-01-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-56},"pfs_months":41.59},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.1,"censored":true},"longitudinal_labs":[{"date":"2023-12-18","hemoglobin_g_dL":14.6,"wbc_k_uL":9.6,"platelets_k_uL":361,"creatinine_mg_dL":1.17,"alt_U_L":59},{"date":"2024-07-14","hemoglobin_g_dL":12.9,"wbc_k_uL":6.7,"platelets_k_uL":152,"creatinine_mg_dL":1.27,"alt_U_L":18},{"date":"2027-07-29","hemoglobin_g_dL":11.9,"wbc_k_uL":7.7,"platelets_k_uL":164,"creatinine_mg_dL":1.38,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_2557","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":60,"sex":"male","bmi":31.8,"smoking_pack_years":32,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-11-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-44},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.0,"censored":false},"longitudinal_labs":[{"date":"2023-10-13","hemoglobin_g_dL":12.8,"wbc_k_uL":7.0,"platelets_k_uL":262,"creatinine_mg_dL":0.79,"alt_U_L":32},{"date":"2024-05-10","hemoglobin_g_dL":10.4,"wbc_k_uL":6.6,"platelets_k_uL":334,"creatinine_mg_dL":0.85,"alt_U_L":45},{"date":"2024-03-14","hemoglobin_g_dL":11.1,"wbc_k_uL":3.6,"platelets_k_uL":127,"creatinine_mg_dL":0.99,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_2558","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":70,"sex":"female","bmi":26.7,"smoking_pack_years":44,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-04-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-58},"pfs_months":35.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":53.3,"censored":false},"longitudinal_labs":[{"date":"2025-03-19","hemoglobin_g_dL":14.0,"wbc_k_uL":9.9,"platelets_k_uL":154,"creatinine_mg_dL":0.66,"alt_U_L":76},{"date":"2025-10-14","hemoglobin_g_dL":11.0,"wbc_k_uL":4.3,"platelets_k_uL":262,"creatinine_mg_dL":1.13,"alt_U_L":68},{"date":"2028-05-08","hemoglobin_g_dL":12.4,"wbc_k_uL":7.9,"platelets_k_uL":207,"creatinine_mg_dL":0.97,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_2559","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":83,"sex":"male","bmi":28.0,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-11-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-63},"pfs_months":43.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":70.6,"censored":false},"longitudinal_labs":[{"date":"2022-10-11","hemoglobin_g_dL":12.8,"wbc_k_uL":9.0,"platelets_k_uL":201,"creatinine_mg_dL":0.88,"alt_U_L":14},{"date":"2023-05-28","hemoglobin_g_dL":10.7,"wbc_k_uL":7.9,"platelets_k_uL":211,"creatinine_mg_dL":1.57,"alt_U_L":99},{"date":"2026-07-31","hemoglobin_g_dL":10.2,"wbc_k_uL":3.9,"platelets_k_uL":280,"creatinine_mg_dL":1.84,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_2560","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":48,"sex":"female","bmi":25.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-60},"pfs_months":29.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":51.8,"censored":false},"longitudinal_labs":[{"date":"2025-08-03","hemoglobin_g_dL":15.0,"wbc_k_uL":6.6,"platelets_k_uL":280,"creatinine_mg_dL":0.64,"alt_U_L":65},{"date":"2026-03-15","hemoglobin_g_dL":13.6,"wbc_k_uL":5.8,"platelets_k_uL":370,"creatinine_mg_dL":1.24,"alt_U_L":38},{"date":"2028-04-10","hemoglobin_g_dL":12.6,"wbc_k_uL":7.5,"platelets_k_uL":109,"creatinine_mg_dL":1.98,"alt_U_L":58}]}
{"patient_id":"ANODE_SYNTH_2025_2561","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":63,"sex":"female","bmi":21.0,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-77},"pfs_months":35.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":58.3,"censored":true},"longitudinal_labs":[{"date":"2025-01-06","hemoglobin_g_dL":14.7,"wbc_k_uL":6.4,"platelets_k_uL":433,"creatinine_mg_dL":0.61,"alt_U_L":65},{"date":"2025-08-18","hemoglobin_g_dL":12.9,"wbc_k_uL":5.4,"platelets_k_uL":188,"creatinine_mg_dL":1.42,"alt_U_L":51},{"date":"2028-03-29","hemoglobin_g_dL":11.4,"wbc_k_uL":5.8,"platelets_k_uL":263,"creatinine_mg_dL":1.96,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_2562","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":48,"sex":"female","bmi":35.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-46},"pfs_months":30.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":51.6,"censored":false},"longitudinal_labs":[{"date":"2023-06-26","hemoglobin_g_dL":14.7,"wbc_k_uL":5.9,"platelets_k_uL":223,"creatinine_mg_dL":1.14,"alt_U_L":30},{"date":"2024-02-15","hemoglobin_g_dL":13.9,"wbc_k_uL":5.6,"platelets_k_uL":380,"creatinine_mg_dL":0.83,"alt_U_L":52},{"date":"2026-03-19","hemoglobin_g_dL":10.7,"wbc_k_uL":4.8,"platelets_k_uL":168,"creatinine_mg_dL":1.71,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_2563","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":68,"sex":"female","bmi":34.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-77},"pfs_months":24.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.6,"censored":false},"longitudinal_labs":[{"date":"2023-10-10","hemoglobin_g_dL":13.9,"wbc_k_uL":10.4,"platelets_k_uL":323,"creatinine_mg_dL":0.81,"alt_U_L":30},{"date":"2024-04-26","hemoglobin_g_dL":13.0,"wbc_k_uL":3.8,"platelets_k_uL":162,"creatinine_mg_dL":1.04,"alt_U_L":30},{"date":"2025-12-05","hemoglobin_g_dL":10.8,"wbc_k_uL":7.5,"platelets_k_uL":227,"creatinine_mg_dL":1.75,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_2564","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":68,"sex":"female","bmi":34.3,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-12-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-84},"pfs_months":14.72},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.9,"censored":false},"longitudinal_labs":[{"date":"2020-10-14","hemoglobin_g_dL":15.1,"wbc_k_uL":8.5,"platelets_k_uL":152,"creatinine_mg_dL":0.67,"alt_U_L":17},{"date":"2021-06-14","hemoglobin_g_dL":12.5,"wbc_k_uL":5.3,"platelets_k_uL":187,"creatinine_mg_dL":1.31,"alt_U_L":55},{"date":"2022-03-28","hemoglobin_g_dL":10.8,"wbc_k_uL":4.1,"platelets_k_uL":213,"creatinine_mg_dL":1.22,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_2565","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":88,"sex":"female","bmi":23.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-36},"pfs_months":20.3},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":false},"longitudinal_labs":[{"date":"2020-08-24","hemoglobin_g_dL":11.5,"wbc_k_uL":9.6,"platelets_k_uL":180,"creatinine_mg_dL":0.8,"alt_U_L":50},{"date":"2021-04-22","hemoglobin_g_dL":12.6,"wbc_k_uL":6.3,"platelets_k_uL":193,"creatinine_mg_dL":1.19,"alt_U_L":86},{"date":"2022-08-21","hemoglobin_g_dL":10.5,"wbc_k_uL":3.5,"platelets_k_uL":255,"creatinine_mg_dL":1.06,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_2566","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":49,"sex":"female","bmi":32.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-46},"pfs_months":28.19},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-18","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.9,"censored":false},"longitudinal_labs":[{"date":"2021-11-12","hemoglobin_g_dL":13.2,"wbc_k_uL":4.6,"platelets_k_uL":295,"creatinine_mg_dL":0.67,"alt_U_L":77},{"date":"2022-05-28","hemoglobin_g_dL":13.4,"wbc_k_uL":3.8,"platelets_k_uL":137,"creatinine_mg_dL":1.16,"alt_U_L":43},{"date":"2024-04-18","hemoglobin_g_dL":12.8,"wbc_k_uL":6.5,"platelets_k_uL":141,"creatinine_mg_dL":1.63,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_2567","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":86,"sex":"male","bmi":27.5,"smoking_pack_years":17,"ecog_performance_status":2,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-06-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-63},"pfs_months":19.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.0,"censored":false},"longitudinal_labs":[{"date":"2025-04-01","hemoglobin_g_dL":11.9,"wbc_k_uL":8.4,"platelets_k_uL":384,"creatinine_mg_dL":0.77,"alt_U_L":47},{"date":"2025-12-03","hemoglobin_g_dL":12.8,"wbc_k_uL":5.4,"platelets_k_uL":342,"creatinine_mg_dL":1.56,"alt_U_L":63},{"date":"2027-03-28","hemoglobin_g_dL":10.2,"wbc_k_uL":6.3,"platelets_k_uL":342,"creatinine_mg_dL":1.13,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_2568","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":85,"sex":"male","bmi":34.8,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-66},"pfs_months":6.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-03-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":14.8,"censored":false},"longitudinal_labs":[{"date":"2020-06-18","hemoglobin_g_dL":13.9,"wbc_k_uL":6.8,"platelets_k_uL":407,"creatinine_mg_dL":0.75,"alt_U_L":24},{"date":"2021-01-11","hemoglobin_g_dL":13.6,"wbc_k_uL":6.8,"platelets_k_uL":173,"creatinine_mg_dL":1.37,"alt_U_L":94},{"date":"2021-03-03","hemoglobin_g_dL":12.7,"wbc_k_uL":4.9,"platelets_k_uL":224,"creatinine_mg_dL":1.87,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_2569","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":83,"sex":"female","bmi":29.8,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-02-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-60},"pfs_months":17.45},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.2,"censored":false},"longitudinal_labs":[{"date":"2022-01-13","hemoglobin_g_dL":15.2,"wbc_k_uL":7.3,"platelets_k_uL":368,"creatinine_mg_dL":1.06,"alt_U_L":76},{"date":"2022-08-19","hemoglobin_g_dL":10.9,"wbc_k_uL":5.9,"platelets_k_uL":319,"creatinine_mg_dL":1.43,"alt_U_L":30},{"date":"2023-09-25","hemoglobin_g_dL":10.2,"wbc_k_uL":7.2,"platelets_k_uL":303,"creatinine_mg_dL":1.23,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_2570","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":67,"sex":"female","bmi":36.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-79},"pfs_months":6.57},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.1,"censored":false},"longitudinal_labs":[{"date":"2024-07-21","hemoglobin_g_dL":12.8,"wbc_k_uL":6.9,"platelets_k_uL":194,"creatinine_mg_dL":0.7,"alt_U_L":68},{"date":"2025-02-26","hemoglobin_g_dL":13.6,"wbc_k_uL":4.4,"platelets_k_uL":313,"creatinine_mg_dL":1.12,"alt_U_L":120},{"date":"2025-05-08","hemoglobin_g_dL":11.3,"wbc_k_uL":5.6,"platelets_k_uL":282,"creatinine_mg_dL":0.94,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_2571","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":72,"sex":"female","bmi":33.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-68},"pfs_months":8.87},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.7,"censored":true},"longitudinal_labs":[{"date":"2022-12-19","hemoglobin_g_dL":13.5,"wbc_k_uL":9.9,"platelets_k_uL":221,"creatinine_mg_dL":0.74,"alt_U_L":36},{"date":"2023-08-05","hemoglobin_g_dL":11.5,"wbc_k_uL":5.0,"platelets_k_uL":377,"creatinine_mg_dL":0.81,"alt_U_L":20},{"date":"2023-12-17","hemoglobin_g_dL":12.3,"wbc_k_uL":3.2,"platelets_k_uL":325,"creatinine_mg_dL":1.32,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2572","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":87,"sex":"male","bmi":36.4,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-40},"pfs_months":18.69},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":false},"longitudinal_labs":[{"date":"2022-06-03","hemoglobin_g_dL":15.5,"wbc_k_uL":9.5,"platelets_k_uL":326,"creatinine_mg_dL":0.61,"alt_U_L":51},{"date":"2022-12-21","hemoglobin_g_dL":10.6,"wbc_k_uL":5.7,"platelets_k_uL":291,"creatinine_mg_dL":0.93,"alt_U_L":46},{"date":"2024-02-22","hemoglobin_g_dL":9.7,"wbc_k_uL":6.0,"platelets_k_uL":336,"creatinine_mg_dL":1.39,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_2573","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":71,"sex":"female","bmi":21.1,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-72},"pfs_months":43.93},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":70.9,"censored":false},"longitudinal_labs":[{"date":"2022-10-19","hemoglobin_g_dL":14.1,"wbc_k_uL":5.5,"platelets_k_uL":173,"creatinine_mg_dL":1.07,"alt_U_L":44},{"date":"2023-06-23","hemoglobin_g_dL":11.0,"wbc_k_uL":4.6,"platelets_k_uL":368,"creatinine_mg_dL":0.89,"alt_U_L":73},{"date":"2026-09-29","hemoglobin_g_dL":11.9,"wbc_k_uL":5.4,"platelets_k_uL":273,"creatinine_mg_dL":0.81,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_2574","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":75,"sex":"female","bmi":24.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-44},"pfs_months":30.39},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-24","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.1,"censored":true},"longitudinal_labs":[{"date":"2021-01-11","hemoglobin_g_dL":11.6,"wbc_k_uL":10.0,"platelets_k_uL":404,"creatinine_mg_dL":0.66,"alt_U_L":53},{"date":"2021-08-04","hemoglobin_g_dL":12.7,"wbc_k_uL":8.6,"platelets_k_uL":266,"creatinine_mg_dL":1.49,"alt_U_L":50},{"date":"2023-08-24","hemoglobin_g_dL":11.9,"wbc_k_uL":4.0,"platelets_k_uL":153,"creatinine_mg_dL":1.29,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_2575","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":78,"sex":"male","bmi":30.7,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-04-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-69},"pfs_months":6.21},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":20.5,"censored":true},"longitudinal_labs":[{"date":"2023-04-02","hemoglobin_g_dL":12.3,"wbc_k_uL":9.6,"platelets_k_uL":168,"creatinine_mg_dL":0.93,"alt_U_L":50},{"date":"2023-10-15","hemoglobin_g_dL":10.9,"wbc_k_uL":7.0,"platelets_k_uL":330,"creatinine_mg_dL":1.41,"alt_U_L":97},{"date":"2023-11-16","hemoglobin_g_dL":9.7,"wbc_k_uL":7.8,"platelets_k_uL":252,"creatinine_mg_dL":1.12,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_2576","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":70,"sex":"female","bmi":19.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-31},"pfs_months":27.56},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.7,"censored":false},"longitudinal_labs":[{"date":"2025-06-22","hemoglobin_g_dL":14.9,"wbc_k_uL":9.2,"platelets_k_uL":227,"creatinine_mg_dL":1.26,"alt_U_L":45},{"date":"2026-01-17","hemoglobin_g_dL":11.9,"wbc_k_uL":6.4,"platelets_k_uL":262,"creatinine_mg_dL":0.72,"alt_U_L":78},{"date":"2028-01-03","hemoglobin_g_dL":12.5,"wbc_k_uL":7.7,"platelets_k_uL":126,"creatinine_mg_dL":1.33,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_2577","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":69,"sex":"male","bmi":25.3,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-04-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-47},"pfs_months":3.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":7.6,"censored":false},"longitudinal_labs":[{"date":"2025-02-23","hemoglobin_g_dL":12.5,"wbc_k_uL":4.8,"platelets_k_uL":323,"creatinine_mg_dL":1.29,"alt_U_L":13},{"date":"2025-10-09","hemoglobin_g_dL":13.6,"wbc_k_uL":7.5,"platelets_k_uL":260,"creatinine_mg_dL":0.82,"alt_U_L":70},{"date":"2025-09-09","hemoglobin_g_dL":11.1,"wbc_k_uL":4.5,"platelets_k_uL":290,"creatinine_mg_dL":1.23,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_2578","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":52,"sex":"female","bmi":21.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-39},"pfs_months":27.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":false},"longitudinal_labs":[{"date":"2025-10-01","hemoglobin_g_dL":12.4,"wbc_k_uL":8.6,"platelets_k_uL":344,"creatinine_mg_dL":0.96,"alt_U_L":45},{"date":"2026-05-28","hemoglobin_g_dL":10.3,"wbc_k_uL":5.4,"platelets_k_uL":122,"creatinine_mg_dL":1.1,"alt_U_L":40},{"date":"2028-04-06","hemoglobin_g_dL":10.0,"wbc_k_uL":7.6,"platelets_k_uL":302,"creatinine_mg_dL":1.02,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_2579","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":64,"sex":"female","bmi":35.5,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-59},"pfs_months":42.18},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":67.8,"censored":true},"longitudinal_labs":[{"date":"2022-04-28","hemoglobin_g_dL":12.0,"wbc_k_uL":5.5,"platelets_k_uL":152,"creatinine_mg_dL":0.79,"alt_U_L":16},{"date":"2022-12-08","hemoglobin_g_dL":13.7,"wbc_k_uL":6.5,"platelets_k_uL":332,"creatinine_mg_dL":1.25,"alt_U_L":53},{"date":"2026-01-08","hemoglobin_g_dL":10.1,"wbc_k_uL":7.9,"platelets_k_uL":304,"creatinine_mg_dL":0.91,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_2580","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":79,"sex":"female","bmi":37.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-47},"pfs_months":20.63},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":true},"longitudinal_labs":[{"date":"2023-05-09","hemoglobin_g_dL":11.5,"wbc_k_uL":7.7,"platelets_k_uL":427,"creatinine_mg_dL":1.07,"alt_U_L":39},{"date":"2024-01-14","hemoglobin_g_dL":10.1,"wbc_k_uL":7.6,"platelets_k_uL":178,"creatinine_mg_dL":1.4,"alt_U_L":113},{"date":"2025-04-23","hemoglobin_g_dL":9.7,"wbc_k_uL":3.6,"platelets_k_uL":202,"creatinine_mg_dL":1.3,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_2581","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":54,"sex":"female","bmi":35.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-59},"pfs_months":23.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.7,"censored":false},"longitudinal_labs":[{"date":"2024-05-06","hemoglobin_g_dL":14.9,"wbc_k_uL":6.5,"platelets_k_uL":227,"creatinine_mg_dL":1.22,"alt_U_L":44},{"date":"2024-12-19","hemoglobin_g_dL":13.4,"wbc_k_uL":7.1,"platelets_k_uL":241,"creatinine_mg_dL":1.4,"alt_U_L":46},{"date":"2026-07-16","hemoglobin_g_dL":10.8,"wbc_k_uL":6.8,"platelets_k_uL":151,"creatinine_mg_dL":1.89,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_2582","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":59,"sex":"female","bmi":33.9,"smoking_pack_years":57,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-09-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-79},"pfs_months":10.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.0,"censored":false},"longitudinal_labs":[{"date":"2022-08-09","hemoglobin_g_dL":13.1,"wbc_k_uL":9.9,"platelets_k_uL":171,"creatinine_mg_dL":0.62,"alt_U_L":58},{"date":"2023-03-16","hemoglobin_g_dL":13.7,"wbc_k_uL":7.7,"platelets_k_uL":330,"creatinine_mg_dL":0.89,"alt_U_L":21},{"date":"2023-09-16","hemoglobin_g_dL":10.0,"wbc_k_uL":5.8,"platelets_k_uL":103,"creatinine_mg_dL":0.94,"alt_U_L":90}]}
{"patient_id":"ANODE_SYNTH_2025_2583","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":75,"sex":"female","bmi":28.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-10-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-50},"pfs_months":35.22},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-10-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":51.0,"censored":true},"longitudinal_labs":[{"date":"2025-08-26","hemoglobin_g_dL":13.7,"wbc_k_uL":9.5,"platelets_k_uL":445,"creatinine_mg_dL":1.01,"alt_U_L":15},{"date":"2026-04-26","hemoglobin_g_dL":13.8,"wbc_k_uL":8.0,"platelets_k_uL":238,"creatinine_mg_dL":0.72,"alt_U_L":80},{"date":"2028-10-26","hemoglobin_g_dL":11.6,"wbc_k_uL":7.8,"platelets_k_uL":118,"creatinine_mg_dL":1.49,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_2584","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":79,"sex":"male","bmi":31.6,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-43},"pfs_months":4.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":11.8,"censored":true},"longitudinal_labs":[{"date":"2021-08-21","hemoglobin_g_dL":13.2,"wbc_k_uL":8.0,"platelets_k_uL":293,"creatinine_mg_dL":1.08,"alt_U_L":20},{"date":"2022-03-26","hemoglobin_g_dL":12.7,"wbc_k_uL":5.1,"platelets_k_uL":131,"creatinine_mg_dL":1.55,"alt_U_L":57},{"date":"2022-02-08","hemoglobin_g_dL":13.0,"wbc_k_uL":6.1,"platelets_k_uL":313,"creatinine_mg_dL":1.9,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_2585","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":88,"sex":"female","bmi":19.8,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-12-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-79},"pfs_months":11.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.9,"censored":false},"longitudinal_labs":[{"date":"2024-11-11","hemoglobin_g_dL":13.9,"wbc_k_uL":4.9,"platelets_k_uL":408,"creatinine_mg_dL":1.2,"alt_U_L":25},{"date":"2025-06-02","hemoglobin_g_dL":10.6,"wbc_k_uL":5.7,"platelets_k_uL":285,"creatinine_mg_dL":1.59,"alt_U_L":37},{"date":"2026-01-11","hemoglobin_g_dL":10.6,"wbc_k_uL":4.4,"platelets_k_uL":274,"creatinine_mg_dL":1.32,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_2586","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":75,"sex":"female","bmi":24.2,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-12-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-73},"pfs_months":38.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":72.5,"censored":false},"longitudinal_labs":[{"date":"2023-11-02","hemoglobin_g_dL":14.4,"wbc_k_uL":10.2,"platelets_k_uL":190,"creatinine_mg_dL":1.25,"alt_U_L":21},{"date":"2024-06-28","hemoglobin_g_dL":13.1,"wbc_k_uL":6.0,"platelets_k_uL":221,"creatinine_mg_dL":0.86,"alt_U_L":109},{"date":"2027-03-27","hemoglobin_g_dL":10.7,"wbc_k_uL":4.1,"platelets_k_uL":335,"creatinine_mg_dL":0.87,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_2587","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":52,"sex":"female","bmi":18.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-09-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-38},"pfs_months":20.44},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.8,"censored":false},"longitudinal_labs":[{"date":"2025-08-19","hemoglobin_g_dL":11.9,"wbc_k_uL":10.3,"platelets_k_uL":357,"creatinine_mg_dL":0.88,"alt_U_L":48},{"date":"2026-03-04","hemoglobin_g_dL":10.7,"wbc_k_uL":6.2,"platelets_k_uL":155,"creatinine_mg_dL":0.77,"alt_U_L":85},{"date":"2027-06-03","hemoglobin_g_dL":12.6,"wbc_k_uL":4.5,"platelets_k_uL":192,"creatinine_mg_dL":1.01,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_2588","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":81,"sex":"female","bmi":23.5,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-12-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-84},"pfs_months":12.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.8,"censored":false},"longitudinal_labs":[{"date":"2024-11-19","hemoglobin_g_dL":11.9,"wbc_k_uL":8.2,"platelets_k_uL":266,"creatinine_mg_dL":1.19,"alt_U_L":50},{"date":"2025-06-18","hemoglobin_g_dL":13.5,"wbc_k_uL":4.3,"platelets_k_uL":183,"creatinine_mg_dL":0.76,"alt_U_L":83},{"date":"2026-01-28","hemoglobin_g_dL":12.6,"wbc_k_uL":4.7,"platelets_k_uL":102,"creatinine_mg_dL":1.48,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_2589","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":88,"sex":"male","bmi":20.6,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-63},"pfs_months":15.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.6,"censored":false},"longitudinal_labs":[{"date":"2020-10-08","hemoglobin_g_dL":14.0,"wbc_k_uL":8.0,"platelets_k_uL":365,"creatinine_mg_dL":1.06,"alt_U_L":43},{"date":"2021-05-13","hemoglobin_g_dL":11.6,"wbc_k_uL":5.4,"platelets_k_uL":143,"creatinine_mg_dL":1.59,"alt_U_L":47},{"date":"2022-05-01","hemoglobin_g_dL":12.7,"wbc_k_uL":3.5,"platelets_k_uL":217,"creatinine_mg_dL":1.81,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_2590","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":77,"sex":"male","bmi":33.7,"smoking_pack_years":56,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-09-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-79},"pfs_months":34.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":true},"longitudinal_labs":[{"date":"2022-07-26","hemoglobin_g_dL":13.5,"wbc_k_uL":8.8,"platelets_k_uL":370,"creatinine_mg_dL":1.09,"alt_U_L":28},{"date":"2023-03-10","hemoglobin_g_dL":11.8,"wbc_k_uL":4.4,"platelets_k_uL":241,"creatinine_mg_dL":0.92,"alt_U_L":116},{"date":"2025-07-18","hemoglobin_g_dL":12.5,"wbc_k_uL":7.9,"platelets_k_uL":289,"creatinine_mg_dL":1.35,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_2591","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":78,"sex":"male","bmi":23.3,"smoking_pack_years":80,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-01-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-81},"pfs_months":28.81},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":44.5,"censored":false},"longitudinal_labs":[{"date":"2023-12-09","hemoglobin_g_dL":11.9,"wbc_k_uL":5.6,"platelets_k_uL":246,"creatinine_mg_dL":0.75,"alt_U_L":40},{"date":"2024-07-08","hemoglobin_g_dL":13.2,"wbc_k_uL":6.7,"platelets_k_uL":128,"creatinine_mg_dL":1.33,"alt_U_L":61},{"date":"2026-07-20","hemoglobin_g_dL":10.3,"wbc_k_uL":7.3,"platelets_k_uL":197,"creatinine_mg_dL":1.02,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_2592","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":50,"sex":"male","bmi":33.7,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-39},"pfs_months":28.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.1,"censored":false},"longitudinal_labs":[{"date":"2024-07-22","hemoglobin_g_dL":13.2,"wbc_k_uL":8.8,"platelets_k_uL":176,"creatinine_mg_dL":1.16,"alt_U_L":36},{"date":"2025-03-24","hemoglobin_g_dL":13.4,"wbc_k_uL":6.1,"platelets_k_uL":198,"creatinine_mg_dL":1.41,"alt_U_L":26},{"date":"2027-03-29","hemoglobin_g_dL":10.7,"wbc_k_uL":6.5,"platelets_k_uL":207,"creatinine_mg_dL":1.9,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_2593","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":69,"sex":"female","bmi":33.9,"smoking_pack_years":49,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-69},"pfs_months":19.45},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.0,"censored":true},"longitudinal_labs":[{"date":"2023-11-11","hemoglobin_g_dL":12.5,"wbc_k_uL":9.6,"platelets_k_uL":295,"creatinine_mg_dL":1.26,"alt_U_L":45},{"date":"2024-06-12","hemoglobin_g_dL":13.8,"wbc_k_uL":8.7,"platelets_k_uL":175,"creatinine_mg_dL":1.11,"alt_U_L":87},{"date":"2025-09-05","hemoglobin_g_dL":10.3,"wbc_k_uL":7.4,"platelets_k_uL":186,"creatinine_mg_dL":1.5,"alt_U_L":28}]}
{"patient_id":"ANODE_SYNTH_2025_2594","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":58,"sex":"female","bmi":27.3,"smoking_pack_years":41,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-08-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-35},"pfs_months":23.82},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.9,"censored":true},"longitudinal_labs":[{"date":"2023-06-27","hemoglobin_g_dL":14.9,"wbc_k_uL":5.6,"platelets_k_uL":309,"creatinine_mg_dL":1.01,"alt_U_L":49},{"date":"2024-02-07","hemoglobin_g_dL":13.1,"wbc_k_uL":5.7,"platelets_k_uL":128,"creatinine_mg_dL":1.18,"alt_U_L":98},{"date":"2025-08-24","hemoglobin_g_dL":11.6,"wbc_k_uL":3.7,"platelets_k_uL":181,"creatinine_mg_dL":1.24,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_2595","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":63,"sex":"male","bmi":19.6,"smoking_pack_years":39,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-10-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-45},"pfs_months":3.71},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.2,"censored":false},"longitudinal_labs":[{"date":"2024-09-10","hemoglobin_g_dL":13.6,"wbc_k_uL":5.2,"platelets_k_uL":195,"creatinine_mg_dL":1.2,"alt_U_L":27},{"date":"2025-04-17","hemoglobin_g_dL":13.1,"wbc_k_uL":8.6,"platelets_k_uL":266,"creatinine_mg_dL":0.9,"alt_U_L":38},{"date":"2025-02-14","hemoglobin_g_dL":11.0,"wbc_k_uL":3.1,"platelets_k_uL":225,"creatinine_mg_dL":1.13,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_2596","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":83,"sex":"male","bmi":21.8,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-10-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-34},"pfs_months":30.52},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.1,"censored":true},"longitudinal_labs":[{"date":"2023-09-15","hemoglobin_g_dL":11.7,"wbc_k_uL":7.6,"platelets_k_uL":314,"creatinine_mg_dL":1.08,"alt_U_L":46},{"date":"2024-04-13","hemoglobin_g_dL":13.3,"wbc_k_uL":6.0,"platelets_k_uL":332,"creatinine_mg_dL":1.47,"alt_U_L":50},{"date":"2026-06-12","hemoglobin_g_dL":12.9,"wbc_k_uL":6.8,"platelets_k_uL":170,"creatinine_mg_dL":1.75,"alt_U_L":145}]}
{"patient_id":"ANODE_SYNTH_2025_2597","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":79,"sex":"male","bmi":21.1,"smoking_pack_years":37,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-11-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-83},"pfs_months":8.18},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":19.4,"censored":false},"longitudinal_labs":[{"date":"2021-09-24","hemoglobin_g_dL":14.0,"wbc_k_uL":9.5,"platelets_k_uL":229,"creatinine_mg_dL":1.21,"alt_U_L":26},{"date":"2022-05-01","hemoglobin_g_dL":11.7,"wbc_k_uL":8.5,"platelets_k_uL":276,"creatinine_mg_dL":1.4,"alt_U_L":46},{"date":"2022-07-30","hemoglobin_g_dL":11.6,"wbc_k_uL":4.5,"platelets_k_uL":150,"creatinine_mg_dL":1.4,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_2598","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":57,"sex":"female","bmi":37.1,"smoking_pack_years":59,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-50},"pfs_months":45.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":64.1,"censored":false},"longitudinal_labs":[{"date":"2022-07-08","hemoglobin_g_dL":15.4,"wbc_k_uL":4.6,"platelets_k_uL":349,"creatinine_mg_dL":1.2,"alt_U_L":37},{"date":"2023-02-09","hemoglobin_g_dL":12.7,"wbc_k_uL":8.4,"platelets_k_uL":293,"creatinine_mg_dL":0.98,"alt_U_L":85},{"date":"2026-07-21","hemoglobin_g_dL":12.8,"wbc_k_uL":3.9,"platelets_k_uL":130,"creatinine_mg_dL":1.78,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_2599","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":68,"sex":"female","bmi":21.9,"smoking_pack_years":46,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-79},"pfs_months":13.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.0,"censored":true},"longitudinal_labs":[{"date":"2025-05-20","hemoglobin_g_dL":14.8,"wbc_k_uL":10.8,"platelets_k_uL":375,"creatinine_mg_dL":0.77,"alt_U_L":19},{"date":"2025-12-05","hemoglobin_g_dL":13.7,"wbc_k_uL":6.2,"platelets_k_uL":288,"creatinine_mg_dL":0.76,"alt_U_L":16},{"date":"2026-09-01","hemoglobin_g_dL":12.9,"wbc_k_uL":7.1,"platelets_k_uL":326,"creatinine_mg_dL":1.93,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_2600","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":69,"sex":"female","bmi":35.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-66},"pfs_months":26.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.8,"censored":true},"longitudinal_labs":[{"date":"2020-08-03","hemoglobin_g_dL":14.1,"wbc_k_uL":8.6,"platelets_k_uL":329,"creatinine_mg_dL":0.77,"alt_U_L":37},{"date":"2021-02-28","hemoglobin_g_dL":13.2,"wbc_k_uL":8.2,"platelets_k_uL":206,"creatinine_mg_dL":0.88,"alt_U_L":101},{"date":"2022-11-30","hemoglobin_g_dL":10.1,"wbc_k_uL":3.5,"platelets_k_uL":335,"creatinine_mg_dL":1.35,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_2601","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":54,"sex":"female","bmi":37.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-54},"pfs_months":22.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.0,"censored":false},"longitudinal_labs":[{"date":"2024-07-23","hemoglobin_g_dL":13.3,"wbc_k_uL":10.1,"platelets_k_uL":403,"creatinine_mg_dL":1.29,"alt_U_L":69},{"date":"2025-02-21","hemoglobin_g_dL":11.6,"wbc_k_uL":4.1,"platelets_k_uL":135,"creatinine_mg_dL":1.37,"alt_U_L":49},{"date":"2026-07-27","hemoglobin_g_dL":11.2,"wbc_k_uL":5.9,"platelets_k_uL":140,"creatinine_mg_dL":1.38,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_2602","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":51,"sex":"female","bmi":22.3,"smoking_pack_years":44,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-08-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-85},"pfs_months":15.87},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":false},"longitudinal_labs":[{"date":"2020-06-15","hemoglobin_g_dL":14.2,"wbc_k_uL":8.2,"platelets_k_uL":210,"creatinine_mg_dL":0.8,"alt_U_L":34},{"date":"2021-01-29","hemoglobin_g_dL":10.6,"wbc_k_uL":8.8,"platelets_k_uL":179,"creatinine_mg_dL":0.73,"alt_U_L":88},{"date":"2022-01-21","hemoglobin_g_dL":9.9,"wbc_k_uL":6.6,"platelets_k_uL":235,"creatinine_mg_dL":1.48,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_2603","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":82,"sex":"male","bmi":21.7,"smoking_pack_years":50,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-10-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-35},"pfs_months":10.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.0,"censored":false},"longitudinal_labs":[{"date":"2020-09-10","hemoglobin_g_dL":13.9,"wbc_k_uL":5.8,"platelets_k_uL":278,"creatinine_mg_dL":0.77,"alt_U_L":14},{"date":"2021-04-08","hemoglobin_g_dL":11.3,"wbc_k_uL":3.9,"platelets_k_uL":265,"creatinine_mg_dL":0.84,"alt_U_L":44},{"date":"2021-09-27","hemoglobin_g_dL":10.1,"wbc_k_uL":6.9,"platelets_k_uL":195,"creatinine_mg_dL":1.15,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2604","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":80,"sex":"female","bmi":19.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-83},"pfs_months":13.08},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":23.2,"censored":false},"longitudinal_labs":[{"date":"2025-10-15","hemoglobin_g_dL":13.5,"wbc_k_uL":8.3,"platelets_k_uL":205,"creatinine_mg_dL":1.2,"alt_U_L":26},{"date":"2026-05-07","hemoglobin_g_dL":12.1,"wbc_k_uL":7.8,"platelets_k_uL":201,"creatinine_mg_dL":1.58,"alt_U_L":35},{"date":"2026-12-23","hemoglobin_g_dL":12.0,"wbc_k_uL":4.0,"platelets_k_uL":101,"creatinine_mg_dL":1.34,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_2605","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":66,"sex":"female","bmi":28.3,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-07-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-60},"pfs_months":31.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":66.6,"censored":true},"longitudinal_labs":[{"date":"2020-06-06","hemoglobin_g_dL":15.0,"wbc_k_uL":6.7,"platelets_k_uL":402,"creatinine_mg_dL":1.16,"alt_U_L":71},{"date":"2021-01-23","hemoglobin_g_dL":11.3,"wbc_k_uL":4.6,"platelets_k_uL":148,"creatinine_mg_dL":0.95,"alt_U_L":16},{"date":"2023-05-02","hemoglobin_g_dL":12.6,"wbc_k_uL":7.8,"platelets_k_uL":131,"creatinine_mg_dL":1.9,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_2606","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":75,"sex":"female","bmi":23.7,"smoking_pack_years":66,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-11-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-34},"pfs_months":38.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.6,"censored":false},"longitudinal_labs":[{"date":"2020-09-19","hemoglobin_g_dL":15.0,"wbc_k_uL":8.4,"platelets_k_uL":227,"creatinine_mg_dL":1.03,"alt_U_L":42},{"date":"2021-05-22","hemoglobin_g_dL":12.5,"wbc_k_uL":8.0,"platelets_k_uL":216,"creatinine_mg_dL":1.07,"alt_U_L":44},{"date":"2024-01-29","hemoglobin_g_dL":12.7,"wbc_k_uL":6.8,"platelets_k_uL":339,"creatinine_mg_dL":1.32,"alt_U_L":31}]}
{"patient_id":"ANODE_SYNTH_2025_2607","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":68,"sex":"male","bmi":31.3,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-01-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-67},"pfs_months":12.85},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":17.1,"censored":false},"longitudinal_labs":[{"date":"2025-12-06","hemoglobin_g_dL":14.8,"wbc_k_uL":6.5,"platelets_k_uL":385,"creatinine_mg_dL":0.94,"alt_U_L":79},{"date":"2026-07-02","hemoglobin_g_dL":12.4,"wbc_k_uL":5.9,"platelets_k_uL":190,"creatinine_mg_dL":1.17,"alt_U_L":42},{"date":"2027-02-13","hemoglobin_g_dL":12.5,"wbc_k_uL":7.5,"platelets_k_uL":333,"creatinine_mg_dL":1.46,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_2608","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":77,"sex":"female","bmi":31.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-31},"pfs_months":18.04},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.1,"censored":true},"longitudinal_labs":[{"date":"2025-05-23","hemoglobin_g_dL":14.0,"wbc_k_uL":7.6,"platelets_k_uL":350,"creatinine_mg_dL":0.94,"alt_U_L":22},{"date":"2026-01-02","hemoglobin_g_dL":11.3,"wbc_k_uL":6.0,"platelets_k_uL":143,"creatinine_mg_dL":0.84,"alt_U_L":68},{"date":"2027-01-20","hemoglobin_g_dL":9.8,"wbc_k_uL":7.7,"platelets_k_uL":217,"creatinine_mg_dL":1.21,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_2609","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":84,"sex":"female","bmi":37.4,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-78},"pfs_months":6.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":10.8,"censored":true},"longitudinal_labs":[{"date":"2024-11-13","hemoglobin_g_dL":13.1,"wbc_k_uL":7.5,"platelets_k_uL":177,"creatinine_mg_dL":0.92,"alt_U_L":78},{"date":"2025-07-19","hemoglobin_g_dL":10.5,"wbc_k_uL":5.8,"platelets_k_uL":280,"creatinine_mg_dL":1.13,"alt_U_L":76},{"date":"2025-09-16","hemoglobin_g_dL":12.2,"wbc_k_uL":7.5,"platelets_k_uL":291,"creatinine_mg_dL":1.3,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_2610","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":52,"sex":"female","bmi":31.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-65},"pfs_months":25.76},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.4,"censored":false},"longitudinal_labs":[{"date":"2020-02-11","hemoglobin_g_dL":12.7,"wbc_k_uL":4.7,"platelets_k_uL":255,"creatinine_mg_dL":1.19,"alt_U_L":72},{"date":"2020-10-06","hemoglobin_g_dL":13.2,"wbc_k_uL":6.9,"platelets_k_uL":355,"creatinine_mg_dL":1.39,"alt_U_L":58},{"date":"2022-06-26","hemoglobin_g_dL":10.8,"wbc_k_uL":4.3,"platelets_k_uL":166,"creatinine_mg_dL":1.95,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_2611","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":87,"sex":"female","bmi":29.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-12-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-59},"pfs_months":27.56},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":41.6,"censored":true},"longitudinal_labs":[{"date":"2024-11-21","hemoglobin_g_dL":15.3,"wbc_k_uL":5.7,"platelets_k_uL":262,"creatinine_mg_dL":0.75,"alt_U_L":54},{"date":"2025-06-19","hemoglobin_g_dL":13.6,"wbc_k_uL":5.7,"platelets_k_uL":237,"creatinine_mg_dL":1.01,"alt_U_L":70},{"date":"2027-05-10","hemoglobin_g_dL":11.7,"wbc_k_uL":5.3,"platelets_k_uL":274,"creatinine_mg_dL":1.89,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_2612","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":53,"sex":"female","bmi":27.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-70},"pfs_months":21.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.0,"censored":false},"longitudinal_labs":[{"date":"2021-06-26","hemoglobin_g_dL":11.9,"wbc_k_uL":7.7,"platelets_k_uL":361,"creatinine_mg_dL":1.23,"alt_U_L":64},{"date":"2022-02-08","hemoglobin_g_dL":13.4,"wbc_k_uL":7.6,"platelets_k_uL":227,"creatinine_mg_dL":0.74,"alt_U_L":79},{"date":"2023-07-27","hemoglobin_g_dL":9.6,"wbc_k_uL":4.7,"platelets_k_uL":319,"creatinine_mg_dL":1.29,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_2613","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":77,"sex":"male","bmi":37.1,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-02-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-43},"pfs_months":19.32},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.4,"censored":false},"longitudinal_labs":[{"date":"2020-01-07","hemoglobin_g_dL":15.4,"wbc_k_uL":10.7,"platelets_k_uL":376,"creatinine_mg_dL":1.07,"alt_U_L":36},{"date":"2020-08-14","hemoglobin_g_dL":12.8,"wbc_k_uL":3.9,"platelets_k_uL":374,"creatinine_mg_dL":0.88,"alt_U_L":42},{"date":"2021-10-04","hemoglobin_g_dL":10.9,"wbc_k_uL":3.2,"platelets_k_uL":261,"creatinine_mg_dL":0.97,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_2614","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":61,"sex":"male","bmi":31.0,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-69},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":16.1,"censored":true},"longitudinal_labs":[{"date":"2021-06-12","hemoglobin_g_dL":15.3,"wbc_k_uL":8.0,"platelets_k_uL":192,"creatinine_mg_dL":0.62,"alt_U_L":29},{"date":"2022-01-18","hemoglobin_g_dL":10.7,"wbc_k_uL":6.8,"platelets_k_uL":348,"creatinine_mg_dL":1.08,"alt_U_L":108},{"date":"2021-11-17","hemoglobin_g_dL":11.9,"wbc_k_uL":6.8,"platelets_k_uL":291,"creatinine_mg_dL":1.67,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_2615","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":62,"sex":"male","bmi":38.0,"smoking_pack_years":38,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-12-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-51},"pfs_months":26.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.8,"censored":false},"longitudinal_labs":[{"date":"2020-12-10","hemoglobin_g_dL":13.1,"wbc_k_uL":9.2,"platelets_k_uL":167,"creatinine_mg_dL":1.26,"alt_U_L":66},{"date":"2021-06-24","hemoglobin_g_dL":13.4,"wbc_k_uL":3.8,"platelets_k_uL":267,"creatinine_mg_dL":0.95,"alt_U_L":21},{"date":"2023-03-25","hemoglobin_g_dL":12.6,"wbc_k_uL":3.2,"platelets_k_uL":110,"creatinine_mg_dL":1.54,"alt_U_L":139}]}
{"patient_id":"ANODE_SYNTH_2025_2616","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":66,"sex":"female","bmi":30.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-76},"pfs_months":20.6},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.5,"censored":false},"longitudinal_labs":[{"date":"2023-09-18","hemoglobin_g_dL":14.4,"wbc_k_uL":10.0,"platelets_k_uL":173,"creatinine_mg_dL":0.71,"alt_U_L":68},{"date":"2024-05-19","hemoglobin_g_dL":10.8,"wbc_k_uL":8.2,"platelets_k_uL":149,"creatinine_mg_dL":0.89,"alt_U_L":52},{"date":"2025-09-09","hemoglobin_g_dL":10.2,"wbc_k_uL":4.2,"platelets_k_uL":133,"creatinine_mg_dL":1.33,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_2617","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":72,"sex":"male","bmi":24.7,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-57},"pfs_months":35.55},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":64.5,"censored":true},"longitudinal_labs":[{"date":"2020-10-09","hemoglobin_g_dL":14.7,"wbc_k_uL":5.6,"platelets_k_uL":208,"creatinine_mg_dL":1.01,"alt_U_L":36},{"date":"2021-06-02","hemoglobin_g_dL":11.4,"wbc_k_uL":4.8,"platelets_k_uL":218,"creatinine_mg_dL":1.59,"alt_U_L":82},{"date":"2023-12-24","hemoglobin_g_dL":9.7,"wbc_k_uL":6.0,"platelets_k_uL":201,"creatinine_mg_dL":0.95,"alt_U_L":28}]}
{"patient_id":"ANODE_SYNTH_2025_2618","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":72,"sex":"female","bmi":36.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-45},"pfs_months":24.11},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.2,"censored":false},"longitudinal_labs":[{"date":"2025-05-11","hemoglobin_g_dL":14.3,"wbc_k_uL":5.2,"platelets_k_uL":246,"creatinine_mg_dL":0.82,"alt_U_L":64},{"date":"2026-01-12","hemoglobin_g_dL":10.1,"wbc_k_uL":5.3,"platelets_k_uL":356,"creatinine_mg_dL":0.72,"alt_U_L":47},{"date":"2027-09-14","hemoglobin_g_dL":11.2,"wbc_k_uL":3.2,"platelets_k_uL":152,"creatinine_mg_dL":1.76,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_2619","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.8,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":56,"sex":"male","bmi":31.3,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-05-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-78},"pfs_months":12.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.9,"censored":false},"longitudinal_labs":[{"date":"2025-03-14","hemoglobin_g_dL":13.7,"wbc_k_uL":7.0,"platelets_k_uL":339,"creatinine_mg_dL":0.6,"alt_U_L":41},{"date":"2025-11-06","hemoglobin_g_dL":11.4,"wbc_k_uL":4.4,"platelets_k_uL":271,"creatinine_mg_dL":1.57,"alt_U_L":107},{"date":"2026-07-22","hemoglobin_g_dL":9.9,"wbc_k_uL":6.4,"platelets_k_uL":284,"creatinine_mg_dL":1.95,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_2620","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":70,"sex":"female","bmi":31.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-58},"pfs_months":19.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":true},"longitudinal_labs":[{"date":"2024-04-04","hemoglobin_g_dL":13.5,"wbc_k_uL":6.8,"platelets_k_uL":289,"creatinine_mg_dL":0.7,"alt_U_L":40},{"date":"2024-10-20","hemoglobin_g_dL":11.7,"wbc_k_uL":4.6,"platelets_k_uL":185,"creatinine_mg_dL":1.23,"alt_U_L":83},{"date":"2026-01-01","hemoglobin_g_dL":11.1,"wbc_k_uL":4.0,"platelets_k_uL":343,"creatinine_mg_dL":1.61,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_2621","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":70,"sex":"female","bmi":25.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-84},"pfs_months":21.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":false},"longitudinal_labs":[{"date":"2023-11-01","hemoglobin_g_dL":13.3,"wbc_k_uL":10.6,"platelets_k_uL":300,"creatinine_mg_dL":0.91,"alt_U_L":37},{"date":"2024-06-19","hemoglobin_g_dL":13.3,"wbc_k_uL":4.0,"platelets_k_uL":312,"creatinine_mg_dL":1.0,"alt_U_L":39},{"date":"2025-11-12","hemoglobin_g_dL":10.7,"wbc_k_uL":5.4,"platelets_k_uL":183,"creatinine_mg_dL":1.82,"alt_U_L":99}]}
{"patient_id":"ANODE_SYNTH_2025_2622","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":68,"sex":"female","bmi":27.9,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-02-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-33},"pfs_months":40.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":57.5,"censored":false},"longitudinal_labs":[{"date":"2023-01-12","hemoglobin_g_dL":12.6,"wbc_k_uL":10.3,"platelets_k_uL":430,"creatinine_mg_dL":1.29,"alt_U_L":73},{"date":"2023-08-27","hemoglobin_g_dL":10.8,"wbc_k_uL":5.7,"platelets_k_uL":324,"creatinine_mg_dL":1.09,"alt_U_L":81},{"date":"2026-07-14","hemoglobin_g_dL":10.8,"wbc_k_uL":7.5,"platelets_k_uL":255,"creatinine_mg_dL":1.0,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_2623","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":57,"sex":"male","bmi":20.6,"smoking_pack_years":75,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-04-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-61},"pfs_months":5.65},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":15.3,"censored":false},"longitudinal_labs":[{"date":"2025-04-02","hemoglobin_g_dL":14.1,"wbc_k_uL":5.2,"platelets_k_uL":244,"creatinine_mg_dL":1.19,"alt_U_L":57},{"date":"2025-10-19","hemoglobin_g_dL":11.8,"wbc_k_uL":8.6,"platelets_k_uL":326,"creatinine_mg_dL":1.49,"alt_U_L":86},{"date":"2025-12-01","hemoglobin_g_dL":11.6,"wbc_k_uL":5.1,"platelets_k_uL":115,"creatinine_mg_dL":1.2,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_2624","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":74,"sex":"male","bmi":26.7,"smoking_pack_years":73,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-10-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-31},"pfs_months":43.14},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":67.3,"censored":true},"longitudinal_labs":[{"date":"2022-10-02","hemoglobin_g_dL":13.7,"wbc_k_uL":7.7,"platelets_k_uL":292,"creatinine_mg_dL":0.83,"alt_U_L":48},{"date":"2023-04-17","hemoglobin_g_dL":11.4,"wbc_k_uL":6.4,"platelets_k_uL":217,"creatinine_mg_dL":1.55,"alt_U_L":109},{"date":"2026-06-30","hemoglobin_g_dL":11.8,"wbc_k_uL":4.1,"platelets_k_uL":224,"creatinine_mg_dL":1.94,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_2625","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.2,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":62,"sex":"male","bmi":20.5,"smoking_pack_years":13,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-07-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-48},"pfs_months":34.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":62.9,"censored":true},"longitudinal_labs":[{"date":"2023-05-25","hemoglobin_g_dL":11.6,"wbc_k_uL":8.9,"platelets_k_uL":387,"creatinine_mg_dL":0.63,"alt_U_L":50},{"date":"2024-01-12","hemoglobin_g_dL":10.8,"wbc_k_uL":3.9,"platelets_k_uL":372,"creatinine_mg_dL":0.94,"alt_U_L":116},{"date":"2026-06-16","hemoglobin_g_dL":11.9,"wbc_k_uL":4.4,"platelets_k_uL":296,"creatinine_mg_dL":0.85,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_2626","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":62,"sex":"male","bmi":27.5,"smoking_pack_years":55,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-03-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-44},"pfs_months":45.8},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":68.5,"censored":false},"longitudinal_labs":[{"date":"2022-12-23","hemoglobin_g_dL":11.7,"wbc_k_uL":7.5,"platelets_k_uL":197,"creatinine_mg_dL":1.14,"alt_U_L":46},{"date":"2023-08-30","hemoglobin_g_dL":12.6,"wbc_k_uL":7.5,"platelets_k_uL":209,"creatinine_mg_dL":1.38,"alt_U_L":46},{"date":"2027-02-23","hemoglobin_g_dL":9.8,"wbc_k_uL":5.9,"platelets_k_uL":226,"creatinine_mg_dL":1.34,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_2627","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":67,"sex":"male","bmi":36.1,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-08-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-52},"pfs_months":14.88},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":18.8,"censored":true},"longitudinal_labs":[{"date":"2024-06-18","hemoglobin_g_dL":12.9,"wbc_k_uL":9.1,"platelets_k_uL":342,"creatinine_mg_dL":0.92,"alt_U_L":61},{"date":"2025-02-15","hemoglobin_g_dL":13.4,"wbc_k_uL":5.0,"platelets_k_uL":227,"creatinine_mg_dL":1.2,"alt_U_L":91},{"date":"2026-01-12","hemoglobin_g_dL":12.8,"wbc_k_uL":3.8,"platelets_k_uL":155,"creatinine_mg_dL":1.78,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_2628","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":53,"sex":"female","bmi":34.5,"smoking_pack_years":65,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-11-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-37},"pfs_months":37.91},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-02-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":57.2,"censored":true},"longitudinal_labs":[{"date":"2025-10-18","hemoglobin_g_dL":13.2,"wbc_k_uL":6.6,"platelets_k_uL":266,"creatinine_mg_dL":1.03,"alt_U_L":43},{"date":"2026-05-08","hemoglobin_g_dL":12.0,"wbc_k_uL":3.8,"platelets_k_uL":247,"creatinine_mg_dL":1.49,"alt_U_L":72},{"date":"2029-02-09","hemoglobin_g_dL":10.4,"wbc_k_uL":6.0,"platelets_k_uL":251,"creatinine_mg_dL":1.14,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_2629","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":74,"sex":"male","bmi":29.4,"smoking_pack_years":63,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-02-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-81},"pfs_months":3.15},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-07-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":7.8,"censored":false},"longitudinal_labs":[{"date":"2021-01-24","hemoglobin_g_dL":12.4,"wbc_k_uL":8.7,"platelets_k_uL":233,"creatinine_mg_dL":0.94,"alt_U_L":25},{"date":"2021-08-20","hemoglobin_g_dL":10.6,"wbc_k_uL":5.0,"platelets_k_uL":255,"creatinine_mg_dL":1.51,"alt_U_L":84},{"date":"2021-07-01","hemoglobin_g_dL":10.2,"wbc_k_uL":4.0,"platelets_k_uL":304,"creatinine_mg_dL":1.23,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_2630","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":76,"sex":"female","bmi":34.4,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-03-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-49},"pfs_months":23.95},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.6,"censored":false},"longitudinal_labs":[{"date":"2022-01-02","hemoglobin_g_dL":13.2,"wbc_k_uL":5.5,"platelets_k_uL":261,"creatinine_mg_dL":0.74,"alt_U_L":51},{"date":"2022-09-06","hemoglobin_g_dL":13.9,"wbc_k_uL":8.9,"platelets_k_uL":323,"creatinine_mg_dL":1.2,"alt_U_L":70},{"date":"2024-03-15","hemoglobin_g_dL":12.7,"wbc_k_uL":5.3,"platelets_k_uL":299,"creatinine_mg_dL":1.92,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_2631","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":56,"sex":"female","bmi":20.9,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-57},"pfs_months":37.72},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.8,"censored":false},"longitudinal_labs":[{"date":"2024-05-24","hemoglobin_g_dL":13.1,"wbc_k_uL":4.7,"platelets_k_uL":192,"creatinine_mg_dL":1.05,"alt_U_L":41},{"date":"2024-12-05","hemoglobin_g_dL":10.9,"wbc_k_uL":6.4,"platelets_k_uL":213,"creatinine_mg_dL":0.8,"alt_U_L":116},{"date":"2027-08-21","hemoglobin_g_dL":11.9,"wbc_k_uL":7.0,"platelets_k_uL":258,"creatinine_mg_dL":1.46,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_2632","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":69,"sex":"female","bmi":30.9,"smoking_pack_years":30,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-11-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-85},"pfs_months":8.51},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-23","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.5,"censored":true},"longitudinal_labs":[{"date":"2023-09-16","hemoglobin_g_dL":13.6,"wbc_k_uL":7.2,"platelets_k_uL":390,"creatinine_mg_dL":1.12,"alt_U_L":63},{"date":"2024-05-05","hemoglobin_g_dL":10.5,"wbc_k_uL":5.9,"platelets_k_uL":185,"creatinine_mg_dL":1.09,"alt_U_L":55},{"date":"2024-08-23","hemoglobin_g_dL":11.2,"wbc_k_uL":6.1,"platelets_k_uL":256,"creatinine_mg_dL":1.19,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_2633","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":62,"sex":"female","bmi":24.9,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-03-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-49},"pfs_months":14.72},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":false},"longitudinal_labs":[{"date":"2025-01-18","hemoglobin_g_dL":15.0,"wbc_k_uL":6.1,"platelets_k_uL":221,"creatinine_mg_dL":1.28,"alt_U_L":14},{"date":"2025-09-14","hemoglobin_g_dL":12.6,"wbc_k_uL":5.7,"platelets_k_uL":187,"creatinine_mg_dL":1.36,"alt_U_L":28},{"date":"2026-06-23","hemoglobin_g_dL":11.0,"wbc_k_uL":4.4,"platelets_k_uL":337,"creatinine_mg_dL":1.58,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_2634","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":62,"sex":"male","bmi":34.6,"smoking_pack_years":32,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-02-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-81},"pfs_months":12.19},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.4,"censored":false},"longitudinal_labs":[{"date":"2025-12-25","hemoglobin_g_dL":14.0,"wbc_k_uL":8.2,"platelets_k_uL":362,"creatinine_mg_dL":0.67,"alt_U_L":14},{"date":"2026-08-10","hemoglobin_g_dL":11.6,"wbc_k_uL":6.9,"platelets_k_uL":146,"creatinine_mg_dL":0.77,"alt_U_L":50},{"date":"2027-04-13","hemoglobin_g_dL":12.1,"wbc_k_uL":7.8,"platelets_k_uL":268,"creatinine_mg_dL":1.26,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_2635","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":72,"sex":"female","bmi":18.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-78},"pfs_months":28.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":52.6,"censored":false},"longitudinal_labs":[{"date":"2020-06-05","hemoglobin_g_dL":12.8,"wbc_k_uL":8.1,"platelets_k_uL":341,"creatinine_mg_dL":1.28,"alt_U_L":22},{"date":"2020-12-31","hemoglobin_g_dL":13.6,"wbc_k_uL":5.8,"platelets_k_uL":249,"creatinine_mg_dL":1.07,"alt_U_L":98},{"date":"2022-11-20","hemoglobin_g_dL":12.0,"wbc_k_uL":3.5,"platelets_k_uL":274,"creatinine_mg_dL":1.09,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_2636","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":77,"sex":"female","bmi":36.5,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-12-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-78},"pfs_months":45.47},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":76.7,"censored":true},"longitudinal_labs":[{"date":"2021-11-05","hemoglobin_g_dL":13.0,"wbc_k_uL":9.3,"platelets_k_uL":367,"creatinine_mg_dL":1.08,"alt_U_L":44},{"date":"2022-06-06","hemoglobin_g_dL":10.5,"wbc_k_uL":4.5,"platelets_k_uL":247,"creatinine_mg_dL":1.03,"alt_U_L":105},{"date":"2025-10-12","hemoglobin_g_dL":10.7,"wbc_k_uL":6.3,"platelets_k_uL":332,"creatinine_mg_dL":1.19,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_2637","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":66,"sex":"male","bmi":34.0,"smoking_pack_years":28,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-85},"pfs_months":8.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":16.4,"censored":false},"longitudinal_labs":[{"date":"2025-07-24","hemoglobin_g_dL":12.4,"wbc_k_uL":7.6,"platelets_k_uL":313,"creatinine_mg_dL":0.8,"alt_U_L":71},{"date":"2026-02-11","hemoglobin_g_dL":12.3,"wbc_k_uL":5.9,"platelets_k_uL":169,"creatinine_mg_dL":0.95,"alt_U_L":22},{"date":"2026-06-15","hemoglobin_g_dL":11.0,"wbc_k_uL":3.1,"platelets_k_uL":315,"creatinine_mg_dL":1.87,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_2638","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":55,"sex":"female","bmi":22.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-75},"pfs_months":28.42},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.1,"censored":false},"longitudinal_labs":[{"date":"2021-08-03","hemoglobin_g_dL":13.6,"wbc_k_uL":7.3,"platelets_k_uL":446,"creatinine_mg_dL":1.01,"alt_U_L":64},{"date":"2022-04-08","hemoglobin_g_dL":11.8,"wbc_k_uL":4.2,"platelets_k_uL":274,"creatinine_mg_dL":1.39,"alt_U_L":59},{"date":"2024-03-26","hemoglobin_g_dL":10.9,"wbc_k_uL":6.2,"platelets_k_uL":131,"creatinine_mg_dL":1.45,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_2639","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":52,"sex":"female","bmi":31.8,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-30},"pfs_months":46.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":75.0,"censored":true},"longitudinal_labs":[{"date":"2020-02-19","hemoglobin_g_dL":12.5,"wbc_k_uL":6.1,"platelets_k_uL":339,"creatinine_mg_dL":0.95,"alt_U_L":42},{"date":"2020-09-13","hemoglobin_g_dL":11.1,"wbc_k_uL":4.1,"platelets_k_uL":324,"creatinine_mg_dL":1.11,"alt_U_L":87},{"date":"2024-04-09","hemoglobin_g_dL":9.8,"wbc_k_uL":3.2,"platelets_k_uL":303,"creatinine_mg_dL":1.83,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_2640","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":76,"sex":"male","bmi":20.3,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-54},"pfs_months":30.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-25","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.3,"censored":false},"longitudinal_labs":[{"date":"2022-08-13","hemoglobin_g_dL":15.2,"wbc_k_uL":5.3,"platelets_k_uL":157,"creatinine_mg_dL":0.83,"alt_U_L":20},{"date":"2023-02-26","hemoglobin_g_dL":14.0,"wbc_k_uL":5.5,"platelets_k_uL":236,"creatinine_mg_dL":1.45,"alt_U_L":41},{"date":"2025-03-25","hemoglobin_g_dL":9.9,"wbc_k_uL":4.3,"platelets_k_uL":252,"creatinine_mg_dL":0.93,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_2641","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":77,"sex":"female","bmi":20.3,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-77},"pfs_months":40.8},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":60.8,"censored":true},"longitudinal_labs":[{"date":"2022-05-11","hemoglobin_g_dL":12.5,"wbc_k_uL":10.4,"platelets_k_uL":440,"creatinine_mg_dL":0.64,"alt_U_L":76},{"date":"2022-12-05","hemoglobin_g_dL":10.0,"wbc_k_uL":4.4,"platelets_k_uL":321,"creatinine_mg_dL":0.99,"alt_U_L":112},{"date":"2025-11-30","hemoglobin_g_dL":11.5,"wbc_k_uL":7.3,"platelets_k_uL":277,"creatinine_mg_dL":1.54,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_2642","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":68,"sex":"female","bmi":31.6,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-76},"pfs_months":9.53},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-01-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":13.5,"censored":false},"longitudinal_labs":[{"date":"2020-01-28","hemoglobin_g_dL":15.0,"wbc_k_uL":5.6,"platelets_k_uL":299,"creatinine_mg_dL":0.77,"alt_U_L":53},{"date":"2020-09-04","hemoglobin_g_dL":13.8,"wbc_k_uL":6.6,"platelets_k_uL":156,"creatinine_mg_dL":1.51,"alt_U_L":22},{"date":"2021-01-27","hemoglobin_g_dL":12.6,"wbc_k_uL":3.2,"platelets_k_uL":271,"creatinine_mg_dL":1.23,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_2643","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":72,"sex":"male","bmi":21.3,"smoking_pack_years":29,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-03-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-50},"pfs_months":37.78},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":57.6,"censored":false},"longitudinal_labs":[{"date":"2023-02-22","hemoglobin_g_dL":13.5,"wbc_k_uL":8.7,"platelets_k_uL":408,"creatinine_mg_dL":1.01,"alt_U_L":21},{"date":"2023-09-23","hemoglobin_g_dL":12.6,"wbc_k_uL":5.1,"platelets_k_uL":276,"creatinine_mg_dL":1.24,"alt_U_L":40},{"date":"2026-06-27","hemoglobin_g_dL":11.1,"wbc_k_uL":4.2,"platelets_k_uL":145,"creatinine_mg_dL":1.97,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_2644","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":79,"sex":"female","bmi":21.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-60},"pfs_months":18.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.5,"censored":false},"longitudinal_labs":[{"date":"2021-02-23","hemoglobin_g_dL":11.6,"wbc_k_uL":8.3,"platelets_k_uL":342,"creatinine_mg_dL":1.29,"alt_U_L":68},{"date":"2021-10-01","hemoglobin_g_dL":12.4,"wbc_k_uL":6.7,"platelets_k_uL":300,"creatinine_mg_dL":0.85,"alt_U_L":65},{"date":"2022-12-23","hemoglobin_g_dL":9.8,"wbc_k_uL":6.1,"platelets_k_uL":248,"creatinine_mg_dL":1.85,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_2645","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":86,"sex":"female","bmi":33.1,"smoking_pack_years":38,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-41},"pfs_months":42.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":72.1,"censored":true},"longitudinal_labs":[{"date":"2021-05-01","hemoglobin_g_dL":12.1,"wbc_k_uL":9.7,"platelets_k_uL":323,"creatinine_mg_dL":0.62,"alt_U_L":40},{"date":"2021-11-17","hemoglobin_g_dL":13.2,"wbc_k_uL":5.3,"platelets_k_uL":205,"creatinine_mg_dL":1.3,"alt_U_L":80},{"date":"2025-02-12","hemoglobin_g_dL":11.4,"wbc_k_uL":5.9,"platelets_k_uL":229,"creatinine_mg_dL":0.98,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_2646","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":55,"sex":"female","bmi":27.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-45},"pfs_months":22.41},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":false},"longitudinal_labs":[{"date":"2022-10-25","hemoglobin_g_dL":11.6,"wbc_k_uL":10.9,"platelets_k_uL":239,"creatinine_mg_dL":1.23,"alt_U_L":79},{"date":"2023-06-14","hemoglobin_g_dL":11.8,"wbc_k_uL":8.3,"platelets_k_uL":226,"creatinine_mg_dL":1.52,"alt_U_L":45},{"date":"2024-12-26","hemoglobin_g_dL":10.6,"wbc_k_uL":6.1,"platelets_k_uL":287,"creatinine_mg_dL":1.21,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_2647","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":54,"sex":"female","bmi":33.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-47},"pfs_months":26.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.3,"censored":false},"longitudinal_labs":[{"date":"2023-02-03","hemoglobin_g_dL":13.3,"wbc_k_uL":7.3,"platelets_k_uL":289,"creatinine_mg_dL":1.22,"alt_U_L":33},{"date":"2023-09-21","hemoglobin_g_dL":10.1,"wbc_k_uL":6.9,"platelets_k_uL":143,"creatinine_mg_dL":0.92,"alt_U_L":91},{"date":"2025-07-19","hemoglobin_g_dL":10.7,"wbc_k_uL":7.3,"platelets_k_uL":175,"creatinine_mg_dL":1.09,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_2648","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":75,"sex":"female","bmi":34.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-02-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-54},"pfs_months":25.0},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":37.8,"censored":true},"longitudinal_labs":[{"date":"2025-12-15","hemoglobin_g_dL":13.5,"wbc_k_uL":7.4,"platelets_k_uL":250,"creatinine_mg_dL":0.61,"alt_U_L":40},{"date":"2026-08-22","hemoglobin_g_dL":10.5,"wbc_k_uL":6.7,"platelets_k_uL":309,"creatinine_mg_dL":1.32,"alt_U_L":15},{"date":"2028-05-20","hemoglobin_g_dL":10.4,"wbc_k_uL":3.5,"platelets_k_uL":344,"creatinine_mg_dL":1.36,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_2649","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":84,"sex":"male","bmi":24.1,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2022-02-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-75},"pfs_months":13.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":17.1,"censored":false},"longitudinal_labs":[{"date":"2022-01-06","hemoglobin_g_dL":12.2,"wbc_k_uL":6.7,"platelets_k_uL":311,"creatinine_mg_dL":0.81,"alt_U_L":48},{"date":"2022-08-17","hemoglobin_g_dL":11.8,"wbc_k_uL":7.1,"platelets_k_uL":205,"creatinine_mg_dL":0.76,"alt_U_L":56},{"date":"2023-04-17","hemoglobin_g_dL":12.7,"wbc_k_uL":5.8,"platelets_k_uL":212,"creatinine_mg_dL":1.28,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_2650","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":68,"sex":"male","bmi":36.2,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-38},"pfs_months":35.02},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.1,"censored":false},"longitudinal_labs":[{"date":"2021-04-19","hemoglobin_g_dL":14.3,"wbc_k_uL":4.8,"platelets_k_uL":319,"creatinine_mg_dL":1.12,"alt_U_L":63},{"date":"2021-11-15","hemoglobin_g_dL":13.6,"wbc_k_uL":4.4,"platelets_k_uL":290,"creatinine_mg_dL":1.36,"alt_U_L":29},{"date":"2024-05-14","hemoglobin_g_dL":10.2,"wbc_k_uL":3.1,"platelets_k_uL":334,"creatinine_mg_dL":1.18,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_2651","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":62,"sex":"female","bmi":27.2,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-11-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-42},"pfs_months":25.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":true},"longitudinal_labs":[{"date":"2024-09-04","hemoglobin_g_dL":13.4,"wbc_k_uL":9.4,"platelets_k_uL":400,"creatinine_mg_dL":0.84,"alt_U_L":48},{"date":"2025-05-04","hemoglobin_g_dL":11.7,"wbc_k_uL":6.0,"platelets_k_uL":320,"creatinine_mg_dL":1.0,"alt_U_L":21},{"date":"2027-02-01","hemoglobin_g_dL":11.3,"wbc_k_uL":5.3,"platelets_k_uL":106,"creatinine_mg_dL":1.54,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_2652","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":68,"sex":"male","bmi":23.3,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-51},"pfs_months":31.47},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":63.4,"censored":false},"longitudinal_labs":[{"date":"2025-01-07","hemoglobin_g_dL":12.6,"wbc_k_uL":9.4,"platelets_k_uL":198,"creatinine_mg_dL":0.83,"alt_U_L":38},{"date":"2025-08-04","hemoglobin_g_dL":10.8,"wbc_k_uL":8.6,"platelets_k_uL":265,"creatinine_mg_dL":1.5,"alt_U_L":90},{"date":"2027-09-25","hemoglobin_g_dL":11.0,"wbc_k_uL":6.6,"platelets_k_uL":290,"creatinine_mg_dL":0.98,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_2653","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":55,"sex":"female","bmi":36.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-82},"pfs_months":26.61},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.7,"censored":false},"longitudinal_labs":[{"date":"2023-06-14","hemoglobin_g_dL":13.7,"wbc_k_uL":5.3,"platelets_k_uL":212,"creatinine_mg_dL":1.24,"alt_U_L":38},{"date":"2024-01-27","hemoglobin_g_dL":10.6,"wbc_k_uL":8.8,"platelets_k_uL":171,"creatinine_mg_dL":0.78,"alt_U_L":16},{"date":"2025-11-27","hemoglobin_g_dL":10.5,"wbc_k_uL":6.8,"platelets_k_uL":252,"creatinine_mg_dL":1.37,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_2654","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.2,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":88,"sex":"female","bmi":26.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-42},"pfs_months":37.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":52.5,"censored":true},"longitudinal_labs":[{"date":"2025-03-05","hemoglobin_g_dL":14.9,"wbc_k_uL":8.9,"platelets_k_uL":182,"creatinine_mg_dL":0.68,"alt_U_L":32},{"date":"2025-09-27","hemoglobin_g_dL":12.9,"wbc_k_uL":8.7,"platelets_k_uL":231,"creatinine_mg_dL":1.0,"alt_U_L":19},{"date":"2028-06-21","hemoglobin_g_dL":10.1,"wbc_k_uL":6.4,"platelets_k_uL":194,"creatinine_mg_dL":1.26,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_2655","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":69,"sex":"male","bmi":22.3,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-12-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-69},"pfs_months":18.76},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.1,"censored":false},"longitudinal_labs":[{"date":"2024-10-11","hemoglobin_g_dL":13.3,"wbc_k_uL":7.1,"platelets_k_uL":316,"creatinine_mg_dL":0.8,"alt_U_L":32},{"date":"2025-06-04","hemoglobin_g_dL":12.2,"wbc_k_uL":8.9,"platelets_k_uL":275,"creatinine_mg_dL":1.02,"alt_U_L":81},{"date":"2026-08-24","hemoglobin_g_dL":12.3,"wbc_k_uL":7.3,"platelets_k_uL":332,"creatinine_mg_dL":1.84,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_2656","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":50,"sex":"male","bmi":35.8,"smoking_pack_years":74,"ecog_performance_status":2,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-05-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-64},"pfs_months":20.11},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.0,"censored":false},"longitudinal_labs":[{"date":"2021-03-18","hemoglobin_g_dL":14.5,"wbc_k_uL":7.3,"platelets_k_uL":368,"creatinine_mg_dL":0.86,"alt_U_L":72},{"date":"2021-11-10","hemoglobin_g_dL":10.3,"wbc_k_uL":5.0,"platelets_k_uL":220,"creatinine_mg_dL":0.87,"alt_U_L":30},{"date":"2023-01-21","hemoglobin_g_dL":12.0,"wbc_k_uL":4.1,"platelets_k_uL":333,"creatinine_mg_dL":1.41,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_2657","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":74,"sex":"female","bmi":37.4,"smoking_pack_years":15,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-47},"pfs_months":30.95},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":46.8,"censored":false},"longitudinal_labs":[{"date":"2021-01-26","hemoglobin_g_dL":13.0,"wbc_k_uL":9.0,"platelets_k_uL":168,"creatinine_mg_dL":0.64,"alt_U_L":49},{"date":"2021-09-18","hemoglobin_g_dL":11.0,"wbc_k_uL":6.1,"platelets_k_uL":324,"creatinine_mg_dL":1.15,"alt_U_L":36},{"date":"2023-10-25","hemoglobin_g_dL":11.8,"wbc_k_uL":7.7,"platelets_k_uL":335,"creatinine_mg_dL":1.63,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_2658","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":83,"sex":"male","bmi":36.2,"smoking_pack_years":51,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-12-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-78},"pfs_months":36.11},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.0,"censored":false},"longitudinal_labs":[{"date":"2023-11-24","hemoglobin_g_dL":14.4,"wbc_k_uL":10.0,"platelets_k_uL":246,"creatinine_mg_dL":0.87,"alt_U_L":71},{"date":"2024-06-24","hemoglobin_g_dL":11.1,"wbc_k_uL":8.6,"platelets_k_uL":311,"creatinine_mg_dL":1.13,"alt_U_L":22},{"date":"2027-01-26","hemoglobin_g_dL":11.2,"wbc_k_uL":3.2,"platelets_k_uL":195,"creatinine_mg_dL":1.71,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_2659","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":70,"sex":"male","bmi":29.8,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-51},"pfs_months":15.15},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.1,"censored":false},"longitudinal_labs":[{"date":"2024-02-27","hemoglobin_g_dL":12.3,"wbc_k_uL":5.0,"platelets_k_uL":301,"creatinine_mg_dL":0.85,"alt_U_L":36},{"date":"2024-10-04","hemoglobin_g_dL":13.4,"wbc_k_uL":3.8,"platelets_k_uL":166,"creatinine_mg_dL":1.11,"alt_U_L":103},{"date":"2025-09-06","hemoglobin_g_dL":10.5,"wbc_k_uL":6.8,"platelets_k_uL":121,"creatinine_mg_dL":1.5,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_2660","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":48,"sex":"female","bmi":27.8,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-37},"pfs_months":9.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":13.3,"censored":false},"longitudinal_labs":[{"date":"2024-12-15","hemoglobin_g_dL":13.8,"wbc_k_uL":7.4,"platelets_k_uL":380,"creatinine_mg_dL":0.65,"alt_U_L":70},{"date":"2025-06-30","hemoglobin_g_dL":10.8,"wbc_k_uL":5.8,"platelets_k_uL":311,"creatinine_mg_dL":1.5,"alt_U_L":41},{"date":"2025-11-11","hemoglobin_g_dL":11.6,"wbc_k_uL":6.5,"platelets_k_uL":322,"creatinine_mg_dL":1.3,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_2661","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":66,"sex":"female","bmi":25.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-39},"pfs_months":25.33},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.4,"censored":false},"longitudinal_labs":[{"date":"2024-04-11","hemoglobin_g_dL":13.6,"wbc_k_uL":7.8,"platelets_k_uL":376,"creatinine_mg_dL":0.85,"alt_U_L":37},{"date":"2024-12-09","hemoglobin_g_dL":11.7,"wbc_k_uL":5.6,"platelets_k_uL":197,"creatinine_mg_dL":1.09,"alt_U_L":95},{"date":"2026-08-03","hemoglobin_g_dL":10.3,"wbc_k_uL":4.9,"platelets_k_uL":299,"creatinine_mg_dL":1.65,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_2662","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":58,"sex":"female","bmi":24.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-53},"pfs_months":23.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":false},"longitudinal_labs":[{"date":"2023-12-08","hemoglobin_g_dL":12.4,"wbc_k_uL":6.2,"platelets_k_uL":244,"creatinine_mg_dL":0.72,"alt_U_L":24},{"date":"2024-07-05","hemoglobin_g_dL":11.2,"wbc_k_uL":8.9,"platelets_k_uL":165,"creatinine_mg_dL":1.13,"alt_U_L":81},{"date":"2026-01-22","hemoglobin_g_dL":12.0,"wbc_k_uL":5.6,"platelets_k_uL":219,"creatinine_mg_dL":1.75,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_2663","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":70,"sex":"female","bmi":23.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-73},"pfs_months":29.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.4,"censored":false},"longitudinal_labs":[{"date":"2023-09-20","hemoglobin_g_dL":14.6,"wbc_k_uL":6.2,"platelets_k_uL":230,"creatinine_mg_dL":0.72,"alt_U_L":70},{"date":"2024-05-10","hemoglobin_g_dL":11.3,"wbc_k_uL":4.4,"platelets_k_uL":135,"creatinine_mg_dL":1.54,"alt_U_L":78},{"date":"2026-05-14","hemoglobin_g_dL":9.8,"wbc_k_uL":4.9,"platelets_k_uL":196,"creatinine_mg_dL":1.41,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_2664","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":80,"sex":"female","bmi":35.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-59},"pfs_months":18.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.9,"censored":false},"longitudinal_labs":[{"date":"2024-04-26","hemoglobin_g_dL":13.5,"wbc_k_uL":10.1,"platelets_k_uL":349,"creatinine_mg_dL":0.79,"alt_U_L":52},{"date":"2024-11-17","hemoglobin_g_dL":12.2,"wbc_k_uL":9.0,"platelets_k_uL":250,"creatinine_mg_dL":1.23,"alt_U_L":119},{"date":"2025-12-30","hemoglobin_g_dL":11.8,"wbc_k_uL":5.4,"platelets_k_uL":106,"creatinine_mg_dL":0.99,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_2665","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":81,"sex":"female","bmi":24.9,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-02-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-81},"pfs_months":7.69},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":17.1,"censored":false},"longitudinal_labs":[{"date":"2025-12-23","hemoglobin_g_dL":13.5,"wbc_k_uL":8.0,"platelets_k_uL":411,"creatinine_mg_dL":1.23,"alt_U_L":21},{"date":"2026-08-18","hemoglobin_g_dL":10.7,"wbc_k_uL":6.2,"platelets_k_uL":178,"creatinine_mg_dL":0.95,"alt_U_L":36},{"date":"2026-10-16","hemoglobin_g_dL":10.7,"wbc_k_uL":4.1,"platelets_k_uL":195,"creatinine_mg_dL":1.11,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_2666","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.2,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":63,"sex":"male","bmi":31.9,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2026-01-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-37},"pfs_months":44.75},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-12-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":62.9,"censored":false},"longitudinal_labs":[{"date":"2025-11-22","hemoglobin_g_dL":14.0,"wbc_k_uL":7.7,"platelets_k_uL":261,"creatinine_mg_dL":1.02,"alt_U_L":64},{"date":"2026-07-20","hemoglobin_g_dL":13.0,"wbc_k_uL":6.2,"platelets_k_uL":290,"creatinine_mg_dL":1.47,"alt_U_L":97},{"date":"2029-12-04","hemoglobin_g_dL":9.9,"wbc_k_uL":4.7,"platelets_k_uL":179,"creatinine_mg_dL":1.25,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_2667","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":85,"sex":"female","bmi":24.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-49},"pfs_months":17.41},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":false},"longitudinal_labs":[{"date":"2021-10-22","hemoglobin_g_dL":13.3,"wbc_k_uL":7.8,"platelets_k_uL":263,"creatinine_mg_dL":1.0,"alt_U_L":49},{"date":"2022-05-11","hemoglobin_g_dL":12.8,"wbc_k_uL":8.7,"platelets_k_uL":362,"creatinine_mg_dL":1.23,"alt_U_L":81},{"date":"2023-06-07","hemoglobin_g_dL":13.0,"wbc_k_uL":4.4,"platelets_k_uL":129,"creatinine_mg_dL":1.01,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_2668","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":87,"sex":"male","bmi":32.0,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-74},"pfs_months":34.1},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":52.6,"censored":false},"longitudinal_labs":[{"date":"2021-10-27","hemoglobin_g_dL":12.2,"wbc_k_uL":10.6,"platelets_k_uL":445,"creatinine_mg_dL":0.95,"alt_U_L":33},{"date":"2022-05-15","hemoglobin_g_dL":13.7,"wbc_k_uL":5.0,"platelets_k_uL":195,"creatinine_mg_dL":1.22,"alt_U_L":87},{"date":"2024-11-14","hemoglobin_g_dL":10.3,"wbc_k_uL":6.8,"platelets_k_uL":221,"creatinine_mg_dL":1.54,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_2669","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":56,"sex":"female","bmi":26.2,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-37},"pfs_months":32.76},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.7,"censored":false},"longitudinal_labs":[{"date":"2021-01-07","hemoglobin_g_dL":13.6,"wbc_k_uL":7.5,"platelets_k_uL":227,"creatinine_mg_dL":0.92,"alt_U_L":75},{"date":"2021-07-25","hemoglobin_g_dL":13.2,"wbc_k_uL":6.6,"platelets_k_uL":298,"creatinine_mg_dL":0.96,"alt_U_L":111},{"date":"2023-11-23","hemoglobin_g_dL":11.3,"wbc_k_uL":4.9,"platelets_k_uL":293,"creatinine_mg_dL":0.83,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_2670","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":70,"sex":"female","bmi":33.7,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-31},"pfs_months":43.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":61.1,"censored":false},"longitudinal_labs":[{"date":"2024-03-04","hemoglobin_g_dL":13.4,"wbc_k_uL":8.3,"platelets_k_uL":216,"creatinine_mg_dL":1.18,"alt_U_L":68},{"date":"2024-09-20","hemoglobin_g_dL":12.4,"wbc_k_uL":4.5,"platelets_k_uL":181,"creatinine_mg_dL":1.31,"alt_U_L":59},{"date":"2027-12-02","hemoglobin_g_dL":12.1,"wbc_k_uL":7.7,"platelets_k_uL":269,"creatinine_mg_dL":1.22,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_2671","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":81,"sex":"male","bmi":21.1,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-04-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-69},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-08-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":14.9,"censored":false},"longitudinal_labs":[{"date":"2020-03-27","hemoglobin_g_dL":15.2,"wbc_k_uL":5.9,"platelets_k_uL":305,"creatinine_mg_dL":0.88,"alt_U_L":80},{"date":"2020-10-11","hemoglobin_g_dL":13.8,"wbc_k_uL":6.3,"platelets_k_uL":290,"creatinine_mg_dL":1.17,"alt_U_L":95},{"date":"2020-08-18","hemoglobin_g_dL":10.6,"wbc_k_uL":7.1,"platelets_k_uL":159,"creatinine_mg_dL":1.37,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_2672","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":65,"sex":"male","bmi":22.4,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-02-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-31},"pfs_months":36.4},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.7,"censored":false},"longitudinal_labs":[{"date":"2021-12-25","hemoglobin_g_dL":14.5,"wbc_k_uL":7.4,"platelets_k_uL":220,"creatinine_mg_dL":1.28,"alt_U_L":77},{"date":"2022-07-31","hemoglobin_g_dL":10.3,"wbc_k_uL":4.7,"platelets_k_uL":302,"creatinine_mg_dL":1.39,"alt_U_L":52},{"date":"2025-04-08","hemoglobin_g_dL":11.1,"wbc_k_uL":5.3,"platelets_k_uL":122,"creatinine_mg_dL":1.34,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_2673","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":78,"sex":"female","bmi":37.5,"smoking_pack_years":36,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-08-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-31},"pfs_months":33.15},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.3,"censored":false},"longitudinal_labs":[{"date":"2023-06-18","hemoglobin_g_dL":12.6,"wbc_k_uL":7.3,"platelets_k_uL":290,"creatinine_mg_dL":1.22,"alt_U_L":63},{"date":"2024-02-13","hemoglobin_g_dL":12.3,"wbc_k_uL":5.1,"platelets_k_uL":330,"creatinine_mg_dL":1.29,"alt_U_L":103},{"date":"2026-06-18","hemoglobin_g_dL":13.0,"wbc_k_uL":6.1,"platelets_k_uL":142,"creatinine_mg_dL":1.4,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_2674","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":86,"sex":"male","bmi":37.9,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-10-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-67},"pfs_months":16.16},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":false},"longitudinal_labs":[{"date":"2024-08-16","hemoglobin_g_dL":15.2,"wbc_k_uL":7.6,"platelets_k_uL":185,"creatinine_mg_dL":0.63,"alt_U_L":20},{"date":"2025-03-30","hemoglobin_g_dL":10.7,"wbc_k_uL":8.3,"platelets_k_uL":177,"creatinine_mg_dL":1.48,"alt_U_L":33},{"date":"2026-02-18","hemoglobin_g_dL":12.8,"wbc_k_uL":4.8,"platelets_k_uL":252,"creatinine_mg_dL":1.47,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_2675","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":67,"sex":"female","bmi":24.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-31},"pfs_months":25.59},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":false},"longitudinal_labs":[{"date":"2025-11-05","hemoglobin_g_dL":12.5,"wbc_k_uL":6.7,"platelets_k_uL":225,"creatinine_mg_dL":1.28,"alt_U_L":29},{"date":"2026-06-10","hemoglobin_g_dL":10.8,"wbc_k_uL":6.8,"platelets_k_uL":332,"creatinine_mg_dL":1.03,"alt_U_L":61},{"date":"2028-03-12","hemoglobin_g_dL":12.8,"wbc_k_uL":3.6,"platelets_k_uL":235,"creatinine_mg_dL":1.98,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_2676","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":75,"sex":"female","bmi":33.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-09-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-46},"pfs_months":27.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.6,"censored":true},"longitudinal_labs":[{"date":"2023-07-24","hemoglobin_g_dL":14.7,"wbc_k_uL":5.1,"platelets_k_uL":284,"creatinine_mg_dL":0.8,"alt_U_L":40},{"date":"2024-03-28","hemoglobin_g_dL":11.0,"wbc_k_uL":5.7,"platelets_k_uL":178,"creatinine_mg_dL":1.4,"alt_U_L":96},{"date":"2026-02-25","hemoglobin_g_dL":11.1,"wbc_k_uL":4.9,"platelets_k_uL":319,"creatinine_mg_dL":1.85,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_2677","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":85,"sex":"male","bmi":37.2,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-09-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-63},"pfs_months":38.9},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":60.2,"censored":false},"longitudinal_labs":[{"date":"2025-08-02","hemoglobin_g_dL":13.9,"wbc_k_uL":5.8,"platelets_k_uL":306,"creatinine_mg_dL":1.08,"alt_U_L":13},{"date":"2026-03-12","hemoglobin_g_dL":12.6,"wbc_k_uL":7.6,"platelets_k_uL":282,"creatinine_mg_dL":1.22,"alt_U_L":111},{"date":"2029-01-18","hemoglobin_g_dL":12.6,"wbc_k_uL":5.2,"platelets_k_uL":156,"creatinine_mg_dL":1.16,"alt_U_L":84}]}
{"patient_id":"ANODE_SYNTH_2025_2678","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":69,"sex":"female","bmi":21.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-40},"pfs_months":23.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-16","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.8,"censored":false},"longitudinal_labs":[{"date":"2020-05-28","hemoglobin_g_dL":15.1,"wbc_k_uL":5.0,"platelets_k_uL":319,"creatinine_mg_dL":1.0,"alt_U_L":43},{"date":"2020-12-24","hemoglobin_g_dL":12.0,"wbc_k_uL":6.0,"platelets_k_uL":363,"creatinine_mg_dL":0.93,"alt_U_L":101},{"date":"2022-08-16","hemoglobin_g_dL":9.8,"wbc_k_uL":6.0,"platelets_k_uL":127,"creatinine_mg_dL":1.88,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_2679","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":83,"sex":"female","bmi":31.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-84},"pfs_months":21.78},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.2,"censored":true},"longitudinal_labs":[{"date":"2022-05-25","hemoglobin_g_dL":14.1,"wbc_k_uL":5.3,"platelets_k_uL":162,"creatinine_mg_dL":0.77,"alt_U_L":25},{"date":"2023-01-29","hemoglobin_g_dL":11.1,"wbc_k_uL":6.0,"platelets_k_uL":239,"creatinine_mg_dL":1.21,"alt_U_L":55},{"date":"2024-06-12","hemoglobin_g_dL":12.6,"wbc_k_uL":5.7,"platelets_k_uL":229,"creatinine_mg_dL":1.31,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_2680","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":83,"sex":"male","bmi":35.0,"smoking_pack_years":19,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-05-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-74},"pfs_months":34.33},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":59.9,"censored":false},"longitudinal_labs":[{"date":"2020-04-14","hemoglobin_g_dL":13.7,"wbc_k_uL":7.0,"platelets_k_uL":254,"creatinine_mg_dL":1.1,"alt_U_L":68},{"date":"2020-10-29","hemoglobin_g_dL":12.1,"wbc_k_uL":8.4,"platelets_k_uL":271,"creatinine_mg_dL":1.07,"alt_U_L":82},{"date":"2023-03-28","hemoglobin_g_dL":9.8,"wbc_k_uL":6.5,"platelets_k_uL":281,"creatinine_mg_dL":1.66,"alt_U_L":139}]}
{"patient_id":"ANODE_SYNTH_2025_2681","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":81,"sex":"female","bmi":22.6,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-81},"pfs_months":15.51},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.3,"censored":false},"longitudinal_labs":[{"date":"2020-06-18","hemoglobin_g_dL":11.6,"wbc_k_uL":4.9,"platelets_k_uL":150,"creatinine_mg_dL":1.21,"alt_U_L":69},{"date":"2021-01-11","hemoglobin_g_dL":11.5,"wbc_k_uL":6.3,"platelets_k_uL":145,"creatinine_mg_dL":1.05,"alt_U_L":36},{"date":"2021-11-24","hemoglobin_g_dL":12.9,"wbc_k_uL":4.3,"platelets_k_uL":123,"creatinine_mg_dL":1.66,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_2682","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.2,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":55,"sex":"female","bmi":27.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-37},"pfs_months":24.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.0,"censored":true},"longitudinal_labs":[{"date":"2021-03-08","hemoglobin_g_dL":12.5,"wbc_k_uL":5.1,"platelets_k_uL":191,"creatinine_mg_dL":0.7,"alt_U_L":19},{"date":"2021-10-09","hemoglobin_g_dL":12.0,"wbc_k_uL":5.6,"platelets_k_uL":165,"creatinine_mg_dL":0.93,"alt_U_L":98},{"date":"2023-06-25","hemoglobin_g_dL":10.0,"wbc_k_uL":3.4,"platelets_k_uL":292,"creatinine_mg_dL":1.31,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_2683","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":66,"sex":"male","bmi":33.4,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-05-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-44},"pfs_months":31.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":58.0,"censored":true},"longitudinal_labs":[{"date":"2023-03-03","hemoglobin_g_dL":14.0,"wbc_k_uL":4.7,"platelets_k_uL":393,"creatinine_mg_dL":0.81,"alt_U_L":70},{"date":"2023-11-01","hemoglobin_g_dL":10.3,"wbc_k_uL":6.1,"platelets_k_uL":221,"creatinine_mg_dL":1.24,"alt_U_L":106},{"date":"2026-01-24","hemoglobin_g_dL":10.5,"wbc_k_uL":3.3,"platelets_k_uL":142,"creatinine_mg_dL":1.54,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_2684","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":60,"sex":"female","bmi":23.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-45},"pfs_months":33.08},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.9,"censored":true},"longitudinal_labs":[{"date":"2023-06-06","hemoglobin_g_dL":11.6,"wbc_k_uL":6.7,"platelets_k_uL":246,"creatinine_mg_dL":0.64,"alt_U_L":37},{"date":"2023-12-29","hemoglobin_g_dL":12.9,"wbc_k_uL":4.6,"platelets_k_uL":147,"creatinine_mg_dL":1.23,"alt_U_L":108},{"date":"2026-05-01","hemoglobin_g_dL":10.5,"wbc_k_uL":7.5,"platelets_k_uL":234,"creatinine_mg_dL":1.89,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_2685","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":81,"sex":"male","bmi":28.5,"smoking_pack_years":34,"ecog_performance_status":2,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-42},"pfs_months":18.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.4,"censored":false},"longitudinal_labs":[{"date":"2021-11-14","hemoglobin_g_dL":14.6,"wbc_k_uL":9.4,"platelets_k_uL":240,"creatinine_mg_dL":1.04,"alt_U_L":30},{"date":"2022-06-23","hemoglobin_g_dL":10.4,"wbc_k_uL":4.0,"platelets_k_uL":237,"creatinine_mg_dL":1.46,"alt_U_L":96},{"date":"2023-08-03","hemoglobin_g_dL":11.1,"wbc_k_uL":5.5,"platelets_k_uL":293,"creatinine_mg_dL":1.24,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_2686","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":84,"sex":"male","bmi":35.3,"smoking_pack_years":65,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-12-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-67},"pfs_months":32.03},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":55.4,"censored":false},"longitudinal_labs":[{"date":"2023-10-17","hemoglobin_g_dL":15.3,"wbc_k_uL":7.6,"platelets_k_uL":247,"creatinine_mg_dL":1.16,"alt_U_L":25},{"date":"2024-06-21","hemoglobin_g_dL":12.2,"wbc_k_uL":7.0,"platelets_k_uL":170,"creatinine_mg_dL":0.83,"alt_U_L":113},{"date":"2026-09-15","hemoglobin_g_dL":12.3,"wbc_k_uL":6.0,"platelets_k_uL":148,"creatinine_mg_dL":1.9,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_2687","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":74,"sex":"female","bmi":31.4,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-02-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-41},"pfs_months":14.39},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.8,"censored":false},"longitudinal_labs":[{"date":"2022-12-22","hemoglobin_g_dL":14.3,"wbc_k_uL":6.9,"platelets_k_uL":282,"creatinine_mg_dL":0.8,"alt_U_L":29},{"date":"2023-08-07","hemoglobin_g_dL":12.4,"wbc_k_uL":6.4,"platelets_k_uL":312,"creatinine_mg_dL":1.37,"alt_U_L":45},{"date":"2024-06-19","hemoglobin_g_dL":12.2,"wbc_k_uL":6.3,"platelets_k_uL":136,"creatinine_mg_dL":1.11,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_2688","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":86,"sex":"male","bmi":29.4,"smoking_pack_years":78,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-10-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-80},"pfs_months":29.7},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":40.1,"censored":false},"longitudinal_labs":[{"date":"2021-09-06","hemoglobin_g_dL":15.3,"wbc_k_uL":10.4,"platelets_k_uL":290,"creatinine_mg_dL":1.07,"alt_U_L":20},{"date":"2022-04-26","hemoglobin_g_dL":10.9,"wbc_k_uL":6.1,"platelets_k_uL":375,"creatinine_mg_dL":1.07,"alt_U_L":45},{"date":"2024-05-23","hemoglobin_g_dL":10.8,"wbc_k_uL":3.6,"platelets_k_uL":253,"creatinine_mg_dL":1.21,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_2689","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":67,"sex":"female","bmi":34.4,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-42},"pfs_months":35.94},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.1,"censored":true},"longitudinal_labs":[{"date":"2025-01-09","hemoglobin_g_dL":11.7,"wbc_k_uL":9.1,"platelets_k_uL":426,"creatinine_mg_dL":1.16,"alt_U_L":17},{"date":"2025-07-27","hemoglobin_g_dL":10.9,"wbc_k_uL":6.1,"platelets_k_uL":126,"creatinine_mg_dL":1.0,"alt_U_L":115},{"date":"2028-03-18","hemoglobin_g_dL":13.0,"wbc_k_uL":4.0,"platelets_k_uL":172,"creatinine_mg_dL":1.03,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_2690","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":64,"sex":"male","bmi":36.5,"smoking_pack_years":34,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-82},"pfs_months":49.58},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":67.5,"censored":false},"longitudinal_labs":[{"date":"2022-07-18","hemoglobin_g_dL":11.9,"wbc_k_uL":4.8,"platelets_k_uL":433,"creatinine_mg_dL":0.95,"alt_U_L":72},{"date":"2023-02-17","hemoglobin_g_dL":13.1,"wbc_k_uL":8.0,"platelets_k_uL":357,"creatinine_mg_dL":1.37,"alt_U_L":112},{"date":"2026-10-25","hemoglobin_g_dL":11.5,"wbc_k_uL":4.8,"platelets_k_uL":273,"creatinine_mg_dL":0.86,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_2691","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":77,"sex":"female","bmi":34.1,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-09-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-54},"pfs_months":8.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.3,"censored":true},"longitudinal_labs":[{"date":"2025-08-22","hemoglobin_g_dL":14.6,"wbc_k_uL":6.0,"platelets_k_uL":190,"creatinine_mg_dL":0.7,"alt_U_L":77},{"date":"2026-03-22","hemoglobin_g_dL":12.5,"wbc_k_uL":6.7,"platelets_k_uL":121,"creatinine_mg_dL":0.88,"alt_U_L":108},{"date":"2026-07-03","hemoglobin_g_dL":10.0,"wbc_k_uL":5.0,"platelets_k_uL":233,"creatinine_mg_dL":1.09,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_2692","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":81,"sex":"female","bmi":28.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-38},"pfs_months":19.94},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.8,"censored":true},"longitudinal_labs":[{"date":"2025-06-05","hemoglobin_g_dL":13.6,"wbc_k_uL":7.9,"platelets_k_uL":437,"creatinine_mg_dL":1.13,"alt_U_L":68},{"date":"2026-02-01","hemoglobin_g_dL":10.2,"wbc_k_uL":4.4,"platelets_k_uL":300,"creatinine_mg_dL":1.36,"alt_U_L":94},{"date":"2027-05-16","hemoglobin_g_dL":11.7,"wbc_k_uL":6.1,"platelets_k_uL":101,"creatinine_mg_dL":1.91,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_2693","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":84,"sex":"female","bmi":20.9,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-03-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-69},"pfs_months":19.88},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.9,"censored":true},"longitudinal_labs":[{"date":"2020-01-15","hemoglobin_g_dL":14.3,"wbc_k_uL":7.2,"platelets_k_uL":173,"creatinine_mg_dL":1.0,"alt_U_L":73},{"date":"2020-09-16","hemoglobin_g_dL":12.7,"wbc_k_uL":5.6,"platelets_k_uL":141,"creatinine_mg_dL":1.59,"alt_U_L":18},{"date":"2021-12-24","hemoglobin_g_dL":11.7,"wbc_k_uL":6.7,"platelets_k_uL":328,"creatinine_mg_dL":1.07,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_2694","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":83,"sex":"male","bmi":32.4,"smoking_pack_years":36,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-11-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-41},"pfs_months":39.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-04-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":64.9,"censored":false},"longitudinal_labs":[{"date":"2025-10-01","hemoglobin_g_dL":13.0,"wbc_k_uL":5.0,"platelets_k_uL":443,"creatinine_mg_dL":0.77,"alt_U_L":47},{"date":"2026-05-22","hemoglobin_g_dL":10.4,"wbc_k_uL":4.0,"platelets_k_uL":342,"creatinine_mg_dL":1.45,"alt_U_L":54},{"date":"2029-04-20","hemoglobin_g_dL":9.7,"wbc_k_uL":3.6,"platelets_k_uL":118,"creatinine_mg_dL":1.35,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_2695","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":69,"sex":"female","bmi":23.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-55},"pfs_months":25.1},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":false},"longitudinal_labs":[{"date":"2022-07-11","hemoglobin_g_dL":15.1,"wbc_k_uL":10.6,"platelets_k_uL":155,"creatinine_mg_dL":0.78,"alt_U_L":80},{"date":"2023-02-27","hemoglobin_g_dL":13.3,"wbc_k_uL":5.9,"platelets_k_uL":141,"creatinine_mg_dL":1.09,"alt_U_L":97},{"date":"2024-10-29","hemoglobin_g_dL":11.0,"wbc_k_uL":7.3,"platelets_k_uL":146,"creatinine_mg_dL":1.1,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_2696","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":58,"sex":"male","bmi":32.2,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-02-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-56},"pfs_months":13.6},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-06-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":23.4,"censored":false},"longitudinal_labs":[{"date":"2020-01-07","hemoglobin_g_dL":15.4,"wbc_k_uL":8.1,"platelets_k_uL":409,"creatinine_mg_dL":1.13,"alt_U_L":60},{"date":"2020-08-23","hemoglobin_g_dL":13.9,"wbc_k_uL":8.4,"platelets_k_uL":139,"creatinine_mg_dL":0.94,"alt_U_L":103},{"date":"2021-06-13","hemoglobin_g_dL":12.1,"wbc_k_uL":3.8,"platelets_k_uL":208,"creatinine_mg_dL":1.55,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_2697","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":69,"sex":"male","bmi":36.0,"smoking_pack_years":58,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-07-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-50},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":false},"longitudinal_labs":[{"date":"2024-06-19","hemoglobin_g_dL":14.0,"wbc_k_uL":5.0,"platelets_k_uL":261,"creatinine_mg_dL":0.76,"alt_U_L":77},{"date":"2025-01-03","hemoglobin_g_dL":10.4,"wbc_k_uL":6.8,"platelets_k_uL":365,"creatinine_mg_dL":1.08,"alt_U_L":21},{"date":"2026-06-11","hemoglobin_g_dL":10.9,"wbc_k_uL":4.3,"platelets_k_uL":293,"creatinine_mg_dL":1.22,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_2698","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":85,"sex":"female","bmi":19.4,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-30},"pfs_months":28.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":47.8,"censored":true},"longitudinal_labs":[{"date":"2021-09-19","hemoglobin_g_dL":13.1,"wbc_k_uL":9.6,"platelets_k_uL":267,"creatinine_mg_dL":0.75,"alt_U_L":60},{"date":"2022-05-06","hemoglobin_g_dL":13.4,"wbc_k_uL":7.0,"platelets_k_uL":232,"creatinine_mg_dL":1.24,"alt_U_L":107},{"date":"2024-05-15","hemoglobin_g_dL":12.5,"wbc_k_uL":6.2,"platelets_k_uL":335,"creatinine_mg_dL":1.24,"alt_U_L":108}]}
{"patient_id":"ANODE_SYNTH_2025_2699","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":60,"sex":"female","bmi":34.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-55},"pfs_months":11.3},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.3,"censored":false},"longitudinal_labs":[{"date":"2020-05-19","hemoglobin_g_dL":12.0,"wbc_k_uL":10.7,"platelets_k_uL":263,"creatinine_mg_dL":1.06,"alt_U_L":29},{"date":"2020-12-04","hemoglobin_g_dL":13.1,"wbc_k_uL":7.4,"platelets_k_uL":147,"creatinine_mg_dL":1.22,"alt_U_L":46},{"date":"2021-05-28","hemoglobin_g_dL":10.9,"wbc_k_uL":6.9,"platelets_k_uL":107,"creatinine_mg_dL":1.99,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2700","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":55,"sex":"female","bmi":25.6,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-12-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-50},"pfs_months":33.58},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.1,"censored":true},"longitudinal_labs":[{"date":"2024-10-28","hemoglobin_g_dL":14.5,"wbc_k_uL":9.8,"platelets_k_uL":419,"creatinine_mg_dL":1.11,"alt_U_L":56},{"date":"2025-06-02","hemoglobin_g_dL":11.5,"wbc_k_uL":4.2,"platelets_k_uL":367,"creatinine_mg_dL":0.79,"alt_U_L":100},{"date":"2027-11-19","hemoglobin_g_dL":11.2,"wbc_k_uL":4.6,"platelets_k_uL":290,"creatinine_mg_dL":1.13,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_2701","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":50,"sex":"female","bmi":25.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["pleura","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-30},"pfs_months":29.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.1,"censored":true},"longitudinal_labs":[{"date":"2020-09-04","hemoglobin_g_dL":15.5,"wbc_k_uL":8.2,"platelets_k_uL":202,"creatinine_mg_dL":0.78,"alt_U_L":22},{"date":"2021-03-17","hemoglobin_g_dL":13.3,"wbc_k_uL":7.3,"platelets_k_uL":153,"creatinine_mg_dL":1.15,"alt_U_L":98},{"date":"2023-04-01","hemoglobin_g_dL":11.0,"wbc_k_uL":4.1,"platelets_k_uL":188,"creatinine_mg_dL":0.83,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_2702","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":80,"sex":"female","bmi":23.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-82},"pfs_months":17.94},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.2,"censored":true},"longitudinal_labs":[{"date":"2022-01-28","hemoglobin_g_dL":14.7,"wbc_k_uL":9.3,"platelets_k_uL":430,"creatinine_mg_dL":1.29,"alt_U_L":25},{"date":"2022-09-20","hemoglobin_g_dL":13.5,"wbc_k_uL":7.2,"platelets_k_uL":185,"creatinine_mg_dL":0.97,"alt_U_L":46},{"date":"2023-11-20","hemoglobin_g_dL":11.8,"wbc_k_uL":5.5,"platelets_k_uL":144,"creatinine_mg_dL":0.87,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_2703","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":52,"sex":"female","bmi":32.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-52},"pfs_months":26.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.0,"censored":true},"longitudinal_labs":[{"date":"2020-12-08","hemoglobin_g_dL":14.1,"wbc_k_uL":9.1,"platelets_k_uL":298,"creatinine_mg_dL":0.79,"alt_U_L":36},{"date":"2021-08-12","hemoglobin_g_dL":12.7,"wbc_k_uL":5.6,"platelets_k_uL":330,"creatinine_mg_dL":0.96,"alt_U_L":113},{"date":"2023-05-26","hemoglobin_g_dL":11.5,"wbc_k_uL":4.6,"platelets_k_uL":218,"creatinine_mg_dL":1.59,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_2704","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":66,"sex":"male","bmi":18.8,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-02-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-42},"pfs_months":20.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.1,"censored":false},"longitudinal_labs":[{"date":"2022-01-08","hemoglobin_g_dL":13.2,"wbc_k_uL":6.7,"platelets_k_uL":374,"creatinine_mg_dL":1.09,"alt_U_L":69},{"date":"2022-08-10","hemoglobin_g_dL":12.1,"wbc_k_uL":8.3,"platelets_k_uL":213,"creatinine_mg_dL":0.85,"alt_U_L":62},{"date":"2023-11-09","hemoglobin_g_dL":11.8,"wbc_k_uL":5.2,"platelets_k_uL":262,"creatinine_mg_dL":1.98,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_2705","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":82,"sex":"female","bmi":33.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-84},"pfs_months":16.53},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.2,"censored":false},"longitudinal_labs":[{"date":"2020-02-16","hemoglobin_g_dL":12.1,"wbc_k_uL":9.1,"platelets_k_uL":206,"creatinine_mg_dL":0.98,"alt_U_L":13},{"date":"2020-10-14","hemoglobin_g_dL":12.9,"wbc_k_uL":5.6,"platelets_k_uL":214,"creatinine_mg_dL":1.12,"alt_U_L":109},{"date":"2021-09-24","hemoglobin_g_dL":10.7,"wbc_k_uL":3.7,"platelets_k_uL":101,"creatinine_mg_dL":1.64,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_2706","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.4,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":49,"sex":"male","bmi":23.5,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-09-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-52},"pfs_months":9.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-08-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.6,"censored":true},"longitudinal_labs":[{"date":"2020-07-16","hemoglobin_g_dL":15.0,"wbc_k_uL":5.0,"platelets_k_uL":397,"creatinine_mg_dL":1.06,"alt_U_L":74},{"date":"2021-03-15","hemoglobin_g_dL":10.4,"wbc_k_uL":4.8,"platelets_k_uL":142,"creatinine_mg_dL":1.49,"alt_U_L":112},{"date":"2021-08-28","hemoglobin_g_dL":12.9,"wbc_k_uL":3.3,"platelets_k_uL":160,"creatinine_mg_dL":1.24,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_2707","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":64,"sex":"male","bmi":24.5,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-12-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-82},"pfs_months":38.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.0,"censored":true},"longitudinal_labs":[{"date":"2021-10-22","hemoglobin_g_dL":15.0,"wbc_k_uL":11.0,"platelets_k_uL":354,"creatinine_mg_dL":0.99,"alt_U_L":29},{"date":"2022-06-12","hemoglobin_g_dL":11.3,"wbc_k_uL":6.7,"platelets_k_uL":373,"creatinine_mg_dL":0.8,"alt_U_L":118},{"date":"2025-03-16","hemoglobin_g_dL":12.0,"wbc_k_uL":4.1,"platelets_k_uL":326,"creatinine_mg_dL":1.12,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_2708","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":63,"sex":"female","bmi":20.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-02-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-34},"pfs_months":15.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.3,"censored":false},"longitudinal_labs":[{"date":"2024-01-06","hemoglobin_g_dL":12.5,"wbc_k_uL":5.1,"platelets_k_uL":179,"creatinine_mg_dL":0.93,"alt_U_L":79},{"date":"2024-08-21","hemoglobin_g_dL":12.6,"wbc_k_uL":8.5,"platelets_k_uL":222,"creatinine_mg_dL":1.18,"alt_U_L":42},{"date":"2025-06-17","hemoglobin_g_dL":9.8,"wbc_k_uL":6.2,"platelets_k_uL":326,"creatinine_mg_dL":1.18,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_2709","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":59,"sex":"female","bmi":29.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-73},"pfs_months":20.4},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.9,"censored":false},"longitudinal_labs":[{"date":"2020-04-07","hemoglobin_g_dL":12.9,"wbc_k_uL":5.8,"platelets_k_uL":316,"creatinine_mg_dL":0.76,"alt_U_L":70},{"date":"2020-11-18","hemoglobin_g_dL":10.0,"wbc_k_uL":6.2,"platelets_k_uL":354,"creatinine_mg_dL":1.22,"alt_U_L":112},{"date":"2022-02-07","hemoglobin_g_dL":10.6,"wbc_k_uL":5.3,"platelets_k_uL":113,"creatinine_mg_dL":1.71,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_2710","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":69,"sex":"female","bmi":19.7,"smoking_pack_years":73,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-06-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-71},"pfs_months":4.73},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":10.3,"censored":true},"longitudinal_labs":[{"date":"2021-05-14","hemoglobin_g_dL":15.0,"wbc_k_uL":9.1,"platelets_k_uL":426,"creatinine_mg_dL":1.19,"alt_U_L":58},{"date":"2021-12-24","hemoglobin_g_dL":10.5,"wbc_k_uL":8.3,"platelets_k_uL":148,"creatinine_mg_dL":0.73,"alt_U_L":74},{"date":"2021-12-20","hemoglobin_g_dL":10.5,"wbc_k_uL":7.6,"platelets_k_uL":237,"creatinine_mg_dL":1.41,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_2711","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":88,"sex":"female","bmi":19.6,"smoking_pack_years":41,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-08-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-76},"pfs_months":36.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-09","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":61.5,"censored":true},"longitudinal_labs":[{"date":"2020-07-16","hemoglobin_g_dL":15.5,"wbc_k_uL":6.9,"platelets_k_uL":364,"creatinine_mg_dL":0.81,"alt_U_L":23},{"date":"2021-02-06","hemoglobin_g_dL":11.8,"wbc_k_uL":6.5,"platelets_k_uL":238,"creatinine_mg_dL":1.59,"alt_U_L":119},{"date":"2023-10-09","hemoglobin_g_dL":10.2,"wbc_k_uL":7.5,"platelets_k_uL":312,"creatinine_mg_dL":2.0,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_2712","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":59,"sex":"female","bmi":18.6,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-05-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-72},"pfs_months":25.36},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.0,"censored":false},"longitudinal_labs":[{"date":"2025-03-02","hemoglobin_g_dL":13.7,"wbc_k_uL":5.6,"platelets_k_uL":250,"creatinine_mg_dL":1.13,"alt_U_L":39},{"date":"2025-10-30","hemoglobin_g_dL":10.6,"wbc_k_uL":8.2,"platelets_k_uL":329,"creatinine_mg_dL":1.34,"alt_U_L":86},{"date":"2027-08-04","hemoglobin_g_dL":9.6,"wbc_k_uL":3.1,"platelets_k_uL":117,"creatinine_mg_dL":1.3,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_2713","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":87,"sex":"female","bmi":33.4,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-12-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-72},"pfs_months":12.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.2,"censored":true},"longitudinal_labs":[{"date":"2020-11-22","hemoglobin_g_dL":12.3,"wbc_k_uL":8.0,"platelets_k_uL":401,"creatinine_mg_dL":0.72,"alt_U_L":61},{"date":"2021-06-10","hemoglobin_g_dL":11.0,"wbc_k_uL":5.0,"platelets_k_uL":141,"creatinine_mg_dL":1.35,"alt_U_L":110},{"date":"2022-02-28","hemoglobin_g_dL":10.9,"wbc_k_uL":6.3,"platelets_k_uL":302,"creatinine_mg_dL":1.81,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_2714","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":50,"sex":"female","bmi":19.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-50},"pfs_months":11.5},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.3,"censored":false},"longitudinal_labs":[{"date":"2023-08-11","hemoglobin_g_dL":15.5,"wbc_k_uL":4.8,"platelets_k_uL":436,"creatinine_mg_dL":1.18,"alt_U_L":33},{"date":"2024-04-16","hemoglobin_g_dL":13.5,"wbc_k_uL":7.6,"platelets_k_uL":209,"creatinine_mg_dL":1.42,"alt_U_L":17},{"date":"2024-10-24","hemoglobin_g_dL":12.9,"wbc_k_uL":8.0,"platelets_k_uL":302,"creatinine_mg_dL":1.45,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_2715","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":70,"sex":"male","bmi":19.0,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-04-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-47},"pfs_months":11.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.9,"censored":false},"longitudinal_labs":[{"date":"2023-03-13","hemoglobin_g_dL":12.3,"wbc_k_uL":4.7,"platelets_k_uL":250,"creatinine_mg_dL":0.86,"alt_U_L":41},{"date":"2023-10-25","hemoglobin_g_dL":10.6,"wbc_k_uL":7.0,"platelets_k_uL":281,"creatinine_mg_dL":0.74,"alt_U_L":25},{"date":"2024-05-07","hemoglobin_g_dL":11.0,"wbc_k_uL":5.2,"platelets_k_uL":176,"creatinine_mg_dL":1.01,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_2716","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":53,"sex":"male","bmi":27.7,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-10-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-76},"pfs_months":30.59},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":58.4,"censored":false},"longitudinal_labs":[{"date":"2024-09-05","hemoglobin_g_dL":13.8,"wbc_k_uL":9.2,"platelets_k_uL":219,"creatinine_mg_dL":1.0,"alt_U_L":52},{"date":"2025-04-04","hemoglobin_g_dL":13.3,"wbc_k_uL":8.1,"platelets_k_uL":320,"creatinine_mg_dL":1.58,"alt_U_L":54},{"date":"2027-05-12","hemoglobin_g_dL":11.6,"wbc_k_uL":4.4,"platelets_k_uL":273,"creatinine_mg_dL":1.53,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_2717","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":84,"sex":"female","bmi":21.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-37},"pfs_months":14.19},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-31","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.4,"censored":false},"longitudinal_labs":[{"date":"2021-01-01","hemoglobin_g_dL":13.9,"wbc_k_uL":9.9,"platelets_k_uL":321,"creatinine_mg_dL":0.89,"alt_U_L":62},{"date":"2021-07-15","hemoglobin_g_dL":11.1,"wbc_k_uL":6.1,"platelets_k_uL":299,"creatinine_mg_dL":1.06,"alt_U_L":42},{"date":"2022-03-31","hemoglobin_g_dL":9.7,"wbc_k_uL":6.3,"platelets_k_uL":275,"creatinine_mg_dL":1.18,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_2718","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":80,"sex":"female","bmi":37.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-33},"pfs_months":36.93},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.5,"censored":false},"longitudinal_labs":[{"date":"2020-01-24","hemoglobin_g_dL":13.4,"wbc_k_uL":4.9,"platelets_k_uL":324,"creatinine_mg_dL":1.23,"alt_U_L":54},{"date":"2020-09-30","hemoglobin_g_dL":10.0,"wbc_k_uL":8.0,"platelets_k_uL":172,"creatinine_mg_dL":1.23,"alt_U_L":36},{"date":"2023-06-04","hemoglobin_g_dL":11.0,"wbc_k_uL":6.6,"platelets_k_uL":305,"creatinine_mg_dL":1.14,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_2719","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":49,"sex":"female","bmi":32.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-31},"pfs_months":22.6},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.3,"censored":false},"longitudinal_labs":[{"date":"2020-04-21","hemoglobin_g_dL":12.0,"wbc_k_uL":5.3,"platelets_k_uL":383,"creatinine_mg_dL":0.73,"alt_U_L":40},{"date":"2020-12-27","hemoglobin_g_dL":13.6,"wbc_k_uL":6.6,"platelets_k_uL":369,"creatinine_mg_dL":1.31,"alt_U_L":70},{"date":"2022-07-05","hemoglobin_g_dL":12.8,"wbc_k_uL":7.2,"platelets_k_uL":221,"creatinine_mg_dL":0.84,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_2720","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":77,"sex":"female","bmi":30.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-81},"pfs_months":28.06},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":50.2,"censored":false},"longitudinal_labs":[{"date":"2024-05-10","hemoglobin_g_dL":12.3,"wbc_k_uL":5.6,"platelets_k_uL":364,"creatinine_mg_dL":1.15,"alt_U_L":22},{"date":"2024-12-24","hemoglobin_g_dL":12.0,"wbc_k_uL":5.3,"platelets_k_uL":280,"creatinine_mg_dL":1.13,"alt_U_L":15},{"date":"2026-11-23","hemoglobin_g_dL":12.9,"wbc_k_uL":3.3,"platelets_k_uL":157,"creatinine_mg_dL":1.19,"alt_U_L":58}]}
{"patient_id":"ANODE_SYNTH_2025_2721","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":74,"sex":"male","bmi":21.0,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-35},"pfs_months":37.68},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.8,"censored":true},"longitudinal_labs":[{"date":"2023-02-16","hemoglobin_g_dL":13.5,"wbc_k_uL":10.3,"platelets_k_uL":333,"creatinine_mg_dL":1.1,"alt_U_L":49},{"date":"2023-09-04","hemoglobin_g_dL":11.4,"wbc_k_uL":6.1,"platelets_k_uL":129,"creatinine_mg_dL":1.46,"alt_U_L":23},{"date":"2026-05-06","hemoglobin_g_dL":11.9,"wbc_k_uL":3.1,"platelets_k_uL":261,"creatinine_mg_dL":1.19,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_2722","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.8,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":57,"sex":"male","bmi":36.6,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-57},"pfs_months":37.22},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":63.4,"censored":false},"longitudinal_labs":[{"date":"2020-01-15","hemoglobin_g_dL":13.0,"wbc_k_uL":5.2,"platelets_k_uL":215,"creatinine_mg_dL":0.82,"alt_U_L":12},{"date":"2020-09-11","hemoglobin_g_dL":13.9,"wbc_k_uL":5.2,"platelets_k_uL":172,"creatinine_mg_dL":0.86,"alt_U_L":74},{"date":"2023-05-10","hemoglobin_g_dL":12.9,"wbc_k_uL":5.7,"platelets_k_uL":176,"creatinine_mg_dL":1.44,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_2723","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":56,"sex":"female","bmi":28.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-09-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-45},"pfs_months":15.8},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.4,"censored":true},"longitudinal_labs":[{"date":"2023-08-16","hemoglobin_g_dL":12.0,"wbc_k_uL":5.6,"platelets_k_uL":274,"creatinine_mg_dL":0.91,"alt_U_L":34},{"date":"2024-03-05","hemoglobin_g_dL":10.1,"wbc_k_uL":5.5,"platelets_k_uL":172,"creatinine_mg_dL":1.09,"alt_U_L":54},{"date":"2025-01-20","hemoglobin_g_dL":12.0,"wbc_k_uL":4.4,"platelets_k_uL":163,"creatinine_mg_dL":1.23,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_2724","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":70,"sex":"female","bmi":34.6,"smoking_pack_years":63,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-32},"pfs_months":30.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":53.0,"censored":false},"longitudinal_labs":[{"date":"2025-01-02","hemoglobin_g_dL":15.3,"wbc_k_uL":9.4,"platelets_k_uL":420,"creatinine_mg_dL":1.17,"alt_U_L":35},{"date":"2025-08-24","hemoglobin_g_dL":12.7,"wbc_k_uL":6.0,"platelets_k_uL":132,"creatinine_mg_dL":1.39,"alt_U_L":83},{"date":"2027-11-18","hemoglobin_g_dL":10.6,"wbc_k_uL":3.7,"platelets_k_uL":312,"creatinine_mg_dL":1.28,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_2725","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":66,"sex":"female","bmi":35.6,"smoking_pack_years":33,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-05-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-36},"pfs_months":45.04},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":69.5,"censored":false},"longitudinal_labs":[{"date":"2024-04-16","hemoglobin_g_dL":13.6,"wbc_k_uL":5.1,"platelets_k_uL":251,"creatinine_mg_dL":1.2,"alt_U_L":46},{"date":"2024-11-26","hemoglobin_g_dL":11.4,"wbc_k_uL":7.5,"platelets_k_uL":355,"creatinine_mg_dL":1.42,"alt_U_L":77},{"date":"2028-03-25","hemoglobin_g_dL":12.1,"wbc_k_uL":7.0,"platelets_k_uL":212,"creatinine_mg_dL":1.18,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_2726","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":62,"sex":"female","bmi":35.6,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-06-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-33},"pfs_months":27.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.8,"censored":false},"longitudinal_labs":[{"date":"2024-05-11","hemoglobin_g_dL":11.6,"wbc_k_uL":5.2,"platelets_k_uL":397,"creatinine_mg_dL":0.67,"alt_U_L":65},{"date":"2024-12-15","hemoglobin_g_dL":12.7,"wbc_k_uL":7.5,"platelets_k_uL":271,"creatinine_mg_dL":1.24,"alt_U_L":87},{"date":"2026-11-28","hemoglobin_g_dL":12.2,"wbc_k_uL":5.1,"platelets_k_uL":205,"creatinine_mg_dL":1.83,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_2727","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":63,"sex":"male","bmi":33.1,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-10-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-83},"pfs_months":33.58},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":63.6,"censored":false},"longitudinal_labs":[{"date":"2021-08-24","hemoglobin_g_dL":13.9,"wbc_k_uL":6.1,"platelets_k_uL":399,"creatinine_mg_dL":0.79,"alt_U_L":24},{"date":"2022-04-04","hemoglobin_g_dL":13.8,"wbc_k_uL":7.7,"platelets_k_uL":338,"creatinine_mg_dL":1.45,"alt_U_L":25},{"date":"2024-09-05","hemoglobin_g_dL":12.7,"wbc_k_uL":6.9,"platelets_k_uL":350,"creatinine_mg_dL":1.18,"alt_U_L":149}]}
{"patient_id":"ANODE_SYNTH_2025_2728","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":72,"sex":"female","bmi":34.5,"smoking_pack_years":34,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-74},"pfs_months":12.81},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":18.0,"censored":true},"longitudinal_labs":[{"date":"2024-12-19","hemoglobin_g_dL":13.6,"wbc_k_uL":6.0,"platelets_k_uL":259,"creatinine_mg_dL":0.94,"alt_U_L":44},{"date":"2025-07-09","hemoglobin_g_dL":11.0,"wbc_k_uL":6.7,"platelets_k_uL":205,"creatinine_mg_dL":1.55,"alt_U_L":112},{"date":"2026-03-25","hemoglobin_g_dL":11.6,"wbc_k_uL":3.9,"platelets_k_uL":325,"creatinine_mg_dL":1.41,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_2729","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":64,"sex":"female","bmi":29.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-78},"pfs_months":15.15},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.3,"censored":true},"longitudinal_labs":[{"date":"2023-04-13","hemoglobin_g_dL":15.3,"wbc_k_uL":5.4,"platelets_k_uL":219,"creatinine_mg_dL":1.02,"alt_U_L":35},{"date":"2023-12-02","hemoglobin_g_dL":13.4,"wbc_k_uL":5.6,"platelets_k_uL":337,"creatinine_mg_dL":1.17,"alt_U_L":114},{"date":"2024-10-20","hemoglobin_g_dL":11.8,"wbc_k_uL":4.3,"platelets_k_uL":220,"creatinine_mg_dL":1.39,"alt_U_L":104}]}
{"patient_id":"ANODE_SYNTH_2025_2730","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":60,"sex":"female","bmi":25.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-01-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-41},"pfs_months":15.84},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.9,"censored":false},"longitudinal_labs":[{"date":"2025-12-27","hemoglobin_g_dL":14.6,"wbc_k_uL":4.5,"platelets_k_uL":214,"creatinine_mg_dL":1.12,"alt_U_L":59},{"date":"2026-07-14","hemoglobin_g_dL":13.9,"wbc_k_uL":7.5,"platelets_k_uL":270,"creatinine_mg_dL":1.5,"alt_U_L":76},{"date":"2027-06-05","hemoglobin_g_dL":12.9,"wbc_k_uL":3.6,"platelets_k_uL":122,"creatinine_mg_dL":0.87,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_2731","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":88,"sex":"female","bmi":33.2,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-01-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-58},"pfs_months":32.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-10-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.4,"censored":false},"longitudinal_labs":[{"date":"2025-12-17","hemoglobin_g_dL":13.0,"wbc_k_uL":8.6,"platelets_k_uL":163,"creatinine_mg_dL":0.63,"alt_U_L":66},{"date":"2026-07-04","hemoglobin_g_dL":12.2,"wbc_k_uL":8.5,"platelets_k_uL":311,"creatinine_mg_dL":1.48,"alt_U_L":116},{"date":"2028-10-06","hemoglobin_g_dL":9.7,"wbc_k_uL":3.4,"platelets_k_uL":239,"creatinine_mg_dL":1.51,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_2732","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":74,"sex":"female","bmi":29.9,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-31},"pfs_months":44.09},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":62.1,"censored":true},"longitudinal_labs":[{"date":"2023-09-20","hemoglobin_g_dL":13.7,"wbc_k_uL":4.9,"platelets_k_uL":205,"creatinine_mg_dL":0.98,"alt_U_L":18},{"date":"2024-05-06","hemoglobin_g_dL":10.9,"wbc_k_uL":7.5,"platelets_k_uL":248,"creatinine_mg_dL":0.78,"alt_U_L":91},{"date":"2027-07-27","hemoglobin_g_dL":11.1,"wbc_k_uL":7.2,"platelets_k_uL":139,"creatinine_mg_dL":1.24,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_2733","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":53,"sex":"female","bmi":19.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-01-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-67},"pfs_months":34.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":false},"longitudinal_labs":[{"date":"2022-12-23","hemoglobin_g_dL":12.7,"wbc_k_uL":10.4,"platelets_k_uL":282,"creatinine_mg_dL":0.89,"alt_U_L":24},{"date":"2023-07-18","hemoglobin_g_dL":13.7,"wbc_k_uL":8.5,"platelets_k_uL":371,"creatinine_mg_dL":1.05,"alt_U_L":25},{"date":"2026-01-16","hemoglobin_g_dL":12.1,"wbc_k_uL":4.8,"platelets_k_uL":287,"creatinine_mg_dL":0.82,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_2734","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":71,"sex":"female","bmi":36.2,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-03-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-33},"pfs_months":34.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":54.9,"censored":false},"longitudinal_labs":[{"date":"2022-02-02","hemoglobin_g_dL":14.3,"wbc_k_uL":6.1,"platelets_k_uL":286,"creatinine_mg_dL":0.97,"alt_U_L":78},{"date":"2022-09-01","hemoglobin_g_dL":13.8,"wbc_k_uL":8.1,"platelets_k_uL":173,"creatinine_mg_dL":1.05,"alt_U_L":63},{"date":"2025-03-23","hemoglobin_g_dL":12.0,"wbc_k_uL":3.7,"platelets_k_uL":214,"creatinine_mg_dL":1.23,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_2735","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":73,"sex":"male","bmi":24.2,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-10-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-67},"pfs_months":43.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":66.3,"censored":false},"longitudinal_labs":[{"date":"2023-09-10","hemoglobin_g_dL":14.0,"wbc_k_uL":7.7,"platelets_k_uL":171,"creatinine_mg_dL":0.81,"alt_U_L":47},{"date":"2024-04-05","hemoglobin_g_dL":13.3,"wbc_k_uL":7.8,"platelets_k_uL":187,"creatinine_mg_dL":1.37,"alt_U_L":111},{"date":"2027-05-26","hemoglobin_g_dL":10.4,"wbc_k_uL":7.4,"platelets_k_uL":305,"creatinine_mg_dL":0.94,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_2736","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":56,"sex":"male","bmi":32.7,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-02-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-68},"pfs_months":29.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":45.6,"censored":true},"longitudinal_labs":[{"date":"2023-12-24","hemoglobin_g_dL":12.1,"wbc_k_uL":10.8,"platelets_k_uL":247,"creatinine_mg_dL":0.72,"alt_U_L":49},{"date":"2024-08-15","hemoglobin_g_dL":12.2,"wbc_k_uL":5.2,"platelets_k_uL":165,"creatinine_mg_dL":1.17,"alt_U_L":56},{"date":"2026-08-29","hemoglobin_g_dL":10.6,"wbc_k_uL":5.7,"platelets_k_uL":325,"creatinine_mg_dL":1.29,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_2737","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":84,"sex":"female","bmi":29.2,"smoking_pack_years":42,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["brain","pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-11-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-64},"pfs_months":28.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":47.6,"censored":false},"longitudinal_labs":[{"date":"2024-10-09","hemoglobin_g_dL":13.7,"wbc_k_uL":7.3,"platelets_k_uL":236,"creatinine_mg_dL":1.29,"alt_U_L":71},{"date":"2025-05-14","hemoglobin_g_dL":13.9,"wbc_k_uL":6.8,"platelets_k_uL":134,"creatinine_mg_dL":1.59,"alt_U_L":48},{"date":"2027-04-29","hemoglobin_g_dL":11.7,"wbc_k_uL":5.6,"platelets_k_uL":295,"creatinine_mg_dL":1.1,"alt_U_L":145}]}
{"patient_id":"ANODE_SYNTH_2025_2738","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":61,"sex":"female","bmi":26.6,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-04-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-34},"pfs_months":13.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.4,"censored":false},"longitudinal_labs":[{"date":"2023-02-13","hemoglobin_g_dL":12.9,"wbc_k_uL":10.8,"platelets_k_uL":263,"creatinine_mg_dL":0.76,"alt_U_L":19},{"date":"2023-10-16","hemoglobin_g_dL":11.1,"wbc_k_uL":7.1,"platelets_k_uL":307,"creatinine_mg_dL":1.26,"alt_U_L":104},{"date":"2024-07-09","hemoglobin_g_dL":11.3,"wbc_k_uL":5.5,"platelets_k_uL":109,"creatinine_mg_dL":1.9,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_2739","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":66,"sex":"male","bmi":30.7,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-62},"pfs_months":14.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.8,"censored":false},"longitudinal_labs":[{"date":"2025-08-21","hemoglobin_g_dL":12.4,"wbc_k_uL":7.0,"platelets_k_uL":337,"creatinine_mg_dL":1.04,"alt_U_L":80},{"date":"2026-03-14","hemoglobin_g_dL":13.4,"wbc_k_uL":6.4,"platelets_k_uL":246,"creatinine_mg_dL":1.15,"alt_U_L":104},{"date":"2026-12-26","hemoglobin_g_dL":12.4,"wbc_k_uL":7.9,"platelets_k_uL":104,"creatinine_mg_dL":1.86,"alt_U_L":199}]}
{"patient_id":"ANODE_SYNTH_2025_2740","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":87,"sex":"male","bmi":32.4,"smoking_pack_years":47,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-02-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-67},"pfs_months":11.37},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.6,"censored":true},"longitudinal_labs":[{"date":"2020-12-14","hemoglobin_g_dL":11.7,"wbc_k_uL":5.5,"platelets_k_uL":329,"creatinine_mg_dL":1.04,"alt_U_L":18},{"date":"2021-08-08","hemoglobin_g_dL":13.9,"wbc_k_uL":8.4,"platelets_k_uL":209,"creatinine_mg_dL":0.99,"alt_U_L":31},{"date":"2022-03-02","hemoglobin_g_dL":11.4,"wbc_k_uL":5.3,"platelets_k_uL":264,"creatinine_mg_dL":1.78,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_2741","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":60,"sex":"female","bmi":35.3,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-05-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-52},"pfs_months":11.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-06","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.9,"censored":false},"longitudinal_labs":[{"date":"2021-04-22","hemoglobin_g_dL":11.7,"wbc_k_uL":5.1,"platelets_k_uL":348,"creatinine_mg_dL":0.94,"alt_U_L":55},{"date":"2021-11-04","hemoglobin_g_dL":10.7,"wbc_k_uL":8.8,"platelets_k_uL":314,"creatinine_mg_dL":0.75,"alt_U_L":49},{"date":"2022-06-06","hemoglobin_g_dL":11.1,"wbc_k_uL":3.8,"platelets_k_uL":122,"creatinine_mg_dL":0.98,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_2742","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":84,"sex":"female","bmi":21.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-38},"pfs_months":27.93},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":44.8,"censored":true},"longitudinal_labs":[{"date":"2022-10-10","hemoglobin_g_dL":11.6,"wbc_k_uL":6.3,"platelets_k_uL":295,"creatinine_mg_dL":0.64,"alt_U_L":74},{"date":"2023-05-15","hemoglobin_g_dL":10.1,"wbc_k_uL":6.4,"platelets_k_uL":147,"creatinine_mg_dL":1.48,"alt_U_L":45},{"date":"2025-04-09","hemoglobin_g_dL":9.5,"wbc_k_uL":4.1,"platelets_k_uL":320,"creatinine_mg_dL":1.34,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_2743","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":65,"sex":"female","bmi":27.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-81},"pfs_months":29.21},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.6,"censored":false},"longitudinal_labs":[{"date":"2023-05-25","hemoglobin_g_dL":13.3,"wbc_k_uL":8.1,"platelets_k_uL":371,"creatinine_mg_dL":1.12,"alt_U_L":28},{"date":"2024-01-05","hemoglobin_g_dL":10.7,"wbc_k_uL":8.9,"platelets_k_uL":205,"creatinine_mg_dL":1.24,"alt_U_L":80},{"date":"2026-01-27","hemoglobin_g_dL":10.3,"wbc_k_uL":7.3,"platelets_k_uL":217,"creatinine_mg_dL":1.65,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_2744","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":49,"sex":"female","bmi":19.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-60},"pfs_months":19.09},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":false},"longitudinal_labs":[{"date":"2022-09-16","hemoglobin_g_dL":13.6,"wbc_k_uL":9.3,"platelets_k_uL":248,"creatinine_mg_dL":1.23,"alt_U_L":60},{"date":"2023-05-14","hemoglobin_g_dL":10.6,"wbc_k_uL":6.1,"platelets_k_uL":148,"creatinine_mg_dL":1.53,"alt_U_L":51},{"date":"2024-08-11","hemoglobin_g_dL":12.2,"wbc_k_uL":5.4,"platelets_k_uL":254,"creatinine_mg_dL":1.82,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_2745","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":79,"sex":"male","bmi":20.4,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-07-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-79},"pfs_months":22.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.9,"censored":false},"longitudinal_labs":[{"date":"2020-05-16","hemoglobin_g_dL":13.2,"wbc_k_uL":7.0,"platelets_k_uL":409,"creatinine_mg_dL":0.92,"alt_U_L":49},{"date":"2021-01-21","hemoglobin_g_dL":10.7,"wbc_k_uL":6.9,"platelets_k_uL":273,"creatinine_mg_dL":0.98,"alt_U_L":24},{"date":"2022-07-17","hemoglobin_g_dL":10.7,"wbc_k_uL":7.7,"platelets_k_uL":238,"creatinine_mg_dL":1.91,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_2746","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":80,"sex":"female","bmi":20.4,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-45},"pfs_months":15.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.9,"censored":false},"longitudinal_labs":[{"date":"2025-07-09","hemoglobin_g_dL":12.6,"wbc_k_uL":5.8,"platelets_k_uL":315,"creatinine_mg_dL":1.1,"alt_U_L":27},{"date":"2026-02-16","hemoglobin_g_dL":10.6,"wbc_k_uL":4.0,"platelets_k_uL":347,"creatinine_mg_dL":1.5,"alt_U_L":69},{"date":"2027-02-11","hemoglobin_g_dL":10.0,"wbc_k_uL":4.0,"platelets_k_uL":155,"creatinine_mg_dL":1.26,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_2747","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":58,"sex":"male","bmi":33.9,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-34},"pfs_months":26.81},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.6,"censored":false},"longitudinal_labs":[{"date":"2024-06-17","hemoglobin_g_dL":12.9,"wbc_k_uL":6.9,"platelets_k_uL":439,"creatinine_mg_dL":1.28,"alt_U_L":50},{"date":"2025-02-14","hemoglobin_g_dL":10.8,"wbc_k_uL":5.1,"platelets_k_uL":342,"creatinine_mg_dL":1.05,"alt_U_L":26},{"date":"2026-11-30","hemoglobin_g_dL":11.4,"wbc_k_uL":3.2,"platelets_k_uL":311,"creatinine_mg_dL":1.06,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_2748","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":55,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-53},"pfs_months":26.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.2,"censored":false},"longitudinal_labs":[{"date":"2023-09-21","hemoglobin_g_dL":14.6,"wbc_k_uL":10.8,"platelets_k_uL":208,"creatinine_mg_dL":0.89,"alt_U_L":34},{"date":"2024-05-23","hemoglobin_g_dL":11.5,"wbc_k_uL":5.8,"platelets_k_uL":263,"creatinine_mg_dL":0.71,"alt_U_L":107},{"date":"2026-03-24","hemoglobin_g_dL":9.7,"wbc_k_uL":5.7,"platelets_k_uL":347,"creatinine_mg_dL":1.04,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_2749","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":70,"sex":"male","bmi":26.5,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-07-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-62},"pfs_months":15.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.4,"censored":false},"longitudinal_labs":[{"date":"2025-07-01","hemoglobin_g_dL":15.1,"wbc_k_uL":6.0,"platelets_k_uL":380,"creatinine_mg_dL":0.84,"alt_U_L":80},{"date":"2026-01-15","hemoglobin_g_dL":11.2,"wbc_k_uL":6.5,"platelets_k_uL":143,"creatinine_mg_dL":0.74,"alt_U_L":54},{"date":"2027-01-04","hemoglobin_g_dL":12.8,"wbc_k_uL":3.4,"platelets_k_uL":157,"creatinine_mg_dL":1.72,"alt_U_L":168}]}
{"patient_id":"ANODE_SYNTH_2025_2750","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":74,"sex":"female","bmi":29.9,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["liver","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-12-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-73},"pfs_months":25.82},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.5,"censored":true},"longitudinal_labs":[{"date":"2024-10-25","hemoglobin_g_dL":15.0,"wbc_k_uL":9.5,"platelets_k_uL":388,"creatinine_mg_dL":1.06,"alt_U_L":74},{"date":"2025-06-15","hemoglobin_g_dL":11.4,"wbc_k_uL":4.5,"platelets_k_uL":219,"creatinine_mg_dL":1.27,"alt_U_L":59},{"date":"2027-04-01","hemoglobin_g_dL":9.8,"wbc_k_uL":5.1,"platelets_k_uL":321,"creatinine_mg_dL":1.06,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_2751","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.0,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":75,"sex":"male","bmi":20.0,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-11-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-54},"pfs_months":13.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.1,"censored":true},"longitudinal_labs":[{"date":"2025-09-15","hemoglobin_g_dL":12.7,"wbc_k_uL":10.6,"platelets_k_uL":439,"creatinine_mg_dL":1.04,"alt_U_L":66},{"date":"2026-05-16","hemoglobin_g_dL":13.0,"wbc_k_uL":7.1,"platelets_k_uL":166,"creatinine_mg_dL":1.24,"alt_U_L":59},{"date":"2027-03-04","hemoglobin_g_dL":12.0,"wbc_k_uL":5.6,"platelets_k_uL":258,"creatinine_mg_dL":1.76,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_2752","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":77,"sex":"female","bmi":20.1,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-02-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-35},"pfs_months":16.92},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.9,"censored":false},"longitudinal_labs":[{"date":"2022-12-28","hemoglobin_g_dL":14.6,"wbc_k_uL":10.7,"platelets_k_uL":240,"creatinine_mg_dL":1.26,"alt_U_L":65},{"date":"2023-08-04","hemoglobin_g_dL":11.5,"wbc_k_uL":5.3,"platelets_k_uL":132,"creatinine_mg_dL":0.74,"alt_U_L":92},{"date":"2024-08-18","hemoglobin_g_dL":12.7,"wbc_k_uL":4.1,"platelets_k_uL":207,"creatinine_mg_dL":1.54,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_2753","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":67,"sex":"male","bmi":34.7,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-11-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-36},"pfs_months":10.45},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":19.7,"censored":false},"longitudinal_labs":[{"date":"2022-10-01","hemoglobin_g_dL":12.0,"wbc_k_uL":5.5,"platelets_k_uL":210,"creatinine_mg_dL":1.22,"alt_U_L":31},{"date":"2023-05-09","hemoglobin_g_dL":12.2,"wbc_k_uL":6.8,"platelets_k_uL":166,"creatinine_mg_dL":1.01,"alt_U_L":81},{"date":"2023-11-19","hemoglobin_g_dL":12.5,"wbc_k_uL":4.0,"platelets_k_uL":210,"creatinine_mg_dL":1.92,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_2754","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":49,"sex":"male","bmi":37.7,"smoking_pack_years":74,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-34},"pfs_months":41.72},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":68.4,"censored":true},"longitudinal_labs":[{"date":"2024-12-27","hemoglobin_g_dL":14.3,"wbc_k_uL":5.0,"platelets_k_uL":219,"creatinine_mg_dL":0.74,"alt_U_L":14},{"date":"2025-07-13","hemoglobin_g_dL":12.5,"wbc_k_uL":3.9,"platelets_k_uL":229,"creatinine_mg_dL":1.11,"alt_U_L":70},{"date":"2028-07-13","hemoglobin_g_dL":12.1,"wbc_k_uL":7.3,"platelets_k_uL":106,"creatinine_mg_dL":1.29,"alt_U_L":108}]}
{"patient_id":"ANODE_SYNTH_2025_2755","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.2,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":77,"sex":"male","bmi":22.8,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-79},"pfs_months":36.76},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":60.8,"censored":false},"longitudinal_labs":[{"date":"2021-03-11","hemoglobin_g_dL":14.4,"wbc_k_uL":8.2,"platelets_k_uL":178,"creatinine_mg_dL":1.29,"alt_U_L":75},{"date":"2021-11-03","hemoglobin_g_dL":12.5,"wbc_k_uL":8.0,"platelets_k_uL":272,"creatinine_mg_dL":1.29,"alt_U_L":41},{"date":"2024-06-08","hemoglobin_g_dL":10.9,"wbc_k_uL":6.2,"platelets_k_uL":294,"creatinine_mg_dL":1.25,"alt_U_L":155}]}
{"patient_id":"ANODE_SYNTH_2025_2756","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":73,"sex":"male","bmi":37.3,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-01-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-84},"pfs_months":35.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":64.7,"censored":true},"longitudinal_labs":[{"date":"2021-01-14","hemoglobin_g_dL":12.7,"wbc_k_uL":7.6,"platelets_k_uL":420,"creatinine_mg_dL":0.81,"alt_U_L":26},{"date":"2021-07-28","hemoglobin_g_dL":10.3,"wbc_k_uL":5.4,"platelets_k_uL":267,"creatinine_mg_dL":1.11,"alt_U_L":41},{"date":"2024-02-15","hemoglobin_g_dL":10.8,"wbc_k_uL":7.2,"platelets_k_uL":245,"creatinine_mg_dL":1.67,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_2757","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":86,"sex":"female","bmi":20.9,"smoking_pack_years":49,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-09-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-73},"pfs_months":41.17},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":71.5,"censored":false},"longitudinal_labs":[{"date":"2023-07-14","hemoglobin_g_dL":12.8,"wbc_k_uL":5.3,"platelets_k_uL":223,"creatinine_mg_dL":1.3,"alt_U_L":34},{"date":"2024-03-02","hemoglobin_g_dL":13.6,"wbc_k_uL":4.6,"platelets_k_uL":260,"creatinine_mg_dL":1.04,"alt_U_L":61},{"date":"2027-04-06","hemoglobin_g_dL":9.7,"wbc_k_uL":6.0,"platelets_k_uL":182,"creatinine_mg_dL":1.96,"alt_U_L":58}]}
{"patient_id":"ANODE_SYNTH_2025_2758","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":54,"sex":"female","bmi":31.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-80},"pfs_months":19.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.4,"censored":false},"longitudinal_labs":[{"date":"2024-08-24","hemoglobin_g_dL":14.6,"wbc_k_uL":9.3,"platelets_k_uL":390,"creatinine_mg_dL":0.88,"alt_U_L":51},{"date":"2025-04-28","hemoglobin_g_dL":12.4,"wbc_k_uL":4.4,"platelets_k_uL":235,"creatinine_mg_dL":0.76,"alt_U_L":106},{"date":"2026-06-14","hemoglobin_g_dL":12.7,"wbc_k_uL":3.7,"platelets_k_uL":280,"creatinine_mg_dL":1.6,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_2759","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":60,"sex":"female","bmi":32.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-79},"pfs_months":27.24},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":false},"longitudinal_labs":[{"date":"2023-09-09","hemoglobin_g_dL":15.0,"wbc_k_uL":10.1,"platelets_k_uL":346,"creatinine_mg_dL":0.71,"alt_U_L":22},{"date":"2024-04-19","hemoglobin_g_dL":10.5,"wbc_k_uL":8.0,"platelets_k_uL":311,"creatinine_mg_dL":1.57,"alt_U_L":95},{"date":"2026-03-16","hemoglobin_g_dL":12.5,"wbc_k_uL":7.4,"platelets_k_uL":303,"creatinine_mg_dL":1.48,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_2760","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":78,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-60},"pfs_months":21.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.3,"censored":false},"longitudinal_labs":[{"date":"2020-03-15","hemoglobin_g_dL":14.3,"wbc_k_uL":7.4,"platelets_k_uL":408,"creatinine_mg_dL":0.66,"alt_U_L":45},{"date":"2020-11-02","hemoglobin_g_dL":13.5,"wbc_k_uL":3.9,"platelets_k_uL":325,"creatinine_mg_dL":1.17,"alt_U_L":52},{"date":"2022-04-21","hemoglobin_g_dL":12.2,"wbc_k_uL":3.8,"platelets_k_uL":218,"creatinine_mg_dL":1.53,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_2761","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":63,"sex":"male","bmi":26.3,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-11-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-74},"pfs_months":25.53},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-25","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":42.9,"censored":true},"longitudinal_labs":[{"date":"2020-10-23","hemoglobin_g_dL":12.9,"wbc_k_uL":5.8,"platelets_k_uL":328,"creatinine_mg_dL":0.99,"alt_U_L":36},{"date":"2021-05-14","hemoglobin_g_dL":11.5,"wbc_k_uL":8.3,"platelets_k_uL":260,"creatinine_mg_dL":1.47,"alt_U_L":83},{"date":"2023-01-25","hemoglobin_g_dL":12.0,"wbc_k_uL":4.9,"platelets_k_uL":232,"creatinine_mg_dL":1.31,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_2762","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":70,"sex":"female","bmi":25.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-09-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-66},"pfs_months":23.85},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.5,"censored":false},"longitudinal_labs":[{"date":"2022-07-09","hemoglobin_g_dL":13.7,"wbc_k_uL":10.5,"platelets_k_uL":345,"creatinine_mg_dL":0.9,"alt_U_L":70},{"date":"2023-03-07","hemoglobin_g_dL":10.8,"wbc_k_uL":8.1,"platelets_k_uL":318,"creatinine_mg_dL":1.04,"alt_U_L":42},{"date":"2024-10-28","hemoglobin_g_dL":12.8,"wbc_k_uL":3.6,"platelets_k_uL":190,"creatinine_mg_dL":0.81,"alt_U_L":198}]}
{"patient_id":"ANODE_SYNTH_2025_2763","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":81,"sex":"female","bmi":33.8,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-62},"pfs_months":16.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.6,"censored":false},"longitudinal_labs":[{"date":"2022-02-04","hemoglobin_g_dL":14.3,"wbc_k_uL":9.8,"platelets_k_uL":388,"creatinine_mg_dL":1.24,"alt_U_L":33},{"date":"2022-09-18","hemoglobin_g_dL":12.2,"wbc_k_uL":8.0,"platelets_k_uL":124,"creatinine_mg_dL":1.13,"alt_U_L":80},{"date":"2023-08-17","hemoglobin_g_dL":12.0,"wbc_k_uL":6.4,"platelets_k_uL":306,"creatinine_mg_dL":1.12,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_2764","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":85,"sex":"male","bmi":25.4,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-12-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-32},"pfs_months":11.56},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":15.5,"censored":false},"longitudinal_labs":[{"date":"2023-10-23","hemoglobin_g_dL":11.6,"wbc_k_uL":4.6,"platelets_k_uL":206,"creatinine_mg_dL":1.27,"alt_U_L":13},{"date":"2024-06-07","hemoglobin_g_dL":12.5,"wbc_k_uL":7.1,"platelets_k_uL":293,"creatinine_mg_dL":1.12,"alt_U_L":30},{"date":"2025-01-10","hemoglobin_g_dL":12.5,"wbc_k_uL":5.9,"platelets_k_uL":211,"creatinine_mg_dL":1.84,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_2765","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":58,"sex":"female","bmi":22.6,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-04-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-33},"pfs_months":19.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.3,"censored":true},"longitudinal_labs":[{"date":"2022-03-10","hemoglobin_g_dL":12.6,"wbc_k_uL":6.7,"platelets_k_uL":360,"creatinine_mg_dL":1.14,"alt_U_L":28},{"date":"2022-10-23","hemoglobin_g_dL":12.2,"wbc_k_uL":5.8,"platelets_k_uL":245,"creatinine_mg_dL":1.2,"alt_U_L":83},{"date":"2024-01-10","hemoglobin_g_dL":10.5,"wbc_k_uL":4.7,"platelets_k_uL":187,"creatinine_mg_dL":1.17,"alt_U_L":139}]}
{"patient_id":"ANODE_SYNTH_2025_2766","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":61,"sex":"male","bmi":19.2,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-10-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-84},"pfs_months":24.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":false},"longitudinal_labs":[{"date":"2024-09-18","hemoglobin_g_dL":11.7,"wbc_k_uL":4.8,"platelets_k_uL":279,"creatinine_mg_dL":1.19,"alt_U_L":12},{"date":"2025-04-29","hemoglobin_g_dL":13.8,"wbc_k_uL":7.1,"platelets_k_uL":330,"creatinine_mg_dL":1.36,"alt_U_L":54},{"date":"2026-12-24","hemoglobin_g_dL":12.5,"wbc_k_uL":3.6,"platelets_k_uL":214,"creatinine_mg_dL":1.04,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_2767","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":84,"sex":"female","bmi":36.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-57},"pfs_months":16.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.9,"censored":false},"longitudinal_labs":[{"date":"2022-06-16","hemoglobin_g_dL":15.1,"wbc_k_uL":9.9,"platelets_k_uL":304,"creatinine_mg_dL":1.06,"alt_U_L":61},{"date":"2023-01-30","hemoglobin_g_dL":12.6,"wbc_k_uL":4.4,"platelets_k_uL":268,"creatinine_mg_dL":0.85,"alt_U_L":110},{"date":"2024-02-06","hemoglobin_g_dL":11.9,"wbc_k_uL":4.9,"platelets_k_uL":340,"creatinine_mg_dL":0.82,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_2768","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":62,"sex":"male","bmi":28.8,"smoking_pack_years":44,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-07-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-65},"pfs_months":30.13},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":55.6,"censored":false},"longitudinal_labs":[{"date":"2020-06-10","hemoglobin_g_dL":13.8,"wbc_k_uL":5.7,"platelets_k_uL":223,"creatinine_mg_dL":1.1,"alt_U_L":74},{"date":"2021-01-19","hemoglobin_g_dL":12.0,"wbc_k_uL":4.6,"platelets_k_uL":286,"creatinine_mg_dL":0.72,"alt_U_L":27},{"date":"2023-02-06","hemoglobin_g_dL":10.7,"wbc_k_uL":7.0,"platelets_k_uL":343,"creatinine_mg_dL":0.88,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_2769","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":75,"sex":"female","bmi":35.5,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-04-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-35},"pfs_months":5.19},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-10","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":9.1,"censored":true},"longitudinal_labs":[{"date":"2023-03-06","hemoglobin_g_dL":13.5,"wbc_k_uL":6.1,"platelets_k_uL":446,"creatinine_mg_dL":0.81,"alt_U_L":36},{"date":"2023-10-21","hemoglobin_g_dL":13.9,"wbc_k_uL":8.8,"platelets_k_uL":237,"creatinine_mg_dL":1.37,"alt_U_L":90},{"date":"2023-11-10","hemoglobin_g_dL":12.3,"wbc_k_uL":4.7,"platelets_k_uL":242,"creatinine_mg_dL":1.08,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_2770","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":71,"sex":"male","bmi":29.5,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-09-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-58},"pfs_months":48.59},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":80.1,"censored":false},"longitudinal_labs":[{"date":"2023-08-03","hemoglobin_g_dL":12.2,"wbc_k_uL":10.7,"platelets_k_uL":234,"creatinine_mg_dL":0.64,"alt_U_L":49},{"date":"2024-03-09","hemoglobin_g_dL":10.6,"wbc_k_uL":4.5,"platelets_k_uL":263,"creatinine_mg_dL":1.08,"alt_U_L":97},{"date":"2027-11-11","hemoglobin_g_dL":10.7,"wbc_k_uL":4.8,"platelets_k_uL":310,"creatinine_mg_dL":1.58,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_2771","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":84,"sex":"female","bmi":28.1,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-12-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-80},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":13.8,"censored":false},"longitudinal_labs":[{"date":"2023-11-14","hemoglobin_g_dL":11.5,"wbc_k_uL":5.2,"platelets_k_uL":261,"creatinine_mg_dL":0.94,"alt_U_L":70},{"date":"2024-05-29","hemoglobin_g_dL":11.1,"wbc_k_uL":4.0,"platelets_k_uL":133,"creatinine_mg_dL":1.5,"alt_U_L":43},{"date":"2024-03-31","hemoglobin_g_dL":12.2,"wbc_k_uL":7.3,"platelets_k_uL":153,"creatinine_mg_dL":1.43,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_2772","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":87,"sex":"female","bmi":21.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-83},"pfs_months":18.43},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.4,"censored":true},"longitudinal_labs":[{"date":"2020-03-08","hemoglobin_g_dL":12.8,"wbc_k_uL":6.7,"platelets_k_uL":304,"creatinine_mg_dL":0.76,"alt_U_L":79},{"date":"2020-11-02","hemoglobin_g_dL":11.0,"wbc_k_uL":5.1,"platelets_k_uL":179,"creatinine_mg_dL":0.95,"alt_U_L":111},{"date":"2021-12-16","hemoglobin_g_dL":12.9,"wbc_k_uL":5.5,"platelets_k_uL":275,"creatinine_mg_dL":1.54,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_2773","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":76,"sex":"male","bmi":31.7,"smoking_pack_years":50,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-10-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-67},"pfs_months":26.71},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":false},"longitudinal_labs":[{"date":"2022-09-24","hemoglobin_g_dL":12.6,"wbc_k_uL":9.9,"platelets_k_uL":358,"creatinine_mg_dL":0.69,"alt_U_L":50},{"date":"2023-04-07","hemoglobin_g_dL":12.2,"wbc_k_uL":3.8,"platelets_k_uL":191,"creatinine_mg_dL":1.6,"alt_U_L":42},{"date":"2025-02-07","hemoglobin_g_dL":11.4,"wbc_k_uL":7.5,"platelets_k_uL":237,"creatinine_mg_dL":0.81,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_2774","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":80,"sex":"male","bmi":32.2,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-03-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-61},"pfs_months":15.54},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":28.9,"censored":false},"longitudinal_labs":[{"date":"2021-02-15","hemoglobin_g_dL":11.5,"wbc_k_uL":6.5,"platelets_k_uL":210,"creatinine_mg_dL":0.63,"alt_U_L":23},{"date":"2021-09-15","hemoglobin_g_dL":12.7,"wbc_k_uL":4.2,"platelets_k_uL":364,"creatinine_mg_dL":1.28,"alt_U_L":83},{"date":"2022-08-14","hemoglobin_g_dL":10.5,"wbc_k_uL":7.8,"platelets_k_uL":253,"creatinine_mg_dL":0.87,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_2775","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":72,"sex":"male","bmi":25.8,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-01-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-82},"pfs_months":40.31},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.9,"censored":false},"longitudinal_labs":[{"date":"2021-12-17","hemoglobin_g_dL":11.7,"wbc_k_uL":9.7,"platelets_k_uL":223,"creatinine_mg_dL":1.12,"alt_U_L":56},{"date":"2022-07-22","hemoglobin_g_dL":11.9,"wbc_k_uL":8.0,"platelets_k_uL":325,"creatinine_mg_dL":1.12,"alt_U_L":85},{"date":"2025-07-01","hemoglobin_g_dL":12.1,"wbc_k_uL":7.6,"platelets_k_uL":268,"creatinine_mg_dL":1.65,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_2776","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":69,"sex":"female","bmi":23.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-68},"pfs_months":21.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-10","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.9,"censored":false},"longitudinal_labs":[{"date":"2022-11-09","hemoglobin_g_dL":14.1,"wbc_k_uL":8.7,"platelets_k_uL":358,"creatinine_mg_dL":0.71,"alt_U_L":36},{"date":"2023-06-20","hemoglobin_g_dL":11.4,"wbc_k_uL":7.2,"platelets_k_uL":205,"creatinine_mg_dL":1.51,"alt_U_L":81},{"date":"2024-10-10","hemoglobin_g_dL":9.7,"wbc_k_uL":4.5,"platelets_k_uL":192,"creatinine_mg_dL":1.38,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_2777","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":62,"sex":"female","bmi":31.5,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-08-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-46},"pfs_months":28.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":49.7,"censored":true},"longitudinal_labs":[{"date":"2024-07-11","hemoglobin_g_dL":11.6,"wbc_k_uL":9.3,"platelets_k_uL":421,"creatinine_mg_dL":1.18,"alt_U_L":26},{"date":"2025-01-29","hemoglobin_g_dL":10.6,"wbc_k_uL":8.9,"platelets_k_uL":366,"creatinine_mg_dL":1.13,"alt_U_L":34},{"date":"2027-01-31","hemoglobin_g_dL":12.8,"wbc_k_uL":5.9,"platelets_k_uL":191,"creatinine_mg_dL":1.46,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_2778","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":82,"sex":"female","bmi":34.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-57},"pfs_months":18.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.3,"censored":false},"longitudinal_labs":[{"date":"2024-05-08","hemoglobin_g_dL":14.4,"wbc_k_uL":9.4,"platelets_k_uL":441,"creatinine_mg_dL":0.96,"alt_U_L":19},{"date":"2025-01-06","hemoglobin_g_dL":13.4,"wbc_k_uL":8.3,"platelets_k_uL":139,"creatinine_mg_dL":1.36,"alt_U_L":49},{"date":"2026-01-20","hemoglobin_g_dL":10.9,"wbc_k_uL":5.0,"platelets_k_uL":324,"creatinine_mg_dL":1.78,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_2779","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":83,"sex":"male","bmi":22.1,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-11-28","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-85},"pfs_months":13.73},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.2,"censored":false},"longitudinal_labs":[{"date":"2024-10-17","hemoglobin_g_dL":12.5,"wbc_k_uL":6.1,"platelets_k_uL":264,"creatinine_mg_dL":0.94,"alt_U_L":26},{"date":"2025-05-27","hemoglobin_g_dL":10.5,"wbc_k_uL":4.8,"platelets_k_uL":343,"creatinine_mg_dL":0.99,"alt_U_L":55},{"date":"2026-02-13","hemoglobin_g_dL":9.8,"wbc_k_uL":4.6,"platelets_k_uL":113,"creatinine_mg_dL":0.93,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_2780","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":85,"sex":"female","bmi":18.6,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-10-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-34},"pfs_months":14.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.9,"censored":false},"longitudinal_labs":[{"date":"2023-07-26","hemoglobin_g_dL":14.9,"wbc_k_uL":5.1,"platelets_k_uL":288,"creatinine_mg_dL":0.66,"alt_U_L":22},{"date":"2024-03-29","hemoglobin_g_dL":13.6,"wbc_k_uL":8.7,"platelets_k_uL":280,"creatinine_mg_dL":0.89,"alt_U_L":91},{"date":"2025-01-17","hemoglobin_g_dL":12.2,"wbc_k_uL":7.1,"platelets_k_uL":220,"creatinine_mg_dL":0.89,"alt_U_L":108}]}
{"patient_id":"ANODE_SYNTH_2025_2781","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":84,"sex":"male","bmi":30.0,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-02-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-32},"pfs_months":16.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.4,"censored":false},"longitudinal_labs":[{"date":"2021-01-25","hemoglobin_g_dL":14.5,"wbc_k_uL":7.3,"platelets_k_uL":155,"creatinine_mg_dL":0.69,"alt_U_L":20},{"date":"2021-08-10","hemoglobin_g_dL":11.4,"wbc_k_uL":7.4,"platelets_k_uL":264,"creatinine_mg_dL":1.58,"alt_U_L":74},{"date":"2022-07-16","hemoglobin_g_dL":12.4,"wbc_k_uL":3.9,"platelets_k_uL":339,"creatinine_mg_dL":1.2,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_2782","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":55,"sex":"male","bmi":37.3,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-49},"pfs_months":4.34},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":8.3,"censored":false},"longitudinal_labs":[{"date":"2021-01-21","hemoglobin_g_dL":15.4,"wbc_k_uL":9.4,"platelets_k_uL":264,"creatinine_mg_dL":0.69,"alt_U_L":10},{"date":"2021-09-18","hemoglobin_g_dL":11.5,"wbc_k_uL":7.1,"platelets_k_uL":144,"creatinine_mg_dL":1.21,"alt_U_L":78},{"date":"2021-09-17","hemoglobin_g_dL":9.6,"wbc_k_uL":3.8,"platelets_k_uL":287,"creatinine_mg_dL":1.91,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_2783","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":75,"sex":"male","bmi":31.7,"smoking_pack_years":80,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-03-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-53},"pfs_months":23.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":true},"longitudinal_labs":[{"date":"2022-02-14","hemoglobin_g_dL":11.9,"wbc_k_uL":10.6,"platelets_k_uL":226,"creatinine_mg_dL":0.66,"alt_U_L":29},{"date":"2022-09-07","hemoglobin_g_dL":12.9,"wbc_k_uL":7.2,"platelets_k_uL":121,"creatinine_mg_dL":0.81,"alt_U_L":37},{"date":"2024-04-09","hemoglobin_g_dL":11.7,"wbc_k_uL":6.1,"platelets_k_uL":167,"creatinine_mg_dL":1.16,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_2784","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":61,"sex":"male","bmi":36.1,"smoking_pack_years":66,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-12-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-54},"pfs_months":15.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":25.6,"censored":true},"longitudinal_labs":[{"date":"2020-11-23","hemoglobin_g_dL":14.7,"wbc_k_uL":4.8,"platelets_k_uL":341,"creatinine_mg_dL":1.01,"alt_U_L":78},{"date":"2021-06-13","hemoglobin_g_dL":11.6,"wbc_k_uL":6.0,"platelets_k_uL":253,"creatinine_mg_dL":0.98,"alt_U_L":52},{"date":"2022-04-22","hemoglobin_g_dL":12.0,"wbc_k_uL":7.1,"platelets_k_uL":339,"creatinine_mg_dL":1.02,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_2785","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":70,"sex":"female","bmi":23.2,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-33},"pfs_months":3.61},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":7.6,"censored":true},"longitudinal_labs":[{"date":"2023-11-26","hemoglobin_g_dL":13.7,"wbc_k_uL":6.8,"platelets_k_uL":315,"creatinine_mg_dL":0.88,"alt_U_L":63},{"date":"2024-06-22","hemoglobin_g_dL":10.1,"wbc_k_uL":8.5,"platelets_k_uL":155,"creatinine_mg_dL":1.0,"alt_U_L":105},{"date":"2024-06-05","hemoglobin_g_dL":10.4,"wbc_k_uL":4.9,"platelets_k_uL":193,"creatinine_mg_dL":1.68,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_2786","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":67,"sex":"female","bmi":28.7,"smoking_pack_years":22,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-08-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-46},"pfs_months":36.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":52.8,"censored":true},"longitudinal_labs":[{"date":"2021-07-12","hemoglobin_g_dL":11.5,"wbc_k_uL":6.6,"platelets_k_uL":218,"creatinine_mg_dL":0.83,"alt_U_L":31},{"date":"2022-02-25","hemoglobin_g_dL":13.4,"wbc_k_uL":5.6,"platelets_k_uL":332,"creatinine_mg_dL":0.92,"alt_U_L":52},{"date":"2024-10-03","hemoglobin_g_dL":9.6,"wbc_k_uL":4.6,"platelets_k_uL":217,"creatinine_mg_dL":1.01,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_2787","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":51,"sex":"male","bmi":22.7,"smoking_pack_years":34,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["contralateral lung","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-08-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-78},"pfs_months":14.19},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.1,"censored":false},"longitudinal_labs":[{"date":"2020-07-07","hemoglobin_g_dL":12.2,"wbc_k_uL":10.0,"platelets_k_uL":355,"creatinine_mg_dL":1.1,"alt_U_L":37},{"date":"2021-02-03","hemoglobin_g_dL":12.4,"wbc_k_uL":8.8,"platelets_k_uL":152,"creatinine_mg_dL":0.99,"alt_U_L":96},{"date":"2021-11-12","hemoglobin_g_dL":11.4,"wbc_k_uL":3.5,"platelets_k_uL":318,"creatinine_mg_dL":1.41,"alt_U_L":58}]}
{"patient_id":"ANODE_SYNTH_2025_2788","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":52,"sex":"male","bmi":30.0,"smoking_pack_years":73,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-06-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-32},"pfs_months":19.71},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.6,"censored":false},"longitudinal_labs":[{"date":"2021-06-10","hemoglobin_g_dL":13.5,"wbc_k_uL":5.0,"platelets_k_uL":415,"creatinine_mg_dL":0.64,"alt_U_L":48},{"date":"2021-12-24","hemoglobin_g_dL":11.2,"wbc_k_uL":7.4,"platelets_k_uL":365,"creatinine_mg_dL":1.42,"alt_U_L":37},{"date":"2023-04-12","hemoglobin_g_dL":12.1,"wbc_k_uL":3.1,"platelets_k_uL":230,"creatinine_mg_dL":1.3,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_2789","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":51,"sex":"male","bmi":34.0,"smoking_pack_years":30,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-01-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-31},"pfs_months":46.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":71.7,"censored":false},"longitudinal_labs":[{"date":"2020-11-17","hemoglobin_g_dL":13.7,"wbc_k_uL":6.4,"platelets_k_uL":391,"creatinine_mg_dL":0.84,"alt_U_L":38},{"date":"2021-07-13","hemoglobin_g_dL":13.7,"wbc_k_uL":4.6,"platelets_k_uL":350,"creatinine_mg_dL":1.45,"alt_U_L":38},{"date":"2025-01-11","hemoglobin_g_dL":12.1,"wbc_k_uL":3.8,"platelets_k_uL":298,"creatinine_mg_dL":1.03,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_2790","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":50,"sex":"female","bmi":22.9,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-66},"pfs_months":7.75},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":18.3,"censored":false},"longitudinal_labs":[{"date":"2021-01-17","hemoglobin_g_dL":12.4,"wbc_k_uL":7.6,"platelets_k_uL":341,"creatinine_mg_dL":0.69,"alt_U_L":40},{"date":"2021-09-22","hemoglobin_g_dL":12.9,"wbc_k_uL":6.0,"platelets_k_uL":167,"creatinine_mg_dL":1.48,"alt_U_L":76},{"date":"2021-12-20","hemoglobin_g_dL":12.2,"wbc_k_uL":7.1,"platelets_k_uL":250,"creatinine_mg_dL":1.13,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_2791","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":58,"sex":"male","bmi":23.9,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-09-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-58},"pfs_months":34.83},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.7,"censored":true},"longitudinal_labs":[{"date":"2024-07-21","hemoglobin_g_dL":12.4,"wbc_k_uL":9.9,"platelets_k_uL":365,"creatinine_mg_dL":1.09,"alt_U_L":75},{"date":"2025-03-10","hemoglobin_g_dL":13.1,"wbc_k_uL":6.4,"platelets_k_uL":219,"creatinine_mg_dL":1.53,"alt_U_L":30},{"date":"2027-09-23","hemoglobin_g_dL":11.5,"wbc_k_uL":3.1,"platelets_k_uL":279,"creatinine_mg_dL":1.97,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_2792","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":73,"sex":"female","bmi":34.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-49},"pfs_months":17.31},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.5,"censored":true},"longitudinal_labs":[{"date":"2023-05-11","hemoglobin_g_dL":12.9,"wbc_k_uL":5.7,"platelets_k_uL":427,"creatinine_mg_dL":0.84,"alt_U_L":54},{"date":"2023-12-01","hemoglobin_g_dL":10.3,"wbc_k_uL":4.6,"platelets_k_uL":163,"creatinine_mg_dL":0.8,"alt_U_L":109},{"date":"2024-12-18","hemoglobin_g_dL":12.4,"wbc_k_uL":6.2,"platelets_k_uL":322,"creatinine_mg_dL":0.98,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_2793","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":84,"sex":"female","bmi":19.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-07-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-61},"pfs_months":13.6},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.9,"censored":false},"longitudinal_labs":[{"date":"2024-05-14","hemoglobin_g_dL":11.9,"wbc_k_uL":7.5,"platelets_k_uL":430,"creatinine_mg_dL":0.86,"alt_U_L":74},{"date":"2025-01-02","hemoglobin_g_dL":12.2,"wbc_k_uL":4.4,"platelets_k_uL":226,"creatinine_mg_dL":1.46,"alt_U_L":54},{"date":"2025-10-14","hemoglobin_g_dL":11.5,"wbc_k_uL":7.8,"platelets_k_uL":153,"creatinine_mg_dL":1.14,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_2794","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":59,"sex":"female","bmi":26.0,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-68},"pfs_months":38.24},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":66.4,"censored":false},"longitudinal_labs":[{"date":"2023-07-15","hemoglobin_g_dL":12.7,"wbc_k_uL":8.8,"platelets_k_uL":405,"creatinine_mg_dL":1.25,"alt_U_L":16},{"date":"2024-02-14","hemoglobin_g_dL":11.1,"wbc_k_uL":6.7,"platelets_k_uL":145,"creatinine_mg_dL":1.41,"alt_U_L":60},{"date":"2026-11-02","hemoglobin_g_dL":11.3,"wbc_k_uL":4.9,"platelets_k_uL":182,"creatinine_mg_dL":1.35,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_2795","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":85,"sex":"female","bmi":25.6,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-44},"pfs_months":20.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.3,"censored":true},"longitudinal_labs":[{"date":"2022-04-28","hemoglobin_g_dL":13.4,"wbc_k_uL":10.4,"platelets_k_uL":254,"creatinine_mg_dL":0.9,"alt_U_L":14},{"date":"2022-12-19","hemoglobin_g_dL":13.8,"wbc_k_uL":7.6,"platelets_k_uL":318,"creatinine_mg_dL":1.11,"alt_U_L":17},{"date":"2024-05-05","hemoglobin_g_dL":10.1,"wbc_k_uL":6.8,"platelets_k_uL":319,"creatinine_mg_dL":1.43,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_2796","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":60,"sex":"female","bmi":31.5,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-08-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-85},"pfs_months":32.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":52.8,"censored":false},"longitudinal_labs":[{"date":"2024-06-20","hemoglobin_g_dL":14.1,"wbc_k_uL":8.0,"platelets_k_uL":271,"creatinine_mg_dL":0.74,"alt_U_L":36},{"date":"2025-02-13","hemoglobin_g_dL":11.0,"wbc_k_uL":6.5,"platelets_k_uL":315,"creatinine_mg_dL":1.24,"alt_U_L":26},{"date":"2027-06-27","hemoglobin_g_dL":10.8,"wbc_k_uL":7.0,"platelets_k_uL":296,"creatinine_mg_dL":1.08,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_2797","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.8,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":67,"sex":"female","bmi":28.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-03-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-31},"pfs_months":11.47},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.2,"censored":true},"longitudinal_labs":[{"date":"2020-01-15","hemoglobin_g_dL":14.6,"wbc_k_uL":9.2,"platelets_k_uL":153,"creatinine_mg_dL":0.79,"alt_U_L":73},{"date":"2020-09-19","hemoglobin_g_dL":11.5,"wbc_k_uL":6.2,"platelets_k_uL":122,"creatinine_mg_dL":1.05,"alt_U_L":54},{"date":"2021-05-01","hemoglobin_g_dL":10.1,"wbc_k_uL":7.0,"platelets_k_uL":246,"creatinine_mg_dL":1.23,"alt_U_L":197}]}
{"patient_id":"ANODE_SYNTH_2025_2798","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":52,"sex":"female","bmi":19.4,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-10-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-57},"pfs_months":21.13},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.7,"censored":false},"longitudinal_labs":[{"date":"2025-08-15","hemoglobin_g_dL":15.3,"wbc_k_uL":5.8,"platelets_k_uL":440,"creatinine_mg_dL":0.69,"alt_U_L":32},{"date":"2026-04-19","hemoglobin_g_dL":11.5,"wbc_k_uL":8.0,"platelets_k_uL":246,"creatinine_mg_dL":1.17,"alt_U_L":41},{"date":"2027-09-17","hemoglobin_g_dL":11.1,"wbc_k_uL":5.3,"platelets_k_uL":166,"creatinine_mg_dL":1.0,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_2799","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":59,"sex":"male","bmi":29.6,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-02-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-55},"pfs_months":8.97},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-16","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":12.9,"censored":true},"longitudinal_labs":[{"date":"2022-01-06","hemoglobin_g_dL":15.1,"wbc_k_uL":8.7,"platelets_k_uL":204,"creatinine_mg_dL":0.83,"alt_U_L":50},{"date":"2022-08-11","hemoglobin_g_dL":11.7,"wbc_k_uL":4.8,"platelets_k_uL":286,"creatinine_mg_dL":1.52,"alt_U_L":34},{"date":"2022-12-16","hemoglobin_g_dL":10.8,"wbc_k_uL":6.4,"platelets_k_uL":186,"creatinine_mg_dL":2.0,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_2800","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":50,"sex":"female","bmi":26.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-70},"pfs_months":19.06},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.9,"censored":false},"longitudinal_labs":[{"date":"2020-04-15","hemoglobin_g_dL":11.8,"wbc_k_uL":7.6,"platelets_k_uL":294,"creatinine_mg_dL":1.08,"alt_U_L":32},{"date":"2020-11-11","hemoglobin_g_dL":13.4,"wbc_k_uL":5.6,"platelets_k_uL":239,"creatinine_mg_dL":1.23,"alt_U_L":89},{"date":"2022-01-30","hemoglobin_g_dL":11.4,"wbc_k_uL":4.2,"platelets_k_uL":125,"creatinine_mg_dL":0.84,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2801","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":71,"sex":"female","bmi":21.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-56},"pfs_months":20.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":false},"longitudinal_labs":[{"date":"2023-10-12","hemoglobin_g_dL":13.7,"wbc_k_uL":8.1,"platelets_k_uL":371,"creatinine_mg_dL":1.06,"alt_U_L":15},{"date":"2024-06-02","hemoglobin_g_dL":10.4,"wbc_k_uL":5.4,"platelets_k_uL":176,"creatinine_mg_dL":1.26,"alt_U_L":50},{"date":"2025-09-11","hemoglobin_g_dL":12.2,"wbc_k_uL":5.9,"platelets_k_uL":167,"creatinine_mg_dL":1.41,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_2802","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":70,"sex":"female","bmi":24.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-56},"pfs_months":26.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.8,"censored":false},"longitudinal_labs":[{"date":"2024-02-14","hemoglobin_g_dL":13.1,"wbc_k_uL":10.1,"platelets_k_uL":295,"creatinine_mg_dL":0.75,"alt_U_L":50},{"date":"2024-08-29","hemoglobin_g_dL":12.8,"wbc_k_uL":6.8,"platelets_k_uL":232,"creatinine_mg_dL":1.49,"alt_U_L":80},{"date":"2026-06-12","hemoglobin_g_dL":12.0,"wbc_k_uL":7.8,"platelets_k_uL":234,"creatinine_mg_dL":1.11,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_2803","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":64,"sex":"female","bmi":36.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-66},"pfs_months":14.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-08-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.6,"censored":false},"longitudinal_labs":[{"date":"2020-03-04","hemoglobin_g_dL":15.4,"wbc_k_uL":7.8,"platelets_k_uL":193,"creatinine_mg_dL":1.3,"alt_U_L":25},{"date":"2020-10-06","hemoglobin_g_dL":13.0,"wbc_k_uL":5.1,"platelets_k_uL":188,"creatinine_mg_dL":1.2,"alt_U_L":93},{"date":"2021-08-02","hemoglobin_g_dL":10.1,"wbc_k_uL":3.4,"platelets_k_uL":304,"creatinine_mg_dL":1.61,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_2804","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":73,"sex":"female","bmi":32.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-80},"pfs_months":30.19},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.0,"censored":true},"longitudinal_labs":[{"date":"2023-03-08","hemoglobin_g_dL":13.2,"wbc_k_uL":10.0,"platelets_k_uL":187,"creatinine_mg_dL":1.06,"alt_U_L":39},{"date":"2023-10-21","hemoglobin_g_dL":10.3,"wbc_k_uL":5.5,"platelets_k_uL":343,"creatinine_mg_dL":0.74,"alt_U_L":43},{"date":"2025-12-03","hemoglobin_g_dL":9.7,"wbc_k_uL":6.9,"platelets_k_uL":173,"creatinine_mg_dL":1.67,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_2805","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":88,"sex":"male","bmi":31.1,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["contralateral lung","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-02-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-69},"pfs_months":10.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.5,"censored":false},"longitudinal_labs":[{"date":"2020-12-09","hemoglobin_g_dL":14.0,"wbc_k_uL":9.1,"platelets_k_uL":388,"creatinine_mg_dL":1.15,"alt_U_L":32},{"date":"2021-08-03","hemoglobin_g_dL":12.3,"wbc_k_uL":7.9,"platelets_k_uL":125,"creatinine_mg_dL":0.76,"alt_U_L":93},{"date":"2021-12-26","hemoglobin_g_dL":12.6,"wbc_k_uL":6.6,"platelets_k_uL":200,"creatinine_mg_dL":1.52,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_2806","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.9,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":71,"sex":"female","bmi":36.1,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-06-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-44},"pfs_months":32.59},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.8,"censored":false},"longitudinal_labs":[{"date":"2025-04-08","hemoglobin_g_dL":13.2,"wbc_k_uL":10.6,"platelets_k_uL":396,"creatinine_mg_dL":1.15,"alt_U_L":38},{"date":"2025-12-05","hemoglobin_g_dL":13.3,"wbc_k_uL":3.9,"platelets_k_uL":181,"creatinine_mg_dL":1.29,"alt_U_L":46},{"date":"2028-04-22","hemoglobin_g_dL":12.2,"wbc_k_uL":5.8,"platelets_k_uL":341,"creatinine_mg_dL":1.13,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_2807","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":70,"sex":"female","bmi":19.6,"smoking_pack_years":42,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-08-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-34},"pfs_months":11.3},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.0,"censored":false},"longitudinal_labs":[{"date":"2021-07-22","hemoglobin_g_dL":11.6,"wbc_k_uL":5.3,"platelets_k_uL":208,"creatinine_mg_dL":0.8,"alt_U_L":11},{"date":"2022-02-21","hemoglobin_g_dL":13.5,"wbc_k_uL":7.7,"platelets_k_uL":270,"creatinine_mg_dL":1.3,"alt_U_L":43},{"date":"2022-09-18","hemoglobin_g_dL":10.6,"wbc_k_uL":3.2,"platelets_k_uL":103,"creatinine_mg_dL":1.05,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_2808","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":64,"sex":"female","bmi":35.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-02-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-72},"pfs_months":18.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":38.2,"censored":true},"longitudinal_labs":[{"date":"2024-01-18","hemoglobin_g_dL":13.1,"wbc_k_uL":6.8,"platelets_k_uL":306,"creatinine_mg_dL":0.69,"alt_U_L":60},{"date":"2024-07-31","hemoglobin_g_dL":13.9,"wbc_k_uL":7.4,"platelets_k_uL":269,"creatinine_mg_dL":1.02,"alt_U_L":43},{"date":"2025-09-21","hemoglobin_g_dL":11.8,"wbc_k_uL":6.9,"platelets_k_uL":215,"creatinine_mg_dL":1.46,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_2809","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":77,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-84},"pfs_months":24.08},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":false},"longitudinal_labs":[{"date":"2020-10-18","hemoglobin_g_dL":15.4,"wbc_k_uL":9.4,"platelets_k_uL":191,"creatinine_mg_dL":0.64,"alt_U_L":18},{"date":"2021-05-24","hemoglobin_g_dL":11.8,"wbc_k_uL":7.5,"platelets_k_uL":357,"creatinine_mg_dL":1.12,"alt_U_L":52},{"date":"2022-12-17","hemoglobin_g_dL":11.9,"wbc_k_uL":6.7,"platelets_k_uL":206,"creatinine_mg_dL":1.73,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_2810","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":58,"sex":"female","bmi":33.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-71},"pfs_months":33.31},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-24","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":49.6,"censored":false},"longitudinal_labs":[{"date":"2020-08-04","hemoglobin_g_dL":12.5,"wbc_k_uL":7.7,"platelets_k_uL":445,"creatinine_mg_dL":1.29,"alt_U_L":41},{"date":"2021-02-15","hemoglobin_g_dL":10.4,"wbc_k_uL":6.2,"platelets_k_uL":244,"creatinine_mg_dL":1.0,"alt_U_L":67},{"date":"2023-06-24","hemoglobin_g_dL":9.7,"wbc_k_uL":3.4,"platelets_k_uL":350,"creatinine_mg_dL":1.2,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_2811","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":80,"sex":"female","bmi":28.5,"smoking_pack_years":44,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-03-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-81},"pfs_months":17.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.0,"censored":false},"longitudinal_labs":[{"date":"2022-03-07","hemoglobin_g_dL":15.1,"wbc_k_uL":10.1,"platelets_k_uL":427,"creatinine_mg_dL":1.16,"alt_U_L":12},{"date":"2022-09-17","hemoglobin_g_dL":13.4,"wbc_k_uL":4.7,"platelets_k_uL":344,"creatinine_mg_dL":0.88,"alt_U_L":43},{"date":"2023-10-16","hemoglobin_g_dL":11.2,"wbc_k_uL":5.3,"platelets_k_uL":268,"creatinine_mg_dL":1.78,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_2812","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":81,"sex":"male","bmi":28.1,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-04-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-57},"pfs_months":12.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.0,"censored":false},"longitudinal_labs":[{"date":"2025-02-22","hemoglobin_g_dL":12.1,"wbc_k_uL":6.4,"platelets_k_uL":196,"creatinine_mg_dL":0.66,"alt_U_L":39},{"date":"2025-09-28","hemoglobin_g_dL":12.6,"wbc_k_uL":8.9,"platelets_k_uL":178,"creatinine_mg_dL":1.09,"alt_U_L":117},{"date":"2026-05-17","hemoglobin_g_dL":12.7,"wbc_k_uL":5.4,"platelets_k_uL":115,"creatinine_mg_dL":1.91,"alt_U_L":25}]}
{"patient_id":"ANODE_SYNTH_2025_2813","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":68,"sex":"male","bmi":29.3,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-07-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-64},"pfs_months":23.89},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.4,"censored":false},"longitudinal_labs":[{"date":"2022-06-07","hemoglobin_g_dL":12.7,"wbc_k_uL":5.1,"platelets_k_uL":151,"creatinine_mg_dL":1.12,"alt_U_L":11},{"date":"2023-01-24","hemoglobin_g_dL":11.8,"wbc_k_uL":8.7,"platelets_k_uL":362,"creatinine_mg_dL":1.35,"alt_U_L":44},{"date":"2024-08-04","hemoglobin_g_dL":11.2,"wbc_k_uL":7.9,"platelets_k_uL":325,"creatinine_mg_dL":0.96,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_2814","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":76,"sex":"female","bmi":23.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-46},"pfs_months":10.41},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":true},"longitudinal_labs":[{"date":"2023-04-01","hemoglobin_g_dL":14.6,"wbc_k_uL":4.9,"platelets_k_uL":360,"creatinine_mg_dL":1.14,"alt_U_L":27},{"date":"2023-12-01","hemoglobin_g_dL":11.2,"wbc_k_uL":7.6,"platelets_k_uL":373,"creatinine_mg_dL":1.0,"alt_U_L":75},{"date":"2024-06-14","hemoglobin_g_dL":10.1,"wbc_k_uL":4.1,"platelets_k_uL":175,"creatinine_mg_dL":1.08,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_2815","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":49,"sex":"female","bmi":31.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-66},"pfs_months":23.82},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.0,"censored":true},"longitudinal_labs":[{"date":"2021-04-15","hemoglobin_g_dL":12.6,"wbc_k_uL":10.3,"platelets_k_uL":362,"creatinine_mg_dL":1.15,"alt_U_L":79},{"date":"2021-11-04","hemoglobin_g_dL":13.0,"wbc_k_uL":5.4,"platelets_k_uL":331,"creatinine_mg_dL":0.71,"alt_U_L":52},{"date":"2023-06-16","hemoglobin_g_dL":10.4,"wbc_k_uL":3.9,"platelets_k_uL":331,"creatinine_mg_dL":1.76,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2816","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":69,"sex":"female","bmi":27.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-30},"pfs_months":23.52},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.6,"censored":false},"longitudinal_labs":[{"date":"2021-10-02","hemoglobin_g_dL":13.2,"wbc_k_uL":5.8,"platelets_k_uL":238,"creatinine_mg_dL":1.27,"alt_U_L":43},{"date":"2022-04-14","hemoglobin_g_dL":13.8,"wbc_k_uL":8.3,"platelets_k_uL":186,"creatinine_mg_dL":1.06,"alt_U_L":90},{"date":"2023-10-19","hemoglobin_g_dL":11.1,"wbc_k_uL":7.2,"platelets_k_uL":286,"creatinine_mg_dL":1.01,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_2817","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":51,"sex":"female","bmi":34.1,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-01-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-70},"pfs_months":23.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.3,"censored":false},"longitudinal_labs":[{"date":"2025-12-08","hemoglobin_g_dL":11.5,"wbc_k_uL":9.1,"platelets_k_uL":194,"creatinine_mg_dL":1.18,"alt_U_L":56},{"date":"2026-07-04","hemoglobin_g_dL":14.0,"wbc_k_uL":6.2,"platelets_k_uL":148,"creatinine_mg_dL":0.93,"alt_U_L":27},{"date":"2028-01-08","hemoglobin_g_dL":12.4,"wbc_k_uL":5.6,"platelets_k_uL":308,"creatinine_mg_dL":1.68,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_2818","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":54,"sex":"female","bmi":26.5,"smoking_pack_years":56,"ecog_performance_status":2,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-04-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-72},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":9.5,"censored":false},"longitudinal_labs":[{"date":"2025-03-12","hemoglobin_g_dL":13.3,"wbc_k_uL":9.8,"platelets_k_uL":356,"creatinine_mg_dL":0.66,"alt_U_L":73},{"date":"2025-10-07","hemoglobin_g_dL":10.5,"wbc_k_uL":4.9,"platelets_k_uL":285,"creatinine_mg_dL":1.52,"alt_U_L":114},{"date":"2025-08-22","hemoglobin_g_dL":12.8,"wbc_k_uL":6.7,"platelets_k_uL":226,"creatinine_mg_dL":0.9,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_2819","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":74,"sex":"male","bmi":27.9,"smoking_pack_years":58,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-01-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-72},"pfs_months":21.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.1,"censored":false},"longitudinal_labs":[{"date":"2020-11-19","hemoglobin_g_dL":12.6,"wbc_k_uL":5.8,"platelets_k_uL":181,"creatinine_mg_dL":0.81,"alt_U_L":59},{"date":"2021-07-08","hemoglobin_g_dL":10.1,"wbc_k_uL":6.7,"platelets_k_uL":126,"creatinine_mg_dL":1.44,"alt_U_L":108},{"date":"2022-11-23","hemoglobin_g_dL":12.3,"wbc_k_uL":6.0,"platelets_k_uL":134,"creatinine_mg_dL":1.75,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_2820","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":75,"sex":"female","bmi":29.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-40},"pfs_months":11.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":true},"longitudinal_labs":[{"date":"2023-12-21","hemoglobin_g_dL":14.1,"wbc_k_uL":10.3,"platelets_k_uL":163,"creatinine_mg_dL":0.8,"alt_U_L":59},{"date":"2024-07-02","hemoglobin_g_dL":12.1,"wbc_k_uL":4.0,"platelets_k_uL":257,"creatinine_mg_dL":1.38,"alt_U_L":40},{"date":"2025-01-24","hemoglobin_g_dL":10.7,"wbc_k_uL":5.0,"platelets_k_uL":104,"creatinine_mg_dL":1.98,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_2821","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":52,"sex":"female","bmi":27.3,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-11-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-38},"pfs_months":19.22},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.7,"censored":true},"longitudinal_labs":[{"date":"2025-09-12","hemoglobin_g_dL":13.2,"wbc_k_uL":7.4,"platelets_k_uL":308,"creatinine_mg_dL":0.78,"alt_U_L":31},{"date":"2026-05-05","hemoglobin_g_dL":12.0,"wbc_k_uL":5.4,"platelets_k_uL":169,"creatinine_mg_dL":0.75,"alt_U_L":107},{"date":"2027-06-23","hemoglobin_g_dL":9.7,"wbc_k_uL":4.5,"platelets_k_uL":305,"creatinine_mg_dL":1.11,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_2822","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":85,"sex":"female","bmi":18.8,"smoking_pack_years":74,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-45},"pfs_months":16.16},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.1,"censored":false},"longitudinal_labs":[{"date":"2021-01-19","hemoglobin_g_dL":12.6,"wbc_k_uL":7.0,"platelets_k_uL":162,"creatinine_mg_dL":0.96,"alt_U_L":61},{"date":"2021-09-15","hemoglobin_g_dL":11.8,"wbc_k_uL":4.9,"platelets_k_uL":254,"creatinine_mg_dL":1.13,"alt_U_L":108},{"date":"2022-08-27","hemoglobin_g_dL":11.5,"wbc_k_uL":3.1,"platelets_k_uL":239,"creatinine_mg_dL":1.76,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_2823","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":69,"sex":"female","bmi":37.8,"smoking_pack_years":79,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-10-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-54},"pfs_months":5.06},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":11.5,"censored":false},"longitudinal_labs":[{"date":"2025-08-22","hemoglobin_g_dL":12.0,"wbc_k_uL":7.1,"platelets_k_uL":258,"creatinine_mg_dL":1.22,"alt_U_L":52},{"date":"2026-04-08","hemoglobin_g_dL":10.8,"wbc_k_uL":8.6,"platelets_k_uL":156,"creatinine_mg_dL":0.71,"alt_U_L":77},{"date":"2026-05-07","hemoglobin_g_dL":12.7,"wbc_k_uL":3.7,"platelets_k_uL":202,"creatinine_mg_dL":1.14,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_2824","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":53,"sex":"female","bmi":32.5,"smoking_pack_years":50,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-09-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-36},"pfs_months":25.53},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":47.3,"censored":false},"longitudinal_labs":[{"date":"2025-08-10","hemoglobin_g_dL":14.4,"wbc_k_uL":6.1,"platelets_k_uL":416,"creatinine_mg_dL":0.67,"alt_U_L":25},{"date":"2026-03-02","hemoglobin_g_dL":13.4,"wbc_k_uL":5.0,"platelets_k_uL":344,"creatinine_mg_dL":0.83,"alt_U_L":73},{"date":"2027-11-14","hemoglobin_g_dL":12.9,"wbc_k_uL":5.5,"platelets_k_uL":340,"creatinine_mg_dL":0.92,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_2825","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":61,"sex":"male","bmi":20.5,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-02-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-62},"pfs_months":22.8},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.3,"censored":true},"longitudinal_labs":[{"date":"2025-12-07","hemoglobin_g_dL":14.6,"wbc_k_uL":7.5,"platelets_k_uL":450,"creatinine_mg_dL":0.9,"alt_U_L":10},{"date":"2026-07-31","hemoglobin_g_dL":10.4,"wbc_k_uL":6.0,"platelets_k_uL":363,"creatinine_mg_dL":1.26,"alt_U_L":76},{"date":"2028-02-14","hemoglobin_g_dL":11.0,"wbc_k_uL":3.5,"platelets_k_uL":239,"creatinine_mg_dL":1.05,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_2826","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":88,"sex":"female","bmi":32.0,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-76},"pfs_months":35.22},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":50.8,"censored":false},"longitudinal_labs":[{"date":"2024-12-28","hemoglobin_g_dL":13.7,"wbc_k_uL":5.7,"platelets_k_uL":300,"creatinine_mg_dL":0.71,"alt_U_L":43},{"date":"2025-07-22","hemoglobin_g_dL":10.6,"wbc_k_uL":8.4,"platelets_k_uL":220,"creatinine_mg_dL":0.99,"alt_U_L":53},{"date":"2028-01-16","hemoglobin_g_dL":9.7,"wbc_k_uL":3.6,"platelets_k_uL":220,"creatinine_mg_dL":1.25,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_2827","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":83,"sex":"male","bmi":33.3,"smoking_pack_years":38,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-05-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-34},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":10.5,"censored":true},"longitudinal_labs":[{"date":"2022-03-24","hemoglobin_g_dL":12.7,"wbc_k_uL":6.5,"platelets_k_uL":259,"creatinine_mg_dL":0.9,"alt_U_L":36},{"date":"2022-11-21","hemoglobin_g_dL":10.6,"wbc_k_uL":6.7,"platelets_k_uL":197,"creatinine_mg_dL":1.51,"alt_U_L":89},{"date":"2022-09-12","hemoglobin_g_dL":9.9,"wbc_k_uL":4.2,"platelets_k_uL":223,"creatinine_mg_dL":1.52,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_2828","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":55,"sex":"male","bmi":19.6,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-07-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-79},"pfs_months":12.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":30.0,"censored":false},"longitudinal_labs":[{"date":"2024-06-13","hemoglobin_g_dL":14.6,"wbc_k_uL":4.9,"platelets_k_uL":264,"creatinine_mg_dL":1.03,"alt_U_L":70},{"date":"2025-01-20","hemoglobin_g_dL":10.3,"wbc_k_uL":6.1,"platelets_k_uL":266,"creatinine_mg_dL":1.51,"alt_U_L":74},{"date":"2025-08-28","hemoglobin_g_dL":11.4,"wbc_k_uL":7.6,"platelets_k_uL":109,"creatinine_mg_dL":1.27,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_2829","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":88,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-81},"pfs_months":25.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":40.6,"censored":false},"longitudinal_labs":[{"date":"2025-06-02","hemoglobin_g_dL":14.2,"wbc_k_uL":9.2,"platelets_k_uL":397,"creatinine_mg_dL":0.94,"alt_U_L":24},{"date":"2025-12-14","hemoglobin_g_dL":10.0,"wbc_k_uL":7.4,"platelets_k_uL":161,"creatinine_mg_dL":1.39,"alt_U_L":118},{"date":"2027-07-25","hemoglobin_g_dL":10.1,"wbc_k_uL":3.6,"platelets_k_uL":232,"creatinine_mg_dL":1.45,"alt_U_L":166}]}
{"patient_id":"ANODE_SYNTH_2025_2830","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":56,"sex":"female","bmi":37.8,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-02-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-34},"pfs_months":20.11},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":true},"longitudinal_labs":[{"date":"2020-01-21","hemoglobin_g_dL":14.7,"wbc_k_uL":9.1,"platelets_k_uL":426,"creatinine_mg_dL":0.82,"alt_U_L":38},{"date":"2020-08-17","hemoglobin_g_dL":10.4,"wbc_k_uL":6.8,"platelets_k_uL":303,"creatinine_mg_dL":1.43,"alt_U_L":81},{"date":"2021-12-20","hemoglobin_g_dL":9.6,"wbc_k_uL":5.3,"platelets_k_uL":106,"creatinine_mg_dL":1.24,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2831","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":69,"sex":"male","bmi":19.0,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-03-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-55},"pfs_months":12.32},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":18.5,"censored":true},"longitudinal_labs":[{"date":"2022-01-16","hemoglobin_g_dL":13.9,"wbc_k_uL":10.8,"platelets_k_uL":202,"creatinine_mg_dL":0.75,"alt_U_L":41},{"date":"2022-09-10","hemoglobin_g_dL":11.9,"wbc_k_uL":7.8,"platelets_k_uL":193,"creatinine_mg_dL":1.52,"alt_U_L":50},{"date":"2023-04-13","hemoglobin_g_dL":10.1,"wbc_k_uL":4.7,"platelets_k_uL":119,"creatinine_mg_dL":1.37,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_2832","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":70,"sex":"female","bmi":31.7,"smoking_pack_years":43,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-10-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-64},"pfs_months":17.68},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-03","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.8,"censored":false},"longitudinal_labs":[{"date":"2025-10-01","hemoglobin_g_dL":12.4,"wbc_k_uL":9.2,"platelets_k_uL":270,"creatinine_mg_dL":1.05,"alt_U_L":59},{"date":"2026-04-20","hemoglobin_g_dL":10.6,"wbc_k_uL":8.5,"platelets_k_uL":184,"creatinine_mg_dL":1.34,"alt_U_L":25},{"date":"2027-06-03","hemoglobin_g_dL":12.1,"wbc_k_uL":4.4,"platelets_k_uL":165,"creatinine_mg_dL":1.45,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_2833","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":53,"sex":"female","bmi":24.1,"smoking_pack_years":51,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2020-12-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-73},"pfs_months":29.4},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":59.0,"censored":false},"longitudinal_labs":[{"date":"2020-12-07","hemoglobin_g_dL":14.4,"wbc_k_uL":10.8,"platelets_k_uL":272,"creatinine_mg_dL":1.04,"alt_U_L":67},{"date":"2021-06-26","hemoglobin_g_dL":10.8,"wbc_k_uL":8.2,"platelets_k_uL":365,"creatinine_mg_dL":1.52,"alt_U_L":112},{"date":"2023-06-27","hemoglobin_g_dL":9.6,"wbc_k_uL":3.2,"platelets_k_uL":330,"creatinine_mg_dL":0.82,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_2834","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":49,"sex":"male","bmi":29.5,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-06-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-58},"pfs_months":33.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.8,"censored":true},"longitudinal_labs":[{"date":"2020-05-08","hemoglobin_g_dL":15.5,"wbc_k_uL":5.2,"platelets_k_uL":161,"creatinine_mg_dL":0.77,"alt_U_L":45},{"date":"2020-12-15","hemoglobin_g_dL":12.8,"wbc_k_uL":4.4,"platelets_k_uL":252,"creatinine_mg_dL":0.82,"alt_U_L":15},{"date":"2023-05-30","hemoglobin_g_dL":10.9,"wbc_k_uL":4.9,"platelets_k_uL":307,"creatinine_mg_dL":0.99,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_2835","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":85,"sex":"female","bmi":25.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-23","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-45},"pfs_months":21.45},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.1,"censored":false},"longitudinal_labs":[{"date":"2020-06-28","hemoglobin_g_dL":13.5,"wbc_k_uL":8.5,"platelets_k_uL":428,"creatinine_mg_dL":0.62,"alt_U_L":60},{"date":"2021-02-19","hemoglobin_g_dL":13.0,"wbc_k_uL":7.8,"platelets_k_uL":345,"creatinine_mg_dL":0.88,"alt_U_L":102},{"date":"2022-07-23","hemoglobin_g_dL":11.1,"wbc_k_uL":4.4,"platelets_k_uL":166,"creatinine_mg_dL":1.83,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_2836","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":71,"sex":"female","bmi":20.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-51},"pfs_months":27.33},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":45.1,"censored":false},"longitudinal_labs":[{"date":"2021-04-04","hemoglobin_g_dL":11.5,"wbc_k_uL":5.6,"platelets_k_uL":286,"creatinine_mg_dL":0.99,"alt_U_L":45},{"date":"2021-11-25","hemoglobin_g_dL":11.7,"wbc_k_uL":5.2,"platelets_k_uL":344,"creatinine_mg_dL":1.09,"alt_U_L":117},{"date":"2023-10-05","hemoglobin_g_dL":10.3,"wbc_k_uL":3.9,"platelets_k_uL":189,"creatinine_mg_dL":1.6,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_2837","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":65,"sex":"female","bmi":29.7,"smoking_pack_years":17,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-11-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-80},"pfs_months":41.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-07-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":68.3,"censored":false},"longitudinal_labs":[{"date":"2025-11-01","hemoglobin_g_dL":11.8,"wbc_k_uL":10.1,"platelets_k_uL":166,"creatinine_mg_dL":1.21,"alt_U_L":56},{"date":"2026-05-29","hemoglobin_g_dL":12.1,"wbc_k_uL":8.9,"platelets_k_uL":222,"creatinine_mg_dL":1.12,"alt_U_L":48},{"date":"2029-07-09","hemoglobin_g_dL":11.0,"wbc_k_uL":6.0,"platelets_k_uL":135,"creatinine_mg_dL":1.02,"alt_U_L":49}]}
{"patient_id":"ANODE_SYNTH_2025_2838","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":81,"sex":"male","bmi":24.1,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-04-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-62},"pfs_months":12.58},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.5,"censored":false},"longitudinal_labs":[{"date":"2021-04-01","hemoglobin_g_dL":15.0,"wbc_k_uL":7.4,"platelets_k_uL":351,"creatinine_mg_dL":0.76,"alt_U_L":27},{"date":"2021-10-23","hemoglobin_g_dL":11.9,"wbc_k_uL":4.2,"platelets_k_uL":367,"creatinine_mg_dL":1.28,"alt_U_L":35},{"date":"2022-06-01","hemoglobin_g_dL":9.6,"wbc_k_uL":4.5,"platelets_k_uL":152,"creatinine_mg_dL":1.91,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_2839","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":81,"sex":"female","bmi":25.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-60},"pfs_months":26.78},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":false},"longitudinal_labs":[{"date":"2025-01-09","hemoglobin_g_dL":11.5,"wbc_k_uL":10.9,"platelets_k_uL":276,"creatinine_mg_dL":1.27,"alt_U_L":61},{"date":"2025-08-21","hemoglobin_g_dL":10.8,"wbc_k_uL":5.1,"platelets_k_uL":372,"creatinine_mg_dL":1.23,"alt_U_L":97},{"date":"2027-05-24","hemoglobin_g_dL":10.0,"wbc_k_uL":3.8,"platelets_k_uL":324,"creatinine_mg_dL":1.72,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_2840","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":63,"sex":"male","bmi":33.5,"smoking_pack_years":20,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-12-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-74},"pfs_months":9.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.3,"censored":false},"longitudinal_labs":[{"date":"2025-10-07","hemoglobin_g_dL":11.5,"wbc_k_uL":9.6,"platelets_k_uL":428,"creatinine_mg_dL":1.27,"alt_U_L":43},{"date":"2026-06-01","hemoglobin_g_dL":13.0,"wbc_k_uL":5.2,"platelets_k_uL":349,"creatinine_mg_dL":1.45,"alt_U_L":29},{"date":"2026-10-29","hemoglobin_g_dL":12.0,"wbc_k_uL":7.6,"platelets_k_uL":229,"creatinine_mg_dL":1.57,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_2841","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":73,"sex":"male","bmi":21.1,"smoking_pack_years":56,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-07-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-76},"pfs_months":37.16},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":73.7,"censored":false},"longitudinal_labs":[{"date":"2020-04-25","hemoglobin_g_dL":12.0,"wbc_k_uL":8.0,"platelets_k_uL":413,"creatinine_mg_dL":0.68,"alt_U_L":25},{"date":"2020-12-31","hemoglobin_g_dL":13.9,"wbc_k_uL":5.1,"platelets_k_uL":226,"creatinine_mg_dL":0.94,"alt_U_L":22},{"date":"2023-08-26","hemoglobin_g_dL":12.4,"wbc_k_uL":3.4,"platelets_k_uL":252,"creatinine_mg_dL":1.34,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_2842","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":74,"sex":"female","bmi":34.5,"smoking_pack_years":48,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-10-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-48},"pfs_months":13.83},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.9,"censored":false},"longitudinal_labs":[{"date":"2025-09-07","hemoglobin_g_dL":13.0,"wbc_k_uL":4.7,"platelets_k_uL":169,"creatinine_mg_dL":0.96,"alt_U_L":80},{"date":"2026-03-30","hemoglobin_g_dL":13.9,"wbc_k_uL":5.4,"platelets_k_uL":122,"creatinine_mg_dL":1.37,"alt_U_L":113},{"date":"2027-01-09","hemoglobin_g_dL":10.9,"wbc_k_uL":7.2,"platelets_k_uL":134,"creatinine_mg_dL":1.23,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_2843","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":81,"sex":"female","bmi":37.5,"smoking_pack_years":18,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-07-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-85},"pfs_months":23.1},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":34.5,"censored":true},"longitudinal_labs":[{"date":"2021-06-18","hemoglobin_g_dL":14.2,"wbc_k_uL":5.5,"platelets_k_uL":189,"creatinine_mg_dL":0.73,"alt_U_L":44},{"date":"2022-01-18","hemoglobin_g_dL":13.5,"wbc_k_uL":8.8,"platelets_k_uL":181,"creatinine_mg_dL":1.0,"alt_U_L":30},{"date":"2023-07-16","hemoglobin_g_dL":10.5,"wbc_k_uL":7.0,"platelets_k_uL":126,"creatinine_mg_dL":1.34,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_2844","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":50,"sex":"female","bmi":35.4,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-11-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-78},"pfs_months":28.65},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.4,"censored":false},"longitudinal_labs":[{"date":"2020-10-04","hemoglobin_g_dL":11.8,"wbc_k_uL":9.0,"platelets_k_uL":253,"creatinine_mg_dL":0.93,"alt_U_L":27},{"date":"2021-05-27","hemoglobin_g_dL":11.6,"wbc_k_uL":8.7,"platelets_k_uL":316,"creatinine_mg_dL":1.42,"alt_U_L":107},{"date":"2023-05-11","hemoglobin_g_dL":11.4,"wbc_k_uL":4.9,"platelets_k_uL":215,"creatinine_mg_dL":1.08,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_2845","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":67,"sex":"female","bmi":25.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-06-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-41},"pfs_months":26.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.2,"censored":false},"longitudinal_labs":[{"date":"2025-04-10","hemoglobin_g_dL":14.9,"wbc_k_uL":10.3,"platelets_k_uL":341,"creatinine_mg_dL":1.12,"alt_U_L":15},{"date":"2025-12-02","hemoglobin_g_dL":12.4,"wbc_k_uL":9.0,"platelets_k_uL":366,"creatinine_mg_dL":0.92,"alt_U_L":48},{"date":"2027-09-23","hemoglobin_g_dL":10.0,"wbc_k_uL":5.2,"platelets_k_uL":253,"creatinine_mg_dL":0.97,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_2846","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":81,"sex":"male","bmi":26.7,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-03-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-61},"pfs_months":3.15},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-06-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":10.3,"censored":false},"longitudinal_labs":[{"date":"2020-01-26","hemoglobin_g_dL":13.8,"wbc_k_uL":10.5,"platelets_k_uL":386,"creatinine_mg_dL":1.21,"alt_U_L":27},{"date":"2020-08-29","hemoglobin_g_dL":12.0,"wbc_k_uL":5.6,"platelets_k_uL":321,"creatinine_mg_dL":1.17,"alt_U_L":109},{"date":"2020-06-27","hemoglobin_g_dL":11.8,"wbc_k_uL":4.8,"platelets_k_uL":226,"creatinine_mg_dL":1.05,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_2847","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":70,"sex":"female","bmi":23.8,"smoking_pack_years":40,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-10-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-82},"pfs_months":17.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.8,"censored":false},"longitudinal_labs":[{"date":"2020-08-23","hemoglobin_g_dL":14.1,"wbc_k_uL":10.2,"platelets_k_uL":270,"creatinine_mg_dL":1.05,"alt_U_L":78},{"date":"2021-04-08","hemoglobin_g_dL":12.9,"wbc_k_uL":4.9,"platelets_k_uL":254,"creatinine_mg_dL":1.58,"alt_U_L":47},{"date":"2022-05-03","hemoglobin_g_dL":11.5,"wbc_k_uL":4.5,"platelets_k_uL":132,"creatinine_mg_dL":1.22,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_2848","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":63,"sex":"female","bmi":36.0,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-08-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-74},"pfs_months":4.14},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":13.6,"censored":false},"longitudinal_labs":[{"date":"2025-08-11","hemoglobin_g_dL":12.1,"wbc_k_uL":9.5,"platelets_k_uL":327,"creatinine_mg_dL":1.27,"alt_U_L":20},{"date":"2026-02-22","hemoglobin_g_dL":10.2,"wbc_k_uL":5.6,"platelets_k_uL":234,"creatinine_mg_dL":1.21,"alt_U_L":101},{"date":"2026-02-22","hemoglobin_g_dL":10.8,"wbc_k_uL":4.8,"platelets_k_uL":336,"creatinine_mg_dL":1.87,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_2849","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":70,"sex":"male","bmi":22.8,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-12-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-40},"pfs_months":20.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.0,"censored":false},"longitudinal_labs":[{"date":"2025-11-09","hemoglobin_g_dL":14.9,"wbc_k_uL":5.7,"platelets_k_uL":210,"creatinine_mg_dL":0.86,"alt_U_L":59},{"date":"2026-06-27","hemoglobin_g_dL":12.2,"wbc_k_uL":7.7,"platelets_k_uL":274,"creatinine_mg_dL":0.97,"alt_U_L":41},{"date":"2027-11-04","hemoglobin_g_dL":12.5,"wbc_k_uL":4.1,"platelets_k_uL":167,"creatinine_mg_dL":1.14,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_2850","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":84,"sex":"male","bmi":33.3,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-48},"pfs_months":31.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":46.3,"censored":true},"longitudinal_labs":[{"date":"2022-05-19","hemoglobin_g_dL":13.4,"wbc_k_uL":6.5,"platelets_k_uL":277,"creatinine_mg_dL":0.66,"alt_U_L":19},{"date":"2022-12-17","hemoglobin_g_dL":13.0,"wbc_k_uL":7.7,"platelets_k_uL":351,"creatinine_mg_dL":1.15,"alt_U_L":41},{"date":"2025-02-07","hemoglobin_g_dL":10.0,"wbc_k_uL":3.9,"platelets_k_uL":172,"creatinine_mg_dL":1.72,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_2851","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":78,"sex":"male","bmi":37.8,"smoking_pack_years":17,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-36},"pfs_months":39.62},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":57.4,"censored":false},"longitudinal_labs":[{"date":"2023-10-11","hemoglobin_g_dL":14.5,"wbc_k_uL":7.1,"platelets_k_uL":315,"creatinine_mg_dL":0.66,"alt_U_L":51},{"date":"2024-05-20","hemoglobin_g_dL":11.8,"wbc_k_uL":7.0,"platelets_k_uL":132,"creatinine_mg_dL":1.2,"alt_U_L":40},{"date":"2027-03-21","hemoglobin_g_dL":12.4,"wbc_k_uL":6.2,"platelets_k_uL":318,"creatinine_mg_dL":0.95,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_2852","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":64,"sex":"male","bmi":24.9,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-01-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-56},"pfs_months":31.93},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":58.8,"censored":false},"longitudinal_labs":[{"date":"2023-11-28","hemoglobin_g_dL":14.3,"wbc_k_uL":7.0,"platelets_k_uL":398,"creatinine_mg_dL":0.74,"alt_U_L":30},{"date":"2024-07-12","hemoglobin_g_dL":10.6,"wbc_k_uL":8.2,"platelets_k_uL":253,"creatinine_mg_dL":0.95,"alt_U_L":22},{"date":"2026-10-11","hemoglobin_g_dL":12.2,"wbc_k_uL":6.4,"platelets_k_uL":286,"creatinine_mg_dL":1.22,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_2853","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":60,"sex":"female","bmi":37.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-02-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-40},"pfs_months":22.6},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.6,"censored":false},"longitudinal_labs":[{"date":"2024-01-11","hemoglobin_g_dL":13.8,"wbc_k_uL":6.3,"platelets_k_uL":180,"creatinine_mg_dL":1.16,"alt_U_L":75},{"date":"2024-08-07","hemoglobin_g_dL":12.4,"wbc_k_uL":5.3,"platelets_k_uL":217,"creatinine_mg_dL":1.31,"alt_U_L":27},{"date":"2026-01-12","hemoglobin_g_dL":11.5,"wbc_k_uL":7.6,"platelets_k_uL":316,"creatinine_mg_dL":1.89,"alt_U_L":48}]}
{"patient_id":"ANODE_SYNTH_2025_2854","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":80,"sex":"female","bmi":19.4,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-04-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-60},"pfs_months":39.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":63.4,"censored":false},"longitudinal_labs":[{"date":"2023-03-27","hemoglobin_g_dL":14.5,"wbc_k_uL":10.0,"platelets_k_uL":448,"creatinine_mg_dL":1.01,"alt_U_L":58},{"date":"2023-10-26","hemoglobin_g_dL":10.8,"wbc_k_uL":4.5,"platelets_k_uL":171,"creatinine_mg_dL":1.43,"alt_U_L":113},{"date":"2026-09-05","hemoglobin_g_dL":10.3,"wbc_k_uL":7.7,"platelets_k_uL":277,"creatinine_mg_dL":1.51,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_2855","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":88,"sex":"female","bmi":29.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-48},"pfs_months":23.2},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-10","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.3,"censored":true},"longitudinal_labs":[{"date":"2020-12-25","hemoglobin_g_dL":14.5,"wbc_k_uL":10.9,"platelets_k_uL":366,"creatinine_mg_dL":1.12,"alt_U_L":54},{"date":"2021-07-13","hemoglobin_g_dL":12.9,"wbc_k_uL":8.1,"platelets_k_uL":176,"creatinine_mg_dL":1.2,"alt_U_L":106},{"date":"2023-01-10","hemoglobin_g_dL":12.2,"wbc_k_uL":6.6,"platelets_k_uL":127,"creatinine_mg_dL":0.97,"alt_U_L":85}]}
{"patient_id":"ANODE_SYNTH_2025_2856","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.2,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":51,"sex":"male","bmi":22.5,"smoking_pack_years":73,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-12-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-39},"pfs_months":9.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.8,"censored":false},"longitudinal_labs":[{"date":"2024-10-27","hemoglobin_g_dL":12.4,"wbc_k_uL":5.4,"platelets_k_uL":440,"creatinine_mg_dL":0.62,"alt_U_L":33},{"date":"2025-06-27","hemoglobin_g_dL":10.5,"wbc_k_uL":4.1,"platelets_k_uL":191,"creatinine_mg_dL":1.58,"alt_U_L":27},{"date":"2025-10-24","hemoglobin_g_dL":12.7,"wbc_k_uL":6.9,"platelets_k_uL":305,"creatinine_mg_dL":1.16,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_2857","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":48,"sex":"male","bmi":28.2,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-78},"pfs_months":3.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-01-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.3,"censored":false},"longitudinal_labs":[{"date":"2020-06-13","hemoglobin_g_dL":14.8,"wbc_k_uL":5.6,"platelets_k_uL":169,"creatinine_mg_dL":1.06,"alt_U_L":66},{"date":"2021-01-06","hemoglobin_g_dL":12.2,"wbc_k_uL":5.4,"platelets_k_uL":281,"creatinine_mg_dL":1.48,"alt_U_L":110},{"date":"2021-01-03","hemoglobin_g_dL":12.0,"wbc_k_uL":4.1,"platelets_k_uL":116,"creatinine_mg_dL":1.42,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_2858","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":62,"sex":"male","bmi":22.1,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-38},"pfs_months":5.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":9.8,"censored":false},"longitudinal_labs":[{"date":"2021-07-02","hemoglobin_g_dL":13.0,"wbc_k_uL":6.6,"platelets_k_uL":253,"creatinine_mg_dL":1.16,"alt_U_L":60},{"date":"2022-01-20","hemoglobin_g_dL":11.8,"wbc_k_uL":8.6,"platelets_k_uL":243,"creatinine_mg_dL":1.49,"alt_U_L":103},{"date":"2022-01-23","hemoglobin_g_dL":11.8,"wbc_k_uL":3.4,"platelets_k_uL":128,"creatinine_mg_dL":0.93,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_2859","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":54,"sex":"female","bmi":19.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-02-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-51},"pfs_months":22.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":true},"longitudinal_labs":[{"date":"2023-12-16","hemoglobin_g_dL":11.7,"wbc_k_uL":8.0,"platelets_k_uL":402,"creatinine_mg_dL":1.06,"alt_U_L":39},{"date":"2024-08-05","hemoglobin_g_dL":10.7,"wbc_k_uL":7.2,"platelets_k_uL":353,"creatinine_mg_dL":1.45,"alt_U_L":111},{"date":"2026-01-27","hemoglobin_g_dL":12.3,"wbc_k_uL":6.8,"platelets_k_uL":270,"creatinine_mg_dL":1.62,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_2860","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":83,"sex":"female","bmi":25.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-50},"pfs_months":12.12},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":17.2,"censored":false},"longitudinal_labs":[{"date":"2025-05-19","hemoglobin_g_dL":13.0,"wbc_k_uL":7.4,"platelets_k_uL":264,"creatinine_mg_dL":0.68,"alt_U_L":19},{"date":"2026-01-05","hemoglobin_g_dL":13.2,"wbc_k_uL":5.9,"platelets_k_uL":291,"creatinine_mg_dL":1.44,"alt_U_L":34},{"date":"2026-07-21","hemoglobin_g_dL":10.0,"wbc_k_uL":7.2,"platelets_k_uL":239,"creatinine_mg_dL":1.42,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_2861","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":68,"sex":"male","bmi":29.8,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-07-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-76},"pfs_months":46.59},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-06-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":61.1,"censored":false},"longitudinal_labs":[{"date":"2025-05-05","hemoglobin_g_dL":11.6,"wbc_k_uL":4.5,"platelets_k_uL":444,"creatinine_mg_dL":1.02,"alt_U_L":74},{"date":"2026-01-03","hemoglobin_g_dL":10.7,"wbc_k_uL":7.9,"platelets_k_uL":312,"creatinine_mg_dL":0.75,"alt_U_L":117},{"date":"2029-06-14","hemoglobin_g_dL":9.8,"wbc_k_uL":3.6,"platelets_k_uL":126,"creatinine_mg_dL":1.55,"alt_U_L":149}]}
{"patient_id":"ANODE_SYNTH_2025_2862","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":18.0,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":48,"sex":"male","bmi":19.5,"smoking_pack_years":26,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-31},"pfs_months":34.3},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":52.4,"censored":true},"longitudinal_labs":[{"date":"2020-11-08","hemoglobin_g_dL":13.9,"wbc_k_uL":6.8,"platelets_k_uL":160,"creatinine_mg_dL":1.27,"alt_U_L":53},{"date":"2021-06-03","hemoglobin_g_dL":13.6,"wbc_k_uL":7.1,"platelets_k_uL":281,"creatinine_mg_dL":1.47,"alt_U_L":96},{"date":"2023-12-08","hemoglobin_g_dL":10.0,"wbc_k_uL":5.9,"platelets_k_uL":105,"creatinine_mg_dL":1.34,"alt_U_L":82}]}
{"patient_id":"ANODE_SYNTH_2025_2863","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":77,"sex":"female","bmi":29.9,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-02-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-56},"pfs_months":26.51},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.8,"censored":true},"longitudinal_labs":[{"date":"2022-02-07","hemoglobin_g_dL":15.5,"wbc_k_uL":5.7,"platelets_k_uL":326,"creatinine_mg_dL":1.09,"alt_U_L":42},{"date":"2022-08-20","hemoglobin_g_dL":11.1,"wbc_k_uL":8.7,"platelets_k_uL":341,"creatinine_mg_dL":1.3,"alt_U_L":30},{"date":"2024-05-23","hemoglobin_g_dL":9.6,"wbc_k_uL":5.9,"platelets_k_uL":183,"creatinine_mg_dL":1.96,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_2864","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":54,"sex":"female","bmi":32.8,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-07-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-48},"pfs_months":28.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":49.6,"censored":false},"longitudinal_labs":[{"date":"2020-06-17","hemoglobin_g_dL":12.2,"wbc_k_uL":10.8,"platelets_k_uL":394,"creatinine_mg_dL":1.01,"alt_U_L":46},{"date":"2021-01-19","hemoglobin_g_dL":12.6,"wbc_k_uL":8.1,"platelets_k_uL":203,"creatinine_mg_dL":1.41,"alt_U_L":60},{"date":"2023-01-04","hemoglobin_g_dL":12.2,"wbc_k_uL":7.8,"platelets_k_uL":210,"creatinine_mg_dL":1.78,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_2865","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":69,"sex":"male","bmi":36.0,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-08-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-77},"pfs_months":35.38},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":55.7,"censored":false},"longitudinal_labs":[{"date":"2020-08-13","hemoglobin_g_dL":15.2,"wbc_k_uL":9.4,"platelets_k_uL":267,"creatinine_mg_dL":1.07,"alt_U_L":25},{"date":"2021-02-25","hemoglobin_g_dL":10.7,"wbc_k_uL":8.5,"platelets_k_uL":351,"creatinine_mg_dL":1.03,"alt_U_L":68},{"date":"2023-09-11","hemoglobin_g_dL":11.9,"wbc_k_uL":5.0,"platelets_k_uL":255,"creatinine_mg_dL":1.27,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_2866","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":76,"sex":"male","bmi":29.5,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-01-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-65},"pfs_months":43.01},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":71.5,"censored":true},"longitudinal_labs":[{"date":"2023-12-11","hemoglobin_g_dL":15.0,"wbc_k_uL":8.8,"platelets_k_uL":199,"creatinine_mg_dL":0.91,"alt_U_L":34},{"date":"2024-07-01","hemoglobin_g_dL":10.6,"wbc_k_uL":7.2,"platelets_k_uL":123,"creatinine_mg_dL":0.88,"alt_U_L":62},{"date":"2027-10-03","hemoglobin_g_dL":9.8,"wbc_k_uL":5.2,"platelets_k_uL":305,"creatinine_mg_dL":1.16,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_2867","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":85,"sex":"female","bmi":35.3,"smoking_pack_years":65,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-05-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-58},"pfs_months":9.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":13.2,"censored":true},"longitudinal_labs":[{"date":"2023-04-10","hemoglobin_g_dL":14.8,"wbc_k_uL":5.4,"platelets_k_uL":312,"creatinine_mg_dL":1.16,"alt_U_L":52},{"date":"2023-11-09","hemoglobin_g_dL":11.7,"wbc_k_uL":4.2,"platelets_k_uL":296,"creatinine_mg_dL":1.49,"alt_U_L":115},{"date":"2024-03-09","hemoglobin_g_dL":10.4,"wbc_k_uL":4.3,"platelets_k_uL":125,"creatinine_mg_dL":1.36,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_2868","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":51,"sex":"male","bmi":28.7,"smoking_pack_years":59,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2022-09-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-54},"pfs_months":36.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.3,"censored":true},"longitudinal_labs":[{"date":"2022-08-19","hemoglobin_g_dL":11.6,"wbc_k_uL":9.9,"platelets_k_uL":355,"creatinine_mg_dL":0.62,"alt_U_L":24},{"date":"2023-03-09","hemoglobin_g_dL":12.6,"wbc_k_uL":4.0,"platelets_k_uL":294,"creatinine_mg_dL":1.31,"alt_U_L":106},{"date":"2025-11-02","hemoglobin_g_dL":10.4,"wbc_k_uL":3.5,"platelets_k_uL":188,"creatinine_mg_dL":1.34,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_2869","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":67,"sex":"female","bmi":28.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-57},"pfs_months":17.54},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.4,"censored":false},"longitudinal_labs":[{"date":"2023-08-28","hemoglobin_g_dL":12.4,"wbc_k_uL":7.7,"platelets_k_uL":381,"creatinine_mg_dL":0.73,"alt_U_L":79},{"date":"2024-04-03","hemoglobin_g_dL":13.9,"wbc_k_uL":6.8,"platelets_k_uL":178,"creatinine_mg_dL":1.58,"alt_U_L":71},{"date":"2025-05-05","hemoglobin_g_dL":10.3,"wbc_k_uL":7.2,"platelets_k_uL":274,"creatinine_mg_dL":1.53,"alt_U_L":88}]}
{"patient_id":"ANODE_SYNTH_2025_2870","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":52,"sex":"female","bmi":21.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-81},"pfs_months":19.48},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":30.1,"censored":false},"longitudinal_labs":[{"date":"2023-09-27","hemoglobin_g_dL":13.8,"wbc_k_uL":10.5,"platelets_k_uL":327,"creatinine_mg_dL":1.19,"alt_U_L":36},{"date":"2024-05-03","hemoglobin_g_dL":12.9,"wbc_k_uL":6.5,"platelets_k_uL":187,"creatinine_mg_dL":1.45,"alt_U_L":18},{"date":"2025-08-07","hemoglobin_g_dL":11.1,"wbc_k_uL":6.6,"platelets_k_uL":170,"creatinine_mg_dL":1.21,"alt_U_L":184}]}
{"patient_id":"ANODE_SYNTH_2025_2871","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":53,"sex":"male","bmi":18.9,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["pleura","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-12-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-55},"pfs_months":12.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.8,"censored":false},"longitudinal_labs":[{"date":"2024-10-26","hemoglobin_g_dL":12.7,"wbc_k_uL":7.9,"platelets_k_uL":345,"creatinine_mg_dL":1.01,"alt_U_L":76},{"date":"2025-06-26","hemoglobin_g_dL":11.2,"wbc_k_uL":6.6,"platelets_k_uL":221,"creatinine_mg_dL":0.79,"alt_U_L":15},{"date":"2026-02-13","hemoglobin_g_dL":12.4,"wbc_k_uL":7.5,"platelets_k_uL":273,"creatinine_mg_dL":0.99,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_2872","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":48,"sex":"female","bmi":21.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-74},"pfs_months":22.8},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-25","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.1,"censored":false},"longitudinal_labs":[{"date":"2020-03-11","hemoglobin_g_dL":14.9,"wbc_k_uL":9.3,"platelets_k_uL":227,"creatinine_mg_dL":1.27,"alt_U_L":61},{"date":"2020-09-28","hemoglobin_g_dL":11.5,"wbc_k_uL":8.5,"platelets_k_uL":247,"creatinine_mg_dL":1.21,"alt_U_L":92},{"date":"2022-04-25","hemoglobin_g_dL":12.7,"wbc_k_uL":5.8,"platelets_k_uL":226,"creatinine_mg_dL":1.82,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2873","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":67,"sex":"male","bmi":20.6,"smoking_pack_years":13,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-10-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-37},"pfs_months":23.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.6,"censored":false},"longitudinal_labs":[{"date":"2024-09-02","hemoglobin_g_dL":12.5,"wbc_k_uL":9.7,"platelets_k_uL":225,"creatinine_mg_dL":0.81,"alt_U_L":30},{"date":"2025-04-02","hemoglobin_g_dL":13.2,"wbc_k_uL":5.8,"platelets_k_uL":171,"creatinine_mg_dL":1.44,"alt_U_L":40},{"date":"2026-10-25","hemoglobin_g_dL":10.7,"wbc_k_uL":3.3,"platelets_k_uL":258,"creatinine_mg_dL":1.64,"alt_U_L":43}]}
{"patient_id":"ANODE_SYNTH_2025_2874","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":80,"sex":"female","bmi":28.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-38},"pfs_months":23.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":false},"longitudinal_labs":[{"date":"2022-02-24","hemoglobin_g_dL":15.0,"wbc_k_uL":4.7,"platelets_k_uL":371,"creatinine_mg_dL":0.83,"alt_U_L":56},{"date":"2022-10-28","hemoglobin_g_dL":12.4,"wbc_k_uL":6.7,"platelets_k_uL":254,"creatinine_mg_dL":0.76,"alt_U_L":99},{"date":"2024-06-11","hemoglobin_g_dL":12.6,"wbc_k_uL":3.9,"platelets_k_uL":142,"creatinine_mg_dL":0.89,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_2875","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.9,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":83,"sex":"female","bmi":26.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-57},"pfs_months":24.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.7,"censored":true},"longitudinal_labs":[{"date":"2021-02-09","hemoglobin_g_dL":14.9,"wbc_k_uL":8.3,"platelets_k_uL":416,"creatinine_mg_dL":1.01,"alt_U_L":44},{"date":"2021-09-02","hemoglobin_g_dL":12.4,"wbc_k_uL":4.1,"platelets_k_uL":334,"creatinine_mg_dL":1.58,"alt_U_L":102},{"date":"2023-03-26","hemoglobin_g_dL":9.9,"wbc_k_uL":4.9,"platelets_k_uL":119,"creatinine_mg_dL":1.94,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_2876","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":69,"sex":"female","bmi":37.4,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-02-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-84},"pfs_months":28.65},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":true},"longitudinal_labs":[{"date":"2020-01-20","hemoglobin_g_dL":13.6,"wbc_k_uL":8.8,"platelets_k_uL":179,"creatinine_mg_dL":1.07,"alt_U_L":39},{"date":"2020-08-07","hemoglobin_g_dL":10.7,"wbc_k_uL":5.3,"platelets_k_uL":227,"creatinine_mg_dL":0.79,"alt_U_L":117},{"date":"2022-07-09","hemoglobin_g_dL":10.1,"wbc_k_uL":6.4,"platelets_k_uL":151,"creatinine_mg_dL":1.04,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_2877","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":64,"sex":"female","bmi":30.8,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-04-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-30},"pfs_months":24.31},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":true},"longitudinal_labs":[{"date":"2022-04-02","hemoglobin_g_dL":14.6,"wbc_k_uL":8.9,"platelets_k_uL":157,"creatinine_mg_dL":0.87,"alt_U_L":46},{"date":"2022-10-24","hemoglobin_g_dL":12.2,"wbc_k_uL":5.6,"platelets_k_uL":364,"creatinine_mg_dL":1.3,"alt_U_L":54},{"date":"2024-06-05","hemoglobin_g_dL":11.8,"wbc_k_uL":3.2,"platelets_k_uL":225,"creatinine_mg_dL":1.28,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_2878","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":61,"sex":"female","bmi":35.7,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-01-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-34},"pfs_months":45.77},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-10","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":60.7,"censored":false},"longitudinal_labs":[{"date":"2023-12-25","hemoglobin_g_dL":13.4,"wbc_k_uL":7.1,"platelets_k_uL":231,"creatinine_mg_dL":0.99,"alt_U_L":23},{"date":"2024-07-16","hemoglobin_g_dL":13.7,"wbc_k_uL":5.2,"platelets_k_uL":245,"creatinine_mg_dL":0.72,"alt_U_L":56},{"date":"2028-01-10","hemoglobin_g_dL":11.0,"wbc_k_uL":6.3,"platelets_k_uL":163,"creatinine_mg_dL":1.95,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_2879","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":70,"sex":"male","bmi":27.9,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-10-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-83},"pfs_months":39.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-19","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":69.4,"censored":false},"longitudinal_labs":[{"date":"2024-10-01","hemoglobin_g_dL":11.7,"wbc_k_uL":7.9,"platelets_k_uL":282,"creatinine_mg_dL":0.97,"alt_U_L":32},{"date":"2025-04-26","hemoglobin_g_dL":13.9,"wbc_k_uL":5.1,"platelets_k_uL":159,"creatinine_mg_dL":1.28,"alt_U_L":93},{"date":"2028-03-19","hemoglobin_g_dL":9.7,"wbc_k_uL":3.9,"platelets_k_uL":328,"creatinine_mg_dL":1.28,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_2880","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":60,"sex":"male","bmi":32.3,"smoking_pack_years":11,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-11-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-68},"pfs_months":32.39},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":62.8,"censored":false},"longitudinal_labs":[{"date":"2020-10-15","hemoglobin_g_dL":13.2,"wbc_k_uL":5.1,"platelets_k_uL":238,"creatinine_mg_dL":1.16,"alt_U_L":29},{"date":"2021-05-28","hemoglobin_g_dL":10.6,"wbc_k_uL":4.8,"platelets_k_uL":284,"creatinine_mg_dL":0.99,"alt_U_L":36},{"date":"2023-09-22","hemoglobin_g_dL":11.1,"wbc_k_uL":4.9,"platelets_k_uL":214,"creatinine_mg_dL":1.95,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_2881","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":65,"sex":"female","bmi":30.7,"smoking_pack_years":19,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-71},"pfs_months":9.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.7,"censored":true},"longitudinal_labs":[{"date":"2025-06-13","hemoglobin_g_dL":12.6,"wbc_k_uL":5.7,"platelets_k_uL":248,"creatinine_mg_dL":1.17,"alt_U_L":72},{"date":"2026-01-06","hemoglobin_g_dL":11.9,"wbc_k_uL":5.5,"platelets_k_uL":360,"creatinine_mg_dL":0.75,"alt_U_L":118},{"date":"2026-05-08","hemoglobin_g_dL":11.0,"wbc_k_uL":5.7,"platelets_k_uL":287,"creatinine_mg_dL":1.1,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_2882","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":56,"sex":"male","bmi":36.4,"smoking_pack_years":18,"ecog_performance_status":2,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-12-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-69},"pfs_months":18.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.9,"censored":false},"longitudinal_labs":[{"date":"2020-10-06","hemoglobin_g_dL":11.6,"wbc_k_uL":10.5,"platelets_k_uL":182,"creatinine_mg_dL":1.26,"alt_U_L":28},{"date":"2021-06-03","hemoglobin_g_dL":10.6,"wbc_k_uL":5.7,"platelets_k_uL":130,"creatinine_mg_dL":1.49,"alt_U_L":60},{"date":"2022-08-28","hemoglobin_g_dL":11.3,"wbc_k_uL":7.5,"platelets_k_uL":188,"creatinine_mg_dL":1.29,"alt_U_L":89}]}
{"patient_id":"ANODE_SYNTH_2025_2883","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":74,"sex":"female","bmi":37.8,"smoking_pack_years":63,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-02-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-71},"pfs_months":23.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":27.7,"censored":true},"longitudinal_labs":[{"date":"2025-12-15","hemoglobin_g_dL":12.3,"wbc_k_uL":5.8,"platelets_k_uL":443,"creatinine_mg_dL":0.71,"alt_U_L":59},{"date":"2026-08-09","hemoglobin_g_dL":10.9,"wbc_k_uL":6.7,"platelets_k_uL":203,"creatinine_mg_dL":1.15,"alt_U_L":83},{"date":"2028-03-27","hemoglobin_g_dL":10.5,"wbc_k_uL":3.2,"platelets_k_uL":298,"creatinine_mg_dL":1.55,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_2884","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":62,"sex":"male","bmi":20.9,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-09-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-52},"pfs_months":42.32},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":53.8,"censored":false},"longitudinal_labs":[{"date":"2020-07-10","hemoglobin_g_dL":13.4,"wbc_k_uL":10.2,"platelets_k_uL":351,"creatinine_mg_dL":0.91,"alt_U_L":33},{"date":"2021-03-03","hemoglobin_g_dL":10.3,"wbc_k_uL":8.6,"platelets_k_uL":223,"creatinine_mg_dL":1.31,"alt_U_L":32},{"date":"2024-04-28","hemoglobin_g_dL":11.9,"wbc_k_uL":5.9,"platelets_k_uL":247,"creatinine_mg_dL":1.13,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_2885","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":61,"sex":"male","bmi":21.6,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-81},"pfs_months":23.13},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.7,"censored":false},"longitudinal_labs":[{"date":"2023-12-02","hemoglobin_g_dL":13.4,"wbc_k_uL":7.5,"platelets_k_uL":160,"creatinine_mg_dL":0.88,"alt_U_L":50},{"date":"2024-06-16","hemoglobin_g_dL":13.7,"wbc_k_uL":7.7,"platelets_k_uL":152,"creatinine_mg_dL":1.19,"alt_U_L":115},{"date":"2026-01-12","hemoglobin_g_dL":11.8,"wbc_k_uL":3.3,"platelets_k_uL":141,"creatinine_mg_dL":1.79,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_2886","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":80,"sex":"female","bmi":23.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-35},"pfs_months":19.48},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":37.9,"censored":true},"longitudinal_labs":[{"date":"2023-02-10","hemoglobin_g_dL":13.2,"wbc_k_uL":8.8,"platelets_k_uL":306,"creatinine_mg_dL":1.07,"alt_U_L":79},{"date":"2023-10-16","hemoglobin_g_dL":10.2,"wbc_k_uL":5.8,"platelets_k_uL":274,"creatinine_mg_dL":1.16,"alt_U_L":28},{"date":"2024-12-15","hemoglobin_g_dL":12.5,"wbc_k_uL":6.2,"platelets_k_uL":139,"creatinine_mg_dL":1.16,"alt_U_L":125}]}
{"patient_id":"ANODE_SYNTH_2025_2887","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":58,"sex":"female","bmi":22.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-41},"pfs_months":14.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":22.9,"censored":true},"longitudinal_labs":[{"date":"2024-02-28","hemoglobin_g_dL":14.4,"wbc_k_uL":9.1,"platelets_k_uL":357,"creatinine_mg_dL":0.79,"alt_U_L":39},{"date":"2024-11-02","hemoglobin_g_dL":14.0,"wbc_k_uL":5.8,"platelets_k_uL":240,"creatinine_mg_dL":1.22,"alt_U_L":107},{"date":"2025-07-16","hemoglobin_g_dL":13.0,"wbc_k_uL":3.5,"platelets_k_uL":344,"creatinine_mg_dL":1.3,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_2888","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":82,"sex":"female","bmi":25.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-49},"pfs_months":34.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":45.2,"censored":false},"longitudinal_labs":[{"date":"2021-01-14","hemoglobin_g_dL":13.2,"wbc_k_uL":8.3,"platelets_k_uL":212,"creatinine_mg_dL":0.99,"alt_U_L":52},{"date":"2021-09-02","hemoglobin_g_dL":12.1,"wbc_k_uL":8.2,"platelets_k_uL":281,"creatinine_mg_dL":0.86,"alt_U_L":90},{"date":"2024-02-26","hemoglobin_g_dL":12.0,"wbc_k_uL":5.1,"platelets_k_uL":106,"creatinine_mg_dL":0.8,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_2889","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":58,"sex":"male","bmi":21.9,"smoking_pack_years":20,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["contralateral lung","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-05-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-43},"pfs_months":3.19},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":7.1,"censored":true},"longitudinal_labs":[{"date":"2023-04-05","hemoglobin_g_dL":11.9,"wbc_k_uL":7.8,"platelets_k_uL":336,"creatinine_mg_dL":0.72,"alt_U_L":10},{"date":"2023-11-20","hemoglobin_g_dL":12.5,"wbc_k_uL":8.5,"platelets_k_uL":364,"creatinine_mg_dL":0.8,"alt_U_L":23},{"date":"2023-10-16","hemoglobin_g_dL":12.6,"wbc_k_uL":7.4,"platelets_k_uL":302,"creatinine_mg_dL":1.52,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_2890","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":78,"sex":"female","bmi":33.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-53},"pfs_months":22.21},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.8,"censored":false},"longitudinal_labs":[{"date":"2025-01-02","hemoglobin_g_dL":13.8,"wbc_k_uL":10.3,"platelets_k_uL":319,"creatinine_mg_dL":1.15,"alt_U_L":42},{"date":"2025-07-27","hemoglobin_g_dL":13.7,"wbc_k_uL":4.6,"platelets_k_uL":308,"creatinine_mg_dL":0.71,"alt_U_L":99},{"date":"2026-12-19","hemoglobin_g_dL":9.8,"wbc_k_uL":5.2,"platelets_k_uL":305,"creatinine_mg_dL":2.0,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_2891","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":81,"sex":"female","bmi":19.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-01-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-41},"pfs_months":29.37},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.3,"censored":false},"longitudinal_labs":[{"date":"2025-11-07","hemoglobin_g_dL":13.4,"wbc_k_uL":8.9,"platelets_k_uL":406,"creatinine_mg_dL":1.01,"alt_U_L":16},{"date":"2026-07-01","hemoglobin_g_dL":10.6,"wbc_k_uL":6.1,"platelets_k_uL":169,"creatinine_mg_dL":1.39,"alt_U_L":32},{"date":"2028-07-19","hemoglobin_g_dL":12.9,"wbc_k_uL":3.7,"platelets_k_uL":114,"creatinine_mg_dL":0.8,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_2892","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":85,"sex":"male","bmi":23.0,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-06-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-73},"pfs_months":9.72},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.6,"censored":false},"longitudinal_labs":[{"date":"2023-03-23","hemoglobin_g_dL":14.4,"wbc_k_uL":10.4,"platelets_k_uL":400,"creatinine_mg_dL":0.79,"alt_U_L":22},{"date":"2023-11-28","hemoglobin_g_dL":14.0,"wbc_k_uL":4.1,"platelets_k_uL":322,"creatinine_mg_dL":1.29,"alt_U_L":118},{"date":"2024-04-25","hemoglobin_g_dL":9.5,"wbc_k_uL":3.3,"platelets_k_uL":288,"creatinine_mg_dL":1.33,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_2893","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":48,"sex":"male","bmi":32.9,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-35},"pfs_months":33.05},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":50.0,"censored":true},"longitudinal_labs":[{"date":"2023-04-22","hemoglobin_g_dL":11.7,"wbc_k_uL":7.1,"platelets_k_uL":254,"creatinine_mg_dL":1.29,"alt_U_L":78},{"date":"2023-12-15","hemoglobin_g_dL":10.4,"wbc_k_uL":4.5,"platelets_k_uL":311,"creatinine_mg_dL":1.19,"alt_U_L":78},{"date":"2026-05-11","hemoglobin_g_dL":13.0,"wbc_k_uL":4.1,"platelets_k_uL":177,"creatinine_mg_dL":1.69,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_2894","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":54,"sex":"female","bmi":31.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-85},"pfs_months":25.72},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.7,"censored":true},"longitudinal_labs":[{"date":"2024-05-17","hemoglobin_g_dL":12.7,"wbc_k_uL":5.1,"platelets_k_uL":204,"creatinine_mg_dL":1.05,"alt_U_L":63},{"date":"2024-12-20","hemoglobin_g_dL":12.7,"wbc_k_uL":8.6,"platelets_k_uL":280,"creatinine_mg_dL":1.54,"alt_U_L":23},{"date":"2026-09-09","hemoglobin_g_dL":12.3,"wbc_k_uL":7.8,"platelets_k_uL":127,"creatinine_mg_dL":1.12,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_2895","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":86,"sex":"female","bmi":28.3,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-07-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-74},"pfs_months":11.99},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-25","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":15.9,"censored":false},"longitudinal_labs":[{"date":"2025-06-05","hemoglobin_g_dL":15.1,"wbc_k_uL":10.6,"platelets_k_uL":391,"creatinine_mg_dL":0.85,"alt_U_L":55},{"date":"2026-01-24","hemoglobin_g_dL":12.4,"wbc_k_uL":4.8,"platelets_k_uL":168,"creatinine_mg_dL":1.15,"alt_U_L":37},{"date":"2026-09-25","hemoglobin_g_dL":12.9,"wbc_k_uL":5.8,"platelets_k_uL":188,"creatinine_mg_dL":1.54,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_2896","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":74,"sex":"female","bmi":36.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-70},"pfs_months":26.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.1,"censored":true},"longitudinal_labs":[{"date":"2023-06-04","hemoglobin_g_dL":14.1,"wbc_k_uL":10.0,"platelets_k_uL":346,"creatinine_mg_dL":1.14,"alt_U_L":19},{"date":"2024-01-03","hemoglobin_g_dL":12.0,"wbc_k_uL":6.0,"platelets_k_uL":370,"creatinine_mg_dL":0.94,"alt_U_L":71},{"date":"2025-10-17","hemoglobin_g_dL":13.0,"wbc_k_uL":7.9,"platelets_k_uL":313,"creatinine_mg_dL":0.9,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_2897","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":70,"sex":"female","bmi":22.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-49},"pfs_months":11.89},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.3,"censored":true},"longitudinal_labs":[{"date":"2025-04-01","hemoglobin_g_dL":13.8,"wbc_k_uL":6.3,"platelets_k_uL":344,"creatinine_mg_dL":1.27,"alt_U_L":43},{"date":"2025-10-14","hemoglobin_g_dL":12.8,"wbc_k_uL":3.9,"platelets_k_uL":258,"creatinine_mg_dL":0.72,"alt_U_L":91},{"date":"2026-05-18","hemoglobin_g_dL":11.0,"wbc_k_uL":3.1,"platelets_k_uL":172,"creatinine_mg_dL":1.83,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_2898","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":74,"sex":"female","bmi":36.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-46},"pfs_months":20.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-10","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.7,"censored":false},"longitudinal_labs":[{"date":"2023-06-26","hemoglobin_g_dL":14.5,"wbc_k_uL":9.9,"platelets_k_uL":435,"creatinine_mg_dL":0.99,"alt_U_L":48},{"date":"2024-01-11","hemoglobin_g_dL":12.4,"wbc_k_uL":7.3,"platelets_k_uL":258,"creatinine_mg_dL":1.32,"alt_U_L":41},{"date":"2025-04-10","hemoglobin_g_dL":10.9,"wbc_k_uL":4.9,"platelets_k_uL":195,"creatinine_mg_dL":1.88,"alt_U_L":200}]}
{"patient_id":"ANODE_SYNTH_2025_2899","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":82,"sex":"female","bmi":34.1,"smoking_pack_years":30,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-05-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-31},"pfs_months":7.92},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.9,"censored":false},"longitudinal_labs":[{"date":"2022-05-04","hemoglobin_g_dL":14.3,"wbc_k_uL":10.6,"platelets_k_uL":312,"creatinine_mg_dL":1.13,"alt_U_L":72},{"date":"2022-11-22","hemoglobin_g_dL":12.2,"wbc_k_uL":6.6,"platelets_k_uL":184,"creatinine_mg_dL":1.1,"alt_U_L":16},{"date":"2023-02-06","hemoglobin_g_dL":10.2,"wbc_k_uL":5.5,"platelets_k_uL":170,"creatinine_mg_dL":1.92,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_2900","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":77,"sex":"female","bmi":36.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-31},"pfs_months":17.74},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.4,"censored":true},"longitudinal_labs":[{"date":"2021-02-12","hemoglobin_g_dL":13.5,"wbc_k_uL":5.6,"platelets_k_uL":174,"creatinine_mg_dL":0.85,"alt_U_L":54},{"date":"2021-09-29","hemoglobin_g_dL":12.7,"wbc_k_uL":6.6,"platelets_k_uL":301,"creatinine_mg_dL":1.11,"alt_U_L":95},{"date":"2022-10-12","hemoglobin_g_dL":9.6,"wbc_k_uL":3.3,"platelets_k_uL":180,"creatinine_mg_dL":1.65,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_2901","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":74,"sex":"male","bmi":20.7,"smoking_pack_years":14,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-01-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-32},"pfs_months":7.39},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-22","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.6,"censored":false},"longitudinal_labs":[{"date":"2022-12-13","hemoglobin_g_dL":13.2,"wbc_k_uL":5.2,"platelets_k_uL":266,"creatinine_mg_dL":0.71,"alt_U_L":72},{"date":"2023-07-28","hemoglobin_g_dL":11.2,"wbc_k_uL":7.7,"platelets_k_uL":351,"creatinine_mg_dL":1.3,"alt_U_L":21},{"date":"2023-10-22","hemoglobin_g_dL":10.2,"wbc_k_uL":7.0,"platelets_k_uL":285,"creatinine_mg_dL":1.0,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2902","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":54,"sex":"male","bmi":24.7,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-02-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-64},"pfs_months":21.72},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.4,"censored":false},"longitudinal_labs":[{"date":"2022-01-23","hemoglobin_g_dL":11.8,"wbc_k_uL":9.8,"platelets_k_uL":257,"creatinine_mg_dL":1.19,"alt_U_L":12},{"date":"2022-08-12","hemoglobin_g_dL":13.9,"wbc_k_uL":4.8,"platelets_k_uL":337,"creatinine_mg_dL":1.26,"alt_U_L":86},{"date":"2024-01-23","hemoglobin_g_dL":9.6,"wbc_k_uL":5.6,"platelets_k_uL":282,"creatinine_mg_dL":1.13,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_2903","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":48,"sex":"male","bmi":24.0,"smoking_pack_years":40,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-02-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-70},"pfs_months":31.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.9,"censored":false},"longitudinal_labs":[{"date":"2021-01-16","hemoglobin_g_dL":14.7,"wbc_k_uL":6.3,"platelets_k_uL":315,"creatinine_mg_dL":0.67,"alt_U_L":17},{"date":"2021-08-09","hemoglobin_g_dL":11.1,"wbc_k_uL":5.9,"platelets_k_uL":210,"creatinine_mg_dL":1.13,"alt_U_L":105},{"date":"2023-10-28","hemoglobin_g_dL":10.8,"wbc_k_uL":3.3,"platelets_k_uL":194,"creatinine_mg_dL":0.86,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_2904","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":67,"sex":"female","bmi":30.6,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-30},"pfs_months":35.65},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.0,"censored":false},"longitudinal_labs":[{"date":"2020-02-19","hemoglobin_g_dL":14.6,"wbc_k_uL":7.9,"platelets_k_uL":216,"creatinine_mg_dL":0.93,"alt_U_L":64},{"date":"2020-09-19","hemoglobin_g_dL":12.0,"wbc_k_uL":4.0,"platelets_k_uL":297,"creatinine_mg_dL":1.13,"alt_U_L":73},{"date":"2023-04-17","hemoglobin_g_dL":10.3,"wbc_k_uL":4.9,"platelets_k_uL":293,"creatinine_mg_dL":0.97,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_2905","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":81,"sex":"female","bmi":19.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-01-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-50},"pfs_months":16.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.5,"censored":false},"longitudinal_labs":[{"date":"2021-12-19","hemoglobin_g_dL":13.4,"wbc_k_uL":5.8,"platelets_k_uL":189,"creatinine_mg_dL":0.88,"alt_U_L":76},{"date":"2022-07-16","hemoglobin_g_dL":12.6,"wbc_k_uL":6.3,"platelets_k_uL":371,"creatinine_mg_dL":1.13,"alt_U_L":18},{"date":"2023-06-13","hemoglobin_g_dL":11.0,"wbc_k_uL":5.8,"platelets_k_uL":256,"creatinine_mg_dL":1.71,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_2906","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":52,"sex":"male","bmi":30.1,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-04-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-63},"pfs_months":25.63},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":31.3,"censored":false},"longitudinal_labs":[{"date":"2022-02-24","hemoglobin_g_dL":14.3,"wbc_k_uL":6.9,"platelets_k_uL":160,"creatinine_mg_dL":0.95,"alt_U_L":11},{"date":"2022-10-06","hemoglobin_g_dL":11.4,"wbc_k_uL":6.8,"platelets_k_uL":197,"creatinine_mg_dL":1.26,"alt_U_L":83},{"date":"2024-06-26","hemoglobin_g_dL":13.0,"wbc_k_uL":7.3,"platelets_k_uL":283,"creatinine_mg_dL":1.24,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_2907","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":51,"sex":"female","bmi":20.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-38},"pfs_months":18.43},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.5,"censored":false},"longitudinal_labs":[{"date":"2025-09-08","hemoglobin_g_dL":14.4,"wbc_k_uL":7.9,"platelets_k_uL":216,"creatinine_mg_dL":1.16,"alt_U_L":12},{"date":"2026-05-06","hemoglobin_g_dL":12.1,"wbc_k_uL":4.8,"platelets_k_uL":208,"creatinine_mg_dL":1.6,"alt_U_L":119},{"date":"2027-06-18","hemoglobin_g_dL":11.4,"wbc_k_uL":3.4,"platelets_k_uL":229,"creatinine_mg_dL":1.66,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_2908","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":60,"sex":"female","bmi":21.3,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-02-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-46},"pfs_months":35.75},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":61.6,"censored":false},"longitudinal_labs":[{"date":"2025-01-09","hemoglobin_g_dL":12.9,"wbc_k_uL":5.7,"platelets_k_uL":227,"creatinine_mg_dL":1.28,"alt_U_L":49},{"date":"2025-08-11","hemoglobin_g_dL":12.2,"wbc_k_uL":6.3,"platelets_k_uL":164,"creatinine_mg_dL":1.47,"alt_U_L":70},{"date":"2028-03-25","hemoglobin_g_dL":11.3,"wbc_k_uL":8.0,"platelets_k_uL":161,"creatinine_mg_dL":1.95,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_2909","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":49,"sex":"female","bmi":34.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-02-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-72},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-21","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.2,"censored":false},"longitudinal_labs":[{"date":"2020-02-10","hemoglobin_g_dL":13.9,"wbc_k_uL":4.5,"platelets_k_uL":421,"creatinine_mg_dL":1.17,"alt_U_L":61},{"date":"2020-08-22","hemoglobin_g_dL":10.6,"wbc_k_uL":5.3,"platelets_k_uL":273,"creatinine_mg_dL":0.89,"alt_U_L":52},{"date":"2021-12-21","hemoglobin_g_dL":9.7,"wbc_k_uL":5.3,"platelets_k_uL":228,"creatinine_mg_dL":1.14,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_2910","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":87,"sex":"female","bmi":23.1,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-10-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-37},"pfs_months":18.5},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":true},"longitudinal_labs":[{"date":"2022-10-03","hemoglobin_g_dL":12.3,"wbc_k_uL":8.4,"platelets_k_uL":179,"creatinine_mg_dL":1.2,"alt_U_L":74},{"date":"2023-04-27","hemoglobin_g_dL":12.2,"wbc_k_uL":5.5,"platelets_k_uL":261,"creatinine_mg_dL":1.11,"alt_U_L":47},{"date":"2024-05-20","hemoglobin_g_dL":11.9,"wbc_k_uL":7.7,"platelets_k_uL":170,"creatinine_mg_dL":1.78,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_2911","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":77,"sex":"female","bmi":28.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-53},"pfs_months":19.38},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.2,"censored":false},"longitudinal_labs":[{"date":"2020-10-28","hemoglobin_g_dL":15.2,"wbc_k_uL":5.0,"platelets_k_uL":220,"creatinine_mg_dL":0.98,"alt_U_L":36},{"date":"2021-05-21","hemoglobin_g_dL":10.1,"wbc_k_uL":5.9,"platelets_k_uL":197,"creatinine_mg_dL":1.39,"alt_U_L":104},{"date":"2022-08-05","hemoglobin_g_dL":12.7,"wbc_k_uL":6.7,"platelets_k_uL":258,"creatinine_mg_dL":1.34,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_2912","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":63,"sex":"male","bmi":23.7,"smoking_pack_years":31,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-03-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-31},"pfs_months":43.99},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-12-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":74.0,"censored":false},"longitudinal_labs":[{"date":"2025-02-20","hemoglobin_g_dL":12.7,"wbc_k_uL":7.0,"platelets_k_uL":420,"creatinine_mg_dL":0.67,"alt_U_L":73},{"date":"2025-09-07","hemoglobin_g_dL":11.9,"wbc_k_uL":3.8,"platelets_k_uL":340,"creatinine_mg_dL":0.76,"alt_U_L":120},{"date":"2028-12-28","hemoglobin_g_dL":10.9,"wbc_k_uL":6.6,"platelets_k_uL":108,"creatinine_mg_dL":0.95,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_2913","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":58,"sex":"female","bmi":23.0,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-05-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-37},"pfs_months":7.1},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":14.8,"censored":true},"longitudinal_labs":[{"date":"2024-03-06","hemoglobin_g_dL":13.5,"wbc_k_uL":7.3,"platelets_k_uL":366,"creatinine_mg_dL":1.12,"alt_U_L":64},{"date":"2024-11-08","hemoglobin_g_dL":13.2,"wbc_k_uL":6.5,"platelets_k_uL":262,"creatinine_mg_dL":0.79,"alt_U_L":94},{"date":"2024-12-28","hemoglobin_g_dL":10.4,"wbc_k_uL":5.5,"platelets_k_uL":129,"creatinine_mg_dL":1.67,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_2914","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":59,"sex":"female","bmi":34.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-32},"pfs_months":16.92},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-31","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.6,"censored":false},"longitudinal_labs":[{"date":"2025-01-02","hemoglobin_g_dL":12.6,"wbc_k_uL":5.0,"platelets_k_uL":267,"creatinine_mg_dL":0.81,"alt_U_L":41},{"date":"2025-08-21","hemoglobin_g_dL":12.2,"wbc_k_uL":6.9,"platelets_k_uL":145,"creatinine_mg_dL":1.18,"alt_U_L":115},{"date":"2026-07-31","hemoglobin_g_dL":11.3,"wbc_k_uL":5.4,"platelets_k_uL":322,"creatinine_mg_dL":1.57,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_2915","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":68,"sex":"female","bmi":35.6,"smoking_pack_years":68,"ecog_performance_status":2,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-05-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-54},"pfs_months":20.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.3,"censored":false},"longitudinal_labs":[{"date":"2020-04-15","hemoglobin_g_dL":15.5,"wbc_k_uL":5.8,"platelets_k_uL":360,"creatinine_mg_dL":0.73,"alt_U_L":53},{"date":"2020-11-25","hemoglobin_g_dL":11.8,"wbc_k_uL":5.1,"platelets_k_uL":313,"creatinine_mg_dL":0.83,"alt_U_L":85},{"date":"2022-03-07","hemoglobin_g_dL":10.2,"wbc_k_uL":5.2,"platelets_k_uL":159,"creatinine_mg_dL":1.96,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_2916","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":71,"sex":"male","bmi":28.9,"smoking_pack_years":38,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-02-16","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-73},"pfs_months":17.81},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.6,"censored":true},"longitudinal_labs":[{"date":"2023-12-10","hemoglobin_g_dL":12.1,"wbc_k_uL":4.7,"platelets_k_uL":299,"creatinine_mg_dL":0.82,"alt_U_L":30},{"date":"2024-08-14","hemoglobin_g_dL":13.5,"wbc_k_uL":7.3,"platelets_k_uL":181,"creatinine_mg_dL":1.25,"alt_U_L":51},{"date":"2025-10-06","hemoglobin_g_dL":10.9,"wbc_k_uL":5.3,"platelets_k_uL":316,"creatinine_mg_dL":1.4,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_2917","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":69,"sex":"female","bmi":28.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-01-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-79},"pfs_months":20.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.2,"censored":false},"longitudinal_labs":[{"date":"2023-01-10","hemoglobin_g_dL":12.8,"wbc_k_uL":9.3,"platelets_k_uL":287,"creatinine_mg_dL":0.99,"alt_U_L":43},{"date":"2023-07-26","hemoglobin_g_dL":11.6,"wbc_k_uL":4.3,"platelets_k_uL":301,"creatinine_mg_dL":1.51,"alt_U_L":117},{"date":"2024-11-29","hemoglobin_g_dL":12.5,"wbc_k_uL":3.9,"platelets_k_uL":202,"creatinine_mg_dL":1.18,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_2918","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":84,"sex":"female","bmi":37.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-84},"pfs_months":25.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-30","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.3,"censored":true},"longitudinal_labs":[{"date":"2021-08-21","hemoglobin_g_dL":13.7,"wbc_k_uL":5.4,"platelets_k_uL":282,"creatinine_mg_dL":0.92,"alt_U_L":24},{"date":"2022-04-08","hemoglobin_g_dL":13.5,"wbc_k_uL":7.1,"platelets_k_uL":364,"creatinine_mg_dL":0.82,"alt_U_L":27},{"date":"2023-12-30","hemoglobin_g_dL":12.9,"wbc_k_uL":7.9,"platelets_k_uL":142,"creatinine_mg_dL":1.98,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_2919","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":62,"sex":"male","bmi":33.6,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-05-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-62},"pfs_months":28.22},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.6,"censored":false},"longitudinal_labs":[{"date":"2021-05-02","hemoglobin_g_dL":14.6,"wbc_k_uL":9.2,"platelets_k_uL":423,"creatinine_mg_dL":0.72,"alt_U_L":70},{"date":"2021-11-19","hemoglobin_g_dL":12.7,"wbc_k_uL":5.5,"platelets_k_uL":242,"creatinine_mg_dL":1.45,"alt_U_L":26},{"date":"2023-10-17","hemoglobin_g_dL":12.4,"wbc_k_uL":6.7,"platelets_k_uL":144,"creatinine_mg_dL":1.05,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_2920","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":51,"sex":"female","bmi":33.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-80},"pfs_months":22.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.1,"censored":false},"longitudinal_labs":[{"date":"2020-07-19","hemoglobin_g_dL":15.2,"wbc_k_uL":10.1,"platelets_k_uL":414,"creatinine_mg_dL":0.63,"alt_U_L":32},{"date":"2021-02-13","hemoglobin_g_dL":13.3,"wbc_k_uL":4.7,"platelets_k_uL":196,"creatinine_mg_dL":0.98,"alt_U_L":90},{"date":"2022-07-05","hemoglobin_g_dL":9.7,"wbc_k_uL":4.1,"platelets_k_uL":163,"creatinine_mg_dL":1.08,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_2921","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":49,"sex":"female","bmi":29.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-74},"pfs_months":16.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-18","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.9,"censored":true},"longitudinal_labs":[{"date":"2023-11-17","hemoglobin_g_dL":11.6,"wbc_k_uL":10.4,"platelets_k_uL":348,"creatinine_mg_dL":0.85,"alt_U_L":75},{"date":"2024-06-15","hemoglobin_g_dL":11.6,"wbc_k_uL":4.1,"platelets_k_uL":343,"creatinine_mg_dL":1.16,"alt_U_L":83},{"date":"2025-06-18","hemoglobin_g_dL":12.5,"wbc_k_uL":5.1,"platelets_k_uL":155,"creatinine_mg_dL":0.85,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_2922","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":84,"sex":"female","bmi":18.9,"smoking_pack_years":35,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-11-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-67},"pfs_months":42.81},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":62.1,"censored":false},"longitudinal_labs":[{"date":"2024-10-12","hemoglobin_g_dL":13.2,"wbc_k_uL":8.1,"platelets_k_uL":431,"creatinine_mg_dL":0.76,"alt_U_L":66},{"date":"2025-05-18","hemoglobin_g_dL":13.4,"wbc_k_uL":7.5,"platelets_k_uL":216,"creatinine_mg_dL":1.53,"alt_U_L":58},{"date":"2028-06-21","hemoglobin_g_dL":11.9,"wbc_k_uL":3.4,"platelets_k_uL":339,"creatinine_mg_dL":1.33,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_2923","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":62,"sex":"female","bmi":36.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-06-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-43},"pfs_months":28.16},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.0,"censored":false},"longitudinal_labs":[{"date":"2020-05-14","hemoglobin_g_dL":12.1,"wbc_k_uL":8.4,"platelets_k_uL":194,"creatinine_mg_dL":0.99,"alt_U_L":39},{"date":"2020-12-16","hemoglobin_g_dL":10.5,"wbc_k_uL":7.2,"platelets_k_uL":260,"creatinine_mg_dL":0.85,"alt_U_L":78},{"date":"2022-12-17","hemoglobin_g_dL":10.4,"wbc_k_uL":6.8,"platelets_k_uL":343,"creatinine_mg_dL":1.63,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_2924","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":88,"sex":"female","bmi":25.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-03-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-50},"pfs_months":20.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.6,"censored":false},"longitudinal_labs":[{"date":"2020-02-27","hemoglobin_g_dL":14.9,"wbc_k_uL":4.7,"platelets_k_uL":275,"creatinine_mg_dL":1.02,"alt_U_L":15},{"date":"2020-09-08","hemoglobin_g_dL":13.3,"wbc_k_uL":6.0,"platelets_k_uL":345,"creatinine_mg_dL":1.3,"alt_U_L":27},{"date":"2021-12-20","hemoglobin_g_dL":11.9,"wbc_k_uL":6.9,"platelets_k_uL":343,"creatinine_mg_dL":1.77,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_2925","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":49,"sex":"female","bmi":32.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-63},"pfs_months":9.46},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-30","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.4,"censored":false},"longitudinal_labs":[{"date":"2022-07-17","hemoglobin_g_dL":12.1,"wbc_k_uL":5.9,"platelets_k_uL":185,"creatinine_mg_dL":0.72,"alt_U_L":33},{"date":"2023-01-27","hemoglobin_g_dL":11.5,"wbc_k_uL":7.5,"platelets_k_uL":217,"creatinine_mg_dL":0.73,"alt_U_L":79},{"date":"2023-05-30","hemoglobin_g_dL":11.3,"wbc_k_uL":3.4,"platelets_k_uL":249,"creatinine_mg_dL":1.54,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_2926","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.8,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":75,"sex":"male","bmi":23.0,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-08-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-40},"pfs_months":28.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.7,"censored":false},"longitudinal_labs":[{"date":"2025-06-20","hemoglobin_g_dL":15.4,"wbc_k_uL":9.6,"platelets_k_uL":292,"creatinine_mg_dL":1.26,"alt_U_L":67},{"date":"2026-01-30","hemoglobin_g_dL":11.5,"wbc_k_uL":8.8,"platelets_k_uL":208,"creatinine_mg_dL":1.07,"alt_U_L":44},{"date":"2028-02-27","hemoglobin_g_dL":10.0,"wbc_k_uL":7.7,"platelets_k_uL":138,"creatinine_mg_dL":1.57,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_2927","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":79,"sex":"male","bmi":25.0,"smoking_pack_years":65,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["bone","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2023-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-65},"pfs_months":21.85},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.5,"censored":false},"longitudinal_labs":[{"date":"2023-04-20","hemoglobin_g_dL":14.5,"wbc_k_uL":6.5,"platelets_k_uL":208,"creatinine_mg_dL":1.01,"alt_U_L":11},{"date":"2023-12-08","hemoglobin_g_dL":13.0,"wbc_k_uL":8.2,"platelets_k_uL":225,"creatinine_mg_dL":0.95,"alt_U_L":60},{"date":"2025-04-25","hemoglobin_g_dL":12.0,"wbc_k_uL":3.5,"platelets_k_uL":170,"creatinine_mg_dL":1.76,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_2928","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":78,"sex":"male","bmi":20.1,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-02-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-72},"pfs_months":31.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-10","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":50.3,"censored":true},"longitudinal_labs":[{"date":"2024-02-08","hemoglobin_g_dL":14.2,"wbc_k_uL":4.8,"platelets_k_uL":239,"creatinine_mg_dL":0.62,"alt_U_L":36},{"date":"2024-08-22","hemoglobin_g_dL":11.7,"wbc_k_uL":6.5,"platelets_k_uL":122,"creatinine_mg_dL":0.87,"alt_U_L":39},{"date":"2026-10-10","hemoglobin_g_dL":9.8,"wbc_k_uL":4.9,"platelets_k_uL":123,"creatinine_mg_dL":1.25,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_2929","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":85,"sex":"female","bmi":26.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-34},"pfs_months":16.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-20","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.7,"censored":false},"longitudinal_labs":[{"date":"2022-04-11","hemoglobin_g_dL":13.6,"wbc_k_uL":9.8,"platelets_k_uL":311,"creatinine_mg_dL":1.08,"alt_U_L":78},{"date":"2022-12-16","hemoglobin_g_dL":11.2,"wbc_k_uL":4.5,"platelets_k_uL":316,"creatinine_mg_dL":0.72,"alt_U_L":65},{"date":"2023-11-20","hemoglobin_g_dL":11.5,"wbc_k_uL":7.3,"platelets_k_uL":150,"creatinine_mg_dL":1.71,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_2930","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":51,"sex":"female","bmi":20.9,"smoking_pack_years":20,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-09-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-44},"pfs_months":28.75},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.7,"censored":false},"longitudinal_labs":[{"date":"2021-08-08","hemoglobin_g_dL":12.4,"wbc_k_uL":6.7,"platelets_k_uL":150,"creatinine_mg_dL":1.06,"alt_U_L":72},{"date":"2022-03-27","hemoglobin_g_dL":10.1,"wbc_k_uL":4.9,"platelets_k_uL":326,"creatinine_mg_dL":1.1,"alt_U_L":69},{"date":"2024-03-13","hemoglobin_g_dL":10.4,"wbc_k_uL":6.3,"platelets_k_uL":309,"creatinine_mg_dL":1.5,"alt_U_L":99}]}
{"patient_id":"ANODE_SYNTH_2025_2931","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":87,"sex":"female","bmi":30.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-37},"pfs_months":17.45},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.6,"censored":true},"longitudinal_labs":[{"date":"2023-12-09","hemoglobin_g_dL":12.5,"wbc_k_uL":8.6,"platelets_k_uL":282,"creatinine_mg_dL":1.15,"alt_U_L":26},{"date":"2024-07-28","hemoglobin_g_dL":13.1,"wbc_k_uL":8.6,"platelets_k_uL":239,"creatinine_mg_dL":1.41,"alt_U_L":58},{"date":"2025-08-04","hemoglobin_g_dL":9.9,"wbc_k_uL":4.7,"platelets_k_uL":169,"creatinine_mg_dL":1.83,"alt_U_L":124}]}
{"patient_id":"ANODE_SYNTH_2025_2932","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":87,"sex":"female","bmi":33.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-09-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-79},"pfs_months":32.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":49.1,"censored":false},"longitudinal_labs":[{"date":"2023-08-10","hemoglobin_g_dL":15.4,"wbc_k_uL":7.1,"platelets_k_uL":177,"creatinine_mg_dL":1.14,"alt_U_L":58},{"date":"2024-03-18","hemoglobin_g_dL":11.2,"wbc_k_uL":8.8,"platelets_k_uL":171,"creatinine_mg_dL":1.44,"alt_U_L":56},{"date":"2026-06-14","hemoglobin_g_dL":11.7,"wbc_k_uL":3.8,"platelets_k_uL":124,"creatinine_mg_dL":1.83,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_2933","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":59,"sex":"female","bmi":33.7,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-12-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-69},"pfs_months":34.89},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.9,"censored":false},"longitudinal_labs":[{"date":"2020-10-21","hemoglobin_g_dL":14.0,"wbc_k_uL":10.3,"platelets_k_uL":158,"creatinine_mg_dL":1.04,"alt_U_L":58},{"date":"2021-06-27","hemoglobin_g_dL":12.7,"wbc_k_uL":8.5,"platelets_k_uL":298,"creatinine_mg_dL":1.04,"alt_U_L":46},{"date":"2024-01-11","hemoglobin_g_dL":9.6,"wbc_k_uL":3.7,"platelets_k_uL":235,"creatinine_mg_dL":1.82,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_2934","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":48,"sex":"female","bmi":19.4,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-68},"pfs_months":17.77},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":27.0,"censored":true},"longitudinal_labs":[{"date":"2022-04-18","hemoglobin_g_dL":14.7,"wbc_k_uL":5.7,"platelets_k_uL":274,"creatinine_mg_dL":1.0,"alt_U_L":49},{"date":"2022-12-15","hemoglobin_g_dL":13.3,"wbc_k_uL":4.6,"platelets_k_uL":238,"creatinine_mg_dL":0.91,"alt_U_L":82},{"date":"2023-12-31","hemoglobin_g_dL":11.5,"wbc_k_uL":3.4,"platelets_k_uL":247,"creatinine_mg_dL":1.06,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_2935","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":81,"sex":"female","bmi":26.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-66},"pfs_months":13.8},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.7,"censored":false},"longitudinal_labs":[{"date":"2020-06-04","hemoglobin_g_dL":12.2,"wbc_k_uL":10.0,"platelets_k_uL":219,"creatinine_mg_dL":1.05,"alt_U_L":30},{"date":"2021-01-06","hemoglobin_g_dL":11.4,"wbc_k_uL":4.2,"platelets_k_uL":231,"creatinine_mg_dL":1.57,"alt_U_L":108},{"date":"2021-09-15","hemoglobin_g_dL":10.0,"wbc_k_uL":5.3,"platelets_k_uL":258,"creatinine_mg_dL":1.08,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_2936","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":84,"sex":"female","bmi":24.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-31},"pfs_months":26.35},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.8,"censored":false},"longitudinal_labs":[{"date":"2021-06-20","hemoglobin_g_dL":14.4,"wbc_k_uL":5.3,"platelets_k_uL":188,"creatinine_mg_dL":0.93,"alt_U_L":78},{"date":"2022-01-31","hemoglobin_g_dL":12.7,"wbc_k_uL":4.7,"platelets_k_uL":223,"creatinine_mg_dL":1.35,"alt_U_L":53},{"date":"2023-11-11","hemoglobin_g_dL":9.6,"wbc_k_uL":5.4,"platelets_k_uL":135,"creatinine_mg_dL":1.98,"alt_U_L":175}]}
{"patient_id":"ANODE_SYNTH_2025_2937","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":83,"sex":"male","bmi":30.6,"smoking_pack_years":51,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-02-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-59},"pfs_months":36.47},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":56.5,"censored":true},"longitudinal_labs":[{"date":"2023-01-04","hemoglobin_g_dL":13.5,"wbc_k_uL":5.0,"platelets_k_uL":242,"creatinine_mg_dL":0.82,"alt_U_L":10},{"date":"2023-07-31","hemoglobin_g_dL":10.8,"wbc_k_uL":8.2,"platelets_k_uL":184,"creatinine_mg_dL":1.22,"alt_U_L":116},{"date":"2026-03-12","hemoglobin_g_dL":10.8,"wbc_k_uL":5.1,"platelets_k_uL":295,"creatinine_mg_dL":0.89,"alt_U_L":23}]}
{"patient_id":"ANODE_SYNTH_2025_2938","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":56,"sex":"female","bmi":27.5,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-76},"pfs_months":36.3},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-01-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.6,"censored":true},"longitudinal_labs":[{"date":"2025-11-11","hemoglobin_g_dL":13.9,"wbc_k_uL":9.7,"platelets_k_uL":283,"creatinine_mg_dL":0.66,"alt_U_L":37},{"date":"2026-06-22","hemoglobin_g_dL":11.3,"wbc_k_uL":8.5,"platelets_k_uL":196,"creatinine_mg_dL":1.4,"alt_U_L":56},{"date":"2029-01-22","hemoglobin_g_dL":12.3,"wbc_k_uL":5.1,"platelets_k_uL":251,"creatinine_mg_dL":1.43,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_2939","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":55,"sex":"female","bmi":21.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-50},"pfs_months":9.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-03-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":21.0,"censored":false},"longitudinal_labs":[{"date":"2020-04-24","hemoglobin_g_dL":12.0,"wbc_k_uL":6.6,"platelets_k_uL":438,"creatinine_mg_dL":0.66,"alt_U_L":60},{"date":"2020-11-12","hemoglobin_g_dL":12.1,"wbc_k_uL":7.9,"platelets_k_uL":317,"creatinine_mg_dL":1.35,"alt_U_L":64},{"date":"2021-03-01","hemoglobin_g_dL":11.9,"wbc_k_uL":5.5,"platelets_k_uL":197,"creatinine_mg_dL":1.51,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_2940","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":56,"sex":"female","bmi":35.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-12-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-55},"pfs_months":17.54},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.5,"censored":false},"longitudinal_labs":[{"date":"2023-10-23","hemoglobin_g_dL":11.8,"wbc_k_uL":5.2,"platelets_k_uL":365,"creatinine_mg_dL":0.85,"alt_U_L":56},{"date":"2024-06-12","hemoglobin_g_dL":12.9,"wbc_k_uL":8.2,"platelets_k_uL":353,"creatinine_mg_dL":0.7,"alt_U_L":46},{"date":"2025-06-06","hemoglobin_g_dL":11.5,"wbc_k_uL":7.4,"platelets_k_uL":284,"creatinine_mg_dL":1.36,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_2941","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":68,"sex":"female","bmi":22.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-37},"pfs_months":30.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.3,"censored":false},"longitudinal_labs":[{"date":"2023-10-09","hemoglobin_g_dL":11.7,"wbc_k_uL":10.2,"platelets_k_uL":270,"creatinine_mg_dL":1.23,"alt_U_L":43},{"date":"2024-05-23","hemoglobin_g_dL":13.6,"wbc_k_uL":8.3,"platelets_k_uL":245,"creatinine_mg_dL":0.84,"alt_U_L":74},{"date":"2026-06-23","hemoglobin_g_dL":11.5,"wbc_k_uL":5.8,"platelets_k_uL":236,"creatinine_mg_dL":1.25,"alt_U_L":139}]}
{"patient_id":"ANODE_SYNTH_2025_2942","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":58,"sex":"female","bmi":27.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-66},"pfs_months":26.91},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.7,"censored":false},"longitudinal_labs":[{"date":"2020-03-17","hemoglobin_g_dL":13.8,"wbc_k_uL":8.1,"platelets_k_uL":361,"creatinine_mg_dL":1.13,"alt_U_L":43},{"date":"2020-11-11","hemoglobin_g_dL":12.8,"wbc_k_uL":5.0,"platelets_k_uL":250,"creatinine_mg_dL":1.26,"alt_U_L":109},{"date":"2022-08-26","hemoglobin_g_dL":12.0,"wbc_k_uL":6.2,"platelets_k_uL":168,"creatinine_mg_dL":0.89,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_2943","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":56,"sex":"male","bmi":25.3,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-02-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-36},"pfs_months":29.47},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-31","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.5,"censored":true},"longitudinal_labs":[{"date":"2024-12-23","hemoglobin_g_dL":14.4,"wbc_k_uL":9.9,"platelets_k_uL":265,"creatinine_mg_dL":1.09,"alt_U_L":66},{"date":"2025-08-04","hemoglobin_g_dL":12.0,"wbc_k_uL":8.2,"platelets_k_uL":351,"creatinine_mg_dL":0.77,"alt_U_L":39},{"date":"2027-08-31","hemoglobin_g_dL":10.8,"wbc_k_uL":6.6,"platelets_k_uL":104,"creatinine_mg_dL":1.78,"alt_U_L":60}]}
{"patient_id":"ANODE_SYNTH_2025_2944","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":83,"sex":"female","bmi":32.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-45},"pfs_months":25.92},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":false},"longitudinal_labs":[{"date":"2023-09-04","hemoglobin_g_dL":15.3,"wbc_k_uL":9.0,"platelets_k_uL":421,"creatinine_mg_dL":1.14,"alt_U_L":12},{"date":"2024-05-07","hemoglobin_g_dL":10.5,"wbc_k_uL":4.0,"platelets_k_uL":309,"creatinine_mg_dL":0.83,"alt_U_L":47},{"date":"2026-01-31","hemoglobin_g_dL":12.3,"wbc_k_uL":3.5,"platelets_k_uL":291,"creatinine_mg_dL":1.98,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_2945","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":56,"sex":"female","bmi":21.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-41},"pfs_months":25.56},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":37.1,"censored":true},"longitudinal_labs":[{"date":"2025-01-18","hemoglobin_g_dL":15.3,"wbc_k_uL":4.8,"platelets_k_uL":153,"creatinine_mg_dL":1.13,"alt_U_L":21},{"date":"2025-08-31","hemoglobin_g_dL":12.9,"wbc_k_uL":5.4,"platelets_k_uL":223,"creatinine_mg_dL":0.75,"alt_U_L":38},{"date":"2027-05-11","hemoglobin_g_dL":10.7,"wbc_k_uL":6.5,"platelets_k_uL":284,"creatinine_mg_dL":1.86,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_2946","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":63,"sex":"female","bmi":32.7,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-08-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-42},"pfs_months":47.51},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":76.6,"censored":true},"longitudinal_labs":[{"date":"2023-06-28","hemoglobin_g_dL":12.3,"wbc_k_uL":8.9,"platelets_k_uL":206,"creatinine_mg_dL":1.15,"alt_U_L":25},{"date":"2024-02-02","hemoglobin_g_dL":13.9,"wbc_k_uL":9.0,"platelets_k_uL":209,"creatinine_mg_dL":0.87,"alt_U_L":104},{"date":"2027-08-18","hemoglobin_g_dL":12.9,"wbc_k_uL":3.1,"platelets_k_uL":208,"creatinine_mg_dL":1.19,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_2947","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":85,"sex":"female","bmi":19.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-60},"pfs_months":23.1},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.3,"censored":true},"longitudinal_labs":[{"date":"2020-11-06","hemoglobin_g_dL":14.5,"wbc_k_uL":4.8,"platelets_k_uL":363,"creatinine_mg_dL":1.18,"alt_U_L":69},{"date":"2021-06-21","hemoglobin_g_dL":10.6,"wbc_k_uL":7.2,"platelets_k_uL":321,"creatinine_mg_dL":1.46,"alt_U_L":44},{"date":"2022-12-25","hemoglobin_g_dL":10.4,"wbc_k_uL":5.6,"platelets_k_uL":125,"creatinine_mg_dL":1.75,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_2948","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":49,"sex":"female","bmi":25.1,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-10-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-65},"pfs_months":35.61},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.2,"censored":true},"longitudinal_labs":[{"date":"2023-08-09","hemoglobin_g_dL":15.1,"wbc_k_uL":10.4,"platelets_k_uL":405,"creatinine_mg_dL":0.74,"alt_U_L":39},{"date":"2024-04-15","hemoglobin_g_dL":11.8,"wbc_k_uL":8.6,"platelets_k_uL":299,"creatinine_mg_dL":0.71,"alt_U_L":119},{"date":"2026-11-13","hemoglobin_g_dL":12.6,"wbc_k_uL":7.6,"platelets_k_uL":231,"creatinine_mg_dL":1.75,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_2949","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":69,"sex":"male","bmi":22.2,"smoking_pack_years":50,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-02-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-74},"pfs_months":13.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.8,"censored":true},"longitudinal_labs":[{"date":"2024-01-17","hemoglobin_g_dL":14.9,"wbc_k_uL":9.9,"platelets_k_uL":433,"creatinine_mg_dL":0.82,"alt_U_L":62},{"date":"2024-08-12","hemoglobin_g_dL":10.6,"wbc_k_uL":5.8,"platelets_k_uL":229,"creatinine_mg_dL":1.5,"alt_U_L":85},{"date":"2025-05-18","hemoglobin_g_dL":11.5,"wbc_k_uL":7.7,"platelets_k_uL":120,"creatinine_mg_dL":1.31,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_2950","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":72,"sex":"male","bmi":22.3,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-12-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-42},"pfs_months":41.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":69.4,"censored":false},"longitudinal_labs":[{"date":"2021-11-16","hemoglobin_g_dL":14.3,"wbc_k_uL":9.9,"platelets_k_uL":284,"creatinine_mg_dL":0.92,"alt_U_L":39},{"date":"2022-06-15","hemoglobin_g_dL":12.1,"wbc_k_uL":7.5,"platelets_k_uL":153,"creatinine_mg_dL":1.42,"alt_U_L":32},{"date":"2025-07-09","hemoglobin_g_dL":9.8,"wbc_k_uL":3.4,"platelets_k_uL":193,"creatinine_mg_dL":1.27,"alt_U_L":40}]}
{"patient_id":"ANODE_SYNTH_2025_2951","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":65,"sex":"male","bmi":26.6,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-12-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-54},"pfs_months":16.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.6,"censored":false},"longitudinal_labs":[{"date":"2021-10-19","hemoglobin_g_dL":14.4,"wbc_k_uL":9.3,"platelets_k_uL":230,"creatinine_mg_dL":0.6,"alt_U_L":74},{"date":"2022-06-19","hemoglobin_g_dL":10.4,"wbc_k_uL":8.7,"platelets_k_uL":127,"creatinine_mg_dL":1.32,"alt_U_L":106},{"date":"2023-05-19","hemoglobin_g_dL":10.4,"wbc_k_uL":6.9,"platelets_k_uL":143,"creatinine_mg_dL":1.14,"alt_U_L":133}]}
{"patient_id":"ANODE_SYNTH_2025_2952","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.9,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":78,"sex":"female","bmi":18.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-02-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-39},"pfs_months":9.1},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.2,"censored":false},"longitudinal_labs":[{"date":"2025-12-04","hemoglobin_g_dL":15.1,"wbc_k_uL":8.6,"platelets_k_uL":292,"creatinine_mg_dL":0.81,"alt_U_L":56},{"date":"2026-08-10","hemoglobin_g_dL":13.5,"wbc_k_uL":5.0,"platelets_k_uL":235,"creatinine_mg_dL":0.86,"alt_U_L":111},{"date":"2027-01-12","hemoglobin_g_dL":9.8,"wbc_k_uL":3.3,"platelets_k_uL":238,"creatinine_mg_dL":1.38,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_2953","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":66,"sex":"female","bmi":22.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-49},"pfs_months":22.83},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.5,"censored":false},"longitudinal_labs":[{"date":"2025-04-07","hemoglobin_g_dL":12.9,"wbc_k_uL":8.8,"platelets_k_uL":393,"creatinine_mg_dL":0.85,"alt_U_L":12},{"date":"2025-11-09","hemoglobin_g_dL":10.3,"wbc_k_uL":5.7,"platelets_k_uL":364,"creatinine_mg_dL":1.58,"alt_U_L":99},{"date":"2027-05-07","hemoglobin_g_dL":12.8,"wbc_k_uL":7.4,"platelets_k_uL":151,"creatinine_mg_dL":1.71,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_2954","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":58,"sex":"female","bmi":21.1,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-05-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-41},"pfs_months":18.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":false},"longitudinal_labs":[{"date":"2025-04-16","hemoglobin_g_dL":12.8,"wbc_k_uL":4.6,"platelets_k_uL":298,"creatinine_mg_dL":1.19,"alt_U_L":12},{"date":"2025-11-10","hemoglobin_g_dL":10.2,"wbc_k_uL":5.0,"platelets_k_uL":348,"creatinine_mg_dL":1.17,"alt_U_L":110},{"date":"2027-01-26","hemoglobin_g_dL":10.4,"wbc_k_uL":4.4,"platelets_k_uL":206,"creatinine_mg_dL":1.07,"alt_U_L":181}]}
{"patient_id":"ANODE_SYNTH_2025_2955","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":61,"sex":"female","bmi":24.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-37},"pfs_months":12.35},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.8,"censored":true},"longitudinal_labs":[{"date":"2020-12-12","hemoglobin_g_dL":12.0,"wbc_k_uL":10.0,"platelets_k_uL":410,"creatinine_mg_dL":0.99,"alt_U_L":14},{"date":"2021-08-10","hemoglobin_g_dL":10.1,"wbc_k_uL":4.0,"platelets_k_uL":279,"creatinine_mg_dL":1.48,"alt_U_L":16},{"date":"2022-03-05","hemoglobin_g_dL":12.1,"wbc_k_uL":3.0,"platelets_k_uL":229,"creatinine_mg_dL":0.82,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_2956","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":49,"sex":"female","bmi":23.5,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-06-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-62},"pfs_months":18.76},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":true},"longitudinal_labs":[{"date":"2024-05-15","hemoglobin_g_dL":14.2,"wbc_k_uL":8.8,"platelets_k_uL":318,"creatinine_mg_dL":1.23,"alt_U_L":12},{"date":"2024-12-25","hemoglobin_g_dL":10.8,"wbc_k_uL":6.7,"platelets_k_uL":332,"creatinine_mg_dL":1.2,"alt_U_L":105},{"date":"2026-02-23","hemoglobin_g_dL":9.7,"wbc_k_uL":4.6,"platelets_k_uL":161,"creatinine_mg_dL":1.1,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_2957","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":85,"sex":"female","bmi":20.7,"smoking_pack_years":48,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-41},"pfs_months":23.72},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-03","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.6,"censored":true},"longitudinal_labs":[{"date":"2023-12-04","hemoglobin_g_dL":13.4,"wbc_k_uL":5.6,"platelets_k_uL":194,"creatinine_mg_dL":0.83,"alt_U_L":61},{"date":"2024-06-22","hemoglobin_g_dL":11.9,"wbc_k_uL":5.8,"platelets_k_uL":186,"creatinine_mg_dL":0.7,"alt_U_L":88},{"date":"2026-02-03","hemoglobin_g_dL":11.5,"wbc_k_uL":7.5,"platelets_k_uL":107,"creatinine_mg_dL":1.21,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_2958","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":80,"sex":"male","bmi":28.6,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-45},"pfs_months":38.93},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.3,"censored":false},"longitudinal_labs":[{"date":"2024-03-14","hemoglobin_g_dL":15.2,"wbc_k_uL":7.7,"platelets_k_uL":324,"creatinine_mg_dL":1.2,"alt_U_L":66},{"date":"2024-09-25","hemoglobin_g_dL":13.9,"wbc_k_uL":5.0,"platelets_k_uL":268,"creatinine_mg_dL":1.19,"alt_U_L":69},{"date":"2027-08-14","hemoglobin_g_dL":10.5,"wbc_k_uL":7.9,"platelets_k_uL":196,"creatinine_mg_dL":1.84,"alt_U_L":144}]}
{"patient_id":"ANODE_SYNTH_2025_2959","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":76,"sex":"female","bmi":33.0,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-03-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-82},"pfs_months":45.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":60.2,"censored":false},"longitudinal_labs":[{"date":"2020-02-06","hemoglobin_g_dL":14.8,"wbc_k_uL":10.7,"platelets_k_uL":284,"creatinine_mg_dL":0.88,"alt_U_L":24},{"date":"2020-09-15","hemoglobin_g_dL":11.7,"wbc_k_uL":7.4,"platelets_k_uL":156,"creatinine_mg_dL":0.9,"alt_U_L":67},{"date":"2024-01-23","hemoglobin_g_dL":11.2,"wbc_k_uL":5.1,"platelets_k_uL":132,"creatinine_mg_dL":1.42,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_2960","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":67,"sex":"female","bmi":21.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-52},"pfs_months":19.32},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.6,"censored":true},"longitudinal_labs":[{"date":"2020-07-13","hemoglobin_g_dL":15.5,"wbc_k_uL":7.8,"platelets_k_uL":373,"creatinine_mg_dL":0.74,"alt_U_L":31},{"date":"2021-03-12","hemoglobin_g_dL":10.7,"wbc_k_uL":7.2,"platelets_k_uL":135,"creatinine_mg_dL":1.16,"alt_U_L":32},{"date":"2022-05-26","hemoglobin_g_dL":11.0,"wbc_k_uL":6.0,"platelets_k_uL":165,"creatinine_mg_dL":1.88,"alt_U_L":193}]}
{"patient_id":"ANODE_SYNTH_2025_2961","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":64,"sex":"female","bmi":25.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-52},"pfs_months":16.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":37.5,"censored":false},"longitudinal_labs":[{"date":"2022-07-03","hemoglobin_g_dL":12.0,"wbc_k_uL":8.7,"platelets_k_uL":364,"creatinine_mg_dL":0.63,"alt_U_L":53},{"date":"2023-02-05","hemoglobin_g_dL":12.7,"wbc_k_uL":8.0,"platelets_k_uL":188,"creatinine_mg_dL":0.99,"alt_U_L":39},{"date":"2023-12-31","hemoglobin_g_dL":12.8,"wbc_k_uL":7.3,"platelets_k_uL":321,"creatinine_mg_dL":0.83,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_2962","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":67,"sex":"female","bmi":34.7,"smoking_pack_years":64,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-01-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-72},"pfs_months":18.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.2,"censored":true},"longitudinal_labs":[{"date":"2025-12-25","hemoglobin_g_dL":12.8,"wbc_k_uL":10.4,"platelets_k_uL":176,"creatinine_mg_dL":1.13,"alt_U_L":34},{"date":"2026-07-20","hemoglobin_g_dL":13.0,"wbc_k_uL":8.3,"platelets_k_uL":226,"creatinine_mg_dL":1.25,"alt_U_L":65},{"date":"2027-10-10","hemoglobin_g_dL":10.2,"wbc_k_uL":6.9,"platelets_k_uL":313,"creatinine_mg_dL":1.65,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_2963","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.8,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":71,"sex":"male","bmi":23.6,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-01-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-67},"pfs_months":18.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.9,"censored":false},"longitudinal_labs":[{"date":"2024-11-02","hemoglobin_g_dL":15.4,"wbc_k_uL":5.8,"platelets_k_uL":436,"creatinine_mg_dL":0.82,"alt_U_L":49},{"date":"2025-07-05","hemoglobin_g_dL":10.9,"wbc_k_uL":8.5,"platelets_k_uL":143,"creatinine_mg_dL":0.86,"alt_U_L":62},{"date":"2026-09-15","hemoglobin_g_dL":10.3,"wbc_k_uL":7.5,"platelets_k_uL":269,"creatinine_mg_dL":1.24,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_2964","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":62,"sex":"female","bmi":19.0,"smoking_pack_years":19,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-07","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-45},"pfs_months":9.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":21.5,"censored":false},"longitudinal_labs":[{"date":"2021-07-24","hemoglobin_g_dL":11.9,"wbc_k_uL":10.2,"platelets_k_uL":426,"creatinine_mg_dL":1.07,"alt_U_L":34},{"date":"2022-03-06","hemoglobin_g_dL":10.4,"wbc_k_uL":7.8,"platelets_k_uL":345,"creatinine_mg_dL":1.4,"alt_U_L":88},{"date":"2022-07-15","hemoglobin_g_dL":12.2,"wbc_k_uL":4.4,"platelets_k_uL":107,"creatinine_mg_dL":1.35,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_2965","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":72,"sex":"female","bmi":32.2,"smoking_pack_years":58,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-03-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-67},"pfs_months":9.69},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.1,"censored":false},"longitudinal_labs":[{"date":"2024-01-17","hemoglobin_g_dL":12.8,"wbc_k_uL":9.0,"platelets_k_uL":379,"creatinine_mg_dL":0.93,"alt_U_L":56},{"date":"2024-09-20","hemoglobin_g_dL":13.5,"wbc_k_uL":7.1,"platelets_k_uL":371,"creatinine_mg_dL":1.22,"alt_U_L":112},{"date":"2025-02-21","hemoglobin_g_dL":10.5,"wbc_k_uL":7.3,"platelets_k_uL":227,"creatinine_mg_dL":1.89,"alt_U_L":179}]}
{"patient_id":"ANODE_SYNTH_2025_2966","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":86,"sex":"female","bmi":36.4,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-04-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-66},"pfs_months":4.04},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":17.6,"censored":false},"longitudinal_labs":[{"date":"2023-03-09","hemoglobin_g_dL":11.8,"wbc_k_uL":5.0,"platelets_k_uL":373,"creatinine_mg_dL":1.28,"alt_U_L":11},{"date":"2023-10-21","hemoglobin_g_dL":13.9,"wbc_k_uL":6.7,"platelets_k_uL":318,"creatinine_mg_dL":0.82,"alt_U_L":82},{"date":"2023-08-30","hemoglobin_g_dL":9.8,"wbc_k_uL":7.2,"platelets_k_uL":334,"creatinine_mg_dL":1.87,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_2967","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":51,"sex":"female","bmi":23.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-67},"pfs_months":22.11},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.6,"censored":true},"longitudinal_labs":[{"date":"2022-03-05","hemoglobin_g_dL":13.5,"wbc_k_uL":5.5,"platelets_k_uL":376,"creatinine_mg_dL":0.79,"alt_U_L":71},{"date":"2022-09-15","hemoglobin_g_dL":12.0,"wbc_k_uL":3.9,"platelets_k_uL":232,"creatinine_mg_dL":1.32,"alt_U_L":35},{"date":"2024-02-08","hemoglobin_g_dL":12.0,"wbc_k_uL":3.4,"platelets_k_uL":236,"creatinine_mg_dL":1.1,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_2968","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":78,"sex":"female","bmi":33.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-37},"pfs_months":31.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":false},"longitudinal_labs":[{"date":"2023-09-09","hemoglobin_g_dL":12.2,"wbc_k_uL":5.4,"platelets_k_uL":441,"creatinine_mg_dL":1.23,"alt_U_L":51},{"date":"2024-05-15","hemoglobin_g_dL":10.7,"wbc_k_uL":9.0,"platelets_k_uL":153,"creatinine_mg_dL":1.59,"alt_U_L":76},{"date":"2026-07-19","hemoglobin_g_dL":12.9,"wbc_k_uL":7.6,"platelets_k_uL":233,"creatinine_mg_dL":1.52,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_2969","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":88,"sex":"female","bmi":20.5,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-01-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-56},"pfs_months":16.26},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.5,"censored":true},"longitudinal_labs":[{"date":"2021-12-12","hemoglobin_g_dL":11.8,"wbc_k_uL":10.8,"platelets_k_uL":296,"creatinine_mg_dL":1.03,"alt_U_L":19},{"date":"2022-07-28","hemoglobin_g_dL":11.1,"wbc_k_uL":4.5,"platelets_k_uL":237,"creatinine_mg_dL":1.28,"alt_U_L":107},{"date":"2023-06-26","hemoglobin_g_dL":11.2,"wbc_k_uL":7.1,"platelets_k_uL":102,"creatinine_mg_dL":0.97,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_2970","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":53,"sex":"female","bmi":31.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-31},"pfs_months":15.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":28.6,"censored":false},"longitudinal_labs":[{"date":"2021-02-17","hemoglobin_g_dL":12.6,"wbc_k_uL":10.7,"platelets_k_uL":166,"creatinine_mg_dL":0.81,"alt_U_L":74},{"date":"2021-10-19","hemoglobin_g_dL":10.5,"wbc_k_uL":6.9,"platelets_k_uL":122,"creatinine_mg_dL":1.48,"alt_U_L":51},{"date":"2022-09-19","hemoglobin_g_dL":11.9,"wbc_k_uL":4.9,"platelets_k_uL":120,"creatinine_mg_dL":1.55,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_2971","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":72,"sex":"female","bmi":25.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-45},"pfs_months":22.93},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":38.4,"censored":true},"longitudinal_labs":[{"date":"2022-02-16","hemoglobin_g_dL":11.6,"wbc_k_uL":7.6,"platelets_k_uL":251,"creatinine_mg_dL":1.24,"alt_U_L":19},{"date":"2022-09-04","hemoglobin_g_dL":10.1,"wbc_k_uL":4.1,"platelets_k_uL":174,"creatinine_mg_dL":1.47,"alt_U_L":93},{"date":"2024-03-01","hemoglobin_g_dL":11.4,"wbc_k_uL":5.9,"platelets_k_uL":350,"creatinine_mg_dL":1.61,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_2972","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":78,"sex":"female","bmi":23.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-78},"pfs_months":15.47},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":24.4,"censored":true},"longitudinal_labs":[{"date":"2024-08-17","hemoglobin_g_dL":12.0,"wbc_k_uL":5.9,"platelets_k_uL":448,"creatinine_mg_dL":0.96,"alt_U_L":41},{"date":"2025-03-29","hemoglobin_g_dL":10.0,"wbc_k_uL":5.1,"platelets_k_uL":363,"creatinine_mg_dL":1.48,"alt_U_L":70},{"date":"2026-02-18","hemoglobin_g_dL":12.1,"wbc_k_uL":3.6,"platelets_k_uL":130,"creatinine_mg_dL":1.36,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_2973","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":73,"sex":"male","bmi":33.1,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-09-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-70},"pfs_months":20.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.3,"censored":false},"longitudinal_labs":[{"date":"2022-08-19","hemoglobin_g_dL":15.5,"wbc_k_uL":10.2,"platelets_k_uL":405,"creatinine_mg_dL":0.67,"alt_U_L":49},{"date":"2023-03-27","hemoglobin_g_dL":13.5,"wbc_k_uL":7.2,"platelets_k_uL":298,"creatinine_mg_dL":1.5,"alt_U_L":63},{"date":"2024-07-26","hemoglobin_g_dL":10.1,"wbc_k_uL":3.3,"platelets_k_uL":299,"creatinine_mg_dL":1.69,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_2974","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":62,"sex":"male","bmi":23.0,"smoking_pack_years":38,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["brain","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-04-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-43},"pfs_months":11.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.4,"censored":false},"longitudinal_labs":[{"date":"2025-02-20","hemoglobin_g_dL":12.2,"wbc_k_uL":10.6,"platelets_k_uL":374,"creatinine_mg_dL":0.93,"alt_U_L":60},{"date":"2025-10-03","hemoglobin_g_dL":11.7,"wbc_k_uL":5.7,"platelets_k_uL":155,"creatinine_mg_dL":0.74,"alt_U_L":108},{"date":"2026-03-29","hemoglobin_g_dL":12.2,"wbc_k_uL":7.5,"platelets_k_uL":305,"creatinine_mg_dL":1.62,"alt_U_L":29}]}
{"patient_id":"ANODE_SYNTH_2025_2975","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":57,"sex":"female","bmi":37.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-63},"pfs_months":28.52},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.5,"censored":false},"longitudinal_labs":[{"date":"2020-05-05","hemoglobin_g_dL":14.5,"wbc_k_uL":9.5,"platelets_k_uL":393,"creatinine_mg_dL":0.85,"alt_U_L":46},{"date":"2020-11-26","hemoglobin_g_dL":13.0,"wbc_k_uL":3.9,"platelets_k_uL":262,"creatinine_mg_dL":0.93,"alt_U_L":33},{"date":"2022-10-27","hemoglobin_g_dL":10.9,"wbc_k_uL":3.2,"platelets_k_uL":164,"creatinine_mg_dL":1.52,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_2976","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.4,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":87,"sex":"female","bmi":22.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-64},"pfs_months":30.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.5,"censored":false},"longitudinal_labs":[{"date":"2024-02-27","hemoglobin_g_dL":11.9,"wbc_k_uL":6.4,"platelets_k_uL":305,"creatinine_mg_dL":0.91,"alt_U_L":70},{"date":"2024-10-17","hemoglobin_g_dL":11.8,"wbc_k_uL":8.7,"platelets_k_uL":295,"creatinine_mg_dL":0.8,"alt_U_L":103},{"date":"2026-12-02","hemoglobin_g_dL":12.4,"wbc_k_uL":5.1,"platelets_k_uL":198,"creatinine_mg_dL":1.65,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_2977","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":88,"sex":"female","bmi":20.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-70},"pfs_months":23.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.1,"censored":false},"longitudinal_labs":[{"date":"2022-10-06","hemoglobin_g_dL":11.7,"wbc_k_uL":6.7,"platelets_k_uL":263,"creatinine_mg_dL":0.86,"alt_U_L":33},{"date":"2023-05-21","hemoglobin_g_dL":13.1,"wbc_k_uL":7.5,"platelets_k_uL":195,"creatinine_mg_dL":1.14,"alt_U_L":23},{"date":"2024-12-27","hemoglobin_g_dL":11.7,"wbc_k_uL":6.0,"platelets_k_uL":148,"creatinine_mg_dL":1.23,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_2978","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.9,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":59,"sex":"female","bmi":30.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-36},"pfs_months":23.23},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.1,"censored":false},"longitudinal_labs":[{"date":"2023-04-09","hemoglobin_g_dL":13.9,"wbc_k_uL":5.5,"platelets_k_uL":158,"creatinine_mg_dL":0.78,"alt_U_L":42},{"date":"2023-10-22","hemoglobin_g_dL":10.3,"wbc_k_uL":8.1,"platelets_k_uL":310,"creatinine_mg_dL":1.29,"alt_U_L":103},{"date":"2025-04-18","hemoglobin_g_dL":11.2,"wbc_k_uL":6.9,"platelets_k_uL":342,"creatinine_mg_dL":1.41,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_2979","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":80,"sex":"female","bmi":19.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-63},"pfs_months":34.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":49.1,"censored":false},"longitudinal_labs":[{"date":"2022-09-09","hemoglobin_g_dL":13.3,"wbc_k_uL":9.9,"platelets_k_uL":251,"creatinine_mg_dL":0.82,"alt_U_L":54},{"date":"2023-05-15","hemoglobin_g_dL":13.0,"wbc_k_uL":4.1,"platelets_k_uL":157,"creatinine_mg_dL":1.3,"alt_U_L":20},{"date":"2025-11-19","hemoglobin_g_dL":10.6,"wbc_k_uL":7.7,"platelets_k_uL":205,"creatinine_mg_dL":1.54,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_2980","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":70,"sex":"female","bmi":29.1,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2020-06-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-77},"pfs_months":19.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-17","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.6,"censored":false},"longitudinal_labs":[{"date":"2020-04-25","hemoglobin_g_dL":12.3,"wbc_k_uL":4.7,"platelets_k_uL":184,"creatinine_mg_dL":0.7,"alt_U_L":20},{"date":"2020-12-16","hemoglobin_g_dL":13.6,"wbc_k_uL":8.3,"platelets_k_uL":244,"creatinine_mg_dL":0.73,"alt_U_L":107},{"date":"2022-03-17","hemoglobin_g_dL":12.6,"wbc_k_uL":7.1,"platelets_k_uL":155,"creatinine_mg_dL":1.05,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_2981","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":72,"sex":"female","bmi":27.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-03-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-40},"pfs_months":22.97},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.0,"censored":true},"longitudinal_labs":[{"date":"2020-02-01","hemoglobin_g_dL":13.3,"wbc_k_uL":8.1,"platelets_k_uL":339,"creatinine_mg_dL":0.98,"alt_U_L":49},{"date":"2020-09-23","hemoglobin_g_dL":10.1,"wbc_k_uL":5.1,"platelets_k_uL":267,"creatinine_mg_dL":1.52,"alt_U_L":100},{"date":"2022-03-01","hemoglobin_g_dL":10.4,"wbc_k_uL":3.7,"platelets_k_uL":170,"creatinine_mg_dL":0.94,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_2982","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":81,"sex":"female","bmi":27.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-38},"pfs_months":21.36},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.4,"censored":true},"longitudinal_labs":[{"date":"2020-09-26","hemoglobin_g_dL":12.6,"wbc_k_uL":10.1,"platelets_k_uL":196,"creatinine_mg_dL":0.94,"alt_U_L":71},{"date":"2021-04-19","hemoglobin_g_dL":11.5,"wbc_k_uL":4.4,"platelets_k_uL":140,"creatinine_mg_dL":1.06,"alt_U_L":112},{"date":"2022-08-08","hemoglobin_g_dL":12.5,"wbc_k_uL":7.2,"platelets_k_uL":235,"creatinine_mg_dL":1.83,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_2983","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":82,"sex":"male","bmi":23.4,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-11-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-56},"pfs_months":21.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.0,"censored":false},"longitudinal_labs":[{"date":"2023-09-18","hemoglobin_g_dL":13.5,"wbc_k_uL":8.9,"platelets_k_uL":257,"creatinine_mg_dL":0.98,"alt_U_L":11},{"date":"2024-05-13","hemoglobin_g_dL":11.1,"wbc_k_uL":8.9,"platelets_k_uL":271,"creatinine_mg_dL":1.02,"alt_U_L":31},{"date":"2025-10-21","hemoglobin_g_dL":12.5,"wbc_k_uL":7.0,"platelets_k_uL":112,"creatinine_mg_dL":1.51,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_2984","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":53,"sex":"male","bmi":37.4,"smoking_pack_years":52,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-67},"pfs_months":22.83},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.9,"censored":true},"longitudinal_labs":[{"date":"2024-08-09","hemoglobin_g_dL":11.7,"wbc_k_uL":11.0,"platelets_k_uL":268,"creatinine_mg_dL":0.96,"alt_U_L":28},{"date":"2025-03-03","hemoglobin_g_dL":12.8,"wbc_k_uL":7.0,"platelets_k_uL":327,"creatinine_mg_dL":1.29,"alt_U_L":69},{"date":"2026-08-06","hemoglobin_g_dL":11.2,"wbc_k_uL":4.4,"platelets_k_uL":239,"creatinine_mg_dL":1.31,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_2985","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":78,"sex":"male","bmi":38.0,"smoking_pack_years":55,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-03-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-78},"pfs_months":24.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.8,"censored":false},"longitudinal_labs":[{"date":"2022-02-04","hemoglobin_g_dL":12.5,"wbc_k_uL":6.2,"platelets_k_uL":385,"creatinine_mg_dL":0.79,"alt_U_L":53},{"date":"2022-09-20","hemoglobin_g_dL":12.0,"wbc_k_uL":4.8,"platelets_k_uL":174,"creatinine_mg_dL":0.95,"alt_U_L":53},{"date":"2024-05-22","hemoglobin_g_dL":10.3,"wbc_k_uL":4.8,"platelets_k_uL":144,"creatinine_mg_dL":1.22,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_2986","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":68,"sex":"female","bmi":31.9,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-52},"pfs_months":13.6},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.1,"censored":false},"longitudinal_labs":[{"date":"2025-05-11","hemoglobin_g_dL":13.3,"wbc_k_uL":6.3,"platelets_k_uL":377,"creatinine_mg_dL":1.06,"alt_U_L":77},{"date":"2026-01-13","hemoglobin_g_dL":12.7,"wbc_k_uL":6.2,"platelets_k_uL":178,"creatinine_mg_dL":1.13,"alt_U_L":111},{"date":"2026-09-24","hemoglobin_g_dL":11.1,"wbc_k_uL":3.2,"platelets_k_uL":188,"creatinine_mg_dL":1.07,"alt_U_L":71}]}
{"patient_id":"ANODE_SYNTH_2025_2987","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":70,"sex":"female","bmi":27.3,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-06-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-82},"pfs_months":16.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":false},"longitudinal_labs":[{"date":"2021-04-17","hemoglobin_g_dL":15.0,"wbc_k_uL":4.8,"platelets_k_uL":167,"creatinine_mg_dL":0.62,"alt_U_L":37},{"date":"2021-12-04","hemoglobin_g_dL":10.0,"wbc_k_uL":7.5,"platelets_k_uL":291,"creatinine_mg_dL":1.28,"alt_U_L":78},{"date":"2022-11-19","hemoglobin_g_dL":9.8,"wbc_k_uL":6.6,"platelets_k_uL":232,"creatinine_mg_dL":1.39,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_2988","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":59,"sex":"male","bmi":28.3,"smoking_pack_years":72,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-10-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-75},"pfs_months":45.37},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-08-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":67.5,"censored":false},"longitudinal_labs":[{"date":"2025-09-26","hemoglobin_g_dL":13.2,"wbc_k_uL":10.2,"platelets_k_uL":230,"creatinine_mg_dL":1.24,"alt_U_L":10},{"date":"2026-04-17","hemoglobin_g_dL":13.8,"wbc_k_uL":8.0,"platelets_k_uL":172,"creatinine_mg_dL":1.24,"alt_U_L":87},{"date":"2029-08-25","hemoglobin_g_dL":9.6,"wbc_k_uL":7.9,"platelets_k_uL":346,"creatinine_mg_dL":1.2,"alt_U_L":95}]}
{"patient_id":"ANODE_SYNTH_2025_2989","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":87,"sex":"female","bmi":28.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-76},"pfs_months":17.35},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.9,"censored":true},"longitudinal_labs":[{"date":"2020-05-19","hemoglobin_g_dL":13.2,"wbc_k_uL":4.9,"platelets_k_uL":267,"creatinine_mg_dL":0.97,"alt_U_L":68},{"date":"2021-01-18","hemoglobin_g_dL":13.9,"wbc_k_uL":7.8,"platelets_k_uL":147,"creatinine_mg_dL":0.74,"alt_U_L":51},{"date":"2022-03-01","hemoglobin_g_dL":10.9,"wbc_k_uL":7.7,"platelets_k_uL":323,"creatinine_mg_dL":0.99,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_2990","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":51,"sex":"female","bmi":27.3,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-02-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-69},"pfs_months":29.93},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.0,"censored":true},"longitudinal_labs":[{"date":"2024-12-20","hemoglobin_g_dL":15.1,"wbc_k_uL":8.2,"platelets_k_uL":430,"creatinine_mg_dL":0.82,"alt_U_L":12},{"date":"2025-08-07","hemoglobin_g_dL":13.8,"wbc_k_uL":6.8,"platelets_k_uL":154,"creatinine_mg_dL":1.23,"alt_U_L":83},{"date":"2027-08-31","hemoglobin_g_dL":12.0,"wbc_k_uL":4.1,"platelets_k_uL":201,"creatinine_mg_dL":0.9,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_2991","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":55,"sex":"female","bmi":33.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-67},"pfs_months":26.09},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.3,"censored":false},"longitudinal_labs":[{"date":"2022-03-25","hemoglobin_g_dL":15.2,"wbc_k_uL":6.6,"platelets_k_uL":249,"creatinine_mg_dL":1.11,"alt_U_L":17},{"date":"2022-11-28","hemoglobin_g_dL":13.5,"wbc_k_uL":5.1,"platelets_k_uL":198,"creatinine_mg_dL":0.87,"alt_U_L":111},{"date":"2024-09-08","hemoglobin_g_dL":11.4,"wbc_k_uL":3.7,"platelets_k_uL":110,"creatinine_mg_dL":1.77,"alt_U_L":195}]}
{"patient_id":"ANODE_SYNTH_2025_2992","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":87,"sex":"female","bmi":37.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-61},"pfs_months":32.95},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":48.3,"censored":false},"longitudinal_labs":[{"date":"2024-03-25","hemoglobin_g_dL":11.9,"wbc_k_uL":5.2,"platelets_k_uL":301,"creatinine_mg_dL":0.62,"alt_U_L":76},{"date":"2024-11-26","hemoglobin_g_dL":13.8,"wbc_k_uL":8.8,"platelets_k_uL":197,"creatinine_mg_dL":1.26,"alt_U_L":62},{"date":"2027-04-17","hemoglobin_g_dL":9.5,"wbc_k_uL":7.4,"platelets_k_uL":130,"creatinine_mg_dL":0.88,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_2993","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":49,"sex":"female","bmi":32.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-51},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.6,"censored":false},"longitudinal_labs":[{"date":"2021-03-12","hemoglobin_g_dL":13.4,"wbc_k_uL":5.8,"platelets_k_uL":280,"creatinine_mg_dL":0.97,"alt_U_L":25},{"date":"2021-10-16","hemoglobin_g_dL":10.7,"wbc_k_uL":7.4,"platelets_k_uL":146,"creatinine_mg_dL":1.42,"alt_U_L":32},{"date":"2023-02-20","hemoglobin_g_dL":12.1,"wbc_k_uL":7.0,"platelets_k_uL":135,"creatinine_mg_dL":0.91,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_2994","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":84,"sex":"female","bmi":28.1,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-06-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-32},"pfs_months":25.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.1,"censored":false},"longitudinal_labs":[{"date":"2021-05-28","hemoglobin_g_dL":13.5,"wbc_k_uL":4.6,"platelets_k_uL":446,"creatinine_mg_dL":1.1,"alt_U_L":65},{"date":"2021-12-14","hemoglobin_g_dL":11.3,"wbc_k_uL":6.6,"platelets_k_uL":332,"creatinine_mg_dL":1.36,"alt_U_L":81},{"date":"2023-09-16","hemoglobin_g_dL":10.7,"wbc_k_uL":5.4,"platelets_k_uL":319,"creatinine_mg_dL":1.64,"alt_U_L":170}]}
{"patient_id":"ANODE_SYNTH_2025_2995","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":59,"sex":"female","bmi":19.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-33},"pfs_months":18.79},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":false},"longitudinal_labs":[{"date":"2020-11-20","hemoglobin_g_dL":11.8,"wbc_k_uL":10.9,"platelets_k_uL":417,"creatinine_mg_dL":0.84,"alt_U_L":36},{"date":"2021-06-08","hemoglobin_g_dL":12.1,"wbc_k_uL":8.1,"platelets_k_uL":201,"creatinine_mg_dL":1.51,"alt_U_L":115},{"date":"2022-08-23","hemoglobin_g_dL":12.8,"wbc_k_uL":7.5,"platelets_k_uL":254,"creatinine_mg_dL":1.44,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_2996","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.6,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":49,"sex":"female","bmi":26.9,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-04-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-49},"pfs_months":10.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":true},"longitudinal_labs":[{"date":"2024-03-06","hemoglobin_g_dL":13.3,"wbc_k_uL":10.0,"platelets_k_uL":219,"creatinine_mg_dL":1.09,"alt_U_L":63},{"date":"2024-10-21","hemoglobin_g_dL":11.8,"wbc_k_uL":7.7,"platelets_k_uL":188,"creatinine_mg_dL":1.07,"alt_U_L":26},{"date":"2025-04-18","hemoglobin_g_dL":9.5,"wbc_k_uL":3.2,"platelets_k_uL":268,"creatinine_mg_dL":0.92,"alt_U_L":80}]}
{"patient_id":"ANODE_SYNTH_2025_2997","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":70,"sex":"female","bmi":28.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-78},"pfs_months":14.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.2,"censored":false},"longitudinal_labs":[{"date":"2024-08-23","hemoglobin_g_dL":12.6,"wbc_k_uL":6.1,"platelets_k_uL":419,"creatinine_mg_dL":0.81,"alt_U_L":37},{"date":"2025-04-09","hemoglobin_g_dL":10.3,"wbc_k_uL":8.2,"platelets_k_uL":309,"creatinine_mg_dL":0.74,"alt_U_L":53},{"date":"2026-02-21","hemoglobin_g_dL":11.5,"wbc_k_uL":5.4,"platelets_k_uL":264,"creatinine_mg_dL":0.99,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_2998","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":84,"sex":"female","bmi":23.8,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-44},"pfs_months":23.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":27.6,"censored":false},"longitudinal_labs":[{"date":"2023-06-04","hemoglobin_g_dL":15.1,"wbc_k_uL":8.1,"platelets_k_uL":185,"creatinine_mg_dL":0.78,"alt_U_L":55},{"date":"2024-01-15","hemoglobin_g_dL":10.8,"wbc_k_uL":7.6,"platelets_k_uL":245,"creatinine_mg_dL":1.22,"alt_U_L":97},{"date":"2025-08-07","hemoglobin_g_dL":12.2,"wbc_k_uL":5.2,"platelets_k_uL":208,"creatinine_mg_dL":1.85,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_2999","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":82,"sex":"female","bmi":20.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-12-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-62},"pfs_months":16.76},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":31.8,"censored":false},"longitudinal_labs":[{"date":"2024-11-05","hemoglobin_g_dL":14.9,"wbc_k_uL":8.7,"platelets_k_uL":432,"creatinine_mg_dL":0.76,"alt_U_L":30},{"date":"2025-06-24","hemoglobin_g_dL":11.1,"wbc_k_uL":8.8,"platelets_k_uL":322,"creatinine_mg_dL":1.18,"alt_U_L":25},{"date":"2026-07-01","hemoglobin_g_dL":10.4,"wbc_k_uL":3.5,"platelets_k_uL":331,"creatinine_mg_dL":1.69,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_3000","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":48,"sex":"male","bmi":21.2,"smoking_pack_years":13,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-03-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-32},"pfs_months":25.03},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-05-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.4,"censored":true},"longitudinal_labs":[{"date":"2022-01-16","hemoglobin_g_dL":11.9,"wbc_k_uL":9.9,"platelets_k_uL":308,"creatinine_mg_dL":0.64,"alt_U_L":26},{"date":"2022-09-06","hemoglobin_g_dL":14.0,"wbc_k_uL":5.4,"platelets_k_uL":130,"creatinine_mg_dL":0.95,"alt_U_L":115},{"date":"2024-05-07","hemoglobin_g_dL":12.5,"wbc_k_uL":7.7,"platelets_k_uL":181,"creatinine_mg_dL":1.51,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_3001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":53,"sex":"female","bmi":19.9,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","bone","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-48},"pfs_months":9.23},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.1,"censored":false},"longitudinal_labs":[{"date":"2025-05-20","hemoglobin_g_dL":14.1,"wbc_k_uL":6.2,"platelets_k_uL":431,"creatinine_mg_dL":0.77,"alt_U_L":13},{"date":"2025-12-31","hemoglobin_g_dL":11.2,"wbc_k_uL":7.8,"platelets_k_uL":380,"creatinine_mg_dL":0.72,"alt_U_L":44},{"date":"2026-05-07","hemoglobin_g_dL":11.4,"wbc_k_uL":7.3,"platelets_k_uL":322,"creatinine_mg_dL":1.95,"alt_U_L":115}]}
{"patient_id":"ANODE_SYNTH_2025_3002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":78,"sex":"male","bmi":25.8,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-34},"pfs_months":42.71},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":59.8,"censored":false},"longitudinal_labs":[{"date":"2020-11-01","hemoglobin_g_dL":13.9,"wbc_k_uL":10.5,"platelets_k_uL":409,"creatinine_mg_dL":0.7,"alt_U_L":27},{"date":"2021-06-28","hemoglobin_g_dL":10.2,"wbc_k_uL":8.5,"platelets_k_uL":156,"creatinine_mg_dL":1.48,"alt_U_L":115},{"date":"2024-08-02","hemoglobin_g_dL":12.6,"wbc_k_uL":4.7,"platelets_k_uL":159,"creatinine_mg_dL":1.99,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_3003","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":60,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-51},"pfs_months":20.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.8,"censored":false},"longitudinal_labs":[{"date":"2024-06-23","hemoglobin_g_dL":12.5,"wbc_k_uL":5.5,"platelets_k_uL":279,"creatinine_mg_dL":1.26,"alt_U_L":39},{"date":"2025-02-23","hemoglobin_g_dL":11.5,"wbc_k_uL":6.2,"platelets_k_uL":350,"creatinine_mg_dL":1.01,"alt_U_L":104},{"date":"2026-06-04","hemoglobin_g_dL":10.9,"wbc_k_uL":5.4,"platelets_k_uL":336,"creatinine_mg_dL":1.32,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_3004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.1,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":68,"sex":"female","bmi":18.5,"smoking_pack_years":58,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-04-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-34},"pfs_months":34.3},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":63.7,"censored":false},"longitudinal_labs":[{"date":"2021-03-19","hemoglobin_g_dL":14.1,"wbc_k_uL":9.3,"platelets_k_uL":202,"creatinine_mg_dL":0.85,"alt_U_L":46},{"date":"2021-10-07","hemoglobin_g_dL":10.9,"wbc_k_uL":5.0,"platelets_k_uL":170,"creatinine_mg_dL":0.72,"alt_U_L":97},{"date":"2024-03-19","hemoglobin_g_dL":11.5,"wbc_k_uL":6.2,"platelets_k_uL":326,"creatinine_mg_dL":0.86,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_3005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":48,"sex":"female","bmi":20.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-31},"pfs_months":29.73},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":38.9,"censored":false},"longitudinal_labs":[{"date":"2023-04-22","hemoglobin_g_dL":12.8,"wbc_k_uL":8.8,"platelets_k_uL":346,"creatinine_mg_dL":0.85,"alt_U_L":76},{"date":"2023-12-13","hemoglobin_g_dL":10.5,"wbc_k_uL":5.7,"platelets_k_uL":158,"creatinine_mg_dL":1.48,"alt_U_L":52},{"date":"2026-01-15","hemoglobin_g_dL":11.0,"wbc_k_uL":5.5,"platelets_k_uL":163,"creatinine_mg_dL":1.75,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_3006","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":62,"sex":"male","bmi":34.7,"smoking_pack_years":41,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-02-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-65},"pfs_months":29.5},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-09-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.5,"censored":false},"longitudinal_labs":[{"date":"2025-12-05","hemoglobin_g_dL":13.3,"wbc_k_uL":6.3,"platelets_k_uL":447,"creatinine_mg_dL":0.82,"alt_U_L":66},{"date":"2026-08-09","hemoglobin_g_dL":11.3,"wbc_k_uL":8.6,"platelets_k_uL":367,"creatinine_mg_dL":1.29,"alt_U_L":60},{"date":"2028-09-16","hemoglobin_g_dL":10.8,"wbc_k_uL":3.3,"platelets_k_uL":125,"creatinine_mg_dL":1.89,"alt_U_L":162}]}
{"patient_id":"ANODE_SYNTH_2025_3007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":80,"sex":"male","bmi":36.4,"smoking_pack_years":11,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-05-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-60},"pfs_months":38.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":69.0,"censored":false},"longitudinal_labs":[{"date":"2022-03-10","hemoglobin_g_dL":12.8,"wbc_k_uL":10.1,"platelets_k_uL":203,"creatinine_mg_dL":0.89,"alt_U_L":14},{"date":"2022-11-06","hemoglobin_g_dL":13.0,"wbc_k_uL":4.2,"platelets_k_uL":189,"creatinine_mg_dL":1.6,"alt_U_L":44},{"date":"2025-07-25","hemoglobin_g_dL":11.4,"wbc_k_uL":6.4,"platelets_k_uL":242,"creatinine_mg_dL":1.39,"alt_U_L":177}]}
{"patient_id":"ANODE_SYNTH_2025_3008","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":51,"sex":"male","bmi":35.0,"smoking_pack_years":20,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-01-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-59},"pfs_months":22.6},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":false},"longitudinal_labs":[{"date":"2024-12-22","hemoglobin_g_dL":12.9,"wbc_k_uL":7.6,"platelets_k_uL":291,"creatinine_mg_dL":0.97,"alt_U_L":59},{"date":"2025-07-25","hemoglobin_g_dL":10.2,"wbc_k_uL":8.2,"platelets_k_uL":163,"creatinine_mg_dL":1.6,"alt_U_L":34},{"date":"2027-01-29","hemoglobin_g_dL":11.2,"wbc_k_uL":6.1,"platelets_k_uL":164,"creatinine_mg_dL":1.5,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_3009","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":51,"sex":"male","bmi":21.8,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-79},"pfs_months":21.06},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":true},"longitudinal_labs":[{"date":"2023-05-04","hemoglobin_g_dL":15.2,"wbc_k_uL":10.0,"platelets_k_uL":286,"creatinine_mg_dL":1.13,"alt_U_L":54},{"date":"2023-12-02","hemoglobin_g_dL":12.6,"wbc_k_uL":8.3,"platelets_k_uL":239,"creatinine_mg_dL":0.85,"alt_U_L":59},{"date":"2025-04-16","hemoglobin_g_dL":9.8,"wbc_k_uL":4.4,"platelets_k_uL":200,"creatinine_mg_dL":1.19,"alt_U_L":56}]}
{"patient_id":"ANODE_SYNTH_2025_3010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":68,"sex":"female","bmi":20.6,"smoking_pack_years":26,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-79},"pfs_months":33.35},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":57.2,"censored":false},"longitudinal_labs":[{"date":"2024-12-23","hemoglobin_g_dL":14.5,"wbc_k_uL":7.3,"platelets_k_uL":154,"creatinine_mg_dL":1.05,"alt_U_L":37},{"date":"2025-07-17","hemoglobin_g_dL":13.0,"wbc_k_uL":8.8,"platelets_k_uL":286,"creatinine_mg_dL":1.32,"alt_U_L":117},{"date":"2027-12-26","hemoglobin_g_dL":12.7,"wbc_k_uL":5.5,"platelets_k_uL":201,"creatinine_mg_dL":0.91,"alt_U_L":129}]}
{"patient_id":"ANODE_SYNTH_2025_3011","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":58,"sex":"female","bmi":24.5,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-10-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-84},"pfs_months":14.55},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.5,"censored":false},"longitudinal_labs":[{"date":"2021-08-17","hemoglobin_g_dL":13.1,"wbc_k_uL":5.8,"platelets_k_uL":155,"creatinine_mg_dL":1.09,"alt_U_L":53},{"date":"2022-04-19","hemoglobin_g_dL":11.5,"wbc_k_uL":7.3,"platelets_k_uL":331,"creatinine_mg_dL":0.87,"alt_U_L":84},{"date":"2023-01-12","hemoglobin_g_dL":12.4,"wbc_k_uL":4.0,"platelets_k_uL":310,"creatinine_mg_dL":1.72,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_3012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":75,"sex":"female","bmi":34.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-02-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-47},"pfs_months":22.08},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.2,"censored":false},"longitudinal_labs":[{"date":"2022-01-14","hemoglobin_g_dL":11.8,"wbc_k_uL":5.1,"platelets_k_uL":199,"creatinine_mg_dL":0.8,"alt_U_L":51},{"date":"2022-08-02","hemoglobin_g_dL":13.1,"wbc_k_uL":3.9,"platelets_k_uL":239,"creatinine_mg_dL":0.91,"alt_U_L":90},{"date":"2023-12-13","hemoglobin_g_dL":12.2,"wbc_k_uL":6.5,"platelets_k_uL":177,"creatinine_mg_dL":1.93,"alt_U_L":27}]}
{"patient_id":"ANODE_SYNTH_2025_3013","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":75,"sex":"male","bmi":27.5,"smoking_pack_years":26,"ecog_performance_status":2,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-60},"pfs_months":14.39},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.3,"censored":true},"longitudinal_labs":[{"date":"2023-03-22","hemoglobin_g_dL":12.2,"wbc_k_uL":9.8,"platelets_k_uL":320,"creatinine_mg_dL":1.21,"alt_U_L":78},{"date":"2023-11-23","hemoglobin_g_dL":13.4,"wbc_k_uL":4.1,"platelets_k_uL":264,"creatinine_mg_dL":0.77,"alt_U_L":86},{"date":"2024-09-13","hemoglobin_g_dL":12.3,"wbc_k_uL":5.5,"platelets_k_uL":207,"creatinine_mg_dL":1.64,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_3014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":64,"sex":"female","bmi":30.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-07-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-63},"pfs_months":21.06},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.0,"censored":false},"longitudinal_labs":[{"date":"2021-05-24","hemoglobin_g_dL":11.6,"wbc_k_uL":9.7,"platelets_k_uL":196,"creatinine_mg_dL":0.87,"alt_U_L":64},{"date":"2022-01-16","hemoglobin_g_dL":11.2,"wbc_k_uL":6.2,"platelets_k_uL":179,"creatinine_mg_dL":1.19,"alt_U_L":91},{"date":"2023-06-16","hemoglobin_g_dL":10.8,"wbc_k_uL":8.0,"platelets_k_uL":270,"creatinine_mg_dL":1.25,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_3015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":65,"sex":"female","bmi":21.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-43},"pfs_months":27.24},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.5,"censored":false},"longitudinal_labs":[{"date":"2025-11-11","hemoglobin_g_dL":13.6,"wbc_k_uL":5.2,"platelets_k_uL":322,"creatinine_mg_dL":0.76,"alt_U_L":80},{"date":"2026-06-07","hemoglobin_g_dL":14.0,"wbc_k_uL":7.1,"platelets_k_uL":120,"creatinine_mg_dL":1.4,"alt_U_L":102},{"date":"2028-04-21","hemoglobin_g_dL":9.6,"wbc_k_uL":5.9,"platelets_k_uL":320,"creatinine_mg_dL":1.75,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_3016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":56,"sex":"female","bmi":23.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-83},"pfs_months":28.78},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":46.1,"censored":false},"longitudinal_labs":[{"date":"2023-11-15","hemoglobin_g_dL":13.4,"wbc_k_uL":7.2,"platelets_k_uL":180,"creatinine_mg_dL":0.99,"alt_U_L":69},{"date":"2024-06-30","hemoglobin_g_dL":13.4,"wbc_k_uL":4.3,"platelets_k_uL":326,"creatinine_mg_dL":1.23,"alt_U_L":84},{"date":"2026-06-03","hemoglobin_g_dL":10.9,"wbc_k_uL":7.7,"platelets_k_uL":335,"creatinine_mg_dL":1.2,"alt_U_L":87}]}
{"patient_id":"ANODE_SYNTH_2025_3017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.2,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":50,"sex":"female","bmi":32.5,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-03-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-67},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":8.1,"censored":false},"longitudinal_labs":[{"date":"2023-01-14","hemoglobin_g_dL":14.1,"wbc_k_uL":5.4,"platelets_k_uL":404,"creatinine_mg_dL":0.68,"alt_U_L":37},{"date":"2023-09-12","hemoglobin_g_dL":11.8,"wbc_k_uL":4.5,"platelets_k_uL":172,"creatinine_mg_dL":1.43,"alt_U_L":114},{"date":"2023-07-04","hemoglobin_g_dL":12.0,"wbc_k_uL":5.6,"platelets_k_uL":344,"creatinine_mg_dL":1.43,"alt_U_L":119}]}
{"patient_id":"ANODE_SYNTH_2025_3018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.2,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":81,"sex":"female","bmi":26.6,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-04-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-38},"pfs_months":47.47},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":71.5,"censored":false},"longitudinal_labs":[{"date":"2022-03-18","hemoglobin_g_dL":15.0,"wbc_k_uL":7.6,"platelets_k_uL":229,"creatinine_mg_dL":0.65,"alt_U_L":68},{"date":"2022-10-07","hemoglobin_g_dL":11.8,"wbc_k_uL":8.8,"platelets_k_uL":299,"creatinine_mg_dL":0.97,"alt_U_L":27},{"date":"2026-04-18","hemoglobin_g_dL":10.2,"wbc_k_uL":6.2,"platelets_k_uL":292,"creatinine_mg_dL":1.79,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_3019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":80,"sex":"male","bmi":20.6,"smoking_pack_years":77,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-10-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-76},"pfs_months":9.95},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":13.9,"censored":false},"longitudinal_labs":[{"date":"2022-08-18","hemoglobin_g_dL":13.5,"wbc_k_uL":10.3,"platelets_k_uL":243,"creatinine_mg_dL":1.05,"alt_U_L":11},{"date":"2023-04-17","hemoglobin_g_dL":13.6,"wbc_k_uL":6.8,"platelets_k_uL":367,"creatinine_mg_dL":1.26,"alt_U_L":63},{"date":"2023-08-25","hemoglobin_g_dL":12.9,"wbc_k_uL":7.0,"platelets_k_uL":217,"creatinine_mg_dL":1.7,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_3020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":55,"sex":"female","bmi":28.2,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-02-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-71},"pfs_months":7.89},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-22","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":14.4,"censored":false},"longitudinal_labs":[{"date":"2024-12-27","hemoglobin_g_dL":13.7,"wbc_k_uL":9.1,"platelets_k_uL":393,"creatinine_mg_dL":1.15,"alt_U_L":34},{"date":"2025-08-12","hemoglobin_g_dL":10.1,"wbc_k_uL":5.3,"platelets_k_uL":313,"creatinine_mg_dL":0.79,"alt_U_L":116},{"date":"2025-11-22","hemoglobin_g_dL":10.2,"wbc_k_uL":5.8,"platelets_k_uL":129,"creatinine_mg_dL":1.19,"alt_U_L":189}]}
{"patient_id":"ANODE_SYNTH_2025_3021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":50,"sex":"female","bmi":25.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["liver","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-83},"pfs_months":20.44},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-08","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.2,"censored":false},"longitudinal_labs":[{"date":"2020-03-27","hemoglobin_g_dL":15.2,"wbc_k_uL":9.0,"platelets_k_uL":317,"creatinine_mg_dL":0.95,"alt_U_L":61},{"date":"2020-11-05","hemoglobin_g_dL":13.1,"wbc_k_uL":6.1,"platelets_k_uL":135,"creatinine_mg_dL":1.14,"alt_U_L":116},{"date":"2022-02-08","hemoglobin_g_dL":10.5,"wbc_k_uL":7.5,"platelets_k_uL":277,"creatinine_mg_dL":1.0,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_3022","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.4,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":56,"sex":"female","bmi":23.5,"smoking_pack_years":37,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-11-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-63},"pfs_months":22.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":35.4,"censored":false},"longitudinal_labs":[{"date":"2025-10-06","hemoglobin_g_dL":13.6,"wbc_k_uL":4.6,"platelets_k_uL":178,"creatinine_mg_dL":0.81,"alt_U_L":10},{"date":"2026-05-04","hemoglobin_g_dL":10.8,"wbc_k_uL":6.1,"platelets_k_uL":177,"creatinine_mg_dL":0.91,"alt_U_L":50},{"date":"2027-09-28","hemoglobin_g_dL":12.3,"wbc_k_uL":7.3,"platelets_k_uL":232,"creatinine_mg_dL":1.86,"alt_U_L":61}]}
{"patient_id":"ANODE_SYNTH_2025_3023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":50,"sex":"male","bmi":36.6,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-68},"pfs_months":29.14},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":53.5,"censored":false},"longitudinal_labs":[{"date":"2023-09-01","hemoglobin_g_dL":12.0,"wbc_k_uL":9.6,"platelets_k_uL":410,"creatinine_mg_dL":1.18,"alt_U_L":64},{"date":"2024-05-02","hemoglobin_g_dL":10.3,"wbc_k_uL":7.4,"platelets_k_uL":269,"creatinine_mg_dL":1.02,"alt_U_L":56},{"date":"2026-04-17","hemoglobin_g_dL":12.6,"wbc_k_uL":4.8,"platelets_k_uL":209,"creatinine_mg_dL":1.35,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_3024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":58,"sex":"female","bmi":28.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-50},"pfs_months":19.98},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.0,"censored":true},"longitudinal_labs":[{"date":"2020-05-28","hemoglobin_g_dL":13.0,"wbc_k_uL":9.8,"platelets_k_uL":401,"creatinine_mg_dL":0.8,"alt_U_L":69},{"date":"2021-02-01","hemoglobin_g_dL":12.5,"wbc_k_uL":4.7,"platelets_k_uL":127,"creatinine_mg_dL":1.3,"alt_U_L":67},{"date":"2022-05-29","hemoglobin_g_dL":12.9,"wbc_k_uL":6.6,"platelets_k_uL":281,"creatinine_mg_dL":1.32,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_3025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.7,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":73,"sex":"male","bmi":35.2,"smoking_pack_years":36,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-41},"pfs_months":4.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":9.3,"censored":false},"longitudinal_labs":[{"date":"2023-05-22","hemoglobin_g_dL":13.4,"wbc_k_uL":8.7,"platelets_k_uL":172,"creatinine_mg_dL":0.87,"alt_U_L":61},{"date":"2024-01-20","hemoglobin_g_dL":10.0,"wbc_k_uL":6.4,"platelets_k_uL":136,"creatinine_mg_dL":0.74,"alt_U_L":89},{"date":"2024-01-29","hemoglobin_g_dL":12.2,"wbc_k_uL":6.2,"platelets_k_uL":320,"creatinine_mg_dL":1.93,"alt_U_L":120}]}
{"patient_id":"ANODE_SYNTH_2025_3026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":56,"sex":"female","bmi":23.6,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-45},"pfs_months":21.39},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.8,"censored":true},"longitudinal_labs":[{"date":"2020-03-09","hemoglobin_g_dL":13.9,"wbc_k_uL":9.8,"platelets_k_uL":396,"creatinine_mg_dL":0.84,"alt_U_L":50},{"date":"2020-10-02","hemoglobin_g_dL":11.7,"wbc_k_uL":8.2,"platelets_k_uL":316,"creatinine_mg_dL":1.46,"alt_U_L":45},{"date":"2022-02-06","hemoglobin_g_dL":10.4,"wbc_k_uL":3.1,"platelets_k_uL":259,"creatinine_mg_dL":1.13,"alt_U_L":44}]}
{"patient_id":"ANODE_SYNTH_2025_3027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.6,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":79,"sex":"male","bmi":33.3,"smoking_pack_years":45,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-07-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-55},"pfs_months":3.65},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2020-12-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":9.3,"censored":false},"longitudinal_labs":[{"date":"2020-06-05","hemoglobin_g_dL":13.6,"wbc_k_uL":10.7,"platelets_k_uL":434,"creatinine_mg_dL":1.09,"alt_U_L":63},{"date":"2020-12-31","hemoglobin_g_dL":12.6,"wbc_k_uL":6.7,"platelets_k_uL":373,"creatinine_mg_dL":1.43,"alt_U_L":28},{"date":"2020-12-14","hemoglobin_g_dL":12.0,"wbc_k_uL":3.1,"platelets_k_uL":212,"creatinine_mg_dL":1.33,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_3028","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.7,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":62,"sex":"male","bmi":34.1,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-31},"pfs_months":16.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":true},"longitudinal_labs":[{"date":"2024-11-17","hemoglobin_g_dL":15.5,"wbc_k_uL":9.8,"platelets_k_uL":353,"creatinine_mg_dL":0.67,"alt_U_L":26},{"date":"2025-07-12","hemoglobin_g_dL":13.1,"wbc_k_uL":7.9,"platelets_k_uL":136,"creatinine_mg_dL":0.96,"alt_U_L":98},{"date":"2026-07-15","hemoglobin_g_dL":12.1,"wbc_k_uL":7.9,"platelets_k_uL":155,"creatinine_mg_dL":1.46,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_3029","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":68,"sex":"female","bmi":30.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-80},"pfs_months":18.14},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":28.2,"censored":true},"longitudinal_labs":[{"date":"2024-08-13","hemoglobin_g_dL":12.5,"wbc_k_uL":8.3,"platelets_k_uL":336,"creatinine_mg_dL":1.01,"alt_U_L":54},{"date":"2025-02-27","hemoglobin_g_dL":12.9,"wbc_k_uL":8.8,"platelets_k_uL":301,"creatinine_mg_dL":1.2,"alt_U_L":91},{"date":"2026-04-04","hemoglobin_g_dL":9.8,"wbc_k_uL":4.5,"platelets_k_uL":113,"creatinine_mg_dL":1.01,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_3030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":65,"sex":"female","bmi":33.0,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-78},"pfs_months":13.21},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":21.9,"censored":false},"longitudinal_labs":[{"date":"2020-12-24","hemoglobin_g_dL":11.8,"wbc_k_uL":10.2,"platelets_k_uL":251,"creatinine_mg_dL":0.61,"alt_U_L":79},{"date":"2021-08-12","hemoglobin_g_dL":12.1,"wbc_k_uL":7.0,"platelets_k_uL":380,"creatinine_mg_dL":1.44,"alt_U_L":19},{"date":"2022-05-20","hemoglobin_g_dL":9.9,"wbc_k_uL":5.2,"platelets_k_uL":101,"creatinine_mg_dL":1.42,"alt_U_L":94}]}
{"patient_id":"ANODE_SYNTH_2025_3031","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.3,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":86,"sex":"female","bmi":24.8,"smoking_pack_years":30,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-01-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-46},"pfs_months":22.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.4,"censored":true},"longitudinal_labs":[{"date":"2022-12-18","hemoglobin_g_dL":13.0,"wbc_k_uL":4.8,"platelets_k_uL":169,"creatinine_mg_dL":0.79,"alt_U_L":63},{"date":"2023-07-11","hemoglobin_g_dL":12.7,"wbc_k_uL":7.9,"platelets_k_uL":161,"creatinine_mg_dL":1.16,"alt_U_L":47},{"date":"2024-12-22","hemoglobin_g_dL":11.4,"wbc_k_uL":7.8,"platelets_k_uL":256,"creatinine_mg_dL":1.21,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_3032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":76,"sex":"male","bmi":33.9,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-01-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-41},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-05-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.9,"censored":false},"longitudinal_labs":[{"date":"2024-11-21","hemoglobin_g_dL":13.4,"wbc_k_uL":4.9,"platelets_k_uL":196,"creatinine_mg_dL":0.94,"alt_U_L":32},{"date":"2025-07-08","hemoglobin_g_dL":11.1,"wbc_k_uL":8.1,"platelets_k_uL":268,"creatinine_mg_dL":1.55,"alt_U_L":119},{"date":"2025-05-12","hemoglobin_g_dL":9.9,"wbc_k_uL":7.8,"platelets_k_uL":302,"creatinine_mg_dL":1.15,"alt_U_L":140}]}
{"patient_id":"ANODE_SYNTH_2025_3033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.0,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":55,"sex":"female","bmi":34.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-58},"pfs_months":16.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.1,"censored":true},"longitudinal_labs":[{"date":"2024-04-21","hemoglobin_g_dL":13.3,"wbc_k_uL":5.5,"platelets_k_uL":221,"creatinine_mg_dL":1.25,"alt_U_L":60},{"date":"2024-12-04","hemoglobin_g_dL":10.7,"wbc_k_uL":7.9,"platelets_k_uL":260,"creatinine_mg_dL":1.45,"alt_U_L":73},{"date":"2025-12-17","hemoglobin_g_dL":10.7,"wbc_k_uL":4.6,"platelets_k_uL":224,"creatinine_mg_dL":1.79,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_3034","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.2,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":83,"sex":"female","bmi":25.8,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-02-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-66},"pfs_months":20.8},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":false},"longitudinal_labs":[{"date":"2020-02-03","hemoglobin_g_dL":11.8,"wbc_k_uL":7.9,"platelets_k_uL":390,"creatinine_mg_dL":0.9,"alt_U_L":10},{"date":"2020-08-27","hemoglobin_g_dL":11.0,"wbc_k_uL":5.8,"platelets_k_uL":297,"creatinine_mg_dL":0.74,"alt_U_L":59},{"date":"2022-01-20","hemoglobin_g_dL":11.5,"wbc_k_uL":6.8,"platelets_k_uL":339,"creatinine_mg_dL":1.37,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_3035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":61,"sex":"female","bmi":23.6,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-02-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-33},"pfs_months":24.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":46.5,"censored":true},"longitudinal_labs":[{"date":"2021-12-25","hemoglobin_g_dL":11.8,"wbc_k_uL":4.7,"platelets_k_uL":275,"creatinine_mg_dL":0.83,"alt_U_L":56},{"date":"2022-08-22","hemoglobin_g_dL":10.3,"wbc_k_uL":5.8,"platelets_k_uL":301,"creatinine_mg_dL":1.53,"alt_U_L":54},{"date":"2024-03-12","hemoglobin_g_dL":11.7,"wbc_k_uL":6.1,"platelets_k_uL":321,"creatinine_mg_dL":1.53,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_3036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":50,"sex":"male","bmi":35.1,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-11-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-84},"pfs_months":35.88},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.4,"censored":false},"longitudinal_labs":[{"date":"2021-09-26","hemoglobin_g_dL":14.9,"wbc_k_uL":9.0,"platelets_k_uL":374,"creatinine_mg_dL":1.05,"alt_U_L":47},{"date":"2022-05-01","hemoglobin_g_dL":10.6,"wbc_k_uL":8.3,"platelets_k_uL":178,"creatinine_mg_dL":0.75,"alt_U_L":84},{"date":"2024-12-06","hemoglobin_g_dL":12.6,"wbc_k_uL":5.7,"platelets_k_uL":205,"creatinine_mg_dL":1.89,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_3037","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":80,"sex":"female","bmi":26.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-80},"pfs_months":22.8},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-24","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.9,"censored":false},"longitudinal_labs":[{"date":"2021-07-24","hemoglobin_g_dL":12.7,"wbc_k_uL":10.7,"platelets_k_uL":419,"creatinine_mg_dL":0.69,"alt_U_L":48},{"date":"2022-03-18","hemoglobin_g_dL":10.0,"wbc_k_uL":5.1,"platelets_k_uL":377,"creatinine_mg_dL":1.47,"alt_U_L":41},{"date":"2023-08-24","hemoglobin_g_dL":11.6,"wbc_k_uL":7.5,"platelets_k_uL":241,"creatinine_mg_dL":0.99,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_3038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":57,"sex":"female","bmi":35.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-08-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-41},"pfs_months":24.21},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.8,"censored":false},"longitudinal_labs":[{"date":"2021-05-25","hemoglobin_g_dL":13.6,"wbc_k_uL":8.0,"platelets_k_uL":200,"creatinine_mg_dL":1.26,"alt_U_L":27},{"date":"2022-01-29","hemoglobin_g_dL":11.0,"wbc_k_uL":8.9,"platelets_k_uL":190,"creatinine_mg_dL":1.48,"alt_U_L":43},{"date":"2023-08-29","hemoglobin_g_dL":9.7,"wbc_k_uL":7.0,"platelets_k_uL":211,"creatinine_mg_dL":1.74,"alt_U_L":69}]}
{"patient_id":"ANODE_SYNTH_2025_3039","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":65,"sex":"male","bmi":23.0,"smoking_pack_years":48,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-01-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-56},"pfs_months":42.32},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":68.2,"censored":false},"longitudinal_labs":[{"date":"2021-11-25","hemoglobin_g_dL":15.0,"wbc_k_uL":6.1,"platelets_k_uL":306,"creatinine_mg_dL":0.96,"alt_U_L":18},{"date":"2022-07-18","hemoglobin_g_dL":11.6,"wbc_k_uL":6.6,"platelets_k_uL":194,"creatinine_mg_dL":0.9,"alt_U_L":58},{"date":"2025-09-24","hemoglobin_g_dL":9.8,"wbc_k_uL":5.1,"platelets_k_uL":227,"creatinine_mg_dL":1.87,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_3040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.7,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":83,"sex":"female","bmi":29.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-71},"pfs_months":18.14},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":44.6,"censored":false},"longitudinal_labs":[{"date":"2020-03-27","hemoglobin_g_dL":11.7,"wbc_k_uL":7.2,"platelets_k_uL":414,"creatinine_mg_dL":1.01,"alt_U_L":14},{"date":"2020-10-10","hemoglobin_g_dL":10.4,"wbc_k_uL":7.0,"platelets_k_uL":152,"creatinine_mg_dL":0.99,"alt_U_L":48},{"date":"2021-10-25","hemoglobin_g_dL":10.6,"wbc_k_uL":4.9,"platelets_k_uL":118,"creatinine_mg_dL":0.93,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_3041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":76,"sex":"female","bmi":27.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-08-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-33},"pfs_months":20.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.8,"censored":false},"longitudinal_labs":[{"date":"2020-07-21","hemoglobin_g_dL":12.8,"wbc_k_uL":7.3,"platelets_k_uL":432,"creatinine_mg_dL":1.12,"alt_U_L":64},{"date":"2021-02-20","hemoglobin_g_dL":10.7,"wbc_k_uL":4.2,"platelets_k_uL":225,"creatinine_mg_dL":1.37,"alt_U_L":95},{"date":"2022-05-14","hemoglobin_g_dL":12.3,"wbc_k_uL":7.5,"platelets_k_uL":114,"creatinine_mg_dL":1.61,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_3042","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":81,"sex":"female","bmi":19.9,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-79},"pfs_months":10.78},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-04","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":23.4,"censored":false},"longitudinal_labs":[{"date":"2023-09-21","hemoglobin_g_dL":12.7,"wbc_k_uL":10.8,"platelets_k_uL":293,"creatinine_mg_dL":0.91,"alt_U_L":75},{"date":"2024-04-03","hemoglobin_g_dL":10.1,"wbc_k_uL":7.4,"platelets_k_uL":233,"creatinine_mg_dL":0.89,"alt_U_L":54},{"date":"2024-09-04","hemoglobin_g_dL":12.2,"wbc_k_uL":5.6,"platelets_k_uL":304,"creatinine_mg_dL":1.62,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_3043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":73,"sex":"female","bmi":21.6,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-03-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-35},"pfs_months":18.5},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2024-02-10","hemoglobin_g_dL":14.4,"wbc_k_uL":10.9,"platelets_k_uL":209,"creatinine_mg_dL":1.25,"alt_U_L":63},{"date":"2024-09-24","hemoglobin_g_dL":13.8,"wbc_k_uL":6.5,"platelets_k_uL":356,"creatinine_mg_dL":1.38,"alt_U_L":30},{"date":"2025-10-30","hemoglobin_g_dL":12.2,"wbc_k_uL":6.6,"platelets_k_uL":249,"creatinine_mg_dL":1.94,"alt_U_L":147}]}
{"patient_id":"ANODE_SYNTH_2025_3044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":55,"sex":"female","bmi":22.8,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-56},"pfs_months":23.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.6,"censored":false},"longitudinal_labs":[{"date":"2023-03-17","hemoglobin_g_dL":11.7,"wbc_k_uL":5.8,"platelets_k_uL":278,"creatinine_mg_dL":0.87,"alt_U_L":61},{"date":"2023-10-12","hemoglobin_g_dL":12.4,"wbc_k_uL":8.5,"platelets_k_uL":343,"creatinine_mg_dL":1.29,"alt_U_L":27},{"date":"2025-04-24","hemoglobin_g_dL":13.0,"wbc_k_uL":7.2,"platelets_k_uL":162,"creatinine_mg_dL":1.33,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_3045","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":52,"sex":"male","bmi":22.4,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-11-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-37},"pfs_months":26.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-02-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":53.7,"censored":true},"longitudinal_labs":[{"date":"2022-11-03","hemoglobin_g_dL":13.3,"wbc_k_uL":8.4,"platelets_k_uL":158,"creatinine_mg_dL":1.01,"alt_U_L":24},{"date":"2023-05-20","hemoglobin_g_dL":11.7,"wbc_k_uL":5.7,"platelets_k_uL":346,"creatinine_mg_dL":1.11,"alt_U_L":44},{"date":"2025-02-08","hemoglobin_g_dL":10.3,"wbc_k_uL":4.8,"platelets_k_uL":349,"creatinine_mg_dL":0.98,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_3046","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.9,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":56,"sex":"male","bmi":26.0,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-04-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-41},"pfs_months":23.39},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.2,"censored":false},"longitudinal_labs":[{"date":"2021-03-23","hemoglobin_g_dL":13.6,"wbc_k_uL":9.3,"platelets_k_uL":325,"creatinine_mg_dL":0.81,"alt_U_L":68},{"date":"2021-10-14","hemoglobin_g_dL":11.7,"wbc_k_uL":4.8,"platelets_k_uL":251,"creatinine_mg_dL":1.25,"alt_U_L":68},{"date":"2023-05-27","hemoglobin_g_dL":11.0,"wbc_k_uL":6.4,"platelets_k_uL":230,"creatinine_mg_dL":1.12,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_3047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.2,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":65,"sex":"female","bmi":19.1,"smoking_pack_years":44,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-11-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-44},"pfs_months":34.4},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":69.6,"censored":true},"longitudinal_labs":[{"date":"2023-10-13","hemoglobin_g_dL":12.6,"wbc_k_uL":9.2,"platelets_k_uL":356,"creatinine_mg_dL":0.85,"alt_U_L":16},{"date":"2024-05-01","hemoglobin_g_dL":10.6,"wbc_k_uL":6.1,"platelets_k_uL":360,"creatinine_mg_dL":0.89,"alt_U_L":119},{"date":"2026-10-26","hemoglobin_g_dL":12.8,"wbc_k_uL":4.0,"platelets_k_uL":211,"creatinine_mg_dL":1.36,"alt_U_L":135}]}
{"patient_id":"ANODE_SYNTH_2025_3048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":49,"sex":"female","bmi":23.5,"smoking_pack_years":70,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-40},"pfs_months":8.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.4,"censored":true},"longitudinal_labs":[{"date":"2021-01-10","hemoglobin_g_dL":12.8,"wbc_k_uL":8.7,"platelets_k_uL":330,"creatinine_mg_dL":1.12,"alt_U_L":65},{"date":"2021-09-06","hemoglobin_g_dL":12.9,"wbc_k_uL":7.9,"platelets_k_uL":344,"creatinine_mg_dL":1.16,"alt_U_L":56},{"date":"2021-12-26","hemoglobin_g_dL":11.1,"wbc_k_uL":7.9,"platelets_k_uL":204,"creatinine_mg_dL":1.76,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_3049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":82,"sex":"female","bmi":35.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-80},"pfs_months":24.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.7,"censored":false},"longitudinal_labs":[{"date":"2020-08-11","hemoglobin_g_dL":12.2,"wbc_k_uL":7.4,"platelets_k_uL":176,"creatinine_mg_dL":0.8,"alt_U_L":32},{"date":"2021-03-30","hemoglobin_g_dL":13.5,"wbc_k_uL":7.5,"platelets_k_uL":352,"creatinine_mg_dL":1.35,"alt_U_L":28},{"date":"2022-11-10","hemoglobin_g_dL":10.7,"wbc_k_uL":5.3,"platelets_k_uL":322,"creatinine_mg_dL":0.89,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_3050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.9,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":73,"sex":"female","bmi":33.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-47},"pfs_months":18.4},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.1,"censored":false},"longitudinal_labs":[{"date":"2020-06-19","hemoglobin_g_dL":14.4,"wbc_k_uL":5.5,"platelets_k_uL":302,"creatinine_mg_dL":0.9,"alt_U_L":59},{"date":"2021-01-26","hemoglobin_g_dL":10.1,"wbc_k_uL":4.1,"platelets_k_uL":213,"creatinine_mg_dL":0.75,"alt_U_L":27},{"date":"2022-03-17","hemoglobin_g_dL":10.9,"wbc_k_uL":4.8,"platelets_k_uL":247,"creatinine_mg_dL":1.37,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_3051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":85,"sex":"male","bmi":33.7,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-09-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-55},"pfs_months":39.82},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":49.8,"censored":false},"longitudinal_labs":[{"date":"2024-07-14","hemoglobin_g_dL":13.4,"wbc_k_uL":4.9,"platelets_k_uL":317,"creatinine_mg_dL":1.21,"alt_U_L":78},{"date":"2025-03-21","hemoglobin_g_dL":10.7,"wbc_k_uL":4.5,"platelets_k_uL":204,"creatinine_mg_dL":1.09,"alt_U_L":17},{"date":"2028-03-12","hemoglobin_g_dL":12.0,"wbc_k_uL":4.0,"platelets_k_uL":222,"creatinine_mg_dL":1.37,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_3052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":59,"sex":"female","bmi":25.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-03-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-45},"pfs_months":17.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.7,"censored":false},"longitudinal_labs":[{"date":"2025-12-23","hemoglobin_g_dL":14.4,"wbc_k_uL":9.9,"platelets_k_uL":319,"creatinine_mg_dL":0.71,"alt_U_L":75},{"date":"2026-08-30","hemoglobin_g_dL":10.0,"wbc_k_uL":8.0,"platelets_k_uL":263,"creatinine_mg_dL":0.82,"alt_U_L":32},{"date":"2027-09-23","hemoglobin_g_dL":12.7,"wbc_k_uL":6.1,"platelets_k_uL":171,"creatinine_mg_dL":1.59,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_3053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":61,"sex":"female","bmi":33.0,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-07-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-56},"pfs_months":8.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":20.3,"censored":true},"longitudinal_labs":[{"date":"2022-05-23","hemoglobin_g_dL":11.6,"wbc_k_uL":10.7,"platelets_k_uL":278,"creatinine_mg_dL":0.99,"alt_U_L":36},{"date":"2023-01-16","hemoglobin_g_dL":12.5,"wbc_k_uL":5.0,"platelets_k_uL":327,"creatinine_mg_dL":1.39,"alt_U_L":93},{"date":"2023-04-01","hemoglobin_g_dL":12.4,"wbc_k_uL":7.2,"platelets_k_uL":119,"creatinine_mg_dL":1.89,"alt_U_L":97}]}
{"patient_id":"ANODE_SYNTH_2025_3054","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.2,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":86,"sex":"female","bmi":32.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-78},"pfs_months":20.3},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.5,"censored":true},"longitudinal_labs":[{"date":"2021-03-01","hemoglobin_g_dL":12.2,"wbc_k_uL":10.4,"platelets_k_uL":150,"creatinine_mg_dL":0.97,"alt_U_L":40},{"date":"2021-09-28","hemoglobin_g_dL":10.5,"wbc_k_uL":5.2,"platelets_k_uL":126,"creatinine_mg_dL":1.35,"alt_U_L":55},{"date":"2023-01-11","hemoglobin_g_dL":10.2,"wbc_k_uL":3.5,"platelets_k_uL":115,"creatinine_mg_dL":1.12,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_3055","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":77,"sex":"male","bmi":34.2,"smoking_pack_years":63,"ecog_performance_status":2,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-04-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-81},"pfs_months":15.67},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":false},"longitudinal_labs":[{"date":"2025-03-15","hemoglobin_g_dL":13.5,"wbc_k_uL":5.3,"platelets_k_uL":447,"creatinine_mg_dL":0.66,"alt_U_L":35},{"date":"2025-10-17","hemoglobin_g_dL":10.3,"wbc_k_uL":4.4,"platelets_k_uL":337,"creatinine_mg_dL":1.24,"alt_U_L":25},{"date":"2026-09-09","hemoglobin_g_dL":10.7,"wbc_k_uL":4.3,"platelets_k_uL":141,"creatinine_mg_dL":1.84,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_3056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":63,"sex":"male","bmi":21.8,"smoking_pack_years":60,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-31},"pfs_months":17.12},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":22.4,"censored":true},"longitudinal_labs":[{"date":"2023-07-19","hemoglobin_g_dL":11.7,"wbc_k_uL":9.7,"platelets_k_uL":277,"creatinine_mg_dL":0.85,"alt_U_L":69},{"date":"2024-03-03","hemoglobin_g_dL":13.8,"wbc_k_uL":6.4,"platelets_k_uL":203,"creatinine_mg_dL":1.31,"alt_U_L":98},{"date":"2025-04-05","hemoglobin_g_dL":10.2,"wbc_k_uL":4.1,"platelets_k_uL":149,"creatinine_mg_dL":1.85,"alt_U_L":167}]}
{"patient_id":"ANODE_SYNTH_2025_3057","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":84,"sex":"female","bmi":37.8,"smoking_pack_years":42,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-03-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-54},"pfs_months":16.85},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.5,"censored":true},"longitudinal_labs":[{"date":"2022-01-28","hemoglobin_g_dL":15.0,"wbc_k_uL":7.5,"platelets_k_uL":218,"creatinine_mg_dL":0.62,"alt_U_L":77},{"date":"2022-09-24","hemoglobin_g_dL":10.8,"wbc_k_uL":6.3,"platelets_k_uL":194,"creatinine_mg_dL":0.95,"alt_U_L":24},{"date":"2023-10-17","hemoglobin_g_dL":12.5,"wbc_k_uL":4.0,"platelets_k_uL":301,"creatinine_mg_dL":1.83,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_3058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":60,"sex":"female","bmi":27.0,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-08-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-31},"pfs_months":32.95},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.1,"censored":false},"longitudinal_labs":[{"date":"2021-06-04","hemoglobin_g_dL":14.2,"wbc_k_uL":9.9,"platelets_k_uL":446,"creatinine_mg_dL":0.65,"alt_U_L":42},{"date":"2022-01-29","hemoglobin_g_dL":10.1,"wbc_k_uL":5.7,"platelets_k_uL":190,"creatinine_mg_dL":0.79,"alt_U_L":19},{"date":"2024-06-05","hemoglobin_g_dL":12.6,"wbc_k_uL":6.2,"platelets_k_uL":147,"creatinine_mg_dL":1.83,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_3059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":67,"sex":"female","bmi":20.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-12-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-31},"pfs_months":11.37},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.9,"censored":false},"longitudinal_labs":[{"date":"2020-12-06","hemoglobin_g_dL":13.7,"wbc_k_uL":8.4,"platelets_k_uL":425,"creatinine_mg_dL":0.98,"alt_U_L":43},{"date":"2021-06-27","hemoglobin_g_dL":12.6,"wbc_k_uL":8.3,"platelets_k_uL":169,"creatinine_mg_dL":1.26,"alt_U_L":58},{"date":"2021-12-15","hemoglobin_g_dL":11.6,"wbc_k_uL":7.8,"platelets_k_uL":347,"creatinine_mg_dL":1.75,"alt_U_L":98}]}
{"patient_id":"ANODE_SYNTH_2025_3060","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":55,"sex":"female","bmi":32.2,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-07-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-49},"pfs_months":30.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":47.4,"censored":false},"longitudinal_labs":[{"date":"2025-07-01","hemoglobin_g_dL":12.5,"wbc_k_uL":9.3,"platelets_k_uL":164,"creatinine_mg_dL":1.07,"alt_U_L":27},{"date":"2026-01-13","hemoglobin_g_dL":12.9,"wbc_k_uL":7.0,"platelets_k_uL":197,"creatinine_mg_dL":1.41,"alt_U_L":114},{"date":"2028-03-22","hemoglobin_g_dL":10.3,"wbc_k_uL":6.3,"platelets_k_uL":280,"creatinine_mg_dL":1.28,"alt_U_L":56}]}
{"patient_id":"ANODE_SYNTH_2025_3061","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":79,"sex":"female","bmi":25.7,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-61},"pfs_months":17.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":25.9,"censored":true},"longitudinal_labs":[{"date":"2021-05-23","hemoglobin_g_dL":12.0,"wbc_k_uL":5.4,"platelets_k_uL":376,"creatinine_mg_dL":1.26,"alt_U_L":40},{"date":"2021-12-24","hemoglobin_g_dL":11.7,"wbc_k_uL":8.0,"platelets_k_uL":164,"creatinine_mg_dL":1.39,"alt_U_L":26},{"date":"2022-12-14","hemoglobin_g_dL":11.2,"wbc_k_uL":8.0,"platelets_k_uL":139,"creatinine_mg_dL":1.18,"alt_U_L":165}]}
{"patient_id":"ANODE_SYNTH_2025_3062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":55,"sex":"male","bmi":20.6,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-39},"pfs_months":15.51},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.9,"censored":false},"longitudinal_labs":[{"date":"2021-09-09","hemoglobin_g_dL":12.7,"wbc_k_uL":5.7,"platelets_k_uL":369,"creatinine_mg_dL":0.83,"alt_U_L":23},{"date":"2022-03-28","hemoglobin_g_dL":10.2,"wbc_k_uL":8.4,"platelets_k_uL":345,"creatinine_mg_dL":0.78,"alt_U_L":62},{"date":"2023-02-02","hemoglobin_g_dL":10.7,"wbc_k_uL":5.3,"platelets_k_uL":312,"creatinine_mg_dL":1.86,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_3063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":59,"sex":"female","bmi":24.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-43},"pfs_months":25.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":49.0,"censored":false},"longitudinal_labs":[{"date":"2023-04-15","hemoglobin_g_dL":14.3,"wbc_k_uL":4.9,"platelets_k_uL":281,"creatinine_mg_dL":1.23,"alt_U_L":62},{"date":"2023-12-01","hemoglobin_g_dL":12.9,"wbc_k_uL":6.8,"platelets_k_uL":329,"creatinine_mg_dL":0.79,"alt_U_L":64},{"date":"2025-07-19","hemoglobin_g_dL":10.9,"wbc_k_uL":6.9,"platelets_k_uL":192,"creatinine_mg_dL":0.86,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_3064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":52,"sex":"female","bmi":21.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-01-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-53},"pfs_months":27.66},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.3,"censored":false},"longitudinal_labs":[{"date":"2022-01-03","hemoglobin_g_dL":15.1,"wbc_k_uL":8.4,"platelets_k_uL":163,"creatinine_mg_dL":0.86,"alt_U_L":33},{"date":"2022-07-28","hemoglobin_g_dL":13.2,"wbc_k_uL":3.9,"platelets_k_uL":124,"creatinine_mg_dL":1.1,"alt_U_L":28},{"date":"2024-06-15","hemoglobin_g_dL":10.2,"wbc_k_uL":5.8,"platelets_k_uL":144,"creatinine_mg_dL":0.94,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_3065","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":82,"sex":"female","bmi":30.2,"smoking_pack_years":36,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-07-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-64},"pfs_months":15.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-28","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":35.8,"censored":false},"longitudinal_labs":[{"date":"2025-07-11","hemoglobin_g_dL":14.8,"wbc_k_uL":5.8,"platelets_k_uL":185,"creatinine_mg_dL":0.69,"alt_U_L":18},{"date":"2026-01-21","hemoglobin_g_dL":13.6,"wbc_k_uL":4.7,"platelets_k_uL":160,"creatinine_mg_dL":1.31,"alt_U_L":27},{"date":"2026-11-28","hemoglobin_g_dL":12.3,"wbc_k_uL":5.1,"platelets_k_uL":138,"creatinine_mg_dL":0.89,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_3066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":65,"sex":"female","bmi":31.3,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-06-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-76},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":11.2,"censored":false},"longitudinal_labs":[{"date":"2024-04-23","hemoglobin_g_dL":14.2,"wbc_k_uL":7.3,"platelets_k_uL":351,"creatinine_mg_dL":1.02,"alt_U_L":46},{"date":"2024-12-21","hemoglobin_g_dL":12.3,"wbc_k_uL":8.3,"platelets_k_uL":376,"creatinine_mg_dL":0.78,"alt_U_L":87},{"date":"2024-10-18","hemoglobin_g_dL":10.7,"wbc_k_uL":7.6,"platelets_k_uL":298,"creatinine_mg_dL":1.39,"alt_U_L":125}]}
{"patient_id":"ANODE_SYNTH_2025_3067","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":73,"sex":"male","bmi":37.7,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-08-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-35},"pfs_months":24.44},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-31","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.1,"censored":false},"longitudinal_labs":[{"date":"2022-07-11","hemoglobin_g_dL":14.8,"wbc_k_uL":10.0,"platelets_k_uL":337,"creatinine_mg_dL":0.98,"alt_U_L":18},{"date":"2023-02-07","hemoglobin_g_dL":10.9,"wbc_k_uL":4.3,"platelets_k_uL":375,"creatinine_mg_dL":1.47,"alt_U_L":55},{"date":"2024-08-31","hemoglobin_g_dL":12.8,"wbc_k_uL":7.2,"platelets_k_uL":157,"creatinine_mg_dL":1.9,"alt_U_L":55}]}
{"patient_id":"ANODE_SYNTH_2025_3068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":84,"sex":"female","bmi":36.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-01-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-48},"pfs_months":20.57},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":false},"longitudinal_labs":[{"date":"2022-12-01","hemoglobin_g_dL":13.6,"wbc_k_uL":5.7,"platelets_k_uL":258,"creatinine_mg_dL":0.78,"alt_U_L":68},{"date":"2023-07-02","hemoglobin_g_dL":12.0,"wbc_k_uL":5.2,"platelets_k_uL":123,"creatinine_mg_dL":0.91,"alt_U_L":62},{"date":"2024-10-10","hemoglobin_g_dL":11.1,"wbc_k_uL":6.5,"platelets_k_uL":346,"creatinine_mg_dL":1.39,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_3069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":81,"sex":"female","bmi":27.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-12-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-56},"pfs_months":21.55},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-19","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.3,"censored":false},"longitudinal_labs":[{"date":"2024-10-14","hemoglobin_g_dL":12.8,"wbc_k_uL":5.9,"platelets_k_uL":209,"creatinine_mg_dL":1.15,"alt_U_L":15},{"date":"2025-06-05","hemoglobin_g_dL":11.9,"wbc_k_uL":7.2,"platelets_k_uL":220,"creatinine_mg_dL":1.02,"alt_U_L":16},{"date":"2026-10-19","hemoglobin_g_dL":12.2,"wbc_k_uL":7.5,"platelets_k_uL":235,"creatinine_mg_dL":1.16,"alt_U_L":161}]}
{"patient_id":"ANODE_SYNTH_2025_3070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":69,"sex":"female","bmi":33.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-01-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-66},"pfs_months":25.59},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.3,"censored":false},"longitudinal_labs":[{"date":"2021-12-19","hemoglobin_g_dL":12.3,"wbc_k_uL":7.4,"platelets_k_uL":280,"creatinine_mg_dL":0.7,"alt_U_L":67},{"date":"2022-07-03","hemoglobin_g_dL":10.8,"wbc_k_uL":4.1,"platelets_k_uL":270,"creatinine_mg_dL":0.8,"alt_U_L":65},{"date":"2024-03-13","hemoglobin_g_dL":12.2,"wbc_k_uL":3.6,"platelets_k_uL":140,"creatinine_mg_dL":1.16,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_3071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":60,"sex":"female","bmi":19.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-55},"pfs_months":29.11},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.8,"censored":true},"longitudinal_labs":[{"date":"2023-02-20","hemoglobin_g_dL":15.1,"wbc_k_uL":5.0,"platelets_k_uL":295,"creatinine_mg_dL":0.69,"alt_U_L":60},{"date":"2023-10-12","hemoglobin_g_dL":12.0,"wbc_k_uL":7.0,"platelets_k_uL":303,"creatinine_mg_dL":0.89,"alt_U_L":101},{"date":"2025-10-09","hemoglobin_g_dL":10.0,"wbc_k_uL":5.0,"platelets_k_uL":228,"creatinine_mg_dL":1.83,"alt_U_L":141}]}
{"patient_id":"ANODE_SYNTH_2025_3072","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.3,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":68,"sex":"female","bmi":33.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-52},"pfs_months":26.58},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-03-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.8,"censored":false},"longitudinal_labs":[{"date":"2025-10-21","hemoglobin_g_dL":14.6,"wbc_k_uL":10.0,"platelets_k_uL":162,"creatinine_mg_dL":0.72,"alt_U_L":31},{"date":"2026-06-18","hemoglobin_g_dL":11.0,"wbc_k_uL":6.8,"platelets_k_uL":220,"creatinine_mg_dL":1.09,"alt_U_L":47},{"date":"2028-03-20","hemoglobin_g_dL":10.3,"wbc_k_uL":4.8,"platelets_k_uL":285,"creatinine_mg_dL":1.71,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_3073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":88,"sex":"male","bmi":24.0,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-02-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-38},"pfs_months":40.84},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-29","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":71.4,"censored":false},"longitudinal_labs":[{"date":"2020-12-04","hemoglobin_g_dL":13.2,"wbc_k_uL":9.9,"platelets_k_uL":405,"creatinine_mg_dL":0.87,"alt_U_L":74},{"date":"2021-08-02","hemoglobin_g_dL":13.7,"wbc_k_uL":5.5,"platelets_k_uL":268,"creatinine_mg_dL":1.18,"alt_U_L":73},{"date":"2024-08-29","hemoglobin_g_dL":9.7,"wbc_k_uL":4.4,"platelets_k_uL":231,"creatinine_mg_dL":1.91,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_3074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":63,"sex":"female","bmi":34.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-83},"pfs_months":21.13},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":false},"longitudinal_labs":[{"date":"2020-02-23","hemoglobin_g_dL":13.2,"wbc_k_uL":10.5,"platelets_k_uL":425,"creatinine_mg_dL":0.8,"alt_U_L":59},{"date":"2020-10-27","hemoglobin_g_dL":13.7,"wbc_k_uL":4.8,"platelets_k_uL":266,"creatinine_mg_dL":1.06,"alt_U_L":63},{"date":"2022-03-25","hemoglobin_g_dL":11.5,"wbc_k_uL":7.9,"platelets_k_uL":348,"creatinine_mg_dL":1.07,"alt_U_L":47}]}
{"patient_id":"ANODE_SYNTH_2025_3075","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":84,"sex":"female","bmi":18.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-09-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-57},"pfs_months":16.99},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.3,"censored":true},"longitudinal_labs":[{"date":"2021-08-17","hemoglobin_g_dL":15.5,"wbc_k_uL":6.1,"platelets_k_uL":230,"creatinine_mg_dL":0.66,"alt_U_L":60},{"date":"2022-03-10","hemoglobin_g_dL":13.4,"wbc_k_uL":6.1,"platelets_k_uL":365,"creatinine_mg_dL":0.75,"alt_U_L":39},{"date":"2023-02-22","hemoglobin_g_dL":11.0,"wbc_k_uL":3.6,"platelets_k_uL":207,"creatinine_mg_dL":1.28,"alt_U_L":76}]}
{"patient_id":"ANODE_SYNTH_2025_3076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.5,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":87,"sex":"female","bmi":32.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.5,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-02-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-46},"pfs_months":31.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.7,"censored":false},"longitudinal_labs":[{"date":"2020-01-19","hemoglobin_g_dL":14.1,"wbc_k_uL":5.5,"platelets_k_uL":371,"creatinine_mg_dL":0.96,"alt_U_L":71},{"date":"2020-08-14","hemoglobin_g_dL":10.7,"wbc_k_uL":4.7,"platelets_k_uL":318,"creatinine_mg_dL":1.56,"alt_U_L":95},{"date":"2022-11-11","hemoglobin_g_dL":11.9,"wbc_k_uL":6.0,"platelets_k_uL":114,"creatinine_mg_dL":1.75,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_3077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":51,"sex":"male","bmi":37.5,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-03-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-64},"pfs_months":40.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-09-16","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":71.1,"censored":false},"longitudinal_labs":[{"date":"2023-01-21","hemoglobin_g_dL":12.0,"wbc_k_uL":5.8,"platelets_k_uL":441,"creatinine_mg_dL":1.15,"alt_U_L":28},{"date":"2023-09-09","hemoglobin_g_dL":13.0,"wbc_k_uL":4.3,"platelets_k_uL":252,"creatinine_mg_dL":1.19,"alt_U_L":48},{"date":"2026-09-16","hemoglobin_g_dL":12.7,"wbc_k_uL":5.5,"platelets_k_uL":275,"creatinine_mg_dL":1.5,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_3078","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":57,"sex":"female","bmi":20.8,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-08-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-51},"pfs_months":14.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.5,"censored":false},"longitudinal_labs":[{"date":"2023-08-07","hemoglobin_g_dL":12.7,"wbc_k_uL":5.0,"platelets_k_uL":425,"creatinine_mg_dL":1.21,"alt_U_L":12},{"date":"2024-02-18","hemoglobin_g_dL":13.3,"wbc_k_uL":4.6,"platelets_k_uL":201,"creatinine_mg_dL":1.36,"alt_U_L":67},{"date":"2024-12-17","hemoglobin_g_dL":10.0,"wbc_k_uL":6.4,"platelets_k_uL":182,"creatinine_mg_dL":0.85,"alt_U_L":182}]}
{"patient_id":"ANODE_SYNTH_2025_3079","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":79,"sex":"male","bmi":21.6,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-09-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-84},"pfs_months":29.5},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":46.8,"censored":false},"longitudinal_labs":[{"date":"2022-08-11","hemoglobin_g_dL":14.2,"wbc_k_uL":5.7,"platelets_k_uL":222,"creatinine_mg_dL":1.27,"alt_U_L":32},{"date":"2023-03-10","hemoglobin_g_dL":10.5,"wbc_k_uL":8.0,"platelets_k_uL":361,"creatinine_mg_dL":1.14,"alt_U_L":118},{"date":"2025-04-14","hemoglobin_g_dL":12.4,"wbc_k_uL":5.2,"platelets_k_uL":117,"creatinine_mg_dL":1.32,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_3080","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":68,"sex":"female","bmi":35.7,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-05-31","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-59},"pfs_months":21.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.3,"censored":false},"longitudinal_labs":[{"date":"2025-03-24","hemoglobin_g_dL":11.9,"wbc_k_uL":5.5,"platelets_k_uL":335,"creatinine_mg_dL":0.83,"alt_U_L":78},{"date":"2025-11-27","hemoglobin_g_dL":12.6,"wbc_k_uL":7.6,"platelets_k_uL":257,"creatinine_mg_dL":1.08,"alt_U_L":29},{"date":"2027-05-04","hemoglobin_g_dL":12.6,"wbc_k_uL":4.7,"platelets_k_uL":185,"creatinine_mg_dL":1.82,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_3081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":69,"sex":"female","bmi":28.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-61},"pfs_months":27.7},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":48.0,"censored":false},"longitudinal_labs":[{"date":"2020-12-18","hemoglobin_g_dL":14.5,"wbc_k_uL":10.9,"platelets_k_uL":245,"creatinine_mg_dL":0.81,"alt_U_L":22},{"date":"2021-07-09","hemoglobin_g_dL":13.4,"wbc_k_uL":5.3,"platelets_k_uL":300,"creatinine_mg_dL":1.28,"alt_U_L":73},{"date":"2023-06-15","hemoglobin_g_dL":9.7,"wbc_k_uL":7.8,"platelets_k_uL":274,"creatinine_mg_dL":0.89,"alt_U_L":121}]}
{"patient_id":"ANODE_SYNTH_2025_3082","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":62,"sex":"female","bmi":32.5,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-11-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-81},"pfs_months":15.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":19.8,"censored":false},"longitudinal_labs":[{"date":"2025-10-16","hemoglobin_g_dL":14.9,"wbc_k_uL":5.3,"platelets_k_uL":269,"creatinine_mg_dL":0.76,"alt_U_L":64},{"date":"2026-05-06","hemoglobin_g_dL":13.2,"wbc_k_uL":5.4,"platelets_k_uL":252,"creatinine_mg_dL":1.6,"alt_U_L":19},{"date":"2027-02-11","hemoglobin_g_dL":12.8,"wbc_k_uL":5.4,"platelets_k_uL":165,"creatinine_mg_dL":1.51,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_3083","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":73,"sex":"female","bmi":29.3,"smoking_pack_years":19,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-08-14","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-62},"pfs_months":37.03},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":54.4,"censored":false},"longitudinal_labs":[{"date":"2020-07-05","hemoglobin_g_dL":14.4,"wbc_k_uL":5.5,"platelets_k_uL":166,"creatinine_mg_dL":0.74,"alt_U_L":53},{"date":"2021-02-10","hemoglobin_g_dL":12.4,"wbc_k_uL":4.8,"platelets_k_uL":158,"creatinine_mg_dL":1.3,"alt_U_L":88},{"date":"2023-10-27","hemoglobin_g_dL":12.1,"wbc_k_uL":6.3,"platelets_k_uL":297,"creatinine_mg_dL":1.06,"alt_U_L":123}]}
{"patient_id":"ANODE_SYNTH_2025_3084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":85,"sex":"female","bmi":22.4,"smoking_pack_years":30,"ecog_performance_status":2,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-05-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-52},"pfs_months":39.26},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":68.8,"censored":true},"longitudinal_labs":[{"date":"2022-03-20","hemoglobin_g_dL":14.2,"wbc_k_uL":4.8,"platelets_k_uL":324,"creatinine_mg_dL":1.18,"alt_U_L":62},{"date":"2022-11-02","hemoglobin_g_dL":12.9,"wbc_k_uL":5.5,"platelets_k_uL":235,"creatinine_mg_dL":1.06,"alt_U_L":69},{"date":"2025-09-15","hemoglobin_g_dL":11.9,"wbc_k_uL":4.7,"platelets_k_uL":168,"creatinine_mg_dL":1.9,"alt_U_L":113}]}
{"patient_id":"ANODE_SYNTH_2025_3085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":78,"sex":"female","bmi":18.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-56},"pfs_months":15.21},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.9,"censored":false},"longitudinal_labs":[{"date":"2025-11-12","hemoglobin_g_dL":13.5,"wbc_k_uL":9.3,"platelets_k_uL":430,"creatinine_mg_dL":0.93,"alt_U_L":20},{"date":"2026-06-19","hemoglobin_g_dL":10.5,"wbc_k_uL":8.4,"platelets_k_uL":244,"creatinine_mg_dL":1.27,"alt_U_L":64},{"date":"2027-05-15","hemoglobin_g_dL":10.4,"wbc_k_uL":7.8,"platelets_k_uL":148,"creatinine_mg_dL":1.96,"alt_U_L":112}]}
{"patient_id":"ANODE_SYNTH_2025_3086","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":67,"sex":"male","bmi":22.5,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-06-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-76},"pfs_months":11.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":18.5,"censored":true},"longitudinal_labs":[{"date":"2021-05-12","hemoglobin_g_dL":11.5,"wbc_k_uL":7.0,"platelets_k_uL":340,"creatinine_mg_dL":1.08,"alt_U_L":71},{"date":"2021-12-20","hemoglobin_g_dL":11.8,"wbc_k_uL":8.2,"platelets_k_uL":252,"creatinine_mg_dL":1.48,"alt_U_L":86},{"date":"2022-07-17","hemoglobin_g_dL":12.9,"wbc_k_uL":4.5,"platelets_k_uL":274,"creatinine_mg_dL":1.96,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_3087","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.1,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":79,"sex":"male","bmi":29.1,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-06-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-49},"pfs_months":26.09},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.4,"censored":true},"longitudinal_labs":[{"date":"2025-05-15","hemoglobin_g_dL":11.8,"wbc_k_uL":4.6,"platelets_k_uL":207,"creatinine_mg_dL":0.7,"alt_U_L":50},{"date":"2025-12-16","hemoglobin_g_dL":13.7,"wbc_k_uL":5.7,"platelets_k_uL":184,"creatinine_mg_dL":0.94,"alt_U_L":80},{"date":"2027-10-11","hemoglobin_g_dL":10.5,"wbc_k_uL":3.3,"platelets_k_uL":283,"creatinine_mg_dL":1.63,"alt_U_L":26}]}
{"patient_id":"ANODE_SYNTH_2025_3088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":74,"sex":"female","bmi":37.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-21","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-30},"pfs_months":23.69},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":38.1,"censored":false},"longitudinal_labs":[{"date":"2023-01-06","hemoglobin_g_dL":14.5,"wbc_k_uL":8.1,"platelets_k_uL":199,"creatinine_mg_dL":0.74,"alt_U_L":48},{"date":"2023-08-20","hemoglobin_g_dL":10.9,"wbc_k_uL":8.0,"platelets_k_uL":289,"creatinine_mg_dL":1.14,"alt_U_L":88},{"date":"2025-04-06","hemoglobin_g_dL":11.5,"wbc_k_uL":6.2,"platelets_k_uL":105,"creatinine_mg_dL":1.96,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_3089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":63,"sex":"female","bmi":34.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-02-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-65},"pfs_months":21.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-07","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.2,"censored":false},"longitudinal_labs":[{"date":"2020-01-04","hemoglobin_g_dL":13.6,"wbc_k_uL":10.1,"platelets_k_uL":365,"creatinine_mg_dL":0.71,"alt_U_L":30},{"date":"2020-08-06","hemoglobin_g_dL":13.5,"wbc_k_uL":6.1,"platelets_k_uL":185,"creatinine_mg_dL":1.4,"alt_U_L":117},{"date":"2022-01-07","hemoglobin_g_dL":12.5,"wbc_k_uL":6.5,"platelets_k_uL":126,"creatinine_mg_dL":1.08,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_3090","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":62,"sex":"female","bmi":21.8,"smoking_pack_years":58,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-84},"pfs_months":20.73},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.4,"censored":false},"longitudinal_labs":[{"date":"2022-06-09","hemoglobin_g_dL":11.7,"wbc_k_uL":7.9,"platelets_k_uL":275,"creatinine_mg_dL":1.08,"alt_U_L":69},{"date":"2022-12-27","hemoglobin_g_dL":10.4,"wbc_k_uL":5.9,"platelets_k_uL":318,"creatinine_mg_dL":1.2,"alt_U_L":41},{"date":"2024-04-16","hemoglobin_g_dL":10.9,"wbc_k_uL":3.3,"platelets_k_uL":122,"creatinine_mg_dL":1.93,"alt_U_L":90}]}
{"patient_id":"ANODE_SYNTH_2025_3091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":66,"sex":"female","bmi":36.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-73},"pfs_months":19.61},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.0,"censored":false},"longitudinal_labs":[{"date":"2022-01-09","hemoglobin_g_dL":12.1,"wbc_k_uL":7.2,"platelets_k_uL":169,"creatinine_mg_dL":0.9,"alt_U_L":34},{"date":"2022-09-08","hemoglobin_g_dL":12.0,"wbc_k_uL":6.3,"platelets_k_uL":152,"creatinine_mg_dL":1.06,"alt_U_L":24},{"date":"2023-12-26","hemoglobin_g_dL":10.5,"wbc_k_uL":5.6,"platelets_k_uL":212,"creatinine_mg_dL":1.55,"alt_U_L":187}]}
{"patient_id":"ANODE_SYNTH_2025_3092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":82,"sex":"male","bmi":27.5,"smoking_pack_years":49,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-08-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-41},"pfs_months":33.51},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":53.7,"censored":false},"longitudinal_labs":[{"date":"2021-06-20","hemoglobin_g_dL":15.4,"wbc_k_uL":10.6,"platelets_k_uL":208,"creatinine_mg_dL":1.13,"alt_U_L":23},{"date":"2022-02-15","hemoglobin_g_dL":10.9,"wbc_k_uL":5.5,"platelets_k_uL":292,"creatinine_mg_dL":0.79,"alt_U_L":52},{"date":"2024-06-15","hemoglobin_g_dL":10.4,"wbc_k_uL":3.9,"platelets_k_uL":260,"creatinine_mg_dL":1.37,"alt_U_L":171}]}
{"patient_id":"ANODE_SYNTH_2025_3093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.0,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":49,"sex":"female","bmi":23.4,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-02-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-84},"pfs_months":27.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.5,"censored":false},"longitudinal_labs":[{"date":"2023-01-01","hemoglobin_g_dL":12.6,"wbc_k_uL":6.7,"platelets_k_uL":167,"creatinine_mg_dL":0.81,"alt_U_L":21},{"date":"2023-08-10","hemoglobin_g_dL":12.9,"wbc_k_uL":6.9,"platelets_k_uL":363,"creatinine_mg_dL":0.72,"alt_U_L":75},{"date":"2025-07-02","hemoglobin_g_dL":12.6,"wbc_k_uL":5.6,"platelets_k_uL":143,"creatinine_mg_dL":0.93,"alt_U_L":100}]}
{"patient_id":"ANODE_SYNTH_2025_3094","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":60,"sex":"male","bmi":27.8,"smoking_pack_years":64,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-02-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-42},"pfs_months":15.41},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-06-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.1,"censored":true},"longitudinal_labs":[{"date":"2020-01-14","hemoglobin_g_dL":14.4,"wbc_k_uL":5.2,"platelets_k_uL":324,"creatinine_mg_dL":0.83,"alt_U_L":56},{"date":"2020-08-05","hemoglobin_g_dL":11.7,"wbc_k_uL":6.6,"platelets_k_uL":254,"creatinine_mg_dL":1.1,"alt_U_L":116},{"date":"2021-06-23","hemoglobin_g_dL":11.4,"wbc_k_uL":4.8,"platelets_k_uL":128,"creatinine_mg_dL":1.69,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_3095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":60,"sex":"male","bmi":28.0,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-11-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-47},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":13.8,"censored":false},"longitudinal_labs":[{"date":"2024-09-24","hemoglobin_g_dL":12.3,"wbc_k_uL":9.7,"platelets_k_uL":406,"creatinine_mg_dL":1.15,"alt_U_L":31},{"date":"2025-05-03","hemoglobin_g_dL":12.0,"wbc_k_uL":7.3,"platelets_k_uL":224,"creatinine_mg_dL":1.36,"alt_U_L":104},{"date":"2025-03-26","hemoglobin_g_dL":11.3,"wbc_k_uL":3.5,"platelets_k_uL":300,"creatinine_mg_dL":1.66,"alt_U_L":87}]}
{"patient_id":"ANODE_SYNTH_2025_3096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":61,"sex":"female","bmi":27.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-10-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-68},"pfs_months":17.15},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":22.8,"censored":true},"longitudinal_labs":[{"date":"2021-09-11","hemoglobin_g_dL":14.0,"wbc_k_uL":5.5,"platelets_k_uL":261,"creatinine_mg_dL":1.03,"alt_U_L":25},{"date":"2022-03-31","hemoglobin_g_dL":12.4,"wbc_k_uL":8.8,"platelets_k_uL":269,"creatinine_mg_dL":0.75,"alt_U_L":74},{"date":"2023-05-04","hemoglobin_g_dL":10.4,"wbc_k_uL":3.4,"platelets_k_uL":100,"creatinine_mg_dL":1.51,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_3097","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":80,"sex":"female","bmi":22.7,"smoking_pack_years":27,"ecog_performance_status":2,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-07-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-56},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.3,"censored":false},"longitudinal_labs":[{"date":"2022-06-25","hemoglobin_g_dL":11.8,"wbc_k_uL":9.7,"platelets_k_uL":213,"creatinine_mg_dL":1.14,"alt_U_L":55},{"date":"2023-01-20","hemoglobin_g_dL":13.9,"wbc_k_uL":4.6,"platelets_k_uL":258,"creatinine_mg_dL":1.3,"alt_U_L":48},{"date":"2022-11-27","hemoglobin_g_dL":12.4,"wbc_k_uL":7.2,"platelets_k_uL":219,"creatinine_mg_dL":1.04,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_3098","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":50,"sex":"male","bmi":21.9,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-01-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-61},"pfs_months":19.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.4,"censored":true},"longitudinal_labs":[{"date":"2022-12-19","hemoglobin_g_dL":14.6,"wbc_k_uL":7.7,"platelets_k_uL":197,"creatinine_mg_dL":0.68,"alt_U_L":33},{"date":"2023-07-01","hemoglobin_g_dL":13.6,"wbc_k_uL":8.7,"platelets_k_uL":237,"creatinine_mg_dL":1.58,"alt_U_L":116},{"date":"2024-10-15","hemoglobin_g_dL":10.9,"wbc_k_uL":5.8,"platelets_k_uL":323,"creatinine_mg_dL":1.93,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_3099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":79,"sex":"female","bmi":26.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-76},"pfs_months":22.01},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-02","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":false},"longitudinal_labs":[{"date":"2025-03-02","hemoglobin_g_dL":13.4,"wbc_k_uL":7.6,"platelets_k_uL":257,"creatinine_mg_dL":1.08,"alt_U_L":43},{"date":"2025-09-25","hemoglobin_g_dL":10.8,"wbc_k_uL":7.3,"platelets_k_uL":164,"creatinine_mg_dL":1.01,"alt_U_L":115},{"date":"2027-03-02","hemoglobin_g_dL":10.0,"wbc_k_uL":4.5,"platelets_k_uL":271,"creatinine_mg_dL":1.16,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_3100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":55,"sex":"male","bmi":27.1,"smoking_pack_years":54,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-05-20","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-34},"pfs_months":17.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":23.0,"censored":true},"longitudinal_labs":[{"date":"2022-04-15","hemoglobin_g_dL":14.8,"wbc_k_uL":8.9,"platelets_k_uL":169,"creatinine_mg_dL":1.03,"alt_U_L":80},{"date":"2022-11-16","hemoglobin_g_dL":10.3,"wbc_k_uL":8.0,"platelets_k_uL":169,"creatinine_mg_dL":1.42,"alt_U_L":51},{"date":"2023-11-15","hemoglobin_g_dL":10.3,"wbc_k_uL":5.4,"platelets_k_uL":238,"creatinine_mg_dL":1.82,"alt_U_L":139}]}
{"patient_id":"ANODE_SYNTH_2025_3101","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":71,"sex":"female","bmi":30.3,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-03-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-52},"pfs_months":18.76},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.7,"censored":false},"longitudinal_labs":[{"date":"2023-01-02","hemoglobin_g_dL":14.9,"wbc_k_uL":5.0,"platelets_k_uL":290,"creatinine_mg_dL":0.72,"alt_U_L":19},{"date":"2023-09-06","hemoglobin_g_dL":12.4,"wbc_k_uL":8.9,"platelets_k_uL":163,"creatinine_mg_dL":1.17,"alt_U_L":15},{"date":"2024-11-27","hemoglobin_g_dL":11.2,"wbc_k_uL":6.9,"platelets_k_uL":176,"creatinine_mg_dL":0.8,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_3102","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.9,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":56,"sex":"female","bmi":20.3,"smoking_pack_years":18,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-06-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-53},"pfs_months":7.49},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":25.5,"censored":false},"longitudinal_labs":[{"date":"2024-05-17","hemoglobin_g_dL":11.7,"wbc_k_uL":8.3,"platelets_k_uL":268,"creatinine_mg_dL":1.13,"alt_U_L":57},{"date":"2024-12-22","hemoglobin_g_dL":12.4,"wbc_k_uL":4.2,"platelets_k_uL":287,"creatinine_mg_dL":1.01,"alt_U_L":42},{"date":"2025-03-07","hemoglobin_g_dL":9.6,"wbc_k_uL":4.5,"platelets_k_uL":275,"creatinine_mg_dL":1.08,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_3103","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":65,"sex":"female","bmi":32.3,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-02-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-76},"pfs_months":37.82},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":62.8,"censored":false},"longitudinal_labs":[{"date":"2022-12-15","hemoglobin_g_dL":15.0,"wbc_k_uL":6.8,"platelets_k_uL":367,"creatinine_mg_dL":0.69,"alt_U_L":58},{"date":"2023-08-16","hemoglobin_g_dL":10.8,"wbc_k_uL":5.0,"platelets_k_uL":262,"creatinine_mg_dL":1.5,"alt_U_L":57},{"date":"2026-04-29","hemoglobin_g_dL":9.7,"wbc_k_uL":7.0,"platelets_k_uL":150,"creatinine_mg_dL":1.91,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_3104","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":84,"sex":"male","bmi":29.6,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-33},"pfs_months":40.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-05-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":67.3,"censored":false},"longitudinal_labs":[{"date":"2025-11-15","hemoglobin_g_dL":12.6,"wbc_k_uL":10.7,"platelets_k_uL":269,"creatinine_mg_dL":1.3,"alt_U_L":23},{"date":"2026-06-23","hemoglobin_g_dL":13.7,"wbc_k_uL":6.8,"platelets_k_uL":143,"creatinine_mg_dL":0.86,"alt_U_L":47},{"date":"2029-05-28","hemoglobin_g_dL":12.5,"wbc_k_uL":3.7,"platelets_k_uL":206,"creatinine_mg_dL":0.91,"alt_U_L":70}]}
{"patient_id":"ANODE_SYNTH_2025_3105","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":51,"sex":"male","bmi":29.6,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-05-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-30},"pfs_months":16.26},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.2,"censored":true},"longitudinal_labs":[{"date":"2022-03-21","hemoglobin_g_dL":14.8,"wbc_k_uL":8.8,"platelets_k_uL":223,"creatinine_mg_dL":0.86,"alt_U_L":10},{"date":"2022-11-01","hemoglobin_g_dL":11.7,"wbc_k_uL":4.3,"platelets_k_uL":302,"creatinine_mg_dL":1.37,"alt_U_L":46},{"date":"2023-11-11","hemoglobin_g_dL":11.9,"wbc_k_uL":4.2,"platelets_k_uL":312,"creatinine_mg_dL":0.93,"alt_U_L":156}]}
{"patient_id":"ANODE_SYNTH_2025_3106","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":87,"sex":"female","bmi":25.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["brain","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-10-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-38},"pfs_months":32.39},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":52.9,"censored":true},"longitudinal_labs":[{"date":"2025-08-19","hemoglobin_g_dL":12.3,"wbc_k_uL":8.9,"platelets_k_uL":373,"creatinine_mg_dL":0.8,"alt_U_L":60},{"date":"2026-04-02","hemoglobin_g_dL":13.8,"wbc_k_uL":5.2,"platelets_k_uL":213,"creatinine_mg_dL":1.4,"alt_U_L":56},{"date":"2028-07-30","hemoglobin_g_dL":10.5,"wbc_k_uL":3.7,"platelets_k_uL":251,"creatinine_mg_dL":1.77,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_3107","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":51,"sex":"female","bmi":32.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-03-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-67},"pfs_months":29.34},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-06","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":36.8,"censored":false},"longitudinal_labs":[{"date":"2025-03-09","hemoglobin_g_dL":12.6,"wbc_k_uL":6.4,"platelets_k_uL":213,"creatinine_mg_dL":1.2,"alt_U_L":24},{"date":"2025-09-21","hemoglobin_g_dL":11.4,"wbc_k_uL":4.0,"platelets_k_uL":248,"creatinine_mg_dL":1.34,"alt_U_L":84},{"date":"2027-10-06","hemoglobin_g_dL":11.6,"wbc_k_uL":6.5,"platelets_k_uL":322,"creatinine_mg_dL":1.86,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_3108","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":71,"sex":"female","bmi":22.4,"smoking_pack_years":58,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-08-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-39},"pfs_months":11.56},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.5,"censored":false},"longitudinal_labs":[{"date":"2023-06-21","hemoglobin_g_dL":13.9,"wbc_k_uL":6.2,"platelets_k_uL":309,"creatinine_mg_dL":1.18,"alt_U_L":66},{"date":"2024-02-20","hemoglobin_g_dL":10.9,"wbc_k_uL":5.8,"platelets_k_uL":359,"creatinine_mg_dL":1.02,"alt_U_L":20},{"date":"2024-09-11","hemoglobin_g_dL":11.9,"wbc_k_uL":3.8,"platelets_k_uL":234,"creatinine_mg_dL":1.36,"alt_U_L":79}]}
{"patient_id":"ANODE_SYNTH_2025_3109","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":85,"sex":"female","bmi":31.0,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-04-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-72},"pfs_months":40.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":62.1,"censored":false},"longitudinal_labs":[{"date":"2022-02-20","hemoglobin_g_dL":14.0,"wbc_k_uL":4.5,"platelets_k_uL":222,"creatinine_mg_dL":1.01,"alt_U_L":78},{"date":"2022-10-07","hemoglobin_g_dL":13.7,"wbc_k_uL":5.9,"platelets_k_uL":180,"creatinine_mg_dL":1.1,"alt_U_L":35},{"date":"2025-09-05","hemoglobin_g_dL":10.8,"wbc_k_uL":5.1,"platelets_k_uL":316,"creatinine_mg_dL":1.78,"alt_U_L":102}]}
{"patient_id":"ANODE_SYNTH_2025_3110","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":52,"sex":"female","bmi":32.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-62},"pfs_months":21.36},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.5,"censored":true},"longitudinal_labs":[{"date":"2022-06-09","hemoglobin_g_dL":13.8,"wbc_k_uL":5.1,"platelets_k_uL":399,"creatinine_mg_dL":0.76,"alt_U_L":53},{"date":"2023-01-25","hemoglobin_g_dL":12.0,"wbc_k_uL":8.1,"platelets_k_uL":310,"creatinine_mg_dL":1.35,"alt_U_L":26},{"date":"2024-06-11","hemoglobin_g_dL":10.7,"wbc_k_uL":5.5,"platelets_k_uL":258,"creatinine_mg_dL":1.19,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_3111","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":87,"sex":"female","bmi":21.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-71},"pfs_months":9.86},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.4,"censored":false},"longitudinal_labs":[{"date":"2020-09-11","hemoglobin_g_dL":14.2,"wbc_k_uL":4.9,"platelets_k_uL":430,"creatinine_mg_dL":1.11,"alt_U_L":54},{"date":"2021-04-29","hemoglobin_g_dL":10.4,"wbc_k_uL":7.1,"platelets_k_uL":263,"creatinine_mg_dL":0.92,"alt_U_L":16},{"date":"2021-10-02","hemoglobin_g_dL":11.9,"wbc_k_uL":3.0,"platelets_k_uL":121,"creatinine_mg_dL":1.76,"alt_U_L":71}]}
{"patient_id":"ANODE_SYNTH_2025_3112","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":48,"sex":"male","bmi":33.8,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-72},"pfs_months":10.64},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.6,"censored":false},"longitudinal_labs":[{"date":"2025-05-23","hemoglobin_g_dL":11.7,"wbc_k_uL":9.3,"platelets_k_uL":237,"creatinine_mg_dL":0.75,"alt_U_L":54},{"date":"2025-12-13","hemoglobin_g_dL":13.5,"wbc_k_uL":6.8,"platelets_k_uL":262,"creatinine_mg_dL":0.74,"alt_U_L":101},{"date":"2026-06-21","hemoglobin_g_dL":13.0,"wbc_k_uL":4.3,"platelets_k_uL":224,"creatinine_mg_dL":1.59,"alt_U_L":117}]}
{"patient_id":"ANODE_SYNTH_2025_3113","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":79,"sex":"female","bmi":24.8,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-30","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-31},"pfs_months":38.67},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":60.3,"censored":true},"longitudinal_labs":[{"date":"2025-01-02","hemoglobin_g_dL":14.8,"wbc_k_uL":5.4,"platelets_k_uL":279,"creatinine_mg_dL":0.8,"alt_U_L":28},{"date":"2025-07-29","hemoglobin_g_dL":11.6,"wbc_k_uL":6.3,"platelets_k_uL":200,"creatinine_mg_dL":1.19,"alt_U_L":83},{"date":"2028-06-07","hemoglobin_g_dL":11.0,"wbc_k_uL":3.1,"platelets_k_uL":318,"creatinine_mg_dL":1.61,"alt_U_L":103}]}
{"patient_id":"ANODE_SYNTH_2025_3114","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.2,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":59,"sex":"female","bmi":18.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-02-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-73},"pfs_months":18.1},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.1,"censored":false},"longitudinal_labs":[{"date":"2022-01-14","hemoglobin_g_dL":15.4,"wbc_k_uL":8.3,"platelets_k_uL":445,"creatinine_mg_dL":0.92,"alt_U_L":26},{"date":"2022-08-21","hemoglobin_g_dL":13.1,"wbc_k_uL":5.5,"platelets_k_uL":342,"creatinine_mg_dL":0.73,"alt_U_L":20},{"date":"2023-08-31","hemoglobin_g_dL":10.9,"wbc_k_uL":6.6,"platelets_k_uL":217,"creatinine_mg_dL":1.89,"alt_U_L":106}]}
{"patient_id":"ANODE_SYNTH_2025_3115","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.3,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":55,"sex":"male","bmi":20.0,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-82},"pfs_months":38.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":63.6,"censored":true},"longitudinal_labs":[{"date":"2021-01-18","hemoglobin_g_dL":13.5,"wbc_k_uL":10.2,"platelets_k_uL":389,"creatinine_mg_dL":1.01,"alt_U_L":58},{"date":"2021-09-10","hemoglobin_g_dL":11.8,"wbc_k_uL":3.9,"platelets_k_uL":210,"creatinine_mg_dL":1.29,"alt_U_L":73},{"date":"2024-06-16","hemoglobin_g_dL":12.9,"wbc_k_uL":7.5,"platelets_k_uL":328,"creatinine_mg_dL":0.81,"alt_U_L":163}]}
{"patient_id":"ANODE_SYNTH_2025_3116","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":51,"sex":"male","bmi":36.5,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-09-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-30},"pfs_months":37.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":67.3,"censored":true},"longitudinal_labs":[{"date":"2021-09-09","hemoglobin_g_dL":12.3,"wbc_k_uL":7.6,"platelets_k_uL":286,"creatinine_mg_dL":0.7,"alt_U_L":41},{"date":"2022-03-25","hemoglobin_g_dL":10.2,"wbc_k_uL":8.9,"platelets_k_uL":298,"creatinine_mg_dL":1.22,"alt_U_L":110},{"date":"2024-11-23","hemoglobin_g_dL":11.6,"wbc_k_uL":5.0,"platelets_k_uL":331,"creatinine_mg_dL":1.17,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_3117","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.9,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":78,"sex":"female","bmi":26.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain","pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-62},"pfs_months":30.13},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.6,"censored":false},"longitudinal_labs":[{"date":"2022-05-23","hemoglobin_g_dL":14.7,"wbc_k_uL":8.6,"platelets_k_uL":240,"creatinine_mg_dL":0.91,"alt_U_L":31},{"date":"2022-12-24","hemoglobin_g_dL":11.4,"wbc_k_uL":7.7,"platelets_k_uL":264,"creatinine_mg_dL":0.74,"alt_U_L":86},{"date":"2025-01-13","hemoglobin_g_dL":9.5,"wbc_k_uL":7.5,"platelets_k_uL":307,"creatinine_mg_dL":1.64,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_3118","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":51,"sex":"female","bmi":19.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-58},"pfs_months":26.71},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":37.8,"censored":false},"longitudinal_labs":[{"date":"2022-03-05","hemoglobin_g_dL":14.8,"wbc_k_uL":6.4,"platelets_k_uL":337,"creatinine_mg_dL":1.21,"alt_U_L":49},{"date":"2022-09-15","hemoglobin_g_dL":11.2,"wbc_k_uL":6.4,"platelets_k_uL":192,"creatinine_mg_dL":1.0,"alt_U_L":118},{"date":"2024-07-16","hemoglobin_g_dL":11.6,"wbc_k_uL":4.4,"platelets_k_uL":208,"creatinine_mg_dL":1.79,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_3119","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":70,"sex":"female","bmi":35.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-01-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-67},"pfs_months":30.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":48.7,"censored":true},"longitudinal_labs":[{"date":"2023-01-12","hemoglobin_g_dL":11.6,"wbc_k_uL":9.7,"platelets_k_uL":220,"creatinine_mg_dL":1.08,"alt_U_L":70},{"date":"2023-07-30","hemoglobin_g_dL":11.5,"wbc_k_uL":5.6,"platelets_k_uL":242,"creatinine_mg_dL":1.04,"alt_U_L":60},{"date":"2025-10-05","hemoglobin_g_dL":12.9,"wbc_k_uL":7.3,"platelets_k_uL":191,"creatinine_mg_dL":1.66,"alt_U_L":81}]}
{"patient_id":"ANODE_SYNTH_2025_3120","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":86,"sex":"female","bmi":20.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-70},"pfs_months":17.68},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-29","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":29.7,"censored":false},"longitudinal_labs":[{"date":"2020-06-28","hemoglobin_g_dL":13.9,"wbc_k_uL":8.8,"platelets_k_uL":329,"creatinine_mg_dL":0.61,"alt_U_L":18},{"date":"2021-01-12","hemoglobin_g_dL":10.3,"wbc_k_uL":4.6,"platelets_k_uL":355,"creatinine_mg_dL":1.34,"alt_U_L":100},{"date":"2022-01-29","hemoglobin_g_dL":10.8,"wbc_k_uL":4.3,"platelets_k_uL":327,"creatinine_mg_dL":1.11,"alt_U_L":42}]}
{"patient_id":"ANODE_SYNTH_2025_3121","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":21},"baseline_clinical":{"age":85,"sex":"male","bmi":24.5,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-09-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-60},"pfs_months":28.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":52.4,"censored":false},"longitudinal_labs":[{"date":"2024-08-27","hemoglobin_g_dL":14.5,"wbc_k_uL":9.3,"platelets_k_uL":436,"creatinine_mg_dL":0.95,"alt_U_L":66},{"date":"2025-03-13","hemoglobin_g_dL":13.1,"wbc_k_uL":8.7,"platelets_k_uL":270,"creatinine_mg_dL":1.52,"alt_U_L":50},{"date":"2027-03-27","hemoglobin_g_dL":11.1,"wbc_k_uL":5.2,"platelets_k_uL":246,"creatinine_mg_dL":0.86,"alt_U_L":62}]}
{"patient_id":"ANODE_SYNTH_2025_3122","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":52,"sex":"female","bmi":18.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-56},"pfs_months":22.47},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.2,"censored":true},"longitudinal_labs":[{"date":"2021-10-22","hemoglobin_g_dL":13.3,"wbc_k_uL":8.8,"platelets_k_uL":413,"creatinine_mg_dL":0.63,"alt_U_L":29},{"date":"2022-05-06","hemoglobin_g_dL":11.9,"wbc_k_uL":6.2,"platelets_k_uL":230,"creatinine_mg_dL":0.97,"alt_U_L":25},{"date":"2023-11-13","hemoglobin_g_dL":10.8,"wbc_k_uL":4.8,"platelets_k_uL":235,"creatinine_mg_dL":1.99,"alt_U_L":151}]}
{"patient_id":"ANODE_SYNTH_2025_3123","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":58,"sex":"male","bmi":36.3,"smoking_pack_years":26,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["contralateral lung","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-02-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-80},"pfs_months":14.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.1,"censored":false},"longitudinal_labs":[{"date":"2022-12-17","hemoglobin_g_dL":13.4,"wbc_k_uL":6.1,"platelets_k_uL":185,"creatinine_mg_dL":1.18,"alt_U_L":20},{"date":"2023-08-12","hemoglobin_g_dL":11.9,"wbc_k_uL":6.4,"platelets_k_uL":159,"creatinine_mg_dL":0.74,"alt_U_L":62},{"date":"2024-06-12","hemoglobin_g_dL":9.6,"wbc_k_uL":5.3,"platelets_k_uL":197,"creatinine_mg_dL":1.58,"alt_U_L":87}]}
{"patient_id":"ANODE_SYNTH_2025_3124","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":86,"sex":"female","bmi":37.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-55},"pfs_months":26.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-25","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":46.8,"censored":false},"longitudinal_labs":[{"date":"2023-04-04","hemoglobin_g_dL":13.8,"wbc_k_uL":10.0,"platelets_k_uL":405,"creatinine_mg_dL":0.76,"alt_U_L":24},{"date":"2023-11-29","hemoglobin_g_dL":12.8,"wbc_k_uL":8.6,"platelets_k_uL":346,"creatinine_mg_dL":0.79,"alt_U_L":73},{"date":"2025-09-25","hemoglobin_g_dL":11.1,"wbc_k_uL":8.0,"platelets_k_uL":230,"creatinine_mg_dL":1.46,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_3125","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":81,"sex":"male","bmi":24.7,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-05-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-83},"pfs_months":28.65},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.3,"censored":true},"longitudinal_labs":[{"date":"2024-04-07","hemoglobin_g_dL":12.2,"wbc_k_uL":10.2,"platelets_k_uL":230,"creatinine_mg_dL":0.78,"alt_U_L":36},{"date":"2024-11-22","hemoglobin_g_dL":12.5,"wbc_k_uL":7.5,"platelets_k_uL":236,"creatinine_mg_dL":1.52,"alt_U_L":111},{"date":"2026-11-17","hemoglobin_g_dL":9.6,"wbc_k_uL":7.4,"platelets_k_uL":110,"creatinine_mg_dL":1.0,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_3126","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":81,"sex":"male","bmi":30.0,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-79},"pfs_months":8.28},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.9,"censored":false},"longitudinal_labs":[{"date":"2023-06-01","hemoglobin_g_dL":12.1,"wbc_k_uL":10.5,"platelets_k_uL":383,"creatinine_mg_dL":1.01,"alt_U_L":57},{"date":"2024-01-14","hemoglobin_g_dL":12.6,"wbc_k_uL":4.3,"platelets_k_uL":346,"creatinine_mg_dL":0.81,"alt_U_L":91},{"date":"2024-04-13","hemoglobin_g_dL":10.5,"wbc_k_uL":7.3,"platelets_k_uL":161,"creatinine_mg_dL":1.95,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_3127","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":81,"sex":"female","bmi":25.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-69},"pfs_months":20.6},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-15","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.5,"censored":true},"longitudinal_labs":[{"date":"2025-07-02","hemoglobin_g_dL":12.8,"wbc_k_uL":4.8,"platelets_k_uL":251,"creatinine_mg_dL":0.95,"alt_U_L":49},{"date":"2026-02-24","hemoglobin_g_dL":10.8,"wbc_k_uL":5.7,"platelets_k_uL":283,"creatinine_mg_dL":0.87,"alt_U_L":52},{"date":"2027-06-15","hemoglobin_g_dL":12.1,"wbc_k_uL":4.6,"platelets_k_uL":191,"creatinine_mg_dL":1.15,"alt_U_L":148}]}
{"patient_id":"ANODE_SYNTH_2025_3128","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":70,"sex":"female","bmi":22.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-73},"pfs_months":10.28},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.4,"censored":false},"longitudinal_labs":[{"date":"2022-05-20","hemoglobin_g_dL":12.6,"wbc_k_uL":9.6,"platelets_k_uL":174,"creatinine_mg_dL":1.2,"alt_U_L":45},{"date":"2022-12-30","hemoglobin_g_dL":12.8,"wbc_k_uL":5.9,"platelets_k_uL":213,"creatinine_mg_dL":1.34,"alt_U_L":66},{"date":"2023-06-06","hemoglobin_g_dL":11.5,"wbc_k_uL":4.4,"platelets_k_uL":233,"creatinine_mg_dL":1.77,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_3129","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":62,"sex":"female","bmi":35.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-07-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-68},"pfs_months":22.67},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":true},"longitudinal_labs":[{"date":"2021-06-25","hemoglobin_g_dL":13.4,"wbc_k_uL":8.1,"platelets_k_uL":354,"creatinine_mg_dL":0.8,"alt_U_L":27},{"date":"2022-01-21","hemoglobin_g_dL":10.7,"wbc_k_uL":7.1,"platelets_k_uL":222,"creatinine_mg_dL":1.26,"alt_U_L":61},{"date":"2023-06-28","hemoglobin_g_dL":12.8,"wbc_k_uL":6.1,"platelets_k_uL":308,"creatinine_mg_dL":1.22,"alt_U_L":160}]}
{"patient_id":"ANODE_SYNTH_2025_3130","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":62,"sex":"female","bmi":24.3,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-02-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-40},"pfs_months":41.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":65.7,"censored":false},"longitudinal_labs":[{"date":"2020-01-14","hemoglobin_g_dL":12.3,"wbc_k_uL":10.3,"platelets_k_uL":213,"creatinine_mg_dL":0.61,"alt_U_L":74},{"date":"2020-07-30","hemoglobin_g_dL":11.6,"wbc_k_uL":4.0,"platelets_k_uL":360,"creatinine_mg_dL":1.31,"alt_U_L":53},{"date":"2023-08-18","hemoglobin_g_dL":10.8,"wbc_k_uL":5.8,"platelets_k_uL":236,"creatinine_mg_dL":1.47,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_3131","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":82,"sex":"female","bmi":36.0,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-03-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-74},"pfs_months":15.8},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":23.4,"censored":true},"longitudinal_labs":[{"date":"2021-02-28","hemoglobin_g_dL":11.7,"wbc_k_uL":4.5,"platelets_k_uL":376,"creatinine_mg_dL":1.03,"alt_U_L":17},{"date":"2021-09-11","hemoglobin_g_dL":10.1,"wbc_k_uL":5.8,"platelets_k_uL":167,"creatinine_mg_dL":1.39,"alt_U_L":115},{"date":"2022-07-30","hemoglobin_g_dL":9.6,"wbc_k_uL":4.7,"platelets_k_uL":275,"creatinine_mg_dL":1.76,"alt_U_L":21}]}
{"patient_id":"ANODE_SYNTH_2025_3132","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":62,"sex":"female","bmi":36.0,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-03-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-57},"pfs_months":37.26},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":65.2,"censored":false},"longitudinal_labs":[{"date":"2023-02-14","hemoglobin_g_dL":14.0,"wbc_k_uL":5.7,"platelets_k_uL":246,"creatinine_mg_dL":0.91,"alt_U_L":62},{"date":"2023-09-07","hemoglobin_g_dL":12.1,"wbc_k_uL":7.4,"platelets_k_uL":312,"creatinine_mg_dL":0.91,"alt_U_L":100},{"date":"2026-06-14","hemoglobin_g_dL":10.0,"wbc_k_uL":8.0,"platelets_k_uL":138,"creatinine_mg_dL":1.71,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_3133","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":80,"sex":"male","bmi":33.9,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-08-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-34},"pfs_months":26.78},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":45.4,"censored":true},"longitudinal_labs":[{"date":"2023-06-05","hemoglobin_g_dL":12.3,"wbc_k_uL":6.3,"platelets_k_uL":163,"creatinine_mg_dL":1.02,"alt_U_L":47},{"date":"2024-02-01","hemoglobin_g_dL":13.8,"wbc_k_uL":5.1,"platelets_k_uL":199,"creatinine_mg_dL":1.48,"alt_U_L":109},{"date":"2025-12-07","hemoglobin_g_dL":10.3,"wbc_k_uL":7.4,"platelets_k_uL":336,"creatinine_mg_dL":1.23,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_3134","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":67,"sex":"male","bmi":24.0,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-02-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-58,"peak_response_20wk_change_percent":-36},"pfs_months":11.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-03-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":19.6,"censored":false},"longitudinal_labs":[{"date":"2020-01-22","hemoglobin_g_dL":14.7,"wbc_k_uL":5.6,"platelets_k_uL":415,"creatinine_mg_dL":0.87,"alt_U_L":76},{"date":"2020-08-20","hemoglobin_g_dL":11.4,"wbc_k_uL":7.1,"platelets_k_uL":172,"creatinine_mg_dL":1.27,"alt_U_L":88},{"date":"2021-03-16","hemoglobin_g_dL":10.4,"wbc_k_uL":3.3,"platelets_k_uL":321,"creatinine_mg_dL":1.09,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_3135","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.5,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":78,"sex":"female","bmi":31.8,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-12-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-61},"pfs_months":17.31},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":28.1,"censored":true},"longitudinal_labs":[{"date":"2024-11-04","hemoglobin_g_dL":15.1,"wbc_k_uL":10.1,"platelets_k_uL":180,"creatinine_mg_dL":1.0,"alt_U_L":43},{"date":"2025-06-20","hemoglobin_g_dL":10.6,"wbc_k_uL":5.0,"platelets_k_uL":120,"creatinine_mg_dL":0.82,"alt_U_L":61},{"date":"2026-07-18","hemoglobin_g_dL":10.4,"wbc_k_uL":3.3,"platelets_k_uL":122,"creatinine_mg_dL":0.98,"alt_U_L":83}]}
{"patient_id":"ANODE_SYNTH_2025_3136","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":68,"sex":"female","bmi":25.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["bone","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-11-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-75},"pfs_months":26.84},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.8,"censored":false},"longitudinal_labs":[{"date":"2021-10-26","hemoglobin_g_dL":13.1,"wbc_k_uL":9.1,"platelets_k_uL":240,"creatinine_mg_dL":1.17,"alt_U_L":53},{"date":"2022-05-11","hemoglobin_g_dL":10.1,"wbc_k_uL":5.1,"platelets_k_uL":156,"creatinine_mg_dL":0.8,"alt_U_L":28},{"date":"2024-03-17","hemoglobin_g_dL":12.8,"wbc_k_uL":3.0,"platelets_k_uL":308,"creatinine_mg_dL":1.45,"alt_U_L":77}]}
{"patient_id":"ANODE_SYNTH_2025_3137","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.7,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":76,"sex":"female","bmi":37.4,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-09-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-41},"pfs_months":11.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":20.4,"censored":false},"longitudinal_labs":[{"date":"2025-07-24","hemoglobin_g_dL":12.7,"wbc_k_uL":9.4,"platelets_k_uL":430,"creatinine_mg_dL":1.28,"alt_U_L":18},{"date":"2026-03-21","hemoglobin_g_dL":12.1,"wbc_k_uL":8.5,"platelets_k_uL":282,"creatinine_mg_dL":1.47,"alt_U_L":16},{"date":"2026-10-19","hemoglobin_g_dL":9.5,"wbc_k_uL":4.4,"platelets_k_uL":280,"creatinine_mg_dL":1.85,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_3138","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":66,"sex":"male","bmi":19.3,"smoking_pack_years":52,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-02-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-58},"pfs_months":18.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":24.8,"censored":false},"longitudinal_labs":[{"date":"2020-02-11","hemoglobin_g_dL":15.3,"wbc_k_uL":10.3,"platelets_k_uL":305,"creatinine_mg_dL":1.18,"alt_U_L":57},{"date":"2020-08-24","hemoglobin_g_dL":13.1,"wbc_k_uL":4.8,"platelets_k_uL":310,"creatinine_mg_dL":1.51,"alt_U_L":72},{"date":"2021-09-20","hemoglobin_g_dL":12.7,"wbc_k_uL":6.8,"platelets_k_uL":192,"creatinine_mg_dL":1.61,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_3139","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":61,"sex":"female","bmi":30.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-37},"pfs_months":14.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":false},"longitudinal_labs":[{"date":"2022-07-09","hemoglobin_g_dL":14.1,"wbc_k_uL":4.6,"platelets_k_uL":326,"creatinine_mg_dL":0.85,"alt_U_L":17},{"date":"2023-02-04","hemoglobin_g_dL":13.7,"wbc_k_uL":7.9,"platelets_k_uL":279,"creatinine_mg_dL":1.55,"alt_U_L":103},{"date":"2023-11-26","hemoglobin_g_dL":9.7,"wbc_k_uL":3.1,"platelets_k_uL":148,"creatinine_mg_dL":1.51,"alt_U_L":109}]}
{"patient_id":"ANODE_SYNTH_2025_3140","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":57,"sex":"female","bmi":27.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-12-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-55},"pfs_months":24.18},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-02","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.7,"censored":false},"longitudinal_labs":[{"date":"2025-12-11","hemoglobin_g_dL":14.9,"wbc_k_uL":7.9,"platelets_k_uL":404,"creatinine_mg_dL":0.63,"alt_U_L":17},{"date":"2026-06-28","hemoglobin_g_dL":12.4,"wbc_k_uL":3.8,"platelets_k_uL":311,"creatinine_mg_dL":1.09,"alt_U_L":85},{"date":"2028-02-02","hemoglobin_g_dL":9.9,"wbc_k_uL":7.3,"platelets_k_uL":117,"creatinine_mg_dL":1.84,"alt_U_L":130}]}
{"patient_id":"ANODE_SYNTH_2025_3141","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":56,"sex":"female","bmi":34.7,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-01-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-66},"pfs_months":12.58},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.4,"censored":true},"longitudinal_labs":[{"date":"2021-12-20","hemoglobin_g_dL":15.2,"wbc_k_uL":6.6,"platelets_k_uL":307,"creatinine_mg_dL":1.14,"alt_U_L":57},{"date":"2022-07-19","hemoglobin_g_dL":11.7,"wbc_k_uL":5.3,"platelets_k_uL":242,"creatinine_mg_dL":1.09,"alt_U_L":105},{"date":"2023-02-22","hemoglobin_g_dL":11.1,"wbc_k_uL":3.6,"platelets_k_uL":297,"creatinine_mg_dL":1.87,"alt_U_L":137}]}
{"patient_id":"ANODE_SYNTH_2025_3142","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":73,"sex":"female","bmi":38.0,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-09-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-75},"pfs_months":13.24},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":17.2,"censored":false},"longitudinal_labs":[{"date":"2022-08-18","hemoglobin_g_dL":15.2,"wbc_k_uL":10.2,"platelets_k_uL":159,"creatinine_mg_dL":1.26,"alt_U_L":35},{"date":"2023-02-28","hemoglobin_g_dL":11.2,"wbc_k_uL":6.4,"platelets_k_uL":268,"creatinine_mg_dL":1.52,"alt_U_L":74},{"date":"2023-10-21","hemoglobin_g_dL":12.1,"wbc_k_uL":5.8,"platelets_k_uL":179,"creatinine_mg_dL":1.26,"alt_U_L":20}]}
{"patient_id":"ANODE_SYNTH_2025_3143","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":53,"sex":"female","bmi":19.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-61},"pfs_months":21.62},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.4,"censored":true},"longitudinal_labs":[{"date":"2020-09-17","hemoglobin_g_dL":15.3,"wbc_k_uL":7.6,"platelets_k_uL":387,"creatinine_mg_dL":1.08,"alt_U_L":75},{"date":"2021-05-10","hemoglobin_g_dL":10.8,"wbc_k_uL":6.2,"platelets_k_uL":251,"creatinine_mg_dL":0.85,"alt_U_L":84},{"date":"2022-09-09","hemoglobin_g_dL":10.5,"wbc_k_uL":3.8,"platelets_k_uL":238,"creatinine_mg_dL":1.78,"alt_U_L":139}]}
{"patient_id":"ANODE_SYNTH_2025_3144","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.4,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":55,"sex":"female","bmi":22.4,"smoking_pack_years":57,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-04-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-41},"pfs_months":6.01},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-11-04","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":17.0,"censored":true},"longitudinal_labs":[{"date":"2024-03-16","hemoglobin_g_dL":13.9,"wbc_k_uL":7.2,"platelets_k_uL":439,"creatinine_mg_dL":0.69,"alt_U_L":72},{"date":"2024-10-25","hemoglobin_g_dL":13.6,"wbc_k_uL":6.8,"platelets_k_uL":223,"creatinine_mg_dL":1.07,"alt_U_L":19},{"date":"2024-11-04","hemoglobin_g_dL":11.5,"wbc_k_uL":6.7,"platelets_k_uL":193,"creatinine_mg_dL":1.5,"alt_U_L":58}]}
{"patient_id":"ANODE_SYNTH_2025_3145","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":63,"sex":"female","bmi":34.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-04-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-32},"pfs_months":21.85},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-24","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":false},"longitudinal_labs":[{"date":"2021-03-20","hemoglobin_g_dL":13.8,"wbc_k_uL":6.8,"platelets_k_uL":369,"creatinine_mg_dL":0.63,"alt_U_L":70},{"date":"2021-10-04","hemoglobin_g_dL":10.7,"wbc_k_uL":7.7,"platelets_k_uL":219,"creatinine_mg_dL":0.9,"alt_U_L":80},{"date":"2023-02-24","hemoglobin_g_dL":10.5,"wbc_k_uL":7.7,"platelets_k_uL":280,"creatinine_mg_dL":0.93,"alt_U_L":149}]}
{"patient_id":"ANODE_SYNTH_2025_3146","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":85,"sex":"female","bmi":25.9,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-01-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-30},"pfs_months":13.08},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":33.9,"censored":false},"longitudinal_labs":[{"date":"2023-11-20","hemoglobin_g_dL":15.1,"wbc_k_uL":9.8,"platelets_k_uL":417,"creatinine_mg_dL":1.19,"alt_U_L":51},{"date":"2024-06-29","hemoglobin_g_dL":12.5,"wbc_k_uL":6.2,"platelets_k_uL":249,"creatinine_mg_dL":1.09,"alt_U_L":92},{"date":"2025-03-25","hemoglobin_g_dL":10.9,"wbc_k_uL":4.3,"platelets_k_uL":157,"creatinine_mg_dL":1.95,"alt_U_L":138}]}
{"patient_id":"ANODE_SYNTH_2025_3147","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":76,"sex":"male","bmi":26.0,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-09-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-66},"pfs_months":27.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-02-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.8,"censored":true},"longitudinal_labs":[{"date":"2025-07-02","hemoglobin_g_dL":11.9,"wbc_k_uL":7.8,"platelets_k_uL":297,"creatinine_mg_dL":1.06,"alt_U_L":58},{"date":"2026-03-01","hemoglobin_g_dL":11.5,"wbc_k_uL":8.3,"platelets_k_uL":362,"creatinine_mg_dL":0.97,"alt_U_L":111},{"date":"2028-02-14","hemoglobin_g_dL":12.8,"wbc_k_uL":4.4,"platelets_k_uL":111,"creatinine_mg_dL":1.82,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_3148","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":75,"sex":"female","bmi":19.9,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-11-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-67},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":7.9,"censored":true},"longitudinal_labs":[{"date":"2022-10-17","hemoglobin_g_dL":14.8,"wbc_k_uL":10.8,"platelets_k_uL":299,"creatinine_mg_dL":1.1,"alt_U_L":48},{"date":"2023-05-16","hemoglobin_g_dL":10.1,"wbc_k_uL":5.2,"platelets_k_uL":220,"creatinine_mg_dL":1.6,"alt_U_L":87},{"date":"2023-04-15","hemoglobin_g_dL":12.7,"wbc_k_uL":7.5,"platelets_k_uL":201,"creatinine_mg_dL":1.99,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_3149","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":82,"sex":"female","bmi":23.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.5,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-10-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-43},"pfs_months":13.83},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.8,"censored":false},"longitudinal_labs":[{"date":"2020-09-16","hemoglobin_g_dL":14.3,"wbc_k_uL":7.6,"platelets_k_uL":417,"creatinine_mg_dL":1.14,"alt_U_L":25},{"date":"2021-03-31","hemoglobin_g_dL":12.9,"wbc_k_uL":5.9,"platelets_k_uL":337,"creatinine_mg_dL":1.44,"alt_U_L":104},{"date":"2022-01-12","hemoglobin_g_dL":12.6,"wbc_k_uL":6.3,"platelets_k_uL":144,"creatinine_mg_dL":1.92,"alt_U_L":68}]}
{"patient_id":"ANODE_SYNTH_2025_3150","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.4,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":76,"sex":"female","bmi":26.4,"smoking_pack_years":20,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-01-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-37},"pfs_months":35.19},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":57.6,"censored":false},"longitudinal_labs":[{"date":"2022-11-27","hemoglobin_g_dL":14.8,"wbc_k_uL":7.2,"platelets_k_uL":192,"creatinine_mg_dL":0.92,"alt_U_L":32},{"date":"2023-07-02","hemoglobin_g_dL":11.4,"wbc_k_uL":7.3,"platelets_k_uL":266,"creatinine_mg_dL":1.35,"alt_U_L":108},{"date":"2026-01-09","hemoglobin_g_dL":11.1,"wbc_k_uL":3.3,"platelets_k_uL":308,"creatinine_mg_dL":0.85,"alt_U_L":28}]}
{"patient_id":"ANODE_SYNTH_2025_3151","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":74,"sex":"female","bmi":19.9,"smoking_pack_years":80,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-11-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-79},"pfs_months":18.14},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":true},"longitudinal_labs":[{"date":"2023-10-17","hemoglobin_g_dL":13.5,"wbc_k_uL":8.7,"platelets_k_uL":336,"creatinine_mg_dL":1.06,"alt_U_L":75},{"date":"2024-05-24","hemoglobin_g_dL":13.4,"wbc_k_uL":4.2,"platelets_k_uL":207,"creatinine_mg_dL":1.01,"alt_U_L":57},{"date":"2025-06-30","hemoglobin_g_dL":10.0,"wbc_k_uL":6.5,"platelets_k_uL":276,"creatinine_mg_dL":1.7,"alt_U_L":126}]}
{"patient_id":"ANODE_SYNTH_2025_3152","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":68,"sex":"female","bmi":35.7,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.8,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-02-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-63},"pfs_months":28.42},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":47.7,"censored":false},"longitudinal_labs":[{"date":"2023-12-27","hemoglobin_g_dL":14.4,"wbc_k_uL":6.7,"platelets_k_uL":371,"creatinine_mg_dL":1.14,"alt_U_L":12},{"date":"2024-08-16","hemoglobin_g_dL":12.7,"wbc_k_uL":7.3,"platelets_k_uL":220,"creatinine_mg_dL":1.54,"alt_U_L":107},{"date":"2026-07-12","hemoglobin_g_dL":10.2,"wbc_k_uL":4.7,"platelets_k_uL":340,"creatinine_mg_dL":1.97,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_3153","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":53,"sex":"female","bmi":27.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-72},"pfs_months":18.2},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-11","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":true},"longitudinal_labs":[{"date":"2020-03-01","hemoglobin_g_dL":12.3,"wbc_k_uL":7.3,"platelets_k_uL":168,"creatinine_mg_dL":0.9,"alt_U_L":16},{"date":"2020-10-17","hemoglobin_g_dL":10.1,"wbc_k_uL":6.1,"platelets_k_uL":345,"creatinine_mg_dL":0.76,"alt_U_L":88},{"date":"2021-12-11","hemoglobin_g_dL":12.7,"wbc_k_uL":6.3,"platelets_k_uL":156,"creatinine_mg_dL":1.8,"alt_U_L":118}]}
{"patient_id":"ANODE_SYNTH_2025_3154","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":62,"sex":"male","bmi":20.2,"smoking_pack_years":31,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-12-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-63},"pfs_months":4.47},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":15.3,"censored":false},"longitudinal_labs":[{"date":"2022-10-22","hemoglobin_g_dL":13.6,"wbc_k_uL":10.2,"platelets_k_uL":195,"creatinine_mg_dL":1.14,"alt_U_L":54},{"date":"2023-06-29","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":165,"creatinine_mg_dL":1.31,"alt_U_L":82},{"date":"2023-06-23","hemoglobin_g_dL":11.6,"wbc_k_uL":7.8,"platelets_k_uL":263,"creatinine_mg_dL":1.91,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_3155","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":80,"sex":"female","bmi":30.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-46},"pfs_months":35.02},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":51.9,"censored":false},"longitudinal_labs":[{"date":"2023-12-06","hemoglobin_g_dL":13.6,"wbc_k_uL":6.7,"platelets_k_uL":254,"creatinine_mg_dL":1.21,"alt_U_L":17},{"date":"2024-07-29","hemoglobin_g_dL":11.4,"wbc_k_uL":4.5,"platelets_k_uL":186,"creatinine_mg_dL":1.38,"alt_U_L":35},{"date":"2027-01-29","hemoglobin_g_dL":10.8,"wbc_k_uL":3.5,"platelets_k_uL":277,"creatinine_mg_dL":0.98,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_3156","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":57,"sex":"female","bmi":24.8,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["bone","liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-47},"pfs_months":38.41},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":53.9,"censored":false},"longitudinal_labs":[{"date":"2023-04-06","hemoglobin_g_dL":14.6,"wbc_k_uL":4.8,"platelets_k_uL":177,"creatinine_mg_dL":0.92,"alt_U_L":23},{"date":"2023-10-23","hemoglobin_g_dL":11.7,"wbc_k_uL":7.8,"platelets_k_uL":346,"creatinine_mg_dL":1.16,"alt_U_L":32},{"date":"2026-07-28","hemoglobin_g_dL":12.6,"wbc_k_uL":4.3,"platelets_k_uL":211,"creatinine_mg_dL":0.88,"alt_U_L":145}]}
{"patient_id":"ANODE_SYNTH_2025_3157","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.4,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":66,"sex":"male","bmi":34.9,"smoking_pack_years":43,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-02-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-72},"pfs_months":11.63},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.8,"censored":true},"longitudinal_labs":[{"date":"2025-12-13","hemoglobin_g_dL":11.7,"wbc_k_uL":10.5,"platelets_k_uL":274,"creatinine_mg_dL":1.19,"alt_U_L":30},{"date":"2026-08-15","hemoglobin_g_dL":10.7,"wbc_k_uL":6.5,"platelets_k_uL":263,"creatinine_mg_dL":1.01,"alt_U_L":48},{"date":"2027-03-22","hemoglobin_g_dL":10.8,"wbc_k_uL":7.1,"platelets_k_uL":238,"creatinine_mg_dL":1.96,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_3158","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":57,"sex":"male","bmi":36.4,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-76},"pfs_months":10.25},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-25","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.9,"censored":true},"longitudinal_labs":[{"date":"2023-05-21","hemoglobin_g_dL":15.0,"wbc_k_uL":7.3,"platelets_k_uL":205,"creatinine_mg_dL":0.7,"alt_U_L":12},{"date":"2024-01-23","hemoglobin_g_dL":12.1,"wbc_k_uL":6.1,"platelets_k_uL":180,"creatinine_mg_dL":1.21,"alt_U_L":72},{"date":"2024-06-25","hemoglobin_g_dL":11.3,"wbc_k_uL":3.7,"platelets_k_uL":225,"creatinine_mg_dL":1.28,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_3159","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":50,"sex":"female","bmi":33.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-07-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-43},"pfs_months":23.66},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-08","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":32.2,"censored":false},"longitudinal_labs":[{"date":"2023-06-03","hemoglobin_g_dL":13.2,"wbc_k_uL":6.3,"platelets_k_uL":166,"creatinine_mg_dL":0.96,"alt_U_L":75},{"date":"2024-01-24","hemoglobin_g_dL":12.8,"wbc_k_uL":7.0,"platelets_k_uL":364,"creatinine_mg_dL":1.36,"alt_U_L":56},{"date":"2025-09-08","hemoglobin_g_dL":9.9,"wbc_k_uL":7.5,"platelets_k_uL":340,"creatinine_mg_dL":0.86,"alt_U_L":190}]}
{"patient_id":"ANODE_SYNTH_2025_3160","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":50,"sex":"female","bmi":23.8,"smoking_pack_years":67,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-05-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-62},"pfs_months":16.72},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-28","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":false},"longitudinal_labs":[{"date":"2024-04-12","hemoglobin_g_dL":14.4,"wbc_k_uL":5.4,"platelets_k_uL":257,"creatinine_mg_dL":1.06,"alt_U_L":18},{"date":"2024-11-09","hemoglobin_g_dL":12.9,"wbc_k_uL":5.6,"platelets_k_uL":380,"creatinine_mg_dL":0.93,"alt_U_L":106},{"date":"2025-11-28","hemoglobin_g_dL":12.7,"wbc_k_uL":3.3,"platelets_k_uL":213,"creatinine_mg_dL":1.24,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_3161","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":72,"sex":"male","bmi":27.3,"smoking_pack_years":72,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-05-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-76},"pfs_months":35.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":48.9,"censored":false},"longitudinal_labs":[{"date":"2025-04-03","hemoglobin_g_dL":14.5,"wbc_k_uL":7.1,"platelets_k_uL":215,"creatinine_mg_dL":0.82,"alt_U_L":30},{"date":"2025-11-18","hemoglobin_g_dL":11.4,"wbc_k_uL":8.8,"platelets_k_uL":344,"creatinine_mg_dL":1.56,"alt_U_L":36},{"date":"2028-05-30","hemoglobin_g_dL":10.9,"wbc_k_uL":5.5,"platelets_k_uL":350,"creatinine_mg_dL":0.89,"alt_U_L":33}]}
{"patient_id":"ANODE_SYNTH_2025_3162","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":81,"sex":"female","bmi":24.6,"smoking_pack_years":55,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-02-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-43},"pfs_months":37.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-31","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":55.1,"censored":false},"longitudinal_labs":[{"date":"2022-12-12","hemoglobin_g_dL":12.3,"wbc_k_uL":10.5,"platelets_k_uL":425,"creatinine_mg_dL":0.65,"alt_U_L":76},{"date":"2023-08-12","hemoglobin_g_dL":13.9,"wbc_k_uL":5.2,"platelets_k_uL":280,"creatinine_mg_dL":1.6,"alt_U_L":93},{"date":"2026-05-31","hemoglobin_g_dL":10.6,"wbc_k_uL":7.8,"platelets_k_uL":263,"creatinine_mg_dL":1.82,"alt_U_L":183}]}
{"patient_id":"ANODE_SYNTH_2025_3163","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":82,"sex":"female","bmi":23.8,"smoking_pack_years":66,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-10-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-30},"pfs_months":26.84},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-19","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":47.2,"censored":false},"longitudinal_labs":[{"date":"2023-08-09","hemoglobin_g_dL":12.9,"wbc_k_uL":9.2,"platelets_k_uL":254,"creatinine_mg_dL":0.82,"alt_U_L":25},{"date":"2024-04-08","hemoglobin_g_dL":13.9,"wbc_k_uL":5.7,"platelets_k_uL":188,"creatinine_mg_dL":1.11,"alt_U_L":70},{"date":"2026-02-19","hemoglobin_g_dL":11.2,"wbc_k_uL":5.0,"platelets_k_uL":174,"creatinine_mg_dL":1.28,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_3164","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":58,"sex":"female","bmi":26.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-48},"pfs_months":17.05},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-09","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.4,"censored":true},"longitudinal_labs":[{"date":"2025-03-26","hemoglobin_g_dL":13.2,"wbc_k_uL":5.7,"platelets_k_uL":398,"creatinine_mg_dL":0.78,"alt_U_L":70},{"date":"2025-10-10","hemoglobin_g_dL":10.0,"wbc_k_uL":7.8,"platelets_k_uL":130,"creatinine_mg_dL":0.8,"alt_U_L":29},{"date":"2026-10-09","hemoglobin_g_dL":10.4,"wbc_k_uL":3.9,"platelets_k_uL":193,"creatinine_mg_dL":1.85,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_3165","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.9,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":63,"sex":"male","bmi":23.8,"smoking_pack_years":11,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2026-03-01","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-80},"pfs_months":21.78},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.2,"censored":false},"longitudinal_labs":[{"date":"2025-12-28","hemoglobin_g_dL":12.2,"wbc_k_uL":7.1,"platelets_k_uL":282,"creatinine_mg_dL":0.78,"alt_U_L":48},{"date":"2026-08-28","hemoglobin_g_dL":11.8,"wbc_k_uL":4.4,"platelets_k_uL":220,"creatinine_mg_dL":1.25,"alt_U_L":102},{"date":"2028-01-17","hemoglobin_g_dL":10.0,"wbc_k_uL":5.9,"platelets_k_uL":207,"creatinine_mg_dL":1.89,"alt_U_L":91}]}
{"patient_id":"ANODE_SYNTH_2025_3166","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.0,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":76,"sex":"male","bmi":33.4,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-84},"pfs_months":11.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.8,"censored":true},"longitudinal_labs":[{"date":"2022-02-06","hemoglobin_g_dL":15.0,"wbc_k_uL":9.5,"platelets_k_uL":238,"creatinine_mg_dL":1.09,"alt_U_L":79},{"date":"2022-09-04","hemoglobin_g_dL":12.8,"wbc_k_uL":7.1,"platelets_k_uL":152,"creatinine_mg_dL":0.76,"alt_U_L":38},{"date":"2023-03-26","hemoglobin_g_dL":12.4,"wbc_k_uL":5.0,"platelets_k_uL":304,"creatinine_mg_dL":1.9,"alt_U_L":125}]}
{"patient_id":"ANODE_SYNTH_2025_3167","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":74,"sex":"female","bmi":21.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-05-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-81},"pfs_months":25.23},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.7,"censored":true},"longitudinal_labs":[{"date":"2021-04-08","hemoglobin_g_dL":15.4,"wbc_k_uL":5.0,"platelets_k_uL":364,"creatinine_mg_dL":0.77,"alt_U_L":61},{"date":"2021-11-22","hemoglobin_g_dL":13.1,"wbc_k_uL":4.5,"platelets_k_uL":228,"creatinine_mg_dL":1.47,"alt_U_L":40},{"date":"2023-08-26","hemoglobin_g_dL":9.7,"wbc_k_uL":4.9,"platelets_k_uL":172,"creatinine_mg_dL":1.37,"alt_U_L":173}]}
{"patient_id":"ANODE_SYNTH_2025_3168","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":65,"sex":"male","bmi":32.6,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-10-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-70},"pfs_months":29.04},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.5,"censored":false},"longitudinal_labs":[{"date":"2020-08-25","hemoglobin_g_dL":11.6,"wbc_k_uL":10.5,"platelets_k_uL":301,"creatinine_mg_dL":1.01,"alt_U_L":23},{"date":"2021-04-27","hemoglobin_g_dL":12.3,"wbc_k_uL":8.2,"platelets_k_uL":370,"creatinine_mg_dL":1.46,"alt_U_L":111},{"date":"2023-05-18","hemoglobin_g_dL":10.7,"wbc_k_uL":5.0,"platelets_k_uL":136,"creatinine_mg_dL":1.06,"alt_U_L":157}]}
{"patient_id":"ANODE_SYNTH_2025_3169","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.3,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":53,"sex":"female","bmi":20.1,"smoking_pack_years":47,"ecog_performance_status":2,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-01-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-60},"pfs_months":10.02},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":15.0,"censored":false},"longitudinal_labs":[{"date":"2023-12-12","hemoglobin_g_dL":14.5,"wbc_k_uL":9.6,"platelets_k_uL":237,"creatinine_mg_dL":0.67,"alt_U_L":44},{"date":"2024-07-11","hemoglobin_g_dL":13.7,"wbc_k_uL":6.7,"platelets_k_uL":351,"creatinine_mg_dL":1.14,"alt_U_L":46},{"date":"2024-12-05","hemoglobin_g_dL":12.5,"wbc_k_uL":5.9,"platelets_k_uL":299,"creatinine_mg_dL":1.94,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_3170","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":56,"sex":"female","bmi":31.3,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-03-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-52},"pfs_months":24.84},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":38.6,"censored":false},"longitudinal_labs":[{"date":"2024-02-03","hemoglobin_g_dL":13.8,"wbc_k_uL":8.4,"platelets_k_uL":404,"creatinine_mg_dL":0.74,"alt_U_L":44},{"date":"2024-08-28","hemoglobin_g_dL":13.7,"wbc_k_uL":8.4,"platelets_k_uL":158,"creatinine_mg_dL":1.58,"alt_U_L":36},{"date":"2026-05-14","hemoglobin_g_dL":12.0,"wbc_k_uL":4.0,"platelets_k_uL":248,"creatinine_mg_dL":1.57,"alt_U_L":32}]}
{"patient_id":"ANODE_SYNTH_2025_3171","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":55,"sex":"male","bmi":36.1,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-03-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-61},"pfs_months":18.07},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-11-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":false},"longitudinal_labs":[{"date":"2020-02-24","hemoglobin_g_dL":12.6,"wbc_k_uL":10.4,"platelets_k_uL":439,"creatinine_mg_dL":0.96,"alt_U_L":48},{"date":"2020-09-22","hemoglobin_g_dL":11.6,"wbc_k_uL":4.9,"platelets_k_uL":253,"creatinine_mg_dL":0.79,"alt_U_L":53},{"date":"2021-11-23","hemoglobin_g_dL":13.0,"wbc_k_uL":6.7,"platelets_k_uL":142,"creatinine_mg_dL":0.9,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_3172","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.4,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":85,"sex":"female","bmi":30.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-71},"pfs_months":19.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.2,"censored":true},"longitudinal_labs":[{"date":"2024-03-10","hemoglobin_g_dL":13.2,"wbc_k_uL":8.1,"platelets_k_uL":151,"creatinine_mg_dL":1.26,"alt_U_L":10},{"date":"2024-11-02","hemoglobin_g_dL":10.3,"wbc_k_uL":4.4,"platelets_k_uL":372,"creatinine_mg_dL":1.54,"alt_U_L":98},{"date":"2026-01-13","hemoglobin_g_dL":12.8,"wbc_k_uL":4.2,"platelets_k_uL":208,"creatinine_mg_dL":1.03,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_3173","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":63,"sex":"female","bmi":29.8,"smoking_pack_years":24,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-08-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-84},"pfs_months":13.47},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":20.2,"censored":false},"longitudinal_labs":[{"date":"2022-07-06","hemoglobin_g_dL":13.5,"wbc_k_uL":5.6,"platelets_k_uL":380,"creatinine_mg_dL":0.8,"alt_U_L":24},{"date":"2023-02-12","hemoglobin_g_dL":11.0,"wbc_k_uL":6.8,"platelets_k_uL":133,"creatinine_mg_dL":1.11,"alt_U_L":67},{"date":"2023-10-27","hemoglobin_g_dL":11.6,"wbc_k_uL":3.6,"platelets_k_uL":258,"creatinine_mg_dL":1.37,"alt_U_L":154}]}
{"patient_id":"ANODE_SYNTH_2025_3174","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":61,"sex":"female","bmi":34.1,"smoking_pack_years":21,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-12-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-39},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-04-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":10.8,"censored":false},"longitudinal_labs":[{"date":"2020-10-28","hemoglobin_g_dL":14.9,"wbc_k_uL":5.2,"platelets_k_uL":306,"creatinine_mg_dL":1.02,"alt_U_L":28},{"date":"2021-06-16","hemoglobin_g_dL":12.7,"wbc_k_uL":8.4,"platelets_k_uL":183,"creatinine_mg_dL":1.39,"alt_U_L":57},{"date":"2021-04-01","hemoglobin_g_dL":11.4,"wbc_k_uL":5.5,"platelets_k_uL":306,"creatinine_mg_dL":1.52,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_3175","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":87,"sex":"male","bmi":31.4,"smoking_pack_years":13,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-02-24","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-60},"pfs_months":49.12},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":69.8,"censored":false},"longitudinal_labs":[{"date":"2023-01-10","hemoglobin_g_dL":13.6,"wbc_k_uL":6.0,"platelets_k_uL":234,"creatinine_mg_dL":1.23,"alt_U_L":20},{"date":"2023-08-23","hemoglobin_g_dL":11.5,"wbc_k_uL":6.2,"platelets_k_uL":201,"creatinine_mg_dL":1.54,"alt_U_L":73},{"date":"2027-04-05","hemoglobin_g_dL":11.3,"wbc_k_uL":6.1,"platelets_k_uL":171,"creatinine_mg_dL":1.61,"alt_U_L":93}]}
{"patient_id":"ANODE_SYNTH_2025_3176","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":87,"sex":"male","bmi":37.8,"smoking_pack_years":72,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["bone","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-01-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-77},"pfs_months":50.53},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":77.0,"censored":false},"longitudinal_labs":[{"date":"2022-11-24","hemoglobin_g_dL":11.6,"wbc_k_uL":10.1,"platelets_k_uL":274,"creatinine_mg_dL":0.68,"alt_U_L":72},{"date":"2023-07-03","hemoglobin_g_dL":10.9,"wbc_k_uL":7.0,"platelets_k_uL":130,"creatinine_mg_dL":0.93,"alt_U_L":39},{"date":"2027-05-16","hemoglobin_g_dL":10.2,"wbc_k_uL":4.7,"platelets_k_uL":313,"creatinine_mg_dL":1.44,"alt_U_L":169}]}
{"patient_id":"ANODE_SYNTH_2025_3177","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.5,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":86,"sex":"female","bmi":28.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-53},"pfs_months":15.44},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.7,"censored":false},"longitudinal_labs":[{"date":"2023-05-11","hemoglobin_g_dL":15.4,"wbc_k_uL":5.5,"platelets_k_uL":150,"creatinine_mg_dL":0.65,"alt_U_L":70},{"date":"2023-12-02","hemoglobin_g_dL":13.3,"wbc_k_uL":8.4,"platelets_k_uL":252,"creatinine_mg_dL":1.28,"alt_U_L":52},{"date":"2024-10-08","hemoglobin_g_dL":9.9,"wbc_k_uL":8.0,"platelets_k_uL":260,"creatinine_mg_dL":1.64,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_3178","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":63,"sex":"male","bmi":25.9,"smoking_pack_years":26,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-37},"pfs_months":38.51},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-05","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.1,"censored":false},"longitudinal_labs":[{"date":"2022-12-04","hemoglobin_g_dL":14.9,"wbc_k_uL":6.3,"platelets_k_uL":207,"creatinine_mg_dL":1.11,"alt_U_L":24},{"date":"2023-06-18","hemoglobin_g_dL":12.2,"wbc_k_uL":6.0,"platelets_k_uL":235,"creatinine_mg_dL":1.01,"alt_U_L":92},{"date":"2026-04-05","hemoglobin_g_dL":9.8,"wbc_k_uL":4.9,"platelets_k_uL":170,"creatinine_mg_dL":1.73,"alt_U_L":164}]}
{"patient_id":"ANODE_SYNTH_2025_3179","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":64,"sex":"male","bmi":20.0,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-01-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-38},"pfs_months":12.32},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-03-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":23.2,"censored":true},"longitudinal_labs":[{"date":"2020-11-06","hemoglobin_g_dL":12.5,"wbc_k_uL":6.6,"platelets_k_uL":151,"creatinine_mg_dL":0.95,"alt_U_L":78},{"date":"2021-07-08","hemoglobin_g_dL":10.7,"wbc_k_uL":4.4,"platelets_k_uL":338,"creatinine_mg_dL":1.02,"alt_U_L":48},{"date":"2022-03-09","hemoglobin_g_dL":12.5,"wbc_k_uL":7.4,"platelets_k_uL":109,"creatinine_mg_dL":0.92,"alt_U_L":192}]}
{"patient_id":"ANODE_SYNTH_2025_3180","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":88,"sex":"female","bmi":36.4,"smoking_pack_years":53,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-04-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-61},"pfs_months":46.88},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":67.6,"censored":false},"longitudinal_labs":[{"date":"2021-03-03","hemoglobin_g_dL":14.6,"wbc_k_uL":8.0,"platelets_k_uL":211,"creatinine_mg_dL":0.95,"alt_U_L":18},{"date":"2021-10-14","hemoglobin_g_dL":10.8,"wbc_k_uL":7.9,"platelets_k_uL":154,"creatinine_mg_dL":1.03,"alt_U_L":19},{"date":"2025-04-05","hemoglobin_g_dL":11.3,"wbc_k_uL":6.6,"platelets_k_uL":336,"creatinine_mg_dL":1.85,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_3181","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":62,"sex":"female","bmi":18.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-08-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-49},"pfs_months":14.72},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.0,"censored":false},"longitudinal_labs":[{"date":"2024-07-15","hemoglobin_g_dL":14.2,"wbc_k_uL":4.5,"platelets_k_uL":359,"creatinine_mg_dL":0.66,"alt_U_L":34},{"date":"2025-02-27","hemoglobin_g_dL":13.2,"wbc_k_uL":4.9,"platelets_k_uL":336,"creatinine_mg_dL":0.82,"alt_U_L":90},{"date":"2025-11-26","hemoglobin_g_dL":10.0,"wbc_k_uL":7.3,"platelets_k_uL":152,"creatinine_mg_dL":2.0,"alt_U_L":67}]}
{"patient_id":"ANODE_SYNTH_2025_3182","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.8,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":83,"sex":"female","bmi":25.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["brain","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-08","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-59},"pfs_months":21.68},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-15","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.7,"censored":true},"longitudinal_labs":[{"date":"2022-10-09","hemoglobin_g_dL":15.4,"wbc_k_uL":7.4,"platelets_k_uL":337,"creatinine_mg_dL":1.09,"alt_U_L":62},{"date":"2023-05-07","hemoglobin_g_dL":11.6,"wbc_k_uL":5.1,"platelets_k_uL":217,"creatinine_mg_dL":1.46,"alt_U_L":20},{"date":"2024-10-15","hemoglobin_g_dL":12.6,"wbc_k_uL":7.3,"platelets_k_uL":168,"creatinine_mg_dL":1.23,"alt_U_L":131}]}
{"patient_id":"ANODE_SYNTH_2025_3183","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.5,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":81,"sex":"female","bmi":27.7,"smoking_pack_years":69,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2024-10-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-41},"pfs_months":26.87},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-02-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":43.5,"censored":true},"longitudinal_labs":[{"date":"2024-09-18","hemoglobin_g_dL":13.2,"wbc_k_uL":9.8,"platelets_k_uL":165,"creatinine_mg_dL":1.18,"alt_U_L":15},{"date":"2025-04-13","hemoglobin_g_dL":11.8,"wbc_k_uL":5.3,"platelets_k_uL":303,"creatinine_mg_dL":1.28,"alt_U_L":89},{"date":"2027-02-09","hemoglobin_g_dL":10.2,"wbc_k_uL":4.7,"platelets_k_uL":152,"creatinine_mg_dL":1.47,"alt_U_L":35}]}
{"patient_id":"ANODE_SYNTH_2025_3184","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":87,"sex":"female","bmi":29.7,"smoking_pack_years":15,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["bone","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-09-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-74},"pfs_months":14.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":false},"longitudinal_labs":[{"date":"2020-08-12","hemoglobin_g_dL":11.7,"wbc_k_uL":6.2,"platelets_k_uL":296,"creatinine_mg_dL":0.61,"alt_U_L":76},{"date":"2021-03-06","hemoglobin_g_dL":11.1,"wbc_k_uL":4.9,"platelets_k_uL":331,"creatinine_mg_dL":1.25,"alt_U_L":36},{"date":"2022-01-11","hemoglobin_g_dL":9.9,"wbc_k_uL":3.3,"platelets_k_uL":104,"creatinine_mg_dL":1.02,"alt_U_L":198}]}
{"patient_id":"ANODE_SYNTH_2025_3185","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":63,"sex":"male","bmi":26.5,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-04-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-32},"pfs_months":36.57},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":55.9,"censored":false},"longitudinal_labs":[{"date":"2023-04-02","hemoglobin_g_dL":11.7,"wbc_k_uL":6.8,"platelets_k_uL":253,"creatinine_mg_dL":0.67,"alt_U_L":70},{"date":"2023-10-25","hemoglobin_g_dL":11.9,"wbc_k_uL":5.7,"platelets_k_uL":140,"creatinine_mg_dL":1.28,"alt_U_L":34},{"date":"2026-05-21","hemoglobin_g_dL":12.8,"wbc_k_uL":6.1,"platelets_k_uL":146,"creatinine_mg_dL":1.87,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_3186","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":64,"sex":"male","bmi":30.6,"smoking_pack_years":79,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-06-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-74},"pfs_months":36.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.1,"censored":true},"longitudinal_labs":[{"date":"2021-05-21","hemoglobin_g_dL":12.7,"wbc_k_uL":5.4,"platelets_k_uL":195,"creatinine_mg_dL":0.91,"alt_U_L":33},{"date":"2021-12-08","hemoglobin_g_dL":13.5,"wbc_k_uL":4.8,"platelets_k_uL":146,"creatinine_mg_dL":1.09,"alt_U_L":101},{"date":"2024-08-12","hemoglobin_g_dL":12.9,"wbc_k_uL":5.6,"platelets_k_uL":147,"creatinine_mg_dL":1.57,"alt_U_L":196}]}
{"patient_id":"ANODE_SYNTH_2025_3187","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":50,"sex":"female","bmi":25.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-58},"pfs_months":18.73},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":31.5,"censored":true},"longitudinal_labs":[{"date":"2024-02-26","hemoglobin_g_dL":12.5,"wbc_k_uL":6.2,"platelets_k_uL":194,"creatinine_mg_dL":1.08,"alt_U_L":27},{"date":"2024-11-01","hemoglobin_g_dL":11.1,"wbc_k_uL":6.5,"platelets_k_uL":164,"creatinine_mg_dL":1.32,"alt_U_L":28},{"date":"2026-01-05","hemoglobin_g_dL":12.3,"wbc_k_uL":5.4,"platelets_k_uL":254,"creatinine_mg_dL":1.65,"alt_U_L":45}]}
{"patient_id":"ANODE_SYNTH_2025_3188","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.5,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":81,"sex":"male","bmi":35.1,"smoking_pack_years":39,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-09-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-36},"pfs_months":11.33},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-09-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":21.2,"censored":false},"longitudinal_labs":[{"date":"2020-07-15","hemoglobin_g_dL":14.9,"wbc_k_uL":5.4,"platelets_k_uL":300,"creatinine_mg_dL":0.94,"alt_U_L":20},{"date":"2021-02-28","hemoglobin_g_dL":10.1,"wbc_k_uL":6.9,"platelets_k_uL":176,"creatinine_mg_dL":1.32,"alt_U_L":29},{"date":"2021-09-27","hemoglobin_g_dL":11.7,"wbc_k_uL":5.7,"platelets_k_uL":254,"creatinine_mg_dL":1.26,"alt_U_L":53}]}
{"patient_id":"ANODE_SYNTH_2025_3189","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":85,"sex":"female","bmi":33.1,"smoking_pack_years":41,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-01-26","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-52},"pfs_months":21.95},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.8,"censored":false},"longitudinal_labs":[{"date":"2025-01-11","hemoglobin_g_dL":13.8,"wbc_k_uL":9.9,"platelets_k_uL":326,"creatinine_mg_dL":0.97,"alt_U_L":15},{"date":"2025-07-25","hemoglobin_g_dL":13.7,"wbc_k_uL":6.1,"platelets_k_uL":287,"creatinine_mg_dL":1.51,"alt_U_L":99},{"date":"2026-12-31","hemoglobin_g_dL":12.1,"wbc_k_uL":6.8,"platelets_k_uL":320,"creatinine_mg_dL":0.9,"alt_U_L":75}]}
{"patient_id":"ANODE_SYNTH_2025_3190","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":86,"sex":"female","bmi":33.1,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain","pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-05-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-41},"pfs_months":15.41},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":35.9,"censored":false},"longitudinal_labs":[{"date":"2020-04-04","hemoglobin_g_dL":15.4,"wbc_k_uL":10.5,"platelets_k_uL":217,"creatinine_mg_dL":0.68,"alt_U_L":58},{"date":"2020-11-15","hemoglobin_g_dL":13.4,"wbc_k_uL":7.4,"platelets_k_uL":309,"creatinine_mg_dL":1.31,"alt_U_L":98},{"date":"2021-10-04","hemoglobin_g_dL":11.4,"wbc_k_uL":3.7,"platelets_k_uL":348,"creatinine_mg_dL":0.89,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_3191","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":81,"sex":"male","bmi":23.0,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.1,"metastatic_sites":["pleura","bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-68},"pfs_months":27.43},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-01-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":49.2,"censored":false},"longitudinal_labs":[{"date":"2022-07-28","hemoglobin_g_dL":14.4,"wbc_k_uL":5.2,"platelets_k_uL":246,"creatinine_mg_dL":1.01,"alt_U_L":27},{"date":"2023-02-12","hemoglobin_g_dL":11.3,"wbc_k_uL":8.7,"platelets_k_uL":222,"creatinine_mg_dL":1.36,"alt_U_L":108},{"date":"2025-01-18","hemoglobin_g_dL":10.0,"wbc_k_uL":7.4,"platelets_k_uL":220,"creatinine_mg_dL":1.52,"alt_U_L":142}]}
{"patient_id":"ANODE_SYNTH_2025_3192","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":57,"sex":"female","bmi":20.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-42},"pfs_months":24.8},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":38.0,"censored":false},"longitudinal_labs":[{"date":"2024-07-09","hemoglobin_g_dL":13.2,"wbc_k_uL":7.0,"platelets_k_uL":158,"creatinine_mg_dL":1.08,"alt_U_L":30},{"date":"2025-03-13","hemoglobin_g_dL":12.8,"wbc_k_uL":7.8,"platelets_k_uL":216,"creatinine_mg_dL":1.28,"alt_U_L":72},{"date":"2026-11-12","hemoglobin_g_dL":10.7,"wbc_k_uL":5.1,"platelets_k_uL":306,"creatinine_mg_dL":1.83,"alt_U_L":188}]}
{"patient_id":"ANODE_SYNTH_2025_3193","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":58,"sex":"female","bmi":27.4,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-12-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-56},"pfs_months":15.97},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.4,"censored":false},"longitudinal_labs":[{"date":"2024-11-19","hemoglobin_g_dL":14.5,"wbc_k_uL":10.4,"platelets_k_uL":229,"creatinine_mg_dL":1.0,"alt_U_L":23},{"date":"2025-06-02","hemoglobin_g_dL":13.9,"wbc_k_uL":7.8,"platelets_k_uL":321,"creatinine_mg_dL":0.88,"alt_U_L":60},{"date":"2026-05-13","hemoglobin_g_dL":12.3,"wbc_k_uL":4.2,"platelets_k_uL":342,"creatinine_mg_dL":1.27,"alt_U_L":72}]}
{"patient_id":"ANODE_SYNTH_2025_3194","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.8,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":69,"sex":"female","bmi":30.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.9,"metastatic_sites":["liver","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-40},"pfs_months":34.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":49.0,"censored":false},"longitudinal_labs":[{"date":"2024-03-13","hemoglobin_g_dL":13.0,"wbc_k_uL":8.1,"platelets_k_uL":242,"creatinine_mg_dL":1.08,"alt_U_L":68},{"date":"2024-11-16","hemoglobin_g_dL":11.7,"wbc_k_uL":3.9,"platelets_k_uL":237,"creatinine_mg_dL":1.44,"alt_U_L":80},{"date":"2027-04-27","hemoglobin_g_dL":12.9,"wbc_k_uL":5.7,"platelets_k_uL":304,"creatinine_mg_dL":1.15,"alt_U_L":96}]}
{"patient_id":"ANODE_SYNTH_2025_3195","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":51,"sex":"male","bmi":37.4,"smoking_pack_years":14,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2026-01-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-58},"pfs_months":9.56},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":18.4,"censored":false},"longitudinal_labs":[{"date":"2025-12-11","hemoglobin_g_dL":13.2,"wbc_k_uL":4.8,"platelets_k_uL":389,"creatinine_mg_dL":0.6,"alt_U_L":32},{"date":"2026-07-20","hemoglobin_g_dL":11.5,"wbc_k_uL":7.7,"platelets_k_uL":373,"creatinine_mg_dL":1.13,"alt_U_L":34},{"date":"2026-12-03","hemoglobin_g_dL":10.7,"wbc_k_uL":7.0,"platelets_k_uL":231,"creatinine_mg_dL":1.18,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_3196","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":85,"sex":"female","bmi":31.4,"smoking_pack_years":44,"ecog_performance_status":2,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-10-25","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-36},"pfs_months":23.06},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":43.4,"censored":true},"longitudinal_labs":[{"date":"2020-10-02","hemoglobin_g_dL":13.3,"wbc_k_uL":6.9,"platelets_k_uL":416,"creatinine_mg_dL":0.77,"alt_U_L":27},{"date":"2021-04-23","hemoglobin_g_dL":11.2,"wbc_k_uL":6.3,"platelets_k_uL":352,"creatinine_mg_dL":1.05,"alt_U_L":19},{"date":"2022-11-04","hemoglobin_g_dL":12.3,"wbc_k_uL":6.4,"platelets_k_uL":227,"creatinine_mg_dL":0.85,"alt_U_L":180}]}
{"patient_id":"ANODE_SYNTH_2025_3197","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.0,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":85,"sex":"female","bmi":37.5,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-04-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-82},"pfs_months":21.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.6,"censored":false},"longitudinal_labs":[{"date":"2023-02-28","hemoglobin_g_dL":14.0,"wbc_k_uL":7.2,"platelets_k_uL":361,"creatinine_mg_dL":1.02,"alt_U_L":30},{"date":"2023-10-09","hemoglobin_g_dL":11.6,"wbc_k_uL":5.8,"platelets_k_uL":292,"creatinine_mg_dL":1.22,"alt_U_L":40},{"date":"2025-03-27","hemoglobin_g_dL":12.8,"wbc_k_uL":3.8,"platelets_k_uL":264,"creatinine_mg_dL":0.84,"alt_U_L":36}]}
{"patient_id":"ANODE_SYNTH_2025_3198","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":56,"sex":"female","bmi":28.3,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-06-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-52},"pfs_months":25.33},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":52.2,"censored":false},"longitudinal_labs":[{"date":"2024-04-25","hemoglobin_g_dL":15.2,"wbc_k_uL":5.3,"platelets_k_uL":430,"creatinine_mg_dL":0.78,"alt_U_L":51},{"date":"2024-12-02","hemoglobin_g_dL":12.5,"wbc_k_uL":3.8,"platelets_k_uL":209,"creatinine_mg_dL":1.08,"alt_U_L":39},{"date":"2026-07-22","hemoglobin_g_dL":9.9,"wbc_k_uL":7.6,"platelets_k_uL":259,"creatinine_mg_dL":1.97,"alt_U_L":134}]}
{"patient_id":"ANODE_SYNTH_2025_3199","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":77,"sex":"male","bmi":31.0,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-05-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-54},"pfs_months":40.94},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":62.2,"censored":false},"longitudinal_labs":[{"date":"2022-03-22","hemoglobin_g_dL":14.8,"wbc_k_uL":5.7,"platelets_k_uL":158,"creatinine_mg_dL":1.26,"alt_U_L":76},{"date":"2022-11-02","hemoglobin_g_dL":13.8,"wbc_k_uL":8.3,"platelets_k_uL":142,"creatinine_mg_dL":1.06,"alt_U_L":111},{"date":"2025-11-14","hemoglobin_g_dL":9.6,"wbc_k_uL":5.1,"platelets_k_uL":130,"creatinine_mg_dL":0.82,"alt_U_L":110}]}
{"patient_id":"ANODE_SYNTH_2025_3200","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":49,"sex":"female","bmi":28.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-03-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-20,"peak_response_20wk_change_percent":-42},"pfs_months":9.59},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":19.5,"censored":true},"longitudinal_labs":[{"date":"2022-02-02","hemoglobin_g_dL":12.8,"wbc_k_uL":5.2,"platelets_k_uL":320,"creatinine_mg_dL":1.1,"alt_U_L":75},{"date":"2022-08-29","hemoglobin_g_dL":13.5,"wbc_k_uL":4.1,"platelets_k_uL":363,"creatinine_mg_dL":1.56,"alt_U_L":105},{"date":"2023-01-11","hemoglobin_g_dL":11.3,"wbc_k_uL":7.6,"platelets_k_uL":210,"creatinine_mg_dL":1.59,"alt_U_L":46}]}
{"patient_id":"ANODE_SYNTH_2025_3201","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":72,"sex":"female","bmi":37.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-09-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-33},"pfs_months":26.94},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-12-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":46.0,"censored":false},"longitudinal_labs":[{"date":"2023-07-27","hemoglobin_g_dL":12.0,"wbc_k_uL":8.7,"platelets_k_uL":162,"creatinine_mg_dL":0.65,"alt_U_L":80},{"date":"2024-03-01","hemoglobin_g_dL":11.4,"wbc_k_uL":7.0,"platelets_k_uL":221,"creatinine_mg_dL":1.08,"alt_U_L":70},{"date":"2025-12-05","hemoglobin_g_dL":10.8,"wbc_k_uL":3.3,"platelets_k_uL":259,"creatinine_mg_dL":1.29,"alt_U_L":159}]}
{"patient_id":"ANODE_SYNTH_2025_3202","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.7,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":50,"sex":"female","bmi":25.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-11-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-59},"pfs_months":30.59},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.2,"censored":false},"longitudinal_labs":[{"date":"2025-11-09","hemoglobin_g_dL":12.4,"wbc_k_uL":5.7,"platelets_k_uL":196,"creatinine_mg_dL":1.02,"alt_U_L":80},{"date":"2026-05-25","hemoglobin_g_dL":11.2,"wbc_k_uL":6.2,"platelets_k_uL":311,"creatinine_mg_dL":1.12,"alt_U_L":37},{"date":"2028-06-26","hemoglobin_g_dL":9.6,"wbc_k_uL":6.8,"platelets_k_uL":288,"creatinine_mg_dL":1.96,"alt_U_L":22}]}
{"patient_id":"ANODE_SYNTH_2025_3203","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.4,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":53,"sex":"female","bmi":20.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.3,"metastatic_sites":["bone","brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-02-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-71},"pfs_months":23.49},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.3,"censored":true},"longitudinal_labs":[{"date":"2021-12-18","hemoglobin_g_dL":15.3,"wbc_k_uL":5.1,"platelets_k_uL":275,"creatinine_mg_dL":1.04,"alt_U_L":52},{"date":"2022-08-16","hemoglobin_g_dL":13.2,"wbc_k_uL":5.3,"platelets_k_uL":314,"creatinine_mg_dL":0.98,"alt_U_L":79},{"date":"2024-02-21","hemoglobin_g_dL":9.7,"wbc_k_uL":3.7,"platelets_k_uL":133,"creatinine_mg_dL":1.48,"alt_U_L":111}]}
{"patient_id":"ANODE_SYNTH_2025_3204","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.2,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":78,"sex":"male","bmi":24.3,"smoking_pack_years":45,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-11-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-51},"pfs_months":45.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":70.0,"censored":false},"longitudinal_labs":[{"date":"2020-09-28","hemoglobin_g_dL":12.8,"wbc_k_uL":9.7,"platelets_k_uL":179,"creatinine_mg_dL":0.66,"alt_U_L":41},{"date":"2021-05-09","hemoglobin_g_dL":13.3,"wbc_k_uL":7.6,"platelets_k_uL":296,"creatinine_mg_dL":1.51,"alt_U_L":116},{"date":"2024-10-01","hemoglobin_g_dL":12.9,"wbc_k_uL":5.9,"platelets_k_uL":160,"creatinine_mg_dL":1.59,"alt_U_L":194}]}
{"patient_id":"ANODE_SYNTH_2025_3205","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.5,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":73,"sex":"female","bmi":35.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung","brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-36},"pfs_months":12.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-08","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.7,"censored":true},"longitudinal_labs":[{"date":"2025-03-20","hemoglobin_g_dL":14.7,"wbc_k_uL":8.5,"platelets_k_uL":399,"creatinine_mg_dL":0.77,"alt_U_L":52},{"date":"2025-10-05","hemoglobin_g_dL":12.1,"wbc_k_uL":8.3,"platelets_k_uL":284,"creatinine_mg_dL":0.72,"alt_U_L":91},{"date":"2026-06-08","hemoglobin_g_dL":12.3,"wbc_k_uL":6.9,"platelets_k_uL":126,"creatinine_mg_dL":1.88,"alt_U_L":64}]}
{"patient_id":"ANODE_SYNTH_2025_3206","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":64,"sex":"female","bmi":29.2,"smoking_pack_years":16,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-03-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-38},"pfs_months":32.2},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-31","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":54.4,"censored":false},"longitudinal_labs":[{"date":"2024-01-26","hemoglobin_g_dL":11.7,"wbc_k_uL":7.4,"platelets_k_uL":389,"creatinine_mg_dL":1.13,"alt_U_L":18},{"date":"2024-09-16","hemoglobin_g_dL":13.0,"wbc_k_uL":5.7,"platelets_k_uL":222,"creatinine_mg_dL":0.89,"alt_U_L":47},{"date":"2026-12-31","hemoglobin_g_dL":9.6,"wbc_k_uL":6.9,"platelets_k_uL":342,"creatinine_mg_dL":1.47,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_3207","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":55,"sex":"female","bmi":19.1,"smoking_pack_years":79,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-08-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-66},"pfs_months":16.92},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":23.4,"censored":true},"longitudinal_labs":[{"date":"2021-06-20","hemoglobin_g_dL":12.2,"wbc_k_uL":5.8,"platelets_k_uL":365,"creatinine_mg_dL":0.71,"alt_U_L":41},{"date":"2022-02-08","hemoglobin_g_dL":12.2,"wbc_k_uL":4.1,"platelets_k_uL":346,"creatinine_mg_dL":1.46,"alt_U_L":88},{"date":"2023-02-10","hemoglobin_g_dL":11.4,"wbc_k_uL":6.8,"platelets_k_uL":320,"creatinine_mg_dL":1.69,"alt_U_L":63}]}
{"patient_id":"ANODE_SYNTH_2025_3208","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.7,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":66,"sex":"female","bmi":31.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-60},"pfs_months":17.38},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-18","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":true},"longitudinal_labs":[{"date":"2022-05-16","hemoglobin_g_dL":12.0,"wbc_k_uL":10.3,"platelets_k_uL":298,"creatinine_mg_dL":0.82,"alt_U_L":22},{"date":"2022-11-28","hemoglobin_g_dL":10.6,"wbc_k_uL":6.4,"platelets_k_uL":245,"creatinine_mg_dL":1.51,"alt_U_L":68},{"date":"2023-11-18","hemoglobin_g_dL":11.7,"wbc_k_uL":6.8,"platelets_k_uL":164,"creatinine_mg_dL":1.34,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_3209","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.7,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":60,"sex":"female","bmi":37.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-07-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-77},"pfs_months":18.0},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-03-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":37.8,"censored":false},"longitudinal_labs":[{"date":"2025-06-05","hemoglobin_g_dL":14.6,"wbc_k_uL":9.7,"platelets_k_uL":158,"creatinine_mg_dL":0.82,"alt_U_L":32},{"date":"2026-01-25","hemoglobin_g_dL":11.1,"wbc_k_uL":8.0,"platelets_k_uL":369,"creatinine_mg_dL":0.82,"alt_U_L":90},{"date":"2027-03-20","hemoglobin_g_dL":11.6,"wbc_k_uL":4.6,"platelets_k_uL":168,"creatinine_mg_dL":1.56,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_3210","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":75,"sex":"female","bmi":27.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-10-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-62},"pfs_months":20.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-08-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":28.5,"censored":false},"longitudinal_labs":[{"date":"2022-09-19","hemoglobin_g_dL":12.5,"wbc_k_uL":9.0,"platelets_k_uL":409,"creatinine_mg_dL":1.13,"alt_U_L":32},{"date":"2023-04-09","hemoglobin_g_dL":12.3,"wbc_k_uL":7.2,"platelets_k_uL":157,"creatinine_mg_dL":1.07,"alt_U_L":54},{"date":"2024-08-01","hemoglobin_g_dL":12.1,"wbc_k_uL":3.5,"platelets_k_uL":278,"creatinine_mg_dL":1.46,"alt_U_L":146}]}
{"patient_id":"ANODE_SYNTH_2025_3211","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.4,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":80,"sex":"male","bmi":27.6,"smoking_pack_years":74,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["pleura","brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-07-21","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-40},"pfs_months":6.77},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":18.3,"censored":false},"longitudinal_labs":[{"date":"2023-06-26","hemoglobin_g_dL":13.0,"wbc_k_uL":5.8,"platelets_k_uL":401,"creatinine_mg_dL":0.61,"alt_U_L":14},{"date":"2024-01-17","hemoglobin_g_dL":12.1,"wbc_k_uL":7.5,"platelets_k_uL":257,"creatinine_mg_dL":0.77,"alt_U_L":47},{"date":"2024-02-27","hemoglobin_g_dL":11.8,"wbc_k_uL":5.1,"platelets_k_uL":129,"creatinine_mg_dL":1.85,"alt_U_L":50}]}
{"patient_id":"ANODE_SYNTH_2025_3212","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.7,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":50,"sex":"male","bmi":19.7,"smoking_pack_years":69,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-03-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-61},"pfs_months":16.59},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-08-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":30.3,"censored":false},"longitudinal_labs":[{"date":"2020-01-10","hemoglobin_g_dL":11.7,"wbc_k_uL":6.1,"platelets_k_uL":211,"creatinine_mg_dL":1.18,"alt_U_L":12},{"date":"2020-08-28","hemoglobin_g_dL":11.1,"wbc_k_uL":5.0,"platelets_k_uL":150,"creatinine_mg_dL":1.59,"alt_U_L":55},{"date":"2021-08-18","hemoglobin_g_dL":10.7,"wbc_k_uL":4.4,"platelets_k_uL":243,"creatinine_mg_dL":1.05,"alt_U_L":172}]}
{"patient_id":"ANODE_SYNTH_2025_3213","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":69,"sex":"female","bmi":21.1,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-05-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-50,"peak_response_20wk_change_percent":-50},"pfs_months":21.95},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-30","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":39.7,"censored":false},"longitudinal_labs":[{"date":"2025-03-21","hemoglobin_g_dL":14.1,"wbc_k_uL":10.6,"platelets_k_uL":220,"creatinine_mg_dL":1.19,"alt_U_L":62},{"date":"2025-11-09","hemoglobin_g_dL":10.6,"wbc_k_uL":8.6,"platelets_k_uL":326,"creatinine_mg_dL":1.58,"alt_U_L":90},{"date":"2027-04-30","hemoglobin_g_dL":9.8,"wbc_k_uL":6.9,"platelets_k_uL":222,"creatinine_mg_dL":1.81,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_3214","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":68,"sex":"female","bmi":31.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-32},"pfs_months":28.29},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-01-05","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":47.1,"censored":false},"longitudinal_labs":[{"date":"2025-07-15","hemoglobin_g_dL":12.7,"wbc_k_uL":8.7,"platelets_k_uL":394,"creatinine_mg_dL":0.64,"alt_U_L":13},{"date":"2026-02-12","hemoglobin_g_dL":12.8,"wbc_k_uL":5.5,"platelets_k_uL":273,"creatinine_mg_dL":1.07,"alt_U_L":88},{"date":"2028-01-05","hemoglobin_g_dL":12.9,"wbc_k_uL":7.9,"platelets_k_uL":102,"creatinine_mg_dL":1.47,"alt_U_L":153}]}
{"patient_id":"ANODE_SYNTH_2025_3215","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":52,"sex":"female","bmi":35.8,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-71},"pfs_months":43.3},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":65.0,"censored":false},"longitudinal_labs":[{"date":"2020-11-17","hemoglobin_g_dL":15.1,"wbc_k_uL":7.2,"platelets_k_uL":438,"creatinine_mg_dL":1.24,"alt_U_L":57},{"date":"2021-06-20","hemoglobin_g_dL":13.0,"wbc_k_uL":8.2,"platelets_k_uL":221,"creatinine_mg_dL":1.26,"alt_U_L":70},{"date":"2024-09-15","hemoglobin_g_dL":12.8,"wbc_k_uL":5.6,"platelets_k_uL":152,"creatinine_mg_dL":1.23,"alt_U_L":158}]}
{"patient_id":"ANODE_SYNTH_2025_3216","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.1,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":56,"sex":"female","bmi":29.7,"smoking_pack_years":18,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.3,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-68},"pfs_months":36.17},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-11","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":57.6,"censored":false},"longitudinal_labs":[{"date":"2024-02-20","hemoglobin_g_dL":12.6,"wbc_k_uL":5.6,"platelets_k_uL":416,"creatinine_mg_dL":1.07,"alt_U_L":76},{"date":"2024-10-23","hemoglobin_g_dL":11.0,"wbc_k_uL":8.0,"platelets_k_uL":262,"creatinine_mg_dL":0.72,"alt_U_L":56},{"date":"2027-06-11","hemoglobin_g_dL":11.7,"wbc_k_uL":6.3,"platelets_k_uL":325,"creatinine_mg_dL":1.44,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_3217","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.4,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":55,"sex":"female","bmi":20.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-38},"pfs_months":18.66},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.7,"censored":false},"longitudinal_labs":[{"date":"2022-06-16","hemoglobin_g_dL":12.8,"wbc_k_uL":8.7,"platelets_k_uL":156,"creatinine_mg_dL":0.62,"alt_U_L":21},{"date":"2022-12-29","hemoglobin_g_dL":11.2,"wbc_k_uL":5.6,"platelets_k_uL":372,"creatinine_mg_dL":1.17,"alt_U_L":53},{"date":"2024-03-20","hemoglobin_g_dL":9.6,"wbc_k_uL":7.8,"platelets_k_uL":180,"creatinine_mg_dL":1.11,"alt_U_L":86}]}
{"patient_id":"ANODE_SYNTH_2025_3218","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":49,"sex":"female","bmi":22.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-12-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-52},"pfs_months":21.29},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.1,"censored":false},"longitudinal_labs":[{"date":"2024-10-22","hemoglobin_g_dL":12.5,"wbc_k_uL":8.5,"platelets_k_uL":443,"creatinine_mg_dL":0.93,"alt_U_L":53},{"date":"2025-06-11","hemoglobin_g_dL":13.5,"wbc_k_uL":6.7,"platelets_k_uL":170,"creatinine_mg_dL":0.72,"alt_U_L":48},{"date":"2026-10-23","hemoglobin_g_dL":10.7,"wbc_k_uL":6.7,"platelets_k_uL":238,"creatinine_mg_dL":1.14,"alt_U_L":122}]}
{"patient_id":"ANODE_SYNTH_2025_3219","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":48,"sex":"female","bmi":28.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-04-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-57},"pfs_months":25.76},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-17","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.8,"censored":false},"longitudinal_labs":[{"date":"2020-02-25","hemoglobin_g_dL":14.0,"wbc_k_uL":6.9,"platelets_k_uL":187,"creatinine_mg_dL":1.21,"alt_U_L":37},{"date":"2020-10-02","hemoglobin_g_dL":13.0,"wbc_k_uL":7.5,"platelets_k_uL":205,"creatinine_mg_dL":0.75,"alt_U_L":105},{"date":"2022-06-17","hemoglobin_g_dL":10.0,"wbc_k_uL":6.4,"platelets_k_uL":149,"creatinine_mg_dL":0.97,"alt_U_L":66}]}
{"patient_id":"ANODE_SYNTH_2025_3220","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":7},"baseline_clinical":{"age":67,"sex":"female","bmi":29.8,"smoking_pack_years":74,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-01-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-81},"pfs_months":25.1},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-28","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.1,"censored":false},"longitudinal_labs":[{"date":"2022-01-06","hemoglobin_g_dL":12.4,"wbc_k_uL":9.4,"platelets_k_uL":174,"creatinine_mg_dL":1.3,"alt_U_L":28},{"date":"2022-07-29","hemoglobin_g_dL":13.5,"wbc_k_uL":8.4,"platelets_k_uL":203,"creatinine_mg_dL":0.98,"alt_U_L":21},{"date":"2024-03-28","hemoglobin_g_dL":10.6,"wbc_k_uL":3.1,"platelets_k_uL":155,"creatinine_mg_dL":1.0,"alt_U_L":78}]}
{"patient_id":"ANODE_SYNTH_2025_3221","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":72,"sex":"female","bmi":23.3,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-10-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-48,"peak_response_20wk_change_percent":-67},"pfs_months":13.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-01-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.2,"censored":false},"longitudinal_labs":[{"date":"2020-08-08","hemoglobin_g_dL":13.0,"wbc_k_uL":6.3,"platelets_k_uL":179,"creatinine_mg_dL":0.65,"alt_U_L":17},{"date":"2021-04-01","hemoglobin_g_dL":12.7,"wbc_k_uL":3.9,"platelets_k_uL":254,"creatinine_mg_dL":0.85,"alt_U_L":71},{"date":"2022-01-24","hemoglobin_g_dL":12.4,"wbc_k_uL":5.0,"platelets_k_uL":334,"creatinine_mg_dL":1.66,"alt_U_L":116}]}
{"patient_id":"ANODE_SYNTH_2025_3222","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.1,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":88,"sex":"female","bmi":29.6,"smoking_pack_years":72,"ecog_performance_status":0,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["contralateral lung","brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-11-07","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-55},"pfs_months":18.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.2,"censored":false},"longitudinal_labs":[{"date":"2020-09-01","hemoglobin_g_dL":12.0,"wbc_k_uL":8.1,"platelets_k_uL":406,"creatinine_mg_dL":0.83,"alt_U_L":31},{"date":"2021-05-06","hemoglobin_g_dL":12.5,"wbc_k_uL":8.9,"platelets_k_uL":226,"creatinine_mg_dL":1.38,"alt_U_L":69},{"date":"2022-06-27","hemoglobin_g_dL":10.6,"wbc_k_uL":6.4,"platelets_k_uL":107,"creatinine_mg_dL":1.69,"alt_U_L":185}]}
{"patient_id":"ANODE_SYNTH_2025_3223","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.5,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":74,"sex":"female","bmi":23.0,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-09-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-64},"pfs_months":13.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-12","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.9,"censored":false},"longitudinal_labs":[{"date":"2024-08-27","hemoglobin_g_dL":14.7,"wbc_k_uL":5.7,"platelets_k_uL":164,"creatinine_mg_dL":1.07,"alt_U_L":20},{"date":"2025-03-09","hemoglobin_g_dL":10.7,"wbc_k_uL":8.7,"platelets_k_uL":177,"creatinine_mg_dL":1.14,"alt_U_L":18},{"date":"2025-11-12","hemoglobin_g_dL":11.7,"wbc_k_uL":7.8,"platelets_k_uL":246,"creatinine_mg_dL":1.88,"alt_U_L":114}]}
{"patient_id":"ANODE_SYNTH_2025_3224","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.0,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":74,"sex":"female","bmi":24.4,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2020-09-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-67},"pfs_months":18.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.2,"censored":true},"longitudinal_labs":[{"date":"2020-08-05","hemoglobin_g_dL":13.8,"wbc_k_uL":8.9,"platelets_k_uL":440,"creatinine_mg_dL":0.82,"alt_U_L":69},{"date":"2021-03-28","hemoglobin_g_dL":10.1,"wbc_k_uL":7.7,"platelets_k_uL":254,"creatinine_mg_dL":1.46,"alt_U_L":46},{"date":"2022-05-20","hemoglobin_g_dL":12.1,"wbc_k_uL":3.9,"platelets_k_uL":213,"creatinine_mg_dL":1.54,"alt_U_L":54}]}
{"patient_id":"ANODE_SYNTH_2025_3225","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":63,"sex":"male","bmi":33.2,"smoking_pack_years":48,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-11-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-76},"pfs_months":24.38},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-01-07","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":52.2,"censored":false},"longitudinal_labs":[{"date":"2024-09-18","hemoglobin_g_dL":13.3,"wbc_k_uL":10.0,"platelets_k_uL":320,"creatinine_mg_dL":0.62,"alt_U_L":41},{"date":"2025-05-03","hemoglobin_g_dL":11.4,"wbc_k_uL":7.8,"platelets_k_uL":353,"creatinine_mg_dL":1.11,"alt_U_L":58},{"date":"2027-01-07","hemoglobin_g_dL":10.0,"wbc_k_uL":7.7,"platelets_k_uL":198,"creatinine_mg_dL":1.5,"alt_U_L":30}]}
{"patient_id":"ANODE_SYNTH_2025_3226","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.4,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":66,"sex":"female","bmi":20.0,"smoking_pack_years":17,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-02-22","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-79},"pfs_months":16.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.0,"censored":true},"longitudinal_labs":[{"date":"2025-02-08","hemoglobin_g_dL":14.1,"wbc_k_uL":6.7,"platelets_k_uL":197,"creatinine_mg_dL":0.73,"alt_U_L":28},{"date":"2025-08-21","hemoglobin_g_dL":12.8,"wbc_k_uL":6.1,"platelets_k_uL":141,"creatinine_mg_dL":1.44,"alt_U_L":19},{"date":"2026-07-20","hemoglobin_g_dL":12.9,"wbc_k_uL":4.5,"platelets_k_uL":338,"creatinine_mg_dL":1.75,"alt_U_L":92}]}
{"patient_id":"ANODE_SYNTH_2025_3227","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":69,"sex":"male","bmi":35.6,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-06-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-61},"pfs_months":39.75},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":62.6,"censored":false},"longitudinal_labs":[{"date":"2022-04-17","hemoglobin_g_dL":13.6,"wbc_k_uL":9.9,"platelets_k_uL":203,"creatinine_mg_dL":1.01,"alt_U_L":57},{"date":"2022-12-08","hemoglobin_g_dL":13.6,"wbc_k_uL":8.3,"platelets_k_uL":159,"creatinine_mg_dL":1.41,"alt_U_L":81},{"date":"2025-10-23","hemoglobin_g_dL":11.0,"wbc_k_uL":3.8,"platelets_k_uL":223,"creatinine_mg_dL":1.75,"alt_U_L":38}]}
{"patient_id":"ANODE_SYNTH_2025_3228","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.5,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":49,"sex":"female","bmi":19.9,"smoking_pack_years":22,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-04-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-57},"pfs_months":39.69},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":57.5,"censored":true},"longitudinal_labs":[{"date":"2022-03-06","hemoglobin_g_dL":14.5,"wbc_k_uL":6.2,"platelets_k_uL":266,"creatinine_mg_dL":0.73,"alt_U_L":36},{"date":"2022-10-06","hemoglobin_g_dL":11.6,"wbc_k_uL":7.2,"platelets_k_uL":377,"creatinine_mg_dL":0.72,"alt_U_L":26},{"date":"2025-09-03","hemoglobin_g_dL":12.6,"wbc_k_uL":6.0,"platelets_k_uL":288,"creatinine_mg_dL":1.96,"alt_U_L":136}]}
{"patient_id":"ANODE_SYNTH_2025_3229","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":67,"sex":"female","bmi":24.2,"smoking_pack_years":29,"ecog_performance_status":0,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-10-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-36},"pfs_months":6.93},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":19.2,"censored":true},"longitudinal_labs":[{"date":"2021-09-11","hemoglobin_g_dL":13.5,"wbc_k_uL":4.5,"platelets_k_uL":245,"creatinine_mg_dL":1.07,"alt_U_L":37},{"date":"2022-04-04","hemoglobin_g_dL":13.8,"wbc_k_uL":5.2,"platelets_k_uL":326,"creatinine_mg_dL":1.44,"alt_U_L":50},{"date":"2022-05-14","hemoglobin_g_dL":11.4,"wbc_k_uL":3.5,"platelets_k_uL":295,"creatinine_mg_dL":1.48,"alt_U_L":178}]}
{"patient_id":"ANODE_SYNTH_2025_3230","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.9,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":86,"sex":"female","bmi":19.8,"smoking_pack_years":75,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-59},"pfs_months":19.94},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":30.9,"censored":false},"longitudinal_labs":[{"date":"2021-07-18","hemoglobin_g_dL":13.5,"wbc_k_uL":9.9,"platelets_k_uL":382,"creatinine_mg_dL":0.95,"alt_U_L":18},{"date":"2022-03-02","hemoglobin_g_dL":10.5,"wbc_k_uL":5.8,"platelets_k_uL":160,"creatinine_mg_dL":0.71,"alt_U_L":27},{"date":"2023-06-11","hemoglobin_g_dL":11.6,"wbc_k_uL":3.6,"platelets_k_uL":319,"creatinine_mg_dL":1.88,"alt_U_L":128}]}
{"patient_id":"ANODE_SYNTH_2025_3231","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.4,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":85,"sex":"female","bmi":30.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["bone","pleura","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-39},"pfs_months":20.8},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-09-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":31.0,"censored":false},"longitudinal_labs":[{"date":"2020-10-13","hemoglobin_g_dL":12.2,"wbc_k_uL":9.4,"platelets_k_uL":191,"creatinine_mg_dL":1.16,"alt_U_L":62},{"date":"2021-05-17","hemoglobin_g_dL":12.8,"wbc_k_uL":6.6,"platelets_k_uL":288,"creatinine_mg_dL":1.36,"alt_U_L":21},{"date":"2022-09-14","hemoglobin_g_dL":9.7,"wbc_k_uL":4.6,"platelets_k_uL":139,"creatinine_mg_dL":1.37,"alt_U_L":143}]}
{"patient_id":"ANODE_SYNTH_2025_3232","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.1,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":72,"sex":"female","bmi":36.5,"smoking_pack_years":26,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["contralateral lung","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-05-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-53},"pfs_months":49.02},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-19","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":74.4,"censored":false},"longitudinal_labs":[{"date":"2021-03-05","hemoglobin_g_dL":12.7,"wbc_k_uL":10.2,"platelets_k_uL":308,"creatinine_mg_dL":0.67,"alt_U_L":77},{"date":"2021-11-01","hemoglobin_g_dL":12.7,"wbc_k_uL":7.6,"platelets_k_uL":370,"creatinine_mg_dL":1.12,"alt_U_L":58},{"date":"2025-07-19","hemoglobin_g_dL":11.4,"wbc_k_uL":4.7,"platelets_k_uL":106,"creatinine_mg_dL":1.52,"alt_U_L":174}]}
{"patient_id":"ANODE_SYNTH_2025_3233","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.4,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":81,"sex":"female","bmi":37.6,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-06-19","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-39},"pfs_months":23.89},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-24","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.2,"censored":false},"longitudinal_labs":[{"date":"2024-04-10","hemoglobin_g_dL":14.6,"wbc_k_uL":10.2,"platelets_k_uL":298,"creatinine_mg_dL":0.78,"alt_U_L":19},{"date":"2024-12-16","hemoglobin_g_dL":13.2,"wbc_k_uL":6.6,"platelets_k_uL":157,"creatinine_mg_dL":1.33,"alt_U_L":114},{"date":"2026-06-24","hemoglobin_g_dL":9.9,"wbc_k_uL":5.7,"platelets_k_uL":132,"creatinine_mg_dL":1.74,"alt_U_L":101}]}
{"patient_id":"ANODE_SYNTH_2025_3234","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":68,"sex":"female","bmi":26.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-04-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-40},"pfs_months":25.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":false},"longitudinal_labs":[{"date":"2024-02-25","hemoglobin_g_dL":12.8,"wbc_k_uL":5.9,"platelets_k_uL":264,"creatinine_mg_dL":1.14,"alt_U_L":80},{"date":"2024-10-22","hemoglobin_g_dL":13.3,"wbc_k_uL":5.2,"platelets_k_uL":186,"creatinine_mg_dL":1.34,"alt_U_L":110},{"date":"2026-07-10","hemoglobin_g_dL":10.0,"wbc_k_uL":4.2,"platelets_k_uL":338,"creatinine_mg_dL":1.67,"alt_U_L":150}]}
{"patient_id":"ANODE_SYNTH_2025_3235","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":66,"sex":"male","bmi":27.3,"smoking_pack_years":20,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-08-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-34},"pfs_months":13.01},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":21.4,"censored":true},"longitudinal_labs":[{"date":"2024-07-26","hemoglobin_g_dL":12.6,"wbc_k_uL":9.9,"platelets_k_uL":193,"creatinine_mg_dL":0.68,"alt_U_L":54},{"date":"2025-02-27","hemoglobin_g_dL":11.6,"wbc_k_uL":7.9,"platelets_k_uL":187,"creatinine_mg_dL":0.75,"alt_U_L":70},{"date":"2025-10-30","hemoglobin_g_dL":12.6,"wbc_k_uL":7.3,"platelets_k_uL":115,"creatinine_mg_dL":1.29,"alt_U_L":57}]}
{"patient_id":"ANODE_SYNTH_2025_3236","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.7,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":56,"sex":"female","bmi":29.0,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-34},"pfs_months":30.36},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":43.0,"censored":true},"longitudinal_labs":[{"date":"2024-07-14","hemoglobin_g_dL":13.4,"wbc_k_uL":8.0,"platelets_k_uL":326,"creatinine_mg_dL":0.78,"alt_U_L":59},{"date":"2025-03-02","hemoglobin_g_dL":10.4,"wbc_k_uL":6.7,"platelets_k_uL":266,"creatinine_mg_dL":0.75,"alt_U_L":43},{"date":"2027-04-26","hemoglobin_g_dL":11.9,"wbc_k_uL":5.1,"platelets_k_uL":313,"creatinine_mg_dL":1.95,"alt_U_L":191}]}
{"patient_id":"ANODE_SYNTH_2025_3237","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.8,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":59,"sex":"male","bmi":28.6,"smoking_pack_years":59,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-84},"pfs_months":9.99},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-03","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":16.4,"censored":true},"longitudinal_labs":[{"date":"2021-06-09","hemoglobin_g_dL":14.8,"wbc_k_uL":10.0,"platelets_k_uL":426,"creatinine_mg_dL":1.29,"alt_U_L":52},{"date":"2022-01-25","hemoglobin_g_dL":12.2,"wbc_k_uL":4.2,"platelets_k_uL":337,"creatinine_mg_dL":0.89,"alt_U_L":108},{"date":"2022-07-03","hemoglobin_g_dL":10.2,"wbc_k_uL":6.1,"platelets_k_uL":241,"creatinine_mg_dL":1.2,"alt_U_L":24}]}
{"patient_id":"ANODE_SYNTH_2025_3238","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":60,"sex":"female","bmi":19.0,"smoking_pack_years":28,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-36},"pfs_months":3.55},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-02-27","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":14.8,"censored":false},"longitudinal_labs":[{"date":"2023-07-11","hemoglobin_g_dL":14.5,"wbc_k_uL":7.4,"platelets_k_uL":407,"creatinine_mg_dL":0.82,"alt_U_L":69},{"date":"2024-03-17","hemoglobin_g_dL":10.5,"wbc_k_uL":8.7,"platelets_k_uL":342,"creatinine_mg_dL":0.98,"alt_U_L":105},{"date":"2024-02-27","hemoglobin_g_dL":10.8,"wbc_k_uL":4.2,"platelets_k_uL":345,"creatinine_mg_dL":0.83,"alt_U_L":152}]}
{"patient_id":"ANODE_SYNTH_2025_3239","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":49,"sex":"female","bmi":28.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["bone","brain","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-01-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-43},"pfs_months":20.07},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-11-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.1,"censored":false},"longitudinal_labs":[{"date":"2021-01-05","hemoglobin_g_dL":13.2,"wbc_k_uL":5.0,"platelets_k_uL":216,"creatinine_mg_dL":1.13,"alt_U_L":63},{"date":"2021-07-19","hemoglobin_g_dL":11.9,"wbc_k_uL":6.4,"platelets_k_uL":258,"creatinine_mg_dL":1.52,"alt_U_L":78},{"date":"2022-11-05","hemoglobin_g_dL":9.6,"wbc_k_uL":7.5,"platelets_k_uL":146,"creatinine_mg_dL":1.72,"alt_U_L":59}]}
{"patient_id":"ANODE_SYNTH_2025_3240","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.8,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":87,"sex":"female","bmi":23.8,"smoking_pack_years":23,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.1,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-09-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-34},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-02-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":11.1,"censored":true},"longitudinal_labs":[{"date":"2021-07-20","hemoglobin_g_dL":14.5,"wbc_k_uL":8.1,"platelets_k_uL":183,"creatinine_mg_dL":0.77,"alt_U_L":41},{"date":"2022-03-21","hemoglobin_g_dL":10.1,"wbc_k_uL":4.4,"platelets_k_uL":313,"creatinine_mg_dL":0.91,"alt_U_L":38},{"date":"2022-02-03","hemoglobin_g_dL":11.4,"wbc_k_uL":4.7,"platelets_k_uL":138,"creatinine_mg_dL":0.84,"alt_U_L":37}]}
{"patient_id":"ANODE_SYNTH_2025_3241","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.8,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":76,"sex":"female","bmi":25.4,"smoking_pack_years":60,"ecog_performance_status":2,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["liver","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-11-13","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-45},"pfs_months":41.53},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":60.8,"censored":false},"longitudinal_labs":[{"date":"2022-09-22","hemoglobin_g_dL":12.1,"wbc_k_uL":7.9,"platelets_k_uL":175,"creatinine_mg_dL":0.73,"alt_U_L":18},{"date":"2023-05-12","hemoglobin_g_dL":13.8,"wbc_k_uL":8.7,"platelets_k_uL":226,"creatinine_mg_dL":1.52,"alt_U_L":105},{"date":"2026-06-16","hemoglobin_g_dL":11.1,"wbc_k_uL":3.9,"platelets_k_uL":241,"creatinine_mg_dL":1.06,"alt_U_L":39}]}
{"patient_id":"ANODE_SYNTH_2025_3242","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.6,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":75,"sex":"female","bmi":34.5,"smoking_pack_years":14,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-08-22","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-57},"pfs_months":24.87},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":41.5,"censored":true},"longitudinal_labs":[{"date":"2025-06-15","hemoglobin_g_dL":13.3,"wbc_k_uL":6.4,"platelets_k_uL":351,"creatinine_mg_dL":0.82,"alt_U_L":73},{"date":"2026-02-18","hemoglobin_g_dL":11.2,"wbc_k_uL":6.3,"platelets_k_uL":332,"creatinine_mg_dL":1.28,"alt_U_L":62},{"date":"2027-10-02","hemoglobin_g_dL":10.9,"wbc_k_uL":6.1,"platelets_k_uL":253,"creatinine_mg_dL":1.6,"alt_U_L":127}]}
{"patient_id":"ANODE_SYNTH_2025_3243","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":54,"sex":"female","bmi":25.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-03-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-42},"pfs_months":8.74},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-12-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":26.9,"censored":true},"longitudinal_labs":[{"date":"2021-01-20","hemoglobin_g_dL":13.6,"wbc_k_uL":7.7,"platelets_k_uL":251,"creatinine_mg_dL":0.91,"alt_U_L":51},{"date":"2021-09-14","hemoglobin_g_dL":10.7,"wbc_k_uL":8.6,"platelets_k_uL":280,"creatinine_mg_dL":1.4,"alt_U_L":78},{"date":"2021-12-22","hemoglobin_g_dL":13.0,"wbc_k_uL":7.6,"platelets_k_uL":139,"creatinine_mg_dL":1.05,"alt_U_L":186}]}
{"patient_id":"ANODE_SYNTH_2025_3244","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":72,"sex":"female","bmi":19.3,"smoking_pack_years":61,"ecog_performance_status":2,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.7,"metastatic_sites":["brain","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-06-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-45},"pfs_months":37.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":56.7,"censored":false},"longitudinal_labs":[{"date":"2020-04-09","hemoglobin_g_dL":13.8,"wbc_k_uL":9.0,"platelets_k_uL":186,"creatinine_mg_dL":1.22,"alt_U_L":54},{"date":"2020-12-11","hemoglobin_g_dL":10.4,"wbc_k_uL":4.7,"platelets_k_uL":364,"creatinine_mg_dL":1.21,"alt_U_L":40},{"date":"2023-09-18","hemoglobin_g_dL":11.7,"wbc_k_uL":6.2,"platelets_k_uL":284,"creatinine_mg_dL":0.96,"alt_U_L":52}]}
{"patient_id":"ANODE_SYNTH_2025_3245","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":51,"sex":"male","bmi":23.3,"smoking_pack_years":64,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-10-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-47},"pfs_months":4.8},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":8.7,"censored":true},"longitudinal_labs":[{"date":"2022-10-02","hemoglobin_g_dL":12.8,"wbc_k_uL":8.3,"platelets_k_uL":310,"creatinine_mg_dL":0.77,"alt_U_L":65},{"date":"2023-04-22","hemoglobin_g_dL":11.2,"wbc_k_uL":4.2,"platelets_k_uL":202,"creatinine_mg_dL":1.4,"alt_U_L":77},{"date":"2023-03-29","hemoglobin_g_dL":12.3,"wbc_k_uL":3.5,"platelets_k_uL":261,"creatinine_mg_dL":1.63,"alt_U_L":41}]}
{"patient_id":"ANODE_SYNTH_2025_3246","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":77,"sex":"male","bmi":33.1,"smoking_pack_years":77,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-06-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-46,"peak_response_20wk_change_percent":-79},"pfs_months":18.3},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-31","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":false},"longitudinal_labs":[{"date":"2022-04-07","hemoglobin_g_dL":11.8,"wbc_k_uL":8.7,"platelets_k_uL":220,"creatinine_mg_dL":1.03,"alt_U_L":48},{"date":"2022-12-13","hemoglobin_g_dL":13.6,"wbc_k_uL":8.6,"platelets_k_uL":269,"creatinine_mg_dL":1.43,"alt_U_L":43},{"date":"2024-01-31","hemoglobin_g_dL":12.2,"wbc_k_uL":6.2,"platelets_k_uL":166,"creatinine_mg_dL":1.57,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_3247","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.7,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":60,"sex":"female","bmi":27.5,"smoking_pack_years":51,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","bone","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-10-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-37},"pfs_months":18.04},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-26","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":33.8,"censored":false},"longitudinal_labs":[{"date":"2025-08-22","hemoglobin_g_dL":11.6,"wbc_k_uL":10.1,"platelets_k_uL":332,"creatinine_mg_dL":1.13,"alt_U_L":57},{"date":"2026-04-08","hemoglobin_g_dL":10.4,"wbc_k_uL":8.4,"platelets_k_uL":371,"creatinine_mg_dL":1.22,"alt_U_L":58},{"date":"2027-05-26","hemoglobin_g_dL":10.6,"wbc_k_uL":3.6,"platelets_k_uL":215,"creatinine_mg_dL":0.97,"alt_U_L":105}]}
{"patient_id":"ANODE_SYNTH_2025_3248","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":65,"sex":"male","bmi":20.2,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-08-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-16,"peak_response_20wk_change_percent":-38},"pfs_months":19.45},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-04-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":42.1,"censored":false},"longitudinal_labs":[{"date":"2022-06-20","hemoglobin_g_dL":12.3,"wbc_k_uL":11.0,"platelets_k_uL":187,"creatinine_mg_dL":0.86,"alt_U_L":21},{"date":"2023-02-24","hemoglobin_g_dL":10.9,"wbc_k_uL":6.7,"platelets_k_uL":347,"creatinine_mg_dL":1.21,"alt_U_L":55},{"date":"2024-04-26","hemoglobin_g_dL":12.3,"wbc_k_uL":6.7,"platelets_k_uL":138,"creatinine_mg_dL":1.11,"alt_U_L":107}]}
{"patient_id":"ANODE_SYNTH_2025_3249","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.1,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":51,"sex":"female","bmi":20.9,"smoking_pack_years":72,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-08-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-55,"peak_response_20wk_change_percent":-30},"pfs_months":25.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":31.0,"censored":false},"longitudinal_labs":[{"date":"2023-07-18","hemoglobin_g_dL":12.0,"wbc_k_uL":6.8,"platelets_k_uL":191,"creatinine_mg_dL":0.91,"alt_U_L":69},{"date":"2024-02-27","hemoglobin_g_dL":13.2,"wbc_k_uL":8.8,"platelets_k_uL":172,"creatinine_mg_dL":1.33,"alt_U_L":86},{"date":"2025-11-05","hemoglobin_g_dL":12.4,"wbc_k_uL":5.2,"platelets_k_uL":254,"creatinine_mg_dL":0.97,"alt_U_L":51}]}
{"patient_id":"ANODE_SYNTH_2025_3250","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.3,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":85,"sex":"female","bmi":30.8,"smoking_pack_years":32,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.7,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-10-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-56},"pfs_months":13.73},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-26","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":26.8,"censored":false},"longitudinal_labs":[{"date":"2022-08-16","hemoglobin_g_dL":13.7,"wbc_k_uL":6.2,"platelets_k_uL":219,"creatinine_mg_dL":1.13,"alt_U_L":66},{"date":"2023-04-09","hemoglobin_g_dL":12.6,"wbc_k_uL":8.2,"platelets_k_uL":155,"creatinine_mg_dL":0.95,"alt_U_L":73},{"date":"2023-12-26","hemoglobin_g_dL":12.6,"wbc_k_uL":7.1,"platelets_k_uL":201,"creatinine_mg_dL":0.95,"alt_U_L":132}]}
{"patient_id":"ANODE_SYNTH_2025_3251","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.8,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":51,"sex":"female","bmi":23.5,"smoking_pack_years":37,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-01-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-33},"pfs_months":9.4},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":25.8,"censored":false},"longitudinal_labs":[{"date":"2025-11-17","hemoglobin_g_dL":14.6,"wbc_k_uL":5.3,"platelets_k_uL":449,"creatinine_mg_dL":0.75,"alt_U_L":50},{"date":"2026-07-10","hemoglobin_g_dL":11.4,"wbc_k_uL":4.4,"platelets_k_uL":332,"creatinine_mg_dL":1.44,"alt_U_L":77},{"date":"2026-12-16","hemoglobin_g_dL":11.6,"wbc_k_uL":6.5,"platelets_k_uL":147,"creatinine_mg_dL":1.64,"alt_U_L":65}]}
{"patient_id":"ANODE_SYNTH_2025_3252","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":81,"sex":"female","bmi":29.6,"smoking_pack_years":26,"ecog_performance_status":2,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-05-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-67},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":8.6,"censored":true},"longitudinal_labs":[{"date":"2023-04-19","hemoglobin_g_dL":11.5,"wbc_k_uL":9.8,"platelets_k_uL":306,"creatinine_mg_dL":0.74,"alt_U_L":46},{"date":"2023-11-22","hemoglobin_g_dL":10.3,"wbc_k_uL":8.2,"platelets_k_uL":234,"creatinine_mg_dL":1.4,"alt_U_L":83},{"date":"2023-09-14","hemoglobin_g_dL":12.7,"wbc_k_uL":7.3,"platelets_k_uL":255,"creatinine_mg_dL":1.72,"alt_U_L":74}]}
{"patient_id":"ANODE_SYNTH_2025_3253","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.1,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":75,"sex":"female","bmi":30.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["brain","bone","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with m